<SEC-DOCUMENT>0000879407-25-000029.txt : 20251125
<SEC-HEADER>0000879407-25-000029.hdr.sgml : 20251125
<ACCEPTANCE-DATETIME>20251125161358
ACCESSION NUMBER:		0000879407-25-000029
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		121
CONFORMED PERIOD OF REPORT:	20250930
FILED AS OF DATE:		20251125
DATE AS OF CHANGE:		20251125

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38042
		FILM NUMBER:		251521352

	BUSINESS ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105
		BUSINESS PHONE:		626-696-4702

	MAIL ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>arwr-20250930.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:67e6a79e-2429-4a7b-924a-105395255933,g:bc385ee3-281d-4402-b0c2-11a4f6b4f5dd,d:fa97f0f616f442a39c9869ed1f483476-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:arwr="http://www.arrowheadresearch.com/20250930" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arwr-20250930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-33">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-35">0000879407</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-36">false</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-105">111</ix:nonNumeric><ix:nonNumeric contextRef="c-7" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-106">461</ix:nonNumeric><ix:nonNumeric contextRef="c-9" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-107">226</ix:nonNumeric><ix:nonNumeric contextRef="c-11" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-108">135</ix:nonNumeric><ix:nonNumeric contextRef="c-13" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-109">97</ix:nonNumeric><ix:nonNumeric contextRef="c-15" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-110">126</ix:nonNumeric><ix:nonNumeric contextRef="c-18" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-111">119</ix:nonNumeric><ix:nonNumeric contextRef="c-20" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-112">119</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" scale="0" id="f-1326">1</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="arwr-20250930.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="subsidiary"><xbrli:measure>arwr:subsidiary</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="bundle"><xbrli:measure>arwr:bundle</xbrli:measure></xbrli:unit><xbrli:unit id="obligation"><xbrli:measure>arwr:obligation</xbrli:measure></xbrli:unit><xbrli:unit id="agreement"><xbrli:measure>arwr:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="program"><xbrli:measure>arwr:program</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="option"><xbrli:measure>arwr:option</xbrli:measure></xbrli:unit><xbrli:unit id="cny"><xbrli:measure>iso4217:CNY</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>arwr:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:AdeoyeOlukotunMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:AdeoyeOlukotunMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:ChristopherAnzaloneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:ChristopherAnzaloneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:DanielApelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:DanielApelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:JamesHamiltonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:JamesHamiltonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:MauroFerrariMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:MauroFerrariMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:PatrickOBrienMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:PatrickOBrienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:PatrickOBrienSharesVestingAndSubjectToSellToCoverMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:PatrickOBrienMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:PatrickOBrienOtherSharesBeingSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:VictoriaVakienerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:VictoriaVakienerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:WilliamWaddillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:WilliamWaddillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-24</xbrli:startDate><xbrli:endDate>2025-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-07</xbrli:startDate><xbrli:endDate>2025-02-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2025-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ComputersAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ComputersAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHSDLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-22</xbrli:startDate><xbrli:endDate>2021-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHSDLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHSDLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHSDLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHSDLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-22</xbrli:startDate><xbrli:endDate>2021-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-14</xbrli:startDate><xbrli:endDate>2025-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-25</xbrli:startDate><xbrli:endDate>2024-11-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SanofiLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2025-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SanofiLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ComputersAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ComputersAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ConstructionInProgressReclassifiedToBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ConstructionInProgressReclassifiedToManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ConstructionInProgressReclassifiedToBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ConstructionInProgressReclassifiedToManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-25</xbrli:startDate><xbrli:endDate>2024-11-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-25</xbrli:startDate><xbrli:endDate>2024-11-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-13</xbrli:startDate><xbrli:endDate>2025-08-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-02</xbrli:startDate><xbrli:endDate>2022-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:DrugManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-25</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">arwr:EmployeeContributionsUpToThreePercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">arwr:EmployeeContributionNextTwoPercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-07</xbrli:startDate><xbrli:endDate>2024-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMOICPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-07</xbrli:startDate><xbrli:endDate>2024-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementInitialTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-26</xbrli:startDate><xbrli:endDate>2024-11-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMOICPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-26</xbrli:startDate><xbrli:endDate>2024-11-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMOICPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-07</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMOICPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementInitialTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementInitialTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementInitialTermLoanInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementInitialTermLoanInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-01</xbrli:startDate><xbrli:endDate>2025-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arwr:OperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arwr:OperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arwr:OperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arwr:OperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arwr:OperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arwr:OperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arwr:OperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arwr:OperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arwr:OperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:NovartisCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-17</xbrli:startDate><xbrli:endDate>2025-10-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:NovartisCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:NovartisCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-17</xbrli:startDate><xbrli:endDate>2025-10-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:NovartisCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-17</xbrli:startDate><xbrli:endDate>2025-10-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:NovartisCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:NovartisCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-20</xbrli:startDate><xbrli:endDate>2025-11-20</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ifa97f0f616f442a39c9869ed1f483476_1"></div><div style="min-height:31.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:3.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">September 30</ix:nonNumeric>, 2025</ix:nonNumeric></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:3.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-38042</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">ARROWHEAD PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">46-0408024</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-10">626</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-11">304-3400</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-12">177 E. Colorado Blvd</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-13">Suite 700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-14">Pasadena</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-15">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-16">91105</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">(Address and telephone number of principal executive offices) </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:37.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.293%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:2pt;font-weight:400;line-height:115%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Title of each class</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">ARWR</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Exchange Act: None </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by a check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by a check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-25">Smaller reporting company</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-26">Emerging growth company</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-27">x</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-29">&#9744;</ix:nonNumeric></span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:112%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#9744;</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">The aggregate market value of issuer&#8217;s voting and non-voting outstanding common stock held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-8" name="dei:EntityPublicFloat" scale="9" id="f-30">1.4</ix:nonFraction> billion based upon the closing stock price of issuer&#8217;s common stock on March 31, 2025. Shares of common stock held by each officer and director and by each person who is known to own 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates of the Company. This determination of affiliate status is not necessarily a conclusive determination for other purposes. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">As of November&#160;19, 2025, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">135,809,558</ix:nonFraction> shares of the issuer&#8217;s Common Stock were issued and outstanding.</span></div><div style="margin-top:6pt;text-align:center;text-indent:27.78pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-32" escape="true"><div style="margin-top:6pt;text-indent:30.6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">Portions of the Definitive Proxy Statement to be filed for Arrowhead Pharmaceuticals, Inc.&#8217;s 2026 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.</span></div></ix:nonNumeric><div style="text-indent:30.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:4.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_13">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_16">ITEM 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_16">BUSINESS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_19">ITEM 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_19">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_19">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_22">ITEM 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_22">UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_22">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ITEM 1C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_25">CYBERSECURITY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_25">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_28">ITEM 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_28">PROPERTIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_28">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_31">ITEM 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_31">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_31">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_34">ITEM 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_34">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_34">60</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_37">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_40">ITEM 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_40">MARKET FOR THE REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_40">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_43">ITEM 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_43">RESERVED</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_43">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_46">ITEM 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_46">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_46">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_67">ITEM 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_67">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_67">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_70">ITEM 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_70">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_70">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_73">ITEM 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_73">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_73">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_76">ITEM 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_76">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_76">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_79">ITEM 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_79">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_79">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_85">ITEM 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_85">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_85">74</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_88">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_91">ITEM 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_91">DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_91">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_94">ITEM 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_94">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_94">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_97">ITEM 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_97">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_97">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_100">ITEM 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_100">CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTORS INDEPENDENCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_100">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_103">ITEM 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_103">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_103">75</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_106">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_109">ITEM 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_109">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_109">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_112">ITEM 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:107%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_112">FORM 10-K SUMMARY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_112">79</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_115">SIGNATURE</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_118">INDEX TO FINANCIAL STATEMENTS AND SCHEDULES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_118">1</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">This Annual Report on Form 10-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and we intend that such forward-looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this Annual Report on Form 10-K except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as &#8220;may,&#8221;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8220;might,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221;  &#8220;goal,&#8221; &#8220;endeavor,&#8221; &#8220;strive,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;might,&#8221; &#8220;forecast,&#8221; or &#8220;continue&#8221; or the negative of these words or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding our commercialization efforts for REDEMPLO; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding the amount and timing of future milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The forward-looking statements included herein are based on current expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately, and many of which are beyond our control. As such, our actual results and outcomes may differ materially from those discussed, projected, anticipated or indicated in any forward-looking statements. Forward-looking statements are not guarantees of future performance and our actual results or outcomes may differ materially. Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail in &#8220;Item 1. Business&#8221; and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8221; of Part I and &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of Part II of this Annual Report on Form 10-K. Readers should carefully review these risks, as well as the additional risks described in other documents we file from time to time with the Securities and Exchange Commission (the &#8220;SEC&#8221;). In light of the significant risks and uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking information. Statements made herein are as of the date of the filing of this Annual Report on Form 10-K with the SEC and should not be relied upon as of any subsequent date. Except as may be required by law, we disclaim any intent to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless otherwise noted, (1) the term &#8220;Arrowhead&#8221; refers to Arrowhead Pharmaceuticals, Inc., a Delaware corporation and its Subsidiaries, (2) the terms &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to the ongoing business operations of Arrowhead and its Subsidiaries, whether conducted through Arrowhead or a subsidiary of Arrowhead, (3) the term &#8220;Subsidiaries&#8221; refers to Arrowhead Madison Inc. (&#8220;Arrowhead Madison&#8221;), Arrowhead Australia Pty Ltd (&#8220;Arrowhead Australia&#8221;), Arrowhead Pharmaceuticals NZ Limited (&#8220;Arrowhead New Zealand&#8221;), Arrowhead Pharmaceuticals Ireland Limited (&#8220;Arrowhead Ireland&#8221;), and Visirna Therapeutics Inc. (&#8220;Visirna&#8221;) (4) the term &#8220;common stock&#8221; refers to Arrowhead&#8217;s common stock, (5) the term &#8220;preferred stock&#8221; refers to Arrowhead&#8217;s preferred stock and (6) the term &#8220;stockholder(s)&#8221; refers to the holders of Arrowhead common stock. </span></div><div id="ifa97f0f616f442a39c9869ed1f483476_16"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">BUSINESS</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and modes of delivery, the Company&#8217;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are currently 18 Arrowhead discovered drug candidates in clinical trials ranging from early stage (Phase 1) to late stage (Phase 3). In addition, the company has a robust discovery stage pipeline which is capable of generating multiple new clinical candidates each year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recently achieved a transformational milestone with its first commercial launch in 2025, when the U.S. Food and Drug Administration ("FDA") approved REDEMPLO</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (plozasiran) as an adjunct to diet to reduce triglycerides in adults with Familial Chylomicronemia Syndrome ("FCS"). Additionally, phase 3 studies (SHASTA-3, SHASTA-4 and SHASTA-5) for severe hypertriglyceridemia ("sHTG") have been fully enrolled and the Company plans to file a supplemental NDA for this indication in 2026, pending successful completion of Phase 3 clinical studies. The Company has built a commercial organization to support marketing in FCS, a rare disease, and plans to progressively build its commercial capabilities to also support marketing in sHTG, a higher prevalence disease which will require a larger commercial footprint. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into multiple license and collaboration agreements with leading biotech and pharmaceutical companies, including Sarepta Therapeutics, Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Glaxosmithkline Intellectual Property (No. 3) Limited and Novartis Pharma AG, for programs that the Company does not intend to commercialize independently. This approach aims to expand the reach of the Company&#8217;s technology and provides a source of non-dilutive capital to support REDEMPLO and other wholly-owned programs through commercial stage. </span></div><div style="margin-top:6pt;text-align:justify"><img src="arwr-20250930_g1.jpg" alt="2.jpg" style="height:243px;margin-bottom:5pt;vertical-align:text-bottom;width:660px" id="i-1"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RNA Interference and the Benefits of RNAi Therapeutics</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Small molecule and antibody drugs have proven effective at inhibiting certain cell surface, intracellular, and extracellular targets. However, other drug targets have proven difficult to inhibit with traditional drug-based and biologic therapeutics. Developing effective drugs for these targets would have the potential to address large underserved markets for the treatment of many diseases. Using the ability to specifically silence any gene, RNAi therapeutics may be able to address previously &#8220;undruggable&#8221; targets, unlocking the market potential of such targets. </span></div><div style="margin-top:12pt;text-align:center"><img src="arwr-20250930_g2.jpg" alt="Benefits of RNAi Therapeutics.jpg" style="height:340px;margin-bottom:5pt;vertical-align:text-bottom;width:454px" id="i-2"/></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This figure depicts the mechanism by which gene silencing occurs. Double stranded RNAi triggers (commonly referred to as small interfering RNAs (&#8220;siRNAs&#8221;)) are introduced into a cell and are loaded into the RNA-induced silencing complex (&#8220;RISC&#8221;). The strands are then separated, leaving an active RISC/RNAi trigger complex. This complex can then pair with and degrade the complementary messenger RNAs (&#8220;mRNA&#8221;) and stop the production of the target proteins. RNAi is a catalytic process, so each RNAi trigger can degrade mRNA hundreds of times, which results in a relatively long duration of effect for RNAi therapeutics.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Key Benefits of RNAi and proprietary TRiM</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> platform as a Therapeutic Modality:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Silences the expression of disease associated genes; </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Potential to address any target in the transcriptome including previously &#8220;undruggable&#8221; targets;</span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Rapid lead identification;</span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">High specificity;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Opportunity to use multiple RNA sequences in one drug product for synergistic silencing of multiple targets; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">RNAi therapeutics are uniquely suited for personalized medicine through target and cell specific delivery and gene knockdown.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Targeted RNAi Molecule (TRiM</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">) Platform</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s TRiM platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. Targeting has been core to the Company&#8217;s development philosophy and the TRiM platform builds on more than a decade of work on actively targeted drug delivery vehicles. The Company&#8217;s scientists have discovered ways to progressively &#8220;TRiM&#8221; away extraneous features and chemistries and retain optimal pharmacologic activity.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The TRiM platform is comprised of a highly potent RNA trigger identified using the Company&#8217;s proprietary trigger selection rules and algorithms with the following components optimized, as needed, for each drug candidate: a high affinity targeting ligand; various linker chemistries; structures that enhance pharmacokinetics; and highly potent RNAi triggers with sequence specific stabilization chemistries. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Therapeutics developed with the TRiM platform offer several advantages: simplified manufacturing and reduced costs; multiple routes of administration; and potential for improved safety because there are less metabolites from smaller molecules, thereby reducing the risk of intracellular buildup.</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><img src="arwr-20250930_g3.jpg" alt="2.jpg" style="height:267px;margin-bottom:5pt;vertical-align:text-bottom;width:660px" id="i-3"/><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br/><br/>     </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that for RNAi to reach its true potential, it must target organs outside the liver. The Company is leading this expansion with the TRiM platform, which has shown the potential to reach multiple tissues throughout the body. The TRiM platform currently enables delivery of siRNA to seven cell types: </span></div><div style="margin-top:12pt;text-align:justify"><img src="arwr-20250930_g4.jpg" alt="3.jpg" style="height:255px;margin-bottom:5pt;vertical-align:text-bottom;width:660px" id="i-4"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RNA Chemistries</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The structure and chemistries of the oligonucleotide molecules used to trigger the RNAi mechanism can be tailored for optimal activity. The Company&#8217;s broad portfolio of RNA trigger structures and chemistries, including certain proprietary structures, enable the Company to optimize each drug candidate on a target-by-target basis and utilize the combination of structure and chemical modifications that yield the most potent RNAi therapeutic candidate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a component of the TRiM platform, the Company&#8217;s design philosophy for RNA chemical modifications is to start with a structurally simple molecule and add only selective modification and stabilization chemistries as necessary to achieve the desired level of target knockdown and duration of effect. The conceptual framework for the stabilization strategy starts with a more sophisticated RNAi trigger screening and selection process that identifies potent sequences rapidly in locations that others may miss. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Approved Products</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">REDEMPLO (plozasiran) is approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides for adults with Familial Chylomicronemia Syndrome (FCS). REDEMPLO is an siRNA therapeutic designed to suppress the production of apolipoprotein C-III (APOC3), a protein produced in the liver that raises triglyceride levels by slowing their breakdown and clearance. By targeting the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APOC3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> gene with sustained silencing, REDEMPLO delivers significant reductions in triglyceride levels. REDEMPLO is the first and only FDA-approved siRNA treatment studied in both genetically confirmed and clinically diagnosed patients living with FCS. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For more information about REDEMPLO, visit Our Medicines. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IMPORTANT SAFETY INFORMATION  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CONTRAINDICATIONS </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADVERSE REACTIONS </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Most common adverse reactions in REDEMPLO treated patients (incidence &#8805;10% of patients treated with REDEMPLO and &gt;5% more frequently than with placebo) are hyperglycemia, headache, nausea, and injection site reaction. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Please see full Prescribing Information for REDEMPLO.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Pipeline</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on developing innovative drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. The depth and versatility of the Company&#8217;s RNAi technologies enables the Company to potentially address conditions across many therapeutic areas and pursue disease targets that are not otherwise addressable by small molecules and biologics</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:27pt"><img src="arwr-20250930_g5.jpg" alt="Picture2.jpg" style="height:355px;margin-bottom:5pt;vertical-align:text-bottom;width:656px" id="i-5"/><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><br/>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-style:italic;font-weight:400;line-height:120%">(1) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Greater China rights for plozasiran are out-licensed to Sanofi.</span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plozasiran (ARO-APOC3) - Severe Hypertriglyceridemia (sHTG)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Severe Hypertriglyceridemia is a disease characterized by elevated triglyceride levels &gt; 500 mg/dL. Severely elevated triglycerides in patients with severe hypertriglyceridemia (sHTG) or familial chylomicronemia syndrome (FCS), a rare genetic disorder, can result in potentially fatal acute pancreatitis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Plozasiran (formerly ARO-APOC3) is designed to reduce production of apolipoprotein C-III (APOC3), a component of triglyceride rich lipoproteins (TRLs) including Very Low Density Lipoprotein (VLDL) and chylomicrons, a key regulator of triglyceride metabolism. The Company believes that knocking down the hepatic production of APOC3 may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting multiple Phase 3 studies to potentially support regulatory filings, pending successful completion, for approval in sHTG including SHASTA-3, SHASTA-4, SHASTA-5, and MUIR-3.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zodasiran (ARO-ANG3) - Homozygous Familial Hypercholesterolemia (HoFH)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dyslipidemia and Hypertriglyceridemia are risk factors for atherosclerotic coronary heart disease and cardiovascular events. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Zodasiran (formerly ARO-ANG3) is designed to reduce production of angiopoietin-like protein 3 (ANGPTL3), a liver synthesized inhibitor of lipoprotein lipase and endothelial lipase. ANGPTL3 inhibition has been shown to lower serum LDL, serum and liver triglyceride and has genetic validation as a novel target for cardiovascular disease. The Company is currently investigating zodasiran in one Phase 3 clinical trial (YOSEMITE) to evaluate the efficacy and safety of zodasiran in adolescent and adult subjects with HoFH. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-DIMER-PA - Mixed Hyperlipidemia</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Mixed Hyperlipidemia is a highly prevalent disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels and is a major risk factor for ASCVD, which is the leading cause of mortality worldwide and associated with substantial morbidity and healthcare costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ARO-DIMER-PA is a dual functional RNAi molecule designed to silence expression of the proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (APOC3) genes in hepatocytes. Prior clinical experience with other investigational and approved agents suggests that PCSK9 and APOC3 inhibition may lead to robust reductions in LDL-C, TGs, triglyceride rich lipoprotein remnants, and total atherogenic lipoproteins. This represents an important step forward for the RNAi field as it is the first clinical candidate to target two genes simultaneously in one molecule, enabled by Arrowhead&#8217;s innovative and proprietary TRiM platform. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has filed for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-DIMER-PA.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-PNPLA3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">- Metabolic-dysfunction Associated Steatohepatitis (MASH)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MASH is a subgroup of steatotic liver disease (MASLD) in which hepatic cell injury and inflammation has developed over background steatosis. The I148M genetic variant in the PNPLA3 gene is involved with the underlying pathophysiology and is a known risk factor for hepatic steatosis, steatohepatitis, elevated plasma liver enzyme levels, hepatic fibrosis and cirrhosis. The rising prevalence of MASH presents a significant health burden in many developed countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ARO-PNPLA3 (formerly JNJ-75220795) is an investigational RNAi therapeutic designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with metabolic-dysfunction associated steatohepatitis (MASH). PNPLA3 has strong genetic and preclinical validation as a driver of fat accumulation and damage in the livers of patients who carry the common I148M mutation. Former licensee Janssen Pharmaceuticals, Inc. investigated ARO-PNPLA3 in two Phase 1 clinical trials. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-INHBE - Obesity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ARO-INHBE is designed to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E. INHBE is a promising genetically validated target in which loss-of-function INHBE variants in humans are associated with lower risk of obesity and metabolic diseases, such as type 2 diabetes. The Company is currently investigating ARO-INHBE in a Phase 1/2a clinical trial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-ALK7- Obesity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ARO-ALK7 is designed to silence adipocyte expression of the ACVR1C gene to reduce the production of Activin receptor-like kinase 7 (ALK7), which acts as a receptor in a pathway that regulates energy homeostasis in adipose tissue. In large genetic datasets, reduced ACVR1C expression has been associated with healthier adipose distribution and reduced </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">risk of obesity-related metabolic complications. The Company is currently investigating ARO-ALK7 in a Phase 1/2a clinical trial. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-RAGE - Inflammatory Pulmonary Disease</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ARO-RAGE is designed to reduce production of the Receptor for Advanced Glycation End products (RAGE) as a potential treatment for various inflammatory pulmonary diseases. The Company is currently investigating ARO-RAGE in a Phase 1/2a clinical trial. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-MAPT - Alzheimer's and Tauopathies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Aggregation of the toxic tau protein is believed to be a key driver in multiple tauopathies, including Alzheimer&#8217;s disease. By preventing or potentially reversing tau protein accumulation in subjects with mild cognitive impairment due to Alzheimer&#8217;s disease and mild Alzheimer&#8217;s disease dementia, ARO-MAPT has the potential to prevent or slow disease progression. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ARO-MAPT is Arrowhead&#8217;s first investigational RNAi-based therapy to utilize a new proprietary delivery system which, in preclinical studies, has achieved blood-brain-barrier penetration and deep knockdown of target genes across the central nervous system (CNS), including deep brain regions, after subcutaneous injections. ARO-MAPT is designed to silence CNS expression of the microtubule associated protein tau (MAPT) gene, which encodes the tau protein. The Company has filed for regulatory clearance to initiate a phase 1/2a clinical trial of ARO-MAPT. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-C3 - Complement Mediated Renal Disease</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A number of rare renal diseases result from uncontrolled activation of the alternative pathway of complement, leading to progressive glomerular damage, proteinuria, hematuria, and impaired kidney function, and often resulting in end-stage renal disease (ESRD). In addition, dysregulation of the alternative complement pathway has been shown to play a role in the pathogenesis and progression of disease in some of the more common glomerulopathies. Silencing complement component 3 (C3) may be a therapeutic approach for treatment of these conditions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ARO-C3 is designed to reduce production of C3 as a potential therapy for patients with various complement mediated or complement associated renal diseases. The Company is currently investigating ARO-C3 in a Phase 1/2a clinical trial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-CFB - Complement Mediated Disease</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A number of rare renal diseases result from uncontrolled activation of the alternative pathway of complement, leading to progressive glomerular damage, proteinuria, hematuria, and impaired kidney function, and often resulting in end-stage renal disease (ESRD). In addition, dysregulation of the alternative complement pathway has been shown to play a role in the pathogenesis and progression of disease in some of the more common glomerulopathies. Silencing complement factor B (CFB) may be a therapeutic approach for treatment of these conditions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ARO-CFB is designed to reduce hepatic expression of CFB, which plays an important regulatory role in amplifying complement alternative pathway activation and has been identified as a promising therapeutic target. ARO-CFB is being developed as a potential treatment for complement mediated kidney diseases such as immunoglobulin A nephropathy (IgAN), which is the most common glomerular disease worldwide and carries a high lifetime risk of progression to end-stage renal disease. Additionally, ARO-CFB may have clinical applications in non-renal diseases involving complement activation. The Company is currently investigating ARO-CFB in a Phase 1/2a clinical trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Collaboration and License Agreements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Glaxosmithkline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;)</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">GSK-HSD License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#8220;GSK-HSD License Agreement&#8221;). Under the GSK-HSD License Agreement, GSK has received an exclusive license for GSK-4532990 (formerly ARO-HSD). The exclusive license is worldwide with the exception of greater China. GSK is wholly responsible for all clinical development and commercialization of GSK-4532990 in its territory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">GSK-4532990</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> - </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Metabolic-Dysfunction Associated Steatohepatitis (MASH)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">MASH is liver inflammation and damage caused by a buildup of fat in the liver. This can cause scarring of the liver and in advanced cases can lead to cirrhosis. Alcochol-related liver disease (ALD) represents a spectrum of liver injury </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">resulting from alcohol use, ranging from hepatic steatosis to more advances forms including alcoholic hepatitis (AH), alcohol-associated cirrhosis (AC), and acute AH presenting as acute-on-chronic liver failure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">GSK-4532990 (formerly ARO-HSD) is designed to reduce production of HSD17B13, a hydroxysteroid dehydrogenase involved in the metabolism of hormones, fatty acids and bile acids. Published human genetic data indicate that a loss of function mutation in HSD17B13 provides strong protection against metabolic-dysfunction associated steatohepatitis (MASH) cirrhosis and alcoholic hepatitis and cirrhosis. GSK is conducting Phase 2b clinical trials in patients with MASH and alcohol-related liver disease (ALD).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">GSK-HBV Agreement - Chronic Hepatitis B Virus Infection</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">        On December 11, 2023, the Company entered into an Amended and Restated License Agreement with GSK (the &#8220;GSK-HBV Agreement&#8221;) pursuant to which GSK received a worldwide, exclusive license to develop and commercialize daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989), the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. daplusiran/tomligisiran had previously been licensed to Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;) in October 2018. GSK is currently in the process of initiating a Phase 2 study of daplusiran/tomligisiran followed by bepirovirsen in patients with chronic hepatitis B.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;). Under the Takeda License Agreement, Takeda and the Company co-develop the Company&#8217;s fazirsiran program (formerly TAK-999 and ARO-AAT), the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, fazirsiran, if approved, will be co-commercialized under a 50/50 profit sharing structure. Outside the United States, Takeda received an exclusive license to commercialize fazirsiran and will lead the global commercialization strategy, while the Company will be eligible to receive tiered royalties of 20% to 25% on net sales. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Fazirsiran - Alpha-1 Antitrypsin Deficiency (AATD)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">AATD is a genetic disorder associated with liver disease in children and adults, and pulmonary disease in adults. AAT is a circulating glycoprotein protease inhibitor that is primarily synthesized and secreted by liver hepatocytes. Its physiologic function is the inhibition of neutrophil protease to protect healthy lung tissues during inflammation and prevent tissue damage. The most common disease variant, the Z mutant, has a single amino acid substitution that results in improper folding of the protein. The mutant protein cannot be effectively secreted and accumulates in globules in the hepatocytes. This triggers continuous hepatocyte injury, leading to fibrosis, cirrhosis, and increased risk of hepatocellular carcinoma.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Individuals with the homozygous PiZZ genotype have severe deficiency of functional AAT leading to pulmonary disease and hepatocyte injury and liver disease. Lung disease in this patient population is frequently treated with AAT augmentation therapy. However, augmentation therapy does nothing to treat liver disease, and there is no specific therapy for hepatic manifestations. There is a significant unmet need as liver transplant, with its attendant morbidity and mortality, is currently the only available treatment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fazirsiran is a subcutaneously administered RNAi therapeutic being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency (AATD), which is a rare genetic disorder that severely damages the liver and lungs of affected individuals. Fazirsiran is designed to reduce production of the mutant Z-AAT protein by silencing the AAT gene in order to prevent accumulation of Z-AAT in the liver, allow clearance of the accumulated Z-AAT protein, prevent repeated cycles of cellular damage, and possibly prevent or even reverse the progression of liver fibrosis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The goal of fazirsiran treatment is prevention and potential reversal of Z-AAT accumulation-related liver injury and fibrosis. Reduction of inflammatory Z-AAT protein, which has been clearly defined as the cause of progressive liver disease in AATD patients, is important as it is expected to halt the progression of liver disease and allow fibrotic tissue repair.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Takeda is conducting multiple Phase 3 studies for the treatment of AATD liver disease including the REDWOOD study.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amgen Inc. (&#8220;Amgen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen received a worldwide, exclusive license to the Company&#8217;s novel RNAi olpasiran (previously referred to as AMG </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the Olpasiran Agreement, Amgen is wholly responsible for clinical development and commercialization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;) and the Company entered into a Royalty Purchase Agreement (the &#8220;Royalty Pharma Agreement&#8221;). In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional $485.0&#160;million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Olpasiran - Atherosclerotic Cardiovascular Disease (ASCVD)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Olpasiran is designed to reduce production of apolipoprotein A, a key component of lipoprotein(a), which has been genetically linked with increased risk of cardiovascular diseases, independent of cholesterol and LDL levels. Amgen completed a Phase 2 clinical study evaluating the efficacy, safety, and tolerability of olpasiran in subjects with elevated levels of lipoprotein(a). Amgen reported Phase 2 clinical results at the American Heart Association (AHA) Scientific Sessions in November 2022 and simultaneously published in the New England Journal of Medicine. Amgen began evaluating olpasiran in a Phase 3 study (OCEAN) to assess the impact of olpasiran on major cardiovascular events in participants with atherosclerotic cardiovascular disease and elevated lipoprotein(a), in a double-blind, randomized, placebo-controlled, multi center study in December 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sarepta Therapeutics, Inc. (&#8220;Sarepta&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 25, 2024, Sarepta and Company entered into a global licensing and collaboration agreement. The Sarepta Agreement covers multiple clinical and preclinical programs in rare, genetic diseases of the muscle, central nervous system (CNS), and the lungs, as well as allows Sarepta to select up to six new targets for Company to conduct discovery and preclinical development activities in areas complementary to Sarepta&#8217;s leadership in precision genetic medicine for rare diseases, which can utilize Arrowhead&#8217;s proprietary and differentiated TRiM platform. Clinical stage programs under the license and collaboration agreement include SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1002 (ARO-MMP7), and SRP-1004 (ARO-ATXN2). Preclinical stage programs under the Sarepta Agreement include ARO-HTT for patients with Huntington&#8217;s disease, ARO-ATXN1 for patients with spinocerebellar ataxia 1 (SCA1), and ARO-ATXN3 for patients with spinocerebellar ataxia 3 (SCA3). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">SRP-1001 (ARO-DUX4) - Facioscapulohumeral Muscular Dystrophy (FSHD)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant disease associated with the failure to maintain complete epigenetic suppression of DUX4 expression in differentiated skeletal muscle, leading to overexpression of DUX4, which is myotoxic and can lead to muscle degeneration. As DUX4 expression is recognized as the cause of muscle pathology in FSHD patients, the Company believes that the selective targeting and knockdown of DUX4 using RNAi may prevent or reverse downstream myotoxicity and lead to muscle repair and improvement in muscle function in patients. There are currently no effective treatments specifically for FSHD.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ARO-DUX4 is designed to target the gene that encodes human double homeobox 4 (DUX4) protein as a potential treatment for patients with facioscapulohumeral muscular dystrophy. The Company is currently investigating ARO-DUX4 in a Phase 1/2a clinical trial. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">SRP-1003 (ARO-DM1) - Type 1 Myotonic Dystrophy</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Type 1 myotonic dystrophy is an autosomal dominant, debilitating, chronic progressive multisystem disorder characterized by an expansion of a highly unstable CUGexp in the DMPK gene. Patients with DM1 have muscle weakness and wasting, myotonia, cataracts, and often have cardiac conduction abnormalities, and may become physically disabled and have a shortened life span.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ARO-DM1 is designed to reduce expression of the dystrophia myotonica protein kinase (DMPK) gene. There is currently no approved disease-modifying therapy for type 1 myotonic dystrophy (DM1). Treatments have focused on symptomatic management, including physical therapy, exercise, ankle-foot orthoses, wheelchairs, and other assistive devices. The Company is currently investigating ARO-DM1 in a Phase 1/2a clinical trial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">SRP-1002 (ARO-MMP7) - Idiopathic Pulmonary Fibrosis (IPF)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Idiopathic Pulmonary Fibrosis (IPF) is a chronic interstitial lung disease characterized by progressive fibrosis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ARO-MMP7 is designed to reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for IPF. The Company is currently investigating ARO-MMP7 in a Phase 1/2a clinical trial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">SRP-1004 (ARO-ATXN2) - Spinocerebellar Ataxia 2 (SCA2)</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> SCA2 is a progressive cerebellar ataxia with instability of stance, speech and swallow disorder, pain, spasticity, and ocular signs, caused by gain of function of mutant expanded polyQ ATXN2 protein. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ARO-ATXN2 is designed to reduce the expression of the ATXN2 gene as a potential treatment for spinocerebellar ataxia 2 (SCA2). The Company is currently investigating ARO-ATXN2 in a Phase 1 clinical trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novartis Pharma AG (&#8220;Novartis&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2025, Novartis and the Company entered into a global licensing and collaboration agreement. The agreement covers ARO-SNCA, Arrowhead&#8217;s preclinical stage siRNA therapy against alpha-synuclein for the treatment of synucleinopathies, such as Parkinson&#8217;s Disease, and other additional collaboration targets that will utilize Arrowhead&#8217;s proprietary TRiM platform. The transaction closed in October 2025.</span></div><div><span><br/></span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Intellectual Property and Other Key Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company controls approximately 643 issued patents (including 404 directed to RNAi trigger molecules and 159 directed to targeting groups or targeting compounds), including European validations, and approximately 833 currently pending patent applications worldwide from 103 different patent families. The Company&#8217;s patent applications have been filed throughout the world, including, in the United States, Argentina, ARIPO (Africa Regional Intellectual Property Organization), Australia, Brazil, Canada, Chile, China, Eurasian Patent Organization, Europe, GCC (Gulf Cooperation Council), Hong Kong, Israel, India, Indonesia, Iraq, Jordan, Japan, Lebanon, Mexico, New Zealand, OAPI (African Intellectual Property Organization), Peru, Philippines, Russian Federation, South Africa, Saudi Arabia, Singapore, South Korea, Thailand, Taiwan, Uruguay, Venezuela, and Vietnam.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RNAi Triggers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The Company owns issued patents or has filed patent applications directed to RNAi trigger molecules, which serve as the foundation of the Company&#8217;s TRiM platform, and are targeted to reduce expression of various gene targets. However, the Company cannot guarantee that issued patents will be enforceable or provide adequate protection for the Company, or that pending patent applications will result in issued patents. These patents and patent applications that relate to partnered and non-partnered products in the Company's clinical pipeline include the following: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Patent Group</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Year(s) of Expiration*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">AAT</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2035, 2038</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:30pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">ALK7</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:30pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2044</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">ANGPTL3</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">APOC3</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:30pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:30pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">APOC3/PCSK9 Dimer</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:30pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2045</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">ATXN2</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2044</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">C3</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2043</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">CFB</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2044</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">DM1</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2043</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">DUX4</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">HBV </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2032, 2036, 2037</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">HSD17B13</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:30pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2039, 2043</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:30pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">INHBE</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:30pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2044</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">LPA</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">MMP7</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">PNPLA3</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">RAGE (AGER)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*Assuming issuance of any pending patent applications, and excluding any patent term adjustments or patent term extensions.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delivery Technologies</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The delivery technology-related patents and patent applications, which include components used in the Company&#8217;s TRiM platform, have been filed and/or issued in various jurisdictions worldwide including the United States, Argentina, Australia, Brazil, Canada, China, Eurasian Patent Organization, Europe (including validations in France, Germany, Italy, Spain, Switzerland, United Kingdom), GCC (Gulf Cooperation Council), </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Israel, India, Japan, Lebanon, Mexico, New Zealand, Philippines, Russia, South Africa, South Korea, Singapore, Taiwan, and Uruguay. However, the Company cannot guarantee that issued patents will be enforceable or provide adequate protection for the Company, or that pending patent applications will result in issued patents. These various groups of patents and applications that relate to partnered and non-partnered products in the Company's clinical pipeline are set forth below: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Patent Group</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Year(s) of Expiration*</span></td></tr><tr><td colspan="3" style="background-color:#eeece1;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Targeting ligands and other RNAi delivery and platform technologies</span></td><td colspan="3" style="background-color:#eeece1;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">CNS Intrathecal Delivery Platform</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2043</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adipose Delivery Platform</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2044</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">BBB Shuttle Delivery Platform</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:30pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2045</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Muscle delivery platform</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:30pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">PK/PD lipid modifiers</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">RNAi agent design (5&#8242;-phosphate mimic)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Targeting groups (&#945;v&#946;6 integrin ligands)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2037, 2038, 2041</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Targeting groups (N-acetylgalactosamine ligands)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:30pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Trialkyne linkers</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*Assuming issuance of any pending patent applications, and excluding any patent term adjustments or patent term extensions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The RNAi and drug delivery patent landscapes are complex and rapidly evolving. As such, the Company may need to obtain additional patent licenses prior to commercialization of its candidates. Please see &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition of Assets from Novartis</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2015, Novartis and the Company entered into an Asset Purchase and Exclusive License Agreement (the &#8220;RNAi Purchase Agreement&#8221;) pursuant to which the Company acquired Novartis&#8217;s RNAi assets and rights thereunder. Pursuant to the RNAi Purchase Agreement, the Company acquired or was granted a license to certain patents and patent applications owned or controlled by Novartis related to RNAi therapeutics, was assigned Novartis&#8217;s rights under a license from Alnylam Pharmaceuticals, Inc. (&#8220;Alnylam&#8221;) (the &#8220;Alnylam-Novartis License&#8221;) and acquired a license to certain additional Novartis assets (the &#8220;Licensed Novartis Assets&#8221;). The patents acquired from Novartis include multiple patent families covering delivery technologies and RNAi-trigger design rules and modifications. The Licensed Novartis Assets include an exclusive, worldwide right and license, solely in the RNAi field, with the right to grant sublicenses through multiple tiers under or with respect to certain patent rights and know how relating to delivery technologies and RNAi-trigger design rules and modifications. Under the assigned Alnylam-Novartis License, the Company acquired a worldwide, royalty-bearing, exclusive license with limited sublicensing rights to existing and future Alnylam intellectual property (including intellectual property that came under Alnylam&#8217;s control on or before March 31, 2016), excluding intellectual property concerning delivery technology, to research, develop and commercialize 30 undisclosed gene targets. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Exclusively Licensed Patent Rights from Roche</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2011, the Company acquired the RNAi therapeutics business of Hoffmann-La Roche, Inc. and F. Hoffmann-La Roche Ltd. (collectively, &#8220;Roche&#8221;). The acquisition provided the Company with two primary sources of value:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Broad freedom to operate with respect to key patents directed to the primary RNAi-trigger formats: canonical, unlocked nucleotide analogs (&#8220;UNA&#8221;), meroduplex, and dicer substrate structures; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">A large team of scientists experienced in RNAi and oligonucleotide delivery. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this acquisition, Roche assigned to the Company its entire rights under certain licenses including: the License and Collaboration Agreement between Roche and Alnylam dated July 8, 2007; the Non-Exclusive Patent License Agreement between Roche and MDRNA, Inc. dated February 12, 2009 (&#8220;MDRNA License&#8221;); and the Non-Exclusive License Agreement between Roche and City of Hope dated September 19, 2011 (collectively the &#8220;RNAi Licenses&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The RNAi Licenses included licenses to patents related to modifications of double-stranded oligonucleotides, including modifications to the base, sugar, or internucleoside linkage, nucleotide mimetics, and end modifications, which do not abolish the RNAi activity of the double-stranded oligonucleotides. Also included are patents relating to modified </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">double-stranded oligonucleotides, such as meroduplexes described in U.S. Patent No. 9,074,205 assigned to Marina Biotech (f/k/a MDRNA, Inc.), as well as U.S. Patent Nos. 8,314,227, 9,051,570, and 9,303,260 related to UNA. The UNA patents were assigned by Marina Biotech to Arcturus Therapeutics, Inc., but remain part of the MDRNA License.  </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Government Regulation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state, and local levels, and in other countries and jurisdictions, including the European Union (&#8220;EU&#8221;), extensively regulate, among other things, the research, development, testing, product approval, manufacture, quality control, manufacturing changes, packaging, storage, recordkeeping, labeling, promotion, advertising, sales, distribution, marketing, and import and export of drugs and biologic products. All of the Company&#8217;s current product candidates are expected to be regulated as drugs. The processes for obtaining regulatory approval in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory authorities both pre- and post-commercialization, are a significant factor in the production and marketing of the Company&#8217;s products and its R&amp;D activities and require the expenditure of substantial time and financial resources.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review and Approval of Drugs in the United States</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other government entities regulate drugs under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;),  and the regulations promulgated under those statutes, as well as other federal and state statutes and regulations. Failure to comply with applicable legal and regulatory requirements in the United States at any time during the product development process, approval process, or after approval, may subject us to a variety of administrative or judicial sanctions, such as a delay in approving or refusal by the FDA to approve pending applications, withdrawal of approvals, delay or suspension of clinical trials, issuance of warning letters and other types of regulatory letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil monetary penalties, refusals of or debarment from government contracts, exclusion from the federal healthcare programs, restitution, disgorgement of profits, civil or criminal investigations by the FDA, U.S. Department of Justice, State Attorneys General, and/or other agencies, False Claims Act suits and/or other litigation, and/or criminal prosecutions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">An applicant seeking approval to market and distribute a new drug in the United States must typically undertake the following: </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1) completion of preclinical laboratory tests, which may include animal and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> studies, and formulation studies in compliance with the FDA&#8217;s good laboratory practice (&#8220;GLP&#8221;) regulations; </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2) submission to the FDA of an Investigational New Drug application (&#8220;IND&#8221;) for human clinical testing, which must become effective without FDA objection before human clinical trials may begin; </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3) approval by an independent institutional review board (&#8220;IRB&#8221;), representing each clinical site before each clinical trial may be initiated; </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4) performance of adequate and well-controlled human clinical trials in accordance with the FDA&#8217;s current good clinical practice (&#8220;cGCP&#8221;) regulations, to establish the safety and effectiveness of the proposed drug product for each indication for which approval is sought; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5) preparation and submission to the FDA of an NDA;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(6) satisfactory review of the NDA by an FDA advisory committee, where appropriate or if applicable;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(7) satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the drug product, and the active pharmaceutical ingredient or ingredients thereof, are produced to assess compliance with current good manufacturing practice (&#8220;cGMP&#8221;) regulations and to assure that the facilities, methods, and controls are adequate to ensure the product&#8217;s identity, strength, quality, and purity; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(8) payment of user fees, as applicable, and securing FDA approval of the NDA; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(9) compliance with any post-approval requirements, such as any Risk Evaluation and Mitigation Strategies (&#8220;REMS&#8221;) or post-approval studies required by the FDA. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Preclinical Studies and an IND </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies can include </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and animal studies to assess the potential for adverse events and, in some cases, to establish a rationale for therapeutic use, which studies are subject to federal regulations and requirements, including GLP regulations. Other studies include laboratory evaluation of the purity, stability and physical form of the manufactured drug substance or active pharmaceutical ingredient and the physical properties, stability and reproducibility of the formulated drug or drug product. An IND sponsor must submit the results of the preclinical tests, together with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. Some preclinical testing, such as longer-term toxicity testing, animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. However, submission of an IND may not result in the FDA allowing clinical trials to commence, and clinical trials that have commenced may be paused,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">if the FDA has any concerns and places the trial on hold. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation in part or in full. Following issuance of a full or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed, which determination will be based on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Human Clinical Studies in Support of an NDA </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with cGCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. The plan for, and protocols and informed consent processes and documentation for, any clinical trial is also subject to certain requirements for approval, and periodic review and reapproval, by an IRB representing each institution participating in the clinical trial. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for public dissemination on its ClinicalTrials.gov website. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined: </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1: The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Phase 2: The product candidate is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3: The product candidate is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. An IRB also may suspend or terminate a clinical trial under certain circumstances.  The FDA will typically inspect one or more clinical sites in late-stage clinical trials to assure compliance with cGCP and the integrity of the clinical data submitted.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application for marketing approval or licensure, including that the study was conducted in accordance with cGCP, including review and approval by an independent ethics committee and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the study through an onsite inspection if the FDA deems such inspection necessary. The cGCP requirements encompass both ethical and data integrity standards for clinical studies.  </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Submission of an NDA to the FDA </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more indications. Under federal law, the submission of most NDAs is additionally subject to an application user fee, currently approximately $4.682 million for fiscal year 2026, for applications requiring clinical data, and the sponsor of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">an approved NDA is also subject to an annual program fee, currently approximately $0.442 million for fiscal year 2026. These fees are adjusted annually.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA conducts a preliminary review of an NDA within 60 days of its receipt and informs the sponsor by the 74th day after the FDA&#8217;s receipt of the submission to determine whether the application is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Most such applications are meant to be reviewed within ten months from the date of filing, and most applications for &#8220;priority review&#8221; products are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCP. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may require submission of a REMS plan to mitigate any identified or suspected serious risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">The FDA&#8217;s Decision on an NDA </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies be conducted to further assess the drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market and profitability of the product. After approval, the FDA may seek to prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. Some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. Orphan drug designation entitles the applicant to incentives such as grant funding towards clinical study costs, tax advantages, and waivers of FDA user fees. Orphan drug designation must be requested before submitting an NDA, and both the drug and the disease or condition must meet certain criteria specified in the Orphan Drug Act and FDA&#8217;s regulations. The granting of an orphan drug designation does not alter the standard regulatory requirements and process for obtaining marketing approval. Safety and effectiveness of a drug must be established through adequate and well-controlled studies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">FDA may not approve any other application to market the same drug for the same indication, except in very limited circumstances, for seven years. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s interpretation of the scope of orphan drug exclusivity may change. The FDA&#8217;s longstanding interpretation of the Orphan Drug Act is that exclusivity is specific to the orphan indication for which the drug was actually approved. As a result, the scope of exclusivity has been narrow and protected only against competition from the same &#8220;use or indication&#8221; rather than the broader &#8220;disease or condition.&#8221; Recent court decisions have created uncertainty in the application and interpretation of orphan drug exclusivity, which may limit the drugs that can receive orphan drug exclusivity. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Expedited Review and Accelerated Approval Programs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor may seek approval of its product candidate under programs designed to accelerate the FDA&#8217;s review and approval of NDAs. For example, Fast Track Designation may be granted to a drug intended for treatment of a serious or life-threatening disease or condition and data demonstrate its potential to address unmet medical needs for the disease or condition. The key benefits of Fast Track Designation are the eligibility for priority review, rolling review (submission of portions of an application before the complete marketing application is submitted), and accelerated approval, if relevant criteria are met.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may approve an NDA under the accelerated approval program if the drug treats a serious condition, provides a meaningful advantage over available therapies, and demonstrates an effect on either (1) a surrogate endpoint that is reasonably likely to predict clinical benefit, or (2) on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval, which the FDA may require to be underway prior to approval, are generally required to verify the drug&#8217;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. In addition, promotional materials is required for drugs granted accelerated approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Food and Drug Administration Safety and Innovation Act of 2012 (&#8220;FDASIA&#8221;) established the Breakthrough Therapy designation. A sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the drug is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If a drug is designated as breakthrough therapy, FDA will provide more intensive guidance on the drug development program and expedite its review. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Post-Approval Requirements </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events or problems with manufacturing processes of unanticipated severity or frequency, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fines, warning, untitled, or it has come to our attention letters, or holds on post-approval clinical trials; </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals; </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product seizure or detention, or refusal to permit the import or export of products; or </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">injunctions or the imposition of civil or criminal penalties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (&#8220;PDMA&#8221;), which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Abbreviated New Drug Applications for Generic Drugs </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 1984, with passage of the Drug Price Competition and Patent Term Restoration Act of 1984 (commonly referred to as the &#8220;Hatch-Waxman Amendments&#8221;) amending the FDCA, Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application (&#8220;ANDA&#8221;) to the agency. In support of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference listed drug (&#8220;RLD&#8221;). In order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, and the strength of the drug. However, an applicant may submit an ANDA suitability petition to request the FDA&#8217;s prior permission to submit an abbreviated application for a drug that differs from the RLD in route of administration, dosage form, or strength, or for a drug that has one different active ingredient in a fixed combination drug product (i.e., a drug product with multiple active ingredients).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At the same time, the FDA must also determine that the generic drug is &#8220;bioequivalent&#8221; to the innovator drug. Under the statute, a generic drug is bioequivalent to a RLD if the rate and extent of absorption of the generic drug do not show a significant difference from the rate and extent of absorption of the RLD. Upon approval of an ANDA, the FDA indicates that the generic product is &#8220;therapeutically equivalent&#8221; to the RLD and it assigns a therapeutic equivalence rating to the approved generic drug in its publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; also referred to as the &#8220;Orange Book.&#8221; Physicians and pharmacists consider the therapeutic equivalence rating to mean that a generic drug is fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, the FDA&#8217;s designation of a therapeutic equivalence rating often results in substitution of the generic drug without the knowledge or consent of either the prescribing physician or patient. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Hatch-Waxman Amendments, the FDA may not approve an ANDA until any applicable period of nonpatent exclusivity for the RLD has expired. The FDCA provides a period of five years of data exclusivity for NDAs containing a new chemical entity. In cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, in which case the applicant may submit its application four years following the original product approval. The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Hatch-Waxman Patent Certification and the 30 Month Stay </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or a method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the referenced product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A certification that the new product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicate that it is not seeking approval of a patented method of use, the ANDA application will not be approved until all the listed patents for the referenced product have expired. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months after the receipt of the Paragraph IV certification, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">505(b)(2) New Drug Applications</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As an alternative path to FDA approval for modifications to formulations or uses of products previously approved by the FDA pursuant to an NDA, an applicant may submit an NDA under Section 505(b)(2) of the FDCA. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by, or for, the applicant, and for which the applicant has not obtained a right of reference. If the 505(b)(2) applicant can establish that reliance on the FDA&#8217;s previous findings of safety and effectiveness is scientifically and legally appropriate, it may eliminate the need to conduct certain preclinical studies or clinical trials of the new product. The FDA may also require companies to perform additional bridging studies or measurements, including clinical trials, to support the change from the previously approved reference drug. The FDA may then approve the new drug candidate for all, or some, of the label indications for which the reference drug has been approved, as well as for any new indication sought by the 505(b)(2) applicant.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a Section 505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. As a result, approval of a 505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the referenced product has expired, and, in the case of a Paragraph IV certification and subsequent patent infringement suit, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section 505(b)(2) applicant. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pediatric Studies and Exclusivity </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act of 2003, an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. With the enactment of FDASIA, sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The applicant, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension under 35 U.S.C. &#167; 156, but it effectively extends the regulatory period during which the FDA cannot accept or approve another application. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Patent Term Restoration and Extension </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Amendments. Those Amendments permit a patent restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically one-half the time between the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">effective date of an IND and the submission date of a NDA, plus the time between the submission date of a NDA and ultimate approval. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question. The U.S. Patent and Trademark Office reviews and approves the application for any patent term extension or restoration in consultation with the FDA.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review and Approval of Drugs in the European Union</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and United Kingdom</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any pharmaceutical product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions governing, among other things, research and development, testing, manufacturing, quality control, safety, efficacy, labeling, clinical trials, marketing authorization, packaging, storage, record keeping, reporting, export and import, advertising, marketing and other promotional practices involving pharmaceutical products, as well as commercial sales, distribution, authorization, approval and post-approval monitoring and reporting of its products. Whether or not a company obtains FDA approval for a pharmaceutical product, the company would need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the pharmaceutical product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The United Kingdom (&#8220;UK&#8221;) formally left the EU on January 31, 2020 (&#8220;Brexit&#8221;) and EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Protocol on Ireland and Northern Ireland. The EU and the UK have agreed on a trade and cooperation agreement (&#8220;TCA&#8221;) which includes provisions affecting the life sciences sector (including on customs and tariffs). There are some specific provisions concerning pharmaceuticals, including the mutual recognition of Good Manufacturing Practice (&#8220;GMP&#8221;) and issued GMP documents. The TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The UK government has enacted the Medicines and Medical Devices Act 2021. The purpose of the act is to enable the existing regulatory frameworks in relation to human medicines and clinical trials of human medicines, among others, to be updated. The powers under the act may only be exercised in relation to specified matters and must safeguard public health.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Medicines and Medical Devices Act 2021 supplements the UK Medical Devices Regulations 2002 (&#8220;UK Regulations&#8221;), which are based on the EU Medical Devices Directive as amended to reflect the UK&#8217;s post-Brexit regulatory regime. Notably, the UK Regulations do not include any of the revisions that have been made by the EU Medical Devices Regulation (EU) 2017/745, which, since May 26, 2021, applies in all EU member states. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2025, new post-market surveillance requirements for medical devices entered into force under the Medical Devices (Post-market Surveillance Requirements (Amendment) (Great Britain) Regulations 2024. These requirements represent a significant tightening of post-market surveillance obligations, including the introduction of mandatory post-market surveillance plans and periodic safety update reports, reduced incident reporting deadlines, and new requirements to report and analyze incident trends.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In July 2025, the UK&#8217;s Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) published its responses to the consultation on </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Device Regulations: Routes to market and in vitro diagnostic devices</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> carried out in 2024. In its responses, the MHRA confirmed that it will be moving forward with a number of the proposed changes, and intends to table &#8216;Pre-Market Regulations&#8217; in Parliament later this year, with implementation aimed for 2026.  Among other things, MHRA will extend the sunset period for four key EU-derived regulations (covering IVDs, electronic instructions, animal tissue devices, and approved bodies)  beyond May 26, 2025 while new UK-specific laws are established.  MHRA also plans to rely on approvals from Australia, Canada, EU, and US, given their comparable regulatory systems, and will implement three routes to market. Also, manufacturers will be required to assign a Unique Device Identification (UDI) to devices before they are placed on the Great Britain market.  Once UDI is operational, the requirement for mandatory UKCA (UK Conformit Assessed) marking on devices or packaging will be removed.  Under the Medical Devices (Amendment) (Great Britain) Regulations 2023, CE (Conformit&#233; Europ&#233;ene, or European Conformity) marked European medical devices will continue to be accepted for sale in the UK until 2028 or 2030 (depending on the type of device).</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Drug and Biologic Development Process</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The conduct of clinical trials in the EU is governed by the EU Clinical Trials Regulation (EU) No. 536/2014 (&#8220;CTR&#8221;) which became applicable on January 31, 2022. The CTR replaced the Clinical Trials Directive 2001/20/EC, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Clinical Trials Directive) and introduced a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the new CTR, a sponsor is able to submit a single application for approval of a clinical trial through a centralized EU clinical trials portal, the Clinical Trials Information System (&#8220;CTIS&#8221;). One national regulatory authority (the reporting EU member state proposed by the applicant) takes the lead in validating and evaluating the application, and consults and coordinates with the other concerned EU member states. If an application is rejected, it may be amended and resubmitted through the CTIS. If an approval is issued, the sponsor may start the clinical trial in all concerned EU member states. However, a concerned EU member state may in limited circumstances declare an &#8220;opt-out&#8221; from an approval and prevent the clinical trial from being conducted in such EU member state. The CTR also aims to streamline and simplify the rules on safety reporting and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the CTIS. The CTR included a three-year transition period. Since January 31, 2023, submission of initial Clinical Trial Applications &#8220;CTA") via CTIS has been mandatory and CTIS serves as the single entry point for submission of clinical trial-related information and data. As of January 31, 2025, all ongoing trials approved under the former Clinical Trials Directive  need to comply with the CTR and have to be transitioned to CTIS.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under both the former regime and the new CTR, national laws, regulations, and the applicable GCP and Good Laboratory Practice standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines on GCP, and the ethical principles that have their origin in the Declaration of Helsinki.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the development of a medicinal product, the European Medicines Agency (&#8220;EMA&#8221;) and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) on the recommendation of the Scientific Advice Working Party (&#8220;SAWP&#8221;). A fee is incurred with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future Marketing Authorization Application (&#8220;MAA&#8221;) of the product concerned.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Marketing Authorization Procedures </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the EU and in Iceland, Norway and Liechtenstein (together the European Economic Area or &#8220;EEA&#8221;), after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining a Marketing Authorization (&#8220;MA&#8221;). To obtain an MA of a drug under EU regulatory systems, an applicant can submit a MAA through, amongst others, a centralized or decentralized procedure. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The centralized procedure provides for the grant of a single MA by the European Commission (&#8220;EC&#8221;) that is valid for all EU member states and, after respective national implementing decisions which must be rendered within 30 days, in the three additional member states of the EEA. The centralized procedure is compulsory for specific pharmaceutical products, including for medicines developed by means of certain biotechnological processes, products designated as orphan pharmaceutical products, advanced therapy pharmaceutical products and pharmaceutical products with a new active substance indicated for the treatment of certain diseases (AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune diseases and other immune dysfunctions and viral diseases). For pharmaceutical products containing a new active substance not yet authorized in the European Economic Area before May 20, 2004 and indicated for the treatment of other diseases, pharmaceutical products that constitute significant therapeutic, scientific or technical innovations or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level, an applicant may voluntarily submit an application for a marketing authorization through the centralized procedure. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the centralized procedure, the CHMP established at the EMA is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA&#8217;s CHMP is, in principle, 210 days from receipt of a valid MAA. However, this timeline excludes clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless the application is eligible for an accelerated assessment. Accelerated assessment might be granted by the CHMP in exceptional cases when a pharmaceutical product is expected to be of major public health interest, particularly from the point of therapeutic innovation. On request, the CHMP can reduce the time frame to 150 days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements. However, the EC has final authority for granting the MA within 67 days after receipt of the CHMP opinion.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The decentralized procedure permits companies to file identical MA applications for a pharmaceutical product to the competent authorities in various EU member states simultaneously if such pharmaceutical product has not received marketing approval in any EU member state before. This procedure is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority of a single EU member state, known as the reference EU member state, is appointed to review the application and provide an assessment report. Under this procedure, an applicant submits an application based on identical dossiers and related materials, including a draft summary of product characteristics, and draft labeling and package leaflet, to the reference EU member state and concerned EU member states. The reference EU member state prepares a draft assessment report and drafts of the related materials within 120 days after receipt of a valid application. Subsequently, each concerned EU member state must decide whether to approve the assessment report and related materials. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an EU member state cannot approve the assessment report and related materials on the grounds of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the EC, whose decision is binding for all EU member states. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All new MAAs must include a Risk Management Plan (&#8220;RMP&#8221;), describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available. New RMPs are required to be submitted (i) at the request of EMA or a national competent authority, or (ii) whenever the risk-management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit-risk profile or as a result of an important pharmacovigilance or risk-minimization milestone being reached. The regulatory authorities may also impose specific obligations as a condition of the MA. Since October 20, 2023, all RMPs for centrally authorized products are published by the EMA subject to only limited redactions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketing Authorizations have an initial duration of five years. After these five years, the authorization may subsequently be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal. Applications for renewal must be made to the EMA at least nine months before the five-year period expires.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Data and Market Exclusivity in the European Union</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As in the United States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received an MA) and prohibiting another applicant from relying on the MA holder&#8217;s pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the market. New Chemical Entities (&#8220;NCE&#8221;) approved in the EU qualify for eight years of data exclusivity and ten years of marketing exclusivity. The overall ten-year period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are deemed to bring a significant clinical benefit in comparison with existing therapies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The data exclusivity period begins on the date of the product&#8217;s first MA in the EU. After eight years, a generic product application may be submitted and generic companies may rely on the MA holder&#8217;s data. However, a generic product cannot launch until two years later (or a total of 10 years after the first MA in the EU of the innovator product), or three years later (or a total of 11 years after the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within the eight-year data exclusivity period. Additionally, another noncumulative one-year period of data exclusivity can be added to the eight years of data exclusivity where an application is made for a new indication for a well-established substance, provided that significant preclinical or clinical studies were carried out in relation to the new indication. Another year of data exclusivity may be added to the eight years, where a change of classification of a pharmaceutical product has been authorized on the basis of significant pre-trial tests or clinical trials (when examining an application by another applicant for or holder of market authorization for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for one year after the initial change was authorized).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to include an NCE. Even if a compound is considered to be an NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the pharmaceutical product if such company can complete a full MAA with their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its pharmaceutical product. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2023, the EC submitted a proposal for the reform of the European pharmaceutical legislation. After the European Parliament adopted an approving position on the reform on April 10, 2024, the Council of the European Union took a position and commented on the draft on June 4, 2025, clearing the way for the next legislative step, the trilogue proceedings. The first trilogue meeting took place on June 17, 2025, and negotiations are still ongoing. Finalization of these negotiations and / or entry into force are yet unclear; however, conclusion of the legislative process is not expected within the current Council Presidency, which ends on December 31, 2025.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The current drafts envisage:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">a shortening of the periods of data exclusivity from eight to six years (with transferrable vouchers for an additional year of market protection as an incentive for the development of new antibiotics), </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">earlier regulatory guidance and extension of market exclusivity for orphan medicines (depending on certain conditions), </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">four-year data exclusivity for additional indications of existing products, and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">rules governing the availability of products (including shortage prevention plans and some supply obligations for manufacturers).</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There is currently no final version of the draft package. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All details, in particular dates and timeframes within the package, are still subject to negotiations between the parties involved and vary between drafts. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Orphan Designation and Exclusivity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The criteria for designating an orphan medicinal product in the EU are similar in principle to those in the United States. The EMA&#8217;s Committee for Orphan Medicinal Products (&#8220;COMP&#8221;) evaluates applications for orphan drug designation within 90 days and will issue a recommendation if the medicinal product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the EU (prevalence criterion). In addition, Orphan Drug Designation can be granted if, for economic reasons, the medicinal product would be unlikely to be developed without incentives and if there is no other satisfactory method approved in the EU of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed medicinal product is a significant benefit to patients affected by the condition. Orphan drug designations are granted by the EC. An application for orphan drug designation (which is not a marketing authorization, as not all orphan-designated medicines reach the authorization application stage) must be submitted first before an application for marketing authorization of the medicinal product is submitted. The applicant will receive a fee reduction for the marketing authorization application if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted, and sponsors must submit an annual report to EMA summarizing the status of development of the medicine. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Designated orphan medicines are eligible for conditional marketing authorization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">COMP reassesses the orphan drug designation of a product in parallel with the review for a marketing authorization; for a product to benefit from market exclusivity it must maintain its orphan drug designation at the time of marketing authorization review by the EMA and approval by the EC. Additionally, any marketing authorization granted for an orphan medicinal product must only cover the therapeutic indication(s) that are covered by the orphan drug designation. Upon the grant of a marketing authorization, orphan drug designation provides up to ten years of market exclusivity in the orphan indication.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the 10-year period of market exclusivity, with a limited number of exceptions, the regulatory authorities of the EU member states and the EMA may not accept applications for marketing authorization, accept an application to extend an existing marketing authorization or grant marketing authorization for other similar medicinal products for the same therapeutic indication. A similar medicinal product is defined as a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan medicinal product can also obtain an additional two years of market exclusivity for an orphan-designated condition when the results of specific studies are reflected in the Summary of Product Characteristics (&#8220;SmPC&#8221;), addressing the pediatric population and completed in accordance with a fully compliant Pediatric Investigation Plan (&#8220;PIP&#8221;). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, i.e. the condition prevalence or financial returns criteria under Article 3 of Regulation (EC) No. 141/2000 on orphan medicinal products. When the period of orphan market exclusivity for an indication ends, the orphan drug designation for that indication expires as well. Orphan exclusivity runs in parallel </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">with normal rules on data exclusivity and market protection. Additionally, a marketing authorization may be granted to a similar medicinal product (orphan or not) for the same or overlapping indication subject to certain requirements.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pediatric Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, companies developing a new pharmaceutical product are obligated to study their product in children and must therefore submit a PIP together with a request for agreement to the EMA. The EMA issues a decision on the PIP based on an opinion of the EMA&#8217;s Pediatric Committee (&#8220;PDCO&#8221;). Companies must conduct pediatric clinical trials in accordance with the PIP approved by the EMA, unless a deferral (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> until enough information to demonstrate its effectiveness and safety in adults is available) or waiver (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> because the relevant disease or condition occurs only in adults) has been granted by the EMA. The MAA for the pharmaceutical product must include the results of all pediatric clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral has been granted, in which case the pediatric clinical trials may be completed at a later date. Pharmaceutical products that are granted a marketing authorization on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan pharmaceutical products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required when a marketing authorization holder wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized and covered by intellectual property rights.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Post-Approval Regulation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the United States, both MA holders and manufacturers of pharmaceutical products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory authorities of the EU member states. This oversight applies both before and after grant of manufacturing licenses and marketing authorizations. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of pharmaceutical products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Failure by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with EU laws and the related national laws of individual EU member states governing the conduct of clinical trials, manufacturing approval, MA of pharmaceutical products and marketing of such products, both before and after grant of MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The holder of an EU MA for a pharmaceutical product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of pharmaceutical products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed pharmaceutical products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a medicine&#8217;s safety, or to measure the effectiveness of risk-management measures, which may be time consuming and expensive and could impact our profitability. MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of Periodic Safety Update Reports (&#8220;PSURs&#8221;) in relation to pharmaceutical products for which they hold MAs. The EMA reviews PSURs for pharmaceutical products authorized through the centralized procedure. If the EMA has concerns that the risk-benefit profile of a product has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise that the MA holder be obliged to conduct post-authorization Phase 4 safety studies. If the EC agrees with the opinion, it can adopt a decision varying the existing MA. Failure by the MA holder to fulfill the obligations for which the European Commission&#8217;s decision provides can undermine the on-going validity of the MA.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">More generally, non-compliance with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the marketing authorization for the pharmaceutical product or imposition of financial penalties or other enforcement measures.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for pharmaceutical products in the EU is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice (&#8220;GMP&#8221;). These requirements include compliance with EU GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical ingredients into the EU. Amendments or replacements of Directive 2001/83/EC and Regulation (EC) No 726/2004 are part of the reform proposal for European pharmaceutical legislation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#231f20;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, the distribution of pharmaceutical products into and within the EU is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU member states. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for commercial distribution in the EU or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Advertising and Promotion</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The advertising and promotion of our products is also subject to EU laws concerning promotion of pharmaceutical products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU member states may apply to the advertising and promotion of pharmaceutical products and may differ from one country to another. These laws require that promotional materials and advertising in relation to pharmaceutical products comply with the product&#8217;s SmPC as approved by the competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the pharmaceutical product. It forms an intrinsic and integral part of the marketing authorization granted for the pharmaceutical product. Promotion of a pharmaceutical product that does not comply with the SmPC is considered to constitute off-label promotion. All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all off-label promotion of pharmaceutical products is prohibited in the EU. Direct-to-consumer advertising of prescription-only pharmaceutical products is prohibited in the EU. Violations of the rules governing the promotion of pharmaceutical products in the EU could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public and may also impose limitations on its promotional activities with healthcare professionals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pricing and Reimbursement Environment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Even if a pharmaceutical product obtains a marketing authorization in the EU, there can be no assurance that reimbursement for such product will be secured on a timely basis or at all. The EU member states are free to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement, and to control the prices and reimbursement levels of pharmaceutical products for human use. An EU member state may approve a specific price or level of reimbursement for the pharmaceutical product, or alternatively adopt a system of direct or indirect controls on the profitability of the company responsible for placing the pharmaceutical product on the market, including volume-based arrangements, caps and reference pricing mechanisms.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of our product candidates, if any, to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, pharmaceutical products launched in the EU do not follow price structures of the United States and generally published and actual prices tend to be significantly lower. Publication of discounts by third-party payers or authorities and public tenders may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The so-called health technology assessment (&#8220;HTA&#8221;) of pharmaceutical products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU member states, including France, Germany, Ireland, Italy and Sweden. The HTA process, which is governed by the national laws of these countries, is the procedure according to which the assessment of the public health impact, therapeutic impact, and the economic and societal impact of use of a given pharmaceutical product in the national healthcare systems of the individual country is conducted. HTA generally focuses on the clinical efficacy and effectiveness, safety, cost, and cost-effectiveness of individual pharmaceutical products as well as their potential implications for the healthcare system. Those elements of pharmaceutical products are compared with other treatment options available on the market. The outcome of HTA regarding specific </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">pharmaceutical products will often influence the pricing and reimbursement status granted to pharmaceutical products by the regulatory authorities of individual EU member states. A negative HTA of one of our products by a leading and recognized HTA body could not only undermine our ability to obtain reimbursement for such product in the EU member state in which such negative assessment was issued, but also in other EU member states. For example, EU member states that have not yet developed HTA mechanisms could rely to some extent on the HTA performed in other countries with a developed HTA framework, when adopting decisions concerning the pricing and reimbursement of a specific pharmaceutical product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2018, the European Commission adopted Regulation (EU) 2021/2282 on health technology assessment (&#8220;HTAR&#8221;). HTAR entered into force on January 11, 2022 and applies from January 12, 2025 onwards, followed by a further three-year transitional period during which EU member states must fully adapt to the new system. HTAR intends to boost EU level cooperation among EU member states in assessing health technologies, including new pharmaceutical products, and to provide the basis for cooperation at the EU level for joint clinical assessments in these areas. Under HTAR, EU member states will be able to use common HTA tools, methodologies and procedures across the EU, working together in four main areas: the joint clinical assessment of the innovative health technologies with the most potential impact for patients; joint scientific consultations whereby developers can seek advice from HTA authorities; identification of emerging health technologies to identify promising technologies early; and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement. While EU member states can choose to delay participation in the joint network until three years after the rules enter into force, it will become mandatory after six years. The European Commission has stated that the role of the HTA regulation is not to influence pricing and reimbursement decisions in the individual EU member states, but there can be no assurance that the HTA regulation will not have effects on pricing and reimbursement decisions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To obtain reimbursement or pricing approval in some countries, including the EU member states, we may be required to conduct studies that compare the cost-effectiveness of our product candidates to other therapies that are considered the local standard of care. There can be no assurance that any country will allow favorable pricing, reimbursement and market access conditions for any of our products, or that we will be feasible to conduct additional cost-effectiveness studies, if required.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In certain EU member states, pharmaceutical products designated as orphan pharmaceutical products may be exempted or waived from having to provide certain clinical, cost-effectiveness and other economic data in connection with their filings for pricing/reimbursement approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 27, 2025, the Council of the European Union approved a framework for compulsory licensing of crisis-relevant products (including medicinal products) in crisis situations. While the proposal focuses on voluntary agreements with intellectual property rights holders, it includes rules on compulsory licensing as a measure of last resort upon declaration of a crisis or emergency. The European Parliament is yet to vote on the proposal. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Data Privacy and Security Laws</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous U.S. federal, state, and local laws and regulations, as well as foreign legislation, in particular in the EU and UK, which regulate personal information, including how that information may be used, processed, and disclosed. These regulations also cover sensitive personal information, including medical and health information, and impose requirements on entities that handle such information to implement certain privacy and security measures.  We and/or our partners may be subject to these laws.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, at the federal level, the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH Act&#8221;), and the regulations promulgated thereunder, impose data privacy, security and data breach reporting obligations with respect to protected health information (&#8220;PHI&#8221;) on covered entities&#8212;which include health plans, healthcare clearinghouses and certain healthcare providers&#8212;and business associates&#8212;which include persons or entities that perform certain functions or activities that involve the use or disclosure of PHI on behalf of, or in connection with providing a service for, a covered entity.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are also a number of U.S. state privacy laws, such as the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;), as amended by the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;), that govern the privacy and security of personal information in certain circumstances. The CCPA/CPRA applies to personal data of consumers (which is defined to include business representatives and employees) who are California residents, imposes obligations on certain businesses that do business in California, including to provide specific disclosures in privacy notices, and affords rights to California residents in relation to their personal information. Health information falls under the CCPA/CPRA&#8217;s definition of personal information where it identifies, relates to, describes, is reasonably capable of being associated with or could reasonably be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">linked, directly or indirectly, with a particular consumer or household and is considered &#8220;sensitive personal information,&#8221; which is offered greater protection. However, the CCPA/CPRA, like other U.S. state privacy laws, does not apply to PHI, and most other U.S. state laws exempt covered entities and business associates altogether. Some of these laws and regulations impose different, and in certain instances, more stringent requirements than HIPAA. Failing to comply with these laws and regulations can result in significant civil and/or criminal penalties, as well as, in some cases, exposure to private litigation, all of which can result in financial and reputational risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The processing of personal data, including health-related personal data, in the EEA is mainly governed by the provisions of the European General Data Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;),  and by data protection related national laws, which supplement, interpret, and in some cases go beyond the GRDP. In the UK, the processing of personal data is mainly governed by the GDPR as incorporated into UK law pursuant to the European Union (Withdrawal) Act 2018 (the &#8220;UK GDPR&#8221;). Compliance with the GDPR and UK GDPR requirements has a number of significant practical consequences, including for international data transfers and enforcement of the GDPR by competent data protection authorities. The GDPR and UK GDPR imposed specific responsibility and liability in relation to personal data that we process, particularly when we act as a controller.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR and UK GDPR imposes a number of strict obligations and restrictions on the ability to process (processing means any operation or set of operations which is performed on personal data or on sets of personal data, whether or not by automated means, such as collection, storage, use and transfer of) personal data of individuals in the EEA, including health data from clinical trials and adverse event reporting. The GDPR and UK GDPR also includes requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals prior to processing their personal data (including health data), data breach notification obligations to the national data protection authorities and obligations relating to the security and confidentiality of the personal data. EEA countries may also impose additional requirements in relation to processing of health, genetic and biometric data through their national  legislation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with the requirements of the GDPR or UK GDPR and the related national data protection laws of the EEA countries may result in significant monetary fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8211; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">whichever is greater. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, violations of national laws can trigger additional</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> administrative penalties and investigations, corrective orders, temporary or definitive bans and, in some jurisdictions, a number of criminal offenses (punishable by capped or uncapped fines) for organizations and in certain cases their directors and officers as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EEA countries may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EEA. Guidance developed at both EEA level and at the national level in individual EEA countries concerning implementation and compliance practices are often updated or otherwise revised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There is, moreover, a growing trend towards required public disclosure of clinical trial data in the EU which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the EU Clinical Trials Regulation, EMA disclosure initiatives and voluntary commitments by industry. Failing to comply with these obligations could lead to government enforcement actions and significant penalties against us, harm to our reputation, and adversely impact our business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the Clinical Trials Regulation and the GDPR, further adds to the complexity that we face with regard to data protection regulation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR also imposes specific restrictions on the transfer of personal data to countries outside of the EEA that are not considered by the European Commission to provide an adequate level of data protection. Appropriate safeguards are required to enable such transfers to countries outside the EEA that are not considered to provide an adequate level of data protection. Among the appropriate safeguards that can be used, the data exporter may use the standard contractual clauses (&#8220;SCCs&#8221;). In this respect, on June 4, 2021, the EU Commission issued a new set of SCCs which replace the old sets of SCCs that were adopted under the previous European Data Protection Directive 95/46. In addition, when relying on SCCs, the data exporters are required to conduct a transfer risk assessment to verify if anything in the law and/or practices of the third country may impinge on the effectiveness of the SCCs in the context of the transfer at stake and, if so, to identify and adopt supplementary measures that are necessary to ensure compliance with the EU level of protection of personal data. Where no supplementary measure is suitable, the data exporter should avoid, suspend or terminate the transfer. On June 18, 2021, the European Data Protection Board adopted recommendations to assist data exporters with such assessment and their duty to identify and implement supplementary measures where they are needed to ensure compliance with the EU level of protection to the personal data they transfer to third countries. With regard to the transfer of data from the EEA to the US, on July 10, 2023, the European Commission adopted its adequacy decision for the EU-US Data Privacy Framework. On the basis of the new adequacy decision, personal data can flow from the EEA to US companies participating in the Data Privacy Framework. With regard to the transfer of data from the EEA to the UK, based on the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">European Commission&#8217;s adequacy decision of June 28, 2021, personal data may now  flow from the EU to the UK until June 27, 2025. In May 2025, the Commission adopted a decision to extend the validity of such adequacy decision for six more months, from June until December 2025. In July 2025, the Commission issued draft decisions on the extension of the validity of the UK adequacy decisions until December 2031 &#8211; if not adopted, as of December 2025, transfer of personal data from the EEA to the UK will be restricted and further measures will have to be implemented to comply with the GDPR.  With respect to transfers from the UK to other countries, these transfers are also subject to specific transfer rules under the UK regime. These UK international transfer rules broadly mirror the EU GDPR rules. On February 2, 2022, the UK Secretary of State laid before the UK Parliament the international data transfer agreement (IDTA) and the international data transfer addendum to the European Commission&#8217;s standard contractual clauses for international data transfers (Addendum) and a document setting out transitional provisions. The IDTA and Addendum came into force on March 21, 2022 and replaced the EU SCCs for the purposes of international transfers under the UK GDPR regime. With regard to the transfer of data from the UK to the US, the UK government has adopted an adequacy decision for the UK Extension to the EU-US Data Privacy Framework, the UK-US Data Bridge, which came into force on October 12, 2023. The UK-US Data Bridge recognizes the US as offering an adequate level of data protection where the transfer is to a US company listed on the EU-US Data Privacy Framework and participating in the UK Extension to the EU-US Data Privacy Framework.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Promotional Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU member states. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of pharmaceutical products is prohibited in the EU. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of the EU member states. Violation of these laws could result in substantial fines and imprisonment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payments made to physicians in certain EU member states must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#8217;s employer, their regulatory professional organization, and/or the competent authorities of the individual EU member states. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While the UK has left the EU, as mentioned above, it should be noted that the UK still has the strictest anti-bribery regime in Europe, the UK Bribery Act 2010. The Act is applicable English law and continues to apply to any company incorporated in or &#8220;carrying on business&#8221; in the UK, irrespective of where in the world the alleged bribery activity occurs. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Legislation Regarding Marketing, Authorization and Pricing of Pharmaceutical Products in the European Union</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Other core legislation relating to the marketing, authorization and pricing of pharmaceutical products in the EU exists as regulations and directives, while the implementing acts and guidelines based on these may vary in each EU member state. In addition, the respective national provisions of the member states, as well as self-committed codes of the pharmaceutical industry, must be observed. Such regulations and directives include the following: </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 2001/83/EC, establishing the requirements and procedures governing the marketing authorization for medicinal products for human use, as well as the rules for the constant supervision of products following authorization. This Directive has been amended several times, most recently by Directive 2012/26/EU regarding pharmacovigilance, and the Falsified Medicines Directive 2011/62/EU. </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Regulation (EC) 726/2004, as amended, establishing procedures for the authorization, supervision and pharmacovigilance of medicinal products for human and veterinary use and establishing the EMA.</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Regulation (EC) 469/2009, establishing the requirements necessary to obtain a Supplementary Protection Certificate, which extends the period of patent protection applicable to medicinal products at the EU-level. </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 89/105/EEC, ensuring the transparency of measures taken by the EU member states to set the prices and reimbursements of medicinal products. Specifically, while each member state has competence over the pricing and reimbursement of medicines for human use, they must also comply with this Directive, which establishes procedures to ensure that member state decisions and policies do not obstruct trade in medicinal products. The European Commission proposed to repeal and replace Directive 89/105/EEC, but this proposal was withdrawn in 2015. </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 2003/94/EC, laying down the principles of good manufacturing practice in respect of medicinal products and investigational medicinal products for human use (the &#8220;GMP Directive&#8221;); repealed by Directive </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2017/1572 on January 31, 2022; this directive also lays out standards and principles for manufacturing practices of medicinal products for human use and investigational medicinal products for human use.</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 2005/28/EC of April 8, 2005, laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorization of the manufacturing or importation of such products (the &#8220;GCP Directive&#8221;). </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directives 2004/9/EC and 2004/10/EC laying down principles of GLP including on the organizational process under which non-clinical health and safety studies are performed.</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 2010/84/EU and Regulation (EU) 1235/2010 on pharmacovigilance laying down procedures for the authorization and supervision of medicinal products for human and veterinary use. </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 2006/114/EC concerning misleading and comparative advertising. </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 2005/29/EC regulating unfair business-to-consumer commercial practices that occur before, during and after a business-to-consumer transaction.</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Regulation (EC) 1223/2009 on Cosmetic Products, setting mandatory requirements for cosmetics which are available on the market within the EU.</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Regulation (EC) 1901/2006 on Pediatric Use, laying down rules to ensure that medicines for use in children are researched, developed and authorized appropriately.</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive (2004/109/EC) on Transparency laying down rules to improves the harmonization of information duties of issuers, whose securities are listed at a regulated market at a stock exchange within the EU; amended by Directive (EU) 2022/2464 with effect from May 1, 2023 as regards corporate sustainability reporting.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pharmaceutical Coverage, Pricing and Reimbursement</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Sales of products will depend, in part, on the extent to which the costs of the products will be covered by third-party payers, including government health programs such as, in the United States, Medicare and Medicaid, commercial health insurers and managed care organizations. The process for determining whether a payer will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payer will pay for the product once coverage is approved. Third-party payers may limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. A payer&#8217;s decision to provide coverage for a drug product does not necessarily imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on our investment in product development. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. Third-party payers are increasingly challenging the prices charged for medical products and services and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. If these third-party payers do not consider a product to be cost effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, risk sharing, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. For example, in 2022, the U.S. government passed the Inflation Reduction Act </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;IRA&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which authorizes the U.S. Department of Health and Human Services to negotiate prices of certain drugs with participating manufacturers in federal healthcare programs. In 2025, an executive order issued by the White House directed the Department of Health and Human Services (HHS) to implement a &#8220;Most Favored Nation&#8221; drug pricing policy; the federal Centers for Medicare and Medicaid Services has announced a pilot program in this regard for the Medicaid program. Adoption of these and other controls and measures and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals. As a result, the marketability of any product which receives regulatory approval for commercial sale may suffer if the government and third-party payers fail to provide adequate coverage and reimbursement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, an increasing emphasis on managed care in the United States has increased and will continue to increase the pressure on drug pricing. Coverage policies, third-party reimbursement rates and drug pricing regulation may change at any time. In particular, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Affordability Reconciliation Act, contains provisions that may reduce the profitability of drug products, including, for example, increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Even if favorable coverage and reimbursement status is attained for one or more products that receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, pricing and reimbursement schemes vary widely between member states. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some member states may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies. For example, the EU provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU member states may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements for any of our products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Healthcare Laws and Regulations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payers play important roles in the recommendation and prescription of drug products that are granted marketing approval. Arrangements with healthcare providers, physicians, third-party payers and customers are subject to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which the Company markets, sells and distributes products for which it obtains marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing any remuneration (in cash or in kind), directly or indirectly, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any item, facility or service for which payment may be made in whole or in part under a federal healthcare program such as Medicare and Medicaid; </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Foreign Corrupt Practices Act prohibits, among other things, U.S. corporations and persons acting on their behalf from offering, promising, authorizing or making payments to any foreign government official (including certain healthcare professionals in many countries), political party, or political candidate in an attempt to obtain or retain business or otherwise seek preferential treatment abroad;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal False Claims Act, which may be enforced by the U.S. Department of Justice or private whistleblowers who bring civil actions (qui tam actions) on behalf of the federal government, imposes civil penalties, as well as liability for treble damages and for attorneys&#8217; fees and costs, on individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, making a false statement material to a false or fraudulent claim, or improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the U.S. Department of Health and Human Services&#8217; Civil Monetary Penalty authorities, which imposes administrative sanctions for, among other things, presenting or causing to be presented false claims for government payment and providing remuneration to government health program beneficiaries to influence them to order or receive healthcare items or services; </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">HIPAA imposes criminal and civil liability for, among other conduct, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters; </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">HIPAA, as amended by the HITECH Act and its implementing regulations, also imposes criminal and civil liability and penalties on those who violate requirements, including mandatory contractual terms, intended to safeguard the privacy, security, transmission and use of individually identifiable health information; </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal false statements statute relating to healthcare matters imposes criminal liability for knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Physician Payment Sunshine Act requires manufacturers of drugs (among other products) to report to the Centers for Medicare and Medicaid Services within the U.S. Department of Health and Human </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Services information related to payments and other transfers of value to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives and teaching hospitals, as well as physician ownership and investment interests in the reporting manufacturers; </span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">similar state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply (e.g., in the EU, where the implementation of EU-wide regulations as well as independent national legislation may vary for each EU member state) to sales or marketing arrangements and claims involving healthcare items or services reimbursed by nongovernmental third-party payers, including private insurers; and</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">certain state laws require pharmaceutical companies to comply with voluntary compliance guidelines promulgated by a pharmaceutical industry association and relevant compliance guidance issues by the U.S. Department of Health and Human Services Office of Inspector General; bar drug manufacturers from offering or providing certain types of payments or gifts to physicians and other health care providers; and/or require disclosure of gifts or payments to physicians and other healthcare providers. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Various state and foreign laws also govern the privacy and security of health information in some circumstances; many of these laws differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">E.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Facilities and Resources</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s principal executive offices are located in Pasadena, California. During the first quarter of fiscal 2025, the Company further expanded its footprint with a new manufacturing and laboratory facility to manufacture drug substance (API) under current Good Manufacturing Practices (GMP) in Verona, Wisconsin.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Facilities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates research laboratory facilities in San Diego, California and Madison, Wisconsin, where its pre-clinical research and development activities, including the discovery and early development of RNAi therapeutics, take place. A summary is provided below:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">State-of-the-art laboratories with supporting office space that comprise more than 251,000 total square feet;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Cell culture laboratories;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Animal efficacy models for numerous diseases, including cardio metabolic, viral, liver, skeletal muscle, ocular, central nervous system (CNS), metabolic, renal, obesity and lung diseases;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Animal safety screening and assessment;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Clinical pathology laboratories and in-house histopathology and pathology evaluation capabilities; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Integrated in-house expertise in clinical biomarker assay development and analytical evaluation;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Advanced Artificial Intelligence-leveraged data science capabilities dedicated to analyzing human genetics databases for target discovery and validation;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Drug metabolism and pharmacokinetics (DMPK), bioanalytical, biodistribution, and clearance assessment and methodology capabilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Primate colony housed at the Wisconsin National Primate Research Center, an affiliate of the University of Wisconsin, and at other contract research organizations (CROs).</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Pharmacodynamic method development and analysis and translational biomarker development capabilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Conventional and confocal microscopy, flow cytometry, Luminex platform, qRT-PCR and clinical chemistry analytics; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Oligonucleotide, peptide, antibody, and small molecule discovery, synthesis, production, and analytics capabilities (for example, HPLC, NMR, and LCMS).</span></div><div style="padding-left:18pt;text-indent:-9pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GMP Manufacturing and Related Development Laboratory Facility</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of fiscal 2025, the Company further expanded into a new, state-of-the-art GMP manufacturing facility in Verona, Wisconsin that includes related laboratories and office space to support chemistry, manufacturing, and controls (CMC) and quality activities. A summary is provided below:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">State-of-the-art, custom-designed GMP oligonucleotide manufacturing facility with related support laboratories for process development and analytical development, comprising approximately 300,000 total square feet;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Full certificate of occupancy for laboratory, office &amp; manufacturing spaces obtained August 2024; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Full analytical chemistry capabilities including method development and validation, transfer of methods, and support of in-process and final product analysis;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Drug product formulation development capabilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In-house capabilities to release GMP drug substance and finished drug product;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Multiple equipment scales for oligonucleotide manufacturing with maximum capacity to manufacture hundreds of kilograms of GMP drug substance annually; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Drug substance manufacturing capabilities to produce and release GMP material (API) and capabilities to release finished drug product pending ongoing commissioning, qualification, and validation (CQV) activities, allowing for the manufacture of GMP drug substance at the facility.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">F.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.4pt">Human Capital Management</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the Company employed 711 full-time employees based at four facilities in the United States, including Pasadena and San Diego, California, and Madison and Verona, Wisconsin.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2025, the Company continued to expand its workforce, focusing on increasing in-house manufacturing capacity, as well as enhancing expertise and throughput in clinical and preclinical research and development and commercialization preparation. The Company continually evaluates the business need and opportunity and balances in-house expertise and capacity with outsourced expertise and capacity. Currently, the Company outsources substantial clinical trial work to clinical research organizations and certain drug manufacturing to contract manufacturers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Drug development is a complex endeavor which requires deep expertise and experience across a broad array of disciplines. Pharmaceutical companies both large and small compete for a limited number of qualified applicants to fill specialized positions. To attract qualified applicants to the Company, it offers a total compensation package consisting of base salary and cash target bonus targeting the 50</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to 75</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> percentile of market, and offers a comprehensive benefit package and equity compensation to every employee. Bonus opportunity and equity compensation increase as a percentage of total compensation based on level of responsibility. Actual bonus payout is based on performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the Company&#8217;s employees have obtained advanced degrees in their professions. The Company supports its employees&#8217; further development with individualized development plans, mentoring, coaching, group training, conference attendance and financial support including tuition reimbursement. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inclusion  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dedicated to fostering a welcoming, healthy and equitable environment where all employees can thrive and contribute to its mission of delivering safe and effective medicine to patients in need. Ongoing efforts include programs and processes that promote awareness of inclusion and belonging, such as anti-bias training and employee engagement initiatives. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">G.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:7.73pt">Investor Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s website address is http://www.arrowheadpharma.com. The Company&#8217;s website address is not intended to function as a hyperlink and the information contained on its website is not, and should not be considered part of, and is not incorporated by reference into, this Annual Report on Form 10-K. The Company&#8217;s reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), including its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, Proxy Statements, and amendments to such periodic reports and Proxy Statements, are accessible through its website, free of charge, as soon as reasonably practicable after these reports are filed electronically with, or otherwise furnished to, the SEC. These SEC reports can be accessed through the &#8220;Investors&#8221; section of the Company&#8217;s website. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The SEC maintains an Internet website that contains reports, proxy and information statements, and other information regarding the Company and other issuers that file electronically with the SEC. The SEC&#8217;s Internet website address is </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http://www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.14pt">RISK FACTORS</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The Company&#8217;s business involves various risks and uncertainties in addition to the normal risks of business, some of which are discussed in this section. It should be noted that the Company&#8217;s business may be adversely affected by general economic conditions and other factors beyond the Company&#8217;s control. In addition, other risks and uncertainties not presently known or that the Company currently believes to be immaterial may also adversely affect the Company&#8217;s business. Some of the factors, events, and contingencies discussed below may have occurred in the past, but the disclosures below are not representations as to whether or not the factors, events, or contingencies have occurred in the past, and instead reflect our beliefs and opinions as to the factors, events or contingencies that could materially and adversely affect us in the future. Any such risks or uncertainties, or any of the following risks or uncertainties, that develop into actual events could result in a material and adverse effect on the Company&#8217;s business, financial condition, results of operations, or liquidity.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The information discussed below should be considered carefully with the other information contained in this Annual Report on Form 10-K and the other documents and materials filed by the Company with the SEC, as well as news releases and other information publicly disseminated by the Company from time to time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risk Factors Summary</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Discovery, Development, and Commercialization of Medicines</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our prospects substantially depend on the success of our clinical-stage product candidates. If we and our licensees are unable to obtain approval for and commercialize these product candidates, or successfully commercialize REDEMPLO, our business could be materially harmed.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There are substantial risks inherent in attempting to commercialize our new drugs, and, as a result, we may not be able to successfully develop additional products for commercial use.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates are in clinical development, which is a lengthy and expensive process with uncertain outcomes and the potential for substantial delays. There can be no assurance that our product candidates will obtain regulatory approval, which is necessary before they can be commercialized.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may not yield successful results for the product candidates that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may reveal significant adverse events, toxicities or other side effects and may result in a safety profile that could impede regulatory approval or market acceptance of any of our product candidates.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Results of earlier studies or clinical trials may not be predictive of future clinical trial results, and initial studies or clinical trials may not establish an adequate safety or efficacy profile for our product candidates to justify proceeding to advanced clinical trials or an application for regulatory approval.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability from REDEMPLO, or any other approved product candidate, and may have to limit its commercialization.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The successful commercialization of REDEMPLO, or any other product candidates, will depend in part on the extent to which government authorities and health insurers establish adequate reimbursement levels and pricing policies.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our commercialization, collaborative and other arrangements may give rise to disputes over commercial terms, contract interpretation, and ownership or protection of our intellectual property and may adversely affect the commercial success of our product candidates. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Regulatory Review and Approval of Our Candidates</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Fast Track or Breakthrough Therapy product designation may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our licensees conduct clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">if</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> we obtain FDA approval for products in the United States, we may never obtain approval to commercialize any product candidates outside of the United States, which would limit our ability to realize their full market potential.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">If the FDA or comparable foreign regulatory authorities approve generic versions of REDEMPLO, or any other potential products that receive marketing approval, or such authorities do not grant REDEMPLO appropriate periods of data or market exclusivity before approving a generic version, the sales of REDEMPLO could be adversely affected.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to comply with regulatory requirements or unanticipated problems with our products may result in various adverse actions such as the suspension or withdrawal of one or more of our products, closure of a facility or enforcement of substantial penalties or fines.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pharmaceutical and biological product marketing is subject to substantial regulation in the U.S. and any failure by us or our commercial and collaborative partners to comply with applicable statutes or regulations can adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are party to technology license agreements with third parties that require us to satisfy obligations to keep them effective and, if these agreements are terminated, our technology and our business could be seriously and adversely affected.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We may be and have been subject to patent infringement claims, which could result in substantial costs and liability and prevent us from commercializing our potential products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Business Model</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business model assumes we will generate revenue by, among other activities, marketing or out-licensing the products we develop. Our product candidates are in various stages of development and we have only one product based on RNAi  and our delivery technologies approved in November 2025. Accordingly, there is a limited amount of information about us upon which you can evaluate our business and prospects.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need to establish additional relationships with strategic and development partners to fully develop our product candidates and market any approved products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to generate milestone and royalty payments under our current and potential future licensing and collaboration agreements is substantially controlled by our partners, and as such, we will likely need other sources of financing to continue to develop our internal product candidates. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may lose a considerable amount of control over our intellectual property and may not receive anticipated revenues in </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">strategic</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> transactions, particularly where the consideration is contingent on the achievement of development or sales milestones.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need to achieve commercial acceptance of REDEMPLO and our other product candidates to generate revenues and achieve </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">profitability</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the market opportunities for REDEMPLO, or any other approved product candidates, are smaller than we expect, it could materially and adversely affect our financial condition and results of operations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited manufacturing capability and capacity and must rely on third-party manufacturers to manufacture certain of our clinical supplies and our commercial products, if and when approved, and if they fail to meet their obligations, the development and commercialization of our products could be adversely affected.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> third parties to conduct our clinical trials, and if they fail to fulfill their obligations, the development of our products may be adversely affected.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may have difficulty expanding our operations successfully as we evolve our pipeline and move toward </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">commercializing drugs.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because we use biological materials, hazardous materials, chemicals and radioactive compounds, if we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations, including our relationships with healthcare providers, physicians, and third-party payers are subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations, which, in the event of a violation, exposes us to liability for criminal sanctions, civil penalties, contractual damages, and reputational harm and diminished profits and future earnings.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The actions of distributors and specialty pharmacies could affect our ability to sell or market products profitably. Fluctuations in buying or distribution patterns by such distributors and specialty pharmacies could adversely affect our revenues, financial condition, or results of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Financial Condition</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require substantial additional funds to complete our research and development activities.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The terms of our Sixth Street Financing Agreement and our indebtedness could adversely affect our operations and limit our ability to plan for or respond to changes in our business. If we are unable to comply with restrictions in our Sixth Street Financing Agreement, the repayment of our existing indebtedness could be accelerated.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to utilize net operating loss carryforwards and other tax benefits may be limited. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Investment and Securities</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market for purchases and sales of our common stock may be limited, and the sale of a limited number of shares could cause the price to fall sharply.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our common stock price has fluctuated significantly over the last several years and may continue to do so in the future, without regard to our results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Economic and Industry Risks</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drug development is time consuming, expensive and risky.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Evolving regulatory standards make it difficult to accurately predict the likelihood of marketing approval even when clinical trials meet their endpoints.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Discovery, Development, and Commercialization of Medicines</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our prospects substantially depend on the success of our clinical-stage product candidates. If we and our licensees are unable to obtain approval for and commercialize these product candidates, or successfully commercialize REDEMPLO, our business could be materially harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is substantially dependent on the ability of the Company and our licensees to timely complete clinical trials and obtain marketing approval for, and then successfully commercialize our clinical-stage product candidates. We are not permitted to market or promote our product candidates before we receive marketing approval from the FDA and comparable foreign regulatory authorities, and we may never receive such marketing approvals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The success of developing and commercializing our product candidates will depend on several factors, including the following: </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining positive data that supports demonstration of efficacy, safety and tolerability profiles and durability of effect for our product candidates that are satisfactory to the FDA or any comparable foreign regulatory authority for marketing approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful inspections by FDA or any comparable foreign regulatory authority of our manufacturing facilities and clinical trial sites, including as part of the review process for marketing approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful and timely enrollment of appropriate patients for the indications included in our current and future clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential variability of patient outcomes;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the extent of any required post-marketing approval commitments, potentially including post-marketing clinical trials or other studies, to applicable regulatory authorities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the establishment of and maintenance of sufficient internal manufacturing capabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the maintenance of existing or the establishment of new supply arrangements with third-party drug product suppliers and manufacturers for clinical development and, if approved, commercialization of our product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the maintenance of existing or the establishment of new scaled production arrangements with third-party manufacturers to obtain finished products that are appropriately packaged for sale;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">protecting our rights in our intellectual property portfolio, including our licensed intellectual property;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing sales, marketing and distribution capabilities and the successful launch of commercial sales of our product candidates if and when approved for marketing, whether alone or in collaboration with others;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety profile following any marketing approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercial acceptance by patients, the medical community and third-party payers; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete with other therapies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any collaborator or licensee. For development programs that are licensed to third parties, we generally do not have control over the design or conduct of clinical trials and will not have discretion over marketing decisions. If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize any product candidates from our lead programs, which would materially harm our business. If we do not receive marketing approvals for such product candidates, we may not be able to continue our operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">are substantial risks inherent in attempting to commercialize our new drugs, and, as a result, we may not be able to successfully develop additional products for commercial use.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Scientific research and development requires significant amounts of capital and even approved drug candidates take a long time to reach commercial viability if it can be achieved at all.  During the research and development process, we may experience technological barriers that we may be unable to overcome. Because we use platform technology to develop drug candidates, toxicology signals that may emerge in the course of testing of one particular candidate may apply broadly across our drug candidate platform. Further, certain underlying premises in our development programs are not proven and many of the drug targets that we are pursuing have not yet been validated clinically. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For instance, ARO-RAGE has demonstrated the ability to reduce the expression of RAGE in the lung, however it has not been established that this will have an anti-inflammatory effect sufficient for a meaningful clinical benefit in patients with inflammatory lung disease. Further, it is also unknown at this time what may be required to gain adequate reimbursement by either commercial or government payers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> With respect to fazirsiran, it is also unknown at this time what changes in the liver may be required to gain regulatory approval and/or adequate reimbursement for a drug that reduces the production of mutant alpha-1 antitrypsin in the liver. Similar uncertainties and risks exist that are specific to each of our development programs.  If we are unable to successfully develop commercial products, we will be unable to generate revenue or build a sustainable or profitable business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are in clinical development, which is a lengthy and expensive process with uncertain outcomes and the potential for substantial delays. There can be no assurance that our product candidates will obtain regulatory approval, which is necessary before they can be commercialized.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The sale of human therapeutic products in the United States and foreign jurisdictions is subject to extensive and time-consuming regulatory approval which requires, among other things:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">controlled research and human clinical testing;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of the safety and efficacy of the product;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government review and approval of a submission containing manufacturing, preclinical and clinical data; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adherence to cGMP regulations during production and storage.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since 2011, we have focused substantially all of our efforts and financial resources on identifying, acquiring and developing our product candidates, including conducting lead optimization, nonclinical studies, preclinical studies and clinical trials, and providing general administrative support for these operations. And, the clinical-stage product candidates we currently have under development will require significant development, preclinical and clinical testing and investment of significant funds to gain regulatory approval before they can be approved for commercialization. The results of our research and human clinical testing of our products may not meet regulatory requirements. Some of our product candidates, if approved, may require the completion of post-market studies. There can be no assurance that any of our products will be further developed and approved. The process of completing clinical testing and obtaining required approvals will take several years and require the use of substantial resources.  Further, there can be no assurance that product candidates employing a new technology will be shown to be safe and effective in clinical trials or receive applicable regulatory approvals. If we fail to obtain regulatory approvals for any or all of our products, we will not be able to market such product and our operations may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may not yield successful results for the product candidates that</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> we may</span><span style="color:#ee2724;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">dentify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We must demonstrate our product candidates&#8217; safety and efficacy in humans for each target indication through extensive clinical testing. We may experience numerous unforeseen events during, or as a result of, the testing process that could delay or prevent commercialization of any products, including the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of preclinical studies may be inconclusive, or they may not be indicative of results that will be obtained in human clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety and efficacy results attained in early human clinical trials may not be indicative of results that are obtained in later clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">after reviewing test results, we may abandon projects that we might previously have believed to be promising;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our regulators may suspend or terminate clinical trials because the participating subjects or patients are being exposed to unacceptable health risks; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may not have the desired effects or may include undesirable side effects or other characteristics that preclude regulatory approval or limit their commercial use if approved.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that current clinical trials or any future clinical trials, whether conducted by us or our licensees, will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operation. Success in clinical trials in a particular indication does not ensure that a product candidate will be successful in other indications. Similarly, approval of a product candidate in a particular indication does not ensure that the product candidate will be successful in other indications. For instance, although REDEMPLO</span><span style="color:#008080;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s Phase 3 PALISADE trial for patients with FCS was successful in achieving its primary endpoint and all multiplicity-controlled key secondary endpoints, and we have filed for regulatory approval with global regulatory authorities, there can be no guarantee that global regulatory authorities that have not already approved REDEMPLO for the treatment of FCS will do so, and REDEMPLO may not succeed in achieving its clinical trial endpoints or be approved for the treatment of larger indications such as sHTG because the endpoints and clinical data required for approval in a rare disease indication are different from what is required for a broader patient population. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results of the trials are not satisfactory to the FDA or comparable foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for a product candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit its commercial potential.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may reveal significant adverse events, toxicities or other side effects and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In order to obtain marketing approval for any of our product candidates, we must demonstrate the safety and efficacy of the product candidate for the relevant clinical indication or indications through preclinical studies and clinical trials as well as additional supporting data. As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events (&#8220;AEs&#8221;) associated with the use of our products or product candidates. If our product candidates are associated with undesirable side effects in preclinical studies or clinical trials, or have unexpected characteristics, we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If further significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether. We, the FDA, the EMA, other applicable regulatory authorities or an institutional review board may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage studies have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the drug from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability relative to other therapies. Any of these developments could materially harm our business, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials of our product candidates may not uncover all possible adverse events that patients may experience.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are conducted in representative samples of the potential patient population, which may have significant variability. By design, clinical trials are based on a limited number of subjects and are of limited duration of exposure to the product, to determine whether the product candidate demonstrates the substantial evidence of efficacy and safety necessary to obtain regulatory approval. As with the results of any statistical sampling, we cannot be sure that all side effects of our product candidates may be uncovered. It may be the case that only with a significantly larger number of patients exposed to the product candidate for a longer duration may a more complete safety profile be identified. Further, even larger clinical trials may not identify rare significant AEs, and the duration of such studies may not be sufficient to identify when those events may occur. Other products have been approved by the regulatory authorities for which safety concerns have been uncovered following approval. Such safety concerns have led to labeling changes, restrictions on distribution through use of a REMS, or withdrawal of products from the market, and any of our product candidates may be subject to similar risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Although to date our current product candidates have generally evidenced an acceptable safety profile in clinical trials, patients treated with REDEMPLO or any of our product candidates, if approved, may experience previously unreported adverse reactions or minor incidences of adverse reactions may manifest with greater frequency in subsequent larger trials, and it is possible that the FDA or other regulatory authorities may ask for additional safety data as a condition of, or in connection with, our efforts to obtain approval of our product candidates. If toxicities, adverse events or any other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">safety problems occur or are identified after our products reach the market, we may make the decision or be required by regulatory authorities to conduct additional clinical safety trials, amend the labeling of our products or add additional warnings to the labeling, recall our products, or even withdraw approval for our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Topline data may not accurately reflect the complete results of a particular study or trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may publicly disclose topline or interim data from time to time, which is based on a preliminary analysis of then-available efficacy and safety data which are based on preliminary analysis of key efficacy and safety data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimations, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular drug candidate or drug and the Company in general. In addition, the information we may publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the topline data that we report differ from a future analysis of results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of earlier studies or clinical trials </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">may not be predictive of future clinical trial results, and initial studies or clinical trials may not establish an adequate safety or efficacy profile for our product candidates to justify proceeding to advanced clinical trials or an application for regulatory approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The results of nonclinical and preclinical studies and clinical trials may not be predictive of the results of later-stage clinical trials, and interim results of clinical trials do not necessarily predict final results. The results of preclinical studies and clinical trials in one set of patients or disease indications, or from preclinical studies or clinical trials that we did not lead, may not be predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. In addition, preclinical and clinical data are often susceptible to various interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through nonclinical studies and initial clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, or after achieving positive results in pivotal trials, and we cannot be certain that we will not face similar setbacks. Even if early-stage clinical trials are successful, we may need to conduct additional clinical trials of our product candidates in additional patient populations or under different treatment conditions before we are able to seek approvals from the FDA and regulatory authorities outside the United States to market and sell these product candidates. Our failure to obtain marketing approval for our product candidates for commercially viable indications, or at all, would substantially harm our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It may take us longer than we project to complete clinical trials, and we may not be able to complete them at all.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Although for planning purposes we project the commencement, continuation and completion of our clinical trials, a number of factors, including scheduling conflicts with participating clinicians and clinical institutions, and difficulties in identifying or enrolling patients who meet trial eligibility criteria, may cause significant delays. Enrollment of clinical trials may be particularly difficult in orphan diseases or limited-sized patient populations. The FDA or other regulatory bodies may require additional, longer or broader clinical trials to establish safety and effectiveness, notwithstanding guidance the Company may have received from those bodies during clinical trial planning and execution. Further, the cost for conducting clinical trials is significant and if our cash resources become limited we may not be able to commence, continue and/or complete our clinical trials. We may not commence or complete clinical trials involving any of our product candidates as projected or may not conduct them successfully.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability from REDEMPLO, or any other approved product candidate, and may have to limit its commercialization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The use of our product candidates in clinical trials and the sale of REDEMPLO, or any other products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by clinical trial participants, consumers, healthcare providers, pharmaceutical companies, or others selling our products. If we cannot successfully defend ourselves against these claims, we may incur substantial liabilities. Regardless of merit or eventual outcomes of such claims, product liability claims may result in:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of litigation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenues.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our insurance coverage may not be sufficient to reimburse us for all expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The successful commercialization of REDEMPLO, or any other approved product candidates, will depend in part on the extent to which government authorities and health insurers establish adequate reimbursement levels and pricing policies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sales of REDEMPLO, or any other approved drug candidate, will depend in part on the availability of coverage and reimbursement from third-party payers such as government insurance programs, including Medicare and Medicaid, private health insurers, health maintenance organizations and other health care related organizations, who are increasingly challenging the price of medical products and services. Accordingly, coverage and reimbursement may be uncertain. Adoption of any drug by the medical community may be limited if third-party payers will not offer adequate coverage. Additionally, significant uncertainty exists as to the reimbursement status of newly-approved drugs, including REDEMPLO. Cost control initiatives may decrease coverage and payment levels for any drug and, in turn, the price that we will be able to charge and/or the volume of our sales. We are unable to predict all changes to the coverage or reimbursement methodologies that will be applied by private or government payers. Any denial of private or government payer coverage or inadequate reimbursement could harm our business and reduce our revenue. With respect to our partnered product candidates, we will be reliant on that partner to obtain reimbursement from government and private payers for the drug, if approved, and any failure of that partner to establish adequate reimbursement could have a negative impact on our revenues and profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, both the federal and state governments in the United States and foreign governments continue to propose and pass new legislation, regulations, and policies affecting coverage and reimbursement rates, which are designed to contain or reduce the cost of health care. Further federal and state proposals and healthcare reforms are likely, which could limit the prices that can be charged for the product candidates that we develop and may further limit our commercial opportunity. For example, the IRA includes several measures intended to lower the cost of prescription drugs and related healthcare reforms, including limits on price increases and subjecting an escalating number of drugs to annual price negotiations with the Centers for Medicare &amp; Medicaid Services ("CMS"). In addition, an executive order issued by the White House on May 12, 2025, directs the Department of Health and Human Services (the &#8220;HHS&#8221;) to implement a &#8220;Most Favored Nation&#8221; drug pricing policy. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See also &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The healthcare system is under significant financial pressure to reduce costs, which could reduce payment and reimbursement rates for drugs.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> And the recently-enacted One Big Beautiful Bill Act (the &#8220;OBBBA&#8221;) imposes new restrictions on funding for government health care programs and on individual eligibility for coverage under those programs, which may lead to lower reimbursements for drugs covered by those programs. We cannot be sure whether additional legislation or rulemaking related to these developments will be issued or enacted, or what impact, if any, such changes will have on the profitability of any of our drug candidates, if approved for commercial use, in the future. There also may be future changes unrelated to these that result in reductions in potential coverage and reimbursement levels for our product candidates, if approved and commercialized, and we cannot predict the scope of any future changes or the impact that those changes would have on our operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If future reimbursement for approved product candidates, if any, is substantially less than we project, or rebate obligations associated with them are substantially greater than we expect, our future net revenue and profitability could be materially diminished.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not enjoy the market exclusivity benefits of our orphan drug designations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Although we may obtain orphan designations in the treatment of certain diseases our products are intended to treat, the designation may not be applicable to any particular product we might get approved and that product may not be the first product to receive approval for that indication. Under the Orphan Drug Act, the first approved product with an orphan designation receives market exclusivity, which prohibits the FDA from approving the &#8220;same&#8221; drug for the same indication. The FDA has stated that drugs can be the &#8220;same&#8221; even when they are not identical but has not provided guidance with respect to how it will determine &#8220;sameness&#8221; for RNAi drugs. It is possible that another RNAi drug could be approved for the treatment of a disease that one of our orphan products is intended to treat before our product is approved, which means that we may not obtain orphan drug exclusivity and could also potentially be blocked from approval until the first product&#8217;s orphan drug exclusivity period expires or we demonstrate, if we can, that our product is superior. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved and granted orphan drug exclusivity, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a designated Orphan Drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the disease for which it received orphan designation. Recent court decisions have created uncertainty in the application and interpretation of orphan drug exclusivity. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, orphan drug exclusivity can be lost if the FDA later determines that the request for designation was materially defective or if the applicant is unable to assure the availability of sufficient quantities of the drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan Drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on the attraction and retention of senior management and scientists with relevant expertise.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our future success depends to a significant extent on the continued services of our key employees, including our senior scientific, technical and managerial personnel. We do not maintain key person life insurance for any of our executives and we do not maintain employment agreements with many senior employees. Competition for qualified employees in the pharmaceutical industry is high, and our ability to execute our strategy will depend in part on our ability to continue to attract and retain qualified scientists, management and other employees. This will depend in part on our ability to create and maintain a desirable workplace culture, which may be impacted by employee preferences for remote working. In addition, the market for qualified employees in the pharmaceutical industry is experiencing labor shortages and inflationary pressures are causing salaries and wages to increase, all of which exacerbates these competitive dynamics. If we are unable to find, hire and retain qualified individuals, we will have difficulty implementing our business plan in a timely manner, or at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our commercialization, collaborative and other arrangements may give rise to disputes over commercial terms, contract interpretation and ownership or protection of our intellectual property and may adversely affect the commercial success of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past and may again in the future enter into collaboration or license arrangements, including commercialization or collaborative arrangements, some of which may be based on less definitive agreements, such as memoranda of understanding, material transfer agreements, options or feasibility agreements. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Commercialization and collaborative relationships are generally complex and can give rise to disputes regarding the relative rights, obligations and revenues of the parties, including the ownership of intellectual property and associated rights and obligations, especially when the applicable collaborative provisions have not been fully negotiated and documented. Such disputes have arisen in the past from time to time and, if they arise again could delay collaborative research, development or commercialization of potential product candidates, and can lead to lengthy, expensive litigation or arbitration. The terms of such arrangements may also limit or preclude us from commercializing products or technologies developed pursuant to such collaborations. Additionally, the commercialization or collaborative partners under these arrangements might breach the terms of their respective agreements or fail to maintain, protect or prevent infringement of the licensed patents or our other intellectual property rights by third parties. Moreover, negotiating commercialization and collaborative arrangements often takes considerably longer to conclude than the parties initially anticipate, which could cause us to enter into less favorable agreement terms that delay or defer recovery of our development costs and reduce the funding available to support key programs. Any failure by our commercialization or collaborative partners to abide by the terms of their respective agreements with us (including their failure to accurately calculate, report or pay any royalties payable to either us or a third party or their failure to repay, in full or in part, either any outstanding receivables or any other amounts for which we are entitled to reimbursement) may adversely affect our results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are not always able to enter into commercialization or collaborative arrangements on acceptable terms, which can harm our ability to develop and commercialize our current and potential future products and technologies. Other factors relating to collaborations that may adversely affect the commercial success of our product candidates include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any parallel development by a commercialization or collaborative partner of competitive technologies or products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">arrangements with commercialization or collaborative partners that limit or preclude us from developing products or technologies;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">premature termination of a commercialization or collaboration agreement or the inability to renegotiate existing agreements on favorable terms; or</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure by a commercialization or collaborative partner to devote sufficient resources to the development and commercial sales of products using our current and potential future products and technologies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our commercialization or collaborative arrangements do not necessarily restrict our commercialization or collaborative partners from competing with us or restrict their ability to market or sell competitive products. Our current and any future commercialization or collaborative partners may pursue existing or other development-stage products or alternative technologies in preference to those being commercialized or developed in collaboration with us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, contract disputes with customers or other third parties may arise from time to time. Our commercialization or collaborative partners, or customers or other third parties, may also terminate their relationships with us or otherwise decide not to proceed with the development, commercialization or purchase of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Regulatory Review and Approval of Our Product Candidates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Breakthrough Therapy designation for Fazirsiran (formerly ARO-AAT) and other of our current or future product candidates and other of our current or future product candidates</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">may not lead to a faster development or review process.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have been granted a Breakthrough Therapy designation for fazirsiran in the United States for the treatment of liver disease associated with AATD, and we may seek Breakthrough Therapy designation for other current or future product candidates. Breakthrough Therapy designation is intended to facilitate the development and expedite the review of new therapies to treat serious conditions with unmet medical needs by providing sponsors with the opportunity for frequent interactions and additional drug development guidance with the FDA and its senior managers. Breakthrough Therapy designation applies to the combination of the product candidate and the specific indication for which it is being studied. Product candidates that receive Breakthrough Therapy designation may receive more frequent interactions with the FDA regarding the product candidate&#8217;s development plan and clinical trials and may be eligible for the FDA&#8217;s Rolling Review.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Despite receiving Breakthrough Therapy designation,  fazirsiran or other product candidates may not actually benefit from faster clinical development or regulatory review or approval any sooner than other product candidates that do not have such designation, or at all. For example, although we received Breakthrough Therapy designation for REDEMPLO in the United States for the treatment of FCS, REDEMPLO was ultimately reviewed on a standard timeline. Furthermore, such a designation does not increase the likelihood that fazirsiran or other product candidates will receive marketing approval in the United States. The FDA may also rescind Breakthrough Therapy designation if it determines that fazirsiran</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> or other product candidates no longer meets the relevant criteria.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A Fast Track product designation may not lead to faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have received a Fast Track product designation for fazirsiran in the United States for the treatment of liver disease associated with AATD, and we may seek Fast Track designation for other of our current or future product candidates. The Fast Track designation is a program offered by the FDA designed to facilitate drug development and to expedite the review of new drugs that are intended to treat serious or life-threatening conditions. Compounds selected must demonstrate the potential to address unmet medical needs. The FDA&#8217;s Fast Track designation allows for close and frequent interaction with the FDA. A designated Fast Track drug may also be considered for priority review with a shortened review time, rolling submission, and accelerated approval if applicable. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A Fast Track designation does not, however, guarantee FDA approval or expedited approval of any application for the product candidate. The receipt of such a designation for a product candidate may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate marketing approval by the FDA. For example, although we received Fast Track designation for REDEMPLO in the United States for the treatment of FCS, REDEMPLO was ultimately reviewed on a standard timeline. In addition, the FDA may later decide that the products no longer meet the designation conditions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek priority review designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such designation may not lead to faster development or regulatory review or approval process.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months from the filing date, rather than the standard review period of ten months. We may request priority review for our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily mean a faster development or regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We intend to deliver some of our product candidates via drug delivery devices that will have their own regulatory, development, supply and other risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We intend to deliver some of our product candidates via drug delivery devices, such as an autoinjector or nebulizer. There may be unforeseen technical complications related to the development activities required to bring such a product to market, including container compatibility and/or dose volume requirements. If our product candidates are intended to be used with drug delivery devices, we expect to utilize drug delivery devices authorized for marketing under clearances of approvals held by third parties. Our product candidates may not be approved or may be substantially delayed in receiving approval if the devices do not gain and/or maintain their own regulatory approvals or clearances. Where approval of the drug product and device is sought under a single application, the increased complexity of the review process may delay approval. In addition, some drug delivery devices are provided by single-source unaffiliated third-party companies. We may be dependent on the sustained cooperation and effort of those third-party companies both to supply the devices and, in some cases, to conduct the studies required for approval or other regulatory clearance of the devices. Even if approval is obtained for our products, we may also be dependent on those third-party companies continuing to maintain such approvals or clearances, if required, for their drug delivery devices once they have been received. Failure of third-party companies to supply the devices, to successfully complete studies on the devices in a timely manner, or to obtain or maintain required approvals or clearances of the devices could result in increased development costs, delays in or failure to obtain regulatory approval and delays in product candidates reaching the market or in gaining approval or clearance for expanded labels for new indications.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our licensees con</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">duct clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We and our licensees currently conduct clinical trials outside the United States. The acceptance by the FDA or comparable foreign regulatory authority of study data from clinical trials conducted outside the United States or another jurisdiction may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such as inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. Most of our clinical trials involve study subjects outside of the United States</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, including most of our Phase 1 clinical trials (which often enroll study subjects in Australia and New Zealand), and our Phase 3 clinical trials of plozasiran and zodasiran, for which we have enrolled and plan to enroll  cohorts outside the United States. If</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in product candidates that we may develop not receiving approval or clearance for commercialization in the applicable jurisdiction. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain FDA approval for products in the United States, we may never obtain approval to commercialize any product candidates outside of the United States, which would limit our ability to realize their full market potential. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and effectiveness, and the chemistry, manufacturing and controls for the product. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval processes and requirements vary among countries and can involve additional product testing and validation and additional or different administrative review periods from those in the United States, including additional preclinical studies or clinical trials. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval before a product can be marketed in that jurisdiction, even after establishing safety and efficacy in a clinical setting.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Seeking foreign regulatory approval could result in difficulties and costs and require additional nonclinical studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates in those countries. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We do not have any product candidates approved for sale in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approval in international markets is delayed, our target market will be reduced and our ability to realize the full market potential of our products will be harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the FDA or comparable foreign regulatory authorities approve generic versions of REDEMPLO, or any other potential products that receive marketing approval, or such authorities do not grant REDEMPLO appropriate periods of data or market exclusivity before approving a generic version, the sales of REDEMPLO could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Once an NDA is approved, the drug covered thereby becomes a &#8220;reference-listed drug&#8221; in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations.&#8221; Manufacturers may seek marketing approval of generic versions of reference-listed drugs through submission of ANDAs in the United States. Generic drugs may be significantly less costly to bring to market than the reference-listed drug and companies that produce generic drugs are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference-listed drug is typically lost to the generic drug.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may not approve an ANDA or a 505(b)(2) NDA for a generic drug until any applicable period of non-patent exclusivity for the reference-listed drug has expired. The FDCA provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity. During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2) NDA submitted by another company for another version of such product candidate where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an approved NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages or strengths of an existing product candidate. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for product candidates containing the original active agent for other conditions of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Manufacturers may seek to launch generic drugs following the expiration of the marketing exclusivity period, even if we still have patent protection for such drugs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Competition that REDEMPLO, or any other potential product candidates, may face from generic drugs could materially and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in those products. Our future revenues, profitability and cash flows could also be materially and adversely affected and our ability to obtain a return on the investments we have made in REDEMPLO or other product candidates may be substantially limited if REDEMPLO, or any other potential products, product candidates, are not afforded the appropriate periods of non-patent exclusivity.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to comply with regulatory requirements or unanticipated problems with our products may result in various adverse actions such as the suspension or withdrawal of one or more of our products, closure of a facility or enforcement of substantial penalties or fines.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory agencies subject any marketed product(s), such as REDEMPLO, and the facilities where they are manufactured to continual review and periodic inspection. If previously unknown problems with a product, manufacturing and laboratory facilities or regulatory requirements are discovered, such as AEs of unanticipated severity or frequency, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">problems with a manufacturing process or laboratory facility, or failure to comply with applicable regulatory approval requirements, a regulatory agency may impose restrictions or penalties on that product or on us. Such restrictions or penalties may include, among other things:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, the withdrawal of the product from the market or product recalls;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning, untitled, or it has come to our attention letters, or holds on clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of our product candidates; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">closure of the facility, enforcement of substantial fines, injunctions, or the imposition of civil or criminal penalties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical and biological product marketing is subject to substantial regulation in the U.S. and any failure by us or our commercial and collaborative partners to comply with applicable statutes or regulations can adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any marketing activities associated with REDEMPLO, or any other product candidates approved for commercialization</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, will be subject to numerous federal and state laws governing the marketing and promotion of pharmaceutical and biological products. The FDA regulates post-approval promotional labeling and advertising to ensure that they conform to statutory and regulatory requirements. In addition to FDA restrictions, the marketing of prescription drugs is subject to laws and regulations prohibiting fraud and abuse under government healthcare programs. Similarly, many states have similar statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, and, in some states, such statutes or regulations apply regardless of the payer. In addition, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">government authorities may also seek to hold us responsible for any failure of our commercialization or collaborative partners to comply with applicable statutes or regulations. If we, or our commercial or collaborative partners, fail to comply with applicable FDA regulations or other laws or regulations relating to the marketing of REDEMPLO, or any other approved product candidates, we could be subject to criminal prosecution, civil penalties, seizure of products, injunctions and exclusion of our product candidates from reimbursement under government programs, as well as other regulatory or investigatory actions against our future product candidates, our commercial or collaborative partners or us. See also &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our operations, including our relationships with healthcare providers, physicians and third-party payers, are subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations, which, in the event of a violation, exposes us to liability for criminal sanctions, civil penalties, and contractual damages, and reputational harm and diminished profits and future earnings.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Intellectual Property</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed rights to patents and have filed and expect to continue to file patent applications. Researchers sponsored by us may also file patent applications that we may need to license. Such patent applications may not be available for licensing or may not be economically feasible to license. Certain of our patents may not be granted or may not contain claims of the necessary breadth because, for example, prior patents or publications exist. If a particular patent is not granted, the value of the invention described in the patent would be diminished. Further, even if these patents are granted, they may be difficult to enforce. Patent prosecution and maintenance is expensive, and we may be forced to curtail prosecution or maintenance if our cash resources are limited. Thus, the patents held by or licensed to us may not afford us any meaningful competitive advantage. Even if ultimately successful in obtaining patent protection, efforts to enforce our patent rights could be expensive, distracting for management, cause our patents to be invalidated or held unenforceable, and thus frustrate commercialization of products. Even if patents are issued and are enforceable, others may develop similar, superior or parallel technologies to any technology developed by us and not infringe on our patents. Additionally, our technology may be accused of infringing and may ultimately prove to infringe upon patents or rights owned by others.  The Company may be subject to intellectual property litigation that could negatively impact our ability to commercialize REDEMPLO and our product candidates, if approved.  For example, on September 10, 2025, the Company filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ionis Pharmaceuticals, Inc. (&#8220;Ionis&#8221;) to declare that the United States Patent No. 9,593,333 (&#8220;the &#8217;333 patent&#8221;) is invalid and not infringed by the Company&#8217;s planned commercialization of investigational plozasiran, and on September 11, 2025, Ionis filed a Complaint for Patent Infringement against the Company in the United States District Court for the Central District of California alleging patent infringement of the &#8217;333 patent.  In addition, the laws of some foreign countries in which we do business, including through our joint ventures, do not protect intellectual property rights to the same extent or in the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">same manner as the laws of the United States. Moreover, if we or our licensors fail to maintain the patents and patent applications covering our product candidates or technologies, including as a result of geopolitical events such as civil or political unrest (including the ongoing conflicts between Ukraine and Russia and Israel and Palestine), we may not be able to use such patents and patent applications or stop a competitor from marketing products that are the same as or similar to our product candidates. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to adequately protect our owned intellectual property or derive sufficient value from our licensed or owned intellectual property, the value of your investment may decline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patent grant standards by the USPTO and its foreign counterparts are not always uniform or predictable, and subject to change. For example, the America Invents Act enacted a number of changes to U.S. patent laws, which may prevent us from adequately protecting our inventions and discoveries, including our ability to seek injunctive relief, pursue infringement claims, and obtain substantial damage awards. An example of a major provision of the America Invents Act is the change in the U.S. patent policy from a first-to-invent to a first-to-file practice. Additionally, the USPTO and patent offices in other jurisdictions have often required that patent applications directed to pharmaceutical and/or biotechnology-related inventions be limited or narrowed substantially to cover only the specific innovations exemplified in the patent application, thereby limiting the scope of protection against competitive challenges.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, even if we or our licensors are able to obtain patents, the patents might be substantially narrower than anticipated.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Thus, there is no assurance as to the degree and range of protections any of our patents, if issued, may afford us or whether patents will be issues.  Foreign counterparts to this law are also not uniform, and there is no worldwide policy governing the subject matter and scope of claims granted in a pharmaceutical or biotechnology patent. Uncertainty, arising from changing laws, can impact our ability to protect our patents and other proprietary rights.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are party to technology license agreements with third parties that require us to satisfy obligations to keep them effective and, if these agreements are terminated, our technology and our business could be seriously and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are party to license agreements to incorporate third-party proprietary technologies into our drug products under development or our manufacturing processes. These license agreements require us to pay royalties and satisfy other conditions. If we fail to satisfy our obligations under these agreements, the terms of the licenses may be materially modified, such as by rendering currently exclusive licenses non-exclusive, or may give our licensors the right to terminate their respective agreement with us, which could limit our ability to implement our current business plan and harm our business and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be and have been subject to patent infringement claims, which could result in substantial costs and liability and prevent us from commercializing our potential products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Because the intellectual property landscape in the fields in which we participate is rapidly evolving and interdisciplinary, it is difficult to conclusively assess our freedom to operate without infringing on third-party rights. However, if granted marketing approval, we are currently aware of certain patent rights held by third parties that, if found to be valid and enforceable, could be alleged to render one or more of our drug products or candidates infringing. For example, a</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">he Company previously reported in Form 8-K filed on September 12, 2025, Ionis Pharmaceuticals, Inc. (&#8220;Ionis&#8221;) filed a complaint for patent infringement against the Company in the United States District Court for the Central District of California alleging patent infringement of United States Patent No. 9,593,333 (&#8220;the &#8217;333 patent&#8221;) (the "Ionis Claim"), which may impact our planned commercialization of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">REDEMPLO</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. See also &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage.&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> If the Ionis Claim or any potential future claim by another party is successful, we may be required to pay substantial damages, be forced to abandon any affected drug product and/or product candidates and/or seek a license from the patent holder. In addition, the Ionis Claim and any future patent infringement claims brought against us, whether or not successful, may cause us to incur significant expenses and divert the attention of our management and key personnel from other business concerns. These could negatively affect our results of operations and prospects. We cannot be certain that patents owned or licensed by us will not be challenged, potentially successfully, by others.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our products and/or product candidates are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our customers, licensees and other parties with whom we have business relationships, and we may be required to indemnify those parties for any damages they suffer as a result of these claims. The claims may require us to initiate or defend protracted and costly litigation on behalf of customers, licensees, and other parties regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use. If we cannot obtain all necessary licenses on commercially reasonable terms, we may be unable to continue selling such products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We license patent rights from third-party owners and we rely on such owners to obtain, maintain and enforce the patents underlying such licenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of licenses that give us rights to third-party intellectual property that is necessary or useful for our business. We also expect to enter into additional licenses to third-party intellectual property in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our success may depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property, in particular, those patents to which we have secured exclusive rights. Our licensors may not successfully prosecute the patent applications to which we are licensed. Even if patents are issued in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our technology licensed from various third parties may be subject to retained rights.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our licensors often retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with our collaborators, employees, consultants, outside scientific collaborators and sponsored researchers, and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. As our organization grows, so does the risk of unauthorized disclosure of confidential information. In addition, while we undertake efforts to protect our trade secrets and other confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, we may not be able to assert any trade secret rights against such party. Enforcing a claim that a party illegally obtained and is using our trade secrets is challenging and the outcome is unpredictable.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, courts outside of the U.S. may be less willing to protect trade secrets. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to effectively secure first-tier technologies when competing against other companies or investors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our future success may require that we acquire patent rights and know-how to new or complimentary technologies. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">However, we also compete with a substantial number of other companies that are working to develop novel drugs using technology that compete directly with us. We are aware of several other companies that are working to develop RNAi therapeutic products and any one of these companies may develop its RNAi technology more rapidly and more effectively than us may also compete for technologies we desire.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, many venture capital firms and other institutional investors, as well as other pharmaceutical and biotech companies, invest in companies seeking to commercialize various types of emerging technologies. Many of these companies have greater financial, scientific and commercial resources than us. Therefore, we may not be able to secure the technologies we desire or to otherwise effectively compete. Furthermore, should any commercial undertaking by us prove to be successful, there can be no assurance competitors with greater financial resources will not offer competitive products and/or technologies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents covering our current and any future product candidates in all countries throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we or our licensors have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection but where patent enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued or licensed patents, and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing. Issued patents may be challenged by third parties in the courts or patent offices in various countries throughout the world. Invalidation proceedings may result in patent claims being narrowed, invalidated or held unenforceable. Uncertainties regarding the outcome of such proceedings, as well as any resulting losses of patent protection, could harm our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. Some countries do not enforce patents related to medical treatments, or limit enforceability in the case of a public emergency. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The intellectual property systems in other countries can be destabilized or unpredictable as a result of geopolitical events such as civil or political unrest (including the ongoing conflicts between Ukraine and Russia and Israel and Palestine). Therefore, during such geopolitical events, the ability to obtain, retain and enforce intellectual property protection in the affected countries may be uncertain and evolve during the course of such geopolitical event. The U.S. government&#8217;s response to geopolitical events may also negatively affect our ability to obtain, retain and enforce intellectual property protection in the affected countries. Uncertainties regarding geopolitical events, as well as any resulting losses of intellectual property protection, could harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Business Model</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business model assumes we will generate revenue by, among other activities, marketing or out-licensing the products we deve</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">lop. Our product candidates are in various stages of development and we currently have only one product based on RNAi  and our delivery technologies which was approved in November 2025. Accordingly, there is a limited amount of information about us upon which you can evalua</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">te our business and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have not begun to generate revenues from the commercialization of REDEMPLO or any product candidates. As such, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area. For example, to execute our business plan, we will need to successfully:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">execute product development activities using technologies that have not yet generated revenues;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">build, maintain, and protect a strong intellectual property portfolio;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">demonstrate safety and efficacy of our product candidates in multiple human clinical studies;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receive FDA approval and approval from similar foreign regulatory bodies;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">gain market acceptance for the development and commercialization of any drugs we develop;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ensure our products are reimbursed by commercial and/or government payers at a rate that permits commercial viability;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop and maintain successful strategic relationships with suppliers, distributors, and commercial licensing partners;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our spending and cash requirements as our expenses will increase in the near term if we add programs and additional preclinical and clinical trials; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively market any products for which we obtain marketing approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we are unsuccessful in accomplishing these objectives, we may not be able to develop products, raise capital, expand our business or continue our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to establish additional relationships with strategic and development partners to fully develop our product candidates and market any approved products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Over the past several years we have entered into license and collaboration agreements with Takeda, Janssen, Amgen, Horizon, GSK, Sarepta, Visirna and Novartis Pharma AG (&#8220;Novartis&#8221;). Our business strategy includes securing additional collaborations with other pharmaceutical and biotech companies to support the development of our RNAi therapeutics and other product candidates. We do not possess all of the financial and development resources necessary to develop and commercialize all of the products that may result from our technologies. Unless we expand our own product development capacity and enhance our own internal marketing capability, we may need to make arrangements with other strategic partners to develop and commercialize any product candidates that may be approved. We may not be able to attract such partners, and even if we are able to enter into such partnerships, the terms may be less favorable than anticipated. Further, entering into partnership agreements may limit our commercialization options and/or require us to share revenues and profits with our partners. If we do not find appropriate partners, or if our existing arrangements or future agreements are not successful, our ability to develop and commercialize products could be adversely affected. Even if we are able to find collaborative partners, the overall success of the development and commercialization of product candidates in those programs will depend largely on the efforts of other parties and will be beyond our control, particularly </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as partnered programs progress and our licensees may elect to assume greater control over these programs. In addition, in the event we pursue our commercialization strategy through collaboration or licenses to third parties, there are a variety of technical, business and legal risks, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to control the amount and timing of resources that our collaborators may be willing or able to devote to the development or commercialization of our product candidates or to their marketing and distribution; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise between us and our collaborators that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts our management&#8217;s resources.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of the above events or other related events could impair our ability to generate revenues and harm our business and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to generate milestone and royalty payments under our current and potential future licensing and collaboration agreements is substantially controlled by our partners, and as such, we will likely need other sources of financing to continue to develop our internal </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">product</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> candidates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under our licensing and collaboration agreements with Amgen, Takeda, GSK, Sarepta, Visirna, Sanofi, and Novartis, our partners substantially control clinical development and commercialization for all of the candidates covered under those agreements in their relevant territories. To the extent that (i) our partners&#8217; interests in advancing these candidates or targets changes, (ii) unforeseen scientific issues with the candidates arise, or (iii) the pace at which our partners move the candidates through clinical trials toward commercialization slows, our ability to collect milestones and royalties may be significantly diminished. This would further cause us to rely upon other sources of financing to continue to develop our other internal </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> candidates. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may lose a considerable amount of control over our intellectual property and may not receive anticipated revenues in strategic transactions, particularly where the consideration is contingent on the achievement of development or sales milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our business model has been to develop new technologies and to utilize the intellectual property created through the research and development process to develop commercially successful products. If the acquirers of our technologies fail to achieve performance milestones, we may not receive a significant portion of the total value of any sale, license or other strategic transaction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to achieve commercial acceptance of REDEMPLO and our </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">product</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> candidates to generate revenues and achieve profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Even if our research and development efforts yield technologically feasible applications, we may not successfully develop commercial products. Drug development takes years of study in human clinical trials prior to regulatory approval, and, even if we are successful in getting regulatory approval of our </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> candidates, it may not be on a timely basis. During our drug development period, superior competitive technologies may be introduced which could diminish or extinguish the potential commercial uses for our </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> candidates. Additionally, the degree to which the medical community and consumers will adopt any product we develop is uncertain. The rate and degree of market acceptance of our products will depend on a number of factors, including the establishment and demonstration in the medical community of the clinical efficacy and safety of our products, their potential advantage over alternative treatments, and the costs to patients and third-party payers, including commercial insurance companies and government health care programs. Recent efforts in the United States and abroad to reduce overall healthcare spending has put significant pressure on the price of prescription drugs and certain companies have been publicly criticized for the relatively high cost of their therapies. These pressures may force us to sell any approved drugs at a lower price than we or analysts may anticipate or may result in lower levels of reimbursement and coverage from third parties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Moreover</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, we have </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">not yet generated any revenue from product sales. Our ability to generate significant revenue and achieve profitability depends on our ability, alone or with potential strategic collaboration partners, to complete the development of and obtain the regulatory and marketing approvals necessary to commercialize our </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> candidates and introduce products that will be accepted by the medical community</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The commercial success of REDEMPLO or any of our product candidates, if approved,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> will depend on many factors, including, but not limited to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of coverage and adequate and timely reimbursement from managed care plans, private insurers, government payers (such as Medicare and Medicaid and similar foreign authorities) and other third-party payers for </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our products</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients&#8217; ability and willingness to pay out-of-pocket for </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our products</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in the absence of coverage and/or adequate reimbursement from third-party payers;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient demand for </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our products</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the overall health benefits and costs savings that patients derive from REDEMPLO;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and enforce intellectual property rights in and to </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our products</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict whether significant commercial market acceptance for </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">REDEMPLO or any of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our products, if approved, will ever develop, and we cannot reliably estimate the projected size of any such potential market. Our revenue growth and achievement of consistent profitability will depend substantially on our ability to introduce products that will be accepted by the medical community. If we are unable to cost-effectively achieve acceptance of our technology among the medical establishment and patients, or if the associated products do not achieve wide market acceptance, our business will be materially and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunities for </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">REDEMPLO or any other</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> approved product candidates, are smaller than we expect, it could materially adversely affect our financial condition and results of operation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If the market opportunity for </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">REDEMPLO or any other approved</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> products, is smaller than we expect, we may never become or remain profitable nor generate sufficient revenue growth to sustain our business even if we obtain significant market share for them. The potentially addressable patient population for our products may be limited or may not be amenable to treatment with our products, and new patients may become increasingly difficult to identify or access, which would adversely affect our results of operations and our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on outside sources for various components and processes for our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third parties for various components and processes for REDEMPLO and our product candidates. We may not be able to achieve multiple sourcing because there may be no acceptable second source, other companies may choose not to work with us, or the component or process sought may be so new that a second source does not exist or does not exist on acceptable terms. For instance, drug substance and drug product for REDEMPLO are each currently sourced from a single, third-party manufacturer, and many of our pulmonary </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> candidates are administered using a proprietary delivery device which is currently sourced from a single manufacturer. There may be a disruption or delay in the performance of our third-party contractors, suppliers or collaborators which is beyond our control. If such third parties are unable to satisfy their commitments to us, the development of our products would be adversely affected. Therefore, it is possible that our development plans will have to be slowed down or stopped completely at times due to our inability to obtain required raw materials, components, and outsourced processes at an acceptable cost, if at all, or to get a timely response from vendors, particularly as a result of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">recent labor market and global supply chain constraints.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited manufacturing capability and must rely on third-party manufacturers to manufacture our clinical supplies and commercial products, if and when approved, and if they fail to meet their obligations, the development and commercialization of our products could be adversely affected. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Although we have developed our own internal manufacturing capabilities which allow us to manufacture oligonucleotide drug substance for our clinical product candidates, we do not currently have internal manufacturing capabilities beyond such clinical-stage oligonucleotide drug substance. We</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> rely, and expect to continue to rely, on third-party manufacturers for the production of REDEMPLO and our drug product candidates for clinical trials and commercialization. We may choose to utilize third-party manufacturers to produce some or all of our development candidates, even if we have internal manufacturing capabilities to do so. Further, we have not developed the ability to manufacture drug product ourselves, nor have we developed the capabilities to manufacture biologics. If we were to experience an unexpected loss or interruption of supply for REDEMPLO or any of our product candidates, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience disruptions in our commercial sales or delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. Further, our </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> candidates are composed of multiple components and require specific formulations for which scale-up and manufacturing could be difficult. For certain products, we have limited experience in such scale-up and manufacturing which may require us to depend on a limited number of third parties, who may not be able to deliver in a timely manner, or at all. In order to develop products, apply for regulatory approvals, and commercialize our products, we will need to develop, contract for, or otherwise arrange for the necessary manufacturing capabilities. We have increased our GMP drug substance manufacturing capacity following the substantially completed build out and integration of our manufacturing facility in Verona, Wisconsin. There are a limited number of manufacturers that supply synthetic oligonucleotides. There are risks inherent in pharmaceutical manufacturing that could affect the ability of our contract manufacturers to meet our delivery time requirements or provide adequate amounts of material to meet our needs. Included in these risks are synthesis and purification failures and contamination during the manufacturing process, which could result in unusable product and cause delays in our development process, as well as additional expense to us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as more of our product candidates become approved for commercial sale, we will need to establish either internal or third-party manufacturing and analytical capacity. For example, we have entered into third-party agreements for the manufacturing of REDEMPLO for drug substance and drug product, in conjunction with its commercial launch in 2025. Further, some manufacturing partners may require us to fund capital improvements, perhaps on behalf of third parties, to support the scale-up of manufacturing and related activities. We may not be able to establish scaled manufacturing capacity for an approved product in a timely or economic manner, if at all. If we or our third-party manufacturers are unable to provide commercial quantities of such an approved product, we will have to successfully transfer manufacturing technology to a different or additional manufacturer. Engaging a new manufacturer for such an approved product could require us to conduct comparative studies or utilize other means to determine bioequivalence of the new and prior manufacturers&#8217; products, which could delay or prevent our ability to commercialize such an approved product. If we or any of these manufacturers is unable or unwilling to increase its manufacturing capacity or if we are unable to establish alternative arrangements on a timely basis or on acceptable terms, the development and commercialization of such an approved product may be delayed or there may be a shortage in supply. Any inability to manufacture our product candidates or future approved drugs in sufficient quantities when needed would seriously harm our business. While we are exploring alternative suppliers for certain critical materials, some of which are sole sourced, and there can be no assurance that our efforts will be successful. Accordingly, there is a risk that supplies of our products and product candidates may be significantly delayed by, or may become unavailable as a result of manufacturing, equipment, process, regulatory or business-related issues affecting that company.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of our approved products (including us, if we chose to internally manufacture) must comply with cGMP requirements relating to methods, facilities and controls used in the manufacturing, processing and packaging of the product, which are intended to ensure that drug products are safe and that they consistently meet applicable requirements and specifications. These requirements include quality control, quality assurance, and the maintenance of records and documentation. These manufacturers (including us, if we chose to internally manufacture) may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. These requirements are enforced by the FDA and other health authorities through periodic announced and unannounced inspections of manufacturing facilities. A failure to comply with these requirements or to provide adequate and timely corrective actions in response to deficiencies identified in an inspection may result in enforcement action, including warning letters, fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, plant shutdown, or the delay, withholding, or withdrawal of product approval. If the safety of any quantities supplied is compromised due to a manufacturer&#8217;s failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products, which would seriously harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct our clinical trials, and if they fail to fulfill their obligations, the development of our products may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We rely on independent clinical investigators, contract research organizations (CROs) and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our clinical trials. We contract with certain third-parties to provide certain services, including site selection, enrollment, monitoring and data management services. We rely on these parties to carry out our clinical trials in compliance with GCP and other relevant requirements. Although we depend heavily on these parties, we do not control them and therefore we cannot be assured that these third parties will adequately perform all of their contractual obligations to us. If our third-party service providers cannot adequately and timely fulfill their obligations to us, or if the quality and accuracy of our clinical trial data is compromised due to failure by such third parties to adhere to our protocols, GCP, or other regulatory requirements or if such third parties otherwise fail to meet deadlines or quality requirements, our development plans may be delayed or terminated. Further, if clinical study results are compromised, then we may need to repeat the affected studies, which could result in significant additional costs and delays to us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition from various entities including large pharmaceutical companies, small biotech companies, private companies, and research institutions.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have greater financial resources and may have more experience in research and development, manufacturing, managing clinical trials, commercialization and/or regulatory compliance than we do. Our competitors may compete with us for lead clinical trial investigators, clinical trial site locations and patient enrollment. These competitors may also compete with us in recruiting scientific and management personnel. Because our products are in vario</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">us stages </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of preclinical and clinical development, along with many of the competing products, and given unpredictability inherent in drug development, it is difficult to predict which third party may be our most direct competitor, and on what factors that competition may be focused. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we also face increased competition from other companies that are using artificial intelligence, some of whom may be able to more quickly and effectively identify and develop novel product candidates compared to us and our business partners, which could impair our ability to compete effectively and have a material adverse effect on our business, results of operations or financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may have difficulty expanding our operations successfully as we evolve our pipeline and move toward commercializing drugs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize products and compete effectively will depend, in part, on our ability to effectively manage future growth. We expect that as we increase the number of product candidates we are developing we will also need to expand our operations. This expected growth may place a strain on our administrative and operational infrastructure and information technology systems. As product candidates we develop enter and advance through clinical trials, we will need to expand our development, regulatory, manufacturing, marketing, sales, and customer support capabilities or contract with other organizations to provide these capabilities for us. We are currently establishing a sales, customer support, and marketing infrastructure for REDEMPLO and certain of our product candidates, and although we have hired individuals with significant experience in the sales, customer support, marketing, and distribution of pharmaceutical products, the Company does not have prior experience in commercialization of a product. To achieve commercial success for REDEMPLO or any approved product for which we retain sales and marketing rights, we must continue to develop a sales and marketing organization or outsource these functions to third parties. If we or our collaborators are unable to establish sales, marketing, customer support, and distribution capabilities or successfully enter into or maintain agreements with third parties to market and sell our products, we may not be successful in commercializing our products. Further, as our operations expand due to our development progress, we expect that we will need to manage additional relationships with various collaborators, suppliers, and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial, information technology and management controls, reporting systems and procedures. We may not be able to effectively manage the expansion of our operations or implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations could suffer in the event of a cybersecurity incident or other information technology system failures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, ransomware and other cyber-attacks, human error, natural disasters, terrorism, war, and telecommunication and electrical failures. Such events could cause interruption of our operations and loss of intellectual property. For example, the loss of preclinical trial data or data from completed or ongoing clinical trials for our product candidates could result in delays in our regulatory filings and development efforts and significantly increase our costs. Further, cybersecurity breaches or other cybersecurity incidents may allow hackers access to our preclinical compounds, strategies, discoveries, trade secrets, and/or other confidential information. Additionally, sensitive data could be leaked, disclosed, or revealed as a result of or in connection with our employees&#8217;, personnel&#8217;s, vendors&#8217; or partners&#8217; use of generative AI technologies. To the extent that any disruption or cybersecurity incident were to result in a loss of or damage to our data, or inappropriate disclosure of confidential, proprietary or private information, we could incur liability or regulatory penalties, including under laws and regulations governing the protection of protected health information and other personal data, we could be subject to litigation (including class-action claims), we could lose valuable trade secret rights, the development of our product candidates could be delayed, and we could suffer reputational damage and damage to key business relationships. The risk of a cybersecurity incident or other informational technology disruption, particularly through cyber-attacks, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. W</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">e, and certain of the third parties for which we depend on to operate our business, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">have experienced cyber-security attacks in the past, which to date have not had a material impact on our operations or development programs; however; there is no assurance that such impacts will not be material in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we use biological materials, hazardous materials, chemicals and radioactive compounds, if we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our research, development and manufacturing activities involve the use of potentially harmful biological materials as well as materials, chemicals and various radioactive compounds that could be hazardous to human health and safety or the environment. We store most of these materials and various wastes resulting from their use at our facilities in</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Madison, Wisconsin, Verona, Wisconsin, and San Diego, California</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> pending ultimate use and disposal. We cannot completely eliminate the risk of contamination, which could cause interruption to our research and development and manufacturing efforts, injury to our employees and others, environmental damage, and liabilities under federal, state and local law. In such an event, we may be held liable for any resulting damages, and any liability could exceed our resources. Although we carry insurance in amounts and types that we consider commercially reasonable, we do not have insurance coverage for losses relating to an interruption of our research, development or manufacturing efforts caused by contamination, and the coverage or coverage limits of our insurance policies may not be adequate. If our losses exceed our insurance coverage, our financial condition would be affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities litigation claims may result in financial losses or harm our reputation and may divert management resources.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.51pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">When the market price of a stock is volatile, holders of that stock have often initiated securities class action litigation against the company that issued the stock. We cannot predict with certainty the eventual outcome of such litigation, arbitration or third-party inquiry. We may not be successful in defending ourselves or asserting our rights in current or future lawsuits, investigations, or claims that have been or may be brought against us and, as a result, our business could be materially harmed. These lawsuits, arbitrations, investigations or claims may result in large judgments or settlements against us, any of which could have a negative effect on our financial performance and business. Additionally, lawsuits, arbitrations and investigations can be expensive to defend, whether or not the lawsuit, arbitration or investigation has merit, and the defense of these actions may divert the attention of our management and other resources that would otherwise be engaged in running our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations, including our relationships with healthcare providers, physicians and third-party payers, are subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations, which, in the event of a violation, exposes us to liability for criminal sanctions, civil penalties, and contractual damages, and reputational harm and diminished profits and future earnings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our operations, including any arrangements that we enter into with healthcare providers, physicians, and third-party payers, are subject to broadly applicable fraud and abuse and other healthcare laws and regulations. Such laws and regulations, including applicable U.S. federal and state healthcare laws and regulations, as well as foreign laws, such as the federal Anti-Kickback Statute, the False Claims Act, the Health Insurance Portability and Accountability Act of 1996, or the Foreign Corrupt Practices Act, may constrain our operation and the business or financial arrangements through which we can market, sell and distribute any </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> candidates for which we obtain marketing approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to confirm that our business arrangements with third parties comply with applicable healthcare laws and regulations involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may become subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, and compliance and reporting obligations that could adversely affect our revenues, financial condition or results of operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The actions of distributors and specialty pharmacies could affect our ability to sell or market products profitably. Fluctuations in buying or distribution patterns by such distributors and specialty pharmacies could adversely affect our revenues, financial condition, or results of operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have an exclusive agreement with Vanscoy Rare Pharmacy for drug delivery services, and we expect to rely on this pharmacy for a considerable portion of our sales for </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">REDEMPLO</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The financial failure of Vanscoy Rare Pharmacy could adversely affect our revenues, financial condition or results of operations. Our revenues, financial condition or results of operations may also be affected by fluctuations in their buying or distribution patterns. These fluctuations may result from seasonality, pricing, wholesaler inventory objectives, or other factors. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Financial Condition</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception and we expect that our operating losses will continue for the foreseeable future as we continue our drug development efforts and begin commercialization of our product candidates. To achieve profitability, we must, either directly or through licensing and/or partnering relationships, meet certain milestones, successfully develop and obtain regulatory approval for drug candidates and effectively manufacture, market and sell any drugs we successfully develop. Even if we successfully commercialize </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> candidates that receive regulatory approval, we may not be able to realize revenues at a level that would allow us to achieve or sustain profitability. Accordingly, we may never generate significant revenue and, even if we do generate significant revenue, we may never achieve consistent profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">W</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">e will</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> require substantial additional funds to complete our research and development activities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our business currently does not generate the cash that is necessary to finance our operations. Subject to the success of the research and development programs of the Company and our partners, and potential licensing or partnering transactions, we may need to raise additional capital to:  </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fund research and development infrastructure and activities relating to the development of our product candidates, including preclinical and clinical trials and manufacturing to support these efforts;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fund a commercialization infrastructure and activities related to the sale, marketing, customer support, and distribution of our drug products ;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fund our general and administrative infrastructure and activities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pursue business development opportunities for our technologies;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add to and protect our intellectual property; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">retain our management and technical staff.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital needs depend on many factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, duration, and expenditures associated with our research and development, including the progression of our clinical trials, with late-stage trials generally requiring greater capital than early-stage trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory requirements for our clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our research and development and clinical efforts are successful;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenditures to build out or contract for sales, marketing and distribution capabilities ;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of potential partnering or licensing transactions, if any, and the extent to which our business development efforts result in the acquisition of new programs or technologies;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological developments;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intellectual property positions, if any, in our products; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the regulatory approval process and regulatory standards for our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> will</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> need to raise additional funds through public or private equity offerings, debt financings or additional strategic alliances and licensing arrangements in the future to continue our operations. We may not be able to obtain additional financing on terms favorable to us, if at all. General market conditions may make it very difficult for us to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of our stockholders. For example, if we raise additional funds by issuing equity securities, further dilution to our stockholders will result, which may substantially dilute the value of investment. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, may involve restrictive covenants that could limit our flexibility in conducting future business activities and, in the event of insolvency, would be paid before holders of equity securities receive any distribution of corporate assets. In order to raise additional funds through partnerships, joint ventures or licensing arrangements, we may be required to relinquish rights to our technologies or </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> candidates or grant licenses on terms that are not favorable to us. If adequate funds are not available, we may have to further delay, reduce or eliminate one or more of our planned activities. These actions would likely reduce the market price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The terms of our financing agreement with Sixth Street Lending Partners and our indebtedness could adversely affect our operations and limit our ability to plan for or respond to changes in our business. If we are unable to comply with restrictions in the financing agreement, the repayment of our existing indebtedness could be accelerated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2024, we entered into a financing agreement with Sixth Street Lending Partners, as the administrative agent and collateral agent for several lenders.  The financing agreement establishes a senior secured term loan facility of $500.0 million (the&#160;&#8220;Credit Facility&#8221;), consisting of $400.0 million funded on the closing date and an additional $100.0 million available at our option, subject to mutual agreement with Sixth Street, over a seven-year term. On November 26, 2024, the Company entered into an amendment to the Financing Agreement to modify, amongst other things, some of the prepayment terms of the loans under the Credit Facility, including the prepayment terms related to the Sarepta Collaboration Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The financing agreement requires us to make certain payments over time and contains several other negative covenants that, subject to certain exceptions, restrict indebtedness, liens, investments (including acquisitions), fundamental changes, asset sales and licensing transactions, dividends, modifications to material agreements, payment of subordinated indebtedness, and other matters customarily restricted in such agreements. Among other requirements of the financing agreement, we and our subsidiaries party to the financing agreement must maintain certain liquidity thresholds based on our market capitalization. We are also subject to restrictions on sales and licensing transactions with respect to our core intellectual property and product assets, including, but not limited to, olpasiran, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">REDEMPLO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, zodasiran, fazirsiran, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">GSK4532990, and daplusiran/tomligisiran, subject to certain exceptions. These and other terms in the financing agreement could restrict our ability to grow our business or enter into transactions that we believe would be beneficial to our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness could affect our business in the following ways, among other things: make it more difficult for us to satisfy our contractual and commercial commitments; require us to use a substantial portion of our cash flow subject to mandatory prepayments to pay interest and principal when due, which would reduce funds available for working capital, capital expenditures and other general corporate purposes; limit our ability to obtain additional financing for working capital, capital expenditures, acquisitions and other investments or general corporate purposes; heighten our vulnerability to downturns in our business, our industry or in the general economy; place us at a disadvantage compared to those of our competitors that may have proportionately less debt; limit management&#8217;s discretion in operating our business; and limit our flexibility in planning for, or reacting to, changes in our business, the industry in which we operate or the general economy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our business may not generate cash flows from operations in the future that are sufficient to service our debt and support our growth strategies. In addition, our ability to generate sufficient cash flows to meet our debt obligations depends upon several factors, such as the ability of the Company and our licensees to timely complete clinical trials and obtain marketing approval for our clinical-stage product candidates, to successfully commercialize REDEMLPO and our clinical-stage product candidates, and our future performance, which is subject to financial, business, and other impacts on our operations, many of which are beyond our control. If we are unable to generate sufficient cash flows, we may be required to adopt one or more alternatives, such as obtaining additional equity capital on terms that may be onerous or highly dilutive, selling assets, or restructuring debt. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the estimates we make, or the assumptions on which we rely, in preparing our consolidated financial statements prove inaccurate, our actual results may vary from those reflected in our accruals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities, revenues and expenses, the amounts of charges accrued by us and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. We cannot assure you, however, that our estimates, or the assumptions underlying them, will be correct.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly and annual operating results have fluctuated and may continue to fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. From time to time, we may enter into license or collaboration agreements or strategic partnerships with other companies that include development funding and significant upfront and milestone payments and/or royalties. These upfront and milestone payments may vary significantly from period to period and any such variance could cause a significant fluctuation in our operating results from one period to the next.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award, and recognize the cost as an expense over the employee&#8217;s requisite service period. As the variables that we use as a basis for valuing these awards change over time, including our underlying stock price and stock price volatility, the magnitude of the expense that we must recognize may vary significantly.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the following: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to successfully commercialize REDEMPLO or any of our product candidates, if approved;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and cost of, and level of investment in, research and development activities relating to our current and any future product candidates, which will change from time to time;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enroll patients in clinical trials and the timing of enrollment;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our current and any future product candidates, which may vary depending on FDA guidelines and requirements, the quantity of production and the terms of our agreements with manufacturers and other suppliers;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenditures that we will or may incur to acquire or develop additional product candidates and technologies;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and outcomes of clinical trials for product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to conduct unanticipated clinical trials or trials that are larger or more complex than anticipated;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition from existing and potential future products that compete with REDEMPLO or any of our product candidates, and changes in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delays in regulatory review or approval of any of our product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of demand for REDEMPLO or any of our product candidates, of approved, which may fluctuate significantly and be difficult to predict;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk/benefit profile, cost and reimbursement policies with respect to REDEMPLO or any of our product candidates, if approved, and existing and potential future products that compete with our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to commercialize any of our products inside and outside of the United States, either independently or working with third parties;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations, licensing or other arrangements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to adequately support future growth;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential unforeseen business disruptions that increase our costs or expenses;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future accounting pronouncements or changes in our accounting policies; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the changing and volatile global economic environment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative effect of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The investment of our cash, cash equivalents and fixed income securities is subject to risks which may cause losses and affect the liquidity of these investments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2025, we h</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ad $919.4 million in cash, cash equivalents, restricted cash and available-for-sale securities. Ou</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">r investments may also include commercial paper, securities issued by the U.S. government obligations, and money market funds meeting the criteria of our investment policy, which is focused on the preservation of our capital. These investments are subject to general credit, liquidity, and market and interest rate risks, particularly in the current economic environment. We may realize losses in the fair value of these investments or a complete loss of these investments, which would have a negative effect on our consolidated financial statements. In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. The market risks associated with our investment portfolio may have an adverse effect on our results of operations, liquidity and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize net operating loss carryforwards and other tax benefits may be limited.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have historically incurred net losses. Under the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), a corporation is generally allowed a deduction for net operating losses (NOLs) carried forward from a prior taxable year. Under that provision, we can carryforward our NOLs to offset our future taxable income, if any, until such NOLs are used or expire. As a result of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (&#8220;CARES Act&#8221;) and legislation commonly referred to as the Tax Cuts and Jobs Act of 2017 (&#8220;2017 Tax Act&#8221;), NOLs arising before January 1, 2018, and NOLs arising after January 1, 2018, are subject to different rules. Under the CARES Act and 2017 Tax Act, federal NOLs incurred in 2018, 2019 and 2020 can generally be carried back five years, carried forward indefinitely and can offset 100% of future taxable income for tax years before January 1, 2021 and up to 80% of future taxable income for tax years after December 31, 2020. Any NOLs arising on or after January 1, 2021, cannot be carried back,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> but can generally be carried forward indefinitely and can offset up to 80% of future taxable income. It is uncertain if and to what extent various states will conform to the newly enacted federal tax law. These NOL carryforwards could expire unused before offsetting potential future income tax liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under Section 382 and 383 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">of the Code and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50 percent change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. It is possible that we have experienced an ownership change limitation. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an ownership change occurs and our ability to use our NOL carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be subject to additional tax liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal, state, and local taxes in the United States and other countries. Significant judgment is required in evaluating our tax positions. During the ordinary course of business, there are many activities and transactions for which the ultimate tax determination is uncertain. In addition, our tax obligations and effective tax rates could be adversely affected by changes in the relevant tax, accounting and other laws, regulations, principles and interpretations, including those relating to income tax nexus, by recognizing tax losses or lower than anticipated earnings in jurisdictions where we have lower statutory rates and higher than anticipated earnings in jurisdictions where we have higher statutory rates, by changes in foreign currency exchange rates, or by changes in the valuation of our deferred tax assets and liabilities. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For instance, beginning in 2022, the 2017 Tax Act eliminated the option of expensing all research and development expenditures in the current year, instead requiring amortization over five years for expenditures in the U.S. and over fifteen years for foreign-based expenditures. The One Big Beautiful Bill Act, enacted in 2025, permits the expensing of certain research and development expenditures in the U.S. incurred in tax years beginning in 2025, while amortization over fifteen years continues to be required for foreign-based expenditures. We continue to monitor new tax legislation or other developments since significant changes in tax legislation, or in the interpretation of existing legislation, could materially and adversely affect our financial condition and operating results.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Additionally,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> we may be audited in various jurisdictions, and such jurisdictions may assess additional taxes, sales taxes and value-added taxes against us. Although we believe our tax estimates are reasonable, the final determination of any tax audits or litigation could be materially different from our historical tax provisions and accruals, which could have a material adverse effect on our operating results or cash flows in the period for which a determination is made.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to changing regulations for corporate governance and public disclosure that have increased both our costs and the risk of noncompliance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Each year we are required to evaluate our internal controls systems in order to allow management to report on and our Independent Registered Public Accounting Firm to attest to, our internal controls as required by Section 404 of the Sarbanes-Oxley Act. As a result, we continue to incur additional expenses and divert our management&#8217;s time to comply with these regulations. In addition, if we cannot continue to comply with the requirements of Section 404 in a timely manner, we might be subject to sanctions or investigation by regulatory authorities, such as the SEC, the Public Company Accounting Oversight Board or The Nasdaq Global Select Market. Any such action could adversely affect our financial results and the market price of our common stock. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Investment and Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Board of Directors has the authority to issue shares of &#8220;blank check&#8221; preferred stock, which may make an acquisition of the Company by another company more difficult.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted and may in the future adopt certain measures that may have the effect of delaying, deferring or preventing a takeover or other change in control of the Company that a holder of our common stock might consider in its best interest. For example, our Board of Directors, without further action by our stockholders, currently has the authority to issue up to 5,000,000 shares of preferred stock and to fix the rights (including voting rights), preferences and privileges of these shares (&#8220;blank check&#8221; preferred). Such preferred stock may have rights, including economic rights, senior to our common stock. These factors could also reduce the price that certain investors might be willing to pay for shares of our common stock and result in the market price being lower than it would be without these provisions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to declare cash dividends on our common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We will not distribute cash to our stockholders unless and until we can develop sufficient funds from operations to meet our ongoing needs and implement our business plan. The time frame for that is unpredictable and investors should not expect dividends in the near future, if at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research reports about our business or if they make adverse recommendations regarding an investment in our stock, our stock price and trading volume may decline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock can be influenced by the research and reports that industry or securities analysts publish about our business. Investors have many investment opportunities and may limit their investments to companies that receive greater coverage from analysts. If additional industry or securities analysts do not commence coverage of the Company, the trading price of our stock could be negatively impacted. If one or more of the analysts downgrade our stock or comment negatively on our prospects, our stock price may decline. If one or more of these analysts cease to cover our industry or us or fail to publish reports about the Company regularly, our common stock could lose </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">visibility in the financial markets, which could also cause our stock price or trading volume to decline. Further, incorrect judgments, estimates or assumptions made by research analysts may adversely affect our stock price, particularly if subsequent performance falls below the levels that were projected by the research analyst(s), even if we did not set or endorse such expectations. Any of these events could cause further volatility in our stock price and could result in substantial declines in the value of our stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market for purchases and sales of our common stock may be limited, and the sale of a limited number of shares could cause the price to fall sharply.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Although our common stock is listed for trading on the Nasdaq Global Select Market, at various times our securities are relatively thinly traded. Investor trading patterns could serve to exacerbate the volatility of the price of our stock. For example, mandatory sales of our common stock by institutional holders could be triggered if an investment in our common stock no longer satisfies their investment standards and guidelines. It may be difficult to sell shares of our common stock quickly without significantly depressing the value of the stock. Unless we are successful in developing continued investor interest in our stock, sales of our stock could result in major fluctuations in the price of the stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our common stock price has fluctuated significantly over the last several years and may continue to do so in the future, without regard to our results of operations and prospects.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The stock market in general and the market for smaller pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. Consequently, we expect that the market price of our common stock will continue to fluctuate significantly. We may not generate substantial revenue from the sale of our products for several years, if at all. In the absence of product revenue as a measure of our operating performance, we anticipate that investors and market analysts will assess our performance by considering factors such as:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of developments related to our business;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into or extend investigation phase, development phase, commercialization phase and other agreements with new and/or existing partners;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements regarding the status of any or all of our collaborations or products, including clinical trial results;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market perception and/or investor sentiment regarding our technology;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the success of competitive products or technologies;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of actions taken by regulatory authorities, such as the FDA;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements regarding developments in the RNAi, antisense technologies, gene editing technologies or biotechnology fields in general;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements regarding clinical trial results with our products or competitors&#8217; products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market perception and/or announcements regarding other companies developing products in the field of biotechnology generally or specifically RNAi;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issuance of competitive patents or disallowance or loss of our patent rights;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the addition or departure of key executives; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our operating results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We will not have control over many of these factors but expect that they may influence our stock price. As a result, our stock price may be volatile and such volatility could result in the loss of all or part of your investment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder equity interest may be substantially diluted in any additional equity issuances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share confidential, proprietary, and sensitive information, including personal information, business data, trade secrets, intellectual property, information we collect about trial participants in connection with clinical trials, sensitive third-party data, business plans, transactions, and financial information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These activities may subject us to numerous data privacy and security obligations governing the collection, use, disclosure, protection, and other processing of personal data, such as various laws, regulations, guidance, industry standards, external and internal data privacy and security policies, contractual requirements, and other obligations relating to data privacy and security. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there are both state and federal data privacy and security laws, including data breach notification laws, data privacy laws (including biometric privacy laws and wiretapping laws), consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and the Health Insurance Portability and Accountability Act (&#8220;HIPPA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH Act&#8221;), and the regulations promulgated thereunder. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020 (together, the &#8220;CCPA&#8221;), applies to personal data of consumers, including business representatives and employees, who are California residents, and requires businesses to provide specific disclosures in their privacy notices and affords certain rights to California residents with respect to their personal data. However, the CCPA does not apply to protected health information that is subject to HIPAA/HITECH. The CCPA provides for civil penalties of up to $7,500 per intentional violation and $2,500 per unintentional violation and allows private litigants affected by certain data breaches to recover significant statutory damages. In addition, state health information privacy laws, such as California&#8217;s Confidentiality of Medical Information Act, Washington&#8217;s My Health My Data Act and the Nevada Consumer Health Data Privacy Law, govern the privacy and security of health-related information, specifically, may apply even when HIPAA/HITECH does not and impose additional requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States there are additional laws, regulations, and industry standards governing data privacy and security. For example, in the EEA, the General Data Protection Regulation (&#8220;GDPR&#8221;) and, in the UK, the GDPR as incorporated into UK law pursuant to the European Union (Withdrawal) Act 2018 (the &#8220;UK GDPR&#8221;) impose strict requirements for processing personal data, including health-related data which is subject to specific requirements. Under the GDPR and UK GDPR, companies may face fines of up to 20 million Euros or 4% of annual global revenue, whichever is greater, , as well as claims from individuals who suffered damages as a result of an infringement. In addition, the GDPR and UK GDPR impose specific restrictions on the transfer of personal data to countries outside of the EEA and UK that are not considered to provide an adequate level of data protection. Although there are currently various mechanisms that may be used to ensure appropriate safeguards to the personal data, such as the EEA and UK&#8217;s standard contractual clauses, these mechanisms are subject to further requirements, in particular the conduct of transfer risk/impact assessments to verify if anything in the law and/or practices of the third country may impinge on the effectiveness of the safeguards in the context of the transfer at stake and, if so, to identify and adopt supplementary measures. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions are subject to potential scrutiny from regulators, individuals and associations. In the EEA, beyond the GDPR framework, companies must also comply with national data protection laws, which supplement, interpret, and in some cases go beyond the GDPR or other EEA-level requirements, including with respect to health-related data. Data protection authorities from the different member states may also implement certain variations, enforce data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EEA. Guidance developed at both EEA level and at the national level in each member state concerning implementation and compliance practices is often updated or otherwise revised. Violations of national laws can trigger administrative investigations, corrective orders, temporary or definitive bans on processing, and, in some jurisdictions, criminal penalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our use of artificial intelligence may be subject to laws and evolving regulations regarding the use of artificial intelligence, including as they relate to controlling for data bias and antidiscrimination.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Preparing for and complying with these obligations require us to devote resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government regulatory enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims); additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; inability to process personal data or to operate in certain </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Economic and Industry Risks</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions, whether brought about by material global crises, health epidemics, military conflicts or war, geopolitical and tariffs or other trade disputes or other factors, may adversely affect our business and financial results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our business is sensitive to global economic conditions, which can be adversely affected by epidemics and other public health crises (such as the COVID-19 pandemic), political and military conflict, tariffs or other trade restrictions or the threat of such actions and retaliatory actions, and other international disputes, significant natural disasters (including as a result of climate change) or other events that disrupt macroeconomic conditions. Adverse macroeconomic conditions, including inflation, slower growth or recession, new or increased tariffs and other trade restrictions or the threat of such actions and retaliatory actions, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), tighter credit, higher interest rates, volatility in financial markets, high unemployment, labor availability constraints, currency fluctuations and other challenges in the global economy have in the past adversely affected, and may in the future adversely affect, us and our business partners and suppliers.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Trade policies and geopolitical disputes (including as a result of China-Taiwan relations) and other international conflicts can result in tariffs, sanctions and other measures that restrict international trade, and can materially and adversely affect our business, particularly if these measures occur in regions where we source components or raw materials. For example, tensions between the United States and China have led to a series of tariffs being imposed by the United States on imports from mainland China, as well as other business restrictions. In response to tariffs, countries have implemented retaliatory tariffs on U.S. goods. Furthermore, in September 2025, the current Presidential Administration announced plans to impose up to 100% tariffs on imported branded or patented pharmaceutical products, subject to certain exceptions. There is substantial uncertainty as to when such tariffs may go into effect and whether such tariffs would apply to the importation of active pharmaceutical ingredients or bulk drug products that are intended for use in clinical trials, and, more generally, </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">about the duration of existing tariffs, implementation of announced tariffs, litigation challenging tariffs and whether additional tariffs or other retaliatory measures may be imposed, modified or suspended. Tariffs increase the costs of the components and raw materials we source. Countries may also adopt other measures, such as controls on imports or exports of goods, technology or data, that could adversely impact the Company&#8217;s operations and supply chain. These geopolitical risks could also adversely affect Visirna. Political tensions as a result of trade policies could reduce trade volume, investment, technological exchange and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, military conflicts or wars (such as the ongoing conflicts between Russia and Ukraine </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and in the Middle East</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">) can cause exacerbated volatility and disruptions to various aspects of the global economy. The uncertain nature, magnitude, and duration of hostilities stemming from such conflicts, including the potential effects of sanctions and counter-sanctions, or retaliatory cyber-attacks on the world economy and markets, have contributed to increased market volatility and uncertainty, which could have an adverse impact on macroeconomic factors that affect our business and operations, such as worldwide supply chain issues. Additionally, the ongoing conflict between Russia and Ukraine has impacted our business decisions with respect to potential clinical trial sites in Europe. For example, a number of our clinical trial sites we had previously planned to use in Russia, Ukraine, and Belarus were shut down and we had to seek alternatives in other geographies.  </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the conflict between Israel and Palestine could impact future business decisions to locate potential clinical trials in Israel</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. It is not possible to predict the short and long-term implications of military conflicts or wars or geopolitical tensions which could include further sanctions, uncertainty about economic and political stability, increases in inflation rate and energy prices, cyber-attacks, supply chain challenges and adverse effects on currency exchange rates and financial markets. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our operations and facilities, as well as operations of our suppliers and manufacturers, may be located in areas that are prone to earthquakes, wildfires and other natural disasters. Such operations and facilities are also subject to the risk of interruption by drought, power shortages, nuclear power plant accidents and other industrial accidents, terrorist attacks and other hostile acts, ransomware and other cybersecurity attacks, labor disputes, public health crises, and other events beyond the Company&#8217;s control. Global climate change is resulting in certain types of natural disasters occurring more frequently or with more intense effects. Such events can create delays or interruptions to the Company&#8217;s development efforts and inefficiencies in the Company&#8217;s supply and manufacturing chain. Significant delays in our development efforts could materially impact our ability to obtain regulatory approval and to commercialize our products. Any insurance we maintain against damage to our property and the disruption of our business due to disaster may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. Further, because the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Company relies on single or limited sources for the supply and manufacture of many critical components, a business interruption affecting such sources would exacerbate any negative consequences to the Company. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any future public health crises  may affect our operations and those of third parties on which we rely, including our business partners and suppliers. We may in the future experience: </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in receiving authorization from regulatory authorities to initiate any planned clinical trials, inspections, reviews and approvals of products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties enrolling patients in our clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in or disruptions to the conduct of preclinical programs and clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">constraints on the movement of products and supplies through the supply chain, which can disrupt our ability to conduct clinical trials and develop our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">price increases in raw materials and capital equipment, as well as increasing price competition in our markets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse impacts on our workforce and/or key employees; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased risk that counterparties to our contractual arrangements will become insolvent or otherwise unable to fulfill their contractual obligations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug development is time consuming, expensive and risky.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on technology related to new and improved pharmaceutical candidates. Product candidates that appear promising in the early phases of development, such as in animal and early human clinical trials, often fail to reach the market for a number of reasons, such as:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial results may be unacceptable, even though preclinical trial results were promising;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inefficacy and/or harmful side effects in humans or animals;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the necessary regulatory bodies, such as the FDA, may not approve our potential product for the intended use, or at all; and/or</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing and distribution may be uneconomical.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For example, any positive preclinical results in animals may not be replicated in human clinical studies. These programs may be also found to be unsafe in humans, particularly if higher doses are needed to achieve the desired levels of efficacy. Also, the positive safety results from single dose human clinical studies may not be replicated in other human studies, including multiple dose studies. Clinical and preclinical study results are frequently susceptible to varying interpretations by scientists, medical personnel, regulatory personnel, statisticians and others, which often delays, limits, or prevents further clinical development or regulatory approvals of potential products. Clinical trials can take many years to complete, including the process of study design, clinical site selection and the recruitment of patients. As a result, we can experience significant delays in completing clinical studies, which can increase the cost of developing a drug candidate and shorten the time that an approved product may be protected by patents. If our drug candidates are not successful in human clinical trials, we may be forced to curtail or abandon certain development programs. If we experience significant delays in commencing or completing our clinical studies, we could suffer from significant cost overruns, which could negatively affect our capital resources and our ability to complete these studies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The healthcare system is under significant financial pressure to reduce costs, which could reduce payment and reimbursement rates for drugs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the world and particularly in the United States, the healthcare system is under significant financial pressure to reduce costs. The price of pharmaceuticals has been a topic of considerable public discussion that could lead to price controls or other price-limiting strategies by payers that have the effect of lowering payment and reimbursement rates for drugs or otherwise making the commercialization of pharmaceuticals less profitable. Many federal and state legislatures have considered, and adopted, healthcare policies intended to curb rising healthcare costs, such as the Inflation Reduction Act of 2022. These cost-containment measures may include, among other measures: requirements for pharmaceutical companies to negotiate prescription drug prices with government healthcare programs; controls on government-funded reimbursement for drugs; new or increased requirements to pay prescription drug rebates to government healthcare programs, including if drug prices increase at a higher rate than inflation; controls on healthcare providers; challenges to or limits on the pricing of drugs, including pricing controls or limits or prohibitions on reimbursement for specific products through other means; requirements to try less expensive products or generics before a more expensive branded product; and public funding for cost effectiveness research, which may be used by government and private third-party payers to make coverage and payment decisions. In addition, in May 2025, the Trump administration issued an executive order entitled &#8220;Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,&#8221; which, among other things, directs the HHS and other agencies to communicate most-favored-nation (&#8220;MFN&#8221;) price targets to pharmaceutical manufacturers to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">bring prices for U.S. patients in line with comparably developed nations and to facilitate direct-to-consumer purchasing programs. The HHS subsequently issued guidance indicating the MFN target price is the lowest price paid in an Organization for Economic Co-operation and Development country with a gross domestic product (&#8220;GDP&#8221;) per capita of at least 60% of the U.S. GDP per capita. It is currently unclear whether and to what extent these measures will be implemented and what impact any such implementation would have on our business. Further, there can be no assurance that the current administration or future administrations will not pursue different or additional measures that could impact drug pricing in the U.S. Political, economic and regulatory developments may further complicate developments in healthcare systems and pharmaceutical drug pricing. These developments could, for example, impact our potential licensing agreements as  commercial and collaborative partners may also consider the impact of these pressures on their licensing strategies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any new laws or regulations that have the effect of imposing additional costs or regulatory burden on pharmaceutical manufacturers, or otherwise negatively affect the industry, could adversely affect our ability to successfully commercialize our product candidates. The implementation of any price controls, caps on prescription drugs or price transparency requirements could adversely affect our business, operating results and financial condition.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Evolving regulatory standards, including as a result of changes in government leadership, make it difficult to accurately predict the likelihood of marketing approval even when clinical trials meet their endpoints.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory standards are promulgated by various government entities and are subject to change based on factors such as scientific developments, public perceptions of risk, and political forces. Because clinical trials often take years to complete, it is sometimes possible for standards that exist during the conception and initiation of a clinical trial to change before the clinical trial is completed or reviewed by government regulators. For example, we may initiate clinical trials that are designed to show benefits on relatively short-term endpoints, but ultimately be required to show benefits in longer-term outcome studies. While some government entities have safeguards intended to ensure standards agreed upon by sponsors and regulators at the outset of a clinical trial are applied during regulatory review processes, those safeguards generally permit regulators to apply more rigorous standards where regulators believe doing so is necessary. As such, there can be no assurance that regulatory standards that are appropriate at the outset of a clinical trial program will not become more rigorous during the regulatory approval process and could potentially result in a delayed approval or denial of marketing authorization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA, EMA and other regulatory authorities may change their policies, issue additional regulations or revise existing regulations, or take other actions, including as a result of changes in leadership at the FDA and other federal agencies under the current U.S. administration, which may prevent or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained. In June 2024, the Supreme Court overruled the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chevron </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">doctrine, which had given deference to regulatory agencies&#8217; statutory interpretations of ambiguous regulations in litigation against federal government agencies, such as the FDA. The overruling of the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chevron </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">doctrine may significantly increase the number of challenges brought by companies and other stakeholders against federal agencies such as the FDA and its longstanding decisions and policies, including the FDA&#8217;s statutory interpretations of market exclusivities and the &#8220;substantial evidence&#8221; requirements for drug approvals, which could undermine the FDA&#8217;s authority, lead to uncertainties in the industry, and disrupt the FDA&#8217;s normal operations, any of which could delay the FDA&#8217;s review of our regulatory submissions. We cannot predict the full impact of this decision, future judicial challenges brought against the FDA, or the nature or extent of government regulation that may arise from future legislation or administrative action.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, under the new leadership at the HHS under the current administration, agency reorganization, mass layoffs due to the reduction in force initiative and other measures implemented by the Department of Government Efficiency may impact the normal operations of the FDA as well as other federal agencies. FDA may lack adequate staff and resources to meet current review, approval, and inspection schedules, which could delay our anticipated timelines and may have a material impact on the industry and our clinical development plans. For example, average review times at the FDA have fluctuated in recent years as a result. Our business depends upon the ability of the FDA to accept and review our potential regulatory filings. If a prolonged government shutdown occurs or if a significant number of federal employees are laid off or leave federal agencies, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our ability to advance clinical development of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. In January 2025, an executive order entitled &#8220;Unleashing Prosperity Through Deregulation&#8221;, was issued which calls for at least 10 existing regulations to be repealed whenever an executive department or agency publicly proposes for notice and comment or otherwise promulgates a new regulation. Recent developments at the FDA include announcement of a plan to phase out animal testing for monoclonal antibodies </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and certain other drugs, the proposed rare disease evidence principles (RDEP) program to facilitate approval of drugs to treat rare diseases with very small patient populations with significant unmet medical need and with a known genetic defect that is the major driver of the pathophysiology, and the announcement of a new Commissioner&#8217;s National Priority Voucher program for companies supporting certain U.S. national health priorities and interests. To the extent our competitors are selected for this new voucher pilot program, or are otherwise able to participate in any of these initiatives intended to accelerate drug development and application review, and obtain faster approval than us, our competitive position may be harmed. FDA has also increased its scrutiny of foreign drug manufacturing facilities and other contractors based in China, especially with respect to the transfer of biological materials, genetic data, and other sensitive data of American patients to parties located in China. It is unclear how our industry and our clinical programs will be impacted by policies and regulations implemented under the current administration and FDA leadership, or other executive orders. There is significant uncertainty in the industry and how federal agencies like the FDA will change in the coming years under the current administration. To the extent the agency reorganization and other agency changes lead to disruptions in FDA&#8217;s operations, our correspondence and regulatory review processes with the FDA may be materially delayed.</span></div><div id="ifa97f0f616f442a39c9869ed1f483476_22"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.7pt">UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="ifa97f0f616f442a39c9869ed1f483476_25"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1C.           CYBERSECURITY</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-37" continuedAt="f-37-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a cybersecurity program, with direct oversight from senior management and the Audit Committee (the &#8220;Audit Committee&#8221;) of the Board of Directors (the &#8220;Board&#8221;), to manage information, data, and technology security. The cybersecurity program is informed in part by the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF) and is designed to help identify, assess, and manage cybersecurity risks relevant to the Company&#8217;s business. The Company&#8217;s cybersecurity program has been developed in light of the nature of the Company&#8217;s business, resource availability, requirements from stakeholders, and industry trends. The Company has formed an internal cross-functional Technology Risk Management Committee comprised of representative leaders from various aspects of the Company&#8217;s business to broadly implement its cybersecurity program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cybersecurity program prioritizes vulnerability management, risk reduction, detection, and prevention to help protect against material risks from cybersecurity threats to its information systems. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-38">The Company periodically conducts internal and third-party cybersecurity risk assessments and penetration tests and incorporates relevant findings and recommendations into its overall cybersecurity strategy, as appropriate.</ix:nonNumeric> Through these assessments, the Company develops targeted strategies intended to address the most significant cybersecurity risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cybersecurity program emphasizes defense, rapid detection, and remediation of cybersecurity threats and incidents, including the use of various security tools and systems based on defense-in-depth and zero-trust principles that are intended to meet control requirements. The cybersecurity program also encompasses crisis incident response guidelines that detail the processes for the detection, response, mitigation, and remediation of cybersecurity incidents, in order to support the effective management of, response to, communication during, and recovery from any such incidents.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A key element of the Company&#8217;s strategy is fostering training and awareness through annual cybersecurity training and role-based phishing tests for employees and certain third parties having access to the Company&#8217;s information systems. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-39">The Company also utilizes a third-party cybersecurity operations monitoring center to help identify threats and incidents to the Company&#8217;s servers and computers.</ix:nonNumeric> The Company&#8217;s cybersecurity program includes specific requirements and guidelines for the information security team relating to the Company's computer emergency response preparedness, intrusion response preparedness, and incident response preparedness.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">When a potential cybersecurity threat or incident is identified, our processes require that the Senior Director of Information Security be promptly notified of the incident, who then is to conduct an initial investigation to determine the probability and potential of the threat or incident to have a material impact on key business systems and processes. If there is a reasonable possibility for a material impact to the Company&#8217;s business or information systems, the cybersecurity program requires that the Technology Risk Management Committee be promptly notified, which then assigns a risk level to the threat or incident. All threats and incidents identified as high-risk are promptly escalated to Company leadership and the legal department, who, in collaboration with the Company's Information Security department, are tasked with activating and implementing a high-risk information security incident mitigation and response plan, which details the roles, responsibilities, and strategies to respond. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-40">Our cybersecurity program also requires that high-risk cybersecurity incidents or threats be reported to the Company&#8217;s Materiality Committee and the Audit Committee within 24 hours of their designation as high-risk by the Technology Risk Management Committee.</ix:nonNumeric></span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-43" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-42" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-41" escape="true"><ix:continuation id="f-37-1" continuedAt="f-37-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-44">Cybersecurity risks are incorporated into our overall risk management program.</ix:nonNumeric> If a cybersecurity risk is identified as high-risk, a response and mitigation plan is developed, and progress updates on the plan are routinely reported to the Technology Risk Management Committee and tracked by the Audit Committee as part of our overall risk management process.</span></div></ix:continuation></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-37-2"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-45">The Company is not aware of any cybersecurity threats or incidents in the last fiscal year, including as a result of any prior cybersecurity incidents, that have had a material impact on the Company, including its business strategy, operations, or financial condition.</ix:nonNumeric> However, we face certain ongoing cybersecurity risks and threats that, if realized, are reasonably likely to materially affect us.  Additional information on cybersecurity risks we face is discussed in Part I, Item 1A &#8220;Risk Factors,&#8221; under the heading &#8220;Our business and operations could suffer in the event of a cybersecurity incident or other information technology system failures.&#8221;</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-46" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-47" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-48" escape="true">Execution of the Company&#8217;s cybersecurity program is delegated by the Board to the <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-49">Senior Director of Information Security</ix:nonNumeric>, who has over 25 years of relevant experience in information security, including 14 years at the Company, and is further supported by a team of security professionals within the Information Systems &amp; Informatics department.</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-50" escape="true">The Senior Director of Information Security reports to the Vice President, Treasury &amp; Head of Information Systems, and they meet periodically with senior leadership and the Audit Committee to review metrics on cybersecurity preparedness, incidents, mitigations and remediation efforts.</ix:nonNumeric></ix:nonNumeric> </span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-51" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also established a management-level Technology Risk Management Committee, which includes leaders from finance, legal, operations, quality &amp; compliance, and information systems &amp; informatics, who are responsible for overseeing the execution of high-risk incident response and mitigation plans. This committee actively reviews technology strategies, physical and cybersecurity threat assessment, and emerging issues and related initiatives. It is also responsible for evaluating the materiality of information for SEC filings and, as required or as otherwise appropriate, coordinates with the Company&#8217;s Materiality Committee to support timely disclosure of relevant information.</span></div></ix:nonNumeric></ix:nonNumeric><div id="ifa97f0f616f442a39c9869ed1f483476_28"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">PROPERTIES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s leased facilities as of November&#160;19, 2025.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Square Footage</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Primary Use</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Lease<br/>Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Lease <br/>Term (year)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Pasadena, California</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">49,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Headquarters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">April 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Madison, Wisconsin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">110,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">September 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">San Diego, California</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">144,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research and Office Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">April 2038</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">12.5</span></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company owns land in the Verona Technology Park in Verona, Wisconsin, which has been developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company&#8217;s manufacturing process development and analytical activities. The Company completed the build out of one of its laboratory and office facilities during the first quarter of fiscal year 2024 and substantially completed the build out of its manufacturing facility during the first quarter of fiscal year 2025.</span></div><div id="ifa97f0f616f442a39c9869ed1f483476_31"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">LEGAL PROCEEDINGS</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Legal Proceedings are set forth in the Company&#8217;s financial statement schedules in Part IV, Item 15 of this Annual Report on Form 10-K and are incorporated herein by reference. See Note 7 &#8212; Commitments and Contingencies of Notes to Consolidated Financial Statements of Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221;</span></div><div id="ifa97f0f616f442a39c9869ed1f483476_34"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">60</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="ifa97f0f616f442a39c9869ed1f483476_40"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Shares of the Company&#8217;s common stock are traded on The Nasdaq Global Select Market under the symbol &#8220;ARWR.&#8221; There were 86 holders of record of the Company&#8217;s common stock as of November&#160;19, 2025.  </span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has never paid dividends on its common stock and does not anticipate that it will do so in the foreseeable future. </span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Repurchases of Equity Securities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table contains information relating to the repurchases of our common stock during the three months ended September&#160;30, 2025 :</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Per Share</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchase as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares that May Yet Be Purchase Under the Plans or Programs</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">July 1 - July 31, 2025</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">August 1 - August 31, 2025</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,660,989&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">18.79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">September 1 - September 30, 2025</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,660,989&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">18.79&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In August 2025, the Company repurchased 2,660,989 shares of our common stock from Sarepta  in accordance with the share repurchase agreement related to the first development milestone payment for SRP-1003 under the Sarepta Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following performance graph shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933 or Securities Exchange Act of 1934, each as amended, except to the extent that we specifically incorporate it by reference into such filing. The graph compares the cumulative 5-year total return to stockholders on the Company&#8217;s common stock relative to the cumulative total returns of the Nasdaq Composite Index and the Nasdaq Biotechnology Index. The Company selected the Nasdaq Biotechnology Index because it believes the index reflects the market conditions within the industry in which the Company primarily operates. The comparison of total return on investment, defined as the change in year-end stock price plus reinvested dividends, for each of the periods assumes that $100 was invested on September 30, 2020 in each of the Company&#8217;s common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index, with investment weighted on the basis of market capitalization.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The comparisons in the following graph are based on historical data and are not intended to forecast the possible future performance of the Company&#8217;s common stock.</span></div><div style="margin-top:12pt;text-align:center"><img src="arwr-20250930_g6.jpg" alt="2058" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:613px" id="i-6"/></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:18.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$100 investment in stock or index</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Ticker</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Arrowhead Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">ARWR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">152.80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">221.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">117.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">95.35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">68.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">122.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">NASDAQ Biotechnology Index</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#x5E;NBI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">136.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">162.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">120.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">126.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">152.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">156.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">NASDAQ Composite Index</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#x5E;IXIC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">139.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">180.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">132.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">165.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">227.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">283.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div id="ifa97f0f616f442a39c9869ed1f483476_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.               RESERVED</span></div><div id="ifa97f0f616f442a39c9869ed1f483476_46"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div id="ifa97f0f616f442a39c9869ed1f483476_49"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and modes of delivery, the Company&#8217;s therapies trigger the RNAi interference mechanism to induce rapid, deep and durable knockdown of target genes. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that TRiM enabled therapeutics offer several potential advantages over prior generations and competing technologies, including: simplified manufacturing and reduced costs; multiple routes of administration including subcutaneous injection and inhaled administration; the ability to target multiple tissue types including liver, lung, skeletal muscle, central nervous system (CNS), adipose tissue, ocular, and cardio-myocytes; and the potential for improved safety and reduced risk of intracellular buildup, because there are fewer metabolites from smaller, simpler molecules. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pipeline includes:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Severe Hypertriglyceridemia - plozasiran (formerly ARO-APOC3, Greater China rights out-licensed to Sanofi);</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Homozygous familial hypercholesterolemia (HoFH) - zodasiran (formerly ARO-ANG3);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">Cardiovascular disease - olpasiran (formerly AMG 890 or ARO-LPA, out-licensed to Amgen);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">Mixed hyperlipidemia &#8211; ARO-DIMERPA (Greater China rights out-licensed to Sanofi);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">Inflammatory pulmonary conditions - ARO-RAGE;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">Idiopathic pulmonary fibrosis - SRP-1002 (formerly ARO-MMP7, out-licensed to Sarepta);</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">Metabolic-dysfunction associated steatohepatitis (MASH) - GSK4532990 (formerly ARO-HSD, out<br/>licensed to GSK and Visirna);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">Alpha-1 antitrypsin deficiency (AATD) - fazirsiran (formerly ARO-AAT, a collaboration with Takeda);</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">Chronic Hepatitis B virus - daplusiran/tomligisiran - GSK5637608 (formerly JNJ-3989 and ARO-HBV, out-licensed to GSK); </span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">Complement mediated diseases - ARO-C3 and ARO-CFB;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">Metabolic-dysfunction associated steatohepatitis (MASH) - ARO-PNPLA3 (formerly JNJ-75220795 or ARO-JNJ1);</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">Obesity - ARO-INHBE and ARO-ALK7</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">Facioscapulohumeral muscular dystrophy - SRP-1001 (formerly ARO-DUX4, out-licensed to Sarepta);</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">Myotonic Dystrophy Type 1 - SRP-1003 (formerly ARO-DM1 out-licensed to Sarepta; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">Spinocerebellar ataxia 2 - SRP-1004 (formerly ARO-ATXN2, out-licensed to Sarepta).</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">Parkinson&#8217;s disease &#8211; ARO-SNCA (out-licensed to Novartis) </span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">Alzheimer&#8217;s disease &#8211; ARO-MAPT </span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in California and Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to develop other clinical candidates for future clinical trials. Clinical candidates are tested internally and through Good Laboratory Practice (GLP) toxicology studies at outside laboratories. Drug materials for such studies and clinical trials are either manufactured internally or contracted to third-party manufacturers. The Company engages third-party contract research organizations (CROs) to manage clinical trials and works cooperatively with such organizations on all aspects of clinical trial management, including plan design, patient recruiting, and follow up. These outside costs, including toxicology/efficacy testing and manufacturing costs, as well as the preparation for and administration of clinical trials, are referred to as &#8220;candidate costs.&#8221; As clinical candidates progress through clinical development, candidate costs will increase. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2025 Business Highlights</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2025 and through the date of filing, the Company continued to develop and advance its pipeline and partnered candidates and expand its facilities to support its growing programs. The bullets below highlight some of these key developments; however, this list is not all-inclusive and is meant to be read in conjunction with the entirety of management&#8217;s discussion and analysis, the Company&#8217;s Consolidated Financial Statements and notes thereto, and all other items contained within this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">On November 20, 2025, the Company earned a $200.0&#160;million milestone payment from Sarepta. The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ARO-DM1, also called SRP-1003, an investigational RNAi therapeutic for the treatment of type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy. The second milestone event included the achievement of a patient enrollment target, drug safety committee review and subsequent authorization to dose escalate and proceed, and completion of day 105 study visit by at least one patient in the clinical trial;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">The FDA approved the Company's New Drug Application (NDA) for REDEMPLO (plozasiran) injection for Familial Chylomicronemia Syndrome (FCS), on November 18, 2025. This approval was supported by clinical data from the Phase 3 PALISADE study, a randomized, double-blind, placebo-controlled trial in adults with clinically diagnosed or genetically confirmed FCS. The PALISADE study met its primary endpoint and all multiplicity-controlled key secondary endpoints, including demonstrating significant reductions in triglycerides and APOC3. In PALISADE, 25 mg REDEMPLO achieved deep and durable reductions in triglycerides, with a median change from baseline of -80% versus -17% in the pooled placebo group, and a lower numerical incidence of acute pancreatitis compared with placebo;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-DIMER-PA, the Company&#8217;s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of the proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(APOC3) genes. This represents an important step forward for the RNAi field as it is the first clinical candidate to target two genes simultaneously in one molecule, enabled by Arrowhead&#8217;s innovative and proprietary TRiM platform;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-MAPT, the Company&#8217;s investigational RNAi therapeutic being developed as a potential treatment for tauopathies including Alzheimer&#8217;s disease, a progressive neurodegenerative disease characterized by cognitive and functional decline. Alzheimer&#8217;s disease is the most common cause of dementia and is estimated to affect 32 million people worldwide and is part of a group of neurodegenerative diseases called tauopathies that are marked by the abnormal accumulation and formation of tau tangles in neurons.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">On August 29, 2025, the Company entered into a global licensing and collaboration agreement with Novartis for ARO-SNCA, Arrowhead&#8217;s preclinical stage siRNA therapy against alpha-synuclein for the treatment of synucleinopathies, such as Parkinson&#8217;s Disease, and for other additional collaboration targets that will utilize Arrowhead&#8217;s proprietary TRiM platform. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions. Upon closing in October 2025, the Company received $200.0 million as an upfront payment and is eligible to receive up to $2.0 billion in potential milestone payments plus royalties on commercial sales. </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Triggered a $100.0 million milestone payment from Sarepta, which was achieved on July 27, 2025, when the Company reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNAi therapeutic for the treatment of type 1 myotonic dystrophy (DM1). Arrowhead received $53.2 million worth of Arrowhead common stock and $50.0 million in cash from Sarepta Therapeutics, satisfying the payment of the $100.0 million milestone owed to Arrowhead. </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Announced the signing of an asset purchase agreement between Sanofi and Visirna, a majority-owned subsidiary of the Company, created to develop and commercialize four of the Company&#8217;s investigational cardiometabolic candidates in Greater China. Under the terms of the agreement, Sanofi will acquire rights to develop and commercialize investigational plozasiran, the Company's first-in-class RNAi therapeutic candidate designed to reduce production of apolipoprotein C-III (APOC3) as a potential treatment for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (sHTG), in Greater China;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">Initiated and dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the Company&#8217;s investigational RNAi therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that leads to severely elevated LDL-cholesterol and early onset cardiovascular disease; <br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10pt">Completed enrollment of SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 clinical trials of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">REDEMPLO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">. The Company&#8217;s global Phase 3 clinical studies are designed to support regulatory submissions for approval of investigational </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">REDEMPLO</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> in the treatment of severe hypertriglyceridemia. </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">Initiated a Phase 1/2a clinical trial of ARO-ALK7 for the treatment of obesity. ARO-ALK7 is the first RNAi-based therapy designed to silence adipocyte expression of the ACVR1C gene to reduce the production of Activin receptor-like kinase 7 (ALK7), which acts as a receptor in a pathway that regulates energy homeostasis in adipose tissue;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">Announced Topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the Company&#8217;s investigational RNAi therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. ARO-C3 achieved reductions in alternative pathway complement activity and proteinuria;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">Entered into a global licensing and collaboration agreement with Sarepta on November 25, 2024, which closed on February 7, 2025. Upon closing, the Company received $325.0 million through the purchase of 11,926,301 shares of Company common stock by Sarepta, at a price per share of $27.25, and received $500.0 million as an upfront payment on February 24, 2025. The Company will also receive $250.0 million to be paid in equal installments over five years and is eligible to receive an additional $300.0 million in near-term payments. Additionally, the Company is eligible to receive royalties on commercial sales and up to approximately $10.0 billion in future potential milestone payments;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">GSK dosed its fifth patient in a Phase 2 trial in December 2024, triggering a $2.5 million milestone payment to the Company which was paid in the second quarter of fiscal 2025;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">Announced that the Company dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">Presented interim results from a Phase 1/2a clinical study of ARO-CFB at the 8th Complement-Based Drug Development Summit. The study resulted in multiple findings including: (1) ARO-CFB led to dose dependent reductions in circulating CFB protein by up to 90% with greater than 3 months duration, (2) single and multiple doses of ARO-CFB led to near complete inhibition of alternative pathway activity based on Wieslab AP, and (3) single and multiple doses of ARO-CFB led to near complete inhibition of alternative pathway hemolytic activity, measured by AH50.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Estimates </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management makes certain judgments and uses certain estimates and assumptions when applying U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) in the preparation of the Company&#8217;s Consolidated Financial Statements. On an ongoing basis, the Company evaluates its estimates, judgments and assumptions. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may vary from what the Company anticipates and different assumptions or estimates about the future could change its reported results. The Company believes the following accounting policies are the most critical to it, in that they require its most difficult, subjective or complex judgments in the preparation of the Company&#8217;s Consolidated Financial Statements. For further information, see Note 1, Organization and Significant Accounting Policies of the Notes to the Company&#8217;s Consolidated Financial Statements in Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221; </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has adopted Financial Accounting Standards Board (&#8220;FASB&#8221;) Topic 606 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue for Contracts from Customers. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not yet achieved commercial sales of its drug candidates to date; however, this standard is applicable to its licensing and collaboration agreements. This is discussed further in Note 2, Collaboration and License Agreements of the Notes to the Company&#8217;s Consolidated Financial Statements in Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that it determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing. If the license is not considered to be distinct from other performance obligations, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time. If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Typically, the Company&#8217;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a NDA in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most-likely-amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#8217;s consolidated statements of operations and comprehensive income (loss). Typically, milestone payments and royalties are achieved after the Company&#8217;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or preclinical program. Milestones or royalties achieved after the Company&#8217;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its licensing or collaboration agreements. Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment. Additionally, future royalty payments are not substantially within the control of the Company or the customer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. The estimates includes forecasted revenues and expenses, phase dates, probability of success, development timelines, and the discount rate. The estimates of the stand-alone selling price for research and development or other service-related performance obligations generally include forecasting the expected costs of satisfying a performance obligation at market rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Whenever we determine that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using the input method. Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations. If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on the Company&#8217;s consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of FASB Topic 808&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to research and development expense or general and administrative expense, as appropriate. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Accruals</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company accrues liabilities for products received or services incurred, particularly for ongoing clinical trials, where service providers have not yet billed or where billing terms do not align with the timing of the work performed as of the period-end. These costs mainly include third-party clinical management or clinical research organization (CRO), laboratory analysis, and investigator fees. Accrual estimates may be based on vendor communications to obtain pending invoices and/or estimates for services performed during the period. In some cases, these estimates require significant judgment, drawing on an understanding of research and development programs, services provided during the period, prior experience, and, where applicable, the expected duration of third-party contracts. Actual costs upon settlement may differ significantly from the accrued amounts in the Company&#8217;s consolidated financial statements, though historical estimates have not differed materially from actual costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liability Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Based on its evaluation of the agreement terms, the Company classifies the liability related to the sale of future royalties as a debt financing. The Company records the obligations at their carrying value using the effective interest method. In order to amortize the sale of future royalties, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize non-cash interest expense for the remaining periods. The Company periodically assesses the amount and the timing of expected royalty payments using a combination of internal projections and forecasts from external sources. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration, probability of success and sales price, among others. To the extent such payments are greater or less than the Company&#8217;s initial estimates or the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">timing of such payments is different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate. </span></div><div id="ifa97f0f616f442a39c9869ed1f483476_52"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following data summarizes the Company&#8217;s results of operations for the following periods indicated: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.005%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">829,448&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">240,735&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Operating income (loss)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">98,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(601,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(205,002)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Arrowhead</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1,631)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(599,493)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(205,275)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share (diluted) attributable to Arrowhead</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(5.00)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1.92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div id="ifa97f0f616f442a39c9869ed1f483476_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended September 30, 2025 Compared to Year Ended September 30, 2024</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue for the year ended September&#160;30, 2025 increased by $825.9 million, from the same period of 2024. The change was primarily driven by increased revenue recognition associated with the Sarepta, Sanofi, and GSK license  agreements as discussed below. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated each agreement in accordance with FASB Topic 808&#8211;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and Topic 606-</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue for Contracts from Customers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. See Note 2 &#8212; Collaboration and License Agreements of the Notes to Consolidated Financial Statements of Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Sarepta:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 25, 2024, the Company entered into the Sarepta Collaboration Agreement and Stock Purchase Agreement with Sarepta for the development and commercialization of multiple clinical and preclinical programs in rare, genetic diseases of the muscle, central nervous system, and lungs. During the fourth quarter of fiscal 2025, a </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$100.0 million milestone payment from Sarepta Therapeutics, Inc. was triggered, when the Company reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNAi therapeutic for the treatment of type 1 myotonic dystrophy (DM1). The Company received $53.2 million of Arrowhead common stock and $50.0 million cash from Sarepta to satisfy the milestone payment. </span><span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2025</span><span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recorded </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$696.8 million</span><span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Visirna</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: On August 1, 2025, Visirna Therapeutics HK Limited (&#8220;Visirna HK&#8221;), a wholly owned subsidiary of Visirna Therapeutics, Inc, a majority owned subsidiary of the Company, entered into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with Genzyme Corporation (&#8220;Sanofi&#8221;), a wholly owned subsidiary of Sanofi S.A., pursuant to which Visirna HK sold all of its assets and rights in investigational plozasiran to Sanofi, which included an assignment of Visirna HK&#8217;s rights (as successor by assignment from Visirna) to develop and commercialize investigational plozasiran in Greater China pursuant to that certain License Agreement by and between the Company and Visirna dated, April 25, 2022 (the &#8220;Visirna License Agreement&#8221;). </span><span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2025</span><span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recorded </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$130.0 million</span><span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GSK</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: On December 11, 2023, the Company entered into the GSK-HBV Agreement pursuant to which GSK received a worldwide, exclusive license to develop and commercialize daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989), the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of the GSK-HBV Agreement, the Company received $2.7 million in December 2023, upon signing the GSK-HBV Agreement. Further, GSK dosed the fifth patient in a Phase 2 trial in December 2024, triggering a $2.5 million milestone payment to the Company which was paid in the second qu</span><span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">arter of fiscal 2025. During the year ended </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">September&#160;30, 2025</span><span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">, the Company recorded </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">$2.6 million</span><span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> revenue.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">67</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The analysis below details the operating expenses and discusses the expenditures of the Company within the major expense categories. For purposes of comparison, the amounts for the years ended September&#160;30, 2025 and 2024 are shown in the tables below. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development (R&amp;D) Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses for drug candidate and drug discovery costs, which are comprised primarily of outsourced costs related to the manufacturing of clinical supplies, toxicity/efficacy studies and clinical trial expenses. Internal costs primarily relate to discovery operations at the Company&#8217;s research facilities in California and Wisconsin, including facility costs and laboratory-related expenses. The Company operates in a cross-functional manner across projects and does not separately allocate facilities-related costs, candidate costs, discovery costs, compensation expenses, depreciation and amortization expenses, and other expenses related to research and development activities. The Company does not separately track research and development expenses by individual research and development projects, or by individual drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of research and development expenses for the period indicated:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.580%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>September 30, 2025</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">% of<br/>Expense<br/>Category </span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>September 30, 2024</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">% of<br/>Expense<br/>Category </span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease) </span></td></tr><tr style="height:18pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Candidate costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">347,571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">259,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">88,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D discovery costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">66,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">74,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(7,362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Salaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">109,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">96,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">12,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Facilities related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">29,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">25,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expense, excluding non-cash expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">552,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">455,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">97,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">32,582&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">33,586&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1,004)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">607,159&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">505,870&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">101,289&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Candidate costs increased $88.3 million, or 34%, for the year ended September&#160;30, 2025 compared to the same period of 2024. The increase was primarily due to the additional progression of the Company&#8217;s pipeline of candidates into and through clinical trials, which resulted in higher manufacturing, outsourced clinical trial, and toxicity study costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D discovery costs decreased $7.4 million, or (10)%, for the year ended September&#160;30, 2025 compared to the same period of 2024. This decrease was primarily driven by strategic shifts toward clinical development and commercial launch. R&amp;D discovery costs are influenced by the Company&#8217;s ongoing discovery efforts, continued advancements into novel therapeutic areas and tissue types.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Salaries consist of salary, bonuses, payroll taxes, and related benefits for the Company&#8217;s R&amp;D personnel. Salaries expense increased $12.7 million, or 13%, for the year ended September&#160;30, 2025 compared to the same period of 2024. The increase was primarily due to an increase in headcount that has occurred as the Company has expanded its pipeline of candidates, in addition to annual salary increases.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facilities-related expense includes lease costs for the Company&#8217;s research and development facilities in San Diego, California and Madison and Verona, Wisconsin. These expenses increased $3.5 million, or 13%, for the year ended September&#160;30, 2025 compared to the same period of 2024. The increase was primarily due to full-year expenses such as utilities and repair and maintenance charges associated with the new facilities in Verona, Wisconsin, which completed their build out during the first quarter of fiscal 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense, a non-cash expense, is primarily based on the valuation of  restricted stock units granted to employees, which is based on the closing stock price on the grant date. Stock compensation expense decreased $1.0 million, or 3%, for the year ended September&#160;30, 2025 compared to the same period of 2024. The decrease was primarily due to the cancellation of awards upon the departure of employees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense, a non-cash expense, relates to depreciation on buildings, lab equipment and leasehold improvements. Depreciation and amortization expense increased $5.2 million, or 31% for the year ended September&#160;30, 2025 compared to the same period of 2024. The increase was primarily attributable to completion of the build out of facilities in Verona, Wisconsin, and the commencement of depreciation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General &amp; Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of general and administrative expenses for the periods indicated: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.580%"/><td style="width:0.1%"/></tr><tr style="height:16pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">% of<br/>Expense<br/>Category </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">% of<br/>Expense<br/>Category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease) </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$ </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">% </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Salaries</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">31,916&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">27,589&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,327&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Professional, outside services, and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">53,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">24,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">28,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Facilities related</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,625&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,116&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,509&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total general &amp; administrative expense, excluding non-cash expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">91,130&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">56,438&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">34,692&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">30,785&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">40,382&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(9,597)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation/amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total general &amp; administrative expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">123,943&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">98,761&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">25,182&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Salaries expense increased $4.3 million, or 16%, for the year ended September&#160;30, 2025 compared to the same period of 2024. The increase was driven by the combination of annual salary increases and an increase in headcount required to support the Company&#8217;s growth as the Company prepares for commercialization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Professional, outside services, and other expenses include costs related to legal, audit, consulting, patent filings, business insurance, other external services, as well as travel, communication, and technology expenses. These expenses increased $28.9 million, or 117%, for the year ended September&#160;30, 2025 compared to the same period of 2024. The increase was mainly due to professional services associated with commercialization and business development efforts as the Company prepares for a product launch, including costs for data analytics, marketing and commercial launch support. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facilities related expense primarily includes rental costs and other facilities-related costs for the Company&#8217;s corporate headquarters in Pasadena, California. These expenses increased $1.5 million, or 37%, for the year ended September&#160;30, 2025 compared to the same periods of 2024. The increase was primarily driven by higher common area maintenance charges, increased staff amenities expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense, a non-cash expense, is based on the valuation of restricted stock units granted to employees, which is based on the closing stock price on the grant date. This expense decreased by $9.6 million, or 24%, for the year ended September&#160;30, 2025 compared to the same period of 2024. The decrease was primarily due to lower compensation costs related to performance awards, as the timing of these expenses can vary based on the achievement of related performance targets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense, a noncash expense, was primarily related to amortization of leasehold improvements for the Company&#8217;s corporate headquarters.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other (Expense) Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income is primarily related to interest income and expense. Other expense increased $35.4 million for the year ended September&#160;30, 2025 compared to the same period of 2024. The increase was primarily due to non-cash interest expense associated with the liability related to the sale of future royalties and the Credit Facility, partially offset by higher income from increased investment yields.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Arrowhead Pharmaceuticals, Inc. was $1.6 million for the year ended September&#160;30, 2025 compared to a net loss attributable to Arrowhead Pharmaceuticals, Inc. of $599.5 million for the year ended September&#160;30, 2024. Net loss per share &#8211; diluted was $0.01 for the year ended September&#160;30, 2025 compared to net loss per share &#8211; diluted $5.00 for the year ended September&#160;30, 2024. The decrease in net loss attributable to Arrowhead Pharmaceuticals, Inc. for the year ended September&#160;30, 2025 compared to the same period of 2024 was primarily due to an increase in revenue from the Sarepta Collaboration Agreement, partially offset by higher research and development expenses, associated with the expansion of the Company's pipeline and progression through clinical trial phases.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Income Tax Expense (Benefit)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense was $21.4 million for the year ended September&#160;30, 2025, compared to an income tax benefit of $2.8 million for the same period in 2024. The change of $24.2 million was primarily due to higher taxable income in fiscal 2025 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">resulting from the recognition of $696.8 million in revenue under the Sarepta Collaboration Agreement and $130.0 million in revenue recognized by Visirna.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Non-controlling Interest</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to non-controlling interest was $31.7 million for the year ended September&#160;30, 2025, compared to a loss attributable to non-controlling interest of $10.2 million for the same period in 2024. The change of $41.9 million was primarily due to Visirna&#8217;s recognition of $130.0 million in revenue during fiscal 2025, resulting in a significant increase in net income, whereas Visirna incurred a net loss in fiscal 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended September 30, 2024 Compared to Year Ended September 30, 2023</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of the Company&#8217;s Form 10-K for the year ended September&#160;30, 2024 for a discussion of changes in its results of operations from the year ended September&#160;30, 2024 to the year ended September 30, 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">70</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically financed its operations through the sale of its equity securities, credit facility, revenue from its licensing and collaboration agreements, and the sale of certain future royalties. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure as the Company&#8217;s pipeline continues to expand and matures into later stage clinical trials, including commercialization efforts. For further information on the Company&#8217;s capital needs, see the section titled &#8220;Risks Related to Our Financial Condition&#8221; in &#8220;Item 1A. Risk Factors&#8221; of this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and restricted cash was $226.5 million at September&#160;30, 2025 compared to $102.7 million at September&#160;30, 2024. Cash invested in available-for-sale securities was $692.8 million at September&#160;30, 2025 compared to $578.3 million at September&#160;30, 2024.   </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On December 2, 2022, the Company entered into an open market sale agreement (&#8220;the Open Market Sale Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $250.0&#160;million in shares of the Company&#8217;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering. As of September&#160;30, 2025, no shares have been issued under the Open Market Sale Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, the Company entered into the Credit Facility, which provides for a senior secured term loan facility of $500.0&#160;million, which includes $400.0&#160;million funded on the closing date with an additional $100.0&#160;million at the Company&#8217;s option during the seven-year term of the agreement. The Company received net proceeds of $388.9&#160;million, after issuance costs as of September&#160;30, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On November 25, 2024, the Company entered into a licensing and collaboration agreement with Sarepta. Upon closing, the Company received $325.0 million for the purchase of 11,926,301 shares of common stock, at a price per share of $27.25, and received $500.0 million as an upfront payment on February 24, 2025. </span><span style="color:#242424;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">During the fourth quarter of fiscal 2025, a </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">$100.0 million milestone payment from Sarepta was triggered, when the Company reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNAi therapeutic for the treatment of type 1 myotonic dystrophy (DM1). The Company received $53.2 million of Arrowhead common stock and $50.0 million cash from Sarepta to satisfy the milestone payment. The Company is eligible to receive additional milestones of up to $250.0 million over the 12 months from the date of this report, inclusive of the second DM1 milestone payment of $200.0 million earned in November 2025. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On August 29, 2025, the Company entered into a licensing and collaboration agreement with Novartis. Upon closing in October 2025, the Company received $200.0 million as an upfront payment. The Company projects it will be eligible to receive additional milestones of up to $25.0 million over the 12 months from the date of this report. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Based upon the Company's current cash and investment resources and operating plan, the Company expects to have sufficient liquidity to fund its operations through at least the next twelve months from the date of the issuance of these consolidated financial statements.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of cash flows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash Flow from:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">179,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(462,851)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(153,890)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(129,294)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(420,072)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(96,155)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">74,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">870,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">253,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">124,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(12,403)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">226,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">102,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">110,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended September&#160;30, 2025, cash flow provided by operating activities was $179.6 million, which was primarily due to $500.0 million upfront payment and $50.0 million milestone payment received as part of the Sarepta agreement, partially offset by the ongoing expenses related to the Company&#8217;s research and development programs and general and administrative expenses. Cash used in investing activities amounted to $129.3 million, which was primarily attributable to capital expenditures of $22.7 million and investment purchases of $796.3 million, partially offset by proceeds from sales and maturities of investments of $689.6 million. Cash provided by financing activities of $74.0 million was related to cash received from the issuance of common stock in the Sarepta agreement, pre-funded warrants, and stock </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">option exercises. (See Note 6 &#8212; Stockholders' Equity of Notes to Consolidated Financial Statements of Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221;), partially offset by $201.6 million repayments of the Credit Facility. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended September&#160;30, 2024, cash flow used in operating activities was $462.9 million, which was primarily due to the ongoing expenses related to the Company&#8217;s research and development programs and general and administrative expenses, Cash used in investing activities amounted to $420.1 million, which was primarily attributable to capital expenditures of $141.5 million and investment purchases of $720.9 million, offset by proceeds from sales and maturities of investments of $442.3 million. Cash provided by financing activities of $870.5 million was related to cash received from the issuance of common stock, the Credit Facility, a milestone payment from Royalty Pharma, and stock option exercises.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of the Company&#8217;s Form 10-K for the year ended September&#160;30, 2024 for a discussion of cash flows from the year ended September 30, 2023.</span></div><div id="ifa97f0f616f442a39c9869ed1f483476_64"></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contractual Obligations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s current operating plan, it believes that cash, cash equivalents and short-term investments as of September&#160;30, 2025 will be sufficient to satisfy its near-term capital and operating needs. Recent and expected working and other capital requirements include the items described below. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">For information related to the Company&#8217;s future commitments for its collaboration and licensing agreements, see Note 2 of Notes to the Company&#8217;s Consolidated Financial Statements of Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Amounts related to future lease payments for operating lease obligations at September&#160;30, 2025 totaled $111.4 million, with</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$7.3 million expected to be paid within the next 12 months.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Cash outflows for capital expenditures related to the manufacturing facility build-out at Verona, Wisconsin were $12.5 million in 2025 and $136.9 million in 2024. The Company expects to spend an additional $0.1 million to complete the build out of the facilities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">A secured term loan facility of $500.0 million, which includes $400.0 million funded on the closing date with an additional $100.0 million at the Company&#8217;s option during the seven-year term of the agreement. The Company expects to make $40.0 million of prepayments on the facility within the next 12 months in additional to the $66.7 million prepayment made in November 2025 relating to the receipt of the upfront payment under the terms of the Novartis Collaboration Agreement. See Note 14 of Notes to the Company&#8217;s Consolidated Financial Statements of Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Commitments related to the Company&#8217;s clinical, manufacturing and business operation related agreements totaled $665.5 million as of September&#160;30, 2025. However, many of these agreements are cancellable. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The Company has not entered into, nor does it currently have, any off-balance sheet arrangements (as defined under SEC rules).  </span></div><div id="ifa97f0f616f442a39c9869ed1f483476_67"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.14pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to market risk exposures primarily due to its investing activities. The primary market risk exposure is change in interest rates. Adverse changes to rates may occur due to changes in the liquidity of a market or to changes in market perceptions of creditworthiness and risk tolerance. </span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s investment criteria are governed by its Investment Policy. The Company primarily invests its excess cash in securities of reputable financial institutions, corporations, and US government agencies with strong credit ratings. On September 30, 2023, the Company changed the classification of its investment securities from held-to-maturity to available-for-sale. This change enables the Company to sell securities to diversify its portfolio, reduce exposure to market risks, and provide flexibility to meet cash flow needs and new investment opportunities. Due to the relatively short-term nature of the investments that the Company holds, a hypothetical 100 basis point change in interest rates during any of the periods presented would not have had a material impact on the Company&#8217;s investment portfolio as of September 30, 2025.</span></div><div id="ifa97f0f616f442a39c9869ed1f483476_70"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is included in Item 15 of this Annual Report on Form 10-K. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">72</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ifa97f0f616f442a39c9869ed1f483476_76"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.14pt">CONTROLS AND PROCEDURES</span></div><div style="margin-top:12pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains disclosure controls and procedures designed to ensure that information required to be disclosed in its reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to its management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost benefit relationship of possible controls and procedures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As required by Rule 13a-15(b) of the Exchange Act, the Company carried out an evaluation, under the supervision and with the participation of its management, including its Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company&#8217;s disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Based on the foregoing, the Company&#8217;s Chief Executive Officer and Chief Financial Officer concluded that the Company&#8217;s disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. The Company&#8217;s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of its Consolidated Financial Statements for external purposes in accordance with GAAP. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This process includes those policies and procedures that:</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company&#8217;s assets; </span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures are being made only in accordance with authorizations of the Company&#8217;s management and directors; and </span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the Company&#8217;s financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the internal control over financial reporting to future periods are subject to risk that controls may become inadequate because either conditions change or the degree of compliance with policies or procedures may deteriorate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management has assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of September&#160;30, 2025. In making this assessment, the Company used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). Based on this assessment, management concluded that the Company&#8217;s internal control over financial reporting was effective as of September&#160;30, 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">KPMG LLP, the independent registered public accounting firm that audited the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Financial Statements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> included in this 2025 Annual Report on Form 10-K, has issued an audit report on the effectiveness of the Company&#8217;s internal control over financial reporting as of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which is included herein.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in the Company&#8217;s internal control over financial reporting during the Company&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company regularly evaluates its controls and procedures and makes improvements in the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">design and effectiveness of established controls and procedures and the remediation of any deficiencies which may be identified during this process.</span></div><div id="ifa97f0f616f442a39c9869ed1f483476_79"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.7pt">OTHER INFORMATION</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(b) <ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-52"><ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-53"><ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-54">Trading Plans</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-4" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-55" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal quarter ended September&#160;30, 2025, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.242%"><tr><td style="width:1.0%"/><td style="width:15.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.479%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.479%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.479%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.479%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.479%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.429%"/><td style="width:0.1%"/></tr><tr style="height:28pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Title</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Adoption or Termination Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Plan End Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Shares Vesting and Subject to Sell-To-Cover </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:114%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Other Shares Being Sold (Subject to Certain Conditions)</span></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-5" name="ecd:TrdArrIndName" id="f-56">Adeoye Olukotun</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-5" name="ecd:TrdArrIndTitle" id="f-57">Board Member</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-58"><ix:nonNumeric contextRef="c-5" name="ecd:TrdArrAdoptionDate" id="f-59">09/04/2025</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-5" name="ecd:TrdArrExpirationDate" id="f-60">12/24/2025</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-61">10,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-7" name="ecd:TrdArrIndName" id="f-62">Christopher Anzalone</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-7" name="ecd:TrdArrIndTitle" id="f-63">President and Chief Executive Officer</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-7" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-64"><ix:nonNumeric contextRef="c-7" name="ecd:TrdArrAdoptionDate" id="f-65">09/19/2025</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-7" name="ecd:TrdArrExpirationDate" id="f-66">12/24/2026</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-67">50,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-9" name="ecd:TrdArrIndName" id="f-68">Daniel Apel</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-9" name="ecd:TrdArrIndTitle" id="f-69">Chief Financial Officer</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-9" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-70"><ix:nonNumeric contextRef="c-9" name="ecd:TrdArrAdoptionDate" id="f-71">09/16/2025</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-9" name="ecd:TrdArrExpirationDate" id="f-72">04/30/2026</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-73">25,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-11" name="ecd:TrdArrIndName" id="f-74">James Hamilton</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-11" name="ecd:TrdArrIndTitle" id="f-75">Chief Medical Officer, Head of R&amp;D</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-11" name="ecd:TrdArrAdoptionDate" id="f-76"><ix:nonNumeric contextRef="c-11" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-77">09/03/2025</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-11" name="ecd:TrdArrExpirationDate" id="f-78">01/16/2026</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-79">72,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-13" name="ecd:TrdArrIndName" id="f-80">Mauro Ferrari</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-13" name="ecd:TrdArrIndTitle" id="f-81">Board Member</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-13" name="ecd:TrdArrAdoptionDate" id="f-82"><ix:nonNumeric contextRef="c-13" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-83">09/25/2025</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-13" name="ecd:TrdArrExpirationDate" id="f-84">12/31/2025</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-85">7,530</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-15" name="ecd:TrdArrIndName" id="f-86">Patrick O'Brien</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-15" name="ecd:TrdArrIndTitle" id="f-87">Chief Operating Officer &amp; General Counsel</ix:nonNumeric><br/></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-15" name="ecd:TrdArrAdoptionDate" id="f-88"><ix:nonNumeric contextRef="c-15" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-89">09/03/2025</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-15" name="ecd:TrdArrExpirationDate" id="f-90">01/07/2026</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-91">77,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-92">20,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-18" name="ecd:TrdArrIndName" id="f-93">Victoria Vakiener</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-18" name="ecd:TrdArrIndTitle" id="f-94">Board Member</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-18" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-95"><ix:nonNumeric contextRef="c-18" name="ecd:TrdArrAdoptionDate" id="f-96">09/03/2025</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-18" name="ecd:TrdArrExpirationDate" id="f-97">12/31/2025</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-98">10,040</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-20" name="ecd:TrdArrIndName" id="f-99">William Waddill</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-20" name="ecd:TrdArrIndTitle" id="f-100">Board Member</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-20" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-101"><ix:nonNumeric contextRef="c-20" name="ecd:TrdArrAdoptionDate" id="f-102">09/03/2025</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-20" name="ecd:TrdArrExpirationDate" id="f-103">12/31/2025</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-104">8,367</ix:nonFraction></span></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) This column indicates the total number of shares vesting, but the 10b5-1 Plan provides for the sale of only those shares necessary to satisfy payment of applicable withholding taxes.</span></div></ix:nonNumeric><div id="ifa97f0f616f442a39c9869ed1f483476_85"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.14pt">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ifa97f0f616f442a39c9869ed1f483476_88"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="ifa97f0f616f442a39c9869ed1f483476_91"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item will be incorporated by reference from the Company&#8217;s Definitive Proxy Statement, under the headings Proposal One &#8212; Election of Directors, Equity Compensation Plan Information, Corporate Governance, Environmental and Social Commitment, Executive Compensation, and, if applicable, Delinquent Section 16(a) Reports &#8212; to be filed for the Company&#8217;s 2026 Annual Meeting of Stockholders (the &#8220;Definitive Proxy Statement&#8221;).</span></div><div id="ifa97f0f616f442a39c9869ed1f483476_94"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">EXECUTIVE COMPENSATION</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item will be incorporated by reference from the Definitive Proxy Statement, under the heading Executive Compensation.</span></div><div id="ifa97f0f616f442a39c9869ed1f483476_97"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item will be incorporated by reference from the Definitive Proxy Statement, under the heading Voting Securities of Principal Stockholders and Management.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">74</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item will be incorporated by reference from the Definitive Proxy Statement, under the headings Review and Approval of Related-Party Transactions and Certain Relationships and Related Transactions, and Director Independence.</span></div><div id="ifa97f0f616f442a39c9869ed1f483476_103"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">PRINCIPAL ACCOUNTANT FEES AND SERVICES </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item will be incorporated by reference from the Definitive Proxy Statement, under the heading Audit Fees.</span></div><div id="ifa97f0f616f442a39c9869ed1f483476_106"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ifa97f0f616f442a39c9869ed1f483476_109"></div><div style="-sec-extract:summary;margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as part of this Annual Report on Form 10-K: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:33.34pt">Financial Statements.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See Index to Financial Statements and Schedule on page F-1. </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:33.34pt">Financial Statement Schedules.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See Index to Financial Statements and Schedule on page F-1. All other schedules are omitted as the required information is not present or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the Consolidated Financial Statements or notes thereto. </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:33.34pt">Exhibits. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed (or incorporated by reference herein) as part of this Annual Report on Form 10-K:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312511347334/d265091dex21.htm">Stock and Asset Purchase Agreement between Arrowhead Research Corporation and Roche entities, dated October 21, 2011</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Annual Report on Form 10-K as Exhibit 2.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">December 20, 2011</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459015003902/arwr-ex21_20150331298.htm">Asset Purchase and Exclusive License Agreement between Arrowhead Research Corporation and Novartis Institutes for BioMedical Research, Inc., dated March 3, 2015</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Quarterly Report on Form 10-Q, as Exhibit 2.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">May 11, 2015</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex33.htm">Amended and Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Current Report on Form 8-K as Exhibit 3.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">April 6, 2016</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828023014856/arrowheadpharmaceuticals.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Arrowhead Pharmaceuticals, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Quarterly Report on Form 10-Q, as Exhibit 3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">May 2, 2023</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828023002413/exhibit32.htm">Second Amended and Restated Bylaws</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Current Report on Form 8-K as Exhibit 3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">January 30, 2023</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex41.htm">Form of Common Stock Certificate of Arrowhead Pharmaceuticals, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Current Report on Form 8-K, as Exhibit 4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">April 6, 2016</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000879407/000119312519304271/d807419ds3asr.htm">Form of Indenture</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Registration Statement on Form S-3, as Exhibit 4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">December 2, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312517092797/d319463dex41.htm">Rights Agreement dated as of March 21, 2017, between the Company and Computershare Trust Company, N.A., as rights agent, which includes as Exhibit B the Form of Rights Certificate</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Current Report on Form 8-K, as Exhibit 4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">March 23, 2017</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459019044376/arwr-ex44_92.htm">Description of Registrant&#8217;s Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Annual Report on Form 10-K, as Exhibit 4.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">November 25, 2019</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000095012319000828/arwr-ex104_153.htm">Registration Rights Agreement by and between Arrowhead Pharmaceuticals, Inc. and Johnson &amp; Johnson Innovation-JJDC, Inc., dated October 3, 2018</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Quarterly Report on Form 10-Q, as Exhibit 10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">February 7, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828024049277/arrowhead-avoroxregistra.htm">Form of Registration Rights Agreement by and between Company and Avoro Life Sciences Fund LLC (included as Exhibit B in Exhibit 10.49)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 4.7</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">November 26, 2024</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828024049277/arrowhead-avoroxformofpr.htm">Form of Pre-Funded Warrant for Avoro Life Sciences Fund LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 4.8</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">November 26, 2024</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10.1**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312512009893/d275001ddef14a.htm">Arrowhead Research Corporation 2004 Equity Incentive Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Schedule 14C, as Annex B</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">January 12, 2012</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10.2**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312513481209/d647635ddef14a.htm">Arrowhead Research Corporation 2013 Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Schedule 14C, as Annex A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">December 20, 2013</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10.3**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312514048097/d675317dex101.htm">Form of Stock Option Agreement for use with the 2013 Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Current Report on Form 8-K, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">February 12, 2014</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10.4**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312514048097/d675317dex102.htm">Form of Restricted Stock Unit Agreement for use with the 2013 Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Current Report on Form 8-K, as Exhibit 10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">February 12, 2014</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10.5**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000879407/000119312521019640/d76219ddef14a.htm">Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Schedule 14A, as Exhibit A</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">January 28, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10.6**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000879407/000156459021041593/arwr-ex101_33.htm">Form of RSU Agreement for Officers and Certain Other Employees (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan- Inducement Award)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Registration Statement on Form S-8, as Exhibit 99.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">December 22, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10.7**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312521365055/d278970dex991.htm">Form of RSU Agreement for Officers and Certain Other Employees (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Registration Statement on Form S-8, as Exhibit 99.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">February 28, 2024</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10.8**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312521365055/d278970dex992.htm">Form of RSU Agreement for Employees (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan - Inducement Award)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Registration Statement on Form S-8, as Exhibit 99.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">December 22, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10.9**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312521365055/d278970dex992.htm">Form of RSU Agreement for Employees (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Registration Statement on Form S-8, as Exhibit 99.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">February 28, 2024</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10.10**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312521365055/d278970dex993.htm">Form of Stock Option Grant (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan- Inducement Award)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Registration Statement on Form S-8, as Exhibit 99.3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">December 22, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10.11**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828023040219/a1011-arrowhead_2021plan.htm">Form of Stock Option Grant (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Annual Report on Form 10-K, as Exhibit 10.11</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">November 29, 2023</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.12**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312506253375/dex1011.htm">Executive Incentive Plan, adopted December 12, 2006</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">December 14, 2006</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.13**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828024022215/exhibit101-arrowheadindu.htm">Arrowhead Pharmaceuticals, Inc. Inducement Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">May 9, 2024</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.14**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312508133616/dex101.htm">Employment Agreement between Arrowhead and Dr. Christopher Anzalone, dated June 11, 2008</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Current Report on Form 8-K, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">June 13, 2008</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.15**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312509258134/dex108.htm">Amendment to Employment Agreement between Arrowhead and Dr. Christopher Anzalone, effective May 12, 2009</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">December 22, 2009</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.16&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312511347334/d265091dex1036.htm">Collaboration Agreement by and among Alnylam Pharmaceuticals, Inc. and F. Hoffmann-La Roche Ltd and Hoffman-La Roche Inc., dated October 29, 2009</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.36</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">December 20, 2011</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.17&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312511347334/d265091dex1033.htm">Non-Exclusive License Agreement between Arrowhead Research Corporation and Roche entities, dated October 21, 2011</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.33</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">December 20, 2011</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.18&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459014003557/arwr-ex10_20140630353.htm">License Agreement by and between Alnylam Pharmaceuticals, Inc., Arrowhead Research Corporation and Arrowhead Madison, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">August 12, 2014</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.19&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459016030217/arwr-ex1019_309.htm">Second Collaboration and Licensing Agreement between Arrowhead Pharmaceuticals, Inc. and Amgen Inc., dated September 28, 2016</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">December 14, 2016</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312516776646/d272157dex101.htm">Common Stock Purchase Agreement between the Company and Amgen Inc., dated September 28, 2016</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Amendment No. 1 to the Registration Statement on Form S-3, as Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">November 25, 2016</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.21&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000095012319000828/arwr-ex101_156.htm">License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated October 3, 2018</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">February 7, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.22&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000879407/000156459019044376/arwr-ex1019_310.htm">Amendment No. 1 to License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated December 18, 2018</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">November 25, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.23&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459019044376/arwr-ex1020_311.htm">Amendment No. 2 to License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated February 4, 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">November 25, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.24&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828024003492/gsk-amendedandrestatedli.htm">Amended and Restated License Agreement by and between Arrowhead Pharmaceuticals, Inc. and GlaxoSmithKline Intellectual Property (No. 3) Limited, dated December 11, 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">August 8, 2024</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000095012319000828/arwr-ex103_154.htm">Stock Purchase Agreement by and between Johnson &amp; Johnson Innovation-JJDC, Inc. and Arrowhead Pharmaceuticals, Inc., dated October 3, 2018</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">February 7, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.26&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000879407/000156459021004319/arwr-ex101_863.htm">Exclusive License and Co-Funding Agreement by and between Arrowhead Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc., dated October 7, 2020</a></span><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">February 4, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.27</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459022019275/arwr-ex101_473.htm">First Amendment to Exclusive License and Co-Funding Agreement by and between Arrowhead Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. dated March 15, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">May 10, 2022</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.28&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000879407/000156459021041593/arwr-ex104_195.htm">Collaboration and License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Horizon Therapeutics Ireland DAC, dated June 18, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">August 5, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.29</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459022003616/arwr-ex101_514.htm">Collaboration and License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Glaxosmithkline Intellectual Property, dated November 22, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">February 2, 2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828023002413/exhibit101.htm">Royalty Purchase Agreement, dated as of November 9, 2022, by and between Arrowhead Pharmaceuticals, Inc. and Royalty Pharma Investments 2019 ICAV</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">February 6, 2023</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">10.31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459016012515/arwr-ex101_83.htm">Lease Agreement between University Research Park, Incorporated and Arrowhead Madison, Inc., dated January 8, 2016</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">February 9. 2016</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.32</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459020054893/arwr-ex1023_125.htm">Amendment No. 1 to Lease Agreement between Arrowhead Madison, Inc. and University Research Park, Incorporated, dated October 22, 2018</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">Annual Report on Form 10-K, as Exhibit 10.23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">November 23, 2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.33</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459020054893/arwr-ex1024_124.htm">Amendment No. 2 to Lease Agreement between Arrowhead Madison, Inc. and University Research Park, Incorporated, dated January 10, 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">November 23, 2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.34</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459020054893/arwr-ex1025_123.htm">Amendment No. 3 to Lease Agreement between Arrowhead Madison, Inc. and University Research Park, Incorporated, dated January 11, 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">November 23, 2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.35</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459020054893/arwr-ex1026_121.htm">Amendment No. 4 to Lease Agreement between Arrowhead Madison, Inc. and University Research Park, Incorporated, dated September 19, 2019 </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.26</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">November 23, 2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.36</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459020054893/arwr-ex1027_122.htm">Amendment No. 5 to Lease Agreement between Arrowhead Madison, Inc. and University Research Park, Incorporated, dated May 14, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.27</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">November 23, 2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.37</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459021004319/arwr-ex103_51.htm">Amendment No. 6 to Lease Agreement by and between Arrowhead </a></span><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459021004319/arwr-ex103_51.htm">Madison</a></span><span style="background-color:#ffffff;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459021004319/arwr-ex103_51.htm">, Inc. and University Research Park, dated November 23, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">February 4, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.38</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459021004319/arwr-ex104_52.htm">Amendment No. 7 to Lease Agreement by and between Arrowhead </a></span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459021004319/arwr-ex104_52.htm">Madison</a></span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459021004319/arwr-ex104_52.htm">, Inc. and University Research Park, dated December 9, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">Quarterly Report on Form 10-Q, as Exhibit 10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">February 4, 2021</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.39</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment No. 8 to Lease Agreement by and between Arrowhead <a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459016012515/arwr-ex101_83.htm">Madison</a>, Inc. and University Research Park, dated August 26, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.40</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment No. 9 to Lease Agreement by and between Arrowhead <a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459016012515/arwr-ex101_83.htm">Madison</a>, Inc. and University Research Park, dated April 3, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.41</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment No. 10 to Lease Agreement by and between Arrowhead <a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459016012515/arwr-ex101_83.htm">Madison</a>, Inc. and University Research Park, dated June 28, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.42</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment No. 11 to Lease Agreement by and between Arrowhead <a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459016012515/arwr-ex101_83.htm">Madison</a>, Inc. and University Research Park, dated September 13, 2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.43</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025038858/a106amendmentno12tolease.htm">Amendment No. 1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025038858/a106amendmentno12tolease.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025038858/a106amendmentno12tolease.htm"> to Lease Agreement by and between Arrowhead Madison, Inc. and University Research Park, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025038858/a106amendmentno12tolease.htm">June 11, 2025</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.6</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">August 7, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.44</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459019028760/arwr-ex101_67.htm">Office Lease by and between 177 Colorado Owner LLC and Arrowhead Pharmaceuticals, Inc., dated April 17, 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">August 5, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.45</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">First Amendment to Office Lease by<a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000879407/000156459021004319/arwr-ex102_50.htm"> and between Arrowhead Pharmaceuticals, Inc. and 177 Colorado Owner LLC., dated October 23, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">Quarterly Report on Form 10-Q, as Exhibit 10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">February 4, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.46</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459022003616/arwr-ex102_515.htm">Lease Agreement by and between Arrowhead Pharmaceuticals, Inc. and ARE-SD Region No. 72, LLC, dated November 19, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">February 2, 2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.47</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828023040219/a1039-firstamendmenttole.htm">First Amendment to Lease Agreement by and between Arrowhead Pharmaceuticals, Inc. and ARE-SD Region No. 72, LLC, dated September 26, 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.39</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">November 29, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10.48</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828022031597/arrowhead-atmxsalesagreeme.htm">Open Market Sale Agreement, dated as of December 2, 2022, by and between Arrowhead Pharmaceuticals, Inc. and Jefferies LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Current Report on Form 8-K as Exhibit 1.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">December 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.49</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828024049277/arrowhead-financingagree.htm">Financing Agreement by and between Company and Sixth Street Lending Partners, dated August 7, 2024</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.47</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">November 26, 2024</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.50</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025004634/exhibit104-arrowheadxame.htm">First Amendment to Financing Agreement by and between Company and Sixth Street Lending Partners, dated November 26, 2024</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">February 10, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.51</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025004634/sarepta-arrowheadxlicensea.htm">Exclusive License and Collaboration Agreement by and between the Company and Sarepta Therapeutics, Inc., dated November 25, 2024</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">February 10, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.52*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="projectauckland-licensecol.htm">Exclusive License and Collaboration Agreement by and between Arrowhead Pharmaceuticals, Inc. and Novartis Pharma AG, dated August 29, 2025</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.53</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/ceoseveranceandchangeofcon.htm">Severance and Change of Control Agreement by and between Company and Christopher Anzalone, dated May 9, 2025</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">May 12, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.54</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/cfoseveranceandchangeofcon.htm">Severance and Change of Control Agreement by and between Company and Daniel Apel, dated May 8, 2025</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">May 12, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.55</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/severanceandchangeofcontro.htm">Severance and Change of Control Agreement by and between Company and Patrick O'Brien, dated May 9, 2025</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">May 12, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.56</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/cmoseveranceandchangeofcon.htm">Severance and Change of Control Agreement by and between Company and James Hamilton, dated May 8, 2025</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">May 12, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10.57</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828025024666/retirementletteragreement-.htm">CFO Retirement Letter by and between Company and Ken Myszkowski, dated May 9, 2025</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">May 12, 2025</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">19.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828024049277/arwr-insidertradingpolic.htm"><ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-113">Arrowhead Pharmaceuticals, Inc. Insider Trading Policy</ix:nonNumeric></a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 19.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">November 26, 2024</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">21.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="subsidiarylisting-ex211.htm">List of Subsidiaries</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">23.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-20250930xex231.htm">Consent of Independent Public Registered Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">23.2*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="arrowheadengagementlette.htm">Consent of Independent Public Registered Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-20250930xex311.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-20250930xex312.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">32.1***</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-20250930xex321.htm">Certification by Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">32.2***</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-20250930xex322.htm">Certification by Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">97**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828023040219/a97-arwrxclawbackpolicyf.htm">Arrowhead Pharmaceuticals, Inc. Compensation Recoupment (Clawback) Policy, dated November 20, 2023</a></span><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%">     </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 97</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">November 29, 2023</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Instance Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">104*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#212529;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">The cover page from the Company&#8217;s Annual Report on Form 10-K for the year ended September 30, 2024, formatted in Inline XBRL (included as Exhibit 101)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Indicates compensation plan, contract or arrangement.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">***&#160;&#160;&#160;&#160;Furnished herewith</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Certain portions of this exhibit were redacted by means of marking such portions with asterisks because the identified portions are (i) not material and (ii) treated as private or confidential by the Company.</span></div><div id="ifa97f0f616f442a39c9869ed1f483476_112"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">FORM 10-K SUMMARY</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">79</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURE</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dated: November&#160;25, 2025</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">ARROWHEAD PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christopher Anzalone</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Christopher Anzalone</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">POWER OF ATTORNEY</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Christopher Anzalone and Daniel Apel, and each of them, as true and lawful attorneys-in-fact and agents, with full powers of substitution and resubstitution, for them and in their name, place and stead, in any and all capacities, to sign in any and all capacities (including, without limitation, the capacities listed below), this Annual Report on Form 10-K, any and all amendments thereto, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to such attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and anything necessary to be done to enable the registrant to comply with the provisions of the Securities Exchange Act and all the requirements of the Securities and Exchange Commission, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute, or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christopher Anzalone</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer, President and Director, Chairman of the Board of Directors  (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">November 25, 2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Christopher Anzalone</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Daniel Apel</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">November 25, 2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Daniel Apel</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mauro Ferrari</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">November 25, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Mauro Ferrari</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Douglass Ingram</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">November 25, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Douglass Ingram</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Hongbo Lu</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">November 25, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Hongbo Lu</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Adeoye Olukotun</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">November 25, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Adeoye Olukotun</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael S. Perry</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">November 25, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Michael S. Perry</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Victoria Vakiener</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">November 25, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Victoria Vakiener</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ William Waddill</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">November 25, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">William Waddill</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">80</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FINANCIAL STATEMENTS AND SCHEDULE</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:91.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_124">Reports of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"> (PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-114">185</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_124">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_127">Report</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_127"> of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_127">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_130">Consolidated Balance Sheets as of September 30, 202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_130">5</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_130"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_130">4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_130">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_133">Consolidated Statements of Operations and Comprehensive </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_133">Income (</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_133">Loss</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_133">)</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_133"> for the years ended September 30, 202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_133">5</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_133">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_133">4</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_133"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_133">3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_133">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_136">Consolidated Statements of Stockholders&#8217; Equity for the years ended September 30, 202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_136">5</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_136">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_136">4</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_136"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_136">3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_136">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_139">Consolidated Statements of Cash Flows for the years ended September 30, 202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_139">5</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_139">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_139">4</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_139"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_139">3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_139">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#ifa97f0f616f442a39c9869ed1f483476_142">Notes to Consolidated Financial Statements </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#ifa97f0f616f442a39c9869ed1f483476_142">10</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-1</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and <span id="i38ac65b4d4db4ae69c71d92d571b5fd3_75300"></span>Stockholders<br/>Arrowhead Pharmaceuticals, Inc.:</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Arrowhead Pharmaceuticals, Inc. and subsidiaries (the Company) as of September 30, 2025 and 2024, the related consolidated statements of operations and comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the years in the two-year period ended September 30, 2025, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2025 and 2024, and the results of its operations and its cash flows for each of the years in the two-year period ended September 30, 2025, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of September 30, 2025, based on criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated November&#160;25, 2025 expressed an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Sufficiency of audit evidence over valuation of future royalty sales liability</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 13 to the consolidated financial statements, the Company records the obligations under the Royalty Pharma Agreement with Royalty Pharma Investments (RPI) at carrying value using the effective interest method. The Company amortizes the sale of future royalties utilizing the prospective method to estimate future royalties to be paid by the Company to RPI over the life of the arrangement. The Company periodically assesses the amount and timing of expected royalty payments using a combination of internal projections and forecasts from external sources. To the extent such payments differ from the Company&#8217;s initial estimates, the Company will prospectively adjust the amortization of the royalty obligation and the effective interest rate. The estimate of the carrying value of the liability related to the sale of future royalties is derived from the estimate of future sales of olpasiran and the probability of success assumption. The estimate of future sales of olpasiran is based on key assumptions such as patient population, market penetration, olpasiran sales price, and the comparable guideline drug. The liability related to the sale of future royalties was $367,397 thousand as of September 30, 2025.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We identified the evaluation of the sufficiency of audit evidence over the determination of the carrying value of the liability related to the sale of future royalties as a critical audit matter. Subjective auditor judgment was required to evaluate the sufficiency of audit evidence obtained because of the level of audit effort associated with evaluating the carrying value of the liability related to the sale of future royalties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We applied auditor judgment to determine the nature and extent of procedures to be performed over the evaluation of the carrying value of the liability related to the sale of future royalties. We evaluated the design and tested the operating effectiveness of certain internal controls related to management&#8217;s valuation process, including the determination of the key assumptions into the carrying value of the liability related to the sale of future royalties as described above. We assessed the patient population and market penetration assumptions by comparing to independently sourced external market and industry data. We performed sensitivity analyses over the estimated olpasiran sales price and probability of success using independently sourced external market and industry data and evaluated the impact of changes in those assumptions on the carrying value of the liability related to the sale of future royalties. We assessed the reasonableness of the comparable guideline drug by evaluating against drugs similar to olpasiran in the marketplace. We evaluated the sufficiency of audit evidence obtained by assessing the cumulative results of the audit procedures performed and potential bias in the accounting estimate, including the appropriateness of the nature and extent of such evidence.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of distinct performance obligations related to the license and collaboration agreement with Sarepta Therapeutics, Inc</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 1 and 2 to the consolidated financial statements, the Company entered into an Exclusive License and Collaboration Agreement with Sarepta Therapeutics, Inc. (Sarepta). At contract inception, the Company assesses whether the goods or services promised within the contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price and allocates it to each performance obligation. The Company identified 17 performance obligations under the license and collaboration agreement with Sarepta. Fixed consideration of $833.6 million and an estimated variable consideration of $71.2 million were allocated to all performance obligations based on their relative standalone selling price.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We identified the evaluation of distinct performance obligations, including understanding the nature and significance of the contractual obligations and their standalone selling prices, related to the license and collaboration agreement with Sarepta as a critical audit matter. Subjective and complex auditor judgment was required to assess the Company&#8217;s identification of distinct performance obligations, including evaluating the rights and obligations described in the agreement, their benefit to the customer, and the level of modification or customization among the performance obligations. In addition, subjective auditor judgment was required to evaluate certain significant assumptions in the discounted cash flow model used by management to determine the standalone selling prices of the distinct performance obligations, including the discount rate and certain forecasted expenses. The audit effort associated with assessing the discount rate assumption required specialized skills and knowledge.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company&#8217;s revenue recognition process, including management&#8217;s identification of distinct performance obligations in the license and collaboration agreement and determination of the standalone selling prices. We evaluated management&#8217;s identification of distinct performance obligations and the significance of the contractual obligations by obtaining and reading the license and collaboration agreement to gain an understanding of the contractual terms and conditions and the commitments being made in the agreement. We conducted inquiries with personnel responsible for clinical development to understand the nature of the research and development activities specific to the clinical, preclinical, and discovery stage programs to evaluate the nature of the commitments made to the customer. We evaluated certain forecasted expenses within the discounted cash flow model by comparing such amounts to external market and industry data. We involved valuation professionals with specialized skills and knowledge, who assisted in the assessment of the discount rate within the discounted cash flow model by comparing it to a discount rate that was independently developed using publicly available market data for comparable companies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-115">KPMG LLP</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-116">San Diego, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">November&#160;25, 2025</span></div><div><span><br/></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><br/>Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders<br/>Arrowhead Pharmaceuticals, Inc.:</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Arrowhead Pharmaceuticals, Inc. and subsidiaries' (the Company) internal control over financial reporting as of September 30, 2025, based on criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of September 30, 2025, based on criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of September 30, 2025 and 2024, the related consolidated statements of operations and comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the years in the two-year period ended September 30, 2025, and the related notes (collectively, the consolidated financial statements), and our report dated November&#160;25, 2025 expressed an unqualified opinion on those consolidated financial statements.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">KPMG LLP</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">November&#160;25, 2025</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-4</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders of Arrowhead Pharmaceuticals, Inc. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying consolidated statements of operations and comprehensive income (loss), stockholders&#8217; equity, and cash flows for period ended September 30, 2023 of Arrowhead Pharmaceuticals, Inc. and Subsidiaries (the Company), and the related notes (collectively referred to as the financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated results of the Company&#8217;s operations and cash flows for the period ended September 30, 2023, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Rose, Snyder &amp; Jacobs LLP</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor from 2004 to 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Encino, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">November 29, 2023</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-5</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-117">88,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-118">76,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash at variable interest entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-119">137,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-120">26,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-121">6,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-122">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale securities, at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-123">692,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-124">578,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-125">10,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-126">9,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-127">13,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-128">4,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-129">950,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-130">695,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-131">382,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-132">386,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-133">6,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-134">8,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-135">43,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-136">45,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-137">1,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-138">4,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total Assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-139">1,385,295</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-140">1,139,802</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-141">17,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-142">11,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-143">90,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-144">63,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-145">26,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-146">21,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-147">7,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-148">6,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-149">2,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-150">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Credit facility</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:LinesOfCreditCurrent" format="ixt:num-dot-decimal" scale="3" id="f-151">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:LinesOfCreditCurrent" format="ixt:fixed-zero" scale="3" id="f-152">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-153">10,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-154">432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-155">195,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-156">103,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-157">104,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-158">111,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-159">367,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-160">341,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Credit facility, net of current portion</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-161">214,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-162">393,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-163">686,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-164">845,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-26" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-165"></ix:nonFraction></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-27" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-166"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interest and stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-167"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-168">0.001</ix:nonFraction></ix:nonFraction> par value:</span></div><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Authorized <ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-169"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-170">290,000</ix:nonFraction></ix:nonFraction> shares; issued and outstanding <ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-171"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-172">135,702</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-173"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-174">124,376</ix:nonFraction></ix:nonFraction> shares at September 30, 2025 and 2024, respectively </span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-175">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-176">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-177">2,139,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-178">1,806,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-179">6,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-180">4,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-181">1,627,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-182">1,625,523</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock; at cost; <ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-183">2,661</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="0" id="f-184">0</ix:nonFraction> shares of common stock at September 30, 2025 and 2024, respectively</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="f-185">53,193</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:fixed-zero" scale="3" id="f-186">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total Arrowhead Pharmaceuticals, Inc. stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-187">466,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-188">185,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-189">37,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-190">5,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total noncontrolling interest and stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-191">503,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-192">191,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total Liabilities, Noncontrolling Interest and Stockholders' Equity</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-193">1,385,295</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-194">1,139,802</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-6</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Income (Loss)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-195">829,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-196">3,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-197">240,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-198">607,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-199">505,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-200">353,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-201">123,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-202">98,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-203">92,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-204">731,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-205">604,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-206">445,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-207">98,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-208">601,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-209">205,002</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="3" id="f-210">37,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="3" id="f-211">22,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="3" id="f-212">15,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-213">89,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-214">32,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-215">18,326</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-216">5,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-217">1,748</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-218">1,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total other expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-219">46,813</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-220">11,380</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-221">1,489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) before income tax expense and noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-222">51,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-223">612,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-224">206,491</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-225">21,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-226">2,767</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-227">2,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) including noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-228">30,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-229">609,693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-230">209,275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to noncontrolling interest, net of tax</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-231">31,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-232">10,200</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-233">4,000</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-234">1,631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-235">599,493</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-236">205,275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share attributable to Arrowhead Pharmaceuticals, Inc.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-237">0.01</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-238">5.00</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-29" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-239">1.92</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-240">0.01</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-241">5.00</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-29" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-242">1.92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-243">133,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-244">119,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-245">106,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-246">133,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-247">119,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-248">106,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-249">2,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-250">3,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-251">2,964</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-252">432</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-253">4,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-254">122</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributed to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-255">31,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-256">10,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-257">4,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-258">31,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-259">601,721</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-260">212,361</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-7</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock in Treasury</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Totals </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-261">105,960</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-262">198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-263">1,219,213</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-264">136</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-265">820,755</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-266">19,819</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-267">418,339</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-268">78,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-269">78,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-270">439</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-271">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-272">3,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-273">3,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-274">913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-275">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-276">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="f-277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-278">2,964</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-279">2,964</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-280">122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-281">122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Net loss </span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-282">205,275</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-283">4,000</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-284">209,275</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Balance at September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-285">107,312</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-286">200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-287">1,300,395</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-288">3,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-289">1,026,030</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-290">15,819</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-291">287,162</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss) Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock in Treasury</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Totals </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Balance at September 30, 2023</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-292">107,312</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-293">200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-294">1,300,395</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-295">3,222</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-296">1,026,030</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-297">15,819</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-298">287,162</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-299">73,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-300">73,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-301">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-302">2,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-303">2,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="f-304">1,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-305">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-306">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="f-307">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Common stock issued, net of offering costs</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-308">15,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-309">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-310">429,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-311">429,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized gains on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-312">3,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-313">3,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-314">4,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-315">4,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-316">599,493</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-317">10,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-318">609,693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Balance at September 30, 2024</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-319">124,376</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-320">217</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-321">1,806,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-322">4,750</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-323">1,625,523</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-324">5,619</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-325">191,063</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock in Treasury</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Balance at September 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-326">124,376</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-327">217</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-328">1,806,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-329">4,750</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-330">1,625,523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-57" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:fixed-zero" scale="3" id="f-331">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-332">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-333">5,619</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-334">191,063</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-335">63,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-336">63,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-337">535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-338">3,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-339">3,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="f-340">1,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-341">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-342">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-343">11,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-344">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-345">241,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-346">241,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Common stock - repurchase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-60" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="f-347">2,661</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-348">53,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-349">53,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of pre-funded warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="f-350">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="f-351">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized gains on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-352">2,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-353">2,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-354">432</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-355">432</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-356">1,631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-357">31,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-358">30,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">Balance at September 30, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-359">138,363</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-360">231</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-361">2,139,725</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-362">6,443</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-363">1,627,154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-68" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-364">2,661</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-365">53,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-366">37,364</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-367">503,416</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-8</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_139"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:700;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-368">30,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-369">609,693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-370">209,275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash flow from operating activities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-371">63,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-372">73,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-373">78,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-374">23,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-375">18,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-376">12,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Accretion of note premiums/discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="f-377">5,789</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="f-378">3,244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="f-379">2,017</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-cash interest expense on liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-380">26,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="arwr:NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-381">23,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="arwr:NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-382">18,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-cash interest expense on credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:num-dot-decimal" scale="3" id="f-383">63,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:num-dot-decimal" scale="3" id="f-384">9,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:fixed-zero" scale="3" id="f-385">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-cash gain on treasury stock received</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:GainLossOnTreasuryStockSettlement" format="ixt:num-dot-decimal" scale="3" id="f-386">3,193</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="arwr:GainLossOnTreasuryStockSettlement" format="ixt:fixed-zero" scale="3" id="f-387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="arwr:GainLossOnTreasuryStockSettlement" format="ixt:fixed-zero" scale="3" id="f-388">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Realized loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RealizedInvestmentGainsLosses" format="ixt:fixed-zero" scale="3" id="f-389">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="3" id="f-390">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:RealizedInvestmentGainsLosses" format="ixt:fixed-zero" scale="3" id="f-391">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-392">56,967</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-393">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-394">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-395">9,939</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-396">1,664</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-397">11,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-398">6,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-399">5,536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-400">32,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-401">41,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-402">32,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-403">14,965</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-404">2,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-405">866</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-406">129,183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Operating lease, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-407">4,605</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-408">2,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-409">46,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:num-dot-decimal" scale="3" id="f-410">3,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:num-dot-decimal" scale="3" id="f-411">1,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:fixed-zero" scale="3" id="f-412">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-413">179,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-414">462,851</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-415">153,890</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:700;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-416">22,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-417">141,469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-418">176,737</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-419">796,258</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-420">720,947</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-421">246,141</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="f-422">689,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="f-423">442,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="f-424">326,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-425">129,294</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-426">420,072</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-427">96,155</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:700;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from the exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-428">3,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-429">2,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-430">3,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from the issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-431">429,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-432">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:ProceedsFromSaleOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="f-433">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="arwr:ProceedsFromSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-434">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="arwr:ProceedsFromSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-435">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from the issuance of warrants</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-436">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:fixed-zero" scale="3" id="f-437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:fixed-zero" scale="3" id="f-438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Payment of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-439">5,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-440">3,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from the issuance of common stock</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-442">241,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-444">392,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Repayments of credit facility</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-446">201,625</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from Visirna credit agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-449">10,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-450">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-452">74,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-453">870,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-454">253,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-455">124,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-456">12,403</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-457">3,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Effect of exchange rate on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-458">401</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-459">4,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-460">122</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:700;line-height:100%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">BEGINNING OF PERIOD</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-461">102,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-462">110,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-463">108,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">END OF PERIOD</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-464">226,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-465">102,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-466">110,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:700;line-height:100%">Supplementary disclosure of cash flows:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-467">19</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-468">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-469">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Income taxes (refund) paid</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-470">814</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-471">3,744</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="f-472">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Treasury stock received to settle accounts receivable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-473">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="arwr:TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-474">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="arwr:TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-475">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:700;line-height:100%">Supplementary disclosure of non-cash investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">Capital expenditures included in accrued expenses</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-476">277</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-477">4,206</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-478">14,044</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-9</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_142"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div id="ifa97f0f616f442a39c9869ed1f483476_145"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-479" continuedAt="f-479-1" escape="true">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-479-1" continuedAt="f-479-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#8220;Company&#8221;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#8217;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><ix:nonNumeric contextRef="c-1" name="arwr:ScheduleOfCurrentProductsTableTextBlock" id="f-480" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.962%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:27pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">plozasiran</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">zodasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">olpasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-PNPLA3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">GSK4532990</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">GSK</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-INHBE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-ALK7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-DIMERPA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-RAGE</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">SRP-1002 (ARO-MMP7)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">fazirsiran</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Takeda and Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">daplusiran/tomligisiran</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Neuromuscular</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">SRP-1001 (ARO-DUX4)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">SRP-1003 (ARO-DM1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">SRP-1004 (ARO-ATXN2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-SNCA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Pre-clinical</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Novartis</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-MAPT </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-C3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-CFB</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-style:italic;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Greater China rights for plozasiran are out-licensed to Sanofi.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in California and Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company also operates an active pharmaceutical ingredient manufacturing and supporting laboratory facility in Verona, Wisconsin. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity for which the Company is the primary beneficiary). Subsidiaries refer to Arrowhead Madison, Inc., Arrowhead Australia Pty Ltd., Arrowhead Pharmaceuticals Ireland Limited, Arrowhead Pharmaceuticals NZ Limited, and Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;). For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). All intercompany transactions and balances have been eliminated.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-479-2" continuedAt="f-479-3"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as a single segment as the chief operating decision maker, or CODM, reviews operating results on an aggregate basis and manages the operations as a single operating segment. Refer to Note 16, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, for further details on the segment information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s primary sources of financing have been through the sale of its equity securities, credit facility, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#8217;s pipeline of drug candidates and its headcount have both expanded. Additionally, significant investment will be required as the Company&#8217;s pipeline matures into later stage clinical trials and commercialization efforts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-481">226.5</ix:nonFraction> million in cash, cash equivalents and restricted cash ($<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="f-482">1.9</ix:nonFraction> million in restricted cash) and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="f-483">692.8</ix:nonFraction> million in available-for-sale securities to fund operations. During the year ended September&#160;30, 2025, the Company&#8217;s cash, cash equivalents and restricted cash and investments balance increased by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arwr:IncreaseDecreaseInCashAndInvestments" scale="6" id="f-484">238.4</ix:nonFraction> million, which was primarily due to the $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="arwr:ProceedsFromCollaborationArrangements" scale="6" id="f-485">500.0</ix:nonFraction> million as an upfront payment under the Sarepta agreement and $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="f-486">325.0</ix:nonFraction> million in the form of an equity investment under the Sarepta agreement, $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="arwr:DevelopmentMilestonePayments" scale="6" id="f-487">100.0</ix:nonFraction> million relating to the achievement of partnership milestone achievement of which $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="arwr:ProceedsFromCollaborationArrangements" scale="6" id="f-488">50.0</ix:nonFraction> million was settled in cash and the remaining $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-489">50.0</ix:nonFraction> million was settled through the repurchase of Company's common stock , $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="f-490">37.3</ix:nonFraction> million interest income earned on investments, and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" id="f-491">25.0</ix:nonFraction> million in the form of pre-funded warrants, partially offset by ongoing expenses related to the Company&#8217;s research and development programs, $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" scale="6" id="f-492">201.6</ix:nonFraction> million payments on its credit facility and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-493">22.7</ix:nonFraction> million relating to capital expenditure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-8" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" scale="9" id="f-494">13.4</ix:nonFraction> billion in additional developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-495" continuedAt="f-495-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-495-1">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, judgments and assumptions. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results could materially differ from those estimates.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-496" continuedAt="f-496-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash, Cash Equivalents and Restricted Cash</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-496-1">All highly liquid interest-bearing investments are classified as cash equivalents. These investments mainly include  term deposits, money market instruments, corporate debt securities, and certificate of deposits with maturities of three months or less when purchased. The carrying value of these cash equivalents approximate fair value.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There was $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="f-497">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="f-498">3.5</ix:nonFraction> million restricted cash at September&#160;30, 2025 and 2024, respectively, that is primarily held as collateral associated with letters of credit for the Company&#8217;s facility leases. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-499" continuedAt="f-499-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company classified all of its investments in debt securities as available-for-sale and as current assets as they represent the investment of funds available for current operations as of September&#160;30, 2025 and 2024. The available-for-sale investments may consist of investment-grade interest bearing instruments, primarily corporate debt securities, U.S. government and agency securities, commercial notes, certificate of deposits, and municipal securities, which are accounted for at fair value.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dividends from these funds were automatically re-invested. Changes in fair values are reported as unrealized gains or losses and are recorded in the Company&#8217;s consolidated statement of operations and comprehensive income (loss).</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its investments for impairment based on a security-specific analysis as of each balance sheet date. If the fair value of a security is below its amortized cost, the Company first assesses whether it intends to sell the security or is more likely than not required to sell it before recovery of its amortized cost. If neither condition is met, the Company evaluates whether a portion of the decline is attributable to credit loss. Any credit-related impairment is recorded as an allowance for credit losses through earnings, with non-credit-related unrealized losses recorded in other </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-479-3" continuedAt="f-479-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-499-1">comprehensive income (loss). The Company did not recognize any credit loss relating to its investment for the years ended September&#160;30, 2025, 2024, and 2023.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-500" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentration of credit risk primarily consist of cash, cash equivalents and restricted cash and investments. As of September&#160;30, 2025 and 2024, the Company&#8217;s investments were primarily invested in money market funds, U.S. Government, commercial paper, and corporate debt securities and term deposit through highly rated financial institutions. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity. The Company also maintains several bank accounts at two financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Visirna maintains several deposit and term accounts in mainland China, Hong Kong, and Singapore. Cash balances are held with various local and international financial institutions, which are subject to their respective jurisdictional deposit insurance programs. The Deposit Insurance Fund Management Corporation in China provides coverage of up to RMB 500,000 per depositor per institution, and the Hong Kong Deposit Protection Scheme provides protection of up to HKD 800,000 per depositor per bank, and the Singapore Deposit Insurance Corporation provides coverage of up to SGD 100,000 per depositor per member bank.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-501" continuedAt="f-501-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property, Plant and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at cost, net of accumulated depreciation. Depreciation expense is recorded on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the asset life or lease term. Construction in progress reflects amounts incurred for construction or improvements of property, plant and equipment that have not been placed in service. Upon disposition, the cost and accumulated depreciation of assets retired or sold are removed from the respective asset category, and any gain or loss is recognized in the Company&#8217;s consolidated statement of operations and comprehensive income (loss).</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-502" continuedAt="f-502-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The estimated useful lives of property, plant and equipment are as follows (in years):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Buildings</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-73" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-503">39</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-74" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-504">5</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-75" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-505">7</ix:nonNumeric> to <ix:nonNumeric contextRef="c-76" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-506">10</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-77" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-507">7</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-78" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-508">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-79" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-509">5</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Shorter of asset life or lease term</span></div></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-501-1">The Company periodically assesses long-lived assets or asset groups, including property, plant and equipment, for recoverability when events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the Company identifies an indicator of impairment, the Company assesses recoverability by comparing the carrying amount of the asset to the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset. An impairment loss is recognized when the carrying amount is not recoverable and is measured as the excess of carrying value over fair value. There were no impairment charges during the years ended September&#160;30, 2025, 2024, and 2023.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="f-510" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intangible Assets Subject to Amortization</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include certain patents and license agreements. The Company evaluates intangible assets for impairment annually or whenever events or changes in circumstances indicate that it is more likely than not that the carrying amount of intangible assets may exceed their implied fair values. <ix:nonFraction unitRef="usd" contextRef="c-28" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-511"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-512"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-513">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment charges were recorded during the years ended September&#160;30, 2025, 2024, and 2023.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-514" continuedAt="f-514-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether a contract is, or contains, a lease at inception. All of the Company&#8217;s leases are classified as operating leases. Leases with terms greater than one-year are recognized on the Company&#8217;s consolidated balance sheets as right-of-use assets that represent the Company&#8217;s right to use an underlying asset for the lease term, and lease liabilities that represent its obligation to make lease payments arising from the lease. Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the expected lease term. As of September&#160;30, 2025 and 2024, the Company is not reasonably certain that it will exercise renewal options for any lease facilities. Therefore, these options are not included in the right-of-use assets and liabilities. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-479-4" continuedAt="f-479-5"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-514-1">The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="arwr:ClinicalAccrualPolicyPolicyTextBlock" id="f-515" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Accruals</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues liabilities for products received or services incurred, particularly for ongoing clinical trials, where service providers have not yet billed or where billing terms do not align with the timing of the work performed as of the period-end. These costs mainly include third-party clinical management or clinical research organization (CRO), laboratory analysis, and investigator fees. Accrual estimates may be based on vendor communications to obtain pending invoices and/or estimates for services performed during the period. In some cases, these estimates require significant judgment, drawing on an understanding of research and development programs, services provided during the period, prior experience, and, where applicable, the expected duration of third-party contracts. Actual costs upon settlement may differ significantly from the accrued amounts in the Company&#8217;s consolidated financial statements, though historical estimates have not differed materially from actual costs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-516" continuedAt="f-516-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that it determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing. If the license is not considered to be distinct from other performance obligations, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time. If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Typically, the Company&#8217;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a New Drug Application (&#8220;NDA&#8221;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#8217;s consolidated statements of operations and comprehensive income (loss). Typically, milestone payments and royalties are achieved after the Company&#8217;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or preclinical program. Milestones or royalties achieved after the Company&#8217;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-479-5" continuedAt="f-479-6"><ix:continuation id="f-516-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its licensing or collaboration agreements. Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment. Additionally, future royalty payments are not substantially within the control of the Company or the customer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, the revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using the input method; Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations. If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#8217;s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="f-517" continuedAt="f-517-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Arrangements</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><ix:continuation id="f-517-1" continuedAt="f-517-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of Financial Accounting Standards Board (&#8220;FASB&#8221;) Topic 808 - </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606 - </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue for Contracts from Customers</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-517-2">. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to research and development expense or general and administrative expense, as appropriate.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-518" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred. Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#8217;s research and development operations, and costs to acquire technology licenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-519" continuedAt="f-519-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense for all stock grants are based on their estimated grant-date fair value. The fair value of stock option awards is estimated using the Black-Scholes option valuation model which requires the input of subjective assumptions to calculate the value of stock options. The Company uses historical data and other information to estimate the expected price volatility and the expected forfeiture rate for stock option awards. For restricted stock units, the value of the award is based on the Company&#8217;s stock price at the grant date. For performance-based restricted stock unit awards, the value of the award is based on the Company&#8217;s stock price at the grant date, with consideration given to the </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-479-6" continuedAt="f-479-7"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-519-1">probability of the performance condition being achieved. Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#8217;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-520" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting basis and the respective tax basis of the Company&#8217;s assets and liabilities, and expected benefits of utilizing net operating loss, capital loss, and tax-credit carryforwards. The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent management does not believe these assets are more likely than not to be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or laws is recognized in earnings in the period that includes the enactment date.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="f-521" continuedAt="f-521-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Variable Interest Entity (&#8220;VIE&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is an entity that, by design, either (i) lacks sufficient equity to permit the entity to finance its activities without additional subordinated financial support from other parties; or (ii) has equity investors that do not have the ability to make significant decisions relating to the entity&#8217;s operations through voting rights, or do not have the obligation to absorb the expected losses, or do not have the right to receive the residual returns of the entity. The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. The primary beneficiary is the party that has both (i) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance, and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE through its interest in the VIE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, the Company entered into a license agreement with Visirna (Note 2) and consolidated Visirna&#8217;s financial statements in which the Company has a direct controlling financial interest based on the VIE model. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all the facts and circumstances, including its role in establishing Visirna and its ongoing rights and responsibilities to assess whether the Company has the power to direct the activities of Visirna. In general, the parties that make the most significant decisions affecting a VIE and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company also considers all of its economic interests to assess whether the Company has the obligation to absorb losses of Visirna or the right to receive benefits from it that could potentially be significant to Visirna. This assessment requires the Company to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to Visirna. Factors considered in assessing the significance include: the design of  Visirna, including its capitalization structure, subordination of interests, payment priority, and the reasons why the interests are held by the Company. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-521-1">At Visirna&#8217;s inception, the Company determined it was the primary beneficiary and that Visirna should be consolidated based on the facts and circumstances. The Company performs ongoing reassessments of the VIE based on reconsideration events and reevaluates whether a change to the consolidation conclusion is required. As of September&#160;30, 2025, there were no events to be reconsidered in the consolidation.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-522" continuedAt="f-522-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Loss per Share</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units outstanding. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-522-1">During the years ended September&#160;30, 2025, 2024 and 2023, the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units outstanding during the period due to their anti-dilutive effect.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-523" continuedAt="f-523-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Currency Translation Adjustments</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-523-1"><ix:nonFraction unitRef="subsidiary" contextRef="c-26" decimals="INF" name="arwr:NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency" format="ixt-sec:numwordsen" scale="0" id="f-524">Three</ix:nonFraction> of the Company&#8217;s wholly-owned subsidiaries&#8217; functional currencies is not the United States dollar, which is the Company&#8217;s reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Translation adjustments arising from the use of different exchange rates from period to period are included in the accumulated other comprehensive income (loss).</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-479-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-525" continuedAt="f-525-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Segment Information</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-525-1">The Company operates as a single segment because its CODM reviews operating results on an aggregate basis and manages its operations as a single operating segment.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-526" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in November 2024, and ASU 2025-01,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Clarifying the Effective Date</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. These updates require entities to provide disaggregated disclosures of income statement expenses. The ASUs do not affect the expense captions presented on the face of the income statement but instead require the disaggregation of certain expense captions into specified categories within the footnotes to the financial statements. The ASUs will become effective for the Company beginning October 1, 2027, and the Company is currently evaluating the impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standard Update (&#8220;ASU&#8221;) 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to improve its income tax disclosure requirements. Under the guidance, entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. This guidance became effective for the Company beginning on October 1, 2025. The Company does not expect any material impact on its consolidated financial statements and related disclosures resulting from applying this ASU. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses. The guidance requires public companies with a single reportable segment to provide all disclosures required under ASC 280. In addition, the guidance requires public companies to include in interim reports all disclosures related to a reportable segment&#8217;s profit or loss and assets that are currently required in annual reports. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. This ASU is applicable to the Company&#8217;s Annual Report on Form 10-K for the year ending September 30, 2025, and subsequent interim periods. Refer to Note 16, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, for further details on segment information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. ASC 740, "Income Taxes", requires the effects of changes in tax rates and laws to be recognized in the period in which the legislation is enacted. The Company has implemented OBBBA in the fourth quarter of fiscal 2025. Refer to Note 11, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, for further details.</span></div></ix:nonNumeric></ix:continuation><div id="ifa97f0f616f442a39c9869ed1f483476_148"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-527" continuedAt="f-527-1" escape="true">COLLABORATION AND LICENSE AGREEMENTS</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-528" escape="true"><ix:continuation id="f-527-1" continuedAt="f-527-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of revenue recognized:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">GSK</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-529">2,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-530">2,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-531">29,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Horizon</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-532">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-533">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-534">23,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-535">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-536">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-537">162,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-538">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-539">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-540">356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-541">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-543">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Sarepta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-544">696,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-545">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-546">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-547">130,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-548">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-549">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-550">829,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-551">3,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-552">240,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-527-2" continuedAt="f-527-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-553" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of receivables and contract liabilities related to the Company&#8217;s collaboration and license agreements:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Receivables included in accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="3" id="f-554">6,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:fixed-zero" scale="3" id="f-555">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities included in deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-556">2,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GlaxoSmithKline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;)</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">           </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">GSK-HSD License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#8220;GSK-HSD License Agreement&#8221;). Under the GSK-HSD License Agreement, GSK has received an exclusive license for GSK-4532990 (formerly ARO-HSD). The exclusive license is worldwide with the exception of greater China. GSK is wholly responsible for all clinical development and commercialization of GSK-4532990 in its territory. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has completed its performance obligation related to this agreement, and the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-558">120.0</ix:nonFraction>&#160;million was fully recognized in the year ended September 30, 2022. Further, GSK dosed the first patient in a Phase 2b trial in March 2023 and paid a $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="arwr:MilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="f-559">30.0</ix:nonFraction>&#160;million milestone payment to the Company in the third quarter of fiscal 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is eligible for an additional payment of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" format="ixt:num-dot-decimal" scale="6" id="f-560">100.0</ix:nonFraction>&#160;million upon achieving the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="arwr:CommercialMilestonePaymentsAtFirstCommercialSale" format="ixt:num-dot-decimal" scale="6" id="f-561">190.0</ix:nonFraction>&#160;million at first commercial sale, and up to $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="arwr:SalesRelatedMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-562">590.0</ix:nonFraction>&#160;million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to <ix:nonFraction unitRef="number" contextRef="c-105" decimals="2" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" format="ixt-sec:numwordsen" scale="-2" id="f-563">twenty</ix:nonFraction> percent. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">           </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">GSK-HBV Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">           On December 11, 2023, the Company entered into an Amended and Restated License Agreement with GSK (the &#8220;GSK-HBV Agreement&#8221;) pursuant to which GSK received a worldwide, exclusive license to develop and commercialize daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989), the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">           Under the terms of the GSK-HBV Agreement, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-564">2.7</ix:nonFraction>&#160;million in December 2023, upon signing the amended GSK-HBV Agreement. Further, GSK dosed the fifth patient in a Phase 2 trial in December 2024, triggering a $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="arwr:DevelopmentMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-565">2.5</ix:nonFraction>&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2025. The Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="arwr:DevelopmentAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="f-566">830.0</ix:nonFraction>&#160;million in development and sales milestone payments under the GSK-HBV Agreement. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">           There were <ix:nonFraction unitRef="usd" contextRef="c-109" decimals="INF" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="f-567"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="f-568">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded as of September&#160;30, 2025.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, Horizon and the Company entered into a collaboration and license agreement (the &#8220;Horizon License Agreement&#8221;). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for HZN-457, a clinical-stage medicine being developed by Horizon as a potential treatment for people with uncontrolled gout.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 6, 2023, Amgen completed its acquisition of Horizon and subsequently notified the Company of Amgen&#8217;s intent to terminate the HZN-457 license. Horizon exercised its right to terminate the Horizon License Agreement for convenience, which took effect on December 21, 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;). Under the Takeda License Agreement, Takeda and the Company will co-develop the Company&#8217;s fazirsiran program (formerly TAK-999 and ARO-AAT), the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, fazirsiran, if approved, will be co-commercialized under a 50/50 profit sharing structure. Outside the United States, Takeda received an exclusive license to commercialize fazirsiran and will lead the global commercialization strategy, while the Company will be eligible to receive tiered royalties of <ix:nonFraction unitRef="number" contextRef="c-110" decimals="2" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" scale="-2" id="f-569">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-111" decimals="2" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" scale="-2" id="f-570">25</ix:nonFraction>% on net sales.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-527-3" continuedAt="f-527-4"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the key deliverables included the license and certain research and development services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study, and to ensure certain manufacturing of fazirsiran drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent <ix:nonFraction unitRef="bundle" contextRef="c-112" decimals="INF" name="arwr:NumberOfDistinctBundle" format="ixt-sec:numwordsen" scale="0" id="f-571">one</ix:nonFraction> distinct bundle and, thus, <ix:nonFraction unitRef="obligation" contextRef="c-112" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-572">one</ix:nonFraction> performance obligation. Takeda is responsible for managing clinical development and commercialization outside the United States. Within the United States, the Company and Takeda are responsible in the co-development and co-commercialization efforts. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Takeda License Agreement, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-573">300.0</ix:nonFraction>&#160;million as an upfront payment in January 2021 and an additional $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="f-574">40.0</ix:nonFraction>&#160;million upon Takeda&#8217;s initiation of a Phase 3 REDWOOD clinical study of fazirsiran in March 2023, and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="f-575">527.5</ix:nonFraction>&#160;million in additional potential development, regulatory and commercial milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the total $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-576">300.0</ix:nonFraction>&#160;million initial transaction price to its <ix:nonFraction unitRef="obligation" contextRef="c-112" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-577">one</ix:nonFraction> distinct performance obligation for the fazirsiran license and the associated Takeda R&amp;D Services. The Company has substantially completed its performance obligation under the Takeda License Agreement by December 31, 2023. As such, all revenue has been fully recognized as of December 31, 2023. There were <ix:nonFraction unitRef="usd" contextRef="c-116" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt-sec:numwordsen" scale="0" id="f-578">no</ix:nonFraction> further deferred revenue and contract liabilities as of September&#160;30, 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-579">31.3</ix:nonFraction>&#160;million as accrued expenses as of September&#160;30, 2025 that was primarily driven by co-development and co-commercialization activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 7, 2023, Janssen voluntarily terminated its collaboration agreement with the Company and the Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795. There are no currently active trials for ARO-PNPLA3.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, on December 11, 2023, the Company entered into the GSK-HBV Agreement, as discussed above, pursuant to which GSK received an exclusive license for JNJ-3989 (formerly ARO-HBV). JNJ-3989 had previously been licensed to Janssen in October 2018.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amgen Inc. (&#8220;Amgen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, Amgen and the Company entered into <ix:nonFraction unitRef="agreement" contextRef="c-117" decimals="INF" name="arwr:NumberOfAgreements" format="ixt-sec:numwordsen" scale="0" id="f-580">two</ix:nonFraction> collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen received a worldwide, exclusive license to the Company&#8217;s novel RNAi olpasiran (previously referred to as AMG-890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the Olpasiran Agreement, Amgen is wholly responsible for clinical development and commercialization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has substantially completed its performance obligations under the Olpasiran Agreement. There were <ix:nonFraction unitRef="usd" contextRef="c-118" decimals="INF" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="f-581"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="f-582">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded as of September&#160;30, 2025. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;) and the Company entered into a Royalty Purchase Agreement with Royalty Pharma (the &#8220;Royalty Pharma Agreement&#8221;). In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional  $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" scale="6" id="f-583">485.0</ix:nonFraction> million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma. See Note 13.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sarepta Therapeutics, Inc.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 25, 2024, the Company entered into an Exclusive License and Collaboration Agreement (the &#8220;Sarepta Collaboration Agreement&#8221;) with Sarepta for the development and commercialization of multiple clinical and preclinical programs in rare, genetic diseases of the muscle, central nervous system, and lungs. The Company concurrently entered into a Stock Purchase Agreement (the &#8220;Stock Purchase Agreement&#8221;) with Sarepta (see Note 6). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Under the Sarepta Collaboration Agreement, Sarepta received an exclusive sublicensable worldwide license to SRP-1001 (formerly ARO-DUX4), SRP-1003 (formerly ARO-DM1), SRP-1002 (formerly ARO-MMP7), and SRP-1004 (formerly ARO-ATXN2) clinical stage programs (the &#8220;C1&#8221; programs). Sarepta also received an exclusive sublicensable </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-527-4" continuedAt="f-527-5"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">worldwide license to the Company&#8217;s ARO-HTT, ARO-ATXN1, and ARO-ATXN3 preclinical stage programs (the &#8220;C2&#8221; programs). The Company will perform certain research and development activities for the C1 and C2 programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Further, Sarepta may select up to <ix:nonFraction unitRef="program" contextRef="c-120" decimals="INF" name="arwr:NumberOfNewTargetPrograms" format="ixt-sec:numwordsen" scale="0" id="f-584">six</ix:nonFraction> gene targets for which the Company will perform discovery, optimization and preclinical development activities to identify RNAi compounds against each selected target (the &#8220;C3&#8221; programs). Upon target acceptance, Sarepta will receive an exclusive license to the Company&#8217;s intellectual property rights to exploit  compounds directed to those targets and is wholly responsible for clinical development and commercialization of each compound after the Company delivers a Clinical Trial Application ready data package (the "CTA package").</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company identified <ix:nonFraction unitRef="obligation" contextRef="c-121" decimals="INF" name="arwr:NumberOfPerformanceObligations" scale="0" id="f-585">17</ix:nonFraction> performance obligations under the Sarepta Collaboration Agreement. The four C1 licenses are distinct performance obligations from the four C1 research and development performance obligations since the customer can use and benefit from the licenses separately. The performance obligations for the licenses were satisfied in the second quarter of fiscal 2025 upon delivery and the research and development performance obligations will be satisfied as the work is performed. The remaining nine performance obligations include three C2 preclinical stage program licenses and research and development activities, and six C3 unidentified discovery target licenses and research and development activity. Each of the three C2 programs and the six C3 programs were determined to represent one performance obligation, as the customer cannot benefit from the use of the product license at the point of transfer until the specified research and development activities are performed. As such, each of the C2 and C3 product licenses and respective research and development work will be combined to form one performance obligation. For these nine performance obligations, revenue is recognized over time as the work is performed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For performance obligations recognized over time, the estimated performance period over which revenue will be recognized is determined to be the period over which the Company estimates it will perform the research and development activities. The Company determined that the most appropriate method of measuring progress for these performance obligations is an input method based on research and development costs in the program budget. Accordingly, the Company has estimated the total cost required to complete its obligation and recognized an amount of revenue equal to the proportion of services performed, which is reassessed on an ongoing basis as the program progresses. In the period an agreement expires or is terminated, remaining deferred revenue, if any, is recognized as revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of the Sarepta Collaboration Agreement, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="arwr:ProceedsFromCollaborationArrangements" format="ixt:num-dot-decimal" scale="6" id="f-586">500.0</ix:nonFraction>&#160;million on February 14, 2025. In addition, on February 7, 2025, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-587">325.0</ix:nonFraction>&#160;million in the form of an equity investment under the Stock Purchase Agreement. Based upon the Company's share price on February 7, 2025, (the &#8220;Closing Date&#8221;), the difference between the $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-588">325.0</ix:nonFraction>&#160;million and the fair value of the shares on the Closing date resulted in a premium of $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="arwr:SaleOfStockPremiumOnIssuanceOfShares" format="ixt:num-dot-decimal" scale="6" id="f-589">83.6</ix:nonFraction>&#160;million. The premium is included as part of the total consideration of the Sarepta Collaboration Agreement for revenue recognition purposes. The Company is entitled to receive $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="arwr:AdditionalCashReceivableUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-590">250.0</ix:nonFraction>&#160;million to be paid in annual installments of $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="arwr:CashReceivableUnderCollaborationAgreementAnnualInstallments" format="ixt:num-dot-decimal" scale="6" id="f-591">50.0</ix:nonFraction>&#160;million over the first <ix:nonNumeric contextRef="c-123" name="arwr:CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod" format="ixt-sec:durwordsen" id="f-592">five years</ix:nonNumeric> of the agreement. The Company is also eligible receive reimbursement of certain costs related to carrying out the research and development activities for the C1 programs. The fixed consideration of $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="arwr:CollaborationArrangementFixedConsideration" format="ixt:num-dot-decimal" scale="6" id="f-593">833.6</ix:nonFraction>&#160;million and an estimated variable consideration of $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="arwr:CollaborationArrangementVariableConsideration" format="ixt:num-dot-decimal" scale="6" id="f-594">71.2</ix:nonFraction>&#160;million for a total of $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="arwr:CollaborationArrangementConsideration" format="ixt:num-dot-decimal" scale="6" id="f-595">904.9</ix:nonFraction>&#160;million were allocated to all performance obligations based on their relative standalone selling price. Standalone selling prices for the product licenses were determined using an adjusted market-based approach through the net present value of the expected future cash flows for each program. The standalone selling prices for the research and development work were determined based on an expected cost plus margin approach. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company estimates the stand-alone selling price for each distinct performance obligation, which involves assumptions that may require significant judgment. The Company&#8217;s estimates of the stand-alone selling price for license-related performance obligations includes forecasted revenues and expenses, phase dates, probability of success, development timelines, and the discount rate. The estimates of the stand-alone selling price for research and development performance obligations generally include forecasting the expected costs of satisfying a performance obligation at market rates. The Company identified a discount based on the difference between the aggregate stand-alone selling price and the transaction price for accounting revenue recognition purposes. The Company allocated the discount proportionally to each of the performance obligations based upon their standalone selling price. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company receives reimbursement of certain costs related to carrying out the research and development activities for the C1 programs and may receive development milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="arwr:EnrollmentRelatedMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-596">300.0</ix:nonFraction>&#160;million. Further, for each of the <ix:nonFraction unitRef="program" contextRef="c-121" decimals="INF" name="arwr:NumberOfCollaborationPrograms" scale="0" id="f-597">13</ix:nonFraction> programs, the Company is eligible to receive regulatory milestone payments between $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="arwr:RegulatoryMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-598">110.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="arwr:RegulatoryMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-599">180.0</ix:nonFraction>&#160;million per program. Variable consideration associated with the milestones that may be achieved will be allocated to the performance obligation to which it is determined to be related, which will be the respective development work that is being reimbursed and the respective programs to which the milestones relate. ARO-DM1 development milestones were allocated between the license and development work based on the allocation of the standalone selling price. The Company will recognize the ARO-DM1 development milestones and other development milestones as revenue in the periods the underlying milestone events are achieved as achievement of the milestone events are highly susceptible to factors outside of the entity's influence and therefore there is a possibility that the milestone event will not be achieved.  </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-527-5"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company is also eligible to receive sales milestone payments between $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="arwr:SalesRelatedMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-600">500.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="arwr:SalesRelatedMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-601">700.0</ix:nonFraction>&#160;million per program as well as tiered royalties on net sales of licensed products of up to the low double digits, subject to the terms and conditions of the Sarepta Collaboration Agreement. The Company has applied the sales-based scope exception to the sales milestones and the royalty-based payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Sarepta Collaboration Agreement commenced in February 2025 and may be terminated by either party in the event of a material breach as defined therein. In addition, Sarepta may voluntarily terminate the Sarepta Collaboration Agreement with <ix:nonNumeric contextRef="c-121" name="arwr:CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval" format="ixt-sec:durday" id="f-602">30</ix:nonNumeric> days' written notice to the Company if terminated prior to any regulatory approval of a licensed product. Unless earlier terminated, the Sarepta Collaboration Agreement expires on a product-by-product and country-by-country basis, upon the date of expiration of the relevant royalty term for such product in such country.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2025, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="c-72" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-603">2,660,989</ix:nonFraction> shares of its common stock from Sarepta in connection with the $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="arwr:DevelopmentMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-604">100.0</ix:nonFraction>&#160;million DM1 first development milestone under the Sarepta Collaboration Agreement. The repurchase satisfied $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-605">50.0</ix:nonFraction>&#160;million of the milestone payment through delivery of the Company&#8217;s common stock, with the remaining $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="arwr:ProceedsFromCollaborationArrangements" format="ixt:num-dot-decimal" scale="6" id="f-606">50.0</ix:nonFraction>&#160;million settled in cash. The shares were recorded as treasury stock at their fair value of $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="f-607">53.2</ix:nonFraction>&#160;million, resulting in a $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="arwr:GainLossOnTreasuryStockSettlement" format="ixt:num-dot-decimal" scale="6" id="f-608">3.2</ix:nonFraction>&#160;million gain on settlement. The repurchased shares are presented as a reduction to total stockholders&#8217; equity in accordance with ASC 505-30.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of September&#160;30, 2025, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-609">696.8</ix:nonFraction>&#160;million in revenue from Sarepta and $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-610">6.8</ix:nonFraction>&#160;million in accounts receivable. The recognition of the remaining revenue for the performance obligations is dependent upon the time it takes to complete the respective research and development activities and in consideration of the timing of the selection of the C3 programs. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Visirna Therapeutics Inc. (&#8220;Visirna&#8221;) and Genzyme Corporation (&#8220;Sanofi&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2025, Visirna Therapeutics HK Limited (&#8220;Visirna HK&#8221;), a wholly owned subsidiary of Visirna Therapeutics, Inc, a majority owned subsidiary of the Company, entered into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with Genzyme Corporation (&#8220;Sanofi&#8221;), a wholly owned subsidiary of Sanofi S.A., pursuant to which Visirna HK sold all of its assets and rights in investigational plozasiran to Sanofi, which included an assignment of Visirna HK&#8217;s rights (as successor by assignment from Visirna) to develop and commercialize investigational plozasiran in Greater China pursuant to that certain License Agreement by and between the Company and Visirna dated, April 25, 2022 (the &#8220;Visirna License Agreement&#8221;). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Asset Purchase Agreement, the Company consented to the partial assignment of the Visirna License Agreement by Visirna HK to Sanofi (as so assigned, the &#8220;Sanofi License Agreement&#8221;), amongst other agreements between the Company and Visirna, effective as of the closing of the Asset Purchase Agreement. This agreement was not deemed a legal sale of intellectual property from the consolidated perspective of the Company. After giving effect to the Asset Purchase Agreement, Visirna HK retains rights to develop and commercialize in Greater China three other cardiometabolic drugs licensed to it pursuant to the Visirna License Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing of the Asset Purchase Agreement, Visirna received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-611">130.0</ix:nonFraction>&#160;million from Sanofi and is eligible to receive further development milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="arwr:FuturePotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-612">265.0</ix:nonFraction>&#160;million upon approval of plozasiran across various indications in mainland China. The Company is also eligible to receive royalties from Sanofi on net commercial product sales in Greater China under the Sanofi License Agreement. During the year ended September&#160;30, 2025, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-613">130.0</ix:nonFraction>&#160;million in revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Visirna identified the licenses as defined in the agreement as the performance obligations under the Asset Purchase Agreement. The performance obligations for the licenses was satisfied in the fourth quarter of fiscal 2025 upon delivery. The fixed consideration of $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="arwr:CollaborationArrangementFixedConsideration" format="ixt:num-dot-decimal" scale="6" id="f-614">130.0</ix:nonFraction>&#160;million was allocated to the performance obligations. The Company will recognize the development milestones as revenue in the periods the underlying milestone events are achieved as achievement of the milestone events are highly susceptible to factors outside of the entity's influence and therefore there is a possibility that the milestone events will not be achieved. The Company has also applied the sales-based scope exception to the royalty-based payments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Sanofi License Agreement may be terminated by either party in the event of a material breach as defined therein. Unless earlier terminated, the Sanofi License Agreement expires on a product-by-product basis, upon the date of expiration of the relevant royalty term for such product in Greater China.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-20</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_151"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-615" continuedAt="f-615-1" escape="true">BALANCE SHEET ACCOUNTS</ix:nonNumeric><br/><br/></span><ix:continuation id="f-615-1" continuedAt="f-615-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></ix:continuation></div><ix:continuation id="f-615-2"><ix:continuation id="f-502-1"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property, plant and equipment: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-616">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-617">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Buildings</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-618">251,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-619">75,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-620">62,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-621">65,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing equipment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-622">18,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="f-623">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-624">5,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-625">5,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-626">1,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-627">981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-628">104,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-629">104,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-630">15,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-631">188,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-632">462,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-633">444,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-634">80,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-635">58,021</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-636">382,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-637">386,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for property, plant and equipment for the years ended September&#160;30, 2025, 2024, and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-638">22.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-639">16.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-640">10.7</ix:nonFraction> million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of fiscal 2025, the Company substantially completed the build out of its manufacturing facility in Verona, Wisconsin, leading to the reclassification of $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" sign="-" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" scale="6" id="f-641"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" scale="6" id="f-642">162.7</ix:nonFraction></ix:nonFraction> million from construction in progress to buildings and $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" sign="-" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" scale="6" id="f-643"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" scale="6" id="f-644">2.6</ix:nonFraction></ix:nonFraction> million from construction in progress to manufacturing equipment. The Company subsequently incurred and capitalized $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" scale="6" id="f-645"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" sign="-" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" scale="6" id="f-646">10.6</ix:nonFraction></ix:nonFraction> million to buildings and $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" scale="6" id="f-647"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" sign="-" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" scale="6" id="f-648">16.0</ix:nonFraction></ix:nonFraction> million to manufacturing equipment during the remainder of fiscal 2025. Furthermore, the Company began depreciating the newly completed manufacturing facility over a <ix:nonNumeric contextRef="c-152" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-649">39</ix:nonNumeric>-year period and the manufacturing equipment over <ix:nonNumeric contextRef="c-75" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-650">7</ix:nonNumeric>- or <ix:nonNumeric contextRef="c-76" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-651">10</ix:nonNumeric>-year periods.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of fiscal 2024, the Company completed the build out of its laboratory and office facilities in Verona, Wisconsin, which resulted in the reclassification of $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" scale="6" id="f-652"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" sign="-" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" scale="6" id="f-653">71.8</ix:nonFraction></ix:nonFraction> million from construction in progress to buildings. The Company subsequently incurred and capitalized $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" scale="6" id="f-654"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" sign="-" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" scale="6" id="f-655">4.2</ix:nonFraction></ix:nonFraction> million from construction in progress to buildings in fiscal 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-656" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></div></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="arwr:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-657">30,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="arwr:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-658">28,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accrued research and development expenses; co-development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="arwr:AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-659">31,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="arwr:AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-660">23,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accrued capital expenditures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="arwr:AccruedCapitalExpenditureCurrent" scale="3" id="f-661">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="arwr:AccruedCapitalExpenditureCurrent" format="ixt:num-dot-decimal" scale="3" id="f-662">4,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accrued income taxes (benefits)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-663">20,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:fixed-zero" scale="3" id="f-664">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-665">7,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-666">7,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-667">90,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-668">63,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the Company&#8217;s accrued research and development expenses was primarily attributable to ongoing clinical trial operations, preclinical animal studies, and associated toxicology assessments. In addition, accrued research and development expenses; co-development relates to the co-development and co-commercialization activities under the Takeda License Agreement (see Note 2).</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-21</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_154"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-669" continuedAt="f-669-1" escape="true">INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="f-669-1"><ix:nonNumeric contextRef="c-1" name="arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" id="f-670" escape="true"><div style="margin-top:6pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:7pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"/><td style="width:35.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.449%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="f-671">689,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" format="ixt:num-dot-decimal" scale="3" id="f-672">2,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" scale="3" id="f-673">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-674">692,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total current investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="f-675">689,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" format="ixt:num-dot-decimal" scale="3" id="f-676">2,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" scale="3" id="f-677">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-678">692,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"/><td style="width:35.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.449%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale securities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="f-679">577,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" scale="3" id="f-680">837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" scale="3" id="f-681">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-682">578,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total current investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="f-683">577,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" scale="3" id="f-684">837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" scale="3" id="f-685">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-686">578,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="f-687" escape="true"><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the contract maturity of the available-for-sale securities as of:</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">   </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.807%"><tr><td style="width:1.0%"/><td style="width:51.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.440%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-688">224,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-689">578,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">After one to two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" format="ixt:num-dot-decimal" scale="3" id="f-690">468,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" format="ixt:fixed-zero" scale="3" id="f-691">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">After two to three years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree" format="ixt:fixed-zero" scale="3" id="f-692">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree" format="ixt:fixed-zero" scale="3" id="f-693">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-694">692,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-695">578,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="padding-left:36pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of September&#160;30, 2025, the gross unrealized losses were immaterial. The Company has determined that the available-for-sale securities that were in an unrealized loss position did not have any credit loss impairment as of September&#160;30, 2025 and 2024.</span></div></ix:continuation><div style="margin-top:7pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-22</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_157"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="f-696" continuedAt="f-696-1" escape="true">INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="f-696-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-697" continuedAt="f-697-1" escape="true">The following table presents the components of intangible assets: </ix:nonNumeric></span></div><ix:continuation id="f-697-1"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"/><td style="width:24.967%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.476%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.476%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.476%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.476%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-698">21,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-699">16,426</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-700">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-701">5,302</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-159" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-702">14</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-703">3,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-704">1,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-705">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-706">1,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-160" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-707">21</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-708">24,857</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-709">17,996</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-710">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-711">6,861</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-712">21,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-713">14,873</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-714">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-715">6,855</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-162" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-716">14</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-717">3,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-718">1,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-720">1,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-163" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-721">21</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total intangible assets, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-722">24,857</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-723">16,295</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-724">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-725">8,562</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during fiscal 2025 and 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense in each of fiscal 2025, 2024, and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-726"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-727"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-728">1.7</ix:nonFraction></ix:nonFraction></ix:nonFraction> million. None of the intangible assets with definite useful lives are anticipated to have a residual value.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-729" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the estimated future amortization expense related to intangible assets as of September&#160;30, 2025:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.272%"><tr><td style="width:1.0%"/><td style="width:60.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.106%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Expense</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-730">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-731">1,700</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-732">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="f-733">795</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="f-734">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="3" id="f-735">817</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-736">6,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-23</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_160"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-737" continuedAt="f-737-1" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="f-737-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockByClassTextBlock" id="f-738" escape="true"><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s shares of common stock and preferred stock:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"><tr><td style="width:1.0%"/><td style="width:31.294%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Common stock </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-739">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-740">290,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-741">135,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-742">135,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-743">0.001</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-744">5,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-745">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-746">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-747">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-748">290,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-749">124,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-750">124,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-751">0.001</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-752">5,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-753">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-754">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(1) Does not include shares of common stock into which the Avoro Pre-Funded Warrants may be exercised.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025 and 2024, respectively, <ix:nonFraction unitRef="shares" contextRef="c-165" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-755">9,851,400</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-166" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-756">11,492,293</ix:nonFraction> shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#8217;s 2013 and 2021 Incentive Plans, as well as for other inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  <br/>         <br/>        On November 25, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;Securities Purchase Agreement&#8221;) with an institutional and accredited investor for a private placement of pre-funded warrants to purchase shares of common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-167" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-757">0.001</ix:nonFraction> per share (&#8220;Avoro Pre-Funded Warrants&#8221;). Pursuant to the Securities Purchase Agreement, the Company sold pre-funded warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-167" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-758">917,441</ix:nonFraction> shares of common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-168" decimals="2" name="arwr:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" scale="0" id="f-759">27.25</ix:nonFraction> per pre-funded warrant, for an aggregate value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" id="f-760">25.0</ix:nonFraction> million. The outstanding Avoro Pre-Funded Warrants are exercisable at any time and do not have an expiration date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined that the Avoro Pre-Funded Warrants are freestanding financial instruments because they (i) are immediately exercisable, (ii) do not embody an obligation for the Company to repurchase its shares, (iii) permit the holders to receive a fixed number of shares of common stock upon exercise, and (iv) are indexed to the Company&#8217;s common stock. As such, the Company evaluated the Avoro Pre-Funded Warrants to determine whether they represent instruments that require liability classification pursuant to the guidance in ASC 480. However, the Company concluded that the Avoro Pre-Funded Warrants are not a liability within the scope of ASC 480 due to their characteristics. Further, the Company determined that the Avoro Pre-Funded Warrants do not meet the definition of a derivative under ASC 815 because they do not meet the criteria regarding no or little initial net investment. Accordingly, the Company assessed the Avoro Pre-Funded Warrants relative to the guidance in ASC 815-40, Contracts in Entity's Own Equity, to determine the appropriate treatment. The Company concluded that the Avoro Pre-funded Warrants are both indexed to its own stock and meet all other conditions for equity classification. Accordingly, the Company has classified the Avoro Pre-funded Warrants as permanent equity. As of September&#160;30, 2025, <ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="arwr:ClassOfWarrantOrRightNumberOfWarrantsExercised" format="ixt-sec:numwordsen" scale="0" id="f-761">no</ix:nonFraction> shares underlying the Avoro Pre-Funded Warrants had been exercised. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Sarepta Collaboration Agreement, on November 25, 2024, the Company entered into the Stock Purchase Agreement with an affiliate of Sarepta for a private placement of shares of common stock of the Company (the &#8220;Private Placement&#8221;). Pursuant to the Stock Purchase Agreement, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-762">11,926,301</ix:nonFraction> shares of common stock, at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-170" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-763">27.25</ix:nonFraction>, for an aggregate value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-764">325.0</ix:nonFraction>&#160;million. The Private Placement closed on February 7, 2025. On August 13, 2025, the Company subsequently entered into an agreement with Sarepta to repurchase <ix:nonFraction unitRef="shares" contextRef="c-171" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-765">2,660,989</ix:nonFraction> common stock of the Company from Sarepta at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-171" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-766">18.79</ix:nonFraction> for an aggregate value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-767">50.0</ix:nonFraction>&#160;million and approximately $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="arwr:ProceedsFromCollaborationArrangements" format="ixt:num-dot-decimal" scale="6" id="f-768">50.0</ix:nonFraction>&#160;million in cash to satisfy the milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="arwr:MilestonePaymentDueFromCollaborativeAgreement" format="ixt:num-dot-decimal" scale="6" id="f-769">100.0</ix:nonFraction>&#160;million due from Sarepta. The shares were recorded as treasury stock at their fair value of $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="f-770">53.2</ix:nonFraction>&#160;million, resulting in a $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="arwr:GainLossOnTreasuryStockSettlement" format="ixt:num-dot-decimal" scale="6" id="f-771">3.2</ix:nonFraction>&#160;million gain on settlement. As of the end of fiscal 2025, Sarepta no longer holds an equity position in the Company. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On December 2, 2022, the Company entered into an open market sale agreement (the &#8220;Open Market Sale Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="INF" name="arwr:CommonStockCapitalSharesValueReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-772">250,000,000</ix:nonFraction> in shares of the Company&#8217;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#8220;ATM Offering&#8221;). The Company is not required to sell shares under the Open Market Sale Agreement. The Company will pay Jefferies LLC a commission of up to <ix:nonFraction unitRef="number" contextRef="c-174" decimals="3" name="arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" scale="-2" id="f-773">3.0</ix:nonFraction>% of the aggregate gross proceeds received from all sales of the common stock under the Open Market Sale Agreement. Unless otherwise terminated, the ATM Offering shall terminate upon the earlier of (i) the sale of all shares of common stock subject to the Open Market Sale Agreement and (ii) the termination of the Open Market Sale Agreement as permitted therein. The Company and Jefferies may each terminate the Open Market Sale Agreement at any time upon prior notice. As of September&#160;30, 2025, <ix:nonFraction unitRef="shares" contextRef="c-175" decimals="INF" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="f-774">no</ix:nonFraction> shares have been issued under the Open Market Sale Agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-24</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_163"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-775" continuedAt="f-775-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-775-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were <ix:nonFraction unitRef="usd" contextRef="c-26" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="f-776"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="f-777">no</ix:nonFraction></ix:nonFraction> contingent liabilities recorded as of September&#160;30, 2025 and 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2025, the Company filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ionis Pharmaceuticals, Inc. (&#8220;Ionis&#8221;) to declare that the United States Patent No. 9,593,333 (&#8220;the &#8217;333 patent&#8221;) is invalid and not infringed by the Company&#8217;s planned commercialization of investigational plozasiran. On September 11, 2025, Ionis filed a Complaint for Patent Infringement against the Company in the United States District Court for the Central District of California alleging patent infringement of the &#8217;333 patent by the Company&#8217;s planned commercialization of investigational plozasiran and seeking damages. There were no contingent liabilities recorded related to this litigation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns land in the Verona Technology Park in Verona, Wisconsin, where it has constructed an approximately <ix:nonFraction unitRef="sqft" contextRef="c-176" decimals="-3" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="f-778">160,000</ix:nonFraction> square foot drug manufacturing facility and an approximately <ix:nonFraction unitRef="sqft" contextRef="c-177" decimals="-3" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="f-779">140,000</ix:nonFraction> square foot laboratory and office facility to support the Company&#8217;s manufacturing, process development, and analytical activities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the build-out of these facilities was substantially completed, with total costs incurred of $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="arwr:CommitmentsCapitalExpendituresIncurredToDate" scale="6" id="f-780">296.4</ix:nonFraction> million. These costs included $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="arwr:CommitmentsCapitalExpendituresIncurredToDate" scale="6" id="f-781">173.4</ix:nonFraction> million capitalized to building related to the drug manufacturing facility, $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="arwr:CommitmentsCapitalExpendituresIncurredToDate" scale="6" id="f-782">78.0</ix:nonFraction> million capitalized to building related to the laboratory and office facility, $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="arwr:CommitmentsCapitalExpendituresIncurredToDate" scale="6" id="f-783">18.6</ix:nonFraction> million capitalized to manufacturing equipment, $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="arwr:CommitmentsCapitalExpendituresIncurredToDate" scale="6" id="f-784">15.9</ix:nonFraction> million in construction in progress and $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="arwr:CommitmentsCapitalExpendituresIncurredToDate" scale="6" id="f-785">7.9</ix:nonFraction> million capitalized to research equipment and $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="arwr:CommitmentsCapitalExpendituresIncurredToDate" scale="6" id="f-786">2.6</ix:nonFraction> million capitalized to furniture.</span></div></ix:continuation><div id="ifa97f0f616f442a39c9869ed1f483476_166"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-787" continuedAt="f-787-1" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="f-787-1" continuedAt="f-787-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pasadena, California</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases <ix:nonFraction unitRef="sqft" contextRef="c-180" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="f-788">49,000</ix:nonFraction> square feet of office space located at 177 East Colorado Blvd. for its corporate headquarters from 177 Colorado Owner, LLC, which lease expires on April&#160;30, 2027. The lease contains an option to renew for <ix:nonFraction unitRef="option" contextRef="c-181" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="f-789">one</ix:nonFraction> additional <ix:nonNumeric contextRef="c-181" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-790">five-year</ix:nonNumeric> term. The Company is not reasonably certain that it will exercise this option to renew and therefore it is not included in right-of-use assets and liabilities as of September&#160;30, 2025.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">San Diego, California</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases <ix:nonFraction unitRef="sqft" contextRef="c-182" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="f-791">144,000</ix:nonFraction> square feet of office and research and development laboratory space located at 10102 Hoyt Park from 11404 &amp; 11408 Sorrento Valley Owner, LLC, which lease expires on April&#160;30, 2038. Pursuant to the lease, within twelve months of the expiration of the initial <ix:nonNumeric contextRef="c-182" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-792">15</ix:nonNumeric>-year term, the Company has the option to extend the lease for up to <ix:nonFraction unitRef="option" contextRef="c-183" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="f-793">one</ix:nonFraction> additional <ix:nonNumeric contextRef="c-182" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-794">ten-year</ix:nonNumeric> term, with certain annual increases in base rent. The Company is not reasonably certain that it will exercise this option to renew and therefore it is not included in right-of-use assets and liabilities as of September&#160;30, 2025. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The lease agreement, as amended, granted the Company the right to receive an Additional Tenant Improvement Allowance (&#8220;ATIA&#8221;) funded by the lessor. The Company received $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="arwr:ProceedsFromTenantImprovementAllowance" format="ixt:num-dot-decimal" scale="6" id="f-795">30.8</ix:nonFraction>&#160;million in ATIA, including a final payment of $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="arwr:ProceedsFromTenantImprovementAllowance" scale="6" id="f-796">3.1</ix:nonFraction> million during the first quarter of fiscal 2024. As a result, the Company remeasured its lease liability and right-of-use assets to reflect these additional allowances and the related increased lease payments. The Company has further concluded that these ATIAs have no effects on the classification of the lease.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Madison, Wisconsin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases <ix:nonFraction unitRef="sqft" contextRef="c-186" decimals="0" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="f-797">110,956</ix:nonFraction> square feet space, which it increased from <ix:nonFraction unitRef="sqft" contextRef="c-187" decimals="0" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="f-798">107,000</ix:nonFraction> square feet on June&#160;30, 2025, located at 502 South Rosa Road for its office and laboratory facilities, which lease expires on September&#160;30, 2031. The lease contains options to renew for <ix:nonFraction unitRef="option" contextRef="c-186" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="f-799">two</ix:nonFraction> terms of <ix:nonNumeric contextRef="c-186" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-800">five years</ix:nonNumeric>. The Company is not reasonably certain that it will exercise this option and therefore it is not included in right-of-use assets and liabilities as of September&#160;30, 2025.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-787-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-801" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"/><td style="width:33.503%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.476%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.080%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-802">43,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-803">45,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-804">7,289</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-805">6,342</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-806">104,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-807">111,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.388%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-808">10,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-809">11,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-810">10,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-811">1,952</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-812">2,006</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-813">1,730</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease cost</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-814">4,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-815">3,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-816">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="f-817">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="f-818">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="f-819">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-820">16,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-821">16,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-822">13,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) Variable lease cost is primarily related to operating expenses associated with the Company&#8217;s operating leases.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShortTermLeaseCost" scale="6" id="f-823">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:ShortTermLeaseCost" scale="6" id="f-824">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-825">1.4</ix:nonFraction>&#160;million in short-term lease cost during the years ended September&#160;30, 2025, 2024, and 2023, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-826" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents maturities of operating lease liabilities on an undiscounted basis as of September&#160;30, 2025:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:82.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-827">15,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-828">15,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-829">13,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-830">13,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-831">14,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2031 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-832">100,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-833">173,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-834">62,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-835">111,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:64.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash received for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-836">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-837">3,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-838">48,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets adjusted in exchange for new/amended operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-839">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" scale="3" id="f-840">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-841">17,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-842">15,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-843">11,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-844">5,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-26" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-845">11.70</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-27" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-846">12.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-46" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-847">13.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-848">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-27" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-849">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-46" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-850">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-26</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_169"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-851" continuedAt="f-851-1" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="f-851-1" continuedAt="f-851-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three plans that provide for equity-based compensation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2013 Incentive Plan (the &#8220;2013 Plan&#8221;), <ix:nonFraction unitRef="shares" contextRef="c-194" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-852">2,276,279</ix:nonFraction> awards are granted and outstanding, relating to stock options and restricted stock awards to employees and directors as of September&#160;30, 2025. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2021 Incentive Plan (the &#8220;2021 Plan&#8221;), <ix:nonFraction unitRef="shares" contextRef="c-195" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-853">8,000,000</ix:nonFraction> shares (subject to certain adjustments) of the Company&#8217;s common stock are authorized for grants of stock options, stock appreciation rights, restricted and unrestricted stock, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#8217;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of September&#160;30, 2025, <ix:nonFraction unitRef="shares" contextRef="c-196" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-854">6,231,559</ix:nonFraction> shares have been granted under the 2021 Plan. The total number of shares available for issuance was <ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-855">2,378,770</ix:nonFraction> shares, which includes <ix:nonFraction unitRef="shares" contextRef="c-197" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-856">170,898</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-196" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-857">439,431</ix:nonFraction> shares that were forfeited under the 2013 and 2021 Plans, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s Inducement Plan (the &#8220;Inducement Plan&#8221;), <ix:nonFraction unitRef="shares" contextRef="c-198" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-858">832,950</ix:nonFraction> shares of the Company&#8217;s common stock are authorized for issuance pursuant to grants of stock options, stock appreciation rights, restricted and unrestricted stock, stock units (including restricted stock units), performance awards, cash awards, and other awards convertible into or otherwise based on shares of the Company&#8217;s common stock. Awards under the Inducement Plan may only be granted to new employees of the Company in accordance with the provisions of Rule 5635(c)(4) of the Nasdaq Listing Rules. As of September&#160;30, 2025, <ix:nonFraction unitRef="shares" contextRef="c-199" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-859">660,020</ix:nonFraction> shares have been granted under the Inducement Plan. The total number of shares remaining available for issuance was <ix:nonFraction unitRef="shares" contextRef="c-198" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-860">255,244</ix:nonFraction> shares.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, prior to adoption of the Inducement Plan, the Company previously granted stand-alone inducement awards in the form of stock options and restricted stock units outside of the Company&#8217;s equity plans to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules. As of September&#160;30, 2025, there were <ix:nonFraction unitRef="shares" contextRef="c-198" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-861">598,605</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-200" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-862">53,713</ix:nonFraction> shares underlying outstanding stand-alone inducement options and restricted stock units, respectively.   </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="f-863" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding attributable to Arrowhead Pharmaceuticals, Inc.:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.852%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.529%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Inducement Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-194" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-864">776,279</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-201" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-865">32,151</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-202" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-866">598,605</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-867">1,407,035</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-203" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-868">1,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-204" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-869">3,750,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-205" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-870">560,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-206" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-871">5,810,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-194" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-872">2,276,279</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-201" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-873">3,782,222</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-202" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-874">1,158,885</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-875">7,217,386</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-876" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expenses included in operating expenses attributable to Arrowhead Pharmaceuticals, Inc.:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.940%"><tr><td style="width:1.0%"/><td style="width:28.210%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.583%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-877">27,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-878">29,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-879">34,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-880">27,528</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-881">37,570</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-882">43,798</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-883">54,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-884">67,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-885">78,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/></span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-851-2" continuedAt="f-851-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Awards</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-886" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the stock option activity for the year ended September&#160;30, 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 30, 2024</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-887">1,978,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-888">23.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-889">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-890">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cancelled or expired</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-891">36,341</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-892">45.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-893">535,140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-894">7.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 30, 2025</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-895">1,407,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-896">28.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-897">3.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-898">19,099,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at September 30, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-899">1,407,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-900">28.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-901">3.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="f-902">19,099,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values represent the amount by which the market price of the underlying stock exceeds the exercise price of the option. The total intrinsic value of the options exercised during the years ended September&#160;30, 2025, 2024, and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-903">6.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-904">4.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-905">12.2</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to stock options outstanding for the years ended September&#160;30, 2025, 2024, and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-906">0.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-907">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-908">8.4</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the pre-tax compensation expense for all outstanding unvested stock options is considered nominal.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. <ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-909"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-910">No</ix:nonFraction></ix:nonFraction> options were granted during the years ended September 30, 2025 and 2024.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-911" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Black-Scholes option pricing model: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-912">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-28" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-913">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-29" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-914">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-29" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-915">3.69</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="c-29" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-916">4.57</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-29" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-917">86.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-29" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-918">6.25</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-29" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-919">25.61</ix:nonFraction></span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) The dividend yield is <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-920">zero</ix:nonFraction> as the Company currently does not pay a dividend. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(3) Volatility is estimated based on volatility average of the Company&#8217;s common stock price. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(4) The computation of expected term was determined based on safe harbor rules, considering the contractual terms of the awards and vesting schedules.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(5) <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-921"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-922">No</ix:nonFraction></ix:nonFraction> options were granted during the year ended September&#160;30, 2025 and September&#160;30, 2024.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Visirna ESOP</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: As of September&#160;30, 2025, Visirna, a subsidiary of the Company, granted <ix:nonFraction unitRef="shares" contextRef="c-210" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-923">14,612,000</ix:nonFraction> stock options to its employees from the Employee Stock Option Plan (the &#8220;Visirna ESOP&#8221;), which authorizes <ix:nonFraction unitRef="shares" contextRef="c-211" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-924">20,000,000</ix:nonFraction> shares for issuance. The Visirna ESOP is independently managed by Visirna, including the valuation process. For the years ended September&#160;30, 2025 and 2024, stock-based compensation expense related to the Visirna ESOP was $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-925">8.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-926">6.9</ix:nonFraction> million, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted Stock Units (&#8220;RSUs&#8221;), including market-based, time-based and performance-based awards, have been granted under the Company&#8217;s 2013 and 2021 Plans, the Inducement Plan and as inducements awards granted outside of the Company&#8217;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-851-3" continuedAt="f-851-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s common stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-927" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2024</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-214" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-928">4,913,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-214" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-929">49.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-215" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-930">2,779,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-215" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-931">19.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-215" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-932">1,525,693</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-215" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-933">47.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-215" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-934">356,957</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-215" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-935">30.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2025</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-206" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-936">5,810,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-206" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-937">36.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs was determined based on the closing price of the Company&#8217;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-851-4">For the years ended September&#160;30, 2025, 2024 and 2023, the Company recorded stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-938">54.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-939">64.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-940">69.7</ix:nonFraction> million, respectively, related to shares of RSUs. As of September&#160;30, 2025, there was $<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="f-941">73.3</ix:nonFraction> million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-215" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-942">1.7</ix:nonNumeric> years.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-29</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_172"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-943" continuedAt="f-943-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="f-943-1" continuedAt="f-943-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date using the exit price. Accordingly, when market observable data are not readily available, the Company&#8217;s own assumptions are used to reflect those that market participants would be presumed to use in pricing the asset or liability at the measurement date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on the consolidated balance sheets are categorized based on the level of judgment associated with inputs used to measure their fair values and the level of market price observability, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#160;&#160;&#160;&#160;Unadjusted quoted prices are available in active markets for identical assets or liabilities as of the reporting date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#160;&#160;&#160;&#160;Pricing inputs are other than quoted prices in active markets, which are based on the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Quoted prices for similar assets or liabilities in active markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Quoted prices for identical or similar assets or liabilities in non-active markets; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Either directly or indirectly observable inputs as of the reporting date.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#160;&#160;&#160;&#160;Pricing inputs are unobservable and significant to the overall fair value measurement, and the determination of fair value requires significant management judgment or estimation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. Thus, a Level 3 fair value measurement may include inputs that are observable (Level 1 or Level 2) and unobservable (Level 3). The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and consideration of factors specific to the asset or liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. At September&#160;30, 2025 and 2024, the Company did not have any financial assets or financial liabilities based on Level 3 measurements.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-944" continuedAt="f-944-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicate the fair value hierarchy of the valuation techniques utilized by the Company: </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-944-1" continuedAt="f-944-2"><ix:continuation id="f-943-2" continuedAt="f-943-3"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:33.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.077%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-945">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-946">150,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-947">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-948">150,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-949">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-950">12,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-951">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-952">12,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-953">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-954">7,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-955">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-956">7,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Commercial notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-957">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-958">13,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-959">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-960">13,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-961">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-962">509,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-963">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-964">509,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-965">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-966">692,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-967">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-968">692,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-969">64,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-970">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-971">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-972">64,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Term deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-973">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-974">134,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-975">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-976">134,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-977">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-978">3,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-979">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-980">3,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-981">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-982">16,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-983">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-984">16,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-985">64,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-986">153,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-987">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-988">218,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-989">64,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-990">846,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-991">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-992">910,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">     </span></div></ix:continuation></ix:continuation><div style="margin-top:12pt;text-align:center"><ix:continuation id="f-944-2"><ix:continuation id="f-943-3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:33.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.077%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-993">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-994">160,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-995">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-996">160,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Commercial notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-997">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-998">179,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-999">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1000">179,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-1001">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1002">237,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-1003">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1004">237,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-1005">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1006">578,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-1007">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1008">578,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1009">66,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1010">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1011">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1012">66,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1013">66,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1014">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1015">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1016">66,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1017">66,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1018">578,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1019">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1020">645,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div id="ifa97f0f616f442a39c9869ed1f483476_175"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1021" continuedAt="f-1021-1" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="f-1021-1" continuedAt="f-1021-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Provision (Benefit)</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-1022" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income (loss) before income tax expense and noncontrolling interest are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-1023">42,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-1024">582,333</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-1025">194,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-1026">94,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-1027">30,127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-1028">7,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1029">51,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1030">612,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1031">202,491</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-1032" continuedAt="f-1032-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision (benefit) consisted of the following components:</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-1021-2" continuedAt="f-1021-3"><ix:continuation id="f-1032-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:69.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.174%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1033">21,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="f-1034">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1035">1,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1036">56</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1037">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1038">1,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-1039">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1040">3,290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1041">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total current tax</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1042">21,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1043">2,767</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1044">2,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1045">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1046">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1047">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1048">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1049">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1050">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1051">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1052">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1053">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1054">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1055">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1056">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Income tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1057">21,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1058">2,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1059">2,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1060" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the tax expense based on the statutory rate to the Company&#8217;s actual tax expense in the consolidated statements of operations and comprehensive income (loss). A notional 21% tax rate was applied as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. federal statutory income tax</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1061">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-28" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1062">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-29" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1063">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1064">3.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-28" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1065">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-29" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1066">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1067">44.4</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-28" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1068">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-29" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1069">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Permanent and other items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1070">37.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-28" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1071">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-29" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1072">4.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="arwr:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" scale="-2" id="f-1073">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-28" decimals="3" sign="-" name="arwr:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" scale="-2" id="f-1074">0.9</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-29" decimals="3" sign="-" name="arwr:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" scale="-2" id="f-1075">4.6</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent" scale="-2" id="f-1076">16.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-28" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent" format="ixt:fixed-zero" scale="-2" id="f-1077">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-29" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent" scale="-2" id="f-1078">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="arwr:EffectiveIncomeTaxRateReconciliationOtherIncomePercent" scale="-2" id="f-1079">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-28" decimals="3" name="arwr:EffectiveIncomeTaxRateReconciliationOtherIncomePercent" format="ixt:fixed-zero" scale="-2" id="f-1080">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-29" decimals="3" name="arwr:EffectiveIncomeTaxRateReconciliationOtherIncomePercent" format="ixt:fixed-zero" scale="-2" id="f-1081">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1082">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-28" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1083">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-29" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-1084">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1085">95.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-28" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1086">27.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-29" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1087">20.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1088">41.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-28" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1089">0.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-29" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1090">1.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Income Taxes</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1091" continuedAt="f-1091-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant components of the Company&#8217;s net deferred tax assets and liabilities: </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-1021-3" continuedAt="f-1021-4"><ix:continuation id="f-1091-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1092">70,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1093">102,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost" format="ixt:num-dot-decimal" scale="3" id="f-1094">232,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost" format="ixt:num-dot-decimal" scale="3" id="f-1095">156,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1096">48,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1097">85,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-1098">171,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-1099">81,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1100">23,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1101">27,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1102">9,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1103">10,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1104">4,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1105">4,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1106">1,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1107">1,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-1108">948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-1109">2,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1110">562,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1111">473,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Valuation allowance</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1112">497,543</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1113">448,867</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1114">30,503</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1115">13,155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-1116">9,424</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-1117">10,792</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome" scale="3" id="f-1118">630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome" scale="3" id="f-1119">194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Original Issue Discount</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="arwr:DeferredTaxLiabilitiesOriginalIssueDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1120">24,586</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="arwr:DeferredTaxLiabilitiesOriginalIssueDiscount" format="ixt:fixed-zero" scale="3" id="f-1121">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax liability</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1122">65,143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1123">24,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-1124">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-1125">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded to reduce deferred tax assets to the amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended September&#160;30, 2025. Such objective evidence limits the ability to consider other subjective evidence such as its projections for future growth. On the basis of this evaluation at September&#160;30, 2025 and 2024, a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-1126">497.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-1127">448.9</ix:nonFraction> million, respectively, has been recorded. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> As of September&#160;30, 2025, the Company had accumulated federal, state, and foreign net operating loss (&#8220;NOL&#8221;) carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1128">20.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1129">815.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1130">46.3</ix:nonFraction> million, respectively. Of the $<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1131">20.6</ix:nonFraction> million in federal NOL carryforwards, $<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-5" name="arwr:OperatingLossCarryforwardsSubjectToExpiration" scale="6" id="f-1132">20.6</ix:nonFraction> million was generated before January 1, 2018, and is subject to a 20-year carryforward period (&#8220;pre-Tax Act losses&#8221;), with expiration beginning in 2031. Of the $<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1133">815.5</ix:nonFraction> million in state NOL carryforwards, $<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" name="arwr:OperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="f-1134">2.7</ix:nonFraction> million can be carried forward indefinitely, while the remaining balance begins to expire in 2031. The Company also has foreign NOL carryforwards totaling $<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1135">46.3</ix:nonFraction> million, which begin to expire in 2027. Additionally, the Company has federal and state income tax credits of $<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1136">49.4</ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1137">26.3</ix:nonFraction> million, respectively. The federal credits begin to expire in 2041. Of the state income tax credits, $<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" name="arwr:TaxCreditCarryforwardAmountSubjectToExpiration" scale="6" id="f-1138">13.6</ix:nonFraction> million begins to expire in 2035, while the remaining credits can be carried forward indefinitely.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), the annual use of an entity&#8217;s NOL and research and development credit carryforwards may be limited if there is a cumulative ownership change of greater than 50% within a three-year period. The annual limitation is determined based on the entity&#8217;s value immediately prior to the ownership change. Future ownership changes could further affect the limitation. If a limitation is applied, the related tax asset would be removed from the deferred tax asset schedule, with a corresponding reduction in the valuation allowance. To date, the Company has completed an analysis pursuant to Sections 382 and 383 through September&#160;30, 2024. Ownership Changes may have occurred since then, and future changes could potentially limit the Company&#8217;s ability to utilize these attributes. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertainty in Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold of more-likely-than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more-likely-than not that a tax position </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-1021-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-1139" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s gross unrecognized tax benefits:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance of unrecognized tax benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1140">16,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1141">14,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1142">3,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Gross increase for prior period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1143">1,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-1144">654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1145">9,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Gross decrease for prior period tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-1146">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-1147">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1148">1,489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Gross increase for current period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1149">4,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1150">3,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1151">3,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Lapse of statue of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="3" id="f-1152">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:num-dot-decimal" scale="3" id="f-1153">1,992</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="3" id="f-1154">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance of unrecognized tax benefits</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1155">22,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1156">16,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1157">14,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded income tax (benefit) expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="f-1158">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="f-1159">3.3</ix:nonFraction> million for the years ended September&#160;30, 2025 and 2024, respectively, related to uncertain tax positions inclusive of interest and penalties. The Company&#8217;s policy is to recognize potential interest and penalties related to unrecognized tax benefits associated with uncertain tax positions, if any, in the income tax provision. As of September&#160;30, 2025, the Company has not accrued any interest or penalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If the unrecognized tax benefit as of September&#160;30, 2025 is ultimately recognized, there would be no reduction in the Company&#8217;s income tax expense or effective tax rate, excluding the impact of U.S. Tax benefits netted against deferred taxes that are subject to a valuation allowance. The Company does not anticipate any changes in its unrecognized tax benefits over the next 12 months.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to taxation in the U.S. and various states along with other foreign countries. Due to the presence of NOL carryforwards, all of the income tax years remain open for examination. The Company is currently under audit by the IRS for September&#160;30, 2023. California income tax examination has been closed. There are no other audits in any other jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes undistributed earnings of each foreign subsidiary and has determined that no withholding taxes are applicable to earnings which are currently available for distribution. No additional deferred tax liability has been recorded as the parent entity would not be required to include the distribution into income under the current law.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act subjects a U.S. shareholder to tax on Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740 No. 5. Accounting for GILTI, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year that the tax is incurred as a period expense only. The Company has elected to account for GILTI in the year the tax is incurred. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. ASC 740, "Income Taxes", requires the effects of changes in tax rates and laws to be recognized in the period in which the legislation is enacted. The Company has implemented OBBBA in the fourth quarter of the current year.</span></div></ix:continuation><div id="ifa97f0f616f442a39c9869ed1f483476_178"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. <ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="f-1160" continuedAt="f-1160-1" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="f-1160-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a defined contribution retirement plan which is under Section 401(k) of the Internal Revenue Code and is designed to adhere to ERISA Fiduciary standards. All of the Company&#8217;s full-time employees are eligible to participate this plan. Under the terms of the plan, an eligible employee may elect to contribute a portion of their salary on a pre-tax basis, subject to federal statutory limitations. The plan allows for a discretionary match in an amount up to <ix:nonFraction unitRef="number" contextRef="c-281" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="f-1161">100</ix:nonFraction>% of each participant&#8217;s first <ix:nonFraction unitRef="number" contextRef="c-281" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-1162">3</ix:nonFraction>% of compensation contributed plus <ix:nonFraction unitRef="number" contextRef="c-282" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="f-1163">50</ix:nonFraction>% of each participant&#8217;s next <ix:nonFraction unitRef="number" contextRef="c-282" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-1164">2</ix:nonFraction>% of compensation contributed. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended September&#160;30, 2025, 2024, and 2023, the Company recorded expenses for the matching contributions under this plan of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-1165">3.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-1166">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-1167">2.2</ix:nonFraction> million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company also provides certain employee benefit plans, including those which provide health and life insurance benefits to employees.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-34</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_181"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTE 13. <ix:nonNumeric contextRef="c-1" name="arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" id="f-1168" continuedAt="f-1168-1" escape="true">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES</ix:nonNumeric></span></div><ix:continuation id="f-1168-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-5" name="arwr:InitialTransactionPrice" scale="6" id="f-1169">410.0</ix:nonFraction> million in cash to the Company in consideration for the Company&#8217;s future royalty interest in olpasiran, a siRNA originally developed by the Company and licensed to Amgen in September 2016 under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-5" name="arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" scale="6" id="f-1170">250.0</ix:nonFraction> million upfront and agreed to pay up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="arwr:MilestonePaymentReceivable" scale="6" id="f-1171">160.0</ix:nonFraction> million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $<ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-5" name="arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" scale="6" id="f-1172">50.0</ix:nonFraction> million on completion of enrollment in the OCEAN Phase 3 clinical trial for olpasiran, (ii) $<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="arwr:MilestonePaymentReceivableUponFDAApproval" scale="6" id="f-1173">50.0</ix:nonFraction> million upon receipt of FDA approval of olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" scale="6" id="f-1174">60.0</ix:nonFraction> million upon Royalty Pharma&#8217;s receipt of at least $<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="arwr:RoyaltyPaymentThreshold" scale="6" id="f-1175">70.0</ix:nonFraction> million of royalty payments under the Royalty Pharma Agreement in any single calendar year. During the third quarter of fiscal 2024, Amgen completed enrollment of the Phase 3 OCEAN(a) outcomes trial of olpasiran, which triggered a $<ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-5" name="arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="f-1176">50.0</ix:nonFraction>&#160;million milestone payment that the Company received in the same quarter. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the terms of the Royalty Pharma Agreement and concluded in accordance with the relevant accounting guidance that the Company accounted for the transaction as debt and the funding of $<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-5" name="arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" scale="6" id="f-1177">250.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-5" name="arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="f-1178">50.0</ix:nonFraction>&#160;million from Royalty Pharma were recorded as liabilities related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay these funds received under the Royalty Pharma Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company records the obligations at their carrying value using the effective interest method. In order to amortize the sale of future royalties, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize non-cash interest expense for the remaining periods. The Company periodically assesses the amount and the timing of expected royalty payments using a combination of internal projections and forecasts from external sources. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration, probability of success and sales price, among others. To the extent such payments are greater or less than the Company&#8217;s initial estimates or the timing of such payments is different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate. As of September&#160;30, 2025, the estimated effective interest rate was <ix:nonFraction unitRef="number" contextRef="c-286" decimals="3" name="arwr:LiabilitySaleOfFutureRoyaltiesInterestRate" scale="-2" id="f-1179">8.3</ix:nonFraction>%. </span></div><ix:nonNumeric contextRef="c-1" name="arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" id="f-1180" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the activity with respect to the liability related to the sale of future royalties.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Beginning carrying value </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1181">341,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1182">268,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Upfront payment received</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="f-1183">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="f-1184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Milestone payment received</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="f-1185">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-1186">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-1187">26,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="arwr:NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-1188">23,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Ending carrying value</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1189">367,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1190">341,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ifa97f0f616f442a39c9869ed1f483476_184"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTE 14. <ix:nonNumeric contextRef="c-1" name="us-gaap:LongTermDebtTextBlock" id="f-1191" continuedAt="f-1191-1" escape="true">FINANCING AGREEMENT </ix:nonNumeric></span></div><ix:continuation id="f-1191-1" continuedAt="f-1191-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2024 (the &#8220;Closing Date&#8221;), the Company entered into a Financing Agreement with the guarantors party thereto, the lenders party thereto (the &#8220;Lenders&#8221;), and Sixth Street Lending Partners (&#8220;Sixth Street&#8221;), as the administrative agent and collateral agent for the Lenders (the &#8220;Financing Agreement&#8221;). The Financing Agreement establishes a senior secured term loan facility of $<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1192">500.0</ix:nonFraction>&#160;million (the &#8220;Credit Facility&#8221;), consisting of $<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-1193">400.0</ix:nonFraction>&#160;million funded on the Closing Date and an additional $<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1194">100.0</ix:nonFraction>&#160;million available at the Company&#8217;s option, subject to mutual agreement with Sixth Street. The loans under the Credit Facility bear interest at an annual rate of <ix:nonFraction unitRef="number" contextRef="c-289" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1195">15.0</ix:nonFraction>%, which is paid in kind and added to the outstanding principal balance of the Credit Facility each period. The outstanding principal balance of this Credit </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-1191-2" continuedAt="f-1191-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facility, including amounts representing accrued but unpaid interest previously paid in kind, is due and payable on August 7, 2031.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is permitted to use the net proceeds for working capital, capital expenditures and general corporate purposes of the Company and its subsidiaries.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company will have the right to prepay loans under the Credit Facility at any time. The Company is required to partially repay loans under the Credit Facility with proceeds from certain asset sales, condemnation events and extraordinary receipts, subject, in some cases, to reinvestment rights. If the Company repays in full the aggregate principal outstanding under the Credit Facility and such payment in full occurs on or prior to August 7, 2028, the Company will be required to make an additional payment to the lenders under the Credit Facility on such date in an amount necessary for the lenders to achieve a <ix:nonFraction unitRef="number" contextRef="c-290" decimals="INF" name="arwr:DebtInstrumentCovenantMultipleOfInvestedCapital" format="ixt-sec:numwordsen" scale="0" id="f-1196">two</ix:nonFraction> times multiple of invested capital (&#8220;MOIC&#8221;) of the aggregate principal amount funded on the Closing Date (the &#8220;MOIC Payment&#8221;). If such payment in full occurs after August 7, 2028, the Company will be required to make a payment to the lenders under the Credit Facility on such date in an amount necessary for the lenders to achieve the greater of the MOIC Payment and the present value of all interest payments that would have been payable from such date through the maturity date of the Credit Facility discounted at the Treasury Rate (as defined in the Financing Agreement) plus <ix:nonFraction unitRef="number" contextRef="c-290" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1197">0.5</ix:nonFraction>%; provided that such payment amount in this instance will not exceed the amount necessary for the lenders to achieve a <ix:nonFraction unitRef="number" contextRef="c-291" decimals="INF" name="arwr:DebtInstrumentCovenantMultipleOfInvestedCapital" scale="0" id="f-1198">2.5</ix:nonFraction> times MOIC.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 26, 2024, the Company entered into an amendment to the Financing Agreement (the "Amendment") to modify, amongst other things, some of the prepayment terms of the loans under the Credit Facility, including, the prepayment terms related to the Sarepta Collaboration Agreement. The Amendment was effective on February 14, 2025, following the closing of the Sarepta Collaboration Agreement and receipt of the $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="arwr:ProceedsFromCollaborationArrangements" format="ixt:num-dot-decimal" scale="6" id="f-1199">500.0</ix:nonFraction>&#160;million upfront payment from Sarepta. The Amendment added an additional prepayment clause that requires certain contractual prepayments of principle and MOIC payments throughout the life of the loans under the Credit Facility. Additionally, any prepayment will be split with <ix:nonFraction unitRef="number" contextRef="c-292" decimals="2" name="arwr:DebtInstrumentPrepaymentPercentage" scale="-2" id="f-1200">50</ix:nonFraction>% of any such prepayment paying down the principle balance of the loans under the Credit Facility and the other <ix:nonFraction unitRef="number" contextRef="c-293" decimals="2" name="arwr:DebtInstrumentPrepaymentPercentage" scale="-2" id="f-1201">50</ix:nonFraction>% being applied to prepay the MOIC Payment. In the event the prepayment amounts result in fees being prepaid in excess of the actual amounts required to be paid, the excess fees shall be reallocated and applied to reduce the amount of the principal balance upon repayment in full of the loans under the Credit Facility. As of September&#160;30, 2025, the Company has paid $<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-5" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-1202">100.0</ix:nonFraction>&#160;million in MOIC payments of which $<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-5" name="arwr:DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment" format="ixt:num-dot-decimal" scale="6" id="f-1203">25.3</ix:nonFraction>&#160;million is expected to be applied to principal upon repayment in full. To date, the Company has paid $<ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-5" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-1204">201.6</ix:nonFraction>&#160;million of the loans under the Credit Facility during fiscal 2025. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Amendment was accounted for as a debt modification under ASC 470-50, &#8220;Debt&#8212;Modification and extinguishments&#8221; since the Amendment did not result in substantially different terms. In connection with the Amendment, the Company did not incur significant third-party fees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">All obligations under the Financing Agreement are secured on a first-priority basis by security interests in substantially all assets of the Company and material subsidiaries of the Company, including its intellectual property, subject to certain exceptions, and is guaranteed by material subsidiaries of the Company, including foreign subsidiaries, subject to certain exceptions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Financing Agreement contains customary covenants, including, without limitation, a financial covenant to maintain liquidity (cash, cash equivalents and investments) of at least $<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-5" name="arwr:DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold" format="ixt:num-dot-decimal" scale="6" id="f-1205">100.0</ix:nonFraction>&#160;million if the Company&#8217;s market capitalization is above $<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-8" name="arwr:DebtInstrumentCovenantMarketCapitalizationThreshold" scale="9" id="f-1206">1.5</ix:nonFraction> billion, and negative covenants that, subject to certain exceptions, restrict indebtedness, liens, investments (including acquisitions), fundamental changes, asset sales and licensing transactions, dividends, modifications to material agreements, payment of subordinated indebtedness, distributions from certain parties, and other matters customarily restricted in such agreements. The Company is subject to restrictions on sales and licensing transactions with respect to certain core intellectual property, subject to certain exceptions, including certain transactions related to areas outside the United States, United Kingdom, European Union, Japan and China.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Financing Agreement contains certain embedded features that were identified and evaluated as not material to the consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 13, 2025, the Company entered into second amendment to the Financing Agreement (the "Second Amendment") that permitted the share repurchase of the Company's common stock from Sarepta and required the Company to pay a nominal administrative fee.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="f-1207" continuedAt="f-1207-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding balance of the Credit Facility consisted of the following:</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-1191-3"><ix:continuation id="f-1207-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Initial Term Loan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1208">400,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1209">400,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated interest on the Initial Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1210">66,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1211">9,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated accretion of the MOIC Payment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-1212">3,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="3" id="f-1213">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Less: Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="3" id="f-1214">13,912</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="3" id="f-1215">15,817</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of credit facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:LinesOfCreditCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1216">40,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:LinesOfCreditCurrent" format="ixt:fixed-zero" scale="3" id="f-1217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Less: Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-1218">201,625</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-1219">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Credit facility, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1220">214,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1221">393,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="arwr:SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock" id="f-1222" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth total interest expense recognized related to the Credit Facility:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:54.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.016%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-1223">1,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-1224">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:fixed-zero" scale="3" id="f-1225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of the MOIC Payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-1226">3,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="3" id="f-1227">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="3" id="f-1228">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1229">57,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1230">9,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:fixed-zero" scale="3" id="f-1231">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Total interest expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1232">63,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1233">9,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="3" id="f-1234">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-1235" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The amounts shown in the table below, related to the Credit Facility, represent the expected repayments of principle and accrued interest balance as of September&#160;30, 2025 as well as any mandatory prepayments that the Company is obligated to make to the Lenders during the indicated periods. The principal balance will increase from accrued paid in kind interest and the table does not include MOIC payments beyond those contractually determined. Actual payments on current principal may vary from the amounts presented in the table. </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.840%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1236">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1237">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1238">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1239">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1240">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1241">214,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1242">339,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2025, Visirna entered into the Revolving Credit Agreement with Bank of Zhejiang. The maximum aggregate credit facility is <ix:nonFraction unitRef="cny" contextRef="c-305" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1243">72.9</ix:nonFraction>&#160;million Chinese Yuan ($<ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1244">10.3</ix:nonFraction>&#160;million) bearing an annual interest rate of <ix:nonFraction unitRef="number" contextRef="c-305" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1245">4.1</ix:nonFraction>%. The term of each loan is <ix:nonNumeric contextRef="c-306" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1246">twelve months</ix:nonNumeric>. The amount outstanding as of September&#160;30, 2025 was <ix:nonFraction unitRef="cny" contextRef="c-307" decimals="-5" name="us-gaap:LinesOfCreditCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1247">72.9</ix:nonFraction>&#160;million Chinese Yuan ($<ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-5" name="us-gaap:LinesOfCreditCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1248">10.3</ix:nonFraction>&#160;million) on the credit facility which was classified as other current liabilities.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-37</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_187"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTE 15. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-1249" continuedAt="f-1249-1" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="f-1249-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-1250" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted net loss per share for the years ended September&#160;30, 2025, 2024 and 2023. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1251">1,631</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1252">599,493</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1253">205,275</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average basic shares outstanding</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1254">133,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1255">119,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1256">106,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="f-1257">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="f-1258">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="f-1259">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average diluted shares outstanding</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1260">133,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1261">119,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1262">106,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Basic net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1263">0.01</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1264">5.00</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-29" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1265">1.92</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Diluted net loss per share</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1266">0.01</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1267">5.00</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-29" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1268">1.92</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-1269" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:52.395%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.798%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-308" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-1270">744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-309" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-1271">707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-310" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-1272">633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-311" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1273">4,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-312" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1274">4,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-313" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1275">3,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1276">5,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1277">4,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-1278">4,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-38</span></div></div></div><div id="ifa97f0f616f442a39c9869ed1f483476_472"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTE 16. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1279" continuedAt="f-1279-1" escape="true">SEGMENT INFORMATION</ix:nonNumeric></span></div><ix:continuation id="f-1279-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a single segment dedicated to the discovery, development, manufacturing and commercialization of RNAi therapeutics. The Company's RNAi therapeutics are comprised of siRNAs that function upstream of conventional medicines by potently silencing messenger RNA (&#8220;mRNA&#8221;) that encode for proteins implicated in the cause or pathway of disease, thus preventing them from being made. Consistent with our operational structure, our Chief Executive Officer (&#8220;CEO&#8221;), as the CODM, manages and allocates resources on a consolidated basis at the global corporate level. Our global research and development and technical operations and quality organizations are responsible for the discovery, development, and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region and therapeutic area. All of these activities are supported by corporate staff functions. Managing and allocating resources at the corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources in line with our overarching long-term, corporate-wide strategic goals. The determination of a single segment is consistent with the consolidated financial information regularly reviewed by the CODM for the purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with our management reporting, results of our operations are reported on a consolidated basis for purposes of segment reporting. The CEO evaluates performance and decides how to allocate resources based on consolidated net loss that is reported on the consolidated statements of operations and comprehensive income (loss). The measure of segment assets is reported on the consolidated balance sheets as total assets. The CEO uses consolidated net loss to evaluate income generated from the Company&#8217;s business activities in deciding how to allocate company resources (such as pursuing clinical development or entering a strategic collaboration), monitoring budget versus actual results, and establishing management&#8217;s compensation. Please refer to the consolidated financial statements for further information related to these measures of segment performance. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-1280" continuedAt="f-1280-1" escape="true">In addition, research and development and selling, general and administrative expenses are significant segment expenses regularly provided to the CEO with the following categories:</ix:nonNumeric></span></div><ix:continuation id="f-1280-1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Candidate costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="arwr:ResearchAndDevelopmentExpenseCandidateCosts" format="ixt:num-dot-decimal" scale="3" id="f-1281">347,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="arwr:ResearchAndDevelopmentExpenseCandidateCosts" format="ixt:num-dot-decimal" scale="3" id="f-1282">259,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="arwr:ResearchAndDevelopmentExpenseCandidateCosts" format="ixt:num-dot-decimal" scale="3" id="f-1283">162,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D discovery costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="arwr:ResearchAndDevelopmentExpenseDiscoveryCosts" format="ixt:num-dot-decimal" scale="3" id="f-1284">66,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="arwr:ResearchAndDevelopmentExpenseDiscoveryCosts" format="ixt:num-dot-decimal" scale="3" id="f-1285">74,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="arwr:ResearchAndDevelopmentExpenseDiscoveryCosts" format="ixt:num-dot-decimal" scale="3" id="f-1286">55,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Salaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="arwr:ResearchAndDevelopmentExpenseSalariesExpense" format="ixt:num-dot-decimal" scale="3" id="f-1287">109,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="arwr:ResearchAndDevelopmentExpenseSalariesExpense" format="ixt:num-dot-decimal" scale="3" id="f-1288">96,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="arwr:ResearchAndDevelopmentExpenseSalariesExpense" format="ixt:num-dot-decimal" scale="3" id="f-1289">73,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Facilities related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="arwr:ResearchAndDevelopmentExpenseFacilitiesRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-1290">29,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="arwr:ResearchAndDevelopmentExpenseFacilitiesRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-1291">25,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="arwr:ResearchAndDevelopmentExpenseFacilitiesRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-1292">16,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expense, excluding non-cash expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="arwr:ResearchAndDevelopmentExpenseExcludingNoncashExpense" format="ixt:num-dot-decimal" scale="3" id="f-1293">552,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="arwr:ResearchAndDevelopmentExpenseExcludingNoncashExpense" format="ixt:num-dot-decimal" scale="3" id="f-1294">455,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="arwr:ResearchAndDevelopmentExpenseExcludingNoncashExpense" format="ixt:num-dot-decimal" scale="3" id="f-1295">307,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1296">32,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1297">33,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1298">34,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1299">21,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1300">16,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1301">10,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1302">607,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1303">505,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1304">353,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General &amp; Administrative</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Salaries</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="us-gaap:SalariesWagesAndOfficersCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1305">31,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="us-gaap:SalariesWagesAndOfficersCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1306">27,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="us-gaap:SalariesWagesAndOfficersCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1307">22,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Professional, outside services, and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="f-1308">53,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="f-1309">24,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="f-1310">20,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Facilities related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="arwr:GeneralAndAdministrativeExpenseFacilitiesRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-1311">5,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="arwr:GeneralAndAdministrativeExpenseFacilitiesRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-1312">4,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="arwr:GeneralAndAdministrativeExpenseFacilitiesRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-1313">3,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total general and administrative expense, excluding non-cash expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="arwr:GeneralAndAdministrativeExpenseExcludingNoncashExpense" format="ixt:num-dot-decimal" scale="3" id="f-1314">91,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="arwr:GeneralAndAdministrativeExpenseExcludingNoncashExpense" format="ixt:num-dot-decimal" scale="3" id="f-1315">56,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="arwr:GeneralAndAdministrativeExpenseExcludingNoncashExpense" format="ixt:num-dot-decimal" scale="3" id="f-1316">47,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1317">30,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1318">40,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1319">43,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation/amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1320">2,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1321">1,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1322">1,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total general and administrative expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1323">123,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1324">98,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1325">92,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ifa97f0f616f442a39c9869ed1f483476_190"></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">NOTE 17. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-1327" continuedAt="f-1327-1" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-1327-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Novartis</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2025, the Company entered into an Exclusive License and Collaboration Agreement (the &#8220;Novartis Collaboration Agreement&#8221;) with Novartis Pharma AG (&#8220;Novartis&#8221;) for the co-development and commercialization of multiple preclinical programs in rare, genetic diseases. Under the Novartis Collaboration Agreement, Novartis has received an exclusive worldwide license to the Company's ARO-SNCA preclinical stage program. The Novartis Collaboration Agreement closed on October 17, 2025 subsequent to clearance under the Hart-Scott-Rodino Antitrust Improvement Act. Under the terms of the Novartis Collaboration Agreement, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-5" name="arwr:ProceedsFromCollaborationArrangements" format="ixt:num-dot-decimal" scale="6" id="f-1328">200.0</ix:nonFraction>&#160;million as an upfront payment. The Company is also eligible to receive $<ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-5" name="arwr:PaymentReceivableInCollaborationArrangementsUponTargetNomination" format="ixt:num-dot-decimal" scale="6" id="f-1329">30.0</ix:nonFraction>&#160;million associated with certain target nominations. Further, for each of the <ix:nonFraction unitRef="program" contextRef="c-324" decimals="INF" name="arwr:NumberOfCollaborationPrograms" scale="0" id="f-1330">4</ix:nonFraction> programs, the Company is eligible to receive development milestone payments between $<ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-5" name="arwr:DevelopmentMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-1331">175.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-5" name="arwr:DevelopmentMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-1332">245.0</ix:nonFraction>&#160;million per program and sales milestone payments between $<ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-5" name="arwr:SalesRelatedMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-1333">285.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-5" name="arwr:SalesRelatedMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-1334">370.0</ix:nonFraction>&#160;million per program. The Company is also eligible to receive tiered royalties on net sales of licensed products of up to the low double digits.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Sarepta DM1 Milestone</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2025, the Company earned a $<ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-5" name="arwr:DevelopmentMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-1335">200.0</ix:nonFraction>&#160;million milestone payment from</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sarepta. The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ARO-DM1, also called SRP-1003, an investigational RNAi therapeutic for the treatment of type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy. The second milestone event included the achievement of a patient enrollment target, drug safety committee review and subsequent authorization to dose escalate and proceed, and completion of day 105 study visit by at least one patient in the clinical trial. </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">REDEMPLO Commercial Launch</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA approved the Company's New Drug Application (NDA) for REDEMPLO (plozasiran) injection for Familial Chylomicronemia Syndrome (FCS), on November 18, 2025. This approval, which was based on the results of the Phase 3 PALISADE clinical trial, was completed within the Prescription Drug User Fee Act (PDUFA) VI timeframe. This approval is a significant milestone for the Company, and the commercial launch of REDEMPLO is in progress. We expect to begin generating revenue from sales of REDEMPLO in the upcoming fiscal year.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">F-40</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.52
<SEQUENCE>2
<FILENAME>projectauckland-licensecol.htm
<DESCRIPTION>EX-10.52
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i60193035b9004bf98ef76cef2b3574e3_1"></div><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">By and Between</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">and</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Novartis Pharma AG</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">August 29, 2025</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><div id="i60193035b9004bf98ef76cef2b3574e3_4"></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">THIS EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), entered into as of August 29, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Execution Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), is entered into by and between Novartis Pharma AG, a company organized under the laws of Switzerland located at Lichtstrasse 35, CH-4056, Basel, Switzerland (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Novartis</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and Arrowhead Pharmaceuticals, Inc., a Delaware corporation having its principal offices at 177 East Colorado Boulevard, Suite 700, Pasadena, California, USA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Arrowhead</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Arrowhead and Novartis are referred to in this Agreement individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, Novartis is a pharmaceutical company engaged in the research, development, and commercialization of products useful in the amelioration, treatment, or prevention of genetic human diseases and conditions&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, Arrowhead is a biopharmaceutical company focused on discovering and developing medicines that treat intractable diseases by silencing the genes that cause them, including advancing RNA interference based treatments for protein-based genetic disorders&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, the Parties wish to enter into a collaboration to develop targeted siRNA therapies against (a) SNCA for the treatment of synucleinopathies, such as Parkinson&#8217;s Disease, and (b) other Collaboration Targets targeting the central nervous system or cardiomyocytes&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, Novartis wishes to obtain, and Arrowhead desires to grant, an exclusive worldwide license under certain Patent Rights, Know-How, and other intellectual property rights Controlled by Arrowhead to Research, Develop, Manufacture, Commercialize, and otherwise Exploit the Licensed Compounds and Licensed Products on the terms and conditions set forth herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">NOW</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, the Parties hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, will have the respective meanings set forth below&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Accounting Standards</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means&#58; (a) with respect to Novartis, IFRS or an internationally recognized accounting principles approved by Novartis, and (b) with respect to Arrowhead, GAAP, in each case, consistently applied throughout the applicable Party&#8217;s organization. Each Party shall promptly notify the other Party in the event that it changes the Accounting Standards pursuant to which its records are maintained&#59; provided, that each Party may only use internationally recognized accounting principles (e.g., IFRS, GAAP, etc.) as its Accounting Standards.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Acquired Business</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.10.3 (Acquired Business Exception).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Acquirer</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, collectively, the Third Party referenced in the definition of Change of Control and such Third Party&#8217;s Affiliates, other than the applicable Party in the definition of Change of Control and such Party&#8217;s Affiliates immediately prior to the closing of such Change of Control.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Additional R&#38;D Activities</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.4 (Additional R&#38;D Activities).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Additional R&#38;D Budget</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.33.4 (Additional R&#38;D Activities).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Additional R&#38;D Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.33.4 (Additional R&#38;D Activities).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Adverse Event</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any untoward medical occurrence in a human clinical study subject or in a patient who is administered a Licensed Product, whether or not considered related to such Licensed Product, including any undesirable sign (including abnormal laboratory findings of clinical concern), symptom, or disease associated with the use of a Licensed Product.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.8.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Affiliate</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Person directly or indirectly controlled by, controlling, or under common control with, a Party, but only for so long as such control continues.  For purposes of this definition, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">control</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; (including, with correlative meanings, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">controlled by</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">,&#8221; &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">controlling</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">,&#8221; and &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">under common control with</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) will be presumed to exist with respect to a Person in the event of the possession, direct or indirect, of (a) the power to direct or cause the direction of the management and policies of such Person (whether through ownership of securities, by contract or otherwise), or (b) 50% or more of the voting securities or other comparable equity interests.  The Parties acknowledge that in the case of certain entities organized under the laws of certain countries outside of the United States, the maximum percentage ownership permitted by law for a foreign investor may be less than 50%, and that in such case, such lower percentage will be substituted in the preceding sentence, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">such foreign investor has the power to direct or cause the direction of the management and policies of such Person.  Neither of the Parties will be deemed to be an &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Affiliate</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; of the other solely as a result of their entering into this Agreement.  The Parties acknowledge that for the purposes of this Agreement, Visirna Therapeutics, Inc. (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Visirna</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) will not be an Affiliate of Arrowhead.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.9.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the preamble.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.10.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Alliance Manager</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.1 (Alliance Managers).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.11.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Antitrust Clearance Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the earliest date on which all applicable waiting periods and approvals required under Antitrust Laws with respect to the transactions contemplated under this Agreement have expired or have been terminated (in the case of waiting periods) or been received (in the case of approvals), in each case, without the imposition of any conditions.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.12.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Antitrust Filing</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any filing with the United States Federal Trade Commission and the Antitrust Division of the United States Department of Justice and any other applicable Governmental Authority in the Territory, as required under any Antitrust Laws with respect to the transactions contemplated under this Agreement, together with all required documentary attachments thereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.13.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Antitrust Laws</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any federal, state, or foreign law, regulation, or decree, including the HSR Act, designed to prohibit, restrict, or regulate actions for the purpose or effect of monopolization or restraint of trade.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.14.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arising Delivery Ligand Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 12.2.2(a) (Arrowhead).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.15.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arising Delivery Ligand Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 12.2.2(a) (Arrowhead).</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.16.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arising Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any and all Know-How conceived, invented, developed, or otherwise made during the Term by or on behalf of one or more Personnel of a Party (or any of its Affiliates, licensees, sublicensees, or subcontractors), either alone or jointly with one or more Personnel of the other Party (or any of its Affiliates, licensees, sublicensees, or subcontractors), in each case, in the performance of activities under any of the Transaction Agreements relating to the Exploitation of Licensed Compounds or Licensed Products.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.17.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arising Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Patent Right that (a) has a priority date after the Effective Date, and (b) Covers any Arising Know-How.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.18.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Products</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.19.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">ARO-SNCA SC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the chemical composition internally coded by Arrowhead as ARO-SNCA SC, the chemical structure of which is set forth on </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.19</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (ARO-SNCA SC Structure).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.20.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the preamble.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.21.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Arising Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 12.2.2(a) (Arrowhead).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.22.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Arising Patent Right</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 12.2.2(a) (Arrowhead).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.23.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead BBB Platform</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Know-How or other intellectual property rights Controlled by Arrowhead or its Affiliates that is related to, or Patent Rights Controlled by Arrowhead or its Affiliates that Cover, any Arrowhead Platform that utilizes the conjugation or other incorporation (or fragments thereof) of an antibody that is designed to shuttle certain compounds, including RNAi Molecules, across the blood brain barrier.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.24.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Cardiomyocyte Platform</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Know-How or other intellectual property rights Controlled by Arrowhead or its Affiliates that is related to, or Patent Rights Controlled by Arrowhead or its Affiliates that Cover, any Arrowhead Platform that utilizes the conjugation or other incorporation of a ligand that is designed to deliver compounds, including RNAi Molecules, to cardiomyocytes.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.25.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.26.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Development Costs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.6 (Arrowhead Development Costs Reimbursement).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.27.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Excluded Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, collectively, any and all Know-How (a) relating to Arrowhead&#8217;s RNAi Molecule trigger sequence selection and design process, or (b) that Arrowhead or any of its Affiliates comes to own or otherwise Control after the Execution Date relating to the Manufacture of RNAi Molecules generally, but only to the extent such Know-How is not (i) utilized in connection with any Development or Manufacturing work performed by Arrowhead or any of its Affiliates either (A) prior to the Execution Date for itself or (B) for Novartis under this Agreement during the Term or under any other supply or development agreement or plan between the Parties after the Effective Date, (ii) otherwise disclosed in writing by Arrowhead to Novartis during the Term, (iii) necessary for the Exploitation of a Licensed Compound or Licensed Product, or (iv) Arising Delivery Ligand Know-How.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.28.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Excluded Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Patent Rights that Cover any Arrowhead Excluded Know-How.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.29.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Indemnitees</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section&#160;11.2 (Indemnification by Novartis).</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.30.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any and all Know-How that (a) relates to the composition of matter, formulation, form, or a method of use or treatment, delivery, or Manufacture of a Licensed Compound or a Licensed Product, (b) is Controlled by Arrowhead or any of its Affiliates as of the Effective Date or during the Term, and (c) is necessary or reasonably useful to Exploit one or more Licensed Compounds or Licensed Products in the Field in the Territory, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">including</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> any and all Arrowhead Arising Know-How and Arrowhead&#8217;s interest in any and all Joint Arising Know-How but</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> excluding</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> Arrowhead Excluded Know-How.  Notwithstanding anything herein to the contrary, Arrowhead Know-How excludes the Licensed Product-Specific Patent Rights and the Arrowhead Platform Patent Rights.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.31.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Manufacturing Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.4 (Manufacturing Technology Transfer).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.32.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any and all Patent Rights that (a) are Controlled by Arrowhead or any of its Affiliates as of the Effective Date or during the Term and (b) (i) Cover a Licensed Compound or a Licensed Product (including, for clarity, its composition of matter, formulation, form, or a method of use or treatment, delivery, or Manufacture) or (ii) are necessary or reasonably useful to Exploit one or more Licensed Compounds or Licensed Products in the Field in the Territory, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">including</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> any and all Arrowhead Arising Patent Rights and Arrowhead&#8217;s interest in any and all Joint Arising Patent Rights but</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> excluding</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> all Arrowhead Excluded Patents Rights.  The Arrowhead Patent Rights include the Arrowhead Platform Patent Rights.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.33.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Platform</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Arrowhead&#8217;s proprietary siRNA platform for RNAi Molecule sequence selection and delivery, including for Licensed Products and Licensed Compounds (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, TRiM&#8482; technology).  For clarity, the Arrowhead Platform includes the Arrowhead BBB Platform and Arrowhead Cardiomyocyte Platform.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.34.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Platform Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any and all Arrowhead Patent Rights that are not Licensed Product-Specific Patent Rights.  The Arrowhead Platform Patent Rights relevant to the contemplated Licensed Compounds and Licensed Products as of the Execution Date, and, if applicable, the Effective Date, are set forth on </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.34</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (Arrowhead Platform Patent Rights).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.35.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Prosecuted Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section&#160;12.3.2(a) (Arrowhead&#8217;s Right to Prosecute Patents).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.36.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Records</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section&#160;8.7.3 (Records and Audits).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.37.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, collectively, (a)&#160;the Arrowhead Patent Rights and (b) the Arrowhead Know-How.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.38.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Audited Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section&#160;8.7.3 (Records and Audits).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.39.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Auditing Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section&#160;8.7.3 (Records and Audits).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.40.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Auditor</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section&#160;8.7.3 (Records and Audits).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.41.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Bankrupt Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 13.3 (Termination for Bankruptcy).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.42.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Bankruptcy Code</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Title 11, United States Code, as amended, or analogous provisions of Law outside the United States.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.43.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Breaching Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 13.4.1 (Material Breach and Cure Period).</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.44.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Business Day</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a calendar day other than a Saturday, Sunday, or a bank or other public holiday in Basel, Switzerland&#59; Zurich, Switzerland&#59; New York, New York&#59; Boston, Massachusetts&#59; or Pasadena, California.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.45.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Calendar Quarter</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the respective periods of three consecutive calendar months ending on March 31</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, June 30</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, September 30</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, or December 31</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> in any Calendar Year&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, that the first Calendar Quarter of the Term will extend from the Effective Date to the end of the first complete Calendar Quarter thereafter and the last Calendar Quarter of the Term will end at the end of the Term.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.46.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Calendar Year</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any calendar year beginning on January 1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> and ending on December 31</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, that the first Calendar Year of the Term will begin on the Effective Date and end on December 31 and the last Calendar Year of the Term will end at the end of the Term.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.47.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Cardiomyocyte Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any genetic target that a potential therapeutic product could be Directed To that would </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">cardiomyocytes, in each case, using the Arrowhead Cardiomyocyte Platform.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.48.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Change of Control</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party, that&#58; (a) any Third Party acquires directly or indirectly the beneficial ownership of any voting security of such Party, or if the percentage ownership of such Third Party in the voting securities of such Party is increased through stock redemption, cancellation, or other recapitalization, and immediately after such acquisition or increase such Third Party is, directly or indirectly, the beneficial owner of voting securities representing at least 50% of the total voting power of all of the then-outstanding voting securities of such Party&#59; (b) a merger, consolidation, recapitalization, or reorganization of such Party is consummated, other than any such transaction that would result in shareholders or equity holders of such Party immediately prior to such transaction owning at least 50% of the outstanding voting securities of the surviving entity (or its parent entity) immediately following such transaction&#59; (c) the shareholders or equity holders of such Party approve a plan of complete liquidation of such Party, or an agreement for the sale or disposition by such Party of all or substantially all of such Party&#8217;s assets, other than pursuant to the transactions described above or to an Affiliate&#59; or (d) the sale or transfer to a Third Party of all or substantially all of such Party&#8217;s consolidated assets taken as a whole. Notwithstanding the foregoing, any transaction or series of transactions effected for the purpose of financing the operations of the applicable Party or one or more of its applicable Affiliates (such as an initial public offering or other offering of equity securities to non-strategic investors) will not be deemed a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Change of Control</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; for purposes of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.49.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Claims</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 11.1 (Indemnification by Arrowhead).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.50.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Trial</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any clinical investigation in which a pharmaceutical product is administered or dispensed to, or used involving human subjects, including any Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial or other Pivotal Trial, or any post-approval clinical trial in humans.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.51.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CMC Activities</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Licensed Compound or Licensed Product, all Manufacturing activities (including the generation of all CMC Data) necessary to support the Development or Commercialization of such Licensed Compound or Licensed Product, as applicable, at the applicable stage of Development or Commercialization, including formulation, process development, process qualification and validation, scale-up, analytic development, product characterization, stability testing, quality assurance, and quality control.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.52.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CMC Data</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the chemistry, manufacturing and controls data for each Licensed Compound or Licensed Product, as applicable, required by applicable Law to be included or referenced in, or that otherwise supports, an application for Regulatory Approval for such Licensed Product.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.53.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CMO</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a contract manufacturing organization or a contract testing organization.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.54.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CNS Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any genetic target, other than SNCA, that a potential therapeutic product could be Directed To that would inhibit or otherwise modulate expression within the central nervous system, using the Arrowhead BBB Platform, but excluding </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.55.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Collaboration Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CT</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means each CNS Target or Cardiomyocyte Target, as the case may be, that is selected by Novartis in accordance with Section 3.1.2(a)(iii)(B) (Selection of Collaboration Targets), Section 3.1.2(b)(ii) (For Target Failure) or Section 3.1.2(b)(iii) (For Convenience), as applicable.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.56.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Collaboration Target Selection Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.1.2(a)(iii)(B) (Selection of Collaboration Targets).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.57.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Collaboration Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, on a Collaboration Target-by-Collaboration Target basis, the earlier of (a) the completion of the Development Plan for the CT Program of which such Collaboration Target is the subject, (b) the date on which the Futility Criteria has been achieved for such Collaboration Target, or (c) the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">anniversary of the Effective Date, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that, solely in the case of this clause (c), (i) if a Proposed Replacement Target for such failed Collaboration Target is nominated by Novartis as permitted under Section 3.1.2(b) (Novartis Collaboration Target Substitution Right) and becomes a new Collaboration Target in accordance with Section 3.1.2(a) (Selection of Collaboration Targets) and (ii) the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> anniversary of the Execution Date is less than </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">after the date on which the Parties agree on a CT Development Plan for such new Collaboration Target pursuant to Section 3.1.2(d) (CT Development Plans), then such </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">period will be extended by such an amount of time as is necessary such that there are </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">from the date on which such Proposed Replacement Target became a new Collaboration Target.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.58.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Combination Product</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 1.165 (&#8220;Net Sales&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.59.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Commercialization</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any and all activities directed to the marketing, promotion, distribution, offering for sale, sale, having sold, importing, having imported, exporting, having exported, or other commercialization of a pharmaceutical or biologic product, but excluding activities directed to Manufacturing, Development, or Medical Affairs.  &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Commercialize</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">,&#8221; &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Commercializing</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">,&#8221; and &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Commercialized</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; will be construed accordingly.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.60.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Commercially Reasonable Efforts</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) with respect to the efforts and resources to be expended, or considerations to be undertaken, by Novartis with respect to any objective or activity related to the Development, Regulatory Approval, Manufacture, Medical Affairs or Commercialization of a Licensed Compound or a Licensed Product, the efforts, resources and considerations to accomplish such objective or activity as Novartis would normally use in the relevant jurisdiction to accomplish a similar objective or activity under similar circumstances, consistent with the exercise of prudent scientific and business judgment, for a similar compound or product owned by it or to which it has similar rights, which compound or product, as applicable, is at a similar stage in its development or product life and of similar commercial, profit, and market potential, taking into account all relevant factors, including&#58; (i) issues of efficacy, safety, and expected and actual approved labeling, (ii) the likely timing of entry into the market and the expected and actual competitiveness of alternative products sold by Third Parties in the marketplace, (iii) the expected and actual product profile of the Licensed Product, (iv) issues of intellectual property coverage, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, the expected and actual patent coverage and other proprietary position of the Licensed Product, (v) the likelihood of receiving Regulatory Approval given the regulatory structure involved, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> regulatory or data exclusivity, (vi) the expected and actual profitability of the Licensed Product </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, and (vii) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, and (b) with respect to the efforts and resources to be expended by Arrowhead, with respect to any objective or activity under this Agreement, the reasonable, diligent, good faith efforts and resources to accomplish </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">such objective or activity as Arrowhead would normally use to accomplish for its own similar objective under similar circumstances.  Commercially Reasonable Efforts will be determined on a country-by-country and indication-by-indication basis for each Licensed Product, as applicable, and it is anticipated that the level of effort and resources that constitute &#8220;Commercially Reasonable Efforts&#8221; with respect to a particular country or indication may change over time, reflecting changes in the status of each Licensed Product, as applicable, and the country(ies) involved.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.61.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Committee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the JSC, the JMC, or any joint committees, subcommittees, working groups or other directed teams established by the JSC, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.62.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Competitive Infringement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) the making, using, selling, offering for sale, importing, or exporting by a Third Party of a pharmaceutical or biologic product in a country that actually or potentially infringes a Valid Claim of an Arrowhead Patent Right or a Novartis Arising Patent Right in such country or (b) the filing of an ANDA under Section 505(j) of the FD&#38;C Act or an application under Section 505(b)(2) of the FD&#38;C Act naming a Licensed Product as a reference listed drug and including a certification under Section 505(j)(2)(A)(vii)(IV) or 505(b)(2)(A)(IV), respectively.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.63.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Confidential Information</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) the terms of this Agreement and (b) with respect to a Party, subject to Section 9.3 (Exemptions), all Know-How or other information, including proprietary information and materials (whether or not patentable) embodying such Party&#8217;s technology, products, business information, or objectives, that is communicated by or on behalf of such Party (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Disclosing Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; with respect to such information) to the other Party (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Receiving Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; with respect to such information) or its permitted recipients, including information disclosed by such Party prior to the Effective Date pursuant to the Confidentiality Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.64.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Confidentiality Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means that certain Mutual Confidential Disclosure Agreement dated </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">by and between Arrowhead and Novartis Services Inc..</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.65.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Control</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Controlled</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the possession by a Party or its Affiliates (whether by ownership, license, sublicense or otherwise, other than pursuant to this Agreement) of, (a) with respect to any tangible Know-How or materials, the legal authority or right to physical possession of such tangible Know-How or materials, with the right to provide such tangible Know-How or materials to the other Party on the terms set forth herein, (b) with respect to Patent Rights, Regulatory Approvals, Regulatory Submissions, intangible Know-How, or other intellectual property, the legal authority or right to grant a license, sublicense, access, or right to use (as applicable) to the other Party under such Patent Rights, Regulatory Approvals, Regulatory Submissions, intangible Know-How, or other intellectual property on the terms set forth herein, or (c) with respect to a product or component thereof, the legal authority or right to grant a license, sublicense, access, or right to use (as applicable) to the other Party under Patent Rights that Cover, or proprietary Know-How that is incorporated in or embodies, such product or component on the terms set forth herein, in each case ((a), (b), and (c)), without (i) breaching or otherwise violating the terms of any arrangement or agreement with a Third Party in existence as of the time such Party or its Affiliates would first be required hereunder to grant the other Party such access, right to use, license, or sublicense, or (ii) incurring any additional payment obligations to a Third Party that are not subject to an allocation agreed between the Parties pursuant to this Agreement, including in accordance with Section 2.9 (Third Party In-License Payments) or otherwise in writing.  Notwithstanding any provision in this Agreement to the contrary, following the closing of a Change of Control of Arrowhead, the Parties agree that Arrowhead will be deemed not to Control any materials, tangible Know-How, Patent Rights, Regulatory Submissions, Regulatory Approvals, intangible Know-How, or other intellectual property that are owned or in-licensed by an Acquirer or any of its Affiliates immediately prior to the closing of such Change of Control, except to the extent such materials, tangible Know-How, Patent Rights, Regulatory Submissions, Regulatory Approvals, intangible Know-How, or other </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">intellectual property owned or in-licensed by the Acquirer or such Affiliate (A) were included in the licenses or other rights granted to Novartis pursuant to this Agreement immediately prior to the closing of such Change of Control or (B) are used in the performance of any of Arrowhead&#8217;s or its Affiliates&#8217; obligations, or exercise of its or their rights, under this Agreement following the closing of such Change of Control.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.66.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Cover,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Covering</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">,&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Covered</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a particular subject matter at issue and a relevant Patent Right or individual claim in such Patent Right, as applicable, that the manufacture, use, sale, offer for sale, or importation of such subject matter would fall within the scope of one or more claims in such Patent Right or the individual claim of such Patent Right.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.67.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CTP Research Milestone Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">has the meaning set forth in Section 8.3.1 (CT Programs Research Milestones).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.68.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CTA</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 1.125 (&#8220;IND&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.69.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CTA Ready Data Package</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a specific Program,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">the data, results, and other material Arrowhead Know-How, including the chemical structures and sequences of the lead Licensed SNCA Product, in the case of the SNCA Program, or of the Lead Development Candidate, in the case of a CT Program (but, in each case, excluding (i) all Arrowhead Manufacturing Know-How, which will be provided to Novartis in accordance with Section 5.4 (Manufacturing Technology Transfer) and (ii) any physical material, which will be provided to Novartis in accordance with Section 5.2 (Remaining Inventory at Technology Transfer Date))&#58; (a) generated in the performance of all activities under the applicable Development Plan for such Program (including, for clarity, any such Arrowhead Know-How arising from Arrowhead&#8217;s sponsorship of the NHP MAD Study) and (b) necessary for the filing of a CTA for such lead Licensed SNCA Product or such Lead Development Candidate, as applicable, to commence a Phase I Clinical Trial, but, in each case, in any event, including all information set forth on and (if specified therein) in the format specified in</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.69</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (CTA Ready Data Package Form).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.70.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CT Development Plans</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.1.2(d) (CT Development Plans).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.71.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CT Program Research Activities</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.1.2(d) (CT Development Plans).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.72.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CT Programs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the programs for the Research, Development, Manufacture, Commercialization, and other Exploitation of Licensed CT Compounds and Licensed CT Products, in each case, individually or collectively as the context requires.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.73.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CT Substitution Fee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.2 (CT Substitution Fee).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.74.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CTP Research Milestone Event</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.3.1 (CT Programs Research Milestones).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.75.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CTP Research Milestone Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">has the meaning set forth in Section 8.3.1 (CT Programs Research Milestones).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.76.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Cure Period</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 13.4.1 (Material Breach and Cure Period).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.77.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Data</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any and all data and results that has arisen or arises from the Exploitation of a Licensed Compound or Licensed Product, including pharmacology data, preclinical data, clinical data, investigator reports (both preliminary and final), statistical analysis, expert opinions and reports, and safety and other electronic databases, in each case, in any and all forms, including files, reports, raw data, source data (including patient medical records and original patient report forms, but excluding patient-specific data to the extent required by applicable Laws) and the like.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.78.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Debarred</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to an individual or entity, that such individual or entity has been debarred or suspended under 21 U.S.C. &#167;335(a) or (b), the subject of a conviction described in Section 306 of the FD&#38;C Act, excluded from a federal or governmental health care program, debarred from federal contracting, convicted of or pled </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">nolo contendere</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> to any felony, or to any federal or state legal violation (including misdemeanors) relating to prescription drug products or fraud.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.79.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Delivery Ligand</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a ligand (including any linkers, whether incorporated into the ligand or a separate component) that is (a) conjugated to an RNAi Molecule to help facilitate delivery </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">in vivo</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> to specific tissues or cell types, which may include lipid moieties, antibodies, peptides, and small molecule compounds, (b) a component of, or used in the Manufacture of, Licensed Compounds or Licensed Products, and (c) based on, evolved from, a process improvement to, or is otherwise derived from the Arrowhead Platform.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.80.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Development</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all internal and external research, development, and regulatory activities related to pharmaceutical or biologic products (including Research), including (a) toxicology testing and studies, non-clinical and preclinical testing, studies, and other activities, and Clinical Trials, and (b)&#160;preparation, submission, review, and development of data or information for the purpose of submission to a Regulatory Authority to obtain authorization to conduct Clinical Trials and to obtain, support, or maintain Regulatory Approval of a pharmaceutical or biologic product and interacting with Regulatory Authorities following receipt of Regulatory Approval in the applicable country or region for such pharmaceutical or biologic product regarding the foregoing, but excluding activities directed to Manufacturing, Medical Affairs, or Commercialization.  Development will include development and regulatory activities for additional forms, formulations, or indications for a pharmaceutical or biologic product after receipt of Regulatory Approval of such product (including label expansion), including Clinical Trials initiated following receipt of Regulatory Approval or any Clinical Trial to be conducted after receipt of Regulatory Approval that was mandated by the applicable Regulatory Authority as a condition of such Regulatory Approval with respect to an approved formulation or indication (such as post-marketing studies or observational studies, in either case, if required by any Regulatory Authority in any region in the Territory to support or maintain Regulatory Approval for a pharmaceutical or biologic product in such region).  &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Develop</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">,&#8221; &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Developing</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">,&#8221; and &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Developed</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; will be construed accordingly.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.81.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Development Plans</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, individually or collectively as the context requires, the SNCA Development Plan in respect of the SNCA Program and the CT Development Plan in respect of a CT Program.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.82.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Development Report</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.8.1 (Arrowhead Development Reports).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.83.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Direct Costs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the sum of the following as incurred for the applicable Licensed Compound, Licensed Product, or any other tangible material to be provided by one Party to the other Party hereunder&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.84.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Directed To</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a compound or product and a gene target, that the mechanism of such compound or product </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> such target.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.85.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Disclosing Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 1.63 (&#8220;Confidential Information&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.86.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Disputes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section&#160;15.1 (Exclusive Dispute Resolution Mechanism).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.87.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Dollars</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">$</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the legal tender of the United States of America.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.88.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Drug Product</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.3 (Novartis Manufacturing Options).</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.89.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Drug Substance</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.3 (Novartis Manufacturing Options).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.90.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Effective Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 14.1 (Effective Date).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.91.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">EMA</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the European Medicines Agency or any successor entity.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.92.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">European Union</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">EU</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; mean the European Union, as may be redefined from time to time.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.93.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Exclusivity Period</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.94.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Execution Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the preamble.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.95.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Executive Officer</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> of Arrowhead (or </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">of Arrowhead designated by </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">of Arrowhead who has the power and authority to resolve a given Dispute or matter) and (b) the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">of Novartis (or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> his&#47;her designee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.96.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Expedited</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arbitrator</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 15.3.1 (Expedited Arbitration).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.97.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Exploitation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means to Develop, Manufacture, Commercialize, or otherwise exploit.  When used as a verb, to &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Exploit</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means to engage in any of the foregoing activities.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.98.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">FD&#38;C Act</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the United States Federal Food, Drug, and Cosmetic Act, 21 U.S.C. &#167; 301 </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">et seq.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, as amended together with any rules, regulations, and requirements promulgated thereunder.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.99.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">FDA</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the United States Food and Drug Administration or any successor agency thereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.100.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Field</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all human and animal therapeutic uses for the treatment, prevention, or prophylaxis of any disease, disorder, or condition.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.101.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">First Commercial Sale</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, on a country-by-country and Licensed Product-by-Licensed Product basis, the first sale under this Agreement by Novartis or any of its Affiliates or Sublicensees to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">a Third Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> for use, consumption, or resale of such Licensed Product in such country following receipt of Marketing Approval </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">for such Licensed Product in such country.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.102.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.103.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Force Majeure</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any event beyond the reasonable control of the affected Party, including embargoes, tariffs or other trade restrictions, war or acts of war, including terrorism, insurrections, riots, or civil unrest&#59; strikes, lockouts, or other labor disturbances (other than strikes, lockouts, or labor disturbances involving such Party&#8217;s own employees)&#59; epidemics, pandemics, the spread of infectious diseases, and quarantines&#59; fire, floods, earthquakes, or other acts of nature&#59; or acts, omissions, or delays in acting by any Governmental Authority.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.104.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">FTE</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a qualified full-time person, or more than one person working the equivalent of a full-time person, where &#8220;full time&#8221; is based upon a total of &#91;***&#93;.  Overtime, and work on weekends, holidays, and the like will not be counted with any multiplier (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> time-and-a-half or double time) toward the number of hours that are used to calculate the FTE contribution. Each employee utilized by Arrowhead or any of its Affiliates in connection with Arrowhead&#8217;s or such Affiliate&#8217;s performance under this Agreement may be less than or greater than one FTE based on the hours actually worked by such employee and will be treated as an FTE on a pro rata basis based upon the actual number of such hours worked divided by &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.105.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">FTE Costs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, for any period, the FTE Rate multiplied by the number of FTEs in such period.  FTEs will be pro-rated on a daily basis if necessary.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.106.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">FTE Rate</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, for the period commencing on the Effective Date until such time as the Parties agree otherwise, $</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">per year, subject to annual increases beginning on January 1, 2026 to reflect percentage increase in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, calculated by </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. For the avoidance of doubt, such rate is intended to cover the cost of salaries, benefits, infrastructure costs, travel, general laboratory or office supplies, postage, insurance, training and all other general expenses and overhead items.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.107.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Fully Burdened Cost</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party and Licensed Compound, Licensed Product, or any other tangible material to be provided by one Party to the other Party hereunder, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  All costs and expenses included in this definition will be calculated in accordance with Accounting Standards by such Party on a consistent basis.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.108.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Futility Criteria</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, on a Collaboration Target-by-Collaboration Target, the futility criteria specified in the CT Development Plan for such Collaboration Target.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.109.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">GAAP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means United States generally accepted accounting principles, which principles are currently used at the relevant time and consistently applied by the applicable Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.110.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Gatekeeper</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.1.2(a)(ii) (Selection of Collaboration Targets).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.111.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Generic Entry Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.5.2 (Reduction for Generic Competition).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.112.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Generic Product</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Licensed Product in a particular country of the Territory, any product that&#160;is approved, or is sought to be approved, in reliance, in whole or in part, on the prior Regulatory Approval (or on safety or efficacy data submitted in support of the prior Regulatory Approval) of such Licensed Product in such country as determined by the applicable Regulatory Authority of such country, including any product authorized for sale (a)&#160;in the U.S. pursuant to, as applicable, (i) &#160;Section 505(j) of the FD&#38;C Act (21 U.S.C. 355(j)) or Section 505(b)(2) of the FD&#38;C Act (21 U.S.C. 355(b)(2)), or (ii) Section 351(k) of the Public Health Service Act (PHS Act) as amended by the Biologics Price Competition and Innovation Act (BPCIA), in each case ((i) and (ii)), as amended from time to time, (b)&#160;in countries of the European Economic Area pursuant to Article 10 (but excluding Art. 10(3)), Article 10a, or Article 10b of Parliament and Council Directive 2001&#47;83&#47;EC as amended from time to time (including an application under Article 6.1 of Parliament and Council Regulation (EC) No. 726&#47;2004 that relies for its content on any such provision), or (c)&#160;in any other country or other jurisdiction pursuant to all equivalents of such provisions, including any amendments and successor statutes with respect to any of the foregoing.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.113.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Good Clinical Practices</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">GCP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the then-current good clinical practice standards, practices, and procedures promulgated or endorsed by the applicable Regulatory Authority as set forth in the guidelines imposed by such Regulatory Authority, as may be updated from time-to-time, including those as set forth in FDA regulations in 21 C.F.R. Parts 11, 50, 54, 56, 312, 314, and 320 and all related FDA rules, regulations, orders, and guidances, and by the International Conference on Harmonization E6&#58; Good Clinical Practices Consolidated Guideline.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.114.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Good Laboratory Practices</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">GLP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the then-current and phase appropriate standards, practices and procedures promulgated or endorsed by the FDA as set forth in 21 C.F.R. Part 58 (or any successor statute or regulation) and FDA guidance, including related regulatory requirements imposed by the FDA and comparable applicable regulatory standards, practices and procedures promulgated by the EMA, PMDA, or other Regulatory Authority applicable to the Territory, as they may be updated from time to time, including applicable guidelines promulgated under the ICH.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">11</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.115.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Good Manufacturing Practices</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">GMP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the then-current good manufacturing practices required by the FDA, as set forth in the FD&#38;C Act, 21 C.F.R. Parts 210 and 211, and FDA guidance issued thereunder, for the Manufacture and testing of pharmaceutical materials, and comparable applicable Law related to the manufacture and testing of pharmaceutical materials in jurisdictions outside the United States.  &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Good Manufacturing Practices</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">,&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">GMP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; also means the quality guidelines promulgated by the ICH, including the ICH Q7A, titled &#8220;Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients&#8221; and the policies promulgated thereunder, in each case, as they may be updated from time to time.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.116.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Governmental Authority</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any court, tribunal, arbitrator, agency, commission, department, ministry, official, authority, or other instrumentality of any nation, state, county, city, or other political subdivision thereof or of any multinational governmental body.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.117.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Greater China</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the People&#8217;s Republic of China, the Special Administrative Region of Hong Kong, the Special Administrative Region of Macau, and Taiwan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.118.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">H-W Suit Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 12.4.4 (Hatch-Waxman).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.119.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Hatch-Waxman Act</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means rights conferred in the U.S. under the Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. &#167;355, as amended (or any successor statute or regulation).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.120.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">HSR Act</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules promulgated thereunder.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.121.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">ICC</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the International Chamber of Commerce.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.122.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">ICC Rules</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Section 15.3.1 (Expedited Arbitration).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.123.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">ICH</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means International Conference on Harmonization.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.124.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">IFRS</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means International Financial Reporting Standards, which principles are currently used at the relevant time and consistently applied by the applicable Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.125.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">IND</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) an Investigational New Drug application pursuant to the FD&#38;C Act, as amended, and applicable regulations promulgated thereunder by the FDA, (b) a Clinical Trial authorization application for a product filed with a Regulatory Authority in any other regulatory jurisdiction outside the U.S., the filing of which is necessary to commence or conduct clinical testing of a pharmaceutical or biologic product in humans in such jurisdiction (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CTA</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), or (c) documentation issued by a Regulatory Authority that permits the conduct of clinical testing of a pharmaceutical or biologic product in humans in such jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.126.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section&#160;11.3.1 (Notice).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.127.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Indemnifying Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section&#160;11.3.1 (Notice).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.128.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Indirect Costs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the sum of the following as incurred for the applicable Licensed Compound, Licensed Product, or any other tangible material to be provided by one Party to the other Party hereunder&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.129.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Indirect Taxes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.7.5(e) (Indirect Taxes).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.130.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.131.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">JMC Communication Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.3.3 (Meetings).</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">12</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.132.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Joint Arising Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 12.2.2(c) (Joint).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.133.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Joint Arising Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 12.2.2(c) (Joint).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.134.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Joint Arising Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 12.2.2(c) (Joint).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.135.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Joint Manufacturing Committee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;JMC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.3.1 (Formation&#59; Composition&#59; Dissolution).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.136.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Joint Steering Committee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;JSC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.2.1 (Formation&#59; Composition&#59; Dissolution).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.137.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any (a) proprietary scientific or business information or materials, including records, improvements, modifications, techniques, assays, designs, protocols, formulas, data (including physical data, chemical data, toxicology data, animal data, raw data, clinical data, and analytical and quality control data), Data, dosage regimens, control assays, product specifications, marketing, pricing and distribution costs, inventions, algorithms, technology, forecasts, profiles, strategies, plans, results in any form whatsoever, know-how, and trade secrets (in each case, whether or not patentable, copyrightable, or otherwise protectable), and (b) any information embodied in chemical or biological materials or physical embodiments of any of the foregoing.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.138.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Laws</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means applicable laws, statutes, rules, regulations, and other pronouncements having the effect of law of any Governmental Authority that may be in effect from time to time, including disclosure obligations required by any stock exchange or securities commission having authority over a Party and any applicable rules, regulations, guidances, or other requirements of any Regulatory Authority that may be in effect from time to time.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.139.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">LDC Criteria</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.1.2(d) (CT Development Plans).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.140.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">LDC Nomination Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">means, with respect to a CT Program and a Lead Development Candidate therefor, as applicable, the date of the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.141.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Lead Development Candidate</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">LDC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a CT Program, the first Licensed CT Product that is the subject of such CT Program satisfying the LDC Criteria specified in the CT Development Plan for such CT Program </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.142.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Licensed Compounds</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Licensed SNCA Compounds and the Licensed CT Compounds, in each case, individually or collectively as the context requires.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.143.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Licensed CT Compounds</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, on a CT Program-by-CT Program basis, (a) the Lead Development Candidate that is the subject of such CT Program, (b) any backups of the Lead Development Candidate Controlled by Arrowhead or any of its Affiliates as of the Technology Transfer Date for such CT Program, and (c) any modification, improvement, or other derivative to or of the RNAi Molecules described in clauses (a) or (b).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.144.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Licensed CT Product-Specific Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Arrowhead Patent Rights having claims Covering solely (a) the composition of matter comprising the nucleotide sequence of one or more Licensed CT Compounds or Licensed CT Products, (b) the method of use (including method of treatment by use) of one or more Licensed CT Compounds or Licensed CT Products, (c) the formulation comprising, and biomarkers or companion diagnostics specifically relating to, one or more Licensed CT Compounds or Licensed CT Products, or (d) the method of manufacture specific to the Manufacture of Licensed CT Compounds or Licensed CT Products.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.145.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Licensed CT Products</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any pharmaceutical or biologic product that is comprised of or contains a Licensed CT Compound, alone or in combination with one or more Other </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">13</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Components, in any and all forms, presentations, delivery systems, dosages, and formulations and any improved or modified versions thereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.146.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Licensed Product-Specific Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, collectively, the Licensed SNCA Product-Specific Patent Rights and the Licensed CT Product-Specific Patent Rights.  The Licensed Product-Specific Patent Rights existing as of the Execution Date are set forth on </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.146</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (Licensed Product-Specific Patent Rights).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.147.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Licensed Products</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Licensed SNCA Products and the Licensed CT Products, in each case, individually or collectively as the context requires.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.148.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Licensed SNCA Compound</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any and all of the following (a) ARO-SNCA SC, (b) the SNCA Backup Compounds, and (c) any modification, improvement, or other derivative to or of ARO-SNCA or any SNCA Backup Compound that is Directed To SNCA.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.149.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Licensed SNCA Product</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any pharmaceutical or biologic product that is comprised of or contains a Licensed SNCA Compound, alone or in combination with one or more Other Components, in any and all forms, presentations, delivery systems, dosages, and formulations and any improved or modified versions thereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.150.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Licensed SNCA Product-Specific Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Arrowhead Patent Rights having claims Covering solely (a) the composition of matter comprising the nucleotide sequence of one or more Licensed SNCA Compounds or Licensed SNCA Products, (b) the method of use (including method of treatment by use) of one or more Licensed SNCA Compounds or Licensed SNCA Products, (c) the formulation comprising, and biomarkers or companion diagnostics specifically relating to, one or more Licensed SNCA Compounds or Licensed SNCA Products, or (d) the method of manufacture specific to the Manufacture of Licensed SNCA Compounds or Licensed SNCA Products.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.151.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Losses</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section&#160;11.1 (Indemnification by Arrowhead).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.152.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">MAA</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any new drug application or other marketing authorization application, in each case, filed with the applicable Regulatory Authority in a country or other regulatory jurisdiction (and all supplements and amendments thereto), which application is required to commercially market or sell a pharmaceutical or biologic product in such country or jurisdiction, including (a) all New Drug Applications submitted to the FDA in the United States pursuant to the FD&#38;C Act (21 U.S.C. &#167; 355(b)(1)) and the regulations promulgated thereunder with respect to a pharmaceutical product and (b) a Biologics License Application submitted to the FDA in the United States pursuant to the FD&#38;C Act (21 C.F.R. &#167; 601.2) and the regulations promulgated thereunder with respect to a pharmaceutical product, or, in each case ((a) and (b)), any analogous application or submission with any Regulatory Authority in any other country or regulatory jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.153.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Major European Markets</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.154.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Major Region</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.155.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Manufacture</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means activities directed to manufacturing, processing, formulating, packaging, labeling, filling, finishing, assembly, quality assurance, quality control, testing, and release, shipping, or storage of any pharmaceutical or biologic product (or any components or process steps involving any product or any companion diagnostic), placebo, or comparator agent, as the case may be, including process development, process qualification, validation and scale-up, pre-clinical, clinical and commercial manufacture, and analytic development, product characterization, and stability testing, as the case may be, but excluding activities directed to </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">14</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Development, Commercialization, or Medical Affairs.  &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; will be construed accordingly.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.156.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Technology Transfer Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.4 (Manufacturing Technology Transfer).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.157.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.158.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Marketing Approval</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a country or extra-national territory, any and all approvals (including Regulatory Approval and Pricing and Reimbursement Approval), licenses, registrations, or authorizations of any Governmental Authority that are required in order to Commercialize a Licensed Product in such country or some or all of such extra-national territory.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.159.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Materials</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all tangible compositions of matter, devices, articles of manufacture, assays, biological, chemical or physical materials, and other similar materials.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.160.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.161.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Medical Affairs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means activities conducted by a Party&#8217;s medical affairs departments (or, if a Party does not have a medical affairs department, the equivalent function thereof), including communications with key opinion leaders, medical education, symposia, advisory boards (to the extent related to medical affairs or clinical guidance), activities performed in connection with patient registries, and other medical programs and communications, including educational grants, research grants (including conducting investigator-initiated studies), and charitable donations to the extent related to medical affairs and not to other activities that do not involve the promotion, marketing, sale, or other Commercialization of the Licensed Products and are not conducted by a Party&#8217;s medical affairs (or equivalent) departments.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.162.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.163.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Milestone Events</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the CTP Research Milestone Events, the Regulatory Milestone Events, and the Sales Milestone Events.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.164.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Milestone Payments</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the CTP Research Milestone Payments, the Regulatory Milestone Payments, and the Sales Milestone Payments.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.165.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Net Sales</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the net sales recorded by Novartis or any of its Affiliates or their Sublicensees (excluding, for clarity, any distributors or wholesalers) for any Licensed Product sold to Third Parties other than Sublicensees as determined in accordance with Novartis&#8217; Accounting Standards as consistently applied, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. The deductions booked on an accrual basis by Novartis and its Affiliates under its Accounting Standards as consistently applied to calculate the recorded net sales from gross sales include the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">1.166.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">With respect to the calculation of Net Sales&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.167.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">NHP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 1.268 (&#8220;Unavailable&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.168.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">NHP MAD Study</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">15</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.169.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Non-Bankrupt Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 16.2 (Section 365(n) of the Bankruptcy Code).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.170.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Non-Breaching Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 13.4.1 (Material Breach and Cure Period).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.171.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Arising Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 12.2.2(b) (Novartis).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.172.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Arising LC&#47;LP Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Novartis Arising Patent Rights having claims Covering solely</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#59; but expressly excluding any Novartis Arising Patent Rights that also claim or otherwise disclose </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.173.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> means </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.174.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Arising Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 12.2.2(b) (Novartis).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.175.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Arising Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 12.2.2(b) (Novartis).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.176.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Background Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Know-How and Patent Rights Controlled by Novartis or any of its Affiliates, which Know-How and Patent Rights&#58; (a) &#91;***&#93;, or (b) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">1.177.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Licensed Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, collectively, the Novartis Arising Know-How, Novartis Arising Patent Rights, and Novartis&#8217; interest in the Joint Arising Technology, in each case, without limiting any of Novartis&#8217; obligations under this Agreement, that are Controlled by Novartis or any of its Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.176.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Novartis Prosecuted Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 12.3.1(a) (Novartis&#8217; Right to Prosecute Patent Rights).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.177.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Novartis Records</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section&#160;8.7.3 (Records and Audits).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.178.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">OFAC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Office of Foreign Assets Control of the United States Department of the Treasury or any successor agency thereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.179.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.5pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> has the meaning set forth in Section </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.180.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Orange&#47;Purple Book</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (a) the then-current edition of the United States Food and Drug Administration publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations&#8221;, (b) the then-current edition of the United States Food and Drug Administration publication &#8220;Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations&#8221;, or (c) the equivalent patent listing to that set forth in clause (a) or clause (b), as applicable, in any other country within the Territory.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.181.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.5pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> has the meaning set forth in Section </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.182.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Out-of-Pocket Costs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to certain activities for a Licensed Compound or Licensed Product hereunder, specifically identifiable</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">expenses paid or payable by a Party or its Affiliates to Third Parties to conduct such activities, including payments to contract personnel (including contractors, consultants, and Subcontractors) incurred after the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.183.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Parties</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the preamble.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">16</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.184.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Patent Challenge</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 13.5 (Termination for Patent Challenge).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.185.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Patent Costs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Out-of-Pocket Costs paid to outside legal counsel and other Third Parties incurred in the Prosecution and Maintenance of Patent Rights hereunder or enforcing and defending any such Patent Rights, determining freedom to operate for any Licensed Products (including challenging any Patent Right Controlled by Third Parties).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.186.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Patent Offices</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section&#160;10.2.6 (Validity and Enforceability).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.187.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Patent Right</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any and all (a) patents, (b) patent applications, including all provisional and non-provisional applications, patent cooperation treaty (PCT) applications, substitutions, continuations, continuations-in-part, divisions and renewals, and all patent rights granted thereon or claiming priority thereto, (c) all patents-of-addition, reissues, re-examinations and extensions or restorations by existing or future extension or restoration mechanisms, including supplementary protection certificates, patent term extensions, and equivalents thereof, (d) inventor&#8217;s certificates, letters patent, (e) any other substantially equivalent form of government issued right substantially similar to any of the foregoing described in subsections (a) through (e) above, anywhere in the world.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.188.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Patent Term Extensions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 12.8 (Patent Right Extensions).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.189.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Payments</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 8.7.5(a) (Withholding Taxes).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.190.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Person</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any natural person, corporation, unincorporated organization, partnership, association, sole proprietorship, joint stock company, joint venture, limited liability company, trust or government, Governmental Authority, or any other similar entity.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.191.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Personnel</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, its officers, directors, employees, workers, contractors, advisors, consultants, agents, or other representatives.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.192.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Pharmacovigilance Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 4.3 (Pharmacovigilance Agreement).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.193.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Phase I Clinical Trial</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Clinical Trial (or any arm thereof) of a pharmaceutical or biologic product with the endpoint of determining initial tolerance, safety, metabolism, pharmacokinetic or pharmacodynamic information in single dose, single ascending dose, multiple dose, or multiple ascending dose regimens, and that satisfies the requirements of U.S. federal regulation 21 C.F.R. &#167;&#167; 312.21(a) and its successor regulation or equivalents in other jurisdictions.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.194.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Phase II Clinical Trial</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Clinical Trial (or any arm thereof) of a pharmaceutical or biologic product with the primary objective of characterizing its effectiveness in a specific disease state as well as generating more detailed safety, tolerability, and pharmacokinetics information, and that satisfies the requirements of U.S. federal regulation 21 C.F.R. &#167;&#167; 312.21(b) and its successor regulation or equivalents in other jurisdictions.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">17</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.195.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Phase III Clinical Trial</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Clinical Trial (or any arm thereof) of a pharmaceutical or biologic product on a sufficient number of patients, which trial a Regulatory Authority permits to be conducted under an open IND and is designed to&#58; (a) establish that the pharmaceutical or biologic product is safe and efficacious for its intended use&#59; (b) define warnings, precautions and adverse reactions that are associated with the pharmaceutical or biologic product in the dosage range to be prescribed&#59; and (c) support an MAA filed with a Regulatory Authority for the pharmaceutical or biologic product, and that satisfies the requirements of U.S. federal regulation 21 C.F.R. &#167; 312.21(c) and its successor regulation or equivalents in other jurisdictions.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.196.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Pivotal Trial</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (a) a Phase III Clinical Trial or (b) any other Clinical Trial for which the applicable Regulatory Authority has reviewed the existing efficacy and safety data from a prior Clinical Trial for the applicable Licensed Product and has agreed, whether before </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">dosing of the first patient in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">such Clinical Trial (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, pursuant to an agreement with or statement from the FDA or the EMA on a &#8216;Special Protocol Assessment&#8217; or equivalent or other guidance or minutes issued by the FDA or EMA) or after </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">dosing of the first patient in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">such Clinical Trial (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, based on an interim data analysis), is sufficient to form the primary basis of an efficacy claim in a submission for Regulatory Approval, regardless of whether the sponsor of such study characterizes or refers to such study as a &#8220;Phase III,&#8221; &#8220;Phase IIb&#8221;, &#8220;Phase IIb&#47;III&#8221; or &#8220;Phase I&#47;II&#8221; study (or otherwise) in the applicable protocol, on clinicaltrials.gov, or in any other context.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.197.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Platform Third Party Agreements</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2.9.2(b)(i) (Platform Third Party Rights).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.198.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Platform Third Party Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2.9.2(b)(i) (Platform Third Party Rights).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.199.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.5pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> has the meaning set forth in Section </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.200.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Pre-Existing Third Party Agreements</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means those certain agreements between Arrowhead and a Third Party set forth on </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Schedule 1.200</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(Pre-Existing Third Party Agreements).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.201.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.5pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> means </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.202.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.5pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.203.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Pricing and Reimbursement Approval</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the later of (a) the approval, agreement, determination, or governmental decision establishing a price for the applicable Licensed Product that can be legally charged to consumers, if required in a given jurisdiction or country in connection with Commercialization of such Licensed Product in such jurisdiction or country&#59; and (b) the approval, agreement, determination, or governmental decision establishing the level of reimbursement for the applicable Licensed Product that will be reimbursed by Governmental Authorities, if required in a given jurisdiction or country in connection with the Commercialization of such Licensed Product in such jurisdiction or country.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.204.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Product-Specific Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 9.1 (Confidential Information).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.205.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Program</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means each of the SNCA Program and the CT Programs.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">18</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.206.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Program-Specific Third Party Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2.9.2(a) (Program-Specific Third Party Rights).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.207.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Proposed</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Replacement Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 3.1.2(b)(i)(Novartis Collaboration Target Substitution Right).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.208.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Proposed</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 3.1.2(a)(iii) (Selection of Collaboration Targets).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.209.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Proposed</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Target Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 3.1.2(a)(iii) (Selection of Collaboration Targets).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.210.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Prosecution and Maintenance</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Prosecute and Maintain</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the filing, preparation, prosecution (including any interferences, reissue proceedings, reexaminations, oppositions and similar proceedings), post-grant reviews, requests for patent term adjustments, and maintenance of Patent Rights.  For the avoidance of doubt, Prosecution and Maintenance excludes any applications or requests for patent term extension.  When used as a verb, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Prosecute and Maintain</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means to engage in Prosecution and Maintenance.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.211.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.212.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.213.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.214.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.5pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> means </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.215.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Receiving Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 1.63 (&#8220;Confidential Information&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.216.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Regulatory Approval</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to a particular country or other regulatory jurisdiction, any approval of an MAA, or other approval, product, or establishment license, registration, or authorization of any Regulatory Authority necessary for the Manufacture, Commercialization, or other Exploitation of a pharmaceutical or biologic product in such country or other regulatory jurisdiction, including all supplements and amendments thereto, excluding, in each case, Pricing and Reimbursement Approval.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.217.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Regulatory Authority</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any applicable Governmental Authority with jurisdiction or authority over the Development, Manufacture, Commercialization, or other Exploitation (including Marketing Approval, Regulatory Approval, or Pricing and Reimbursement Approval) of pharmaceutical or biologic products in a particular country or other regulatory jurisdiction, and any corresponding national or regional regulatory authorities.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.218.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Regulatory Exclusivity</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to a Licensed Product in a country or jurisdiction in the Territory, other than a Patent Right, that prohibits a Person from relying on or otherwise using safety or efficacy data generated by or on behalf of a Party with respect to such Licensed Product, including new use or indication exclusivity, new formulation, new chemical entity exclusivity, orphan drug exclusivity, or non-patent related pediatric exclusivity.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">19</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.219.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Regulatory Milestone Event</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 8.3.2 (Regulatory Milestones).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.220.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Regulatory Milestone Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 8.3.2 (Regulatory Milestones).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.221.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Regulatory Submissions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any filing, application, dossier, or submission with any Regulatory Authority in support of the Development, Manufacture, Commercialization, or other Exploitation of a pharmaceutical or biologic product (including to obtain, support, or maintain Regulatory Approval from that Regulatory Authority), including all supplements, amendments, data, and documents with respect thereto, and all correspondence or communication with or from the relevant Regulatory Authority, as well as minutes of any material meetings, telephone conferences, or discussions with the relevant Regulatory Authority.  Regulatory Submissions include all INDs, MAAs, and other applications for Regulatory Approval and their equivalents.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.222.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Reimbursable Development Costs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 3.6 (Arrowhead Development Costs Reimbursement).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.223.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Research</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all internal and external research, identification of composition of matter, screening, and non-human testing, including all non-clinical toxicology testing and studies, non-clinical and preclinical testing, studies, and other activities.  When used as a verb, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">to Research</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Researching</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; mean to engage or engaging in Research.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.224.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Restricted Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any individual or entity on one or more of the Restricted Party Lists.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.225.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Restricted Party List</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the list of sanctioned entities maintained by the United Nations&#59; the Specially Designated Nationals and Blocked Persons List, the Foreign Sanctions Evaders List and the Sectoral Sanctions Identifications List, all administered by OFAC&#59; the U.S. Denied Persons List, the U.S. Entity List, and the U.S. Unverified List, all administered by the U.S. Department of Commerce&#59; and the entities subject to restrictive measures and the consolidated list of Persons, Groups, and Entities Subject to E.U. Financial Sanctions, as implemented by the E.U. Common Foreign &#38; Security Policy.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.226.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Reversion License</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 13.6.2(a) (Termination by Arrowhead for Cause or by Novartis Without Cause).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.227.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Reversion Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in 13.6.2 (Termination by Arrowhead for Cause or by Novartis Without Cause).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.228.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Reversion Trademarks</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in 13.6.2 (Termination by Arrowhead for Cause or by Novartis Without Cause).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.229.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">RNAi Molecule</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an exogenous double-stranded oligomeric (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, RNA or modified variants thereof) molecule.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.230.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Royalties</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 8.4 (Royalties).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.231.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Royalty Rates</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the applicable royalty rates set forth in Table 8.4</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(Royalty Payments).</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">20</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.232.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Royalty Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, on a Licensed Product-by-Licensed Product and country-by-country basis, the period commencing on the First Commercial Sale of such Licensed Product in such country and expiring upon the last to occur of (a) the expiration of the last Valid Claim of the last to expire of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, (b) the expiration of all Regulatory Exclusivity for such Licensed Product in such country, and (c) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> after the First Commercial Sale of such Licensed Product in such country.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.233.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Sales Milestone Event</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 8.3.3 (Sales Milestones).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.234.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Sales Milestone Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 8.3.3 (Sales Milestones).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.235.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Sanctioned Person</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any Person that is the subject or target of sanctions or restrictions under the Global Trade Laws, including, any Person&#58; (a) listed on any list of sanctioned persons maintained by the United States, United Nations Security Council, including (i) the &#8220;Specially Designated Nationals and Blocked Persons&#8221; list maintained by the U.S. Office of Foreign Assets Control or (ii) the Entity List or Military End User List maintained by the U.S. Department of Commerce&#8217;s Bureau of Industry and Security&#59; (b) located in, ordinarily resident in or incorporated in a Sanctioned Territory&#59; or (c) which is 50% or more owned, directly or indirectly, individually or in the aggregate, or otherwise controlled, as applicable, by any Person or Persons described in subclauses (a) or (b) of this definition.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">1.236.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.237.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Sanctioned Territory</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any country or territory which is itself the subject or target of any country-wide or territory-wide comprehensive economic sanctions imposed by the United States at any point over the previous five years, including Cuba, Iran, North Korea, Syria and the Crimea and so-called Donetsk People&#8217;s Republic and Luhansk People&#8217;s Republic regions of Ukraine.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.238.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">SEC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the United States Securities and Exchange Commission or any successor Governmental Authority having substantially the same function.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.239.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Securitization Transaction</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 16.1.2 (Securitization Transaction).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.240.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Selection Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the period commencing on the Effective Date and expiring </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.241.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">SNCA</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means alpha-synuclein.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.242.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">SNCA Backup Compound</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any backups of ARO-SNCA SC Controlled by Arrowhead or any of its Affiliates as of the Technology Transfer Date for the SNCA Program.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.243.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">SNCA Development Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 3.1.1(b) (SNCA Development Plan).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.244.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">SNCA Program</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the program for the Research, Development, Manufacture, Commercialization, and other Exploitation of Licensed SNCA Compounds and Licensed SNCA Products.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">21</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.245.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">SNCA Program Research Activities</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 3.1.1(b) (SNCA Development Plan).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.246.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Subcontractor</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Third Party contractor engaged by a Party to perform certain obligations or exercise certain rights of such Party under this Agreement on a fee-for-service basis (including contract research organizations, distributors, wholesalers, or CMOs).  For clarity, a Subcontractor will not include a Third Party contractor engaged by a Party to perform ancillary facility support activities, like, by way of non-limiting example, security services.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.247.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Sublicensee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Third Party (excluding distributors and wholesalers) to whom a Party or any of its Affiliates has granted or grants a sublicense of its rights hereunder to Develop, Manufacture, Commercialize, or otherwise Exploit a Licensed Product, or any further sublicensee of such rights (regardless of the number of tiers, layers or levels of sublicenses of such rights) in accordance with Section 2.2 (Sublicensing Terms).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.248.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any of SNCA or a Collaboration Target, in each case, individually or collectively as the context requires.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.249.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Target Competing Product</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2.10.1 (Exclusivity Covenants).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.250.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Target Competitive Activities</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2.10.1 (Exclusivity Covenants).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.251.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Target Exclusivity Period</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2.10.1 (Exclusivity Covenants).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.252.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Target Failure</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 3.1.2(c) (Arrowhead CT Program Development Responsibility).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.253.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Tax</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Taxation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any form of tax or taxation, levy, duty, charge, social security charge, contribution, or withholding of whatever nature (including any related fine, penalty, surcharge, or interest) imposed by, or payable to, any government, state or municipality, or any local, state, federal, or other fiscal, revenue, customs, or excise authority, body, or official in the Territory.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.254.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Technology Transfer Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 3.2.2(a) (Transition of Research &#38; Development Activities).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.255.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 13.1 (Term).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.256.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Terminated Products</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (a) if this Agreement is terminated in its entirety, all Licensed Compounds and all Licensed Products under this Agreement, (b) if this Agreement is terminated in part with respect to a Program in the entire Territory, all Licensed Compounds and all Licensed Products that are the subject of such Program in the entire Territory </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.257.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">22</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.258.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Territory</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all of the countries of the world, and their territories and possessions.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.259.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Third Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Person other than Arrowhead, Novartis, or their respective Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.260.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Third Party Experts</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 7.4.3(a)(A) (Final Decision-Making Authority).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.261.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Trade Control Laws and Sanctions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all applicable Laws governing the export, import and provision of goods (including technical data and technology) and services, including (a) the applicable Laws of the United States governing embargoes, sanctions and boycotts, the International Emergency Economic Powers Act (50 U.S.C. &#167; 1701 et seq.), the Trading with the Enemy Act (50 U.S.C. App. &#167;&#167; 1-44), and all rules, regulations and executive orders relating to any of the foregoing, including regulations promulgated by the Office of Foreign Assets Control of the United States Department of the Treasury at 15 C.F.R. Parts 500-599 and by the U.S. Department of State&#59; (b) all Laws governing the export, re-export, or transfer of goods, software, technology, or technical data, including the Export Administration Act of 1979 (50 U.S.C. App. &#167;&#167; 2401-2420), the Export Control Reform Act of 2018 (Pub. L. 115-232), the Export Administration Regulations (&#8220;EAR&#8221;, 15 C.F.R. Parts 730-774), the Arms Export Control Act (22 U.S.C. &#167; 2778), and the International Traffic in Arms Regulations (22 C.F.R. &#167; 120.1 et seq.)&#59; (c) the Foreign Trade Regulations (15 C.F.R. Part 30) administered by the Census Bureau&#59; (d) all applicable Laws governing the importation of products, technology, technical data, and services, including those administered by United States Customs and Border Protection (19 C.F.R. Parts 1-199)&#59; (e) the antiboycott laws set forth in section 999 of the Internal Revenue Code, the Department of the Treasury Guidelines concerning international boycotts promulgated thereunder, and Part 760 of the EAR&#59; and (f) any other applicable Laws relating to the export and import activities of an applicable Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.262.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Trademark</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any trademark, trade name, service mark, service name, brand, domain name, trade dress, logo, slogan, or other indicia of origin or ownership, including the goodwill and activities associated with each of the foregoing.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.263.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Transaction Agreements</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means this Agreement, the Pharmacovigilance Agreement, and any clinical supply agreement, commercial supply agreement, and related quality agreements, or any other agreement that supplements this Agreement, in each case, between the Parties, individually or collectively as the context may require.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.264.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.5pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> has the meaning set forth in Section </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.265.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.5pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> means </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.266.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.5pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> has the meaning set forth in Section </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.267.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.5pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> means </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.268.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.5pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> has the meaning set forth in Section </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.269.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Unavailable</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">23</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.270.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">United States</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">U.S.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the United States and its territories, possessions and commonwealths.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.271.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Upfront Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 8.1 (Upfront Payment).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.272.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Valid Claim</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (a) a claim of any issued and unexpired Patent Right whose validity, enforceability, or patentability has not been affected by any of the following&#58; (i)&#160;irretrievable lapse, abandonment, revocation, cancellation, dedication to the public, or disclaimer&#59; or (ii)&#160;a holding, finding, or decision of invalidity, unenforceability, or non-patentability by a court, governmental agency, national or regional patent office, or other appropriate body that has competent jurisdiction, such holding, finding, or decision being final and unappealable or unappealed within the time allowed for appeal&#59; or (b) a pending claim of an unissued, pending patent application that has not been pending for more than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> from its earliest priority date, in which case it will cease to be considered a Valid Claim until the patent issues and recites said claim.  For clarity, a holding, finding or decision being final and unappealable or unappealed means a holding, finding or decision from which no appeal can be or has been taken.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.273.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Visirna</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 1.8 (Affiliates).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.274.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.5pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Withholding Taxes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 8.7.5(a) (Withholding Taxes).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">LICENSE GRANTS&#59; EXCLUSIVITY</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">2.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">License Grants to Novartis</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> on a Program-by-Program basis, Arrowhead hereby grants to Novartis and its Affiliates, during the Term, an exclusive (even as to Arrowhead and its Affiliates, except as set forth in Section 2.4 (Arrowhead Retained Rights)), non-transferable (except in accordance with Section&#160;16.1 (Assignment)), royalty-bearing, sublicensable (through multiple tiers, in accordance with Section&#160;2.2 (Sublicensing Terms)) license under the Arrowhead Technology to Develop, Manufacture, perform Medical Affairs, Commercialize, and otherwise Exploit the Licensed Compounds and Licensed Products in the Field and in the Territory.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">2.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Sublicensing Terms</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">2.2.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.05pt">Subject to this Section 2.2 (Sublicensing Terms), Novartis and its Affiliates may grant sublicenses under Section 2.1 (License Grants to Novartis) to any Third Party, including to any Subcontractor to the extent a sublicense of the rights granted to Novartis hereunder is necessary for such Subcontractor to satisfy Novartis&#8217; obligations as delegated to such Subcontractor.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">2.2.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.05pt">With respect to any sublicense granted pursuant to Section 2.2.1 (Sublicensing Terms) or Section 2.3 (Performance through Subcontractors) to a Sublicensee or a Subcontractor, as the case may be&#58;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">any such sublicense or subcontract agreement will be consistent with the terms of this Agreement and obligate the Sublicensee or Subcontractor to comply with the applicable terms of this Agreement, including those of Section 10.6.9 (No Reverse Engineering)&#59;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">as between the Parties, Novartis will remain primarily liable to Arrowhead for the performance of all of its obligations under, and its compliance with all provisions of, this Agreement, and for the performance of its Sublicensees and its Subcontractors, and Arrowhead will have the right to proceed directly </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">24</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">against Novartis without any obligation to first proceed against the Sublicensees or Subcontractors&#59;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">without limiting Section 2.2.2(a) (Sublicensing Terms), each Sublicensee and Subcontractor, as applicable, will (i) undertake in writing obligations of confidentiality and non-use regarding Confidential Information that are substantially the same as those undertaken by the Parties with respect to Confidential Information pursuant to Article 9 (Confidentiality and Publication), and (ii) use Commercially Reasonable Efforts to require that each of its Sublicensees and Subcontractors undertakes in writing to assign or exclusively license back (with the right to sublicense through multiple tiers) to Novartis all Arising Know-How and Arising Patent Rights (including intellectual property with respect to any Licensed Compounds and Licensed Products conceived, invented, developed or otherwise made in the course of performing any such work)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">within a reasonable time after execution of any sublicense agreement with a Sublicensee that grants Development or Commercialization rights in a Major Region, Novartis will provide to Arrowhead a copy of such agreement (other than any agreement with a Subcontractor), which agreement may be redacted to omit any terms not necessary to determining Novartis&#8217; and such Sublicensee&#8217;s obligations under this Agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">2.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Performance through Subcontractors</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to Section 2.2.2 (Sublicensing Terms) and Section 5.4 (Manufacturing Technology Transfer), Novartis and any of its Affiliates may perform any of its rights or obligations under this Agreement through one or more Subcontractors.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">2.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Arrowhead Retained Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as expressly granted under Section 2.1 (License Grants to Novartis), Arrowhead hereby expressly retains, on behalf of itself and its Affiliates, all rights under the Arrowhead Technology, including the right to (a) perform the SNCA Program Research Activities and the CT Program Research Activities, (b) Manufacture Licensed Compounds and Licensed Products in accordance with Article 5 (Manufacturing), (c) fulfill its obligations under any agreement between the Parties for Arrowhead&#8217;s performance of Development activities or Manufacturing activities on behalf of Novartis or its Affiliates or its Sublicensees for any Licensed Compounds and Licensed Products, and (d) fulfill any other obligations expressly set forth under this Agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">2.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">No Other Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as otherwise expressly provided in this Agreement, under no circumstances will a Party or any of its Affiliates, as a result of this Agreement, obtain any ownership interest, license, or other right in or to any Know-How, Patent Rights, or other intellectual property of the other Party, including tangible or intangible items owned, Controlled, or developed by the other Party, or provided by the other Party to the receiving Party at any time, pursuant to this Agreement.  Any rights not expressly granted by a Party under this Agreement are hereby retained by such Party.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">2.6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Combination Products</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of this Agreement, for purposes of the license grants under Section 2.1 (License Grants to Novartis), with respect to any Licensed Product that is a Combination Product, such license will not include any Other Component Controlled by, as applicable, Arrowhead or any of its Affiliates or Novartis or any of its Affiliates included in any such Combination Product.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">2.7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">License to Arrowhead</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement, Novartis hereby grants to Arrowhead and its Affiliates a non-exclusive, non-transferable (except in accordance with Section&#160;16.1 (Assignment)), royalty-free, fully paid-up, sublicensable (to a Subcontractor in accordance with Section 2.8 (Arrowhead Performance through Subcontractors)), license under the Novartis Arising Technology, solely to the extent necessary to enable Arrowhead to perform its obligations under and in accordance with the terms of this Agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">2.8.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Arrowhead Performance through Subcontractors</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to this Section 2.8 (Arrowhead Performance through Subcontractors), Arrowhead and its Affiliates may (a) perform any of its rights or obligations under this Agreement through (i) its Affiliates, (ii) one or more of the </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">25</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="padding-left:36pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Subcontractors set forth in the applicable Development Plan, or, subject to Novartis&#8217; prior written approval (not to be unreasonably withheld, conditioned or delayed), any new Subcontractor that Arrowhead proposes to engage to perform Development activities under the applicable Development Plan, or (iii) any of the Subcontractors listed in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 2.8</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (Arrowhead Pre-Approved Subcontractors) for the activities specified in such schedule, and (b) grant sublicenses under Section 2.7 (License to Arrowhead) to any Subcontractor to the extent a sublicense of the rights granted to Arrowhead hereunder is necessary for such Subcontractor to satisfy Arrowhead&#8217;s obligations as delegated to such Subcontractor. With respect to any sublicense granted pursuant to this Section 2.8 (Arrowhead Performance through Subcontractors) to a Subcontractor&#58;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">any such subcontract agreement will be consistent with the terms of this Agreement and obligate the Subcontractor to comply with the applicable terms of this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">as between the Parties, Arrowhead will remain primarily liable to Novartis for the performance of all of its obligations under, and its compliance with all provisions of, this Agreement, and for the performance of its Subcontractors, and Novartis will have the right to proceed directly against Arrowhead without any obligation to first proceed against the Subcontractors&#59; and</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">each Subcontractor will (i) undertake in writing obligations of confidentiality and non-use regarding Confidential Information that are substantially the same as those undertaken by the Parties with respect to Confidential Information pursuant to Article 9 (Confidentiality and Publication), and (ii) use Commercially Reasonable Efforts to require that each of its Subcontractors undertakes in writing to assign or exclusively license back (with the right to sublicense through multiple tiers) to Arrowhead all Arising Know-How and Arising Patent Rights (including intellectual property with respect to any Licensed Compounds and Licensed Products conceived, invented, developed or otherwise made in the course of performing any such work).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">2.9.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Third Party In-License Payments</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">2.9.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Prior to the Effective Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  As between the Parties, Arrowhead will be solely responsible for any license fees, milestones, royalties, and other payments, whether accruing prior to, on or following the Effective Date, under any of the Pre-Existing Third Party Agreements.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">2.9.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">After Effective Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Program-Specific Third Party Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  On a Program-by-Program basis, if, in the reasonable opinion of Novartis, rights under any Patent Rights or Know-How of a Third Party are necessary or reasonably useful for the Exploitation of any of the Licensed Compounds or Licensed Products that are the subject of such Program by Novartis or any of its Affiliates or any of its or their Sublicensees in any country of the Territory that are or is not Platform Third Party Rights (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Program-Specific Third Party Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then, as between the Parties, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Platform Third Party Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:154.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">From and after the Effective Date and continuing during the Term, subject to Novartis&#8217; rights under Section 12.6.2 (Defense), prior to Arrowhead (or any of its Affiliates) entering into an agreement with respect to any Patent Rights or Know-How of a Third Party that are or is&#58;  (A) generally applicable to making, using, or selling RNAi </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">26</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:154.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Molecules&#59; (B) not specific to a Licensed Compound, a Licensed Product, or any other RNAi Molecule Directed To the Target that is the subject of a Program, or any method of manufacture or use thereof&#59; and (C) in the reasonable opinion of Arrowhead is necessary or reasonably useful for the Exploitation of the Licensed Compounds or Licensed Products that are the subject of a Program (such Patent Rights or Know-How, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Platform Third Party Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and such agreement, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Platform Third Party Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Arrowhead will provide written notice to Novartis of Arrowhead&#8217;s (or its Affiliate&#8217;s) intent to enter into such proposed Platform Third Party Agreement, along with reasonably detailed information regarding the proposed financial terms, as well as any other material terms applicable to sublicensees under such proposed Platform Third Party Agreement and the relevant Patent Rights or Know-How owned or otherwise controlled by such Third Party that are proposed to be included as Arrowhead Technology if Novartis elects to take a sublicense under such proposed Platform Third Party Agreement pursuant to Section 2.9.2(b)(ii) (Platform Third Party Rights). After receipt of such notice from Arrowhead with respect to any Platform Third Party Agreement, Novartis will have the right to request discussions with Arrowhead, and, if so requested, the Parties will promptly meet and discuss such Platform Third Party Rights and Platform Third Party Agreement, including the proposed financial terms and other terms applicable to sublicensees thereunder.</font></div><div style="margin-bottom:12pt;padding-left:154.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">Arrowhead (or its Affiliate) will use Commercially Reasonable Efforts to obtain sublicensable licenses or other rights under the relevant Platform Third Party Rights pursuant to its corresponding Platform Third Party Agreement that are sufficient to grant Novartis a license with respect to the Licensed Compounds and Licensed Products that are the subject of the applicable Program on terms substantially consistent with the rights and licenses granted to Novartis under the Arrowhead Technology pursuant to Section 2.1 (Licensed Grants to Novartis)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. In no event will Arrowhead enter into any Platform Third Party Agreement under which rights are not sublicensable to Novartis in a manner that precludes Novartis from entering into an agreement with the applicable Third Party for a grant of such Platform Third Party Rights to Exploit the Licensed Compounds and Licensed Products in the Field in the Territory.</font></div><div style="margin-bottom:12pt;padding-left:154.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">If Arrowhead (or its Affiliate) is successful in obtaining such sublicensable licenses or other rights under the applicable Platform Third Party Agreement in accordance with Section 2.9.2(b) (Platform Third Party Rights), then (A) Novartis will have the right, by delivery of written notice to Arrowhead, to elect to take a sublicense under such relevant Patent Rights or Know-How in-licensed by Arrowhead (or its Affiliate) under such Platform Third Party Agreement, and (B) if Novartis makes such election, (1) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, and (2) Novartis agrees to comply, and will cause its Affiliates and its and their Sublicensees to comply, with any applicable obligations under such Platform Third Party Agreement that apply to Novartis (or its Affiliates or its or their Sublicensees) as sublicensees thereunder and of which Novartis was informed by Arrowhead in writing prior to such election by Novartis pursuant to this Section 2.9.2(b)(ii) (Platform Third Party Rights), including </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. If Novartis fails to deliver such written notice to Arrowhead or otherwise declines such a sublicense, then the Platform </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">27</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:154.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Third Party Right subject to such Platform Third Party Agreement will not be included within the Arrowhead Technology or in any of the licenses and other rights granted to Novartis and its Affiliates and its and their Sublicensees under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:154.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">Nothing in this Section 2.9.2(b) (Platform Third Party Rights) restricts Novartis&#8217; right to obtain any license or other rights in or to any Platform Third Party Right directly from any Third Party that owns or otherwise controls any Platform Third Party Right.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">2.10.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Exclusivity</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">2.10.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Exclusivity Covenants</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to Section </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">2.10.2 (Arrowhead Change of Control), except as expressly permitted under this Agreement, during </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">and on a Target-by-Target basis (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Target Exclusivity Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Arrowhead will not, and will ensure that its Affiliates do not, directly or indirectly, independently or for or with any Third Party, Develop or Commercialize and will not collaborate with, enable, or otherwise authorize, license or grant any right to any Third Party to, Develop or Commercialize in the Territory any compound or product that is Directed To such Target </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, including through the use of Arrowhead Technology, ligand and antibody technologies, or siRNA (such compound or product, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Target Competing Product</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and such activities, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Target Competitive Activities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), except in accordance with Section 13.6.1(b) (Exclusivity).</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">2.10.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Arrowhead Change of Control</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">If, during, as applicable the Target Exclusivity Period, Arrowhead undergoes a Change of Control and the Acquirer is (a) engaged in Target Competitive Activities as of the closing of such Change of Control or (b) initiates Target Competitive Activities thereafter, then the restrictions set forth in Section 2.10.1 (Exclusivity Covenants) will not apply to such Acquirer and such Target Competitive Activities&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that (i) no Licensed Product-Specific Patent Rights, Novartis Arising Technology, or Confidential Information of Novartis or Confidential Information of both Parties is used by or on behalf of such Acquirer in connection with any performance of such Target Competitive Activities, and (ii) such Acquirer institutes commercially reasonable technical and administrative safeguards to ensure the requirements set forth in the foregoing clause (i) are met, including by creating &#8220;firewalls&#8221; between the personnel working on the Target Competing Product and the personnel teams charged with working on any Licensed Compound or Licensed Product that is the subject of any Program hereunder having as its Target the same as that of such Target Competitive Activities or having access to data from activities performed under this Agreement or Confidential Information of Novartis or Confidential Information of both Parties.  Notwithstanding the foregoing, the foregoing clause (ii) will not apply to employees or members of the Board of Directors of Arrowhead who do not perform any day-to-day responsibilities for a Licensed Compound or a Licensed Product or Target Competitive Activities if Arrowhead ensures that such employees and members of its Board of Directors comply with Arrowhead&#8217;s obligations of confidentiality and non-use as set forth in this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">In the event of a Change of Control of Arrowhead, Arrowhead shall provide Novartis with written notice thereof within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">following the consummation of such Change of Control, which notice shall identify the Acquirer. Novartis may, effective upon written notice delivered to Arrowhead within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> following the consummation of such Change of Control, elect any or all of the following&#58; (i) to disband or restructure, in whole or in part, any or all </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">28</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Committees, as determined by Novartis&#59; or (ii) to reasonably limit the scope of information to be provided by Novartis to Arrowhead (including through the JSC or any other Committee).</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">2.10.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Acquired Business Exception</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding the restrictions set forth in Section 2.10.1 (Exclusivity Covenants), if, during the Target Exclusivity Period, Arrowhead or any of its Affiliates acquires any assets or business, whether by way of merger, business combination, asset purchase, stock purchase, or otherwise (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Acquired Business</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and such Acquired Business, immediately prior to such acquisition, owns, has, or includes any license or other right to any Target Competing Product that would otherwise violate Section 2.10.1 (Exclusivity Covenants), then Arrowhead will (i) notify Novartis of such Target Competing Product in writing no later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">after the consummation of such acquisition, and (ii) perform one of the following acts (and specify which of the following it will perform in such notice, which decision will be final and binding on Arrowhead and its Affiliates), and in the case of all acts specified under the clauses below Arrowhead and its Affiliates also will comply with the firewalling and other requirements specified in clauses (i) and (ii) of Section 2.10.2 (Arrowhead Change of Control)&#58;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Arrowhead may elect to terminate the Development, Manufacture, or Commercialization of, as applicable, such Target Competing Product in which case Arrowhead and its Affiliates will cease the Development, Manufacture, and Commercialization of, as applicable, such Target Competing Product as soon as reasonably practicable and in any event within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after the consummation of the acquisition of the Acquired Business, giving due consideration to ethical concerns and requirements under applicable Law and any agreements with Third Parties and notify Novartis in writing of such completed termination&#59; or</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Arrowhead may elect to divest itself (or cause its Affiliate to divest itself) of, as applicable, such Target Competing Product and notify Novartis in writing of such completed divestiture, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that such divestiture is completed within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after the consummation of the acquisition of the Acquired Business.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">2.11.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:14pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">2.11.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">2.11.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">2.11.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">2.11.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">RESEARCH AND DEVELOPMENT</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">3.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Arrowhead Research and Development Activities</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">3.1.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">SNCA Program Research and Development</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Arrowhead SNCA Program Development Responsibility</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Arrowhead will be responsible, at its cost and expense, for conducting and completing the SNCA Program Research Activities in accordance with the SNCA Development Plan, but excluding all costs and expenses for the Manufacture by or on behalf of Arrowhead of Licensed SNCA Compounds used in the performance of such SNCA Program Research Activities which will be borne </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">29</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">solely by Novartis as set forth in Section 5.1 (Arrowhead Manufacturing Activities).</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">SNCA Development Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Arrowhead will conduct the SNCA Program Research Activities in accordance with a written plan to be prepared by Arrowhead and submitted by Arrowhead to the JSC to review, discuss, and determine whether to approve as promptly as reasonably practicable after the Effective Date (and in any event no later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after the Effective Date) (as such plan may be updated thereafter in accordance with this Agreement, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">SNCA Development Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The SNCA Development Plan will include (and any subsequent update thereof will include) (i) the planned Research and pre-clinical Development activities to be conducted by or on behalf of Arrowhead that are necessary to support a filing of a CTA for the first lead Licensed SNCA Product for the SNCA Program to commence a Phase I Clinical Trial and the timelines of such activities, (ii) the Manufacturing activities to be conducted by or on behalf of Arrowhead in support of the activities described in the foregoing clause (i) (if any), and (iii) the anticipated costs (on a batch pricing or Fully Burdened Cost basis) for the Manufacturing activities described in the foregoing clause (ii) (collectively, the activities of clause (i) and clause (ii), the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">SNCA Program Research Activities</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The initial draft of the SNCA Development Plan is </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">attached to this Agreement as </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 3.1.1(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (Initial </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">SNCA Development Plan)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Either Party, through the JSC, may propose updates to the SNCA Development Plan and the JSC will review, discuss, and determine whether to approve each such update. The Parties agree that, as of the Execution Date, the anticipated lead Licensed SNCA Product for the SNCA Program is ARO-SNCA SC.  Promptly following the JSC&#8217;s approval of the SNCA Development Plan, Arrowhead will provide to Novartis&#8217; Alliance Manager&#58; (a) a one-time good faith estimate of the costs and expenses to be incurred by Arrowhead for its performance of the SNCA Program Research Activities thereunder, and (b) a good faith estimate of the costs and expenses to be incurred by Novartis in connection with Arrowhead&#8217;s performance of the SNCA Program Research Activities (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, costs and expenses for the Manufacture by or on behalf of Arrowhead of Licensed SNCA Compounds used in the performance of SNCA Program Research Activities), which shall be updated by Arrowhead on a Calendar Quarter basis to reflect a forecast of the costs to be incurred by Novartis for the immediately following Calendar Quarter.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">3.1.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">CT Program Research and Development</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Selection of Collaboration Targets</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:154.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.63pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;padding-left:154.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">Each Party hereby confirms, as of the Execution Date, that (A) it has engaged with the other Party a mutually agreed, independent, third-party gatekeeper (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Gatekeeper</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> through which Novartis may inquire whether a CNS Target or a Cardiomyocyte Target, as applicable, that Novartis would like </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">is available, (B) it has executed and is a party to a written agreement with such Gatekeeper with customary terms and conditions that are consistent with this Section 3.1.2(a) (Selection of Collaboration Target), including appropriate confidentiality obligations, and (C) it has agreed to share equally the fees and expenses of the Gatekeeper with the other Party.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">30</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:154.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.53pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Novartis has submitted one or more written inquiries to the Gatekeeper to determine if, as applicable, a CNS Target or Cardiomyocyte Target was available for inclusion as a Collaboration Target under this Agreement (each, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Proposed Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Novartis&#8217; written inquiry(ies) to the Gatekeeper for each Proposed Target included the following information (each, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Proposed Target Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) the identity of such Proposed Target (including the NCBI Gene ID for known targets or, if no such NCBI Gene ID exists, an unequivocal identifier of such target), and whether such Proposed Target was a CNS Target or a Cardiomyocyte Target. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:154.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">Arrowhead will use Commercially Reasonable Efforts to include the gatekeeping process set forth in Section 3.1.2(a)(iii) (Selection of Collaboration Targets) in any collaboration, license, or other arrangement with a Third Party that includes Arrowhead using the Arrowhead Platform to Exploit compounds and products Directed To CNS Targets or Cardiomyocyte Targets. Notwithstanding the foregoing, Novartis agrees to negotiate in good faith and execute an amendment to this Agreement in the event any such Third Party requires any reasonable changes to the gatekeeping process set forth in Section 3.1.2(a)(iii) (Selection of Collaboration Targets).</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Novartis Collaboration Target Substitution Right</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:154.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.63pt">Definitions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Any alternate proposed CNS Target or Cardiomyocyte Target, as the case may be, will be a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Proposed Replacement Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and, if such alternate target becomes the subject of a Collaboration Target Selection Notice delivered by Novartis to Arrowhead in accordance with this Section 3.1.2(b) (Novartis Collaboration Target Substitution Right), it will be deemed a Collaboration Target upon Arrowhead&#8217;s receipt of such Collaboration Target Selection Notice.</font></div><div style="margin-bottom:12pt;padding-left:154.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.58pt">For Target Failure</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:190.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(A)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.74pt">If, during the Selection Term, Arrowhead notifies Novartis in writing of a Target Failure with respect to an ongoing CT Program as contemplated under Section 3.1.2(c) (Arrowhead CT Development Responsibility), then Novartis will have the right (but not the obligation) to provide to the Gatekeeper a Proposed Target Notice nominating a Proposed Replacement Target prior to the end of the Selection Term, which Proposed Replacement Target will be subject to the selection process set forth under Section 3.1.2(a)(iii) (Selection of Collaboration Target).</font></div><div style="margin-bottom:12pt;padding-left:190.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(B)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.35pt">During the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> period after the expiration of the Selection Term, if Arrowhead notifies Novartis in writing of a Target Failure with respect to an ongoing CT Program as contemplated under Section 3.1.2(c) (Arrowhead CT Development Responsibility), then Novartis will have the right (but not the obligation) to provide to the Gatekeeper a Proposed Target Notice nominating a Proposed Replacement Target, which alternate proposed target will be subject to the selection process set forth under Section 3.1.2(a)(iii) </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">31</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:190.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(Selection of Collaboration Target),</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">after the date that Novartis is notified by Arrowhead of the Target Failure.</font></div><div style="margin-bottom:12pt;padding-left:190.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(C)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.35pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:190.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(D)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.74pt">Novartis will have no further rights of any kind with respect to any Collaboration Target for which there was a Target Failure, including under Section 2.10.1 (Exclusivity Covenants) and Section 3.5.1 (Arrowhead Development Diligence Obligations), and either Party will be free to pursue any compounds and products Directed To such Targets outside of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:154.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.53pt">For Convenience</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  In addition to Novartis&#8217; right to nominate a Proposed Replacement Target in accordance with Section 3.1.2(b)(ii) (For Target Failure), Novartis will have the right (but not the obligation) to nominate </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> Proposed Replacement Target at its convenience during the first </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">of the Selection Term, which Proposed Replacement Target will be subject to the selection process set forth under Section 3.1.2(a)(iii) (Selection of Collaboration Target). </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. In the event Arrowhead receives a Collaboration Target Selection Notice from Novartis for such Proposed Replacement Target and it becomes a &#8220;Collaboration Target&#8221; under this Agreement pursuant to Section 3.1.2(a)(iii) (Selection of Collaboration Target), Novartis will pay to Arrowhead the CT Substitution Fee in accordance with Section 8.2 (CT Substitution Fee).</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Arrowhead CT Program Development Responsibility</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  During the Collaboration Term, on a CT Program-by-CT Program basis, Arrowhead will be responsible, at its sole cost and expense, for conducting and completing the CT Program Research Activities for the Collaboration Target of such CT Program in accordance with the applicable CT Development Plan for such CT Program, but excluding all costs and expenses for the Manufacture by or on behalf of Arrowhead of Licensed CT Compounds used in the performance of such CT Program Research Activities which will be borne solely by Novartis as set forth in Section 5.1 (Arrowhead Manufacturing Activities).  Arrowhead will not perform any Research or other non-clinical or clinical Development activities for any Collaboration Target other than in accordance with the applicable CT Development Plan for such CT Program.  If Arrowhead, acting in good faith, determines that the data and results generated in its performance of the CT Program Research Activities for a CT Program show achievement of the Futility Criteria specified for such CT Program in the applicable CT Development Plan, then Arrowhead will promptly notify Novartis in writing of such determination, and each Party&#8217;s rights and obligations with respect to such CT Program and its corresponding Collaboration Target will terminate (a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Target Failure</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), including pursuant to Section 2.10 (Exclusivity) and Section 3.5.1 (Arrowhead Development Diligence Obligations) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">CT Development Plans</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Arrowhead will conduct the CT Program Research Activities for each CT Program in accordance with a written plan prepared by Arrowhead and submitted by Arrowhead to the JSC to review, discuss, and determine whether to approve (A) with respect to such plan for each </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Collaboration Targets </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> and (B)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">with respect to such plan for any Proposed Replacement Target that becomes a Collaboration Target in accordance with Section 3.1.2(b)(ii) (For Target Failure) or Section 3.1.2(b)(iii) (For Convenience), as promptly as reasonably practicable after the date of </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">32</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Arrowhead&#8217;s receipt of the corresponding Collaboration Target Selection Notice therefor but in any event no later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after the date of such notice (as each such plan may be updated thereafter in accordance with this Agreement, each a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CT Development Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The CT Development Plan for a CT Program will include (and any subsequent update thereof will include) (i) the planned Research and pre-clinical Development activities to be conducted by or on behalf of Arrowhead that are necessary to support a filing of a CTA for the first Lead Development Candidate for such CT Program to commence a Phase I Clinical Trial and the timelines of such activities, (ii) the Manufacturing activities to be conducted by or on behalf of Arrowhead in support of the activities described in the foregoing clause (i) (if any), (iii) the anticipated costs (on a batch pricing or Fully Burdened Cost basis) for the Manufacturing activities described in the foregoing clause (ii), and (iv) the criteria to be achieved by a Licensed Compound of such CT Program for it to be nominated and accepted as the Lead Development Candidate for such CT Program </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">LDC Criteria</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (collectively, the activities of clause (i) and clause (ii), the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CT Program Research Activities</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Either Party, through the JSC, may propose updates to any CT Development Plan and the JSC will review, discuss, and determine whether to approve each such update. Promptly following the JSC&#8217;s approval of each CT Development Plan, Arrowhead will provide to Novartis&#8217; Alliance Manager&#58; (a) a one-time good faith estimate of the costs and expenses to be incurred by Arrowhead for its performance of the CT Program Research Activities thereunder, and (b) a good faith estimate of the costs and expenses to be incurred by Novartis in connection with Arrowhead&#8217;s performance of the CT Program Research Activities (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, costs and expenses for the Manufacture by or on behalf of Arrowhead of Licensed CT Compounds used in the performance of CT Program Research Activities), which shall be updated by Arrowhead on a Calendar Quarter basis to reflect a forecast of the costs to be incurred by Novartis for the immediately following Calendar Quarter.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Lead Development Candidate Continuation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  On a CT Program-by-CT Program basis, no later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, Novartis will deliver to Arrowhead a written notice indicating whether (i) Arrowhead is to continue with the CT Program Research Activities to prepare the CTA Ready Data Package for the Lead Development Candidate that is the subject of such LDC Nomination Date and deliver such CTA Ready Data Package to Novartis in accordance with Section 3.2.2(a) (Transition of Research &#38; Development Activities), and whether (ii) (A) Arrowhead is to Manufacture, or have Manufactured, (1) an initial batch of such Lead Development Candidate in support of preclinical GLP toxicity studies, and (2) an initial batch of such Lead Development Candidate for the use in a Phase I Clinical Trial pursuant to Novartis&#8217; option in Section 5.3 (Novartis Manufacturing Options), or (B) (1) Novartis is assuming the Manufacture of and supply to Arrowhead of the requirements of such Lead Development Candidate to be used in the performance of the activities of the corresponding CT Program Research Activities until delivery of the CTA Ready Data Package for such applicable CT Program, and (2) Novartis is requesting a manufacturing technology transfer for such CT Program in accordance with Section 5.4 (Manufacturing Technology Transfer)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however that</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, at Novartis&#8217; election, all foregoing confirmations can be given by Novartis to Arrowhead instead during the same meeting of the JSC </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. In the event that Arrowhead has not received such confirmations, whether by written notice or through the JSC, for a certain CT Program within such </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> period (or such longer period mutually agreed by the Parties), such CT Program will be deemed terminated by Novartis in accordance with Section 13.2 (Termination for Convenience) and Section 13.6 (Effects of Termination) </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">33</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">as of the date of the expiration of such</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%"> &#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> period or, if applicable, such longer period mutually agreed by the Parties </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">3.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Novartis Development and Medical Affairs Activities</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">3.2.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Novartis Development and Medical Affairs Responsibility</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  For each Program, from and after the Technology Transfer Date for such Program, Novartis will have sole control over and decision-making authority for the Development of, and performance of Medical Affairs for, all Licensed Compounds and Licensed Products that are the subject of such Program.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">3.2.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Transition of Research &#38; Development Activities</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">For each Program, promptly following Arrowhead&#8217;s completion of the last of its activities specified under the applicable Development Plan for such Program, Arrowhead will provide to Novartis, at Arrowhead&#8217;s cost and expense, the CTA Ready Data Package for such Program (on a Program-by-Program basis, the date of completion of such technology transfer for such Program, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Technology Transfer Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). For clarity, Arrowhead will not be required to create any documentation or data with respect to any Program that does not already exist as of immediately prior to its applicable Technology Transfer Date.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Following its receipt of a CTA Ready Data Package for a certain Program, Novartis will have </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> to (i) review the contents of such CTA Ready Data Package and (ii) ask any reasonable questions regarding such CTA Ready Data Package, which Arrowhead will promptly answer. If Novartis, acting in good faith, determines that a CTA Ready Data Package for a certain Program is incomplete, as compared to the information set forth on </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.69</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (CTA Ready Data Package Form) to be included in such CTA Ready Data Package or that Arrowhead has not otherwise provided Novartis with any Arrowhead Know-How that is generated in the performance of activities under the applicable Development Plan for such Program that is necessary to support a filing by Novartis of a CTA for, as applicable, the first lead Licensed SNCA Product or the first Lead Development Candidate of such Program, then Novartis will promptly notify Arrowhead of such deficiency and identify in reasonable detail in such notice such missing information or other Arrowhead Know-How. Unless Arrowhead disputes in good faith such deficiency, in which case such dispute will be referred to the JSC for resolution, Arrowhead will promptly deliver to Novartis such previously missing information or other Arrowhead Know-How, as applicable. Novartis will be deemed to have accepted the CTA Ready Data Package for a certain Program as complete and final upon the date of expiration of such </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> period </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Upon Novartis&#8217; reasonable request and for a period not to exceed </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> following the Technology Transfer Date for a Program, Arrowhead will provide such assistance, including making its Personnel reasonably available to Novartis during normal business hours, as is reasonably necessary to support the transition of Development and Medical Affairs activities to Novartis for such Program. Novartis will reimburse Arrowhead for (i) any reasonable Out-of-Pocket Costs incurred in providing such assistance and (ii) Arrowhead&#8217;s reasonable costs, at the FTE Rate, incurred in connection with its Personnel&#8217;s participation in any such assistance activities, including working group meetings or any other one-on-one meetings with Personnel of Novartis or its designee&#59; in each case (i) and (ii) in accordance with a mutually agreed work plan and budget </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">34</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">3.3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Transition of NHP MAD Study Activities</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">3.3.1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.05pt">Without limiting Section 3.2.2 above, following the Effective Date, Novartis may elect to, at its sole discretion&#58; (a) sponsor and conduct the NHP MAD Study at a contract research organization designated by Novartis or (b) have Arrowhead sponsor and conduct (or have conducted) the NHP MAD Study at a contract research organization designated by Novartis </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">3.3.2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.05pt">In the event that Novartis elects to its sponsor the NHP MAD Study and have the NHP MAD Study transferred to a contract research organization in accordance with Section 3.3.1(a) above </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. From and after such transition, Novartis shall conduct (or have conducted on its behalf) the NHP MAD Study at its sole cost and expense.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">3.3.3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.05pt">In the event that Novartis elects to have Arrowhead sponsor the NHP MAD Study in accordance with Section 3.3.1(b) above, Novartis shall be responsible for (and shall reimburse Arrowhead for) reasonable and documented costs incurred by Arrowhead in engaging the designated contract research organization for such NHP MAD Study.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">3.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Additional R&#38;D Activities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">During the Term, subject to Section 3.6 (Arrowhead Development Costs Reimbursement), on a Program-by-Program basis, Novartis may request through the JSC that Arrowhead perform certain (a) Research or other non-clinical Development activities for the Licensed Compounds and Licensed Products that are the subject of such Program or (b) CMC Activities, in each case ((a) and (b)), as may be reasonably useful to support the filing of an IND with the FDA for the Licensed Compounds and Licensed Product that are the subject of such Program (&#8220;Additional R&#38;D Activities&#8221;). If the Parties mutually agree through the JSC that Additional R&#38;D Activities for a specific Program are to be performed by Arrowhead, Arrowhead will prepare a written plan that sets forth such Additional R&#38;D Activities for such Program (for each Program, as such plan may be amended in accordance with this Agreement, an &#8220;Additional R&#38;D Plan&#8221;) and submit such proposed Additional R&#38;D Plan to the JSC to review, discuss, and determine whether to approve. Each Additional R&#38;D Plan will include (and any subsequent update thereof will include) (i) the planned Additional R&#38;D Activities to be conducted by or on behalf of Arrowhead and the timelines of such Additional R&#38;D Activities, (ii) the Manufacturing activities to be conducted by or on behalf of Arrowhead in support of the activities described in the foregoing clauses (a) or (b) (if any), and (c) a budget that sets forth all FTE Costs and Out-of-Pocket Costs to be incurred by or on behalf of Arrowhead in the performance of such Additional R&#38;D Activities under such plan (for each Program, an &#8220;Additional R&#38;D Budget&#8221;). Either Party may propose (through the JSC) updates to any Additional R&#38;D Plan (including the Additional R&#38;D Budget set forth therein) and the JSC will review, discuss, and determine whether to approve each such update to any Additional R&#38;D Plan, including updates to the Additional R&#38;D Budget therein. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">For clarity, in the event that the JSC does not approve (or the Parties are unable to come to a unanimous agreement to approve) any Additional R&#38;D Activities, Novartis shall have the right under this Agreement to conduct such Additional R&#38;D Activities on behalf of itself for the Development of the Licensed Products and Arrowhead shall provide reasonable assistance at Novartis&#8217; cost in connection with Novartis&#8217; performance of such activities.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">3.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Development Diligence Obligations</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">3.5.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Arrowhead Development Diligence Obligations</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  For each Program, Arrowhead will use Commercially Reasonable Efforts to (a) conduct the SNCA Program Research Activities in case of the SNCA Program and the CT Program Research Activities in case of a CT Program, each, in accordance with its applicable Development Plan (including the timelines set forth therein), as may be amended by the Parties through the JSC, and (b) if applicable, to conduct any Additional R&#38;D Activities in accordance with the applicable Additional R&#38;D Plan approved by the JSC (including the timelines set forth therein), as may be amended by the Parties through the JSC. For clarity, and in relation to a specific CT Program, the preceding sentence does not </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Arrowhead will have the right to perform any of its obligations under this Agreement through its Affiliates and one or more Subcontractors.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">35</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">3.5.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Novartis Development Diligence Obligations</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  For the SNCA Program and each CT Program, upon the Technology Transfer Date with respect to such Program, Novartis, either itself or through its Affiliates or Sublicensees, will use Commercially Reasonable Efforts to Develop and seek Regulatory Approval for at least one Licensed Product that is the subject of such Program in each of &#91;***&#93;.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">3.6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Arrowhead Development Costs Reimbursement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  In consideration for Arrowhead&#8217;s performance of, if any, the Additional R&#38;D Activities for any Program in accordance with the applicable Additional R&#38;D Plan, Novartis will reimburse Arrowhead for the amount of all FTE Costs and Out-of-Pocket Costs incurred by or on behalf of Arrowhead in the performance of any such Additional R&#38;D Activities from and after the Effective Date for each Program (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Development Costs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to the extent such Arrowhead Development Costs do not exceed </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> of the amounts set forth in the corresponding Additional R&#38;D Budget set forth in the corresponding Additional R&#38;D Plan (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Reimbursable Development Costs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> following the final day of each Calendar Quarter, Arrowhead will issue to Novartis an invoice for, if any, the amount of the Reimbursable Development Costs for each applicable Program incurred by Arrowhead during such Calendar Quarter, specifying whether such costs are FTE Costs or Out-of-Pocket Costs and setting forth reasonable details regarding the individual costs of activities included in the Additional R&#38;D Activities. Novartis will reimburse Arrowhead for all undisputed amounts set forth in any such invoice within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after receipt thereof.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">3.7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Novartis Program Costs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  For the SNCA Program and each CT Program, from and after the Technology Transfer Date for such applicable Program, Novartis will be responsible for 100% of all costs and expenses incurred by or on behalf of Novartis for the Development of all Licensed Compounds and Licensed Products that are the subject of such applicable Program for the Territory.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">3.8.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Licensed Products Research and Development Reports</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">3.8.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Arrowhead Development Reports</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  During the period commencing on the Effective Date and continuing until the dissolution of the JSC, Arrowhead will keep the JSC informed regarding the progress of the SNCA Program Research Activities and the CT Program Research Activities, in each case, for all Licensed Compounds and Licensed Products by providing to the JSC reasonably in advance of each meeting of the JSC (or at a different frequency determined by the JSC) a report (i) summarizing results and describing progress made against timelines in all Development Plans, and the SNCA Program Research Activities and the CT Program Research Activities planned to be undertaken for the applicable corresponding Licensed Compounds and Licensed Products prior to the next meeting of the JSC, and (ii) for all Licensed Compounds and Licensed Products, a reasonable summary of results, information, and data generated from the SNCA Program Research Activities and the CT Program Research Activities, as are applicable, for such Licensed Compounds and Licensed Products (each such report, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Development</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Report</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, that if the JSC meets more often than once per Calendar Quarter, then Arrowhead will only be required to provide one Development Report to the JSC in such Calendar Quarter. In addition, through the Parties&#8217; respective Alliance Managers, Arrowhead will promptly share with Novartis all other material developments and material information that it comes to possess relating to the Research and Development of the Licensed Compounds and Licensed Products conducted by or on behalf of Arrowhead under the applicable Development Plan, including any additional information regarding the Development of the Licensed Products reasonably requested by Novartis from time to time to the extent and in the form readily available to Arrowhead and able to be disclosed to Novartis, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, that Arrowhead will not be required to provide any Arrowhead Excluded Know-How.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">3.8.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Novartis Development Reports</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  On a Program-by-Program basis, following the assumption of all Development activities for such Program by Novartis in accordance with Section 3.2.1 (Novartis Development and Medical Affairs Responsibility), and until the receipt of Regulatory Approval for the first Licensed Product that is the </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">36</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">subject of such Program in the United States or any of the Major European Markets, Novartis will provide Arrowhead with a reasonably detailed report (which may be in the form of slides) on </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, summarizing the material Development activities conducted by Novartis and its Affiliates and their respective Sublicensees with respect to the Licensed Compounds and the Licensed Products that are the subject of such Program, including (a) material developments with respect to such Licensed Compounds and Licensed Products, &#91;***&#93;, and (b) any Regulatory Approvals received for such Licensed Products in the Territory. All information in such reports will be deemed Novartis&#8217; Confidential Information.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">3.9.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Scientific Records</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Arrowhead (with respect to the SNCA Program Research Activities and the CT Program Research Activities for the applicable Programs) and Novartis (with respect to all other Development activities hereunder for all Programs) will maintain scientific records in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes, and, to the extent applicable, in compliance with GLP, GMP, and GCP with respect to activities intended to be submitted in regulatory filings (including INDs), all of which records will fully and accurately reflect all work done and results achieved in the performance of the Development activities and Clinical Trials by or on behalf of such Party with respect to Licensed Products under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">REGULATORY MATTERS</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">4.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Regulatory Responsibilities</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">4.1.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Arrowhead Regulatory Responsibilities</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  With respect to each Program, at least </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">prior to the anticipated</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Technology Transfer Date for such Program, the JSC will meet to discuss the status of such Program, including the results of all studies conducted in support thereof.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">4.1.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Novartis Regulatory Responsibilities</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  With respect to each Licensed SNCA Product and each Licensed CT Product at all times, including prior to and following the Technology Transfer Date for, respectively, the SNCA Program and the applicable CT Program, (a) Novartis (itself or through its Affiliate or Sublicensee) will have sole control over, and decision-making authority with respect to, all regulatory matters in the Territory relating to such applicable Licensed Products, will own and maintain all INDs, MAAs, Regulatory Approvals, other Regulatory Submissions, and related regulatory documents, in the Territory with respect to such applicable Licensed Products (in each case, as applicable), and will be responsible, and act as the sole point of contact, for communications with all Regulatory Authorities in the Territory relating to such applicable Licensed Products&#59; (b) Novartis (itself or through its Affiliate or Sublicensee) will have sole control over, and decision-making authority with respect to, preparing, filing, and maintaining all INDs, MAAs, Regulatory Approvals, other Regulatory Submissions, and related regulatory documents, for such applicable Licensed Products, and, at Novartis&#8217; cost and expense, Arrowhead will provide reasonable support and cooperation for such INDs, MAAs, Regulatory Approvals, other Regulatory Submissions, and related regulatory documents, as requested by Novartis&#59; and (c) Novartis will be responsible, and act as the sole point of contact, for all meetings with all applicable Regulatory Authorities in the Territory related to such applicable Licensed Products.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">4.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Costs of Regulatory Affairs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Novartis will be solely responsible for all costs and expenses incurred by or on behalf of Novartis or its Affiliates associated with preparing, filing, obtaining, and maintaining Regulatory Approvals in the Territory for the Licensed Products.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">4.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Pharmacovigilance Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">The Parties shall cooperate with respect to the reporting and handling of safety information involving or relating to the Licensed Products.  Prior to the first dosing of the first patient by or on behalf of Novartis in any Clinical Trial with a Licensed Product, or such </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">earlier date as may be required under applicable Law, the Parties will negotiate and execute a pharmacovigilance agreement, on reasonable and customary terms that may </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">37</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="padding-left:36pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">provide for, among other things, (a) the establishment of a joint safety committee that will oversee each Party&#8217;s activities under such pharmacovigilance agreement as a subcommittee of the JSC and (b) guidelines and responsibilities for (i) the receipt, investigation, recording, review, communication, reporting, and exchange between the Parties of Adverse Event reports and other safety information relating to the Licensed Compounds and Licensed Products, (ii) reconciliation procedures to ensure adequate and compliant exchange of safety data, (iii) contact with Regulatory Authorities with respect to the foregoing, and (iv) the maintenance of a global safety database with respect to the Licensed Compounds and Licensed Products, in each case ((i) &#8211; (iv)), in accordance with applicable Law (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Pharmacovigilance Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Pharmacovigilance Agreement will contain terms no less stringent than those required by ICH or other applicable guidelines in order to allow the Parties to meet the applicable regulatory and legal requirements regarding the management of safety data. Pending entry into such Pharmacovigilance Agreement, the Parties will, if necessary, implement an interim procedure for exchange of any and all information concerning all Adverse Events related to use of the Licensed Products.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">MANUFACTURING</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">5.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Arrowhead Manufacturing Activities under Development Plans</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  For the SNCA Program and the SNCA Program Research Activities in accordance with the SNCA Development Plan, (a) Arrowhead will be responsible for the Manufacture and supply of the requirements of the Licensed SNCA Compounds that are used in the performance of such activities until delivery of the CTA Ready Data Package for the SNCA Program, and (b) Novartis will reimburse Arrowhead </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding the foregoing, Arrowhead will be responsible for the Manufacture and supply </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">of the requirements of ARO-SNCA SC that are used in Novartis&#8217; performance of the NHP MAD Study. For each CT Program and the CT Program Research Activities in accordance with its corresponding CT Development Plan, (i) if Novartis does not elect to have Arrowhead undertake such activities pursuant to Section 3.1.2(e) (Lead Development Candidate Continuation), Novartis, at its sole cost and expense, will be responsible for the Manufacture and supply to Arrowhead of the requirements of the applicable Licensed Compounds that are used in the performance of such activities until delivery of the CTA Ready Data Package for such applicable Program, or (ii) if Novartis has elected to have Arrowhead undertake such activities pursuant to Section 3.1.2(e) (Lead Development Candidate Continuation), (A) Arrowhead will be responsible for the Manufacture and supply of the requirements of the applicable Licensed Compounds that are used in the performance of such activities until delivery of the CTA Ready Data Package for such applicable Program, and (B) Novartis will reimburse Arrowhead </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">5.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Remaining Inventory at Technology Transfer Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  For each Program, promptly following the Technology Transfer Date for such Program (or such earlier date as the Parties may mutually agree), Arrowhead will deliver, or have delivered, to Novartis any and all remaining useable inventory of the Licensed Compounds of such Program that is in Arrowhead&#8217;s possession as of such date and which Arrowhead reasonably purchased or Manufactured (or had Manufactured) for meeting Novartis&#8217; requirements in accordance with Section 5.1 (Arrowhead Manufacturing Activities under Development Plans), and Novartis will pay Arrowhead </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">5.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Novartis Manufacturing Options</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Without limiting Novartis&#8217; right to request and have completed a Manufacturing technology transfer pursuant to Section 5.4 (Manufacturing Technology Transfer), for each Program, Novartis will have the option (a) to have Arrowhead Manufacture and supply to Novartis and its Affiliates and Sublicensees from and after the Technology Transfer Date for such Program, all Licensed Products that are the subject of such Program, as necessary for the continued Development thereof by Novartis or any of its Affiliates or Sublicensees in the Territory at Arrowhead&#8217;s Fully Burdened Cost without markup, and (b) to discuss with Arrowhead having Arrowhead Manufacture and supply to Novartis and its Affiliates and Sublicensees, all Licensed Products that are the subject of such Program, for Commercialization thereof by Novartis or any of its Affiliates or its Sublicensees in the Territory at a supply price to be negotiated and agreed in writing by the Parties, in each case ((a) and (b)), of (i) the active pharmaceutical ingredient or drug substance for such Licensed Product (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Drug Substance</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and (ii) if further requested by Novartis, the drug product form of such Licensed </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">38</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="padding-left:36pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Product (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Drug Product</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Promptly following (A) Novartis providing Arrowhead written notice of Novartis&#8217; exercise of its option under the foregoing clause (a) or (B) the Parties&#8217; agreement through good faith negotiations that Arrowhead will Manufacture and supply commercial requirements necessary for Commercialization of any of the Licensed Products of a specific Program in the Territory if Novartis elects to exercise its option under the foregoing clause (b), the Parties will negotiate in good faith, respectively, a clinical supply agreement or a commercial supply agreement on reasonable and customary terms for such agreements, and a related quality agreement. For clarity, (1) any clinical supply agreement will specify that all Licensed Products will be provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, and (2) whether Arrowhead engages in clinical or commercial Manufacture and supply pursuant to this Section 5.3 (Novartis Manufacturing Options), Novartis will be solely responsible, itself or through an Affiliate or a CMO, for final packaging and labelling of the Drug Product for each of the Licensed Products for the Territory.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">5.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Manufacturing Technology Transfer</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  With respect to each Program, at any time after the Effective Date, Novartis may request in writing the transfer from Arrowhead or Arrowhead&#8217;s CMO to Novartis or any CMO designated by Novartis, copies or samples of all Arrowhead Know-How that is necessary or reasonably useful to enable the Manufacture of the Licensed Compounds and Licensed Products that are the subject of such Program (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Manufacturing Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Promptly following any such written request by Novartis (but in any event no later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after such written request), the JMC will prepare, and submit to the JSC to review, discuss, and determine whether to approve, a written Manufacturing technology transfer plan that provides for (i) Arrowhead or Arrowhead&#8217;s Third Party CMO transferring copies of relevant documentation, samples of Drug Substance, and copies of other embodiments of such Arrowhead Manufacturing Know-How (including data within reports, notebooks, and electronic files), and (ii) Arrowhead making available its technical Personnel on a reasonable basis and as more specifically specified therein to consult with Novartis with respect to such transferred Arrowhead Manufacturing Know-How (such plan, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Technology Transfer Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Pursuant to the timelines set forth in the Manufacturing Technology Transfer Plan that is agreed to by the Parties, and in any event no later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">thereafter, Arrowhead will work with Novartis to complete the transfer of the Arrowhead Manufacturing Know-How and other activities set forth in the Manufacturing Technology Transfer Plan on the timelines and in accordance with the budget set forth therein. Novartis will reimburse Arrowhead for its Out-of-Pocket Costs, but for clarity not its FTE Costs, incurred in completing such transfer in accordance with the Manufacturing Technology Transfer Plan. Any additional assistance to be provided by Arrowhead in connection with Arrowhead Know-How that has been transferred pursuant to a completed Manufacturing Technology Transfer Plan may be requested by Novartis and provided by Arrowhead pursuant to a separate written agreement between the Parties providing for reasonable compensation to be paid to Arrowhead for providing such additional assistance. Following completion of the transfer of the Arrowhead Manufacturing Know-How and other activities set forth in the applicable Manufacturing Technology Transfer Plan for a Program, Novartis shall be solely responsible for the Manufacture and supply of the Licensed Compounds and Licensed Products for such Program.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">COMMERCIALIZATION</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">6.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Commercialization of the Licensed Products</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">6.1.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Commercialization Diligence Obligations</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  On a Program-by-Program basis, following receipt by Novartis or its Affiliates or Sublicensees of Marketing Approval for a Licensed Product that is the subject of such Program in the applicable country, Novartis, either itself or through its Affiliates or Sublicensees, will use Commercially Reasonable Efforts to Commercialize at least one Licensed Product that is the subject of such Program in each of&#58;  &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">6.1.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Commercialization Responsibility</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  As between the Parties, Novartis will have sole control over and decision-making authority with respect to all Commercialization activities for the Licensed Products in the Territory, at its sole cost and expense.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">39</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">6.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Reporting Obligations</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Novartis will report to Arrowhead in writing, &#91;***&#93;, summarizing in reasonable detail Novartis&#8217; and its Affiliates&#8217; and its and their Sublicensees&#8217; Commercialization activities for such Licensed Product performed to date (or updating such report for activities performed since the last such report was given hereunder, as applicable). In addition, for each Program, Novartis will provide Arrowhead with written notice of the First Commercial Sale of each Licensed Product of such Program in the first country of the Territory reasonably practicable after such event </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. All information in such reports will be deemed Novartis&#8217; Confidential Information.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">6.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Recalls, Market Withdrawals, or Corrective Actions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party will use reasonable efforts to notify the other Party promptly, but in no event later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, following its determination that any event, incident, or circumstance has occurred that may result in the need for a recall, market suspension, or market withdrawal of a Licensed Product in the Territory and will include in such notice the reasoning behind such determination. Novartis will have the sole right to make the final determination as to whether to voluntarily implement any such recall, market suspension, or market withdrawal in the Territory. Except as otherwise set forth in the applicable supply agreement and its corresponding quality agreement, Novartis will be solely responsible for the execution and all costs and expenses of all recalls, market suspensions, or market withdrawals undertaken pursuant to this Section 6.3 (Recalls, Market Withdrawals, or Corrective Actions), and, at Novartis&#8217; cost and expense, Arrowhead will reasonably cooperate in all such efforts.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">GOVERNANCE</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">7.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Alliance Managers</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Promptly following the Effective Date, each Party will designate an individual to facilitate communication and coordination of the Parties&#8217; activities under this Agreement relating to the Development and Manufacture of Licensed Compounds and Licensed Products (each, an &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Alliance Manager</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). For clarity, an Alliance Manager shall have the right to attend the JSC and all governance committees, and will have no voting right on any committee, unless otherwise agreed in writing by the Parties.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">7.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Joint Steering Committee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">7.2.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Formation&#59; Composition&#59; Dissolution</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">after the Effective Date, the Parties will establish a committee (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Joint Steering Committee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">JSC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to provide strategic oversight of the Parties&#8217; activities under this Agreement.  Each Party will initially appoint </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">representatives to the JSC, with each representative having knowledge and expertise in the Development and Manufacture of compounds and products similar to the Licensed Compounds and Licensed Products and having sufficient decision-making authority and seniority within the applicable Party to provide meaningful input and make decisions arising within the scope of the JSC&#8217;s responsibility. The JSC may change its size from time to time by agreement of the Parties, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that the JSC will consist at all times of an equal number of representatives of each of Arrowhead and Novartis. Each Party may replace its JSC representatives at any time upon written notice to the other Party. The JSC will be chaired by a chairperson designated by &#91;***&#93;. The JSC may invite non-members to participate in the discussions and meetings of the JSC, if necessary, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that such participants have no voting authority at the meetings of the JSC and are bound under enforceable obligations of confidentiality and non-use no less protective of the Parties&#8217; Confidential Information than those set forth in this Agreement. The JSC chairperson&#8217;s responsibilities will include conducting meetings, including, when feasible, ensuring that objectives for each meeting are set and achieved. The Alliance Managers will prepare and circulate meeting agendas and ensure the preparation and approval of minutes. The JSC will dissolve upon later of (a) &#91;***&#93; and (b) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">7.2.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Specific Responsibilities of the JSC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The JSC will have the following responsibilities&#58;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">reviewing, discussing, and determining whether to approve the SNCA Development Plan, and any updates thereto as set forth in Section 3.1.1(b) (SNCA Development Plan)&#59;</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">40</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">reviewing, discussing, and determining whether to approve a CT Development Plan, and any updates thereto as set forth in Section 3.1.2(d) (CT Development Plans)&#59;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">resolving any dispute between the Parties as to the achievement of the Futility Criteria with respect to any CT Program as set forth in Section 3.1.2(c) (Arrowhead CT Program Development Responsibility)&#59;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#59;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">with respect to any elements of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.69</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (CTA Ready Data Package Form) expressly marked as to be discussed or pending agreement by the Parties, reviewing and discussing and determining the contents thereof&#59;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">resolving any dispute between the Parties as to whether a CTA Ready Data Package for a certain Program is incomplete as set forth in Section 3.2.2(b) (Transition of Research &#38; Development Activities)&#59;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">(i) reviewing, discussing, and determining whether to approve performance by Arrowhead of Additional R&#38;D Activities for a specific Program, and (ii) if such approval is granted, reviewing, discussing, and determining whether to approve the corresponding Additional R&#38;D Plan, and any updates thereto as set forth in Section 3.3 (Additional R&#38;D Activities)&#59;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">reviewing, discussing, and determining whether to reduce the frequency of Arrowhead&#8217;s reports summarizing Arrowhead&#8217;s Development activities under this Agreement as set forth in Section 3.8.1 (Arrowhead Development Reports)&#59;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">reviewing, discussing, and determining whether to approve the Manufacturing Technology Transfer Plan as set forth in Section 5.4 (Manufacturing Technology Transfer)&#59;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">reviewing, discussing, and determining how to resolve any issue escalated by, or disputes within, the JMC&#59;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">establishing such additional committees, subcommittees, working groups or other directed teams of the JSC as it deems necessary to oversee activities relating to the Licensed Compounds and Licensed Products under this Agreement, including the joint safety committee as described in Section 4.3 (Pharmacovigilance Agreement)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(l)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">performing such other functions expressly allocated to the JSC in this Agreement or by the written agreement of the Parties.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">7.2.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Meetings</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The JSC will meet </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, unless the Parties agree in writing to a different frequency. The JSC may meet in person, by videoconference, or by teleconference, but at least one meeting of the JSC per Calendar Year will be in person unless the Parties otherwise agree in writing. In-person JSC meetings will be held at locations alternately selected by Arrowhead and by Novartis, or at any other location agreed by the members of the JSC. The first JSC meeting will be held within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">following the Effective Date. Meetings of the JSC will be effective only if a quorum is present, which quorum will require the presence of at least one representative from each Party. No later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">prior to any meeting of the JSC (or such shorter time period as the Parties may agree), the JSC chairperson will work with the Alliance Managers to </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">41</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">prepare and circulate an agenda for such meeting. Additional topics may be included on such agenda prior to the meeting, and the Party or the committee proposing an item will provide materials to the JSC representatives no later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">prior to the JSC meeting to support discussion. The JSC chairperson may also call a special meeting of the JSC (by videoconference, teleconference, or in person) if the JSC chairperson reasonably believes that a significant matter must be addressed prior to the next scheduled meeting, in which event such JSC chairperson will work with the Alliance Managers to provide the members of the JSC, promptly after the decision is made to hold such special JSC meeting, with an agenda for the meeting and materials reasonably adequate to enable an informed decision. The Alliance Managers working with the JSC chairperson will be responsible for preparing reasonably detailed written minutes of JSC meetings that reflect all decisions made and action items identified at such meetings within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">after each JSC meeting, and endeavor to finalize such minutes within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">after each JSC meeting.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">7.2.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Decision-Making</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The JSC endeavor to reach decisions by consensus, with each Party, through its representative members of the JSC, having one vote. Approvals of the JSC will require the unanimous agreement of the representatives. If the JSC cannot reach unanimous agreement on an issue that comes before the JSC within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">after the meeting at which such issue was raised and over which the JSC has oversight, then the Parties will refer such issue for resolution in accordance with Section 7.4 (Resolution of Committee Disputes).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">7.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Joint Manufacturing Committee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">7.3.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Formation&#59; Composition&#59; Dissolution</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties will establish a committee to coordinate and oversee Manufacturing activities in connection with the Development of the Licensed Compounds and Licensed Products for the Territory (each, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Joint Manufacturing Committee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">JMC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Each Party will initially appoint </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> representatives to the JMC, with each representative having knowledge and expertise in the performance of Manufacturing activities with respect to compounds and products similar to the applicable Licensed Compounds and Licensed Products, and having sufficient seniority and decision-making authority within the applicable Party to provide meaningful input and make decisions arising within the scope of such JMC&#8217;s responsibilities. The JMC may change its size from time to time by agreement of the Parties, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that the JMC will consist at all times of an equal number of representatives of each of Arrowhead and Novartis. Each Party may replace its JMC representatives at any time upon written notice to the other Party. The JMC may invite non-members to participate in the discussions and meetings of the JMC, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that such participants have no voting authority at the meetings of the JMC and are bound under enforceable obligations of confidentiality and non-use no less protective of the Parties&#8217; Confidential Information than those set forth in this Agreement. The JMC will be chaired by co-chairpersons designated by Arrowhead and Novartis, respectively, whose responsibilities will include conducting meetings, including, when feasible, ensuring that objectives for each meeting are set and achieved. The JMC will exist for so long as &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">7.3.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Specific Responsibilities of the JMC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to any limitations under applicable Law, the JMC will have the following responsibilities&#58;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">discuss Manufacturing activities to be performed by or on behalf of Arrowhead under any applicable clinical supply agreement or commercial supply agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">preparing the Manufacturing Technology Transfer Plan for discussion, review, and approval by the JSC as set forth in Section 5.4 (Manufacturing Technology Transfer)&#59;</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">42</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">overseeing the transfer of the Arrowhead Manufacturing Know-How and other activities set forth in the Manufacturing Technology Transfer Plan as set forth in Section 5.4 (Manufacturing Technology Transfer)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">performing such other functions expressly allocated to the JMC in this Agreement or by the written agreement of the Parties.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">7.3.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Meetings</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The JMC will meet </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, unless the Parties agree in writing to a different frequency, and otherwise as agreed by the Parties with respect to Manufacturing activities-specific matters. The JMC may meet in person, by videoconference, or by teleconference,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">but at least one meeting of the JMC per Calendar Year will be in person unless the Parties otherwise agree in writing. In-person JMC meetings will be held at locations alternately selected by Arrowhead and by Novartis, or at any other location agreed by the members of the JMC. Meetings of the JMC will be effective only if a quorum is present, which quorum will require the presence of at least one representative of each Party. No later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> prior to the first meeting of the JMC in the 2025 stub-Calendar Year and in each Calendar Year thereafter while the JMC exists, the co-chairpersons for the JMC will prepare a communication plan setting forth a schedule of the dates of each meeting for the JMC for that Calendar Year (a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">JMC Communication Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). No later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">prior to any meeting of the JMC (or such shorter time period as the Parties may agree), the co-chairpersons of the JMC will work with the Alliance Managers to prepare and circulate an agenda for such meeting. Additional topics may be included on such agenda, prior to the meeting, and the Party proposing an item will provide materials to the representatives of the JMC no later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">prior to the JMC meeting to support discussion. A JMC co-chairperson may also call a special meeting of the JMC (by videoconference, teleconference, or in person) if such JMC co-chairperson reasonably believes that a significant matter must be addressed prior to the next scheduled meeting, in which event such JMC co-chairperson will work with the Alliance Managers to provide the members of the JMC, promptly after the decision is made to hold such special JMC meeting, with an agenda for the meeting and materials reasonably adequate to enable an informed decision. The Alliance Managers and the co-chairperson of the JMC will be responsible for preparing reasonably detailed written minutes of meetings of the JMC that reflect all decisions made and action items identified at such meetings within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after such meeting of the JMC, and endeavor to finalize such minutes within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after each meeting of the JMC.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">7.3.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Decision-Making</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The JMC will endeavor to reach decisions by consensus, with each Party, through its representative members of the JMC, having one vote. Approvals of each respective applicable JMC matter will require the unanimous agreement of the representatives of the JMC. If the JMC cannot reach unanimous agreement on a matter that comes before it within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">following the meeting at which such issue was raised and over which such JMC has oversight, then the Parties will refer such issue for resolution to the JSC pursuant to Section 7.4.1 (Referral to the JSC).</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">7.3.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">&#91;***&#93;.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">7.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Resolution of Committee Disputes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">7.4.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Referral to the JSC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  If any subcommittee or working group of the JMC or any additional committees or subcommittees formed by the JSC cannot reach consensus on any matter within its decision-making authority within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after the meeting at which such failure to reach consensus occurred, then such matter will first be referred for attempted resolution to the applicable committee. If the JMC or any other committee or subcommittee of the JSC cannot reach consensus on any matter within its decision-making authority within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after the meeting at which such failure to reach </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">43</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">consensus occurred, then the matter will be referred for attempted resolution to the JSC.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">7.4.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Referral to Executive Officers</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  If the JSC cannot reach a consensus decision under Section 7.4.1 (Referral to the JSC), then the matter will be referred to the Executive Officers within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after its determination under Section 7.4.1 (Referral to the JSC) that a consensus cannot be reached. If a matter is referred to the Executive Officers under this Section 7.4.2 (Referral to Executive Officers), then the JSC will submit in writing to their respective Executive Officers the respective positions of the Parties. Such Executive Officers will use good faith efforts to resolve such matter promptly, which good faith efforts will include at least one meeting between such Executive Officers within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after such chairperson&#8217;s submission of their respective positions on such matter to them.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">7.4.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Final Decision</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">-</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Making Authority</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  If the Executive Officers are unable to reach unanimous agreement on any such matter within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after the meeting between the Executive Officers, then, subject to Section 7.4.4 (Exercise of Decision-Making Authority), the following will apply&#58;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">if the escalated matter relates to a dispute over (i) whether the Futility Criteria have been met with respect to a CT Program or (ii) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, then&#58;</font></div><div style="margin-bottom:12pt;padding-left:190.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(A)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.74pt">each Party will appoint an independent Third Party expert having at least 15 years of pharmaceutical and biotechnology industry experience and such Third Party experts will appoint a third independent Third Party expert (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Experts</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to resolve such matter&#59;</font></div><div style="margin-bottom:12pt;padding-left:190.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(B)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.35pt">each Party will be entitled, within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after the appointment of the final Third Party Expert, to make a written submission to the Third Party Experts explaining the basis for such Party&#8217;s position&#59;</font></div><div style="margin-bottom:12pt;padding-left:190.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(C)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.35pt">the Third Party Experts will render a decision on such matter within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after such Third Party Experts&#8217; receipt of the last such written submission by the Parties, which decision (1) will be solely &#8220;yes&#8221; or &#8220;no&#8221; with respect to, as applicable, whether the Futility Criteria of such CT Program have been met or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, and (2) will be final and binding on the Parties&#59; and</font></div><div style="margin-bottom:12pt;padding-left:190.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(D)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.74pt">each Party will be responsible for its own costs and expenses&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, that the fees of the Third Party Experts will be borne by the Party against which the Third Party Experts decide&#59;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">if the escalated matter relates to the day-to-day operational aspects of activities assigned to Arrowhead under a Development Plan, then Arrowhead will have final decision-making authority with respect to such matter&#59;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">if the escalated matter relates to approval of (i) Additional R&#38;D Activities to be performed by Arrowhead for a specific Program, (ii) an Additional R&#38;D Plan or (iii) any updates to an Additional R&#38;D Plan, in each case (i)-(iii) where approval of such activities, plan or updates thereto would (A) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, or (B) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, then, as applicable, no such Additional R&#38;D Activities will be performed or the then-current Additional R&#38;D Plan will continue to govern </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">44</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">and control performance of the Additional R&#38;D Activities for the corresponding Program&#59; and</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">if the escalated matter relates to the establishing of any additional committees, subcommittees, working groups or other directed teams to oversee activities relating to the Licensed Compounds and Licensed Products under this Agreement, such committee, subcommittee, working group or other directed team, as applicable, shall not be established&#59;</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">subject to Section 7.4.4 (Exercise of Decision-Making Authority), </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">7.4.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Exercise of Decision-Making Authority</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  No exercise of a Party&#8217;s decision-making authority on any matters may, without the other Party&#8217;s prior written consent, (a) unilaterally waive its own compliance with, modify, or amend the terms or conditions of this Agreement&#59; (b) otherwise conflict with this Agreement&#59; (c) approve any initial Development Plan for the SNCA Program that would </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#59; (d) approve any initial Development Plan or any amendment to a Development Plan, in each case, that would </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#59; (e) approve any amendment to a Development Plan that would </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#59; or (f) result in a material change of the day-to-day use or operational allocation of such Person&#8217;s personnel, equipment, and resources.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">7.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">General Committee Authority</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Committee has solely the powers expressly assigned to it in this Article 7 (Governance).  No Committee will have any power to amend, modify, or waive the terms or conditions of this Agreement or compliance with the terms and conditions of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">8.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">PAYMENTS</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">8.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Upfront Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  In consideration of the licenses and other rights granted to Novartis hereunder, within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after receipt by Novartis of an invoice therefor from Arrowhead, which invoice shall be issued by Arrowhead no earlier than the Effective Date, Novartis will make an one-time, non-refundable and non-creditable upfront payment to Arrowhead of $200,000,000 via wire transfer of immediately available funds to a U.S. bank account that has been designated by Arrowhead prior to the Effective Date (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Upfront Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">8.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">CT Substitution Fee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Novartis will make a one-time, non-refundable and non-creditable payment to Arrowhead of $</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> for any Proposed Replacement Target that becomes a Collaboration Target under this Agreement pursuant to Novartis&#8217; exercise of its rights under Section 3.1.2(b)(iii) (For Convenience) (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CT Substitution Fee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), no later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after receipt by Novartis of an undisputed invoice for such CT Substitution Fee, with such invoice to be issued by Arrowhead on or promptly following the date of Arrowhead&#8217;s receipt of the Collaboration Target Selection Notice from Novartis for such Proposed Replacement Target pursuant to Section 3.1.2(a)(iii)(B) (Selection of Collaboration Target). For clarity, the CT Substitution Fee will be paid </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">8.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Milestone Payments</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">8.3.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">CT Programs Research Milestones</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  On a CT Program-by-CT Program basis, upon the LDC Nomination Date for such CT Program and Novartis&#8217; confirmation that Arrowhead is to continue with the CT Program Research Activities to prepare the CTA Ready Data Package for the Lead Development Candidate as set forth in Section 3.1.2(e) (collectively, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CTP Research Milestone Event</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Novartis will pay to Arrowhead a one-time, non-refundable, and non-creditable milestone payment of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (each a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CTP Research Milestone Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) no later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after receipt by Novartis of an invoice for such corresponding CTP Research Milestone Payment. For the avoidance of doubt, if an LDC Nomination Date occurs with respect to all CT Programs and Novartis confirms that Arrowhead is to continue with the CT Program Research Activities to prepare the CTA Ready Data Package for all such Lead Development Candidates, then the CTP Research Milestone Payments payable by </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">45</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Novartis under this Section 8.3.1 (CT Programs Research Milestones) will be a maximum of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">8.3.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Regulatory Milestones</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  On a Program-by-Program basis, Novartis will pay to Arrowhead one-time, non-refundable, and non-creditable milestone payments in accordance with Table 8.3.2 (Regulatory Milestones) below (each a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Milestone Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) upon the first achievement by Novartis or its Affiliates or its or their Sublicensees of each of the applicable regulatory milestone events for the applicable Program as set forth in Table 8.3.2 (Regulatory Milestones) below (each a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Milestone Event</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) for the first Licensed Product that is the subject of such applicable Program to achieve such applicable Regulatory Milestone Event. For the avoidance of doubt, if Novartis or its Affiliates or their respective Sublicensees achieve all Regulatory Milestone Events with respect to (a) all Programs, then the Regulatory Milestone Payments payable by Novartis under this Section 8.3.2 (Regulatory Milestones) will be a maximum of $</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, (b) all CT Programs, then the Regulatory Milestone Payments payable by Novartis under this Section 8.3.2 (Regulatory Milestones) will be a maximum of $</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, (c) the SNCA Program, then the Regulatory Milestone Payments payable by Novartis under this Section 8.3.2 (Regulatory Milestones) with respect to the SNCA Program will be a maximum of $</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, and (d) a CT Program, then the Regulatory Milestone Payments payable by Novartis under this Section 8.3.2 (Regulatory Milestones) with respect to such CT Program will be a maximum of $</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="background-color:#bdd6ee;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Table 8.3.2&#8211;Regulatory Milestones</font></td></tr><tr style="height:16pt"><td colspan="3" rowspan="2" style="background-color:#deeaf6;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Regulatory Milestone Event</font></td><td colspan="6" style="background-color:#deeaf6;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Regulatory Milestone Payment</font></td></tr><tr style="height:29pt"><td colspan="3" style="background-color:#dbe5f1;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">SNCA Program</font></td><td colspan="3" style="background-color:#dbe5f1;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Each CT Program</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Novartis will notify Arrowhead in writing of the achievement of a Regulatory Milestone Event no later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> after its occurrence or, if achieved by an Affiliate or a Sublicensee, after Novartis becoming aware of the achievement thereof, and pay to Arrowhead the corresponding Regulatory Milestone Payment no later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> after r</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">eceipt by Novartis of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">an invoice from Arrowhead for such corresponding Regulatory Milestone Payment.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">8.3.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Sales Milestones</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">On a Program-by-Program and Licensed Product-by-Licensed Product basis, Novartis will make non-refundable and non-creditable milestone payments to Arrowhead in accordance with Table 8.3.3 (Sales Milestones) (each a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Sales Milestone Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) upon the first achievement by Novartis or its Affiliates or its or their Sublicensees of each </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">46</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">of the sales milestone events set forth in Table 8.3.3 (Sales Milestones) below for each such Licensed Product of such Program (each a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Sales Milestone Event</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) with respect to the aggregate annual Net Sales of each such Licensed Product in the Territory. For the avoidance of doubt, if Novartis or its Affiliates or their respective Sublicensees achieve all Sales Milestone Events with respect to (a) a Licensed SNCA Product of the SNCA Program, then the Sales Milestone Payments payable by Novartis under this Section 8.3.3 (Sales Milestones) for such Licensed SNCA Product will be a maximum of $</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">, and (b) a Licensed CT Product of a CT Program, then the Sales Milestone Payments payable by Novartis under this Section 8.3.3 (Sales Milestones) for such Licensed CT Product will be a maximum of $</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="background-color:#bdd6ee;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Table 8.3.3 &#8211;Sales Milestones</font></td></tr><tr><td colspan="3" style="background-color:#deeaf6;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Sales Milestone Event</font></td><td colspan="6" style="background-color:#deeaf6;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Sales Milestone Payment</font></td></tr><tr><td colspan="3" style="background-color:#dbe5f1;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbe5f1;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">SNCA Program</font></td><td colspan="3" style="background-color:#dbe5f1;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Each CT Program</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Novartis will notify Arrowhead in writing of the achievement of a Sales Milestone Event by Novartis or any of its Affiliates or any of its or their Sublicensees no later than </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> after the end of the Calendar Year in which such Sales Milestone Payment is payable under this Section 8.3.3 (Sales Milestones), and pay to Arrowhead the corresponding Sales Milestone Payment no later than </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> after receipt by Novartis of an invoice for such Sales Milestone Event.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">For clarity, the Sales Milestone Payments will be due for each Licensed Product that is the subject of a specific Program, but in no event will any Sales Milestone Event be due more than one time for each such Licensed Product. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">8.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Royalties</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  On a Program-by-Program, Licensed Product-by-Licensed Product and country-by-country basis, during the Royalty Term for such Licensed Product that is the subject of such Program in such country in the Territory, Novartis will pay to Arrowhead nonrefundable, non-creditable royalty payments </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">calculated by multiplying </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">the applicable royalty rates set forth in Table 8.4 (Royalty Payments) below by the corresponding amount of incremental Net Sales </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> in the Territory (subject to, if any, applicable permitted reduction pursuant to Section 8.5 (Royalty Reductions)) by Novartis, its Affiliates, or their respective Sublicensees during the applicable Calendar Year (such payments, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Royalties</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">47</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="background-color:#bdd6ee;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Table 8.4 &#8211; Royalty Payments</font></div></td></tr><tr style="height:29pt"><td colspan="3" rowspan="2" style="background-color:#deeaf6;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Aggregate annual Net Sales &#91;***&#93; in a given Calendar Year during the Royalty Term</font></td><td colspan="6" style="background-color:#deeaf6;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Royalty Rate<br></font></td></tr><tr style="height:29pt"><td colspan="3" style="background-color:#dbe5f1;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">SNCA Program</font></td><td colspan="3" style="background-color:#dbe5f1;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.56pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Each CT Program</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The portion of annual Net Sales </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> less than $</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">%</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:3.12pt;padding-right:3.12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">%</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The portion of annual Net Sales </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> greater than or equal to $</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and less than $</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">%</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:3.12pt;padding-right:3.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">%</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The portion of annual Net Sales </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> greater than or equal to $</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and less than $</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">%</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:3.12pt;padding-right:3.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">%</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The portion of annual Net Sales </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> greater than or equal to $</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">and less than $</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">%</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:3.12pt;padding-right:3.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">%</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The portion of annual Net Sales </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> greater than or equal to $</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">%</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:3.12pt;padding-right:3.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">%</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">For clarity, royalties shall be payable only once with respect to the same unit of Licensed Product of a Program.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Following the expiration of the Royalty Term on a Licensed Product-by-Licensed Product and country-by-country basis, Novartis&#8217; and its Affiliates&#8217; licenses under Section 2.1 (License Grants to Novartis) with respect to such Licensed Product in such country shall continue in effect, but become fully paid-up, royalty-free, transferable (in accordance with Section&#160;16.1 (Assignment)), perpetual and irrevocable.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">8.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Royalty Reductions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">8.5.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Reduction for No Valid Claim</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to Section 8.5.7 (Minimum Floor), on a Licensed Product-by-Licensed Product and country-by-country basis, if, within any time period during the Royalty Term for such Licensed Product in such country, such Licensed Product is not Covered by a Valid Claim of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, the Net Sales of such Licensed Product in such country used to calculate Royalties due for such Licensed Product in such country in accordance with Section 8.4 (Royalties) will be reduced by </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">during such time period.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">8.5.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Reduction for Generic Competition</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to Section 8.5.7 (Minimum Floor), on a Licensed Product-by-Licensed Product and country-by-country basis, if, during the Royalty Term for such Licensed Product in such country, one or more Generic Products with respect to such Licensed Product is sold in such country in a given Calendar Quarter (the date of such first sale of a given Generic Product, such Generic Product&#8217;s &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Generic Entry Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then if, in any given Calendar Quarter after the first Generic Entry Date in such country, there has been a reduction in Net Sales of such Licensed Product in such country in such Calendar Quarter of more than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> as compared to the averaged Net Sales of such Licensed Product in such country over the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> immediately preceding the first Generic Entry Date in such country, then, commencing in the first full Calendar Quarter following such Calendar Quarter, the Net Sales of such Licensed Product in such country used to calculate Royalties due for </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">48</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">such Licensed Product in such country in accordance with Section 8.4 (Royalties) will be reduced by </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">8.5.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Third Party Payments</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to Section 8.5.7 (Minimum Floor), in the event that, during the Royalty Term for a Licensed Product in a country, Novartis makes any </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">pursuant to or in connection with an agreement by Novartis with such Third Party as set forth in Section 2.9.2(a) (Program-Specific Third Party Rights) or to Arrowhead for such Third Party pursuant to or in connection with a Platform Third Party Agreement as set forth in Section 2.9.2(b)(iii) (Platform Third Party Rights), in each case, under which Novartis is granted rights by license or sublicense to any </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> of such Party in such country </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> owned or otherwise controlled by such Third Party that are </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> for the Development, Manufacture, or Commercialization of such Licensed Product in such country and where such payments are directly related to Novartis being granted such rights, Novartis may credit </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> of such payments actually paid by Novartis to such Third Party or to Arrowhead for such Third Party pursuant to the terms of, respectively, such agreement or such Platform Third Party Agreement to the extent reasonably allocable to such rights in such country against any Royalties payable for such Licensed Product in such country by Novartis to Arrowhead under Section 8.4 (Royalties).</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">8.5.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">8.5.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">8.5.6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">8.5.7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Minimum Floor&#59; Carry Forward</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.8pt">CT Programs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.  Solely with respect to Royalties owed for a Licensed CT Product, in no event will such Royalties due and payable by Novartis to Arrowhead under Section 8.4 (Royalties) in a given Calendar Quarter for a given Licensed CT Product in the Territory in aggregate be reduced to less than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> of the amount that would otherwise be payable to Arrowhead in respect of such Royalties in such Calendar Quarter for such Licensed CT Product in the Territory as a result of the reductions permitted pursuant to Section 8.5.1 (Reduction for No Valid Claim), Section 8.5.2 (Reduction for Generic Competition), Section 8.5.3 (Third Party Payments) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:23.18pt">SNCA Program</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.  Solely with respect to Royalties owed for a Licensed SNCA Product, the following provisions shall apply.</font></div><div style="margin-bottom:12pt;padding-left:154.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">If one or more of the reductions permitted under Section 8.5.1 (Reduction for No Valid Claim), Section 8.5.2 (Reduction for Generic Competition), Section 8.5.3 (Third Party Payments) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:154.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.58pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">8.6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Other Amounts Payable</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  With respect to any amounts owed under this Agreement by one Party to the other for which no other invoicing and payment procedure is specified in this Agreement, within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after the end of each Calendar Quarter each Party will provide an invoice, together with reasonable supporting documentation, to the other Party for such amounts owed in respect of such Calendar Quarter. The owing Party will pay any undisputed amounts within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">49</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="padding-left:36pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">receipt of the invoice and will pay any disputed amounts owed by such Party within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after resolution of the Dispute.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">8.7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Payment Terms</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">8.7.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Manner of Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  All payments to be made between the Parties under this Agreement will be made in Dollars and will be paid by wire transfer in immediately available funds to a bank account designated by the receiving Party&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that in no event will Novartis be obligated to make payments under this Agreement to any Affiliate of Arrowhead that is organized in any jurisdiction outside of the U.S. without Novartis&#8217; prior written consent.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">8.7.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Reports and Royalty Payments</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  With respect to each Calendar Quarter during which Royalties are due and payable by Novartis to Arrowhead, within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after the end of such Calendar Quarter, Novartis will submit to Arrowhead a written report including the following information listed by Licensed Product and by country or other jurisdiction of sale in the Territory&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">and Novartis will make any such payments within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after receipt of the applicable invoice.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">8.7.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Records and Audits</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party will keep, and will cause its Affiliates and its Sublicensees to keep, complete, true, and accurate books and records in accordance with its Accounting Standards in relation to this Agreement, including in relation to (a) in the case of Novartis, all Net Sales, Royalties, and Sale Milestone Payments (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Records</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)  and (b) in the case of Arrowhead, all costs and expenses incurred in connection with the performance of Manufacturing activities and any other amounts to be reimbursed by Novartis under this Agreement (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Records</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Each Party will keep, and will cause its Affiliates and its Sublicensees to keep, such books and records until the later of (i) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> and (ii) &#91;***&#93;. Either Party (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Auditing Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) may</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, upon written request,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> cause an internationally-recognized independent accounting firm (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Auditor</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that is reasonably acceptable to the other Party (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Audited Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to inspect the relevant records of the Audited Party and its Affiliates and Sublicensees to verify the payments made by the Audited Party and the related reports, statements and books of accounts, as applicable. Before beginning its audit, the Auditor will execute an undertaking reasonably acceptable to the Audited Party by which the Auditor agrees to keep confidential all information reviewed during the audit. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">The Auditor shall have the right to disclose to the Auditing Party only its conclusions regarding any payments under this Agreement. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">The Audited Party and its Affiliates and Sublicensees will make their records available for inspection by the Auditor during regular business hours upon receipt of reasonable advance notice from the Auditing Party. The Auditor will review such records solely to verify the accuracy of (A) in the case of Novartis as the Audited Party, the Novartis Records and the payments owed to Arrowhead under the financial terms of this Agreement and (B) in the case of Arrowhead as the Audited Party, the Arrowhead Records and all costs and expenses reported to have been incurred in connection with its performance of the Manufacturing activities under this Agreement. Each Party will not exercise such inspection right &#91;***&#93;. In addition, the Auditing Party will only be entitled to audit the books and records of the Audited Party, its Affiliates and its Sublicensees from the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> prior to the Calendar Year in which the Auditing Party notifies the Audited Party of such audit request. For clarity, with respect to Arrowhead&#8217;s rights and Novartis&#8217; obligations towards Novartis&#8217; Sublicensees pursuant to this Section 8.7.3 (Records and Audits), Arrowhead will have the right solely to cause Novartis to audit its applicable Sublicensee and such right will further be subject to the terms and conditions of Novartis&#8217; agreement with such Sublicensee. Notwithstanding any provision to the contrary in Article 9 (Confidentiality and Publication), the Auditing Party agrees to hold in strict confidence all information received and all information learned in the course of any audit or inspection, except to the extent necessary for the Auditing Party to enforce its rights under this Agreement or to the extent required to comply with any applicable Law, regulation, or judicial order. The Auditor will provide to the Audited </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">50</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Party its audit report and basis for determination </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">of the accuracy of payments under this Agreement </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">at the time such report is provided to the Auditing Party before it is considered final&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, that, at least </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> prior to the provision of such report, the Auditor shall provide its draft report and basis for any determination to the Audited Party to verify the exclusion of any Confidential Information not necessary to such determination and to allow for the reasonable review and provision of comments by the Audited Party. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">If the final result of the inspection reveals an undisputed underpayment or overpayment by the Audited Party, then the underpaid or overpaid amount will be settled promptly </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. The Auditing Party will pay for such inspections, as well as its expenses associated with enforcing its rights with respect to any payments hereunder&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, that, if the final results of such audit reveal an overpayment or underpayment of more than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">% of the total payments due hereunder for the audited period, then the fees and expenses charged by the Auditor will be paid by the Audited Party.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">8.7.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Currency Exchange</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The rate of exchange to be used in computing the amount of currency equivalent in Dollars owed to a Party under this Agreement will be (a) for Arrowhead, the monthly average exchange rate between each currency of origin and Dollars as reported by </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">The Wall Street Journal</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">East Coast Edition</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> or an equivalent resource as agreed by the Parties, and (b) for Novartis, made by using Novartis&#8217; then-current standard exchange rate methodology as applied in its external reporting for the conversion of foreign currency sales into Dollars.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">8.7.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Taxes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Withholding Taxes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The amounts payable pursuant to this Agreement (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Payments</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) will not be reduced on account of any Taxes unless required by Law. The Parties acknowledge and agree that no Taxes are expected to be deducted or withheld from the Payments. If Novartis, as a result of a change in Law after the Effective Date is required to deduct or withhold from any Payment under any applicable Tax Law, including extra-territorial taxation (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Withholding Taxes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Novartis will promptly (but no later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> ) notify Arrowhead in writing of the potential for Withholding Taxes and the basis therefor, and cooperate with Arrowhead in good faith so as to reduce or eliminate any potential obligation for such withholding of Taxes to the greatest extent possible, including with respect to obtaining the benefit of any present or future treaty against double Taxation or refund or reduction in such Taxes. Subject to Section 8.7.5(c) (Assignments and Transfers), Novartis will deduct and withhold from the Payments any Taxes that it is required by Law to deduct or withhold and will properly remit such Taxes to the appropriate Governmental Authority. Novartis will provide Arrowhead with reasonable evidence of the proper payment of any withholding Taxes applicable to the Payments, and any receipts or certifications provided by or to a Governmental Authority, when and if available. If Withholding Taxes are paid to a Governmental Authority, then Novartis will provide reasonable assistance to Arrowhead to obtain a refund of such Withholding Taxes, or obtain a credit with respect to Taxes paid, to the extent that such a refund or credit is available under applicable Law. If no Withholding Tax deduction has been made on the payments to Arrowhead or its Affiliates under this Agreement, but Governmental Authorities subsequently take the position that a Withholding Tax deduction should have been made, including extra-territorial taxation, Arrowhead shall provide, at Novartis&#8217; expense, all reasonable support to Novartis to obtain relief or reduction of withholding under the applicable Tax Law, including but not limited to the submission or issuance of requisite forms and information. Any refunds of Withholding Taxes that are granted to Arrowhead by the competent tax authority and which would cause Arrowhead </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">51</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">to receive payments in excess of that which Novartis would owe under this Agreement, including related interest, shall be paid (net of expenses) to Novartis by Arrowhead.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Cooperation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The Parties will use reasonable efforts to provide each other with information required by a Party for the purpose of filing applicable tax returns or reducing or eliminating Withholding Taxes.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Assignments and Transfers</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  If a Party that owes a Payment under this Agreement is required by Law to withhold taxes in respect of any Payment, and if such withholding obligation arises as a result of any action taken by such Party or its Affiliate or successor or assignee, including an assignment of this Agreement as permitted under Section 16.1 (Assignment) of this Agreement, a change in tax residency of such Party, or payments arise or are deemed to arise through a branch of such Party then any applicable Payments for which the recipient Party is, in the good faith discretion of the recipient Party&#8217;s tax counsel or accountants (following reasonable discussions with the paying Party or its representatives), not able to recover or credit such withheld amount in the taxable year of such payment will be increased to take into account such Withholding Taxes as may be necessary so that, after making all required Tax withholdings and deductions (including Tax withholdings and deductions on amounts payable under this Section 8.7.5 (Taxes)), the payee receives an amount equal to the sum it would have received had no such increased withholding been made.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Transfer Tax</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  All transfer, documentary, sales, use, stamp, registration, and other such Taxes, and any conveyance fees, recording charges and other fees and charges (including any penalties and interest) incurred in connection with consummation of the transactions contemplated hereby, if any, will be borne and paid by Novartis. Novartis will prepare and timely file all tax returns required to be filed in respect of any such Taxes.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Indirect Taxes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  All amounts expressed to be payable pursuant to this Agreement by Novartis to Arrowhead which (in whole or in part) constitute the consideration for any supply for the purposes of any value-added, sales, use, excise or similar Tax (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Indirect Taxes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) will be exclusive of any Indirect Taxes. If Indirect Taxes are or become chargeable on any supply for Indirect Tax purposes made by Arrowhead to Novartis pursuant to this Agreement and Arrowhead is required to account to the relevant tax authority for the Indirect Tax, Novartis must pay to Arrowhead (in addition to and at the same time as paying any other consideration for such supply) an amount equal to the amount of the Indirect Taxes (and Arrowhead must promptly provide an appropriate Indirect Taxes invoice to Novartis).</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">8.7.6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Blocked Payments</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  If, by reason of Law in any country, it becomes impossible or illegal for a Party to transfer, or have transferred on its behalf, any payment owed to the other Party hereunder, then such Party will (a) promptly notify the other Party of the conditions preventing such transfer and (b) deposit such payment in local currency in the relevant country to the credit of the other Party in a recognized banking institution designated by the other Party or, if none is designated by the other Party within a period of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, in a recognized banking institution selected by the transferring Party, as the case may be, and identified in a written notice given to the other Party.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">8.7.7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Interest Due</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  If a Party does not receive payment of any sum due to it on or before the due date, simple interest will thereafter accrue on the sum due to such Party until </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">52</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">the date of payment at the per annum rate equal to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. In relation to payments disputed in good faith, interest under this Section 8.7.7 (Interest Due) is payable only after the dispute is resolved, on sums found or agreed to be due, from the due date.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">9.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">CONFIDENTIALITY AND PUBLICATION</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">9.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Confidential Information</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The existence and terms of this Agreement are the Confidential Information of each Party, and each Party will be deemed a Receiving Party with respect thereto.  (a) Unpublished patent applications within the Licensed Product-Specific Patent Rights and Arrowhead Know-How that is specific to the composition of matter, form, formulation, or a method of treatment with, or use or manufacture of a Licensed Compound or a Licensed Product (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Product-Specific Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), in each case, will be the Confidential Information of both Parties&#59; (b) except as set forth in clause (a) or clause (e) of this Section 9.1 (Confidential Information), all Arrowhead Know-How that is neither Product-Specific Know-How nor Joint Arising Know-How will be Confidential Information of Arrowhead&#59; (c) except as set forth in clause (e) of this Section 9.1 (Confidential Information), all Novartis Arising Know-How and all reports delivered by Novartis to Arrowhead hereunder, in each case, will be Confidential Information of Novartis, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that Novartis will maintain all Novartis Arising Know-How that (i) solely relates to the composition of matter, formulation, form, or a method of use or treatment, delivery, or Manufacture of a Licensed Compound or Licensed Product and (ii) is necessary or reasonably useful to Develop, Manufacture, Commercialize, and otherwise Exploit such Licensed Compound or Licensed Product, in confidence and not disclose such Know-How to any Third Party for so long as such Know-How remains Confidential Information of Novartis, except as permitted under Section 9.2 (Non-Disclosure and Non-Use Obligation), Section 9.4 (Permitted Disclosures), or Section 9.8 (Publication)&#59; (d) all Know-How within the Joint Arising Know-How will be Confidential Information of both Parties, regardless of which Party initially generated or disclosed the relevant Joint Arising Know-How to the other Party in connection with this Agreement&#59; and (e) all information exchanged between the Parties regarding the Prosecution and Maintenance, defense, and enforcement of the Patent Rights under Article&#160;12 (Intellectual Property) will be the Confidential Information of both Parties. All information disclosed by a Party pursuant to the Confidentiality Agreement is deemed the Confidential Information of such Party pursuant to this Agreement. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#47;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">9.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Non-Disclosure and Non-Use Obligation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as otherwise expressly set forth in this Article 9 (Confidentiality and Publication), the Receiving Party will, during the Term and for a period of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">thereafter, keep the Confidential Information of the Disclosing Party confidential using at least the same degree of care with which the Receiving Party holds its own Confidential Information (but in no event less than a reasonable degree of care) and will not (a) disclose such Confidential Information to any Person without the prior written approval of the Disclosing Party, except, solely to the extent necessary to exercise its rights or perform its obligations under this Agreement, to its employees, Affiliates, Sublicensees, and Subcontractors, consultants, or agents who have a need to know such Confidential Information, all of whom will be similarly bound by confidentiality, non-disclosure, and non-use provisions at least as restrictive or protective of the Parties as those set forth in this Agreement and for whom the Disclosing Party will be responsible, or (b) use such Confidential Information for any purpose other than for the purposes contemplated by this Agreement. The Receiving Party will cause the foregoing Persons to whom Confidential Information is disclosed pursuant to clause (a) of this Section 9.2 (Non-Disclosure and Non-Use Obligation) to comply with the restrictions on use and disclosure set forth in this Section 9.2 (Non-Disclosure and Non-Use Obligation) and will be responsible for ensuring that such Persons maintain the Disclosing Party&#8217;s Confidential Information in accordance with this Article 9 (Confidentiality and Publication). Each Party will promptly notify the other Party of any misuse or unauthorized disclosure of the other Party&#8217;s Confidential Information by it or by those Persons to whom it disclosed Confidential Information pursuant to clause (a) of this Section 9.2 (Non-Disclosure and Non-Use Obligation).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">9.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Exemptions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Information of a Disclosing Party will not be Confidential Information of such Disclosing Party to the extent that the Receiving Party can demonstrate through competent evidence that such information&#58;  (a) is already in the possession of the Receiving Party at the time </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">53</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="padding-left:36pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">of its receipt from the Disclosing Party and not through a prior disclosure by or on behalf of the Disclosing Party&#59; (b) is generally available to the public before its receipt from the Disclosing Party&#59; (c) became generally available to the public or otherwise part of the public domain after its disclosure by the Disclosing Party and other than through any act or omission of the Receiving Party or any of its Affiliates or representatives in breach of this Agreement, including pursuant to Section 9.8 (Publications)&#59; (d) is subsequently disclosed to the Receiving Party or any of its Affiliates without obligation of confidentiality by a Third Party who may rightfully do so and is not under a conflicting obligation of confidentiality to the Disclosing Party&#59; or (e) other than any Arising Know-How, is developed independently by employees, Subcontractors, consultants, or agents of the Receiving Party or any of its Affiliates without use of or reliance upon the Disclosing Party&#8217;s Confidential Information. No combination of features or disclosures will be deemed to fall within the foregoing exclusions merely because individual features are published or available to the general public or in the rightful possession of the Receiving Party unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the Receiving Party. Specific aspects or details of Confidential Information will not be deemed to be within the public domain or in the possession of the Receiving Party merely because the Confidential Information is encompassed by more general information in the public domain or in the possession of the Receiving Party.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">9.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Permitted Disclosures</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  In addition to the exceptions contained in Section 9.2 (Non-Disclosure and Non-Use Obligation), the Receiving Party may disclose Confidential Information of the Disclosing Party to the extent (and solely to the extent) that such disclosure is reasonably necessary in the following instances&#58;</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">9.4.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.05pt">(a) the Prosecution and Maintenance of Patent Rights as contemplated under Article 12 (Intellectual Property)&#59; or (b) Regulatory Submissions and other filings with Governmental Authorities (including Regulatory Authorities), as necessary for the Exploitation of a Licensed Product&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that the Receiving Party will take all reasonable measures to ensure the confidential treatment of such Confidential Information to the extent permitted under applicable Law&#59;</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">9.4.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.05pt">to actual or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">bona fide</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> potential </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, solely for the purpose of evaluating or carrying out an actual or potential </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that, in each such case, (a) such Persons are bound by obligations of confidentiality, non-disclosure, and non-use provisions at least as restrictive or protective of the Parties as those set forth in this Agreement or otherwise customary for such type and scope of disclosure, (b) any such disclosure is limited to the maximum extent practicable for the particular context in which it is being disclosed, and (c) that the term of such confidentiality obligation must be consistent with industry standards&#59;</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">9.4.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.05pt">if required by Law, including as may be required in connection with any filings made with, or by the disclosure policies of a major stock exchange, in which case the terms of such disclosures will be governed by Section 9.5 (Confidential Treatment)&#59;</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">9.4.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.05pt">to prosecute or defend litigation so long as there is </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> prior written notice given by the Receiving Party before filing, and to enforce Patent Rights in connection with the Receiving Party&#8217;s rights and obligations pursuant to this Agreement&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that the Party seeking to disclose the Confidential Information of the other Party&#58; (a) use reasonable efforts to inform the other Party prior to making any such disclosures and reasonably cooperate with the other Party in seeking a protective order or other appropriate remedy (including redaction), and (b) whenever possible, request confidential treatment of such information in accordance with Section 9.5 (Confidential Treatment)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">9.4.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.05pt">to any Third Party to the extent a Party is required to do so pursuant to the terms and conditions of an in-license agreement with such Third Party relating to the intellectual property rights sublicensed to the other Party hereunder, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that any such Third Party receiving Confidential Information are bound by obligations of confidentiality, </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">54</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">non-disclosure, and non-use provisions at least as restrictive or protective of the Parties as those set forth in this Agreement or otherwise customary for such type and scope of disclosure.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">If and whenever any Confidential Information is disclosed in accordance with this Section 9.4 (Permitted Disclosures), such disclosure will not cause any such information to cease to be Confidential Information except to the extent that such disclosure results in a public disclosure of such information (other than by breach of this Agreement).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">9.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Confidential Treatment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  To the extent allowed by applicable Law, each Party will promptly inform the other Party of the disclosure that is being sought (and to the extent possible, as early as possible and at least </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> notice) in order to provide the other Party an opportunity to challenge or limit the disclosure and will reasonably cooperate with the other Party to do so. In the event that no such protective order or other remedy is obtained, or the Disclosing Party waives compliance with certain terms of this Article 9 (Confidentiality and Publication), then the Receiving Party will furnish only that portion of Confidential Information that the Receiving Party is advised by counsel is legally required to be disclosed. Notwithstanding Section 9.2 (Non-Disclosure and Non-Use Obligation), Confidential Information that is permitted or required to be disclosed will remain otherwise subject to the confidentiality and non-use provisions of Section 9.2 (Non-Disclosure and Non-Use Obligation). Notwithstanding the foregoing, if either Party concludes based on the reasonable opinion of counsel that a copy of this Agreement must be filed with the United States Securities and Exchange Commission or similar regulatory agency in a country other than the United States, such Party will, within a reasonable time prior to any such filing (and to the extent possible at least </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> prior to any such filing), provide the other Party with a copy of this Agreement showing any provisions hereof as to which such Party proposes to request confidential treatment, and the Parties will coordinate with each other and will use good faith efforts to mutually agree on the redaction of certain provisions of this Agreement (together with all exhibits and schedules) before filing such copy of this Agreement, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that notwithstanding the foregoing, the filing Party will retain final decision-making authority over the redactions to be made in its filed copy of this Agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">9.6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Relationship to Confidentiality Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement supersedes the Confidentiality Agreement&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, that all &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Confidential Information</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; disclosed or received by the Parties and their Affiliates thereunder will be deemed the Confidential Information of the originally Disclosing Party hereunder and will be subject to the terms and conditions of this Agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">9.7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Use of Name and Logo</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to Section 9.8.2 (Announcements), neither Arrowhead nor Novartis will use the other Party&#8217;s or its Affiliates&#8217; name or logo in any label, press release, or product advertising, or for any other promotional purpose, without first obtaining the other Party&#8217;s written consent.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">9.8.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.5pt">Publications</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">9.8.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Coordination</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  During the Term, Arrowhead and Novartis will, from time to time and at the request of the other Party, discuss the general information content relating to this Agreement that may be publicly disclosed&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that, without limitation of Arrowhead&#8217;s rights under Section 9.8.3 (Publications Rights), Novartis will have no obligation to consult with Arrowhead with respect to public announcement or publications concerning Novartis&#8217; Exploitation of any Licensed Product that does not reference Arrowhead, or disclose any of Arrowhead&#8217;s Confidential Information or the Arrowhead Platform.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">9.8.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Announcements</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as may be expressly permitted under Section 9.8.1 (Coordination), Section 9.8.3 (Publications Rights), Section&#160;9.4 (Permitted Disclosures) or this Section 9.8.2 (Announcements), during the Term, neither Party will make any public announcement regarding this Agreement without the prior written approval of the other Party, except for either Party&#8217;s references to the other as the licensor or licensee (as applicable) or a collaboration partner under this Agreement. On </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">55</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">or following the Execution Date, Arrowhead will issue a press release in substantially the form set forth on </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 9.8.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (Press Releases). After the issuance of such press release or other permitted public disclosure by a Party, either Party may make subsequent public disclosures reiterating such information without having to obtain the other Party&#8217;s prior consent and approval so long as the information in such press release or other public announcement remains true, correct, and the most current information with respect to the subject matters set forth therein. Further, Arrowhead will be permitted to issue press releases indicating the achievement of any Milestone Event and the amount of any Milestone Payment, with Novartis having the right to review and provide reasonable comment on (but not approve) any such press release being prior to issuance by or behalf of Arrowhead.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">9.8.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Publication Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  During the Term, Novartis may, in its sole discretion, publish results of all Clinical Trials and other Development activities conducted with respect to any Licensed Compound or Licensed Product, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that no publication will include any Confidential Information of Arrowhead, other than the Product-Specific Know-How, without Arrowhead&#8217;s prior written consent, not to be unreasonably withheld, conditioned, or delayed. Arrowhead will have no such right to publish the results of Clinical Trials or other Development activities conducted with respect to any Licensed Compound or Licensed Product. Regardless of and without limitation of its foregoing consent right, Arrowhead will have the right to review all proposed publications prior to Novartis&#8217; submission of such publication, in accordance with the procedures set forth in this Section 9.8.3 (Publications Rights). If Novartis intends to make any publication or presentation related to any Clinical Trials or other Development activities conducted with respect to any Licensed Compound or Licensed Product, then Novartis will first provide Arrowhead with a copy of the applicable proposed abstract, manuscript, or presentation no less than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> in the case of abstracts) prior to its intended submission for publication. Arrowhead will respond in writing promptly and in no event later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> in the case of abstracts) after receipt of the proposed material with any concerns regarding the disclosure of any information or subject matter that, in Arrowhead&#8217;s reasonable discretion would present issues as to patentability of the relevant subject matter or requesting the removal of any of Arrowhead&#8217;s Confidential Information (other than the Product-Specific Know-How). In the event of any concern raised regarding protection of intellectual property rights of Arrowhead, Novartis will not submit such publication or to make such presentation that contains such information until Arrowhead is given a reasonable period of time, and in no event more than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (or such other period as may be mutually agreed by the Parties in writing), to seek patent or other intellectual property protections in accordance with the terms of this Agreement covering any material in such publication or presentation that it believes is protectable. Subject to Section 9.4 (Permitted Disclosures), Novartis will remove any Confidential Information of Arrowhead (other than the Product-Specific Know-How) for which Arrowhead requests such removal from any such proposed publication or presentation. Novartis will use reasonable efforts to provide Arrowhead with a copy of each such publication or presentation within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after the date of its submission, and in any event Novartis will provide Arrowhead with a copy of each such publication or presentation within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after Arrowhead&#8217;s written request for such copy (if not previously provided). Without limiting the foregoing, Novartis will acknowledge the contributions of Arrowhead and the employees of Arrowhead in any such publication or presentation, as scientifically appropriate.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">9.8.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.05pt">Clinical Trial Transparency</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Both Parties agree to collaborate to maintain compliance with all Laws related to Clinical Trial transparency that may apply to either the sponsor of any Clinical Trial or the owner of any Regulatory Approval, all as related to any Licensed Product. The Parties will cooperate to maintain Clinical Trial transparency consistent with each sponsor&#8217;s Clinical Trial registration, summary result, </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">56</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">and data sharing transparency policies and will support disclosure of Confidential Information as needed based on the needs of the sponsors of the study or the Regulatory Approval holder with respect to any Licensed Product.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">10.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">REPRESENTATIONS, WARRANTIES AND COVENANTS</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">10.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Mutual Representations and Warranties</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party represents and warrants to the other Party, as of the Execution Date, and as of the Effective Date (as though then made), that&#58;</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.1.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">such Party is a corporation duly organized, validly existing, and in good standing under the Laws of its jurisdiction of incorporation or formation&#59;</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.1.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">such Party has all requisite corporate power and corporate authority to enter into this Agreement and to carry out its obligations under this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.1.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">all requisite corporate action on the part of such Party and its directors and stockholders required by Law for the authorization, execution, and delivery by such Party of this Agreement, and the performance of all obligations of such Party under this Agreement, has been taken&#59;</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.1.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">the execution, delivery, and performance of this Agreement, and compliance with the provisions of this Agreement, by such Party do not and will not&#58; (a)&#160;violate any provision of Law or any ruling, writ, injunction, order, permit, judgment, or decree of any Governmental Authority&#59; (b)&#160;constitute a breach of, or default under (or an event that, with notice or lapse of time or both, would become a default under) or conflict with, or give rise to any right of termination, cancellation or acceleration of, any agreement, arrangement or instrument, whether written or oral, by which such Party or any of its assets are bound&#59; or (c)&#160;violate or conflict with any of the provisions of such Party&#8217;s organizational documents (including any articles or memoranda of organization or association, charter, bylaws, or similar documents)&#59;</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.1.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">such Party has not entered into any agreement with any Third Party that is in conflict with the rights granted to the other Party under this Agreement, and has not taken any action that would prevent it from granting the rights granted to the other Party under this Agreement, or that would otherwise conflict with or adversely affect the other Party&#8217;s rights under this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.1.6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">no consent, approval, authorization, or other order of, or filing with, or notice to, any Governmental Authority or other Third Party is required to be obtained or made by such Party in connection with the authorization, execution, and delivery by such Party of this Agreement, except as required pursuant to the HSR Act and any other applicable Antitrust Laws&#59; and</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.1.7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">this Agreement has been duly executed and delivered on behalf of such Party and is a legal and valid obligation binding upon it and is enforceable in accordance with its terms, subject to applicable bankruptcy, insolvency, moratorium, and other similar laws affecting creditors&#8217; rights generally and by general principles of equity.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">10.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Additional Representations and Warranties by Arrowhead</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Arrowhead represents and warrants to Novartis, except as set forth on </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 10.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (Exceptions to the Representations and Warranties by Arrowhead), which schedule may be updated as of the Effective Date pursuant to Section 14.1 (Effective Date), as of the Execution Date and (following the Antitrust Clearance Date) as of the Effective Date (for clarity, subject to Section 14.3 (Outside Date))&#58;</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.2.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Arrowhead Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  (a) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.146</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (Licensed Product-Specific Patent Rights) and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.34</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(Arrowhead Platform Patent Rights) set forth a complete and accurate list of all Arrowhead Patent Rights issued or pending as of the Execution </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">57</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Date or the Effective Date, as applicable, and (b) the Arrowhead Patent Rights existing as of the Execution Date or the Effective Date, as applicable, constitute all of the Patent Rights owned or in-licensed by Arrowhead or any of its Affiliates as of such respective date that are necessary or reasonably useful for the Development, Manufacture, Commercialization, or other Exploitation, each as contemplated by Arrowhead or any of its Affiliates as of the Execution Date or the Effective Date, as applicable, of ARO-SNCA SC as it exists as of the Execution Date or the Effective Date, as applicable, in the Field in the Territory.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.2.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Licensed SNCA Compounds and Licensed SNCA Compounds</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The Licensed SNCA Compounds and Licensed SNCA Products include all compounds and products owned or in-licensed by Arrowhead or any of its Affiliates as of the Execution Date or the Effective Date, as applicable, that are Directed To SNCA.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.2.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Arrowhead Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Arrowhead has (a)&#160;legal or beneficial title and sole ownership of, or a non-exclusive or exclusive right to use, all Arrowhead Technology existing as of the Execution Date or the Effective Date, as applicable, except as set forth on </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 10.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (Exceptions to the Representations and Warranties by Arrowhead), free and clear of all mortgages, pledges, liens, encumbrances, security interests, or claims of any kind, including claims by any Governmental Authority or academic or non-profit institution&#59; and (b)&#160;authority to grant to Novartis and its Affiliates the licenses set forth in Section 2.1 (License Grants to Novartis) under the Arrowhead Technology. Arrowhead has not granted any license or other interest to any Third Party under the Arrowhead Technology that conflicts with the licenses granted to Novartis and its Affiliates hereunder. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.2.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Ownership of Arrowhead Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  With respect to all Arrowhead Technology existing as of the Execution Date or the Effective Date, as applicable, that is owned or purported to be owned by Arrowhead (a)&#160;Arrowhead and its Affiliates have obtained from all employees and independent contractors who participated in the invention or authorship thereof, assignments of all ownership rights of such employees and independent contractors in such Arrowhead Technology, either pursuant to written agreement or by operation of Law&#59; (b)&#160;all of Arrowhead&#8217;s and its Affiliates&#8217; employees, officers, contractors, and consultants have executed agreements or have existing obligations under Law requiring assignment to Arrowhead or its Affiliate, as applicable, of all rights, title, and interests in and to their inventions made during the course of and as the result of this Agreement&#59; and (c) no officer or employee of Arrowhead or any of its Affiliates is subject to any agreement with any other Third Party that requires such officer or employee to assign any interest in any Arrowhead Technology to such Third Party.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.2.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Prosecution of Arrowhead Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The owned-Arrowhead Patent Rights, the in-licensed Arrowhead Patent Rights for which Arrowhead controls prosecution, and, to Arrowhead&#8217;s knowledge, the in-licensed Arrowhead Patent Rights for which a Third Party controls prosecution, in each case, existing as of the Execution Date or the Effective Date, as applicable, are being diligently prosecuted in the respective patent offices in accordance with Law, and Arrowhead and its Affiliates have presented all references, documents, or information for which it and the inventors had a duty to disclose under Law, including 37 C.F.R. &#167;1.56 or its foreign equivalent, to the relevant patent examiners at the relevant patent offices for each such Arrowhead Patent Right.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.2.6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Validity and Enforceability</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  With respect to owned-Arrowhead Patent Rights, the in-licensed Arrowhead Patent Rights for which Arrowhead controls prosecution,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">and, to Arrowhead&#8217;s knowledge, the in-licensed Arrowhead Patent Rights for which a Third Party controls prosecution, in each case, existing as of the Execution Date or the Effective Date, as applicable, there is no opposition, nullity action, interference, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">inter </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">58</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">partes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> reexamination, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">inter partes </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">review, post-grant review, derivation proceeding, or other proceeding pending or, to Arrowhead&#8217;s knowledge, threatened in writing (but excluding office actions or similar communications issued by the United States Patent and Trademark Office or any analogous foreign Governmental Authority (collectively, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Patent Offices</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) in the ordinary course of Prosecution and Maintenance of any patent application) that challenge the ownership, scope, duration, validity, enforceability, or priority of any such Arrowhead Patent Right owned or purported to be owned by Arrowhead.  To Arrowhead&#8217;s knowledge, the Arrowhead Patent Rights that have issued are subsisting, valid, and enforceable, and Arrowhead does not have knowledge of any fact or circumstance that would cause Arrowhead to reasonably conclude that any issued Arrowhead Patent Right is, or will be upon issuance, invalid, or unenforceable.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.2.7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Inventorship</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Inventorship of each owned-Arrowhead Patent Right and, to Arrowhead&#8217;s knowledge, each in-licensed Arrowhead Patent Right, in each case, existing as of the Execution Date or the Effective Date, as applicable, is properly identified on each patent and patent application.  To Arrowhead&#8217;s knowledge, there is no dispute with respect to inventorship of any Arrowhead Patent Rights.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.2.8.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Good Standing</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  All official fees, maintenance fees, and annuities for any pending or issued owned-Arrowhead Patent Rights, in-licensed Arrowhead Patent Rights for which Arrowhead controls prosecution and maintenance,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">and, to Arrowhead&#8217;s knowledge, in-licensed Arrowhead Patent Rights for which a Third Party controls prosecution and maintenance, in each case, existing as of the Execution Date or the Effective Date, as applicable, have been paid when due, and all administrative procedures with Governmental Authorities have been completed for such Arrowhead Patent Rights such that such Patent Rights are subsisting and in good standing.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.2.9.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Government Funding</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  No government funding, facilities of a university, college, or other educational institution or research center was used in the development of any owned-Arrowhead Patent Rights or, to Arrowhead&#8217;s knowledge, in-licensed Arrowhead Patent Rights.  No Person who was involved in, or who contributed to, the creation or development of any owned-Arrowhead Patent Rights or, to Arrowhead&#8217;s knowledge, any in-licensed Arrowhead Patent Rights, has performed services for the government or any university, college, or other educational institution or research center in a manner that would affect Arrowhead&#8217;s rights in the Arrowhead Patent Rights.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.2.10.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.05pt">No Claims</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  There is (a) no claim, judgment, or settlement against or owed by Arrowhead or any of its Affiliates and (b) no pending or, to Arrowhead&#8217;s knowledge, threatened claim or litigation, in each case ((a) and (b)), related to the Arrowhead Technology or ARO-SNCA SC.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.2.11.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.05pt">Notice of Infringement or Misappropriation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Neither Arrowhead nor any of its Affiliates have received any written notice or written threat from any Third Party asserting or alleging that any Development, Manufacture, Commercialization, or other Exploitation, each as contemplated by Arrowhead or any of its Affiliates prior to the Execution Date or prior to the Effective Date, of ARO-SNCA SC as it exists as of the Execution Date or the Effective Date, as applicable, infringed, misappropriated, or otherwise violated any valid and enforceable Patent Right or Know-How of a Third Party.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.2.12.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.05pt">Third Party Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  To Arrowhead&#8217;s knowledge, the Development, Manufacture, Commercialization, and other Exploitation, each as contemplated by Arrowhead or any of its Affiliates of ARO-SNCA SC as it exists as of the Execution Date or the Effective Date, as applicable, in the Field in the Territory does not infringe, </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">59</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">misappropriate, or otherwise violate any valid and enforceable Patent Right or Know-How of any Third Party.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.2.13.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.05pt">Third Party Infringement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  To Arrowhead&#8217;s knowledge, no Third Party is infringing, misappropriating, or otherwise violating, or threatening to infringe, misappropriate, or otherwise violate the Arrowhead Technology.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.2.14.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.05pt">Confidentiality of Trade Secrets</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Arrowhead and its Affiliates have taken commercially reasonable measures consistent with industry practices to protect the secrecy, confidentiality, and value of all Arrowhead Know-How that constitutes trade secrets under Law (including requiring all employees, consultants, and independent contractors to execute binding and enforceable agreements requiring all such employees, consultants, and independent contractors to maintain the confidentiality of such Arrowhead Know-How).</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.2.15.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.05pt">Third Party Agreements</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Except for the Pre-Existing Third Party Agreements, there are no Third Party agreements pursuant to which Arrowhead Controls any of the Arrowhead Technology.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.2.16.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.05pt">Pre-Existing Third Party Agreements</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.200</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (Pre-Existing Third Party Agreements) contains a true and complete list of all agreements constituting the Pre-Existing Third Party Agreements existing as of the Execution Date or the Effective Date, as applicable, and Arrowhead has provided Novartis with an accurate copy of each Pre-Existing Third Party Agreement.  Each Pre-Existing Third Party Agreement is in full force and effect.  No written notice of default or termination has been received or given under any Pre-Existing Third Party Agreement, and, to Arrowhead&#8217;s knowledge, there is no act or omission by Arrowhead or any of its Affiliates that would provide a right to terminate any Pre-Existing Third Party Agreement.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.2.17.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.05pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.2.18.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.05pt">Compliance with Laws</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Arrowhead and its Affiliates have conducted, and, to Arrowhead&#8217;s knowledge, their respective contractors and consultants have conducted, the Development and Manufacture of ARO-SNCA SC as it exists as of the Execution Date or the Effective Date, as applicable, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> with all applicable Laws, including as applicable GLP, GCP, and GMP, labor and employment and any applicable anti-corruption or anti-bribery laws or regulations of any Governmental Authority with jurisdiction over such Development and Manufacture.  Neither Arrowhead nor its Affiliates, nor, to Arrowhead&#8217;s knowledge, any of their employees, officers, subcontractors, or consultants who have rendered services relating to the Arrowhead Technology or ARO-SNCA SC as it exists as of the Execution Date or the Effective Date, as applicable, (a) has ever been Debarred or is subject to debarment or convicted of a crime for which an entity or person could be Debarred, (b) has ever been under indictment for a crime for which a person or entity could be Debarred, or (c) is a Sanctioned Person.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.2.19.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.05pt">Disclosure</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Arrowhead has </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">made available to Novartis true, correct and complete copies or originals of all material information relating to the Development, Manufacture and Commercialization of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">ARO-SNCA SC in the Field in the Territory</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, each as conducted by or on behalf of Arrowhead </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">or any of its Affiliates as of the Execution Date or the Effective Date, as applicable </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">10.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">10.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">60</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">10.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Warranty Disclaimer</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY WITH RESPECT TO ANY PATENT RIGHTS, KNOW-HOW, MATERIALS, COMPOUND, PRODUCT, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND HEREBY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, OR NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING.  EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE EXPLOITATION OF ANY LICENSED COMPOUND OR LICENSED PRODUCT PURSUANT TO THIS AGREEMENT WILL BE SUCCESSFUL.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">10.6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Certain Covenants</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.6.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Compliance</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party and its Affiliates, Sublicensees, and Subcontractors will conduct the Exploitation of the Licensed Compounds and the Licensed Products in a good scientific manner and materially in accordance with all applicable Laws, including, as applicable, GLP, GCP, and GMP or regulations of any Governmental Authority with jurisdiction over the activities performed by or on behalf of such Party or its Affiliates, Sublicensees or Subcontractors in furtherance of such obligations. In addition, if a Party is or becomes subject to a legal obligation to a Governmental Authority (such as a corporate integrity agreement or settlement agreement with a Governmental Authority), then the other Party will perform such activities as may be reasonably requested by the obligated Party to enable such Party to comply with its legal obligation to such Governmental Authority with respect to the Licensed Products.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.6.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">No Debarment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Neither Party will use or permit its Affiliates, Sublicensees, or Subcontractors to use, in any capacity in connection with the performance of its obligations under this Agreement, any Person that has been Debarred pursuant to Section&#160;306 of the FD&#38;C Act, as amended, or that is the subject of a conviction described in such section. Each Party agrees to inform the other Party in writing immediately if it or any Person that is performing activities under this Agreement is Debarred or is subject to debarment or is the subject of a conviction described in Section&#160;306 of the FD&#38;C Act, or if any action, suit, claim, investigation, or legal or administrative proceeding (a)&#160;has been filed and is pending or (b)&#160;is threatened in writing relating to the debarment or conviction of such notifying Party or, to such Party&#8217;s knowledge, any Person or entity used in any capacity by such Party or any of its Affiliates with respect to this Agreement or the performance of its other obligations under this Agreement. Such notifying Party will use reasonable efforts to include in any agreement with any Person or entity used in any capacity by such Party or any of its Affiliates with respect to this Agreement or the performance of its other obligations under this Agreement an obligation to provide notice to such Party of the matters described in this Section&#160;10.6.2 (No Debarment).</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.6.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">No Bribery</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">In exercising its rights and performing its obligations under this Agreement, each Party will (and will ensure that its Affiliates and its and their employees, directors, officers, sublicensees, subcontractors and agents will) (a) not promise, offer, pay, cause to pay, accept payment, induce payment or take any action that could be considered a bribe&#59; (b) comply with all applicable Laws including those related to bribery and corruption (such as the U.S. Foreign Corrupt Practices Act and UK Bribery Act)&#59; (c) comply with industry standards&#59; (d) comply with all policies and guidelines (and any updates to the same) referenced or included in this Agreement or otherwise provided in written form (including electronically) during the Term to such Party by the other Party&#59; and (e) ensure it has an appropriate (with respect to its size, scope of operations and nature of business activities) and effective ethics, risk and compliance organization and systems&#47;policies in place designed to promote ethical business practices.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">61</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.6.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">&#91;***&#93;&#59; Encumbrances</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Neither Arrowhead nor any of its Affiliates will permit, nor allow to be levied, any lien, encumbrance, charge, mortgage, liability, or security interest on any Arrowhead Technology in a manner that would reasonably be expected to adversely affect the rights granted to Novartis under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.6.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Intellectual Property</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Each Party will make any and all payments owing by such Party or any of its Affiliates to any inventor of, in the case of Arrowhead and its Affiliates, any Arrowhead Technology and, in the case of Novartis and its Affiliates, any Novartis Licensed Technology, in each case, that is required in connection with the creation or exploitation of or transfer of rights thereto&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.6.6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">No Conflicts</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  During the Term, Arrowhead will not enter into any agreement with any Third Party that is in conflict with or could otherwise adversely affect the rights granted to Novartis under this Agreement and will not take any action that would prevent it from granting the rights granted to Novartis under this Agreement or that would otherwise materially conflict with or adversely affect the rights granted to Novartis under this Agreement&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, that the foregoing will not prevent Arrowhead from entering into any collaboration, license, or other arrangement with a Third Party that includes Arrowhead using its platforms and other proprietary technology to Research, Develop, Manufacture, Commercialize, or otherwise Exploit compounds and products Directed To any CNS Target or any Cardiomyocyte Target, in each case, that is not a Collaboration Target under a CT Program. During the Term, each Party will not, and will cause its Affiliates not to, enter into any agreement (or amend any agreement that such Party or its Affiliate is a party to as of the Effective Date) granting any license or other right in, to or under (a) such Party&#8217;s interest in the Joint Arising Technology and (b) if such Party is Novartis, the Novartis Arising Technology, in each case ((a) and (b)), that would prevent it from granting the rights granted to the other Party under this Agreement or that would otherwise conflict with or adversely affect the rights granted to the other Party under this Agreement. Arrowhead will</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> not, and will cause its Affiliates not to, enter into any agreement that would impose additional obligations or liabilities on Novartis without Novartis&#8217; prior written consent.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.6.7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Export Controls</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Novartis will not, and will ensure that its Affiliates and Sublicensees will not, export, transfer, or sell any Licensed Product (a) to any country or territory that is subject to comprehensive economic sanctions administered by OFAC, (b) to any other country or territory in which such activity would violate applicable Laws in the U.S., (c) to any Restricted Party, or (d) in such a manner that would violate the Global Trade Control Laws.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.6.8.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.6.9.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">No Reverse Engineering</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Novartis will not, and will ensure that its Affiliates and Novartis&#8217; and any of its Affiliates&#8217; Subcontractors and Sublicensees will not, reverse engineer, sequence, analyze, disassemble, modify or create derivative works of the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.6.10.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.05pt">SCA</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  During the Term </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, Novartis will not, and will ensure that its Affiliates and Novartis&#8217; and any of its Affiliates&#8217; Sublicensees will not </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">10.6.11.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.05pt">Pre-Existing Third Party Agreements</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Arrowhead and its Affiliates will (i) not breach or be in default under any of its obligations under any Pre-Existing Third Party Agreement, in either case, in a manner that would </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">reasonably be expected to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">give the applicable counterparty </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">62</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">thereto a right to terminate </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">or otherwise alter (in a manner materially adverse to Novartis or any of its Affiliates or their respective Sublicensees) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">such Pre-Existing Third Party Agreement </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">or otherwise diminish the scope or exclusivity of the sublicenses granted to Novartis under applicable Arrowhead Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, (ii) satisfy all of its obligations under each Pre-Existing Third Party Agreements, including any obligations arising due to the execution of, or activities under, this Agreement, the breach of which would give the applicable counterparty thereto a right to terminate such Pre-Existing Third Party Agreement, (iii) not do any other act or make any other omission that could give rise to a termination right of any other party to any Pre-Existing Third Party Agreement, and (iv) not terminate any Pre-Existing Third Party Agreement, or amend or waive any provision thereof without Novartis&#8217; prior written consent, which consent will not be unreasonably withheld, conditioned or delayed.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">To the extent that the licensor in any Pre-Existing Third Party Agreement has retained any right to enforce, defend, prosecute, or maintain any Arrowhead Technology or otherwise be involved in such activities pursuant to the Pre-Existing Third Party Agreement, Arrowhead and its Affiliates will use commercially reasonable efforts to cause such licensor to take actions (or refrain from taking action, as applicable) consistent with Article 12 (Intellectual Property).</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Arrowhead and its Affiliates will furnish Novartis with copies of all notices and correspondences that Arrowhead or any of its Affiliates receives in connection with any Pre-Existing Third Party Agreement the subject matter of which would materially and adversely affect Novartis&#8217; rights or obligations under this Agreement within a reasonable period following Arrowhead&#8217;s or its Affiliates&#8217; receipt of the same.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">11.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">INDEMNIFICATION&#59; LIMITATION OF LIABILITY&#59; INSURANCE</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">11.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Indemnification by Arrowhead</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Arrowhead will indemnify, hold harmless, and defend Novartis, its Affiliates, and their respective directors, officers, employees, and agents (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Indemnitees</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) from and against any and all losses, liabilities, damages, costs, fees, and expenses (including reasonable attorneys&#8217; fees and litigation expenses) (collectively, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Losses</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) incurred from any claims, suits, proceedings, or causes of action brought by a Third Party (collectively, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Claims</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) against such Novartis Indemnitees to the extent arising out of or resulting from&#58;</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">11.1.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">any breach of any representation or warranty made by Arrowhead in this Agreement, or any breach or violation of any covenant or agreement of Arrowhead in this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">11.1.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">the gross negligence or willful misconduct by or of Arrowhead or any of its Affiliates, or any of their respective directors, officers, employees, or agents in the performance of Arrowhead&#8217;s obligations or exercise of its rights under this Agreement&#59; or</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">11.1.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">the Exploitation of any Licensed Compound or Licensed Product, in each case, by or on behalf of Arrowhead or any of its Affiliates (excluding such conduct by or on behalf of Novartis or its Affiliates and its Sublicensees as licensees or sublicensees of Arrowhead hereunder), including the conduct of the SNCA Program Research Activities and the CT Program Research Activities.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, Arrowhead will have no obligation to indemnify the Novartis Indemnitees to the extent that the Losses arise out of or result from matters described under Section 11.2 (Indemnification by Novartis).</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">63</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">11.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Indemnification by Novartis</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Novartis will indemnify, hold harmless, and defend Arrowhead, its Affiliates, and their respective directors, officers, employees, and agents (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Indemnitees</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) from and against any and all Losses incurred from any Claims against such Arrowhead Indemnitees to the extent arising out of or resulting from&#58;</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">11.2.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">any breach of any representation or warranty made by Novartis in this Agreement, or any breach or violation of any covenant or agreement of Novartis in this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">11.2.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">the gross negligence or willful misconduct by or of Novartis or any of its Affiliates or Sublicensees, or any of their respective directors, officers, employees, or agents in the performance of Novartis&#8217; obligations or exercise of its rights under this Agreement&#59; or</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">11.2.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">the Exploitation of any Licensed Compound or Licensed Product, in each case, by or on behalf of Novartis or any of its Affiliates or Sublicensees.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, Novartis will have no obligation to indemnify the Arrowhead Indemnitees to the extent that the Losses arise out of or result from matters described under Section&#160;11.1 (Indemnification by Arrowhead).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">11.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Indemnification Procedure</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">11.3.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The Party entitled to indemnification under this Article 11 (Indemnification&#59; Limitation of Liability&#59; Insurance) (an &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) will notify the Party responsible for such indemnification (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Indemnifying Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) in writing promptly (and in any event no later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">) upon being notified of or having knowledge of any claim or claims asserted or threatened against the Indemnified Party that could give rise to a right of indemnification under this Agreement&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">the failure to give such notice will not relieve the Indemnifying Party of its indemnity obligation hereunder except to the extent that such failure materially prejudices the Indemnifying Party.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">11.3.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Indemnifying Party&#8217;s Right to Defend</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after receipt of notice from the Indemnified Party of the claim, the Indemnifying Party will have the right to defend, at its sole cost and expense and with counsel reasonably selected by the Indemnifying Party, any such claim by all appropriate proceedings and, if it elects to do so, will provide written notice of such election to the Indemnified Party within such </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">- period&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">the Indemnifying Party may not enter into any compromise or settlement, unless (a)&#160;such compromise or settlement (i) imposes only a monetary obligation on the Indemnifying Party and includes as an unconditional term thereof the giving by each claimant or plaintiff of the Indemnified Party a release from all liability in respect of such claim, (ii) admits no liability, wrongdoing, or other admission against interest on the part of the Indemnified Party, and (iii) would not have an adverse effect on the Indemnified Party&#8217;s interests (including any rights under this Agreement or the scope or enforceability of the Patent Rights, Know-How and other intellectual property licensed hereunder)&#59; or (b)&#160;the Indemnified Party consents to such compromise or settlement, which consent will not be unreasonably withheld, conditioned or delayed unless such compromise or settlement involves (i) any admission of legal wrongdoing by the Indemnified Party, (ii) any payment by the Indemnified Party that is not indemnified under this Agreement, or (iii) the imposition of any equitable relief against the Indemnified Party (in which case, (i) through (iii), the Indemnified Party may withhold its consent to such settlement in its sole discretion).</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">11.3.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Indemnified Party&#8217;s Right to Defend</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  If the Indemnifying Party does not elect to assume control of the defense of a claim by written notice to the Indemnified Party in accordance with Section 11.3.2 (Indemnifying Party&#8217;s Right to Defend), then the Indemnified Party will have the right, at the expense of the Indemnifying Party, with </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">64</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">written notice to the Indemnifying Party of its intent to do so, to undertake the defense of such claim for the account of the Indemnifying Party (with counsel reasonably selected by the Indemnified Party)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">that the Indemnified Party will keep the Indemnifying Party apprised of all material developments with respect to such claim. The Indemnified Party may not enter into any compromise or settlement without the prior written consent of the Indemnifying Party, such consent not to be unreasonably withheld, conditioned, or delayed.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">11.3.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Cooperation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The Indemnified Party will cooperate with the Indemnifying Party and may participate in, but not control, any defense or settlement of any claim controlled by the Indemnifying Party pursuant to this Section&#160;11.3 (Indemnification Procedure) and will bear its own costs and expenses with respect to such participation&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">the Indemnifying Party will bear such costs and expenses if counsel for the Indemnifying Party reasonably determines that such counsel may not properly represent both the Indemnifying Party and the Indemnified Party.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">11.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Limitation of Liability</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  NEITHER PARTY WILL BE LIABLE FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES ARISING OUT OF THIS AGREEMENT, OR THE EXERCISE OF ITS RIGHTS OR THE PERFORMANCE OF ITS OBLIGATIONS HEREUNDER, OR ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, OR LOST PROFITS, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES, EXCEPT FOR DAMAGES THAT ARISE AS A RESULT OF (A) THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF A PARTY UNDER SECTION 11.1 (INDEMNIFICATION BY ARROWHEAD) OR SECTION 11.2 (INDEMNIFICATION BY NOVARTIS)&#59; (B)&#160;A PARTY&#8217;S GROSS NEGLIGENCE, WILLFUL MISCONDUCT OR FRAUD, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">OR </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(C)&#160;A BREACH OF ARTICLE 9 (CONFIDENTIALITY AND PUBLICATION)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">11.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Insurance</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party will, at its own expense, procure and maintain during the Term and for a period of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">thereafter, insurance policies, including product liability insurance when applicable, adequate to cover its obligations hereunder and that are consistent with normal business practices of prudent companies similarly situated. Such insurance will not be construed to create a limit of a Party&#8217;s liability with respect to its indemnification obligations under this Article 11 (Indemnification&#59; Limitation of Liability&#59; Insurance). Each Party will provide the other Party with written evidence of such insurance upon request. Each Party will provide the other Party with prompt written notice of cancellation, non-renewal, or material change in such insurance that could materially adversely affect the rights of such other Party hereunder and will provide such notice within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">after any such cancellation, non-renewal, or material change. Notwithstanding any provision to the contrary in this Agreement, Novartis may self-insure, in whole or in part, the foregoing described insurance requirements.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">12.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">INTELLECTUAL PROPERTY</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">12.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Background Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of this Agreement to the contrary, neither Arrowhead nor any of its Affiliates is or shall be at any time, including prior to, on or after expiration or termination of this Agreement, granted any license, interest, access to, disclosure of, or other right with respect to Novartis Background Technology.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">12.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Inventions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12.2.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Inventorship</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Inventorship of Arising Know-How and Arising Patent Rights will be determined in accordance with United States patent Laws.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12.2.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Ownership of Arising Know-How and Arising Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Arrowhead</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the rights or licenses granted by Arrowhead to Novartis under this Agreement, as between the Parties, Arrowhead will own and retain all rights, title, and interest in and to any and all&#58; (i) (A) Arising Know-How, regardless of inventorship, that is solely related to the Delivery Ligand </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#ff0000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arising Delivery Ligand Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and (B) Arising </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">65</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Know-How that is conceived, discovered, developed or otherwise made solely by or on behalf of one or more Personnel of Arrowhead (or any of its Affiliates, (sub)licensees or Subcontractors), but excluding any Arising Delivery Ligand Know-How and Joint Arising Know-How (the Arising Delivery Ligand Know-How and (i)(B), together, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Arising Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and (ii) (A) Arising Patent Rights, regardless of inventorship, that Cover solely any Arising Delivery Ligand Know-How (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arising Delivery Ligand Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and (B) Arising Patent Rights that Cover solely any Arrowhead Arising Know-How set forth in the foregoing clause (i)(B) (together (ii)(A) and (ii)(B), the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Arising Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Novartis hereby assigns and agrees to assign to Arrowhead all rights, title, and interest in and to any Arising Delivery Ligand Know-How that is conceived, discovered, developed, or otherwise made under any of the Transaction Agreements by or on behalf of&#58; (1) one or more Personnel of Novartis (or any of its Affiliates, Sublicensees, or Subcontractors), or (2) one or more Personnel of Novartis (or any of its Affiliates, Sublicensees, or Subcontractors), on the one hand, and one or more Personnel of Arrowhead (or any of its Affiliates, (sub)licensees, or Subcontractors), on the other hand.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Novartis</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the rights or licenses granted by Novartis to Arrowhead under this Agreement, as between the Parties, Novartis will own and retain all rights, title, and interest in and to any and all (i) Arising Know-How that is conceived, discovered, developed, or otherwise made solely by or on behalf of one or more Personnel of Novartis (or any of its Affiliates, Sublicensees or Subcontractors) but excluding any Arising Delivery Ligand Know-How and Joint Arising Know-How (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Arising Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and (ii) Arising Patent Rights that Cover solely any Novartis Arising Know-How set forth in the foregoing clause (i) (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Arising Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;, and together with the Novartis Arising Know-How, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Arising Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Joint</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to any rights or licenses expressly granted by one Party to the other Party under this Agreement, as between the Parties, the Parties will jointly own, on an equal and undivided basis, all rights, title, and interest in and to any and all&#58; (i) Arising Know-How that is conceived, discovered, developed, or otherwise made by or on behalf of one or more Personnel of Arrowhead (or any of its Affiliates, (sub)licensees, or Subcontractors), on the one hand, and one or more Personnel of Novartis (or any of its Affiliates, Sublicensees, or Subcontractors), on the other hand, but excluding any Arising Delivery Ligand Know-How (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Joint Arising Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and (ii) Arising Patent Rights that Cover solely any Joint Arising Know-How set forth in the foregoing clause (i) (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Joint Arising Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (collectively the Joint Arising Know-How and the Joint Arising Patent Rights, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Joint Arising Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Subject to the rights or licenses granted to the other Party under this Agreement, each Party will be entitled to practice, license, assign, and otherwise practice under the Joint Arising Technology without the duty of accounting or seeking consent from the other Party, and where consent is required, such consent is hereby given. Each Party, for itself and on behalf of its Affiliates, hereby assigns and agrees to assign, to the other Party an equal and undivided joint ownership interest in and to all Joint Arising Technology, to be held in accordance with this Section 12.2.2(c) (Joint).</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12.2.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Disclosure</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party will promptly disclose to the other Party all invention disclosures or other similar documents relating to Arising Know-How conceived, invented, developed, or otherwise made by or on behalf of such Party (or its Affiliates, Sublicensees (or in the case of Arrowhead (sub)licensees), or Subcontractors) </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">66</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">hereunder during the Term that is necessary or reasonably useful to Research, Develop, Manufacture, Commercialize, or otherwise Exploit one or more Licensed Compounds or Licensed Products in the Field in the Territory, and all invention disclosures or other similar documents submitted to such Party by its or its Affiliates&#8217; employees, agents, or independent contractors relating to such Arising Know-How, and will also respond promptly to reasonable requests from the other Party for additional information relating to such disclosures, documents, or applications.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12.2.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Personnel Obligations</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Each employee, agent, or independent contractor of a Party or its respective Affiliates performing work under this Agreement will, prior to commencing such work, be bound by written invention assignment obligations, including&#58; (a) promptly reporting any invention, discovery, or other intellectual property right&#59; (b) presently assigning to the applicable Party or Affiliate all of his or her rights, title, and interests in and to any invention, discovery, or other intellectual property&#59; (c) cooperating in the preparation, filing, prosecution, maintenance, and enforcement of any patent and patent application&#59; and (d) performing all acts and signing, executing, acknowledging, and delivering any and all documents required for effecting the obligations and purposes of this Agreement. It is understood and agreed that such invention assignment agreement need not reference or be specific to this Agreement. Each Party will be solely responsible for any payments to inventors with an obligation to assign, or who do assign, their rights, title, and interests in and to any Arising Know-How and Arising Patent Rights to such Party.  Arrowhead will be solely responsible for payments to inventors of any other Arrowhead Patent Rights.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">12.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Prosecution and Maintenance of Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The Parties will conduct the Prosecution and Maintenance of the applicable Patent Rights in accordance with this Section 12.3 (Prosecution and Maintenance of Patent Rights).</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12.3.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Novartis Right to Prosecute Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">On a Program-by-Program basis, with respect to the SNCA Program and each CT Program, beginning on the earlier of (i) the applicable Technology Transfer Date for such Program, and (ii) the date a non-provisional patent application (including an international patent application under the PCT) for a Licensed Product-Specific Patent Right, Novartis Arising LC&#47;LP Patent Right, or Joint Arising Patent Right related to such Program is first filed, as between the Parties, Novartis will have the first right (but not the obligation) to Prosecute and Maintain all Licensed Product-Specific Patent Rights, Novartis Arising LC&#47;LP Patent Rights, and Joint Arising Patent Rights in the Territory of such Program (such Patent Rights, collectively, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Novartis Prosecuted Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), using patent counsel of its choice and, with respect to the Licensed Product-Specific Patent Rights and the Joint Arising Patent Rights, reasonably acceptable to Arrowhead. Novartis will bear all Patent Costs incurred by Novartis for the Prosecution and Maintenance of the Novartis Prosecuted Patent Rights.  Novartis will provide Arrowhead with material communications from any Patent Office in the Territory regarding the Novartis Prosecuted Patent Rights, as well as a reasonable opportunity to review and comment on (A) drafts of any material filings, (B) drafts of any patent applications related to such Program, and (C) responses to be made to such Patent Offices in advance of submitting such filings, applications, or responses. Novartis will consider Arrowhead&#8217;s comments regarding such communications and drafts in good faith. In addition, Novartis will provide Arrowhead with copies of all such final filings, applications and responses made to any Patent Office with respect to the Novartis Prosecuted Patent Rights in a timely manner following submission thereof. Arrowhead will provide, at Novartis&#8217; cost and expense, all assistance reasonably requested by Novartis in Novartis&#8217; Prosecution and Maintenance of the Licensed Product-</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">67</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Specific Patent Rights and the Joint Arising Patent Rights related to a specific Program (including by executing all requested documents and providing additional information with respect to the applicable Patent Rights). At its sole cost and expense, Novartis will have the sole right to Prosecute and Maintain all Novartis Arising Patent Rights that are not Novartis Arising LC&#47;LP Patent Rights.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If Novartis determines in its sole discretion to abandon or not to Prosecute and Maintain any Novartis Prosecuted Patent Right, then Novartis will provide Arrowhead with written notice promptly after such determination to allow Arrowhead a reasonable period of time to determine, on a country-by-country basis, in its sole discretion, its interest in assuming Prosecuting and Maintaining such Patent Right in the Territory (which notice by Novartis will be given no later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> prior to the final deadline for any pending action or response that may be due with respect to such Patent Right with the applicable Patent Office). If Arrowhead provides written notice to Novartis expressing its interest in assuming Prosecuting and Maintaining such Patent Right, then, with respect to such Patent Right in such country in the Territory, (i) Arrowhead may, in its sole discretion and at Arrowhead&#8217;s cost and expense, Prosecute and Maintain or abandon such Patent Right, and (ii) Novartis will promptly&#58; (A) provide to Arrowhead or counsel designated by Arrowhead the file histories for, and correspondence with existing patent counsels related to, such Patent Right&#59; (B) provide to Arrowhead a report detailing the status of such Patent Right as of the applicable date of such notice by Novartis&#59; and (C) at Arrowhead&#8217;s cost and expense, provide all assistance reasonably requested by Arrowhead in Arrowhead&#8217;s Prosecution and Maintenance of the applicable Patent Rights (including by executing all requested documents and providing additional information with respect to the applicable Patent Rights).</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12.3.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Arrowhead Right to Prosecute Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Beginning on the Effective Date, as between the Parties, Arrowhead will (i) have the first right (but not the obligation) to Prosecute and Maintain all Arrowhead Platform Patent Rights, (ii) on a Program-by-Program basis, until the earlier of (A) the applicable Technology Transfer Date for such Program, or (B) the date a non-provisional patent application (including an international patent application under the PCT) for a Licensed Product-Specific Patent Right or Joint Arising Patent Right of such Program is first filed, have the first right (but not the obligation) to Prosecute and Maintain all Licensed Product-Specific Patent Rights and Joint Arising Patent Rights in the Territory related to such Program (such Patent Rights in clauses (i) and (ii), collectively, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arrowhead Prosecuted Patent Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and (iii) have the sole right (but not the obligation) to Prosecute and Maintain all Arising Delivery Ligand Patent Rights, in each case ((i) &#8211; (iii)) in the Territory using outside patent counsel of its choice. Arrowhead will bear all Patent Costs incurred for the Prosecution and Maintenance of such Patent Rights. Arrowhead will keep Novartis reasonably informed of all material matters relating to the Prosecution and Maintenance of the Arrowhead Prosecuted Patent Rights, including providing Novartis with all material communications from any Patent Office in the Territory regarding the Arrowhead Prosecuted Patent Rights, as well as a reasonable opportunity to review and comment on (1) drafts of any material filings, (2) drafts of any patent applications related to such Program, and (3) responses to be made to such Patent Offices in advance of submitting such filings, applications, or responses. Arrowhead will consider in good faith Novartis&#8217; comments with respect to strategies for Prosecution and Maintenance of the Arrowhead Prosecuted Patent Rights. In addition, </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">68</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Arrowhead will provide Novartis with copies of all such final filings, applications, and responses made to any Patent Office with respect to the Arrowhead Prosecuted Patent Rights in a timely manner following submission thereof. Arrowhead will provide to Novartis promptly after the Effective Date a report detailing the status of the Arrowhead Prosecuted Patent Rights.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If Arrowhead determines in its sole discretion to abandon or not to Prosecute and Maintain any Arrowhead Prosecuted Patent Right, then Arrowhead will provide Novartis with written notice promptly after such determination with respect to the Arrowhead Prosecuted Patent Rights, Novartis will determine, on a country-by-country basis, in its sole discretion, its interest in Prosecuting and Maintaining such Patent Right in the Territory (which notice by Arrowhead will be given no later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> prior to the final deadline for any pending action or response that may be due with respect to such Patent Right with the applicable Patent Office). If Novartis provides written notice to Arrowhead expressing its interest in Prosecuting and Maintaining such Patent Right, then, with respect to such Patent Right in such country in the Territory, (i) Novartis may, in its sole discretion and at Novartis&#8217; cost and expense, Prosecute and Maintain or abandon such Patent Right, and (ii) Arrowhead will promptly&#58; (A) provide to Novartis or counsel designated by Novartis the file histories for, and correspondence with existing patent counsel related to, such Patent Right&#59; (B) provide to Novartis a report detailing the status of such Patent Right as of the applicable date of such notice by Arrowhead&#59; and (C) at Novartis&#8217; cost and expense, provide all assistance reasonably requested by Novartis in Novartis&#8217; Prosecution and Maintenance of the applicable Patent Rights (including by executing all requested documents and providing additional information with respect to the applicable Patent Rights).</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12.3.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Cooperation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The Parties will, and will cause their Affiliates to, cooperate and implement reasonable patent drafting, filing and prosecution strategies (including filing divisionals, continuations, or otherwise). To the extent reasonable and feasible, (a) Licensed Product-Specific Patent Rights and Arrowhead Platform Patent Rights will be pursued in mutually exclusive patent applications (which may be simultaneously filed) and in separate and distinct patent families, and (b) Novartis Arising LC&#47;LP Patent Rights and other Novartis Arising Patent Rights will be pursued in mutually exclusive patent applications (which may be simultaneously filed) and in separate and distinct patent families. Further, to the extent possible, the Parties will coordinate and determine (i) the division of Arrowhead Patent Rights as either Licensed Product-Specific Patent Right or Arrowhead Platform Patent Rights, and (ii) the division of Novartis Arising Patent Rights as either Novartis Arising LC&#47;LP Patent Rights or other Novartis Arising Patent Rights.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">12.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Third Party Infringement and Defense</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The Parties will conduct the enforcement and defense of the applicable Patent Rights in accordance with this Section 12.4 (Third Party Infringement and Defense).</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12.4.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Notices</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party will promptly report in writing to the other Party any Competitive Infringement of which such Party (or any of its Affiliates or Sublicensees) becomes aware and will provide the other Party with all available evidence of such Competitive Infringement in such Party&#8217;s control.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12.4.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Novartis Right to Enforce</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">As between the Parties, Novartis, at its own cost and expense, will have (i) the first right, but not the obligation, to bring a suit or other action to abate any existing, alleged, or threatened Competitive Infringement involving one or more Licensed Product-Specific Patent Rights, Novartis Arising LC&#47;LP Patent </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">69</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Rights, or Joint Arising Patent Rights, and (ii) the sole right, but not the obligation, to bring a suit or other action to abate any existing, alleged, or threatened infringement action (A) involving one or more Novartis Arising Patent Rights that are not Novartis Arising LC&#47;LP Patent Rights or (B) that is </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">not</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> a Competitive Infringement involving the Joint Arising Patent Rights.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Novartis will notify Arrowhead of its decision as to whether to take any action in accordance with Section 12.4.2(a)(i) (Novartis Right to Enforce) at least </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> before any time limit set forth in any Law or regulation, or within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after being notified of such Competitive Infringement, whichever is shorter. If Novartis decides not to take such action with respect to a Competitive Infringement involving one or more Licensed Product-Specific Patent Rights, Novartis Arising LC&#47;LP Patent Rights, or Joint Arising Patent Rights, then Novartis will so notify Arrowhead in writing, and following discussion with Novartis and consideration in good faith of any rationale provided by Novartis as to why Novartis elected not to take such action, and with Novartis&#8217; written consent (not to be unreasonably withheld, conditioned or delayed) following consideration in good faith of any rationale provided by Arrowhead, Arrowhead will have the right, but not the obligation, to commence a suit or take action to enforce the applicable Licensed Product-Specific Patent Right, Novartis Arising LC&#47;LP Patent Right, or Joint Arising Patent Right to abate such Competitive Infringement in the Territory, by counsel of its own choice and at its own cost and expense.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12.4.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Arrowhead Right to Enforce</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">As between the Parties, Arrowhead, at its own cost and expense, will have (i) the first right, but not the obligation, to bring a suit or other action to abate any existing, alleged, or threatened Competitive Infringement involving the Arrowhead Platform Patent Rights or Arising Delivery Ligand Patent Rights&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that Arrowhead will seek and reasonably consider Novartis&#8217; comments before determining the strategy for enforcing any Arrowhead Platform Patent Right or Arising Delivery Ligand Patent Rights, and (ii) the sole right, but not the obligation, to bring a suit or other action to abate any existing, alleged, or threatened infringement action that is </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">not</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> a Competitive Infringement involving the Arrowhead Platform Patent Rights or the Arising Delivery Ligand Patent Rights.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Arrowhead will notify Novartis of its decision as to whether to take any action in accordance with Section 12.4.3(a)(i) (Arrowhead Right to Enforce) at least </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> before any time limit set forth in any Law or regulation, or within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after being notified of such Competitive Infringement, whichever is shorter. If Arrowhead decides not to take such action with respect to any Arrowhead Platform Patent Right or Arising Delivery Ligand Patent Right, then Arrowhead will so notify Novartis in writing, and following discussion with Arrowhead and consideration in good faith of any rationale provided by Arrowhead as to why Arrowhead elected not to take such action, and with Arrowhead&#8217;s written consent (not to be unreasonably withheld, conditioned or delayed) following consideration in good faith of any rationale provided by Novartis, Novartis will have the right, but not the obligation, to commence a suit or take action to enforce the applicable Arrowhead Platform Patent Right or Arising Delivery Ligand Patent Right to abate such Competitive Infringement in the Territory, by counsel of its own choice and at its own cost and expense.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">70</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12.4.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Hatch-Waxman</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any provision to the contrary set forth in this Agreement, should a Party receive a certification for a Licensed Product pursuant to the Hatch-Waxman Act, or its equivalent in a country other than the U.S., with respect to any activities under this Agreement in the Field, then such Party will promptly provide the other Party with a copy of such certification. For each Licensed Product, Novartis will have </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> from the date on which it receives or provides a copy of such certification to provide written notice to Arrowhead (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">H-W Suit Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) whether Novartis will bring suit, at its expense, within a </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">- period from the date of such certification. Should such </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">- period expire without Novartis bringing suit or providing such H-W Suit Notice, then Arrowhead will be free to bring suit in its name.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12.4.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Cooperation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party will provide to the Party enforcing any Patent Rights under this Section 12.4 (Third Party Infringement and Defense) reasonable assistance in such enforcement, at such enforcing Party&#8217;s request and expense, including joining such action as a party plaintiff if required by Law to pursue such action or providing the enforcing Party any reasonably requested documentation or other materials. The enforcing Party will keep the other Party regularly informed of the status and progress of such enforcement efforts, including providing the other Party a reasonable opportunity to comment on the enforcing Party&#8217;s determination of litigation strategy and the filing of important papers to the competent court and the enforcing Party will consider such comments in good faith.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12.4.6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Settlement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Neither Party will settle any claim, suit, or action that it brought under this Section 12.4 (Third Party Infringement and Defense) in a manner that would reasonably be expected to affect the other Party&#8217;s rights or interests, admit fault of the other Party, or impose any monetary or other obligation on the other Party, without the prior written consent of the other Party, which consent will not be unreasonably withheld, conditioned or delayed.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12.4.7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Allocation of Proceeds</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Any amount recovered in any suit or other action under this Section 12.4 (Third Party Infringement and Defense), including any amount recovered in any settlement of such suit or other action, will first be used to reimburse each Party&#8217;s costs and expenses with respect to such suit or other action (which reimbursement will be on a </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">pro rata</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> basis to the extent such costs and expenses exceed such recovered amount) and will thereafter be </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">12.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Defense</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  As between the Parties, the Party controlling the Prosecution and Maintenance of any Patent Right under Section 12.3 (Prosecution and Maintenance of Patent Rights), will have the right (but not the obligation), at its sole discretion and its own cost and expense, to defend against a declaratory judgment action, post-grant review proceeding, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">inter partes </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">review, opposition proceeding, interference, or any other legal or administrative action challenging any such Patent Right. If the Party controlling such Prosecution and Maintenance of Arrowhead Platform Patent Rights, Licensed Product-Specific Patent Rights, or Novartis Arising Patent Rights, as the case may be, under Section&#160;12.3 (Prosecution and Maintenance of Patent Rights) does not defend such Patent Right under this Section&#160;12.5 (Defense) within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after the initiation by a Third Party of any of the foregoing actions or proceedings or such shorter period of time as is mandated by the rules of the applicable action or proceeding to commence the defense thereof, or elects not to continue any such defense (in which case it will promptly provide written notice thereof to the other Party), then the other Party will have the right (but not the obligation), at its sole discretion, to defend any such Patent Right. The defending Party will keep the other Party reasonably advised of all material developments in the conduct of any such defense. The defending Party will use reasonable efforts to provide the other Party with drafts of all material documents to be filed with the court or the applicable Patent Office and will consider in good faith all reasonable and timely comments thereto by such other Party before filing such documents. The non-defending Party will reasonably cooperate with the Party conducting the defense of such Third Party action, at such defending Party&#8217;s cost and expense, including if required to conduct such defense, </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">71</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="padding-left:36pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">furnishing a power of attorney. Any awards or amounts received in defending any such action will be allocated between the Parties as provided in Section 12.4.7 (Allocation of Proceeds) applying </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">12.6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Infringement of Third Party Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12.6.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  If any Licensed Product becomes the subject of a Third Party&#8217;s claim or assertion of infringement of a Patent Right of such Third Party within the Territory, then the Party first having notice of the claim or assertion will promptly notify the other Party.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12.6.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Defense</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> will have the first right, but not the obligation, to defend or settle any such Third Party claim or assertion of infringement of such Third Party&#8217;s Patent Right, at </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8217; cost and expense. If </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">does not defend such Third Party claim or assertion of infringement within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after the initiation by such Third Party of such claim or such shorter period of time as is mandated by the rules of such claim to commence the defense thereof, or elects not to continue any such defense (in which case </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">will promptly provide written notice thereof to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">), then </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">will have the right (but not the obligation), at its sole discretion, to defend any such Third Party claim or assertion of infringement. The non-defending Party will reasonably cooperate with the Party conducting the defense of the claim or assertion, at such defending Party&#8217;s cost and expense, including if required to conduct such defense, furnishing a power of attorney. The defending Party will keep the non-defending Party reasonably advised of all material developments in the conduct of any proceedings in defending such Third Party claim or assertion. The defending Party will provide the non-defending Party with drafts of all material papers to be filed with the court and will consider in good faith all reasonable comments thereto by the non-defending Party before filing such papers.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">12.6.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Settlement&#59; Licenses</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as otherwise provided in Article 11 (Indemnification&#59; Limitation of Liability&#59; Insurance), neither Party will enter into any settlement of any claim described in this Section 12.6 (Infringement of Third Party Rights) that affects the other Party&#8217;s rights or interests, admits faults of the other Party, or imposes any monetary or other obligations on the other Party, without such other Party&#8217;s written consent, such consent not to be unreasonably withheld, conditioned, or delayed. Each Party will have the right to decline to defend or to tender the defense of any claim described in this Section 12.6 (Infringement of Third Party Rights) upon reasonable written notice to the other Party, including if the other Party fails to agree to a settlement that the declining Party proposes. Except as otherwise provided in Article 11 (Indemnification&#59; Limitation of Liability&#59; Insurance), any settlement or license fees incurred by </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> under this Section 12.6.3 (Settlement&#59; Licenses) will be allocated in accordance with the principle set forth in Section 8.5.3 (Third Party Payments) to the extent that the Patent Right that is the subject of such settlement license Covers the making, using, selling, offering for sale, or importing of a Licensed Product in the relevant country for which such rights are licensed thereunder.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">12.7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Other Invalidity or Unenforceability Proceedings</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  If either Party desires to bring an opposition, action for declaratory judgment, nullity action, interference, declaration for non-infringement, reexamination, post-grant proceedings, or other attack upon the validity, title, or enforceability of a Patent Right owned or controlled by a Third Party and having one or more claims that Cover a Licensed Product, or the use, sale, offer for sale, or importation of a Licensed Product (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">except</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> insofar as such action is a counterclaim to or defense of, or accompanies a defense of, a Third Party&#8217;s claim or assertion of infringement under Section 12.6 (Infringement of Third Party Rights), in which case the provisions of Section 12.6 (Infringement of Third Party Rights) will govern), such Party will so notify the other Party and the Parties will promptly confer to determine whether to bring such action or the manner in which to settle such action, and if any such action is brought by a Party, each Party will provide such assistance as may be reasonably requested by the other Party (at such other Party&#8217;s cost) in connection with such action.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">72</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">12.8.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Patent Right Extensions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the remainder of this Section 12.8 (Patent Right Extensions), Novartis will have the sole right to elect and file for patent term restoration or extension, supplemental protection certificate, or any of their equivalents (hereinafter, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Patent Term Extensions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) with respect to Novartis Prosecuted </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Patent</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> Rights or other Novartis Arising Patent Rights for any Licensed Product in the Territory, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that, for the avoidance of doubt, Novartis may not file a request for a Patent Term Extension for any Arrowhead Platform Patent Rights without Arrowhead&#8217;s prior written consent, which consent will not be unreasonably withheld, conditioned, or delayed. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Upon Novartis&#8217; request and at its cost and expense, Arrowhead will reasonably cooperate with Novartis in any fillings made by Novartis pursuant to this Section 12.8 (Patent Right Extensions). Novartis will bear all Patent Costs incurred by Novartis in making any such filing in the Territory for such Licensed Product. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">12.9.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Orange&#47;Purple Book Listing</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Novartis and Arrowhead will discuss in good faith the Arrowhead Patent Rights or Joint Arising Patent Rights that will be included in the Orange&#47;Purple Book in connection with the Regulatory Approval of Licensed Products in the Territory, and, after considering Arrowhead&#8217;s comments in good faith, Novartis will have the sole right to determine which Patent Rights will be included. Arrowhead will provide such assistance as may be reasonably requested by Novartis in connection with such listing, at Novartis&#8217; cost and expense.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">12.10.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Trademarks</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Novartis will have the right to brand Licensed Products in the Territory using Novartis-related Trademarks and any other Trademarks it determines appropriate, which may vary by country or within a country of the Territory. Novartis will own all rights, title, and interests in and to such Trademarks, including all goodwill associated therewith, and will have the sole right to register and maintain such Trademarks in the countries and regions of the Territory that it determines, at Novartis&#8217; cost and expense.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">12.11.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Common Interest</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  All non-public information exchanged between the Parties or between a Party&#8217;s outside patent counsel and the other Party regarding the preparation, filing, prosecution, maintenance, defense and enforcement of the Arrowhead Patent Rights, Arising Patent Rights, or otherwise related to any Licensed Compound or any Licensed Product, and all shared information regarding analyses or opinions of Patent Rights or Know-How of a Third Party, will be deemed Confidential Information hereunder. The Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning any such Patent Rights, Know-How, or Confidential Information, including privilege under the common interest doctrine and similar or related doctrines. In furtherance of the foregoing, if the Parties agree that a separate agreement memorializing this understanding would be advantageous, then the Parties will negotiate and enter into a common interest agreement reflecting this understanding or any other common interest agreement as the Parties may mutually agree, including with respect to any product liability for a Licensed Product.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">13.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">TERM AND TERMINATION</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">13.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement will commence upon the Effective Date and, if not otherwise terminated earlier pursuant to this Article 13 (Term and Termination), will continue, on a Licensed Product-by-Licensed Product and country-by-country basis, in full force and effect until the expiration of the Royalty Term applicable to such Licensed Product and such country and will expire in its entirety upon the expiration of the last Royalty Term (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Upon expiration of the Royalty Term for a Licensed Product in a country in the Territory, the licenses granted by Arrowhead to Novartis in Section&#160;2.1 (Exclusive License Grants to Novartis) with respect to such Licensed Product in such country will become fully paid, irrevocable, and perpetual.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">13.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Termination for Convenience</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">13.2.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Prior to First Regulatory Approval</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Novartis will be entitled to terminate this Agreement (a) in its entirety (for all Programs and all Licensed Compounds and all Licensed Products) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">throughout the Territory, prior to receipt of Regulatory Approval in a Major Region of the first Licensed Product that is the subject of any Program </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, or (b) on a Program-by-Program basis </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#ff0000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">throughout the Territory, for all Licensed Compounds and all Licensed Products that are the subject of such Program, prior to receipt of Regulatory Approval in a Major Region of the first Licensed Product that is the subject of such Program </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, in each case ((a) and (b)), at its sole discretion upon </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> prior written notice to Arrowhead thereof.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">73</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">13.2.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">After First Regulatory Approval</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Novartis will be entitled to terminate this Agreement (a) in its entirety (for all Programs and all Licensed Compounds and all Licensed Products) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#ff0000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">throughout the Territory, after receipt of Regulatory Approval in a Major Region of the first Licensed Product that is the subject of any Program has been obtained</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, or (b) on a Program-by-Program basis </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#ff0000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">throughout the Territory, for all Licensed Compounds and all Licensed Products that are the subject of such Program throughout the entire Territory, after receipt of Regulatory Approval in a Major Region of the first Licensed Product that is the subject of such Program has been obtained </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, in each case ((a) and (b) ), at its sole discretion upon </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> prior written notice to Arrowhead thereof.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">13.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Termination for Bankruptcy</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be terminated in its entirety, to the extent permitted by Law, by a Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors, in each case, of the other Party (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Bankrupt Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">that in the case of any involuntary bankruptcy, reorganization, liquidation, or receivership proceeding, such right to terminate will only become effective if the Bankrupt Party consents to the involuntary bankruptcy or such proceeding is not dismissed within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after the filing thereof.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">13.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Termination for Material Breach</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">13.4.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Material Breach and Cure Period</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to Section 13.4.2 (Disputes Regarding Material Breach), either Party (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Non-Breaching Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) may terminate this Agreement (a) with respect to one or more Programs (for all Licensed Compounds and Licensed Products that are the subject of such Program) if the other Party (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Breaching Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) has materially breached this Agreement with respect to such Program, or (b) in its entirety throughout the Territory if the Breaching Party has materially breached this Agreement in a manner that is not specific to a Program, in each case ((a) and (b)), and such material breach has not been cured within (i) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after the Breaching Party&#8217;s receipt of written notice from the Non-Breaching Party of such material breach if such material breach involves a failure to make a payment when due or (ii) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after receipt of written notice of such breach for any other material breach by the Breaching Party from the Non-Breaching Party (such </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">-day period or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">-day period, as applicable, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Cure Period</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The written notice describing the alleged material breach will provide reasonably sufficient detail to put the Breaching Party on notice of such material breach. Any termination of this Agreement in its entirety or with respect to a Program pursuant to this Section 13.4.1 (Material Breach and Cure Period) will become effective at the end of the Cure Period, unless the Breaching Party has cured any such material breach prior to the expiration of such Cure Period, or, if such material breach (other than any breach involving the failure to make a payment when due) is not curable prior to the expiration of the applicable Cure Period, then such Cure Period will be extended so long as the Breaching Party has (A) provided to the Non-Breaching Party a written plan that is reasonably calculated to effect a cure of such material breach, and (B) the Breaching Party has commenced actions to cure such material breach during the Cure Period and commits to diligently carry out such plan as provided to the Non-Breaching Party, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that, in no event will the Cure Period be extended to more than a total of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">13.4.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Disputes Regarding Material Breach</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  If the Parties reasonably and in good faith disagree as to whether there has been a material breach or whether a material breach has been cured within the applicable Cure Period, then the Breaching Party that disputes whether there has been a material breach or cure thereof may contest the allegation in accordance with Article 15 (Dispute Resolution) and the applicable Cure Period will toll upon the initiation of such dispute resolution procedures. If, as a result of such dispute resolution process, it is finally determined pursuant to Article 15 (Dispute Resolution) that the Breaching Party committed a material breach of this </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">74</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Agreement, then the applicable Cure Period will resume and unless such alleged breach was cured during the pendency of such Cure Period (once resumed), this Agreement will terminate effective as of the expiration of such Cure Period. This Agreement will remain in full force and effect during the pendency of any such dispute resolution proceeding and all Cure Periods. Any such dispute resolution proceeding will not suspend any obligations of either Party hereunder, and each Party will use reasonable efforts to mitigate any damages.  Any payments that are made by one Party to the other Party pursuant to this Agreement pending resolution of the Dispute will be promptly refunded if it is determined pursuant to Article 15 (Dispute Resolution) that such payments are to be refunded by one Party to the other Party. If, as a result of such dispute resolution proceeding, it is determined that the Breaching Party did not commit such material breach (or such material breach was cured in accordance with this Section 13.4 (Termination for Material Breach)), then no termination of this Agreement will be effective, and this Agreement will continue in full force and effect.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">13.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Termination for Patent Challenge</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  If, during the Term, Novartis or its Sublicensee (or any Affiliate of Novartis or any Affiliate of a Sublicensee) commences or participates in, or actively assists any other Person in bringing, any action or legal or administrative proceeding (including any patent opposition or re-examination proceeding), or otherwise asserts any claim, challenging or denying the patentability, validity, or enforceability of any claim of any Arrowhead Platform Patent Right listed in the Orange&#47;Purple Book for a Licensed Product or any Licensed Product-Specific Patent Right, in each case, in one or more countries (each a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Patent Challenge</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then Arrowhead will have the right to terminate this Agreement in its entirety upon </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> prior written notice to Novartis unless Novartis or its Sublicensee (or the applicable Affiliate of Novartis or of such Sublicensee) causes such Patent Challenge(s) to be withdrawn within the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">- period following receipt of written notice from Arrowhead (or in the case of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">ex-parte</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> proceedings, multi-party proceedings, or other Patent Challenges in which Novartis or its Sublicensee (or the applicable Affiliate of Novartis or of such Sublicensee) does not have the power to unilaterally cause the Patent Challenge(s) to be withdrawn, Novartis or its Sublicensee (or the applicable Affiliate of Novartis or of such Sublicensee) withdraws as a party from such Patent Challenge(s) and ceases actively assisting any other party to such Patent Challenge(s) within such </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">-day period). The foregoing sentence will not apply with respect to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">13.6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Effects of Termination</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">13.6.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Termination Generally</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Upon any termination of this Agreement in its entirety or in part by either Party as permitted pursuant to this Article 13 (Term and Termination), the following terms will apply with respect to this Agreement and the Terminated Products </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Termination of Licenses</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  As of the effective date of termination, all licenses granted to Novartis under Section 2.1 (License Grants to Novartis) with respect to the Terminated Products </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (other than any license(s) that have become fully paid-up, royalty-free, transferable (in accordance with Section&#160;16.1 (Assignment)), perpetual and irrevocable pursuant to Section 8.4 (Royalties)) will terminate, except that such licenses may continue solely to the extent necessary, and solely for the time periods specified in such Sections, for the prompt and diligent orderly transition or wind-down of ongoing Clinical Trials of the Terminated Products </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> under Section 13.6.1(c) (Ongoing Clinical Trials) or sale or other disposition of any inventory of the Terminated Products </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> as permitted under Section 13.6.1(j) (Sell-Off Right). Further, (a) if this Agreement is terminated in part with respect to a Program for the entire Territory, then the terms &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Licensed Products</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Licensed Compounds</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; will automatically be deemed to be amended to exclude, respectively, all Licensed Products and all Licensed Compounds that are the subject of such terminated Program, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">75</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Exclusivity</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  (i) If this Agreement is terminated in its entirety, then the Parties&#8217; rights and obligations under Section 2.10 (Exclusivity) will terminate in their entirety, (ii) if this Agreement is terminated in part with respect to a Program for the entire Territory, then the Parties&#8217; rights and obligations under Section 2.10 (Exclusivity) will terminate in the entire Territory with respect to the Target that is the subject of such Program and all Licensed Compounds and Licensed Products that are the subject of such Program </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#ff0000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Ongoing Clinical Studies</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  No later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after the effective date of termination, Arrowhead will submit to Novartis a written notice specifying with respect to all Clinical Trials of the Terminated Products </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> being conducted by or on behalf of Novartis or its Affiliates as of the effective date of termination, (i) such Clinical Trials that are to be terminated and (ii) such Clinical Trials that are to be transferred to Arrowhead or its designee. For any such Clinical Trials identified by Arrowhead in its written notice to be terminated, Novartis will wind-down such Clinical Trials, at Novartis&#8217; cost. For any such Clinical Trials identified by Arrowhead in its written notice to be transferred, Novartis will transfer control to Arrowhead or its designee of such Clinical Trials and will continue to conduct such Clinical Trials after the effective date of termination, at Arrowhead&#8217;s cost, for up to a maximum of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (or such longer period as either Party may reasonably request and is agreed by the other Party) to enable such transfer to be completed to Arrowhead or its designee without interruption of any such Clinical Trials. In no event will Novartis be required to enroll patients in any such Clinical Trial except as may be otherwise agreed by the Parties or as is reasonably necessary to protect patients.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Transfer of Regulatory Submissions and Regulatory Approvals</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Promptly following the effective date of termination, in accordance with and to the extent permissible under applicable Law, Novartis, on behalf of itself and its Affiliates and, subject to Section 13.6.1(g) (Sublicense Survival), its Sublicensees will assign to Arrowhead or Arrowhead&#8217;s designee possession and ownership of all Regulatory Submissions and Regulatory Approvals for the applicable Terminated Products </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Controlled by such Person as of the effective date of such termination. In the event that Novartis is unable to transfer and assign, or have transferred and assigned, to Arrowhead (or its designee) any such Regulatory Submissions or Regulatory Approvals, Novartis, on behalf of itself and its Affiliates and, subject to Section 13.6.1(g) (Sublicense Survival), its Sublicensees, hereby consents and grants to Arrowhead an exclusive (even as to Novartis and its Affiliates and Sublicensees), fully-paid, royalty-free, irrevocable, perpetual, license and right of reference under such Regulatory Submissions and Regulatory Approvals (with the right to sublicense and grant further rights of reference through multiple tiers) as necessary to Develop, Manufacture, perform Medical Affairs, Commercialize, and otherwise Exploit the applicable Terminated Products </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Continuation of Supply</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon Arrowhead&#8217;s request, if (i) as of the effective date of such termination, Novartis or its Affiliates or Sublicensees are Manufacturing finished product with respect to the Terminated Products for Development or Commercialization of such Terminated Products </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, and (ii) as of the effective date of such termination, neither Arrowhead nor any of its Affiliates or (sub)licensees has obtained all necessary Regulatory Approvals to Manufacture such Terminated Products </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> and procured or developed its own source of finished product supply with respect to such Terminated Products for Development and Commercialization thereof </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, then, at </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">76</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Arrowhead&#8217;s option and at Arrowhead&#8217;s cost and expense, Novartis or its or its Affiliates or Sublicensees will use Commercially Reasonable Efforts to supply to Arrowhead such finished product with respect to such Terminated Products for Development (if, as of the effective date of termination, Novartis or its Affiliates or Sublicensees are Manufacturing finished product with respect to the Terminated Products for Development) and Commercialization (if, as of the effective date of termination, Novartis or its Affiliates or Sublicensees are Manufacturing finished product with respect to the Terminated Products for Commercialization) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> for a period not to exceed </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> following the applicable effective date of termination at a price equal to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.02pt">Third Party Agreements</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  If Arrowhead so requests in writing, and to the extent permitted under Novartis&#8217; obligations to Third Parties on the effective date of termination, Novartis will assign to Arrowhead, and Arrowhead will assume, any Third Party agreements that solely relate to the Exploitation of the Terminated Products </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">to which Novartis is a party (excluding any master agreement that could relate to the Exploitation of compounds or products other than the Terminated Products, regardless of whether such master agreement does relate to any such Terminated Product at such time)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that (i) if the assignment of any such Third Party agreement requires the consent of any Third Party, then Novartis will not be obligated to assign such Third Party agreement unless and until such consent is obtained (it being understood that if so requested by Arrowhead in writing, Novartis will, at Arrowhead&#8217;s cost, use reasonable efforts to obtain any such consent as promptly as reasonably practicable under the circumstances), and (ii) for any Third Party agreement for which such consent is not obtained or for any excluded master agreement, Novartis will introduce Arrowhead to the counterparty of such agreement and provide such other reasonable assistance to Arrowhead to facilitate Arrowhead&#8217;s negotiation of its direct contract with such counterparty.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Sublicense Survival</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Arrowhead will, at the written election of any Sublicensee (solely to the extent such Sublicensee is not then in breach of the applicable sublicense agreement and solely where such sublicense agreement was entered into by Novartis with such Sublicensee in accordance with the terms of this Agreement) within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after termination of this Agreement (or such longer period mutually agreed between Arrowhead and such Sublicensee) grant a direct license to such terminated Sublicensee, which license will not be broader in license scope, territory, or duration than such sublicense agreement granted by Novartis to such Sublicensee and not more burdensome on Arrowhead in any material manner and no less favorable to Arrowhead than the financial terms of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Article 8</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (Payments).</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Return of Confidential Information</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Except in the case of Arrowhead for any Confidential Information included in the Reversion Technology that is the subject of a Reversion License,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">as soon as reasonably practicable after the effective date of termination, each Party, at its cost, will promptly return to the other Party (or as directed by such other Party destroy and certify to such other Party in writing as to such destruction) all of such other Party&#8217;s Confidential Information that relates to the applicable Terminated Products </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, and that was provided by or on behalf of such other Party hereunder that is in the possession or control of such Party (or any of its Affiliates, Sublicensees or Subcontractors), except that such Party will have the right to retain copies of intangible Confidential Information of such other Party for legal purposes in accordance with such Party&#8217;s internal compliance policies and may maintain records stored in accordance with automatic electronic archiving and back-up procedures until the ordinary course deletion thereof. Notwithstanding the </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">77</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">return or destruction of any Confidential Information, the Parties will continue to be bound by their confidentiality obligations under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">T</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">ermination of Payment Obligations</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Except for any payment obligations under Section 13.6.1(j) (Sell-Off Right), as of the effective date of termination, all payment obligations hereunder with respect to the applicable Terminated Products </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">will terminate, other than those that are accrued and unpaid as of the effective date of such termination. For clarity, notwithstanding any other provision of this Agreement, Novartis will remain liable to pay any Milestone Payments and Royalties to Arrowhead for any Milestone Event occurring, or deemed to have occurred in accordance with the terms of this Agreement, and Net Sales booked by Novartis or its Affiliates or its Sublicensees, in each case, on or before the later of (i) the effective date of such termination, or (ii) if applicable, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> following the effective date of such termination for any sales or dispositions of the applicable Terminated Product </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that occur during such </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">period under Section 13.6.1(j) (Sell-Off Right).</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.63pt">Sell-Off Right</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  If the effective date of termination is after the First Commercial Sale of a Terminated Product </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, then, to the extent permitted by applicable Law, Novartis and its Affiliates and Sublicensees will have the right to sell or otherwise dispose of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, any inventory of the Terminated Products </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> for a period of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">following the effective date of such termination in accordance with the terms and conditions of this Agreement&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that any revenue obtained from such disposal will be treated as Net Sales and the provisions of Article 8 (Payments) will apply to such Net Sales and, in the event that such sales result in the achievement of a Sales Milestone Event, the Sale Milestone Payment associated with such Sale Milestone Event will be owed and payable to Arrowhead. Within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after the end of such </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">period, Novartis will notify Arrowhead of any quantity of Terminated Products </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> remaining in Novartis&#8217;, its Affiliates&#8217; or, subject to Section 13.6.1(g) (Sublicense Survival), its Sublicensees&#8217; inventory, and Arrowhead will have the right to purchase, in its discretion, any such quantities of the Licensed Products from Novartis, its Affiliates or its Sublicensees at a supply price to be negotiated and agreed by the Parties.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">IP Files Transfer</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  With respect to a Terminated Product </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, (i) any Licensed Product-Specific Patent Rights Prosecuted and Maintained by Novartis under Section 12.3.1(a) (Novartis Right to Prosecute Patent Rights) or in respect of which Novartis has engaged in the enforcement thereof or defense under Section 12.4.2(a) (Novartis Right to Enforce), and (ii) any Arrowhead Platform Patent Rights for which Novartis has exercised its Prosecution and Maintenance step-in rights under Section 12.3.2(b) (Arrowhead Right to Prosecute Patent Rights) or enforcement or defense step-in rights under Section 12.4.3(b) (Arrowhead Right to Enforce), in each case at Arrowhead&#8217;s cost and expense, Novartis will transfer to Arrowhead or its designee copies of filings, applications, correspondence and other related records received or generated by Novartis in the course of exercising any Prosecution and Maintenance activities or enforcement or defense activities.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(l)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.63pt">Termination of Rights and Obligations</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as set forth in this Section 13.6 (Effects of Termination) and Section 13.8 (Survival&#59; Effect of Expiration or Termination), (i) as of the applicable effective date of any termination of this Agreement in its entirety all rights and obligations of the Parties under this Agreement will terminate, and (ii) as of the applicable effective date of any termination of this Agreement in part, all rights and obligations of the Parties </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">78</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">under this Agreement with respect to the terminated Program and its Terminated Products </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">will terminate.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">13.6.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Termination by Arrowhead for Cause or by Novartis Without Cause</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon termination of this Agreement in its entirety or in part by Arrowhead pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, in each case after the Technology Transfer Date, the following terms will apply with respect to this Agreement and the Terminated Products </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Novartis, on behalf of itself and its Affiliates, hereby grants and agrees to grant (without any further subsequent action required on the part of Arrowhead) to Arrowhead and its Affiliates, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> license (terminable solely for Arrowhead&#8217;s violation of the scope of such license) under the Novartis Licensed Technology existing as of the effective date of termination hereof </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, in each case, to Develop, Manufacture, perform Medical Affairs, Commercialize, and otherwise Exploit the applicable Terminated Products in the Field </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that are or have been the subject of Development, Manufacture or Commercialization hereunder as of the effective date of termination (in the form such Terminated Products exist as of the effective date of termination) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(such Novartis Licensed Technology, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Reversion Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and such license, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Reversion License</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Arrowhead will have the right (but not the obligation) to assume, at its cost and expense, (i) the sole responsibility for the Prosecution and Maintenance of the Novartis Arising LC&#47;LP Patent Rights and Joint Arising Patent Rights </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> Covering solely the Terminated Products that are included within the Reversion Technology under a Reversion License, and (ii) the sole right to take any action to enforce any such Novartis Arising LC&#47;LP Patent Rights and Joint Arising Patent Rights in connection with any Competitive Infringement of the Terminated Products </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Promptly following the effective date of termination, Novartis will transfer to Arrowhead or its designee copies of filings, applications, correspondence and other related records received or generated by Novartis in the course of exercising any Prosecution and Maintenance activities or enforcement or defense activities with respect to any Novartis Arising LC&#47;LP Patent Rights and Joint Arising Patent Rights </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that Cover solely the Terminated Products included within the Reversion Technology under a Reversion License, at Arrowhead&#8217;s cost and expense.</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Novartis will promptly following the effective date of termination provide to Arrowhead all Novartis Arising Know-How that is included in the Reversion Technology for the applicable Terminated Products in the Field </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that are or have been the subject of Development, Manufacture or Commercialization hereunder as of the effective date of termination (in the form such Terminated Products exist as of the effective date of termination).</font></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">If, as of the effective date of termination, (i) Novartis or any of its Affiliates owns any Trademarks that are used exclusively for the applicable Terminated Products </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> and (ii) such Trademarks have been approved by the Regulatory Authority in a country </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">for use with such Terminated Products (such Trademarks, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Reversion Trademarks</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then, at Arrowhead&#8217;s written request, Novartis, on behalf of itself and its Affiliates&#59; (A) will assign and transfer to Arrowhead, or (B) solely in such jurisdictions where such </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">79</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:118.8pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">assignment is not permitted by applicable Law or if the assignment in the foregoing clause (A) is not effective, hereby grants (without any further subsequent action required on the part of Arrowhead, but exercisable solely upon such effective date of termination) to Arrowhead an </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">license of, in each case ((A) and (B)), all of Novartis&#8217; and its Affiliates&#8217; rights, title, and interests in and to such Reversion Trademarks for the applicable country </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, pursuant to an agreement that the Parties will negotiate and enter into after such effective date of termination, which agreement will contain, to the extent applicable, indemnification obligations customary of such agreements applying to Arrowhead&#8217;s use of such Reversion Trademarks following such assignment or license, as applicable. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">13.7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">13.8.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Survival&#59; Effect of Expiration or Termination</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  In addition to the termination consequences set forth in Section 13.6 (Effects of Termination) (and any Sections referenced therein), the following provisions will survive the expiration or termination of this Agreement in its entirety for any reason&#58;  (a) Article 1 (Definitions) (in each case, solely with respect to defined terms that are used in surviving provisions)&#59; (b) Section 2.9.2(b)(iii) (Platform Third Party Rights), Section 3.2.2(c) (Transition of Research &#38; Development Activities), Section 5.1 (Arrowhead Manufacturing Activities under Development Plans), Section 5.2 (Remaining Inventory at Technology Transfer Date), Section 5.4 (Manufacturing Technology Transfer), </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, Section 8.2 (CT Substitution Fee), Section 8.3 (Milestone Payments), Section 8.4 (Royalties), Section 8.6 (Other Amounts Payable), Section 8.7 (Payment Terms), and Section 12.4.7 (Allocation of Proceeds), in each case, solely with respect to any payment obligations that accrued prior to such expiration or termination of this Agreement but have not been paid&#59; (c) Section 3.9 (Scientific Records) for a period of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> following expiration or termination or such longer period as may be required by applicable Law&#59; (d) Section 9.7 (Use of Name and Logo), Section 10.5 (Warranty Disclaimer), Sections 11.1 (Indemnification by Arrowhead) through and including Section 11.4 (Limitation of Liability), Section 12.2 (Inventions), Section 12.11 (Common Interest), and this Section 13.7 (Survival&#59; Effect of Expiration or Termination), Article 15 (Dispute Resolution), and Article 16 (Miscellaneous)&#59; (e) Section 9.1 (Confidential Information) through and including Section 9.6 (Relationship to Confidentiality Agreement), in each case, solely for the term specified therein&#59; (f) Section 11.5 (Insurance) for </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> following expiration or termination&#59; (g) Section 12.3 (Prosecution and Maintenance of Patent Rights) solely with respect to Joint Arising Patent Rights (other than those Joint Arising Patent Rights that Arrowhead elects to assume control of pursuant to Section 13.6.2(c) (Termination by Arrowhead for Cause or by Novartis Without Cause))&#59; (i) the last sentence of Section 13.1 (Term) solely in the case of expiration and not termination of this Agreement&#59; and (j) any other provisions that, as apparent from their nature and context, are intended to continue or to remain (such as for interpretation purposes). Notwithstanding any provision to the contrary set forth in this Agreement, expiration or termination of this Agreement for any reason will not relieve the Parties of any liability or obligation that accrued hereunder prior to the effective date of such termination or expiration, nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity, with respect to any breach of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">14.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">EFFECTIVENESS</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">14.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Effective Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Except for the Parties&#8217; obligations under Section </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, Article 9 (Confidentiality and Publication), Article 10 (Representations, Warranties, and Covenants), and this Article 14 (Effectiveness), which will be effective as of the Execution Date, this Agreement will not become effective until the first Business Day after the Antitrust Clearance Date (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Effective Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">that the Effective Date will not occur if either Party exercises its termination right under Section 14.3 (Outside Date) prior to the Antitrust Clearance Date. On the Effective Date, Arrowhead will provide to Novartis an updated version of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 10.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> (Exceptions to the Representations and Warranties by Arrowhead) to the extent required as a result of Arrowhead </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">80</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="padding-left:36pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">making anew as of the Effective Date the representations and warranties of Section 10.2 (Additional Representations and Warranties by Arrowhead).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">14.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Filing</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">14.2.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">Each Party will, within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> following the Execution Date, file the notification and report forms required under all Antitrust Laws. The Parties will use reasonable best efforts to cooperate with one another to the extent necessary in the preparation and execution of all such documents that are required to be filed pursuant to the Antitrust Laws. Each Party will be responsible for its own costs and expenses associated with any such filing pursuant to the Antitrust Laws. The Parties will each use reasonable best efforts to ensure that any applicable waiting period under the Antitrust Laws expires or is terminated as soon as practicable and to obtain any necessary approvals or consents under any applicable Antitrust Laws, at the earliest possible date after the date of filing, and in any event prior to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding any provision to the contrary set forth in this Agreement, nothing in this Agreement (including this Section 14.2 (Filing)) will require either Party or any of its Affiliates to (a) disclose to the other Party or any of its Affiliates any information that is subject to obligations of confidentiality or non-use owed to Third Parties (nor will either Party be required to conduct joint meetings with any Governmental Authority in which such information is intended to be disclosed) in connection with any Antitrust Filing, (b) commit to any consent decree or similar undertaking, or any divestiture, license (in whole or in part), or any arrangement to hold separate (or any similar arrangement) with respect to any of its products or assets, or (c) litigate. If a Party receives a request for information or documentary material from any Governmental Authority with respect to this Agreement or the transactions contemplated hereby, including a Second Request for Information under the HSR Act, then such party will in good faith make, or cause to be made, as soon as reasonably practicable and after consultation with the other party, a response that is, at a minimum, in substantial compliance with such request.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">14.2.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">In furtherance of the foregoing, each Party will consult and cooperate with the other Party, including&#58; (a)&#160;promptly notify the other Party of, and if in writing, furnish the other Party with copies of, any communications from or with any Governmental Authority with respect to this Agreement&#59; (b)&#160;permit the other Party to review and discuss in advance, and consider in good faith the view of the other in connection with, any proposed substantive written or oral communication with any Governmental Authority&#59; (c)&#160;not participate in any substantive meeting or have any substantive communication with any Governmental Authority unless it has given the other Party a reasonable opportunity to consult with it in advance and, to the extent permitted by such Governmental Authority, gives the other Party the opportunity to attend&#59; (d)&#160;furnish the other Party&#8217;s outside legal counsel with copies of all filings and communications between it and any such Governmental Authority with respect to this Agreement&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, that such material may be redacted as necessary to (i)&#160;comply with contractual arrangements, (ii)&#160;address legal privilege concerns, and (iii)&#160;comply with Law&#59; and (e)&#160;furnish the other Party&#8217;s outside legal counsel with such necessary information and reasonable assistance as the other Party&#8217;s outside legal counsel may reasonably request in connection with its preparation of submissions of information to any such Governmental Authority. The Parties may, as they deem advisable and necessary, designate any competitively sensitive materials provided to the other Party under this Section 14.2 (Filing) as &#8220;outside counsel only.&#8221; Such materials and the information contained therein will be given only to outside counsel and outside economic consultants of the recipient and will not be disclosed by such outside counsel or outside economic consultants to employees, officers, or directors of the recipient without the advance written consent of the Party providing such materials. Notwithstanding anything to the contrary in this Section 14.2 (Filing), materials provided to the other Party or its outside legal counsel may be redacted to remove references concerning the valuation of the Licensed Compounds or Licensed Products.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">81</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">14.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Outside Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement will terminate at the election of either Party, immediately upon written notice by such Party to the other Party, in the event that the Antitrust Clearance Date has not occurred on or prior to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">and the Parties have not agreed in writing to extend the Antitrust Clearance Date. In the event of such termination, this Agreement will be of no further force and effect.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">15.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">DISPUTE RESOLUTION</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">15.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Exclusive Dispute Resolution Mechanism</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The Parties agree that, except as expressly set forth in Section 7.4 (Resolution of Committee Disputes), the procedures set forth in this Article</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">15 (Dispute Resolution) will be the exclusive mechanism for resolving any dispute, controversy, or claim between the Parties arising out of or relating to this Agreement (whether based on contract, tort or otherwise) (each, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Dispute</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">,&#8221; and collectively, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Disputes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that is not resolved through good faith negotiation between the Parties pursuant to Section 15.2 (Resolution by Executive Officers). For the avoidance of doubt, this Article 15 (Dispute Resolution) will not apply with respect to any decision under the purview of the JSC, for which final decision-making authority is set forth in Section 7.4 (Resolution of Committee Disputes).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">15.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Resolution by Executive Officers</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as expressly set forth in Section 7.4 (Resolution of Committee Disputes) or as provided in Section 15.5 (Preliminary Injunctions), in the event of any Dispute regarding the construction or interpretation of this Agreement, or any right, obligation, or liability of either Party hereunder, the Parties will first attempt in good faith to resolve such Dispute by negotiation and consultation between themselves. In the event that such Dispute is not resolved on an informal basis within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, either Party may, by written notice to the other Party, refer the Dispute to the Executive Officers of the Parties for attempted resolution by good faith negotiation within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">after such notice is received. If the Executive Officers cannot resolve the Dispute within such </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">-day period, then (a) if the Dispute has been expressly stated in this Agreement to be resolved pursuant to expedited arbitration, it will be resolved in accordance with Section 15.3 (Expedited Arbitration), or (b) with respect to any other Dispute, it will be resolved in accordance with Section 15.4 (Arbitration), </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, that any Dispute with respect to (i) the scope, construction, validity, or enforceability of any Patent Right or Trademark relating to a Licensed Product will be resolved by litigation in accordance with Section 15.6 (Patent and Trademark Disputes) or (ii) any antitrust, anti-monopoly, or competition law or regulation, whether or not statutory may be submitted in any court of competent jurisdiction over such Dispute.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">15.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Expedited Arbitration</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Any Dispute remaining unresolved after escalation to the Parties&#8217; respective Executive Officers in accordance with Section 15.2 (Resolution by Executive Officers) and expressly stated in this Agreement to be resolved pursuant to expedited arbitration will be resolved pursuant to the following procedures of this Section 15.3 (Expedited Arbitration).</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">15.3.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">For purposes of arbitration under this Section 15.3 (Expedited Arbitration), the arbitration will be administered by the ICC pursuant to its rules then in effect at the time of submission for such proceedings (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">ICC Rules</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), as modified by this Section 15.3 (Expedited Arbitration). The arbitration will be governed by the Laws of the State of New York, without giving effect to any choice of law principles that would require the application of the laws of a different state or jurisdiction. The arbitration will be heard and determined by a single arbitrator appointed by agreement of the Parties or, failing such mutual agreement, by the ICC, and who will be a single independent, conflict-free arbitrator having the requisite pharmaceutical and biotechnology industry experience (such arbitrator, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Expedited</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Arbitrator</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Parties may select a different Expedited Arbitrator for each Dispute depending on the nature of the issues presented and desired expertise. The arbitration will be conducted as a &#8220;baseball&#8221; form of binding arbitration conducted by the Expedited Arbitrator.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">15.3.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">No later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after the Expedited Arbitrator&#8217;s appointment, each Party will submit to both the Expedited Arbitrator and the other Party a detailed written proposal setting forth its proposed resolution of such Dispute. The Parties will also provide to the Expedited Arbitrator a copy of this Agreement, as may have been amended at such time in accordance with Section 16.4 (Entire Agreement&#59; Amendments).</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">82</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">15.3.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">No later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after the delivery of the Parties&#8217; detailed written proposals to the Expedited Arbitrator, each Party will submit to both the Expedited Arbitrator and the other Party a legal brief (and any exhibits) explaining and supporting the Party&#8217;s detailed written proposal, which legal brief will be no more than 30 pages.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">15.3.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">There will be no discovery and there will be no hearing, although such arbitration proceeding will be deemed to have its seat in New York City, New York, and all arbitration proceedings will be conducted in the English language.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">15.3.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">No later than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> after the submission of the Parties&#8217; legal briefs, the Expedited Arbitrator will select one of the two detailed written proposals (without modification) provided by the Parties that the Expedited Arbitrator believes is most consistent with the intention underlying the agreed principles set forth in this Agreement. The decision of the Expedited Arbitrator will be final and unappealable. The detailed written proposal selected by the Expedited Arbitrator will automatically be binding on the Parties.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">15.3.6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Expedited Arbitrator will select one of the two detailed written proposals and may not combine elements of both detailed written proposals or make any other modifications to the selected detailed written proposal.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">15.3.7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.55pt">Each Party will bear its own attorneys&#8217; fees, costs, and disbursements arising out of the arbitration, and will pay an equal share of the fees and costs of the Expedited Arbitrator.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">15.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Arbitration</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Except for Disputes expressly specified in this Agreement to be resolved pursuant to Section 15.3 (Expedited Arbitration) or Section 15.6 (Patent and Trademark Disputes), unless otherwise prohibited by applicable Law, any unresolved Dispute that was subject to Section 15.2 (Resolution by Executive Officers) will be resolved solely and exclusively by final and binding arbitration conducted as set forth in this Section 15.4 (Arbitration). Whenever a Party will decide to institute arbitration proceedings, it will give written notice to that effect to the other Party. The arbitration will be conducted by a panel of three arbitrators in accordance with the ICC Rules of the ICC. The claimant will nominate an arbitrator in its request for arbitration. The respondent will nominate an arbitrator within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> of the receipt of the request for arbitration. The two arbitrators nominated by the Parties will together, within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> of the appointment of the later-nominated arbitrator, select a third arbitrator as the chairperson of the arbitration panel. If any of the three arbitrators are not nominated within the time prescribed above, then the ICC will appoint the arbitrator(s) in accordance with the ICC Rules. The arbitration will be governed by the Laws of the State of New York, without giving effect to any choice of law principles that would require the application of the laws of a different state or jurisdiction. The seat of the arbitration will be New York City, New York, and all arbitration proceedings will be conducted in the English language. The arbitrators will render their opinion within </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> of the close of the proceedings. No arbitrator (nor the panel of arbitrators) will have the power to award punitive damages under this Agreement and such award is expressly prohibited. Decisions of the panel of arbitrators will be final and binding on the Parties. Judgment on the award so rendered may be entered in any court of competent jurisdiction.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">15.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Equitable Relief</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The Parties agree that monetary damages may not be a sufficient remedy for any breach of this Agreement. Notwithstanding any provision to the contrary set forth in this Agreement, in the event of an actual or threatened breach of a Party&#8217;s obligations under this Agreement, a Party may seek a temporary restraining order, preliminary injunction, or other equitable relief from any court of competent jurisdiction in order to prevent immediate and irreparable injury, loss, or damage on a provisional basis.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">15.6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Patent and Trademark Disputes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any provision to the contrary set forth in this Agreement, any and all issues regarding the scope, construction, validity, and enforceability of any Patent Rights or Trademark relating to a Licensed Compound or Licensed Product that is the subject of this Agreement will be determined in a court or other tribunal, as the case may be, of </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">83</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="padding-left:36pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">competent jurisdiction under the applicable patent or trademark laws of the country in which such Patent Rights or Trademark rights were granted or arose.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">15.7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Payment Tolling</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  During the pendency of any Dispute resolution proceeding between the Parties under this Article 15 (Dispute Resolution) regarding the obligation to make any payment under this Agreement from one Party to the other Party (in whole or in part), the obligation to make such payment will be tolled until the final outcome of such Dispute has been established.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">15.8.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Confidentiality</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Any and all activities conducted under this Article 15 (Dispute Resolution), including any and all proceedings and decisions hereunder, will be deemed Confidential Information of each of the Parties, and will be subject to Article 9 (Confidentiality and Publication) to the extent applicable in accordance with Law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">16.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">MISCELLANEOUS</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">16.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Assignment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">16.1.1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">General</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other Party, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">except</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that a Party may make such an assignment without the other Party&#8217;s consent to (a) an Affiliate pursuant to Section 16.13 (Performance by Affiliates), </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that such assigning Party will remain responsible for such Affiliate&#8217;s conduct and compliance with its obligations under this Agreement, or (b) a Third Party as a successor to all or substantially all of the business of such Party to which this Agreement relates, whether in a merger, sale of stock, acquisition, sale of assets or similar transaction or series of related transactions, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that such transaction is not primarily for the benefit of such Party&#8217;s creditors. Any successor or assignee of any right or obligation permitted hereunder will, in writing to the other Party, expressly assume performance of such right or obligation. Any permitted assignment will be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section 16.1.1 (General) will be null, void, and of no legal effect.</font></div><div style="margin-bottom:12pt;padding-left:82.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">16.1.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.55pt">Securitization Transaction</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any provision to the contrary in Section 16.1.1 (General) or elsewhere in this Agreement, Arrowhead may assign to a Third Party its right to receive the Milestone Payments and the Royalties (such assignment, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Securitization Transaction</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). In connection with a contemplated Securitization Transaction and after the closing of any such Securitization Transaction, Arrowhead may disclose to such Third Party the royalty reports contemplated under Section 8.7.2 (Reports and Royalty Payments), without the prior written consent of Novartis, to the extent reasonably necessary to enable such Third Party to evaluate the Securitization Transaction opportunity (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that such Third Party is under obligations of confidentiality and non-use with respect to Confidential Information included in such reports and plans that are no less protective or restrictive than the terms of Article 9 (Confidentiality and Publication) (but of duration customary in confidentiality agreements entered into for a similar purpose)), and to enable such Third Party to exercise its rights with respect to such Securitization Transaction, as applicable. As part of any consummated Securitization Transaction, subject to the terms of this Section 16.1.2 (Securitization Transaction), Arrowhead may assign, without the prior written consent of Novartis, its right to receive the royalty reports and to conduct audits under, respectively, Section 8.7.2 (Reports and Royalty Payments) and Section 8.7.3 (Records and Audits) to the counterparty in such Securitization Transaction, and to allow such counterparty to exercise its rights under such Sections. Arrowhead agrees to provide written notice to Novartis of any process run by or on behalf of Arrowhead involving a Securitization Transaction and to negotiate in good faith with Novartis should Novartis elect to submit a bid for such Securitization Transaction, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> that Arrowhead will in no way be precluded from soliciting other bids and conducting contemporaneous negotiations with other Third Party bidders for such Securitization Transaction.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">84</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">16.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Section 365(n) of the Bankruptcy Code</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  All rights and licenses granted under or pursuant to this Agreement by a Party to the other are and will otherwise be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, a license of a right to &#8220;intellectual property&#8221; as defined under Section 101 of the Bankruptcy Code. The Parties acknowledge and agree that the Parties and their respective Sublicensees, as licensees of such rights under this Agreement, will retain and may fully exercise all of their rights and elections under the Bankruptcy Code and any foreign counterpart thereto. The Parties further agree that, upon commencement of a bankruptcy proceeding by or against the Bankrupt Party under the Bankruptcy Code, the other Party (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Non-Bankrupt Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) will be entitled to a complete duplicate of, or complete access to (as the Non-Bankrupt Party deems appropriate), all such intellectual property and all embodiments of such intellectual property. Such intellectual property and all embodiments of such intellectual property will be promptly delivered to the Non-Bankrupt Party (a) upon any such commencement of a bankruptcy proceeding and upon written request by the Non-Bankrupt Party, unless the Bankrupt Party elects to continue to perform all of its obligations under this Agreement, or (b) if not delivered under the foregoing clause (a), upon the rejection of this Agreement by or on behalf of the Bankrupt Party and upon written request by the Non-Bankrupt Party. The Bankrupt Party (in any capacity, including debtor-in-possession) and its successors and assigns (including any trustee) agree not to interfere with the exercise by the Non-Bankrupt Party or its Affiliates or Sublicensees of its or their rights and licenses to such intellectual property and such embodiments of intellectual property in accordance with this Agreement, and agree to assist the Non-Bankrupt Party and its Affiliates and Sublicensees in obtaining such intellectual property and such embodiments of intellectual property in the possession or control of Third Parties as are reasonably necessary or desirable for the Non-Bankrupt Party to exercise such rights and licenses in accordance with this Agreement. The foregoing provisions are without prejudice to any rights the Non-Bankrupt Party may have arising under the Bankruptcy Code or other applicable Laws.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">16.3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Governing Law</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement was prepared in the English language, which language will govern the interpretation of, and any Dispute regarding, the terms of this Agreement. This Agreement and all Disputes arising out of or related to this Agreement or any breach hereof will be governed by and construed under the laws of the State of New York, without giving effect to any choice of law principles that would require the application of the laws of a different state or jurisdiction. Notwithstanding any other provision in this Agreement, the Parties expressly reject the application to this Agreement, all transactions and activities contemplated hereby, and all Disputes of (a) the United Nations Convention on Contracts for the International Sale Of Goods, and (b) the 1974 Convention on the Limitation Period in the International Sale of Goods, as amended by that certain Protocol, concluded at Vienna, Austria on April 11, 1980.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">16.4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Entire Agreement&#59; Amendments</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement, including the Exhibits and Schedules hereto, set forth the complete, final, and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions, and understandings between the Parties hereto with respect to the subject matter hereof and supersedes, as of the Effective Date, all prior and contemporaneous agreements and understandings between the Parties with respect to the subject matter hereof. There are no covenants, promises, agreements, warranties, representations, conditions, or understandings, either oral or written, between the Parties other than as are set forth herein and therein. No subsequent alteration, amendment, change, or addition to this Agreement will be binding upon the Parties unless reduced to a writing explicitly stating the Parties&#8217; intent to amend this Agreement that is signed by an authorized officer of each Party.  If there is any inconsistency between the body of this Agreement and either any Exhibits or Schedules to this Agreement or any subsequent agreements ancillary to this Agreement, then, unless otherwise express stated to the contrary in such Exhibit, Schedule or ancillary agreement, the terms contained in this Agreement will control.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">16.5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Severability</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  If any one or more of the provisions of this Agreement is held to be invalid, illegal or unenforceable by any court or tribunal of competent jurisdiction from which no appeal can be or is taken, then the provision will be considered severed from this Agreement and will not serve to invalidate any remaining provisions hereof. The Parties will make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">85</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">16.6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Headings</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  The captions to the Sections hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading the several Sections hereof.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">16.7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Interpretation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Except where the context otherwise requires, wherever used, the singular will include the plural, the plural will include the singular, and the use of any gender will be applicable to all genders. Whenever this Agreement refers to a number of days without using a term otherwise defined herein, such number refers to calendar days. The captions of this Agreement are for the convenience of reference only and in no way define, describe, extend, or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The terms &#8220;including,&#8221; &#8220;include,&#8221; &#8220;includes,&#8221; or &#8220;for example&#8221; will not limit the generality of any description preceding such term and as used herein will have the same meaning as &#8220;including, but not limited to&#8221; or &#8220;including, without limitation.&#8221; The word &#8220;will&#8221; will be construed to have the same meaning and effect as the word &#8220;shall.&#8221; References to any specific law, rule or regulation, or article, section or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof. The term &#8220;or&#8221; will be interpreted in the inclusive sense commonly associated with the term &#8220;and&#47;or.&#8221; Any reference herein to any person or entity will be construed to include the person&#8217;s or entity&#8217;s successors and assigns. The words &#8220;herein,&#8221; &#8220;hereof,&#8221; and &#8220;hereunder&#8221;, and words of similar import, will be construed to refer to this Agreement in its entirety and not any particular provision. The word &#8220;notice&#8221; means notice in writing (whether or not specifically stated) and will include notices, consents, approvals, and other written communications contemplated under this Agreement. References to &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Section</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">Sections</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; are references to the numbered sections of this Agreement, unless expressly stated otherwise. All dollars are U.S. Dollars. Unless the context otherwise requires, countries will include territories. The language of this Agreement will be deemed to be the language chosen by the Parties and no rule of strict construction will be applied against either Party hereto. Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which drafted such terms and provisions.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">16.8.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Waiver and Non-Exclusion of Remedies</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver will be effective unless set forth in a written instrument duly executed by or on behalf of such Party waiving such term or condition. The waiver by either Party of any right hereunder or of the failure to perform or of a breach by the other Party will not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by Law or otherwise available except as expressly set forth herein.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">16.9.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Notices</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  All notices and other communications given or made pursuant hereto will be in writing and will be deemed to have been duly given on the date delivered, if delivered personally, or on the next Business Day after being sent by reputable overnight courier (with delivery tracking provided, signature required, and delivery prepaid), in each case, to the Parties at the following addresses, or on the date sent (and confirmed by confirmatory return email and by a hard copy delivered by reputable overnight courier (with delivery tracking provided, signature required, and delivery prepaid)) to the email address and address specified below (or at such other address, or email address for a Party as will be specified by notice given in accordance with this Section 16.9 (Notices)).</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">86</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.070%"><tr><td style="width:1.0%"></td><td style="width:26.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">If to Arrowhead, to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Arrowhead Pharmaceuticals, Inc.</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">177 E. Colorado Blvd., Suite 700</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Pasadena, CA 91105</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58;  General Counsel</font></div><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">With a copy (which will not constitute notice) to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Gibson Dunn &#38; Crutcher LLP</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">One Embarcadero Center Suite 2600</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">San Francisco, CA 94111-3715</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58;  Karen A. Spindler</font></div><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">If to Novartis, to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Novartis Pharma AG<br>Lichtstrasse 35</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">CH-4056 Basel, Switzerland </font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; &#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">With a copy (which will not constitute notice) to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Novartis Pharma AG </font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Lichtstrasse 35</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">CH-4056 Basel, Switzerland </font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; &#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">With a copy (which will not constitute notice) to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Morrison &#38; Foerster LLP</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">200 Clarendon Street, 21st Floor</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Boston, MA 02116</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Matt Karlyn</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">16.10.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Force Majeure</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party will be excused from the performance of its obligations under this Agreement to the extent that such performance is prevented by Force Majeure and such nonperforming Party promptly provides written notice of the prevention to the other Party. The affected Party also will provide a good faith estimate of the period for which its failure or delay in performance under this Agreement is expected to continue based on currently available information and will undertake reasonable efforts necessary to mitigate and overcome such Force Majeure event and resume normal performance of its obligations hereunder as soon a reasonably practicable under the circumstances. If the Force Majeure event continues, the affected Party will update such notice to the other Party on a weekly basis, or more frequently if requested by the other Party, to provide updated summaries of its mitigation efforts and its estimates of when normal performance under the Agreement will be able to resume. Without limiting the affected Party&#8217;s foregoing obligations, such excuse will be continued so long as the condition constituting Force Majeure continues and such affected Party is exercising reasonable efforts to remedy the Force Majeure. If a Force Majeure persists for more than </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">, then the Parties will discuss in good faith a modification of the Parties&#8217; obligations under this Agreement in order to mitigate the delays caused by such Force Majeure.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">16.11.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Relationship of the Parties</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  It is expressly agreed that Arrowhead, on the one hand, and Novartis, on the other hand, will be independent contractors and that the relationship between the two Parties will not constitute a partnership, joint venture, or agency, including for tax purposes. Neither Arrowhead nor Novartis will have the authority to make any statements, representations, or commitments of any kind, or to take any action that will be binding on the other, without the prior written consent of the other Party to do so. All Persons employed by a Party will be employees of that Party and not of the other Party and all expenses and obligations incurred by reason of such employment will be for the account and expense of such Party.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">87</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93; &#61; CERTAIN PORTIONS OF THIS DOCUMENT, MARKED WITH ASTERISKS, HAVE BEEN REDACTED BECAUSE THE IDENTIFIED PORTIONS ARE (I) NOT MATERIAL AND (II) TREATED AS PRIVATE OR CONFIDENTIAL BY THE REGISTRANT</font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">16.12.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Further Assurances</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party will duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary or as the other Party may reasonably request, and at such other Party&#8217;s cost and expense, in connection with this Agreement or to carry out more effectively the provisions and purposes hereof.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">16.13.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Performance by Affiliates</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party may discharge any obligations and exercise any rights hereunder through delegation of its obligations or rights to any of its Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party&#8217;s obligations under this Agreement and will cause its Affiliates to comply with the provisions of this Agreement in connection with such performance.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">16.14.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Binding Effect&#59; No Third Party Beneficiaries</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  As of the Effective Date, this Agreement will be binding upon and inure to the benefit of the Parties and their respective permitted successors and permitted assigns. Except as expressly set forth in this Agreement, no Person other than the Parties and their respective Affiliates and permitted assignees hereunder will be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">16.15.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Expenses</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as otherwise provided herein, all fees, costs, and expenses (including any legal, accounting and banking fees) incurred in connection with the preparation, negotiation, execution and delivery of this Agreement and to consummate the transactions contemplated hereby will be paid by the Party hereto incurring such fees, costs, and expenses.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">16.16.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:8.5pt">Counterparts</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. This Agreement may be executed by facsimile, .pdf, or other electronically transmitted signatures and such signatures will be deemed to bind each Party as if they were the original signatures.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#91;THE REMAINDER OF THIS PAGE HAS BEEN LEFT INTENTIONALLY BLANK&#93;</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">88</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><div id="i60193035b9004bf98ef76cef2b3574e3_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Parties have caused this Exclusive License and Collaboration Agreement to be executed by their duly authorized representatives as of the Execution Date.</font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">ARROWHEAD PHARMACEUTICALS, INC.</font></div><div style="margin-bottom:12pt;padding-right:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">BY&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-right:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">NAME&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-right:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">TITLE&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">89</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.134%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Parties have caused this Exclusive License and Collaboration Agreement to be executed by their duly authorized representatives as of the Execution Date.</font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">NOVARTIS PHARMA AG</font></div><div style="margin-bottom:12pt;padding-right:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">BY&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-right:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">NAME&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Guillaume Vignon</font></div><div style="margin-bottom:12pt;padding-right:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">TITLE&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Global Head BD&#38;L Transactions</font></div><div style="margin-bottom:12pt;padding-right:252pt;text-align:justify"><font><br></font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">NOVARTIS PHARMA AG</font></div><div style="margin-bottom:12pt;padding-right:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">BY&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-right:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">NAME&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Ian James Hiscock</font></div><div style="margin-bottom:12pt;padding-right:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">TITLE&#58;  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Global Head IP Transactions</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">90</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.134%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>subsidiarylisting-ex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i59646ee200da49bfb1c8c774593452ec_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Arrowhead Subsidiaries</font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:134%">Subsidiary</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:134%">Jurisdiction</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:134%">Arrowhead Madison Inc.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:134%">Delaware</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:134%">Arrowhead Australia Pty Ltd</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:134%">Australia</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:134%">Arrowhead Pharmaceuticals NZ Limited</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:134%">New Zealand</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:134%">Arrowhead Pharmaceuticals Ireland Limited</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:134%">Ireland &#8211; EU</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:134%">Visirna Therapeutics, Inc.</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:134%">Cayman Islands</font></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>arwr-20250930xex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i573dd171e7254cf1982047c109012d58_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">Exhibit 23.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the registration statements (Nos. 333-164039 and 333-161344 ) on Form S-1 and in registration statements (Nos. 333-235324, 333-268665, 333-228598, 333-214315, 333-214311, 333-213484, 333-202737, 333-191922, 333-188718, 333-178532, 333-178073, 333-178072, 333-144109, 333-137329, 333-132310, 333-124065, and 333-113065) on Form S-3 and in registration statements (Nos. 333-277477, 333-270779, 333-261847, 333-256255, 333-238616, 333-230621, 333-223836, 333-210117, 333-202741, 333-198920, 333-194596, 333-190970, 333-180692, 333-170252, 333-136225, 333-124066, and 333-120072) on Form S-8 of our reports dated November 25, 2025, with respect to the consolidated financial statements of Arrowhead Pharmaceuticals Inc. and the effectiveness of internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">KPMG LLP</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">San Diego, California</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">November 25, 2025</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>arrowheadengagementlette.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>arrowheadengagementlette</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- arrowheadengagementlette001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="arrowheadengagementlette001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- arrowheadengagementlette002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="arrowheadengagementlette002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- arrowheadengagementlette003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="arrowheadengagementlette003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- arrowheadengagementlette004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="arrowheadengagementlette004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>arwr-20250930xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i0d970a235d614f9ebd03421181d9cd39_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a) OR RULE 15d-14(a) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, Inc., certify that&#58; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K of Arrowhead Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.  </font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;25, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Christopher Anzalone</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Christopher Anzalone</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Chief Executive Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>arwr-20250930xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i4a4d8e103fca403287f52be237a886e1_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a) OR RULE 15d-14(a) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel Apel, Chief Financial Officer of Arrowhead Pharmaceuticals, Inc., certify that&#58; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K of Arrowhead Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;25, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Apel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Daniel Apel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>arwr-20250930xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ic5efbdbcd6d24d5e8e30b3c9eaf69e1b_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(b) OR RULE 15d-14(b) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AND 18 U.S.C. SECTION 1350 </font></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221;), certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that (i) the Annual Report on Form 10-K of the Company for the year ended September 30, 2025, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) the information contained in such Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of the Company. </font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;25, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47;Christopher Anzalone</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Christopher Anzalone</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Chief Executive Officer</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of these written statements required by 18 U.S.C. Section 1350 has been provided to Arrowhead Pharmaceuticals, Inc. and will be retained by Arrowhead Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>arwr-20250930xex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="id121f11738e442c49034cdaf31cef0ff_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(b) OR RULE 15d-14(b) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AND 18 U.S.C. SECTION 1350 </font></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel Apel, Chief Financial Officer of Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221;), certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that (i) the Annual Report on Form 10-K of the Company for the year ended September 30, 2025, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) the information contained in such Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of the Company. </font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;25, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Apel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Daniel Apel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of these written statements required by 18 U.S.C. Section 1350 has been provided to Arrowhead Pharmaceuticals, Inc. and will be retained by Arrowhead Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>arwr-20250930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:67e6a79e-2429-4a7b-924a-105395255933,g:bc385ee3-281d-4402-b0c2-11a4f6b4f5dd-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arwr="http://www.arrowheadresearch.com/20250930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arrowheadresearch.com/20250930">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20250930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20250930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20250930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20250930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.arrowheadresearch.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.arrowheadresearch.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss">
        <link:definition>9952153 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>9952154 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952155 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPolicies" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies">
        <link:definition>9952156 - Disclosure - Organization and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements">
        <link:definition>9952157 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccounts" roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccounts">
        <link:definition>9952158 - Disclosure - Balance Sheet Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.arrowheadresearch.com/role/Investments">
        <link:definition>9952159 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssets">
        <link:definition>9952160 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquity">
        <link:definition>9952161 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingencies">
        <link:definition>9952162 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.arrowheadresearch.com/role/Leases">
        <link:definition>9952163 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensation">
        <link:definition>9952164 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurements">
        <link:definition>9952165 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxes">
        <link:definition>9952166 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.arrowheadresearch.com/role/EmployeeBenefitPlans">
        <link:definition>9952167 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyalties" roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties">
        <link:definition>9952168 - Disclosure - Liability Related to the Sale of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingAgreement" roleURI="http://www.arrowheadresearch.com/role/FinancingAgreement">
        <link:definition>9952169 - Disclosure - Financing Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.arrowheadresearch.com/role/NetLossPerShare">
        <link:definition>9952170 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.arrowheadresearch.com/role/SegmentInformation">
        <link:definition>9952171 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.arrowheadresearch.com/role/SubsequentEvents">
        <link:definition>9952172 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesPolicies" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Organization and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesTables" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Organization and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTables" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables">
        <link:definition>9955513 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsTables" roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables">
        <link:definition>9955514 - Disclosure - Balance Sheet Accounts (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.arrowheadresearch.com/role/InvestmentsTables">
        <link:definition>9955515 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsTables">
        <link:definition>9955516 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityTables">
        <link:definition>9955517 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.arrowheadresearch.com/role/LeasesTables">
        <link:definition>9955518 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationTables">
        <link:definition>9955519 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables">
        <link:definition>9955520 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesTables">
        <link:definition>9955521 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyaltiesTables" roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables">
        <link:definition>9955522 - Disclosure - Liability Related to the Sale of Future Royalties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingAgreementTables" roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementTables">
        <link:definition>9955523 - Disclosure - Financing Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.arrowheadresearch.com/role/NetLossPerShareTables">
        <link:definition>9955524 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.arrowheadresearch.com/role/SegmentInformationTables">
        <link:definition>9955525 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9955526 - Disclosure - Organization and Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails">
        <link:definition>9955527 - Disclosure - Organization and Significant Accounting Policies - Useful Lives of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsRevenueDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails">
        <link:definition>9955528 - Disclosure - Collaboration and License Agreements - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails">
        <link:definition>9955529 - Disclosure - Collaboration and License Agreements - Receivables and Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails">
        <link:definition>9955530 - Disclosure - Collaboration and License Agreements - GlaxoSmithKline Intellectual Property (No. 3) Limited (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails">
        <link:definition>9955531 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsAmgenIncDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails">
        <link:definition>9955532 - Disclosure - Collaboration and License Agreements - Amgen, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails">
        <link:definition>9955533 - Disclosure - Collaboration and License Agreements - Sarepta Therapeutics, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails">
        <link:definition>9955534 - Disclosure - Collaboration and License Agreements - Visirna Therapeutics Inc. (&#8220;Visirna&#8221;) and Genzyme Corporation (&#8220;Sanofi&#8221;) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsPropertyPlantandEquipmentDetails" roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails">
        <link:definition>9955535 - Disclosure - Balance Sheet Accounts - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails">
        <link:definition>9955536 - Disclosure - Balance Sheet Accounts - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsAccruedExpensesDetails" roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails">
        <link:definition>9955537 - Disclosure - Balance Sheet Accounts - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsCurrentInvestmentsDetails" roleURI="http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails">
        <link:definition>9955538 - Disclosure - Investments - Current Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsContractMaturityofAvailableforSaleSecuritiesDetails" roleURI="http://www.arrowheadresearch.com/role/InvestmentsContractMaturityofAvailableforSaleSecuritiesDetails">
        <link:definition>9955539 - Disclosure - Investments - Contract Maturity of Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>9955540 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsExpectedFutureAmortizationDetails" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails">
        <link:definition>9955541 - Disclosure - Intangible Assets - Expected Future Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySharesofCommonStockandPreferredStockDetails" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquitySharesofCommonStockandPreferredStockDetails">
        <link:definition>9955542 - Disclosure - Stockholders' Equity - Shares of Common Stock and Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>9955543 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9955544 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails">
        <link:definition>9955545 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseAssetsandLiabilitiesDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails">
        <link:definition>9955546 - Disclosure - Leases - Components of Lease Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails">
        <link:definition>9955547 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1">
        <link:definition>9955547 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails">
        <link:definition>9955548 - Disclosure - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>9955549 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails">
        <link:definition>9955550 - Disclosure - Stock-Based Compensation - Summary of Granted and Outstanding Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationExpensesIncludedinOperatingExpensesDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails">
        <link:definition>9955551 - Disclosure - Stock-Based Compensation - Expenses Included in Operating Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummarizedInformationaboutStockOptionsDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails">
        <link:definition>9955552 - Disclosure - Stock-Based Compensation - Summarized Information about Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails">
        <link:definition>9955553 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofRSUsActivityDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails">
        <link:definition>9955554 - Disclosure - Stock-Based Compensation - Schedule of RSUs Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>9955555 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeLossBeforeIncomeTaxesDetails" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofIncomeLossBeforeIncomeTaxesDetails">
        <link:definition>9955556 - Disclosure - Income Taxes - Components of Income (Loss) Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxProvisionBenefitDetails" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails">
        <link:definition>9955557 - Disclosure - Income Taxes - Income Tax Provision (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>9955558 - Disclosure - Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails">
        <link:definition>9955559 - Disclosure - Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9955560 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesGrossUnrecognizedTaxBenefitsDetails" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>9955561 - Disclosure - Income Taxes - Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails" roleURI="http://www.arrowheadresearch.com/role/EmployeeBenefitPlansDetails">
        <link:definition>9955562 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails">
        <link:definition>9955563 - Disclosure - Liability Related to the Sale of Future Royalties - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails" roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails">
        <link:definition>9955564 - Disclosure - Liability Related to the Sale of Future Royalties - Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingAgreementNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails">
        <link:definition>9955565 - Disclosure - Financing Agreement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingAgreementOutstandingBalanceofCreditFacilityDetails" roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails">
        <link:definition>9955566 - Disclosure - Financing Agreement - Outstanding Balance of Credit Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails" roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails">
        <link:definition>9955567 - Disclosure - Financing Agreement - Interest Expense Recognized Related to Credit Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails" roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails">
        <link:definition>9955568 - Disclosure - Financing Agreement - Principal Repayment Related to Credit Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails" roleURI="http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails">
        <link:definition>9955569 - Disclosure - Net Loss Per Share - Basic and Diluted Net Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAntidilutiveSecuritiesDetails" roleURI="http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveSecuritiesDetails">
        <link:definition>9955570 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/SegmentInformationNarrativeDetails">
        <link:definition>9955571 - Disclosure - Segment Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails" roleURI="http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails">
        <link:definition>9955572 - Disclosure - Segment Information - Research and Development and Selling, General and Administrative Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.arrowheadresearch.com/role/SubsequentEventsDetails">
        <link:definition>9955573 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="arwr_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_RoyaltiesLiabilityNoncurrent" abstract="false" name="RoyaltiesLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" abstract="false" name="NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_GainLossOnTreasuryStockSettlement" abstract="false" name="GainLossOnTreasuryStockSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ProceedsFromSaleOfFutureRoyalties" abstract="false" name="ProceedsFromSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable" abstract="false" name="TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract" abstract="true" name="CashFlowNoncashInvestingActivitiesDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" abstract="true" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" abstract="false" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_ClinicalAccrualPolicyPolicyTextBlock" abstract="false" name="ClinicalAccrualPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_ScheduleOfCurrentProductsTableTextBlock" abstract="false" name="ScheduleOfCurrentProductsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" abstract="false" name="HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" abstract="false" name="ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock" abstract="false" name="SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_OrganizationAndSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arwr_SareptaTherapeuticsIncMember" abstract="true" name="SareptaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_SareptaCollaborationAgreementMember" abstract="true" name="SareptaCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_IncreaseDecreaseInCashAndInvestments" abstract="false" name="IncreaseDecreaseInCashAndInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ProceedsFromCollaborationArrangements" abstract="false" name="ProceedsFromCollaborationArrangements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DevelopmentMilestonePayments" abstract="false" name="DevelopmentMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" abstract="false" name="DevelopmentRegulatoryAndSalesMilestonesPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency" abstract="false" name="NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_ResearchEquipmentMember" abstract="true" name="ResearchEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ManufacturingEquipmentMember" abstract="true" name="ManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ComputersAndSoftwareMember" abstract="true" name="ComputersAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_GlaxosmithklineIntellectualPropertyLimitedMember" abstract="true" name="GlaxosmithklineIntellectualPropertyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_HorizonTherapeuticsIrelandDACMember" abstract="true" name="HorizonTherapeuticsIrelandDACMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" abstract="true" name="TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_JanssenPharmaceuticalsIncorporationMember" abstract="true" name="JanssenPharmaceuticalsIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_AmgenIncorporatedMember" abstract="true" name="AmgenIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_SanofiMember" abstract="true" name="SanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_GSKHSDLicenseAgreementMember" abstract="true" name="GSKHSDLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_GSKHBVAgreementMember" abstract="true" name="GSKHBVAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_InitialTransactionPrice" abstract="false" name="InitialTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivable" abstract="false" name="MilestonePaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" abstract="false" name="MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CommercialMilestonePaymentsAtFirstCommercialSale" abstract="false" name="CommercialMilestonePaymentsAtFirstCommercialSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_SalesRelatedMilestonePayments" abstract="false" name="SalesRelatedMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" abstract="false" name="PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_DevelopmentAndSalesMilestonesPayments" abstract="false" name="DevelopmentAndSalesMilestonesPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_LicenseAndCoFundingAgreementMember" abstract="true" name="LicenseAndCoFundingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_NumberOfDistinctBundle" abstract="false" name="NumberOfDistinctBundle" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_NumberOfDistinctPerformanceObligations" abstract="false" name="NumberOfDistinctPerformanceObligations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_MilestonePaymentEarned" abstract="false" name="MilestonePaymentEarned" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_OlpasiranAgreementMember" abstract="true" name="OlpasiranAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_NumberOfAgreements" abstract="false" name="NumberOfAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" abstract="false" name="AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NumberOfNewTargetPrograms" abstract="false" name="NumberOfNewTargetPrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_NumberOfPerformanceObligations" abstract="false" name="NumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_SaleOfStockPremiumOnIssuanceOfShares" abstract="false" name="SaleOfStockPremiumOnIssuanceOfShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AdditionalCashReceivableUnderCollaborationAgreement" abstract="false" name="AdditionalCashReceivableUnderCollaborationAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments" abstract="false" name="CashReceivableUnderCollaborationAgreementAnnualInstallments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod" abstract="false" name="CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arwr_CollaborationArrangementFixedConsideration" abstract="false" name="CollaborationArrangementFixedConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CollaborationArrangementVariableConsideration" abstract="false" name="CollaborationArrangementVariableConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CollaborationArrangementConsideration" abstract="false" name="CollaborationArrangementConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_EnrollmentRelatedMilestonePayments" abstract="false" name="EnrollmentRelatedMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NumberOfCollaborationPrograms" abstract="false" name="NumberOfCollaborationPrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_RegulatoryMilestonePayments" abstract="false" name="RegulatoryMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval" abstract="false" name="CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arwr_SanofiLicenseAgreementMember" abstract="true" name="SanofiLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_FuturePotentialMilestonePayments" abstract="false" name="FuturePotentialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ConstructionInProgressReclassifiedToBuildingMember" abstract="true" name="ConstructionInProgressReclassifiedToBuildingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember" abstract="true" name="ConstructionInProgressReclassifiedToManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AccruedCapitalExpenditureCurrent" abstract="false" name="AccruedCapitalExpenditureCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" abstract="true" name="ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" abstract="true" name="ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NovartisMember" abstract="true" name="NovartisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_FiniteLivedIntangibleAssetsImpairment" abstract="false" name="FiniteLivedIntangibleAssetsImpairment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" abstract="true" name="TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_AtTheMarketAgreementMember" abstract="true" name="AtTheMarketAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised" abstract="false" name="ClassOfWarrantOrRightNumberOfWarrantsExercised" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arwr_MilestonePaymentDueFromCollaborativeAgreement" abstract="false" name="MilestonePaymentDueFromCollaborativeAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" abstract="false" name="CommonStockCapitalSharesValueReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" abstract="false" name="PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_DrugManufacturingFacilityMember" abstract="true" name="DrugManufacturingFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_LaboratoryAndOfficeFacilityMember" abstract="true" name="LaboratoryAndOfficeFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_FacilitiesMember" abstract="true" name="FacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CommitmentsCapitalExpendituresIncurredToDate" abstract="false" name="CommitmentsCapitalExpendituresIncurredToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CorporateHeadquartersInPasadenaMember" abstract="true" name="CorporateHeadquartersInPasadenaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ResearchFacilityInSanDiegoMember" abstract="true" name="ResearchFacilityInSanDiegoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ResearchFacilityInMadisonMember" abstract="true" name="ResearchFacilityInMadisonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ColoradoOwnerLLCMember" abstract="true" name="ColoradoOwnerLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_NumberOfOptionsToRenew" abstract="false" name="NumberOfOptionsToRenew" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_ProceedsFromTenantImprovementAllowance" abstract="false" name="ProceedsFromTenantImprovementAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" abstract="true" name="CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" abstract="false" name="OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" abstract="false" name="RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TwoThousandsThirteenIncentivePlanMember" abstract="true" name="TwoThousandsThirteenIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_TwoThousandTwentyOneIncentivePlanMember" abstract="true" name="TwoThousandTwentyOneIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_InducementPlanMember" abstract="true" name="InducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_VisirnaESOPMember" abstract="true" name="VisirnaESOPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arwr_InducementAwardsMember" abstract="true" name="InducementAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CommercialNotesMember" abstract="true" name="CommercialNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationOtherIncomePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" abstract="false" name="DeferredTaxAssetsInProcessResearchAndDevelopmentCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" abstract="false" name="DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DeferredTaxLiabilitiesOriginalIssueDiscount" abstract="false" name="DeferredTaxLiabilitiesOriginalIssueDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_OperatingLossCarryforwardsSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_OperatingLossCarryforwardsNotSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsNotSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TaxCreditCarryforwardAmountSubjectToExpiration" abstract="false" name="TaxCreditCarryforwardAmountSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_EmployeeContributionsUpToThreePercentMember" abstract="true" name="EmployeeContributionsUpToThreePercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_EmployeeContributionNextTwoPercentMember" abstract="true" name="EmployeeContributionNextTwoPercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_RoyaltyPharmaAgreementMember" abstract="true" name="RoyaltyPharmaAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" abstract="false" name="UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" abstract="false" name="MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponFDAApproval" abstract="false" name="MilestonePaymentReceivableUponFDAApproval" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" abstract="false" name="MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_RoyaltyPaymentThreshold" abstract="false" name="RoyaltyPaymentThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" abstract="false" name="MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" abstract="false" name="LiabilitySaleOfFutureRoyaltiesInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_LiabilitySaleOfFutureRoyaltiesRollForward" abstract="true" name="LiabilitySaleOfFutureRoyaltiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_FinancingAgreementMember" abstract="true" name="FinancingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_FinancingAgreementInitialTermLoanMember" abstract="true" name="FinancingAgreementInitialTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_FinancingAgreementMOICPaymentMember" abstract="true" name="FinancingAgreementMOICPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_DebtInstrumentCovenantMultipleOfInvestedCapital" abstract="false" name="DebtInstrumentCovenantMultipleOfInvestedCapital" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="arwr_DebtInstrumentPrepaymentPercentage" abstract="false" name="DebtInstrumentPrepaymentPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment" abstract="false" name="DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold" abstract="false" name="DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DebtInstrumentCovenantMarketCapitalizationThreshold" abstract="false" name="DebtInstrumentCovenantMarketCapitalizationThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_FinancingAgreementInitialTermLoanInterestMember" abstract="true" name="FinancingAgreementInitialTermLoanInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_OperatingSegmentMember" abstract="true" name="OperatingSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ResearchAndDevelopmentExpenseCandidateCosts" abstract="false" name="ResearchAndDevelopmentExpenseCandidateCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ResearchAndDevelopmentExpenseDiscoveryCosts" abstract="false" name="ResearchAndDevelopmentExpenseDiscoveryCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ResearchAndDevelopmentExpenseSalariesExpense" abstract="false" name="ResearchAndDevelopmentExpenseSalariesExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense" abstract="false" name="ResearchAndDevelopmentExpenseFacilitiesRelatedExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense" abstract="false" name="ResearchAndDevelopmentExpenseExcludingNoncashExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense" abstract="false" name="GeneralAndAdministrativeExpenseFacilitiesRelatedExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense" abstract="false" name="GeneralAndAdministrativeExpenseExcludingNoncashExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NovartisCollaborationAgreementMember" abstract="true" name="NovartisCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination" abstract="false" name="PaymentReceivableInCollaborationArrangementsUponTargetNomination" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AdeoyeOlukotunMember" abstract="true" name="AdeoyeOlukotunMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ChristopherAnzaloneMember" abstract="true" name="ChristopherAnzaloneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_DanielApelMember" abstract="true" name="DanielApelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_JamesHamiltonMember" abstract="true" name="JamesHamiltonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_MauroFerrariMember" abstract="true" name="MauroFerrariMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_PatrickOBrienMember" abstract="true" name="PatrickOBrienMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_PatrickOBrienSharesVestingAndSubjectToSellToCoverMember" abstract="true" name="PatrickOBrienSharesVestingAndSubjectToSellToCoverMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_PatrickOBrienOtherSharesBeingSoldMember" abstract="true" name="PatrickOBrienOtherSharesBeingSoldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_VictoriaVakienerMember" abstract="true" name="VictoriaVakienerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_WilliamWaddillMember" abstract="true" name="WilliamWaddillMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>arwr-20250930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:67e6a79e-2429-4a7b-924a-105395255933,g:bc385ee3-281d-4402-b0c2-11a4f6b4f5dd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arwr-20250930.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a251e60d-0388-4325-b7e1-ca1dea1de8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_63ca3201-5ccd-4032-9bec-b44001740993" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a251e60d-0388-4325-b7e1-ca1dea1de8ad" xlink:to="loc_us-gaap_LiabilitiesCurrent_63ca3201-5ccd-4032-9bec-b44001740993" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_1d3467e0-f6ea-4129-8a6c-59d853cc51b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a251e60d-0388-4325-b7e1-ca1dea1de8ad" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_1d3467e0-f6ea-4129-8a6c-59d853cc51b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8f5f3129-5472-4ba7-83ee-07558c6b4738" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a251e60d-0388-4325-b7e1-ca1dea1de8ad" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8f5f3129-5472-4ba7-83ee-07558c6b4738" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2312ed1d-38b6-432f-b8a5-908fff963521" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a251e60d-0388-4325-b7e1-ca1dea1de8ad" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2312ed1d-38b6-432f-b8a5-908fff963521" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_310c6586-8f56-40d7-b666-1364a0d71c77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_896b2aea-f1b4-413e-a92a-40d30b65856c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_310c6586-8f56-40d7-b666-1364a0d71c77" xlink:to="loc_us-gaap_StockholdersEquity_896b2aea-f1b4-413e-a92a-40d30b65856c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_82c35733-f29a-4a50-9cd0-c283e873f387" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_310c6586-8f56-40d7-b666-1364a0d71c77" xlink:to="loc_us-gaap_MinorityInterest_82c35733-f29a-4a50-9cd0-c283e873f387" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_009496b3-fb9e-4e3c-8cff-0cb069e5d840" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2830d1d3-1b0e-4769-835d-9c749bcdf639" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_009496b3-fb9e-4e3c-8cff-0cb069e5d840" xlink:to="loc_us-gaap_CommonStockValue_2830d1d3-1b0e-4769-835d-9c749bcdf639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d81842d1-e2df-4dd5-a277-e27984685647" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_009496b3-fb9e-4e3c-8cff-0cb069e5d840" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d81842d1-e2df-4dd5-a277-e27984685647" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_63bc4d43-150d-490b-9a13-7053e45941ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_009496b3-fb9e-4e3c-8cff-0cb069e5d840" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_63bc4d43-150d-490b-9a13-7053e45941ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cdadda45-2ceb-4563-854d-dda6d7bf103f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_009496b3-fb9e-4e3c-8cff-0cb069e5d840" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cdadda45-2ceb-4563-854d-dda6d7bf103f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_be0c0d03-20c1-46ca-85ae-c6ca3d782fad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_009496b3-fb9e-4e3c-8cff-0cb069e5d840" xlink:to="loc_us-gaap_TreasuryStockCommonValue_be0c0d03-20c1-46ca-85ae-c6ca3d782fad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_73b5167a-48b1-49dc-85d1-9de2e75abcae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_067048c3-dbaf-47d1-bdf4-50be419f189d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_73b5167a-48b1-49dc-85d1-9de2e75abcae" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_067048c3-dbaf-47d1-bdf4-50be419f189d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d42f96fb-5c42-4d35-b3bd-3d742a3fd50b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_73b5167a-48b1-49dc-85d1-9de2e75abcae" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d42f96fb-5c42-4d35-b3bd-3d742a3fd50b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0681379f-8ccc-46d5-a485-e2ff2b450f84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_73b5167a-48b1-49dc-85d1-9de2e75abcae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0681379f-8ccc-46d5-a485-e2ff2b450f84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_40641ed7-d225-4a38-b939-e1b9011d830d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_73b5167a-48b1-49dc-85d1-9de2e75abcae" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_40641ed7-d225-4a38-b939-e1b9011d830d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5e98a54b-a9dc-46da-8b8d-8860d7e67769" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_73b5167a-48b1-49dc-85d1-9de2e75abcae" xlink:to="loc_us-gaap_OtherAssetsCurrent_5e98a54b-a9dc-46da-8b8d-8860d7e67769" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_86776680-4fdd-4adf-bba8-48a9478fe674" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_43ef8ab4-6569-49b7-bee4-f757f04ace8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_86776680-4fdd-4adf-bba8-48a9478fe674" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_43ef8ab4-6569-49b7-bee4-f757f04ace8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent_c450c981-2125-4586-b3c6-2930dccc8498" xlink:href="arwr-20250930.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_86776680-4fdd-4adf-bba8-48a9478fe674" xlink:to="loc_arwr_RoyaltiesLiabilityNoncurrent_c450c981-2125-4586-b3c6-2930dccc8498" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_7ca95bac-a395-4273-a437-7a88579504aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_86776680-4fdd-4adf-bba8-48a9478fe674" xlink:to="loc_us-gaap_LongTermLineOfCredit_7ca95bac-a395-4273-a437-7a88579504aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7c32096d-bd87-478f-9fb6-b08d2914ecbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ac980ffb-70d4-422c-911b-a5fd45185ece" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7c32096d-bd87-478f-9fb6-b08d2914ecbf" xlink:to="loc_us-gaap_AccountsPayableCurrent_ac980ffb-70d4-422c-911b-a5fd45185ece" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9989f69a-9137-4e76-909a-2282565458ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7c32096d-bd87-478f-9fb6-b08d2914ecbf" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9989f69a-9137-4e76-909a-2282565458ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_983fa50e-32d1-4671-9863-33e660f7de01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7c32096d-bd87-478f-9fb6-b08d2914ecbf" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_983fa50e-32d1-4671-9863-33e660f7de01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_542cf673-2aad-4a0b-b3fb-9545916d1fde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7c32096d-bd87-478f-9fb6-b08d2914ecbf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_542cf673-2aad-4a0b-b3fb-9545916d1fde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_79f7da47-51f1-406e-aaab-97ccbc5f83a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7c32096d-bd87-478f-9fb6-b08d2914ecbf" xlink:to="loc_us-gaap_LinesOfCreditCurrent_79f7da47-51f1-406e-aaab-97ccbc5f83a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a355c8e9-1ec9-4e56-8a7d-c70c7e885e18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7c32096d-bd87-478f-9fb6-b08d2914ecbf" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a355c8e9-1ec9-4e56-8a7d-c70c7e885e18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_56686fce-1022-437d-b02b-830de2d9bf62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7c32096d-bd87-478f-9fb6-b08d2914ecbf" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_56686fce-1022-437d-b02b-830de2d9bf62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b5aa8ccf-60bb-454d-97e0-3bfeb5df0e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7ce9e11d-e8b3-4728-b8e9-08eed24307ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b5aa8ccf-60bb-454d-97e0-3bfeb5df0e7b" xlink:to="loc_us-gaap_AssetsCurrent_7ce9e11d-e8b3-4728-b8e9-08eed24307ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_df23f4e2-b466-4127-ae06-ead8f1a756bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b5aa8ccf-60bb-454d-97e0-3bfeb5df0e7b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_df23f4e2-b466-4127-ae06-ead8f1a756bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dcfa1980-f71a-453d-8018-ad2cc9fd8a06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b5aa8ccf-60bb-454d-97e0-3bfeb5df0e7b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dcfa1980-f71a-453d-8018-ad2cc9fd8a06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3af8d603-f923-4782-8db0-1c3d7d03be15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b5aa8ccf-60bb-454d-97e0-3bfeb5df0e7b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3af8d603-f923-4782-8db0-1c3d7d03be15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_dd30ffdc-33b5-4f98-8f68-f9000b2c9149" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b5aa8ccf-60bb-454d-97e0-3bfeb5df0e7b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_dd30ffdc-33b5-4f98-8f68-f9000b2c9149" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="arwr-20250930.xsd#ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_57b0cec2-f818-4bfe-a2cc-c7731a654420" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_618b57d5-09b7-44df-8bc6-41e1d96f3b41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_57b0cec2-f818-4bfe-a2cc-c7731a654420" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_618b57d5-09b7-44df-8bc6-41e1d96f3b41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_81e029e9-960e-4e89-b2ea-97b5642395be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_57b0cec2-f818-4bfe-a2cc-c7731a654420" xlink:to="loc_us-gaap_InterestExpenseNonoperating_81e029e9-960e-4e89-b2ea-97b5642395be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1f80861f-3a7c-4761-80de-d26fd3fe8155" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_57b0cec2-f818-4bfe-a2cc-c7731a654420" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1f80861f-3a7c-4761-80de-d26fd3fe8155" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_94aeebf8-14e8-4d91-9b14-902dd61ce5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25384fea-8b17-4180-bc0f-47bbfe37794f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_94aeebf8-14e8-4d91-9b14-902dd61ce5d0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25384fea-8b17-4180-bc0f-47bbfe37794f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2a32edea-8061-4388-90de-5792d3501895" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_94aeebf8-14e8-4d91-9b14-902dd61ce5d0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2a32edea-8061-4388-90de-5792d3501895" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_583267e8-a802-44a8-b951-744bac478faa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c3f3b45c-99e7-4101-85de-f1ce50d80d44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_583267e8-a802-44a8-b951-744bac478faa" xlink:to="loc_us-gaap_ProfitLoss_c3f3b45c-99e7-4101-85de-f1ce50d80d44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1d889c70-7acd-467c-9d8f-590173d8a001" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_583267e8-a802-44a8-b951-744bac478faa" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1d889c70-7acd-467c-9d8f-590173d8a001" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_77d0f8ba-b594-4574-9628-8b546b07a496" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1e9dcd31-3279-4508-9b29-d442f496f167" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_77d0f8ba-b594-4574-9628-8b546b07a496" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1e9dcd31-3279-4508-9b29-d442f496f167" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fa9b6264-9ead-4505-9f55-60f4454ecceb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_77d0f8ba-b594-4574-9628-8b546b07a496" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fa9b6264-9ead-4505-9f55-60f4454ecceb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c07d670c-3c40-4c53-bbc4-0262568ce948" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_54787a3e-712b-4c75-b6d2-7f21267bec8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c07d670c-3c40-4c53-bbc4-0262568ce948" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_54787a3e-712b-4c75-b6d2-7f21267bec8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a5f15189-3510-4d04-84ee-21eb70970448" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c07d670c-3c40-4c53-bbc4-0262568ce948" xlink:to="loc_us-gaap_OperatingExpenses_a5f15189-3510-4d04-84ee-21eb70970448" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_503c3239-d114-4d7a-a282-58d262df8893" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_04f93532-c0d3-4e46-b82c-16a9819ed65c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_503c3239-d114-4d7a-a282-58d262df8893" xlink:to="loc_us-gaap_OperatingIncomeLoss_04f93532-c0d3-4e46-b82c-16a9819ed65c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_96c7b4ef-f1b6-4c18-a0c8-412f40189e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_503c3239-d114-4d7a-a282-58d262df8893" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_96c7b4ef-f1b6-4c18-a0c8-412f40189e0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_edbbd8ca-aa4e-472a-b803-8dadd47f5ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1d4f6f9f-41a0-46ea-a7a6-ebd0655935d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_edbbd8ca-aa4e-472a-b803-8dadd47f5ca6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1d4f6f9f-41a0-46ea-a7a6-ebd0655935d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1dbc4713-31bb-41fb-b24b-135d4805ab59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6f367fad-dbdd-4236-9e25-10bcba4f5b70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1dbc4713-31bb-41fb-b24b-135d4805ab59" xlink:to="loc_us-gaap_ProfitLoss_6f367fad-dbdd-4236-9e25-10bcba4f5b70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_07b72d73-3f07-4ff8-9cee-ae5b52f04a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1dbc4713-31bb-41fb-b24b-135d4805ab59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_07b72d73-3f07-4ff8-9cee-ae5b52f04a4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e745a4e3-9c63-40db-ab2a-405d31c68ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1dbc4713-31bb-41fb-b24b-135d4805ab59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e745a4e3-9c63-40db-ab2a-405d31c68ee9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arwr-20250930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_61c3478d-c27f-4668-89ff-40aca51412c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f8b7cf7e-945c-49e6-a8a6-d2dd954d059d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_61c3478d-c27f-4668-89ff-40aca51412c2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f8b7cf7e-945c-49e6-a8a6-d2dd954d059d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_641be3d6-370b-4537-8f26-e2ac436afa68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_61c3478d-c27f-4668-89ff-40aca51412c2" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_641be3d6-370b-4537-8f26-e2ac436afa68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_31c0be5f-0f11-4e5d-9d7d-f3e0b2e7186a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_61c3478d-c27f-4668-89ff-40aca51412c2" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_31c0be5f-0f11-4e5d-9d7d-f3e0b2e7186a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c191eeb9-5ee3-4a02-8b0d-4ab12dd43f02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4c368832-844b-4e79-afd6-494f91503ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c191eeb9-5ee3-4a02-8b0d-4ab12dd43f02" xlink:to="loc_us-gaap_ProfitLoss_4c368832-844b-4e79-afd6-494f91503ca0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_78005939-fa19-489d-aa4f-01e068dbc77f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c191eeb9-5ee3-4a02-8b0d-4ab12dd43f02" xlink:to="loc_us-gaap_ShareBasedCompensation_78005939-fa19-489d-aa4f-01e068dbc77f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_a750440a-261d-4405-b8cd-4e801ecff4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c191eeb9-5ee3-4a02-8b0d-4ab12dd43f02" xlink:to="loc_us-gaap_DepreciationAndAmortization_a750440a-261d-4405-b8cd-4e801ecff4ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_51a4a53a-77c7-4f18-bb85-c7dec855a094" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c191eeb9-5ee3-4a02-8b0d-4ab12dd43f02" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_51a4a53a-77c7-4f18-bb85-c7dec855a094" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_f2b4334b-c5af-4854-a564-898f9eb13526" xlink:href="arwr-20250930.xsd#arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c191eeb9-5ee3-4a02-8b0d-4ab12dd43f02" xlink:to="loc_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_f2b4334b-c5af-4854-a564-898f9eb13526" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_293ab5e2-279d-4595-923d-071236396642" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c191eeb9-5ee3-4a02-8b0d-4ab12dd43f02" xlink:to="loc_us-gaap_PaidInKindInterest_293ab5e2-279d-4595-923d-071236396642" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GainLossOnTreasuryStockSettlement_281c7b42-58d4-4030-8e22-dca2a0acfb6f" xlink:href="arwr-20250930.xsd#arwr_GainLossOnTreasuryStockSettlement"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c191eeb9-5ee3-4a02-8b0d-4ab12dd43f02" xlink:to="loc_arwr_GainLossOnTreasuryStockSettlement_281c7b42-58d4-4030-8e22-dca2a0acfb6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_304c285a-bebb-4bdf-b077-c7100aeadf94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c191eeb9-5ee3-4a02-8b0d-4ab12dd43f02" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_304c285a-bebb-4bdf-b077-c7100aeadf94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b4976225-8d83-4389-bfe3-28eb983ffda9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c191eeb9-5ee3-4a02-8b0d-4ab12dd43f02" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b4976225-8d83-4389-bfe3-28eb983ffda9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1c8ad1ef-3e06-4ae6-8421-0e5576a559ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c191eeb9-5ee3-4a02-8b0d-4ab12dd43f02" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1c8ad1ef-3e06-4ae6-8421-0e5576a559ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e93b8db9-932c-4049-8085-0ff094b06943" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c191eeb9-5ee3-4a02-8b0d-4ab12dd43f02" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e93b8db9-932c-4049-8085-0ff094b06943" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7c74cfdb-b68a-49a8-9e2e-27df83cf3ced" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c191eeb9-5ee3-4a02-8b0d-4ab12dd43f02" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7c74cfdb-b68a-49a8-9e2e-27df83cf3ced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4e68be69-f08e-4a5c-adba-0a110718e563" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c191eeb9-5ee3-4a02-8b0d-4ab12dd43f02" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4e68be69-f08e-4a5c-adba-0a110718e563" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_926d5591-0730-432f-9b51-3accad552b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c191eeb9-5ee3-4a02-8b0d-4ab12dd43f02" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_926d5591-0730-432f-9b51-3accad552b4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_30849487-9f6e-47c6-bbed-764314bed520" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c191eeb9-5ee3-4a02-8b0d-4ab12dd43f02" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_30849487-9f6e-47c6-bbed-764314bed520" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95eb4770-f134-47a9-87cd-790626c09f48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_62a013c8-39e7-4aa9-814d-588e88256533" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95eb4770-f134-47a9-87cd-790626c09f48" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_62a013c8-39e7-4aa9-814d-588e88256533" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1905b51d-b5dd-446a-877f-3cf5be6a3a65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95eb4770-f134-47a9-87cd-790626c09f48" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1905b51d-b5dd-446a-877f-3cf5be6a3a65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromSaleOfFutureRoyalties_4618177a-6808-4609-be3e-4fff79a43bc2" xlink:href="arwr-20250930.xsd#arwr_ProceedsFromSaleOfFutureRoyalties"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95eb4770-f134-47a9-87cd-790626c09f48" xlink:to="loc_arwr_ProceedsFromSaleOfFutureRoyalties_4618177a-6808-4609-be3e-4fff79a43bc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_5f4944fb-793b-4d56-8a76-40e6e8a7449f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95eb4770-f134-47a9-87cd-790626c09f48" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_5f4944fb-793b-4d56-8a76-40e6e8a7449f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9ba3c536-36c8-41df-8d44-b071161315dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95eb4770-f134-47a9-87cd-790626c09f48" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9ba3c536-36c8-41df-8d44-b071161315dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_26c78866-3c09-4f8f-b4f1-b0bb6b6e1cab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95eb4770-f134-47a9-87cd-790626c09f48" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_26c78866-3c09-4f8f-b4f1-b0bb6b6e1cab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_36c257d8-bea6-472f-851a-ce129e9878e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95eb4770-f134-47a9-87cd-790626c09f48" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_36c257d8-bea6-472f-851a-ce129e9878e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_139f5725-338b-4cef-885b-f50a55cadf01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95eb4770-f134-47a9-87cd-790626c09f48" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_139f5725-338b-4cef-885b-f50a55cadf01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_05bee703-3a05-4669-9a98-80231034d826" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_83e96574-82c1-4358-8cd9-dc8f90599e88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_05bee703-3a05-4669-9a98-80231034d826" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_83e96574-82c1-4358-8cd9-dc8f90599e88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52a4b2c4-de32-4fa0-a751-d157f847c20d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_05bee703-3a05-4669-9a98-80231034d826" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52a4b2c4-de32-4fa0-a751-d157f847c20d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1936135f-ff4a-461a-bbb8-3530b1fd4c52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_05bee703-3a05-4669-9a98-80231034d826" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1936135f-ff4a-461a-bbb8-3530b1fd4c52" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#BalanceSheetAccountsPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_af0dd94f-86bf-4616-80a3-40e2d10cb82a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1acf0215-bd7f-4723-8810-6dc3d3a3d343" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_af0dd94f-86bf-4616-80a3-40e2d10cb82a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1acf0215-bd7f-4723-8810-6dc3d3a3d343" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4c0e2533-c3ea-47d1-82bf-20b593068765" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_af0dd94f-86bf-4616-80a3-40e2d10cb82a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4c0e2533-c3ea-47d1-82bf-20b593068765" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#BalanceSheetAccountsAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a263ddf7-bb33-4f36-87ad-eb8b3676034d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedResearchAndDevelopmentExpenseCurrent_57ee92b7-28a9-4009-88ec-f57f3bebd8e8" xlink:href="arwr-20250930.xsd#arwr_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_a263ddf7-bb33-4f36-87ad-eb8b3676034d" xlink:to="loc_arwr_AccruedResearchAndDevelopmentExpenseCurrent_57ee92b7-28a9-4009-88ec-f57f3bebd8e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_2af204f7-be9f-496c-862f-c1f103fe501f" xlink:href="arwr-20250930.xsd#arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_a263ddf7-bb33-4f36-87ad-eb8b3676034d" xlink:to="loc_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_2af204f7-be9f-496c-862f-c1f103fe501f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedCapitalExpenditureCurrent_3c3e5e6c-0c79-494b-b4c2-c28a0c522c63" xlink:href="arwr-20250930.xsd#arwr_AccruedCapitalExpenditureCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_a263ddf7-bb33-4f36-87ad-eb8b3676034d" xlink:to="loc_arwr_AccruedCapitalExpenditureCurrent_3c3e5e6c-0c79-494b-b4c2-c28a0c522c63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_46d2fe1b-3e73-4555-8232-6cb02b400d76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_a263ddf7-bb33-4f36-87ad-eb8b3676034d" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_46d2fe1b-3e73-4555-8232-6cb02b400d76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_79206ffc-f51a-489b-a01d-ea267e69830f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_a263ddf7-bb33-4f36-87ad-eb8b3676034d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_79206ffc-f51a-489b-a01d-ea267e69830f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#InvestmentsCurrentInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_f1baad8c-180b-42e3-ab78-1c79c3e85912" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fdb15772-d301-43b7-8f36-b689dad9f9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_f1baad8c-180b-42e3-ab78-1c79c3e85912" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fdb15772-d301-43b7-8f36-b689dad9f9d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_d9306505-792b-469c-b9be-21ff069824c1" xlink:href="arwr-20250930.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_f1baad8c-180b-42e3-ab78-1c79c3e85912" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_d9306505-792b-469c-b9be-21ff069824c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_184bcadd-d0c1-43fc-9d7b-44a8cf8a971c" xlink:href="arwr-20250930.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_f1baad8c-180b-42e3-ab78-1c79c3e85912" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_184bcadd-d0c1-43fc-9d7b-44a8cf8a971c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsContractMaturityofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#InvestmentsContractMaturityofAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsContractMaturityofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e58d2f7b-9765-47b5-b514-1834deba4f94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree_a858b03e-bddf-4129-9e19-237f42d6b6c6" xlink:href="arwr-20250930.xsd#arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e58d2f7b-9765-47b5-b514-1834deba4f94" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree_a858b03e-bddf-4129-9e19-237f42d6b6c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_9efec543-1453-4882-80e0-d50ed6f5ecb3" xlink:href="arwr-20250930.xsd#arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e58d2f7b-9765-47b5-b514-1834deba4f94" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_9efec543-1453-4882-80e0-d50ed6f5ecb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_fd8c1a73-42b4-47c3-87d9-be4b463caaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e58d2f7b-9765-47b5-b514-1834deba4f94" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_fd8c1a73-42b4-47c3-87d9-be4b463caaa3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a8751294-efb8-4a5c-a57d-585ac8047960" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1ae79a11-c35f-4de8-bba7-0bbdb344871c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a8751294-efb8-4a5c-a57d-585ac8047960" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1ae79a11-c35f-4de8-bba7-0bbdb344871c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_bd673497-093f-4a4a-aa9e-2cb91c00bf15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a8751294-efb8-4a5c-a57d-585ac8047960" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_bd673497-093f-4a4a-aa9e-2cb91c00bf15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_fbacfedb-54dd-4fdf-8507-08a996d220f5" xlink:href="arwr-20250930.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a8751294-efb8-4a5c-a57d-585ac8047960" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_fbacfedb-54dd-4fdf-8507-08a996d220f5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#IntangibleAssetsExpectedFutureAmortizationDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b92dc580-1d38-4e96-9d69-2bacbb0d64cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_330395dc-22ef-4ac9-8624-7ddd0e36f06b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b92dc580-1d38-4e96-9d69-2bacbb0d64cd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_330395dc-22ef-4ac9-8624-7ddd0e36f06b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_37fb1997-2d1e-439b-8cfe-92fb605a658b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b92dc580-1d38-4e96-9d69-2bacbb0d64cd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_37fb1997-2d1e-439b-8cfe-92fb605a658b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7f163f19-04b7-41bf-b505-9ee3e5726b97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b92dc580-1d38-4e96-9d69-2bacbb0d64cd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7f163f19-04b7-41bf-b505-9ee3e5726b97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_caf08613-7782-425e-88cf-80006f860b91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b92dc580-1d38-4e96-9d69-2bacbb0d64cd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_caf08613-7782-425e-88cf-80006f860b91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5796473c-ce1e-4b17-86c5-600b8343f013" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b92dc580-1d38-4e96-9d69-2bacbb0d64cd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5796473c-ce1e-4b17-86c5-600b8343f013" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_d0037290-6268-40e6-b264-3f6421954fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b92dc580-1d38-4e96-9d69-2bacbb0d64cd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_d0037290-6268-40e6-b264-3f6421954fd6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#LeasesComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_60606f3a-4526-444a-a3d9-ba1ad767bc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_3ad2b8e5-5eb1-4c62-b653-2b6a3c1f70a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_60606f3a-4526-444a-a3d9-ba1ad767bc3a" xlink:to="loc_us-gaap_VariableLeaseCost_3ad2b8e5-5eb1-4c62-b653-2b6a3c1f70a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_846f3208-7308-4b0f-b803-94a68655ee15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_60606f3a-4526-444a-a3d9-ba1ad767bc3a" xlink:to="loc_us-gaap_OperatingLeaseCost_846f3208-7308-4b0f-b803-94a68655ee15" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_159f71b1-dd15-4820-8691-200d9dfd0fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_23d1bd9a-ba25-4248-970f-1d600d998460" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_159f71b1-dd15-4820-8691-200d9dfd0fc0" xlink:to="loc_us-gaap_OperatingLeaseLiability_23d1bd9a-ba25-4248-970f-1d600d998460" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5db6632e-9e30-4bbd-a942-4f440327d36d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_159f71b1-dd15-4820-8691-200d9dfd0fc0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5db6632e-9e30-4bbd-a942-4f440327d36d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="simple" xlink:href="arwr-20250930.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fa3f0da9-f6f7-4837-9118-4a10f1573173" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e415e524-dcee-435f-9501-96b11e0d0945" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fa3f0da9-f6f7-4837-9118-4a10f1573173" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e415e524-dcee-435f-9501-96b11e0d0945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7f0361e6-d4d1-4e60-a3b5-26c064408e44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fa3f0da9-f6f7-4837-9118-4a10f1573173" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7f0361e6-d4d1-4e60-a3b5-26c064408e44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_da3e9149-483e-48fb-8359-c0b6d05b159e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fa3f0da9-f6f7-4837-9118-4a10f1573173" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_da3e9149-483e-48fb-8359-c0b6d05b159e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c4699391-19e2-473f-b671-bd8160c5294f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fa3f0da9-f6f7-4837-9118-4a10f1573173" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c4699391-19e2-473f-b671-bd8160c5294f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a21382a2-7a8d-41f5-96ec-850fecf780aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fa3f0da9-f6f7-4837-9118-4a10f1573173" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a21382a2-7a8d-41f5-96ec-850fecf780aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_00ea1048-829b-459f-ace4-188f98304fae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fa3f0da9-f6f7-4837-9118-4a10f1573173" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_00ea1048-829b-459f-ace4-188f98304fae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_4868b801-3c69-4036-949d-106aa497c774" xlink:href="arwr-20250930.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b112714e-ad28-4acd-bbce-59da8bf41986" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_4868b801-3c69-4036-949d-106aa497c774" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b112714e-ad28-4acd-bbce-59da8bf41986" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2f6957b8-7e4c-45d8-a8ad-ac19cac0ff14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_4868b801-3c69-4036-949d-106aa497c774" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2f6957b8-7e4c-45d8-a8ad-ac19cac0ff14" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4a36dfb0-14b4-4728-81ef-b2f454b4ddce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_14ff9939-e470-408c-ba5c-1a0940c1765c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4a36dfb0-14b4-4728-81ef-b2f454b4ddce" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_14ff9939-e470-408c-ba5c-1a0940c1765c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d0e3dfbe-6bdc-483d-9e1c-cbab52b6c21b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4a36dfb0-14b4-4728-81ef-b2f454b4ddce" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d0e3dfbe-6bdc-483d-9e1c-cbab52b6c21b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#IncomeTaxesComponentsofIncomeLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_a7211841-15ae-4235-b4bc-2f6eb9f36b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_649f8e26-6b4b-4050-a692-062daf4a9f44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_a7211841-15ae-4235-b4bc-2f6eb9f36b9f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_649f8e26-6b4b-4050-a692-062daf4a9f44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_37c2d1ae-a361-4ed6-a400-ba7a603cc13d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_a7211841-15ae-4235-b4bc-2f6eb9f36b9f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_37c2d1ae-a361-4ed6-a400-ba7a603cc13d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#IncomeTaxesIncomeTaxProvisionBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_21d33546-043e-4a02-9a1b-05d83a9c3af1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4fc8b113-b9d9-4a22-b9bc-2fab24a73d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_21d33546-043e-4a02-9a1b-05d83a9c3af1" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4fc8b113-b9d9-4a22-b9bc-2fab24a73d9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_10ca1295-0b78-408d-8746-4f1bf965c643" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_21d33546-043e-4a02-9a1b-05d83a9c3af1" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_10ca1295-0b78-408d-8746-4f1bf965c643" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_41794adb-6e36-4d2d-b20e-6d874b448fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_21d33546-043e-4a02-9a1b-05d83a9c3af1" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_41794adb-6e36-4d2d-b20e-6d874b448fb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bdb99cdc-0823-4912-985c-1dadda308328" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b22b651c-2305-4e63-9f93-e33328c3fdaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bdb99cdc-0823-4912-985c-1dadda308328" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b22b651c-2305-4e63-9f93-e33328c3fdaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b1f6903b-0edb-4eb2-8cd8-ee37394b5c24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bdb99cdc-0823-4912-985c-1dadda308328" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b1f6903b-0edb-4eb2-8cd8-ee37394b5c24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3b91b1b0-634e-400d-bb8b-f1a86394c323" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_b4d0eba4-d9a3-4299-9fc4-fe56c7305fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3b91b1b0-634e-400d-bb8b-f1a86394c323" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_b4d0eba4-d9a3-4299-9fc4-fe56c7305fb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ed730327-327a-4bff-b880-0864725768cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3b91b1b0-634e-400d-bb8b-f1a86394c323" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ed730327-327a-4bff-b880-0864725768cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8cc691f3-3bad-4996-9ce2-36bf6a7ef9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3b91b1b0-634e-400d-bb8b-f1a86394c323" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8cc691f3-3bad-4996-9ce2-36bf6a7ef9c0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_98c0998a-c48f-40ff-a781-7a6666b4f3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_877b29bb-343c-4580-b301-b9821b7441d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_98c0998a-c48f-40ff-a781-7a6666b4f3e9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_877b29bb-343c-4580-b301-b9821b7441d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_a4ebdc7d-003c-450f-a48c-d9a572344e02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_98c0998a-c48f-40ff-a781-7a6666b4f3e9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_a4ebdc7d-003c-450f-a48c-d9a572344e02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_976c1d96-c7e9-43fc-9a0d-5af79237c3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_98c0998a-c48f-40ff-a781-7a6666b4f3e9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_976c1d96-c7e9-43fc-9a0d-5af79237c3b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_2959ed37-2943-43e2-b7cf-527508b77b50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_98c0998a-c48f-40ff-a781-7a6666b4f3e9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_2959ed37-2943-43e2-b7cf-527508b77b50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_89249c91-5b48-468c-93d6-8a3d6a4ffc48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_98c0998a-c48f-40ff-a781-7a6666b4f3e9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_89249c91-5b48-468c-93d6-8a3d6a4ffc48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent_2d9a9eb1-9cac-402c-8963-83a97be558b1" xlink:href="arwr-20250930.xsd#arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_98c0998a-c48f-40ff-a781-7a6666b4f3e9" xlink:to="loc_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent_2d9a9eb1-9cac-402c-8963-83a97be558b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent_2dafcc7c-5b19-49c7-884c-67935c101639" xlink:href="arwr-20250930.xsd#arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_98c0998a-c48f-40ff-a781-7a6666b4f3e9" xlink:to="loc_arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent_2dafcc7c-5b19-49c7-884c-67935c101639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ee63937f-3654-4b45-bd0a-5546a49ac546" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_98c0998a-c48f-40ff-a781-7a6666b4f3e9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ee63937f-3654-4b45-bd0a-5546a49ac546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7e80b281-91b7-429a-8321-7bff047bf375" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_98c0998a-c48f-40ff-a781-7a6666b4f3e9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7e80b281-91b7-429a-8321-7bff047bf375" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_3c1309c6-bb4e-40e8-8709-a40691b467d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2ab45d2b-0cbb-4ada-873b-b087d0727bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_3c1309c6-bb4e-40e8-8709-a40691b467d9" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2ab45d2b-0cbb-4ada-873b-b087d0727bc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome_22c794b7-c708-4ad1-baf3-90ce80db9206" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_3c1309c6-bb4e-40e8-8709-a40691b467d9" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome_22c794b7-c708-4ad1-baf3-90ce80db9206" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxLiabilitiesOriginalIssueDiscount_c78480ec-a77f-494d-ad2c-941e0dc3a88a" xlink:href="arwr-20250930.xsd#arwr_DeferredTaxLiabilitiesOriginalIssueDiscount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_3c1309c6-bb4e-40e8-8709-a40691b467d9" xlink:to="loc_arwr_DeferredTaxLiabilitiesOriginalIssueDiscount_c78480ec-a77f-494d-ad2c-941e0dc3a88a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_a148f587-9cef-47c3-90d9-3bd26acc2c80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_3c1309c6-bb4e-40e8-8709-a40691b467d9" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_a148f587-9cef-47c3-90d9-3bd26acc2c80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6406e9aa-4744-4853-a24a-d13d3a933a46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_f2dfc737-f8b5-4416-a2a4-8943d8ff385a" xlink:href="arwr-20250930.xsd#arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6406e9aa-4744-4853-a24a-d13d3a933a46" xlink:to="loc_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_f2dfc737-f8b5-4416-a2a4-8943d8ff385a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_7faa219f-ac03-4266-b2da-d18d356f97e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6406e9aa-4744-4853-a24a-d13d3a933a46" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_7faa219f-ac03-4266-b2da-d18d356f97e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_f358269d-0c85-492c-bc3f-800f53431d3e" xlink:href="arwr-20250930.xsd#arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6406e9aa-4744-4853-a24a-d13d3a933a46" xlink:to="loc_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_f358269d-0c85-492c-bc3f-800f53431d3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_02e40b8a-81d4-4468-a179-7dea97c436a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6406e9aa-4744-4853-a24a-d13d3a933a46" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_02e40b8a-81d4-4468-a179-7dea97c436a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_7cd3c410-b025-4d66-9b9a-6ca5073e547f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6406e9aa-4744-4853-a24a-d13d3a933a46" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_7cd3c410-b025-4d66-9b9a-6ca5073e547f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_adc1980b-a440-46b9-a04a-2c4db05076de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6406e9aa-4744-4853-a24a-d13d3a933a46" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_adc1980b-a440-46b9-a04a-2c4db05076de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_fb967ca1-e87f-4954-88e1-46ceb6df8873" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6406e9aa-4744-4853-a24a-d13d3a933a46" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_fb967ca1-e87f-4954-88e1-46ceb6df8873" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_d81f9b25-d9bd-42a1-a01c-8090efb1c8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6406e9aa-4744-4853-a24a-d13d3a933a46" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_d81f9b25-d9bd-42a1-a01c-8090efb1c8c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_83953240-ce56-4aaf-b66b-920e24200f97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6406e9aa-4744-4853-a24a-d13d3a933a46" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_83953240-ce56-4aaf-b66b-920e24200f97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e2aef050-ff7b-43e4-9d18-0886d5c5fc81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a9f0228c-d181-43f6-9892-a6d3a5ef7d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e2aef050-ff7b-43e4-9d18-0886d5c5fc81" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a9f0228c-d181-43f6-9892-a6d3a5ef7d6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8793c85f-6903-4e72-b083-25f49b155fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e2aef050-ff7b-43e4-9d18-0886d5c5fc81" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_8793c85f-6903-4e72-b083-25f49b155fb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ede3348c-f08f-40e4-8ec9-70a120e4169f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e2aef050-ff7b-43e4-9d18-0886d5c5fc81" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_ede3348c-f08f-40e4-8ec9-70a120e4169f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a2e2727c-ca5f-4e84-b8d1-d1368abca8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_bcd07d1d-1d34-4782-a6d7-f64f089221eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_a2e2727c-ca5f-4e84-b8d1-d1368abca8a3" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_bcd07d1d-1d34-4782-a6d7-f64f089221eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_26590feb-a34e-4158-84cc-8f7445ce95c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_a2e2727c-ca5f-4e84-b8d1-d1368abca8a3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_26590feb-a34e-4158-84cc-8f7445ce95c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_89c13f4c-980b-4e7c-a899-756d8fc44388" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_a2e2727c-ca5f-4e84-b8d1-d1368abca8a3" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_89c13f4c-980b-4e7c-a899-756d8fc44388" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ac6d0a88-091f-44c4-a5c1-2dc78deb13d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_a10a5c89-e4f4-4bec-9291-8e81ab61da38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_ac6d0a88-091f-44c4-a5c1-2dc78deb13d9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_a10a5c89-e4f4-4bec-9291-8e81ab61da38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_0fcf61ab-da48-4839-8ab3-c090f46ee55e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_ac6d0a88-091f-44c4-a5c1-2dc78deb13d9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_0fcf61ab-da48-4839-8ab3-c090f46ee55e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1ab23b94-9aa4-4531-86bb-7ef01570f27f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_ac6d0a88-091f-44c4-a5c1-2dc78deb13d9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1ab23b94-9aa4-4531-86bb-7ef01570f27f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d865c720-d5d9-4301-a6ee-66a2380fc265" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_ac6d0a88-091f-44c4-a5c1-2dc78deb13d9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d865c720-d5d9-4301-a6ee-66a2380fc265" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ae44c094-7706-4d97-941c-144c546ee3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_ac6d0a88-091f-44c4-a5c1-2dc78deb13d9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ae44c094-7706-4d97-941c-144c546ee3d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fa8dc32c-c0e4-43bd-a88a-4b97f86e5cae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_ac6d0a88-091f-44c4-a5c1-2dc78deb13d9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fa8dc32c-c0e4-43bd-a88a-4b97f86e5cae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a8bade3a-4c59-4c56-bf7b-24f353f721b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07061ba0-33e7-439c-8370-c201ef2771eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a8bade3a-4c59-4c56-bf7b-24f353f721b2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07061ba0-33e7-439c-8370-c201ef2771eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b8c040c7-a3dc-48b0-add3-2f4c0320ecec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a8bade3a-4c59-4c56-bf7b-24f353f721b2" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b8c040c7-a3dc-48b0-add3-2f4c0320ecec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense_06544390-472a-49f8-acd8-9fb922af11bb" xlink:href="arwr-20250930.xsd#arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation_07226fe6-81d9-417b-85ca-564ce6e829b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense_06544390-472a-49f8-acd8-9fb922af11bb" xlink:to="loc_us-gaap_SalariesWagesAndOfficersCompensation_07226fe6-81d9-417b-85ca-564ce6e829b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_e336a63f-d8aa-4d18-a43a-1be00463bc79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense_06544390-472a-49f8-acd8-9fb922af11bb" xlink:to="loc_us-gaap_ProfessionalFees_e336a63f-d8aa-4d18-a43a-1be00463bc79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense_ebb19942-fa4a-447a-96ff-7b9be1628fab" xlink:href="arwr-20250930.xsd#arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense_06544390-472a-49f8-acd8-9fb922af11bb" xlink:to="loc_arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense_ebb19942-fa4a-447a-96ff-7b9be1628fab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_36f0d0d1-9852-4c10-8e4d-42bc43e3ec7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense_406fc569-5a98-462a-86de-98512c47fa4c" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_36f0d0d1-9852-4c10-8e4d-42bc43e3ec7c" xlink:to="loc_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense_406fc569-5a98-462a-86de-98512c47fa4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0adb95f4-4a46-4813-8239-8d9ce0396b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_36f0d0d1-9852-4c10-8e4d-42bc43e3ec7c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0adb95f4-4a46-4813-8239-8d9ce0396b2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_15866e33-3e60-484e-948b-9bb1fc39506a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_36f0d0d1-9852-4c10-8e4d-42bc43e3ec7c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_15866e33-3e60-484e-948b-9bb1fc39506a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense_665b0748-bbb7-4948-ac9d-ebe826de48e2" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseCandidateCosts_e5877f18-358f-4bfe-adcb-be1a95ad220b" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseCandidateCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense_665b0748-bbb7-4948-ac9d-ebe826de48e2" xlink:to="loc_arwr_ResearchAndDevelopmentExpenseCandidateCosts_e5877f18-358f-4bfe-adcb-be1a95ad220b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseDiscoveryCosts_189b5549-6c0f-4176-a0db-dfc3d705ea56" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseDiscoveryCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense_665b0748-bbb7-4948-ac9d-ebe826de48e2" xlink:to="loc_arwr_ResearchAndDevelopmentExpenseDiscoveryCosts_189b5549-6c0f-4176-a0db-dfc3d705ea56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseSalariesExpense_5e2b567f-f81a-43d2-9884-12f486f92450" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseSalariesExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense_665b0748-bbb7-4948-ac9d-ebe826de48e2" xlink:to="loc_arwr_ResearchAndDevelopmentExpenseSalariesExpense_5e2b567f-f81a-43d2-9884-12f486f92450" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense_891d8f3a-d294-48f3-96cf-8a61fd152994" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense_665b0748-bbb7-4948-ac9d-ebe826de48e2" xlink:to="loc_arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense_891d8f3a-d294-48f3-96cf-8a61fd152994" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ba2594b9-3616-40e9-a588-92f24ce647cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense_1aca4ac4-46d0-47e8-a9ed-49f2bc240d77" xlink:href="arwr-20250930.xsd#arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_ba2594b9-3616-40e9-a588-92f24ce647cf" xlink:to="loc_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense_1aca4ac4-46d0-47e8-a9ed-49f2bc240d77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_51134403-ff82-457a-a4f3-7326aa404cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_ba2594b9-3616-40e9-a588-92f24ce647cf" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_51134403-ff82-457a-a4f3-7326aa404cb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_232e762f-fae7-48c3-b686-e423dba97e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_ba2594b9-3616-40e9-a588-92f24ce647cf" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_232e762f-fae7-48c3-b686-e423dba97e9f" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>arwr-20250930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:67e6a79e-2429-4a7b-924a-105395255933,g:bc385ee3-281d-4402-b0c2-11a4f6b4f5dd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arwr-20250930.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0649f5eb-496b-4909-9ade-4efb59000478" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bca1d579-9b9f-4cc3-85ab-dc8b6ff7ef59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0649f5eb-496b-4909-9ade-4efb59000478" xlink:to="loc_us-gaap_StatementTable_bca1d579-9b9f-4cc3-85ab-dc8b6ff7ef59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_f570cd97-ada8-416c-ac47-5c8a7817e83e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_bca1d579-9b9f-4cc3-85ab-dc8b6ff7ef59" xlink:to="loc_srt_ConsolidatedEntitiesAxis_f570cd97-ada8-416c-ac47-5c8a7817e83e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_f570cd97-ada8-416c-ac47-5c8a7817e83e_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_f570cd97-ada8-416c-ac47-5c8a7817e83e" xlink:to="loc_srt_ConsolidatedEntitiesDomain_f570cd97-ada8-416c-ac47-5c8a7817e83e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3b328701-d50e-4125-8d73-dbe5cf087ea3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_f570cd97-ada8-416c-ac47-5c8a7817e83e" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3b328701-d50e-4125-8d73-dbe5cf087ea3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember_522898c6-5382-49ec-b889-63ddc106a29f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_3b328701-d50e-4125-8d73-dbe5cf087ea3" xlink:to="loc_srt_ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember_522898c6-5382-49ec-b889-63ddc106a29f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_fe11e775-70ba-4c7b-81fb-017f215dcb36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_3b328701-d50e-4125-8d73-dbe5cf087ea3" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_fe11e775-70ba-4c7b-81fb-017f215dcb36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6eb4867e-09d5-41a9-a1b9-09aa79ad31dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0649f5eb-496b-4909-9ade-4efb59000478" xlink:to="loc_us-gaap_AssetsAbstract_6eb4867e-09d5-41a9-a1b9-09aa79ad31dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_b480a7a6-e65d-4d15-9516-f7675d68714b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6eb4867e-09d5-41a9-a1b9-09aa79ad31dd" xlink:to="loc_us-gaap_AssetsCurrentAbstract_b480a7a6-e65d-4d15-9516-f7675d68714b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_731c0af9-acc3-46c8-b6d1-1391313416ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b480a7a6-e65d-4d15-9516-f7675d68714b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_731c0af9-acc3-46c8-b6d1-1391313416ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_bb480458-e39f-40bf-8d9b-c21ca218d34c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b480a7a6-e65d-4d15-9516-f7675d68714b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_bb480458-e39f-40bf-8d9b-c21ca218d34c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2e102732-6fdc-4d26-a9ed-c73b1e3a92dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b480a7a6-e65d-4d15-9516-f7675d68714b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2e102732-6fdc-4d26-a9ed-c73b1e3a92dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_b9d58f9a-d0e7-4b85-b67c-6efb3cbbac01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b480a7a6-e65d-4d15-9516-f7675d68714b" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_b9d58f9a-d0e7-4b85-b67c-6efb3cbbac01" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_df7b2a73-c4a0-4d40-bf0e-c62deff0576e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b480a7a6-e65d-4d15-9516-f7675d68714b" xlink:to="loc_us-gaap_OtherAssetsCurrent_df7b2a73-c4a0-4d40-bf0e-c62deff0576e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3f282d83-9484-4d20-b6a0-2a789b0c3c24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b480a7a6-e65d-4d15-9516-f7675d68714b" xlink:to="loc_us-gaap_AssetsCurrent_3f282d83-9484-4d20-b6a0-2a789b0c3c24" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b1845707-4afc-4fd6-9811-438ba6baed10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6eb4867e-09d5-41a9-a1b9-09aa79ad31dd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b1845707-4afc-4fd6-9811-438ba6baed10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_42d937da-22c9-4f5a-afe7-01aa59f6fe72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6eb4867e-09d5-41a9-a1b9-09aa79ad31dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_42d937da-22c9-4f5a-afe7-01aa59f6fe72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_47dca8a7-efd6-4de5-b995-400a5ceb241b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6eb4867e-09d5-41a9-a1b9-09aa79ad31dd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_47dca8a7-efd6-4de5-b995-400a5ceb241b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_118724ec-0a6e-451c-bd78-6a17d6fe2e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6eb4867e-09d5-41a9-a1b9-09aa79ad31dd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_118724ec-0a6e-451c-bd78-6a17d6fe2e0d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_605dad12-cd20-400c-b695-d57d9e64e4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6eb4867e-09d5-41a9-a1b9-09aa79ad31dd" xlink:to="loc_us-gaap_Assets_605dad12-cd20-400c-b695-d57d9e64e4c2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8e14fb68-8044-464f-92a1-03241fb2e01d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0649f5eb-496b-4909-9ade-4efb59000478" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8e14fb68-8044-464f-92a1-03241fb2e01d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_892cb833-19fd-4c8e-bead-af7c5928c60b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8e14fb68-8044-464f-92a1-03241fb2e01d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_892cb833-19fd-4c8e-bead-af7c5928c60b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e1ef1534-1815-4d9b-b499-1dc6556fb13e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_892cb833-19fd-4c8e-bead-af7c5928c60b" xlink:to="loc_us-gaap_AccountsPayableCurrent_e1ef1534-1815-4d9b-b499-1dc6556fb13e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_189dc0e5-be2d-4071-959f-71e692c078f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_892cb833-19fd-4c8e-bead-af7c5928c60b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_189dc0e5-be2d-4071-959f-71e692c078f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e0edaec5-3613-4041-adf7-3b43256522a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_892cb833-19fd-4c8e-bead-af7c5928c60b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e0edaec5-3613-4041-adf7-3b43256522a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_30d46788-98e0-4ef9-8643-92065717c227" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_892cb833-19fd-4c8e-bead-af7c5928c60b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_30d46788-98e0-4ef9-8643-92065717c227" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7355a36b-5b44-46eb-9f71-e952ddd3e4df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_892cb833-19fd-4c8e-bead-af7c5928c60b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7355a36b-5b44-46eb-9f71-e952ddd3e4df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_23a85c5b-4ec7-4f32-b423-83eba65a3c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_892cb833-19fd-4c8e-bead-af7c5928c60b" xlink:to="loc_us-gaap_LinesOfCreditCurrent_23a85c5b-4ec7-4f32-b423-83eba65a3c7a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_cb001bf1-508b-4736-ae11-d4f0f5b83049" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_892cb833-19fd-4c8e-bead-af7c5928c60b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_cb001bf1-508b-4736-ae11-d4f0f5b83049" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ece1cb60-324b-4acc-b7f6-0f18b4ac1412" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_892cb833-19fd-4c8e-bead-af7c5928c60b" xlink:to="loc_us-gaap_LiabilitiesCurrent_ece1cb60-324b-4acc-b7f6-0f18b4ac1412" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_7922a042-93c5-40c1-9b24-88f4a5913aec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8e14fb68-8044-464f-92a1-03241fb2e01d" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_7922a042-93c5-40c1-9b24-88f4a5913aec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ded854df-d493-4f08-b34f-e0c039820911" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_7922a042-93c5-40c1-9b24-88f4a5913aec" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ded854df-d493-4f08-b34f-e0c039820911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent_e4668b5f-968e-4ca1-b1e1-77b5df84e017" xlink:href="arwr-20250930.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_7922a042-93c5-40c1-9b24-88f4a5913aec" xlink:to="loc_arwr_RoyaltiesLiabilityNoncurrent_e4668b5f-968e-4ca1-b1e1-77b5df84e017" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_aaa1c66e-d71b-4e8b-a353-1cd566f0db2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_7922a042-93c5-40c1-9b24-88f4a5913aec" xlink:to="loc_us-gaap_LongTermLineOfCredit_aaa1c66e-d71b-4e8b-a353-1cd566f0db2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_606835ce-2ede-4158-a3f5-882e8fa3fda1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_7922a042-93c5-40c1-9b24-88f4a5913aec" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_606835ce-2ede-4158-a3f5-882e8fa3fda1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2f4fba15-f8ae-41ff-8de7-4d73578e3772" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8e14fb68-8044-464f-92a1-03241fb2e01d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2f4fba15-f8ae-41ff-8de7-4d73578e3772" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb5edf2b-d4c2-4cd5-aac4-29ac97cc6f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8e14fb68-8044-464f-92a1-03241fb2e01d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb5edf2b-d4c2-4cd5-aac4-29ac97cc6f1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9d7c795a-3c80-4a7d-bdc3-6aebf954ba8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb5edf2b-d4c2-4cd5-aac4-29ac97cc6f1e" xlink:to="loc_us-gaap_CommonStockValue_9d7c795a-3c80-4a7d-bdc3-6aebf954ba8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3e09703a-801e-417e-92c6-28e6f85a2657" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb5edf2b-d4c2-4cd5-aac4-29ac97cc6f1e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3e09703a-801e-417e-92c6-28e6f85a2657" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ce2c8897-b2b1-44c0-8871-89fce91ce0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb5edf2b-d4c2-4cd5-aac4-29ac97cc6f1e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ce2c8897-b2b1-44c0-8871-89fce91ce0d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_77a44dfc-effc-4b18-878f-a227dff89be5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb5edf2b-d4c2-4cd5-aac4-29ac97cc6f1e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_77a44dfc-effc-4b18-878f-a227dff89be5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_1d3a6741-9d92-4117-9fab-1353a03c8891" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb5edf2b-d4c2-4cd5-aac4-29ac97cc6f1e" xlink:to="loc_us-gaap_TreasuryStockCommonValue_1d3a6741-9d92-4117-9fab-1353a03c8891" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_98e3e82b-831a-4ed5-bbbf-92e90f78b3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb5edf2b-d4c2-4cd5-aac4-29ac97cc6f1e" xlink:to="loc_us-gaap_StockholdersEquity_98e3e82b-831a-4ed5-bbbf-92e90f78b3c8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_c346b38c-c347-4e7a-a789-66bb799a0b24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb5edf2b-d4c2-4cd5-aac4-29ac97cc6f1e" xlink:to="loc_us-gaap_MinorityInterest_c346b38c-c347-4e7a-a789-66bb799a0b24" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_845c0ce5-e87a-4170-895f-95f76faa7156" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb5edf2b-d4c2-4cd5-aac4-29ac97cc6f1e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_845c0ce5-e87a-4170-895f-95f76faa7156" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d41e0149-05ec-4953-a6df-d092bfae3c18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8e14fb68-8044-464f-92a1-03241fb2e01d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d41e0149-05ec-4953-a6df-d092bfae3c18" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="arwr-20250930.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1bddd27f-3754-4e4b-be68-0f88a1dceaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f9009b58-bced-4106-876e-7a4385805ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1bddd27f-3754-4e4b-be68-0f88a1dceaf0" xlink:to="loc_us-gaap_StatementTable_f9009b58-bced-4106-876e-7a4385805ea9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a4515857-d18a-47e6-a9bb-55d238c81a78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f9009b58-bced-4106-876e-7a4385805ea9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a4515857-d18a-47e6-a9bb-55d238c81a78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a4515857-d18a-47e6-a9bb-55d238c81a78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a4515857-d18a-47e6-a9bb-55d238c81a78" xlink:to="loc_us-gaap_EquityComponentDomain_a4515857-d18a-47e6-a9bb-55d238c81a78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dbb31a3e-27f7-4470-8f26-cdf08e55711e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a4515857-d18a-47e6-a9bb-55d238c81a78" xlink:to="loc_us-gaap_EquityComponentDomain_dbb31a3e-27f7-4470-8f26-cdf08e55711e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d1cde91c-10fe-47c3-b9bc-9e00a7b3f073" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dbb31a3e-27f7-4470-8f26-cdf08e55711e" xlink:to="loc_us-gaap_CommonStockMember_d1cde91c-10fe-47c3-b9bc-9e00a7b3f073" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_754324fb-aa7c-4165-9bb6-478ff37d8749" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dbb31a3e-27f7-4470-8f26-cdf08e55711e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_754324fb-aa7c-4165-9bb6-478ff37d8749" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_22a313b5-4f58-4926-955b-aec62c785685" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dbb31a3e-27f7-4470-8f26-cdf08e55711e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_22a313b5-4f58-4926-955b-aec62c785685" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e9f2d731-0aad-4204-887d-02d1390f45c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dbb31a3e-27f7-4470-8f26-cdf08e55711e" xlink:to="loc_us-gaap_RetainedEarningsMember_e9f2d731-0aad-4204-887d-02d1390f45c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_5da190c4-8f76-4bdc-8e87-0f0ea6f2a833" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dbb31a3e-27f7-4470-8f26-cdf08e55711e" xlink:to="loc_us-gaap_TreasuryStockCommonMember_5da190c4-8f76-4bdc-8e87-0f0ea6f2a833" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_0ecf7799-441c-46db-baa3-e6a9344f4583" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dbb31a3e-27f7-4470-8f26-cdf08e55711e" xlink:to="loc_us-gaap_NoncontrollingInterestMember_0ecf7799-441c-46db-baa3-e6a9344f4583" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1bddd27f-3754-4e4b-be68-0f88a1dceaf0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8f775658-cc33-4fc6-9472-9eb061cf5b39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8f775658-cc33-4fc6-9472-9eb061cf5b39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50a8694f-3f6b-4b2a-9fd4-0865e119e417" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50a8694f-3f6b-4b2a-9fd4-0865e119e417" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_0c66fe79-eae1-404a-a898-190890e7a3be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_TreasuryStockCommonShares_0c66fe79-eae1-404a-a898-190890e7a3be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f3f722ce-27a9-4ebc-88c4-950a556ebc74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f3f722ce-27a9-4ebc-88c4-950a556ebc74" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3c03cd7c-79ac-4b98-b30b-30b5b77fb394" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3c03cd7c-79ac-4b98-b30b-30b5b77fb394" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f6c722c3-24c5-41b5-969d-9c6b067e4e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f6c722c3-24c5-41b5-969d-9c6b067e4e8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3d0d27ff-c24d-47e3-9404-86ab64f4752a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3d0d27ff-c24d-47e3-9404-86ab64f4752a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_e65180e0-ec3e-464f-84fd-cd0962838ead" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_e65180e0-ec3e-464f-84fd-cd0962838ead" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6cd6bf50-81a4-4e4e-b7dc-f538550f911c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6cd6bf50-81a4-4e4e-b7dc-f538550f911c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c17020fb-4d50-4e96-858c-15efd74a145f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c17020fb-4d50-4e96-858c-15efd74a145f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_35ee9ff0-c789-4ecd-8605-7a301dfbde80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_35ee9ff0-c789-4ecd-8605-7a301dfbde80" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_1ad1afaa-debd-43b4-9bf5-12814e9cf1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_1ad1afaa-debd-43b4-9bf5-12814e9cf1c9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_7487c792-509c-4d43-a137-c7e8bec809bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_7487c792-509c-4d43-a137-c7e8bec809bc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_51b9b3e8-2551-4850-8b44-7c9314f5a1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_51b9b3e8-2551-4850-8b44-7c9314f5a1dc" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_113af4a4-9478-41d8-a004-76608b98a325" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_113af4a4-9478-41d8-a004-76608b98a325" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_661da765-6d5f-49c9-a23f-80336f143d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_ProfitLoss_661da765-6d5f-49c9-a23f-80336f143d3e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_695c9f32-0850-405c-a91b-150031ecca93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_23bedabb-2c63-439f-affb-804ebb647d17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_dfb03a61-0e8a-4cbb-ba4d-e27031c06212" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#OrganizationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:href="arwr-20250930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_fe516f51-7c96-40a6-8c1c-25f82683fb3f" xlink:href="arwr-20250930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_fe516f51-7c96-40a6-8c1c-25f82683fb3f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_77630827-c4ae-4539-b85a-9e4786932609" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_fe516f51-7c96-40a6-8c1c-25f82683fb3f" xlink:to="loc_srt_CounterpartyNameAxis_77630827-c4ae-4539-b85a-9e4786932609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77630827-c4ae-4539-b85a-9e4786932609_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_77630827-c4ae-4539-b85a-9e4786932609" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77630827-c4ae-4539-b85a-9e4786932609_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7dfb9ec2-96f6-4e31-95c0-ced67148795c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_77630827-c4ae-4539-b85a-9e4786932609" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7dfb9ec2-96f6-4e31-95c0-ced67148795c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaTherapeuticsIncMember_53c13c99-e3dd-4848-ac37-5083fb13a5da" xlink:href="arwr-20250930.xsd#arwr_SareptaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7dfb9ec2-96f6-4e31-95c0-ced67148795c" xlink:to="loc_arwr_SareptaTherapeuticsIncMember_53c13c99-e3dd-4848-ac37-5083fb13a5da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6280b43f-e924-4a31-a55b-f78b0df63744" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_fe516f51-7c96-40a6-8c1c-25f82683fb3f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6280b43f-e924-4a31-a55b-f78b0df63744" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6280b43f-e924-4a31-a55b-f78b0df63744_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6280b43f-e924-4a31-a55b-f78b0df63744" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6280b43f-e924-4a31-a55b-f78b0df63744_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9b8f9b6c-3d3e-4d48-9644-3595154c1cec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6280b43f-e924-4a31-a55b-f78b0df63744" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9b8f9b6c-3d3e-4d48-9644-3595154c1cec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember_9457cf31-d8ca-43f6-9a71-1122898cbf5c" xlink:href="arwr-20250930.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9b8f9b6c-3d3e-4d48-9644-3595154c1cec" xlink:to="loc_arwr_SareptaCollaborationAgreementMember_9457cf31-d8ca-43f6-9a71-1122898cbf5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4c419ba5-fb43-478c-91c6-1c225968ecb2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_fe516f51-7c96-40a6-8c1c-25f82683fb3f" xlink:to="loc_srt_RangeAxis_4c419ba5-fb43-478c-91c6-1c225968ecb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4c419ba5-fb43-478c-91c6-1c225968ecb2_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4c419ba5-fb43-478c-91c6-1c225968ecb2" xlink:to="loc_srt_RangeMember_4c419ba5-fb43-478c-91c6-1c225968ecb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dfa51520-56ba-461d-a7a2-42751dacb739" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4c419ba5-fb43-478c-91c6-1c225968ecb2" xlink:to="loc_srt_RangeMember_dfa51520-56ba-461d-a7a2-42751dacb739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_734dd71e-afeb-4370-98ab-5ffd91d28d09" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dfa51520-56ba-461d-a7a2-42751dacb739" xlink:to="loc_srt_MaximumMember_734dd71e-afeb-4370-98ab-5ffd91d28d09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9369036c-d470-4e13-870c-a586d7acdc21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9369036c-d470-4e13-870c-a586d7acdc21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_e11ad80e-c0af-4304-b7d3-69f49d544319" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_e11ad80e-c0af-4304-b7d3-69f49d544319" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c1eed621-c31f-45a7-b49b-ecacd590bf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c1eed621-c31f-45a7-b49b-ecacd590bf2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments_fa5fbc42-65dc-4d72-a70f-0031e42c8869" xlink:href="arwr-20250930.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_arwr_IncreaseDecreaseInCashAndInvestments_fa5fbc42-65dc-4d72-a70f-0031e42c8869" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements_053a95ab-b19f-4705-953e-84f5d32bfec1" xlink:href="arwr-20250930.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_arwr_ProceedsFromCollaborationArrangements_053a95ab-b19f-4705-953e-84f5d32bfec1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0fa501bc-e43f-4993-9111-cf28651ad9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0fa501bc-e43f-4993-9111-cf28651ad9b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentMilestonePayments_c05c7b8e-e0c2-4cb5-a72a-aa7ded511858" xlink:href="arwr-20250930.xsd#arwr_DevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_arwr_DevelopmentMilestonePayments_c05c7b8e-e0c2-4cb5-a72a-aa7ded511858" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ccd857e6-5bd0-44fd-aa0c-ba6faea35b52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ccd857e6-5bd0-44fd-aa0c-ba6faea35b52" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_b7fa4a72-7d0c-4b57-b71a-dc9999198374" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_b7fa4a72-7d0c-4b57-b71a-dc9999198374" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_de930d23-bffb-4405-92ba-7b60a1fbf9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_de930d23-bffb-4405-92ba-7b60a1fbf9c9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_10f28174-db09-4709-a231-ebf674cda9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_10f28174-db09-4709-a231-ebf674cda9e1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a41fc752-8d8a-4cf0-b834-a0d5e337fa4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a41fc752-8d8a-4cf0-b834-a0d5e337fa4d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_194abf4b-bcb1-4ab6-bded-7212d84b6f4f" xlink:href="arwr-20250930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_194abf4b-bcb1-4ab6-bded-7212d84b6f4f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1962ed40-a334-4636-8490-5fa508d3e032" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1962ed40-a334-4636-8490-5fa508d3e032" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency_1244d564-014a-4355-870a-2a850c3f5b79" xlink:href="arwr-20250930.xsd#arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency_1244d564-014a-4355-870a-2a850c3f5b79" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_97a53544-10cf-4d56-9b98-6617728a6f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_NumberOfOperatingSegments_97a53544-10cf-4d56-9b98-6617728a6f6e" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_ce1b64c6-5d81-4744-b399-c519ab4efd64" xlink:href="arwr-20250930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_744e4e62-6fb4-404c-9f2e-d0369770f792" xlink:href="arwr-20250930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_ce1b64c6-5d81-4744-b399-c519ab4efd64" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_744e4e62-6fb4-404c-9f2e-d0369770f792" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2f388199-c08f-468d-85ee-d5af5492d1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_744e4e62-6fb4-404c-9f2e-d0369770f792" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2f388199-c08f-468d-85ee-d5af5492d1d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2f388199-c08f-468d-85ee-d5af5492d1d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2f388199-c08f-468d-85ee-d5af5492d1d2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2f388199-c08f-468d-85ee-d5af5492d1d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0da545ab-1929-4fcd-8b4c-c8a3e5e4f15f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2f388199-c08f-468d-85ee-d5af5492d1d2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0da545ab-1929-4fcd-8b4c-c8a3e5e4f15f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_9a9010b9-4147-4512-a170-25c320c74210" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0da545ab-1929-4fcd-8b4c-c8a3e5e4f15f" xlink:to="loc_us-gaap_BuildingMember_9a9010b9-4147-4512-a170-25c320c74210" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentMember_a1aee41f-c85c-4143-ab6f-ac9f66a0946c" xlink:href="arwr-20250930.xsd#arwr_ResearchEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0da545ab-1929-4fcd-8b4c-c8a3e5e4f15f" xlink:to="loc_arwr_ResearchEquipmentMember_a1aee41f-c85c-4143-ab6f-ac9f66a0946c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ManufacturingEquipmentMember_23547b56-c3da-4e04-a21d-dec331447885" xlink:href="arwr-20250930.xsd#arwr_ManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0da545ab-1929-4fcd-8b4c-c8a3e5e4f15f" xlink:to="loc_arwr_ManufacturingEquipmentMember_23547b56-c3da-4e04-a21d-dec331447885" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d39b063f-9ae5-4594-9ac4-ecca8385c06e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0da545ab-1929-4fcd-8b4c-c8a3e5e4f15f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d39b063f-9ae5-4594-9ac4-ecca8385c06e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputersAndSoftwareMember_a403fb3a-64ba-4b88-b1d9-5a692299a266" xlink:href="arwr-20250930.xsd#arwr_ComputersAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0da545ab-1929-4fcd-8b4c-c8a3e5e4f15f" xlink:to="loc_arwr_ComputersAndSoftwareMember_a403fb3a-64ba-4b88-b1d9-5a692299a266" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cde9d0d6-d539-420e-997f-eccf2c3cdf03" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_744e4e62-6fb4-404c-9f2e-d0369770f792" xlink:to="loc_srt_RangeAxis_cde9d0d6-d539-420e-997f-eccf2c3cdf03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cde9d0d6-d539-420e-997f-eccf2c3cdf03_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cde9d0d6-d539-420e-997f-eccf2c3cdf03" xlink:to="loc_srt_RangeMember_cde9d0d6-d539-420e-997f-eccf2c3cdf03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3f71d631-21e6-4222-854d-4ba6fc528ad3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cde9d0d6-d539-420e-997f-eccf2c3cdf03" xlink:to="loc_srt_RangeMember_3f71d631-21e6-4222-854d-4ba6fc528ad3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2e7700b9-21b2-45a1-aa55-7e11c5ed75de" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3f71d631-21e6-4222-854d-4ba6fc528ad3" xlink:to="loc_srt_MinimumMember_2e7700b9-21b2-45a1-aa55-7e11c5ed75de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_da19a526-bcf9-4223-9177-4f31f784146d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3f71d631-21e6-4222-854d-4ba6fc528ad3" xlink:to="loc_srt_MaximumMember_da19a526-bcf9-4223-9177-4f31f784146d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d021194f-ae2d-41bf-9d65-b3768e4db0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_ce1b64c6-5d81-4744-b399-c519ab4efd64" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d021194f-ae2d-41bf-9d65-b3768e4db0a2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#CollaborationandLicenseAgreementsRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a42c146a-cf45-4bd0-8219-d22887fddb97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a0097fc4-ec1d-4f9f-87d6-aed5b9d3c8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a42c146a-cf45-4bd0-8219-d22887fddb97" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a0097fc4-ec1d-4f9f-87d6-aed5b9d3c8ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0193a116-1a01-4a5a-b9de-e43df8043361" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a0097fc4-ec1d-4f9f-87d6-aed5b9d3c8ac" xlink:to="loc_srt_MajorCustomersAxis_0193a116-1a01-4a5a-b9de-e43df8043361" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0193a116-1a01-4a5a-b9de-e43df8043361_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_0193a116-1a01-4a5a-b9de-e43df8043361" xlink:to="loc_srt_NameOfMajorCustomerDomain_0193a116-1a01-4a5a-b9de-e43df8043361_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7f041358-3a6e-47cd-b27b-5e0dcf482c55" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_0193a116-1a01-4a5a-b9de-e43df8043361" xlink:to="loc_srt_NameOfMajorCustomerDomain_7f041358-3a6e-47cd-b27b-5e0dcf482c55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_bf65c8c9-8724-4f4b-9e35-1e3af8e8ea7b" xlink:href="arwr-20250930.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7f041358-3a6e-47cd-b27b-5e0dcf482c55" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_bf65c8c9-8724-4f4b-9e35-1e3af8e8ea7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_03bf59d7-3d40-4de4-b0f6-6a4d5fe02b9e" xlink:href="arwr-20250930.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7f041358-3a6e-47cd-b27b-5e0dcf482c55" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_03bf59d7-3d40-4de4-b0f6-6a4d5fe02b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_891295d2-ef13-43fb-a33c-7c799713e7ef" xlink:href="arwr-20250930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7f041358-3a6e-47cd-b27b-5e0dcf482c55" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_891295d2-ef13-43fb-a33c-7c799713e7ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_39bd0565-c2bb-49e0-be52-44bf54606ec7" xlink:href="arwr-20250930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7f041358-3a6e-47cd-b27b-5e0dcf482c55" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_39bd0565-c2bb-49e0-be52-44bf54606ec7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_aaee492c-ea76-4b75-a5ae-90742f8f96c7" xlink:href="arwr-20250930.xsd#arwr_AmgenIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7f041358-3a6e-47cd-b27b-5e0dcf482c55" xlink:to="loc_arwr_AmgenIncorporatedMember_aaee492c-ea76-4b75-a5ae-90742f8f96c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaTherapeuticsIncMember_0a814486-2d3e-4488-ad8f-4ed63a595a9a" xlink:href="arwr-20250930.xsd#arwr_SareptaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7f041358-3a6e-47cd-b27b-5e0dcf482c55" xlink:to="loc_arwr_SareptaTherapeuticsIncMember_0a814486-2d3e-4488-ad8f-4ed63a595a9a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SanofiMember_7f7588f2-d06c-495d-8af6-66d8e93614a9" xlink:href="arwr-20250930.xsd#arwr_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7f041358-3a6e-47cd-b27b-5e0dcf482c55" xlink:to="loc_arwr_SanofiMember_7f7588f2-d06c-495d-8af6-66d8e93614a9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_09cb06c1-833c-4eee-86b8-2bd62a441e91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a42c146a-cf45-4bd0-8219-d22887fddb97" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_09cb06c1-833c-4eee-86b8-2bd62a441e91" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1b8d32d-8eaf-4d34-af2d-175b32305b03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1b8d32d-8eaf-4d34-af2d-175b32305b03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8bfc3111-826b-4a32-a420-7fba8e9ef6f3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1b8d32d-8eaf-4d34-af2d-175b32305b03" xlink:to="loc_srt_CounterpartyNameAxis_8bfc3111-826b-4a32-a420-7fba8e9ef6f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bfc3111-826b-4a32-a420-7fba8e9ef6f3_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8bfc3111-826b-4a32-a420-7fba8e9ef6f3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bfc3111-826b-4a32-a420-7fba8e9ef6f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e64ed03-1ef0-446c-807f-306112fc5966" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8bfc3111-826b-4a32-a420-7fba8e9ef6f3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e64ed03-1ef0-446c-807f-306112fc5966" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_6610a086-9466-4159-9436-88ddef9a17c3" xlink:href="arwr-20250930.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e64ed03-1ef0-446c-807f-306112fc5966" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_6610a086-9466-4159-9436-88ddef9a17c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d19965e3-e171-43ea-b1fe-4269aba21e57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1b8d32d-8eaf-4d34-af2d-175b32305b03" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d19965e3-e171-43ea-b1fe-4269aba21e57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d19965e3-e171-43ea-b1fe-4269aba21e57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d19965e3-e171-43ea-b1fe-4269aba21e57" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d19965e3-e171-43ea-b1fe-4269aba21e57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25d44238-cbd9-461e-8e2e-ececa5aa11f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d19965e3-e171-43ea-b1fe-4269aba21e57" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25d44238-cbd9-461e-8e2e-ececa5aa11f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GSKHSDLicenseAgreementMember_01f808ef-e25a-4c24-a1e5-252c70430e17" xlink:href="arwr-20250930.xsd#arwr_GSKHSDLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25d44238-cbd9-461e-8e2e-ececa5aa11f4" xlink:to="loc_arwr_GSKHSDLicenseAgreementMember_01f808ef-e25a-4c24-a1e5-252c70430e17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GSKHBVAgreementMember_61774c21-88dc-42ba-83cd-ad934d7f6b67" xlink:href="arwr-20250930.xsd#arwr_GSKHBVAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25d44238-cbd9-461e-8e2e-ececa5aa11f4" xlink:to="loc_arwr_GSKHBVAgreementMember_61774c21-88dc-42ba-83cd-ad934d7f6b67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c1296aec-378a-4917-ad1e-1b32c2c5a710" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1b8d32d-8eaf-4d34-af2d-175b32305b03" xlink:to="loc_srt_RangeAxis_c1296aec-378a-4917-ad1e-1b32c2c5a710" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c1296aec-378a-4917-ad1e-1b32c2c5a710_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c1296aec-378a-4917-ad1e-1b32c2c5a710" xlink:to="loc_srt_RangeMember_c1296aec-378a-4917-ad1e-1b32c2c5a710_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3f0a1093-d982-49e0-986f-cb5b3da90f59" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c1296aec-378a-4917-ad1e-1b32c2c5a710" xlink:to="loc_srt_RangeMember_3f0a1093-d982-49e0-986f-cb5b3da90f59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_83117b27-fa13-448b-a602-7ad86a7c169e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3f0a1093-d982-49e0-986f-cb5b3da90f59" xlink:to="loc_srt_MaximumMember_83117b27-fa13-448b-a602-7ad86a7c169e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_b4e18a3c-89a8-4c3c-8b2c-655ffd3ad7b6" xlink:href="arwr-20250930.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_arwr_InitialTransactionPrice_b4e18a3c-89a8-4c3c-8b2c-655ffd3ad7b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_0d7b6913-6f5f-4ea0-9ff1-e1f545ef23cf" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_arwr_MilestonePaymentReceivable_0d7b6913-6f5f-4ea0-9ff1-e1f545ef23cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_714e3a06-369d-453a-b205-e87770177885" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_714e3a06-369d-453a-b205-e87770177885" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_c465b253-e411-4cca-b794-b3f9eec0c0b4" xlink:href="arwr-20250930.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_c465b253-e411-4cca-b794-b3f9eec0c0b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_d3952a9d-dc33-42eb-a93c-a549ed002a9a" xlink:href="arwr-20250930.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_arwr_SalesRelatedMilestonePayments_d3952a9d-dc33-42eb-a93c-a549ed002a9a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_d99e636b-25b8-4ee2-a118-6f5a44aa2f20" xlink:href="arwr-20250930.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_d99e636b-25b8-4ee2-a118-6f5a44aa2f20" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentMilestonePayments_e664d975-ffac-44b0-b07c-1c9cc0cf5481" xlink:href="arwr-20250930.xsd#arwr_DevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_arwr_DevelopmentMilestonePayments_e664d975-ffac-44b0-b07c-1c9cc0cf5481" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentAndSalesMilestonesPayments_25356b40-1115-4c61-b213-f6d230847b23" xlink:href="arwr-20250930.xsd#arwr_DevelopmentAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_arwr_DevelopmentAndSalesMilestonesPayments_25356b40-1115-4c61-b213-f6d230847b23" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_dbb817ef-5611-4f8e-b578-10555f340e72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_dbb817ef-5611-4f8e-b578-10555f340e72" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1c37b9d0-c7f3-47e4-a2b5-228bb6ca147a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1c37b9d0-c7f3-47e4-a2b5-228bb6ca147a" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8356815d-fcdd-4abc-b930-5c7d1bfd7b23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d03a8df4-de49-445c-a47b-e0d2b834bfdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8356815d-fcdd-4abc-b930-5c7d1bfd7b23" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d03a8df4-de49-445c-a47b-e0d2b834bfdd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7df1c6d9-9be7-4c40-857d-f4e25e8dcd6e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d03a8df4-de49-445c-a47b-e0d2b834bfdd" xlink:to="loc_srt_CounterpartyNameAxis_7df1c6d9-9be7-4c40-857d-f4e25e8dcd6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7df1c6d9-9be7-4c40-857d-f4e25e8dcd6e_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7df1c6d9-9be7-4c40-857d-f4e25e8dcd6e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7df1c6d9-9be7-4c40-857d-f4e25e8dcd6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3fb2e64-1613-4ace-9b36-d16ab71b3db8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7df1c6d9-9be7-4c40-857d-f4e25e8dcd6e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3fb2e64-1613-4ace-9b36-d16ab71b3db8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_70c2cb74-4c2a-4e85-b702-f9f81b2bac85" xlink:href="arwr-20250930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3fb2e64-1613-4ace-9b36-d16ab71b3db8" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_70c2cb74-4c2a-4e85-b702-f9f81b2bac85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_025b2485-d687-48b5-b708-960ca87fd531" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d03a8df4-de49-445c-a47b-e0d2b834bfdd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_025b2485-d687-48b5-b708-960ca87fd531" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_025b2485-d687-48b5-b708-960ca87fd531_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_025b2485-d687-48b5-b708-960ca87fd531" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_025b2485-d687-48b5-b708-960ca87fd531_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_acd3883f-477d-4c4f-8cd5-d7d99d6019d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_025b2485-d687-48b5-b708-960ca87fd531" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_acd3883f-477d-4c4f-8cd5-d7d99d6019d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember_9894e812-216e-40a8-8382-2fb9a2687c35" xlink:href="arwr-20250930.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_acd3883f-477d-4c4f-8cd5-d7d99d6019d0" xlink:to="loc_arwr_LicenseAndCoFundingAgreementMember_9894e812-216e-40a8-8382-2fb9a2687c35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a68f084b-2500-425f-a679-dd6531242f4e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d03a8df4-de49-445c-a47b-e0d2b834bfdd" xlink:to="loc_srt_RangeAxis_a68f084b-2500-425f-a679-dd6531242f4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a68f084b-2500-425f-a679-dd6531242f4e_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a68f084b-2500-425f-a679-dd6531242f4e" xlink:to="loc_srt_RangeMember_a68f084b-2500-425f-a679-dd6531242f4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2c222461-b8c5-4499-8989-ce24783de126" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a68f084b-2500-425f-a679-dd6531242f4e" xlink:to="loc_srt_RangeMember_2c222461-b8c5-4499-8989-ce24783de126" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9d89de9b-67f6-4bac-ad2a-64162180e109" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2c222461-b8c5-4499-8989-ce24783de126" xlink:to="loc_srt_MinimumMember_9d89de9b-67f6-4bac-ad2a-64162180e109" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d97141bb-1487-43d1-ae92-8a24e9ac32a0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2c222461-b8c5-4499-8989-ce24783de126" xlink:to="loc_srt_MaximumMember_d97141bb-1487-43d1-ae92-8a24e9ac32a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_65d43f88-c605-4786-8a35-fd94e9c9f8fb" xlink:href="arwr-20250930.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8356815d-fcdd-4abc-b930-5c7d1bfd7b23" xlink:to="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_65d43f88-c605-4786-8a35-fd94e9c9f8fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_ad884b05-a122-45c3-af9e-4defebddbcaa" xlink:href="arwr-20250930.xsd#arwr_NumberOfDistinctBundle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8356815d-fcdd-4abc-b930-5c7d1bfd7b23" xlink:to="loc_arwr_NumberOfDistinctBundle_ad884b05-a122-45c3-af9e-4defebddbcaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_1bdb8342-a594-4c95-b9b8-6fa28d991b4b" xlink:href="arwr-20250930.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8356815d-fcdd-4abc-b930-5c7d1bfd7b23" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_1bdb8342-a594-4c95-b9b8-6fa28d991b4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_525c570c-2e0b-4554-82e3-fb7531ab75a4" xlink:href="arwr-20250930.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8356815d-fcdd-4abc-b930-5c7d1bfd7b23" xlink:to="loc_arwr_InitialTransactionPrice_525c570c-2e0b-4554-82e3-fb7531ab75a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_0eb6f62b-5eb7-4875-95fd-3929b177e517" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8356815d-fcdd-4abc-b930-5c7d1bfd7b23" xlink:to="loc_arwr_MilestonePaymentEarned_0eb6f62b-5eb7-4875-95fd-3929b177e517" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_162ff280-0629-486c-91af-4afddc2c30a8" xlink:href="arwr-20250930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8356815d-fcdd-4abc-b930-5c7d1bfd7b23" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_162ff280-0629-486c-91af-4afddc2c30a8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_930b127a-6ab5-4b91-93ca-92dcb314dfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8356815d-fcdd-4abc-b930-5c7d1bfd7b23" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_930b127a-6ab5-4b91-93ca-92dcb314dfc7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_adc01bd8-5b67-4a78-be62-661136a3b205" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8356815d-fcdd-4abc-b930-5c7d1bfd7b23" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_adc01bd8-5b67-4a78-be62-661136a3b205" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#CollaborationandLicenseAgreementsAmgenIncDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91d623f8-d250-4c09-9d95-866b13fa6e78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a3a162a-737b-47ce-9e5e-61c95e183238" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91d623f8-d250-4c09-9d95-866b13fa6e78" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a3a162a-737b-47ce-9e5e-61c95e183238" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_408760b3-d129-488a-bd6f-2b5d781145a9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a3a162a-737b-47ce-9e5e-61c95e183238" xlink:to="loc_srt_CounterpartyNameAxis_408760b3-d129-488a-bd6f-2b5d781145a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_408760b3-d129-488a-bd6f-2b5d781145a9_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_408760b3-d129-488a-bd6f-2b5d781145a9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_408760b3-d129-488a-bd6f-2b5d781145a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9ee37bb-c4d5-4084-bd4c-258b2e55340f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_408760b3-d129-488a-bd6f-2b5d781145a9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9ee37bb-c4d5-4084-bd4c-258b2e55340f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_b1b4456a-c2b4-4080-8205-3cc7ed745863" xlink:href="arwr-20250930.xsd#arwr_AmgenIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9ee37bb-c4d5-4084-bd4c-258b2e55340f" xlink:to="loc_arwr_AmgenIncorporatedMember_b1b4456a-c2b4-4080-8205-3cc7ed745863" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a9559d56-23ae-490e-9f8e-e6c53ed18902" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a3a162a-737b-47ce-9e5e-61c95e183238" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a9559d56-23ae-490e-9f8e-e6c53ed18902" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9559d56-23ae-490e-9f8e-e6c53ed18902_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a9559d56-23ae-490e-9f8e-e6c53ed18902" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9559d56-23ae-490e-9f8e-e6c53ed18902_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_33e0c08f-505d-45a0-ab87-b89ef5d29dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a9559d56-23ae-490e-9f8e-e6c53ed18902" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_33e0c08f-505d-45a0-ab87-b89ef5d29dc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember_250d9817-6616-4ef0-8bee-b4238ee20303" xlink:href="arwr-20250930.xsd#arwr_OlpasiranAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_33e0c08f-505d-45a0-ab87-b89ef5d29dc9" xlink:to="loc_arwr_OlpasiranAgreementMember_250d9817-6616-4ef0-8bee-b4238ee20303" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_76bb1ef0-0bf0-49f4-8519-fc8394eb7191" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a3a162a-737b-47ce-9e5e-61c95e183238" xlink:to="loc_srt_RangeAxis_76bb1ef0-0bf0-49f4-8519-fc8394eb7191" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_76bb1ef0-0bf0-49f4-8519-fc8394eb7191_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_76bb1ef0-0bf0-49f4-8519-fc8394eb7191" xlink:to="loc_srt_RangeMember_76bb1ef0-0bf0-49f4-8519-fc8394eb7191_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_627cd355-fe23-44fe-a29a-12797997a527" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_76bb1ef0-0bf0-49f4-8519-fc8394eb7191" xlink:to="loc_srt_RangeMember_627cd355-fe23-44fe-a29a-12797997a527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cbd30273-4f0f-4c15-8a09-c0fc835aebd8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_627cd355-fe23-44fe-a29a-12797997a527" xlink:to="loc_srt_MaximumMember_cbd30273-4f0f-4c15-8a09-c0fc835aebd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements_9ae26e34-577c-4cdd-9f68-dc2598fe60dc" xlink:href="arwr-20250930.xsd#arwr_NumberOfAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91d623f8-d250-4c09-9d95-866b13fa6e78" xlink:to="loc_arwr_NumberOfAgreements_9ae26e34-577c-4cdd-9f68-dc2598fe60dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_766aa248-4a68-4dad-9d5c-1cec989b44d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91d623f8-d250-4c09-9d95-866b13fa6e78" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_766aa248-4a68-4dad-9d5c-1cec989b44d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cfa1e708-f1b2-4eea-bf72-d396737863f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91d623f8-d250-4c09-9d95-866b13fa6e78" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cfa1e708-f1b2-4eea-bf72-d396737863f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_ee002e57-6b29-46b5-9c1e-aec0e429f50a" xlink:href="arwr-20250930.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91d623f8-d250-4c09-9d95-866b13fa6e78" xlink:to="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_ee002e57-6b29-46b5-9c1e-aec0e429f50a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e41b2148-81eb-49d4-9978-35f78e20dd90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e41b2148-81eb-49d4-9978-35f78e20dd90" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1afb3872-eb3b-41e0-b568-060d0f3b2bf0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e41b2148-81eb-49d4-9978-35f78e20dd90" xlink:to="loc_srt_CounterpartyNameAxis_1afb3872-eb3b-41e0-b568-060d0f3b2bf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1afb3872-eb3b-41e0-b568-060d0f3b2bf0_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1afb3872-eb3b-41e0-b568-060d0f3b2bf0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1afb3872-eb3b-41e0-b568-060d0f3b2bf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8f23b2d-7008-41c2-80fe-e33204f560fa" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1afb3872-eb3b-41e0-b568-060d0f3b2bf0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8f23b2d-7008-41c2-80fe-e33204f560fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaTherapeuticsIncMember_a7047dcb-79de-42df-8f2f-8d71f10dcfc6" xlink:href="arwr-20250930.xsd#arwr_SareptaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8f23b2d-7008-41c2-80fe-e33204f560fa" xlink:to="loc_arwr_SareptaTherapeuticsIncMember_a7047dcb-79de-42df-8f2f-8d71f10dcfc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7a7fa08e-43dc-4284-89f0-e1639060ca7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e41b2148-81eb-49d4-9978-35f78e20dd90" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7a7fa08e-43dc-4284-89f0-e1639060ca7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7a7fa08e-43dc-4284-89f0-e1639060ca7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7a7fa08e-43dc-4284-89f0-e1639060ca7a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7a7fa08e-43dc-4284-89f0-e1639060ca7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_87758975-4d3b-49a6-a406-aa0168fb14d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7a7fa08e-43dc-4284-89f0-e1639060ca7a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_87758975-4d3b-49a6-a406-aa0168fb14d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember_dc62afdb-29fd-4b67-850c-de8d4a25be4b" xlink:href="arwr-20250930.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_87758975-4d3b-49a6-a406-aa0168fb14d0" xlink:to="loc_arwr_SareptaCollaborationAgreementMember_dc62afdb-29fd-4b67-850c-de8d4a25be4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7874184a-1a73-4e18-a212-2d813fba93ef" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e41b2148-81eb-49d4-9978-35f78e20dd90" xlink:to="loc_srt_RangeAxis_7874184a-1a73-4e18-a212-2d813fba93ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7874184a-1a73-4e18-a212-2d813fba93ef_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7874184a-1a73-4e18-a212-2d813fba93ef" xlink:to="loc_srt_RangeMember_7874184a-1a73-4e18-a212-2d813fba93ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_690d0670-d7a3-44a8-bbcb-105f7dc00b72" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7874184a-1a73-4e18-a212-2d813fba93ef" xlink:to="loc_srt_RangeMember_690d0670-d7a3-44a8-bbcb-105f7dc00b72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_335b679d-c555-4651-9fab-5851630452ad" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_690d0670-d7a3-44a8-bbcb-105f7dc00b72" xlink:to="loc_srt_MaximumMember_335b679d-c555-4651-9fab-5851630452ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_df807ebc-8fb5-4d81-899a-a8a32cc76ad3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_690d0670-d7a3-44a8-bbcb-105f7dc00b72" xlink:to="loc_srt_MinimumMember_df807ebc-8fb5-4d81-899a-a8a32cc76ad3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfNewTargetPrograms_9faa1964-8046-4e4e-a4b6-6f6e36688e93" xlink:href="arwr-20250930.xsd#arwr_NumberOfNewTargetPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_NumberOfNewTargetPrograms_9faa1964-8046-4e4e-a4b6-6f6e36688e93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfPerformanceObligations_c2fa5709-5994-46c2-b7a5-1913d31ed900" xlink:href="arwr-20250930.xsd#arwr_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_NumberOfPerformanceObligations_c2fa5709-5994-46c2-b7a5-1913d31ed900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements_23449e8e-aa5f-43be-a7b0-f0e9da1a3a4d" xlink:href="arwr-20250930.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_ProceedsFromCollaborationArrangements_23449e8e-aa5f-43be-a7b0-f0e9da1a3a4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ea884625-6f46-490c-9475-8dfb286c455c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ea884625-6f46-490c-9475-8dfb286c455c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SaleOfStockPremiumOnIssuanceOfShares_ae88c57a-207f-4a42-bf20-567c2a8a9ab0" xlink:href="arwr-20250930.xsd#arwr_SaleOfStockPremiumOnIssuanceOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_SaleOfStockPremiumOnIssuanceOfShares_ae88c57a-207f-4a42-bf20-567c2a8a9ab0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement_ca77cfdb-d376-414d-9468-6d21d1379e70" xlink:href="arwr-20250930.xsd#arwr_AdditionalCashReceivableUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement_ca77cfdb-d376-414d-9468-6d21d1379e70" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments_6ca1d194-88b0-466a-a93c-abd43f23e251" xlink:href="arwr-20250930.xsd#arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments_6ca1d194-88b0-466a-a93c-abd43f23e251" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod_6bfddd33-f2fb-47ce-bad2-e1e5b8bc92ee" xlink:href="arwr-20250930.xsd#arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod_6bfddd33-f2fb-47ce-bad2-e1e5b8bc92ee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementFixedConsideration_43a92703-822d-4fd1-8596-cac8f7882ae4" xlink:href="arwr-20250930.xsd#arwr_CollaborationArrangementFixedConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_CollaborationArrangementFixedConsideration_43a92703-822d-4fd1-8596-cac8f7882ae4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementVariableConsideration_002ab1a0-e087-4f78-a420-0def187c8100" xlink:href="arwr-20250930.xsd#arwr_CollaborationArrangementVariableConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_CollaborationArrangementVariableConsideration_002ab1a0-e087-4f78-a420-0def187c8100" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementConsideration_ea2863e9-7057-4ca5-a4d0-57c0037d2925" xlink:href="arwr-20250930.xsd#arwr_CollaborationArrangementConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_CollaborationArrangementConsideration_ea2863e9-7057-4ca5-a4d0-57c0037d2925" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EnrollmentRelatedMilestonePayments_b2889c0b-d6f9-40c0-bf85-406f0d604234" xlink:href="arwr-20250930.xsd#arwr_EnrollmentRelatedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_EnrollmentRelatedMilestonePayments_b2889c0b-d6f9-40c0-bf85-406f0d604234" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfCollaborationPrograms_5c20f175-c7ee-467d-bdb4-36ea02639508" xlink:href="arwr-20250930.xsd#arwr_NumberOfCollaborationPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_NumberOfCollaborationPrograms_5c20f175-c7ee-467d-bdb4-36ea02639508" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RegulatoryMilestonePayments_d211e262-5109-4c0c-a3ad-4c1957dca5ce" xlink:href="arwr-20250930.xsd#arwr_RegulatoryMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_RegulatoryMilestonePayments_d211e262-5109-4c0c-a3ad-4c1957dca5ce" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_62b5c9a7-6c88-4f20-a760-ca5df57d6836" xlink:href="arwr-20250930.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_SalesRelatedMilestonePayments_62b5c9a7-6c88-4f20-a760-ca5df57d6836" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval_8a1593d3-09fb-4529-a7df-817efc1e7acd" xlink:href="arwr-20250930.xsd#arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval_8a1593d3-09fb-4529-a7df-817efc1e7acd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_6d1bffb8-a928-4056-a0a5-f4ea1bcda298" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_6d1bffb8-a928-4056-a0a5-f4ea1bcda298" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentMilestonePayments_c03c5f0e-e4ee-4540-8ed6-5bffc3ad7202" xlink:href="arwr-20250930.xsd#arwr_DevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_DevelopmentMilestonePayments_c03c5f0e-e4ee-4540-8ed6-5bffc3ad7202" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d17dc565-79f6-45e1-b52e-0d3a08492639" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d17dc565-79f6-45e1-b52e-0d3a08492639" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_7f2c79d4-67f3-437f-a7b2-01a3f3f3ae51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_us-gaap_TreasuryStockCommonValue_7f2c79d4-67f3-437f-a7b2-01a3f3f3ae51" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GainLossOnTreasuryStockSettlement_13ca79be-9f31-4a91-b655-1585e398c9c4" xlink:href="arwr-20250930.xsd#arwr_GainLossOnTreasuryStockSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_GainLossOnTreasuryStockSettlement_13ca79be-9f31-4a91-b655-1585e398c9c4" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aed3d1df-83e9-4c01-81dc-f74cf4172417" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aed3d1df-83e9-4c01-81dc-f74cf4172417" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ff03b553-1f1b-4d06-aa5f-c9f8aa2c3485" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ff03b553-1f1b-4d06-aa5f-c9f8aa2c3485" xlink:type="arc" order="22"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_077e1341-8dfd-4f4d-b4da-1ab17773aafc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4b3abd2-8344-4261-ab97-5ee99cc85a53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_077e1341-8dfd-4f4d-b4da-1ab17773aafc" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4b3abd2-8344-4261-ab97-5ee99cc85a53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9e674f99-1042-4ff4-b3a7-49dabd60f892" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4b3abd2-8344-4261-ab97-5ee99cc85a53" xlink:to="loc_srt_CounterpartyNameAxis_9e674f99-1042-4ff4-b3a7-49dabd60f892" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e674f99-1042-4ff4-b3a7-49dabd60f892_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9e674f99-1042-4ff4-b3a7-49dabd60f892" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e674f99-1042-4ff4-b3a7-49dabd60f892_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e689db53-a805-43b5-a4d0-b5fbb6c95ed4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9e674f99-1042-4ff4-b3a7-49dabd60f892" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e689db53-a805-43b5-a4d0-b5fbb6c95ed4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SanofiMember_8dfc3fbd-ca7b-450d-80c1-3eac9683a022" xlink:href="arwr-20250930.xsd#arwr_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e689db53-a805-43b5-a4d0-b5fbb6c95ed4" xlink:to="loc_arwr_SanofiMember_8dfc3fbd-ca7b-450d-80c1-3eac9683a022" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e4ed5255-2c8e-4cc4-956e-e16100e8c9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4b3abd2-8344-4261-ab97-5ee99cc85a53" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e4ed5255-2c8e-4cc4-956e-e16100e8c9b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4ed5255-2c8e-4cc4-956e-e16100e8c9b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e4ed5255-2c8e-4cc4-956e-e16100e8c9b2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4ed5255-2c8e-4cc4-956e-e16100e8c9b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d75fcb8-ee42-4661-95ab-cecd264b031a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e4ed5255-2c8e-4cc4-956e-e16100e8c9b2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d75fcb8-ee42-4661-95ab-cecd264b031a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SanofiLicenseAgreementMember_276a789d-9dd5-4aef-81ea-1ff7f36ada19" xlink:href="arwr-20250930.xsd#arwr_SanofiLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d75fcb8-ee42-4661-95ab-cecd264b031a" xlink:to="loc_arwr_SanofiLicenseAgreementMember_276a789d-9dd5-4aef-81ea-1ff7f36ada19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_d17bc731-8cfa-437d-a09e-6d06a21fd7d6" xlink:href="arwr-20250930.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_077e1341-8dfd-4f4d-b4da-1ab17773aafc" xlink:to="loc_arwr_InitialTransactionPrice_d17bc731-8cfa-437d-a09e-6d06a21fd7d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FuturePotentialMilestonePayments_b02c4b21-991e-4d57-96b3-10473f371bb8" xlink:href="arwr-20250930.xsd#arwr_FuturePotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_077e1341-8dfd-4f4d-b4da-1ab17773aafc" xlink:to="loc_arwr_FuturePotentialMilestonePayments_b02c4b21-991e-4d57-96b3-10473f371bb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_adbf167b-1160-4a4c-978e-6a00eb7c6d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_077e1341-8dfd-4f4d-b4da-1ab17773aafc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_adbf167b-1160-4a4c-978e-6a00eb7c6d8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfPerformanceObligations_01e201b8-3e5e-4a1c-9a43-86d6d67d952f" xlink:href="arwr-20250930.xsd#arwr_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_077e1341-8dfd-4f4d-b4da-1ab17773aafc" xlink:to="loc_arwr_NumberOfPerformanceObligations_01e201b8-3e5e-4a1c-9a43-86d6d67d952f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementFixedConsideration_2b3fefcc-bf4e-4684-8d5a-ec5593365e18" xlink:href="arwr-20250930.xsd#arwr_CollaborationArrangementFixedConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_077e1341-8dfd-4f4d-b4da-1ab17773aafc" xlink:to="loc_arwr_CollaborationArrangementFixedConsideration_2b3fefcc-bf4e-4684-8d5a-ec5593365e18" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#BalanceSheetAccountsPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce8db0b7-5350-431d-86a3-8a89b2b92c03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b6da2dff-2f3d-42bb-b106-9a7281b04e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce8db0b7-5350-431d-86a3-8a89b2b92c03" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b6da2dff-2f3d-42bb-b106-9a7281b04e2e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2aa5252-d584-4ea2-9c1c-db9c66871ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b6da2dff-2f3d-42bb-b106-9a7281b04e2e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2aa5252-d584-4ea2-9c1c-db9c66871ee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c2aa5252-d584-4ea2-9c1c-db9c66871ee5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2aa5252-d584-4ea2-9c1c-db9c66871ee5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c2aa5252-d584-4ea2-9c1c-db9c66871ee5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60fbd4d9-a0fc-415f-b04b-23b806896396" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2aa5252-d584-4ea2-9c1c-db9c66871ee5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60fbd4d9-a0fc-415f-b04b-23b806896396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_aa201c65-8e90-4c00-91a3-f0b84abed5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60fbd4d9-a0fc-415f-b04b-23b806896396" xlink:to="loc_us-gaap_LandMember_aa201c65-8e90-4c00-91a3-f0b84abed5c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_29e84093-9b5f-40f7-a245-fbf4e66d96f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60fbd4d9-a0fc-415f-b04b-23b806896396" xlink:to="loc_us-gaap_BuildingMember_29e84093-9b5f-40f7-a245-fbf4e66d96f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentMember_1c854e48-4b1a-46a7-894f-799788819e66" xlink:href="arwr-20250930.xsd#arwr_ResearchEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60fbd4d9-a0fc-415f-b04b-23b806896396" xlink:to="loc_arwr_ResearchEquipmentMember_1c854e48-4b1a-46a7-894f-799788819e66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ManufacturingEquipmentMember_216b5e1f-83a8-4406-a981-7e7ef610e8fa" xlink:href="arwr-20250930.xsd#arwr_ManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60fbd4d9-a0fc-415f-b04b-23b806896396" xlink:to="loc_arwr_ManufacturingEquipmentMember_216b5e1f-83a8-4406-a981-7e7ef610e8fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0538c8d0-db3e-4bc7-8dfa-d17b0461c163" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60fbd4d9-a0fc-415f-b04b-23b806896396" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_0538c8d0-db3e-4bc7-8dfa-d17b0461c163" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputersAndSoftwareMember_d0ecf88d-8152-412b-af60-f0d4a8b78143" xlink:href="arwr-20250930.xsd#arwr_ComputersAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60fbd4d9-a0fc-415f-b04b-23b806896396" xlink:to="loc_arwr_ComputersAndSoftwareMember_d0ecf88d-8152-412b-af60-f0d4a8b78143" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4b87f916-3364-497d-947d-22f7626567b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60fbd4d9-a0fc-415f-b04b-23b806896396" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4b87f916-3364-497d-947d-22f7626567b3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_933d149a-7e49-4d21-a8c1-30a6c885b4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60fbd4d9-a0fc-415f-b04b-23b806896396" xlink:to="loc_us-gaap_ConstructionInProgressMember_933d149a-7e49-4d21-a8c1-30a6c885b4d5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1b6b7e05-5539-43e3-a4b5-5717080577eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce8db0b7-5350-431d-86a3-8a89b2b92c03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1b6b7e05-5539-43e3-a4b5-5717080577eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4f5a8444-82b2-4219-a70e-f6a0624bcf41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce8db0b7-5350-431d-86a3-8a89b2b92c03" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4f5a8444-82b2-4219-a70e-f6a0624bcf41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c0f63ce9-af70-477e-9d26-9096ee2e9627" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce8db0b7-5350-431d-86a3-8a89b2b92c03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c0f63ce9-af70-477e-9d26-9096ee2e9627" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#BalanceSheetAccountsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_59c0df2e-b817-4fb3-9c05-bd3151f5ffb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9440e36b-3e27-4558-bd23-0497935030df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_59c0df2e-b817-4fb3-9c05-bd3151f5ffb0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9440e36b-3e27-4558-bd23-0497935030df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0cd1eebb-cbfa-41ec-9507-7d82463a65c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9440e36b-3e27-4558-bd23-0497935030df" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0cd1eebb-cbfa-41ec-9507-7d82463a65c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0cd1eebb-cbfa-41ec-9507-7d82463a65c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0cd1eebb-cbfa-41ec-9507-7d82463a65c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0cd1eebb-cbfa-41ec-9507-7d82463a65c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c81ab6a-a846-48b7-8614-69736635ee5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0cd1eebb-cbfa-41ec-9507-7d82463a65c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c81ab6a-a846-48b7-8614-69736635ee5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ConstructionInProgressReclassifiedToBuildingMember_c9e8364e-d680-4e07-9d49-74157ccd77e8" xlink:href="arwr-20250930.xsd#arwr_ConstructionInProgressReclassifiedToBuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c81ab6a-a846-48b7-8614-69736635ee5e" xlink:to="loc_arwr_ConstructionInProgressReclassifiedToBuildingMember_c9e8364e-d680-4e07-9d49-74157ccd77e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_17503cef-056c-48fe-b420-5de0b7d40152" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c81ab6a-a846-48b7-8614-69736635ee5e" xlink:to="loc_us-gaap_BuildingMember_17503cef-056c-48fe-b420-5de0b7d40152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember_d3c8ce02-def7-4c40-adff-e34af7e452c3" xlink:href="arwr-20250930.xsd#arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c81ab6a-a846-48b7-8614-69736635ee5e" xlink:to="loc_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember_d3c8ce02-def7-4c40-adff-e34af7e452c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ManufacturingEquipmentMember_f23393e9-a204-4df6-b906-445293855d31" xlink:href="arwr-20250930.xsd#arwr_ManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c81ab6a-a846-48b7-8614-69736635ee5e" xlink:to="loc_arwr_ManufacturingEquipmentMember_f23393e9-a204-4df6-b906-445293855d31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember_0693b211-00f3-4854-a239-100440dbf186" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c81ab6a-a846-48b7-8614-69736635ee5e" xlink:to="loc_us-gaap_ManufacturingFacilityMember_0693b211-00f3-4854-a239-100440dbf186" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_d8ecf180-7f4d-4c0c-b76e-936ab08e49e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c81ab6a-a846-48b7-8614-69736635ee5e" xlink:to="loc_us-gaap_ConstructionInProgressMember_d8ecf180-7f4d-4c0c-b76e-936ab08e49e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ff1b6145-4753-4ee4-94b8-9c977ed93a48" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9440e36b-3e27-4558-bd23-0497935030df" xlink:to="loc_srt_RangeAxis_ff1b6145-4753-4ee4-94b8-9c977ed93a48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ff1b6145-4753-4ee4-94b8-9c977ed93a48_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ff1b6145-4753-4ee4-94b8-9c977ed93a48" xlink:to="loc_srt_RangeMember_ff1b6145-4753-4ee4-94b8-9c977ed93a48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d9cb387d-d0d6-4bcd-9b8b-7229453308a5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ff1b6145-4753-4ee4-94b8-9c977ed93a48" xlink:to="loc_srt_RangeMember_d9cb387d-d0d6-4bcd-9b8b-7229453308a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_06e94516-65ab-4a8a-bdf4-f77171b68792" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d9cb387d-d0d6-4bcd-9b8b-7229453308a5" xlink:to="loc_srt_MinimumMember_06e94516-65ab-4a8a-bdf4-f77171b68792" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e70404f2-a5fa-4845-a554-d120ceba9f5c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d9cb387d-d0d6-4bcd-9b8b-7229453308a5" xlink:to="loc_srt_MaximumMember_e70404f2-a5fa-4845-a554-d120ceba9f5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8245135e-4f2c-4d45-84af-b2499d3f6c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_59c0df2e-b817-4fb3-9c05-bd3151f5ffb0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8245135e-4f2c-4d45-84af-b2499d3f6c6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_ea4d0612-2b9b-46dc-8295-f9c8aed0f240" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTransfersAndChanges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_59c0df2e-b817-4fb3-9c05-bd3151f5ffb0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_ea4d0612-2b9b-46dc-8295-f9c8aed0f240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0cec85ec-7a80-474e-894b-9d865bff7d71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_59c0df2e-b817-4fb3-9c05-bd3151f5ffb0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0cec85ec-7a80-474e-894b-9d865bff7d71" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#InvestmentsCurrentInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_c8082cdc-2a87-4331-b5b6-9fd82a333ca2" xlink:href="arwr-20250930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_d9ae2af1-a922-4588-a8e6-106c80ea2188" xlink:href="arwr-20250930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_c8082cdc-2a87-4331-b5b6-9fd82a333ca2" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_d9ae2af1-a922-4588-a8e6-106c80ea2188" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f095e17b-67d2-403b-9619-2f17822104f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_d9ae2af1-a922-4588-a8e6-106c80ea2188" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f095e17b-67d2-403b-9619-2f17822104f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f095e17b-67d2-403b-9619-2f17822104f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f095e17b-67d2-403b-9619-2f17822104f4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f095e17b-67d2-403b-9619-2f17822104f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_79b96566-a6fd-4199-b87f-4b6f2448919b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f095e17b-67d2-403b-9619-2f17822104f4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_79b96566-a6fd-4199-b87f-4b6f2448919b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_10902bd9-8620-4fe9-a673-5a46da68be68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_79b96566-a6fd-4199-b87f-4b6f2448919b" xlink:to="loc_us-gaap_DebtSecuritiesMember_10902bd9-8620-4fe9-a673-5a46da68be68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_1c83a5ba-b9fb-4b80-a073-31b679b6d441" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_c8082cdc-2a87-4331-b5b6-9fd82a333ca2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_1c83a5ba-b9fb-4b80-a073-31b679b6d441" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_c1b127d0-cfdf-4ea4-a2d9-9f413adbc7dd" xlink:href="arwr-20250930.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_c8082cdc-2a87-4331-b5b6-9fd82a333ca2" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_c1b127d0-cfdf-4ea4-a2d9-9f413adbc7dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_dd11df08-0e07-40c2-8837-38e83b450239" xlink:href="arwr-20250930.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_c8082cdc-2a87-4331-b5b6-9fd82a333ca2" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_dd11df08-0e07-40c2-8837-38e83b450239" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3e32bda5-4bc5-4759-809d-072ef67100e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_c8082cdc-2a87-4331-b5b6-9fd82a333ca2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3e32bda5-4bc5-4759-809d-072ef67100e6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e47d4d12-d1c2-4005-9cdd-a91e57724865" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4484cf3e-ebae-46e5-8ec1-736640ace5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e47d4d12-d1c2-4005-9cdd-a91e57724865" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4484cf3e-ebae-46e5-8ec1-736640ace5b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_14acb4d1-9eb7-4d33-a205-be5d7ca0422e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4484cf3e-ebae-46e5-8ec1-736640ace5b7" xlink:to="loc_us-gaap_AssetAcquisitionAxis_14acb4d1-9eb7-4d33-a205-be5d7ca0422e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_14acb4d1-9eb7-4d33-a205-be5d7ca0422e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_14acb4d1-9eb7-4d33-a205-be5d7ca0422e" xlink:to="loc_us-gaap_AssetAcquisitionDomain_14acb4d1-9eb7-4d33-a205-be5d7ca0422e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_4b8e721a-78bb-4843-98e5-e9a3a0778f60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_14acb4d1-9eb7-4d33-a205-be5d7ca0422e" xlink:to="loc_us-gaap_AssetAcquisitionDomain_4b8e721a-78bb-4843-98e5-e9a3a0778f60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember_f3cd3edf-9153-4ab5-8bfc-92cadb10be37" xlink:href="arwr-20250930.xsd#arwr_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4b8e721a-78bb-4843-98e5-e9a3a0778f60" xlink:to="loc_arwr_NovartisMember_f3cd3edf-9153-4ab5-8bfc-92cadb10be37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6eb052ac-cb77-4768-a63c-615990622961" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4484cf3e-ebae-46e5-8ec1-736640ace5b7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6eb052ac-cb77-4768-a63c-615990622961" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6eb052ac-cb77-4768-a63c-615990622961_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6eb052ac-cb77-4768-a63c-615990622961" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6eb052ac-cb77-4768-a63c-615990622961_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58c158f4-e425-44e0-9f7c-102447765d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6eb052ac-cb77-4768-a63c-615990622961" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58c158f4-e425-44e0-9f7c-102447765d3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_11827101-693b-49ca-92df-9c4dca0c5cab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58c158f4-e425-44e0-9f7c-102447765d3d" xlink:to="loc_us-gaap_PatentsMember_11827101-693b-49ca-92df-9c4dca0c5cab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_9cecf7eb-4597-4005-8f9f-6c08f44ab39d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58c158f4-e425-44e0-9f7c-102447765d3d" xlink:to="loc_us-gaap_LicensingAgreementsMember_9cecf7eb-4597-4005-8f9f-6c08f44ab39d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1abc6cac-2f38-4518-b8d9-e56637d5c66c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e47d4d12-d1c2-4005-9cdd-a91e57724865" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1abc6cac-2f38-4518-b8d9-e56637d5c66c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b24caae2-edde-4c54-9ccc-b28e0b179f41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e47d4d12-d1c2-4005-9cdd-a91e57724865" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b24caae2-edde-4c54-9ccc-b28e0b179f41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_ba87b36e-78df-4073-958c-b87665e7bc80" xlink:href="arwr-20250930.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e47d4d12-d1c2-4005-9cdd-a91e57724865" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_ba87b36e-78df-4073-958c-b87665e7bc80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3cd1eba3-0e44-41b7-9bfd-2b52f05269dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e47d4d12-d1c2-4005-9cdd-a91e57724865" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3cd1eba3-0e44-41b7-9bfd-2b52f05269dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c238ad7b-6180-4a66-8e29-476082738a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e47d4d12-d1c2-4005-9cdd-a91e57724865" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c238ad7b-6180-4a66-8e29-476082738a6c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_461f1fcf-069a-49e4-89a5-e3ca89cc6990" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_461f1fcf-069a-49e4-89a5-e3ca89cc6990" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_67b2a46f-7d2f-4cbb-ba7e-e8b0f1ebc9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_461f1fcf-069a-49e4-89a5-e3ca89cc6990" xlink:to="loc_us-gaap_PlanNameAxis_67b2a46f-7d2f-4cbb-ba7e-e8b0f1ebc9d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_67b2a46f-7d2f-4cbb-ba7e-e8b0f1ebc9d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_67b2a46f-7d2f-4cbb-ba7e-e8b0f1ebc9d1" xlink:to="loc_us-gaap_PlanNameDomain_67b2a46f-7d2f-4cbb-ba7e-e8b0f1ebc9d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4bb3c5b1-78f4-47a4-9425-9f97fc157b69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_67b2a46f-7d2f-4cbb-ba7e-e8b0f1ebc9d1" xlink:to="loc_us-gaap_PlanNameDomain_4bb3c5b1-78f4-47a4-9425-9f97fc157b69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_9a7fe01a-733d-41b3-8905-c4d46004dc30" xlink:href="arwr-20250930.xsd#arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4bb3c5b1-78f4-47a4-9425-9f97fc157b69" xlink:to="loc_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_9a7fe01a-733d-41b3-8905-c4d46004dc30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_901b96dc-d71d-49ac-9aeb-868fa13fc529" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_461f1fcf-069a-49e4-89a5-e3ca89cc6990" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_901b96dc-d71d-49ac-9aeb-868fa13fc529" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_901b96dc-d71d-49ac-9aeb-868fa13fc529_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_901b96dc-d71d-49ac-9aeb-868fa13fc529" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_901b96dc-d71d-49ac-9aeb-868fa13fc529_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3761085e-6a00-41ca-9691-533f6a7bd989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_901b96dc-d71d-49ac-9aeb-868fa13fc529" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3761085e-6a00-41ca-9691-533f6a7bd989" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_ae9fe466-c4ea-4ea8-b918-8efc8bd5d758" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3761085e-6a00-41ca-9691-533f6a7bd989" xlink:to="loc_us-gaap_PrivatePlacementMember_ae9fe466-c4ea-4ea8-b918-8efc8bd5d758" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember_642ac609-711d-46a4-a227-a03efcb0b7d9" xlink:href="arwr-20250930.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3761085e-6a00-41ca-9691-533f6a7bd989" xlink:to="loc_arwr_AtTheMarketAgreementMember_642ac609-711d-46a4-a227-a03efcb0b7d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a9eed897-d75b-43fc-9037-4a176f319729" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_461f1fcf-069a-49e4-89a5-e3ca89cc6990" xlink:to="loc_srt_CounterpartyNameAxis_a9eed897-d75b-43fc-9037-4a176f319729" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9eed897-d75b-43fc-9037-4a176f319729_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a9eed897-d75b-43fc-9037-4a176f319729" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9eed897-d75b-43fc-9037-4a176f319729_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0120a481-cac9-45d6-aeb2-c419c42d3843" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a9eed897-d75b-43fc-9037-4a176f319729" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0120a481-cac9-45d6-aeb2-c419c42d3843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaTherapeuticsIncMember_6634bff7-e793-45dd-8410-f99202962cf4" xlink:href="arwr-20250930.xsd#arwr_SareptaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0120a481-cac9-45d6-aeb2-c419c42d3843" xlink:to="loc_arwr_SareptaTherapeuticsIncMember_6634bff7-e793-45dd-8410-f99202962cf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_32b41050-bac5-48b1-a451-b1b2954ebd23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_461f1fcf-069a-49e4-89a5-e3ca89cc6990" xlink:to="loc_us-gaap_TypeOfArrangementAxis_32b41050-bac5-48b1-a451-b1b2954ebd23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32b41050-bac5-48b1-a451-b1b2954ebd23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_32b41050-bac5-48b1-a451-b1b2954ebd23" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_32b41050-bac5-48b1-a451-b1b2954ebd23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8101b93-97b4-4c5d-b373-e84d2239b34b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_32b41050-bac5-48b1-a451-b1b2954ebd23" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8101b93-97b4-4c5d-b373-e84d2239b34b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember_cdfaeaf3-8830-475e-bd0c-65bd6832ebd8" xlink:href="arwr-20250930.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8101b93-97b4-4c5d-b373-e84d2239b34b" xlink:to="loc_arwr_SareptaCollaborationAgreementMember_cdfaeaf3-8830-475e-bd0c-65bd6832ebd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7e466f09-cb6b-42a5-8d67-ec86a3c06eac" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_461f1fcf-069a-49e4-89a5-e3ca89cc6990" xlink:to="loc_srt_RangeAxis_7e466f09-cb6b-42a5-8d67-ec86a3c06eac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7e466f09-cb6b-42a5-8d67-ec86a3c06eac_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7e466f09-cb6b-42a5-8d67-ec86a3c06eac" xlink:to="loc_srt_RangeMember_7e466f09-cb6b-42a5-8d67-ec86a3c06eac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a61c35ef-e077-49fc-8484-7ae8c9917553" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7e466f09-cb6b-42a5-8d67-ec86a3c06eac" xlink:to="loc_srt_RangeMember_a61c35ef-e077-49fc-8484-7ae8c9917553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c967e931-0a6a-4f7c-9ba1-80c0fdcc11a3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a61c35ef-e077-49fc-8484-7ae8c9917553" xlink:to="loc_srt_MaximumMember_c967e931-0a6a-4f7c-9ba1-80c0fdcc11a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_cdca0f7a-3edc-473f-a4eb-7882e782b314" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_cdca0f7a-3edc-473f-a4eb-7882e782b314" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_032a3d46-57b7-4f17-bb0f-97c38429a50a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_032a3d46-57b7-4f17-bb0f-97c38429a50a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_67e48445-116a-4442-a455-79185f278387" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_67e48445-116a-4442-a455-79185f278387" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_c287ee84-cf77-4f0e-a889-b9423961bf4c" xlink:href="arwr-20250930.xsd#arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_c287ee84-cf77-4f0e-a889-b9423961bf4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_3f627856-20df-4a91-b791-3aa70ddb8886" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_3f627856-20df-4a91-b791-3aa70ddb8886" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised_c123bd91-ddfa-4552-a968-6b23b60bd06c" xlink:href="arwr-20250930.xsd#arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised_c123bd91-ddfa-4552-a968-6b23b60bd06c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_442fdf8b-e1cd-4ecd-924c-ea53e03c8546" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_442fdf8b-e1cd-4ecd-924c-ea53e03c8546" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_da159cce-3d96-4ad2-b6e8-f01003a21df7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_da159cce-3d96-4ad2-b6e8-f01003a21df7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2334cc41-6ada-46e7-99a6-65341f690bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2334cc41-6ada-46e7-99a6-65341f690bd0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_bc46e6e8-78e1-4aca-bbc2-275e93c4aad8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_bc46e6e8-78e1-4aca-bbc2-275e93c4aad8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_ae9cd104-f767-44c3-a859-3f7a6b89dccd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_ae9cd104-f767-44c3-a859-3f7a6b89dccd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2e52fb0e-ac0e-4351-b56b-9f433932f734" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2e52fb0e-ac0e-4351-b56b-9f433932f734" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements_5a3a61e4-00b8-45a6-a71f-45efd66b56b7" xlink:href="arwr-20250930.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_arwr_ProceedsFromCollaborationArrangements_5a3a61e4-00b8-45a6-a71f-45efd66b56b7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentDueFromCollaborativeAgreement_da2d7673-ca05-4780-842e-fef95e759750" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentDueFromCollaborativeAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_arwr_MilestonePaymentDueFromCollaborativeAgreement_da2d7673-ca05-4780-842e-fef95e759750" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_183241af-4ee1-4a50-a6c2-4bfe31d5875e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_TreasuryStockCommonValue_183241af-4ee1-4a50-a6c2-4bfe31d5875e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GainLossOnTreasuryStockSettlement_2a77132d-6e19-425c-947b-fb6cea3d7b28" xlink:href="arwr-20250930.xsd#arwr_GainLossOnTreasuryStockSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_arwr_GainLossOnTreasuryStockSettlement_2a77132d-6e19-425c-947b-fb6cea3d7b28" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_404cf8c1-e27c-423c-a7a1-afb062b95ddd" xlink:href="arwr-20250930.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_404cf8c1-e27c-423c-a7a1-afb062b95ddd" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_6aa72365-f743-4bc2-8886-f80bc6766074" xlink:href="arwr-20250930.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_6aa72365-f743-4bc2-8886-f80bc6766074" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_65492919-9f49-4ccb-ae03-1140139103f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_SharesIssued_65492919-9f49-4ccb-ae03-1140139103f4" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_5fd9721f-3ba6-4d6b-9583-0dc98539304e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_1f8ba867-9896-4b89-bb51-98c7063c4b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5fd9721f-3ba6-4d6b-9583-0dc98539304e" xlink:to="loc_us-gaap_OtherCommitmentsTable_1f8ba867-9896-4b89-bb51-98c7063c4b5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b638f558-f25e-4507-ba85-28d0d9fe2b17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1f8ba867-9896-4b89-bb51-98c7063c4b5e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b638f558-f25e-4507-ba85-28d0d9fe2b17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b638f558-f25e-4507-ba85-28d0d9fe2b17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b638f558-f25e-4507-ba85-28d0d9fe2b17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b638f558-f25e-4507-ba85-28d0d9fe2b17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bbb7454-e631-4829-bbd1-80aec58a5f14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b638f558-f25e-4507-ba85-28d0d9fe2b17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bbb7454-e631-4829-bbd1-80aec58a5f14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember_1eba91d4-322d-4ad3-8da2-9fec44e20009" xlink:href="arwr-20250930.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bbb7454-e631-4829-bbd1-80aec58a5f14" xlink:to="loc_arwr_DrugManufacturingFacilityMember_1eba91d4-322d-4ad3-8da2-9fec44e20009" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember_ebd5b8c5-27c8-4a20-8b6e-eade648665fb" xlink:href="arwr-20250930.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bbb7454-e631-4829-bbd1-80aec58a5f14" xlink:to="loc_arwr_LaboratoryAndOfficeFacilityMember_ebd5b8c5-27c8-4a20-8b6e-eade648665fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember_bcabdccc-4755-413a-9d76-a23acd736df2" xlink:href="arwr-20250930.xsd#arwr_FacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bbb7454-e631-4829-bbd1-80aec58a5f14" xlink:to="loc_arwr_FacilitiesMember_bcabdccc-4755-413a-9d76-a23acd736df2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_96cd5d7e-8ec6-479f-8983-ff62c115044f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bbb7454-e631-4829-bbd1-80aec58a5f14" xlink:to="loc_us-gaap_BuildingMember_96cd5d7e-8ec6-479f-8983-ff62c115044f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ManufacturingEquipmentMember_b2c88eb7-cab6-4b0c-8737-34f5c09906d8" xlink:href="arwr-20250930.xsd#arwr_ManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bbb7454-e631-4829-bbd1-80aec58a5f14" xlink:to="loc_arwr_ManufacturingEquipmentMember_b2c88eb7-cab6-4b0c-8737-34f5c09906d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_a0c50e04-9d0f-4579-bbd9-1d8b5a629c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bbb7454-e631-4829-bbd1-80aec58a5f14" xlink:to="loc_us-gaap_ConstructionInProgressMember_a0c50e04-9d0f-4579-bbd9-1d8b5a629c9a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentMember_ed6468bb-a73d-4633-91af-0ec1befd3595" xlink:href="arwr-20250930.xsd#arwr_ResearchEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bbb7454-e631-4829-bbd1-80aec58a5f14" xlink:to="loc_arwr_ResearchEquipmentMember_ed6468bb-a73d-4633-91af-0ec1befd3595" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_b9184ec8-5d56-4209-bc95-fc4caa0fde4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bbb7454-e631-4829-bbd1-80aec58a5f14" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_b9184ec8-5d56-4209-bc95-fc4caa0fde4d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f1cc78df-829a-47e3-92e1-4f0d6bc0d174" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1f8ba867-9896-4b89-bb51-98c7063c4b5e" xlink:to="loc_srt_StatementGeographicalAxis_f1cc78df-829a-47e3-92e1-4f0d6bc0d174" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f1cc78df-829a-47e3-92e1-4f0d6bc0d174_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f1cc78df-829a-47e3-92e1-4f0d6bc0d174" xlink:to="loc_srt_SegmentGeographicalDomain_f1cc78df-829a-47e3-92e1-4f0d6bc0d174_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_73935a2a-9032-4000-a60e-5201272f161c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f1cc78df-829a-47e3-92e1-4f0d6bc0d174" xlink:to="loc_srt_SegmentGeographicalDomain_73935a2a-9032-4000-a60e-5201272f161c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_04a845dd-9d00-4ffb-a1e6-b6359bc526d6" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_WI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_73935a2a-9032-4000-a60e-5201272f161c" xlink:to="loc_stpr_WI_04a845dd-9d00-4ffb-a1e6-b6359bc526d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_56a7635d-0ede-4f29-b217-8d18e2b8f952" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5fd9721f-3ba6-4d6b-9583-0dc98539304e" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_56a7635d-0ede-4f29-b217-8d18e2b8f952" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_b9f884b6-65af-4ecc-a18a-03ad629588f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5fd9721f-3ba6-4d6b-9583-0dc98539304e" xlink:to="loc_us-gaap_AreaOfLand_b9f884b6-65af-4ecc-a18a-03ad629588f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommitmentsCapitalExpendituresIncurredToDate_469b66e1-351c-471d-b625-c0f82ce24e3a" xlink:href="arwr-20250930.xsd#arwr_CommitmentsCapitalExpendituresIncurredToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5fd9721f-3ba6-4d6b-9583-0dc98539304e" xlink:to="loc_arwr_CommitmentsCapitalExpendituresIncurredToDate_469b66e1-351c-471d-b625-c0f82ce24e3a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8e69758f-fd8b-4df3-95d8-9e880bc2e084" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_69d36c37-2cb3-49a7-bdfa-cc10f35c1bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8e69758f-fd8b-4df3-95d8-9e880bc2e084" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_69d36c37-2cb3-49a7-bdfa-cc10f35c1bf9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c13751a2-9547-41ac-b7ea-5e37d914ecf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_69d36c37-2cb3-49a7-bdfa-cc10f35c1bf9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c13751a2-9547-41ac-b7ea-5e37d914ecf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c13751a2-9547-41ac-b7ea-5e37d914ecf5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c13751a2-9547-41ac-b7ea-5e37d914ecf5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c13751a2-9547-41ac-b7ea-5e37d914ecf5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ccc2a932-ea57-48bf-9427-21dac7bae22a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c13751a2-9547-41ac-b7ea-5e37d914ecf5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ccc2a932-ea57-48bf-9427-21dac7bae22a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember_6e97818b-09f1-4ede-a245-2a169d3869a3" xlink:href="arwr-20250930.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ccc2a932-ea57-48bf-9427-21dac7bae22a" xlink:to="loc_arwr_CorporateHeadquartersInPasadenaMember_6e97818b-09f1-4ede-a245-2a169d3869a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember_2f04c8f8-01da-4b61-b8e5-fee5b41d8c4f" xlink:href="arwr-20250930.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ccc2a932-ea57-48bf-9427-21dac7bae22a" xlink:to="loc_arwr_ResearchFacilityInSanDiegoMember_2f04c8f8-01da-4b61-b8e5-fee5b41d8c4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember_fa6ac228-4557-44cc-b6f2-d401f22091ed" xlink:href="arwr-20250930.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ccc2a932-ea57-48bf-9427-21dac7bae22a" xlink:to="loc_arwr_ResearchFacilityInMadisonMember_fa6ac228-4557-44cc-b6f2-d401f22091ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8bc6d97b-fbe7-4eea-8885-b808aa7fc3f5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_69d36c37-2cb3-49a7-bdfa-cc10f35c1bf9" xlink:to="loc_srt_StatementGeographicalAxis_8bc6d97b-fbe7-4eea-8885-b808aa7fc3f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8bc6d97b-fbe7-4eea-8885-b808aa7fc3f5_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8bc6d97b-fbe7-4eea-8885-b808aa7fc3f5" xlink:to="loc_srt_SegmentGeographicalDomain_8bc6d97b-fbe7-4eea-8885-b808aa7fc3f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_221d1f5f-ceb1-40d8-8767-a89190966c68" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8bc6d97b-fbe7-4eea-8885-b808aa7fc3f5" xlink:to="loc_srt_SegmentGeographicalDomain_221d1f5f-ceb1-40d8-8767-a89190966c68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_93295aa3-661b-44cd-9e29-fbb0ab48914f" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_221d1f5f-ceb1-40d8-8767-a89190966c68" xlink:to="loc_stpr_CA_93295aa3-661b-44cd-9e29-fbb0ab48914f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_75e3714f-7cfb-4bb4-8ac6-d44d7f9c9c96" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_WI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_221d1f5f-ceb1-40d8-8767-a89190966c68" xlink:to="loc_stpr_WI_75e3714f-7cfb-4bb4-8ac6-d44d7f9c9c96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_23ca2b22-6b86-46f9-bdc4-96eba8fcfc05" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_69d36c37-2cb3-49a7-bdfa-cc10f35c1bf9" xlink:to="loc_srt_CounterpartyNameAxis_23ca2b22-6b86-46f9-bdc4-96eba8fcfc05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_23ca2b22-6b86-46f9-bdc4-96eba8fcfc05_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_23ca2b22-6b86-46f9-bdc4-96eba8fcfc05" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_23ca2b22-6b86-46f9-bdc4-96eba8fcfc05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ffc6541b-7bf7-4a0d-892f-c6f9b8fcee60" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_23ca2b22-6b86-46f9-bdc4-96eba8fcfc05" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ffc6541b-7bf7-4a0d-892f-c6f9b8fcee60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember_8efd7cc1-358c-44a3-b077-e9a17c2658f0" xlink:href="arwr-20250930.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ffc6541b-7bf7-4a0d-892f-c6f9b8fcee60" xlink:to="loc_arwr_ColoradoOwnerLLCMember_8efd7cc1-358c-44a3-b077-e9a17c2658f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d404d749-80b5-4797-8d0c-6e57e7752948" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_69d36c37-2cb3-49a7-bdfa-cc10f35c1bf9" xlink:to="loc_srt_RangeAxis_d404d749-80b5-4797-8d0c-6e57e7752948" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d404d749-80b5-4797-8d0c-6e57e7752948_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d404d749-80b5-4797-8d0c-6e57e7752948" xlink:to="loc_srt_RangeMember_d404d749-80b5-4797-8d0c-6e57e7752948_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c5e52299-1e86-4204-9d59-541d399435aa" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d404d749-80b5-4797-8d0c-6e57e7752948" xlink:to="loc_srt_RangeMember_c5e52299-1e86-4204-9d59-541d399435aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_069c07c9-0737-4fa9-8130-856c5c95cdb2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c5e52299-1e86-4204-9d59-541d399435aa" xlink:to="loc_srt_MaximumMember_069c07c9-0737-4fa9-8130-856c5c95cdb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_b378a007-1585-4d4c-a73b-7d2d4c4a0776" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8e69758f-fd8b-4df3-95d8-9e880bc2e084" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_b378a007-1585-4d4c-a73b-7d2d4c4a0776" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew_aeddc1c6-9ba8-4e73-8f75-aef195927713" xlink:href="arwr-20250930.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8e69758f-fd8b-4df3-95d8-9e880bc2e084" xlink:to="loc_arwr_NumberOfOptionsToRenew_aeddc1c6-9ba8-4e73-8f75-aef195927713" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_156d734b-b10f-4f6c-af33-dd2c00142b74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8e69758f-fd8b-4df3-95d8-9e880bc2e084" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_156d734b-b10f-4f6c-af33-dd2c00142b74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b7f3d190-cc92-4b4c-ae9c-df58870e2655" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8e69758f-fd8b-4df3-95d8-9e880bc2e084" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b7f3d190-cc92-4b4c-ae9c-df58870e2655" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromTenantImprovementAllowance_37c53219-34b7-47f1-a66e-94f3e09a41b6" xlink:href="arwr-20250930.xsd#arwr_ProceedsFromTenantImprovementAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8e69758f-fd8b-4df3-95d8-9e880bc2e084" xlink:to="loc_arwr_ProceedsFromTenantImprovementAllowance_37c53219-34b7-47f1-a66e-94f3e09a41b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_673888a4-15f0-4878-85a0-ab90c914c4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8e69758f-fd8b-4df3-95d8-9e880bc2e084" xlink:to="loc_us-gaap_ShortTermLeaseCost_673888a4-15f0-4878-85a0-ab90c914c4ce" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#LeasesComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_113f5da9-2e13-4ae5-bfcf-b7d18522d103" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f8c28bd3-80cf-4587-9058-dd58bc3e72a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_113f5da9-2e13-4ae5-bfcf-b7d18522d103" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f8c28bd3-80cf-4587-9058-dd58bc3e72a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_751e3ebc-8dd3-43b4-863f-e570a7a53a89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f8c28bd3-80cf-4587-9058-dd58bc3e72a8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_751e3ebc-8dd3-43b4-863f-e570a7a53a89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_751e3ebc-8dd3-43b4-863f-e570a7a53a89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_751e3ebc-8dd3-43b4-863f-e570a7a53a89" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_751e3ebc-8dd3-43b4-863f-e570a7a53a89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1092649d-66a9-4e65-8eb8-0d3102b7a74e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_751e3ebc-8dd3-43b4-863f-e570a7a53a89" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1092649d-66a9-4e65-8eb8-0d3102b7a74e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3d36d9f1-0ae6-42f1-8dae-420f3afc40be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1092649d-66a9-4e65-8eb8-0d3102b7a74e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3d36d9f1-0ae6-42f1-8dae-420f3afc40be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_906677a1-b174-40ae-a704-987527982d80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1092649d-66a9-4e65-8eb8-0d3102b7a74e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_906677a1-b174-40ae-a704-987527982d80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_6328ff21-1dd3-4551-9674-2dfdec5451ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_113f5da9-2e13-4ae5-bfcf-b7d18522d103" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_6328ff21-1dd3-4551-9674-2dfdec5451ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0800a959-fb9c-469b-95f2-a545aefa3a08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_6328ff21-1dd3-4551-9674-2dfdec5451ed" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0800a959-fb9c-469b-95f2-a545aefa3a08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_57b90653-2cde-405b-94d5-cf927772346a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_6328ff21-1dd3-4551-9674-2dfdec5451ed" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_57b90653-2cde-405b-94d5-cf927772346a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_439f7e73-2ce7-4e00-baad-a63f512c9c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_6328ff21-1dd3-4551-9674-2dfdec5451ed" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_439f7e73-2ce7-4e00-baad-a63f512c9c5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_0abe8ae8-a052-4bc9-96de-93a1185bc041" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_113f5da9-2e13-4ae5-bfcf-b7d18522d103" xlink:to="loc_us-gaap_LeaseCostAbstract_0abe8ae8-a052-4bc9-96de-93a1185bc041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_b09d88c5-f720-47a4-852f-7d2fbbb50721" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_0abe8ae8-a052-4bc9-96de-93a1185bc041" xlink:to="loc_us-gaap_OperatingLeaseCost_b09d88c5-f720-47a4-852f-7d2fbbb50721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_454a01db-d313-4179-8186-4dfbdc35b58d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_0abe8ae8-a052-4bc9-96de-93a1185bc041" xlink:to="loc_us-gaap_VariableLeaseCost_454a01db-d313-4179-8186-4dfbdc35b58d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_d4cbc9ba-1d3e-4a3b-bf52-8660dd9a3b77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_0abe8ae8-a052-4bc9-96de-93a1185bc041" xlink:to="loc_us-gaap_LeaseCost_d4cbc9ba-1d3e-4a3b-bf52-8660dd9a3b77" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_468c086a-3c94-4faa-b991-b243fdf58374" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_468c086a-3c94-4faa-b991-b243fdf58374" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0130aa08-06a3-4cf4-9f56-1ec60e297cee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_468c086a-3c94-4faa-b991-b243fdf58374" xlink:to="loc_us-gaap_PlanNameAxis_0130aa08-06a3-4cf4-9f56-1ec60e297cee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0130aa08-06a3-4cf4-9f56-1ec60e297cee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0130aa08-06a3-4cf4-9f56-1ec60e297cee" xlink:to="loc_us-gaap_PlanNameDomain_0130aa08-06a3-4cf4-9f56-1ec60e297cee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7fc14f5d-f255-4036-a6e4-7da4a862a6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0130aa08-06a3-4cf4-9f56-1ec60e297cee" xlink:to="loc_us-gaap_PlanNameDomain_7fc14f5d-f255-4036-a6e4-7da4a862a6c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_bd3d79d4-5d5e-4427-be5c-f84da5cdb64b" xlink:href="arwr-20250930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7fc14f5d-f255-4036-a6e4-7da4a862a6c9" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_bd3d79d4-5d5e-4427-be5c-f84da5cdb64b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_226adbe7-f6e7-4192-bad8-f7353bbb5f2c" xlink:href="arwr-20250930.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7fc14f5d-f255-4036-a6e4-7da4a862a6c9" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_226adbe7-f6e7-4192-bad8-f7353bbb5f2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementPlanMember_34ecc363-7c56-4e76-a235-b755cefc726a" xlink:href="arwr-20250930.xsd#arwr_InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7fc14f5d-f255-4036-a6e4-7da4a862a6c9" xlink:to="loc_arwr_InducementPlanMember_34ecc363-7c56-4e76-a235-b755cefc726a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaESOPMember_ea546268-0290-452b-ab7e-7cc21ba07835" xlink:href="arwr-20250930.xsd#arwr_VisirnaESOPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7fc14f5d-f255-4036-a6e4-7da4a862a6c9" xlink:to="loc_arwr_VisirnaESOPMember_ea546268-0290-452b-ab7e-7cc21ba07835" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_66d3a9f6-b81e-48b3-b7a3-f70f0d6e32e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_468c086a-3c94-4faa-b991-b243fdf58374" xlink:to="loc_us-gaap_AwardTypeAxis_66d3a9f6-b81e-48b3-b7a3-f70f0d6e32e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66d3a9f6-b81e-48b3-b7a3-f70f0d6e32e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_66d3a9f6-b81e-48b3-b7a3-f70f0d6e32e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66d3a9f6-b81e-48b3-b7a3-f70f0d6e32e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0765462d-ad96-40a5-95b2-e2d8cbeb8c07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_66d3a9f6-b81e-48b3-b7a3-f70f0d6e32e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0765462d-ad96-40a5-95b2-e2d8cbeb8c07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_37e5e5d1-3988-4558-8de6-d20c2b2ce272" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0765462d-ad96-40a5-95b2-e2d8cbeb8c07" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_37e5e5d1-3988-4558-8de6-d20c2b2ce272" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6dc59a7b-751f-49a3-96df-1660b655aadf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0765462d-ad96-40a5-95b2-e2d8cbeb8c07" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6dc59a7b-751f-49a3-96df-1660b655aadf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_c3efc5ec-bf04-49a9-8c25-2eca2e637e95" xlink:href="arwr-20250930.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_c3efc5ec-bf04-49a9-8c25-2eca2e637e95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_52502a6c-0559-4f37-ae42-bb159311754c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_52502a6c-0559-4f37-ae42-bb159311754c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_91b367fa-cf8b-482f-b698-dbb0061ffc85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_91b367fa-cf8b-482f-b698-dbb0061ffc85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b302ef4a-033b-4a55-bb00-f8cd110d0f13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b302ef4a-033b-4a55-bb00-f8cd110d0f13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4800615c-638a-4977-81ae-d716e763f325" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4800615c-638a-4977-81ae-d716e763f325" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ab32a88b-3693-4594-86cc-6f77ec1591cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ab32a88b-3693-4594-86cc-6f77ec1591cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_973335f2-65ad-463d-8db7-e0b72334a659" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_973335f2-65ad-463d-8db7-e0b72334a659" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8f2c4cc6-c80e-4b0b-b9d5-c9a419a9a711" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8f2c4cc6-c80e-4b0b-b9d5-c9a419a9a711" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4982ce21-17a0-449b-9380-9e54d9eb0c64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4982ce21-17a0-449b-9380-9e54d9eb0c64" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_336b1abd-f6a1-44be-9c64-9d567ca96566" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_336b1abd-f6a1-44be-9c64-9d567ca96566" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a3ae37ae-5eb2-43e7-84c0-e3d5638b2ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a3ae37ae-5eb2-43e7-84c0-e3d5638b2ef6" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f06cfd55-b6eb-44d1-a82e-a7cf7c4b39f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c78dbc2-d3b4-4472-af85-37e154159d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f06cfd55-b6eb-44d1-a82e-a7cf7c4b39f3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c78dbc2-d3b4-4472-af85-37e154159d0c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac22929e-d73e-4e31-bc82-5b5cfb0276bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c78dbc2-d3b4-4472-af85-37e154159d0c" xlink:to="loc_us-gaap_AwardTypeAxis_ac22929e-d73e-4e31-bc82-5b5cfb0276bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac22929e-d73e-4e31-bc82-5b5cfb0276bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ac22929e-d73e-4e31-bc82-5b5cfb0276bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac22929e-d73e-4e31-bc82-5b5cfb0276bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f1627b7-ddc9-4f5d-93fc-5f13ae696ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ac22929e-d73e-4e31-bc82-5b5cfb0276bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f1627b7-ddc9-4f5d-93fc-5f13ae696ce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2cf299b2-c974-4093-aedd-53122e611923" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f1627b7-ddc9-4f5d-93fc-5f13ae696ce1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2cf299b2-c974-4093-aedd-53122e611923" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4b90bcde-f56f-46ea-bede-3f091bfde7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c78dbc2-d3b4-4472-af85-37e154159d0c" xlink:to="loc_us-gaap_PlanNameAxis_4b90bcde-f56f-46ea-bede-3f091bfde7f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4b90bcde-f56f-46ea-bede-3f091bfde7f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4b90bcde-f56f-46ea-bede-3f091bfde7f6" xlink:to="loc_us-gaap_PlanNameDomain_4b90bcde-f56f-46ea-bede-3f091bfde7f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d4fdec0b-d42d-48cb-bbc4-ba8f2c6200dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4b90bcde-f56f-46ea-bede-3f091bfde7f6" xlink:to="loc_us-gaap_PlanNameDomain_d4fdec0b-d42d-48cb-bbc4-ba8f2c6200dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_d0b01d4d-fd49-4ce8-a92a-68d991983d88" xlink:href="arwr-20250930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d4fdec0b-d42d-48cb-bbc4-ba8f2c6200dd" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_d0b01d4d-fd49-4ce8-a92a-68d991983d88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_b3eb8cf9-9eab-4c78-996c-80b4b41b3e90" xlink:href="arwr-20250930.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d4fdec0b-d42d-48cb-bbc4-ba8f2c6200dd" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_b3eb8cf9-9eab-4c78-996c-80b4b41b3e90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember_d91006b0-2886-43f6-bb5b-d3ad56313fea" xlink:href="arwr-20250930.xsd#arwr_InducementAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d4fdec0b-d42d-48cb-bbc4-ba8f2c6200dd" xlink:to="loc_arwr_InducementAwardsMember_d91006b0-2886-43f6-bb5b-d3ad56313fea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25cbb1df-65a5-42c1-a669-833cd779d335" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f06cfd55-b6eb-44d1-a82e-a7cf7c4b39f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25cbb1df-65a5-42c1-a669-833cd779d335" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9b868892-ec5d-491f-b648-283be0dc7343" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f06cfd55-b6eb-44d1-a82e-a7cf7c4b39f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9b868892-ec5d-491f-b648-283be0dc7343" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_334c0df5-3c28-49cd-acbf-cb5e5322c259" xlink:href="arwr-20250930.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f06cfd55-b6eb-44d1-a82e-a7cf7c4b39f3" xlink:to="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_334c0df5-3c28-49cd-acbf-cb5e5322c259" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#StockBasedCompensationExpensesIncludedinOperatingExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ccb1c1b1-9455-4747-b40b-d4ca651351a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ec9c4b00-7b59-41d3-b5f1-88eb73ec8160" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ccb1c1b1-9455-4747-b40b-d4ca651351a6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ec9c4b00-7b59-41d3-b5f1-88eb73ec8160" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5d0db8ac-073c-4c73-bd0b-6a0ba45acad7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ec9c4b00-7b59-41d3-b5f1-88eb73ec8160" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5d0db8ac-073c-4c73-bd0b-6a0ba45acad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5d0db8ac-073c-4c73-bd0b-6a0ba45acad7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5d0db8ac-073c-4c73-bd0b-6a0ba45acad7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5d0db8ac-073c-4c73-bd0b-6a0ba45acad7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c6772088-0a47-4aa7-bde6-a7a7bde7a317" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5d0db8ac-073c-4c73-bd0b-6a0ba45acad7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c6772088-0a47-4aa7-bde6-a7a7bde7a317" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_85b8b22d-f8b3-4312-bbd6-3cb2739dc726" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c6772088-0a47-4aa7-bde6-a7a7bde7a317" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_85b8b22d-f8b3-4312-bbd6-3cb2739dc726" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_bf4a86b7-3153-4c04-b118-99281e35723a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c6772088-0a47-4aa7-bde6-a7a7bde7a317" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_bf4a86b7-3153-4c04-b118-99281e35723a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6b1bb6cf-bed6-4336-964c-5f55530c368e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ccb1c1b1-9455-4747-b40b-d4ca651351a6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6b1bb6cf-bed6-4336-964c-5f55530c368e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#StockBasedCompensationScheduleofRSUsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5ee31cff-c18b-49ee-8eab-e1843d93a49a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf17c2b4-9d35-4379-a6de-61371916e6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5ee31cff-c18b-49ee-8eab-e1843d93a49a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf17c2b4-9d35-4379-a6de-61371916e6d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0cefcabe-0a56-4572-95f8-315d0b3ac00c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf17c2b4-9d35-4379-a6de-61371916e6d8" xlink:to="loc_us-gaap_AwardTypeAxis_0cefcabe-0a56-4572-95f8-315d0b3ac00c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0cefcabe-0a56-4572-95f8-315d0b3ac00c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0cefcabe-0a56-4572-95f8-315d0b3ac00c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0cefcabe-0a56-4572-95f8-315d0b3ac00c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d0dbea1-8498-4ff0-9ac2-6117475e05f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0cefcabe-0a56-4572-95f8-315d0b3ac00c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d0dbea1-8498-4ff0-9ac2-6117475e05f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dead6ab5-eb61-4039-8050-47f964e10656" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d0dbea1-8498-4ff0-9ac2-6117475e05f0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dead6ab5-eb61-4039-8050-47f964e10656" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_519a0936-55c8-41e6-9477-458a99c8b478" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5ee31cff-c18b-49ee-8eab-e1843d93a49a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_519a0936-55c8-41e6-9477-458a99c8b478" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d01e4c06-b500-4e87-bea6-6ef0af9f4555" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_519a0936-55c8-41e6-9477-458a99c8b478" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d01e4c06-b500-4e87-bea6-6ef0af9f4555" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_eb7769cd-5a20-4d6a-917b-40dcb9c7b200" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_519a0936-55c8-41e6-9477-458a99c8b478" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_eb7769cd-5a20-4d6a-917b-40dcb9c7b200" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8a8e3e54-4ecf-49c8-9afa-b5a761633d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_519a0936-55c8-41e6-9477-458a99c8b478" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8a8e3e54-4ecf-49c8-9afa-b5a761633d4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4ec783b5-b178-42b2-acba-e4cf02cd3432" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_519a0936-55c8-41e6-9477-458a99c8b478" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4ec783b5-b178-42b2-acba-e4cf02cd3432" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aaf51267-7dae-4c96-82f4-a1b1f6c1129a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5184c78b-4085-43c5-9336-5f682382efea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5ee31cff-c18b-49ee-8eab-e1843d93a49a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5184c78b-4085-43c5-9336-5f682382efea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ee0a5339-40f9-4131-bcc7-d89b18238997" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5184c78b-4085-43c5-9336-5f682382efea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ee0a5339-40f9-4131-bcc7-d89b18238997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e9022bf7-dfa9-452c-b9b8-a612141a33b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5184c78b-4085-43c5-9336-5f682382efea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e9022bf7-dfa9-452c-b9b8-a612141a33b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_215f4905-b143-4001-a2db-08a736828caf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5184c78b-4085-43c5-9336-5f682382efea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_215f4905-b143-4001-a2db-08a736828caf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3a27eff8-8a6b-443b-ad67-4c7a9621e638" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5184c78b-4085-43c5-9336-5f682382efea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3a27eff8-8a6b-443b-ad67-4c7a9621e638" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_45b6bb28-d79e-44ea-93cd-bf4c22fa28c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a5ac01f-fe1f-45d3-b91b-2227ff27253a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d8eb37a8-48ec-437b-a968-8575769b7391" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a5ac01f-fe1f-45d3-b91b-2227ff27253a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d8eb37a8-48ec-437b-a968-8575769b7391" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_705b7523-9ce6-4812-81d2-4e13b4f36d42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d8eb37a8-48ec-437b-a968-8575769b7391" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_705b7523-9ce6-4812-81d2-4e13b4f36d42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_705b7523-9ce6-4812-81d2-4e13b4f36d42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_705b7523-9ce6-4812-81d2-4e13b4f36d42" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_705b7523-9ce6-4812-81d2-4e13b4f36d42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_75787301-d275-46ab-b87b-b4fb5cf2cded" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_705b7523-9ce6-4812-81d2-4e13b4f36d42" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_75787301-d275-46ab-b87b-b4fb5cf2cded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d5c1140e-8da8-47ff-87d3-bc563b154f15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_75787301-d275-46ab-b87b-b4fb5cf2cded" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d5c1140e-8da8-47ff-87d3-bc563b154f15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5252c658-b572-44be-acbf-e72df4ad7098" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d8eb37a8-48ec-437b-a968-8575769b7391" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5252c658-b572-44be-acbf-e72df4ad7098" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5252c658-b572-44be-acbf-e72df4ad7098_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5252c658-b572-44be-acbf-e72df4ad7098" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5252c658-b572-44be-acbf-e72df4ad7098_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_897c2eb6-2275-438c-9b72-d2c892ed239d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5252c658-b572-44be-acbf-e72df4ad7098" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_897c2eb6-2275-438c-9b72-d2c892ed239d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_519c6e93-da81-4f97-acc3-7c7303e0d8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_897c2eb6-2275-438c-9b72-d2c892ed239d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_519c6e93-da81-4f97-acc3-7c7303e0d8fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_46329b45-5c6b-40b2-87fb-ad857267759c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_897c2eb6-2275-438c-9b72-d2c892ed239d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_46329b45-5c6b-40b2-87fb-ad857267759c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2b7827e8-118c-4252-8434-30f8f0b895bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_897c2eb6-2275-438c-9b72-d2c892ed239d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2b7827e8-118c-4252-8434-30f8f0b895bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6cffd2cb-ded7-4248-b947-493bf2c68ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d8eb37a8-48ec-437b-a968-8575769b7391" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6cffd2cb-ded7-4248-b947-493bf2c68ad3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6cffd2cb-ded7-4248-b947-493bf2c68ad3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6cffd2cb-ded7-4248-b947-493bf2c68ad3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6cffd2cb-ded7-4248-b947-493bf2c68ad3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_163e530c-731d-4712-b071-dccf4b36d9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6cffd2cb-ded7-4248-b947-493bf2c68ad3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_163e530c-731d-4712-b071-dccf4b36d9a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3a3f552b-6263-4ab1-99f5-8eee6169f5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_163e530c-731d-4712-b071-dccf4b36d9a4" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3a3f552b-6263-4ab1-99f5-8eee6169f5fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_870bbbd3-1c32-443a-a0d3-a958ccd47659" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_163e530c-731d-4712-b071-dccf4b36d9a4" xlink:to="loc_us-gaap_CertificatesOfDepositMember_870bbbd3-1c32-443a-a0d3-a958ccd47659" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_abfcaa31-c7c2-473b-85d0-0f158fb5c32a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_163e530c-731d-4712-b071-dccf4b36d9a4" xlink:to="loc_us-gaap_MunicipalBondsMember_abfcaa31-c7c2-473b-85d0-0f158fb5c32a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember_f5357a4a-3e64-4e3a-9f73-8ab8ff48ed77" xlink:href="arwr-20250930.xsd#arwr_CommercialNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_163e530c-731d-4712-b071-dccf4b36d9a4" xlink:to="loc_arwr_CommercialNotesMember_f5357a4a-3e64-4e3a-9f73-8ab8ff48ed77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_53f28a31-04f9-4973-a119-0a918fb7a9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_163e530c-731d-4712-b071-dccf4b36d9a4" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_53f28a31-04f9-4973-a119-0a918fb7a9d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_c8a857f9-49ca-4117-bdc8-e603c6ddbe0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d8eb37a8-48ec-437b-a968-8575769b7391" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_c8a857f9-49ca-4117-bdc8-e603c6ddbe0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c8a857f9-49ca-4117-bdc8-e603c6ddbe0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_c8a857f9-49ca-4117-bdc8-e603c6ddbe0a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c8a857f9-49ca-4117-bdc8-e603c6ddbe0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1b6deda3-ebc2-4c08-992d-8ca67449999c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_c8a857f9-49ca-4117-bdc8-e603c6ddbe0a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1b6deda3-ebc2-4c08-992d-8ca67449999c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_29fd32e4-5ba2-4d33-9c99-4b621c126f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1b6deda3-ebc2-4c08-992d-8ca67449999c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_29fd32e4-5ba2-4d33-9c99-4b621c126f8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_6829bbf7-fe59-4d11-84c2-e4b56f37562a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1b6deda3-ebc2-4c08-992d-8ca67449999c" xlink:to="loc_us-gaap_BankTimeDepositsMember_6829bbf7-fe59-4d11-84c2-e4b56f37562a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_a01c58c7-23e0-409c-85f3-c75d526faf79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1b6deda3-ebc2-4c08-992d-8ca67449999c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_a01c58c7-23e0-409c-85f3-c75d526faf79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_21ebdb41-35d1-4175-a258-d17121be226c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1b6deda3-ebc2-4c08-992d-8ca67449999c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_21ebdb41-35d1-4175-a258-d17121be226c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d236db6f-2e1f-4c51-8384-03eb54f35970" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a5ac01f-fe1f-45d3-b91b-2227ff27253a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d236db6f-2e1f-4c51-8384-03eb54f35970" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_882251b3-f7e5-4ee8-ba0d-277ee2e597be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a5ac01f-fe1f-45d3-b91b-2227ff27253a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_882251b3-f7e5-4ee8-ba0d-277ee2e597be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3b71983f-b76b-4ccf-b65c-aed230ada0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a5ac01f-fe1f-45d3-b91b-2227ff27253a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3b71983f-b76b-4ccf-b65c-aed230ada0d7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_d9453892-d83a-4010-8739-3a8fea099071" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_bdef78cc-567f-4c57-9f7d-228f5ab6e85e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_d9453892-d83a-4010-8739-3a8fea099071" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_bdef78cc-567f-4c57-9f7d-228f5ab6e85e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_7fd7e379-c611-456e-bfe3-4dfe672a7ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_bdef78cc-567f-4c57-9f7d-228f5ab6e85e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_7fd7e379-c611-456e-bfe3-4dfe672a7ec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7fd7e379-c611-456e-bfe3-4dfe672a7ec8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_7fd7e379-c611-456e-bfe3-4dfe672a7ec8" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7fd7e379-c611-456e-bfe3-4dfe672a7ec8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_990e54a2-561c-4d69-81ed-ef24fdae3106" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_7fd7e379-c611-456e-bfe3-4dfe672a7ec8" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_990e54a2-561c-4d69-81ed-ef24fdae3106" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_85898633-8c7c-443f-a627-9c7d8b5cf78f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_990e54a2-561c-4d69-81ed-ef24fdae3106" xlink:to="loc_us-gaap_DomesticCountryMember_85898633-8c7c-443f-a627-9c7d8b5cf78f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_83fb56b2-0ec5-4d06-a559-70b0a79940b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_990e54a2-561c-4d69-81ed-ef24fdae3106" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_83fb56b2-0ec5-4d06-a559-70b0a79940b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_60bb801a-bd2c-4f99-ad49-f309f416efa6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_990e54a2-561c-4d69-81ed-ef24fdae3106" xlink:to="loc_us-gaap_ForeignCountryMember_60bb801a-bd2c-4f99-ad49-f309f416efa6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b3882f7a-03d3-4018-b2a1-324c7f902233" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_d9453892-d83a-4010-8739-3a8fea099071" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b3882f7a-03d3-4018-b2a1-324c7f902233" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_85a06ce2-b540-4760-ab32-9d8f0245f273" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_d9453892-d83a-4010-8739-3a8fea099071" xlink:to="loc_us-gaap_OperatingLossCarryforwards_85a06ce2-b540-4760-ab32-9d8f0245f273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingLossCarryforwardsSubjectToExpiration_ba68d536-e75c-4bc2-9837-2031272797e4" xlink:href="arwr-20250930.xsd#arwr_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_d9453892-d83a-4010-8739-3a8fea099071" xlink:to="loc_arwr_OperatingLossCarryforwardsSubjectToExpiration_ba68d536-e75c-4bc2-9837-2031272797e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingLossCarryforwardsNotSubjectToExpiration_4bd12b13-e0e3-4c3f-86f2-bae2ca380c6e" xlink:href="arwr-20250930.xsd#arwr_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_d9453892-d83a-4010-8739-3a8fea099071" xlink:to="loc_arwr_OperatingLossCarryforwardsNotSubjectToExpiration_4bd12b13-e0e3-4c3f-86f2-bae2ca380c6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_85b0ddf6-2bc7-4956-96bb-1ed5b9c82260" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_d9453892-d83a-4010-8739-3a8fea099071" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_85b0ddf6-2bc7-4956-96bb-1ed5b9c82260" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxCreditCarryforwardAmountSubjectToExpiration_be1c6b18-75d0-4112-897b-e3832721c7e0" xlink:href="arwr-20250930.xsd#arwr_TaxCreditCarryforwardAmountSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_d9453892-d83a-4010-8739-3a8fea099071" xlink:to="loc_arwr_TaxCreditCarryforwardAmountSubjectToExpiration_be1c6b18-75d0-4112-897b-e3832721c7e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_d500dc56-ef7d-4815-948c-547f210920fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_d9453892-d83a-4010-8739-3a8fea099071" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_d500dc56-ef7d-4815-948c-547f210920fa" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#EmployeeBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_92b4deb8-36ad-47b9-a914-0cad459ffe7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9d4c1b42-0da1-4335-9d4f-cfe336dc3b98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_92b4deb8-36ad-47b9-a914-0cad459ffe7d" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9d4c1b42-0da1-4335-9d4f-cfe336dc3b98" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_38f3b60d-c1d5-4bc6-a452-59d38426e6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9d4c1b42-0da1-4335-9d4f-cfe336dc3b98" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_38f3b60d-c1d5-4bc6-a452-59d38426e6a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_38f3b60d-c1d5-4bc6-a452-59d38426e6a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_38f3b60d-c1d5-4bc6-a452-59d38426e6a6" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_38f3b60d-c1d5-4bc6-a452-59d38426e6a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_072dd348-cf9b-482b-bad3-c9585227bb82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_38f3b60d-c1d5-4bc6-a452-59d38426e6a6" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_072dd348-cf9b-482b-bad3-c9585227bb82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EmployeeContributionsUpToThreePercentMember_2db4a2dc-8556-45bf-88f7-6354d51c5131" xlink:href="arwr-20250930.xsd#arwr_EmployeeContributionsUpToThreePercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_072dd348-cf9b-482b-bad3-c9585227bb82" xlink:to="loc_arwr_EmployeeContributionsUpToThreePercentMember_2db4a2dc-8556-45bf-88f7-6354d51c5131" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EmployeeContributionNextTwoPercentMember_fb703d8a-3792-495b-b216-93636e900691" xlink:href="arwr-20250930.xsd#arwr_EmployeeContributionNextTwoPercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_072dd348-cf9b-482b-bad3-c9585227bb82" xlink:to="loc_arwr_EmployeeContributionNextTwoPercentMember_fb703d8a-3792-495b-b216-93636e900691" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_cf52f063-6736-45e0-8e93-acd116572fce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_92b4deb8-36ad-47b9-a914-0cad459ffe7d" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_cf52f063-6736-45e0-8e93-acd116572fce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_807d0c68-039c-4a77-ac1d-c339a15f5348" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_92b4deb8-36ad-47b9-a914-0cad459ffe7d" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_807d0c68-039c-4a77-ac1d-c339a15f5348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_01b3bcd7-4669-4ee9-9f93-79af37cfbc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_92b4deb8-36ad-47b9-a914-0cad459ffe7d" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_01b3bcd7-4669-4ee9-9f93-79af37cfbc3c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0d2205a0-ba0e-4267-ac84-6251742af5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0d2205a0-ba0e-4267-ac84-6251742af5f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5fee4a07-2436-45d4-bcdf-618877835438" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0d2205a0-ba0e-4267-ac84-6251742af5f3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5fee4a07-2436-45d4-bcdf-618877835438" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5fee4a07-2436-45d4-bcdf-618877835438_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5fee4a07-2436-45d4-bcdf-618877835438" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5fee4a07-2436-45d4-bcdf-618877835438_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3aa2ff4-5082-4af0-b4fe-4a4dc56e6842" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5fee4a07-2436-45d4-bcdf-618877835438" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3aa2ff4-5082-4af0-b4fe-4a4dc56e6842" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember_1da0ce0c-392b-4a95-9c7e-0ac3c5927359" xlink:href="arwr-20250930.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3aa2ff4-5082-4af0-b4fe-4a4dc56e6842" xlink:to="loc_arwr_RoyaltyPharmaAgreementMember_1da0ce0c-392b-4a95-9c7e-0ac3c5927359" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a04bc8f4-2226-4a04-bf4c-0db90bb5c5b3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0d2205a0-ba0e-4267-ac84-6251742af5f3" xlink:to="loc_srt_RangeAxis_a04bc8f4-2226-4a04-bf4c-0db90bb5c5b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a04bc8f4-2226-4a04-bf4c-0db90bb5c5b3_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a04bc8f4-2226-4a04-bf4c-0db90bb5c5b3" xlink:to="loc_srt_RangeMember_a04bc8f4-2226-4a04-bf4c-0db90bb5c5b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_01b7aa23-4177-42e2-9b90-e069a6589ff6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a04bc8f4-2226-4a04-bf4c-0db90bb5c5b3" xlink:to="loc_srt_RangeMember_01b7aa23-4177-42e2-9b90-e069a6589ff6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b8170e00-f477-49c1-8ed8-385b28281c9d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_01b7aa23-4177-42e2-9b90-e069a6589ff6" xlink:to="loc_srt_MaximumMember_b8170e00-f477-49c1-8ed8-385b28281c9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_737d956b-2450-446d-8b58-f761d32384cb" xlink:href="arwr-20250930.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:to="loc_arwr_InitialTransactionPrice_737d956b-2450-446d-8b58-f761d32384cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_0b08b957-107e-4acd-83ab-4202705dad6a" xlink:href="arwr-20250930.xsd#arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:to="loc_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_0b08b957-107e-4acd-83ab-4202705dad6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_8dd7ab7e-c92d-4138-a591-403e7a92b39f" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:to="loc_arwr_MilestonePaymentReceivable_8dd7ab7e-c92d-4138-a591-403e7a92b39f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_ecd77645-70a4-4866-b662-8dd7f23744a7" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_ecd77645-70a4-4866-b662-8dd7f23744a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval_8aab6dd1-1129-44eb-ab2a-7ca7c1f03296" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:to="loc_arwr_MilestonePaymentReceivableUponFDAApproval_8aab6dd1-1129-44eb-ab2a-7ca7c1f03296" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_02ce17b6-29d4-425f-971b-62c6be9d6fed" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:to="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_02ce17b6-29d4-425f-971b-62c6be9d6fed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold_9006afc7-f945-4c4a-963c-b627203838a7" xlink:href="arwr-20250930.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:to="loc_arwr_RoyaltyPaymentThreshold_9006afc7-f945-4c4a-963c-b627203838a7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_79e87921-6978-4bb3-a4cf-33af3ffda8f3" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:to="loc_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_79e87921-6978-4bb3-a4cf-33af3ffda8f3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_a709f5ac-b918-4d1f-83de-098526eae40f" xlink:href="arwr-20250930.xsd#arwr_LiabilitySaleOfFutureRoyaltiesInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:to="loc_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_a709f5ac-b918-4d1f-83de-098526eae40f" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#FinancingAgreementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_a2dbaa72-fc87-4762-96d6-340fff61d46a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_a2dbaa72-fc87-4762-96d6-340fff61d46a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_450200a0-48c1-4a6a-9283-a56bb1c5ffb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a2dbaa72-fc87-4762-96d6-340fff61d46a" xlink:to="loc_us-gaap_CreditFacilityAxis_450200a0-48c1-4a6a-9283-a56bb1c5ffb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_450200a0-48c1-4a6a-9283-a56bb1c5ffb8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_450200a0-48c1-4a6a-9283-a56bb1c5ffb8" xlink:to="loc_us-gaap_CreditFacilityDomain_450200a0-48c1-4a6a-9283-a56bb1c5ffb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6673f708-17c2-4478-959e-e30bbf60d6db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_450200a0-48c1-4a6a-9283-a56bb1c5ffb8" xlink:to="loc_us-gaap_CreditFacilityDomain_6673f708-17c2-4478-959e-e30bbf60d6db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_c188d81d-321d-4498-9df0-05847551686e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_6673f708-17c2-4478-959e-e30bbf60d6db" xlink:to="loc_us-gaap_SecuredDebtMember_c188d81d-321d-4498-9df0-05847551686e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_2ec1af2c-d561-419a-8c5b-8a77b643db10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_6673f708-17c2-4478-959e-e30bbf60d6db" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_2ec1af2c-d561-419a-8c5b-8a77b643db10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f63d07e5-09fe-4c99-b0ab-ed7eeadfe8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a2dbaa72-fc87-4762-96d6-340fff61d46a" xlink:to="loc_us-gaap_DebtInstrumentAxis_f63d07e5-09fe-4c99-b0ab-ed7eeadfe8e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f63d07e5-09fe-4c99-b0ab-ed7eeadfe8e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f63d07e5-09fe-4c99-b0ab-ed7eeadfe8e7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f63d07e5-09fe-4c99-b0ab-ed7eeadfe8e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_34a4409d-924f-4518-83fb-325fbdc8c212" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f63d07e5-09fe-4c99-b0ab-ed7eeadfe8e7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_34a4409d-924f-4518-83fb-325fbdc8c212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMember_a6e7776b-8020-497c-9f64-f5429bb3a584" xlink:href="arwr-20250930.xsd#arwr_FinancingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a4409d-924f-4518-83fb-325fbdc8c212" xlink:to="loc_arwr_FinancingAgreementMember_a6e7776b-8020-497c-9f64-f5429bb3a584" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementInitialTermLoanMember_58d8d1b8-7f88-443c-8a95-7a9e03bcac66" xlink:href="arwr-20250930.xsd#arwr_FinancingAgreementInitialTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_FinancingAgreementMember_a6e7776b-8020-497c-9f64-f5429bb3a584" xlink:to="loc_arwr_FinancingAgreementInitialTermLoanMember_58d8d1b8-7f88-443c-8a95-7a9e03bcac66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMOICPaymentMember_6d865f50-a212-4738-8e92-a57090801af4" xlink:href="arwr-20250930.xsd#arwr_FinancingAgreementMOICPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_FinancingAgreementMember_a6e7776b-8020-497c-9f64-f5429bb3a584" xlink:to="loc_arwr_FinancingAgreementMOICPaymentMember_6d865f50-a212-4738-8e92-a57090801af4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ca714435-c263-4f97-a1d2-3a720b80e155" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a2dbaa72-fc87-4762-96d6-340fff61d46a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ca714435-c263-4f97-a1d2-3a720b80e155" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ca714435-c263-4f97-a1d2-3a720b80e155_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ca714435-c263-4f97-a1d2-3a720b80e155" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ca714435-c263-4f97-a1d2-3a720b80e155_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2fd5a138-bebb-4ab4-bb05-a2727e865921" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ca714435-c263-4f97-a1d2-3a720b80e155" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2fd5a138-bebb-4ab4-bb05-a2727e865921" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_745722b6-4e20-4e2a-805e-41f8fe5453fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2fd5a138-bebb-4ab4-bb05-a2727e865921" xlink:to="loc_us-gaap_LineOfCreditMember_745722b6-4e20-4e2a-805e-41f8fe5453fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_65a331a6-74ed-46f3-bed2-b60af8879de4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a2dbaa72-fc87-4762-96d6-340fff61d46a" xlink:to="loc_srt_CounterpartyNameAxis_65a331a6-74ed-46f3-bed2-b60af8879de4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65a331a6-74ed-46f3-bed2-b60af8879de4_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_65a331a6-74ed-46f3-bed2-b60af8879de4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65a331a6-74ed-46f3-bed2-b60af8879de4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6645400a-8711-400e-8173-beae7764a223" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_65a331a6-74ed-46f3-bed2-b60af8879de4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6645400a-8711-400e-8173-beae7764a223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaTherapeuticsIncMember_0d7fd8be-591a-448d-80ca-d8e570355fc0" xlink:href="arwr-20250930.xsd#arwr_SareptaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6645400a-8711-400e-8173-beae7764a223" xlink:to="loc_arwr_SareptaTherapeuticsIncMember_0d7fd8be-591a-448d-80ca-d8e570355fc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_afe94ec8-55d9-47f5-8357-c5106ce5f66e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a2dbaa72-fc87-4762-96d6-340fff61d46a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_afe94ec8-55d9-47f5-8357-c5106ce5f66e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_afe94ec8-55d9-47f5-8357-c5106ce5f66e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_afe94ec8-55d9-47f5-8357-c5106ce5f66e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_afe94ec8-55d9-47f5-8357-c5106ce5f66e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8fed694-f6e0-4c42-aac2-8ef4ee70538e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_afe94ec8-55d9-47f5-8357-c5106ce5f66e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8fed694-f6e0-4c42-aac2-8ef4ee70538e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember_7b8ba146-38f8-4707-bb6d-9b2e9a89c6d0" xlink:href="arwr-20250930.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8fed694-f6e0-4c42-aac2-8ef4ee70538e" xlink:to="loc_arwr_SareptaCollaborationAgreementMember_7b8ba146-38f8-4707-bb6d-9b2e9a89c6d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_6f77246b-3d1f-4d06-a84b-2f12dacf3d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a2dbaa72-fc87-4762-96d6-340fff61d46a" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_6f77246b-3d1f-4d06-a84b-2f12dacf3d1d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_6f77246b-3d1f-4d06-a84b-2f12dacf3d1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_6f77246b-3d1f-4d06-a84b-2f12dacf3d1d" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_6f77246b-3d1f-4d06-a84b-2f12dacf3d1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_66e9090d-96b2-4fdb-a7fd-e4f0097acf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_6f77246b-3d1f-4d06-a84b-2f12dacf3d1d" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_66e9090d-96b2-4fdb-a7fd-e4f0097acf7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_b3f17d75-75a6-4ba9-bde7-ac8423968b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_66e9090d-96b2-4fdb-a7fd-e4f0097acf7c" xlink:to="loc_us-gaap_LineOfCreditMember_b3f17d75-75a6-4ba9-bde7-ac8423968b8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3a5e1b48-a11a-43b0-8b54-bdb6875f9c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3a5e1b48-a11a-43b0-8b54-bdb6875f9c7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_b9f82b01-d2b5-44e1-9864-a7e0818b583b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_us-gaap_LineOfCredit_b9f82b01-d2b5-44e1-9864-a7e0818b583b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_a8ed3008-7f44-4fb4-9ec4-062bbfaa79d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_a8ed3008-7f44-4fb4-9ec4-062bbfaa79d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_014bde9c-51be-424b-a9aa-69556eb7724c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_014bde9c-51be-424b-a9aa-69556eb7724c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentCovenantMultipleOfInvestedCapital_f6a21e7e-b7ea-4635-8641-aa560cbc1532" xlink:href="arwr-20250930.xsd#arwr_DebtInstrumentCovenantMultipleOfInvestedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_arwr_DebtInstrumentCovenantMultipleOfInvestedCapital_f6a21e7e-b7ea-4635-8641-aa560cbc1532" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e76b7ba6-9cae-4014-8f20-0b1f8d599d72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e76b7ba6-9cae-4014-8f20-0b1f8d599d72" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements_d1354b43-a08e-450b-a622-16f6919085be" xlink:href="arwr-20250930.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_arwr_ProceedsFromCollaborationArrangements_d1354b43-a08e-450b-a622-16f6919085be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentPrepaymentPercentage_23756dc2-42ca-41af-a4da-bfe2e85413b4" xlink:href="arwr-20250930.xsd#arwr_DebtInstrumentPrepaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_arwr_DebtInstrumentPrepaymentPercentage_23756dc2-42ca-41af-a4da-bfe2e85413b4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_9380a356-65e7-4755-85f7-8789ec449de8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_9380a356-65e7-4755-85f7-8789ec449de8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment_f286afd3-09f0-46eb-8316-d88e56fb514b" xlink:href="arwr-20250930.xsd#arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment_f286afd3-09f0-46eb-8316-d88e56fb514b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold_06a41c0f-b413-483f-b86e-ebd69b386607" xlink:href="arwr-20250930.xsd#arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold_06a41c0f-b413-483f-b86e-ebd69b386607" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold_d3d9a70f-2a96-4224-b672-d8963393af70" xlink:href="arwr-20250930.xsd#arwr_DebtInstrumentCovenantMarketCapitalizationThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold_d3d9a70f-2a96-4224-b672-d8963393af70" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_5a95ef8d-8e1a-402b-8574-e9ada28ac690" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_us-gaap_DebtInstrumentTerm_5a95ef8d-8e1a-402b-8574-e9ada28ac690" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_546b0b03-b2bd-444e-bebf-eebe79722278" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_us-gaap_LinesOfCreditCurrent_546b0b03-b2bd-444e-bebf-eebe79722278" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#FinancingAgreementOutstandingBalanceofCreditFacilityDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_40818359-1c14-463a-a36e-ac9224728003" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_04cc3d96-cca8-4470-8370-4a5ee4364b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_40818359-1c14-463a-a36e-ac9224728003" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_04cc3d96-cca8-4470-8370-4a5ee4364b2a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_699eba4f-b07f-4711-9465-f2dfe032b787" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_04cc3d96-cca8-4470-8370-4a5ee4364b2a" xlink:to="loc_us-gaap_CreditFacilityAxis_699eba4f-b07f-4711-9465-f2dfe032b787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_699eba4f-b07f-4711-9465-f2dfe032b787_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_699eba4f-b07f-4711-9465-f2dfe032b787" xlink:to="loc_us-gaap_CreditFacilityDomain_699eba4f-b07f-4711-9465-f2dfe032b787_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a40a1611-73f6-44d5-ae7d-8ceedd46da76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_699eba4f-b07f-4711-9465-f2dfe032b787" xlink:to="loc_us-gaap_CreditFacilityDomain_a40a1611-73f6-44d5-ae7d-8ceedd46da76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_9ff0eabc-a684-49de-a74e-59a27d63983e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_a40a1611-73f6-44d5-ae7d-8ceedd46da76" xlink:to="loc_us-gaap_SecuredDebtMember_9ff0eabc-a684-49de-a74e-59a27d63983e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_26a0f0fd-01b9-4734-aa8c-c15a0d5db93b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_04cc3d96-cca8-4470-8370-4a5ee4364b2a" xlink:to="loc_us-gaap_DebtInstrumentAxis_26a0f0fd-01b9-4734-aa8c-c15a0d5db93b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_26a0f0fd-01b9-4734-aa8c-c15a0d5db93b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_26a0f0fd-01b9-4734-aa8c-c15a0d5db93b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_26a0f0fd-01b9-4734-aa8c-c15a0d5db93b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_02772a5a-3ae1-4898-8cc3-328f779c0c02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_26a0f0fd-01b9-4734-aa8c-c15a0d5db93b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_02772a5a-3ae1-4898-8cc3-328f779c0c02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMember_93ebb963-77f7-4787-b877-127a32b7f131" xlink:href="arwr-20250930.xsd#arwr_FinancingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_02772a5a-3ae1-4898-8cc3-328f779c0c02" xlink:to="loc_arwr_FinancingAgreementMember_93ebb963-77f7-4787-b877-127a32b7f131" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementInitialTermLoanMember_19dbe9d9-147a-4058-a2ed-d8db694e3fd0" xlink:href="arwr-20250930.xsd#arwr_FinancingAgreementInitialTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_FinancingAgreementMember_93ebb963-77f7-4787-b877-127a32b7f131" xlink:to="loc_arwr_FinancingAgreementInitialTermLoanMember_19dbe9d9-147a-4058-a2ed-d8db694e3fd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementInitialTermLoanInterestMember_fd7d03de-8212-4764-b80f-959afdfa54d8" xlink:href="arwr-20250930.xsd#arwr_FinancingAgreementInitialTermLoanInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_FinancingAgreementMember_93ebb963-77f7-4787-b877-127a32b7f131" xlink:to="loc_arwr_FinancingAgreementInitialTermLoanInterestMember_fd7d03de-8212-4764-b80f-959afdfa54d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_55939d04-2bf4-42d5-bd90-073ba359adfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_04cc3d96-cca8-4470-8370-4a5ee4364b2a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_55939d04-2bf4-42d5-bd90-073ba359adfa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_55939d04-2bf4-42d5-bd90-073ba359adfa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_55939d04-2bf4-42d5-bd90-073ba359adfa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_55939d04-2bf4-42d5-bd90-073ba359adfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7ec82bab-b5e6-46c2-ae0c-b151019aa69e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_55939d04-2bf4-42d5-bd90-073ba359adfa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7ec82bab-b5e6-46c2-ae0c-b151019aa69e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_99292d72-44e6-402c-a5e4-0780ca6119ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7ec82bab-b5e6-46c2-ae0c-b151019aa69e" xlink:to="loc_us-gaap_LineOfCreditMember_99292d72-44e6-402c-a5e4-0780ca6119ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0b1a12b3-547a-46db-a0b7-6674239494ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_40818359-1c14-463a-a36e-ac9224728003" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0b1a12b3-547a-46db-a0b7-6674239494ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_d8dfa157-d382-44a7-9b20-94302715402b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_40818359-1c14-463a-a36e-ac9224728003" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_d8dfa157-d382-44a7-9b20-94302715402b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_824b54f7-eeb2-4e11-8cea-d8f7b160db5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_40818359-1c14-463a-a36e-ac9224728003" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_824b54f7-eeb2-4e11-8cea-d8f7b160db5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_15416b5e-62d6-4d94-9110-a40da7986efe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_40818359-1c14-463a-a36e-ac9224728003" xlink:to="loc_us-gaap_LinesOfCreditCurrent_15416b5e-62d6-4d94-9110-a40da7986efe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_2ec896ba-bf88-4a1f-8392-b22f81bbcd33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_40818359-1c14-463a-a36e-ac9224728003" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_2ec896ba-bf88-4a1f-8392-b22f81bbcd33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_104e2d7b-7300-4b91-a1f5-424c71bccdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_40818359-1c14-463a-a36e-ac9224728003" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_104e2d7b-7300-4b91-a1f5-424c71bccdfb" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_127737ad-0391-4e3c-844a-8e9b5d14ecbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_2b02ff56-a3f8-4285-879f-1c5b7c007700" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_127737ad-0391-4e3c-844a-8e9b5d14ecbc" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_2b02ff56-a3f8-4285-879f-1c5b7c007700" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ba524cb0-604d-488a-a1d6-84cfb8b4a7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2b02ff56-a3f8-4285-879f-1c5b7c007700" xlink:to="loc_us-gaap_CreditFacilityAxis_ba524cb0-604d-488a-a1d6-84cfb8b4a7cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ba524cb0-604d-488a-a1d6-84cfb8b4a7cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_ba524cb0-604d-488a-a1d6-84cfb8b4a7cf" xlink:to="loc_us-gaap_CreditFacilityDomain_ba524cb0-604d-488a-a1d6-84cfb8b4a7cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d33ce2c6-1abe-497e-ad73-1126fac3270d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_ba524cb0-604d-488a-a1d6-84cfb8b4a7cf" xlink:to="loc_us-gaap_CreditFacilityDomain_d33ce2c6-1abe-497e-ad73-1126fac3270d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_0cea3e53-ba71-453c-96a0-3a3118180439" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d33ce2c6-1abe-497e-ad73-1126fac3270d" xlink:to="loc_us-gaap_SecuredDebtMember_0cea3e53-ba71-453c-96a0-3a3118180439" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_95f4afbd-cb76-4013-835d-f53c84c7ea43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2b02ff56-a3f8-4285-879f-1c5b7c007700" xlink:to="loc_us-gaap_DebtInstrumentAxis_95f4afbd-cb76-4013-835d-f53c84c7ea43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_95f4afbd-cb76-4013-835d-f53c84c7ea43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_95f4afbd-cb76-4013-835d-f53c84c7ea43" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_95f4afbd-cb76-4013-835d-f53c84c7ea43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7eb7f7c5-3276-43d5-aadd-d32c7db53bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_95f4afbd-cb76-4013-835d-f53c84c7ea43" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7eb7f7c5-3276-43d5-aadd-d32c7db53bc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMember_ee64483a-c74c-430f-b4bb-6f366ad2bf5d" xlink:href="arwr-20250930.xsd#arwr_FinancingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7eb7f7c5-3276-43d5-aadd-d32c7db53bc7" xlink:to="loc_arwr_FinancingAgreementMember_ee64483a-c74c-430f-b4bb-6f366ad2bf5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9cf576a5-46f3-40dd-9f7b-93de836b4ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2b02ff56-a3f8-4285-879f-1c5b7c007700" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9cf576a5-46f3-40dd-9f7b-93de836b4ae4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9cf576a5-46f3-40dd-9f7b-93de836b4ae4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9cf576a5-46f3-40dd-9f7b-93de836b4ae4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9cf576a5-46f3-40dd-9f7b-93de836b4ae4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_96359d0f-d107-4110-a6c4-cc76fbcc187f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9cf576a5-46f3-40dd-9f7b-93de836b4ae4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_96359d0f-d107-4110-a6c4-cc76fbcc187f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_b648df31-46f5-4486-81b7-fb9d6bbeecfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_96359d0f-d107-4110-a6c4-cc76fbcc187f" xlink:to="loc_us-gaap_LineOfCreditMember_b648df31-46f5-4486-81b7-fb9d6bbeecfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f4e0c1d9-f89d-47d3-8b83-b72a751817d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_127737ad-0391-4e3c-844a-8e9b5d14ecbc" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f4e0c1d9-f89d-47d3-8b83-b72a751817d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_c8300e74-b3cb-4fd3-8e81-3f914209631e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_127737ad-0391-4e3c-844a-8e9b5d14ecbc" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_c8300e74-b3cb-4fd3-8e81-3f914209631e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_876d71b2-4e87-45a4-a3ae-e9772e15c6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_127737ad-0391-4e3c-844a-8e9b5d14ecbc" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_876d71b2-4e87-45a4-a3ae-e9772e15c6e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_9bdc348f-1933-403d-84d6-bd62f2b6d123" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_127737ad-0391-4e3c-844a-8e9b5d14ecbc" xlink:to="loc_us-gaap_InterestExpenseDebt_9bdc348f-1933-403d-84d6-bd62f2b6d123" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_36c84332-f4bd-4844-bf81-062719b2eb41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_cb60b8ea-b1ca-46f1-8f6b-4845b906472a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_36c84332-f4bd-4844-bf81-062719b2eb41" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_cb60b8ea-b1ca-46f1-8f6b-4845b906472a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7d1f31f9-4995-4e32-9eef-fadcfd0244a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_cb60b8ea-b1ca-46f1-8f6b-4845b906472a" xlink:to="loc_us-gaap_DebtInstrumentAxis_7d1f31f9-4995-4e32-9eef-fadcfd0244a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7d1f31f9-4995-4e32-9eef-fadcfd0244a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7d1f31f9-4995-4e32-9eef-fadcfd0244a8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7d1f31f9-4995-4e32-9eef-fadcfd0244a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_427f088b-abc0-4531-85b9-95e7e0afda80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7d1f31f9-4995-4e32-9eef-fadcfd0244a8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_427f088b-abc0-4531-85b9-95e7e0afda80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMember_035f8e75-5c53-436d-8159-0fc57b114b93" xlink:href="arwr-20250930.xsd#arwr_FinancingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_427f088b-abc0-4531-85b9-95e7e0afda80" xlink:to="loc_arwr_FinancingAgreementMember_035f8e75-5c53-436d-8159-0fc57b114b93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_19961128-2cbe-4c7f-9ac5-c9420c23036d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_cb60b8ea-b1ca-46f1-8f6b-4845b906472a" xlink:to="loc_us-gaap_CreditFacilityAxis_19961128-2cbe-4c7f-9ac5-c9420c23036d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_19961128-2cbe-4c7f-9ac5-c9420c23036d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_19961128-2cbe-4c7f-9ac5-c9420c23036d" xlink:to="loc_us-gaap_CreditFacilityDomain_19961128-2cbe-4c7f-9ac5-c9420c23036d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b207c0cd-aded-41fc-9c69-a991b9d4937f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_19961128-2cbe-4c7f-9ac5-c9420c23036d" xlink:to="loc_us-gaap_CreditFacilityDomain_b207c0cd-aded-41fc-9c69-a991b9d4937f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_f2799d4c-cf14-4487-a443-083a9e081e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_b207c0cd-aded-41fc-9c69-a991b9d4937f" xlink:to="loc_us-gaap_SecuredDebtMember_f2799d4c-cf14-4487-a443-083a9e081e2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_76bf5264-490e-4640-970a-18ed131b2f79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_cb60b8ea-b1ca-46f1-8f6b-4845b906472a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_76bf5264-490e-4640-970a-18ed131b2f79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_76bf5264-490e-4640-970a-18ed131b2f79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_76bf5264-490e-4640-970a-18ed131b2f79" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_76bf5264-490e-4640-970a-18ed131b2f79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_357055c3-ce54-4d12-bcdc-8d0ea526361f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_76bf5264-490e-4640-970a-18ed131b2f79" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_357055c3-ce54-4d12-bcdc-8d0ea526361f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_d7465efe-9d82-47e4-be64-cdc6d825c08b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_357055c3-ce54-4d12-bcdc-8d0ea526361f" xlink:to="loc_us-gaap_LineOfCreditMember_d7465efe-9d82-47e4-be64-cdc6d825c08b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_017c3196-34b8-4fcf-b40c-cbe3c93ea747" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_36c84332-f4bd-4844-bf81-062719b2eb41" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_017c3196-34b8-4fcf-b40c-cbe3c93ea747" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_06f6f7bc-120a-46fe-a924-815c2ee223df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_36c84332-f4bd-4844-bf81-062719b2eb41" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_06f6f7bc-120a-46fe-a924-815c2ee223df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3bd58378-1ab1-4e3a-9e61-d98375a14657" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_36c84332-f4bd-4844-bf81-062719b2eb41" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3bd58378-1ab1-4e3a-9e61-d98375a14657" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_3223f9d6-53e0-4484-8271-57f61580ae99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_36c84332-f4bd-4844-bf81-062719b2eb41" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_3223f9d6-53e0-4484-8271-57f61580ae99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_f9b767a1-16bb-4a6b-9e8c-612e9e4a562a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_36c84332-f4bd-4844-bf81-062719b2eb41" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_f9b767a1-16bb-4a6b-9e8c-612e9e4a562a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_9cef4ad7-c0c6-4f4a-876c-300915554842" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_36c84332-f4bd-4844-bf81-062719b2eb41" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_9cef4ad7-c0c6-4f4a-876c-300915554842" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ed4fad86-d793-44c6-b3b9-df81ce451f47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_36c84332-f4bd-4844-bf81-062719b2eb41" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ed4fad86-d793-44c6-b3b9-df81ce451f47" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#NetLossPerShareAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_02780ca7-a609-4374-8c87-1a9e8cf1cf83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8569765a-0e5d-41c9-b709-db8647a92754" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_02780ca7-a609-4374-8c87-1a9e8cf1cf83" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8569765a-0e5d-41c9-b709-db8647a92754" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec98d959-65a7-4fac-9505-aea79efedc23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8569765a-0e5d-41c9-b709-db8647a92754" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec98d959-65a7-4fac-9505-aea79efedc23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec98d959-65a7-4fac-9505-aea79efedc23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec98d959-65a7-4fac-9505-aea79efedc23" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ec98d959-65a7-4fac-9505-aea79efedc23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a496d25-dc20-4d12-a5e0-f562d74b9aba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec98d959-65a7-4fac-9505-aea79efedc23" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a496d25-dc20-4d12-a5e0-f562d74b9aba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2aca64aa-af87-4768-85b8-ecf62564f286" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a496d25-dc20-4d12-a5e0-f562d74b9aba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2aca64aa-af87-4768-85b8-ecf62564f286" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a4b947ae-c376-480a-b47e-bc520940d90a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a496d25-dc20-4d12-a5e0-f562d74b9aba" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a4b947ae-c376-480a-b47e-bc520940d90a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8bae281f-181f-4623-91d0-34f98ef74e80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_02780ca7-a609-4374-8c87-1a9e8cf1cf83" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8bae281f-181f-4623-91d0-34f98ef74e80" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_438a4175-c466-49db-993e-2313af40a13c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_438a4175-c466-49db-993e-2313af40a13c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4e284540-18ff-4770-a2e5-0f155b81a7da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_438a4175-c466-49db-993e-2313af40a13c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4e284540-18ff-4770-a2e5-0f155b81a7da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4e284540-18ff-4770-a2e5-0f155b81a7da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4e284540-18ff-4770-a2e5-0f155b81a7da" xlink:to="loc_us-gaap_SegmentDomain_4e284540-18ff-4770-a2e5-0f155b81a7da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1f6d315c-576f-4c79-875c-f57ccbf05b36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4e284540-18ff-4770-a2e5-0f155b81a7da" xlink:to="loc_us-gaap_SegmentDomain_1f6d315c-576f-4c79-875c-f57ccbf05b36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingSegmentMember_8f4ed820-adeb-481c-a43b-d0f2cda00bad" xlink:href="arwr-20250930.xsd#arwr_OperatingSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1f6d315c-576f-4c79-875c-f57ccbf05b36" xlink:to="loc_arwr_OperatingSegmentMember_8f4ed820-adeb-481c-a43b-d0f2cda00bad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8258eaa7-0eba-48aa-a20c-8c3471eca889" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_438a4175-c466-49db-993e-2313af40a13c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8258eaa7-0eba-48aa-a20c-8c3471eca889" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8258eaa7-0eba-48aa-a20c-8c3471eca889_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8258eaa7-0eba-48aa-a20c-8c3471eca889" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8258eaa7-0eba-48aa-a20c-8c3471eca889_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e8941b6a-e1f4-4bf4-8c47-78c09ada7c71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8258eaa7-0eba-48aa-a20c-8c3471eca889" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e8941b6a-e1f4-4bf4-8c47-78c09ada7c71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_51eec962-6009-4096-b38d-42ff12cc2fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e8941b6a-e1f4-4bf4-8c47-78c09ada7c71" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_51eec962-6009-4096-b38d-42ff12cc2fa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_87cabdf4-1e3f-42a4-a9b3-e68e42efb876" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e8941b6a-e1f4-4bf4-8c47-78c09ada7c71" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_87cabdf4-1e3f-42a4-a9b3-e68e42efb876" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseCandidateCosts_e7431c70-bd3c-4410-96d5-03a5fbc6ba59" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseCandidateCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_arwr_ResearchAndDevelopmentExpenseCandidateCosts_e7431c70-bd3c-4410-96d5-03a5fbc6ba59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseDiscoveryCosts_cfbf48a1-acac-4cf2-a140-28c3d5c859cb" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseDiscoveryCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_arwr_ResearchAndDevelopmentExpenseDiscoveryCosts_cfbf48a1-acac-4cf2-a140-28c3d5c859cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseSalariesExpense_b50d1bb7-453c-4a69-af15-8e47ae78f54a" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseSalariesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_arwr_ResearchAndDevelopmentExpenseSalariesExpense_b50d1bb7-453c-4a69-af15-8e47ae78f54a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense_a0a21e2a-61e0-49d3-9a4a-92dc940665f5" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense_a0a21e2a-61e0-49d3-9a4a-92dc940665f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense_cd3d56c8-a536-452f-a150-31ad3dc03579" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense_cd3d56c8-a536-452f-a150-31ad3dc03579" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation_08b65544-a190-47f7-a08e-81598bec3c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_us-gaap_SalariesWagesAndOfficersCompensation_08b65544-a190-47f7-a08e-81598bec3c5e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_ce08e6ca-8b75-4fe3-85e0-fda57ce0bdde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_us-gaap_ProfessionalFees_ce08e6ca-8b75-4fe3-85e0-fda57ce0bdde" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense_b436f76c-d9f0-47da-bba9-91ef13342b8a" xlink:href="arwr-20250930.xsd#arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense_b436f76c-d9f0-47da-bba9-91ef13342b8a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense_ee096036-7e68-4d84-b105-6fa6352fa610" xlink:href="arwr-20250930.xsd#arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense_ee096036-7e68-4d84-b105-6fa6352fa610" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fdbd4c41-e513-4dc5-b3e4-04923ce98ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fdbd4c41-e513-4dc5-b3e4-04923ce98ce5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3469cc1e-b9ce-44a1-85de-0b04338ea747" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3469cc1e-b9ce-44a1-85de-0b04338ea747" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_06efb688-459c-4fe7-bb8d-ffcc768a9ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_06efb688-459c-4fe7-bb8d-ffcc768a9ef6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2aea792f-878b-44c3-b50d-dfbbf7775b31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2aea792f-878b-44c3-b50d-dfbbf7775b31" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_977ee384-27cd-4fdb-955f-e6424d00f536" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f537dbe9-8632-4ac0-b824-3d2bf24cc749" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_977ee384-27cd-4fdb-955f-e6424d00f536" xlink:to="loc_us-gaap_SubsequentEventTable_f537dbe9-8632-4ac0-b824-3d2bf24cc749" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1ec12cf9-343a-47cf-88c9-941dcfa25f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f537dbe9-8632-4ac0-b824-3d2bf24cc749" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1ec12cf9-343a-47cf-88c9-941dcfa25f2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1ec12cf9-343a-47cf-88c9-941dcfa25f2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1ec12cf9-343a-47cf-88c9-941dcfa25f2d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1ec12cf9-343a-47cf-88c9-941dcfa25f2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_68785c82-5572-4f26-bd77-a2a3df78f7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1ec12cf9-343a-47cf-88c9-941dcfa25f2d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_68785c82-5572-4f26-bd77-a2a3df78f7c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3fef354d-7ac3-4773-a943-67e5125cc7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_68785c82-5572-4f26-bd77-a2a3df78f7c0" xlink:to="loc_us-gaap_SubsequentEventMember_3fef354d-7ac3-4773-a943-67e5125cc7ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_203102f3-8600-4eb0-9d43-261b93b54880" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f537dbe9-8632-4ac0-b824-3d2bf24cc749" xlink:to="loc_srt_CounterpartyNameAxis_203102f3-8600-4eb0-9d43-261b93b54880" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_203102f3-8600-4eb0-9d43-261b93b54880_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_203102f3-8600-4eb0-9d43-261b93b54880" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_203102f3-8600-4eb0-9d43-261b93b54880_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8eb9e0c5-41a1-4979-ba48-2907fc0d9fa8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_203102f3-8600-4eb0-9d43-261b93b54880" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8eb9e0c5-41a1-4979-ba48-2907fc0d9fa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember_68ef01ae-be4c-41ce-bf19-d09313a6e056" xlink:href="arwr-20250930.xsd#arwr_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8eb9e0c5-41a1-4979-ba48-2907fc0d9fa8" xlink:to="loc_arwr_NovartisMember_68ef01ae-be4c-41ce-bf19-d09313a6e056" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaTherapeuticsIncMember_c45f7e0e-379a-444b-bad9-5baab25046ce" xlink:href="arwr-20250930.xsd#arwr_SareptaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8eb9e0c5-41a1-4979-ba48-2907fc0d9fa8" xlink:to="loc_arwr_SareptaTherapeuticsIncMember_c45f7e0e-379a-444b-bad9-5baab25046ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4d379f40-35e9-4181-91d3-e88bff6c7d37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f537dbe9-8632-4ac0-b824-3d2bf24cc749" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4d379f40-35e9-4181-91d3-e88bff6c7d37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d379f40-35e9-4181-91d3-e88bff6c7d37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4d379f40-35e9-4181-91d3-e88bff6c7d37" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d379f40-35e9-4181-91d3-e88bff6c7d37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c313d3a7-699f-4a33-9708-581cbfdc5f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4d379f40-35e9-4181-91d3-e88bff6c7d37" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c313d3a7-699f-4a33-9708-581cbfdc5f5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisCollaborationAgreementMember_b3ce636b-446e-42e2-b35d-183cf275820e" xlink:href="arwr-20250930.xsd#arwr_NovartisCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c313d3a7-699f-4a33-9708-581cbfdc5f5f" xlink:to="loc_arwr_NovartisCollaborationAgreementMember_b3ce636b-446e-42e2-b35d-183cf275820e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember_fc08ba66-d39e-4ac7-83de-7a786476ea84" xlink:href="arwr-20250930.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c313d3a7-699f-4a33-9708-581cbfdc5f5f" xlink:to="loc_arwr_SareptaCollaborationAgreementMember_fc08ba66-d39e-4ac7-83de-7a786476ea84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8de4e4ba-50e6-4a36-950c-cd7e43671e28" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f537dbe9-8632-4ac0-b824-3d2bf24cc749" xlink:to="loc_srt_RangeAxis_8de4e4ba-50e6-4a36-950c-cd7e43671e28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8de4e4ba-50e6-4a36-950c-cd7e43671e28_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8de4e4ba-50e6-4a36-950c-cd7e43671e28" xlink:to="loc_srt_RangeMember_8de4e4ba-50e6-4a36-950c-cd7e43671e28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2698e1be-baff-4592-8f28-cf01083fa83d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8de4e4ba-50e6-4a36-950c-cd7e43671e28" xlink:to="loc_srt_RangeMember_2698e1be-baff-4592-8f28-cf01083fa83d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2115f442-6aef-43c3-9436-32439e387058" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2698e1be-baff-4592-8f28-cf01083fa83d" xlink:to="loc_srt_MinimumMember_2115f442-6aef-43c3-9436-32439e387058" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1fd124bd-2a27-451d-b762-32ec84274329" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2698e1be-baff-4592-8f28-cf01083fa83d" xlink:to="loc_srt_MaximumMember_1fd124bd-2a27-451d-b762-32ec84274329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements_c4fd72b2-e95d-4c81-ba25-c4f9590cfc8b" xlink:href="arwr-20250930.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_977ee384-27cd-4fdb-955f-e6424d00f536" xlink:to="loc_arwr_ProceedsFromCollaborationArrangements_c4fd72b2-e95d-4c81-ba25-c4f9590cfc8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination_07d85cee-d7aa-4764-8154-cf9efec0c9b0" xlink:href="arwr-20250930.xsd#arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_977ee384-27cd-4fdb-955f-e6424d00f536" xlink:to="loc_arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination_07d85cee-d7aa-4764-8154-cf9efec0c9b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfCollaborationPrograms_ed114cf3-a319-4a35-9d43-d31a851b39cd" xlink:href="arwr-20250930.xsd#arwr_NumberOfCollaborationPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_977ee384-27cd-4fdb-955f-e6424d00f536" xlink:to="loc_arwr_NumberOfCollaborationPrograms_ed114cf3-a319-4a35-9d43-d31a851b39cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentMilestonePayments_46ce8e6f-574f-4d97-a665-99bcde65f2f7" xlink:href="arwr-20250930.xsd#arwr_DevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_977ee384-27cd-4fdb-955f-e6424d00f536" xlink:to="loc_arwr_DevelopmentMilestonePayments_46ce8e6f-574f-4d97-a665-99bcde65f2f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_ae1cef64-c557-4b1b-9eb5-4690b4d5fab7" xlink:href="arwr-20250930.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_977ee384-27cd-4fdb-955f-e6424d00f536" xlink:to="loc_arwr_SalesRelatedMilestonePayments_ae1cef64-c557-4b1b-9eb5-4690b4d5fab7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdeoyeOlukotunMember_5512ed41-9e0f-4917-af0f-3d1b7e32829b" xlink:href="arwr-20250930.xsd#arwr_AdeoyeOlukotunMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_AdeoyeOlukotunMember_5512ed41-9e0f-4917-af0f-3d1b7e32829b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ChristopherAnzaloneMember_a30dfa3e-52ae-46b9-9ec2-e5b2c71f61c8" xlink:href="arwr-20250930.xsd#arwr_ChristopherAnzaloneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_ChristopherAnzaloneMember_a30dfa3e-52ae-46b9-9ec2-e5b2c71f61c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DanielApelMember_492553c1-2333-40d6-bf95-63fd23162693" xlink:href="arwr-20250930.xsd#arwr_DanielApelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_DanielApelMember_492553c1-2333-40d6-bf95-63fd23162693" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JamesHamiltonMember_813e9bed-75e2-4890-bc03-d8dcd4c49d8b" xlink:href="arwr-20250930.xsd#arwr_JamesHamiltonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_JamesHamiltonMember_813e9bed-75e2-4890-bc03-d8dcd4c49d8b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MauroFerrariMember_13754233-e445-44f8-b2cd-7886b84666a5" xlink:href="arwr-20250930.xsd#arwr_MauroFerrariMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_MauroFerrariMember_13754233-e445-44f8-b2cd-7886b84666a5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PatrickOBrienMember_597649b9-f008-4b5a-8900-80a3595cf21a" xlink:href="arwr-20250930.xsd#arwr_PatrickOBrienMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_PatrickOBrienMember_597649b9-f008-4b5a-8900-80a3595cf21a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VictoriaVakienerMember_ff0e1932-51cf-492b-bbc5-e83778e24d09" xlink:href="arwr-20250930.xsd#arwr_VictoriaVakienerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_VictoriaVakienerMember_ff0e1932-51cf-492b-bbc5-e83778e24d09" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_WilliamWaddillMember_a7133966-3c61-4bc9-999b-7a897b7f902e" xlink:href="arwr-20250930.xsd#arwr_WilliamWaddillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_WilliamWaddillMember_a7133966-3c61-4bc9-999b-7a897b7f902e" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PatrickOBrienSharesVestingAndSubjectToSellToCoverMember_2b4f1eb2-e3e1-44b6-8a96-22ce7529863b" xlink:href="arwr-20250930.xsd#arwr_PatrickOBrienSharesVestingAndSubjectToSellToCoverMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arwr_PatrickOBrienSharesVestingAndSubjectToSellToCoverMember_2b4f1eb2-e3e1-44b6-8a96-22ce7529863b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PatrickOBrienOtherSharesBeingSoldMember_27c23baa-1957-4205-956f-33d1c68b73fd" xlink:href="arwr-20250930.xsd#arwr_PatrickOBrienOtherSharesBeingSoldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arwr_PatrickOBrienOtherSharesBeingSoldMember_27c23baa-1957-4205-956f-33d1c68b73fd" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>arwr-20250930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:67e6a79e-2429-4a7b-924a-105395255933,g:bc385ee3-281d-4402-b0c2-11a4f6b4f5dd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_arwr_GSKHSDLicenseAgreementMember_71a58208-1f0f-4c0b-a722-f5810a5ef421_terseLabel_en-US" xlink:label="lab_arwr_GSKHSDLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK-HSD License Agreement</link:label>
    <link:label id="lab_arwr_GSKHSDLicenseAgreementMember_label_en-US" xlink:label="lab_arwr_GSKHSDLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK-HSD License Agreement [Member]</link:label>
    <link:label id="lab_arwr_GSKHSDLicenseAgreementMember_documentation_en-US" xlink:label="lab_arwr_GSKHSDLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GSK-HSD License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GSKHSDLicenseAgreementMember" xlink:href="arwr-20250930.xsd#arwr_GSKHSDLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_GSKHSDLicenseAgreementMember" xlink:to="lab_arwr_GSKHSDLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9f3a20c8-d5d3-4993-95c2-fa752b50e330_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchAndDevelopmentExpenseCandidateCosts_9cc912af-983d-4cb7-963a-f79df5dcb877_terseLabel_en-US" xlink:label="lab_arwr_ResearchAndDevelopmentExpenseCandidateCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Candidate costs</link:label>
    <link:label id="lab_arwr_ResearchAndDevelopmentExpenseCandidateCosts_label_en-US" xlink:label="lab_arwr_ResearchAndDevelopmentExpenseCandidateCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Candidate Costs</link:label>
    <link:label id="lab_arwr_ResearchAndDevelopmentExpenseCandidateCosts_documentation_en-US" xlink:label="lab_arwr_ResearchAndDevelopmentExpenseCandidateCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Candidate Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseCandidateCosts" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseCandidateCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchAndDevelopmentExpenseCandidateCosts" xlink:to="lab_arwr_ResearchAndDevelopmentExpenseCandidateCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_EnrollmentRelatedMilestonePayments_e61f774b-666d-47a4-8c0b-01e167d1d827_terseLabel_en-US" xlink:label="lab_arwr_EnrollmentRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Enrollment related milestone payments</link:label>
    <link:label id="lab_arwr_EnrollmentRelatedMilestonePayments_label_en-US" xlink:label="lab_arwr_EnrollmentRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enrollment Related Milestone Payments</link:label>
    <link:label id="lab_arwr_EnrollmentRelatedMilestonePayments_documentation_en-US" xlink:label="lab_arwr_EnrollmentRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Enrollment Related Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EnrollmentRelatedMilestonePayments" xlink:href="arwr-20250930.xsd#arwr_EnrollmentRelatedMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_EnrollmentRelatedMilestonePayments" xlink:to="lab_arwr_EnrollmentRelatedMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_302fc307-0b3a-4277-98fe-bb1f918d47b3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_9d4e6277-b978-4e2c-b687-f9990525db33_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Realized loss on investments</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7c2d9735-e4c8-4968-96e0-952bffa3cf5a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_3adb8421-bcba-4070-ba50-46f55a1c5f40_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_21163f11-f935-4492-95a1-4811cb14beab_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_4ab5952c-1acd-4a6e-bcd6-c194a93247d2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent_5c23f384-0008-4fe3-a4c4-8630153b5f30_terseLabel_en-US" xlink:label="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:label id="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="arwr-20250930.xsd#arwr_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RegulatoryMilestonePayments_a5694060-70db-418d-ba62-0033e6cc0367_terseLabel_en-US" xlink:label="lab_arwr_RegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory milestone payments</link:label>
    <link:label id="lab_arwr_RegulatoryMilestonePayments_label_en-US" xlink:label="lab_arwr_RegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Milestone Payments</link:label>
    <link:label id="lab_arwr_RegulatoryMilestonePayments_documentation_en-US" xlink:label="lab_arwr_RegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RegulatoryMilestonePayments" xlink:href="arwr-20250930.xsd#arwr_RegulatoryMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RegulatoryMilestonePayments" xlink:to="lab_arwr_RegulatoryMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_109ca0bc-8b5d-4fa1-b8dd-a1357805db9c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_7a9dcc0a-3127-4fe1-be80-05ee633c161b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Stock By Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_9c4a5892-bc65-456b-b7ab-1c0a55d2afe1_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current tax</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d661bffd-e15c-485c-92b7-72fe3bef0b19_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_8f5c291d-ce23-4912-b800-81bca7874583_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_11d475d3-15ea-47cf-88fd-533e90afcf8d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c3153d47-d875-4b86-bcce-a463a11eeb8e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtInstrumentCovenantMultipleOfInvestedCapital_269fd3b0-5806-4837-8343-e9a85a210780_terseLabel_en-US" xlink:label="lab_arwr_DebtInstrumentCovenantMultipleOfInvestedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Multiple of invested capital rate</link:label>
    <link:label id="lab_arwr_DebtInstrumentCovenantMultipleOfInvestedCapital_label_en-US" xlink:label="lab_arwr_DebtInstrumentCovenantMultipleOfInvestedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Multiple Of Invested Capital</link:label>
    <link:label id="lab_arwr_DebtInstrumentCovenantMultipleOfInvestedCapital_documentation_en-US" xlink:label="lab_arwr_DebtInstrumentCovenantMultipleOfInvestedCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Multiple Of Invested Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentCovenantMultipleOfInvestedCapital" xlink:href="arwr-20250930.xsd#arwr_DebtInstrumentCovenantMultipleOfInvestedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtInstrumentCovenantMultipleOfInvestedCapital" xlink:to="lab_arwr_DebtInstrumentCovenantMultipleOfInvestedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c3cda5f6-7fdc-43ad-a520-3be38fd9d152_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Arrowhead Pharmaceuticals, Inc. stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_66506efa-11d5-451a-bd6e-079bcca86ec7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_fae533ef-d8cb-4441-b9a0-7fc9be936c10_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Useful Lives of Property Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_3efce622-a786-46b5-b1f0-bc88181f25e2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_54340e43-d2d6-4a9b-b9d4-83cc7e0344a6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_30385d4a-f80e-4210-8c93-f6fa98132dff_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_4bb80533-b800-4841-85f7-dfdfd79eaceb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_1b7881c7-3649-4c61-b663-093aa2a0e1a4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bc29b60e-1fd5-47af-a330-5d31767c9f6a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_e25f86ab-80d5-413b-adca-e1af5a3f093e_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_735738e5-5b84-4b03-aa81-76347987f87e_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_05ab60ff-4921-4f1c-94fd-e46052d2dcef_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_6c3170ae-46df-4455-871c-52848dc226a6_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e07ffaea-9c9b-4307-a4cb-7cfda7b68ea9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_59ab7707-758f-4f13-90e7-a3a80806d61b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful Lives</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_014d9ef7-9622-4417-86a3-a8ae9d721f18_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to noncontrolling interest, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_33b5699c-eb5c-46fb-90b4-1b9c02561662_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_a328864c-eea0-4d73-918d-05db7f697a3b_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AdditionalCashReceivableUnderCollaborationAgreement_fc1582b6-5df2-4199-8b9a-4cb3c680f7c9_verboseLabel_en-US" xlink:label="lab_arwr_AdditionalCashReceivableUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total annual installments amount</link:label>
    <link:label id="lab_arwr_AdditionalCashReceivableUnderCollaborationAgreement_label_en-US" xlink:label="lab_arwr_AdditionalCashReceivableUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Cash Receivable Under Collaboration Agreement</link:label>
    <link:label id="lab_arwr_AdditionalCashReceivableUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_arwr_AdditionalCashReceivableUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Cash Receivable Under Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement" xlink:href="arwr-20250930.xsd#arwr_AdditionalCashReceivableUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement" xlink:to="lab_arwr_AdditionalCashReceivableUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_a0e7b2ac-f71e-4fae-b8aa-7c532f58035c_terseLabel_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares value reserved for future issuance</link:label>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_label_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Capital Shares Value Reserved For Future Issuance</link:label>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_documentation_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock, capital shares value reserved for future issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:href="arwr-20250930.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:to="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_48874474-62b7-4af2-a43a-86221ab0b8c6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DevelopmentMilestonePayments_08934475-9b81-4167-a694-27f1ef2dbb90_terseLabel_en-US" xlink:label="lab_arwr_DevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development milestone payments</link:label>
    <link:label id="lab_arwr_DevelopmentMilestonePayments_label_en-US" xlink:label="lab_arwr_DevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Milestone Payments</link:label>
    <link:label id="lab_arwr_DevelopmentMilestonePayments_documentation_en-US" xlink:label="lab_arwr_DevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentMilestonePayments" xlink:href="arwr-20250930.xsd#arwr_DevelopmentMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DevelopmentMilestonePayments" xlink:to="lab_arwr_DevelopmentMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination_c73bad67-7db0-4076-a128-7d9b9435f6fc_terseLabel_en-US" xlink:label="lab_arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment receivable upon target nomination</link:label>
    <link:label id="lab_arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination_label_en-US" xlink:label="lab_arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Receivable In Collaboration Arrangements Upon Target Nomination</link:label>
    <link:label id="lab_arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination_documentation_en-US" xlink:label="lab_arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment Receivable In Collaboration Arrangements Upon Target Nomination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination" xlink:href="arwr-20250930.xsd#arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination" xlink:to="lab_arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_a21c8655-f4a7-4a15-b262-360e391eb0f3_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract_9c95fe7f-6952-4d7a-8b6a-06e986fe9df3_terseLabel_en-US" xlink:label="lab_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplementary disclosure of non-cash investing activities:</link:label>
    <link:label id="lab_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract_documentation_en-US" xlink:label="lab_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing Activities Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract" xlink:href="arwr-20250930.xsd#arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract" xlink:to="lab_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3af83c9b-e09e-43bf-a6d3-0dc4edb458a6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income tax expense and noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_91754354-199b-43a4-bad4-722fa1e5c52e_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense_5bfc7576-039b-4dff-b081-3f566fe0496b_terseLabel_en-US" xlink:label="lab_arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facilities related</link:label>
    <link:label id="lab_arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense_label_en-US" xlink:label="lab_arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Facilities Related Expense</link:label>
    <link:label id="lab_arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense_documentation_en-US" xlink:label="lab_arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Facilities Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense" xlink:to="lab_arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_d7011698-984e-4bf3-9ffc-46cb535f9b8b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent_fd4e6acc-5440-4691-b3df-4ef03b092aab_terseLabel_en-US" xlink:label="lab_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-deductible compensation</link:label>
    <link:label id="lab_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent_label_en-US" xlink:label="lab_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation, Percent</link:label>
    <link:label id="lab_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent_documentation_en-US" xlink:label="lab_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" xlink:href="arwr-20250930.xsd#arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" xlink:to="lab_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_89186032-78b0-430f-8f98-219ecd5b1a52_terseLabel_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales-related milestone payments</link:label>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_label_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Related Milestone Payments</link:label>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_documentation_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales-related milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments" xlink:href="arwr-20250930.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SalesRelatedMilestonePayments" xlink:to="lab_arwr_SalesRelatedMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_012da9d8-6c4d-42c7-b2f8-8693e95f4bb0_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributed to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_e7b237a3-3cd0-47f4-bb4b-796fd4341fb1_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_53d9c87b-9961-4ad0-9f9a-492cb005d999_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e6de892d-4622-4ef0-93a6-5c893774152a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Arrangement, Expensed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_ee0f97f7-a93d-4577-bbc3-85f547e9a901_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accretion of note premiums/discounts</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b3598087-66a2-4de5-964c-07209e6363c3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_60a16535-dad2-48ec-a862-34445d8ffe1d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_d6dfe209-c16b-4c3f-8352-663699caa461_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_9ac266c9-7602-46e9-8b48-ec580fd6cb09_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_db799776-93a2-4d84-b565-f12f662320f7_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7178c1-f389-4e13-8974-b4d3b95d4179_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_9a6ea1d3-0646-465d-9dbc-d35c965d05a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ProceedsFromSaleOfFutureRoyalties_bb0dec58-5944-4d4e-9c2c-4a2bf384ad95_terseLabel_en-US" xlink:label="lab_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of future royalties</link:label>
    <link:label id="lab_arwr_ProceedsFromSaleOfFutureRoyalties_label_en-US" xlink:label="lab_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Future Royalties</link:label>
    <link:label id="lab_arwr_ProceedsFromSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:href="arwr-20250930.xsd#arwr_ProceedsFromSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:to="lab_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_30e5cd75-ce94-465b-9fba-db15d18bcfbb_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0e32f509-0864-4e67-a506-e931caef003d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_e07faf74-d9be-4698-85c0-ce6fab487154_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_7fa75429-4ccd-429a-9302-3efc1550e51d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c41ce0a2-1e92-4681-954b-8abbd1b02ff0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_bb7c101a-3801-4148-b3a6-024a9b6c406d_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_5f59989d-f9af-49d8-8a88-e0a7de59f803_terseLabel_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Facility in San Diego</link:label>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_label_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Facility In San Diego [Member]</link:label>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_documentation_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Facility in San Diego.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember" xlink:href="arwr-20250930.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchFacilityInSanDiegoMember" xlink:to="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_9f3fac00-2f03-4c15-afc4-bfc497ee832e_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d580f44b-5c7a-46e5-8438-ddeff3330bb7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_04c4a71a-583b-46b1-a1cd-883a4afbd745_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2013 and 2021 Incentive Plans and other inducement grants</link:label>
    <link:label id="lab_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_label_en-US" xlink:label="lab_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Thirteen Equity Incentive Plan, Two Thousand Twenty One Equity Incentive Plan And Inducement Grants [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Thirteen Equity Incentive Plan, Two Thousand Twenty One Equity Incentive Plan And Inducement Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:href="arwr-20250930.xsd#arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:to="lab_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_b66d577e-7422-418e-8149-fa1935c4ad98_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c4e26358-8a94-4c56-a240-8f308a1ac002_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_37a9e9c5-fbcd-4e7f-b3b3-8e0021dd1bb8_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0cdf08b0-e3be-4d34-a515-913c6fd19165_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f4185136-59d7-45a8-8896-c4552bcf859d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_15752570-5871-4c70-ace8-876991e72504_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ea5ec359-77d9-4ab2-bbd4-77d8e4cc466c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d2e020df-4c01-4c58-87eb-a6fa779cfa38_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_167d861f-3784-4095-822e-3d9786ac84eb_terseLabel_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Short-term, Long-term Investments and Marketable Securities</link:label>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_label_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Held To Maturity Securities And Marketable Securities Table [Table Text Block]</link:label>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_documentation_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:href="arwr-20250930.xsd#arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:to="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4a9cce8c-0942-4a77-acc9-a7268a8d9c86_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3a79450a-f21a-4f80-9bb3-d854d900800f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Common stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_42657aba-7685-4b96-bae3-a18286e89aa9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Common stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfNewTargetPrograms_699f6dc9-8eff-4ad6-8cf4-9c725b3db77b_terseLabel_en-US" xlink:label="lab_arwr_NumberOfNewTargetPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of new target programs</link:label>
    <link:label id="lab_arwr_NumberOfNewTargetPrograms_label_en-US" xlink:label="lab_arwr_NumberOfNewTargetPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of New Target Programs</link:label>
    <link:label id="lab_arwr_NumberOfNewTargetPrograms_documentation_en-US" xlink:label="lab_arwr_NumberOfNewTargetPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of New Target Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfNewTargetPrograms" xlink:href="arwr-20250930.xsd#arwr_NumberOfNewTargetPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfNewTargetPrograms" xlink:to="lab_arwr_NumberOfNewTargetPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_77a302c0-0d1c-4d02-94c4-1aeb99fbc856_terseLabel_en-US" xlink:label="lab_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense on liability related to the sale of future royalties</link:label>
    <link:label id="lab_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_2830fe70-e3fe-45aa-9e48-6183b9d41a71_verboseLabel_en-US" xlink:label="lab_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense recognized</link:label>
    <link:label id="lab_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Interest Expense, Liability Related to Sale of Future Royalties</link:label>
    <link:label id="lab_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash Interest Expense, Liability Related to Sale of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:href="arwr-20250930.xsd#arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:to="lab_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_7901dbb0-f6e4-439f-87fc-b170b1332c28_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_GainLossOnTreasuryStockSettlement_492f8523-2c9d-4d10-9969-082dbe65b0cd_negatedTerseLabel_en-US" xlink:label="lab_arwr_GainLossOnTreasuryStockSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-cash gain on treasury stock received</link:label>
    <link:label id="lab_arwr_GainLossOnTreasuryStockSettlement_6b291a66-0970-437a-a72f-140df368ad51_terseLabel_en-US" xlink:label="lab_arwr_GainLossOnTreasuryStockSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on settlement of treasury stock</link:label>
    <link:label id="lab_arwr_GainLossOnTreasuryStockSettlement_label_en-US" xlink:label="lab_arwr_GainLossOnTreasuryStockSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Treasury Stock Settlement</link:label>
    <link:label id="lab_arwr_GainLossOnTreasuryStockSettlement_documentation_en-US" xlink:label="lab_arwr_GainLossOnTreasuryStockSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Treasury Stock Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GainLossOnTreasuryStockSettlement" xlink:href="arwr-20250930.xsd#arwr_GainLossOnTreasuryStockSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_GainLossOnTreasuryStockSettlement" xlink:to="lab_arwr_GainLossOnTreasuryStockSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_fd58c757-7b09-4728-8f22-62e1c8382565_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency_43aa14c0-7cf3-40fe-9578-6474173de8ce_terseLabel_en-US" xlink:label="lab_arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of subsidiaries with foreign currency as functional currency</link:label>
    <link:label id="lab_arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency_label_en-US" xlink:label="lab_arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Subsidiaries With Foreign Currency As Functional Currency</link:label>
    <link:label id="lab_arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency_documentation_en-US" xlink:label="lab_arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Subsidiaries With Foreign Currency As Functional Currency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency" xlink:href="arwr-20250930.xsd#arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency" xlink:to="lab_arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_f62ce461-7bfb-4c6b-9bbf-06e4e2d794a0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued income taxes (benefits)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0c408dcb-5c24-4b78-a798-0131c95a0714_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_81cf46d0-0f89-4ed1-85d4-34c54234ef03_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_27ad61ba-f808-4866-b232-48355af2e611_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of equity</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_02383bdd-10e8-4298-b253-861759674d72_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1b7977cf-f251-4cda-aa0e-2e54a018acf3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b55cdf2a-5214-4af5-b2e1-d9839b8a4c39_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4c9b76e3-945d-4d8f-886c-7ba71d5258b0_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f756e891-93af-40b1-88c5-b9d83f8a0528_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TaxCreditCarryforwardAmountSubjectToExpiration_72457306-798b-4c92-998b-e857944e6079_terseLabel_en-US" xlink:label="lab_arwr_TaxCreditCarryforwardAmountSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward, amount, subject to expiration</link:label>
    <link:label id="lab_arwr_TaxCreditCarryforwardAmountSubjectToExpiration_label_en-US" xlink:label="lab_arwr_TaxCreditCarryforwardAmountSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount, Subject To Expiration</link:label>
    <link:label id="lab_arwr_TaxCreditCarryforwardAmountSubjectToExpiration_documentation_en-US" xlink:label="lab_arwr_TaxCreditCarryforwardAmountSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount, Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxCreditCarryforwardAmountSubjectToExpiration" xlink:href="arwr-20250930.xsd#arwr_TaxCreditCarryforwardAmountSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TaxCreditCarryforwardAmountSubjectToExpiration" xlink:to="lab_arwr_TaxCreditCarryforwardAmountSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_95a2de7b-14f8-4de0-9219-a766a14adef6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable_8a599a9d-ec11-4662-998c-2dffaec08ffc_terseLabel_en-US" xlink:label="lab_arwr_TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock received to settle accounts receivable</link:label>
    <link:label id="lab_arwr_TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable_label_en-US" xlink:label="lab_arwr_TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock Received In Exchange For Settlement Of Accounts Receivable</link:label>
    <link:label id="lab_arwr_TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable_documentation_en-US" xlink:label="lab_arwr_TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Treasury Stock Received In Exchange For Settlement Of Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable" xlink:href="arwr-20250930.xsd#arwr_TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable" xlink:to="lab_arwr_TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab1d05f1-1ab3-4494-9e8f-470fe0da4746_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_4455807e-7aa7-4773-8e7b-bd1be3c296f6_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current investments, Adjusted Basis</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_635766f4-84f0-4205-8681-289e27872303_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_eb57dea3-f09d-4d81-a4f0-9c0e9284125f_terseLabel_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janssen</link:label>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_label_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen Pharmaceuticals Incorporation [Member]</link:label>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_documentation_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Janssen Pharmaceuticals, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:href="arwr-20250930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:to="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SanofiMember_8bbe4d3e-a791-493e-aac0-da9b8133c48f_terseLabel_en-US" xlink:label="lab_arwr_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_arwr_SanofiMember_label_en-US" xlink:label="lab_arwr_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:label id="lab_arwr_SanofiMember_documentation_en-US" xlink:label="lab_arwr_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sanofi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SanofiMember" xlink:href="arwr-20250930.xsd#arwr_SanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SanofiMember" xlink:to="lab_arwr_SanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_InducementAwardsMember_dc86f5a0-7cb4-4653-8e96-3141513da86b_terseLabel_en-US" xlink:label="lab_arwr_InducementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inducement Awards</link:label>
    <link:label id="lab_arwr_InducementAwardsMember_label_en-US" xlink:label="lab_arwr_InducementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inducement Awards [Member]</link:label>
    <link:label id="lab_arwr_InducementAwardsMember_documentation_en-US" xlink:label="lab_arwr_InducementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inducement Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember" xlink:href="arwr-20250930.xsd#arwr_InducementAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_InducementAwardsMember" xlink:to="lab_arwr_InducementAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_InitialTransactionPrice_55f6cd1c-7eab-4f4a-ad4f-f64e46edb145_terseLabel_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial transaction price</link:label>
    <link:label id="lab_arwr_InitialTransactionPrice_label_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Transaction Price</link:label>
    <link:label id="lab_arwr_InitialTransactionPrice_documentation_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice" xlink:href="arwr-20250930.xsd#arwr_InitialTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_InitialTransactionPrice" xlink:to="lab_arwr_InitialTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_846f144a-3f7e-4cba-b4e4-aa7fb332e61c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercises of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationArrangementConsideration_f6352160-ba56-422d-ae02-cce282f7a825_terseLabel_en-US" xlink:label="lab_arwr_CollaborationArrangementConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total transaction price</link:label>
    <link:label id="lab_arwr_CollaborationArrangementConsideration_label_en-US" xlink:label="lab_arwr_CollaborationArrangementConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Consideration</link:label>
    <link:label id="lab_arwr_CollaborationArrangementConsideration_documentation_en-US" xlink:label="lab_arwr_CollaborationArrangementConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementConsideration" xlink:href="arwr-20250930.xsd#arwr_CollaborationArrangementConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationArrangementConsideration" xlink:to="lab_arwr_CollaborationArrangementConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_InducementPlanMember_4dcd7b5a-a37c-4f77-aaf2-5adfbddce639_terseLabel_en-US" xlink:label="lab_arwr_InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inducement Plan</link:label>
    <link:label id="lab_arwr_InducementPlanMember_label_en-US" xlink:label="lab_arwr_InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inducement Plan [Member]</link:label>
    <link:label id="lab_arwr_InducementPlanMember_documentation_en-US" xlink:label="lab_arwr_InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inducement Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementPlanMember" xlink:href="arwr-20250930.xsd#arwr_InducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_InducementPlanMember" xlink:to="lab_arwr_InducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock_94e3cfae-f066-46d6-b8f3-24e71cec7e64_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Liability Related to the Sale of Future Royalties</link:label>
    <link:label id="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock_label_en-US" xlink:label="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Liability Related To The Sale Of Future Royalties [Table Text Block]</link:label>
    <link:label id="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock_documentation_en-US" xlink:label="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Liability Related To The Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" xlink:href="arwr-20250930.xsd#arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" xlink:to="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_29e3dc72-f4e8-4ff7-b5c4-914418165bb1_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ba30a6dd-2e6b-4cb0-adc0-3ebc35827232_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_7dc23170-90b1-4787-8a93-dda3fb729205_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_febd8df4-fb13-4932-ab22-e05b42a92129_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment award (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0cdd9dbb-d90c-4ee3-a13f-d8f65848e6a9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c01eb7bd-6e8d-44b2-911a-42ecc3771a82_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_162a4019-064b-4980-9a4f-885e49f35000_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">End of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_df575a5e-76f9-4ef7-8cd5-cfc15ae84968_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AuditInformationAbstract_label_en-US" xlink:label="lab_arwr_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_arwr_AuditInformationAbstract_documentation_en-US" xlink:label="lab_arwr_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AuditInformationAbstract" xlink:href="arwr-20250930.xsd#arwr_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AuditInformationAbstract" xlink:to="lab_arwr_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_894f3d15-d306-48bb-b610-16af7f081e97_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_2ecd5686-59fe-4a20-af9d-70818ba986b8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_e6ba3d6d-4372-4c35-b55f-5f14de1c1af6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_6c458150-c21d-49f5-82f1-d06f26130bde_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_cba650cb-58af-404d-a264-c7febf7a1e0b_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_deccf479-32ac-4052-9d9d-f9bf27338267_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0a553622-a1e8-453a-bcd4-77b1976964be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions Used to Value Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_c423d7bf-a59c-4a32-9275-b9a66f959646_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_416894a6-3452-47d7-b3b8-eca21bde6aa8_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market instruments</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_509b892d-9ea5-44b2-9eed-9fa3ff50c1d3_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_1d019946-75b3-49dc-8743-faac49a535f9_terseLabel_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional remaining development regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_label_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Remaining Development Regulatory And Sales Milestones Payments</link:label>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_documentation_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional remaining development regulatory and sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:href="arwr-20250930.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:to="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_bf787f11-8b05-409c-b840-2e2ea729b193_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 Plan</link:label>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty One Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand twenty one incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:href="arwr-20250930.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:to="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_196e7b06-41ae-4dd7-b5e2-1e29517ea3c4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_3f3a9ca4-b018-4a90-991f-736b7ea13236_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FinancingAgreementInitialTermLoanMember_d2a5d306-fe4b-472f-a294-efe5f5b46622_terseLabel_en-US" xlink:label="lab_arwr_FinancingAgreementInitialTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Agreement, Initial Term Loan</link:label>
    <link:label id="lab_arwr_FinancingAgreementInitialTermLoanMember_label_en-US" xlink:label="lab_arwr_FinancingAgreementInitialTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Agreement, Initial Term Loan [Member]</link:label>
    <link:label id="lab_arwr_FinancingAgreementInitialTermLoanMember_documentation_en-US" xlink:label="lab_arwr_FinancingAgreementInitialTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Agreement, Initial Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementInitialTermLoanMember" xlink:href="arwr-20250930.xsd#arwr_FinancingAgreementInitialTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FinancingAgreementInitialTermLoanMember" xlink:to="lab_arwr_FinancingAgreementInitialTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_281454b0-2fc0-403b-8e1c-53614b14ceb3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock - restricted stock units vesting</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WI_6de7a6da-57e0-4826-8161-f650f22f5052_terseLabel_en-US" xlink:label="lab_stpr_WI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wisconsin</link:label>
    <link:label id="lab_stpr_WI_label_en-US" xlink:label="lab_stpr_WI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">WISCONSIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_WI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WI" xlink:to="lab_stpr_WI" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SanofiLicenseAgreementMember_1442648f-fcfe-45f5-b223-b87b485a8005_terseLabel_en-US" xlink:label="lab_arwr_SanofiLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi License Agreement</link:label>
    <link:label id="lab_arwr_SanofiLicenseAgreementMember_label_en-US" xlink:label="lab_arwr_SanofiLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi License Agreement [Member]</link:label>
    <link:label id="lab_arwr_SanofiLicenseAgreementMember_documentation_en-US" xlink:label="lab_arwr_SanofiLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sanofi License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SanofiLicenseAgreementMember" xlink:href="arwr-20250930.xsd#arwr_SanofiLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SanofiLicenseAgreementMember" xlink:to="lab_arwr_SanofiLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_de20be47-1599-44a6-8175-9a69c0f385ef_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_e85999f2-898e-4e3c-b498-522046dbf89b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cancelled or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_1f8e7384-0cff-49b7-99ce-5aad61a0c92d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8500c74a-44e9-4b6a-ba2a-1524db04a58d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d90e76c8-8ad5-49ad-aea8-d8c68ff1c55c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_f985e6c8-f6e1-4aed-b75c-582a72580402_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock - restricted stock units vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_c4ac5a86-11c5-460e-8599-db9b264dace9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee benefits costs</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_c705e72b-f834-43cd-a266-f0da7faa1ad6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_b43ba385-f2f4-4236-a5a2-9f03df5639bf_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_c2241ebf-f78f-4e30-9ee8-8739b1de1da9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfPerformanceObligations_424165a6-333f-4234-b93d-e41fc2d282e0_terseLabel_en-US" xlink:label="lab_arwr_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_arwr_NumberOfPerformanceObligations_label_en-US" xlink:label="lab_arwr_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:label id="lab_arwr_NumberOfPerformanceObligations_documentation_en-US" xlink:label="lab_arwr_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfPerformanceObligations" xlink:href="arwr-20250930.xsd#arwr_NumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfPerformanceObligations" xlink:to="lab_arwr_NumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment_e183ef0a-b5fb-412c-91af-7a01b85790b3_terseLabel_en-US" xlink:label="lab_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MOIC payments expected to be applied to principal upon repayment</link:label>
    <link:label id="lab_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment_label_en-US" xlink:label="lab_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Multiple Of Investment Capital Expected To Be Applied To Principal Upon Repayment</link:label>
    <link:label id="lab_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment_documentation_en-US" xlink:label="lab_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Multiple Of Investment Capital Expected To Be Applied To Principal Upon Repayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment" xlink:href="arwr-20250930.xsd#arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment" xlink:to="lab_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate_61efac02-9cb8-4ea9-875c-836180e668b5_terseLabel_en-US" xlink:label="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital expenditures incurred</link:label>
    <link:label id="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate_label_en-US" xlink:label="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments, Capital Expenditures Incurred To Date</link:label>
    <link:label id="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate_documentation_en-US" xlink:label="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments, Capital Expenditures Incurred To Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommitmentsCapitalExpendituresIncurredToDate" xlink:href="arwr-20250930.xsd#arwr_CommitmentsCapitalExpendituresIncurredToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommitmentsCapitalExpendituresIncurredToDate" xlink:to="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ac94f691-83db-49a9-9ba4-4160f4278301_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_7663423f-b57b-4e2a-8928-6e7500cfb111_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Table]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_label_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Table]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_documentation_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:href="arwr-20250930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:to="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OlpasiranAgreementMember_4e8a0111-465d-45bc-93bd-25de4834b283_terseLabel_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Olpasiran Agreement</link:label>
    <link:label id="lab_arwr_OlpasiranAgreementMember_label_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Olpasiran Agreement [Member]</link:label>
    <link:label id="lab_arwr_OlpasiranAgreementMember_documentation_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Olpasiran agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember" xlink:href="arwr-20250930.xsd#arwr_OlpasiranAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OlpasiranAgreementMember" xlink:to="lab_arwr_OlpasiranAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_f4669a3e-c1e7-47a5-a87a-03605a3bd5a2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ae809b0f-0187-4f11-92c8-fccc27643594_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_53f2fe00-7903-4558-8a20-7ea8459d7e6e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_017921bc-a9c5-41bc-8daf-a6c39b5aee0c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_10e48351-bcf1-4c67-8bf4-0cb26488d9d9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfLand_89b1dafc-50b5-4430-8981-e955469aa62e_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Planned area of site (in sq ft)</link:label>
    <link:label id="lab_us-gaap_AreaOfLand_label_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand" xlink:to="lab_us-gaap_AreaOfLand" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_4ed131e9-5fe2-4ba8-9ccd-1ef829ec3355_terseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After one to two years</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_label_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One Through Two</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One Through Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:href="arwr-20250930.xsd#arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:to="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_66f175d8-3740-458c-8b91-ae35d5e4d903_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SaleOfStockPremiumOnIssuanceOfShares_c7917678-76ed-4396-a463-7b4b4e937226_verboseLabel_en-US" xlink:label="lab_arwr_SaleOfStockPremiumOnIssuanceOfShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity premium</link:label>
    <link:label id="lab_arwr_SaleOfStockPremiumOnIssuanceOfShares_label_en-US" xlink:label="lab_arwr_SaleOfStockPremiumOnIssuanceOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Premium On Issuance Of Shares</link:label>
    <link:label id="lab_arwr_SaleOfStockPremiumOnIssuanceOfShares_documentation_en-US" xlink:label="lab_arwr_SaleOfStockPremiumOnIssuanceOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Premium On Issuance Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SaleOfStockPremiumOnIssuanceOfShares" xlink:href="arwr-20250930.xsd#arwr_SaleOfStockPremiumOnIssuanceOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SaleOfStockPremiumOnIssuanceOfShares" xlink:to="lab_arwr_SaleOfStockPremiumOnIssuanceOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ComputersAndSoftwareMember_4d448367-dea2-4e2a-8a86-c21ee528a540_terseLabel_en-US" xlink:label="lab_arwr_ComputersAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computers and software</link:label>
    <link:label id="lab_arwr_ComputersAndSoftwareMember_label_en-US" xlink:label="lab_arwr_ComputersAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computers And Software [Member]</link:label>
    <link:label id="lab_arwr_ComputersAndSoftwareMember_documentation_en-US" xlink:label="lab_arwr_ComputersAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computers And Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputersAndSoftwareMember" xlink:href="arwr-20250930.xsd#arwr_ComputersAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ComputersAndSoftwareMember" xlink:to="lab_arwr_ComputersAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_5ff79e50-ed35-4d60-a3af-68b050f0ae9f_terseLabel_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Drug Manufacturing Facility</link:label>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_label_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Drug Manufacturing Facility [Member]</link:label>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_documentation_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Drug manufacturing facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember" xlink:href="arwr-20250930.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DrugManufacturingFacilityMember" xlink:to="lab_arwr_DrugManufacturingFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised_8336cb89-4e4f-47b6-8887-b6959492bf42_terseLabel_en-US" xlink:label="lab_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants exercised (in shares)</link:label>
    <link:label id="lab_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised_label_en-US" xlink:label="lab_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Number Of Warrants Exercised</link:label>
    <link:label id="lab_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Number Of Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:href="arwr-20250930.xsd#arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:to="lab_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_c44e50df-c148-47f0-935c-1741e6736009_terseLabel_en-US" xlink:label="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_label_en-US" xlink:label="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Right Of Use Assets Or Lease Liabilities</link:label>
    <link:label id="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_documentation_en-US" xlink:label="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets right of use assets/ lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:href="arwr-20250930.xsd#arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:to="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b311244b-e55e-4bbe-b0af-e6b90d6e0369_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_cdf5b177-cf69-4276-88a2-272ed2d0047b_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_0728cb67-8d93-4b6c-8e32-275b4c9b581d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_292ba1cd-d3ff-4e63-8d3f-ba4e51e968fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FinancingAgreementMOICPaymentMember_2cb46c1d-632c-41fd-b106-55733285b86f_terseLabel_en-US" xlink:label="lab_arwr_FinancingAgreementMOICPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Agreement, MOIC Payment</link:label>
    <link:label id="lab_arwr_FinancingAgreementMOICPaymentMember_label_en-US" xlink:label="lab_arwr_FinancingAgreementMOICPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Agreement, MOIC Payment [Member]</link:label>
    <link:label id="lab_arwr_FinancingAgreementMOICPaymentMember_documentation_en-US" xlink:label="lab_arwr_FinancingAgreementMOICPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Agreement, MOIC Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMOICPaymentMember" xlink:href="arwr-20250930.xsd#arwr_FinancingAgreementMOICPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FinancingAgreementMOICPaymentMember" xlink:to="lab_arwr_FinancingAgreementMOICPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_WilliamWaddillMember_label_en-US" xlink:label="lab_arwr_WilliamWaddillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">William Waddill [Member]</link:label>
    <link:label id="lab_arwr_WilliamWaddillMember_documentation_en-US" xlink:label="lab_arwr_WilliamWaddillMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">William Waddill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_WilliamWaddillMember" xlink:href="arwr-20250930.xsd#arwr_WilliamWaddillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_WilliamWaddillMember" xlink:to="lab_arwr_WilliamWaddillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_bdfa7bad-4cf4-46a8-b4d3-bd78e4c5947d_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_label_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_documentation_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:href="arwr-20250930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_30ec9c0f-ab77-4e33-986d-b88457910e80_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss, net of tax:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8704529c-7ad4-4394-968c-2aa8e96f8df1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_20bfdcfd-ccc8-4323-9caf-3c3f0cd90e27_terseLabel_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization and significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:href="arwr-20250930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ff4e6846-c32e-42bc-a899-448c59d2a819_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DevelopmentAndSalesMilestonesPayments_36ef6630-37ec-4655-bf20-4ba9888a23fe_terseLabel_en-US" xlink:label="lab_arwr_DevelopmentAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and sales milestone payments</link:label>
    <link:label id="lab_arwr_DevelopmentAndSalesMilestonesPayments_label_en-US" xlink:label="lab_arwr_DevelopmentAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development And Sales Milestones Payments</link:label>
    <link:label id="lab_arwr_DevelopmentAndSalesMilestonesPayments_documentation_en-US" xlink:label="lab_arwr_DevelopmentAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development And Sales Milestones Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentAndSalesMilestonesPayments" xlink:href="arwr-20250930.xsd#arwr_DevelopmentAndSalesMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DevelopmentAndSalesMilestonesPayments" xlink:to="lab_arwr_DevelopmentAndSalesMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_d92ec3f9-ac4b-4c77-801e-36a747041074_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c290da3e-6520-41a1-8bc9-f462f446610c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a84cf476-2345-489e-ad9e-2b13461b94ad_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_4ac4bf98-8359-4af4-b665-00025bbc1fb8_terseLabel_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability, Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_label_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_documentation_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability, Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward" xlink:href="arwr-20250930.xsd#arwr_LiabilitySaleOfFutureRoyaltiesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward" xlink:to="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_891d7338-e331-4e60-ad04-edcdc77f3534_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_61ee9305-13ca-417e-b06b-ae8157f345e8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9e68d558-4e42-42f5-84e3-e3f2fa272e8b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. federal statutory income tax</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_485191a6-f11c-4e55-b63a-d3aa990d0a0d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_ac5d937f-b6ea-453a-9962-8aa3e73795b8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit facility, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_74dc8410-f3e6-4fbb-bca0-f253e19c2dcc_terseLabel_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options to renew</link:label>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_label_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Options To Renew</link:label>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_documentation_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of options to renew.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew" xlink:href="arwr-20250930.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfOptionsToRenew" xlink:to="lab_arwr_NumberOfOptionsToRenew" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_fd1e4793-778b-42d8-9f62-85e8a3fbcd0a_terseLabel_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Takeda</link:label>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_label_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceuticals United States Of America Incorporated [Member]</link:label>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_documentation_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceuticals United States of America Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:href="arwr-20250930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:to="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bc462bd2-4bec-4ade-bdd5-1643d6bea1a8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_82b5f648-3aee-4d75-88b4-36fb6eabcd5d_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term deposit</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_a42bbc4c-dc54-413a-a4c5-ca9ff98e290a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_97e88f68-3df4-4181-ae70-d619a59c0729_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_55425b23-4d42-4645-b874-a365547dce9f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_b7e62487-c61e-44c3-b782-49b883024db8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_597203dd-9ee8-4c07-b1a3-7b52f0b4c9da_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b9355868-c8e5-454d-86df-0f504261b87e_totalLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b5e70f54-44fb-4366-8646-ea9c33f0a660_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_5a7e61f1-8dad-42ef-8247-681f265d8475_terseLabel_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Related to the Sale of Future Royalties</link:label>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_label_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Text Block]</link:label>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_documentation_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Related To The Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:href="arwr-20250930.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:to="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_59752f7e-90d2-47dd-81fe-5117be607b0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Shares of Common Stock and Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JamesHamiltonMember_label_en-US" xlink:label="lab_arwr_JamesHamiltonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">James Hamilton [Member]</link:label>
    <link:label id="lab_arwr_JamesHamiltonMember_documentation_en-US" xlink:label="lab_arwr_JamesHamiltonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">James Hamilton</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JamesHamiltonMember" xlink:href="arwr-20250930.xsd#arwr_JamesHamiltonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JamesHamiltonMember" xlink:to="lab_arwr_JamesHamiltonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_d17db871-f227-48e6-8587-85e2941acafa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_4a89f698-cf73-4f6c-b98e-6cb0ef02d20e_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment received</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Received, Liability Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment Received, Liability Related To Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:to="lab_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PatrickOBrienOtherSharesBeingSoldMember_label_en-US" xlink:label="lab_arwr_PatrickOBrienOtherSharesBeingSoldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patrick O'Brien, Other Shares Being Sold [Member]</link:label>
    <link:label id="lab_arwr_PatrickOBrienOtherSharesBeingSoldMember_documentation_en-US" xlink:label="lab_arwr_PatrickOBrienOtherSharesBeingSoldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patrick O'Brien, Other Shares Being Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PatrickOBrienOtherSharesBeingSoldMember" xlink:href="arwr-20250930.xsd#arwr_PatrickOBrienOtherSharesBeingSoldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PatrickOBrienOtherSharesBeingSoldMember" xlink:to="lab_arwr_PatrickOBrienOtherSharesBeingSoldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3e6a7d60-0e3d-41ad-812d-578fa3ac109d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_72b0c4d0-d912-4290-9d75-ae32a81b7730_terseLabel_en-US" xlink:label="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:href="arwr-20250930.xsd#arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_69215af5-80e6-45fa-8c26-275233be26fa_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_63153206-5818-4e54-af7a-2f5b30985559_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_00c17963-475f-4e7a-ba66-0619d1cb9868_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f0627b1c-c819-471f-99d5-7fe8c21a5a1a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a9a2358f-001b-46df-a43d-a6d9daf43ee9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_label_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Abstract]</link:label>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_documentation_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Related To The Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:href="arwr-20250930.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:to="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5eb1b068-bea1-4d9a-8907-3a6c21d9cd6f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_b10be4e5-95a4-4207-997d-2e56b44fef88_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AdeoyeOlukotunMember_label_en-US" xlink:label="lab_arwr_AdeoyeOlukotunMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adeoye Olukotun [Member]</link:label>
    <link:label id="lab_arwr_AdeoyeOlukotunMember_documentation_en-US" xlink:label="lab_arwr_AdeoyeOlukotunMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adeoye Olukotun</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdeoyeOlukotunMember" xlink:href="arwr-20250930.xsd#arwr_AdeoyeOlukotunMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AdeoyeOlukotunMember" xlink:to="lab_arwr_AdeoyeOlukotunMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_da047e49-1367-41d2-9345-d1d522d9ba47_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_57549130-c46f-4120-b611-c14a6a7fd930_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments_19291a39-31dd-47f2-80bc-6d41f46fa72f_terseLabel_en-US" xlink:label="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual installment</link:label>
    <link:label id="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments_label_en-US" xlink:label="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Receivable Under Collaboration Agreement, Annual Installments</link:label>
    <link:label id="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments_documentation_en-US" xlink:label="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Receivable Under Collaboration Agreement, Annual Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments" xlink:href="arwr-20250930.xsd#arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments" xlink:to="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76a890da-5703-4f6d-9552-b0c9fc4bfcdf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense_6a0f17e5-dfca-43b6-a817-4384459b40d8_terseLabel_en-US" xlink:label="lab_arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facilities related</link:label>
    <link:label id="lab_arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense_label_en-US" xlink:label="lab_arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General And Administrative Expense, Facilities Related Expense</link:label>
    <link:label id="lab_arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense_documentation_en-US" xlink:label="lab_arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General And Administrative Expense, Facilities Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense" xlink:href="arwr-20250930.xsd#arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense" xlink:to="lab_arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_45d91bcc-1065-4f3b-a12a-92a5ec594d15_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_0dde7716-7970-46c6-919a-2af913d93294_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_8d3a7d9e-222a-4510-8248-a9006239cb67_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_79897efc-250a-4c5e-b4d1-88a86788c05e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_a901bb10-6b82-4762-abf5-bb10cd2dec91_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_de684121-b15b-4045-bfac-34b09d1fbc91_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_4ed25d37-acce-44dc-98ee-aacd6f9764aa_terseLabel_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and Co-Funding Agreement</link:label>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_label_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Co Funding Agreement [Member]</link:label>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_documentation_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License and co-funding agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember" xlink:href="arwr-20250930.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LicenseAndCoFundingAgreementMember" xlink:to="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_8909137e-4e32-465e-938f-4cd955445046_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f648db7b-8790-4f79-9acf-7a1b5351628c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_3621456c-6a41-49cf-b00c-921738725a1d_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificate of deposits</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_2ea71fb4-f4db-4308-a881-b1823f855ed8_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_599e7ea3-df62-4f6c-bd55-8ffe449cfa22_terseLabel_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization and significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:href="arwr-20250930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_c70947c1-5c36-4bb0-9cbc-5ac0c4c0f9cb_terseLabel_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATM Agreement</link:label>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_label_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Agreement [Member]</link:label>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_documentation_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-the-market agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember" xlink:href="arwr-20250930.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AtTheMarketAgreementMember" xlink:to="lab_arwr_AtTheMarketAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_259fbf8c-fde9-4f08-b82b-fb19cb9071a6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2ee46a92-fe92-4ef5-91df-e081e2c51b6a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_cc7bc5ef-e86e-4615-b865-ba097ed15054_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2b879f00-d4fa-493f-9f19-6c5587bd9b71_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_8956a8fc-e06c-4fe2-a6b6-769d821b1bf9_terseLabel_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payment threshold</link:label>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_label_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Payment Threshold</link:label>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_documentation_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Payment Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold" xlink:href="arwr-20250930.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltyPaymentThreshold" xlink:to="lab_arwr_RoyaltyPaymentThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_63d60f04-1c91-4125-8a4e-563e183d4fbe_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_17e18752-811b-4c6c-bd3c-ced88977cf66_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0f18aa75-62d8-4ddb-afce-6e39f056eaa6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_dd57776b-957c-4e1d-b475-66de0e0e0428_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total gross deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_aba1e8d6-23a4-4bb0-b06c-2771d70e57b0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1c5376e4-bb7c-4b2e-b61d-e3e81f5d1e43_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d9aed32e-7753-4dae-a843-d93ee85f25d8_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_5793777d-6771-4d61-9147-43f8b751f60a_terseLabel_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Pharma Agreement</link:label>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_label_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Pharma Agreement [Member]</link:label>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_documentation_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Pharma Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember" xlink:href="arwr-20250930.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltyPharmaAgreementMember" xlink:to="lab_arwr_RoyaltyPharmaAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SareptaTherapeuticsIncMember_9f5f0e09-f913-405d-9e9e-a558df876676_terseLabel_en-US" xlink:label="lab_arwr_SareptaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sarepta</link:label>
    <link:label id="lab_arwr_SareptaTherapeuticsIncMember_label_en-US" xlink:label="lab_arwr_SareptaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sarepta Therapeutics, Inc [Member]</link:label>
    <link:label id="lab_arwr_SareptaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_arwr_SareptaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sarepta Therapeutics, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaTherapeuticsIncMember" xlink:href="arwr-20250930.xsd#arwr_SareptaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SareptaTherapeuticsIncMember" xlink:to="lab_arwr_SareptaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ba50f406-bdf6-4871-814d-23afacaeee09_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_6a7f6b00-b524-4155-afc0-338261d73cc7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_82e0b273-e4be-45c5-ba70-daed0909876f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ProceedsFromCollaborationArrangements_a27c3668-b266-4d08-a7dd-b2ca68f3c8f1_verboseLabel_en-US" xlink:label="lab_arwr_ProceedsFromCollaborationArrangements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from collaboration arrangements</link:label>
    <link:label id="lab_arwr_ProceedsFromCollaborationArrangements_75b9d2de-92f5-4cf9-a86a-ebe96a3d4a70_terseLabel_en-US" xlink:label="lab_arwr_ProceedsFromCollaborationArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_arwr_ProceedsFromCollaborationArrangements_label_en-US" xlink:label="lab_arwr_ProceedsFromCollaborationArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Collaboration Arrangements</link:label>
    <link:label id="lab_arwr_ProceedsFromCollaborationArrangements_documentation_en-US" xlink:label="lab_arwr_ProceedsFromCollaborationArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Collaboration Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements" xlink:href="arwr-20250930.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ProceedsFromCollaborationArrangements" xlink:to="lab_arwr_ProceedsFromCollaborationArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock_ef51e791-d8cd-47eb-bca7-eb9c39820524_terseLabel_en-US" xlink:label="lab_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Interest Expense Recognized Related to Credit Facility</link:label>
    <link:label id="lab_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock_label_en-US" xlink:label="lab_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Interest Expense Recognized Related To Credit Facility [Table Text Block]</link:label>
    <link:label id="lab_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock_documentation_en-US" xlink:label="lab_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Interest Expense Recognized Related To Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock" xlink:href="arwr-20250930.xsd#arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock" xlink:to="lab_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_269a70b3-080c-49c4-a9a7-5b05fe010d86_terseLabel_en-US" xlink:label="lab_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment Received, Liability Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payment Received, Liability Related To Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:href="arwr-20250930.xsd#arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:to="lab_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_8f1e5b9f-bcf4-4180-bd74-0185586db7a9_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c3e0eaee-8ac4-417e-a04f-606621d0a921_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8d7660ac-e7e9-4b30-baa4-70b30af75130_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fea264e4-6493-4639-bd7b-ddecc1573703_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average diluted shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_f566a6cd-df5f-4db3-aeaa-f6ec7f9504a7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_51871f4e-2997-4c26-aefe-a380ab2557f6_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent_76a6d2a5-7456-489c-aa18-6dbb0557ae00_terseLabel_en-US" xlink:label="lab_arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent_label_en-US" xlink:label="lab_arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Income, Percent</link:label>
    <link:label id="lab_arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent_documentation_en-US" xlink:label="lab_arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Income, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent" xlink:href="arwr-20250930.xsd#arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent" xlink:to="lab_arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_d86654de-1997-4fdb-a829-e58b0ac26f88_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_81f2d2a1-d75b-46a6-8094-7479bdb7a40d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit) related to uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_810b483e-d480-4eac-8d65-d1ad8ca889e6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_15d019f2-2689-4f5b-9225-dec620f288de_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_5b253b5c-84b4-43b3-a622-0afc206dfa3b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Agreement</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_37a18593-be2c-4c90-8739-ae0d19522a59_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold_b5c70f80-e783-4965-8013-d3eb362be62c_terseLabel_en-US" xlink:label="lab_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market capitalization threshold</link:label>
    <link:label id="lab_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold_label_en-US" xlink:label="lab_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Market Capitalization, Threshold</link:label>
    <link:label id="lab_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold_documentation_en-US" xlink:label="lab_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Market Capitalization, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold" xlink:href="arwr-20250930.xsd#arwr_DebtInstrumentCovenantMarketCapitalizationThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold" xlink:to="lab_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_396c445b-b3e6-43d0-af7d-3cc96de3c183_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6c9f45fb-b057-47ff-8653-f6c53ace998b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fc35f77c-e65f-4251-9d5c-d8852939fd2a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_e10dd362-59cd-4839-a561-e3d782fcb97a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit facility, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_1b56d2da-bd99-4c3b-8050-331b33a61e11_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_458768bf-b98c-49b1-8d9b-2edcdde86da3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Visirna credit agreement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ClinicalAccrualPolicyPolicyTextBlock_7542533d-7ce7-40c1-86e7-f388d72aa940_terseLabel_en-US" xlink:label="lab_arwr_ClinicalAccrualPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Accruals</link:label>
    <link:label id="lab_arwr_ClinicalAccrualPolicyPolicyTextBlock_label_en-US" xlink:label="lab_arwr_ClinicalAccrualPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Accrual Policy [Policy Text Block]</link:label>
    <link:label id="lab_arwr_ClinicalAccrualPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_arwr_ClinicalAccrualPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Accrual Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ClinicalAccrualPolicyPolicyTextBlock" xlink:href="arwr-20250930.xsd#arwr_ClinicalAccrualPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ClinicalAccrualPolicyPolicyTextBlock" xlink:to="lab_arwr_ClinicalAccrualPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_3e71fecd-3cf2-4551-a0f7-78f121dfe6b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6aeb08a9-43cc-4111-9958-aed8a3b81b91_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_12fedac1-ed7d-4669-a4f9-dd4802f1f715_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f06c4023-c15f-47a5-b18f-03d0d2326e21_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total noncontrolling interest and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0d5384c-30c0-49ba-970e-15ae73138c38_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d6acf76a-ed81-4f9d-817c-a2e1cf5f1fcb_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_31ff3238-c9c9-4a8e-a53f-403512a80cf3_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock repurchase price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_7532ecf9-3cce-4c5d-83da-2dca7d1a22fe_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated accretion of the MOIC Payment</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_8be83962-c627-42fe-8ff0-9694b629b807_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accretion of the MOIC Payment</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OperatingLossCarryforwardsSubjectToExpiration_70fb7a1b-ad7c-468d-8c23-2d8bd1fe1695_terseLabel_en-US" xlink:label="lab_arwr_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards subject to expiration</link:label>
    <link:label id="lab_arwr_OperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_arwr_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Subject To Expiration</link:label>
    <link:label id="lab_arwr_OperatingLossCarryforwardsSubjectToExpiration_documentation_en-US" xlink:label="lab_arwr_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingLossCarryforwardsSubjectToExpiration" xlink:href="arwr-20250930.xsd#arwr_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_arwr_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_08dbd118-32a5-4e9a-b0b2-7701a91dacee_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7aa15667-2fbd-42af-b069-027e3c6ceaaa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_ea2dbb5a-5283-4a66-8c7f-adda6b707e6a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_dbd4fc30-1173-40b0-89b7-76a5904816bc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_3e30a35a-8983-4105-b880-abb85ecb8105_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0e5e4bf9-75a3-470f-b1ed-ee229b676afa_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c911a24c-7899-44c2-9ea2-fae93a65485d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_731f80bc-7da5-46f4-8609-230a94795011_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment receivable upon FDA approval</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable Upon FDA Approval</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable Upon FDA Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:to="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_deb62afa-7c06-4e60-806e-3e76259f82f2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_618b9311-e3fc-4c52-bf51-cf01466f3d85_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_2a46608d-66af-401f-8488-481627107b1f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_021471a2-8f70-4133-b8e2-a6c52d832460_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_57dfa120-983f-4bf7-a962-89d74418ddcb_terseLabel_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_label_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Impairment</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_documentation_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:href="arwr-20250930.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:to="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_25a4d2be-5758-4efd-8167-2ce5d26c3168_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office space leases (in sq ft)</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_3a7b93f7-1862-4c9c-a0ad-60e7bd51779a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationArrangementVariableConsideration_63ffa294-8821-4e38-8b7a-a221505274d8_terseLabel_en-US" xlink:label="lab_arwr_CollaborationArrangementVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable consideration</link:label>
    <link:label id="lab_arwr_CollaborationArrangementVariableConsideration_label_en-US" xlink:label="lab_arwr_CollaborationArrangementVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Variable Consideration</link:label>
    <link:label id="lab_arwr_CollaborationArrangementVariableConsideration_documentation_en-US" xlink:label="lab_arwr_CollaborationArrangementVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Variable Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementVariableConsideration" xlink:href="arwr-20250930.xsd#arwr_CollaborationArrangementVariableConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationArrangementVariableConsideration" xlink:to="lab_arwr_CollaborationArrangementVariableConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_2361e137-fbbf-450b-8804-5297891d8130_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8f29a2de-a886-4df0-a02a-0df4ec478c8f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_ff10e6a5-848b-43fc-afb4-c47438407ead_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_1713e8cf-6744-4f72-a441-eca3509fa47f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_48c4d506-4e56-4d68-a3d8-a75381acebb3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_6179ef5d-c995-4737-863d-8119e7208484_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_67a92b6c-cce8-4fb2-8352-4c66a466bf4f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6ddc4bfc-b1c2-4715-afd9-2b9128f14e2f_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_EmployeeContributionsUpToThreePercentMember_1c574a26-bf64-42cf-bb9e-cbcf01918f8b_terseLabel_en-US" xlink:label="lab_arwr_EmployeeContributionsUpToThreePercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Contributions up to 3%</link:label>
    <link:label id="lab_arwr_EmployeeContributionsUpToThreePercentMember_label_en-US" xlink:label="lab_arwr_EmployeeContributionsUpToThreePercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Contributions Up To Three Percent [Member]</link:label>
    <link:label id="lab_arwr_EmployeeContributionsUpToThreePercentMember_documentation_en-US" xlink:label="lab_arwr_EmployeeContributionsUpToThreePercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee contributions up to three percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EmployeeContributionsUpToThreePercentMember" xlink:href="arwr-20250930.xsd#arwr_EmployeeContributionsUpToThreePercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_EmployeeContributionsUpToThreePercentMember" xlink:to="lab_arwr_EmployeeContributionsUpToThreePercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_b685caa7-249b-40ac-ac9a-59a08fcdb5ff_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a0f23c55-4693-4854-9585-64308876961a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_EmployeeContributionNextTwoPercentMember_17305aad-ad3d-46e4-bb5f-37a760f8a0b3_terseLabel_en-US" xlink:label="lab_arwr_EmployeeContributionNextTwoPercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Contributions Next 2%</link:label>
    <link:label id="lab_arwr_EmployeeContributionNextTwoPercentMember_label_en-US" xlink:label="lab_arwr_EmployeeContributionNextTwoPercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Contribution Next Two Percent [Member]</link:label>
    <link:label id="lab_arwr_EmployeeContributionNextTwoPercentMember_documentation_en-US" xlink:label="lab_arwr_EmployeeContributionNextTwoPercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee contribution next two percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EmployeeContributionNextTwoPercentMember" xlink:href="arwr-20250930.xsd#arwr_EmployeeContributionNextTwoPercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_EmployeeContributionNextTwoPercentMember" xlink:to="lab_arwr_EmployeeContributionNextTwoPercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_9ec0449c-45a8-4e15-a9a5-64186fba4057_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_fbaa8609-3659-49e6-9a38-63aef2713bfd_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_3a94cc75-1ec8-4f88-8747-8f8c9a7e04e5_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_0025ed7b-a157-4c15-9832-29981d4ae390_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3ba79e34-37a3-4a03-9186-4885d1a338de_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, at fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d904b0da-da05-48ff-9359-4874c850cd80_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current investments, Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_ef63e7e3-e639-452f-a505-7020e533cc7f_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ff04fbfd-c9b8-4f07-b711-1056e73ed2b3_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_9266a821-fe95-42f0-a2a4-7d44aec68284_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes (refund) paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5182453d-0f14-4e6b-9be0-7c22b556f04f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_50ffe059-cbdd-43d2-94b8-32543f906ec2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_368c19fe-f905-4189-8685-49e8e43aabf1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Term Loan</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_e20565cb-c4ed-4be5-afc3-f438b2a77d26_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bf25acba-1757-420c-a20c-2fdfcab04e25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_92c80859-7d67-466b-b655-dd28f7f5809e_terseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current investments, Gross Unrealized Gains</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:href="arwr-20250930.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:to="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_357a5b43-94d0-4d46-9780-11271cac40a4_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_c08c8071-f352-4ac2-8333-4b203134ccd1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_06f62e0e-1619-40b8-b31f-43b1890f870b_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SareptaCollaborationAgreementMember_0385384e-750a-4cb7-a1c6-706ca0947b5a_terseLabel_en-US" xlink:label="lab_arwr_SareptaCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sarepta Collaboration Agreement</link:label>
    <link:label id="lab_arwr_SareptaCollaborationAgreementMember_label_en-US" xlink:label="lab_arwr_SareptaCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sarepta Collaboration Agreement [Member]</link:label>
    <link:label id="lab_arwr_SareptaCollaborationAgreementMember_documentation_en-US" xlink:label="lab_arwr_SareptaCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sarepta Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember" xlink:href="arwr-20250930.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SareptaCollaborationAgreementMember" xlink:to="lab_arwr_SareptaCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_c204ca58-6cd6-49d3-9ae0-ea72ea4d6770_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_95f97af8-8660-466d-9f7a-93fc476ad56e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest and stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_669c5145-368d-471e-a97f-0970cd1c676c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3131d2b9-f26e-4c85-b7ae-6c5b33f50e80_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_895dec10-0358-438d-8cea-d463ec2d0f3d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_35791396-3544-4a6f-9064-fec8c3eff853_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_594e51da-d6a3-4616-8c22-f83abb52493e_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_VisirnaESOPMember_d77bd46d-a989-4c46-b20d-52ef67d2a66d_terseLabel_en-US" xlink:label="lab_arwr_VisirnaESOPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Visirna ESOP</link:label>
    <link:label id="lab_arwr_VisirnaESOPMember_label_en-US" xlink:label="lab_arwr_VisirnaESOPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Visirna ESOP [Member]</link:label>
    <link:label id="lab_arwr_VisirnaESOPMember_documentation_en-US" xlink:label="lab_arwr_VisirnaESOPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Visirna ESOP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaESOPMember" xlink:href="arwr-20250930.xsd#arwr_VisirnaESOPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_VisirnaESOPMember" xlink:to="lab_arwr_VisirnaESOPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_b10e6b29-ef56-4b06-bf40-22a63d9488fd_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_7fb2c6f8-071f-4f07-bb3f-eb7a3833b25a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_902defa7-aa46-4a41-9e17-867464dd126c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0ccd8cdb-ef52-4096-aa88-2e701fb61bb7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income taxes, net of federal tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_c615c0fe-4be1-451a-91a2-4c983add7a2f_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment receivable upon receipt of royalty payments</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable, Upon Receipt Of Royalty Payments</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable, Upon Receipt Of Royalty Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:to="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4a1b7670-dc3d-4f1c-908a-e63a7bfc9d3a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f373f7e6-83d4-4ece-8019-ca2d6b6971c3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4f654c12-d16c-4e17-9791-4922a1b748d5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_5d638221-f4eb-4e11-b0a4-0331a148a12f_terseLabel_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to the sale of future royalties, interest rate</link:label>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_label_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Sale Of Future Royalties, Interest Rate</link:label>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_documentation_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability, Sale Of Future Royalties, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" xlink:href="arwr-20250930.xsd#arwr_LiabilitySaleOfFutureRoyaltiesInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" xlink:to="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalFees_c763f4b4-a0df-4a60-9524-0b3f1c2402c5_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional, outside services, and other</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_566127d9-fc4b-4215-9939-0e03b11abd5d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_cfaf8af7-9248-4386-b266-c347cdc535da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_50d0f28b-b07e-4f96-b8e6-fd157010be34_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7dcadde1-6aaf-4ca1-8f45-4e36c98b9e1b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_d99f7095-df1d-4e45-b407-e0fa92ee8f32_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of pre-funded warrants</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4ea65314-a1ae-4ad5-a629-2223867f2518_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_3769a04c-a16b-4f53-9233-dd1e3d79da2f_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_ef4c810d-edc5-48d8-9574-1b6802932fbd_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_422c110f-e200-4b0d-af8b-3233dd999846_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_acf5aa18-8827-4369-91b4-d873a183d342_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_c822c5a4-ce06-47f2-8933-26faf655f790_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_23aa3916-1abe-4e99-8e94-edbf8453e141_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_ad233449-a323-4364-9fe4-638808d1aa7f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_fac2d329-3076-4e50-9776-fe7bb311c255_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_28eb28e2-6d75-4f4b-91bb-475a1390c692_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_31bdd7ad-1cc9-4c6f-9bbe-d5d92afd35b6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivable_afcf0f21-0e07-4859-a7fc-8de7c041a7c2_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment receivable</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivable_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivable_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivable" xlink:to="lab_arwr_MilestonePaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_36f28696-80a1-4787-adf2-8f8d4046e55b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_39bdb777-b6e7-4086-af99-36743bb04c75_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_19e02775-8204-4516-8dc8-06abd5873de5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a59501d8-c990-4fdb-8873-90aadc34bc95_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4ada262b-141f-4a17-b680-b5c0e458104a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d8f08fcc-87cf-4bef-a4f9-e714c28a8bc3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_3294453a-7c80-4ee0-969d-7434928e3837_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2e91326e-cd77-4006-b983-b75d30c2b0d5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_6f4bbbfd-2909-47d8-8bd3-f1d7d5b884a1_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_81b1efe8-a85c-4f2a-98d7-00c0f0d63826_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_66cecc19-3c0c-4e1c-9aa5-b8fd8d3ad449_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_6e8e930e-df3f-4a57-9795-96f7370abe2f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8e905c9b-af61-4db6-97b6-78b3e6995113_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital expenditures included in accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d25eb9d2-5275-4ffa-8ecc-8e90b436ac25_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_7e4173ed-f56c-4ee9-b281-6448dee1260b_terseLabel_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory and Office Facility</link:label>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_label_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory And Office Facility [Member]</link:label>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_documentation_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory and office facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember" xlink:href="arwr-20250930.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LaboratoryAndOfficeFacilityMember" xlink:to="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_7d2dda0e-683e-489f-a3eb-51902c173916_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_bb92b088-1f14-4f1e-ad1a-da46047f0015_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_ae48ac2a-362d-47a1-8189-aebe00423cf7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_a84030ba-49f8-4eeb-84f5-624ae51982e4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_fdad99b8-0174-4845-b505-65844e989550_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7024b9e0-a392-46c6-9c90-1cc5c5f1e4d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_7e76e649-c972-49f5-a783-226d920ed27d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_20d9201a-af52-4d57-8a7e-39145f16a1f2_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d30e0da6-4882-4057-a296-b689d660a327_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_d8d08e32-fabc-424e-a014-5039955ed11c_terseLabel_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to the sale of future royalties</link:label>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_debad3e8-4de7-449a-84f9-febdbb167172_periodStartLabel_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning carrying value</link:label>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_3347d04d-3e47-4ff1-ab86-ebc93d9c2bcb_periodEndLabel_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending carrying value</link:label>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_label_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalties, Liability, Noncurrent</link:label>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_documentation_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalties, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent" xlink:href="arwr-20250930.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltiesLiabilityNoncurrent" xlink:to="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_c4d6c4c1-57c9-4891-ac9b-442723c7686c_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c078e6d2-d153-4c16-b878-a1aa3be7bc70_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2031 and thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_14423a40-3fdb-4e90-a5c0-71d1ba7d1a9f_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3377c14e-d2e4-4be7-884c-2dc071e3f349_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross increase for prior period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod_1aa9f799-a7e0-4e7f-9aa4-ad77b5599257_terseLabel_en-US" xlink:label="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual installments period</link:label>
    <link:label id="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod_label_en-US" xlink:label="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Receivable Under Collaboration Agreement, Annual Installments Period</link:label>
    <link:label id="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod_documentation_en-US" xlink:label="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Receivable Under Collaboration Agreement, Annual Installments Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod" xlink:href="arwr-20250930.xsd#arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod" xlink:to="lab_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember_94916809-b603-40a4-acdb-30ec37a264e9_terseLabel_en-US" xlink:label="lab_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction In Progress Reclassified To Manufacturing Equipment</link:label>
    <link:label id="lab_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember_label_en-US" xlink:label="lab_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction In Progress Reclassified To Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Construction In Progress Reclassified To Manufacturing Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember" xlink:href="arwr-20250930.xsd#arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember" xlink:to="lab_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_d9bf3a06-9fbb-4443-89cb-e201ae8abc0e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_cf869ebf-c56d-43b1-899a-bd8789a7b675_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_63c84e7a-ffa2-4442-8acd-57d1193dc527_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_6a57a657-3c78-4925-9ff0-18c301d72e56_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_8c9625dc-aef3-4d93-a37c-b85d0727de87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Line of Credit Facilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_a82a2722-da81-4dd7-9dcc-7a0ef290b0dd_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_403cf098-7ea2-4d27-ba14-d6f0881cf00b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_d6b0cea3-6df6-4f43-a754-f3d1b003903d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1a630ab6-4a6b-4d2b-a496-62d6464ece8a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_0dec03a9-ccb0-4052-94ed-2a56060645b5_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_89280f00-e264-4ddb-b5cc-a1acde7f22d8_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_dfd9d21c-ef67-443c-aeca-3b1a4331a1ed_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_c6e89464-d2ff-4e0f-87e2-5b2167176b5a_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_327f4b1d-a260-4c8c-9ee1-d4e54861df27_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a0abec59-2376-4968-a79c-dbccf18eac3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_6da68a59-0012-4d5d-9f11-16b5aa7675e7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities, Noncontrolling Interest and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_326138d6-36d0-4c4a-8f91-0d17e936cde3_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a0ab4fc6-35ff-4a7f-8363-33cf823194f3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_717cafa7-8a03-46b9-997c-1e9ed6279be0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_7c47e794-588b-4c97-968a-d8568b6ffd39_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_09c37825-d739-4df9-a205-0f334d6a71d1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_e88e3ad6-9445-41fd-a48e-dd3a08247fac_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_f0a8a185-f746-4d28-82cb-838ca5b183e9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_46ce8980-6390-4377-9ee9-530edbf2ba49_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities on an Undiscounted Basis</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_2b689d7c-e982-4902-98fa-93010820ba39_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock in Treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c61dd964-c140-4332-a51b-65b72977f9f7_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_0acced89-3185-458c-81a9-63060be23310_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FinancingAgreementMember_29ce1845-bdb5-4b2d-827a-83010379d544_terseLabel_en-US" xlink:label="lab_arwr_FinancingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Agreement</link:label>
    <link:label id="lab_arwr_FinancingAgreementMember_label_en-US" xlink:label="lab_arwr_FinancingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Agreement [Member]</link:label>
    <link:label id="lab_arwr_FinancingAgreementMember_documentation_en-US" xlink:label="lab_arwr_FinancingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMember" xlink:href="arwr-20250930.xsd#arwr_FinancingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FinancingAgreementMember" xlink:to="lab_arwr_FinancingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_b3b9cb8e-4e81-42f6-91d7-03d56fba7f2b_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_6095843c-2b44-44d1-85aa-b3f9a1383030_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2013 Plan</link:label>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousands Thirteen Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousands thirteen incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:href="arwr-20250930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:to="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_925b5946-0733-4e79-9a14-a8b00d7a3b0a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_075655ad-50bb-4f93-9e4e-ad7533911630_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_e44fdd10-bae5-497e-ab5f-9168740640b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_36cf5c37-9564-478d-ba91-b821c17d96b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_8d1134da-46d2-4047-b3f2-bb2f5d7ce27e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income (Loss) Before Income Tax Expense and Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_79ca91bf-e92f-4dab-8f45-5407a86c6478_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_525b7db7-585e-415b-b0d6-5d6c0d93702c_negatedTerseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current investments, Gross Unrealized Losses</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:href="arwr-20250930.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:to="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_058f06e6-19f3-46e6-bb7c-df3299513948_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DanielApelMember_label_en-US" xlink:label="lab_arwr_DanielApelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Daniel Apel [Member]</link:label>
    <link:label id="lab_arwr_DanielApelMember_documentation_en-US" xlink:label="lab_arwr_DanielApelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Daniel Apel</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DanielApelMember" xlink:href="arwr-20250930.xsd#arwr_DanielApelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DanielApelMember" xlink:to="lab_arwr_DanielApelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_0710550d-24a3-4732-8501-cfaf2829660e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_d1a49de7-7495-40ca-bcff-f4f3e861fedd_terseLabel_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of distinct performance obligations</link:label>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_label_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Distinct Performance Obligations</link:label>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_documentation_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of distinct performance obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations" xlink:href="arwr-20250930.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfDistinctPerformanceObligations" xlink:to="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_7e3aff41-cf92-46fc-9f5f-2327f187dd9f_terseLabel_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of commission to sales agent</link:label>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_label_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock</link:label>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_documentation_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of commission on aggregate gross proceeds from sale of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:href="arwr-20250930.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:to="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommercialNotesMember_64002123-e086-4f9a-bb98-cc409fd2c8c7_terseLabel_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial notes</link:label>
    <link:label id="lab_arwr_CommercialNotesMember_label_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Notes [Member]</link:label>
    <link:label id="lab_arwr_CommercialNotesMember_documentation_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember" xlink:href="arwr-20250930.xsd#arwr_CommercialNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommercialNotesMember" xlink:to="lab_arwr_CommercialNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_7871e085-c2ce-4130-8d32-e0327d11e8fa_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a8cfa37c-adbb-4b56-a4e6-70f519d3f923_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_168d8b7a-5564-4159-802e-2a7827a62d73_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_70c96f06-4e12-4c22-941d-4ea21c3d9537_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_ef14bd2c-ce0c-42ab-a738-6abfac09afe8_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_1cac89fb-1c42-4df3-b01a-1b32413fb598_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_38ab3e1c-3fac-4390-8a9c-bb75f1a84ba9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_78b8dd26-5266-4c39-bc4b-eaba6f54bcc9_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_b6b9ef7f-2db2-4557-af77-9b8e3176e083_terseLabel_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_label_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Regulatory And Sales Milestones Payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_documentation_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development regulatory and sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:href="arwr-20250930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:to="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_538388e0-4ee7-4bac-acfb-c829e3269b54_terseLabel_en-US" xlink:label="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued research and development expenses; co-development</link:label>
    <link:label id="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Co-Development Expense, Current</link:label>
    <link:label id="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Co-Development Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" xlink:href="arwr-20250930.xsd#arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" xlink:to="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_83ff0a24-d511-4bfe-9360-f1d93f30489d_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_076c61e4-b891-48cc-9ac6-13a5dc3cdebe_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_aa163d47-cefb-4d38-9ffb-c2cce843213b_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity ("VIE")</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_12103390-445c-44bf-9750-91e8c4c34aae_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability_19047cf1-e44a-4de3-8221-e6634148dd84_terseLabel_en-US" xlink:label="lab_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets adjusted in exchange for new/amended operating lease liabilities</link:label>
    <link:label id="lab_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-Of-Use Asset Adjustment In Exchange For Operating Lease Liability</link:label>
    <link:label id="lab_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability_documentation_en-US" xlink:label="lab_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-Of-Use Asset Adjustment In Exchange For Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" xlink:href="arwr-20250930.xsd#arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" xlink:to="lab_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_c30b1812-8a13-4d16-87ea-11598f37cdf9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_VictoriaVakienerMember_label_en-US" xlink:label="lab_arwr_VictoriaVakienerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Victoria Vakiener [Member]</link:label>
    <link:label id="lab_arwr_VictoriaVakienerMember_documentation_en-US" xlink:label="lab_arwr_VictoriaVakienerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Victoria Vakiener</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VictoriaVakienerMember" xlink:href="arwr-20250930.xsd#arwr_VictoriaVakienerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_VictoriaVakienerMember" xlink:to="lab_arwr_VictoriaVakienerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_37473674-1310-4380-b3a6-abc2b2d01f26_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_53e5e398-64f9-4f7b-87c6-8be20a8b7ab3_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_4fc04f25-d7c7-4069-a9fb-e636b571f2f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Income Taxes for Provisions (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_7d1e299e-8c71-45ef-8945-eb541b0c5d9b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_429774ff-7fbc-4332-af43-f6bd6bd137de_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_47c8f912-bc9f-4988-bfab-0963898b694f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Contract Maturity of Available for Sale Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3b554f6a-e169-415d-96ac-6f5930af9335_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_60d6a600-45aa-4db1-bb38-0f66e4324918_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_a75b57cb-c0b4-45a5-96c4-89e42aba3172_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40aca3c5-e4f9-4613-9042-13f335a42f9f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_5f9853b1-ea99-4e80-b9be-89d78b2e99a2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_708904db-d817-4bd0-bdc2-5878a3623b01_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_bd922db9-2c65-49c2-b9c2-9e8f3b1b695b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7d91236d-5bf5-4966-ac6d-9936ade0348e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b611c7e7-4964-412b-b452-610c805d9023_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c4254d5-1340-4e9b-aee5-0458955a180f_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dbefd7f9-9348-4bd1-a48f-790b024911f5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">BEGINNING OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63aeb811-997a-444b-aba3-0b3ba4945020_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">END OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1019f36d-04e7-42d5-8ff0-4a36372e09ed_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_dfe1803d-3972-4a36-8bc2-fff2c0426048_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Company's Current Pipeline</link:label>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_label_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Current Products [Table Text Block]</link:label>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_documentation_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Current Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:href="arwr-20250930.xsd#arwr_ScheduleOfCurrentProductsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:to="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_4072ac88-793d-45e6-ba0e-48f67f69fb35_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FinancingAgreementInitialTermLoanInterestMember_015b43c2-8752-4a1b-9111-4ec83a838ebb_terseLabel_en-US" xlink:label="lab_arwr_FinancingAgreementInitialTermLoanInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Agreement, Initial Term Loan Interest</link:label>
    <link:label id="lab_arwr_FinancingAgreementInitialTermLoanInterestMember_label_en-US" xlink:label="lab_arwr_FinancingAgreementInitialTermLoanInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Agreement, Initial Term Loan Interest [Member]</link:label>
    <link:label id="lab_arwr_FinancingAgreementInitialTermLoanInterestMember_documentation_en-US" xlink:label="lab_arwr_FinancingAgreementInitialTermLoanInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Agreement, Initial Term Loan Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementInitialTermLoanInterestMember" xlink:href="arwr-20250930.xsd#arwr_FinancingAgreementInitialTermLoanInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FinancingAgreementInitialTermLoanInterestMember" xlink:to="lab_arwr_FinancingAgreementInitialTermLoanInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_27a60cb2-9f4f-488b-8145-0430500aa98a_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) including noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_ef9bc749-d2f1-4b2a-b78b-406ccb68c5ff_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_b496dbd8-6b2e-49ec-9f13-8f49815e6616_netLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_c8854888-0b99-4927-a535-78ae5d7bf2d5_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchEquipmentMember_6df54bac-c7bc-4493-9c44-d81ede1a984b_terseLabel_en-US" xlink:label="lab_arwr_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research equipment</link:label>
    <link:label id="lab_arwr_ResearchEquipmentMember_label_en-US" xlink:label="lab_arwr_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Equipment [Member]</link:label>
    <link:label id="lab_arwr_ResearchEquipmentMember_documentation_en-US" xlink:label="lab_arwr_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentMember" xlink:href="arwr-20250930.xsd#arwr_ResearchEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchEquipmentMember" xlink:to="lab_arwr_ResearchEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8778a9fb-8ad6-491c-9b59-0058f386824e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_e95e844a-4d82-4904-99b4-d0c7142d08bd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from credit facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_ad13489a-8523-46a9-ae2d-d607674f2873_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Receivables and Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_2b5e438f-d250-484b-ac5f-48d15bd7999d_terseLabel_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial milestone payments at first commercial sale</link:label>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_label_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Milestone Payments At First Commercial Sale</link:label>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_documentation_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial milestone payments at first commercial sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:href="arwr-20250930.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:to="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00928917-6293-44f8-b591-699cd2d889b8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_9577aecb-cf66-4aa7-a874-505e28709ea0_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_27c70ae9-cbac-4b9c-8a47-35407c43f066_totalLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total general and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_11bbe479-72db-48e8-a704-b4378df9fa81_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discretionary match percentage</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FuturePotentialMilestonePayments_776de678-dd50-4f82-9389-c47a4061bccf_terseLabel_en-US" xlink:label="lab_arwr_FuturePotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future potential milestone payments</link:label>
    <link:label id="lab_arwr_FuturePotentialMilestonePayments_label_en-US" xlink:label="lab_arwr_FuturePotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Potential Milestone Payments</link:label>
    <link:label id="lab_arwr_FuturePotentialMilestonePayments_documentation_en-US" xlink:label="lab_arwr_FuturePotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Potential Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FuturePotentialMilestonePayments" xlink:href="arwr-20250930.xsd#arwr_FuturePotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FuturePotentialMilestonePayments" xlink:to="lab_arwr_FuturePotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_ba81329e-05af-4523-af83-34ec5772bf73_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_209ee250-11b8-4ad9-871f-595ea7accb8e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lease Assets and Liabilities and Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b3bac66d-fddb-49c9-9929-f989c9c58d93_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0e4a626f-a8ad-4193-a0cf-dbbbb1d8abd5_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_acbb56d1-2e11-4475-85e2-cb19f6ffe22b_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6f94450e-e6c5-4979-902b-b424fe257e09_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplementary disclosure of cash flows:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c797b9c6-b9dc-4194-9539-a8bdc4a4b85d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_991fe561-8d7f-49e1-8a14-7d1b739359c7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense_92e79b0c-95eb-40f9-ace9-2cc2da5166e7_totalLabel_en-US" xlink:label="lab_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total research and development expense, excluding non-cash expense</link:label>
    <link:label id="lab_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense_label_en-US" xlink:label="lab_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Excluding Noncash Expense</link:label>
    <link:label id="lab_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense_documentation_en-US" xlink:label="lab_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Excluding Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense" xlink:to="lab_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OperatingSegmentMember_b79e7b59-8097-4c34-a431-ed4a0d152a32_terseLabel_en-US" xlink:label="lab_arwr_OperatingSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Segment</link:label>
    <link:label id="lab_arwr_OperatingSegmentMember_label_en-US" xlink:label="lab_arwr_OperatingSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segment [Member]</link:label>
    <link:label id="lab_arwr_OperatingSegmentMember_documentation_en-US" xlink:label="lab_arwr_OperatingSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingSegmentMember" xlink:href="arwr-20250930.xsd#arwr_OperatingSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OperatingSegmentMember" xlink:to="lab_arwr_OperatingSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_073f915a-7d1b-4dee-8750-173f8f22b9ac_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentEarned_ff7ed99d-30d8-4879-980d-3489f57c3f91_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_arwr_MilestonePaymentEarned_label_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Earned</link:label>
    <link:label id="lab_arwr_MilestonePaymentEarned_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payment earned.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentEarned" xlink:to="lab_arwr_MilestonePaymentEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_1481439f-f6ab-46f2-afd0-8b88261c1638_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share attributable to Arrowhead Pharmaceuticals, Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_82bbadc4-f63d-4182-a94d-6bbda8b7cd87_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_c7978596-594c-49ac-8fe6-13c882694d4d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_cbaca034-c15d-4e0b-98c4-344a44746417_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ManufacturingEquipmentMember_9526ee0d-297b-4317-a3b9-48c9e33eb183_terseLabel_en-US" xlink:label="lab_arwr_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_arwr_ManufacturingEquipmentMember_af8810e3-2660-4daa-a907-f69e7a027a38_verboseLabel_en-US" xlink:label="lab_arwr_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_arwr_ManufacturingEquipmentMember_label_en-US" xlink:label="lab_arwr_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_arwr_ManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_arwr_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ManufacturingEquipmentMember" xlink:href="arwr-20250930.xsd#arwr_ManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ManufacturingEquipmentMember" xlink:to="lab_arwr_ManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_f085ea9d-dd92-4125-9ffb-ae7f3b6f20e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_448eddb9-40ec-4b52-ae52-4b344decf16e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_76d7adb7-f7ba-4bef-a248-4e7cd54b36ab_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c714c8b9-2a72-4052-a223-44d78d0bda0f_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_54411e2a-0198-4d25-aa1f-416e6c55c2e5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross decrease for prior period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_5e62cac9-b042-4ef8-83c8-11f74b8e4a98_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_57d74695-5f83-4a47-8c33-0e87f296c191_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_f9deba33-7e9f-4fe3-a4c5-023e6420d7c8_terseLabel_en-US" xlink:label="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized research and development</link:label>
    <link:label id="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_label_en-US" xlink:label="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets In Process Research And Development Cost</link:label>
    <link:label id="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_documentation_en-US" xlink:label="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:href="arwr-20250930.xsd#arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:to="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OperatingLossCarryforwardsNotSubjectToExpiration_3d74d894-15d9-402a-a0f2-e75d0e90bc7f_terseLabel_en-US" xlink:label="lab_arwr_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards not subject to expiration</link:label>
    <link:label id="lab_arwr_OperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_arwr_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Expiration</link:label>
    <link:label id="lab_arwr_OperatingLossCarryforwardsNotSubjectToExpiration_documentation_en-US" xlink:label="lab_arwr_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="arwr-20250930.xsd#arwr_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_arwr_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4b669baf-8d41-43a9-9fdd-8128289d6792_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average period to recognize pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_36926d03-dd53-48f0-93d3-1749bb235592_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8abe7b3e-fd77-4f88-884c-55d690183212_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_667f99fd-c891-4024-9212-321f06e6f6d4_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_14228722-7665-4f15-a34c-96f2b67079bb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_e86bf09c-e0aa-4574-8281-39386ad1d1fd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ProceedsFromTenantImprovementAllowance_96d9651a-0048-41ca-89d8-fb0468526af5_verboseLabel_en-US" xlink:label="lab_arwr_ProceedsFromTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from additional tenant improvement allowance</link:label>
    <link:label id="lab_arwr_ProceedsFromTenantImprovementAllowance_label_en-US" xlink:label="lab_arwr_ProceedsFromTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Tenant Improvement Allowance</link:label>
    <link:label id="lab_arwr_ProceedsFromTenantImprovementAllowance_documentation_en-US" xlink:label="lab_arwr_ProceedsFromTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Tenant Improvement Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromTenantImprovementAllowance" xlink:href="arwr-20250930.xsd#arwr_ProceedsFromTenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ProceedsFromTenantImprovementAllowance" xlink:to="lab_arwr_ProceedsFromTenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_eaaa8445-6a2d-4075-836a-f335f4957be9_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets Subject to Amortization</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_3c5d3eb5-62f8-4383-ad42-885d7a07f0fc_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_bb76177e-f3c2-4e8e-a5bf-9a6fe144eb98_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2980ef63-55db-4322-975b-86ed41fdd317_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_34a9149f-f262-47fd-9ffe-ed5e50ef2587_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_7ddcad3b-2188-4b76-afdf-6fe553adc091_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1c0b5c0e-4539-4e16-b129-4172bdf11e06_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_d32fcf40-eb75-424f-8df9-aa3add2bcc74_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_bedb2b9c-f85e-40d4-976e-35d18c3bee7d_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:to="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_26d47abf-8f63-4461-824e-e67dc5d0f248_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_c19a5909-bbaf-4757-b9ec-e11e61d4736a_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_89730358-c37f-4472-a716-c313a279b04d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_6da02391-af79-4833-a4a0-ec033226c37f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalent, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_341a4d20-f9a0-423c-9e09-6af684b604b6_terseLabel_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:href="arwr-20250930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_85f99105-5074-4980-8f33-2f36f8b1c5e0_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense for property and equipment</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_bd65c424-4542-47b6-b51e-9eb8b9b7075b_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4c013eb1-1a21-406e-a2b7-05690ff2cfd5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_bcf10bd1-6612-46ca-848e-7ccb1db63f9d_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_2dd076f1-866d-445a-bc76-26e39d0411cc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7a33ba40-92e0-48e6-ad44-09ec07791d27_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1e884d9-7e10-4ae7-959e-ea0ac958fd97_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_0eedb60a-2c35-43d8-8362-da96c290a1dc_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_aa8edf7b-14d9-4340-89fb-1fbcb3bfaaa9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_7a02bcb6-1448-4546-8a78-e5c238a75308_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_49f4a442-5213-49a6-b0ea-4088158a5911_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ConstructionInProgressReclassifiedToBuildingMember_392b5621-2381-46dd-a385-3844b113b388_terseLabel_en-US" xlink:label="lab_arwr_ConstructionInProgressReclassifiedToBuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction In Progress Reclassified To Building</link:label>
    <link:label id="lab_arwr_ConstructionInProgressReclassifiedToBuildingMember_label_en-US" xlink:label="lab_arwr_ConstructionInProgressReclassifiedToBuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction In Progress Reclassified To Building [Member]</link:label>
    <link:label id="lab_arwr_ConstructionInProgressReclassifiedToBuildingMember_documentation_en-US" xlink:label="lab_arwr_ConstructionInProgressReclassifiedToBuildingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Construction In Progress Reclassified To Building</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ConstructionInProgressReclassifiedToBuildingMember" xlink:href="arwr-20250930.xsd#arwr_ConstructionInProgressReclassifiedToBuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ConstructionInProgressReclassifiedToBuildingMember" xlink:to="lab_arwr_ConstructionInProgressReclassifiedToBuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_b89cf16c-347a-49f3-933b-84650891a05d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1837f367-72c9-40e0-8e6d-bfd993ee9a72_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_06c9a8bc-6f77-4062-a3c5-ddb29ce05846_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_d81b9bc0-b2e9-48eb-921e-31e237c7c740_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_386ba871-6066-4bd6-bbce-c7998cc6bd81_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Common stock - repurchase</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_9fa6196d-2a20-48c6-9163-4b4b714cc8b1_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of stock repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_73f56dba-73fa-44f6-adc8-4fb68812d80c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_a194bec1-022f-4a80-bdbe-985ceb6eb523_terseLabel_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Horizon</link:label>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_label_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Horizon Therapeutics Ireland D A C [Member]</link:label>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_documentation_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Horizon Therapeutics Ireland DAC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember" xlink:href="arwr-20250930.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_HorizonTherapeuticsIrelandDACMember" xlink:to="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_f5b462a9-d4eb-4adc-ae2e-4e5f9fa2f4f2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_fab51cd8-141c-482f-af67-19f2c310a53e_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_e31700e9-e747-4496-9c72-b54fd1eb2c1d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables included in accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_68ae386f-4fd1-4891-8c60-12cc32ce65a3_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_2dbb1949-4add-4726-ad98-ec5f8d0a51d8_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Municipal securities</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_85936dd8-7fe0-4d69-a3af-55958ed94d95_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchAndDevelopmentExpenseDiscoveryCosts_fd8b7ae0-3422-48d1-b0ea-5e5c737a43d3_terseLabel_en-US" xlink:label="lab_arwr_ResearchAndDevelopmentExpenseDiscoveryCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;D discovery costs</link:label>
    <link:label id="lab_arwr_ResearchAndDevelopmentExpenseDiscoveryCosts_label_en-US" xlink:label="lab_arwr_ResearchAndDevelopmentExpenseDiscoveryCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Discovery Costs</link:label>
    <link:label id="lab_arwr_ResearchAndDevelopmentExpenseDiscoveryCosts_documentation_en-US" xlink:label="lab_arwr_ResearchAndDevelopmentExpenseDiscoveryCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Discovery Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseDiscoveryCosts" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseDiscoveryCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchAndDevelopmentExpenseDiscoveryCosts" xlink:to="lab_arwr_ResearchAndDevelopmentExpenseDiscoveryCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_6d431e8a-92bd-46af-b802-91f3d770a1ae_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1f4c0fd5-ac34-4872-97f7-863aef84478a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_36542666-78d5-42eb-b18b-c58fd45a0e34_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_bbdee318-5fca-40a8-800b-3ec39c826dd4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_a67146f4-d12e-4db9-92a0-7c754b4fb811_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments of credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_773b4267-c85e-46df-94bd-30ebb26d13b0_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_5b54f383-a18d-4035-8239-de222b35af32_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Payments</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_e1979d63-43f1-4bc8-bf67-5e392004fad7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome_23357c5b-d4a8-4e0c-ac3c-3c0e01491f9f_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_c68c194a-4faa-46e6-8d73-1d35aaa9ce97_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NovartisMember_77758eef-c766-4120-a36a-39f725df3457_terseLabel_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis</link:label>
    <link:label id="lab_arwr_NovartisMember_label_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis [Member]</link:label>
    <link:label id="lab_arwr_NovartisMember_documentation_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Novartis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember" xlink:href="arwr-20250930.xsd#arwr_NovartisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NovartisMember" xlink:to="lab_arwr_NovartisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_6547e6a9-91f8-4ceb-99c4-a8abd33cd6ff_terseLabel_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and investments</link:label>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_label_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Cash And Investments</link:label>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_documentation_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease in cash and investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments" xlink:href="arwr-20250930.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_IncreaseDecreaseInCashAndInvestments" xlink:to="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_f5b23aa0-b3ba-4644-87af-fa39afa6cef0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Awards Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3e25693e-f60f-42e3-be69-b8640089f540_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b7470ab7-7c94-44cc-aafa-887c348f2e82_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_916ce802-25fd-4767-86b2-199e798b613e_terseLabel_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Headquarters In Pasadena</link:label>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_label_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Headquarters In Pasadena [Member]</link:label>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_documentation_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Headquarters in Pasadena</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember" xlink:href="arwr-20250930.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CorporateHeadquartersInPasadenaMember" xlink:to="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_00ca0482-8190-4a51-93db-07035a1b0274_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_99defe07-e5e3-4a9c-bd95-197b57fd18c0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of compensation</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ee07e5b6-9b03-4848-9c56-9e9fa12edbf6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfDistinctBundle_795f715e-201b-4d4d-bbb2-5d1eb57a569f_terseLabel_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of distinct bundle</link:label>
    <link:label id="lab_arwr_NumberOfDistinctBundle_label_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Distinct Bundle</link:label>
    <link:label id="lab_arwr_NumberOfDistinctBundle_documentation_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of distinct bundle.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle" xlink:href="arwr-20250930.xsd#arwr_NumberOfDistinctBundle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfDistinctBundle" xlink:to="lab_arwr_NumberOfDistinctBundle" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FacilitiesMember_3d6f6a61-427f-4f22-ae8c-5869c701cf97_terseLabel_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facilities</link:label>
    <link:label id="lab_arwr_FacilitiesMember_label_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facilities [Member]</link:label>
    <link:label id="lab_arwr_FacilitiesMember_documentation_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember" xlink:href="arwr-20250930.xsd#arwr_FacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FacilitiesMember" xlink:to="lab_arwr_FacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_ec9036eb-696c-4417-8647-c4af35e59ca2_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_875f95a0-8b93-47ce-8830-64b30355bd50_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_c8b6bc71-2300-4df0-81e2-f9d193c94f47_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_5c96237d-e267-4383-8732-5670c5a46e8a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_eec126cb-bd78-4378-883f-392fda637489_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_53274d58-c65a-4c50-a4d3-5976dc1d4473_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility, remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_806a168c-69d9-409e-a640-6e50bf2250b4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9bc41e76-8966-4df3-a72a-91eb9179ec9d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember_be72d9ad-086f-4124-bcbb-40e94de2b667_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entity Excluding Variable Interest Entities (VIE)</link:label>
    <link:label id="lab_srt_ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember_label_en-US" xlink:label="lab_srt_ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entity, Excluding Consolidated VIE [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember" xlink:to="lab_srt_ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_1d996025-a69d-4a06-8c75-980efa01ac4f_terseLabel_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit facility</link:label>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_2f9f03d6-fed3-48f6-9936-a78302a22097_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Current portion of credit facility</link:label>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_label_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LinesOfCreditCurrent" xlink:to="lab_us-gaap_LinesOfCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_d5cdc7db-266b-4e4e-9468-00de592c52e8_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ae4b3c68-13d4-4edc-b2db-8a667e30e5b1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_52217e34-f637-4e92-a47f-70ef6c2553b3_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_1f54563d-4bc7-4c26-a209-262ac5f7b414_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_de358304-86cc-4c9d-913f-bbfdcdf9e405_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, reclassification</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Transfers and Changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTransfersAndChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_95b0f956-cf88-4f1a-bacf-fb602699e85f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of the Net Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_4c730b43-f1c8-4127-8ed5-a5b83009aa97_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 135,702 and 124,376 shares at September 30, 2025 and 2024, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_b9d1d69c-4a6e-4138-8073-f9ffc9074f27_terseLabel_en-US" xlink:label="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_label_en-US" xlink:label="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities</link:label>
    <link:label id="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_documentation_en-US" xlink:label="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:href="arwr-20250930.xsd#arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:to="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentDueFromCollaborativeAgreement_62947c6d-e52b-4305-9139-7dfa9aa04ca9_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentDueFromCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment due from collaborative agreement</link:label>
    <link:label id="lab_arwr_MilestonePaymentDueFromCollaborativeAgreement_label_en-US" xlink:label="lab_arwr_MilestonePaymentDueFromCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Due From Collaborative Agreement</link:label>
    <link:label id="lab_arwr_MilestonePaymentDueFromCollaborativeAgreement_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentDueFromCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment Due From Collaborative Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentDueFromCollaborativeAgreement" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentDueFromCollaborativeAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentDueFromCollaborativeAgreement" xlink:to="lab_arwr_MilestonePaymentDueFromCollaborativeAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_852758b4-ef70-4049-ac1a-9fbde592a91d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b1dbb0de-f69f-463b-a083-e53a3073edc3_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AmgenIncorporatedMember_656b0213-2c9b-42da-b752-c1027039e1a7_terseLabel_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amgen</link:label>
    <link:label id="lab_arwr_AmgenIncorporatedMember_label_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amgen Incorporated [Member]</link:label>
    <link:label id="lab_arwr_AmgenIncorporatedMember_documentation_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amgen Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember" xlink:href="arwr-20250930.xsd#arwr_AmgenIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AmgenIncorporatedMember" xlink:to="lab_arwr_AmgenIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_bd2c6861-748f-404a-9555-fb9da34a3815_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non- controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_bd6d2914-6919-4925-b840-2a1b7c81a695_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_01e4a6fc-3368-4259-8745-e5d427a73d2f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Accounts</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_80e44e5e-f0a1-4223-a3a5-0e55610f5961_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Gross Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_934c4f67-2455-4812-ba38-22f56ebe7aa4_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfCollaborationPrograms_4dfc413d-3d7a-4e9e-ab7a-06c8ffb839e0_terseLabel_en-US" xlink:label="lab_arwr_NumberOfCollaborationPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of collaboration programs</link:label>
    <link:label id="lab_arwr_NumberOfCollaborationPrograms_label_en-US" xlink:label="lab_arwr_NumberOfCollaborationPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Collaboration Programs</link:label>
    <link:label id="lab_arwr_NumberOfCollaborationPrograms_documentation_en-US" xlink:label="lab_arwr_NumberOfCollaborationPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Collaboration Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfCollaborationPrograms" xlink:href="arwr-20250930.xsd#arwr_NumberOfCollaborationPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfCollaborationPrograms" xlink:to="lab_arwr_NumberOfCollaborationPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9d371320-1f0b-42fc-b46a-becb769c51e3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_c663eb8e-b3f0-44d2-bf6b-2616c9e78a1b_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_efb47eba-bf6c-4295-8cd1-dfc686194e6c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4673facc-6645-40f0-afe4-9788f862524a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c4e22799-9f44-48dc-9501-72fdb361d09f_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital expenditure</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree_d7f3fb4b-cd18-4058-a4f5-dafd660ec1be_terseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After two to three years</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree_label_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year Two Through Three</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year Two Through Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree" xlink:href="arwr-20250930.xsd#arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree" xlink:to="lab_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_f214568d-2906-45f6-923d-7bb9c14b33c0_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:to="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_51a2754f-b83f-49b3-83a8-3c2cb9ac0301_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_427c8ca3-3fd0-4c62-9e15-d2c8d62ccbac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_19c4e286-4203-47aa-a071-af382e5cb9bd_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_e7d83044-a230-4f50-b378-dc535d93c08c_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_35d36d73-75a1-46d7-ae77-016880554761_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Lease Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_9da4e1cd-7e07-4581-b6e8-84d4f72f404d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a683a221-4f7e-44f8-9e00-1591cea9109b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_7480a4fd-ceaa-4252-9a97-815259088543_terseLabel_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage eligible to receive tiered royalties on net sales</link:label>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_label_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Eligible To Receive Tiered Royalties On Net Sales</link:label>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_documentation_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of eligible to receive tiered royalties on net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:href="arwr-20250930.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:to="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b9b29b6e-c015-434f-a82e-926246016012_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security12b Title</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_266be96b-94d9-4464-aa22-88982d7533e5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Lease Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_a4ba9240-0aa0-45ac-b7fd-caa1c236b019_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense on credit facility</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d617163b-c4f8-44a7-956a-79f472825dd2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_488dece2-eeaa-4f54-aca3-5a296d504152_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other expense</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_b7be6252-ff56-4e67-a505-e2cd30636d19_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign-derived intangible income deduction</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, FDII, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_e7826163-a980-4575-87e3-8e5663cb0d9b_verboseLabel_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Awards granted and outstanding (in shares)</link:label>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_b433f7d0-0e28-4e0b-b39b-627a23e2d3f7_totalLabel_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_label_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</link:label>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_documentation_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:href="arwr-20250930.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:to="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchAndDevelopmentExpenseSalariesExpense_295eabf9-4cd3-4b8d-afda-ae734b24abc3_terseLabel_en-US" xlink:label="lab_arwr_ResearchAndDevelopmentExpenseSalariesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Salaries</link:label>
    <link:label id="lab_arwr_ResearchAndDevelopmentExpenseSalariesExpense_label_en-US" xlink:label="lab_arwr_ResearchAndDevelopmentExpenseSalariesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Salaries Expense</link:label>
    <link:label id="lab_arwr_ResearchAndDevelopmentExpenseSalariesExpense_documentation_en-US" xlink:label="lab_arwr_ResearchAndDevelopmentExpenseSalariesExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Salaries Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseSalariesExpense" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseSalariesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchAndDevelopmentExpenseSalariesExpense" xlink:to="lab_arwr_ResearchAndDevelopmentExpenseSalariesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e02dde80-646b-4e48-99c4-6eb904b33ea7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold_39cf3718-598a-4404-a276-9ec2acdfd567_terseLabel_en-US" xlink:label="lab_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, covenant, minimum liquidity cash, cash equivalents and investments</link:label>
    <link:label id="lab_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold_label_en-US" xlink:label="lab_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Minimum Liquidity If Capitalization Is Above Threshold</link:label>
    <link:label id="lab_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold_documentation_en-US" xlink:label="lab_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Minimum Liquidity If Capitalization Is Above Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold" xlink:href="arwr-20250930.xsd#arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold" xlink:to="lab_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_f11afe3e-55dd-415f-9da9-2a023955c388_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax credits</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b54adeee-6dde-496e-9638-b00d653e5726_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtInstrumentPrepaymentPercentage_8de8ae64-a894-46c6-84d9-21b23a18bd3d_terseLabel_en-US" xlink:label="lab_arwr_DebtInstrumentPrepaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, prepayment percentage</link:label>
    <link:label id="lab_arwr_DebtInstrumentPrepaymentPercentage_label_en-US" xlink:label="lab_arwr_DebtInstrumentPrepaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment, Percentage</link:label>
    <link:label id="lab_arwr_DebtInstrumentPrepaymentPercentage_documentation_en-US" xlink:label="lab_arwr_DebtInstrumentPrepaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentPrepaymentPercentage" xlink:href="arwr-20250930.xsd#arwr_DebtInstrumentPrepaymentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtInstrumentPrepaymentPercentage" xlink:to="lab_arwr_DebtInstrumentPrepaymentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_2ee3eedf-a0fb-4dd2-9900-152f48d46cf7_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationArrangementFixedConsideration_48402787-0751-48e0-bc4a-09a1eac1c6ca_terseLabel_en-US" xlink:label="lab_arwr_CollaborationArrangementFixedConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed consideration</link:label>
    <link:label id="lab_arwr_CollaborationArrangementFixedConsideration_label_en-US" xlink:label="lab_arwr_CollaborationArrangementFixedConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Fixed Consideration</link:label>
    <link:label id="lab_arwr_CollaborationArrangementFixedConsideration_documentation_en-US" xlink:label="lab_arwr_CollaborationArrangementFixedConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Fixed Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementFixedConsideration" xlink:href="arwr-20250930.xsd#arwr_CollaborationArrangementFixedConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationArrangementFixedConsideration" xlink:to="lab_arwr_CollaborationArrangementFixedConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MauroFerrariMember_label_en-US" xlink:label="lab_arwr_MauroFerrariMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mauro Ferrari [Member]</link:label>
    <link:label id="lab_arwr_MauroFerrariMember_documentation_en-US" xlink:label="lab_arwr_MauroFerrariMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mauro Ferrari</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MauroFerrariMember" xlink:href="arwr-20250930.xsd#arwr_MauroFerrariMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MauroFerrariMember" xlink:to="lab_arwr_MauroFerrariMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_24da8f9a-80cd-44ce-8b9f-53a27d3444e5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Common stock - repurchase (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_5fbc3861-75c0-4f24-af2f-0807676586ee_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e087b002-d092-4cd5-9ee5-9ff7a715fa2b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_d902f95a-a9b7-4877-af58-45d852dbd894_terseLabel_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_label_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Glaxosmithkline Intellectual Property Limited [Member]</link:label>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_documentation_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Glaxosmithkline Intellectual Property Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:href="arwr-20250930.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:to="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_acba7e2e-d6de-48b9-9c58-97e545133946_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DeferredTaxLiabilitiesOriginalIssueDiscount_2f79a002-b156-4730-adca-19818217a101_negatedTerseLabel_en-US" xlink:label="lab_arwr_DeferredTaxLiabilitiesOriginalIssueDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Original Issue Discount</link:label>
    <link:label id="lab_arwr_DeferredTaxLiabilitiesOriginalIssueDiscount_label_en-US" xlink:label="lab_arwr_DeferredTaxLiabilitiesOriginalIssueDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Original Issue Discount</link:label>
    <link:label id="lab_arwr_DeferredTaxLiabilitiesOriginalIssueDiscount_documentation_en-US" xlink:label="lab_arwr_DeferredTaxLiabilitiesOriginalIssueDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Original Issue Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxLiabilitiesOriginalIssueDiscount" xlink:href="arwr-20250930.xsd#arwr_DeferredTaxLiabilitiesOriginalIssueDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DeferredTaxLiabilitiesOriginalIssueDiscount" xlink:to="lab_arwr_DeferredTaxLiabilitiesOriginalIssueDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_01e1a678-f058-4030-94c8-2d0d80e32791_terseLabel_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Colorado Owner, LLC</link:label>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_label_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Colorado Owner L L C [Member]</link:label>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_documentation_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Colorado Owner, LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember" xlink:href="arwr-20250930.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ColoradoOwnerLLCMember" xlink:to="lab_arwr_ColoradoOwnerLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_fc9e22c3-5107-4844-bec9-c449472eec18_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_22176edc-16f2-419a-a489-f2ec82839347_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfAgreements_47e97623-92d3-4dbc-a768-4e3fb6393749_terseLabel_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of agreements</link:label>
    <link:label id="lab_arwr_NumberOfAgreements_label_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Agreements</link:label>
    <link:label id="lab_arwr_NumberOfAgreements_documentation_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements" xlink:href="arwr-20250930.xsd#arwr_NumberOfAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfAgreements" xlink:to="lab_arwr_NumberOfAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f1ad5fa9-0b70-4593-b540-517fb0fd0462_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d934ddbe-0039-4387-b284-b8c067fb355a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_e5f22aec-1547-481e-bc0d-37b5d8f20fb7_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3c2c5b74-f600-46bf-9036-6ce40dd7bd47_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_aef089d2-69f4-4118-a733-8735bf6dacaa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_35add1a6-2b84-4788-ba4b-6f4565d9f366_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_9bb059bc-383e-4172-8a85-76ade8fc5c86_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_bb3526bf-7d8f-4b5a-abdb-162d24c5ea96_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_fbdb53d4-9750-4cbf-94f8-32c69a115653_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_60898a06-26c9-427a-bcea-732e605da242_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Permanent and other items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_545cafe8-c8b6-431a-b563-38788b317eb1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_70514ee7-0160-4fd7-8b17-53e273554f00_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_87dff24d-fbf6-44c0-aecd-e9b1df68c20d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_c1ee4b38-f1aa-47b7-add2-ec9c84da29f5_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_00d20873-0da6-49a9-8971-119a21c93e54_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_d0439aaa-86f7-4517-a090-d123531e068e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_075dd820-9c57-4700-bf5c-4035c826c345_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_6694b779-cf40-405f-a55e-0205a278a5fe_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_79e01148-343d-4ca7-be72-6d676e336244_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets subject to amortization, impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ChristopherAnzaloneMember_label_en-US" xlink:label="lab_arwr_ChristopherAnzaloneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Christopher Anzalone [Member]</link:label>
    <link:label id="lab_arwr_ChristopherAnzaloneMember_documentation_en-US" xlink:label="lab_arwr_ChristopherAnzaloneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Christopher Anzalone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ChristopherAnzaloneMember" xlink:href="arwr-20250930.xsd#arwr_ChristopherAnzaloneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ChristopherAnzaloneMember" xlink:to="lab_arwr_ChristopherAnzaloneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_51037e7c-47cf-4307-b7dd-e2974f705827_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_a5c6b2b6-3d88-4579-b866-c595e15b0975_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a3cb74cc-d769-46bd-a85d-3be6deecab30_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_99ebbfcc-270c-42b4-8aa0-58e87c09b1d2_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_94cdf1fe-bbf0-4102-ac78-ffb118770cc3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_13b0009c-a823-4e20-89ea-e8bc65a9ec01_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Lapse of statue of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_62c77979-7719-4516-a06e-f2171edb1f0d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_30c201a1-a86c-4846-a8e5-3cbea926a694_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued to institutional investors (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_4c60ce75-3a14-4a73-9e6c-dfcae2fa4e52_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities included in deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_945d4024-7b89-46c9-ac0d-2193e54c52a8_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalariesWagesAndOfficersCompensation_0734ed4f-c92c-4c56-af35-808ba3c36f86_terseLabel_en-US" xlink:label="lab_us-gaap_SalariesWagesAndOfficersCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Salaries</link:label>
    <link:label id="lab_us-gaap_SalariesWagesAndOfficersCompensation_label_en-US" xlink:label="lab_us-gaap_SalariesWagesAndOfficersCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Salary and Wage, Excluding Cost of Good and Service Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="lab_us-gaap_SalariesWagesAndOfficersCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_14daf211-ac56-4a86-aa84-55523274bea8_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock offering price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_27b52eb7-4b5e-4af9-b8d0-0128b332e092_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_30dcb34d-b994-44cd-9643-5a78f2fad5be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock; at cost; 2,661 and 0 shares of common stock at September 30, 2025 and 2024, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_575a8c95-8958-4a80-8a5e-c2f8a2e9a1d1_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock value</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval_e3d83525-ca31-42ee-80fb-6fbaa539d02e_terseLabel_en-US" xlink:label="lab_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement termination notice period prior to any regulatory approval of a licensed product</link:label>
    <link:label id="lab_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval_label_en-US" xlink:label="lab_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Termination Notice Period Prior To Regulatory Approval</link:label>
    <link:label id="lab_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval_documentation_en-US" xlink:label="lab_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Termination Notice Period Prior To Regulatory Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval" xlink:href="arwr-20250930.xsd#arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval" xlink:to="lab_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_88b99798-58a7-4b85-8e3a-f4c706502808_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e7ba5f98-6886-4e21-b874-18863ec9b364_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Summarized Information about Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a27f1874-3995-4600-b388-f4d21d7cbd7d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_92780525-c299-45c4-9c6d-5923eaa5f02f_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average basic shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_981fc832-8df0-46ae-a12b-8b19c8309f4a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_91591c32-9e98-4be0-8532-5a8bb165531a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_9b124119-b99e-4dbe-a53c-bb8ecc7c8043_terseLabel_en-US" xlink:label="lab_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants purchase price (in dollars per share)</link:label>
    <link:label id="lab_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_label_en-US" xlink:label="lab_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Purchase Price of Warrants or Rights</link:label>
    <link:label id="lab_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_documentation_en-US" xlink:label="lab_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Purchase Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:href="arwr-20250930.xsd#arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:to="lab_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AccruedCapitalExpenditureCurrent_017f42c8-6d3a-4ffa-b3a0-27f630d0fd7a_terseLabel_en-US" xlink:label="lab_arwr_AccruedCapitalExpenditureCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued capital expenditures</link:label>
    <link:label id="lab_arwr_AccruedCapitalExpenditureCurrent_label_en-US" xlink:label="lab_arwr_AccruedCapitalExpenditureCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Capital Expenditure, Current</link:label>
    <link:label id="lab_arwr_AccruedCapitalExpenditureCurrent_documentation_en-US" xlink:label="lab_arwr_AccruedCapitalExpenditureCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Capital Expenditure, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedCapitalExpenditureCurrent" xlink:href="arwr-20250930.xsd#arwr_AccruedCapitalExpenditureCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AccruedCapitalExpenditureCurrent" xlink:to="lab_arwr_AccruedCapitalExpenditureCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a682317b-1c19-4ba4-99cf-f375363d8376_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options Outstanding, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_45d2e25a-7a59-423e-88a1-89cc84f2f00c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2df5da54-3243-4f28-be55-bf2a67f34800_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bcd6063c-67ed-4164-b9a3-6a61fbdacbb7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_76945bb4-46a8-4f37-b2eb-e0586d184819_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_fac1fc8f-cf71-4d1d-920e-0040009e0eb3_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PatrickOBrienSharesVestingAndSubjectToSellToCoverMember_label_en-US" xlink:label="lab_arwr_PatrickOBrienSharesVestingAndSubjectToSellToCoverMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patrick O'Brien, Shares Vesting And Subject to Sell-To-Cover [Member]</link:label>
    <link:label id="lab_arwr_PatrickOBrienSharesVestingAndSubjectToSellToCoverMember_documentation_en-US" xlink:label="lab_arwr_PatrickOBrienSharesVestingAndSubjectToSellToCoverMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patrick O'Brien, Shares Vesting And Subject to Sell-To-Cover</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PatrickOBrienSharesVestingAndSubjectToSellToCoverMember" xlink:href="arwr-20250930.xsd#arwr_PatrickOBrienSharesVestingAndSubjectToSellToCoverMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PatrickOBrienSharesVestingAndSubjectToSellToCoverMember" xlink:to="lab_arwr_PatrickOBrienSharesVestingAndSubjectToSellToCoverMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_809dba88-86dd-46d4-addd-1808b5170769_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_c843282b-21d8-4905-9a6f-96f35f139167_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_GSKHBVAgreementMember_debcf017-443a-43c7-b823-30665200a0d3_terseLabel_en-US" xlink:label="lab_arwr_GSKHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK-HBV Agreement</link:label>
    <link:label id="lab_arwr_GSKHBVAgreementMember_label_en-US" xlink:label="lab_arwr_GSKHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK-HBV Agreement [Member]</link:label>
    <link:label id="lab_arwr_GSKHBVAgreementMember_documentation_en-US" xlink:label="lab_arwr_GSKHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GSK-HBV Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GSKHBVAgreementMember" xlink:href="arwr-20250930.xsd#arwr_GSKHBVAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_GSKHBVAgreementMember" xlink:to="lab_arwr_GSKHBVAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_b929d87a-f8e5-4f25-bbe9-4f26e2ec82bf_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_72b8cb88-a9e0-44fa-88a2-6fe866955e8a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1e557461-f809-4026-aa00-f9dcb873f302_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_15407d45-e548-4281-ab91-442bd5a52c42_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_8db1d95d-c2e3-4f30-b9c4-43e34308531b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest and Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense_ea86b49b-fcf8-4266-ad75-2605c381d230_totalLabel_en-US" xlink:label="lab_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total general and administrative expense, excluding non-cash expense</link:label>
    <link:label id="lab_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense_label_en-US" xlink:label="lab_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General And Administrative Expense, Excluding Noncash Expense</link:label>
    <link:label id="lab_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense_documentation_en-US" xlink:label="lab_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General And Administrative Expense, Excluding Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense" xlink:href="arwr-20250930.xsd#arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense" xlink:to="lab_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_75f22a4c-db41-4999-906c-3235b347d5aa_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_552e33bb-b6c7-4faf-99e9-e6b8c337cfa6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PatrickOBrienMember_label_en-US" xlink:label="lab_arwr_PatrickOBrienMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patrick O'Brien [Member]</link:label>
    <link:label id="lab_arwr_PatrickOBrienMember_documentation_en-US" xlink:label="lab_arwr_PatrickOBrienMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patrick O'Brien</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PatrickOBrienMember" xlink:href="arwr-20250930.xsd#arwr_PatrickOBrienMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PatrickOBrienMember" xlink:to="lab_arwr_PatrickOBrienMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_5ede5590-2c6d-4f89-965f-29ecd1b93143_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross increase for current period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManufacturingFacilityMember_c5b78ad5-5e96-43d7-84ea-1816b65adac2_terseLabel_en-US" xlink:label="lab_us-gaap_ManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing Facility</link:label>
    <link:label id="lab_us-gaap_ManufacturingFacilityMember_label_en-US" xlink:label="lab_us-gaap_ManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManufacturingFacilityMember" xlink:to="lab_us-gaap_ManufacturingFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_8c6f14e6-bcc8-4104-88b8-551fdd5f233f_terseLabel_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Facility in Madison</link:label>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_label_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Facility In Madison [Member]</link:label>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_documentation_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research facility in Madison.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember" xlink:href="arwr-20250930.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchFacilityInMadisonMember" xlink:to="lab_arwr_ResearchFacilityInMadisonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1be8e62f-23e6-4817-8fec-11cca315ac90_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_a3067395-c209-4225-be84-a2c7aa7efca8_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_d2830826-bbaa-41a4-b289-30ee620225f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share Activity Related to RSUs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5eb90687-e428-491e-8de7-f38c3fc24ff8_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2d3ae189-66ff-46f5-8ffa-81c8545af870_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_3d487992-9de3-415e-88c7-071645767caa_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_edf9d608-875f-470e-ae1b-d15120c87f94_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NovartisCollaborationAgreementMember_efff79f6-9e0f-46ee-b7db-7c4e0def0717_terseLabel_en-US" xlink:label="lab_arwr_NovartisCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis Collaboration Agreement</link:label>
    <link:label id="lab_arwr_NovartisCollaborationAgreementMember_label_en-US" xlink:label="lab_arwr_NovartisCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Collaboration Agreement [Member]</link:label>
    <link:label id="lab_arwr_NovartisCollaborationAgreementMember_documentation_en-US" xlink:label="lab_arwr_NovartisCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Novartis Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisCollaborationAgreementMember" xlink:href="arwr-20250930.xsd#arwr_NovartisCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NovartisCollaborationAgreementMember" xlink:to="lab_arwr_NovartisCollaborationAgreementMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>arwr-20250930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:67e6a79e-2429-4a7b-924a-105395255933,g:bc385ee3-281d-4402-b0c2-11a4f6b4f5dd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CoverPage" xlink:type="simple" xlink:href="arwr-20250930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_639fe122-b967-4146-b1c4-f86b2a346969" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_DocumentType_639fe122-b967-4146-b1c4-f86b2a346969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_0c7f865d-9bc5-4a00-b5fd-d07b93a48141" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_DocumentAnnualReport_0c7f865d-9bc5-4a00-b5fd-d07b93a48141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8a403bb4-e239-41fd-ae0e-d86c1db6af87" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_DocumentPeriodEndDate_8a403bb4-e239-41fd-ae0e-d86c1db6af87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c8f0fdcc-d0bc-43e6-9689-d27115263771" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_CurrentFiscalYearEndDate_c8f0fdcc-d0bc-43e6-9689-d27115263771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c45b4255-34c9-47d9-bdb5-6a6494a62271" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_DocumentTransitionReport_c45b4255-34c9-47d9-bdb5-6a6494a62271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_6dfddbb3-b419-410b-a144-7089aae0fe48" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_EntityFileNumber_6dfddbb3-b419-410b-a144-7089aae0fe48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_39b5374c-31a0-49ed-9426-f1246a74881d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_EntityRegistrantName_39b5374c-31a0-49ed-9426-f1246a74881d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_587c0700-d9a9-421d-8df4-81bbbe22ae5c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_587c0700-d9a9-421d-8df4-81bbbe22ae5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_92befcae-df4f-4f05-8a27-71b4c01a10a1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_EntityTaxIdentificationNumber_92befcae-df4f-4f05-8a27-71b4c01a10a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_38682c6c-17db-4005-9253-38f272726d95" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_CityAreaCode_38682c6c-17db-4005-9253-38f272726d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1c80ff80-e8e8-432a-8753-ff6f6fa046d7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_LocalPhoneNumber_1c80ff80-e8e8-432a-8753-ff6f6fa046d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5abd2401-6fee-4c42-b567-352dccdba67e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_EntityAddressAddressLine1_5abd2401-6fee-4c42-b567-352dccdba67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_9460ebd3-4128-4e30-9142-1a2e74468c29" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_EntityAddressAddressLine2_9460ebd3-4128-4e30-9142-1a2e74468c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2db35173-df3f-470f-9943-a091fdac3f8a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_EntityAddressCityOrTown_2db35173-df3f-470f-9943-a091fdac3f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f3d97579-bded-411a-918b-08f79d541423" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_EntityAddressStateOrProvince_f3d97579-bded-411a-918b-08f79d541423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_35ab4a81-2eac-46ee-be07-12ac1effb7d5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_EntityAddressPostalZipCode_35ab4a81-2eac-46ee-be07-12ac1effb7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a957c5eb-93fb-4f4e-bfc7-ba05a21839f0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_Security12bTitle_a957c5eb-93fb-4f4e-bfc7-ba05a21839f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_29c83b9b-e56d-4670-a842-a468baeca6d1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_TradingSymbol_29c83b9b-e56d-4670-a842-a468baeca6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d9ec5ce5-2104-49c4-9061-7df2b1b7f6c2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_SecurityExchangeName_d9ec5ce5-2104-49c4-9061-7df2b1b7f6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_26dc2b31-70d7-4a52-9f22-5111193f57f7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_26dc2b31-70d7-4a52-9f22-5111193f57f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_86c85b7c-db56-4b23-a01e-d7b37eaa94ca" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_EntityVoluntaryFilers_86c85b7c-db56-4b23-a01e-d7b37eaa94ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a549d30b-352d-4661-9b83-33fc2211f5e2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_EntityCurrentReportingStatus_a549d30b-352d-4661-9b83-33fc2211f5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_bdcd12e3-8870-46b0-aa62-653846eb77d8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_EntityInteractiveDataCurrent_bdcd12e3-8870-46b0-aa62-653846eb77d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0cc2e07d-2880-4f61-90fb-7a8a5940ffbc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_EntityFilerCategory_0cc2e07d-2880-4f61-90fb-7a8a5940ffbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b668959b-8cb6-410e-a7e1-ef6c83e03875" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_EntitySmallBusiness_b668959b-8cb6-410e-a7e1-ef6c83e03875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_537b034c-fe7d-4e1a-938e-0ed275131b78" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_EntityEmergingGrowthCompany_537b034c-fe7d-4e1a-938e-0ed275131b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_315a9ee5-2c28-4202-8087-470a83d56419" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_IcfrAuditorAttestationFlag_315a9ee5-2c28-4202-8087-470a83d56419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5c090599-530e-44a4-98fb-78e678a9e46e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_EntityShellCompany_5c090599-530e-44a4-98fb-78e678a9e46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_a5c6bb77-0785-4654-8db6-0d91d3e4b400" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_a5c6bb77-0785-4654-8db6-0d91d3e4b400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_e6b59718-b29c-44b8-82c7-caa04fcbb8a2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_EntityPublicFloat_e6b59718-b29c-44b8-82c7-caa04fcbb8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3030e08c-3c51-4ace-ac6d-8a17fc13e6f8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3030e08c-3c51-4ace-ac6d-8a17fc13e6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_d7f9a56d-ccb0-4d44-a562-d6ed3fd6c920" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_d7f9a56d-ccb0-4d44-a562-d6ed3fd6c920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_edc563b2-1f52-4d03-b709-fa0f5c4084c7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_DocumentFiscalYearFocus_edc563b2-1f52-4d03-b709-fa0f5c4084c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_78cd4f7c-8f76-4471-b821-7be718a444f6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_DocumentFiscalPeriodFocus_78cd4f7c-8f76-4471-b821-7be718a444f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c9db8350-1aa2-47d3-aba9-d728613dde3b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_EntityCentralIndexKey_c9db8350-1aa2-47d3-aba9-d728613dde3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0a552a31-557c-4745-a94e-a1c6f4322d6d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d7ee10dc-5daa-4c9e-8b41-88456e5031b8" xlink:to="loc_dei_AmendmentFlag_0a552a31-557c-4745-a94e-a1c6f4322d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/AuditInformation" xlink:type="simple" xlink:href="arwr-20250930.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AuditInformationAbstract_3efea7c7-b0a4-400d-b1d9-aa7f86e80126" xlink:href="arwr-20250930.xsd#arwr_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_7786f70b-9f02-4c22-845a-a32c483fd62f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_AuditInformationAbstract_3efea7c7-b0a4-400d-b1d9-aa7f86e80126" xlink:to="loc_dei_AuditorFirmId_7786f70b-9f02-4c22-845a-a32c483fd62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_dedf14e2-6527-40fe-a72b-b8789b1e25db" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_AuditInformationAbstract_3efea7c7-b0a4-400d-b1d9-aa7f86e80126" xlink:to="loc_dei_AuditorName_dedf14e2-6527-40fe-a72b-b8789b1e25db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_7b7d4093-54e9-4dbb-9f70-25365e3f8591" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_AuditInformationAbstract_3efea7c7-b0a4-400d-b1d9-aa7f86e80126" xlink:to="loc_dei_AuditorLocation_7b7d4093-54e9-4dbb-9f70-25365e3f8591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arwr-20250930.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_07a4d75e-3055-45bf-99dc-82f53f935b91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bca1d579-9b9f-4cc3-85ab-dc8b6ff7ef59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_07a4d75e-3055-45bf-99dc-82f53f935b91" xlink:to="loc_us-gaap_StatementTable_bca1d579-9b9f-4cc3-85ab-dc8b6ff7ef59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_f570cd97-ada8-416c-ac47-5c8a7817e83e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bca1d579-9b9f-4cc3-85ab-dc8b6ff7ef59" xlink:to="loc_srt_ConsolidatedEntitiesAxis_f570cd97-ada8-416c-ac47-5c8a7817e83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3b328701-d50e-4125-8d73-dbe5cf087ea3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_f570cd97-ada8-416c-ac47-5c8a7817e83e" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3b328701-d50e-4125-8d73-dbe5cf087ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember_522898c6-5382-49ec-b889-63ddc106a29f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_3b328701-d50e-4125-8d73-dbe5cf087ea3" xlink:to="loc_srt_ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember_522898c6-5382-49ec-b889-63ddc106a29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_fe11e775-70ba-4c7b-81fb-017f215dcb36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_3b328701-d50e-4125-8d73-dbe5cf087ea3" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_fe11e775-70ba-4c7b-81fb-017f215dcb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0649f5eb-496b-4909-9ade-4efb59000478" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bca1d579-9b9f-4cc3-85ab-dc8b6ff7ef59" xlink:to="loc_us-gaap_StatementLineItems_0649f5eb-496b-4909-9ade-4efb59000478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6eb4867e-09d5-41a9-a1b9-09aa79ad31dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0649f5eb-496b-4909-9ade-4efb59000478" xlink:to="loc_us-gaap_AssetsAbstract_6eb4867e-09d5-41a9-a1b9-09aa79ad31dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_b480a7a6-e65d-4d15-9516-f7675d68714b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6eb4867e-09d5-41a9-a1b9-09aa79ad31dd" xlink:to="loc_us-gaap_AssetsCurrentAbstract_b480a7a6-e65d-4d15-9516-f7675d68714b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_731c0af9-acc3-46c8-b6d1-1391313416ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b480a7a6-e65d-4d15-9516-f7675d68714b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_731c0af9-acc3-46c8-b6d1-1391313416ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_bb480458-e39f-40bf-8d9b-c21ca218d34c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b480a7a6-e65d-4d15-9516-f7675d68714b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_bb480458-e39f-40bf-8d9b-c21ca218d34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2e102732-6fdc-4d26-a9ed-c73b1e3a92dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b480a7a6-e65d-4d15-9516-f7675d68714b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2e102732-6fdc-4d26-a9ed-c73b1e3a92dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_b9d58f9a-d0e7-4b85-b67c-6efb3cbbac01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b480a7a6-e65d-4d15-9516-f7675d68714b" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_b9d58f9a-d0e7-4b85-b67c-6efb3cbbac01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_df7b2a73-c4a0-4d40-bf0e-c62deff0576e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b480a7a6-e65d-4d15-9516-f7675d68714b" xlink:to="loc_us-gaap_OtherAssetsCurrent_df7b2a73-c4a0-4d40-bf0e-c62deff0576e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3f282d83-9484-4d20-b6a0-2a789b0c3c24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b480a7a6-e65d-4d15-9516-f7675d68714b" xlink:to="loc_us-gaap_AssetsCurrent_3f282d83-9484-4d20-b6a0-2a789b0c3c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b1845707-4afc-4fd6-9811-438ba6baed10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6eb4867e-09d5-41a9-a1b9-09aa79ad31dd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b1845707-4afc-4fd6-9811-438ba6baed10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_42d937da-22c9-4f5a-afe7-01aa59f6fe72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6eb4867e-09d5-41a9-a1b9-09aa79ad31dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_42d937da-22c9-4f5a-afe7-01aa59f6fe72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_47dca8a7-efd6-4de5-b995-400a5ceb241b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6eb4867e-09d5-41a9-a1b9-09aa79ad31dd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_47dca8a7-efd6-4de5-b995-400a5ceb241b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_118724ec-0a6e-451c-bd78-6a17d6fe2e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6eb4867e-09d5-41a9-a1b9-09aa79ad31dd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_118724ec-0a6e-451c-bd78-6a17d6fe2e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_605dad12-cd20-400c-b695-d57d9e64e4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6eb4867e-09d5-41a9-a1b9-09aa79ad31dd" xlink:to="loc_us-gaap_Assets_605dad12-cd20-400c-b695-d57d9e64e4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8e14fb68-8044-464f-92a1-03241fb2e01d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0649f5eb-496b-4909-9ade-4efb59000478" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8e14fb68-8044-464f-92a1-03241fb2e01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_892cb833-19fd-4c8e-bead-af7c5928c60b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8e14fb68-8044-464f-92a1-03241fb2e01d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_892cb833-19fd-4c8e-bead-af7c5928c60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e1ef1534-1815-4d9b-b499-1dc6556fb13e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_892cb833-19fd-4c8e-bead-af7c5928c60b" xlink:to="loc_us-gaap_AccountsPayableCurrent_e1ef1534-1815-4d9b-b499-1dc6556fb13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_189dc0e5-be2d-4071-959f-71e692c078f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_892cb833-19fd-4c8e-bead-af7c5928c60b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_189dc0e5-be2d-4071-959f-71e692c078f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e0edaec5-3613-4041-adf7-3b43256522a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_892cb833-19fd-4c8e-bead-af7c5928c60b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e0edaec5-3613-4041-adf7-3b43256522a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_30d46788-98e0-4ef9-8643-92065717c227" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_892cb833-19fd-4c8e-bead-af7c5928c60b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_30d46788-98e0-4ef9-8643-92065717c227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7355a36b-5b44-46eb-9f71-e952ddd3e4df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_892cb833-19fd-4c8e-bead-af7c5928c60b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7355a36b-5b44-46eb-9f71-e952ddd3e4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_23a85c5b-4ec7-4f32-b423-83eba65a3c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_892cb833-19fd-4c8e-bead-af7c5928c60b" xlink:to="loc_us-gaap_LinesOfCreditCurrent_23a85c5b-4ec7-4f32-b423-83eba65a3c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_cb001bf1-508b-4736-ae11-d4f0f5b83049" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_892cb833-19fd-4c8e-bead-af7c5928c60b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_cb001bf1-508b-4736-ae11-d4f0f5b83049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ece1cb60-324b-4acc-b7f6-0f18b4ac1412" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_892cb833-19fd-4c8e-bead-af7c5928c60b" xlink:to="loc_us-gaap_LiabilitiesCurrent_ece1cb60-324b-4acc-b7f6-0f18b4ac1412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_7922a042-93c5-40c1-9b24-88f4a5913aec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8e14fb68-8044-464f-92a1-03241fb2e01d" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_7922a042-93c5-40c1-9b24-88f4a5913aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ded854df-d493-4f08-b34f-e0c039820911" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_7922a042-93c5-40c1-9b24-88f4a5913aec" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ded854df-d493-4f08-b34f-e0c039820911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent_e4668b5f-968e-4ca1-b1e1-77b5df84e017" xlink:href="arwr-20250930.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_7922a042-93c5-40c1-9b24-88f4a5913aec" xlink:to="loc_arwr_RoyaltiesLiabilityNoncurrent_e4668b5f-968e-4ca1-b1e1-77b5df84e017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_aaa1c66e-d71b-4e8b-a353-1cd566f0db2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_7922a042-93c5-40c1-9b24-88f4a5913aec" xlink:to="loc_us-gaap_LongTermLineOfCredit_aaa1c66e-d71b-4e8b-a353-1cd566f0db2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_606835ce-2ede-4158-a3f5-882e8fa3fda1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_7922a042-93c5-40c1-9b24-88f4a5913aec" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_606835ce-2ede-4158-a3f5-882e8fa3fda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2f4fba15-f8ae-41ff-8de7-4d73578e3772" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8e14fb68-8044-464f-92a1-03241fb2e01d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2f4fba15-f8ae-41ff-8de7-4d73578e3772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb5edf2b-d4c2-4cd5-aac4-29ac97cc6f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8e14fb68-8044-464f-92a1-03241fb2e01d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb5edf2b-d4c2-4cd5-aac4-29ac97cc6f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9d7c795a-3c80-4a7d-bdc3-6aebf954ba8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb5edf2b-d4c2-4cd5-aac4-29ac97cc6f1e" xlink:to="loc_us-gaap_CommonStockValue_9d7c795a-3c80-4a7d-bdc3-6aebf954ba8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3e09703a-801e-417e-92c6-28e6f85a2657" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb5edf2b-d4c2-4cd5-aac4-29ac97cc6f1e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3e09703a-801e-417e-92c6-28e6f85a2657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ce2c8897-b2b1-44c0-8871-89fce91ce0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb5edf2b-d4c2-4cd5-aac4-29ac97cc6f1e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ce2c8897-b2b1-44c0-8871-89fce91ce0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_77a44dfc-effc-4b18-878f-a227dff89be5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb5edf2b-d4c2-4cd5-aac4-29ac97cc6f1e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_77a44dfc-effc-4b18-878f-a227dff89be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_1d3a6741-9d92-4117-9fab-1353a03c8891" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb5edf2b-d4c2-4cd5-aac4-29ac97cc6f1e" xlink:to="loc_us-gaap_TreasuryStockCommonValue_1d3a6741-9d92-4117-9fab-1353a03c8891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_98e3e82b-831a-4ed5-bbbf-92e90f78b3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb5edf2b-d4c2-4cd5-aac4-29ac97cc6f1e" xlink:to="loc_us-gaap_StockholdersEquity_98e3e82b-831a-4ed5-bbbf-92e90f78b3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_c346b38c-c347-4e7a-a789-66bb799a0b24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb5edf2b-d4c2-4cd5-aac4-29ac97cc6f1e" xlink:to="loc_us-gaap_MinorityInterest_c346b38c-c347-4e7a-a789-66bb799a0b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_845c0ce5-e87a-4170-895f-95f76faa7156" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb5edf2b-d4c2-4cd5-aac4-29ac97cc6f1e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_845c0ce5-e87a-4170-895f-95f76faa7156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d41e0149-05ec-4953-a6df-d092bfae3c18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8e14fb68-8044-464f-92a1-03241fb2e01d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d41e0149-05ec-4953-a6df-d092bfae3c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="arwr-20250930.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1c11bbe3-8174-4847-ba83-754bbb5add83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3e99b121-4660-4e15-8a34-0310a05b8512" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1c11bbe3-8174-4847-ba83-754bbb5add83" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3e99b121-4660-4e15-8a34-0310a05b8512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fabf8d10-768c-409f-9676-ab0e1a068a49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1c11bbe3-8174-4847-ba83-754bbb5add83" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fabf8d10-768c-409f-9676-ab0e1a068a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4bf5740d-7d3a-450d-a5b4-f318b818c337" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1c11bbe3-8174-4847-ba83-754bbb5add83" xlink:to="loc_us-gaap_CommonStockSharesIssued_4bf5740d-7d3a-450d-a5b4-f318b818c337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e47f212d-005f-46f2-8e72-3a95ef51e98e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1c11bbe3-8174-4847-ba83-754bbb5add83" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e47f212d-005f-46f2-8e72-3a95ef51e98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_bc960195-54e8-4499-85f1-849708b93954" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1c11bbe3-8174-4847-ba83-754bbb5add83" xlink:to="loc_us-gaap_TreasuryStockCommonShares_bc960195-54e8-4499-85f1-849708b93954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="arwr-20250930.xsd#ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e162c3b6-3c5b-4030-9061-6618b81444bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e160b94f-d2c1-41f7-9d62-a2ff63dd3e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e162c3b6-3c5b-4030-9061-6618b81444bf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e160b94f-d2c1-41f7-9d62-a2ff63dd3e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2c965055-0158-42f6-8029-4900e0605676" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e162c3b6-3c5b-4030-9061-6618b81444bf" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2c965055-0158-42f6-8029-4900e0605676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0164f917-29db-488e-8656-aa507f5e83c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2c965055-0158-42f6-8029-4900e0605676" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0164f917-29db-488e-8656-aa507f5e83c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_dbc339d9-9be6-4c2e-ad7b-90c497d98b96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2c965055-0158-42f6-8029-4900e0605676" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_dbc339d9-9be6-4c2e-ad7b-90c497d98b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_79ee2185-720f-4fd5-8e2b-13adb2cd11c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2c965055-0158-42f6-8029-4900e0605676" xlink:to="loc_us-gaap_OperatingExpenses_79ee2185-720f-4fd5-8e2b-13adb2cd11c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_75b1b8dd-345f-4daf-af8d-0c55bcfe6b55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e162c3b6-3c5b-4030-9061-6618b81444bf" xlink:to="loc_us-gaap_OperatingIncomeLoss_75b1b8dd-345f-4daf-af8d-0c55bcfe6b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_31184758-11ae-4538-82a3-ad0d950b913b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e162c3b6-3c5b-4030-9061-6618b81444bf" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_31184758-11ae-4538-82a3-ad0d950b913b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_2af8c9ae-99ca-4b05-a621-f09d868129b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_31184758-11ae-4538-82a3-ad0d950b913b" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_2af8c9ae-99ca-4b05-a621-f09d868129b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_64a1b856-e1ea-44ed-87bd-4189abf0c8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_31184758-11ae-4538-82a3-ad0d950b913b" xlink:to="loc_us-gaap_InterestExpenseNonoperating_64a1b856-e1ea-44ed-87bd-4189abf0c8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_da7168a3-d346-44ca-8283-c665f7343d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_31184758-11ae-4538-82a3-ad0d950b913b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_da7168a3-d346-44ca-8283-c665f7343d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4000680a-71a6-42a9-9830-4805a9bbd350" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_31184758-11ae-4538-82a3-ad0d950b913b" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4000680a-71a6-42a9-9830-4805a9bbd350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_59311d48-faea-4448-afc2-8dd82df6c959" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e162c3b6-3c5b-4030-9061-6618b81444bf" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_59311d48-faea-4448-afc2-8dd82df6c959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1b8d1d53-836c-4ab0-8c1d-28fad405629a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e162c3b6-3c5b-4030-9061-6618b81444bf" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1b8d1d53-836c-4ab0-8c1d-28fad405629a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3e5ba662-0894-47c1-80b3-41bc470a4a18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e162c3b6-3c5b-4030-9061-6618b81444bf" xlink:to="loc_us-gaap_ProfitLoss_3e5ba662-0894-47c1-80b3-41bc470a4a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8104bfd9-aca3-4a19-91cb-6caa4e1766d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e162c3b6-3c5b-4030-9061-6618b81444bf" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8104bfd9-aca3-4a19-91cb-6caa4e1766d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_735e69ba-b4df-451b-9758-3d4ae1ccbad7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e162c3b6-3c5b-4030-9061-6618b81444bf" xlink:to="loc_us-gaap_NetIncomeLoss_735e69ba-b4df-451b-9758-3d4ae1ccbad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_17fa5132-785e-4166-97e2-c87b6ed41308" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e162c3b6-3c5b-4030-9061-6618b81444bf" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_17fa5132-785e-4166-97e2-c87b6ed41308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_dcc86908-11f8-4f6f-b7e9-96789fe67e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_17fa5132-785e-4166-97e2-c87b6ed41308" xlink:to="loc_us-gaap_EarningsPerShareBasic_dcc86908-11f8-4f6f-b7e9-96789fe67e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f2bad43a-1448-49a8-ba6d-89c0ada8d3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_17fa5132-785e-4166-97e2-c87b6ed41308" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f2bad43a-1448-49a8-ba6d-89c0ada8d3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6974214f-c5b3-451e-aa2d-2bad250fb9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e162c3b6-3c5b-4030-9061-6618b81444bf" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6974214f-c5b3-451e-aa2d-2bad250fb9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_92774d3d-aaa7-4021-b6be-dcd501961e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6974214f-c5b3-451e-aa2d-2bad250fb9c8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_92774d3d-aaa7-4021-b6be-dcd501961e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0bb3eda4-6b00-48fe-8fd1-0a30bb5095ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6974214f-c5b3-451e-aa2d-2bad250fb9c8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0bb3eda4-6b00-48fe-8fd1-0a30bb5095ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_4f588129-4fc1-4525-b1ed-1c2eb5aad468" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e162c3b6-3c5b-4030-9061-6618b81444bf" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_4f588129-4fc1-4525-b1ed-1c2eb5aad468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_45bf231d-df05-484d-b564-a518f0ae5234" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_4f588129-4fc1-4525-b1ed-1c2eb5aad468" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_45bf231d-df05-484d-b564-a518f0ae5234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5fde9794-3422-4c9b-b555-63b0a5a1b27d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_4f588129-4fc1-4525-b1ed-1c2eb5aad468" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5fde9794-3422-4c9b-b555-63b0a5a1b27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_404bee46-6f90-44fd-8d7d-e48c6a336a55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_4f588129-4fc1-4525-b1ed-1c2eb5aad468" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_404bee46-6f90-44fd-8d7d-e48c6a336a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_69bdb282-d88e-4bbc-b4b7-73246dae12cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_4f588129-4fc1-4525-b1ed-1c2eb5aad468" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_69bdb282-d88e-4bbc-b4b7-73246dae12cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="arwr-20250930.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9ba4b333-6c71-4794-ab57-a2c1f2047a15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f9009b58-bced-4106-876e-7a4385805ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9ba4b333-6c71-4794-ab57-a2c1f2047a15" xlink:to="loc_us-gaap_StatementTable_f9009b58-bced-4106-876e-7a4385805ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a4515857-d18a-47e6-a9bb-55d238c81a78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f9009b58-bced-4106-876e-7a4385805ea9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a4515857-d18a-47e6-a9bb-55d238c81a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dbb31a3e-27f7-4470-8f26-cdf08e55711e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a4515857-d18a-47e6-a9bb-55d238c81a78" xlink:to="loc_us-gaap_EquityComponentDomain_dbb31a3e-27f7-4470-8f26-cdf08e55711e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d1cde91c-10fe-47c3-b9bc-9e00a7b3f073" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dbb31a3e-27f7-4470-8f26-cdf08e55711e" xlink:to="loc_us-gaap_CommonStockMember_d1cde91c-10fe-47c3-b9bc-9e00a7b3f073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_754324fb-aa7c-4165-9bb6-478ff37d8749" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dbb31a3e-27f7-4470-8f26-cdf08e55711e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_754324fb-aa7c-4165-9bb6-478ff37d8749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_22a313b5-4f58-4926-955b-aec62c785685" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dbb31a3e-27f7-4470-8f26-cdf08e55711e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_22a313b5-4f58-4926-955b-aec62c785685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e9f2d731-0aad-4204-887d-02d1390f45c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dbb31a3e-27f7-4470-8f26-cdf08e55711e" xlink:to="loc_us-gaap_RetainedEarningsMember_e9f2d731-0aad-4204-887d-02d1390f45c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_5da190c4-8f76-4bdc-8e87-0f0ea6f2a833" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dbb31a3e-27f7-4470-8f26-cdf08e55711e" xlink:to="loc_us-gaap_TreasuryStockCommonMember_5da190c4-8f76-4bdc-8e87-0f0ea6f2a833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_0ecf7799-441c-46db-baa3-e6a9344f4583" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dbb31a3e-27f7-4470-8f26-cdf08e55711e" xlink:to="loc_us-gaap_NoncontrollingInterestMember_0ecf7799-441c-46db-baa3-e6a9344f4583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1bddd27f-3754-4e4b-be68-0f88a1dceaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f9009b58-bced-4106-876e-7a4385805ea9" xlink:to="loc_us-gaap_StatementLineItems_1bddd27f-3754-4e4b-be68-0f88a1dceaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1bddd27f-3754-4e4b-be68-0f88a1dceaf0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8f775658-cc33-4fc6-9472-9eb061cf5b39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8f775658-cc33-4fc6-9472-9eb061cf5b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50a8694f-3f6b-4b2a-9fd4-0865e119e417" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50a8694f-3f6b-4b2a-9fd4-0865e119e417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_0c66fe79-eae1-404a-a898-190890e7a3be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_TreasuryStockCommonShares_0c66fe79-eae1-404a-a898-190890e7a3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f3f722ce-27a9-4ebc-88c4-950a556ebc74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f3f722ce-27a9-4ebc-88c4-950a556ebc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3c03cd7c-79ac-4b98-b30b-30b5b77fb394" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3c03cd7c-79ac-4b98-b30b-30b5b77fb394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f6c722c3-24c5-41b5-969d-9c6b067e4e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f6c722c3-24c5-41b5-969d-9c6b067e4e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3d0d27ff-c24d-47e3-9404-86ab64f4752a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3d0d27ff-c24d-47e3-9404-86ab64f4752a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_e65180e0-ec3e-464f-84fd-cd0962838ead" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_e65180e0-ec3e-464f-84fd-cd0962838ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6cd6bf50-81a4-4e4e-b7dc-f538550f911c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6cd6bf50-81a4-4e4e-b7dc-f538550f911c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c17020fb-4d50-4e96-858c-15efd74a145f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c17020fb-4d50-4e96-858c-15efd74a145f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_35ee9ff0-c789-4ecd-8605-7a301dfbde80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_35ee9ff0-c789-4ecd-8605-7a301dfbde80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_1ad1afaa-debd-43b4-9bf5-12814e9cf1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_1ad1afaa-debd-43b4-9bf5-12814e9cf1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_7487c792-509c-4d43-a137-c7e8bec809bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_7487c792-509c-4d43-a137-c7e8bec809bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_51b9b3e8-2551-4850-8b44-7c9314f5a1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_51b9b3e8-2551-4850-8b44-7c9314f5a1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_113af4a4-9478-41d8-a004-76608b98a325" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_113af4a4-9478-41d8-a004-76608b98a325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_661da765-6d5f-49c9-a23f-80336f143d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_ProfitLoss_661da765-6d5f-49c9-a23f-80336f143d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_695c9f32-0850-405c-a91b-150031ecca93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_695c9f32-0850-405c-a91b-150031ecca93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_23bedabb-2c63-439f-affb-804ebb647d17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_23bedabb-2c63-439f-affb-804ebb647d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_dfb03a61-0e8a-4cbb-ba4d-e27031c06212" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bcd4f89-cbd4-4a65-99c6-6af7c2463e9a" xlink:to="loc_us-gaap_TreasuryStockCommonShares_dfb03a61-0e8a-4cbb-ba4d-e27031c06212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arwr-20250930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_849bf28d-9d31-4de5-a76d-396fdecd0990" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_717e23ad-13ec-4051-9a29-285ad576df4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_849bf28d-9d31-4de5-a76d-396fdecd0990" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_717e23ad-13ec-4051-9a29-285ad576df4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8bcaca15-5eb5-4210-8ef2-8c818c13389e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_717e23ad-13ec-4051-9a29-285ad576df4f" xlink:to="loc_us-gaap_ProfitLoss_8bcaca15-5eb5-4210-8ef2-8c818c13389e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c517ac6d-0895-4e7a-ae7d-0fc346b92cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_717e23ad-13ec-4051-9a29-285ad576df4f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c517ac6d-0895-4e7a-ae7d-0fc346b92cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_adfe5601-24e9-4501-b254-f753b9a6be67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c517ac6d-0895-4e7a-ae7d-0fc346b92cbb" xlink:to="loc_us-gaap_ShareBasedCompensation_adfe5601-24e9-4501-b254-f753b9a6be67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_3221d7ef-bf9e-4415-b0ce-474098385890" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c517ac6d-0895-4e7a-ae7d-0fc346b92cbb" xlink:to="loc_us-gaap_DepreciationAndAmortization_3221d7ef-bf9e-4415-b0ce-474098385890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_82cf2756-f71d-4df7-8ddb-8437cf3055de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c517ac6d-0895-4e7a-ae7d-0fc346b92cbb" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_82cf2756-f71d-4df7-8ddb-8437cf3055de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_4aebcee9-d3b0-4b2f-8d88-7a251df1b7dc" xlink:href="arwr-20250930.xsd#arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c517ac6d-0895-4e7a-ae7d-0fc346b92cbb" xlink:to="loc_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_4aebcee9-d3b0-4b2f-8d88-7a251df1b7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_ad0149cf-d249-4134-8dcd-3794cec18e13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c517ac6d-0895-4e7a-ae7d-0fc346b92cbb" xlink:to="loc_us-gaap_PaidInKindInterest_ad0149cf-d249-4134-8dcd-3794cec18e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GainLossOnTreasuryStockSettlement_4b26e25f-5f06-461e-be40-acb5437913d5" xlink:href="arwr-20250930.xsd#arwr_GainLossOnTreasuryStockSettlement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c517ac6d-0895-4e7a-ae7d-0fc346b92cbb" xlink:to="loc_arwr_GainLossOnTreasuryStockSettlement_4b26e25f-5f06-461e-be40-acb5437913d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_ae2c2f81-0171-403a-9a5f-48aac2853664" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c517ac6d-0895-4e7a-ae7d-0fc346b92cbb" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_ae2c2f81-0171-403a-9a5f-48aac2853664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_01b4d093-963d-4d80-84a1-2b34008c2a71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c517ac6d-0895-4e7a-ae7d-0fc346b92cbb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_01b4d093-963d-4d80-84a1-2b34008c2a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_deb68178-a907-4879-bf29-1e4bace27100" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_01b4d093-963d-4d80-84a1-2b34008c2a71" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_deb68178-a907-4879-bf29-1e4bace27100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_190e3794-b8e9-4b15-86f2-91cdba41a5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_01b4d093-963d-4d80-84a1-2b34008c2a71" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_190e3794-b8e9-4b15-86f2-91cdba41a5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ee56f82d-be03-4a55-9886-d3bc96ca999b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_01b4d093-963d-4d80-84a1-2b34008c2a71" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ee56f82d-be03-4a55-9886-d3bc96ca999b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2ccac776-4b33-43c5-aea1-fbc9cde8a803" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_01b4d093-963d-4d80-84a1-2b34008c2a71" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2ccac776-4b33-43c5-aea1-fbc9cde8a803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7108e873-e53c-4bce-9121-1576f81b4460" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_01b4d093-963d-4d80-84a1-2b34008c2a71" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7108e873-e53c-4bce-9121-1576f81b4460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3e9e6bad-1942-4a4f-a9fe-bbba7e397000" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_01b4d093-963d-4d80-84a1-2b34008c2a71" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3e9e6bad-1942-4a4f-a9fe-bbba7e397000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_d2224197-f560-43d6-868f-29fbad588b76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_01b4d093-963d-4d80-84a1-2b34008c2a71" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_d2224197-f560-43d6-868f-29fbad588b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39d2759a-a264-4c20-8b74-a3e7db2480cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_717e23ad-13ec-4051-9a29-285ad576df4f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39d2759a-a264-4c20-8b74-a3e7db2480cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a1b3e31c-fb3c-488c-a430-dd302df9db30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_849bf28d-9d31-4de5-a76d-396fdecd0990" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a1b3e31c-fb3c-488c-a430-dd302df9db30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f54ed763-1a8b-47f8-8172-9820589f25c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a1b3e31c-fb3c-488c-a430-dd302df9db30" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f54ed763-1a8b-47f8-8172-9820589f25c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_48d47d6c-d0b3-4c03-bf20-1ad61f0d5fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a1b3e31c-fb3c-488c-a430-dd302df9db30" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_48d47d6c-d0b3-4c03-bf20-1ad61f0d5fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_718efd12-a689-4f56-bea3-11add9e17707" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a1b3e31c-fb3c-488c-a430-dd302df9db30" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_718efd12-a689-4f56-bea3-11add9e17707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_466db55e-15fd-4479-933f-a74c88a3e602" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a1b3e31c-fb3c-488c-a430-dd302df9db30" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_466db55e-15fd-4479-933f-a74c88a3e602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6ac3beae-0e99-4d94-8356-ca2536e08cef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_849bf28d-9d31-4de5-a76d-396fdecd0990" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6ac3beae-0e99-4d94-8356-ca2536e08cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c45e0a15-ebe4-4805-9617-3093d093cf52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6ac3beae-0e99-4d94-8356-ca2536e08cef" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c45e0a15-ebe4-4805-9617-3093d093cf52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_87c16f63-4120-4c0d-b1da-3d32ea078e33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6ac3beae-0e99-4d94-8356-ca2536e08cef" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_87c16f63-4120-4c0d-b1da-3d32ea078e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromSaleOfFutureRoyalties_ee8dde77-0de5-4f4b-8933-85ff43bb2ac9" xlink:href="arwr-20250930.xsd#arwr_ProceedsFromSaleOfFutureRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6ac3beae-0e99-4d94-8356-ca2536e08cef" xlink:to="loc_arwr_ProceedsFromSaleOfFutureRoyalties_ee8dde77-0de5-4f4b-8933-85ff43bb2ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_07e9f2fd-0ebe-4be7-831c-86e943e50052" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6ac3beae-0e99-4d94-8356-ca2536e08cef" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_07e9f2fd-0ebe-4be7-831c-86e943e50052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b98894cb-88aa-41ad-8a71-c05e556bda10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6ac3beae-0e99-4d94-8356-ca2536e08cef" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b98894cb-88aa-41ad-8a71-c05e556bda10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_326016aa-eb1c-4ed8-87d0-669815bc9b63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6ac3beae-0e99-4d94-8356-ca2536e08cef" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_326016aa-eb1c-4ed8-87d0-669815bc9b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_c803ca78-b802-4874-8a80-5a8442a6da66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6ac3beae-0e99-4d94-8356-ca2536e08cef" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_c803ca78-b802-4874-8a80-5a8442a6da66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_5dfd7d2b-4ec9-425b-8778-a589bd9d6542" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6ac3beae-0e99-4d94-8356-ca2536e08cef" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_5dfd7d2b-4ec9-425b-8778-a589bd9d6542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_796570f6-1e75-4292-b745-d3011711ba49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6ac3beae-0e99-4d94-8356-ca2536e08cef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_796570f6-1e75-4292-b745-d3011711ba49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_4f8baa7f-77f5-4f74-8791-35e6f2642434" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_849bf28d-9d31-4de5-a76d-396fdecd0990" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_4f8baa7f-77f5-4f74-8791-35e6f2642434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bb0aaae9-43ea-4c61-9f1a-d8baad36e4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_849bf28d-9d31-4de5-a76d-396fdecd0990" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bb0aaae9-43ea-4c61-9f1a-d8baad36e4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_ddf98dca-91ba-48b9-9834-a8f284b1f073" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_849bf28d-9d31-4de5-a76d-396fdecd0990" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_ddf98dca-91ba-48b9-9834-a8f284b1f073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f63db2da-c562-424c-9c68-89ceb78be594" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_ddf98dca-91ba-48b9-9834-a8f284b1f073" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f63db2da-c562-424c-9c68-89ceb78be594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b4806fc2-35e8-46e6-b6ba-e92a635727bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_ddf98dca-91ba-48b9-9834-a8f284b1f073" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b4806fc2-35e8-46e6-b6ba-e92a635727bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_33ab64df-53a1-4e5c-b6a7-d7cfa49be3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_849bf28d-9d31-4de5-a76d-396fdecd0990" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_33ab64df-53a1-4e5c-b6a7-d7cfa49be3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_e087a51e-c65b-459f-828e-ed0709614f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_33ab64df-53a1-4e5c-b6a7-d7cfa49be3b8" xlink:to="loc_us-gaap_InterestPaidNet_e087a51e-c65b-459f-828e-ed0709614f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_b73bbf3a-e775-4ba0-b493-8ba872ea9064" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_33ab64df-53a1-4e5c-b6a7-d7cfa49be3b8" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_b73bbf3a-e775-4ba0-b493-8ba872ea9064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable_829b9661-d0c3-49a6-a099-a91d604355b8" xlink:href="arwr-20250930.xsd#arwr_TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_33ab64df-53a1-4e5c-b6a7-d7cfa49be3b8" xlink:to="loc_arwr_TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable_829b9661-d0c3-49a6-a099-a91d604355b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract_4ba1263e-edcb-46a6-85c4-7d4f5e5c53a8" xlink:href="arwr-20250930.xsd#arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_849bf28d-9d31-4de5-a76d-396fdecd0990" xlink:to="loc_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract_4ba1263e-edcb-46a6-85c4-7d4f5e5c53a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4c2ddb53-13ff-4e8d-a28a-a2f37ab126e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract_4ba1263e-edcb-46a6-85c4-7d4f5e5c53a8" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4c2ddb53-13ff-4e8d-a28a-a2f37ab126e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="arwr-20250930.xsd#OrganizationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_38f3593e-0889-4834-a241-acf0bb4bf5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1fb18187-b140-417f-bbe7-7c7c2898ad97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38f3593e-0889-4834-a241-acf0bb4bf5c0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1fb18187-b140-417f-bbe7-7c7c2898ad97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="arwr-20250930.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_9e27d51c-e03f-4399-8f40-5dcb26eb8b64" xlink:href="arwr-20250930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2510dca3-6876-4b6a-bea4-fc52d5b6971e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_9e27d51c-e03f-4399-8f40-5dcb26eb8b64" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2510dca3-6876-4b6a-bea4-fc52d5b6971e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccounts" xlink:type="simple" xlink:href="arwr-20250930.xsd#BalanceSheetAccounts"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccounts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c15e8c30-b2e9-4d83-9d4d-06716fdc5872" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_6df5661c-7dff-4e48-ab75-8a610beccb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c15e8c30-b2e9-4d83-9d4d-06716fdc5872" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_6df5661c-7dff-4e48-ab75-8a610beccb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Investments" xlink:type="simple" xlink:href="arwr-20250930.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b6ee4d42-286a-4b60-8cd3-fc9d5db794b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_3dfd9176-7f56-4cee-bedc-d35a955503e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b6ee4d42-286a-4b60-8cd3-fc9d5db794b3" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_3dfd9176-7f56-4cee-bedc-d35a955503e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssets" xlink:type="simple" xlink:href="arwr-20250930.xsd#IntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2bb6eae3-387c-4361-be4f-69c433e02248" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_f1ef4c10-0539-40a6-9f79-57ee1f3d8028" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2bb6eae3-387c-4361-be4f-69c433e02248" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_f1ef4c10-0539-40a6-9f79-57ee1f3d8028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquity" xlink:type="simple" xlink:href="arwr-20250930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6930e370-00e3-4ec7-bbb7-e3cd43aa5be4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2cbaf3b8-fe5e-43a7-a1d6-811c7a21c436" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6930e370-00e3-4ec7-bbb7-e3cd43aa5be4" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2cbaf3b8-fe5e-43a7-a1d6-811c7a21c436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="arwr-20250930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_091aa519-763c-47d5-bc61-12826a0d48b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e9886d10-081e-4005-9836-a215703afa63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_091aa519-763c-47d5-bc61-12826a0d48b5" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e9886d10-081e-4005-9836-a215703afa63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Leases" xlink:type="simple" xlink:href="arwr-20250930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_441e1a60-2d29-4078-8f43-57799072ad02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_a822c2f9-6ab1-4589-85a7-c18c32a6e6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_441e1a60-2d29-4078-8f43-57799072ad02" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_a822c2f9-6ab1-4589-85a7-c18c32a6e6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="arwr-20250930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4acb953a-494f-4476-9cc8-2276c5827225" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d5bf21c2-8a28-43c6-85b2-38fcfdcbcaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4acb953a-494f-4476-9cc8-2276c5827225" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d5bf21c2-8a28-43c6-85b2-38fcfdcbcaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="arwr-20250930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7b64f163-abfb-4223-93db-6e5d1f1a77b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_4a9f1b64-9579-4420-a215-9aee35f50426" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7b64f163-abfb-4223-93db-6e5d1f1a77b0" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_4a9f1b64-9579-4420-a215-9aee35f50426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxes" xlink:type="simple" xlink:href="arwr-20250930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1095b924-80c8-4510-8d13-1bf1bf5b4074" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_66f4d8ea-2427-4e81-8f24-a1799816ae0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1095b924-80c8-4510-8d13-1bf1bf5b4074" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_66f4d8ea-2427-4e81-8f24-a1799816ae0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="arwr-20250930.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_90c83835-6b25-4845-b8b0-41679466953a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_6c19a73c-bdc8-471d-a9ec-abd96ba94554" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_90c83835-6b25-4845-b8b0-41679466953a" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_6c19a73c-bdc8-471d-a9ec-abd96ba94554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties" xlink:type="simple" xlink:href="arwr-20250930.xsd#LiabilityRelatedtotheSaleofFutureRoyalties"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_0270085a-ac06-4615-ae4e-0cb8da2b360c" xlink:href="arwr-20250930.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_bf89d204-27d8-4df1-8631-386f3dfc2d81" xlink:href="arwr-20250930.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_0270085a-ac06-4615-ae4e-0cb8da2b360c" xlink:to="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_bf89d204-27d8-4df1-8631-386f3dfc2d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreement" xlink:type="simple" xlink:href="arwr-20250930.xsd#FinancingAgreement"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f02c20ce-6292-4d4a-9e8b-4323006da86e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_b75a958f-1dfd-49de-8097-89d118a43071" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f02c20ce-6292-4d4a-9e8b-4323006da86e" xlink:to="loc_us-gaap_LongTermDebtTextBlock_b75a958f-1dfd-49de-8097-89d118a43071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/NetLossPerShare" xlink:type="simple" xlink:href="arwr-20250930.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e4fd1565-57ca-4cfc-a291-f7c07864bb86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_83273323-4928-4faa-9369-1a72318e026f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e4fd1565-57ca-4cfc-a291-f7c07864bb86" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_83273323-4928-4faa-9369-1a72318e026f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/SegmentInformation" xlink:type="simple" xlink:href="arwr-20250930.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e9d83f58-46b0-4e58-a714-f0c46dc489bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_e78f1939-39ad-49ae-996a-107f8cfcddb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e9d83f58-46b0-4e58-a714-f0c46dc489bc" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_e78f1939-39ad-49ae-996a-107f8cfcddb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/SubsequentEvents" xlink:type="simple" xlink:href="arwr-20250930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3ca270f8-599f-4ca9-8205-24a5279a71d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_68eeee84-900d-40a5-bfc0-dc75942d896b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3ca270f8-599f-4ca9-8205-24a5279a71d4" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_68eeee84-900d-40a5-bfc0-dc75942d896b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="arwr-20250930.xsd#OrganizationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_69c7f8ed-8528-46b0-9e34-e91eeee68d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_799c68f5-c62d-4081-a5cd-d84d61b651cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69c7f8ed-8528-46b0-9e34-e91eeee68d5e" xlink:to="loc_us-gaap_UseOfEstimates_799c68f5-c62d-4081-a5cd-d84d61b651cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0b0662a3-e96f-456f-82e3-2256644c4aec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69c7f8ed-8528-46b0-9e34-e91eeee68d5e" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0b0662a3-e96f-456f-82e3-2256644c4aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_ec141437-b33d-4823-88b0-3ccdf2c21271" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69c7f8ed-8528-46b0-9e34-e91eeee68d5e" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_ec141437-b33d-4823-88b0-3ccdf2c21271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_d2b3b871-ffe2-488d-8cea-7e547cf3ce2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69c7f8ed-8528-46b0-9e34-e91eeee68d5e" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_d2b3b871-ffe2-488d-8cea-7e547cf3ce2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_82e7d6eb-a946-4615-a75d-296174021fca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69c7f8ed-8528-46b0-9e34-e91eeee68d5e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_82e7d6eb-a946-4615-a75d-296174021fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_86732d8a-6281-43ca-b092-99dcb5bac87c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69c7f8ed-8528-46b0-9e34-e91eeee68d5e" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_86732d8a-6281-43ca-b092-99dcb5bac87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_8a4c5c15-7f78-455c-b9ce-109c91401d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69c7f8ed-8528-46b0-9e34-e91eeee68d5e" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_8a4c5c15-7f78-455c-b9ce-109c91401d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ClinicalAccrualPolicyPolicyTextBlock_a35a2049-8104-4a5f-9879-5a060b645831" xlink:href="arwr-20250930.xsd#arwr_ClinicalAccrualPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69c7f8ed-8528-46b0-9e34-e91eeee68d5e" xlink:to="loc_arwr_ClinicalAccrualPolicyPolicyTextBlock_a35a2049-8104-4a5f-9879-5a060b645831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_83b15df0-3a65-4138-b739-659c7e32fddf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69c7f8ed-8528-46b0-9e34-e91eeee68d5e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_83b15df0-3a65-4138-b739-659c7e32fddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_af7dbaa7-1fe5-4cc5-95bf-5c9fdff411dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69c7f8ed-8528-46b0-9e34-e91eeee68d5e" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_af7dbaa7-1fe5-4cc5-95bf-5c9fdff411dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e54b8794-f0cb-456e-81b3-75a1dfa6525d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69c7f8ed-8528-46b0-9e34-e91eeee68d5e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e54b8794-f0cb-456e-81b3-75a1dfa6525d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_570926ad-0bc8-4820-9425-b7759534f3db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69c7f8ed-8528-46b0-9e34-e91eeee68d5e" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_570926ad-0bc8-4820-9425-b7759534f3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_bc9c05a9-e3d4-4148-aca0-3326a7ecf061" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69c7f8ed-8528-46b0-9e34-e91eeee68d5e" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_bc9c05a9-e3d4-4148-aca0-3326a7ecf061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_fa99b347-ac06-47a5-bec4-6de6a8b206c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69c7f8ed-8528-46b0-9e34-e91eeee68d5e" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_fa99b347-ac06-47a5-bec4-6de6a8b206c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_0a7ee7c4-b3fc-4a2b-aa34-234e15cfb657" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69c7f8ed-8528-46b0-9e34-e91eeee68d5e" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_0a7ee7c4-b3fc-4a2b-aa34-234e15cfb657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_fb23d983-8492-4fbb-a479-853df3f0e6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69c7f8ed-8528-46b0-9e34-e91eeee68d5e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_fb23d983-8492-4fbb-a479-853df3f0e6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_e5b6ba48-91d4-4e2f-ac54-4358a97935e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69c7f8ed-8528-46b0-9e34-e91eeee68d5e" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_e5b6ba48-91d4-4e2f-ac54-4358a97935e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8d66d676-aa49-41df-8ae8-978a0304c060" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_69c7f8ed-8528-46b0-9e34-e91eeee68d5e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8d66d676-aa49-41df-8ae8-978a0304c060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="arwr-20250930.xsd#OrganizationandSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_402ac498-0c5c-4351-b2e3-5d5c98163582" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfCurrentProductsTableTextBlock_6dc71854-d802-4c31-996f-b6511ea54f27" xlink:href="arwr-20250930.xsd#arwr_ScheduleOfCurrentProductsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_402ac498-0c5c-4351-b2e3-5d5c98163582" xlink:to="loc_arwr_ScheduleOfCurrentProductsTableTextBlock_6dc71854-d802-4c31-996f-b6511ea54f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_dc30212b-926d-4c97-ad04-affa8ba8acdf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_402ac498-0c5c-4351-b2e3-5d5c98163582" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_dc30212b-926d-4c97-ad04-affa8ba8acdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="arwr-20250930.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_98a8a8c9-195a-48c3-963d-c8096568de11" xlink:href="arwr-20250930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_b3584489-513e-4d23-ae04-79feede98437" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_98a8a8c9-195a-48c3-963d-c8096568de11" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_b3584489-513e-4d23-ae04-79feede98437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_700043e3-37c8-4ea2-a8ea-c4657df5cbce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_98a8a8c9-195a-48c3-963d-c8096568de11" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_700043e3-37c8-4ea2-a8ea-c4657df5cbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables" xlink:type="simple" xlink:href="arwr-20250930.xsd#BalanceSheetAccountsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2cedd51d-b0b1-4206-9ecd-ff50bd5e1475" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_def881b0-c917-49a7-a69a-42801f7674a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2cedd51d-b0b1-4206-9ecd-ff50bd5e1475" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_def881b0-c917-49a7-a69a-42801f7674a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_71139994-c1bb-42a1-a93a-a968df506356" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2cedd51d-b0b1-4206-9ecd-ff50bd5e1475" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_71139994-c1bb-42a1-a93a-a968df506356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsTables" xlink:type="simple" xlink:href="arwr-20250930.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2f2fd9d3-f928-49df-bbd2-36948febdf00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_fe0b491b-8d75-41bc-bf75-88b49f9e0761" xlink:href="arwr-20250930.xsd#arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2f2fd9d3-f928-49df-bbd2-36948febdf00" xlink:to="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_fe0b491b-8d75-41bc-bf75-88b49f9e0761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_8552d456-39f7-4579-bb72-e249ceceeb21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2f2fd9d3-f928-49df-bbd2-36948febdf00" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_8552d456-39f7-4579-bb72-e249ceceeb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="arwr-20250930.xsd#IntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_16a86f6d-2c69-4fc9-bdd1-790d67c1f29e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a74460ae-05fe-471c-8fb7-f7e7d6b666d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_16a86f6d-2c69-4fc9-bdd1-790d67c1f29e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a74460ae-05fe-471c-8fb7-f7e7d6b666d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_57d952e4-f68c-4358-b7d6-efd2eca5d534" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_16a86f6d-2c69-4fc9-bdd1-790d67c1f29e" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_57d952e4-f68c-4358-b7d6-efd2eca5d534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="arwr-20250930.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_be1aab2e-444f-40cf-995c-040f027a3a29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_a5d92921-da8f-4cb4-88d3-52470994529c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_be1aab2e-444f-40cf-995c-040f027a3a29" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_a5d92921-da8f-4cb4-88d3-52470994529c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesTables" xlink:type="simple" xlink:href="arwr-20250930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c0cbf1bf-6792-4ad6-9b67-6e582d83175c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_cf5d18a1-7fe4-43e5-b6b9-df01e4dacde9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c0cbf1bf-6792-4ad6-9b67-6e582d83175c" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_cf5d18a1-7fe4-43e5-b6b9-df01e4dacde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_72a0a23f-4ac6-4b39-a68c-4404b348b703" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c0cbf1bf-6792-4ad6-9b67-6e582d83175c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_72a0a23f-4ac6-4b39-a68c-4404b348b703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="arwr-20250930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5728bc3-cc5c-46ec-8e78-cd370024e2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_6096a69e-89db-44c3-8a12-6ff55dc06921" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5728bc3-cc5c-46ec-8e78-cd370024e2b8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_6096a69e-89db-44c3-8a12-6ff55dc06921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1718f102-6235-436b-8512-913f9a473631" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5728bc3-cc5c-46ec-8e78-cd370024e2b8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1718f102-6235-436b-8512-913f9a473631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_16b6a527-bcd1-4696-90f3-590d02f906cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5728bc3-cc5c-46ec-8e78-cd370024e2b8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_16b6a527-bcd1-4696-90f3-590d02f906cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ab4df0c6-b2e2-4bca-873e-824d46a4b3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5728bc3-cc5c-46ec-8e78-cd370024e2b8" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ab4df0c6-b2e2-4bca-873e-824d46a4b3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_72e77d7f-14b8-4bf8-b2c0-b711f693965c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5728bc3-cc5c-46ec-8e78-cd370024e2b8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_72e77d7f-14b8-4bf8-b2c0-b711f693965c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="arwr-20250930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a930734e-52e9-44cc-93ab-8db78341ddfc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5da6d318-1c41-4bbb-8ba7-140dd2dce454" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a930734e-52e9-44cc-93ab-8db78341ddfc" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5da6d318-1c41-4bbb-8ba7-140dd2dce454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="arwr-20250930.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_39a2a493-860a-4a84-8708-3b6bc4c20882" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_96f4f0fd-7941-4abf-89a8-06410a74de47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_39a2a493-860a-4a84-8708-3b6bc4c20882" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_96f4f0fd-7941-4abf-89a8-06410a74de47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_34f5b756-0810-4ba8-ac44-e3c047c5a16c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_39a2a493-860a-4a84-8708-3b6bc4c20882" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_34f5b756-0810-4ba8-ac44-e3c047c5a16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_79098040-69be-4c22-a958-0b022470d1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_39a2a493-860a-4a84-8708-3b6bc4c20882" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_79098040-69be-4c22-a958-0b022470d1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_55b9a400-4655-4990-ab10-d3ba1af55208" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_39a2a493-860a-4a84-8708-3b6bc4c20882" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_55b9a400-4655-4990-ab10-d3ba1af55208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_c9f90aa0-20a4-4e2e-a6bb-59c02d167c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_39a2a493-860a-4a84-8708-3b6bc4c20882" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_c9f90aa0-20a4-4e2e-a6bb-59c02d167c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables" xlink:type="simple" xlink:href="arwr-20250930.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_9ca4aeae-bb7d-498a-afd5-aad7cc3a12dc" xlink:href="arwr-20250930.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock_20b1033c-5b87-4c3b-afad-23679b3fdbf9" xlink:href="arwr-20250930.xsd#arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_9ca4aeae-bb7d-498a-afd5-aad7cc3a12dc" xlink:to="loc_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock_20b1033c-5b87-4c3b-afad-23679b3fdbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementTables" xlink:type="simple" xlink:href="arwr-20250930.xsd#FinancingAgreementTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_27199852-7b84-4734-8489-dcd2dcff6c48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_d4fbeba6-b541-416c-9cc7-0bdd4b7cd4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_27199852-7b84-4734-8489-dcd2dcff6c48" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_d4fbeba6-b541-416c-9cc7-0bdd4b7cd4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock_e81bb01b-afc1-4614-b244-6756ed3f7761" xlink:href="arwr-20250930.xsd#arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_27199852-7b84-4734-8489-dcd2dcff6c48" xlink:to="loc_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock_e81bb01b-afc1-4614-b244-6756ed3f7761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_6e4239b6-0cd5-45d2-9bc6-d170b68adb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_27199852-7b84-4734-8489-dcd2dcff6c48" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_6e4239b6-0cd5-45d2-9bc6-d170b68adb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="arwr-20250930.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fc00d53f-4e3d-479d-b99f-a3c94ef7bd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_39878066-332b-4e0d-9233-3c39a526d5da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc00d53f-4e3d-479d-b99f-a3c94ef7bd1d" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_39878066-332b-4e0d-9233-3c39a526d5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_17ad59ca-ec32-4956-9c87-3159d7045108" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc00d53f-4e3d-479d-b99f-a3c94ef7bd1d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_17ad59ca-ec32-4956-9c87-3159d7045108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="arwr-20250930.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6b51509c-afc1-49d6-816b-7d138b73abb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_f889a38d-5cef-4b10-9702-6966e9a94e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6b51509c-afc1-49d6-816b-7d138b73abb2" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_f889a38d-5cef-4b10-9702-6966e9a94e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#OrganizationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a0dd7abf-d2d3-4e8d-baff-a3db9d6bd19c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_fe516f51-7c96-40a6-8c1c-25f82683fb3f" xlink:href="arwr-20250930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0dd7abf-d2d3-4e8d-baff-a3db9d6bd19c" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_fe516f51-7c96-40a6-8c1c-25f82683fb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_77630827-c4ae-4539-b85a-9e4786932609" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_fe516f51-7c96-40a6-8c1c-25f82683fb3f" xlink:to="loc_srt_CounterpartyNameAxis_77630827-c4ae-4539-b85a-9e4786932609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7dfb9ec2-96f6-4e31-95c0-ced67148795c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_77630827-c4ae-4539-b85a-9e4786932609" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7dfb9ec2-96f6-4e31-95c0-ced67148795c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaTherapeuticsIncMember_53c13c99-e3dd-4848-ac37-5083fb13a5da" xlink:href="arwr-20250930.xsd#arwr_SareptaTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7dfb9ec2-96f6-4e31-95c0-ced67148795c" xlink:to="loc_arwr_SareptaTherapeuticsIncMember_53c13c99-e3dd-4848-ac37-5083fb13a5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6280b43f-e924-4a31-a55b-f78b0df63744" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_fe516f51-7c96-40a6-8c1c-25f82683fb3f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6280b43f-e924-4a31-a55b-f78b0df63744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9b8f9b6c-3d3e-4d48-9644-3595154c1cec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6280b43f-e924-4a31-a55b-f78b0df63744" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9b8f9b6c-3d3e-4d48-9644-3595154c1cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember_9457cf31-d8ca-43f6-9a71-1122898cbf5c" xlink:href="arwr-20250930.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9b8f9b6c-3d3e-4d48-9644-3595154c1cec" xlink:to="loc_arwr_SareptaCollaborationAgreementMember_9457cf31-d8ca-43f6-9a71-1122898cbf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4c419ba5-fb43-478c-91c6-1c225968ecb2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_fe516f51-7c96-40a6-8c1c-25f82683fb3f" xlink:to="loc_srt_RangeAxis_4c419ba5-fb43-478c-91c6-1c225968ecb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dfa51520-56ba-461d-a7a2-42751dacb739" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4c419ba5-fb43-478c-91c6-1c225968ecb2" xlink:to="loc_srt_RangeMember_dfa51520-56ba-461d-a7a2-42751dacb739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_734dd71e-afeb-4370-98ab-5ffd91d28d09" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dfa51520-56ba-461d-a7a2-42751dacb739" xlink:to="loc_srt_MaximumMember_734dd71e-afeb-4370-98ab-5ffd91d28d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:href="arwr-20250930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_fe516f51-7c96-40a6-8c1c-25f82683fb3f" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9369036c-d470-4e13-870c-a586d7acdc21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9369036c-d470-4e13-870c-a586d7acdc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_e11ad80e-c0af-4304-b7d3-69f49d544319" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_e11ad80e-c0af-4304-b7d3-69f49d544319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c1eed621-c31f-45a7-b49b-ecacd590bf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c1eed621-c31f-45a7-b49b-ecacd590bf2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments_fa5fbc42-65dc-4d72-a70f-0031e42c8869" xlink:href="arwr-20250930.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_arwr_IncreaseDecreaseInCashAndInvestments_fa5fbc42-65dc-4d72-a70f-0031e42c8869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements_053a95ab-b19f-4705-953e-84f5d32bfec1" xlink:href="arwr-20250930.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_arwr_ProceedsFromCollaborationArrangements_053a95ab-b19f-4705-953e-84f5d32bfec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0fa501bc-e43f-4993-9111-cf28651ad9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0fa501bc-e43f-4993-9111-cf28651ad9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentMilestonePayments_c05c7b8e-e0c2-4cb5-a72a-aa7ded511858" xlink:href="arwr-20250930.xsd#arwr_DevelopmentMilestonePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_arwr_DevelopmentMilestonePayments_c05c7b8e-e0c2-4cb5-a72a-aa7ded511858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ccd857e6-5bd0-44fd-aa0c-ba6faea35b52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ccd857e6-5bd0-44fd-aa0c-ba6faea35b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_b7fa4a72-7d0c-4b57-b71a-dc9999198374" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_b7fa4a72-7d0c-4b57-b71a-dc9999198374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_de930d23-bffb-4405-92ba-7b60a1fbf9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_de930d23-bffb-4405-92ba-7b60a1fbf9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_10f28174-db09-4709-a231-ebf674cda9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_10f28174-db09-4709-a231-ebf674cda9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a41fc752-8d8a-4cf0-b834-a0d5e337fa4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a41fc752-8d8a-4cf0-b834-a0d5e337fa4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_194abf4b-bcb1-4ab6-bded-7212d84b6f4f" xlink:href="arwr-20250930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_194abf4b-bcb1-4ab6-bded-7212d84b6f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1962ed40-a334-4636-8490-5fa508d3e032" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1962ed40-a334-4636-8490-5fa508d3e032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency_1244d564-014a-4355-870a-2a850c3f5b79" xlink:href="arwr-20250930.xsd#arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency_1244d564-014a-4355-870a-2a850c3f5b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_97a53544-10cf-4d56-9b98-6617728a6f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_6474f7e8-7d53-4c4d-b5a5-cdf0f583a8ff" xlink:to="loc_us-gaap_NumberOfOperatingSegments_97a53544-10cf-4d56-9b98-6617728a6f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_eb04d39e-ec0d-47b8-b8dc-dfd6c40145c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_744e4e62-6fb4-404c-9f2e-d0369770f792" xlink:href="arwr-20250930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb04d39e-ec0d-47b8-b8dc-dfd6c40145c3" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_744e4e62-6fb4-404c-9f2e-d0369770f792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2f388199-c08f-468d-85ee-d5af5492d1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_744e4e62-6fb4-404c-9f2e-d0369770f792" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2f388199-c08f-468d-85ee-d5af5492d1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0da545ab-1929-4fcd-8b4c-c8a3e5e4f15f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2f388199-c08f-468d-85ee-d5af5492d1d2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0da545ab-1929-4fcd-8b4c-c8a3e5e4f15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_9a9010b9-4147-4512-a170-25c320c74210" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0da545ab-1929-4fcd-8b4c-c8a3e5e4f15f" xlink:to="loc_us-gaap_BuildingMember_9a9010b9-4147-4512-a170-25c320c74210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentMember_a1aee41f-c85c-4143-ab6f-ac9f66a0946c" xlink:href="arwr-20250930.xsd#arwr_ResearchEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0da545ab-1929-4fcd-8b4c-c8a3e5e4f15f" xlink:to="loc_arwr_ResearchEquipmentMember_a1aee41f-c85c-4143-ab6f-ac9f66a0946c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ManufacturingEquipmentMember_23547b56-c3da-4e04-a21d-dec331447885" xlink:href="arwr-20250930.xsd#arwr_ManufacturingEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0da545ab-1929-4fcd-8b4c-c8a3e5e4f15f" xlink:to="loc_arwr_ManufacturingEquipmentMember_23547b56-c3da-4e04-a21d-dec331447885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d39b063f-9ae5-4594-9ac4-ecca8385c06e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0da545ab-1929-4fcd-8b4c-c8a3e5e4f15f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d39b063f-9ae5-4594-9ac4-ecca8385c06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputersAndSoftwareMember_a403fb3a-64ba-4b88-b1d9-5a692299a266" xlink:href="arwr-20250930.xsd#arwr_ComputersAndSoftwareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0da545ab-1929-4fcd-8b4c-c8a3e5e4f15f" xlink:to="loc_arwr_ComputersAndSoftwareMember_a403fb3a-64ba-4b88-b1d9-5a692299a266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cde9d0d6-d539-420e-997f-eccf2c3cdf03" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_744e4e62-6fb4-404c-9f2e-d0369770f792" xlink:to="loc_srt_RangeAxis_cde9d0d6-d539-420e-997f-eccf2c3cdf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3f71d631-21e6-4222-854d-4ba6fc528ad3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cde9d0d6-d539-420e-997f-eccf2c3cdf03" xlink:to="loc_srt_RangeMember_3f71d631-21e6-4222-854d-4ba6fc528ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2e7700b9-21b2-45a1-aa55-7e11c5ed75de" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3f71d631-21e6-4222-854d-4ba6fc528ad3" xlink:to="loc_srt_MinimumMember_2e7700b9-21b2-45a1-aa55-7e11c5ed75de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_da19a526-bcf9-4223-9177-4f31f784146d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3f71d631-21e6-4222-854d-4ba6fc528ad3" xlink:to="loc_srt_MaximumMember_da19a526-bcf9-4223-9177-4f31f784146d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_ce1b64c6-5d81-4744-b399-c519ab4efd64" xlink:href="arwr-20250930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_744e4e62-6fb4-404c-9f2e-d0369770f792" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_ce1b64c6-5d81-4744-b399-c519ab4efd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d021194f-ae2d-41bf-9d65-b3768e4db0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_ce1b64c6-5d81-4744-b399-c519ab4efd64" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d021194f-ae2d-41bf-9d65-b3768e4db0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#CollaborationandLicenseAgreementsRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_6f773894-af37-4747-8244-12ad973236fd" xlink:href="arwr-20250930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a0097fc4-ec1d-4f9f-87d6-aed5b9d3c8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_6f773894-af37-4747-8244-12ad973236fd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a0097fc4-ec1d-4f9f-87d6-aed5b9d3c8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0193a116-1a01-4a5a-b9de-e43df8043361" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a0097fc4-ec1d-4f9f-87d6-aed5b9d3c8ac" xlink:to="loc_srt_MajorCustomersAxis_0193a116-1a01-4a5a-b9de-e43df8043361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7f041358-3a6e-47cd-b27b-5e0dcf482c55" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_0193a116-1a01-4a5a-b9de-e43df8043361" xlink:to="loc_srt_NameOfMajorCustomerDomain_7f041358-3a6e-47cd-b27b-5e0dcf482c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_bf65c8c9-8724-4f4b-9e35-1e3af8e8ea7b" xlink:href="arwr-20250930.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7f041358-3a6e-47cd-b27b-5e0dcf482c55" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_bf65c8c9-8724-4f4b-9e35-1e3af8e8ea7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_03bf59d7-3d40-4de4-b0f6-6a4d5fe02b9e" xlink:href="arwr-20250930.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7f041358-3a6e-47cd-b27b-5e0dcf482c55" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_03bf59d7-3d40-4de4-b0f6-6a4d5fe02b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_891295d2-ef13-43fb-a33c-7c799713e7ef" xlink:href="arwr-20250930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7f041358-3a6e-47cd-b27b-5e0dcf482c55" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_891295d2-ef13-43fb-a33c-7c799713e7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_39bd0565-c2bb-49e0-be52-44bf54606ec7" xlink:href="arwr-20250930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7f041358-3a6e-47cd-b27b-5e0dcf482c55" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_39bd0565-c2bb-49e0-be52-44bf54606ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_aaee492c-ea76-4b75-a5ae-90742f8f96c7" xlink:href="arwr-20250930.xsd#arwr_AmgenIncorporatedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7f041358-3a6e-47cd-b27b-5e0dcf482c55" xlink:to="loc_arwr_AmgenIncorporatedMember_aaee492c-ea76-4b75-a5ae-90742f8f96c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaTherapeuticsIncMember_0a814486-2d3e-4488-ad8f-4ed63a595a9a" xlink:href="arwr-20250930.xsd#arwr_SareptaTherapeuticsIncMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7f041358-3a6e-47cd-b27b-5e0dcf482c55" xlink:to="loc_arwr_SareptaTherapeuticsIncMember_0a814486-2d3e-4488-ad8f-4ed63a595a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SanofiMember_7f7588f2-d06c-495d-8af6-66d8e93614a9" xlink:href="arwr-20250930.xsd#arwr_SanofiMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7f041358-3a6e-47cd-b27b-5e0dcf482c55" xlink:to="loc_arwr_SanofiMember_7f7588f2-d06c-495d-8af6-66d8e93614a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a42c146a-cf45-4bd0-8219-d22887fddb97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a0097fc4-ec1d-4f9f-87d6-aed5b9d3c8ac" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a42c146a-cf45-4bd0-8219-d22887fddb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_09cb06c1-833c-4eee-86b8-2bd62a441e91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a42c146a-cf45-4bd0-8219-d22887fddb97" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_09cb06c1-833c-4eee-86b8-2bd62a441e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_52b49dbc-5b99-443d-a52f-d3d1af33e8e1" xlink:href="arwr-20250930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_564ccc02-ed9d-46e9-a552-bab8b5851f08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_52b49dbc-5b99-443d-a52f-d3d1af33e8e1" xlink:to="loc_us-gaap_AccountsReceivableNet_564ccc02-ed9d-46e9-a552-bab8b5851f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9f8bd4af-aab8-45f0-bc83-e36bffb66abd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_52b49dbc-5b99-443d-a52f-d3d1af33e8e1" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9f8bd4af-aab8-45f0-bc83-e36bffb66abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_bdb7221a-4e58-4b96-b1ff-f586341a987e" xlink:href="arwr-20250930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1b8d32d-8eaf-4d34-af2d-175b32305b03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_bdb7221a-4e58-4b96-b1ff-f586341a987e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1b8d32d-8eaf-4d34-af2d-175b32305b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8bfc3111-826b-4a32-a420-7fba8e9ef6f3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1b8d32d-8eaf-4d34-af2d-175b32305b03" xlink:to="loc_srt_CounterpartyNameAxis_8bfc3111-826b-4a32-a420-7fba8e9ef6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e64ed03-1ef0-446c-807f-306112fc5966" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8bfc3111-826b-4a32-a420-7fba8e9ef6f3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e64ed03-1ef0-446c-807f-306112fc5966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_6610a086-9466-4159-9436-88ddef9a17c3" xlink:href="arwr-20250930.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e64ed03-1ef0-446c-807f-306112fc5966" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_6610a086-9466-4159-9436-88ddef9a17c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d19965e3-e171-43ea-b1fe-4269aba21e57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1b8d32d-8eaf-4d34-af2d-175b32305b03" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d19965e3-e171-43ea-b1fe-4269aba21e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25d44238-cbd9-461e-8e2e-ececa5aa11f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d19965e3-e171-43ea-b1fe-4269aba21e57" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25d44238-cbd9-461e-8e2e-ececa5aa11f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GSKHSDLicenseAgreementMember_01f808ef-e25a-4c24-a1e5-252c70430e17" xlink:href="arwr-20250930.xsd#arwr_GSKHSDLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25d44238-cbd9-461e-8e2e-ececa5aa11f4" xlink:to="loc_arwr_GSKHSDLicenseAgreementMember_01f808ef-e25a-4c24-a1e5-252c70430e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GSKHBVAgreementMember_61774c21-88dc-42ba-83cd-ad934d7f6b67" xlink:href="arwr-20250930.xsd#arwr_GSKHBVAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25d44238-cbd9-461e-8e2e-ececa5aa11f4" xlink:to="loc_arwr_GSKHBVAgreementMember_61774c21-88dc-42ba-83cd-ad934d7f6b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c1296aec-378a-4917-ad1e-1b32c2c5a710" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1b8d32d-8eaf-4d34-af2d-175b32305b03" xlink:to="loc_srt_RangeAxis_c1296aec-378a-4917-ad1e-1b32c2c5a710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3f0a1093-d982-49e0-986f-cb5b3da90f59" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c1296aec-378a-4917-ad1e-1b32c2c5a710" xlink:to="loc_srt_RangeMember_3f0a1093-d982-49e0-986f-cb5b3da90f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_83117b27-fa13-448b-a602-7ad86a7c169e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3f0a1093-d982-49e0-986f-cb5b3da90f59" xlink:to="loc_srt_MaximumMember_83117b27-fa13-448b-a602-7ad86a7c169e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1b8d32d-8eaf-4d34-af2d-175b32305b03" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_b4e18a3c-89a8-4c3c-8b2c-655ffd3ad7b6" xlink:href="arwr-20250930.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_arwr_InitialTransactionPrice_b4e18a3c-89a8-4c3c-8b2c-655ffd3ad7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_0d7b6913-6f5f-4ea0-9ff1-e1f545ef23cf" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_arwr_MilestonePaymentReceivable_0d7b6913-6f5f-4ea0-9ff1-e1f545ef23cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_714e3a06-369d-453a-b205-e87770177885" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_714e3a06-369d-453a-b205-e87770177885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_c465b253-e411-4cca-b794-b3f9eec0c0b4" xlink:href="arwr-20250930.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_c465b253-e411-4cca-b794-b3f9eec0c0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_d3952a9d-dc33-42eb-a93c-a549ed002a9a" xlink:href="arwr-20250930.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_arwr_SalesRelatedMilestonePayments_d3952a9d-dc33-42eb-a93c-a549ed002a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_d99e636b-25b8-4ee2-a118-6f5a44aa2f20" xlink:href="arwr-20250930.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_d99e636b-25b8-4ee2-a118-6f5a44aa2f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentMilestonePayments_e664d975-ffac-44b0-b07c-1c9cc0cf5481" xlink:href="arwr-20250930.xsd#arwr_DevelopmentMilestonePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_arwr_DevelopmentMilestonePayments_e664d975-ffac-44b0-b07c-1c9cc0cf5481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentAndSalesMilestonesPayments_25356b40-1115-4c61-b213-f6d230847b23" xlink:href="arwr-20250930.xsd#arwr_DevelopmentAndSalesMilestonesPayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_arwr_DevelopmentAndSalesMilestonesPayments_25356b40-1115-4c61-b213-f6d230847b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_dbb817ef-5611-4f8e-b578-10555f340e72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_dbb817ef-5611-4f8e-b578-10555f340e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1c37b9d0-c7f3-47e4-a2b5-228bb6ca147a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c2c1b2c0-44a0-40f0-84d2-c43043e65da6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1c37b9d0-c7f3-47e4-a2b5-228bb6ca147a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_bd26f380-4b30-4e76-8e6c-370bf599b388" xlink:href="arwr-20250930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d03a8df4-de49-445c-a47b-e0d2b834bfdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_bd26f380-4b30-4e76-8e6c-370bf599b388" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d03a8df4-de49-445c-a47b-e0d2b834bfdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7df1c6d9-9be7-4c40-857d-f4e25e8dcd6e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d03a8df4-de49-445c-a47b-e0d2b834bfdd" xlink:to="loc_srt_CounterpartyNameAxis_7df1c6d9-9be7-4c40-857d-f4e25e8dcd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3fb2e64-1613-4ace-9b36-d16ab71b3db8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7df1c6d9-9be7-4c40-857d-f4e25e8dcd6e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3fb2e64-1613-4ace-9b36-d16ab71b3db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_70c2cb74-4c2a-4e85-b702-f9f81b2bac85" xlink:href="arwr-20250930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3fb2e64-1613-4ace-9b36-d16ab71b3db8" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_70c2cb74-4c2a-4e85-b702-f9f81b2bac85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_025b2485-d687-48b5-b708-960ca87fd531" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d03a8df4-de49-445c-a47b-e0d2b834bfdd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_025b2485-d687-48b5-b708-960ca87fd531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_acd3883f-477d-4c4f-8cd5-d7d99d6019d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_025b2485-d687-48b5-b708-960ca87fd531" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_acd3883f-477d-4c4f-8cd5-d7d99d6019d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember_9894e812-216e-40a8-8382-2fb9a2687c35" xlink:href="arwr-20250930.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_acd3883f-477d-4c4f-8cd5-d7d99d6019d0" xlink:to="loc_arwr_LicenseAndCoFundingAgreementMember_9894e812-216e-40a8-8382-2fb9a2687c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a68f084b-2500-425f-a679-dd6531242f4e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d03a8df4-de49-445c-a47b-e0d2b834bfdd" xlink:to="loc_srt_RangeAxis_a68f084b-2500-425f-a679-dd6531242f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2c222461-b8c5-4499-8989-ce24783de126" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a68f084b-2500-425f-a679-dd6531242f4e" xlink:to="loc_srt_RangeMember_2c222461-b8c5-4499-8989-ce24783de126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9d89de9b-67f6-4bac-ad2a-64162180e109" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2c222461-b8c5-4499-8989-ce24783de126" xlink:to="loc_srt_MinimumMember_9d89de9b-67f6-4bac-ad2a-64162180e109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d97141bb-1487-43d1-ae92-8a24e9ac32a0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2c222461-b8c5-4499-8989-ce24783de126" xlink:to="loc_srt_MaximumMember_d97141bb-1487-43d1-ae92-8a24e9ac32a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8356815d-fcdd-4abc-b930-5c7d1bfd7b23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d03a8df4-de49-445c-a47b-e0d2b834bfdd" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8356815d-fcdd-4abc-b930-5c7d1bfd7b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_65d43f88-c605-4786-8a35-fd94e9c9f8fb" xlink:href="arwr-20250930.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8356815d-fcdd-4abc-b930-5c7d1bfd7b23" xlink:to="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_65d43f88-c605-4786-8a35-fd94e9c9f8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_ad884b05-a122-45c3-af9e-4defebddbcaa" xlink:href="arwr-20250930.xsd#arwr_NumberOfDistinctBundle"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8356815d-fcdd-4abc-b930-5c7d1bfd7b23" xlink:to="loc_arwr_NumberOfDistinctBundle_ad884b05-a122-45c3-af9e-4defebddbcaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_1bdb8342-a594-4c95-b9b8-6fa28d991b4b" xlink:href="arwr-20250930.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8356815d-fcdd-4abc-b930-5c7d1bfd7b23" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_1bdb8342-a594-4c95-b9b8-6fa28d991b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_525c570c-2e0b-4554-82e3-fb7531ab75a4" xlink:href="arwr-20250930.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8356815d-fcdd-4abc-b930-5c7d1bfd7b23" xlink:to="loc_arwr_InitialTransactionPrice_525c570c-2e0b-4554-82e3-fb7531ab75a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_0eb6f62b-5eb7-4875-95fd-3929b177e517" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentEarned"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8356815d-fcdd-4abc-b930-5c7d1bfd7b23" xlink:to="loc_arwr_MilestonePaymentEarned_0eb6f62b-5eb7-4875-95fd-3929b177e517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_162ff280-0629-486c-91af-4afddc2c30a8" xlink:href="arwr-20250930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8356815d-fcdd-4abc-b930-5c7d1bfd7b23" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_162ff280-0629-486c-91af-4afddc2c30a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_930b127a-6ab5-4b91-93ca-92dcb314dfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8356815d-fcdd-4abc-b930-5c7d1bfd7b23" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_930b127a-6ab5-4b91-93ca-92dcb314dfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_adc01bd8-5b67-4a78-be62-661136a3b205" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8356815d-fcdd-4abc-b930-5c7d1bfd7b23" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_adc01bd8-5b67-4a78-be62-661136a3b205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#CollaborationandLicenseAgreementsAmgenIncDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_0cc021ca-1a0a-456a-8015-b1e4403b6aa4" xlink:href="arwr-20250930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a3a162a-737b-47ce-9e5e-61c95e183238" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_0cc021ca-1a0a-456a-8015-b1e4403b6aa4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a3a162a-737b-47ce-9e5e-61c95e183238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_408760b3-d129-488a-bd6f-2b5d781145a9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a3a162a-737b-47ce-9e5e-61c95e183238" xlink:to="loc_srt_CounterpartyNameAxis_408760b3-d129-488a-bd6f-2b5d781145a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9ee37bb-c4d5-4084-bd4c-258b2e55340f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_408760b3-d129-488a-bd6f-2b5d781145a9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9ee37bb-c4d5-4084-bd4c-258b2e55340f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_b1b4456a-c2b4-4080-8205-3cc7ed745863" xlink:href="arwr-20250930.xsd#arwr_AmgenIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9ee37bb-c4d5-4084-bd4c-258b2e55340f" xlink:to="loc_arwr_AmgenIncorporatedMember_b1b4456a-c2b4-4080-8205-3cc7ed745863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a9559d56-23ae-490e-9f8e-e6c53ed18902" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a3a162a-737b-47ce-9e5e-61c95e183238" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a9559d56-23ae-490e-9f8e-e6c53ed18902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_33e0c08f-505d-45a0-ab87-b89ef5d29dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a9559d56-23ae-490e-9f8e-e6c53ed18902" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_33e0c08f-505d-45a0-ab87-b89ef5d29dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember_250d9817-6616-4ef0-8bee-b4238ee20303" xlink:href="arwr-20250930.xsd#arwr_OlpasiranAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_33e0c08f-505d-45a0-ab87-b89ef5d29dc9" xlink:to="loc_arwr_OlpasiranAgreementMember_250d9817-6616-4ef0-8bee-b4238ee20303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_76bb1ef0-0bf0-49f4-8519-fc8394eb7191" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a3a162a-737b-47ce-9e5e-61c95e183238" xlink:to="loc_srt_RangeAxis_76bb1ef0-0bf0-49f4-8519-fc8394eb7191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_627cd355-fe23-44fe-a29a-12797997a527" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_76bb1ef0-0bf0-49f4-8519-fc8394eb7191" xlink:to="loc_srt_RangeMember_627cd355-fe23-44fe-a29a-12797997a527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cbd30273-4f0f-4c15-8a09-c0fc835aebd8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_627cd355-fe23-44fe-a29a-12797997a527" xlink:to="loc_srt_MaximumMember_cbd30273-4f0f-4c15-8a09-c0fc835aebd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91d623f8-d250-4c09-9d95-866b13fa6e78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a3a162a-737b-47ce-9e5e-61c95e183238" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91d623f8-d250-4c09-9d95-866b13fa6e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements_9ae26e34-577c-4cdd-9f68-dc2598fe60dc" xlink:href="arwr-20250930.xsd#arwr_NumberOfAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91d623f8-d250-4c09-9d95-866b13fa6e78" xlink:to="loc_arwr_NumberOfAgreements_9ae26e34-577c-4cdd-9f68-dc2598fe60dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_766aa248-4a68-4dad-9d5c-1cec989b44d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91d623f8-d250-4c09-9d95-866b13fa6e78" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_766aa248-4a68-4dad-9d5c-1cec989b44d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cfa1e708-f1b2-4eea-bf72-d396737863f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91d623f8-d250-4c09-9d95-866b13fa6e78" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cfa1e708-f1b2-4eea-bf72-d396737863f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_ee002e57-6b29-46b5-9c1e-aec0e429f50a" xlink:href="arwr-20250930.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91d623f8-d250-4c09-9d95-866b13fa6e78" xlink:to="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_ee002e57-6b29-46b5-9c1e-aec0e429f50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_4ce944e1-6a2c-4513-8051-ec197bd8dd3d" xlink:href="arwr-20250930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e41b2148-81eb-49d4-9978-35f78e20dd90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_4ce944e1-6a2c-4513-8051-ec197bd8dd3d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e41b2148-81eb-49d4-9978-35f78e20dd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1afb3872-eb3b-41e0-b568-060d0f3b2bf0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e41b2148-81eb-49d4-9978-35f78e20dd90" xlink:to="loc_srt_CounterpartyNameAxis_1afb3872-eb3b-41e0-b568-060d0f3b2bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8f23b2d-7008-41c2-80fe-e33204f560fa" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1afb3872-eb3b-41e0-b568-060d0f3b2bf0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8f23b2d-7008-41c2-80fe-e33204f560fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaTherapeuticsIncMember_a7047dcb-79de-42df-8f2f-8d71f10dcfc6" xlink:href="arwr-20250930.xsd#arwr_SareptaTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8f23b2d-7008-41c2-80fe-e33204f560fa" xlink:to="loc_arwr_SareptaTherapeuticsIncMember_a7047dcb-79de-42df-8f2f-8d71f10dcfc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7a7fa08e-43dc-4284-89f0-e1639060ca7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e41b2148-81eb-49d4-9978-35f78e20dd90" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7a7fa08e-43dc-4284-89f0-e1639060ca7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_87758975-4d3b-49a6-a406-aa0168fb14d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7a7fa08e-43dc-4284-89f0-e1639060ca7a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_87758975-4d3b-49a6-a406-aa0168fb14d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember_dc62afdb-29fd-4b67-850c-de8d4a25be4b" xlink:href="arwr-20250930.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_87758975-4d3b-49a6-a406-aa0168fb14d0" xlink:to="loc_arwr_SareptaCollaborationAgreementMember_dc62afdb-29fd-4b67-850c-de8d4a25be4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7874184a-1a73-4e18-a212-2d813fba93ef" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e41b2148-81eb-49d4-9978-35f78e20dd90" xlink:to="loc_srt_RangeAxis_7874184a-1a73-4e18-a212-2d813fba93ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_690d0670-d7a3-44a8-bbcb-105f7dc00b72" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7874184a-1a73-4e18-a212-2d813fba93ef" xlink:to="loc_srt_RangeMember_690d0670-d7a3-44a8-bbcb-105f7dc00b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_335b679d-c555-4651-9fab-5851630452ad" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_690d0670-d7a3-44a8-bbcb-105f7dc00b72" xlink:to="loc_srt_MaximumMember_335b679d-c555-4651-9fab-5851630452ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_df807ebc-8fb5-4d81-899a-a8a32cc76ad3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_690d0670-d7a3-44a8-bbcb-105f7dc00b72" xlink:to="loc_srt_MinimumMember_df807ebc-8fb5-4d81-899a-a8a32cc76ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e41b2148-81eb-49d4-9978-35f78e20dd90" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfNewTargetPrograms_9faa1964-8046-4e4e-a4b6-6f6e36688e93" xlink:href="arwr-20250930.xsd#arwr_NumberOfNewTargetPrograms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_NumberOfNewTargetPrograms_9faa1964-8046-4e4e-a4b6-6f6e36688e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfPerformanceObligations_c2fa5709-5994-46c2-b7a5-1913d31ed900" xlink:href="arwr-20250930.xsd#arwr_NumberOfPerformanceObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_NumberOfPerformanceObligations_c2fa5709-5994-46c2-b7a5-1913d31ed900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements_23449e8e-aa5f-43be-a7b0-f0e9da1a3a4d" xlink:href="arwr-20250930.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_ProceedsFromCollaborationArrangements_23449e8e-aa5f-43be-a7b0-f0e9da1a3a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ea884625-6f46-490c-9475-8dfb286c455c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ea884625-6f46-490c-9475-8dfb286c455c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SaleOfStockPremiumOnIssuanceOfShares_ae88c57a-207f-4a42-bf20-567c2a8a9ab0" xlink:href="arwr-20250930.xsd#arwr_SaleOfStockPremiumOnIssuanceOfShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_SaleOfStockPremiumOnIssuanceOfShares_ae88c57a-207f-4a42-bf20-567c2a8a9ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement_ca77cfdb-d376-414d-9468-6d21d1379e70" xlink:href="arwr-20250930.xsd#arwr_AdditionalCashReceivableUnderCollaborationAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_AdditionalCashReceivableUnderCollaborationAgreement_ca77cfdb-d376-414d-9468-6d21d1379e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments_6ca1d194-88b0-466a-a93c-abd43f23e251" xlink:href="arwr-20250930.xsd#arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments_6ca1d194-88b0-466a-a93c-abd43f23e251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod_6bfddd33-f2fb-47ce-bad2-e1e5b8bc92ee" xlink:href="arwr-20250930.xsd#arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod_6bfddd33-f2fb-47ce-bad2-e1e5b8bc92ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementFixedConsideration_43a92703-822d-4fd1-8596-cac8f7882ae4" xlink:href="arwr-20250930.xsd#arwr_CollaborationArrangementFixedConsideration"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_CollaborationArrangementFixedConsideration_43a92703-822d-4fd1-8596-cac8f7882ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementVariableConsideration_002ab1a0-e087-4f78-a420-0def187c8100" xlink:href="arwr-20250930.xsd#arwr_CollaborationArrangementVariableConsideration"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_CollaborationArrangementVariableConsideration_002ab1a0-e087-4f78-a420-0def187c8100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementConsideration_ea2863e9-7057-4ca5-a4d0-57c0037d2925" xlink:href="arwr-20250930.xsd#arwr_CollaborationArrangementConsideration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_CollaborationArrangementConsideration_ea2863e9-7057-4ca5-a4d0-57c0037d2925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EnrollmentRelatedMilestonePayments_b2889c0b-d6f9-40c0-bf85-406f0d604234" xlink:href="arwr-20250930.xsd#arwr_EnrollmentRelatedMilestonePayments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_EnrollmentRelatedMilestonePayments_b2889c0b-d6f9-40c0-bf85-406f0d604234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfCollaborationPrograms_5c20f175-c7ee-467d-bdb4-36ea02639508" xlink:href="arwr-20250930.xsd#arwr_NumberOfCollaborationPrograms"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_NumberOfCollaborationPrograms_5c20f175-c7ee-467d-bdb4-36ea02639508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RegulatoryMilestonePayments_d211e262-5109-4c0c-a3ad-4c1957dca5ce" xlink:href="arwr-20250930.xsd#arwr_RegulatoryMilestonePayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_RegulatoryMilestonePayments_d211e262-5109-4c0c-a3ad-4c1957dca5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_62b5c9a7-6c88-4f20-a760-ca5df57d6836" xlink:href="arwr-20250930.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_SalesRelatedMilestonePayments_62b5c9a7-6c88-4f20-a760-ca5df57d6836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval_8a1593d3-09fb-4529-a7df-817efc1e7acd" xlink:href="arwr-20250930.xsd#arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval_8a1593d3-09fb-4529-a7df-817efc1e7acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_6d1bffb8-a928-4056-a0a5-f4ea1bcda298" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_6d1bffb8-a928-4056-a0a5-f4ea1bcda298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentMilestonePayments_c03c5f0e-e4ee-4540-8ed6-5bffc3ad7202" xlink:href="arwr-20250930.xsd#arwr_DevelopmentMilestonePayments"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_DevelopmentMilestonePayments_c03c5f0e-e4ee-4540-8ed6-5bffc3ad7202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d17dc565-79f6-45e1-b52e-0d3a08492639" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d17dc565-79f6-45e1-b52e-0d3a08492639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_7f2c79d4-67f3-437f-a7b2-01a3f3f3ae51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_us-gaap_TreasuryStockCommonValue_7f2c79d4-67f3-437f-a7b2-01a3f3f3ae51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GainLossOnTreasuryStockSettlement_13ca79be-9f31-4a91-b655-1585e398c9c4" xlink:href="arwr-20250930.xsd#arwr_GainLossOnTreasuryStockSettlement"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_arwr_GainLossOnTreasuryStockSettlement_13ca79be-9f31-4a91-b655-1585e398c9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aed3d1df-83e9-4c01-81dc-f74cf4172417" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aed3d1df-83e9-4c01-81dc-f74cf4172417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ff03b553-1f1b-4d06-aa5f-c9f8aa2c3485" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_19416158-6bc7-4cb3-8110-092902b83fa1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ff03b553-1f1b-4d06-aa5f-c9f8aa2c3485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_02b85da4-66ab-488f-9b75-7d69c05052a3" xlink:href="arwr-20250930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4b3abd2-8344-4261-ab97-5ee99cc85a53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_02b85da4-66ab-488f-9b75-7d69c05052a3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4b3abd2-8344-4261-ab97-5ee99cc85a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9e674f99-1042-4ff4-b3a7-49dabd60f892" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4b3abd2-8344-4261-ab97-5ee99cc85a53" xlink:to="loc_srt_CounterpartyNameAxis_9e674f99-1042-4ff4-b3a7-49dabd60f892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e689db53-a805-43b5-a4d0-b5fbb6c95ed4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9e674f99-1042-4ff4-b3a7-49dabd60f892" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e689db53-a805-43b5-a4d0-b5fbb6c95ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SanofiMember_8dfc3fbd-ca7b-450d-80c1-3eac9683a022" xlink:href="arwr-20250930.xsd#arwr_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e689db53-a805-43b5-a4d0-b5fbb6c95ed4" xlink:to="loc_arwr_SanofiMember_8dfc3fbd-ca7b-450d-80c1-3eac9683a022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e4ed5255-2c8e-4cc4-956e-e16100e8c9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4b3abd2-8344-4261-ab97-5ee99cc85a53" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e4ed5255-2c8e-4cc4-956e-e16100e8c9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d75fcb8-ee42-4661-95ab-cecd264b031a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e4ed5255-2c8e-4cc4-956e-e16100e8c9b2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d75fcb8-ee42-4661-95ab-cecd264b031a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SanofiLicenseAgreementMember_276a789d-9dd5-4aef-81ea-1ff7f36ada19" xlink:href="arwr-20250930.xsd#arwr_SanofiLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d75fcb8-ee42-4661-95ab-cecd264b031a" xlink:to="loc_arwr_SanofiLicenseAgreementMember_276a789d-9dd5-4aef-81ea-1ff7f36ada19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_077e1341-8dfd-4f4d-b4da-1ab17773aafc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4b3abd2-8344-4261-ab97-5ee99cc85a53" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_077e1341-8dfd-4f4d-b4da-1ab17773aafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_d17bc731-8cfa-437d-a09e-6d06a21fd7d6" xlink:href="arwr-20250930.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_077e1341-8dfd-4f4d-b4da-1ab17773aafc" xlink:to="loc_arwr_InitialTransactionPrice_d17bc731-8cfa-437d-a09e-6d06a21fd7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FuturePotentialMilestonePayments_b02c4b21-991e-4d57-96b3-10473f371bb8" xlink:href="arwr-20250930.xsd#arwr_FuturePotentialMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_077e1341-8dfd-4f4d-b4da-1ab17773aafc" xlink:to="loc_arwr_FuturePotentialMilestonePayments_b02c4b21-991e-4d57-96b3-10473f371bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_adbf167b-1160-4a4c-978e-6a00eb7c6d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_077e1341-8dfd-4f4d-b4da-1ab17773aafc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_adbf167b-1160-4a4c-978e-6a00eb7c6d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfPerformanceObligations_01e201b8-3e5e-4a1c-9a43-86d6d67d952f" xlink:href="arwr-20250930.xsd#arwr_NumberOfPerformanceObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_077e1341-8dfd-4f4d-b4da-1ab17773aafc" xlink:to="loc_arwr_NumberOfPerformanceObligations_01e201b8-3e5e-4a1c-9a43-86d6d67d952f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationArrangementFixedConsideration_2b3fefcc-bf4e-4684-8d5a-ec5593365e18" xlink:href="arwr-20250930.xsd#arwr_CollaborationArrangementFixedConsideration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_077e1341-8dfd-4f4d-b4da-1ab17773aafc" xlink:to="loc_arwr_CollaborationArrangementFixedConsideration_2b3fefcc-bf4e-4684-8d5a-ec5593365e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#BalanceSheetAccountsPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_376c2e24-7457-4949-8750-da0ded9b52f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b6da2dff-2f3d-42bb-b106-9a7281b04e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_376c2e24-7457-4949-8750-da0ded9b52f4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b6da2dff-2f3d-42bb-b106-9a7281b04e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2aa5252-d584-4ea2-9c1c-db9c66871ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b6da2dff-2f3d-42bb-b106-9a7281b04e2e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2aa5252-d584-4ea2-9c1c-db9c66871ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60fbd4d9-a0fc-415f-b04b-23b806896396" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2aa5252-d584-4ea2-9c1c-db9c66871ee5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60fbd4d9-a0fc-415f-b04b-23b806896396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_aa201c65-8e90-4c00-91a3-f0b84abed5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60fbd4d9-a0fc-415f-b04b-23b806896396" xlink:to="loc_us-gaap_LandMember_aa201c65-8e90-4c00-91a3-f0b84abed5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_29e84093-9b5f-40f7-a245-fbf4e66d96f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60fbd4d9-a0fc-415f-b04b-23b806896396" xlink:to="loc_us-gaap_BuildingMember_29e84093-9b5f-40f7-a245-fbf4e66d96f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentMember_1c854e48-4b1a-46a7-894f-799788819e66" xlink:href="arwr-20250930.xsd#arwr_ResearchEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60fbd4d9-a0fc-415f-b04b-23b806896396" xlink:to="loc_arwr_ResearchEquipmentMember_1c854e48-4b1a-46a7-894f-799788819e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ManufacturingEquipmentMember_216b5e1f-83a8-4406-a981-7e7ef610e8fa" xlink:href="arwr-20250930.xsd#arwr_ManufacturingEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60fbd4d9-a0fc-415f-b04b-23b806896396" xlink:to="loc_arwr_ManufacturingEquipmentMember_216b5e1f-83a8-4406-a981-7e7ef610e8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0538c8d0-db3e-4bc7-8dfa-d17b0461c163" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60fbd4d9-a0fc-415f-b04b-23b806896396" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_0538c8d0-db3e-4bc7-8dfa-d17b0461c163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputersAndSoftwareMember_d0ecf88d-8152-412b-af60-f0d4a8b78143" xlink:href="arwr-20250930.xsd#arwr_ComputersAndSoftwareMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60fbd4d9-a0fc-415f-b04b-23b806896396" xlink:to="loc_arwr_ComputersAndSoftwareMember_d0ecf88d-8152-412b-af60-f0d4a8b78143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4b87f916-3364-497d-947d-22f7626567b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60fbd4d9-a0fc-415f-b04b-23b806896396" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4b87f916-3364-497d-947d-22f7626567b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_933d149a-7e49-4d21-a8c1-30a6c885b4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60fbd4d9-a0fc-415f-b04b-23b806896396" xlink:to="loc_us-gaap_ConstructionInProgressMember_933d149a-7e49-4d21-a8c1-30a6c885b4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce8db0b7-5350-431d-86a3-8a89b2b92c03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b6da2dff-2f3d-42bb-b106-9a7281b04e2e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce8db0b7-5350-431d-86a3-8a89b2b92c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1b6b7e05-5539-43e3-a4b5-5717080577eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce8db0b7-5350-431d-86a3-8a89b2b92c03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1b6b7e05-5539-43e3-a4b5-5717080577eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4f5a8444-82b2-4219-a70e-f6a0624bcf41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce8db0b7-5350-431d-86a3-8a89b2b92c03" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4f5a8444-82b2-4219-a70e-f6a0624bcf41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c0f63ce9-af70-477e-9d26-9096ee2e9627" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ce8db0b7-5350-431d-86a3-8a89b2b92c03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c0f63ce9-af70-477e-9d26-9096ee2e9627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#BalanceSheetAccountsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_593cecd9-a130-4407-a212-75cd9d6ea917" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9440e36b-3e27-4558-bd23-0497935030df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_593cecd9-a130-4407-a212-75cd9d6ea917" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9440e36b-3e27-4558-bd23-0497935030df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0cd1eebb-cbfa-41ec-9507-7d82463a65c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9440e36b-3e27-4558-bd23-0497935030df" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0cd1eebb-cbfa-41ec-9507-7d82463a65c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c81ab6a-a846-48b7-8614-69736635ee5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0cd1eebb-cbfa-41ec-9507-7d82463a65c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c81ab6a-a846-48b7-8614-69736635ee5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ConstructionInProgressReclassifiedToBuildingMember_c9e8364e-d680-4e07-9d49-74157ccd77e8" xlink:href="arwr-20250930.xsd#arwr_ConstructionInProgressReclassifiedToBuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c81ab6a-a846-48b7-8614-69736635ee5e" xlink:to="loc_arwr_ConstructionInProgressReclassifiedToBuildingMember_c9e8364e-d680-4e07-9d49-74157ccd77e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_17503cef-056c-48fe-b420-5de0b7d40152" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c81ab6a-a846-48b7-8614-69736635ee5e" xlink:to="loc_us-gaap_BuildingMember_17503cef-056c-48fe-b420-5de0b7d40152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember_d3c8ce02-def7-4c40-adff-e34af7e452c3" xlink:href="arwr-20250930.xsd#arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c81ab6a-a846-48b7-8614-69736635ee5e" xlink:to="loc_arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember_d3c8ce02-def7-4c40-adff-e34af7e452c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ManufacturingEquipmentMember_f23393e9-a204-4df6-b906-445293855d31" xlink:href="arwr-20250930.xsd#arwr_ManufacturingEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c81ab6a-a846-48b7-8614-69736635ee5e" xlink:to="loc_arwr_ManufacturingEquipmentMember_f23393e9-a204-4df6-b906-445293855d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember_0693b211-00f3-4854-a239-100440dbf186" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c81ab6a-a846-48b7-8614-69736635ee5e" xlink:to="loc_us-gaap_ManufacturingFacilityMember_0693b211-00f3-4854-a239-100440dbf186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_d8ecf180-7f4d-4c0c-b76e-936ab08e49e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c81ab6a-a846-48b7-8614-69736635ee5e" xlink:to="loc_us-gaap_ConstructionInProgressMember_d8ecf180-7f4d-4c0c-b76e-936ab08e49e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ff1b6145-4753-4ee4-94b8-9c977ed93a48" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9440e36b-3e27-4558-bd23-0497935030df" xlink:to="loc_srt_RangeAxis_ff1b6145-4753-4ee4-94b8-9c977ed93a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d9cb387d-d0d6-4bcd-9b8b-7229453308a5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ff1b6145-4753-4ee4-94b8-9c977ed93a48" xlink:to="loc_srt_RangeMember_d9cb387d-d0d6-4bcd-9b8b-7229453308a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_06e94516-65ab-4a8a-bdf4-f77171b68792" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d9cb387d-d0d6-4bcd-9b8b-7229453308a5" xlink:to="loc_srt_MinimumMember_06e94516-65ab-4a8a-bdf4-f77171b68792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e70404f2-a5fa-4845-a554-d120ceba9f5c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d9cb387d-d0d6-4bcd-9b8b-7229453308a5" xlink:to="loc_srt_MaximumMember_e70404f2-a5fa-4845-a554-d120ceba9f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_59c0df2e-b817-4fb3-9c05-bd3151f5ffb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9440e36b-3e27-4558-bd23-0497935030df" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_59c0df2e-b817-4fb3-9c05-bd3151f5ffb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8245135e-4f2c-4d45-84af-b2499d3f6c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_59c0df2e-b817-4fb3-9c05-bd3151f5ffb0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8245135e-4f2c-4d45-84af-b2499d3f6c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_ea4d0612-2b9b-46dc-8295-f9c8aed0f240" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTransfersAndChanges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_59c0df2e-b817-4fb3-9c05-bd3151f5ffb0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_ea4d0612-2b9b-46dc-8295-f9c8aed0f240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0cec85ec-7a80-474e-894b-9d865bff7d71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_59c0df2e-b817-4fb3-9c05-bd3151f5ffb0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0cec85ec-7a80-474e-894b-9d865bff7d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#BalanceSheetAccountsAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_10697eb7-4991-4c25-bc6d-4e6fa0a8395c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedResearchAndDevelopmentExpenseCurrent_423ba164-fc99-4422-b6f3-c0be937357a2" xlink:href="arwr-20250930.xsd#arwr_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_10697eb7-4991-4c25-bc6d-4e6fa0a8395c" xlink:to="loc_arwr_AccruedResearchAndDevelopmentExpenseCurrent_423ba164-fc99-4422-b6f3-c0be937357a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_4f94386b-d2b4-4081-bdd1-b705a9246c69" xlink:href="arwr-20250930.xsd#arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_10697eb7-4991-4c25-bc6d-4e6fa0a8395c" xlink:to="loc_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_4f94386b-d2b4-4081-bdd1-b705a9246c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedCapitalExpenditureCurrent_fe9489be-bf7d-4d6b-a99e-07900e1a55ac" xlink:href="arwr-20250930.xsd#arwr_AccruedCapitalExpenditureCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_10697eb7-4991-4c25-bc6d-4e6fa0a8395c" xlink:to="loc_arwr_AccruedCapitalExpenditureCurrent_fe9489be-bf7d-4d6b-a99e-07900e1a55ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_17d0117d-1444-4fd5-aa1d-1f9f6d368373" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_10697eb7-4991-4c25-bc6d-4e6fa0a8395c" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_17d0117d-1444-4fd5-aa1d-1f9f6d368373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ef0563ea-acb8-4df9-bacc-2f111093e591" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_10697eb7-4991-4c25-bc6d-4e6fa0a8395c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ef0563ea-acb8-4df9-bacc-2f111093e591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c6d82718-4ddc-43f9-b607-3480e64418bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_10697eb7-4991-4c25-bc6d-4e6fa0a8395c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c6d82718-4ddc-43f9-b607-3480e64418bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#InvestmentsCurrentInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d1ed65e6-7541-422f-813f-b95fad42af49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_d9ae2af1-a922-4588-a8e6-106c80ea2188" xlink:href="arwr-20250930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d1ed65e6-7541-422f-813f-b95fad42af49" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_d9ae2af1-a922-4588-a8e6-106c80ea2188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f095e17b-67d2-403b-9619-2f17822104f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_d9ae2af1-a922-4588-a8e6-106c80ea2188" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f095e17b-67d2-403b-9619-2f17822104f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_79b96566-a6fd-4199-b87f-4b6f2448919b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f095e17b-67d2-403b-9619-2f17822104f4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_79b96566-a6fd-4199-b87f-4b6f2448919b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_10902bd9-8620-4fe9-a673-5a46da68be68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_79b96566-a6fd-4199-b87f-4b6f2448919b" xlink:to="loc_us-gaap_DebtSecuritiesMember_10902bd9-8620-4fe9-a673-5a46da68be68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_c8082cdc-2a87-4331-b5b6-9fd82a333ca2" xlink:href="arwr-20250930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_d9ae2af1-a922-4588-a8e6-106c80ea2188" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_c8082cdc-2a87-4331-b5b6-9fd82a333ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_1c83a5ba-b9fb-4b80-a073-31b679b6d441" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_c8082cdc-2a87-4331-b5b6-9fd82a333ca2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_1c83a5ba-b9fb-4b80-a073-31b679b6d441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_c1b127d0-cfdf-4ea4-a2d9-9f413adbc7dd" xlink:href="arwr-20250930.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_c8082cdc-2a87-4331-b5b6-9fd82a333ca2" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_c1b127d0-cfdf-4ea4-a2d9-9f413adbc7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_dd11df08-0e07-40c2-8837-38e83b450239" xlink:href="arwr-20250930.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_c8082cdc-2a87-4331-b5b6-9fd82a333ca2" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_dd11df08-0e07-40c2-8837-38e83b450239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3e32bda5-4bc5-4759-809d-072ef67100e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_c8082cdc-2a87-4331-b5b6-9fd82a333ca2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3e32bda5-4bc5-4759-809d-072ef67100e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsContractMaturityofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#InvestmentsContractMaturityofAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsContractMaturityofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_928a9e59-e5af-40ef-bc83-d98bb5666608" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0a328ea6-9e8f-42b3-bcc6-4b8257e258db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_928a9e59-e5af-40ef-bc83-d98bb5666608" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0a328ea6-9e8f-42b3-bcc6-4b8257e258db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_33fe4dbe-fd8a-4490-962b-b748104a118d" xlink:href="arwr-20250930.xsd#arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_928a9e59-e5af-40ef-bc83-d98bb5666608" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_33fe4dbe-fd8a-4490-962b-b748104a118d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree_dde03723-e822-412c-af52-74341fa56160" xlink:href="arwr-20250930.xsd#arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_928a9e59-e5af-40ef-bc83-d98bb5666608" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree_dde03723-e822-412c-af52-74341fa56160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f08b722e-c817-4afb-963e-18f3facb672f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_928a9e59-e5af-40ef-bc83-d98bb5666608" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f08b722e-c817-4afb-963e-18f3facb672f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1a3255a7-74b5-441a-83cd-06854764787f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4484cf3e-ebae-46e5-8ec1-736640ace5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1a3255a7-74b5-441a-83cd-06854764787f" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4484cf3e-ebae-46e5-8ec1-736640ace5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_14acb4d1-9eb7-4d33-a205-be5d7ca0422e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4484cf3e-ebae-46e5-8ec1-736640ace5b7" xlink:to="loc_us-gaap_AssetAcquisitionAxis_14acb4d1-9eb7-4d33-a205-be5d7ca0422e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_4b8e721a-78bb-4843-98e5-e9a3a0778f60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_14acb4d1-9eb7-4d33-a205-be5d7ca0422e" xlink:to="loc_us-gaap_AssetAcquisitionDomain_4b8e721a-78bb-4843-98e5-e9a3a0778f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember_f3cd3edf-9153-4ab5-8bfc-92cadb10be37" xlink:href="arwr-20250930.xsd#arwr_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4b8e721a-78bb-4843-98e5-e9a3a0778f60" xlink:to="loc_arwr_NovartisMember_f3cd3edf-9153-4ab5-8bfc-92cadb10be37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6eb052ac-cb77-4768-a63c-615990622961" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4484cf3e-ebae-46e5-8ec1-736640ace5b7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6eb052ac-cb77-4768-a63c-615990622961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58c158f4-e425-44e0-9f7c-102447765d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6eb052ac-cb77-4768-a63c-615990622961" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58c158f4-e425-44e0-9f7c-102447765d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_11827101-693b-49ca-92df-9c4dca0c5cab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58c158f4-e425-44e0-9f7c-102447765d3d" xlink:to="loc_us-gaap_PatentsMember_11827101-693b-49ca-92df-9c4dca0c5cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_9cecf7eb-4597-4005-8f9f-6c08f44ab39d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58c158f4-e425-44e0-9f7c-102447765d3d" xlink:to="loc_us-gaap_LicensingAgreementsMember_9cecf7eb-4597-4005-8f9f-6c08f44ab39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e47d4d12-d1c2-4005-9cdd-a91e57724865" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4484cf3e-ebae-46e5-8ec1-736640ace5b7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e47d4d12-d1c2-4005-9cdd-a91e57724865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1abc6cac-2f38-4518-b8d9-e56637d5c66c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e47d4d12-d1c2-4005-9cdd-a91e57724865" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1abc6cac-2f38-4518-b8d9-e56637d5c66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b24caae2-edde-4c54-9ccc-b28e0b179f41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e47d4d12-d1c2-4005-9cdd-a91e57724865" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b24caae2-edde-4c54-9ccc-b28e0b179f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_ba87b36e-78df-4073-958c-b87665e7bc80" xlink:href="arwr-20250930.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e47d4d12-d1c2-4005-9cdd-a91e57724865" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_ba87b36e-78df-4073-958c-b87665e7bc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3cd1eba3-0e44-41b7-9bfd-2b52f05269dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e47d4d12-d1c2-4005-9cdd-a91e57724865" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3cd1eba3-0e44-41b7-9bfd-2b52f05269dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c238ad7b-6180-4a66-8e29-476082738a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e47d4d12-d1c2-4005-9cdd-a91e57724865" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c238ad7b-6180-4a66-8e29-476082738a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_18e29d6a-6aeb-4cd3-a81d-84022cf0da2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1a3255a7-74b5-441a-83cd-06854764787f" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_18e29d6a-6aeb-4cd3-a81d-84022cf0da2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#IntangibleAssetsExpectedFutureAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41249917-3414-4c2f-a5e9-62f895c8fff5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4af03a93-d6ba-4337-bebb-797a10729415" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41249917-3414-4c2f-a5e9-62f895c8fff5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4af03a93-d6ba-4337-bebb-797a10729415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_05bd07aa-91ef-4789-a9ca-8c59e6aa6164" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41249917-3414-4c2f-a5e9-62f895c8fff5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_05bd07aa-91ef-4789-a9ca-8c59e6aa6164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_df30cef2-3856-4157-a83f-d2027b290423" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41249917-3414-4c2f-a5e9-62f895c8fff5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_df30cef2-3856-4157-a83f-d2027b290423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_9b266c48-9a5c-4ec8-bd3b-f02ee8bb9863" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41249917-3414-4c2f-a5e9-62f895c8fff5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_9b266c48-9a5c-4ec8-bd3b-f02ee8bb9863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_d80ef3b8-59c5-4cd0-b8be-6a32fcc039ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41249917-3414-4c2f-a5e9-62f895c8fff5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_d80ef3b8-59c5-4cd0-b8be-6a32fcc039ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5979b667-e200-4c8f-80cc-ffe20919ccc2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41249917-3414-4c2f-a5e9-62f895c8fff5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5979b667-e200-4c8f-80cc-ffe20919ccc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_88e551b4-c110-48fa-98fe-5e6b627c6b98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41249917-3414-4c2f-a5e9-62f895c8fff5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_88e551b4-c110-48fa-98fe-5e6b627c6b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquitySharesofCommonStockandPreferredStockDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#StockholdersEquitySharesofCommonStockandPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquitySharesofCommonStockandPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_042da6ff-4c56-45bf-8d3c-500716e074a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6a6059a4-d2b4-4b2a-afdb-e66c262a3916" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_042da6ff-4c56-45bf-8d3c-500716e074a5" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6a6059a4-d2b4-4b2a-afdb-e66c262a3916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_52da8fc8-7e89-47b3-85c8-45d746f095ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_042da6ff-4c56-45bf-8d3c-500716e074a5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_52da8fc8-7e89-47b3-85c8-45d746f095ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_51cec623-2fd8-4cea-8fb2-6622b66fcba3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_042da6ff-4c56-45bf-8d3c-500716e074a5" xlink:to="loc_us-gaap_CommonStockSharesIssued_51cec623-2fd8-4cea-8fb2-6622b66fcba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a6da5578-e479-41b8-8acb-dfc64dc5694e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_042da6ff-4c56-45bf-8d3c-500716e074a5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a6da5578-e479-41b8-8acb-dfc64dc5694e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fa933b7a-89b8-4cad-9f94-c0c0c1309ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_042da6ff-4c56-45bf-8d3c-500716e074a5" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fa933b7a-89b8-4cad-9f94-c0c0c1309ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_fb16fb8e-e917-4ff5-8bb9-9d1631e029b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_042da6ff-4c56-45bf-8d3c-500716e074a5" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_fb16fb8e-e917-4ff5-8bb9-9d1631e029b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b37d63e3-57a7-4992-9871-862568364cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_042da6ff-4c56-45bf-8d3c-500716e074a5" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b37d63e3-57a7-4992-9871-862568364cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d54fd685-ccbf-4c65-b885-67cdddaf7313" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_042da6ff-4c56-45bf-8d3c-500716e074a5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d54fd685-ccbf-4c65-b885-67cdddaf7313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_459206b8-2695-430f-b4a7-9a18ce5607e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_461f1fcf-069a-49e4-89a5-e3ca89cc6990" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_459206b8-2695-430f-b4a7-9a18ce5607e0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_461f1fcf-069a-49e4-89a5-e3ca89cc6990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_67b2a46f-7d2f-4cbb-ba7e-e8b0f1ebc9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_461f1fcf-069a-49e4-89a5-e3ca89cc6990" xlink:to="loc_us-gaap_PlanNameAxis_67b2a46f-7d2f-4cbb-ba7e-e8b0f1ebc9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4bb3c5b1-78f4-47a4-9425-9f97fc157b69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_67b2a46f-7d2f-4cbb-ba7e-e8b0f1ebc9d1" xlink:to="loc_us-gaap_PlanNameDomain_4bb3c5b1-78f4-47a4-9425-9f97fc157b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_9a7fe01a-733d-41b3-8905-c4d46004dc30" xlink:href="arwr-20250930.xsd#arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4bb3c5b1-78f4-47a4-9425-9f97fc157b69" xlink:to="loc_arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_9a7fe01a-733d-41b3-8905-c4d46004dc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_901b96dc-d71d-49ac-9aeb-868fa13fc529" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_461f1fcf-069a-49e4-89a5-e3ca89cc6990" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_901b96dc-d71d-49ac-9aeb-868fa13fc529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3761085e-6a00-41ca-9691-533f6a7bd989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_901b96dc-d71d-49ac-9aeb-868fa13fc529" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3761085e-6a00-41ca-9691-533f6a7bd989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_ae9fe466-c4ea-4ea8-b918-8efc8bd5d758" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3761085e-6a00-41ca-9691-533f6a7bd989" xlink:to="loc_us-gaap_PrivatePlacementMember_ae9fe466-c4ea-4ea8-b918-8efc8bd5d758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember_642ac609-711d-46a4-a227-a03efcb0b7d9" xlink:href="arwr-20250930.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3761085e-6a00-41ca-9691-533f6a7bd989" xlink:to="loc_arwr_AtTheMarketAgreementMember_642ac609-711d-46a4-a227-a03efcb0b7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a9eed897-d75b-43fc-9037-4a176f319729" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_461f1fcf-069a-49e4-89a5-e3ca89cc6990" xlink:to="loc_srt_CounterpartyNameAxis_a9eed897-d75b-43fc-9037-4a176f319729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0120a481-cac9-45d6-aeb2-c419c42d3843" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a9eed897-d75b-43fc-9037-4a176f319729" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0120a481-cac9-45d6-aeb2-c419c42d3843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaTherapeuticsIncMember_6634bff7-e793-45dd-8410-f99202962cf4" xlink:href="arwr-20250930.xsd#arwr_SareptaTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0120a481-cac9-45d6-aeb2-c419c42d3843" xlink:to="loc_arwr_SareptaTherapeuticsIncMember_6634bff7-e793-45dd-8410-f99202962cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_32b41050-bac5-48b1-a451-b1b2954ebd23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_461f1fcf-069a-49e4-89a5-e3ca89cc6990" xlink:to="loc_us-gaap_TypeOfArrangementAxis_32b41050-bac5-48b1-a451-b1b2954ebd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8101b93-97b4-4c5d-b373-e84d2239b34b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_32b41050-bac5-48b1-a451-b1b2954ebd23" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8101b93-97b4-4c5d-b373-e84d2239b34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember_cdfaeaf3-8830-475e-bd0c-65bd6832ebd8" xlink:href="arwr-20250930.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8101b93-97b4-4c5d-b373-e84d2239b34b" xlink:to="loc_arwr_SareptaCollaborationAgreementMember_cdfaeaf3-8830-475e-bd0c-65bd6832ebd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7e466f09-cb6b-42a5-8d67-ec86a3c06eac" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_461f1fcf-069a-49e4-89a5-e3ca89cc6990" xlink:to="loc_srt_RangeAxis_7e466f09-cb6b-42a5-8d67-ec86a3c06eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a61c35ef-e077-49fc-8484-7ae8c9917553" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7e466f09-cb6b-42a5-8d67-ec86a3c06eac" xlink:to="loc_srt_RangeMember_a61c35ef-e077-49fc-8484-7ae8c9917553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c967e931-0a6a-4f7c-9ba1-80c0fdcc11a3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a61c35ef-e077-49fc-8484-7ae8c9917553" xlink:to="loc_srt_MaximumMember_c967e931-0a6a-4f7c-9ba1-80c0fdcc11a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_461f1fcf-069a-49e4-89a5-e3ca89cc6990" xlink:to="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_cdca0f7a-3edc-473f-a4eb-7882e782b314" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_cdca0f7a-3edc-473f-a4eb-7882e782b314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_032a3d46-57b7-4f17-bb0f-97c38429a50a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_032a3d46-57b7-4f17-bb0f-97c38429a50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_67e48445-116a-4442-a455-79185f278387" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_67e48445-116a-4442-a455-79185f278387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_c287ee84-cf77-4f0e-a889-b9423961bf4c" xlink:href="arwr-20250930.xsd#arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_c287ee84-cf77-4f0e-a889-b9423961bf4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_3f627856-20df-4a91-b791-3aa70ddb8886" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_3f627856-20df-4a91-b791-3aa70ddb8886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised_c123bd91-ddfa-4552-a968-6b23b60bd06c" xlink:href="arwr-20250930.xsd#arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised_c123bd91-ddfa-4552-a968-6b23b60bd06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_442fdf8b-e1cd-4ecd-924c-ea53e03c8546" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_442fdf8b-e1cd-4ecd-924c-ea53e03c8546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_da159cce-3d96-4ad2-b6e8-f01003a21df7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_da159cce-3d96-4ad2-b6e8-f01003a21df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2334cc41-6ada-46e7-99a6-65341f690bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2334cc41-6ada-46e7-99a6-65341f690bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_bc46e6e8-78e1-4aca-bbc2-275e93c4aad8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_bc46e6e8-78e1-4aca-bbc2-275e93c4aad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_ae9cd104-f767-44c3-a859-3f7a6b89dccd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_ae9cd104-f767-44c3-a859-3f7a6b89dccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2e52fb0e-ac0e-4351-b56b-9f433932f734" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2e52fb0e-ac0e-4351-b56b-9f433932f734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements_5a3a61e4-00b8-45a6-a71f-45efd66b56b7" xlink:href="arwr-20250930.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_arwr_ProceedsFromCollaborationArrangements_5a3a61e4-00b8-45a6-a71f-45efd66b56b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentDueFromCollaborativeAgreement_da2d7673-ca05-4780-842e-fef95e759750" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentDueFromCollaborativeAgreement"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_arwr_MilestonePaymentDueFromCollaborativeAgreement_da2d7673-ca05-4780-842e-fef95e759750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_183241af-4ee1-4a50-a6c2-4bfe31d5875e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_TreasuryStockCommonValue_183241af-4ee1-4a50-a6c2-4bfe31d5875e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GainLossOnTreasuryStockSettlement_2a77132d-6e19-425c-947b-fb6cea3d7b28" xlink:href="arwr-20250930.xsd#arwr_GainLossOnTreasuryStockSettlement"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_arwr_GainLossOnTreasuryStockSettlement_2a77132d-6e19-425c-947b-fb6cea3d7b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_404cf8c1-e27c-423c-a7a1-afb062b95ddd" xlink:href="arwr-20250930.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_404cf8c1-e27c-423c-a7a1-afb062b95ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_6aa72365-f743-4bc2-8886-f80bc6766074" xlink:href="arwr-20250930.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_6aa72365-f743-4bc2-8886-f80bc6766074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_65492919-9f49-4ccb-ae03-1140139103f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f7e5f24-744a-42a5-905b-deec54bd7fe8" xlink:to="loc_us-gaap_SharesIssued_65492919-9f49-4ccb-ae03-1140139103f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b6ef9b2e-c9bd-4d95-965f-6290a27f22a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_1f8ba867-9896-4b89-bb51-98c7063c4b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b6ef9b2e-c9bd-4d95-965f-6290a27f22a1" xlink:to="loc_us-gaap_OtherCommitmentsTable_1f8ba867-9896-4b89-bb51-98c7063c4b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b638f558-f25e-4507-ba85-28d0d9fe2b17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1f8ba867-9896-4b89-bb51-98c7063c4b5e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b638f558-f25e-4507-ba85-28d0d9fe2b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bbb7454-e631-4829-bbd1-80aec58a5f14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b638f558-f25e-4507-ba85-28d0d9fe2b17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bbb7454-e631-4829-bbd1-80aec58a5f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember_1eba91d4-322d-4ad3-8da2-9fec44e20009" xlink:href="arwr-20250930.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bbb7454-e631-4829-bbd1-80aec58a5f14" xlink:to="loc_arwr_DrugManufacturingFacilityMember_1eba91d4-322d-4ad3-8da2-9fec44e20009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember_ebd5b8c5-27c8-4a20-8b6e-eade648665fb" xlink:href="arwr-20250930.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bbb7454-e631-4829-bbd1-80aec58a5f14" xlink:to="loc_arwr_LaboratoryAndOfficeFacilityMember_ebd5b8c5-27c8-4a20-8b6e-eade648665fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember_bcabdccc-4755-413a-9d76-a23acd736df2" xlink:href="arwr-20250930.xsd#arwr_FacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bbb7454-e631-4829-bbd1-80aec58a5f14" xlink:to="loc_arwr_FacilitiesMember_bcabdccc-4755-413a-9d76-a23acd736df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_96cd5d7e-8ec6-479f-8983-ff62c115044f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bbb7454-e631-4829-bbd1-80aec58a5f14" xlink:to="loc_us-gaap_BuildingMember_96cd5d7e-8ec6-479f-8983-ff62c115044f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ManufacturingEquipmentMember_b2c88eb7-cab6-4b0c-8737-34f5c09906d8" xlink:href="arwr-20250930.xsd#arwr_ManufacturingEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bbb7454-e631-4829-bbd1-80aec58a5f14" xlink:to="loc_arwr_ManufacturingEquipmentMember_b2c88eb7-cab6-4b0c-8737-34f5c09906d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_a0c50e04-9d0f-4579-bbd9-1d8b5a629c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bbb7454-e631-4829-bbd1-80aec58a5f14" xlink:to="loc_us-gaap_ConstructionInProgressMember_a0c50e04-9d0f-4579-bbd9-1d8b5a629c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentMember_ed6468bb-a73d-4633-91af-0ec1befd3595" xlink:href="arwr-20250930.xsd#arwr_ResearchEquipmentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bbb7454-e631-4829-bbd1-80aec58a5f14" xlink:to="loc_arwr_ResearchEquipmentMember_ed6468bb-a73d-4633-91af-0ec1befd3595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_b9184ec8-5d56-4209-bc95-fc4caa0fde4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5bbb7454-e631-4829-bbd1-80aec58a5f14" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_b9184ec8-5d56-4209-bc95-fc4caa0fde4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f1cc78df-829a-47e3-92e1-4f0d6bc0d174" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1f8ba867-9896-4b89-bb51-98c7063c4b5e" xlink:to="loc_srt_StatementGeographicalAxis_f1cc78df-829a-47e3-92e1-4f0d6bc0d174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_73935a2a-9032-4000-a60e-5201272f161c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f1cc78df-829a-47e3-92e1-4f0d6bc0d174" xlink:to="loc_srt_SegmentGeographicalDomain_73935a2a-9032-4000-a60e-5201272f161c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_04a845dd-9d00-4ffb-a1e6-b6359bc526d6" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_WI"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_73935a2a-9032-4000-a60e-5201272f161c" xlink:to="loc_stpr_WI_04a845dd-9d00-4ffb-a1e6-b6359bc526d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_5fd9721f-3ba6-4d6b-9583-0dc98539304e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1f8ba867-9896-4b89-bb51-98c7063c4b5e" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_5fd9721f-3ba6-4d6b-9583-0dc98539304e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_56a7635d-0ede-4f29-b217-8d18e2b8f952" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5fd9721f-3ba6-4d6b-9583-0dc98539304e" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_56a7635d-0ede-4f29-b217-8d18e2b8f952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_b9f884b6-65af-4ecc-a18a-03ad629588f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5fd9721f-3ba6-4d6b-9583-0dc98539304e" xlink:to="loc_us-gaap_AreaOfLand_b9f884b6-65af-4ecc-a18a-03ad629588f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommitmentsCapitalExpendituresIncurredToDate_469b66e1-351c-471d-b625-c0f82ce24e3a" xlink:href="arwr-20250930.xsd#arwr_CommitmentsCapitalExpendituresIncurredToDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5fd9721f-3ba6-4d6b-9583-0dc98539304e" xlink:to="loc_arwr_CommitmentsCapitalExpendituresIncurredToDate_469b66e1-351c-471d-b625-c0f82ce24e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6a19f448-91fa-404d-ada7-f1031e6bf357" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_69d36c37-2cb3-49a7-bdfa-cc10f35c1bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6a19f448-91fa-404d-ada7-f1031e6bf357" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_69d36c37-2cb3-49a7-bdfa-cc10f35c1bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c13751a2-9547-41ac-b7ea-5e37d914ecf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_69d36c37-2cb3-49a7-bdfa-cc10f35c1bf9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c13751a2-9547-41ac-b7ea-5e37d914ecf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ccc2a932-ea57-48bf-9427-21dac7bae22a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c13751a2-9547-41ac-b7ea-5e37d914ecf5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ccc2a932-ea57-48bf-9427-21dac7bae22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember_6e97818b-09f1-4ede-a245-2a169d3869a3" xlink:href="arwr-20250930.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ccc2a932-ea57-48bf-9427-21dac7bae22a" xlink:to="loc_arwr_CorporateHeadquartersInPasadenaMember_6e97818b-09f1-4ede-a245-2a169d3869a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember_2f04c8f8-01da-4b61-b8e5-fee5b41d8c4f" xlink:href="arwr-20250930.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ccc2a932-ea57-48bf-9427-21dac7bae22a" xlink:to="loc_arwr_ResearchFacilityInSanDiegoMember_2f04c8f8-01da-4b61-b8e5-fee5b41d8c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember_fa6ac228-4557-44cc-b6f2-d401f22091ed" xlink:href="arwr-20250930.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ccc2a932-ea57-48bf-9427-21dac7bae22a" xlink:to="loc_arwr_ResearchFacilityInMadisonMember_fa6ac228-4557-44cc-b6f2-d401f22091ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8bc6d97b-fbe7-4eea-8885-b808aa7fc3f5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_69d36c37-2cb3-49a7-bdfa-cc10f35c1bf9" xlink:to="loc_srt_StatementGeographicalAxis_8bc6d97b-fbe7-4eea-8885-b808aa7fc3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_221d1f5f-ceb1-40d8-8767-a89190966c68" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8bc6d97b-fbe7-4eea-8885-b808aa7fc3f5" xlink:to="loc_srt_SegmentGeographicalDomain_221d1f5f-ceb1-40d8-8767-a89190966c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_93295aa3-661b-44cd-9e29-fbb0ab48914f" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_221d1f5f-ceb1-40d8-8767-a89190966c68" xlink:to="loc_stpr_CA_93295aa3-661b-44cd-9e29-fbb0ab48914f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_75e3714f-7cfb-4bb4-8ac6-d44d7f9c9c96" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_WI"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_221d1f5f-ceb1-40d8-8767-a89190966c68" xlink:to="loc_stpr_WI_75e3714f-7cfb-4bb4-8ac6-d44d7f9c9c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_23ca2b22-6b86-46f9-bdc4-96eba8fcfc05" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_69d36c37-2cb3-49a7-bdfa-cc10f35c1bf9" xlink:to="loc_srt_CounterpartyNameAxis_23ca2b22-6b86-46f9-bdc4-96eba8fcfc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ffc6541b-7bf7-4a0d-892f-c6f9b8fcee60" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_23ca2b22-6b86-46f9-bdc4-96eba8fcfc05" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ffc6541b-7bf7-4a0d-892f-c6f9b8fcee60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember_8efd7cc1-358c-44a3-b077-e9a17c2658f0" xlink:href="arwr-20250930.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ffc6541b-7bf7-4a0d-892f-c6f9b8fcee60" xlink:to="loc_arwr_ColoradoOwnerLLCMember_8efd7cc1-358c-44a3-b077-e9a17c2658f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d404d749-80b5-4797-8d0c-6e57e7752948" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_69d36c37-2cb3-49a7-bdfa-cc10f35c1bf9" xlink:to="loc_srt_RangeAxis_d404d749-80b5-4797-8d0c-6e57e7752948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c5e52299-1e86-4204-9d59-541d399435aa" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d404d749-80b5-4797-8d0c-6e57e7752948" xlink:to="loc_srt_RangeMember_c5e52299-1e86-4204-9d59-541d399435aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_069c07c9-0737-4fa9-8130-856c5c95cdb2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c5e52299-1e86-4204-9d59-541d399435aa" xlink:to="loc_srt_MaximumMember_069c07c9-0737-4fa9-8130-856c5c95cdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8e69758f-fd8b-4df3-95d8-9e880bc2e084" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_69d36c37-2cb3-49a7-bdfa-cc10f35c1bf9" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_8e69758f-fd8b-4df3-95d8-9e880bc2e084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_b378a007-1585-4d4c-a73b-7d2d4c4a0776" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8e69758f-fd8b-4df3-95d8-9e880bc2e084" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_b378a007-1585-4d4c-a73b-7d2d4c4a0776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew_aeddc1c6-9ba8-4e73-8f75-aef195927713" xlink:href="arwr-20250930.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8e69758f-fd8b-4df3-95d8-9e880bc2e084" xlink:to="loc_arwr_NumberOfOptionsToRenew_aeddc1c6-9ba8-4e73-8f75-aef195927713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_156d734b-b10f-4f6c-af33-dd2c00142b74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8e69758f-fd8b-4df3-95d8-9e880bc2e084" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_156d734b-b10f-4f6c-af33-dd2c00142b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b7f3d190-cc92-4b4c-ae9c-df58870e2655" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8e69758f-fd8b-4df3-95d8-9e880bc2e084" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b7f3d190-cc92-4b4c-ae9c-df58870e2655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromTenantImprovementAllowance_37c53219-34b7-47f1-a66e-94f3e09a41b6" xlink:href="arwr-20250930.xsd#arwr_ProceedsFromTenantImprovementAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8e69758f-fd8b-4df3-95d8-9e880bc2e084" xlink:to="loc_arwr_ProceedsFromTenantImprovementAllowance_37c53219-34b7-47f1-a66e-94f3e09a41b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_673888a4-15f0-4878-85a0-ab90c914c4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8e69758f-fd8b-4df3-95d8-9e880bc2e084" xlink:to="loc_us-gaap_ShortTermLeaseCost_673888a4-15f0-4878-85a0-ab90c914c4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#LeasesComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2d884a96-6bdb-445e-9e26-00e02d702737" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f8c28bd3-80cf-4587-9058-dd58bc3e72a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2d884a96-6bdb-445e-9e26-00e02d702737" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f8c28bd3-80cf-4587-9058-dd58bc3e72a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_751e3ebc-8dd3-43b4-863f-e570a7a53a89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f8c28bd3-80cf-4587-9058-dd58bc3e72a8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_751e3ebc-8dd3-43b4-863f-e570a7a53a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1092649d-66a9-4e65-8eb8-0d3102b7a74e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_751e3ebc-8dd3-43b4-863f-e570a7a53a89" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1092649d-66a9-4e65-8eb8-0d3102b7a74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3d36d9f1-0ae6-42f1-8dae-420f3afc40be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1092649d-66a9-4e65-8eb8-0d3102b7a74e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3d36d9f1-0ae6-42f1-8dae-420f3afc40be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_906677a1-b174-40ae-a704-987527982d80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1092649d-66a9-4e65-8eb8-0d3102b7a74e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_906677a1-b174-40ae-a704-987527982d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_113f5da9-2e13-4ae5-bfcf-b7d18522d103" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f8c28bd3-80cf-4587-9058-dd58bc3e72a8" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_113f5da9-2e13-4ae5-bfcf-b7d18522d103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_6328ff21-1dd3-4551-9674-2dfdec5451ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_113f5da9-2e13-4ae5-bfcf-b7d18522d103" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_6328ff21-1dd3-4551-9674-2dfdec5451ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0800a959-fb9c-469b-95f2-a545aefa3a08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_6328ff21-1dd3-4551-9674-2dfdec5451ed" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0800a959-fb9c-469b-95f2-a545aefa3a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_57b90653-2cde-405b-94d5-cf927772346a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_6328ff21-1dd3-4551-9674-2dfdec5451ed" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_57b90653-2cde-405b-94d5-cf927772346a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_439f7e73-2ce7-4e00-baad-a63f512c9c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_6328ff21-1dd3-4551-9674-2dfdec5451ed" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_439f7e73-2ce7-4e00-baad-a63f512c9c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_0abe8ae8-a052-4bc9-96de-93a1185bc041" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_113f5da9-2e13-4ae5-bfcf-b7d18522d103" xlink:to="loc_us-gaap_LeaseCostAbstract_0abe8ae8-a052-4bc9-96de-93a1185bc041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_b09d88c5-f720-47a4-852f-7d2fbbb50721" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_0abe8ae8-a052-4bc9-96de-93a1185bc041" xlink:to="loc_us-gaap_OperatingLeaseCost_b09d88c5-f720-47a4-852f-7d2fbbb50721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_454a01db-d313-4179-8186-4dfbdc35b58d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_0abe8ae8-a052-4bc9-96de-93a1185bc041" xlink:to="loc_us-gaap_VariableLeaseCost_454a01db-d313-4179-8186-4dfbdc35b58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_d4cbc9ba-1d3e-4a3b-bf52-8660dd9a3b77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_0abe8ae8-a052-4bc9-96de-93a1185bc041" xlink:to="loc_us-gaap_LeaseCost_d4cbc9ba-1d3e-4a3b-bf52-8660dd9a3b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_619d406c-f542-440e-b965-1949af34a509" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fe84522c-bf4c-441b-ae5c-b1f80d147572" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_619d406c-f542-440e-b965-1949af34a509" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fe84522c-bf4c-441b-ae5c-b1f80d147572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_abbbb56d-e223-438c-98a3-172685b2bbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_619d406c-f542-440e-b965-1949af34a509" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_abbbb56d-e223-438c-98a3-172685b2bbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d944c307-a308-4676-9b7a-9f01ca70b6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_619d406c-f542-440e-b965-1949af34a509" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d944c307-a308-4676-9b7a-9f01ca70b6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_34982479-0082-4564-9be6-2734ffd73372" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_619d406c-f542-440e-b965-1949af34a509" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_34982479-0082-4564-9be6-2734ffd73372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_b3b687cb-fadc-439a-b60d-690d93c57a50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_619d406c-f542-440e-b965-1949af34a509" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_b3b687cb-fadc-439a-b60d-690d93c57a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9e4d2540-f2e5-4a19-bb83-8bd28bdd8237" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_619d406c-f542-440e-b965-1949af34a509" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9e4d2540-f2e5-4a19-bb83-8bd28bdd8237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_23a36b6e-1703-4963-97cc-c850d2f38114" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_619d406c-f542-440e-b965-1949af34a509" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_23a36b6e-1703-4963-97cc-c850d2f38114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_84f252b9-b114-4aa4-8886-ed98ff3c37e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_619d406c-f542-440e-b965-1949af34a509" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_84f252b9-b114-4aa4-8886-ed98ff3c37e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_779616e7-29a4-4f07-81c4-d5311ecdefd5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_619d406c-f542-440e-b965-1949af34a509" xlink:to="loc_us-gaap_OperatingLeaseLiability_779616e7-29a4-4f07-81c4-d5311ecdefd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b740fc81-8eec-4bc5-9efc-84330c71530d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_6619d07b-df62-43f7-9b52-286971bb5440" xlink:href="arwr-20250930.xsd#arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b740fc81-8eec-4bc5-9efc-84330c71530d" xlink:to="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_6619d07b-df62-43f7-9b52-286971bb5440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_5a5dd5d1-ba83-4700-8d03-ada37aa0268d" xlink:href="arwr-20250930.xsd#arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_6619d07b-df62-43f7-9b52-286971bb5440" xlink:to="loc_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_5a5dd5d1-ba83-4700-8d03-ada37aa0268d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability_8a023fe3-376e-4f9c-bee6-1056a192538a" xlink:href="arwr-20250930.xsd#arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b740fc81-8eec-4bc5-9efc-84330c71530d" xlink:to="loc_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability_8a023fe3-376e-4f9c-bee6-1056a192538a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_dbef8c83-2873-4689-a779-70e60f68ae02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b740fc81-8eec-4bc5-9efc-84330c71530d" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_dbef8c83-2873-4689-a779-70e60f68ae02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_0f2be881-43c4-4fda-9aef-10f116ea9838" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_dbef8c83-2873-4689-a779-70e60f68ae02" xlink:to="loc_us-gaap_OperatingLeasePayments_0f2be881-43c4-4fda-9aef-10f116ea9838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c637ce44-8166-4c39-9fb4-3a15eec2a10d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b740fc81-8eec-4bc5-9efc-84330c71530d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c637ce44-8166-4c39-9fb4-3a15eec2a10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f2391622-e007-449e-8cae-63a244498169" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b740fc81-8eec-4bc5-9efc-84330c71530d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f2391622-e007-449e-8cae-63a244498169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82edea40-1d7e-4f5e-beb3-ae9b6e1b4bac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_468c086a-3c94-4faa-b991-b243fdf58374" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82edea40-1d7e-4f5e-beb3-ae9b6e1b4bac" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_468c086a-3c94-4faa-b991-b243fdf58374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0130aa08-06a3-4cf4-9f56-1ec60e297cee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_468c086a-3c94-4faa-b991-b243fdf58374" xlink:to="loc_us-gaap_PlanNameAxis_0130aa08-06a3-4cf4-9f56-1ec60e297cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7fc14f5d-f255-4036-a6e4-7da4a862a6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0130aa08-06a3-4cf4-9f56-1ec60e297cee" xlink:to="loc_us-gaap_PlanNameDomain_7fc14f5d-f255-4036-a6e4-7da4a862a6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_bd3d79d4-5d5e-4427-be5c-f84da5cdb64b" xlink:href="arwr-20250930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7fc14f5d-f255-4036-a6e4-7da4a862a6c9" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_bd3d79d4-5d5e-4427-be5c-f84da5cdb64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_226adbe7-f6e7-4192-bad8-f7353bbb5f2c" xlink:href="arwr-20250930.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7fc14f5d-f255-4036-a6e4-7da4a862a6c9" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_226adbe7-f6e7-4192-bad8-f7353bbb5f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementPlanMember_34ecc363-7c56-4e76-a235-b755cefc726a" xlink:href="arwr-20250930.xsd#arwr_InducementPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7fc14f5d-f255-4036-a6e4-7da4a862a6c9" xlink:to="loc_arwr_InducementPlanMember_34ecc363-7c56-4e76-a235-b755cefc726a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaESOPMember_ea546268-0290-452b-ab7e-7cc21ba07835" xlink:href="arwr-20250930.xsd#arwr_VisirnaESOPMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7fc14f5d-f255-4036-a6e4-7da4a862a6c9" xlink:to="loc_arwr_VisirnaESOPMember_ea546268-0290-452b-ab7e-7cc21ba07835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_66d3a9f6-b81e-48b3-b7a3-f70f0d6e32e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_468c086a-3c94-4faa-b991-b243fdf58374" xlink:to="loc_us-gaap_AwardTypeAxis_66d3a9f6-b81e-48b3-b7a3-f70f0d6e32e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0765462d-ad96-40a5-95b2-e2d8cbeb8c07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_66d3a9f6-b81e-48b3-b7a3-f70f0d6e32e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0765462d-ad96-40a5-95b2-e2d8cbeb8c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_37e5e5d1-3988-4558-8de6-d20c2b2ce272" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0765462d-ad96-40a5-95b2-e2d8cbeb8c07" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_37e5e5d1-3988-4558-8de6-d20c2b2ce272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6dc59a7b-751f-49a3-96df-1660b655aadf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0765462d-ad96-40a5-95b2-e2d8cbeb8c07" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6dc59a7b-751f-49a3-96df-1660b655aadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_468c086a-3c94-4faa-b991-b243fdf58374" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_c3efc5ec-bf04-49a9-8c25-2eca2e637e95" xlink:href="arwr-20250930.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_c3efc5ec-bf04-49a9-8c25-2eca2e637e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_52502a6c-0559-4f37-ae42-bb159311754c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_52502a6c-0559-4f37-ae42-bb159311754c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_91b367fa-cf8b-482f-b698-dbb0061ffc85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_91b367fa-cf8b-482f-b698-dbb0061ffc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b302ef4a-033b-4a55-bb00-f8cd110d0f13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b302ef4a-033b-4a55-bb00-f8cd110d0f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4800615c-638a-4977-81ae-d716e763f325" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4800615c-638a-4977-81ae-d716e763f325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ab32a88b-3693-4594-86cc-6f77ec1591cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ab32a88b-3693-4594-86cc-6f77ec1591cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_973335f2-65ad-463d-8db7-e0b72334a659" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_973335f2-65ad-463d-8db7-e0b72334a659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8f2c4cc6-c80e-4b0b-b9d5-c9a419a9a711" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8f2c4cc6-c80e-4b0b-b9d5-c9a419a9a711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4982ce21-17a0-449b-9380-9e54d9eb0c64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4982ce21-17a0-449b-9380-9e54d9eb0c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_336b1abd-f6a1-44be-9c64-9d567ca96566" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_336b1abd-f6a1-44be-9c64-9d567ca96566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a3ae37ae-5eb2-43e7-84c0-e3d5638b2ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58a37456-a41f-42f9-ad25-65e0371c8f25" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a3ae37ae-5eb2-43e7-84c0-e3d5638b2ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11e5cba2-0e06-4ea3-afb2-175722e6395b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c78dbc2-d3b4-4472-af85-37e154159d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11e5cba2-0e06-4ea3-afb2-175722e6395b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c78dbc2-d3b4-4472-af85-37e154159d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ac22929e-d73e-4e31-bc82-5b5cfb0276bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c78dbc2-d3b4-4472-af85-37e154159d0c" xlink:to="loc_us-gaap_AwardTypeAxis_ac22929e-d73e-4e31-bc82-5b5cfb0276bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f1627b7-ddc9-4f5d-93fc-5f13ae696ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ac22929e-d73e-4e31-bc82-5b5cfb0276bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f1627b7-ddc9-4f5d-93fc-5f13ae696ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2cf299b2-c974-4093-aedd-53122e611923" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f1627b7-ddc9-4f5d-93fc-5f13ae696ce1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2cf299b2-c974-4093-aedd-53122e611923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4b90bcde-f56f-46ea-bede-3f091bfde7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c78dbc2-d3b4-4472-af85-37e154159d0c" xlink:to="loc_us-gaap_PlanNameAxis_4b90bcde-f56f-46ea-bede-3f091bfde7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d4fdec0b-d42d-48cb-bbc4-ba8f2c6200dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4b90bcde-f56f-46ea-bede-3f091bfde7f6" xlink:to="loc_us-gaap_PlanNameDomain_d4fdec0b-d42d-48cb-bbc4-ba8f2c6200dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_d0b01d4d-fd49-4ce8-a92a-68d991983d88" xlink:href="arwr-20250930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d4fdec0b-d42d-48cb-bbc4-ba8f2c6200dd" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_d0b01d4d-fd49-4ce8-a92a-68d991983d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_b3eb8cf9-9eab-4c78-996c-80b4b41b3e90" xlink:href="arwr-20250930.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d4fdec0b-d42d-48cb-bbc4-ba8f2c6200dd" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_b3eb8cf9-9eab-4c78-996c-80b4b41b3e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember_d91006b0-2886-43f6-bb5b-d3ad56313fea" xlink:href="arwr-20250930.xsd#arwr_InducementAwardsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d4fdec0b-d42d-48cb-bbc4-ba8f2c6200dd" xlink:to="loc_arwr_InducementAwardsMember_d91006b0-2886-43f6-bb5b-d3ad56313fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f06cfd55-b6eb-44d1-a82e-a7cf7c4b39f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c78dbc2-d3b4-4472-af85-37e154159d0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f06cfd55-b6eb-44d1-a82e-a7cf7c4b39f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25cbb1df-65a5-42c1-a669-833cd779d335" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f06cfd55-b6eb-44d1-a82e-a7cf7c4b39f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25cbb1df-65a5-42c1-a669-833cd779d335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9b868892-ec5d-491f-b648-283be0dc7343" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f06cfd55-b6eb-44d1-a82e-a7cf7c4b39f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9b868892-ec5d-491f-b648-283be0dc7343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_334c0df5-3c28-49cd-acbf-cb5e5322c259" xlink:href="arwr-20250930.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f06cfd55-b6eb-44d1-a82e-a7cf7c4b39f3" xlink:to="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_334c0df5-3c28-49cd-acbf-cb5e5322c259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#StockBasedCompensationExpensesIncludedinOperatingExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eb34bfee-bba7-4601-b129-0c4905be831f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ec9c4b00-7b59-41d3-b5f1-88eb73ec8160" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eb34bfee-bba7-4601-b129-0c4905be831f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ec9c4b00-7b59-41d3-b5f1-88eb73ec8160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5d0db8ac-073c-4c73-bd0b-6a0ba45acad7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ec9c4b00-7b59-41d3-b5f1-88eb73ec8160" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5d0db8ac-073c-4c73-bd0b-6a0ba45acad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c6772088-0a47-4aa7-bde6-a7a7bde7a317" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5d0db8ac-073c-4c73-bd0b-6a0ba45acad7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c6772088-0a47-4aa7-bde6-a7a7bde7a317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_85b8b22d-f8b3-4312-bbd6-3cb2739dc726" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c6772088-0a47-4aa7-bde6-a7a7bde7a317" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_85b8b22d-f8b3-4312-bbd6-3cb2739dc726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_bf4a86b7-3153-4c04-b118-99281e35723a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c6772088-0a47-4aa7-bde6-a7a7bde7a317" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_bf4a86b7-3153-4c04-b118-99281e35723a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ccb1c1b1-9455-4747-b40b-d4ca651351a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ec9c4b00-7b59-41d3-b5f1-88eb73ec8160" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ccb1c1b1-9455-4747-b40b-d4ca651351a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6b1bb6cf-bed6-4336-964c-5f55530c368e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ccb1c1b1-9455-4747-b40b-d4ca651351a6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6b1bb6cf-bed6-4336-964c-5f55530c368e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#StockBasedCompensationSummarizedInformationaboutStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_010760b7-4518-44ec-a8e9-f85ddd870693" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d08a867f-263f-4c18-b432-bf036230ac11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_010760b7-4518-44ec-a8e9-f85ddd870693" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d08a867f-263f-4c18-b432-bf036230ac11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70170f87-def8-4877-8ff6-d42df3131ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d08a867f-263f-4c18-b432-bf036230ac11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70170f87-def8-4877-8ff6-d42df3131ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c57efe2a-42d4-4f7b-86d5-e7e921aefb68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d08a867f-263f-4c18-b432-bf036230ac11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c57efe2a-42d4-4f7b-86d5-e7e921aefb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8706b5ab-dd61-4a7f-8da8-3d9c6abc2821" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d08a867f-263f-4c18-b432-bf036230ac11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8706b5ab-dd61-4a7f-8da8-3d9c6abc2821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7b341dcf-0701-4ee2-b4f3-5f52b6de1716" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d08a867f-263f-4c18-b432-bf036230ac11" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7b341dcf-0701-4ee2-b4f3-5f52b6de1716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2350c400-6ccb-4eea-90ba-55ddba3475b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d08a867f-263f-4c18-b432-bf036230ac11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2350c400-6ccb-4eea-90ba-55ddba3475b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9bf3f988-3dc7-4a7d-829a-aeda1a0f478a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_010760b7-4518-44ec-a8e9-f85ddd870693" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9bf3f988-3dc7-4a7d-829a-aeda1a0f478a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1ec1adef-3590-4648-93cd-ddac526af1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_010760b7-4518-44ec-a8e9-f85ddd870693" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1ec1adef-3590-4648-93cd-ddac526af1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ddf274bb-8ee8-4c5f-a858-275346923041" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1ec1adef-3590-4648-93cd-ddac526af1a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ddf274bb-8ee8-4c5f-a858-275346923041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_384f5733-2de9-48c0-bd48-56036405701e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1ec1adef-3590-4648-93cd-ddac526af1a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_384f5733-2de9-48c0-bd48-56036405701e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_f43dbbd3-bdfe-474a-b2b9-dbdecc6b1939" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1ec1adef-3590-4648-93cd-ddac526af1a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_f43dbbd3-bdfe-474a-b2b9-dbdecc6b1939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_61ffed4b-5b5e-4916-9b3c-6740b7922fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1ec1adef-3590-4648-93cd-ddac526af1a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_61ffed4b-5b5e-4916-9b3c-6740b7922fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1c30865a-d126-467f-8cb1-6ff0afa653fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1ec1adef-3590-4648-93cd-ddac526af1a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1c30865a-d126-467f-8cb1-6ff0afa653fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_28419288-b1f8-46ea-af42-c8fe12c85e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_010760b7-4518-44ec-a8e9-f85ddd870693" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_28419288-b1f8-46ea-af42-c8fe12c85e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ada353a8-1f6e-476a-b229-6424e1858cab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_010760b7-4518-44ec-a8e9-f85ddd870693" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ada353a8-1f6e-476a-b229-6424e1858cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a0cf87a4-c22d-416c-b86d-7070e4c0bd34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_010760b7-4518-44ec-a8e9-f85ddd870693" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a0cf87a4-c22d-416c-b86d-7070e4c0bd34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5c41150f-6d12-4e31-9cb3-984f2e7afcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_010760b7-4518-44ec-a8e9-f85ddd870693" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5c41150f-6d12-4e31-9cb3-984f2e7afcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1855cb2f-362b-40f3-a5bd-dc4f61122b06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_010760b7-4518-44ec-a8e9-f85ddd870693" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1855cb2f-362b-40f3-a5bd-dc4f61122b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bfa59453-dc8a-4d3a-8a95-3c3abc082ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c236d065-ee58-41bb-b392-2f472ce4c4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bfa59453-dc8a-4d3a-8a95-3c3abc082ef8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c236d065-ee58-41bb-b392-2f472ce4c4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a8fa9a75-f387-42ba-94ae-6639120f5dda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bfa59453-dc8a-4d3a-8a95-3c3abc082ef8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a8fa9a75-f387-42ba-94ae-6639120f5dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_88cf0c4f-b538-4b78-9f1e-87a133c527af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bfa59453-dc8a-4d3a-8a95-3c3abc082ef8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_88cf0c4f-b538-4b78-9f1e-87a133c527af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_fb6ecd60-15b5-4650-9f90-e837ba9ee52e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bfa59453-dc8a-4d3a-8a95-3c3abc082ef8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_fb6ecd60-15b5-4650-9f90-e837ba9ee52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3f89c6bc-b795-4acb-8099-6e786a4129db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bfa59453-dc8a-4d3a-8a95-3c3abc082ef8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3f89c6bc-b795-4acb-8099-6e786a4129db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a4951cc9-7910-4570-b947-22a1af0d7c36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bfa59453-dc8a-4d3a-8a95-3c3abc082ef8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a4951cc9-7910-4570-b947-22a1af0d7c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_448eac0a-eb1f-4887-ace1-84ae8c583f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bfa59453-dc8a-4d3a-8a95-3c3abc082ef8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_448eac0a-eb1f-4887-ace1-84ae8c583f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#StockBasedCompensationScheduleofRSUsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e4928d9-890c-4d46-bf51-2b5916506a34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf17c2b4-9d35-4379-a6de-61371916e6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e4928d9-890c-4d46-bf51-2b5916506a34" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf17c2b4-9d35-4379-a6de-61371916e6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0cefcabe-0a56-4572-95f8-315d0b3ac00c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf17c2b4-9d35-4379-a6de-61371916e6d8" xlink:to="loc_us-gaap_AwardTypeAxis_0cefcabe-0a56-4572-95f8-315d0b3ac00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d0dbea1-8498-4ff0-9ac2-6117475e05f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0cefcabe-0a56-4572-95f8-315d0b3ac00c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d0dbea1-8498-4ff0-9ac2-6117475e05f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dead6ab5-eb61-4039-8050-47f964e10656" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d0dbea1-8498-4ff0-9ac2-6117475e05f0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dead6ab5-eb61-4039-8050-47f964e10656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5ee31cff-c18b-49ee-8eab-e1843d93a49a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf17c2b4-9d35-4379-a6de-61371916e6d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5ee31cff-c18b-49ee-8eab-e1843d93a49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_519a0936-55c8-41e6-9477-458a99c8b478" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5ee31cff-c18b-49ee-8eab-e1843d93a49a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_519a0936-55c8-41e6-9477-458a99c8b478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d01e4c06-b500-4e87-bea6-6ef0af9f4555" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_519a0936-55c8-41e6-9477-458a99c8b478" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d01e4c06-b500-4e87-bea6-6ef0af9f4555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_eb7769cd-5a20-4d6a-917b-40dcb9c7b200" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_519a0936-55c8-41e6-9477-458a99c8b478" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_eb7769cd-5a20-4d6a-917b-40dcb9c7b200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8a8e3e54-4ecf-49c8-9afa-b5a761633d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_519a0936-55c8-41e6-9477-458a99c8b478" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8a8e3e54-4ecf-49c8-9afa-b5a761633d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4ec783b5-b178-42b2-acba-e4cf02cd3432" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_519a0936-55c8-41e6-9477-458a99c8b478" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4ec783b5-b178-42b2-acba-e4cf02cd3432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aaf51267-7dae-4c96-82f4-a1b1f6c1129a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_519a0936-55c8-41e6-9477-458a99c8b478" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aaf51267-7dae-4c96-82f4-a1b1f6c1129a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5184c78b-4085-43c5-9336-5f682382efea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5ee31cff-c18b-49ee-8eab-e1843d93a49a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5184c78b-4085-43c5-9336-5f682382efea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ee0a5339-40f9-4131-bcc7-d89b18238997" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5184c78b-4085-43c5-9336-5f682382efea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ee0a5339-40f9-4131-bcc7-d89b18238997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e9022bf7-dfa9-452c-b9b8-a612141a33b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5184c78b-4085-43c5-9336-5f682382efea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e9022bf7-dfa9-452c-b9b8-a612141a33b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_215f4905-b143-4001-a2db-08a736828caf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5184c78b-4085-43c5-9336-5f682382efea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_215f4905-b143-4001-a2db-08a736828caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3a27eff8-8a6b-443b-ad67-4c7a9621e638" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5184c78b-4085-43c5-9336-5f682382efea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3a27eff8-8a6b-443b-ad67-4c7a9621e638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_45b6bb28-d79e-44ea-93cd-bf4c22fa28c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5184c78b-4085-43c5-9336-5f682382efea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_45b6bb28-d79e-44ea-93cd-bf4c22fa28c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e9121a31-3ee1-4d1a-b942-6830aac73fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d8eb37a8-48ec-437b-a968-8575769b7391" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e9121a31-3ee1-4d1a-b942-6830aac73fc4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d8eb37a8-48ec-437b-a968-8575769b7391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_705b7523-9ce6-4812-81d2-4e13b4f36d42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d8eb37a8-48ec-437b-a968-8575769b7391" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_705b7523-9ce6-4812-81d2-4e13b4f36d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_75787301-d275-46ab-b87b-b4fb5cf2cded" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_705b7523-9ce6-4812-81d2-4e13b4f36d42" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_75787301-d275-46ab-b87b-b4fb5cf2cded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d5c1140e-8da8-47ff-87d3-bc563b154f15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_75787301-d275-46ab-b87b-b4fb5cf2cded" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d5c1140e-8da8-47ff-87d3-bc563b154f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5252c658-b572-44be-acbf-e72df4ad7098" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d8eb37a8-48ec-437b-a968-8575769b7391" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5252c658-b572-44be-acbf-e72df4ad7098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_897c2eb6-2275-438c-9b72-d2c892ed239d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5252c658-b572-44be-acbf-e72df4ad7098" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_897c2eb6-2275-438c-9b72-d2c892ed239d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_519c6e93-da81-4f97-acc3-7c7303e0d8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_897c2eb6-2275-438c-9b72-d2c892ed239d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_519c6e93-da81-4f97-acc3-7c7303e0d8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_46329b45-5c6b-40b2-87fb-ad857267759c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_897c2eb6-2275-438c-9b72-d2c892ed239d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_46329b45-5c6b-40b2-87fb-ad857267759c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2b7827e8-118c-4252-8434-30f8f0b895bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_897c2eb6-2275-438c-9b72-d2c892ed239d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2b7827e8-118c-4252-8434-30f8f0b895bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6cffd2cb-ded7-4248-b947-493bf2c68ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d8eb37a8-48ec-437b-a968-8575769b7391" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6cffd2cb-ded7-4248-b947-493bf2c68ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_163e530c-731d-4712-b071-dccf4b36d9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6cffd2cb-ded7-4248-b947-493bf2c68ad3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_163e530c-731d-4712-b071-dccf4b36d9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3a3f552b-6263-4ab1-99f5-8eee6169f5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_163e530c-731d-4712-b071-dccf4b36d9a4" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3a3f552b-6263-4ab1-99f5-8eee6169f5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_870bbbd3-1c32-443a-a0d3-a958ccd47659" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_163e530c-731d-4712-b071-dccf4b36d9a4" xlink:to="loc_us-gaap_CertificatesOfDepositMember_870bbbd3-1c32-443a-a0d3-a958ccd47659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_abfcaa31-c7c2-473b-85d0-0f158fb5c32a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_163e530c-731d-4712-b071-dccf4b36d9a4" xlink:to="loc_us-gaap_MunicipalBondsMember_abfcaa31-c7c2-473b-85d0-0f158fb5c32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember_f5357a4a-3e64-4e3a-9f73-8ab8ff48ed77" xlink:href="arwr-20250930.xsd#arwr_CommercialNotesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_163e530c-731d-4712-b071-dccf4b36d9a4" xlink:to="loc_arwr_CommercialNotesMember_f5357a4a-3e64-4e3a-9f73-8ab8ff48ed77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_53f28a31-04f9-4973-a119-0a918fb7a9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_163e530c-731d-4712-b071-dccf4b36d9a4" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_53f28a31-04f9-4973-a119-0a918fb7a9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_c8a857f9-49ca-4117-bdc8-e603c6ddbe0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d8eb37a8-48ec-437b-a968-8575769b7391" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_c8a857f9-49ca-4117-bdc8-e603c6ddbe0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1b6deda3-ebc2-4c08-992d-8ca67449999c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_c8a857f9-49ca-4117-bdc8-e603c6ddbe0a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1b6deda3-ebc2-4c08-992d-8ca67449999c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_29fd32e4-5ba2-4d33-9c99-4b621c126f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1b6deda3-ebc2-4c08-992d-8ca67449999c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_29fd32e4-5ba2-4d33-9c99-4b621c126f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_6829bbf7-fe59-4d11-84c2-e4b56f37562a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1b6deda3-ebc2-4c08-992d-8ca67449999c" xlink:to="loc_us-gaap_BankTimeDepositsMember_6829bbf7-fe59-4d11-84c2-e4b56f37562a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_a01c58c7-23e0-409c-85f3-c75d526faf79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1b6deda3-ebc2-4c08-992d-8ca67449999c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_a01c58c7-23e0-409c-85f3-c75d526faf79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_21ebdb41-35d1-4175-a258-d17121be226c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1b6deda3-ebc2-4c08-992d-8ca67449999c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_21ebdb41-35d1-4175-a258-d17121be226c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a5ac01f-fe1f-45d3-b91b-2227ff27253a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d8eb37a8-48ec-437b-a968-8575769b7391" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a5ac01f-fe1f-45d3-b91b-2227ff27253a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d236db6f-2e1f-4c51-8384-03eb54f35970" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a5ac01f-fe1f-45d3-b91b-2227ff27253a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d236db6f-2e1f-4c51-8384-03eb54f35970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_882251b3-f7e5-4ee8-ba0d-277ee2e597be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a5ac01f-fe1f-45d3-b91b-2227ff27253a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_882251b3-f7e5-4ee8-ba0d-277ee2e597be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3b71983f-b76b-4ccf-b65c-aed230ada0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5a5ac01f-fe1f-45d3-b91b-2227ff27253a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3b71983f-b76b-4ccf-b65c-aed230ada0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#IncomeTaxesComponentsofIncomeLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_46dcb0f8-6462-4c9d-a3aa-389e427458bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a4130970-23bc-4db5-acef-a50ccb184c73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46dcb0f8-6462-4c9d-a3aa-389e427458bf" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a4130970-23bc-4db5-acef-a50ccb184c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4d2d30ad-ac31-4908-849e-4a3718a1344c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46dcb0f8-6462-4c9d-a3aa-389e427458bf" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4d2d30ad-ac31-4908-849e-4a3718a1344c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_7fedcf74-1493-4c99-b306-60d34d5c0915" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46dcb0f8-6462-4c9d-a3aa-389e427458bf" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_7fedcf74-1493-4c99-b306-60d34d5c0915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#IncomeTaxesIncomeTaxProvisionBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_46a5d871-eee9-4690-9f0f-f7ab5edbe752" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e85ffeac-2da5-467d-876c-bac940775962" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46a5d871-eee9-4690-9f0f-f7ab5edbe752" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e85ffeac-2da5-467d-876c-bac940775962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_72fb9567-6005-4ab5-bb50-f8cc14f57505" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e85ffeac-2da5-467d-876c-bac940775962" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_72fb9567-6005-4ab5-bb50-f8cc14f57505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_9728c6d3-371e-4b66-83ac-8d13e0846917" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e85ffeac-2da5-467d-876c-bac940775962" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_9728c6d3-371e-4b66-83ac-8d13e0846917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ad371dd9-80d2-4605-a7ac-18c62cbb1097" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e85ffeac-2da5-467d-876c-bac940775962" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ad371dd9-80d2-4605-a7ac-18c62cbb1097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_90bb1980-8e48-484f-9a57-6427e807ad6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e85ffeac-2da5-467d-876c-bac940775962" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_90bb1980-8e48-484f-9a57-6427e807ad6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e3a703b1-4f8e-4aa2-b623-ddce81c9f8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46a5d871-eee9-4690-9f0f-f7ab5edbe752" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e3a703b1-4f8e-4aa2-b623-ddce81c9f8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4bd5c988-6529-4d64-a207-33e272e1b01f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e3a703b1-4f8e-4aa2-b623-ddce81c9f8a0" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4bd5c988-6529-4d64-a207-33e272e1b01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_07f44523-f707-47f3-918a-08d490785eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e3a703b1-4f8e-4aa2-b623-ddce81c9f8a0" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_07f44523-f707-47f3-918a-08d490785eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_63376e66-50f4-47f7-8e5c-0810d24ef20d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e3a703b1-4f8e-4aa2-b623-ddce81c9f8a0" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_63376e66-50f4-47f7-8e5c-0810d24ef20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1bca2c3f-a6cd-4577-9f09-5133613b92e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e3a703b1-4f8e-4aa2-b623-ddce81c9f8a0" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1bca2c3f-a6cd-4577-9f09-5133613b92e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9dfcf0c0-4fe8-4f75-8833-c77b5bf7bd10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46a5d871-eee9-4690-9f0f-f7ab5edbe752" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9dfcf0c0-4fe8-4f75-8833-c77b5bf7bd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a65e1879-4107-4744-844a-0427b34b08c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_41f31653-58c3-48fb-9c3b-cf4b5d19a2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a65e1879-4107-4744-844a-0427b34b08c0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_41f31653-58c3-48fb-9c3b-cf4b5d19a2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d889c6e4-a801-416d-9158-14fba18da30d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a65e1879-4107-4744-844a-0427b34b08c0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d889c6e4-a801-416d-9158-14fba18da30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_40c351f2-bf62-4881-944d-600882b53d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a65e1879-4107-4744-844a-0427b34b08c0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_40c351f2-bf62-4881-944d-600882b53d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0734cc6a-462c-400c-9432-12deb4b66051" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a65e1879-4107-4744-844a-0427b34b08c0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0734cc6a-462c-400c-9432-12deb4b66051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent_bd6ca556-771e-41d6-9b78-22b36237931c" xlink:href="arwr-20250930.xsd#arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a65e1879-4107-4744-844a-0427b34b08c0" xlink:to="loc_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent_bd6ca556-771e-41d6-9b78-22b36237931c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_6d0e0d07-bc78-4cd8-b034-b11da2d9d4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a65e1879-4107-4744-844a-0427b34b08c0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_6d0e0d07-bc78-4cd8-b034-b11da2d9d4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent_a3c3da73-4b63-4035-8454-2ffd2d347a0a" xlink:href="arwr-20250930.xsd#arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a65e1879-4107-4744-844a-0427b34b08c0" xlink:to="loc_arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent_a3c3da73-4b63-4035-8454-2ffd2d347a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_9874dbb4-8a9f-4d77-8d28-b5137b99ef0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a65e1879-4107-4744-844a-0427b34b08c0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_9874dbb4-8a9f-4d77-8d28-b5137b99ef0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_d4b485e3-7098-491d-a2fb-ba2abc8aea2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a65e1879-4107-4744-844a-0427b34b08c0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_d4b485e3-7098-491d-a2fb-ba2abc8aea2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_dd86c040-0abe-499b-bd6d-278d1b577834" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a65e1879-4107-4744-844a-0427b34b08c0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_dd86c040-0abe-499b-bd6d-278d1b577834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b057de82-c9d4-4c7a-9115-c4b5988cad74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_fac4e62a-8ed3-4059-b8ef-ee672144678e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b057de82-c9d4-4c7a-9115-c4b5988cad74" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_fac4e62a-8ed3-4059-b8ef-ee672144678e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e7d8fe21-aacf-4980-8677-5e80dac383ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_fac4e62a-8ed3-4059-b8ef-ee672144678e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e7d8fe21-aacf-4980-8677-5e80dac383ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_17f05774-7975-47fd-be06-eb22694d1cf5" xlink:href="arwr-20250930.xsd#arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_fac4e62a-8ed3-4059-b8ef-ee672144678e" xlink:to="loc_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_17f05774-7975-47fd-be06-eb22694d1cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_58c8b1c3-bf42-4993-b6fe-861c8e4cc8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_fac4e62a-8ed3-4059-b8ef-ee672144678e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_58c8b1c3-bf42-4993-b6fe-861c8e4cc8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_f5a5a11c-5d91-45ed-bf61-dd91ceec9027" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_fac4e62a-8ed3-4059-b8ef-ee672144678e" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_f5a5a11c-5d91-45ed-bf61-dd91ceec9027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_1f7bfa99-acd0-4629-ba21-4d9a46ad843b" xlink:href="arwr-20250930.xsd#arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_fac4e62a-8ed3-4059-b8ef-ee672144678e" xlink:to="loc_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_1f7bfa99-acd0-4629-ba21-4d9a46ad843b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_bbd15d2b-b3f9-4d29-91df-efaa51bfb181" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_fac4e62a-8ed3-4059-b8ef-ee672144678e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_bbd15d2b-b3f9-4d29-91df-efaa51bfb181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_4d71f575-815f-484b-8d34-8faeb33889fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_fac4e62a-8ed3-4059-b8ef-ee672144678e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_4d71f575-815f-484b-8d34-8faeb33889fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_25b72c10-8f77-48c1-9a55-12086dcd69a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_fac4e62a-8ed3-4059-b8ef-ee672144678e" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_25b72c10-8f77-48c1-9a55-12086dcd69a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_8527ff2b-1a2b-4807-a411-6d3082d910ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_fac4e62a-8ed3-4059-b8ef-ee672144678e" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_8527ff2b-1a2b-4807-a411-6d3082d910ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_bf6e2050-0397-48ea-8a20-adeef0dbec81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_fac4e62a-8ed3-4059-b8ef-ee672144678e" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_bf6e2050-0397-48ea-8a20-adeef0dbec81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_706d4128-1d07-4ce9-b006-7cb6e856d240" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b057de82-c9d4-4c7a-9115-c4b5988cad74" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_706d4128-1d07-4ce9-b006-7cb6e856d240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_516d6afa-04ab-45bc-a2a4-ef412289b311" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b057de82-c9d4-4c7a-9115-c4b5988cad74" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_516d6afa-04ab-45bc-a2a4-ef412289b311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4fba8011-9412-4502-afac-e198a04fd4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_516d6afa-04ab-45bc-a2a4-ef412289b311" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4fba8011-9412-4502-afac-e198a04fd4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_826c2a67-23d5-4480-a600-9b73266711ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_516d6afa-04ab-45bc-a2a4-ef412289b311" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_826c2a67-23d5-4480-a600-9b73266711ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome_c9848469-894c-4424-a62c-fad1108b25d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_516d6afa-04ab-45bc-a2a4-ef412289b311" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome_c9848469-894c-4424-a62c-fad1108b25d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxLiabilitiesOriginalIssueDiscount_d0cf874b-7081-4820-a300-012bf09067bf" xlink:href="arwr-20250930.xsd#arwr_DeferredTaxLiabilitiesOriginalIssueDiscount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_516d6afa-04ab-45bc-a2a4-ef412289b311" xlink:to="loc_arwr_DeferredTaxLiabilitiesOriginalIssueDiscount_d0cf874b-7081-4820-a300-012bf09067bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_094bbc2d-854f-444a-83f5-cf474203b749" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_516d6afa-04ab-45bc-a2a4-ef412289b311" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_094bbc2d-854f-444a-83f5-cf474203b749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_3dcd37e7-0e67-4501-9615-4232130d77a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b057de82-c9d4-4c7a-9115-c4b5988cad74" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_3dcd37e7-0e67-4501-9615-4232130d77a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ad562b98-baef-4de2-b9b5-a67e55728374" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_bdef78cc-567f-4c57-9f7d-228f5ab6e85e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ad562b98-baef-4de2-b9b5-a67e55728374" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_bdef78cc-567f-4c57-9f7d-228f5ab6e85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_7fd7e379-c611-456e-bfe3-4dfe672a7ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_bdef78cc-567f-4c57-9f7d-228f5ab6e85e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_7fd7e379-c611-456e-bfe3-4dfe672a7ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_990e54a2-561c-4d69-81ed-ef24fdae3106" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_7fd7e379-c611-456e-bfe3-4dfe672a7ec8" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_990e54a2-561c-4d69-81ed-ef24fdae3106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_85898633-8c7c-443f-a627-9c7d8b5cf78f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_990e54a2-561c-4d69-81ed-ef24fdae3106" xlink:to="loc_us-gaap_DomesticCountryMember_85898633-8c7c-443f-a627-9c7d8b5cf78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_83fb56b2-0ec5-4d06-a559-70b0a79940b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_990e54a2-561c-4d69-81ed-ef24fdae3106" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_83fb56b2-0ec5-4d06-a559-70b0a79940b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_60bb801a-bd2c-4f99-ad49-f309f416efa6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_990e54a2-561c-4d69-81ed-ef24fdae3106" xlink:to="loc_us-gaap_ForeignCountryMember_60bb801a-bd2c-4f99-ad49-f309f416efa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_d9453892-d83a-4010-8739-3a8fea099071" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_bdef78cc-567f-4c57-9f7d-228f5ab6e85e" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_d9453892-d83a-4010-8739-3a8fea099071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b3882f7a-03d3-4018-b2a1-324c7f902233" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_d9453892-d83a-4010-8739-3a8fea099071" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b3882f7a-03d3-4018-b2a1-324c7f902233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_85a06ce2-b540-4760-ab32-9d8f0245f273" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_d9453892-d83a-4010-8739-3a8fea099071" xlink:to="loc_us-gaap_OperatingLossCarryforwards_85a06ce2-b540-4760-ab32-9d8f0245f273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingLossCarryforwardsSubjectToExpiration_ba68d536-e75c-4bc2-9837-2031272797e4" xlink:href="arwr-20250930.xsd#arwr_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_d9453892-d83a-4010-8739-3a8fea099071" xlink:to="loc_arwr_OperatingLossCarryforwardsSubjectToExpiration_ba68d536-e75c-4bc2-9837-2031272797e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingLossCarryforwardsNotSubjectToExpiration_4bd12b13-e0e3-4c3f-86f2-bae2ca380c6e" xlink:href="arwr-20250930.xsd#arwr_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_d9453892-d83a-4010-8739-3a8fea099071" xlink:to="loc_arwr_OperatingLossCarryforwardsNotSubjectToExpiration_4bd12b13-e0e3-4c3f-86f2-bae2ca380c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_85b0ddf6-2bc7-4956-96bb-1ed5b9c82260" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_d9453892-d83a-4010-8739-3a8fea099071" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_85b0ddf6-2bc7-4956-96bb-1ed5b9c82260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxCreditCarryforwardAmountSubjectToExpiration_be1c6b18-75d0-4112-897b-e3832721c7e0" xlink:href="arwr-20250930.xsd#arwr_TaxCreditCarryforwardAmountSubjectToExpiration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_d9453892-d83a-4010-8739-3a8fea099071" xlink:to="loc_arwr_TaxCreditCarryforwardAmountSubjectToExpiration_be1c6b18-75d0-4112-897b-e3832721c7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_d500dc56-ef7d-4815-948c-547f210920fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_d9453892-d83a-4010-8739-3a8fea099071" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_d500dc56-ef7d-4815-948c-547f210920fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cea5e22f-d0bd-4741-b4e7-921a125c8f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a35d7514-548c-41e5-ba78-2aac8d780810" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cea5e22f-d0bd-4741-b4e7-921a125c8f4f" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a35d7514-548c-41e5-ba78-2aac8d780810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_d4e53851-fc91-41eb-90d0-3b7809b381ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a35d7514-548c-41e5-ba78-2aac8d780810" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_d4e53851-fc91-41eb-90d0-3b7809b381ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_61f71fc6-beda-4eac-a45e-e7e62b800c33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a35d7514-548c-41e5-ba78-2aac8d780810" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_61f71fc6-beda-4eac-a45e-e7e62b800c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_bccbb4cd-6b7d-4257-bd86-b5ff455e2e16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a35d7514-548c-41e5-ba78-2aac8d780810" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_bccbb4cd-6b7d-4257-bd86-b5ff455e2e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_fd0ce096-c540-4a52-aa64-d6704d716f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a35d7514-548c-41e5-ba78-2aac8d780810" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_fd0ce096-c540-4a52-aa64-d6704d716f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_cebafb2a-e08a-458d-8395-21c2159c05e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a35d7514-548c-41e5-ba78-2aac8d780810" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_cebafb2a-e08a-458d-8395-21c2159c05e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_5bea692b-b1aa-44bb-920f-c8fe9f0c571c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a35d7514-548c-41e5-ba78-2aac8d780810" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_5bea692b-b1aa-44bb-920f-c8fe9f0c571c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#EmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d404094b-b557-470d-8494-56a9758c0b90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9d4c1b42-0da1-4335-9d4f-cfe336dc3b98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d404094b-b557-470d-8494-56a9758c0b90" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9d4c1b42-0da1-4335-9d4f-cfe336dc3b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_38f3b60d-c1d5-4bc6-a452-59d38426e6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9d4c1b42-0da1-4335-9d4f-cfe336dc3b98" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_38f3b60d-c1d5-4bc6-a452-59d38426e6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_072dd348-cf9b-482b-bad3-c9585227bb82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_38f3b60d-c1d5-4bc6-a452-59d38426e6a6" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_072dd348-cf9b-482b-bad3-c9585227bb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EmployeeContributionsUpToThreePercentMember_2db4a2dc-8556-45bf-88f7-6354d51c5131" xlink:href="arwr-20250930.xsd#arwr_EmployeeContributionsUpToThreePercentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_072dd348-cf9b-482b-bad3-c9585227bb82" xlink:to="loc_arwr_EmployeeContributionsUpToThreePercentMember_2db4a2dc-8556-45bf-88f7-6354d51c5131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EmployeeContributionNextTwoPercentMember_fb703d8a-3792-495b-b216-93636e900691" xlink:href="arwr-20250930.xsd#arwr_EmployeeContributionNextTwoPercentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_072dd348-cf9b-482b-bad3-c9585227bb82" xlink:to="loc_arwr_EmployeeContributionNextTwoPercentMember_fb703d8a-3792-495b-b216-93636e900691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_92b4deb8-36ad-47b9-a914-0cad459ffe7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9d4c1b42-0da1-4335-9d4f-cfe336dc3b98" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_92b4deb8-36ad-47b9-a914-0cad459ffe7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_cf52f063-6736-45e0-8e93-acd116572fce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_92b4deb8-36ad-47b9-a914-0cad459ffe7d" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_cf52f063-6736-45e0-8e93-acd116572fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_807d0c68-039c-4a77-ac1d-c339a15f5348" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_92b4deb8-36ad-47b9-a914-0cad459ffe7d" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_807d0c68-039c-4a77-ac1d-c339a15f5348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_01b3bcd7-4669-4ee9-9f93-79af37cfbc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_92b4deb8-36ad-47b9-a914-0cad459ffe7d" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_01b3bcd7-4669-4ee9-9f93-79af37cfbc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_271d666b-50bf-4ef3-96d1-7a2e98c14184" xlink:href="arwr-20250930.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0d2205a0-ba0e-4267-ac84-6251742af5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_271d666b-50bf-4ef3-96d1-7a2e98c14184" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0d2205a0-ba0e-4267-ac84-6251742af5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5fee4a07-2436-45d4-bcdf-618877835438" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0d2205a0-ba0e-4267-ac84-6251742af5f3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5fee4a07-2436-45d4-bcdf-618877835438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3aa2ff4-5082-4af0-b4fe-4a4dc56e6842" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5fee4a07-2436-45d4-bcdf-618877835438" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3aa2ff4-5082-4af0-b4fe-4a4dc56e6842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember_1da0ce0c-392b-4a95-9c7e-0ac3c5927359" xlink:href="arwr-20250930.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3aa2ff4-5082-4af0-b4fe-4a4dc56e6842" xlink:to="loc_arwr_RoyaltyPharmaAgreementMember_1da0ce0c-392b-4a95-9c7e-0ac3c5927359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a04bc8f4-2226-4a04-bf4c-0db90bb5c5b3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0d2205a0-ba0e-4267-ac84-6251742af5f3" xlink:to="loc_srt_RangeAxis_a04bc8f4-2226-4a04-bf4c-0db90bb5c5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_01b7aa23-4177-42e2-9b90-e069a6589ff6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a04bc8f4-2226-4a04-bf4c-0db90bb5c5b3" xlink:to="loc_srt_RangeMember_01b7aa23-4177-42e2-9b90-e069a6589ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b8170e00-f477-49c1-8ed8-385b28281c9d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_01b7aa23-4177-42e2-9b90-e069a6589ff6" xlink:to="loc_srt_MaximumMember_b8170e00-f477-49c1-8ed8-385b28281c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0d2205a0-ba0e-4267-ac84-6251742af5f3" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_737d956b-2450-446d-8b58-f761d32384cb" xlink:href="arwr-20250930.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:to="loc_arwr_InitialTransactionPrice_737d956b-2450-446d-8b58-f761d32384cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_0b08b957-107e-4acd-83ab-4202705dad6a" xlink:href="arwr-20250930.xsd#arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:to="loc_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_0b08b957-107e-4acd-83ab-4202705dad6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_8dd7ab7e-c92d-4138-a591-403e7a92b39f" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:to="loc_arwr_MilestonePaymentReceivable_8dd7ab7e-c92d-4138-a591-403e7a92b39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_ecd77645-70a4-4866-b662-8dd7f23744a7" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_ecd77645-70a4-4866-b662-8dd7f23744a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval_8aab6dd1-1129-44eb-ab2a-7ca7c1f03296" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:to="loc_arwr_MilestonePaymentReceivableUponFDAApproval_8aab6dd1-1129-44eb-ab2a-7ca7c1f03296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_02ce17b6-29d4-425f-971b-62c6be9d6fed" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:to="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_02ce17b6-29d4-425f-971b-62c6be9d6fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold_9006afc7-f945-4c4a-963c-b627203838a7" xlink:href="arwr-20250930.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:to="loc_arwr_RoyaltyPaymentThreshold_9006afc7-f945-4c4a-963c-b627203838a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_79e87921-6978-4bb3-a4cf-33af3ffda8f3" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:to="loc_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_79e87921-6978-4bb3-a4cf-33af3ffda8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_a709f5ac-b918-4d1f-83de-098526eae40f" xlink:href="arwr-20250930.xsd#arwr_LiabilitySaleOfFutureRoyaltiesInterestRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c8e1d86-a571-4a5f-b7be-e11d219e7a33" xlink:to="loc_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_a709f5ac-b918-4d1f-83de-098526eae40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_3a68da27-091e-4fcc-b7e1-0e93dbfd89d3" xlink:href="arwr-20250930.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_09478b41-6893-4456-af34-a779a852405a" xlink:href="arwr-20250930.xsd#arwr_LiabilitySaleOfFutureRoyaltiesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_3a68da27-091e-4fcc-b7e1-0e93dbfd89d3" xlink:to="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_09478b41-6893-4456-af34-a779a852405a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent_9c016472-c491-4b8f-a3c5-2b185c36a82f" xlink:href="arwr-20250930.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_09478b41-6893-4456-af34-a779a852405a" xlink:to="loc_arwr_RoyaltiesLiabilityNoncurrent_9c016472-c491-4b8f-a3c5-2b185c36a82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_597f2f20-cc33-4978-bdb0-aef50ffb5104" xlink:href="arwr-20250930.xsd#arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_09478b41-6893-4456-af34-a779a852405a" xlink:to="loc_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_597f2f20-cc33-4978-bdb0-aef50ffb5104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_779ed981-a11c-479e-aed5-f87df6220158" xlink:href="arwr-20250930.xsd#arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_09478b41-6893-4456-af34-a779a852405a" xlink:to="loc_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_779ed981-a11c-479e-aed5-f87df6220158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_9f077f65-f2b7-495b-a719-4f0cac948f2a" xlink:href="arwr-20250930.xsd#arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_09478b41-6893-4456-af34-a779a852405a" xlink:to="loc_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_9f077f65-f2b7-495b-a719-4f0cac948f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent_fe3698f4-be94-421c-8f22-939c4718fe31" xlink:href="arwr-20250930.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_09478b41-6893-4456-af34-a779a852405a" xlink:to="loc_arwr_RoyaltiesLiabilityNoncurrent_fe3698f4-be94-421c-8f22-939c4718fe31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#FinancingAgreementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_67db92f8-415d-4a33-a1ed-6ce95a44292c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_a2dbaa72-fc87-4762-96d6-340fff61d46a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_67db92f8-415d-4a33-a1ed-6ce95a44292c" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_a2dbaa72-fc87-4762-96d6-340fff61d46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_450200a0-48c1-4a6a-9283-a56bb1c5ffb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a2dbaa72-fc87-4762-96d6-340fff61d46a" xlink:to="loc_us-gaap_CreditFacilityAxis_450200a0-48c1-4a6a-9283-a56bb1c5ffb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6673f708-17c2-4478-959e-e30bbf60d6db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_450200a0-48c1-4a6a-9283-a56bb1c5ffb8" xlink:to="loc_us-gaap_CreditFacilityDomain_6673f708-17c2-4478-959e-e30bbf60d6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_c188d81d-321d-4498-9df0-05847551686e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_6673f708-17c2-4478-959e-e30bbf60d6db" xlink:to="loc_us-gaap_SecuredDebtMember_c188d81d-321d-4498-9df0-05847551686e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_2ec1af2c-d561-419a-8c5b-8a77b643db10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_6673f708-17c2-4478-959e-e30bbf60d6db" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_2ec1af2c-d561-419a-8c5b-8a77b643db10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f63d07e5-09fe-4c99-b0ab-ed7eeadfe8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a2dbaa72-fc87-4762-96d6-340fff61d46a" xlink:to="loc_us-gaap_DebtInstrumentAxis_f63d07e5-09fe-4c99-b0ab-ed7eeadfe8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_34a4409d-924f-4518-83fb-325fbdc8c212" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f63d07e5-09fe-4c99-b0ab-ed7eeadfe8e7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_34a4409d-924f-4518-83fb-325fbdc8c212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMember_a6e7776b-8020-497c-9f64-f5429bb3a584" xlink:href="arwr-20250930.xsd#arwr_FinancingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_34a4409d-924f-4518-83fb-325fbdc8c212" xlink:to="loc_arwr_FinancingAgreementMember_a6e7776b-8020-497c-9f64-f5429bb3a584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementInitialTermLoanMember_58d8d1b8-7f88-443c-8a95-7a9e03bcac66" xlink:href="arwr-20250930.xsd#arwr_FinancingAgreementInitialTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_FinancingAgreementMember_a6e7776b-8020-497c-9f64-f5429bb3a584" xlink:to="loc_arwr_FinancingAgreementInitialTermLoanMember_58d8d1b8-7f88-443c-8a95-7a9e03bcac66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMOICPaymentMember_6d865f50-a212-4738-8e92-a57090801af4" xlink:href="arwr-20250930.xsd#arwr_FinancingAgreementMOICPaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_FinancingAgreementMember_a6e7776b-8020-497c-9f64-f5429bb3a584" xlink:to="loc_arwr_FinancingAgreementMOICPaymentMember_6d865f50-a212-4738-8e92-a57090801af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ca714435-c263-4f97-a1d2-3a720b80e155" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a2dbaa72-fc87-4762-96d6-340fff61d46a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ca714435-c263-4f97-a1d2-3a720b80e155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2fd5a138-bebb-4ab4-bb05-a2727e865921" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ca714435-c263-4f97-a1d2-3a720b80e155" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2fd5a138-bebb-4ab4-bb05-a2727e865921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_745722b6-4e20-4e2a-805e-41f8fe5453fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2fd5a138-bebb-4ab4-bb05-a2727e865921" xlink:to="loc_us-gaap_LineOfCreditMember_745722b6-4e20-4e2a-805e-41f8fe5453fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_65a331a6-74ed-46f3-bed2-b60af8879de4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a2dbaa72-fc87-4762-96d6-340fff61d46a" xlink:to="loc_srt_CounterpartyNameAxis_65a331a6-74ed-46f3-bed2-b60af8879de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6645400a-8711-400e-8173-beae7764a223" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_65a331a6-74ed-46f3-bed2-b60af8879de4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6645400a-8711-400e-8173-beae7764a223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaTherapeuticsIncMember_0d7fd8be-591a-448d-80ca-d8e570355fc0" xlink:href="arwr-20250930.xsd#arwr_SareptaTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6645400a-8711-400e-8173-beae7764a223" xlink:to="loc_arwr_SareptaTherapeuticsIncMember_0d7fd8be-591a-448d-80ca-d8e570355fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_afe94ec8-55d9-47f5-8357-c5106ce5f66e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a2dbaa72-fc87-4762-96d6-340fff61d46a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_afe94ec8-55d9-47f5-8357-c5106ce5f66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8fed694-f6e0-4c42-aac2-8ef4ee70538e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_afe94ec8-55d9-47f5-8357-c5106ce5f66e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8fed694-f6e0-4c42-aac2-8ef4ee70538e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember_7b8ba146-38f8-4707-bb6d-9b2e9a89c6d0" xlink:href="arwr-20250930.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8fed694-f6e0-4c42-aac2-8ef4ee70538e" xlink:to="loc_arwr_SareptaCollaborationAgreementMember_7b8ba146-38f8-4707-bb6d-9b2e9a89c6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_6f77246b-3d1f-4d06-a84b-2f12dacf3d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a2dbaa72-fc87-4762-96d6-340fff61d46a" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_6f77246b-3d1f-4d06-a84b-2f12dacf3d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_66e9090d-96b2-4fdb-a7fd-e4f0097acf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_6f77246b-3d1f-4d06-a84b-2f12dacf3d1d" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_66e9090d-96b2-4fdb-a7fd-e4f0097acf7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_b3f17d75-75a6-4ba9-bde7-ac8423968b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_66e9090d-96b2-4fdb-a7fd-e4f0097acf7c" xlink:to="loc_us-gaap_LineOfCreditMember_b3f17d75-75a6-4ba9-bde7-ac8423968b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a2dbaa72-fc87-4762-96d6-340fff61d46a" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3a5e1b48-a11a-43b0-8b54-bdb6875f9c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3a5e1b48-a11a-43b0-8b54-bdb6875f9c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_b9f82b01-d2b5-44e1-9864-a7e0818b583b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_us-gaap_LineOfCredit_b9f82b01-d2b5-44e1-9864-a7e0818b583b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_a8ed3008-7f44-4fb4-9ec4-062bbfaa79d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_a8ed3008-7f44-4fb4-9ec4-062bbfaa79d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_014bde9c-51be-424b-a9aa-69556eb7724c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_014bde9c-51be-424b-a9aa-69556eb7724c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentCovenantMultipleOfInvestedCapital_f6a21e7e-b7ea-4635-8641-aa560cbc1532" xlink:href="arwr-20250930.xsd#arwr_DebtInstrumentCovenantMultipleOfInvestedCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_arwr_DebtInstrumentCovenantMultipleOfInvestedCapital_f6a21e7e-b7ea-4635-8641-aa560cbc1532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e76b7ba6-9cae-4014-8f20-0b1f8d599d72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e76b7ba6-9cae-4014-8f20-0b1f8d599d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements_d1354b43-a08e-450b-a622-16f6919085be" xlink:href="arwr-20250930.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_arwr_ProceedsFromCollaborationArrangements_d1354b43-a08e-450b-a622-16f6919085be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentPrepaymentPercentage_23756dc2-42ca-41af-a4da-bfe2e85413b4" xlink:href="arwr-20250930.xsd#arwr_DebtInstrumentPrepaymentPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_arwr_DebtInstrumentPrepaymentPercentage_23756dc2-42ca-41af-a4da-bfe2e85413b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_9380a356-65e7-4755-85f7-8789ec449de8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_9380a356-65e7-4755-85f7-8789ec449de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment_f286afd3-09f0-46eb-8316-d88e56fb514b" xlink:href="arwr-20250930.xsd#arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment_f286afd3-09f0-46eb-8316-d88e56fb514b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold_06a41c0f-b413-483f-b86e-ebd69b386607" xlink:href="arwr-20250930.xsd#arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold_06a41c0f-b413-483f-b86e-ebd69b386607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold_d3d9a70f-2a96-4224-b672-d8963393af70" xlink:href="arwr-20250930.xsd#arwr_DebtInstrumentCovenantMarketCapitalizationThreshold"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold_d3d9a70f-2a96-4224-b672-d8963393af70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_5a95ef8d-8e1a-402b-8574-e9ada28ac690" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_us-gaap_DebtInstrumentTerm_5a95ef8d-8e1a-402b-8574-e9ada28ac690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_546b0b03-b2bd-444e-bebf-eebe79722278" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fa35a2ea-84e1-4880-bea1-bc1718e872e2" xlink:to="loc_us-gaap_LinesOfCreditCurrent_546b0b03-b2bd-444e-bebf-eebe79722278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#FinancingAgreementOutstandingBalanceofCreditFacilityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a588d4e4-5ba2-4cab-a65a-4c7bc4be0283" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_04cc3d96-cca8-4470-8370-4a5ee4364b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a588d4e4-5ba2-4cab-a65a-4c7bc4be0283" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_04cc3d96-cca8-4470-8370-4a5ee4364b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_699eba4f-b07f-4711-9465-f2dfe032b787" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_04cc3d96-cca8-4470-8370-4a5ee4364b2a" xlink:to="loc_us-gaap_CreditFacilityAxis_699eba4f-b07f-4711-9465-f2dfe032b787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a40a1611-73f6-44d5-ae7d-8ceedd46da76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_699eba4f-b07f-4711-9465-f2dfe032b787" xlink:to="loc_us-gaap_CreditFacilityDomain_a40a1611-73f6-44d5-ae7d-8ceedd46da76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_9ff0eabc-a684-49de-a74e-59a27d63983e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_a40a1611-73f6-44d5-ae7d-8ceedd46da76" xlink:to="loc_us-gaap_SecuredDebtMember_9ff0eabc-a684-49de-a74e-59a27d63983e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_26a0f0fd-01b9-4734-aa8c-c15a0d5db93b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_04cc3d96-cca8-4470-8370-4a5ee4364b2a" xlink:to="loc_us-gaap_DebtInstrumentAxis_26a0f0fd-01b9-4734-aa8c-c15a0d5db93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_02772a5a-3ae1-4898-8cc3-328f779c0c02" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_26a0f0fd-01b9-4734-aa8c-c15a0d5db93b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_02772a5a-3ae1-4898-8cc3-328f779c0c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMember_93ebb963-77f7-4787-b877-127a32b7f131" xlink:href="arwr-20250930.xsd#arwr_FinancingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_02772a5a-3ae1-4898-8cc3-328f779c0c02" xlink:to="loc_arwr_FinancingAgreementMember_93ebb963-77f7-4787-b877-127a32b7f131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementInitialTermLoanMember_19dbe9d9-147a-4058-a2ed-d8db694e3fd0" xlink:href="arwr-20250930.xsd#arwr_FinancingAgreementInitialTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_FinancingAgreementMember_93ebb963-77f7-4787-b877-127a32b7f131" xlink:to="loc_arwr_FinancingAgreementInitialTermLoanMember_19dbe9d9-147a-4058-a2ed-d8db694e3fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementInitialTermLoanInterestMember_fd7d03de-8212-4764-b80f-959afdfa54d8" xlink:href="arwr-20250930.xsd#arwr_FinancingAgreementInitialTermLoanInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_FinancingAgreementMember_93ebb963-77f7-4787-b877-127a32b7f131" xlink:to="loc_arwr_FinancingAgreementInitialTermLoanInterestMember_fd7d03de-8212-4764-b80f-959afdfa54d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_55939d04-2bf4-42d5-bd90-073ba359adfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_04cc3d96-cca8-4470-8370-4a5ee4364b2a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_55939d04-2bf4-42d5-bd90-073ba359adfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7ec82bab-b5e6-46c2-ae0c-b151019aa69e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_55939d04-2bf4-42d5-bd90-073ba359adfa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7ec82bab-b5e6-46c2-ae0c-b151019aa69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_99292d72-44e6-402c-a5e4-0780ca6119ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7ec82bab-b5e6-46c2-ae0c-b151019aa69e" xlink:to="loc_us-gaap_LineOfCreditMember_99292d72-44e6-402c-a5e4-0780ca6119ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_40818359-1c14-463a-a36e-ac9224728003" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_04cc3d96-cca8-4470-8370-4a5ee4364b2a" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_40818359-1c14-463a-a36e-ac9224728003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0b1a12b3-547a-46db-a0b7-6674239494ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_40818359-1c14-463a-a36e-ac9224728003" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0b1a12b3-547a-46db-a0b7-6674239494ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_d8dfa157-d382-44a7-9b20-94302715402b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_40818359-1c14-463a-a36e-ac9224728003" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_d8dfa157-d382-44a7-9b20-94302715402b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_824b54f7-eeb2-4e11-8cea-d8f7b160db5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_40818359-1c14-463a-a36e-ac9224728003" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_824b54f7-eeb2-4e11-8cea-d8f7b160db5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_15416b5e-62d6-4d94-9110-a40da7986efe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_40818359-1c14-463a-a36e-ac9224728003" xlink:to="loc_us-gaap_LinesOfCreditCurrent_15416b5e-62d6-4d94-9110-a40da7986efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_2ec896ba-bf88-4a1f-8392-b22f81bbcd33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_40818359-1c14-463a-a36e-ac9224728003" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_2ec896ba-bf88-4a1f-8392-b22f81bbcd33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_104e2d7b-7300-4b91-a1f5-424c71bccdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_40818359-1c14-463a-a36e-ac9224728003" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_104e2d7b-7300-4b91-a1f5-424c71bccdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e7730c7e-f4d9-4bc5-ae69-138eb8af2174" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_2b02ff56-a3f8-4285-879f-1c5b7c007700" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e7730c7e-f4d9-4bc5-ae69-138eb8af2174" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_2b02ff56-a3f8-4285-879f-1c5b7c007700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ba524cb0-604d-488a-a1d6-84cfb8b4a7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2b02ff56-a3f8-4285-879f-1c5b7c007700" xlink:to="loc_us-gaap_CreditFacilityAxis_ba524cb0-604d-488a-a1d6-84cfb8b4a7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d33ce2c6-1abe-497e-ad73-1126fac3270d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_ba524cb0-604d-488a-a1d6-84cfb8b4a7cf" xlink:to="loc_us-gaap_CreditFacilityDomain_d33ce2c6-1abe-497e-ad73-1126fac3270d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_0cea3e53-ba71-453c-96a0-3a3118180439" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d33ce2c6-1abe-497e-ad73-1126fac3270d" xlink:to="loc_us-gaap_SecuredDebtMember_0cea3e53-ba71-453c-96a0-3a3118180439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_95f4afbd-cb76-4013-835d-f53c84c7ea43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2b02ff56-a3f8-4285-879f-1c5b7c007700" xlink:to="loc_us-gaap_DebtInstrumentAxis_95f4afbd-cb76-4013-835d-f53c84c7ea43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7eb7f7c5-3276-43d5-aadd-d32c7db53bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_95f4afbd-cb76-4013-835d-f53c84c7ea43" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7eb7f7c5-3276-43d5-aadd-d32c7db53bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMember_ee64483a-c74c-430f-b4bb-6f366ad2bf5d" xlink:href="arwr-20250930.xsd#arwr_FinancingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7eb7f7c5-3276-43d5-aadd-d32c7db53bc7" xlink:to="loc_arwr_FinancingAgreementMember_ee64483a-c74c-430f-b4bb-6f366ad2bf5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9cf576a5-46f3-40dd-9f7b-93de836b4ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2b02ff56-a3f8-4285-879f-1c5b7c007700" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9cf576a5-46f3-40dd-9f7b-93de836b4ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_96359d0f-d107-4110-a6c4-cc76fbcc187f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9cf576a5-46f3-40dd-9f7b-93de836b4ae4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_96359d0f-d107-4110-a6c4-cc76fbcc187f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_b648df31-46f5-4486-81b7-fb9d6bbeecfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_96359d0f-d107-4110-a6c4-cc76fbcc187f" xlink:to="loc_us-gaap_LineOfCreditMember_b648df31-46f5-4486-81b7-fb9d6bbeecfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_127737ad-0391-4e3c-844a-8e9b5d14ecbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_2b02ff56-a3f8-4285-879f-1c5b7c007700" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_127737ad-0391-4e3c-844a-8e9b5d14ecbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f4e0c1d9-f89d-47d3-8b83-b72a751817d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_127737ad-0391-4e3c-844a-8e9b5d14ecbc" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f4e0c1d9-f89d-47d3-8b83-b72a751817d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_c8300e74-b3cb-4fd3-8e81-3f914209631e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_127737ad-0391-4e3c-844a-8e9b5d14ecbc" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_c8300e74-b3cb-4fd3-8e81-3f914209631e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_876d71b2-4e87-45a4-a3ae-e9772e15c6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_127737ad-0391-4e3c-844a-8e9b5d14ecbc" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_876d71b2-4e87-45a4-a3ae-e9772e15c6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_9bdc348f-1933-403d-84d6-bd62f2b6d123" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_127737ad-0391-4e3c-844a-8e9b5d14ecbc" xlink:to="loc_us-gaap_InterestExpenseDebt_9bdc348f-1933-403d-84d6-bd62f2b6d123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d2c2895c-351d-4e22-b2bd-17f6ea63f98f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_cb60b8ea-b1ca-46f1-8f6b-4845b906472a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d2c2895c-351d-4e22-b2bd-17f6ea63f98f" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_cb60b8ea-b1ca-46f1-8f6b-4845b906472a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7d1f31f9-4995-4e32-9eef-fadcfd0244a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_cb60b8ea-b1ca-46f1-8f6b-4845b906472a" xlink:to="loc_us-gaap_DebtInstrumentAxis_7d1f31f9-4995-4e32-9eef-fadcfd0244a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_427f088b-abc0-4531-85b9-95e7e0afda80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7d1f31f9-4995-4e32-9eef-fadcfd0244a8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_427f088b-abc0-4531-85b9-95e7e0afda80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FinancingAgreementMember_035f8e75-5c53-436d-8159-0fc57b114b93" xlink:href="arwr-20250930.xsd#arwr_FinancingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_427f088b-abc0-4531-85b9-95e7e0afda80" xlink:to="loc_arwr_FinancingAgreementMember_035f8e75-5c53-436d-8159-0fc57b114b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_19961128-2cbe-4c7f-9ac5-c9420c23036d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_cb60b8ea-b1ca-46f1-8f6b-4845b906472a" xlink:to="loc_us-gaap_CreditFacilityAxis_19961128-2cbe-4c7f-9ac5-c9420c23036d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b207c0cd-aded-41fc-9c69-a991b9d4937f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_19961128-2cbe-4c7f-9ac5-c9420c23036d" xlink:to="loc_us-gaap_CreditFacilityDomain_b207c0cd-aded-41fc-9c69-a991b9d4937f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_f2799d4c-cf14-4487-a443-083a9e081e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_b207c0cd-aded-41fc-9c69-a991b9d4937f" xlink:to="loc_us-gaap_SecuredDebtMember_f2799d4c-cf14-4487-a443-083a9e081e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_76bf5264-490e-4640-970a-18ed131b2f79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_cb60b8ea-b1ca-46f1-8f6b-4845b906472a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_76bf5264-490e-4640-970a-18ed131b2f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_357055c3-ce54-4d12-bcdc-8d0ea526361f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_76bf5264-490e-4640-970a-18ed131b2f79" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_357055c3-ce54-4d12-bcdc-8d0ea526361f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_d7465efe-9d82-47e4-be64-cdc6d825c08b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_357055c3-ce54-4d12-bcdc-8d0ea526361f" xlink:to="loc_us-gaap_LineOfCreditMember_d7465efe-9d82-47e4-be64-cdc6d825c08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_36c84332-f4bd-4844-bf81-062719b2eb41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_cb60b8ea-b1ca-46f1-8f6b-4845b906472a" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_36c84332-f4bd-4844-bf81-062719b2eb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_017c3196-34b8-4fcf-b40c-cbe3c93ea747" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_36c84332-f4bd-4844-bf81-062719b2eb41" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_017c3196-34b8-4fcf-b40c-cbe3c93ea747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_06f6f7bc-120a-46fe-a924-815c2ee223df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_36c84332-f4bd-4844-bf81-062719b2eb41" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_06f6f7bc-120a-46fe-a924-815c2ee223df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3bd58378-1ab1-4e3a-9e61-d98375a14657" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_36c84332-f4bd-4844-bf81-062719b2eb41" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3bd58378-1ab1-4e3a-9e61-d98375a14657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_3223f9d6-53e0-4484-8271-57f61580ae99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_36c84332-f4bd-4844-bf81-062719b2eb41" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_3223f9d6-53e0-4484-8271-57f61580ae99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_f9b767a1-16bb-4a6b-9e8c-612e9e4a562a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_36c84332-f4bd-4844-bf81-062719b2eb41" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_f9b767a1-16bb-4a6b-9e8c-612e9e4a562a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_9cef4ad7-c0c6-4f4a-876c-300915554842" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_36c84332-f4bd-4844-bf81-062719b2eb41" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_9cef4ad7-c0c6-4f4a-876c-300915554842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ed4fad86-d793-44c6-b3b9-df81ce451f47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_36c84332-f4bd-4844-bf81-062719b2eb41" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ed4fad86-d793-44c6-b3b9-df81ce451f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_70768d9b-127d-4e4b-9f89-3159ff2cb624" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_96ea4d15-e795-40ec-993d-7721db4973c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_70768d9b-127d-4e4b-9f89-3159ff2cb624" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_96ea4d15-e795-40ec-993d-7721db4973c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_48cab489-3ec6-4cac-a9b3-0ee0562016b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_96ea4d15-e795-40ec-993d-7721db4973c8" xlink:to="loc_us-gaap_NetIncomeLoss_48cab489-3ec6-4cac-a9b3-0ee0562016b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3c12fc74-1640-4b79-ad96-fae847ade2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_70768d9b-127d-4e4b-9f89-3159ff2cb624" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3c12fc74-1640-4b79-ad96-fae847ade2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bd0a2f73-75b8-4380-8cb7-5b5b09f1d0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3c12fc74-1640-4b79-ad96-fae847ade2f1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bd0a2f73-75b8-4380-8cb7-5b5b09f1d0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_94c7dcd1-666f-428a-b93c-3958546bb0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3c12fc74-1640-4b79-ad96-fae847ade2f1" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_94c7dcd1-666f-428a-b93c-3958546bb0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_736e204d-2e50-43bd-bcbd-613cc70414e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3c12fc74-1640-4b79-ad96-fae847ade2f1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_736e204d-2e50-43bd-bcbd-613cc70414e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9a0f0e69-f8da-4324-bf29-1aa85e2db024" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_70768d9b-127d-4e4b-9f89-3159ff2cb624" xlink:to="loc_us-gaap_EarningsPerShareBasic_9a0f0e69-f8da-4324-bf29-1aa85e2db024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c199663e-c7a8-47bc-ba42-d7f9b5d68a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_70768d9b-127d-4e4b-9f89-3159ff2cb624" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c199663e-c7a8-47bc-ba42-d7f9b5d68a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#NetLossPerShareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2b8081ca-aae0-4722-b71c-9cef3f0b1b58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8569765a-0e5d-41c9-b709-db8647a92754" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2b8081ca-aae0-4722-b71c-9cef3f0b1b58" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8569765a-0e5d-41c9-b709-db8647a92754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec98d959-65a7-4fac-9505-aea79efedc23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8569765a-0e5d-41c9-b709-db8647a92754" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec98d959-65a7-4fac-9505-aea79efedc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a496d25-dc20-4d12-a5e0-f562d74b9aba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ec98d959-65a7-4fac-9505-aea79efedc23" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a496d25-dc20-4d12-a5e0-f562d74b9aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2aca64aa-af87-4768-85b8-ecf62564f286" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a496d25-dc20-4d12-a5e0-f562d74b9aba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2aca64aa-af87-4768-85b8-ecf62564f286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a4b947ae-c376-480a-b47e-bc520940d90a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a496d25-dc20-4d12-a5e0-f562d74b9aba" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a4b947ae-c376-480a-b47e-bc520940d90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_02780ca7-a609-4374-8c87-1a9e8cf1cf83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8569765a-0e5d-41c9-b709-db8647a92754" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_02780ca7-a609-4374-8c87-1a9e8cf1cf83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8bae281f-181f-4623-91d0-34f98ef74e80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_02780ca7-a609-4374-8c87-1a9e8cf1cf83" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8bae281f-181f-4623-91d0-34f98ef74e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1f653475-553b-4c68-980b-db82f3cea096" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_5267f9d6-f7bd-4a7c-9d29-6d60f85a24aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1f653475-553b-4c68-980b-db82f3cea096" xlink:to="loc_us-gaap_NumberOfOperatingSegments_5267f9d6-f7bd-4a7c-9d29-6d60f85a24aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1da81d6e-3bb1-49c4-992e-05cbcc37f758" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_438a4175-c466-49db-993e-2313af40a13c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1da81d6e-3bb1-49c4-992e-05cbcc37f758" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_438a4175-c466-49db-993e-2313af40a13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4e284540-18ff-4770-a2e5-0f155b81a7da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_438a4175-c466-49db-993e-2313af40a13c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4e284540-18ff-4770-a2e5-0f155b81a7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1f6d315c-576f-4c79-875c-f57ccbf05b36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4e284540-18ff-4770-a2e5-0f155b81a7da" xlink:to="loc_us-gaap_SegmentDomain_1f6d315c-576f-4c79-875c-f57ccbf05b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingSegmentMember_8f4ed820-adeb-481c-a43b-d0f2cda00bad" xlink:href="arwr-20250930.xsd#arwr_OperatingSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1f6d315c-576f-4c79-875c-f57ccbf05b36" xlink:to="loc_arwr_OperatingSegmentMember_8f4ed820-adeb-481c-a43b-d0f2cda00bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8258eaa7-0eba-48aa-a20c-8c3471eca889" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_438a4175-c466-49db-993e-2313af40a13c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8258eaa7-0eba-48aa-a20c-8c3471eca889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e8941b6a-e1f4-4bf4-8c47-78c09ada7c71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8258eaa7-0eba-48aa-a20c-8c3471eca889" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e8941b6a-e1f4-4bf4-8c47-78c09ada7c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_51eec962-6009-4096-b38d-42ff12cc2fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e8941b6a-e1f4-4bf4-8c47-78c09ada7c71" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_51eec962-6009-4096-b38d-42ff12cc2fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_87cabdf4-1e3f-42a4-a9b3-e68e42efb876" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e8941b6a-e1f4-4bf4-8c47-78c09ada7c71" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_87cabdf4-1e3f-42a4-a9b3-e68e42efb876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_438a4175-c466-49db-993e-2313af40a13c" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseCandidateCosts_e7431c70-bd3c-4410-96d5-03a5fbc6ba59" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseCandidateCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_arwr_ResearchAndDevelopmentExpenseCandidateCosts_e7431c70-bd3c-4410-96d5-03a5fbc6ba59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseDiscoveryCosts_cfbf48a1-acac-4cf2-a140-28c3d5c859cb" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseDiscoveryCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_arwr_ResearchAndDevelopmentExpenseDiscoveryCosts_cfbf48a1-acac-4cf2-a140-28c3d5c859cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseSalariesExpense_b50d1bb7-453c-4a69-af15-8e47ae78f54a" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseSalariesExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_arwr_ResearchAndDevelopmentExpenseSalariesExpense_b50d1bb7-453c-4a69-af15-8e47ae78f54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense_a0a21e2a-61e0-49d3-9a4a-92dc940665f5" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense_a0a21e2a-61e0-49d3-9a4a-92dc940665f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense_cd3d56c8-a536-452f-a150-31ad3dc03579" xlink:href="arwr-20250930.xsd#arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense_cd3d56c8-a536-452f-a150-31ad3dc03579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation_08b65544-a190-47f7-a08e-81598bec3c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_us-gaap_SalariesWagesAndOfficersCompensation_08b65544-a190-47f7-a08e-81598bec3c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_ce08e6ca-8b75-4fe3-85e0-fda57ce0bdde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_us-gaap_ProfessionalFees_ce08e6ca-8b75-4fe3-85e0-fda57ce0bdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense_b436f76c-d9f0-47da-bba9-91ef13342b8a" xlink:href="arwr-20250930.xsd#arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense_b436f76c-d9f0-47da-bba9-91ef13342b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense_ee096036-7e68-4d84-b105-6fa6352fa610" xlink:href="arwr-20250930.xsd#arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense_ee096036-7e68-4d84-b105-6fa6352fa610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fdbd4c41-e513-4dc5-b3e4-04923ce98ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fdbd4c41-e513-4dc5-b3e4-04923ce98ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3469cc1e-b9ce-44a1-85de-0b04338ea747" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3469cc1e-b9ce-44a1-85de-0b04338ea747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_06efb688-459c-4fe7-bb8d-ffcc768a9ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_06efb688-459c-4fe7-bb8d-ffcc768a9ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2aea792f-878b-44c3-b50d-dfbbf7775b31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ead83cb2-7ef8-4e87-a62d-5f0b61a68566" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2aea792f-878b-44c3-b50d-dfbbf7775b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="arwr-20250930.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_c4bbf83e-fdc7-44ac-ad95-727db066efd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f537dbe9-8632-4ac0-b824-3d2bf24cc749" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_c4bbf83e-fdc7-44ac-ad95-727db066efd1" xlink:to="loc_us-gaap_SubsequentEventTable_f537dbe9-8632-4ac0-b824-3d2bf24cc749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1ec12cf9-343a-47cf-88c9-941dcfa25f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f537dbe9-8632-4ac0-b824-3d2bf24cc749" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1ec12cf9-343a-47cf-88c9-941dcfa25f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_68785c82-5572-4f26-bd77-a2a3df78f7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1ec12cf9-343a-47cf-88c9-941dcfa25f2d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_68785c82-5572-4f26-bd77-a2a3df78f7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3fef354d-7ac3-4773-a943-67e5125cc7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_68785c82-5572-4f26-bd77-a2a3df78f7c0" xlink:to="loc_us-gaap_SubsequentEventMember_3fef354d-7ac3-4773-a943-67e5125cc7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_203102f3-8600-4eb0-9d43-261b93b54880" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f537dbe9-8632-4ac0-b824-3d2bf24cc749" xlink:to="loc_srt_CounterpartyNameAxis_203102f3-8600-4eb0-9d43-261b93b54880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8eb9e0c5-41a1-4979-ba48-2907fc0d9fa8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_203102f3-8600-4eb0-9d43-261b93b54880" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8eb9e0c5-41a1-4979-ba48-2907fc0d9fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember_68ef01ae-be4c-41ce-bf19-d09313a6e056" xlink:href="arwr-20250930.xsd#arwr_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8eb9e0c5-41a1-4979-ba48-2907fc0d9fa8" xlink:to="loc_arwr_NovartisMember_68ef01ae-be4c-41ce-bf19-d09313a6e056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaTherapeuticsIncMember_c45f7e0e-379a-444b-bad9-5baab25046ce" xlink:href="arwr-20250930.xsd#arwr_SareptaTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8eb9e0c5-41a1-4979-ba48-2907fc0d9fa8" xlink:to="loc_arwr_SareptaTherapeuticsIncMember_c45f7e0e-379a-444b-bad9-5baab25046ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4d379f40-35e9-4181-91d3-e88bff6c7d37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f537dbe9-8632-4ac0-b824-3d2bf24cc749" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4d379f40-35e9-4181-91d3-e88bff6c7d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c313d3a7-699f-4a33-9708-581cbfdc5f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4d379f40-35e9-4181-91d3-e88bff6c7d37" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c313d3a7-699f-4a33-9708-581cbfdc5f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisCollaborationAgreementMember_b3ce636b-446e-42e2-b35d-183cf275820e" xlink:href="arwr-20250930.xsd#arwr_NovartisCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c313d3a7-699f-4a33-9708-581cbfdc5f5f" xlink:to="loc_arwr_NovartisCollaborationAgreementMember_b3ce636b-446e-42e2-b35d-183cf275820e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SareptaCollaborationAgreementMember_fc08ba66-d39e-4ac7-83de-7a786476ea84" xlink:href="arwr-20250930.xsd#arwr_SareptaCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c313d3a7-699f-4a33-9708-581cbfdc5f5f" xlink:to="loc_arwr_SareptaCollaborationAgreementMember_fc08ba66-d39e-4ac7-83de-7a786476ea84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8de4e4ba-50e6-4a36-950c-cd7e43671e28" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f537dbe9-8632-4ac0-b824-3d2bf24cc749" xlink:to="loc_srt_RangeAxis_8de4e4ba-50e6-4a36-950c-cd7e43671e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2698e1be-baff-4592-8f28-cf01083fa83d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8de4e4ba-50e6-4a36-950c-cd7e43671e28" xlink:to="loc_srt_RangeMember_2698e1be-baff-4592-8f28-cf01083fa83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2115f442-6aef-43c3-9436-32439e387058" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2698e1be-baff-4592-8f28-cf01083fa83d" xlink:to="loc_srt_MinimumMember_2115f442-6aef-43c3-9436-32439e387058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1fd124bd-2a27-451d-b762-32ec84274329" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2698e1be-baff-4592-8f28-cf01083fa83d" xlink:to="loc_srt_MaximumMember_1fd124bd-2a27-451d-b762-32ec84274329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_977ee384-27cd-4fdb-955f-e6424d00f536" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f537dbe9-8632-4ac0-b824-3d2bf24cc749" xlink:to="loc_us-gaap_SubsequentEventLineItems_977ee384-27cd-4fdb-955f-e6424d00f536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromCollaborationArrangements_c4fd72b2-e95d-4c81-ba25-c4f9590cfc8b" xlink:href="arwr-20250930.xsd#arwr_ProceedsFromCollaborationArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_977ee384-27cd-4fdb-955f-e6424d00f536" xlink:to="loc_arwr_ProceedsFromCollaborationArrangements_c4fd72b2-e95d-4c81-ba25-c4f9590cfc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination_07d85cee-d7aa-4764-8154-cf9efec0c9b0" xlink:href="arwr-20250930.xsd#arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_977ee384-27cd-4fdb-955f-e6424d00f536" xlink:to="loc_arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination_07d85cee-d7aa-4764-8154-cf9efec0c9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfCollaborationPrograms_ed114cf3-a319-4a35-9d43-d31a851b39cd" xlink:href="arwr-20250930.xsd#arwr_NumberOfCollaborationPrograms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_977ee384-27cd-4fdb-955f-e6424d00f536" xlink:to="loc_arwr_NumberOfCollaborationPrograms_ed114cf3-a319-4a35-9d43-d31a851b39cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentMilestonePayments_46ce8e6f-574f-4d97-a665-99bcde65f2f7" xlink:href="arwr-20250930.xsd#arwr_DevelopmentMilestonePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_977ee384-27cd-4fdb-955f-e6424d00f536" xlink:to="loc_arwr_DevelopmentMilestonePayments_46ce8e6f-574f-4d97-a665-99bcde65f2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_ae1cef64-c557-4b1b-9eb5-4690b4d5fab7" xlink:href="arwr-20250930.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_977ee384-27cd-4fdb-955f-e6424d00f536" xlink:to="loc_arwr_SalesRelatedMilestonePayments_ae1cef64-c557-4b1b-9eb5-4690b4d5fab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PatrickOBrienSharesVestingAndSubjectToSellToCoverMember" xlink:href="arwr-20250930.xsd#arwr_PatrickOBrienSharesVestingAndSubjectToSellToCoverMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arwr_PatrickOBrienSharesVestingAndSubjectToSellToCoverMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PatrickOBrienOtherSharesBeingSoldMember" xlink:href="arwr-20250930.xsd#arwr_PatrickOBrienOtherSharesBeingSoldMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arwr_PatrickOBrienOtherSharesBeingSoldMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdeoyeOlukotunMember" xlink:href="arwr-20250930.xsd#arwr_AdeoyeOlukotunMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_AdeoyeOlukotunMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ChristopherAnzaloneMember" xlink:href="arwr-20250930.xsd#arwr_ChristopherAnzaloneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_ChristopherAnzaloneMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DanielApelMember" xlink:href="arwr-20250930.xsd#arwr_DanielApelMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_DanielApelMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JamesHamiltonMember" xlink:href="arwr-20250930.xsd#arwr_JamesHamiltonMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_JamesHamiltonMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MauroFerrariMember" xlink:href="arwr-20250930.xsd#arwr_MauroFerrariMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_MauroFerrariMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PatrickOBrienMember" xlink:href="arwr-20250930.xsd#arwr_PatrickOBrienMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_PatrickOBrienMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VictoriaVakienerMember" xlink:href="arwr-20250930.xsd#arwr_VictoriaVakienerMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_VictoriaVakienerMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_WilliamWaddillMember" xlink:href="arwr-20250930.xsd#arwr_WilliamWaddillMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_WilliamWaddillMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>arrowheadengagementlette001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 arrowheadengagementlette001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 'I5>3_ (^X_P#=-6#TJO)_Q]Q?[IH
M98@"W7']YOYU;JG8_P#'JG^>YJY0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 !Z5!)_Q]Q?[IJ>H'_X^H_H: (K#_CVC^G]35RJFGC_ $.)O4?U
MJW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0L,W*?0U-4+'%R
MGT- #+$8LX@.>.M6:J:?_P >,'^[5N@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *A?_CY3Z&IJ@?\ X^H_]TT ,TX8T^WS_<%6JI:7G^SH-QS\
M@J[0 4444 %%%% !1110 4444 %%%% !1110 4449H **,TF?:@!:*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMST.10!Z;15'1;R74-"T^]F39+<6T<KKC[K,H)'ZU>H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ J%Q^_C/UJ:H6_UZ?C0!'8?\>$'^X*M55L/^/"#_<%
M6J "BBB@ HHHH **** "BBB@ HHI#0 N16'XG\06_AS1Y;Z4AG'$4>>7;M6I
M>7$-I;27$[!(XUW,Q.,5X#XM\0W'B76&N"6CMX_EBB)R !W/N?ZUVX'"/$5-
M?A6YPXW%K#P\WL9MU=W>NZJ\\I::ZN),  =ST4"N^O/AHT/A>.XA8G5(_P!Y
M(,'##^[CVJW\-O"'DH-:OXL2L<0(P^Z/[WUKTUAD8KOQV8>SFJ=%Z1.'"9>J
MD'.KNSR7P'J,VD7AMI,_8Y6PRD?<;_\ 71\2O"GDRMKNGQ?NY,&X51G![/75
M:KX?6SOGO8$'ESL"Z@?=;UK9L&2[LWL[E1(F-A+<AAZ5E/$J-2.)I?,TAAG*
MF\/4Z;'C/@CQ4_AS5-L[%K&? D7^Z?[PKWN*:.:))(W5D89!4Y!%> >-/"LW
MAO5PJ%FLI/FA?'3U6NN^&GBP#;H=]*>"?LS.?_'36V88:%>"Q-'YF>"Q$J,_
MJ]4]5S130PI17A7/<%HHHH \R^+4,EQJG@J&*=[>2368U69 "T9)4!AG(R.O
M-9WB2.^\+^,-$N/%&I7&M>&97*![E%5;:X_A9U0!6Z9&X''S=QFM/XB:1XGU
MGQ-X?N-'T8W%KH]T+IF>ZCC6=LHP !.1C:1DCN:[#4M*B\6^%Y].U>PDMA<H
M5:*1E9HV'1@5)'!P1S0!HW]_'8:3=:BWSQ6\#SG:?O*JEN/RKC_!6FV7BGPK
M;Z]KEI!?WVI!Y)&N$#B,;BH2,'[J@ =/J<FCPC9>)]/TL^&?$>GI>V2(;>+4
M()DVM#MP%="0W XR ?ZU%X5L?$'@:T?0I=-GU?3(Y"UE=6LL8=$8D['1V7&#
MW!(YH 9X8NKC0OB1JOA 7$DVF&T6_LEE8NT ) 9-QY*Y)QG.,"N7N]0T=;_4
MM$\<6-SIVK7-U(;77,':5WGRF1^-@4$#'3 Y[UZ)HF@W'_"37_B?4HQ#>7<*
M6T-LK!O(A4YPS#@L3R<<#H">M<_>V7B+5/"4OA35_#WVRY>,P1ZD;B-H!V69
MB3Y@8#G&TDD=>: )_'6NW<5_X=\-V4<MU+JDC/<?9Y1"TD,:[F56) 7=ZYZ
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M"[^T0))9K,6A<G^$KT;#8Y[XKK=$\&QZ-K]QK!UC4[NXN8MDT=Q-F,MD'<%
MXZ8 Z &LGXD:=KFJ^'M.T[3M.;4+L7,4\TJ,D48\OD_>;()/0<_7U[+3[N6]
MLTGFLKBR<]8;C;O7_OEB/UH M5P?A4VGB?7O%-SJD*7-S9Z@^GQ13H"(;=0,
M;5/3<VXD]3@>@KO*\Y\0^"]>T[Q5-XJ\%7-O'=W"8O;&YXCN".X[ GWQSSGD
MT 8T\&H?!S5FN[19KSP7=R9FA'S/9.>X]OY]#S@G:\/-::E\08KC1M:O+O1H
M],^U" WCR1I-([+R"2?NAOE;H1VXQ*NI^/M;M)M/N/"&FV*RJT4D]Y>"6+!&
M/]6H);OQTK"L?A_XH^'UP-0\)WR:FDI'VW39E6)9.O*$G QGCO\ 7I0!Z[16
M7HFH:EJ-N\FI:+)I;#&U))TE+>OW>F/>M2@#S;3&Q^T%K2[6.[2(^0.!S'UK
M7U33(I-:U&\\5WEF-'V(FGJ;MX3'P=^Y> 6)Z').!QBLW28)6^/&OW C8PII
M4*,^. Q*$#\0I_*GM::QIGQ)U76)O#D^K13PQ1V%U!-'_HZ 89,.PVY;))']
M: (/A=JLBQ^)=*>[EO+/2;UA:S2-N;RCN(7GGC:>I[U9\-:?;>/_  [%X@UP
MW$K7K2&&W2Y>-+9 [*%4(1DX7)8Y)/H.*B\&Z-KFD>+_ !+_ &KI.+76)A<+
M<P3J\2<-E#G#9^;&=O;\:K>&+/Q9X!,^A#1Y-;T59"]E<6\\:/$I))5@Y'KG
M\^M &EXAO+KX=_#=UL[MKJYCE\BUFO&W;1)(=NXGKL4X_P" BM.3P%HTUH5F
M%P]^R\ZCY[B??UWA@>.0#@<>V*B\1^';[QMX*O-,U)(+"ZG820*KF3R2I!4.
MW0G@YQP >,XR5LO$&OP::EO?^%[^758X]K-#)$8)6&!N#E\@$\X(R.>#B@#+
M\*:]?:WX,\0:?JVVZU+2I+FQN' "BXV@@'T&>1^&>]9WP_\ ".G:[\,=);49
M;V4O$XCV73QB$;V^Z%('OD@G\.*Z'1O#-[H?A#6XPZ3:SJ37-Y+Y7W//D!PJ
MY[#@<_6J/A+^V_!?ANTT'4=#N;YK;*Q7.FLDB2!B6P0[*5(SC)&/>@!G@VZU
M>PU#Q/X2>[:\FTK8^G7%V2S,DBED5VQR%. 3[GTKF="U+1M3DMM)U>74=#\8
MQ3H\DUS-(OVF0,"V#G:5;! 7@<\9KNH-"U5M/\0ZDKI::[K$)6(!N+8*A6%2
MPSDC.21W)QD 5A>(-+U#QQH-MI&H>'+JSU>*2+=J#F,QP88%W1PV6!4-@ =2
M,XQF@#TJH+[_ (\+G_KDW\C4X& !6?KD]Q;Z-=/:6,U]<&,K'!$RJ6)&!RQ
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ J-O]:GXU)4;_ .MC_&@"&P_X\(/]P5:JK8?\>$'^X*M4 %%%% !1110
M4444 %%%% "9I&; SVH;@9S7"?$+Q8VE67]FV3_Z;.O+#_EFOK]:UHTI5IJ$
M.IC6JQI0<Y,YGXB^+AJ-RVE6<I%K$V)64_ZQAV^@K-\">$V\0:G]KN@?L$#!
MF(_Y:..0OTZ5CZ)H\WB'5H;*V!R<F1ST5>Y^IKWW2=+M=)TV"RM$"PQ+@>_J
M37MXNM'!4?84OB?]7/&PM*6+K>VJ;(N(@0!5P% P .@J2DQBEKY\]Y;6&2()
M%VLH(-<C>O)I%TL3,50L61O:NP-96N:0FK6+0ERDHYCD Y4UM0J*$K/9F->F
MY1O'=&3/'8^,]%GL+G;YR\@]2I[,*\3OK*\T'6'MI\Q7$#[@PZ^H8&O5K#P=
MKNE:C'=VVHV^5(W@AOF3N#5GQ_X3_MW33?6R :A; L/^FBX^[_A7JX7%4\/6
MY$[PE^!Y=?#5*U+G:M)?B6_ _BE?$6F8E*B]@&V91W]&'UKK%.:^;=#UFZT/
M6([VVSNC.'0]".ZD5]!Z+JMMK6FQ7]JP:.50?<'N#7+F.$]C/GA\+.K 8KVT
M>27Q(T:***\X]$Q9?%&G02O%(M]O0X8)83M^H2F?\)=I?]S41_W#;C_XBM>:
M:"U56FD6-7=8U+'&68X _$D"I<4 8?\ PEVE?W=0_P#!=<?_ !%'_"7:5_=U
M#_P77'_Q%:EY>VFG6YGO+F*WB!QOD8*"?09ZGVI+'4;+4X#-974<Z [248':
M?0CL?K0!F?\ "7Z1ZWW_ (+KC_XW3?\ A,='[O> >IL+C_XBMU@J@LS8 Y))
MX%9]KKFCW]R;:UU*TGFQD)'*&+>N/7'?'2@"G_PF6B?\][G_ , I_P#XBD_X
M3/1/^>]Q_P" <W_Q%;OEKV&*S[K6=&LK@V]WJMC;S#&8Y;A%89Z<$YH Q)->
M\-RZU#JDUS=O/!$8H4:UEV1;OO,HV<,1@9]!@=3F]_PFF@_\_4O_ ("R_P#Q
M-;R@8X/%53J-@-0&GF]MA>D;A;^:OF$8SG;G/3F@#+_X330?^?N7_P !9?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5')_K8_QJ2HI/]='^- $5C_QXV_^XO\ *K55;#_CPM_]P5:H **** "BBB@
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M95M"5\J%B<MLXR 3VR0.P%2ZAI O;R"[BOKNSN(E9 ]NR_,IQPRLK ]...*
M*OA:6QFL+EK/3Y=/D^U/]KM9>L<_!8#!(P<@@KP<Y[UN53TW3HM,MWCC>25Y
M)#++-*07D<]6. !T &     !5R@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "HI/\ 71_C4M1O_K8_QH @L.;"U(Z>6O\ Z#5NJFF\Z;:?]<E_]!JW0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %12?ZV/\ &I:C?_6Q_C0!
M!IO_ "#;7_KDG_H-6ZJ:;_R#;7_KDG_H-6Z "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ IC#,B?C3Z8_P!]/QH KZ;_ ,@VU_ZY)_Z#5NJ>F_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7>GO")891D-Y;X.5.0<<<>]:-M?^*YO%6JZ$=6LMEC:I<K<BSP[EP0JD;B
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_M"WOK:6S"EC<)*IC '4[LXI;#4K'5+<SZ?>6]W"#M+P2!U!],CO0!:HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 44E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8/YVCV@NYVR,%=NX@<]0"OYUSEAXNU,>*O$+1Z/J5\BVUE.MI'*N+=6B+/\
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MZUK[5-''XBETZW6*,.T:[5V+@=1DGU/S"NAMO%NG2_VDMVLVGR:;&LMU'=J
M8XV!*ME200<'H<\=*Y:R\)ZY&LZO'&HD\6_VH?,F#%K8 8(([Y XK3U_PI>Z
MU>^(U1DBCO\ 3;:"WD9N/-C>5L,!SM^9<^Q- &[HVNC61O33-0MH6021S7,:
MHLBGIC#$].>0*UJYRSU/Q0]DXN?#D$5U&J#B^4I*V\!BF 2%"Y;YL'H.>M='
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !4,A NH1ZAOZ5-5>;_C\
MM_HW\A0 S3QML+4#_GFO_H-6ZK67_'E;?[B_^@U9H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBH+VTCOK.6UE>5(Y5VL8I&C;'LRD$?A0 K7ELD4
MTK7,(CA)$KEQB,CDACVZCK5:'7=(N91%!JMC+(<D(EPC$X&3P#Z"N6\ Z58P
M:;XETI;9&L5UFXA\B3YU*;4&T[LY'UJ#0M$TG4/&^H7-KH]E;:?HFZSMO(A5
M%DG=1YS$ #.!A._\5 '7Q:]HT\J10ZM822.0JHERA+'T !YJW<W5O9P&>ZGB
M@B7&9)7"J/Q-<)!H>C77Q!2QTS2-/M;+142ZNC;VRH9+E@?*4D ?=7+=>K#T
MJU\5AGP-(##YV;RU_=<?/^^3Y>>.>G- '66>I6&H;_L5[;7.S&_R95?;GIG!
MXZ&K58?AV% UW<GPRNB3RLH?/DEIP!P28B<XSCFJOQ!O)K'P1J,MO,\,C^5
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MQ8'(48P2!FJUEXZU=]"U-46SU'4X+Z&QM)HXGABE:4+M9U;Y@%).<=<<8ZT
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MM=N;+3=5E-Q<6L<*,?-(&2'/(4D E?U&:[>B@#"/AF%KK5I7N'*:C8Q63J%
M**@D&X'U/F'MVK-;P9>/INEQMXAN/[1TIR;2^6!00FP(4=>C@@<GJ?:NOHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4$V?/AP/[W\
MJGIC??7\: &0?\>\9_V14U,C&$4'TI] !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ J"255GC1B<MG&!4],8#(..: 'T444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !2$@''K2TUE)93Z4 .HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "LW6=;MM#@BFN8;N42R>6JVML
M\S;L$]%!/:M*D/0T <A9_$K0=0L;F\M%OY(;>W:X+FS=%900#M9@%)R?6NN=
MQ'&SD,0H)PHR3]!7DELTB_LVQ&)RCFV"AA[SX_K707KW?AGQ/IUHFI7]V-3L
M+PS?:9RX66)5<2(IX7.YAM7 Y''% '::?>IJ.GV]Y''-&DZ"14F0HZ@]BIZ&
MC4+V+3--NK^XW>3:PO-)M&3M4$G'O@5Y:;W7Y?"GAG6;E]6O='732^H?V?=>
M5<"3@B4G(9P!GC/N:[76[BWN_ACJ5Q:7#W%O)H\K13.<M(IA.&)]3WH Z"TN
M8[VR@NXL^7/&LB;A@X89&?SITEQ#%+%%)-&DDS%8E9@"Y +$*.YP">.P->77
M6HZU>:IH.@V$%[):1Z'%>2):7@M7E8X0?O.N%]!CD\\4]=,UJ:[\&1^);J[B
MU 7=S"S170!9/(E*-E.-^,*2.3SZT >FI<P23RP1S1O-#CS(U8%DSR,CJ,]J
MEKS2U7^R_%GC[58);Z>?38HYHX'NG9)&-N7VE<X(R> >G;%5O#<_BHS:+J;C
M5I[6ZA:349;B[A>!U:,LK1*')0J<8 7D=: /5*K07\-S>W=I&)!+:E1)NC('
MS+N&TGAN/3H:YCX?6][<>'K'6]1UB^OKF]M48I*P$: \C"C^+'5NIK-O;[Q%
M>:KXYL-)N'>>U-F+2/>%**T0:0(2,!CSC/&: /0JC6>%YY($EC::, O&&!90
M<X)';.#CZ&N=\&:C:7UE=102ZH+BWFV7%MJC%IK=B 0N3U!'(.3G-<E&TNA>
M+/B%K,5U>SR:?##.L!D!24F!B XQR%[>@'>@#U.BO.9I=8T2S\,ZS_;]U?R7
M]W;P7<$FTP2B;J4 'R[>HQV%;WCO5KS2]%M8["X6UN+^^ALA=LH86XD;!?!X
M. #U]: .HHKB/$(O/#]GI]A:ZS?F75]1ALS=W+AS I#,Q0[<!F"[1GUR.E9F
MNW^K>%[O6M.BUB\O(9M#N;ZW:;:TEI+&N,[@!\ISQGN* /2JPX/%>FW-[<6\
M2W3)!/\ 9FN!;L8C+NVE PZD'J>@]>#7-V[ZOI6O>&;6[UJ\N_[;MIH[I7VA
M8Y5B$@>/ &W&",<]169HJ76CZ-!-;ZE>L9_$S6TBR2 J4^U.&XQU;OZT >IT
M5YU:/K6H'Q/JDFOW<<.EWEW%;6D2H$(6/(W'&3@D$<\8JIYOB%9O!\0\179D
MU^,_;&*)A (A)F(;?D. 5SSUSUH ]0HKEO"%_=RWFO:5=7,MT-,O1%%/,079
M&17 ; &2"2,_2J8_M+Q1XCUVV36;S3+7366VABM@JNTA0,96)!)'. . 0* .
MUHK@_#'B:_UBY\-M=S*&N+6_281X"3R0RQ('7ZC<?Q-4=9UG63;6T5EJDEO+
M/XJ-AYH56VPE7^7!&.,?I0!Z516++;W>B^#[N-+^YO+NWM9G2YGVM(S89AG
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MJ3MSA>V#GUS4>C7.MZ#;>"I+C6'N[;5%CM9;,P(J1 P[D*,!NR-H!R3G)Z4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_>@8JHYR=RD^XJ!=%F\.ZO#INF.7OK;PK=+%@9:28RH=WIDOSSZUZ=C-'?-
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M\5_\)?\ 93-&B?8_MA 9;;R@<PYZ'?OY7G/X5#X<T8ZYXFT>;Q-;BYN[?P[
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MF)LY3:-IR<GCZT >5:[#%JWC/6X=9N=)B"6<*60U1F41QNF6DAY W;\Y8<C
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MV=2DU*XE?RX7AM<2W#$9"JB9!. >1@?2D\27$X"6C^&)-;T^=")1&\1VMD
MI(1D')Y!XQ7!OX-U^/2-(N9+:["6%_=3+IME?;)X+:481$DW 90=@W() /:@
M#N'\=:!#IXO+FYDMT^U&R=)8'#QS;2VQEQG.!QZ\8SFG/XQTSR+_ ,M;LW=G
M$LLEHUI()MK=&";=Q7)Y(''.<8KA-5T^;2+71;^VT74S>7/B*"3[-?WZRS3[
M8) &+%BJGJ,%OX1G';J+:PU/6?%5YKL^FRZ? NF-86\<[KYLS,VXLP4D!0>
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M.520,/;!(Z^M<UH=CKGARZ\.7,F@7-U%!H2V=UY+)YD+[MV "PW= #@]\]J
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M!.DV[17EM8W BG3?&!N1@PY! R >AJ_#X9D0:/+8Z5J,*_V^M[<?;[@2RE1
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MW."P4!N5VA=N<GJ*JV.A:G%JW@V5[.0)97&HO<MQ^[$F_83]<C\ZC?1=0MO
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M90W .#O4E2<J/EP3SR?2F2I?:'XYU351H]W?VFH6L")+:[&>)X]P*%68'!#
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MT;Z'(J_7#_%22&+PM:-<NRVW]IVPG()'[O?\W3GIGI0!VSNL:,[L%11EF8X
M'J:<#D9'2O&YO(B@\72^'(KR/PVV@2AVN#(L+W)'!C\SG.PD''&<>U=GI_B+
M6;76=(T_6-/LH+;58V%J8)V>2)DC#E9 5 )(S]W@8[]: .QHKA(/'<R>,;71
MKJ71IUO)Y(8XK"Z,LUN5!(,O&.<=."/>J+?$#7SX6O?$XT>P33+5GB$37#&6
M9Q,(P1A<*O)Z\Y'I0!Z317$?\))XJC\2+H,VEZ4+NYM?M5O(MRYCB52%</\
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MS$\#G!SGG'6JM_XLUBYT?1;_ $G35C:YU#[+<17$X4JRR-&T>=K<%E;YA@C
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:#/DVP;^"//.WOVY)X%<KJ7PYU&[EU@12Z4WV^^%V+VXB9[A%W*1$#C"J,$
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MN.M6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ45FZCX@T?2)HH=1U.UM991F-)90I8=,@5%'JPMY=7FU&^TZ.QM)E1720@Q
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M\ :E;6=O+<7#F';%"A=FQ*A. .>@)_"F:/ILH^(_BN\N+-Q!/;V<<,TD9VR
M*^\*3P?X<CZ5UU% '.>!;:XLO 6C6]Q!)#<16JJT4JE64^A!Y%<% ?$.JZYX
M;GU"WUXWD&J%[J)K(1VEJG[P?(P4;A@CYLG(ZGD5[!10!PG@^]?0?M.A7^E:
M@M^VHRM]HCMG>*Z$CEO.WXV@ $9R>.*B\'SW6BZ(OA>]T[5(M266:,WJ6;O
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M!BII?"FK:JVI7FM7]H][/ITVGVD=M$RPP+(/F8[B6+$@?0#WH QKSQ+?7?\
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M[#[%:&3R?-EE^<Y(+N7(^F6./:JL7AFPAT_6;(-,8=7EFEN=S\@R*%;:<<#
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M/JVHW=Y]E:TM[F9TWVL9'_+/:H&[IEB"3@5O6-LUE86]JUQ-<-#&J&:8Y>3
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M)Q775#>74=C8W%W*&,<$;2N%&3A1DX_*@"#5M,BU>Q^R3.Z)YT4V4QG,<BR
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MLB@B\G "QB(,%Q^#?I6M10 4444 %%%% !1110 4444 %%%% !1110 4444
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M,7DUM!++>RN(P8XB&(+'G/&_!/OQ7H?]EV'V:TMOLD)ALRC6R%01$5&%*^A
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M-O-<OC>[ _/CIN .&].:=J&GSV5K?S:!9VO]I7S9DDFD*KNV[0[<'.,#CC-
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M=]=0S7&N26<]S)<,XMXVN-K288D!L'[V,\YKV/&!@5EQ^&]&BN;^X33H!)J
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M6V?)M8EC4GJV.I/N3D_C0!H4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 53U/5K#1K/[7J-TEO!N"!G[L3@  <DGT%7*Y'QA!<IK7A
MS55T^XOK.PN97N(K=/,==T957"?Q;3Z<\\4 :=MXOT&[2^:'44/V !KH,C*8
M0<XW @'L:TIM0M8+^VL99@MS<J[0QX.7"8W'\-P_.O+"UUX@USXA"TTNX@N)
M=.MEB@G3RY)B%?!QVSC S[5T;WM[XA\3V<EMI>J:>D>EW</VFZMS&(YI#%@<
MCMY9YZ'MF@#H;7Q7H5[J"6%MJ4,EP[.B*,X=D^\%;&&([@$TU/%FAR^=Y5\)
M%AW[WCB=E^4X;# 8)&1P":X'PGX?91H=CJ@\4I>:9,K^0\4?V2.10?F$NP90
MY/ 8GG!]:T_":7^F>([?3=(M=93P\T<DEQ#JEML%FYY58G/+ G((^8#UYH U
M=-\:VVNZ+IU_;7<%B\UY'!)'/&S[MS$"-3@?,P'!Y K5U#Q?X?TJ[DM;W5((
M9HMOFJ<GR\]-Y PN??%<3;:?J-QX0\+6 TR]CN=,UVW>Z26$KM19')<$\,N"
M#D9'-7K::[T+_A)]/O- O[R:^NY[BVD@@,L=TD@^1&<<)M&%^8CCI0!UE_XH
MT33)(X[O4H8WEC$T:@EC(AZ,H&=P^E+/XGT2VTRUU*74H/LEU@6\BDMYI/90
M.3_2N;\)>'KO2-4TJ.^B:2:TT*.W,Y7*J_F$L@;IP,#Z"L*'3)K?1K5KV#7;
M/4;74[Z>PNK.R:X\D,Y&&CP<JX8D<8.#R,\@'IVGZA::K8Q7MC.L]M*"4D7H
M<'!_4$5F#QCX=.H+8C6+4SM)Y( ;Y3)_<W?=W>V<T[P[/J]_X4M9M6@6RU2:
M(F1$3'EDD[3M).#C!(/?BO/$M;S_ (5G!X.3PW?C6@1$6:V;R(Y-V3<>=C:1
M_%P<Y.,4 >@WOC'P[IUY-:7FK6\-Q"P66-B<QY (+<<###D\<]:UY+F&*V:Y
M>51 J[S)GC'K7%V^CLT_CPW%C,9+P*BS"'F=/LJ+A"1\V&W=.]=%X4CGA\'Z
M)%=)(EPEA LJ2@AU81KD,#SG/7- &%_PGUC>Z+IVJ6=S##!)?+#=>:?]5'EP
M<DXQ]S-=%IGB'2-8@GFT_4()X[<XF*MCR^,\YZ#'.:X>RLY=2\,Z-I-YH]XK
MV.KI]IBGM7"%0\A#@D;67H<@D<C/6G>)-&U>\USQ>FG6TR_;-"BBB<*5260,
M^5#="VTX]L]J .TTSQ'HVLSR0:;J=M=2HN\I$X)VYQN'J,\9'&>*S-;\4)HW
MBW2=/N;B&WLKBVN)9I)2 ,J4" 'ZL>._%<[X2T];S6M)O&OM;,FG02(+6YTI
M+2. ,H!B9EC4'JI"@GH#5SQ=(UG\0/#>IW.F7MWIUK;W)DE@M7F%NY"X8A0<
M'C'Z]J .B;Q%97NF17NE:GI[Q&Y2%I)6)4$L 4P,$/SP#W(S7-7WC#4K=+\1
MRVQDM_$<&G*!&>('$?7/\7S-SZCBJ4%E/=7FH:W:Z9=06-[K5A-#']G97=8R
M-\Q3&Y02>I'1<U1OK6\>UU5Y;>8RMXTA8%D.XQ#RMI_W0.AZ4 >B)K=O;F_?
M4-0T](8+I8%99,>66"X63/ <ENW8BIM-U[2-8$IT[4K6Z\H R>5*&V C()]
M1WK@M1TBXG.MPW-A,\%UXHLG"O$=LL7[@,1QRO#9/3@U:\5Z3J-UXAUV/2K=
MEDN_#;1*ZJ0KR"0@+GINVD@?6@#J[7Q=X=O;V*SM=:L9KF8D11),I9\9SCUZ
M'\C5S4;F6W^RB*:UB,MPD9^T9^=3G*KC^,XXKS9[W3KSQ#X"M-,TJYMOL<\D
M;K):/%Y!$)S'E@,GC)QGID]:[?Q0CN^A[$9MNJPL<#.!AN: )[OQ9X>L+G[-
M=ZW803[S&8Y)U5@PQP03[BMBO/9]'M6\.^/IY-/+SW,MR"RQYDD40KM"^N#G
M&.]=5+#=W7@UX;=V6]ET\I&S=1(8\ G/O0 L'BKP_<ZG_9L&M6$E]N*^0DZE
M]PZC&>OM4B^(M%;5!IBZI:&_+,OV83+YF5&6&WKP.:\[58=2\':%X;L-)N;?
M7K*6UWA[-U%DZ,I>5G( P0&/!^;=[UIC1;JZ\.>/$TZ'R]2O+ZX6.0C#2#8H
M !_%@/K0!J77CO39_$6B:7HVIV%XUU=O%<I%('94$3MD8/'S <UNR>(]%BU0
M:9)JMHM]O6/[.90'W,,JN/4CH*X1+BSU37O!<>DZ%?0C3I76X=K"2-;0"%E\
MIG91SDC\AZUBZ5H,KC^P-8U76;>__M/[2]M;Z<KJ[>;N283^625QC+%N,$=L
M4 >KC7](;4TTT:G:F^=V1;<2CS"RC+#;UX'-9>O>.-&\.:[IVE:A<PQ/>!W>
M224*L"JI(+9_O$8'OFD\*Z;%;7WB"\-KLGN-3D)E9>74*H&">W7I[U0\88L_
M%_A/5KB&0V-J]TD\J1-)L+Q83(4$\GCI0!O7_BG0-+OA97^LV-M=''[J6=5;
MGID$\5K@@C(Y%>96US!H]OXHTS5](N[G4;^^N988TM'D^W1N/DVL 0 !P1GY
M<=J[#0[?4M'\#64%PINM2M;!0R$C+R*G"9'7GY<]^M %C3_$VA:M>26FG:O9
M75Q&"S1PSJY !P3P>E%CXET/4KJ>VL=7LKF:!2\J13*Q10<$G!Z5YCID]UJV
MO^%KVZEOK@>5<I=VT&FFWAM6:V8M$IVAF;( ^\>1D8R*MZ4L$EA>^%X_[1OO
M#PL'1K@:>\5U9#('DD[?WA// 7(V\YH ]!M/%.@7\$T]IK%E/% Z)*\<P8(S
MMM0$^YX%7I-1LX;HVLEU$EP(3.8F<!O+!P6QZ ]Z\Q:ZU/4/"&LVUK$^JVEA
M+9O:WBV;02W"QS)(T93'S%57[P !STJ[-J":]X]N+ZPM[I[%?#EQ"+E[:2-'
MD,BG:-P&2/\ /2@#M(O$^A3PW4T6L63Q6B+)<.LZD1*PR"QSQFK&F:SIFM6[
M3Z7?VUY$IVL\$@< ^AQTKS_7="G3X;^%X-.AF@MK26UGO%MX1*ZQA"6;RV!W
MX<AB"#TS@UM>"+&V_M+5M7M]5U'46O/*666YLQ;HY0$ H B@X'!(% '0ZCXB
MT72+J&VU'5;.TGF&8XYYE0L,XR >V:TF940N[!549))P *\J^(6HWUS+XATM
MA-:Q+9@6Z6^EF=]0!C).9""JJK$YQR,$@YKMY?)NO .W48KF*"?30EPD4;/*
MBM'A@% )R,GMVH 9<^.?#<&F7M]'K-C<1V:DR+%<*QW<X7KU)&!4\'B_P_-I
M4.HG5[*.VE4L'>=0/EQN&<]1N&?K7&Z-/>ZAHFNZ/#"FIZ?;Z6T-IJ*V36\D
MC;6 A92!N8#'*@#D=S5^V33O$.I^#KE;8SP6L%PP\V%E$<JI&.0P'(R<9[\C
MI0!U%WXGT&P%L;O6+& 72AX/-G5?,4]&&3T/K4U_KNDZ4<:AJ5K:GR_-_?2A
M,KG&>?<BN(M[S3O#WB+Q/!KFFSEKZ96M66T:9;F#RE58DVJ1P01M./O4>%M%
MG@U[PZNJ6K&>TT%P/-&[R6,J87//S!3C\#0!W3:SIB:7_:C:A:BPV[OM)E7R
M\?[V<4FG:UI>KJ6TW4+6["J'/D2J^ 20"<'C[I_(UY7;6AM=/LI;^QEDT33_
M !->231+$Q\I<L(GV#DH&;/ /6NA\&7=C?\ Q%\6W6G1,EO+#9L&,)B\PXDR
MVT@'KW(YQ0!V&J:]I&B^7_:FIVEGYIQ&)YE0M],FB]U_1].4->ZI9VZF+S@9
M9E7*9 W#)Y&2!GWKE/&FIW$&O16 =+.">Q;;=#2VNY)F+%3"O8?PG!R#D5C^
M#].9O$?A-[FT8B#PTP!EB_U;^8H_!L$_F: /2/[6TW^RSJ?V^V^P!=WVGS5\
MO&<9W9QUXK%T?Q9%K?BR]TZQGL[G3X+**X2XMY Y9F9@02#@8 ''6N.ELQ8:
M/ 9["631[/Q1<27-ND+/MAW2;&VC.4#%3C![5K^%Y[6_^)FNZCI]K+'9SV%O
MB9[9HEF8,P+#<!GTS[4 =CJ6MZ5HPB.IZC:V?FG;']HF5-Q]LGW%4$\8:-)X
MFDT(7D'VE($F#><F&+$C8.<E@!G'H17+^.+F#2?$1U6RNBVL+8^5_9\]C)/#
M=1EF(4,H^1R<C.?3(Q5J.?[/\0&N+ZU:U:^T2".)-A8"4/(63(&,C<* .I7Q
M'HC1S2#5K+RX8DFE?SUPB/\ <8G/ /;UJ*;7K:YT<:AI&H:9/$943SI;D"+E
M@"-PS\V#P.Y(]:XZ"$>'?A/HCV>F0B2>&T^URRVAF,.X!FE:,<OM;H.W'I6#
M*;F\TOQ*%CEODDU;3IXY!9-;^>"T><)UQ\O7J>M 'JU_X@T;2[E+?4-5L;29
MUW+'/<*C$>N">G!K/N_%=C8ZS#'<WME#IDE@;I;IY0%8[U PV<$$$FN0U>YT
MK3;CQI:ZS:,=0U!6>U=[=I?M$/DJ$5" >%96R,\=?>K?@^PBN+GPG<S6PD\G
MPS'Y;NN0C$Q]/?'X]: .FUCQCHVC65A=RWL$D-]/'%"Z3)@AF +Y)^ZN<DCI
M5%_&,-WXQM=%TO4M):(P+/+(\P=I<M@1QA6 W;1N[\$<5QTEH(O"#O=6F+/3
M?%C2?-#D0VHN=S$#'W,$DX[5TLL,=]XTNKC3(D+'P\OV698\!69WV[3C@X(_
M"@#J8M=TB?4VTR'4[.2^7.ZV2=3(,9S\N<\8-$VNZ1;RK%/JMC%(SF-4DN$4
ME@<%0">2#QBO,X7L+KPAH&@Z;8S1>);>XMFEC-LRRV\JNIFED)QPP5^<_-D?
MAT%GX6M-3TGQ8CV<8O+Z^NE2=T&X'&$(;&0 >?SH [C[1#]I^S>='Y^SS/*W
M#=MSC=CKC/&:S[KQ+H5E##-=:SI\,4V?*=[E 'P<'!SS@\5Y+-<>(WT]/'4E
MG>#4I5?2UM8U+%4\HHK8_P"O@%OH>_?5UV5?#XA\/.]G8PVVBI'%</IIN9KQ
M@&#1H<X&."1@_>)H ]+O=:TO38S)>ZC:6RA!(3+,J_*3@'D],\5C>+?&6G^'
MM#U&>&_T]]2MX/,BM99UW.2,K\H.XYSGCK7*^%]-%[XE\,27MDT\47A51NN(
M,A)/,08.> V-WOC-96J+I]IX3\7Z9JNF/<>(+FYN)%VVC,TN<M%(KA<;57![
M8P1WY /8C,D=L9YG2.-4WN['"J,9))/054BUS29UN&BU2SD6WC669EG4B-&!
M(9CG@$ G)J#7HA-X1U.%B5#V$JDA<D9C(Z=ZX+4=%^Q?"[PR+"S\B-'LY]1\
MNU\T^6$+.TD8Y<!R&(]C0!UGB#Q;!8Z NI:/<65^#>06Q9)1(@WNJGE3U ;^
M5:]SKND6>H1:?<ZG9PWDQ C@DF57;/3"DYY[5Y3JT%O<:=?:K9ZRFH+/?:?'
M-Y%AY$199N&!_B8 D''3C/04_P ?:N]W)XHTV06MD\2(L$2Z8TMS>G8"KB3.
M H;@'&5XY!XH ]#'C'2&\5R^'1=0B\2$29:9 K.6*^6.<[^,D8[BKMMJB1:(
ME_JUUI\ Y\R6*XS /FP,.P'M^/%<NZ6EC\8VGNX4B%YID<=K(T7$DPD;<%./
MO!2/?%830QVEIX-O]9M'DT6T%W]HW1,ZPRL?W;NHSD<, <<$YS0!Z5!K.EW6
MGC4(-1M)+,D*)UF4IDD #=G&<D#'J:=8ZMINIASI^H6EV$^^;>99-OUP3BO,
MM2M+?5+3Q%<:99DZ)>7>F1JJQ%4G=9U\UU7CC:5!(&#CKQ6OK5G;0>/K[S$E
MMM/G\,2QW$MM$<C$H48P#\P5C@8H VM=\965KX;U'4M&O;'4)K-HU=$F$@4N
MZK\VT^Y_*MF#6=.O_/CT_4K&YFB4EECG5]G^]@Y S7ED-ZEQX0U_0;;[+J>F
MV=G#'%J%K9F+S27P(V X+#KD8Z] <UU>N6=M8>)[06MFL0FT2^MP88< [3$R
M*<#C #XS[^M '10ZY:0:5;W.J:CIL,CP"9VCN08B. 65CC*Y8#/N/6KME?6F
MI6J75C=0W-N_W987#J?Q%>2:=>:?H]S\/Y=9AE$<>BR@?N6?RY/W6"R@$]CV
MX)%=/X9O[/3]1UK45@FM=(U34X(M/7[,Z"21HU5F"8R%9P?F( /6@#O****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ %%%% !2;AFEHH **** "BDI:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>\+J0(U=2QX'3;&@ ![T =]1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 4[_ $G3M4,)U"QM[KR'\R+SX@^QO49Z&KE%% !1110 457O;ZUT
MZU:YO;B."%>KR-@4ECJ%IJ=JMS97$=Q QP'C;(SZ4[.U^@KJ]NI9HHHI#"BB
MB@ HHHH ***BMKF"\MUGMIHYH6SM>-@RG!P>1[B@"6BL[4=?TK29XX=0OX;:
M24902-C(SC-:"LKJ&5@RD9!!R"*;BTKL2DF[)BT45''/#*Q6.6-V'4*P)%(9
M)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &)X@UR73/(M-
M/MA>:I='$%ONP .[L>RBJ<7@Z.\1I/$-Y/JL[\E&D9(8_9$4@?B>>*HZ1?+_
M ,+!U+^V0+74'C6&PB9LAX!DDJ>A)(R1U[=C6[XJU-M'\+ZC?1Y$D<1"$=F8
M[5/X$BNFTH-0AN[:^IS7C-.<]E?3T,'6=#C\)Z=)K'AZ22S%LPEN+7S"T5PG
M ((8\''0CFNTCD66-9$.58!@?4&N)U![W5H=)\*SNLUQ+#')J\BGF-% .,]B
MQ&/Z<UVZ@*  , < "IJWY5S.[U^X=*W,^567ZBT445@= 4444 %9VLZS;:+:
M+-.'=Y'$<,,:[GE<]%4>M:-<++>VEC\0;F[\02O;!8Q'IC3?ZG:0-Y#= Q.>
MN.*UI0YF[]#*K/E2\S6T[0+FZU%-:UV3S;L<P6@.8;7TQ_>?U;\JU]/TN#3&
MNS;E@MS.9V4GA6( (7T'&?J35B"X@N4WP31RKZHP8?I4M3*<GN5&$5L%%%%0
M61S3PVZ;YY4B3(7<[!1DG '/J:DKEO%:G4=4T+1E!*S77VF8C_GG$,X/U)6N
MIJY1M%/N1&5Y-=@HHHJ"S+USQ#IWA^V$M]-AVSY4*#,DI]%'?^59'PZG,O@V
MVC:*2-X998V5Q@YWD_UQ^!K#TO7K#_A/;E=7BE_M62:2&(S +':PH"5QD]6Q
MG/O7HP(90RD$'D$=ZZ*D?9PY&M79W.:G+VD^=/175C \2^%+7Q'Y$K2FWN[?
M(CF"*XP>JLIX8>U<IIFF>*=&UJ'PW%KXBM6@:XAN&M1)D J#&H8G &<XZ?G7
MI=<UXT,EI86FL0+F73KE96.?^61^5Q[C!_2G1JR_AO5>85J4?XBT?D1Q^#!,
MSG5]:U/4E<8:%YS'$?\ @*8]_;!K/\+:-I\'C/4[W2+<0:?;P"S!1BRRR[@S
MD$GMA16OXHUXV&@)+ISI+=WS)#9$'(9GZ,#Z <_E5C1;?3] M;30ENHC=^69
M"I8!Y3GYGQUY.?\ (HYY\C;>^EOS%R0]HDEMK?\ (VJ***YCJ"BJ>G:I::M;
MO/9R^9&DC1,=I'S*<$<U<IM-.S$FFKH*KWE];6$2RW4RQ1LZQAF[LQP!^=6*
MYCQ=,IN-"L6BWK<ZE&2<]-GS=._2JIQYI6)J2Y8W.BN;J"SMI+BYE2*&,9=W
M. H]Z0.E[9![>?Y)H\QS1X/!'##\\UB>./\ D2=6_P"N!_F*T="18M TV),[
M4M8E&?0(*?*N3F\Q<WO\OD<WI?B*30]=_P"$9UZ_2XE8![:])P7#'A''9O0]
MZ[2O/_%5SH-GXPD_MN)#!<Z24)"%G9A)P!CH>.#QTZUO^"9-0D\,0-J FW;F
M\GS_ /6F+/R;_?'Z8K6M!."J+2_]:&5&;4W3>MOZU.AHHHKF.D**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD!SF@!:*** "BBB@ H
MHHH **** &M'&SAV12PZ$CD5Y_\ $77H9(K'1[&:VN+F6Z5I8FE7:%0YVN<X
M )QU]#7H5<'_ ,(;HO\ PG7D#28_L:V!F;<&96E:3'4G&0 >/>NC#N"ES2Z'
M/B%-QY8]3?\ #&DKI]K)///'=:E<MYEW<*V[+=E!/.U1P!6X3BN9;P)I$4K3
M::]WIDS?QV<[*,]LJ<@_2J[77BOP^-UY%'KEB@.9;9-ER/JG0_AS2E%5'>,M
M?/3_ ( 1DZ:M*.GEK_P3F-4\9ZI#XSNKR.23^RM.F-H;53@SN<CIW.X$Y[ >
M_-=/%.OZ=_:VD:C<&*_ED$SSF0N+.)ERP7GJ,J H[GUKF[&^M$UNSU-]-NIK
MJ.:2650I_?7)<E$]@/E)XR>1BM_3_#WB&W\2RZMJOAYM0NY2)8L3*L22$]6^
MG'%>E*G3@K-+;RZ'FQJ5)NZ;W\^IVW@.&_L/#:R:M=2YN9B\*73?.BL<*"3U
M)ZX]ZZVN;TSP]=RW4>I^(KI;R_C<M#%%D06_IM7C)]SS_.K>B7.IW=]JTE\G
ME6T=R8+6(Q[3M7J^>^[(]N*\RK:4G)/^O(].E>,5%K^O,V:CEABGC,<T:2(>
MJNH(/X&I*Q-2\4Z=H^I_8]2=K9#")$G=24<DD%<CN,?K6<8RD[1-92C%7D17
M'@GP]._F)IR6TN#A[1VA(]_D('YUG6_V_P .>(]-TS^UY=1M;XNH@N<&6$*I
M.X,.2. .:MW/C&"XA*:#;S:K=ME4$49$:-VWN< #]:R6T;5K#1=6U[4&-[X@
MGMVCB2%2PMU/1$'MG)^G?DGICSVM4?E9_P!:'+)PO>FMM;K^M2K8>,;[Q!X\
ML8K+?!H\0F#D])]JG+$^@RN/3/O5#7O',\OA>6>*YP\VJO';M%\I\B,AA^?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@KLC+#< 3U?VX[UUGPY\6S>,_"4>IW,"0W*2M#*(_NLRX.1Z @CB@#K****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS>$R98]2CB$@+J DF5#84YR3@YQCL:=J7B[3]+?6%GBN6.DVL=U/L53N1]V
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M=:V=>TWQ_=2PM!=QZ/;P7<##'ES(90ZCU&>0?0BO:(K>"%F:*&.-F #%% )
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MLL/V6-0J0^6-B@= !TXH \OBL'T74?AA;2@^>3<O/C*DR21!GSWZL>M=,_\
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MPRD A@0>ASUH 6BDR"<4M !1110 4444 %%%% !1110 4444 %%%% !1110
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MU."* .DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.[U6)0L-_,7B5> L2C:F!VX XH Z@=!2T@Z"EH **** "BBB@ HHHH ****
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M,>I8GDFM-<X^;K[4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3&!^5:EMXFFGMOL_A;PQ<2P@?)),@M+<>XS\Q_ 5LZ5X/T'13OL=*MHI0/\
M6;=SG_@3<UN@4 <8OAOQ%K#"77->>WB(^:STW,:Y]"YR3^E;NB^'=(T)673=
M/CMRP^9]OSM]6ZFM>B@! JCHH&?04M%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*!P** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *C2"&-RZ1
M(K-U95 )J2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBLKQ'H\VNZ)-86^J7>F2O@K<VC[74@Y[8./49&?6@#5
MHKS+_A%OB/H 231O%T6KHOWK?5(L;AC^]ECZ=Q]>M/@^*5WHMW'9^./#]QHK
M2':EW&?-@<C&>F?7L6H ]*HJEI>L:=K=H+O3+Z"[@/&^%PP!]#Z'V-7: "BB
MB@ HHHH **Q_%.O#PQX;O-9-I)=+:JK-%&V"06 )S[9S^%:L,R7$$<T9RDBA
MU..H(R* 'T444 %%%% !1110 4444 %%%% !117,>)OB!X;\)R>1JE^!=8#"
MVB4O)@].!T_'% '3T5YTWQ/OKM!+HW@?7[V$XQ))%Y0(]N&S4<OC'XB2L$M?
MA[Y9+<--?*1CWZ8_.@#TFBO-F\4_$VW96G\"6TL9X*PWR9_/<<?E2-\0?&-H
MX:_^'-_Y.,DVUQYK#GT"_I0!Z517GVF_&/PO=3K;:B;O2+HG!COH2H!_WAD#
M\<=*[Z*6.:)98G62-QE70Y!'J#0 ^BBB@ HHHH **** "BHY[B&UA::XFCBB
M499Y&"J/J36!>>/O"5A")9O$6FE2P3$-PLIR?923CWZ"@#HZ*JV6IV&I6AN[
M&]M[FV&09895=1CKR#BDL-4T_58FETZ^MKR-6VL]O,L@!]"5)YH MT444 %%
M%4=:U.+1=$O=3F&Y+6%I=N<;B!PN?4G _&@"]134;?&K8QD XIU !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !112'/:@!:*09[TM !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME<CX^7Q%XFT9?&&JV4UEI-G=1K9Z<Z_O!$3\TL@(ZDA0/KZ<D ]]M3*;2$W
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M S=)\/:-H08:5I=I9EQAV@A568=LD<GKWK2HHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KROQ=INH7?Q6%]I#D:IINB1W5O'G FQ/(&C/\ O*6'
MUQ7JE9HT.V'B=M?WR_:VLQ9%,C9L#E\XQG.3Z].U '#Z=XAL]:\?PZW:3)%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI* %HI@4@YR3FGT %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %(3@=,TM!&>M # X+8!!]<&GTT1HI)50"?04Z@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI,T +129I: "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_A,/#?\ T'=-_P# I/\ &E_X3#PW_P!!W3?_  *3_&K/]I6(UW^QRFV[-O\
M:5R@"LF[:<'N0>H[9%/BO+.;4+JR11YEJD;2L5&T;]V!GUPN2/<>M %(^,?#
M8_YCNF_^!2?XTQO&?AL?\QW33_V\I_C6T%A894)Z9 %-D,$,;22M&B*,LSD
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M>'O^@]I?_@9'_C1_PE7A[_H.Z9^%W'_C5\V]HA&8X@>V0*4PVR?>2)<^H H
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M')Q@85U)^N.O% '4XHQ7-1^.=(*7'G?:(I89&41"!V:5=T@5TP/G4B)VR,@
M&KD/BG3+BPO+Z-I_LEJVQI3 P#MG;M3(RYW?+QW(% &SBE%<_IWBNVU6]EBM
M[>XCAM[8SW#SQ,AC.]DV8Q]X&-\CZ8SSC,T/Q_;7T,TNH?98HUA$ZO:RM,H'
MEF1T8A0 Z*!D#/WE[G% '9T5A2>+M*CADEQ>.B3F &.TD?>X#E@F%^;'EODC
MIBJMSXYTJ..<VOF7+PD[@%* J$D?<K$89<0OR,]* .GHKE]9\8IH^J6^G-!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP)'F,>.H4DC&>17H\-K;VZQK#;Q1+&I1 B!0JGJ!CH.!^52JJHH55"J!@ #
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5VJ&CZ5%HMA]BMW<P+([1H>D2EB0B^BJ.!]*OT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
>%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>arrowheadengagementlette002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 arrowheadengagementlette002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%12
MR,KQJN/FSUH CL/^/"#_ '!5FJMCQ96X_P!A?Y5:H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "H)O^/B'_ (%_*IZ@F_X^(?\ @7\J &67_'E;
M_P"XO_H-6JJV/_'E;_[B_P#H-6J "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ J*3_71?C4M12?Z^+\: (K'_CQMO^N:_P#H-6JJ:?\ \>%J?6)/
M_0:MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !44G^NB_&I:BD
M_P!=%^- $.G_ /(/M?\ KDG_ *#5NJFG_P#(.M?^N2?^@U;H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "HI/\ 7Q?C4M0R_P"OA_X%_*@"+3>-
M.M0>OE)_Z#5NJMAQ96W_ %S7_P!!JU0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %0R_P"OA_X%_*IJBD_U\7XT 16/_'E;?]<U_P#0:M55L?\
MCRM_]Q?_ $&K5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%)_
MKHOQJ6HI/]=%^- $5C_QXVW_ %S7_P!!JU5:R_X\K?\ W%_]!JS0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %(W"G S[4M% $<3,Z*S(5)'0]JDHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HI/\
M71?C4M12?ZZ+\: (K'FRM_\ KFI_\=JU56QXL;;_ *YK_P"@U:H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"GJVI0:-I%WJ5SN,-M$TKA!EB .@'<GH*S
MK+Q78W_@Y_$L4<PM8X))GB=0)%\O.Y2,XW J1UK$\>R7VIWVD>&M+B@FGGE^
MVW4<TA1#!"P.UF ) 9]HX!S@URVH/J&CZ1X[T;5XK2VDU"SEU2UBMI6D0[E*
MR@,P4YW -C'\5 '=6/C-;C4=.L[S1=1T_P#M)2;2:?RGCD(7=C,;M@[03SBJ
M,'Q(M9-/M]4FT75+?2)[C[.+]_*,:-O*98*Y<+N&,E:7P]X:NKFW\/:CJ6L"
M[BL+=)+2""W6)%9HMN2026PI(&,#FN=\%>&;OQ%\/[&VO-7*Z.]W+(]E';J&
M?9<NVTR$DX++G@ ]LT =@?%TDNMZCI=AH&HWSZ?(D<\L4D"("RAAC?(I/!]*
MDM_&>F7'C6\\*%9H]0MT5PSJ-DN4#D*<]0&&0<=ZY2W%K#XX\2W,GC)=&D.H
M1"2T+P#SD6"(@_O 3SEAQZ4RXT&37/&/C?[&ZPZI9SV%S8SG^"58,@'_ &6^
MZ1W!H ZC4O'.GZ9!K\LEK=.-%DACG"!<R&7;MV98?WQG.*>GC&*"_MK/5]*U
M#2'N9!%!)=+&T3N1D+OC=@">< XZ5Y7=:LVL^$OB%J,T)MI7NM/6>)N/+D4Q
M*Z_0,K5W7C#5M-\4VUKX>T6ZBU"_FNX)2UI('%LD<BNTC,.%^4$#G))XH V;
M_P ;66GPZG.]E>20Z9=I;7;QHI\L,JL9,9R4 89QS[5I'7;5M=M](@5YYY(#
M<.\6"D,?12QS_$> !D\$].:X72M<M-'C\>7>HJ;A7UE[>.WQN-P[1JJQ =\]
M/I3OAM83^$-2N/#NL11IJ%[$EU;SJ[,)$50#""Q/^KZ >AS0!WVLZM;:%HUW
MJEX6\BUB,CA1DG'0#W)P!]:;H>L6VOZ+:ZI9[A#<)N"N &0]"K ="#D'Z5RW
MCJ:^U/5-)\-:7#:W$\D@U"ZBN7*1F&)P0K$ \,^.W\-,\$R7^C^)-9T#5TMH
M9[ISJMK%;RM(@21B)%#,J]& .,?QT =Y1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %1N/WL?XU)4;_ZV/\ &@"&Q_X\K?\ W%_]!JU5:R_X\[?_ '%_]!JS
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% #=B>9YFU=^-N['./3-(\,4A!
M>-&(! +*#P>HI]% "*JHH50 H&  . *1(TB0)&BHHZ!1@4ZB@""2QM)9#)):
MP.YZLT8)-2K&BNSJBAGQN8#DXZ9IU% $1MH&$@:&,B0Y<%!\Q]_6EB@B@4K#
M$D:DY(10!G\*DHH A6SM4=W6VA5G?S&8( 6?&-Q]3CO4A1696*@LOW21R/I3
MJ* &[$\SS-J[\;=V.<>F:#&AD$A12ZC ;'('UIU% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %,?[Z?C3Z8_WT_&@"*T_X];?V1?_ $&K%5[3FVA_W%_E
MBK% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)N&XKD9'.*6
M@ HHHH **** "BBB@ HHHH **** "BBD5E==RD$>H- "T444 %%%% !11D9Q
MGDT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112$@8R0,\"@!
M:*** "BBB@ HHHH **** "BBB@ HHHH **3<-VW(SC.*6@ HHHH **** "BB
MD+!<9(&3@9/4T +1110 4444 %%%% !12;AN*Y&1SBEH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *8_WT_&GTQ_
MOI^- $=I_P >L7^X*GJ&WXMHL?W14U !1110 4444 %%%% !1110 4444 %%
M%% &!XUMKFZ\':E]CEDBNH8C<0M&Y4[X_G R/4KC\:XWQ+XDNM2U7P]JFE3-
M'I^GP0:G?J&ZQ3.J!&P>H0R-SQ\M>HD @@]#7$^'_A[%I&B:YI=Q=BXBU(-
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MBK_9I;>\^T NB[BC#8I'RY.>1Q3K7QA'<>'- U9K41G6)H84A,W*&3/0X^;
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M=6 CV)MQSU[<]\9K)\1> [G6=?U"_4Z5<)>VR0(VH6OG/9;003$#QSG/..:
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M9D ."#=>?@^^W"_6@"'7_&DWAV\)O-/MUT]9XX6F-^OG$.5&]80I) +<C(.
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MNKJ/5FU)Q-"?(N<LQ\MTR?E^;WQ@=:(O 5^=(\46\^H6@N=:9)$,%N4CA*J
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MNXMVTIV525AD7YSMQR%,4O\ WT* .]U/4[31[![V^E\JW1D1GVDX+,%7@>[
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M2%9KV4Q0*%)W,%+'Z<*>M7*\P_LW4K;Q!X&O;[7KK46NKB221)D0(KFW<Y3
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MUY7DO+;W,D)DCSG:VQAN'UK:\^+S?*\U/,_N;AG\J8][:1RQQ/=0K)(2$1I
M"Q'7 [XH KQZ+IT)T_R;98ET\,+9(_E6,%=IX'L:36-%L=>LEM;^-WC202H8
MY6C9''1E92"#R:M7%W;6@0W-Q%"';:OF.%W'T&>II9;F""/S)IXXTQG<[@#'
MU- &'9>"/#]C9:A:I9&5-1&V[:XF>5YAZ%F)/&3WK'UWP';Q^$-8LM%CNIKV
MZM/L\0N;V20 9!"CS&(4<?I71Z?XDTS5-6OM-M)Q)-9B(NP(*L)%W+M.?FXZ
MUI33Q6T+33RI%$HRSNP4 >Y- '/Z-X)T;1[FVO8H)FN8(]D7FW,DJ09&"(U9
MB$&,C@#CBK,?A/1HYM1<6I,>HAOM5N9&,+EL;F\O.T,<<D#-:Z7$+PK,DT;1
M/]UPP(/T-);W5O=JS6T\4RJQ5C&X8 CJ#CO0!AVO@K1K6TO+55NY8KNV:UD6
M>\EEQ$1@JNYCM'TQ6H^DV<EW8W31DRV*LMN=Q^4,H4_7@=ZS=8\1SZ=K=GI-
MGI<E]=74$DX"S+&%5"H.2W^\*U+>\?\ LY;K4(EL6P3(DDJD)SW8<=.: ,?4
M_ OA_6(;N*]LW=;J[6\E*S.I,JKL# @\<=A4^G>$M'TW[48X)9Y+J/R9I+N=
MYW:/^YN<DA>>G2MA;B!XEE2:-HVX5PP(/T--%Y:E2PN82 <$[QQ0!A:7X'T?
M1Y&:U-\8_*,,<$M[+)'$A&"%4M@<?_6K8TS3;71],MM.LHS':VT8CB0L6PHZ
M<GDU/]HAW(OG1[G&5&X98>U,O;N+3["XO9]WDV\32R;5R=J@DX Z\"@#$U3P
M3I.L:A+=7DFH,LP FMDOI4AEX ^9 V.@ ]^]2ZOX2TK6#;.ZS6L]LGE13V4I
MAD6,\%,K_#[5'HGBVUUBWU6XDM;FPATZ3;(;Q=C;?+#[RO\ "-K \\U3TSQP
M+^^TN*XT:]LK75E9K&ZF9"LF%+ , <H64$@'K0!>M?#,-CJVER6GE0:9IMI)
M#;VJ*01(Y7+DYY^4$>N6)J76_"NF>(+NTNKX70GM X@DM[J2$INQNP4(ZXK4
MNKA;2SGN7!*0QM(P7J0!GBN<A\<6=Z-$33[2XNKC542?R%V[K: C)DDY(4#@
M=>3P* ++>#-)DT>YTR8WL]O.P<FXO))7C8?=9&=B5(Z\5&O@?1?[(O=-E6ZG
M2^D66ZGEN7,TK*05S)G.!@8 X_.NDK@G^(.KIK"Z3_PA.H_;6A-PL7VJ')C#
M!2V=V.I% &]:^#]-M//VW&J2":%H76?4IY!M88. SG!]QR*72O".FZ3?B_66
M]N[M4,<<U[=/.8T.,A=QP.@Y')[FK.GZVEY>ZC:RQ"W:RFCA^>0?.6B23]-^
M._2M*26.%=TLBHN<98X% &7KOAO3O$4=NM\LJR6S^9!/!*T4L1(P=K*01D<&
MH=.\(:-I5HEM;0R[%O/M^9)W=C-C&XLQ)/XUM22QPKNED1%)QEFQ2//%$%,D
MJ(&Z%F S0!1N]!TR^.H?:K59AJ$*07*N20Z+NVC';&X\CG\JH:;X*T?2]8CU
M6!;N2]CA,"2W%Y+-M0_PC>QXKH&944LQ 4#))/ KEO#OBZZ\16MI>P:0%L;N
M5DBE6Z5F5%W99U(&.5' )ZT ;]]IMMJ)M3<H6-K<+<188C#J" ??J:Q]2\$Z
M3J6H3WI>]M9+E0MTMG=/"ER!_P ] IY..,]<5T'FQ[E7S%W-G SR<=:&EC5U
M1I%#M]U2>3]* *$&@Z?;:I!J%O"8I8+3['&D9PBQ;@P&WIP1Q4NKZ39ZYI5Q
MIM_'YEM.NUU!P>#D$'L00"#ZBK331(VUI44YVX+ <^E+)(D2;I'5%]6.!0!F
M67A^QL=1CU!3/+>I:+9_:)YF=FC#%N<]3DDYJK>>#M(O;&.U=)T,-U)>0S13
M,DL4LCL[,K#IRQXZ5I17TLNK26@M&^SK LJ70D4JY)(VXSGMG.,4M]?I:Z=>
MW4925K:)Y"@;NH)P?3I0 S2-(@T:T>"&:ZFWR&1Y;J=I79B ,DM[ <#BN/TW
MP$EWJ'B.;5EO+=+W49&"6]X\:74!5<;U5L=2P['UKKM U0ZWX=T[53$(3>6T
M<YC#;MNY0<9[]:MR74,2REI%S$I=U!R0 ,]* ,?4O"&EZC-:7"_:+&XM(C!#
M-8S&!UBX^3*]5X'!Z=JL6OAS3[.\LKN)9C-9V[V\323,YV.RLVXL26.5')JS
MIFK6>KZ1;ZI:29M+B,2([C;\OOGI3=3UFQTBRCN[N8"*26.)"OS;F=@JX_$B
M@"E)X1T>:SU.UE@=X=2N?M5P/,8'S?EPRD<KC8I&.])IOA+2]-EGFQ<7EQ/#
M]G>:]G:=S%_<!8G"^PZ]\UMO(D>W>ZKN.!N.,GTI'ECC!+R*H'4L<8H YJT\
M Z-9WMC=))J#O8/NM%EOI'6$;2NU03C;@]/PZ<5M:OH]CKNG26&HP":W<@D9
M*E2#D$$<@@]Q5OS8Q*(C(OF$9"YYQ]*5I$1U5G56;[H)P3]* ,&'P=IT5I<V
M\EQJ%S]I,9DDN;MY6Q&VY0"Q. ".W7O6A<Z-9W>KVVIS*[3V\,D"*6^39)MW
M97I_"*NM-$N=TB#! .6'!/056N-4M;;5+/39'875XLCPJ%)!$8&XD]OO+^=
M'/0_#O1();-A-J3QV-PEQ:027KM% RG("J3C';Z=,5:NO!.EW6IW%Z)K^W^U
M,'N8+:[>**=A@995/4X&<8SCFN@\V/S?*\Q?,QG;GG'TIS,J*69@JCDDG %
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M*JC;AP,9W].>E:SND8!=E4$XR3CF@##O?"&E7D5@!]IMY["(0VUS;3M'*D>
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M]10!S=[X$T&_2T62"XC-I:"RC>"ZEB;R!_ Q5AN''>K.F^%-(TA].:R@>/\
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MBZ!!I$4H;9/*UU<7"RM& R>;(SE0?;=CWQ0!PP;2+3Q3?+X^:S,C65LMD^H
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MF0<'->U+:VZ0"!8(EA!R(P@"@YSG'3KS]:BFTO3[B8S3V%K+*<9=X59C^)%
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M[/QJFC746CVFDQ:>K6-OJ080;FD?SBG(&_[O)Y'&*]32RM8U54MH556#J%C
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MD\&,WC-]>EMS?QW<AC65\2H-B[3".NXL/X>_6O5#86;70NFM(#<C_EL8QO\
M3KC-9^G^'K:TN;V>XC@N9+B\:ZC9XAF+(48!.?[N<T <#ISVUSJFEP^/C;E/
M[$MWMDU'B%IN?-)W?*9,;,YY&>*JZ+8Q:S#HUA=-.^BMKEZM@K.5$MH(6*+G
M.2F=V/48'2O6;FSM;Q56ZMH9U4Y E0, ?QI_V>$^5F&/]U_J_E'R<8X]..*
M/+[G3;=+?QKH%KJ-MHFGQ7UJ8!(VR!2\4;O&>1A'.00"/O'Z5%INH6,\.CP6
MNEV.G"V\3)'*VGN'M9W-O)\T; #/&T$8X..]>I2V-I.)!-:P2"4@R!XP=Y'
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M?PFFJ6RZ V463R&-RL1<MY>=VWOC=CIVSS7=1HL4:QH,*H"@>@%.HH ****
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M/<7]_)'')'$+ZZ:98U?AP ?4<<YXHTKPA8Z/-;M;7>I&"VS]GM9+MVAB!!&
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M<V.1C!P>X!H Y>^\:S0:5HMKI^LWFH/JL\Z_VA%IZR3PK& QC\E5 ,G..5X
M)Q71^"-3U>_AU&+54O'2WN MK=7ED;62>,J#RF ,@Y&0 #Z"I/\ A!=(735M
M8FNXIUN7NUODG/V@3/PS[_4C@CH1VK7TG2_[*M6A^VWMXS-N:6[F,C$X X[
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MT.VT634GMWD;^T+Q[R0.0=KLJ@@<=/E'YTZST2SL=2U._B5S-J3(]P&.5)5
M@P.W H \^GUF_P##^D^&?"VF7EPSMI@G?4;*R:\8HH"C9'CH20=QX  XYIUC
MXF\8:C)H>G'_ (EUU=7=Y!+->V)1I8HU5DE6,XP2&Z=,BNF_X0'3(;6SCL+F
M^LI[%G^R7,,H,D*.<F,;@04_V6!Q6;K7A*2X\0>%XOM&IW,%O)=2RWK3DR1.
M4!0[N@&1@#&.V* *5[XLUSP]<>(-*N+F+4;BW%J;"YDC5-OGN8P)0H ^4X/
M&1Z5KK?ZWHGBS0=+U#4H]1@U6.9&)MUB,4L:;]R[?X2.,'D>M:$/@O2A8:C;
M7GG7\FI!?MES<OF27;]WD8"[>H"@8[4_3O"=M9:C#?W-]?:C=6RLEJ]Y*&\A
M&&"%  !)'!8Y8^M 'F>O-XJU?X/W.NZGX@4PW$*.;%+%%!4RJ%^?KZ'TKV+3
MX+JWL8HKR[^UW"YWS^6(]_/]T<#T_"LQ_">F2^$?^$9E$TFG>4(@&D.\ '(^
M;V(&/I4]EHKVEY!=2ZMJ-T\5M]G*S2C9(=V[S&10%W]LXZ4 :M%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(5!(/I2T4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\2Z-!J@TV34(5NMP0H<X#'HI;H&/8$YYH U:*R6\3:,NK?V7]N0WF\1%%5B
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M&U20!@$@G/O0!VE%%8<OB"STMM3FU75;1+6VN(X<^6R>0752%=B2"3N!R,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6,AM[&&Z5G2/*PYB4*&/8=0/>NPHH \G\312Z9<6LCZ?(\4OC*.<0K%S*GD
MEE&/F.03QU(]:T[NUOO$GB#6M2L]-N[6V&A2V"&ZA:%[J5R64!6P<+TR1U8U
MVFJ:+::Q+I\EUYFZPNENX=C8^=00,^HPQK1H \ST:"]NKSX=-_9FH0C2[:>W
MNS<6KQ^4XM57G(Z$\ ]":C\/Z9<R>.SH#G.E^&KB6]A (VGSQF%,#N@:;K[=
MJ],GB\Z"2+>\>]2N^,X9<CJ#V-4-%T*TT.WE2W:666>0R3W-P^^69O5F[X&
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M/M##(5][ET#=./E_#%8<=O>6/@G7?#%QX?O[O4KJXNO+*VQ:&8R.2DIE^Z,
M@Y)!&WZ5ZK10!P-OHFJ1^+[]2)6)\.0VBWI4A'F#.#\WKR#Z\US_ (3\/E+?
MP]::E!XK2]TR3S# Z+]EA= QR'V8*MT #$_-[9KUZB@#S"QM[E%O=(6PUN[\
M*36<WG6MY:F.:V/:*%N&D!R1CG&!S5&\M/$=[H-UI,,&IWVEP7%DUI-?6IBN
M>)AN0K@%E50#N('XUZ[10!P<4UQX<USQ-]LT2_OUU&87%M-;6YF69/*5?*8@
M'9@@_>XPV?6HO!7AB[T6\T*/4+8M-9Z,\9E*[EBD>8,4#=,@'''8>E>@T4 >
M7&/Q%IFAPV]M;ZA;02ZW>M<36UKYL\$#2.5:-"#PQ/4 \'/>JV@Z1J"QZ:_V
M#4]@\6371>\B(E,1A8"5_E&,D]<#DXKUJB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** .>\:W4%GX>$MQ#<S1F[MTV6TIC<EI4 P1SU(X[]*F_X2)/,\0K]F;_
M (DV-WS_ .MS"LO'''WL=^E8OQ(GAN-&MM'BGC.H7=_:"* -ER!,K%MHYV@*
MQSCM4>J^%O$)N_$JZ1=V"VNNQKN:Y+B2W?RO+8K@'=D $<C'H<<@&C)XNDFF
MTVSTS3&N]0O+);YH6F$:0Q'&"SX/.3@ #L>E<UX9\3W&F:#>R-83W>H7OB*Z
MMK>R,RA@Q8L06.0 H#9(R.*V1X6UC3-2TK5-)EL'NH-+33KN.Y+*D@7!5E90
M3D'/!'(]*Q9O"]]H&BVL]UKFEPZK'KDFH0SW.8[>5I%;<C=U)4N1C/2@#9/C
MZ6W7Q E]H<UM<Z);)<31>>KB7=NQL8#D84<G')(QQ4TOB_5XM6@TMO"\WVN[
MC::UQ=IY;(N-Y=L?(1N7@!N2*YK2M-U'Q3?^-I_MMC,+Z""TCGMB3 KJK$JK
M8RP7< 6]<\#I7H%SIDL_B?3=45T$5K:W,+J<[B9&B((]AY9S]10!@-\0[==)
MM)FL'34KF[ELA923HHCEB)$FZ0\;1C.X9ZCCFH1\1XWM8A%I4DNH'4UTV2UC
MN$8*[HSHX<<,A"CGC'/IS7G\ 7;)'=))837MMJ]W?0Q7*%X)(IV.Y'XR&VD<
M@'!'>KO_  BFI7!TR26/1[1K75H[UHK*(HOEK$Z;=V/F;+YR0!B@!NK>+M6A
M\/\ B39I(M-6TJU\[:UP'CV,C%9%;;\V-K?+@=.O-='X>NKZ]T.TN-0MU@N'
MC4D++YFX8'S9P,9].U9>I>&;G4K[Q#ON8H[/5M-2S& 2Z.!(-WIC$E)H;^([
M:]TW2M1@M?)M[%C<7%NKF.1@56-59L8. Y(P>U $_B#Q.^B:MI.F0:9-?76I
MF40K&ZJ%,:@G<3T'/7MCH:SY/'GV*TUPZII$UK>:1''++;K*)!+&YPK1M@9Z
M'/ YXJEXV&H'Q]X+_LMK<78-Z5%QG8P\M-RDCD9&1G!QZ&GW/@W5]4MO$%UJ
M%U:#4M4CA@BCB+&&"*-L@9(R226)..] &C-XONK=+2&?17CU._9C9V1N5RT:
M@%GD;&(\9Y'/. ,TVR\<PW-[96L]A);237TNGS%Y5(AG1-ZC/\0<9VGCZ<U!
MXV\'2^(=1TK4[>'3[J6P\Q6L]00F&=' [@$JP(&#BHI/!$L_@^XL(;72M*U#
M[2MY:_V>A$44R%2A8D98Y7DX'!QVS0!<O/'=K;_:UBLIIY([\:=;JK*!<3;=
MS8)/RJO.6/3!JJ/B+"EA=//I<POK6]ALY+6&59-QEQY;(PP&5@>.E4K[X:K+
MX1T/3HOL=Q>:7-]H=;M"T-T[9,H;J0&))!YQ@<58MO!EVNGPI%IVA:5*-1M;
MMH[%&VE(F!8,Q4;F^]C@ 9_&@#3A\4WTTVJ6$FB20ZK9VZ7,=O\ :4831N6
M(?H""IR#^&:L^#-5U'6?"NG7NI6K0SRVL+F1G0^?N0$N OW02>AQ]*D&B2_\
M)=>:ONC$,^GQV@ )+;E=VR1C&,-ZTWPA8:KI/AVUTO5?LK-91K;PR6[DB2-%
M"JS @;3QTY^M "7/BBWMM"UG56MY3'I3S)(@(R_ECG'UJJ_B]YM??1]-TQKN
MX@AAGN UPD15)/[H/WR!R>@Y'-96K^&/$=Q8^(M'L)=.-AJ[R3)<7#N'A+J
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MCMY3N0;@58^6,D88XSGH,>]8=CXCU+3_ !?XRD_LF^O$A^RS20I,F+8?9E+
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M);_\3+5[6\A&\\1Q2QNV[C@X4X%=/_9L_P#PEQU3*?9_L M\9^;=YF[IZ8H
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MI=Q<S:FMW'JL\[F9(1(K")4V';@#'#8('3F@#T/7]<M/#FBSZI>AS#%M&V,
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MQ N2<8PQ:, 9R.:N>--$O->\.O!ILL<.IP317-G+)]U)48,"?PR/QH J6_Q
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MCP^(+W2/%/BPII5_?QQ>1<S)'*N+=?(4D#<0"3@\+Z?2ND\5Z5?ZG:6$FFF
MW5C?17:QSL564+D%=P!VY#'G!J&#1+T7GB6XE$*_VI'&(E5R=I$(0@G'K^E
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MW8+,BG)0D!@#Z9!!_&N+N=2\6V]UI&DF]TQM0U5WE,JVK!+2%%!< %SO.64
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M4U2W_L>*;R#!D;#*P* YZY&=V/08XKO* "BBB@ HHHH **** "BBB@ HHHH
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M2>,ELKU]S5&?P/:NBFVU"]M;A-2EU..XB*%DDD!###*5*X8C!!KJ:* .1B\
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M+9?^1?0J_E_Q$S X/KBJOA^S@OO$GA5]0MA-,GA9&7S8]P5R8PQ.1P<$_F:
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M )^;T ZGN!S36\1Z?IFE6%QKNIZ99S74:L"+D"-VP,^66P67D<^A%<1X8O\
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M((+> &2-E)#!\L%7!!')ZCC-9&L_$!H=(TB^TK2[R?[9J*VD\;1KOA(<*\;
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M%$/9B5'_  '=BKMSXNM=&G%K>Z?JR6D!BADU*:$>2K,% W-NR>6 ) (!/)H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV4CCKC -9-K9>*[^;PK#?:+#9P:3<*UPXNTD\S$+QAE [<\@\_,.#@FO0:*
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M?KBF:UI]WKOQ+.EG6M3L=/31TG>&RG,1=S,X!R.G3MUP.U '>T5XW:ZAXO\
M$,6HZEIEIJ#ZA#J;Q02)J*1V\*1N 8G@+X/R@Y)&26ZXKH)7O],\=,WB";4A
M97M\B:7>6UXP@4D#;;R0@XY(/S$'.>HZT >B45Y.%N[SP3KOB6;Q/JD%W9W5
MV]LHN=L<'E2OLB9!PV[@?-G@@#M6CI%Q?>-O$%_!J6H7NG+I]I:/':6,S0'S
M)H1(SOSN.UC@ \<<@\T >CT5Y;I=_JVNIX5LY=9NDBDN;^&XF@?:]U%"2$RP
M[D 988/)QC.:G\OQ/-I7BC1=)N[IY['4HUMFGN"LYMRJ.R+*V>V0&;/7J: /
M0[F\CM9+9'29C<2^4ICB9P#@G+8'RCCJ>.E1Z;J4&J0S2P*X6&XEMVW@#YHW
M*-CGID'%>>_VYLM_#\&FSZK:O_PD,=K?6M].TDD>8F8Q%F)++]TCD]:A?3W'
MA?Q7K,6OW]I=66H7TL'D7!6. I([;6C'#;B>=P)P1C% 'H%KKD%WXBU#15BD
M$]C%%*[G&UA)NQCOQMK4KR%_$.I6,_B[Q!';K'J0T'3YS$5R(I&5L\'^Z23@
M^E;/A*+Q1'X@M)Y;+4HM)N+=OM+7^I1W.]L QR* <H3R"J_+R/2@#L=;UZVT
M..W\R&XN;BYD\JWM;9 TLK8). 2!@ $DDCI6FK;D5L$9&<$<BN#\9:4+_P >
M>$,WU]!YDERF+><IMVPNV1CH3T)].*SH_MVM>&O$'B677=0M+VSGNA;113F.
M&W$)(563D-G:"V<]>,4 >G45YMHDVI>+O%UP;S5+ZSM;73]/N?L=I*8U:612
MYW'KC@@CC(QGI6K\0M7U&P71=/TY+@OJ5[Y,AMI$CD*A2VU7;A2<=?3/>@#M
M*@N+VUM&A6YN(H3/((H@[ ;W.2%'J>#Q[5YP;3QU_9=_$EOJ"P'4(I8X)-0C
M-R;8J?,C24$XPP7&3G&>:H:Y!::Q:^$I+34M;C4:X+1TN+AA+"X$FX$GG<I&
MT-D\=S0!Z[6=9ZU:7VL:EI</F?:-.,0GW+A?WB[EP>_%><>--7N[:'5[_0YM
M>FETCRXI+C[6B6T$BA208S@RD@C=D'KQBK]CHXUCXG>-8WU2^M45+0>59SF%
MBQ@&')')VXX'3GD&@#MKW7;6PUO3=)F24W&H+,T+(H*@1 %MW.>C#& :N65W
M'?V4-U$LJQRJ&598RC >ZGD'V->5:5J-]J&L>!KB]F,\T<>K1)=9YG5 JK)[
M$@?U[U;%QKM[X.\*ZH&U/4-.^PF34DM+OR+AW*KA\Y!8*=W 89XSZ4 >@+K5
MH_B*30QYGVR.U6[/R_+L9BHY]<J:GN+^*VO;6U=)V>Y+!&2%F1=HR=S 87VS
MC->;VMK:^)_B-#-::MJ*V+^'('62&9HI)U,C@;F&&SWXQR*T="U'4P_A*VN-
M0GN&:[U&VGD<X,XA,JH6]3\@/UH ]!HKRG25U5_!VE>)YM?U*6\_M&&/RFF/
ME&)KL0LC)T;(;.X\\ # K1EFO=:F\7WTNNWNG#297MK6*"41I$$C#^8X.0VX
ML>O&.P[ 'HM%8?A&[ENO!&B7EW,TDTFGPRRRN<EB8P22:X*TUW4CXF\/W]C=
M:U+I>J7KQ&>]FC\F="K'"0CYDP1P>.![T >LTV1Q'&SG.%!)Q7EFG_VNWA >
M)F\1:HUU'J3(L#2@PF,79CV%<<_+GDG(X]!6FRWOB?4O%AN-9O=.@TQS:6T=
MI-Y2IB,.97_O$[N_  _&@#N-,OX=5TJSU&W#K#=P)/&'&&"NH89QWP:M5A^"
M_P#D1/#W_8,MO_12UY_>7&LP>$[CQ!%K^HB]&MO;PH9,Q)%]J:+:4Z-P<\\\
M =!B@#URHKF=;6UFN'5V2)&=A&I9B ,\ <D^PKA99IO"6NZA%>ZYJ,VDMHK7
M323R"66*2-E0LF1P2&SC&,]L<5SZ:QK>FW^IVOF:S#;3^'[F\A.I722R[T'R
M2+L/[L_-R/7'I0!ZW;SK<VT4Z!PDJ!U#J58 C/(/(/L:;<WEM9K&US<10B61
M8HS(P7<['"J,]23T%<!IO]HZ[K&@6TVLW\-LWAV&[G2"78TTI(&XMU'4DXZU
M@7\MYK?A+P]]LU.^,L/BA; S)+M:1!.0K-@8+J%&#Z\T >R5 +N,Z@]ELE\Q
M8EE+>6=A!)& V,9^4\=>E><>,;R>%M0M=)O_ !!/=:-IR--Y%U'%'"=KL))6
M?!D8@ D#/ ]323^)-5N+74+G[9)&S>"TU!50X"3L)277T/ _(4 >GU6L+V+4
M;*.[A69(Y,X6:)HW&"0<JP!'2N,TV'4=(U_PPLFMWUZ-2MYOMB7+[E9P@<,H
M_@P<C [5F6EQK.L3^"+5M6OX+:\LIY;R2%L-,R;"%+]03SR.<9Q0!Z?17F5W
MJFJZ;I;:,-7N6,OB--)6_E8&>*!XUD.&QC=R5#$=Q6YH<5SIOCJ^THZS>W]J
MFGQ3+%=R;VB9I&!YP,Y [T =C6=K.LVVAV:3SQS3/+*L,,$";I)I#G"J..<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% &=K6MV>@:<;V]9]FX1QI&I9Y7;A44#JQ-9T_B^VM+#[5>Z;J=J[7"6T
M-M+"OFSR-T" ,0>_<8P:9XRT;4-4M],NM+6&2\TR^2\2&=RJ2A0P*YP0#AN"
M1P?2L[6K+7]9.D:Q#I*6UYI-YYRV4UTC&>-D*N-RY56YXR<>N* +DGC[2K>R
MU6:\M[ZTFTR-9KBTGB E\ML8=0&(89XR#VJ2S\;6E[<_9H],U1)WM3=V\<L
M4W,8(&4RW7YAPV#S7/>(?#.N^)[37[][)+2ZN=-73[.S:968@2>86=@=HR>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 8-IX+\/66I+J$&FJ+E'+HSR.XC8YR55B
M0IY/0#K6]110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !169KOB'2O#5DEYK%VMK;
MR2B%7*,V7() ^4$] ?RJY>7MOI]A/?74HCMK>-I99",A549)X]A0!/1573=2
MM-7TV#4+";SK6X3?%)M*[AZX(!JU0 4444 %%%% !1110 4444 %%1Q3PSEQ
M%*DGEN4?8P.UAU!]#STJ%=0MGU.33@[?:HXEF9-C8"$D [L8Z@\9S0!:HHHH
M **** "BBB@ HHHH **K7%_;6MU:6TTFV:[=DA7:3N(4L>0.. >M1Z5JUEK5
MF;NPE,L(E>+<5*_,C%6X/N#0!=HJA::Q9WNJZAIL#L;K3S&+A2I 7>NY<'OQ
M5^@ HK,UG7['0HX#=F=Y+A]D,%O \TLA R=J*"3@#)K3ZB@ HHJK=:A:V=Q:
M6\\A66[D,<*A"=S!2Q&0.. >N* +5%4M7U:ST+2I]2U"4Q6L !D<*6QD@#@<
M]2*NT %%%->1(RH=U4L=JY.,GT% #J*RW\1Z3%%J<DEXJ)I9VWC,C 1':&QT
MYX(Z9ZU8TO4H=6L$O((KF.-\[5N(&B?Z[6 ./2@"Y154:C:MJCZ:)?\ 2TA$
M[1[3PA)4'.,=0>,YJU0 4444 %%%% !1534]3M-'TZ6_OI3%;18WN$9B,D <
M*"3R1T%6Z "BBB@ HHHH **BN;B*TM9KF=]D,*-([8)PH&2<#VI+6ZAO;2&Z
MMV+PS(LD;%2,J1D'!Y''K0!-1110 44FY=VW(W8SC/.*KZ?J%KJEFMW92^;
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MSU-;AK.;S1;SO;2_*1MD0X9>1V/?I0!;HJIJFIVNC:7<ZE>N4MK:,R2,%+$
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M6IBD3RX8W,L@MD/[S<I^7@<+MZGGI78:SHMMKEM##<R7$1AF6>*2WE,;HX!
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MFH007,L>4>:.2-]Z,PY*G: 0>PQTJQXDABL9?']E:11P6JKI<BPQ(%0,SX)
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ME+&?O!<!,;>,9KIK3PYI^M:MXEG\06L,]P(+:-S.@=86^SJ691T#9/4<\#%
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M#9+CX?+H"6YOTO81(T:8D5,-N$I_O%QGGT;'%7+C6=.;P1J'AN>[AM]4?7C
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M**LX9B?PR:[^B@#SRTT_4K3QS')HFFZOI]E+=ROJ27#QM9S [LRH-Y8.QV]
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MH\? D1?-Y!QPH3HQ'2ND\:V6H->^']6L;&34%TR],LUI&5W,C(R;EW$ E<Y
MSWKKJ* /+[C0M:\47/C60Z;<Z6NJ:?;PV?VID#.R!\AMI8#)P#R>#5FTTR+4
M?)DO_"6O--9V4R;+R[1XVWH%:),R'.[IG Z#I7H])D''(YH \?O-$\377A/Q
M%I%E9:L=(>TC6QMM4>-KA91("40JQS&$'\1]A72R?VIX;\9>(-1&B7.HVFJ0
MV[0R6SQXC:-"A63>PVCOD9XKO"0.M8FJ>$](UFYDGOH[IVE01R+'>S1HZC/#
M(CA3U/44 </X/TZ\N[;X<ZC#:G[+;6MZ9V7 6+S%&S\^U=GX<L+BRU7Q))-
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MU)3H\-Q$Y"$>;YI&".>,8J#4? DU]H_B>Q%_&C:U>I=(YC)\H*8^#SS]S]:
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M@L]=\-6VNP;DM9HC(0XY3;D,#ZX((XZXKE=*^))O[S3'EM+--/U6X^SVHBO
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MM.Q$UW";J(26:"2X4M@Q*02"WH, \^U5M,\1:3K'E"QO%E,J-)&I1E+HI +
M, 2/F'/O7*^*IKN[TCQY;"Z:*.VL-RA(TR5-NQ922,X/KU'8BF:7JE_H]_I-
MI<WCW=JGA^:]?,*AB5:/:!M&>%)''7ODT >@T5Q/AZXUV[T.#Q1JOB*&"VGM
MGNFM%MD,$$94LF6^\2H().><8XZUG>'_ !%JA\0VMLVJWNI65[8SSK->:<+4
M;XRF#$, E2'[Y[<T >CT@8$D @D=1Z5YK8ZSXFL-)\):UJ&KK=C6+BUMIK/[
M.BQJDJ<.& W;^A/."20 !6OX9T^_A\:>)II=8FGA6YB#0M#& Q,$9!) !X!
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M39)(PCM+KP[#?FW &%F:5E)!ZXP,8SVK-TS4KG4M6\"7][*9IWCU(NX4 G
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MH6 SP1D"@"LVF6TES97+H?-L@PA(8_+N7:?KQ5"Y\):+>6-_9SVF^&^N3=S
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MV[=O^[C.W=SMSCVK<_L6TW:H?WF=3.;CYO\ IF(^/3Y5'XU'INM)J6KZQ8+
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M %%%% !1110!R/C'2K/6=;\+V5]%YMLUY*S1D\/M@<X/J..1WKD+E]/\._\
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M;P3X-N?LFVZO)[9;FX5BLDT;H=T;,.2A'RX] *]?CC2&)(HD5(T 5448"@=
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MV8KNW6X,T0E"CE&)Q@C'8<]1FN&\::C#/<ZSJ]E!!;7.GWBVPOI]1D6X$J%
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M,B9T!,;8(W+GH<$C(]30!X_J.GVMOX#U_P 51-*^JVFK7,EM<>>_[L+=D!5
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M0O#]]XD72K&QGGMF:2<-<1 XCS X <CHK$A3]:S;5;W48O"ME=>'9M/ETG5
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M+O/M;"*QO"G_  G27/S0D?N_*7=)_N9S\W2@#OKWQ7H&FZDNFWFK6L5ZQ4"
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ML VTR+'G<R=3N]!TK3D\6SR^)VT33-&FO3%Y,EQ<B9(XXHI/X^>6(&3M'7%
M'3U4U.P_M/3I;/[7=6GF8'G6K[)%P0>#@XSC'T-<2GQ.F_LNWU:;PMJ4>FW,
MODPSB2-F=SD* F=WS,, ].:U?^$YALUU@:UI\^FS:9:I=O&\BOYL; XV$'!.
MX;?KWH Z'2],M-&TRWTZQC\NV@7:BYR?J2>I)R2?>K=<?8^/!-<FWO\ 1[G3
MY7LY+RW$LL;^:J %E^4G:P!!P?>M3PWK]QXAM5O#H]U8V<L22V\L[H?-5AG[
MJL2/QZB@#<HKCM9\?1Z9J5_:VVD7=^FFH'O9HGC18\C=M4,078+R0/45'/\
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MI-0DCDL(ID=IAY+X&5;:5S@\D8P3VK6M_&ELFEZM=ZK9W&F2Z4P6Z@E*N?F
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <OXO\
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M0Q(^4# VU-K^BZ_KFF6T4OAW2OM<<!6*Y&I.DMG+D@,CK&"1C:<#'H<UW]%
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M$NX1.2$<J""I(Z95B,UO44 <E!H6IZIX@N-:U2.WLI!I[V%O;PRF;AR&9V;
M[C  'XUGV?AWQ!-'X22_@LXFT2?$K13EA+&(2@8 J,')''ZUWM% '#>(?!E[
MK(\2;&@'VU[2:U$A)5FA )5\<@$C&1ZYJE)X(GN]&U&-?#VE:=?30111R173
M2EOG5G!)4;5XX'->C44 <IXUTN[U2&V2W\/VFJB/<5=[TVLUNYQAHW"DCWP1
MT[U>\/V^O:?;V=AJDL-ZD5FHEOO,/F23YY!7'3'\6<G'(YK=HH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]J->,\P88D!8 KE2V<<$@&@#H=8\0?V9J%EIUO87%]?7@=TAA*J%C3&YV9B
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MGZ5IVDPM#IMA:V<3')2VA6,$_10*FBL[:&YGN8K>*.XN-OG2J@#2;1A=QZG
MX&>E<DWQ!TO3+?04U/4M/EFU)=SSV[%(D3:Q$@#9.TLNWD]34MKXVT^UU36K
M76M2M;;[+J'D0!CM(C,4; MZ#<[#<<#M0!L1>&-!@U4ZI%HUA'?DY^T+;J'S
MZYQUYZ]:2T\,:)IEY+?Z=HVGVU\X/[Z.!5;)'J!D ]\=:U@0RAE((/(([UE6
M'BC0M5U"2PL-6M+FZCR6BBE!/'7'KCVH R_"?@K3M$TG3#=Z;I[:O:P*CW4<
M0+;@,9#$9SCC/7%:VH^&M#U>Z2YU'2;.ZG4 "2:%6)'7!)ZCV/%79;VUAO(+
M26XC2YN QAB9@&D"C+8'?&:@.L::MM<7!OH!#;R^1,^\8CDR!M/H<D#'O0!/
M]AM/M4=U]EA^T11F*.7RQO1#C*@]0.!Q[54O/#^CZA;M;W>EVDL32F<JT2_Z
MP]7_ -X^O6J.I^*M*A@NK>UUO2XM12.78MQ*"J,F=V\ YP"IS]#5-_'NDVOB
M2UT*[O+43RV8G>X64!-Y*@( ><MNR/:@#H8=*TZV%J(+"UB%HK+;[(57R0WW
M@F!\H/?'6J-OX2\.6EVEU;:#IL,Z'<DD=JBE6]1@=??K570/&VC>(([YH+RV
M7['+*''G _ND;'F^RGK5VV\3Z%>VUS<6VK6<L-K'YL[I*"(TP3N;T'!Y]J +
MG]FV.+H?8K?%W_Q\CRE_?<8^?CYN..>U0:9H&D:*9#IFFVMF9,!S#$%+ = 2
M.PSP.@I+/Q!H^H7K6=GJ=I/<J"QBCE#-@'!.!U /%3:CJNGZ/;K/J5[!:0LV
MQ7F<("V"V,GOA2?PH F:UMWNX[IH8S<1HR)*5&Y58@D ]@=H_(50/AK0SJ?]
MI?V19?;=V_S_ "%W;_[V<?>_VNM0MXQ\-)$)6UW3PA9ER9UZKC=GGC&1GZU/
MJ7B31-&:-=2U6SM6D7>@FF52R^H]O>@"Y#8VMO=7-U#;QQW%R5,\BKAI"HVK
MN/? XHFL;6XNK:ZFMXY+BU+&"1ERT98;6VGMD<52OO$VAZ88Q?:M9VYDC$J>
M;,J[T)P&'J*DE\0:/!I,>JRZG:)828V7+2C8V>F#W_\ K4 3G3;(PWD/V6+R
M[TLURH7 E)4*2WKE0!^%4KOPMH%_=+=7FCV5Q.L8C#RPJQVCH#GKCMZ5.==T
MD:1_:QU*U_L[&?M/FCR^N/O=.O%-T_Q#H^K+*VGZG:7*PJ'D,4H;8IR,GT^Z
M?RH E31]-C>5UL;?=+ MO(3&#OB7.$/J!D\5!#X<T6WMWMX=,M8XI+<VK(L8
M ,)))3_=RS''O3;/Q1H.HK<M9:Q97 MD,DQBF5O+09^8X[<'FHT\7^&Y#,$U
MW3B84\R3%PORKQR>?<?G0!HOIUE)):2/:Q-)9DFW8J"8LKM.T]N#BN#U#P9J
M.NZFPOM&T&SCDN!)/J-JS-/*BN&P%*C:S!0"V3QFNUM]=TFZTN34[?4K62QC
MSON%E4HN.N3T&*BM_$VA7=C/?6^KV4MK 0)94F4K'GIN/;- &C<6\-W;R6]Q
M#'-!(I1XY%#*RGJ"#P167;>$_#]G%+';:/9Q)-"T$@2(#?&V-RMZ@X'7TI]M
MXFT*]6Z:VU>RF%HI>X,<RGRU&<D\\#@\U5\*>+M,\7Z9]KT^4!U)$L!<%X_F
M906 Z9VDCVH U(-,L;:X2XAM8DF2!;97"\B)3D(#Z ]JDELK6>[M[N6WB>XM
MMWDRLH+1[AAMI[9'6J<GB+18M1&G/JMFMZ9!$+<S+YF\@$#;US@C\Z+?Q%HU
MWJCZ9;ZI:2WT9(:W28%P1U&/:@"6'1]-M_*\FR@C\F=[B/8@&V1PP9A[D.P_
M&G/I&G2O>O)90,U\BI=%HP?.4 @!O4 $C\:HCQ?X<:>" :YIYEG.V)!<+ESN
M*X'/7((^M69M?TBWU :?-J5K'>%UC$#2@.6894;>O(H @A\*:!;V\]O#H]FD
M5Q$89@(A^\0\X8]ZOOIUG)+:2O:Q-)9DFW<J"8LKM.T]N#BJD/B31+C56TN'
M5K)[]25-NLRE\CJ,9ZCTHM_$FB7FIMIMMJUG-?*2#!',K.".HP#V[T (?#.A
MG5?[3_LJT^V[_,\[RANW_P![_>]^M%QX9T.ZM+2TGTJTDM[/_CWC:(%8QC&
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M4:KX[T#3O#\NL1:C:W<"2"("*=?F<G[OUQS]!0!T,-M!;6R6T$$<5NB[$B1
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M.SN;>T0EF2<8W8^52>Q)P!]:R?"7B/4-6CL;B[U;1+F&[AEF:.V#+)&0(SL
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MO-7LK>Y"[S%+.JL%QG)!/' S6FK*Z!U(*L,@CN* ,K4?"^A:O="ZU#2;2YG
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MPUH=]?I?76DV<UTF,2R0J3QTSZX[9Z=J=9>(M%U&_DL;+5;.XNXP2T,4RLP
M.#P/0FEU+Q!H^CN$U+4[6T<IO"S2A25SC(S[T 2Z=I<&F&[,+.S7=R]S*SG)
M+-CCZ   >PJM=>%] OKZ2]N]%L+BYE7;))+;JY<8QSD<\<?3BF_\)9X>^T6U
MN-:L#-=!3 @G4F3<<+CGG)Z5)=^)=#L-06PN]6LH+QBH$,DRA\MTXSWH N)8
M6<4D\D=I CW  F98P#* , ,>^!P,]JJW'A[1;NWM[>YTBPF@MEVP1R6R,L0Q
MC"@C"C [4W5/$FB:)*D6J:K9V<CKO5)I0I*^N#VJAHWB>V/@[1M6UJ]MK:2^
MMXF+.P17D9<X4?GQ0!M66GV6G1-%8VD%K&SF1D@C" L>I('<^M/%G:K)<.+:
M$/<8\Y@@S+@8&[UXXY[4EG>VNHVD=W97$5Q;RC*2Q,&5A[$5ROC3QUI^@Z)J
M/V+5+$ZO;;56W=PQWDCY2N>N,\4 ;^G>'M%TBX>?3M*LK2:0$,\,"HQ!YQD#
MIGG'3-7H+>&U@2"WACAA086.-0JK] *@_M.Q,MY']KAWV0!NEWC,(*[AN]/E
MY^E4[OQ1H5C:QW5UJUI%#+")XW:0?/&2 &7U'(Z>M &O16+!KEO;6MY=:IJF
MFK;I>-#')&^U4'&$<L?O]<XP.E6K#7-*U1)WL=1MKA;?B8QR ^7QGYO3CUH
MT**QK/Q=X=U&]AL[/6K&>YF!,44<P+. "3@=^A_*MF@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#C/%T\=KXN\+7,NGSWJ0FZ?;!'YCQ_(HWA!RV,]!D\Y XKFM5TB_UEO$N
MJPZ1=)::E=:=%'!-;E994BE'F2&,C<HP>I .!GBO3)]-@N-3L[]R_G6BR+&
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M(!^O7'>N6OI];CL;33S]LT^'_A'X$1K;2_M$UW*4(:(L5.S!QP<=2<BO7**
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M"0J5"YW Y'ICO3?&/@S6]=O]=_T.+4$NX5&G2S7SQI9X4!E\L<%B02#TSC-
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MC>_:WMR@EBBVH$0#<.2%')QU)I-5\&6MW>Z3:6UA9Q:+!!=PW%NB! !*%QL
M& =PSGMUH T?#%IK$-B]UKMVTE]=MYKVRX\JU':-,=<9P22<D5N5RFCV_BK1
MK%-.DCM=1B@NDBANI;@B1[4YRS\?ZQ1@>_\ /JZ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>&]\=#5N@ HHHH **** "BBL_6=8M=#T\WET)&7>L21Q)N>1V(554>I) ]*
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MGR@Q8+R>F23^- ' :0O_  C/@WP5KD-]<&P5(5U!9;EF0+/&B;N3A51PF!T
MSTYKJO!NH3ZGITNKW=Q(%U2Y>6R@E;[D X0*/=5WGZU5UGPCM\/S^'_#EC96
M=EJ+$7DCR']TAQN*)@@DKD#E0#@UM-X?M?[5TF[3"1:7!)%;6ZH-JE@JA@>V
M%5EQZ,: ,GQK>0"XTG2F35I[F^DD\FVT^X$'FA%!;?)D$  @\$9-<WIEQJFH
M:3H>FOJEY ?[>NK*21)]TAACCG(0R8^;A -W7OUKT'5=$TW6TB34;1)_)8M&
M22&0D8.",$<5!IOAC1=(A@AL-/B@CMYVN(E4GY9&0H6Y/4J2/QH X;4=5OO#
MEAXJTNQU"=8[.YLH[>XNY3*T"W&T/\S9)"Y)&<XS5VUT6#0_BCHT%O?WMS&^
MF7+;+NY,Q4[HAN!;)&[TZ<< <UVDFBZ;,U^TMG$YU!52ZW#(E51M (]AQ5/2
MO"'A_1+M;O3=+@M[A4,8E7);:<9&2>G XH JZ[)+_P )?X;MEFE2&?[4LJ(Y
M4.!%QG'IV]*XSP[I&I?\(GXE@T"ZG2[&NW$($EVP+1+*-P5FSM<KD;R":]0F
ML;:>[MKN6%6GMMWDN>J;AAL?45DS^"_#ES+>2S:5"SWCB2X.6&]@<[N#P<CJ
M* *W@C4+*[TRZMK6'4;>6SN##<V^H3M-)')@$@.6;*\\<_@*Z>J.DZ-IVA6A
MM=,M([:$N9&5/XF/4DGDGZU>H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#"O]8N;7QEH^DHL9MKRV
MN99"0=P:/R]N#G_:-3/XIT"*WCN'UFQ6&0N(Y#.NURA 8 YYP2,XKD_B'HNK
MZSKFEQ:4TB-]ANU=@I"R#="3$9/^6>\*PW#GMT)J,)!J7B;P)):Z+<65K9_;
M4>VEMB@MF$2@ \8Z]&'![4 =O%KNDS:2VJQZE:MIZ9+7(E'EK@X.6Z=:JV_B
M_P .7=M-<V^N6$L,!42NDZD)N.%SSQDG%<1JFF7*KKDT.G7$ME#XEM[V6W2)
MLSPK'%YA5?X_FR<#J0:DO=.M_'?B2YGTRVECTYM&FLI[N6!HA+([ QJ P!.P
M@L2![4 >BF_M%OC9&YB%T(O/,)<;Q'G&['IGC-<_I/B<ZMXQOK"VFMY],CL(
M;J":+G<79@3NS@CY:\[O!XA;31XM.GW:ZO>E]&: CYDC:+RPS#G@3J6^C5JZ
MEX:OH[OQ-I.CP2@CPY;6ML1D!RI<;0W3) (_&@#T72_$.C:W+-'I>J6EX\./
M,6"4/MSTSCZ5@ZGX[TT:KHMAH^IV%W/=:BMM<1)('98]C[B,'C#*HS[URL5B
MVN64QTO4-3FU.WTBX@@MYM-6U6$N@7RF8(HW9Q@9(&,T\7MIJ'_""Z=IVC7T
M<^GWD1N2UC(JVH6)E9&<J!RQ4\=<9/:@#O=1\7^'=(OC9:CK-G:W(4,T<LH4
MJ#TSZ9[9ZU8U#Q!H^E00S:AJ=K;13@F)I90H< 9)&>O%>67]U'HW@WQKI&KZ
M=</J]Y<7EPN+9G29&!9)0^-H51SUR-OKQ5N^BN--\5VNH7UY=6-G<:-!;VUQ
M#8K<C<N2\1!1BI.0>G/KQB@#U>&:*Y@CG@D22*10R.ARK \@@]Q67/XJ\/VV
MJ?V9/K5A%?;@GV=YU#[CT&,]3D55\&Z;#I?@RRLK*2Z\I4=HVNX?+D&YV;YD
MXQC=P/3%>?$PQ?#O4/"%UI-S-XFG,R-']D9OM$S,2L_F8VXZ'<3QC':@#L9/
M&"77Q"C\.V6IZ;'%#"'G#_/+++N8&%1N&TA5+$X.,CBNCU36M+T2!)M4U"VL
MXG;:K3R! Q]!GK6'I%E)!XUN3.F^5-%LHVFV_><27&[!_+]*K>-=6N]/U328
MP%M;&02F74OL9N7A8 815 .TMSR01Q0!T,GB#1HK""_DU2T6TN 3#.9E". I
M8X/0X"D_@:+?Q!H]W8QWUOJEI+:R2B%)DE4JTA. N?7/:O+-.T_[1IOAF&6T
MN9(5\3SNT=U:B,JO[P@E ,*.A] 2:Z&\\/+K.I^/-,MH_(:Y@M&B< HHN C,
MK ^N0F2* .]>]M8[V*R>XC6ZE1GCA+#<RKC) ]!D?G7,:]XN^Q^*M/\ #]C?
M:5!<S(\EPUZ^=@&T*@4,OS-NXY['@U0\ S7'B:^N?%U]"T<A@CT^V1TP5" &
M9A]92P^B58OK".7XOZ;<-:*Z#29B9#'D!Q*FWGUQTH Z&/Q)H<LCQIJ]BSQP
MF=P)U^2,'!8\\ 'C)I;3Q%HM_82WUIJMG/:0G$DT<RE4^ISQ^-<!INWP_P#"
M235K/189+R:21IUN+4LVQYR&9U'S, N#M_V:Q TFNW/C1K*6;4X9]&A'F1V9
MMUG923A%[G:< \GMTQ0![,][:Q74%J]Q$MQ.K-%$6 :0+C<0.^,C/UKGO$'C
M33M,"V]EJ.GSZC]LM[=K4SJS@/,J-\H.<@%C[8YKFI-:M-?^(/AE='6Y*VNG
MW>YWA=%C+QKM4E@.?E.:PH)M+_X0S0-'_LNX77;;5+9KI3:MOCE69!+*SXP0
M>F<\Y'IP >TDA022 !R2:S]/U_1]6GD@T[5;*[EBSO2"=79>G) /3D<UC_$:
MRU#4/ >IVVF*[SLBEHX_O21A@74>Y4$8[].]8'V_3?$'B[PR?"T!']G/*;R5
M;=H5A@*8\IMRC)+$8 S@C/O0!W-IK>E7]T+6TU&UN+@PB<1Q2JS>6>C8!Z<C
MGWIM_K^D:7=P6E_J=I;7$Y BBFF56?)P, GUXK ^&>D6NF> ]':.S2"YEME>
M=O+"NS'D[CC)_'T%8'BN\_LOQ==7VBRM=:O+]GMY])N+!WCN5!!4I)@!2 Y.
M<D<<\B@#T4:E8M'=2"\M_+M&*7#^8,0D $AC_#@$$YJM?^(M$TMX4O\ 5K&V
M:8 Q++.JEP>A&3T]^E>9ZSJ=OH&E_$'1;T3&_P!1GFFM(HH7;SDFA15*G&#@
MY#>F/I4NMS_V1?QZGI5P9]7-C:VMQI-S8O*ERG! 1@/E.&/<CUH ]$O/%/A_
M3[@V]YK>G03*P1HY+I%92>Q!.15N[U33]/MTN+V^M;:!\!9)IE16SZ$G!KR^
MVU3PQI7BGQVFKPK/<3W 55^SLYF0Q+^Z4X/))(Q^/09K/6"_\/2>&+G7;K^S
MK>'2&ACFGLS=I;R&3/ED _*WEF-<]]I% 'L$^J:?:Z>-0GOK:*R*AA</*HC(
M/0ALXY[5E3^-?#\%UIT/]JV3"_#-'(+A-H4 G<3GH2,#WKS];:TT5_#%]J,\
M][X8BEO',DEDT<4,CG]V3%R0@^?:2, $=*W=:U/PREYX:UD10?V2)YXC,+-M
MF2A"C&W."W0XQF@#MKC5],M+V.RN=1M(;N7'EP23JKODX&%)R<GBDO=:TO3K
MF"VO=1M+:>X.(HYIE5G/L">:\AU6"&74O$^F:[JXT^>[OF>'=I9GFGA.WR_)
M<')P !M X_&MR*ZL]#\4^)8/$\$U]/>QP+9"2W,OVR(1[3'& ",E\Y7WSVS0
M!VGA/79-=\'Z?K5XL4#W$'FRA3A%ZYZG@<=ZR_#7C2+7M0U1WOM*BL+:[>T@
MC$P,LA#!5D+;L;7YV@#GCDU+\-HGB^'&AQ31LCBVPR.N".3U!K@[C14D\)ZM
M =.^67Q>59!#C=#]H'H/NXS[4 >G2>+O#D-K'=2:[IRP2NR1R&Y3:[*<$ YY
MP<9^M:8NK=I(HUN(B\J%XU#C+J,9('<#(Y]Q7G?B_4X])\01Z2L5AI=A_9SR
MQ71TWSVE<DAH8P,*/E )'4\5E>&KQ?#]GX(U?66DM[-=*N+-Y9$;]V^]&16X
MXR%('TQ0!ZLVH62P3SM>6XAMV*S2&5=L9'4,<X!'O6%I_BZWU7QM/HUA/9W=
MG'IRW7VBWE$F)#(5*D@D= #Z\UPBW*7>A3:NUO*FA?\ "4M=WB/ P9H/EPY3
M&2N_:Q&/Y5N>'9],O/BS?W6CVXCLSHT:F5(#&DC^<>1P,\8&?]GVH [?4M9T
MS1HTDU/4+6S21MJ-<2J@8^@SUK!\6^,8="_LJ"UNM/$^I3A$ENIAY<494GS2
M 02O '4#GK69XZUM;/Q!86%XEE:VCVSR)?W5@;HM)N \F->S$ 'WX&*YC1;*
M.?PK\.!+;>8!J<J'S8N=G[X@$=AP./:@#MM&\8'6?%EYIUO?Z.]E9(@9HYM\
MERQCW,T>&P$4D _>[\UTEAJVFZH'.GZA:783&_[/,LFWZX)Q7FOB#26;3OB/
M'I5FJW0\@1B! K;/L\1=5QZC=D#KGWJ&WMEU=Y[CP]KT<^IP:1<00PV>F&V"
M[E&U)'SA65@I"GD<T >AW'BWP];&Z636M/\ ,M4+S1BY3<@!P<C/!SQCUJ.P
M\1QZS#I-UI<UC+:W>?.#7(\R,^7OV*%R"PSR,C KF=!OO"]YX6CTNRLXY-3A
MTW;+:FS/G*ZQC(<E>&SZGD\C-5O#FH6%Y_P@*:8B&-(YEN&2,KLF2V"L&&.N
M6Z^U '>1Z[H\US%;1:K8O/,,QQ+<(6<<]!G)Z'\C3K[6M*TN18]0U.RM'<;E
M6XG6,L/4 D5YAX>T:S7X0V5VEA&+UM2CF,HC_>%A>[0V>OW>/I5NYNM*T[Q'
MXPA\2VWF7FH%!9*]N91<0>6 J1\'D-G(]>>U 'IL=U;S6JW44\3V[)O657!0
MKUR#TQ[UQNI?$6R'A75=5TE[:YN+"Z$!A:96W#SUBW_*<[3G(/?BM+P H;X=
M>'U8 @V$0(/?Y17G>IFQD^'_ (QTR*T$6H1ZN6DM_)VN(FO$*'@<KCICCB@#
MUZRU73M1>5+&_M;IH3B18)E<H>>N#QT/Y46^J:?=W<UI;7]K-<PY\V&.96>/
MG'S*#D<^M<GKFE?9O$\8T6W2VNI]!OH4, "#<K0^5TXX+''IFN:\&VUI=7WA
MF*36U74M.1O,L(M-,4J-Y9$BS/GIG)RWWC@]Z /5KN\MK"V:YO+B&W@3&Z69
MPBKDX&2>.M11ZKITMK%=1W]J]M*2L<RS*4<C.0#G!^Z?R/I7'?$A)5N/#US)
M*8M.@NW-Q*UO]HCC8QD(SQY&0#GGMG-85OHNEWD-B([Y-2LKSQ''-(J6?V>#
M>MNY.Q3D,K84DC@G- 'H5[XFTBS\/W6MB_MI[*V1F,D,RL&(&=@.<;CP /4B
MJUEXHMM2ATJ\M+BP-C=PO),TEVHDB(0/M &02,G=R-O6N2U#3@=7^(&GVUF@
MAET:)XX$C 4RF.4 @=,\#GV%5]%DL+_4_APU@L4D"6-W%<>7'A1(((@P;CKG
M@YH [70?&>B>((0]K?VRR-/)"D#3IYC%68 A0<_,%+#VK;%U;F[-H)XOM(02
M&'>-X3.-VWKC/&:\HTVQMY_!&KVMA#%'XBT349KQ8_*PZND[R1@],JR94<XP
M:Z+PMJUK+%<^+=0#0_VY=QV]ENBRPA'RQ*=N<9.YCVYH [JBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM4BBX4KM*HY7*@C.>IYX(KH** (;2UAL;."TMDV001K%&F<[548 Y]A4U%%
M!1110 4444 %%%% &9KFE3:SI[64>H3V44ORS- !O>,\%03]TGU'-7K6UALK
M2&UMHQ'!"BQQHO15 P!^52T4 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF/IRB*S\I8E;.6QO.3DT 9:>+?%PM] F?3M'<ZZH%O&LLBF%BOF N3G*[ >
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M#]W QG(Y ]JN?#^*]N-7\2:Q=3RW$=W-#'%<26_D"7RTPS(AY"9; )R>#DT
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MOCSBQ8LN WRYWGGGZ4 9WB+7/$.L:#XKDTRWTX:39)<V;B<OY\Q1")&4@[5
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MB@UO.-HGF#*-WIM>,9]-];.FZIJMR^C&\N)MNHZ7J%[)"QX +QM&,?[*/@4
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M <_>68%2?F;@$\<]NM..O:BW@KQ5>->.+BTU*ZMX9,KE$67:H&.F!QSSW]*
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M (E10IY =N 6W=<YZ^]::7EM((2EQ"PG&8MK@^8,9ROKQZ4Y9XGF>%94:6,
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M)4YSD]3P:U4N8)9Y(8YXWECQOC5P67/3([4)=6\D[P1SQ/-&,O&K@LH]QU%
M%)-!TY$A582!#>/?)\YXF<N6;KZNW'3FDE\/Z7/=:A<3VJRMJ$*070D)99$3
M=M&#Q_$:L6=ZTUE'-=QQVLK;B8_.#@8)_B'!XY]LU%JNM6.C:6VHW4O^CAE7
M*8)8LP48]>30!6T?PQINAW#SV9NV=H_+'VB[EF"KG.%#L0!P.GI4NL^'M/UT
MVK7J2B6TD,D$L$SQ/&2,'#*0<$'!%7VN8%C61IXPC?=8N,'Z5$US,NI+;_9U
M^S&$R-<&4## @!=O7IDYZ<>] %-/#>EI8:M9+ P@U:262\7S&^=I%"N0<\9
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MV7A;QQIVL6Y;7[N[N'CC>$M+,#_J'3CE5&.1P,'UY]JHH S;#4;5IHM,#/\
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MJZ02VI:)5D93&0Y0XR>ASC\:S?B+$\GBSPX;J;3(-/5)RDFJ0M);>?\ +@.
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M,ASGD9VXP >*Z/P@OAXPR2ZLFF-XR-],9!>;#<"?>VP)D;@N NW Z=*]*%M
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>arrowheadengagementlette003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 arrowheadengagementlette003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W[(/>EJ&V
ME,UO'*0 7&2*FH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@G'
M6BHI'*R1J.C9S0!%8?\ 'A!_N"K55;#_ (\(/]P5:H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "H)O^/B'_@7\JGJ";_CXA_X%_*@!++_CUAQT
MV"K%5;#_ (\(/]P5:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"H9/]?%^-35%)_KXOQH BL>+& ?[ _EFK55;'_CRM_\ <7_T&K5 !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5%)_KHOQJ6H93^_A_X%_*@".Q_
MX\K?_<7_ -!JU56Q_P"/*V_ZYK_Z#5J@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *@E_U\/_ OY5/4$W_'Q#_P+^5 #+#_ (\;?_KDG_H-6JJV
M'_'C;_\ 7)/_ $&K5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5#+_ *^'_@7\JFJ*3_71?C0!%8?\>-O_ -<D_P#0:M55L/\ CQM_^N2?^@U:
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HI/]=%^-2U')_K8_
MQH @T_\ Y!]K_P!<D_\ 0:MU5L/^/&V/K$G_ *#5J@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *C?_ %L?XU)4;_ZV/\: (-/_ .0?:_\ 7)/_
M $&K=5;#_CQMAZ1)_P"@U:H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**.E !1110 4444 %,?[Z?C3Z8_WT_&@""R_X\K?_<7_ -!JU5:SXL[<?["_
M^@U9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BD!# $$$'H12T %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4&BB@!H+9Y  IU%% !1
M110 4Q_OK^-/IC_?7\: (K3_ (]+?_<7_P!!JQ5>T_X]8?9!5B@ HHHH ***
M* "BBB@ HHHH **** "BBB@"O?64&HV4MI<J[0RC#A)&0X]F4@C\#7G/AKP]
MIYUGQ6S?;'_LV\V6H>]F81KY*MC!?#<D]<UZ=7/Z3X=ET^\\13O<(PU6Y\Y
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M '2,8J/6/&46DMKZFS>1M'LX[ML. ) ^["CTQL_6L6S\!ZK9:1/]FO;&VO\
M^TTU"V@BC?[)"5&TH%)W88%B<8Y/%9OB/0M<L_#?C?6=<N[*:2^T](XX[1&5
M8UCW<?-R?O4 ='#XQO[>]TH:SH@L++5I%AM9ENA*R2LI*I(H QG'!!/OBJ-M
M\0]0NO#R^)%\.,FB1NWGRM= RB-6VEU0+\P!!SR#QQFK-IX=UG5Y]%FUN]LG
ML-,9+FVCM865Y9 N$:0L2!@$G"]SUXKF?!&B:]K?PVM-,:_LDT.\,RRXB87*
M1F5PR*<[3G!^8C@-TXH GU#5+.TO_B+?W2S75C&FGOLMYS&74Q#&UP>,Y'(K
MJM8\8366K76GZ?IR7DEE"DUP9;M8!\V2$3=]YL#/8#(YYK.UKP%<ZC!XOBM[
MFWA76TM4@7:0(1$H4YQ].,5)JW@J5O%%YK5A8Z+>G4(D2XCU6,MY;H"%=" >
M"" 5XS@<B@"U%XX34IK.#0M-EU":XL4OV!E6)8HV.%#$_P 1.>/8T_X>3O<^
M%GFD22-GU"\8QR?>3_2)/E/N.E5'\,:WIVN6VKZ)+I2RO8)97EM)$T<.5R0\
M07) !)^0]1QD=:V/".BW>@>'TL;ZZCNKKSYII)HUVAS)(SYQV^]0!RVB>(;_
M $U?%4L6DW5];V>J74LTIF5  ",K&"?FPHSV'.*Z&P\::?>&\=T>"W@L(M2C
ME<_ZZW=2V\#J,$$$'V]:QY/"OBFWBUJRT_4-*%EK%W/-(T\4AEMUE&#MP<,<
M8X.![FLKQ/H-C>:GX9\+Z5=EIX(?L5\D9#E;)51F$G/RD[5"YZ[C0!W,>O%O
M!Q\026;PXLFO/L[-E@ A8 GUQ7.Z-X1DUS2+/5];UO5I=0NE6Z_T6]>&*#<
M0L:*<  8'.2>:[2XM(+JQELIHPUO+&8G3H"A&"/RKDM,T?QIH=M!I=IJ>D7>
MG08CAN+R*3SUC&,*0I"L0,C.1G H L7/C&Y,^J_V7H<^H6NELT=Q.LZ1YD5=
MSHBGEB 1Z<G%-3QS]OU"TL]%TB>_:ZTY-15S*L2K&S%0&)Z-D=.?TJ*3P_XE
MTVYU>'0+W3TLM3F:X#W(?S;25\;V4 8<'&0"1@GOC!N:%X4;0M5M'AEC>RM=
M)CL%+ ^:S*Y;)[8P?P.: ,^S^(HN=.M=4DT2ZM]+FNELWN))4S'(6V$[0>4#
M_+D'/M5AO&EY,^K_ -G^'KB[BTJXD@N'%PB;BBACL!Y)P>G';K55O!-\?A_:
M>'_M-O\ :8;Y;AI,ML*BY,N!QG.TXZ=?SK,T>Q\13S>+X=&N=-2"\U:='DN0
MY>W;:H+!0"'RN, E<'GGI0!TEUXP?^S+74M,TMKVRN+87*S/<QP#!YVC<>6X
M^GO4*>.#>W6G6VDZ/<7LE_IRZC'F58U2,G&&)Z'D=,_UK)N_AY<P7-F--32K
MJU@TQ-/5=4C:0VY4D^:B\AB<C(./NCGM6IX:\)7FBZAI-Q// ZV>B+IKA"<F
M0.&W#(^[Q]?:@">Q\:P7C:+NLI8%U*:>U9I'&()XMV4/KDJP!'I[UJ:1K<>L
MW6J1P0.L-A=&U\UB,2.H!? ] 3C/?FN2\4V8T7P-?PRW48U2349K[3%A.YVG
M:X,D2JI&6/S $8(Y/;FNK\+Z.="\-V5A(VZ=$WW#_P!^5CN=OQ8F@#*N/&%Z
M)]66R\.W5W#I<ICGE6=$W80.=@/+'!Z<=N:9)X^M+A[2/1[;[?+<6:WI#3I
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M_M'4/#;6JR0_9O%0L) Q^_M#*Q^AS6MJGQ$@T^XU0Q:;)<V6E2"*[G$\:,&
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MQWS7]]9W]NSW3W%FL2VDH4,-A7^%L[<-DY&<]JM^*+"]NO%_AW[-J]S9AC<
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MBQ:NUU*NJGRQ\L5N=LG&,#>3'@_[7%;OB[4Q8VUI;KJMQ83W4VQ%M+/[1/,
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MUC:7X-T31[N.ZMK:5KA(6@66>X>5O+;&5RY/'RC [5NR2)#&TDKJD: LS,<
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M_P"<<?*7"#C=TSD9K#NK&"TT32Y;S6/#VK1V*W+1:9=7A,,T#-\NQVSEDVE
M2#Q[UZ_>6%GJ,(BOK2"YB!SLGC#C/T(ILNF:?,D:2V-M(D0VQJ\2D(/0<<4
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MI0M+82S2BWB$DZA97V#,@&<!CW R>OK2+96BPV\*VL(BML>0@C&(L# VC^'
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M;L)(9_%+V,DLDLDQ:=KG83(K*3GALC&, 8KT9K:!KE+EH8S/&I1)2HW*IQD
M]0#@?D*@BTG38+Y[Z'3[6.\DSON$A42-]6 R: /)?"MH]V/"^K0ZGH=K?3.K
MW$Z7;M=7FY298Y%(P6SDD=BO&*T?"LUAX<\1P6E\NEZC++!<W"^(;6<-(8U.
MYC<9)V\=\E>P[UZ1'I&F0WSWT6G6B7CG+W"P*)&/NV,GJ:2#1-)M4N$M],LH
MEN 1.([=%$H/4-@?-^- %JWN(;JWBN+>5)895#QR(<JRD9!![C%24R&&*WA2
M&&-(XHU"HB* J@<  #H*?0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %-;M3J#0!'&/D3Z"I*9'_JT^E/H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!(!H ]$HKFO&/BV+PM;V(/V;[1?7 AB-U/Y42#&6=VYP /U(K%TKXC-J%U%
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MW+2\)LDVCOD'(XQWXJ+3;O5;KXPQC5=.CL9%T!]J177GJP,Z<YVK@YXQC\:
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M)^\Q(5<\@ 8%7/#7A6]T632#=7L=P-.L;BR# '<RO+&T9_!8\'WKK** .?\
M^$:\_2?$.G7,X$>KRS-NC'*+)&J=^XP363!X5UV[M='TW6-0L7T_2Y8I0;:)
MUEN3%_J]V3A1D D#.2.U=I)(L4;2.<(@+,?0"HK*\M]0L;>]M9!);W$:RQ.
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MVP8B *CH,Y S]X'\ZOP^']5N-3TF]U*>S!M;*XM+A;<-B02;,%<]/N<UU5%
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M-$4\QW/5N<X]SSTJZ_@.67X;Z?X;:[A^V6)CEBG:/='YB/N&5/53R/QKMZ*
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M#Z\UTSW>MZ+XGNM/EU2XO;:719KV.2>*,%)XV53MVJ.,.IP<_J:W&\(:.?#
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M'\*@8 H \^@UWQ?%X$LO%UWJ%@^Y(9I+!8 J/$Q4??SD.0<^F>,5JR:OK_\
M:>OWWVRVCT?1)VW6XM]TMPHMTD*[B<+@MP<'.?:JGACX?P?\(IH5O?WFJI#%
M%!<RZ7)*HA$X 9@P*[\;\G;NQGM796^CVMN=3X:1=1F,TZ28(R8TC(''3:@Z
MYZF@#CXM;\26>A:-XDO;^TGM;Z6W-Q9);;1%'.P5=C9R67>N<YS@UE^(=2U[
MQ%X+\7:A;WMM;Z=;?:;2.U:WW&6.,%78OG(8_-C'' S75VO@:RMGLD;4=3N+
M&QE$MK8S2J88F4Y3HH9@O8,QQ@>E07WP\T^\BU2W74]5MK'4Y&FN;.WE18R[
M ;F&4+#. 2,X/ICB@!_AS4[EM7M=*++]ECT*TN57;SO9G4G/T45G6?B;6=5T
MW0+2UFMH=1U1[EY;EX\B*&)R#M3NW*@9XZDUMW/A"WEF@N+74M1L+B*R%B9K
M5T#/$#D [D89!R<C!Y-01^ M,AT?2;""[OXI-*9FM+Q)%\Y"V=V25VG.>05H
M R/$.O:[HEYI6AK>37-S<":XGO;;33-((E8!56)<C/S %CQQZFM_P9J^I:QH
MCR:M9SV]W#.\),UL\'G*#\L@1N1D$<>N:2X\)1W*6<C:QJBZA:E]FH(\8F96
MY*-\FPKP.-O\(K8TZR.GV:V[7=S=L"29KEPSL2<\X '?@   <"@#B(-9\3:U
MH^L:_I^I6EO;VD\Z6EHUN&$J0DC]XQ(92VT],8XK:\/>(9]:URY0X6T.F65Y
M%&5P5:7S"V3UZ*OY4R;P'82/?I!J.IVEEJ$C2W=C;S*(I6;[YY4LN[H=K#-6
M+_P=9W=ZMU;7M]IS_95LY%LG11)"I.U3N4D8R0",$9ZT <Y8>(_$>KP^$[>U
MNK:&75;*XGNYW@W%-C1X*KTS\Q'/'/M73>)M6NO#WA.6ZB9+B^4101-*N%>5
MV5 S =!N;) I^D>%;#11I8MI+AO[-M)+.'S&!W([(Q+8 R<QKTQWJ_J^DV>N
M:3<Z9?QF2UN$VNH.#Z@@]B" ?PH XXP:MI_C_1&U74DU#&FWK*RP"(JP,.X<
M<$=,=^M59?$?B:S\'0^-+B]M6M)&BG?34@!"V[L  ),Y+@,#Z9R,5TUCX0@M
M-:@U>XU34K^\@@>W1KN1"-C%21A44=5Z]3DYSQBJGP_TY(TM#?ZD^E1SB=-,
M:53;JP;<!]W?M#<[2V* &I=Z]X@UK54TS4[?3['3IQ:KFW$SS2A59RV2,*-P
M  YZ\U7UCQ+J5EX0\6:E"\?VG3;B6.V)0$* $QD=_O&M:X\)6[ZM=:C9ZEJ.
MG2W91KI+21 LY48!(96(..,J1FJ>K> ;+5QJ43ZKJUO::DV^YM8)D$;/@#<-
MR$C.!D X..E %:34/$.J^*+S2M/U*WLHK?3K>Y5VMA(S2/O&#D_=^49[\<8Y
MJGH^N^)I;#PYK=_=VKV^K3I%)910;1$CHQ5E?.2<JN0?[Q]*ZZTT.UL]:N-4
MC>4SSV\5LRL1M"QEBI QG/S'/-0P^&K*#2-)TU9)S#I;Q/ Q8;F,8P-W'/7G
M&* .#M?'VOW\@U2RL[^YM6OC%'90Z3(T;6XD*%O/ ^_P6].,5?N-<\3_ -D^
M(M;CU.T$.DW\\<=HML")8HGY#N3D-MR..X[UT4'@Z"SNW>RU;5;6T>X-PUC#
M,HAWDY;!V[P">2 P')]:L?\ "*6']BZMI0DN!;ZI-/-.=PW*TIRVTXX'ID&@
M#G3;ZH/BY?/!J)8+I$4JP-$H#KYL@$9;MR#\W7FIO!.NZCJMX8=7U-H]22 M
M<:1-8^0T+;A\R,>70<C/.=PY%;E_X8@O=?764O[^TNOLWV206TBJLL>XL <J
M2""3@J0>:;IGA6"PU9=4GU#4-1O8X#;Q2WDBGRXR02 %51DD#DY/O0!2U75-
M4N_&D/AO3+J.Q5+#[?/=&(2L07**B@G Y!))SVKGKOQ9XDAM[?2X[BS_ +5C
MU]-*ENFA)CD1HC('V9X."N0#U'O79ZMX<@U34(-1CO+RPOX8S$MS:.H8QDY*
M$,K*1GGD=:IQ^!]+B@LHQ+=M):ZB-3,SR!I)Y\$9D)'(P>@QT&,4 :<D\VC>
M'Y[F]G:]DM())I) @C,@4%L8' XXKBY-=\4V?A33O%TU_:2VTY@GGTX6X4+#
M*R@!),YW ,.O4Y^E>ARQ)-$\4JAXW4JRD<$'J*YB#P%80BTMVU#4IM-M)1+!
MILLJF!"#E1]W>P4\@%B.!Z4 9<GBS5/^$3\8:@'B%QI>HSVUL1&,!$V8R.Y^
M8U<CU'7M3^(.K:3;ZA!:Z;IT5M*0+</)(9 25R3@#Y3SUZ8[U-JOP_T_56OT
M.HZI;6NH2":YM+:95BDDP/GY4D'A<@'!P,BMFTT.UL]>U+6(WE-SJ"1)*K$;
M (P0NT8S_$<Y)H Q_'>K:MI=IH\>C3P075_JD5F9)H]ZA75\G'U /X5E:IXH
MU?P=?:A!J=U'JT0TR2^MF6 1.C1D*4?;QM)8$-QT(YK1\?Z1-K,.@6\4-S(B
MZQ%)*]LQ5X4"2#S-PZ;20?RJY;>#-/2:_GU"XO-5N+ZW^RRRWSJ2(>\:A%55
M!// SGG- '*6'B_Q&I!EAO[B*:PFFDFFTB2VCM95C+KM8C#(2".>?N\\TYM7
M\<6WA'3M<>ZBO5OS;O-'9:>6:S@=26=5R3(W*^PYXQTZJQ\(16=JUH^L:M=6
MGV9K5()YD*1HPQQM0%B!P"Q)'XFK,GAX#1M/TRSU34+".Q1(XY;9TWLJKM ;
M<K \<].HH YQO$=_>Q^'K#0];M;QM5DF+ZD]N/DCC + 1C #\XYZ8Y%4M6\6
MZ_H4/B#3I9[:YO=/6TGM;LP[0\<LH0K(@.,CD9'8]C71+X$TN+3+6T@GO89K
M6X>ZBO8Y0)Q*Y)=LD;3NSR-N/:AO NF36-_!<W%Y<SZ@\3W5Y+(OG2>4P9%X
M4*%&,8"CC/?F@"HFH:[I'B*33M0U"&^BN--ENX'6W$9BDC*AA@'E3O7&>>*H
M:?K/B2RB\*ZCJFI6]W;ZU(D$ULEJ$\II(FD0JP.3C;@YZYX KK[S1+:^U2+4
M)7E$T5K-:J%(V[)"I8].OR#'XU!)X:LI;'1;1GG\O1Y8I;<[AEFC0H-W'/#'
M.,4 <'<>.]?O)[J]TJWU"2&VOS"EG%I,DJ31(VU\S '#G#'C@<#UKJ/ QS<>
M*C_U'IO_ $7%5I/!]O;ZA-<66J:I903W'VF6SMYE6%I#RQY4L,GD@, ?2M/2
M]'MM(DU![=I";Z[:[E#D'#LJJ0..GRCU[T <)XN\9:CHFH:E/I^HR7BV,D3/
M8P:<TD<:87<LLX&$8_.1Z#%:.I^(M0M/&KV&HW\FCZ<QB%E,;020W1/W@TIX
M1L\8..WK5K4?ASI6HOJ@-]J5O;:I()KJV@F41O(,?/RI.<@'&<>U:6I^%8-7
MNG:^U&_FLG=)'T]G3R&*$$?P[L94' ;&: -ZBBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH "0.M&1ZUSGCO36U+P=?B)<W-LHN[?VDB.]?Y8_&O.;K4;F>^N_%-K+
M)]F\41RZ39*R'"L%586QUY83=1W'0'@ ]4O-9_LR+5+N_MFAT^QA$PN0X<RC
M:2V$'(Q@#GKFM*.:.6))$=2C*&!!ZBO(+W0[:*#XC:6MLMPEGI-BL"M&"0T=
MNX5@.Q&,\5?T[2?#^H>(/"%O!!8O8_V3<2F")5,4LN82=RC@G)W<]P#VH ]2
MR,9R,>M&1C.1CUKPZ]:6R\+7&GQ/!#HT'B^6UF2=288X,[E1U7'[O>1D9';M
M5]M#L3I6KVR>*-"AMYK^V:&S@0K8I,JL3$Z[B-L@ ) /5?PH ]BW+C.X8]<T
M;AC.1CUS7C3S6.N>&;%X[70--DTV^N0--G(&GZ@R* [*1@'&[()SSG/K4-YJ
M,6MWWA M9Z5IVB76GS/!9ZBFZT6=7P?E!4,<?=)XPV1UH ]KW #)(Q2Y&,YX
MKQBYTRWMO#VE2#6_#^JP6<EW/!IUVQ6VGA+8(3<3S&0RJ>1S^?H>DQZ?XF^'
ML$,%G]DL-0L-BV__ #R5E(P/IGB@#I,CUJH]U<+JD5LMF6M6B9WNO,4!&! "
M;>ISDG/M7BT6M:M&UCXGODE6/PF$TV\4?-YCL&29CW.#Y/(]370:#I7E^)O#
M=CJ,:3&[T.ZFO(I$!5WEE1W!4]>6(Y]* .YG\26XLM.O+-/M,%Y>+:;BQ0KE
MF4M@CG!7IQ]:VP0>AS7CUE9Z(?!VAV.GI%!+<Z\EO=/9,(Y5*R2D;F7G.%P/
M8\5V'A[3[71O'FNZ?IT*6UDUE:7'V>)0J+(3*K, .A(1<^N* .PR!U(HR,XR
M,^E<#J&DV.L?&,P:C;I<VZ:"D@AE^:,L)W )7H<9.,],UQ\%@VIS:M>7FLZ)
M9:TFJOF:[1S=VQ27]VB'>/D*A0 HP0QH ]NR,XR,^E&X>HKRF%[+1O'XN)HM
M+UL:KJQ2WO(I0UY8N01Y97D^6I0C@C'.1VK&2+PQ_P *]UFZ:>,^(H[RZ%LR
MOFYBG\YO*2+^(*25) X.YO>@#V\D#J0*4D 9)P*\>UBVFUCQSJ5EKMSI$133
MK?[-'JJ,54,O[QXB'4!@^06Z\#' JW;K9W.O:+IOBW4[;4=,32%FLIKAL07D
MN[#.P8X9@FW&[U)H ](DU>QCUB#26F_TV:%ITCVGE%(!.>G5A2ZKJUEHE@U[
M?R^5;JZ(6VEN68*HP.>I%>?R:;X:@^)N@26]MIRV4FF2^2X5=CNDD83:>Y'0
M>G:M+XM6-K=>"FGN(5=H+FW*N?X%:9 W/ICK0!W><45YK)'X?NO'+:;JDEH-
M%MM+C?38))A]GD)=A)(.<%@0H[GO6Y\.I0^@7<<$\EQIT%_-%832.6+P C&"
M>H!W 'G@4 ==17DDYT6^T_QG=Z_J(CU>"ZN8X3).8Y+:.,9A\H9R,C#<9R2>
MO2M3POJLT?B>UGUNY$$UQX9M)G\]]H+*[^8>>XW#/UH ]'HKR'PM:)KGA[P1
M!=SS26TLNH-*JRL!,H=\*Q!Y7IQWQBNX\8?:-%^'FIC108);:T(AV$YC4<$@
M^RY(^E '349KQ>?3[[3-*U26TOM%AMFT&Z$UO9:C+-).%C.R7#*/F#'!;ON-
M=#I.F6^BZAX)N[$RI/J<;1W[M(S&Y_T5I 7R>2&0$'MDT >CT5X3=_V3/\/+
M;69[S=XDN-43S6:X(D$OG@/'MSP G;' Q6I\0+^.YF\1W-I#903:6J(;ZZOY
M$F64(KH((U'J1@G@G- 'L5%>:.^DZKXW\10^)[E1%:6-N;6*>78B1,A,DJ\C
MYMV 2.1@5R]G=:A<^$?A[I^8)+6\%P91>73Q12R*245V4$GO@=SCTH ]SHKR
MFTT>[,.E:5J&IP36S^(G"Q:?>.X@C^RRN8"Y ;&>WHV*N)X1TZ;4O%EJ[W)L
M[6-/L=O]H?9;,T.YF09X).#[<^M 'I5%>.W;ZMXAUW1;.Y^QSP#P_#=HE_>2
M0QRR/@22?(IW../IG/>M/0]#EOK_ ,/:=K6IKJ20:5<F5K>X9HKC$Z!,MP6V
M@CKW% 'HUY?VVGQQO=2>6LLJ0I\I.78X4<>I-6:\9N[>VO/!OV:^7S8=)\5?
M8(9)G)*P"Y48))Z;3CZ 5J>*(;7P]K#:K<6]EJ6@QQ6\ @%VR36&&&#&N3N!
MR&/0GZ=0#TG4+Z'3--NK^Y)$%K"\TA R0J@D_H*K:%J%WJNDQ7MYIXL7F&](
M?.$IV$94D@ 9([=JS/B!9V][X!UT7$0D$-A/-'DGY76-B#^%<S<66E/XH\/:
M-<AK7PZ^G/<VD(E9([FY+#*MSR50[@#_ 'CZ4 >ET5Y);JES;7VDV=_=2:1#
MXEM[>VD24@HI"F2-7!S@,2.N17IL4-AH&CE8U6VL;6-G.6)"*,L3D_B: *!\
M6:</&(\,$2_;3!YPDVCR\]=F<_>V_-C'2MVO$/)\6?V#'XN.DV^1J7]NF<7A
M\[[,4V^5LV]/*P/O=!TS7:Z?866N?$35[^:22X@@M[&:U3S&$89@Y#[0<$\#
M&1W- '=45Y#;68TWX2)K$=Q<+>792*[O?-;?';M< .%R<* G<#WZU<O](T]/
M%EEH/AR\9+;5-+N4OH8IV=$39^ZFZG#;CC/>@#U*LYM7C7Q)'HWE-YCVCW0D
MSP KJN/K\U>40>++L3:7XJNIYXK#1HTTK4(BI(:=HW\T]>2'6$?CUK4T/PUY
M^O:#::Q)+-(^B3W5VN]E\V229&8,0<D O_XZ/2@#U2BO'-0:]'A_1O#]K=%[
M0:]=V,CW-VZ!DB:3RH9'4%L$ ?D!QU%S;=>']'FL-1:UOH;[588K"PL=2D$<
M#L"S))(0&6/Y2VW!ZXQ0!ZO6<=7C'B1=&\IO,:T-UYF>,!PN/KS7E45_<67A
MO6[">]6TM!KUO;7#6EXSI9P2+&7"2'! R2I]"373Z+9Z3I_Q5EM=)E&Q=%S)
M LI=8B9EQC)."1R1]#WH Z;6/$MKHU_:6,EM>W-U=(\D<=K#YAVIC<3_ -]"
MJD/C33;NUL9[19I/M-^-/>-T,<D$N&)#J>01MZ>]9?B5=1;XC>'1IDEK'<?8
M;SFYC9TQF+/"D'/XUDZYX3EM+33H[O4G>]U;Q%#/=SVRF(*3&X*Q\DK\JXSD
MGO0!Z=17F5_=V?A2[\86A^VG2DL+:X$$,[;TDD9XSL8G*[B%)/8Y-<]J5S>V
M%GXGM4BCTQ&T 7!L[74&N1&_F%=Q8@8<@D''7 ZT >W45YQ>Z+!;77A/3%NM
M0)U.[::]N#>/YD^RU<E2<\!N 0N.!QVQ4E\.P[O&MDES=_9M.B$FG0FY=5M9
M'A\PLIS_ 'L$9Z<XZF@#U*BO(]8UE=<T:!/LZSZC;Z#%=W5W/J+VT=H9(\AU
M502S]3D#I@9YQ5JPO9?$6I^$-.UR\F^Q76A+>;!*8Q>7/R@JQ'WL*2VW/?G-
M 'J5%>7>($NKOQI::#9VR7NEPZ5YT%M+JCP+(V\JS[PK%RH"X!/&<U/X<;5;
M+5?"-OJFI+/FROD>2.Y\Q)2LB;,MQO8+QG'8T >A7E];:?"LMU)Y:/(D2G!.
M7=@J@ >I(%)'=.^H3VIM9E2)$<3L!L<MG*COD8&?J*\LF2QUCP]?W-[)]IMH
M_%NU)#*2HB:XC!P0>F/R[5K:Y=7.BV?C%M&+*;31[7[,$<D1#]]EE^@Y_"@#
MT:J6L:DFCZ)?ZG)&TB6=O)<,BG!8(I; _*N.D?PWX8\%W&LPW$]V[:?^\FCO
M&\ZX#[5WDEN#N9?F_ASQ7(23W5M<^+M--K!8VTGA>:Y>TM]0:[7S!E0Y8@88
M@X/K@')H ]GM+A;NS@N4!"S1K( >H!&:FKR;4W?2KVTUK4HX]3T6.SM$:)+X
MQRZ>V!EQ&#\^<J>/F]/?U*&\MKF:>&">.26W8),B,"8V(! /H<$'\: *EAK=
MMJ.K:IIT*R"737CCF9@ I+H'&WGT-:5>3:P\J1?$]H)GAE\VU"R(2"I,2#((
MK4GM'\*^-=,MM(\^5[K2KHS1RS._VF6,(4=LG[Y)(S[T >BT5PG@2/1)-!T[
M79-2^TZG/"\L]U-<,&9N3(I4MC"\C&, +FNSBOK2>X-O%<Q23"-92B."=C=&
M^AP<&@!?MMO_ &A]A\T?:?*\[R\'.S.,^G6J^C:FFLZ5#?QQM&DN["L<D88K
M_2N<GL-._P"%IQ22DK<2:;YB?OV4LRRC&!GGZ=*Y$V']D> -,\00W5R=1CU.
M-D<RL L;7&PQ  XV$$Y'<T >P4R66."%YI76.-%+.[' 4#DDGL*\DO8=3U_6
M/%,KW-K:WUA=&&TFN-6D@:Q15#)(L:QE2K?>.3R"0<8KM?'<%[<_#C5XHAON
MS9DN(2?FQ@N!Z@@'CO0 ^R\:0ZE<VXL-&U>YL9Y!&M^MN%AY) ;YB&*<?> (
MKIJQ='\1:#?Z-976G7UHMG*$BA0.J[2<*L>WLV2!MKS2?['/X%\0>)+S4YH_
M$<-S<%'^TLLEI(DA$<*#.,8VC&,'>: /9:*\NATL:]K_ (IN-6>Z,EO86K)
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M)<[KJ_>VMXHP0I8[<[FR1QC/H17*I+?7O@?PUJUU)%K$%G9S&]L9;TPM,@;
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M=.L3:BU-E;FW!R(O*78#ZXQBLBP\9Z1J%Q-;J;NWEB@-SLNK22$O$.K+N W
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MABYBN1HVG">$*L4OV5-R!1A0#C( '3'2JEMXAL;70VU#4=7MI8?M$D0FCC*
MD2,HC"\DL,;>.N,UF7WCFPAUG1C%>JNF7*W2S%X6#F2,1[5"D;L_.> .: .N
MEBCGA>&:-)(I%*NCC*L#P00>HJO>:5IVHVR6]]86MU F"L4\*NJX] 1@4W2]
M7L-:M#=:?<+/$KF-B 5*L.JD$ @^QKGY/'-FVNZQHT89+BR@#12&-R'D(DW
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M@^TBY\F/SPAC$NT;@I()7/7&0#CVK*NO%N@V6KKI-QJD":@SI&+<DE\L 5X
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MJHP !V IU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% &/XJTC^W?"VI:<J@RRP-Y)SC$@Y0
MY[88"O/+SPCXFO+>UU(64<6J:S/+;:TFY&,5I*47&[(#;%C'3^\<"O6Z* /,
M]1\/7FF^+-7N?[/UN\L=16$V_P#95]Y(0I'L,<B[UXX!#<C!KL/L5]IW@C[%
MHT*P7T%CY=K#++Y@C<)\JEC][!XR>.*W** /*-!TGQ#)K]IJUSIFK^9%I,\$
MSZC=(Y>X.WA%#?*I(XP!FKNH>&=4G^%WA>T@LI3>Z6]I<S6L4ODRML7#JK9^
M5_F)SGM7I5% ')>#].BBOM1U$:3J]G).L<?G:I=>;+,J[NVYBH&>YYS5RRL+
MB/Q7XAN6M2L=S;VRQ3<8DVJX*^O!/?UKH:* /+]'T?6?#L/A/5I=*N+O['I;
M6%U:0%3-$S$,& ) (^7!&<C-37.A:Y=:5XIUD:;Y-WJTUL\>G%E,@B@(&20=
MN]@"<9]!FO2J* ,\W)OM!EN&MI[8R0.3#<* Z\'@@$C]:\VT=M4\0_#[PWX?
MBT*]MN+.22_.Q84BC*OYB,&SO( [9RQKU6>%+BWD@E!,<BE& )&01@\BH["Q
MM],TZVL+1/+MK:)88DR3M51@#)Y/ H \H\0Z;XJUQ]1L[G3]9GN/[35K79/'
M'9):I*K*2 PW-@=&!(/TKOM$TR:";Q(TD'EM>7[/&S?QKY,:@_3((_"NAHH
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M"57+MVQL\U?^! >U>AT4 >7Z#X<U6TOM<M+BS86.E6=Q::21&0)5G9I#M]<
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MC:1I7B^ZQ:1FR/\ OJ@# L_%]GIFE--%;:I>FXUR?3TC>022>;ESA<D )E<
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M..*=69I4>KP2S0:A):RVL<<2V\T9;S9&"XD,@/ ^;D8['FM.@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1F"XSGGVI:BDA,DL
M;B1E"9RHZ-GUH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH " >HS1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@5<DY)P/4DG\:FHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M '1T57M;ZVO3.+:99#!*89=O\+@ E?U%/N;F&SM9KJXD$<$*-)([=%4#))_
M4 2T4R&:.X@CGA</%(H=&'1@1D&GT %%%% !115>ZOK:Q$)N9EC\Z588\_Q.
MW110!8HHJIJNI6^CZ5=ZE=EA;VL32R%1DX SP/6@"W15/2[V;4+".YGL9[)W
MY$,Y4N!V)VD@?3J*N4 %%%% !1110 4444 %%%5/MI_M8V'V2YP(/.^T[!Y/
MWL;-V?O=\8Z4 6Z*** "BBB@ HHIDL@BB>0@D(I8@>U #Z*I:/J<6LZ+9:G
MCI%=P).BOC< P! .._-7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-&/B&6Y/_%.6\\\$<[QB60RMM9]I7G'./4^U,(M-9\+^(->U:\FBUZSEN?*
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M\=Z1=K<06L&F1W<-J=2DN&B<I+G,A.[GRU)3)'U!KT2;PIH-Q)?R3:3:R-J
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MTK^S3IW]GP?8S+YQ@V?+OW[]V/7=S4&H>%- U:_6^O\ 2+2YNE 'FR1@D@=
M?7';/2@"MX#_ .2?^'O^P=!_Z *Z&H;2T@L+.&TM8EBMX$$<<:]%4#  _"IJ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** *VH:A::7837U].L%K"NZ21NBBLVU\7Z!>:?>7T&
MIQ-;V6#<L0RF($9!92 0/?%0^-;W5=/\,3W&CVIGN59-VU-[1IGYG5/XB!R!
MSSV/2O.&MY7TGQQ?"/6+FVNM-MO+N-4B\IKD@R [?E7 Z#!&>_0B@#TW3O&'
MA_5M1^P6&JP3W)!947/S@=2IQAA]":KQ>/?"L]S#;Q:W:L\S!$()VECT4MC
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M]>BBC:21K.0*BC))QV% &4_B74(?"^I:G#K>D:EY.E2WD+6\#*3(I8 XWD%
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MEFUPWSGS1MD*,^<XV @CIUK$B^)%A?Z/I&IV<]HD5Q?);WJRR;OLR%)&Y((
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4R.6.4N(Y$?8VUMISM/H?0T /HHIOF)YOE;U\PC=MSSCUQZ4 .HHHH ****
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M@ HHHH **** "BD5U8L%8':<'!Z&EH ***1G5,;F R<#)ZF@!:*** "BBB@
MHHHH **** "BBD#JQ8*P)4X(!Z4 +1110 4444 %%(K*V=K X.#@]Z:)8VE>
M)9%,B %D!Y4'."1[X/Y&@!]%%(KJZAD8,IZ$'(H 6BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB5EW[%*L @ P-Q!Y/3BL:[^(]W%I/AM,V-OJ6K6GVR:62&66*"/ Z(GS$DG
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MME=+A&P2KQJ5 ^8 C!&/>@#'U*Z\6Q^.O#5L9M-3S;:Y:6.-Y?+<J8]Q([D
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M,"PYV[2,;M^['MC/I6FGA=D\):?H?VL$VDUO)YWE_>\J99,8SQG;CKQFK_\
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M["K-YXG\33^(/$6FZ-IVGR1Z.L;>9<2/NEWQ!P@51USGGZ5IQ>%&C\%GP_\
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MDA/3A:ZOQ)HJ^(= NM,,S0/* 8YU&3%(I#(X^C &L$?#JQCUSPYJ$-PR1:-
M(3 5R)RJL(V)SP5+NW?.: ,?6M0U2+3(FT"UL+(/XE%O<%0Z;V^T*JLVWLQ&
M'SU!Q5[SO$J>,M433K;39+PZ;9-<23R.(@P,_P J@#<<DG!/0#GK6E<^#Y9]
M$N+-=1"79U0ZG;W'DY$<GF^8H*9^8#H>1GKQ6KINDW%KJUUJ5U=1S3W-K;P2
M".(HNZ/S"6 R>"9.G;'4T -\,ZXOB/PO8ZNL80W$6YT[*X)##Z!@17G<NMZO
M=>$O =YHD-CIL=YJ*HUM$72/=^\PI"]8S@DCUQ7H7A70/^$:\,6FC?:/M'V<
M.#+LV[MSLW3)Q][UK#'@*>W\(Z!H]IJB)=:+<K<PW,EON1V&_@H&''SGOVH
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M>*YY];O-#^%^EZMX7M],N-/M; 23K-(RX"J,A0HY;.[(..: /04=9(U=#E6
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MPK1(-K$/N8@[#MQG'4XJ>Q\3VLEWJ,-_=65J(+TVUN'F"F4!$;/)Y.7QQ[4
M;D,4=O#'#$H2.-0J*.@ & *P+CP)X7N[V2[FT:W:25BTB\A)&)!)9 =I/ Y(
M]?6MZ>XAM8'GN)HX84&6DD8*JCW)Z4-/"LZ0-*@F=2RQEAN8#&2!U(&1^= &
M)?>"?#NI:@;ZZTR-YC"('PS*LB#HK*#M8# QD'&!Z58N/#.DW3Z<\ELPDTX
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M$"< NP7)_&G/)'$I:1U10,DL< "@# U#P5HFH2P2-#/;F&W%H!:7,D : ?\
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M.DCVQNY?(=TP%)CW;3C:.V/6K>F:_#J%UJ5O(J6[6=\;--TH)F(2-\@8&/\
M68QST]ZU)9HH%W32)&I.,NP S^- %?4],M-8TRXTZ_A$UK<(4D0]Q_0]\U5L
M/#UCI]U!=(UU-=06[6JS7-R\K>6S!R#N/)R!SUP .@K5KDAXSNM1DF/A[P[>
M:M:Q2&,W:SQ0Q.1P=A=@7 (QD#&: +E]X)T._MS%);RQG[<VH+)#.Z.L[=75
M@<C/H.*;'X%T"+2M2TU+64P:D_F7)>XDD=W'1MS,2"" <^HK<^UQQVT4MT5M
M2X&4E=1M)&=N<X)'L:D:6-!EY%4;2W)QP.I^E %9-,A&D'3))+B:!HC"[RS,
MTC*1@Y?.<\]<UBZ=X!T'3+JTF@BN9$LN;2"XNI)8K=O[R*Q(!]^W:NA%S WE
M[9XSYN?+PX^?'7'K2R7$,0)DFC0 [268#GT^M &%=^"M(N]2GOB;R!KD@W,5
MM=R11SG&,NJD G^??-:L>E6<6I7>H+$3<W<:13,SE@R)NVC:3@#YFZ#G-699
M8X8S)+(L:#JS' 'XTHEC(0AU(?[A!^]QGCUXH P;/P7HME?Q7445PP@<R6\$
MES(\-NQSS'&3M7KQ@<=L5HP:-I]O87-C';*;6Y>62:)R6#F1BSYSV)8\>]6T
MGAE4-'*C@G:"K Y/I3BZ"01EEWD9"YY(]<4 8FC^$M-T.[%Q:27SE8_*B2XO
M994B7N%5F('3ZUH7>DV5]J%C?7$.^YL&=[=]Q&PLNUN <'@]ZM^8A#G>N$X8
MY^[]?2JNI7DEG8336T*7%PD9>.!IA%YF.OS'@#GK0!23PKH\:A5M" -0.IC]
MZW_'P<DOU]SQT]JC/A#1S'(AMW*R:D-4;]XW_'P"#NZ].!QTK)UKQM/I5WKT
M"V43'3-)2_7,O+LQ8;3[# Y']:ZRUN1<6,-TP""2)9""?NY&>M %#5=(M)UO
M[W^SDO;N:R-JT+R;5G0;F$9SP,ECSCO7(:!X0<>*]+U3^RK_ $^UTR&41#4+
MX7$FYU""- '8+&JE^^22.*] 6Y@>7REFC:3;NV!@3CUQZ4OGP^8L?FIO8D*N
MX9..N![4 9NN>'-/\0+;?;//26UD\VWFMYVBDB;&"0RD=N*ALO"&C:=%'%:0
M21HE[]NP9G?,VW:6)8GJ#S[\UKK=6[/(BSQ%H_O@.,K]?2GB2-D5PZE7QM8'
M@YZ8H RKJQATV]O==M-.GO-1GACA>*&109%4G&-[!1C<<\]JI>!O#C^&?#@M
M9TA6[N)I+JX6#[BNYSM7V P/PK8L[QY=-2ZO85LW()=&F5PG.!\PX/;\ZJ:+
MKJZQ>ZO;K (UT^Z%N'$FX2YC5]W3C[^,<]* ->BF1313IOAD21<XRC C/X4[
M<I8KD;@,D9Y _P @T +13)9HK=-\TJ1IG&YV 'ZTY6#*&4@@C(([T +1110
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M2%N3\T8!/UYKRJ"[UBWMH?&%S9W'G>&1#I1MPAS<80QS,!W^=T(/3"&O<**
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M<;M_4?>YK.T/2DU>?PA:ZE;^;IB7&I/907"'Y[48\H.I[8(('H%KUR>UM[H
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M%QO/S9P?EJA?^#[R/6]<AET*\U33]4N3<1R6VK/;J"RX=)4W@8XZ@'C [8H
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MKR37>!I !O!Y;9CRNX8X^;((Z9K,\,:7''K%[J9TG5K*9X4@\S4KP3/( 2<
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M,:[3G:.221T(% 'I-%<9KGCM+'5I=,L/[-:XMX$GF.H7PM5.[E43(.YB >>
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M(^4=,]R".!4%KX7N+'5/#FDVRSR:7H4<MU)/*%47$SAE15QZ;G;T'RBN[HH
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M8'GW+97=MR2-J;NO=_:KEYX:U&+Q'=:WH>J0VD]["D5U%<VQFC<ID(XPZD,
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MVIJFG+8E!'S'@."V<\_?Z8[5TE% &5X=T^_TK1+:PU&]AO);=%B2:*$Q915
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MSU[]N.E '(M'>:+_ ,(QJL.O7]]<:G=0074<TV^&=)%)9E3HFWJ"N..N:O\
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MLTFN.Z2;M:B6*\^?JHC,8V^GRFE;PUI<E]>W<L!E>]M5LYT<Y1XES@8_X$:
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MYO;F6;:'DN[AI3A<X SP!R>GK0!I4444 %%%% !1110 4444 %%%% !1110
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M=&CD\1P:UYT@EAM7M?*&-K*S*V3WSE16E10 8%! /49HHH **** $P,YP*"
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M%(6 (!(!)P,]Z6@ HHHH **** "BBB@ HHR!UHH **** "BBB@ HHHH ***
M0>AH **** "BBC(/0T %%%% !1110 4444 %%%% !1110 4444 %%%&1G'>@
M HHHH ***,C..] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%'2B@ HHHH ** 0>E% !1110 4444 %%%% !1110 444F
M1SR..M "T444 %%%% !1110 449 []:* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D
M/'"M8W.@:_$#NT_4$CF8#.()OW;_ *E3^%<Y:WL\/Q6E\0O)G3+V>715RW"F
M*,/N_P"_B2BO0]:TN/6]$O=,F8HEU"T1<#)7(P"/H>?PK!G\"P7'@*+PPU_,
MKQ@.M\J#?YVXL9,>[%LC/(8C/.: .<T.Z,-]X>NQ9VLMSXCO[^]6XN8MSVX,
M;&/8<Y **@/J#63]NUZX\$:Y-JLL5^L'B*...%-Y=F6[CR@+$@)T"CMFO1IO
M"T3ZCX;N8)_)BT,2*D.S/F*T7E@9SQ@<]#66_@.86VIV<.LM'9WFHIJ,:&V#
M/#*)5E;YL_,"5P..,]Z "+Q9JFE:UJ-AXA@LMMMI3ZJKV.\X1&(9#NZGI@\9
M]*K1^+/$UA#H^J:SI^G+I6I31Q%+9W,UMYO^K+$G#]0#C'6MZ_\ "MMJ7B"?
M4[F5FCN-*DTN6W P"CON)W9R#VK*@\#WT@TVTU;Q%)?Z9ILJ36]L+58G=D_U
M?F."=P7T 7.!F@">[\67-MX2N]7,$)FAU-[)4YVE1=^0">>N.?K572;KQ%+\
M3==M9;NT;38(K=O)(?*HPEV[.<!C@;CCG QTIVH>!;V\CN;*/Q T.E37OV[[
M*;1682&42L/,R,J7R<8R,]<#!V!X?N(?&$FNVFH"**YA2*[M6@W^;LW;"KY&
MTC?Z'.* ':I/$GB?08GM+>5Y#/LFD3,D.(^=A[9!P?:N2T?QSXCO- TWQ'>V
M.EQ:7=7<=L\:._F@-+Y7F GY<9/0]AU[5V]YI?VO6--U#SMOV+S?DVYW[UV]
M<\8K 3P&B> [/PM_:#%+>9)?M'E<L%F\W&W/'IG/OCM0!A"]O=(\9^+=<U:/
M3Y[33H8G_=QL9E38Y0(2<*>2&]<YXK8@\1^)+"[T:77++3EL-5E6$&T9S);2
M.,QJV3A\]"0!CKTK1N/!]O>S^)3=W4DD&NQQQO&!@PA(]GRG)S_>Z=?6JEKX
M/U-[K2_[8\1'4+/3)!+!;K9K$7=1A&D8,=Q7KP!DT 8)\?>)E\+:GXF;3-+&
MFV;RQ)'YS^;*RR[ W3 7MC.<C/0XK1;Q)XPA\0V^@S:;I'VR\MC<PS+,_EPJ
MO#AQU8@E0,8SGM5J3P$'\ 7WA;^TB!=2R2?:?(^[NE\S&W=SCIUK9N-!\_Q=
M9:]]IV_9;26V\C9G=O93NW9XQMZ8[T <_9^(_P"UY= &HZ7;?;UU:XLI0&++
M;S11RDLA[Y"_^/'TJ"#QIXAFTL:X=+L5TJ.^-K*HE9IG43&+S%&,#!QP>N#T
MXSKVG@T6NH077V_=Y6KW&I[?)QGS4=-F=W;?G/?'04Z#PAY'A"301>[M]RT_
MG&+&-T_G8VY_#K[^U %>[\2ZU>:IJ]IX>TZSGCTH!)I;N9D\V8KNV(%!Z C)
M..3^-;/A?6'U_P ,:=JTD2PO=P+*T:G(4GMFN%UV]M=!U[7QIGB);2:["R7F
MGO9-+.TA08:WY&21M!X8 Y/M7;^$K.33_!NB6<T7E306$"2)C&'"#=^.<T 9
M-IXRGN?!.F:\;:$R7EW%;E$<E 'N/*W ]>G-,@\6:EJ'C6^T6RBTQ(;":..:
M.ZG9;B56 +21J!C !/7KZBJD'@+5;>SM-'BUZ!=$L[]+R&$V.9BJR^8(B^\#
M;GN%S^'%3:SX-U?7=>L[B\U6R%E:7JW<3166RZ55)(B\S=]WMG'- &YXIUR?
MP_I45W;61O)9+F&W6 -M+%W"\$\ \]^*R?\ A*M7TS5TTW7M.M(I;JUEN+.2
MTF:1&:,;FC<LJX.,'(JQX]MIKS1;*""XDMI7U.T"SQ@$QGS5PV#QP?6F0^%M
M2O=2?4M>U."XN8[62TM4M;<Q1Q*X^9R"S%F. .H  ]Z ,_\ MR_U/3M"U#5]
M%LEM;Z^M#:1F5FEC9E+>8PP ""!@9/7FK%SXKURXEUBYT;2;2XTW297AE,\[
M)+.\8S((U"D<=!GJ:U)_#;RZ3H%BMRH.E3V\K.4_U@C4K@#/&:S;CPIK5O)J
ML&C:S;6VGZI*\TR7%J9)87?_ %AC8,!SUPP.#0!"?&VIZMJ5I:>&M+M[E;K3
M8=16:\G,0C5W92& !)/RCI[\],S?$[4M8TKP1=W>D21PNA023&0JZ*75?DP#
MDG..2,#/>KVC^$H=$UN&[M9C]E@TJ+38XF&6PCLVXMZG([>M6O%N@MXF\+WV
MCI<"W>X5=LI7<%*L&&1Z96@#+G\1:Z-2MM!MK#3Y=;-N;JZ8SN+:&/>57YMN
MXL<#C'KVK2\+Z]-KEE<B]LQ9:C97#6UU;B3>%< $%3W4JP(^M9EQX;U_^U;7
M7;35;"+6!;&UO%:T<VTZ;BRG;OW!ESUW<^PXK3\-: ^AP7DEU=_:]0O[@W-U
M.$V*7(  5<G"@  <F@#.T_Q3J.K^*;[3K.VT]+;3[DP7"3W+"Y90!^\6/;C;
MSQD\^V:L#Q/,?"L>L?9DWO?+:^7N.,&Z$&<^N#GZU0OO"&IZIXJL-4N[S34@
ML;PW$3V]HR73ISB-Y-V"O(!^7G%5Y/!OB 1QZ;#K=F-%34EO?+>U8SE1,)O+
M+[L8W=PH- &I+XCU6_U>^LO#VG6MU'ISB*ZFNKAH@TA&3&F$;) (R3QS7(Z+
MKFL:'9>,+^TTN"YL++7+R>Y:2<K(RAAN$:A3D@#.20*ZI_#FMZ=K.H7?A[4K
M&WMM1D$\\%W;-+LFP%9T*NN,@#@YY%+!X0EA\.>*-+-VA;6KB\F238<1>>N
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MP.>_0U%9>";NWCL'GU1)[I=7.K7LGD[1*YC*;4 /R@#'KT]Z -;0-=N=0O\
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MEM7@9;<K;ARNTQE<DA<%NAXXK:T+0=9M_$]_KNLWUI-)=6T=ND%M&RI"J$G
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M5),$$JW3@@U2NOA]JE]I&O6TDND6LFI6UM!%#96[1PP>5(SX]6SNZX'IC %
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M(+R)5(+*&!P<D$>F#TS72Z'-J=Q%>RZDBQYO9EMHPA5E@5MJEN>2=I;/HPH
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MQ*KR%8X;J>A)Z\4FO^"-4U9K:P@;2HM.M/(6TNV23[;;(@4-M8$ DX/H.>:
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M&&5Y'H:LV>C>(8;6Z=[;PQ#>&'9 (+1_++$_-OY!VD9&!^O2@#5\.:IJ6KV
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M^3S3EEZ  =@?6KEH/$>N:]8:?J>IWVD2KHJ3W<%HT>YI_,92V[#  XS@>PH
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M2S!CQRV6P?T% 'KE%>?7_B+6/"$/B7^T+X:LMC907EJTD*Q,#*\B;&V8! 9
M>F<''O4-IX@\16\LZ.^IWD#Z?//)<W>EFV6VF1<KMRH!5N>#D\#GF@#T>BN?
M\)1ZR^D17VM:F+N:\BCF$20+&MOE<E01RW4<GTK(CNM?\07>N7-CK TZ#3+I
M[2"W6W202LB@EI&89P2W1<8 ZF@#MZ*\YMM=\0^+YO#_ /96H+HT%[ILEY<[
M84F8,KJH"[AZG\JZ;Q7?ZCI'AI9["2-[X7%K"KS !7+S1H=WH"&/3IGB@#H*
M*\^U/5/$?AS5I-/DU5=2-_IEU<6S-;I&;:>),] ,;#D8W9Y'4U ^L>)['2=#
M:?5H9;_Q#-!#'_H@\NQ!0LY7'WSC&-QQGMCB@#TBL_2]<TW6A,VFW2W*0OL9
MT4[2<D<,1AN0>1D5Q]Y?:_I6K7F@2ZR]V9]*EO;:]:U026[1L 0P "LISP2.
M.G-8&D:UJNA^"_!^EPWMP[:O"72>WLA+):Q1QJQ1(U!WDY^\>G)Q0!Z_17F8
M\0>+F\/RC[/J:F#4_):^_L[%P]H5)\P0D8+ X4X'OBIM0U_4DTK1[BTURYN=
M%996O=:M+-))%VGY0T84[>X8A>,<XH [T:A9G4CIPN8OMHB\XP;OG$><;L>F
M>*LUPQ\32V5U=72W<6IVMMX=_M!9E14^T,K.<Y X!"].@J&+4_$.FZ=H>O7>
MJK>PZE-;QW-E]F5$B6; !B(^;*EA]XG(STH [^BO,;W7/$UGX>UGQ/+JH%MI
MFI3QPV2P)MN(4N"A#MC<#C*@C&-H)SFKGC77-0BO+R+0]:ODO;*T$S65IIZS
M(K<L#-(PP P&, @CD\T =NFIV<FJRZ8DX-[%$LSQ8.51B0#GIU!JW7!>';MK
M_P")-Y>.H5Y]!LY64= 69S_6N]H **** "BBB@ HHHH **** "BBB@ HHHH
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M<Y#X M;^]U>YU(WUN;N]D9DMKUXTN82H"B15."/O=>?PKH/#6O)XB\-6>LF
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M/JEO$8YYK>.V*@X0(A.T!>WWOT%3Z;IT&E6"6=L&$2%F&XY.68L?U)JRSJI
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M-%'>(F)4! 8JR,RG&1D9SS6I+=3IJ5O;+9R20RHS/<*ZA8R,8!!.3G/8'WH
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M[+Y*^5M]-F,8]L4 >1ZK'K'AKPSK_P!@N]-2REGM@]KI]W)(;-6(60[R,H&
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MHH **** "BBB@ HHHH **** "BBB@#%\2:7>:O9K:6Z:7+ V1-%J%NTRMZ$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@^)/%
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M'([$$'"CCDBS:7UWXK\4Z5I>HWUS;VG]A0Z@T-M,8#=2OPQ+(0VU?0$<]>*
M/2:S+[7+;3]:TK2I8YFGU-I5A9 "J^6F\[N<C@<8!YKDTM/[4\;77AZYU+48
M]/TS2[<V\<=V\;SEMP,K.I!8C"CDXSV-<LCW&N:IX-M;S5[ETAU74K6'4(Y=
MDEQ%&I"G>.NX#:2.N?6@#VBBO,9+?5&N?%GAS0-4N+D6WV2:*.XNGWQER3)
M)B2P!1!@]1O_ !KIO UQ93:=>I:IJ,,T-TT=U:W]RT[6\H5<HKDG*XP00>]
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M71BC:2W2:4JX**2H)PW3'O3(=<TFXO%LX-4LI;IU#+"EPC.01N!"@YQCGZ4
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MP #CGH*VK&^;5?B/I][!HNI6MG'I4T!N+FR>$;R\;!#N Q@*<9X.3CO7=44
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M;B>.V:WB98[B.+&9@#RJG(QUZBNNJN;&V;44U Q W21&%9,G(0D$C'3J!^5
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M^62 $(QLW*2#T->KT4 (JJBA54*H&  , 4M%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!%<VT-Y:S6MS&LL$R-')&PR&4C!!]B#3H8HX(8X8E"
M1QJ%51T  P!3Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *J:EI=CK%DUGJ-K'<V[$$QR#(R.0?K5NB@#.TC0-*T&*2+
M2K"&T65MTGEKRY]2>IK1HHH PM+\&>'-%OOMNGZ3;PW/.).6*Y&#MR3MX],5
MNT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>arrowheadengagementlette004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 arrowheadengagementlette004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ*1R)4
M1>IR: (;+_5#ZM_.K=5++_5#ZM_.K= !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 =JKR?\ 'W%_NFK%5Y/^/N+Z&@!MG_JOQ;^=6JJV1S"".F6_
MG5J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@?_CXC_&IZB?_
M %T?XT 0V(VVRCK\S=/K5NJ=@?\ 1DSWR?UJY0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %1O_ *V/\:DJ)S^]C_&@"OI__'I$?;^M7:JZ>ZO9
MQD #BK5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5$_P#KH_QJ
M6HG_ -=%^- %;2E(L8CCL?YFKU5-,_Y!\/TJW0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %12?ZZ+\:EJ*3_71?C0!#IG_ "#X?I5NJ>F?\@Z'
MZ5<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HI/\ 71?C4M12
M?ZZ+\: (-+_Y!T/TJY5/3/\ D'0_2KE !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*!%CGNH9)]4!CQY0B'ELN"?E)E( [X4UT5EH=K8ZYJ6K1/*;C45A68.P*@1
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MEWD,4UO!:QL/)#+DAF).[JOZUD:;XEU:_P#%^H:9/>6%BT%P\<&GW-LXEGA
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MQF(CS$.YCNX=<$8SSQ65<W^OZI:^%M3O5T]+*]U&"98(E<2PJP+)EBQ#<<'
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MQIT]I'&T6]()UN)%1#R201E@>3R*W?$'AV35[FQO[+4'T[4[%F\FX6,2*5;
M='0XW @#N,'FJ<7@L?8[PW.HO<:E?7=M<W5XT07=Y$BNB*@.%4!<=2>2>: +
M.E:EJZ^(;G2-7-C*PM8[F&:TC= 025965F;H1P0>1Z56\8>(KC0WM%MM3T>T
M:57)6^CDE=R,8V)&0<=<GMQ6W_9:CQ =6\T[C:BV,>.,!]V<_C67J_A:6_\
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M&U1\OKWH IPZ[K]CK^EZ;K<6FB#589O(6T\PO"\:;]K,W##;GD <CI6+\/\
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MW=UI]T\A8K/IY)A=<\$9)[=>3S7E&K7/B"Y\(_$0:C>6T]K#=/%M57W(P$6
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M?:+=TGEMVM;R<R2I(A^= S,2P''0D 56\;7:+)I.FK:7M[<WDS^5:V]X;59
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MW:K.[[VD F;#%NY/7/?- ':T5YQ;63ZO'XNNKWQ#JD/V*_N(X!!?O"MLJHK
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M,<J.QO+D6R;<<,59LGVPAKSK1(Y=:\9^%=6U"2\CO+G0FNI56Y=%+AH?X0V
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MI%[<FYNM*L9YRNTRRVZ,Q&,8R1G&#BFS^'M%NKJ*ZN-)L9;B$!8Y'MU+*!T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=-;.NCSWDEP58_,)0^W;QS]X9SBIO#?A#4=+L]%6[FMC+97]U=S"(L01*LH
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M%!#YQ\0MJ(R_'DFY,GIUVGI73^)K&XU/PMJMA:)&]Q<VDL,8D.%+,I R?QH
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MMQXX$\2P_P!@W4L-[>H6^9KB(,% 7H03Y;'W3K0!I:CXVLM/N[N :?J=V+(
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MA[Z756F7?L*EHTW'[V>X7&?:@#K=7U^TT>>SMI(Y[B[O7*6]M;H&=\#+'D@
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MY+'4;266)Y83=6_EB54QNQSD'Y@<$ U:M8M6'AB&&>>/^V/L85YL#;Y^S!;
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M"9'\L$ L>P&3CD\]JSM%L=4O/%]]X@U.P-@GV2.RM+=Y4D?:&+NS;20,L0
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MC@8[_4 [2BLKPWK<?B'0;;4HX_+,FY7CSG8ZL58 X&0"#S6K0 4444 %%%%
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MD9G::::0Y>:5CEW;W)KEXOAW+ ?L\>N2+IXU-=2$'V9?,:02"3:\F<NN0<<
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MG>> Y*NSG+'G_(XQ46G>$M&TN6:6VMI/.EA^SF66XDD=8O[BLS$JOL,=!Z4
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MM\)Z%-8W>KZW?VL=MJ.KSK+) C!O)15VHA8<%NI)'&6]LF>'P5H4%[]HCM9
MOGFX%M]HD-N)>N\19V;L\YQ0!SA\0:LOA#Q[>R74B7.GWEU':,R@&)%A0H ,
M?[6>>N:N6[ZOJ_C"2R&L7%K80Z7:7#I"%WM*S2="P( .WGCG Z<YUM4\$Z%K
M-U<SWUO.XN@HN(4NI4BFV\*716 8CCDCL*U+?2;.UU"6^AB*SR01V[-N)&Q"
MQ48]MS4 7:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IC??3\:?
M3'^^GXT 5]-&-.M0>/W2?^@U;JM9?\>5M_N+_P"@U9H **** "BBB@ HHHH
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M4>J0K#;2)%,TN8_+9\;=P8 @'(P>AKCKM=<EU+Q)XETC2+B$3VMM:PQW%O\
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M^EV^F7'VN:66XC<2.$9 D84DD9<G+8X'2NPM[>&TMHK:WB2*")0D<:#"JHX
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M4]2OXWD:74'1Y%8C"E$"#''HHZT <5XV\97>B7E^--U:.2XLK<3-8)ITDX4
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M&7R\28;=@N%#;<\X!'UQQ5C5/ 46I7NL2+K.H6MOK"*M[;P"/Y]J!!ABI*C
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M:Z%=3Z3I9CUP+';1I.X:&1DW*7)'*D!B0!D=,GOOV6@Z^+&>SU3Q%'>0-;/
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M'J]M(+J?4BDL5OMV[6CBV!=Q/.2.O&,UHZ+'?PZ)9)JL_G:@(5-PX  ,A&6
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MWN[:UEF5)[HL(4/5RHW''T S7F^LZO\ VUINDV9L&OM1.C)J%P9-0>S@B1U
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MZ9!&:HS^)=$M]-34)=3MA:2.R1RAPPD9<@JN.6.5/ R>* ''PYH;:F-3;1[
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M@NO!WAR]>)[G1K24Q1)"FY,C8OW5([@>AJ_I.K6>MZ;#?64\<L4J@_(X;:2
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M.E6<C65UI0@0-"4^TW2K)ED!&3@,@W=SZXKTNB@#!\&W=E>>%+!K'&R.%(I
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M+#,L2[5.V6,(>.Z[FQ6'ILFL^)K'4KQ([B+4=$TF33(,C!:^VD22+^"H ?\
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M^&Q)J5GK.E3ZU>.?LT7EP(S0,WEHNXY3<C'J1VYS7L11"FPJI7TQQ0$4  *
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M -AI_P#T5'78"*,# 10,@]/3I2A57. !DY.!UH \UN7\')X]\4-XEET]9Q'
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MTQ-!<2'3[%;Z4H%P49G55&3G),;=L>]5['Q@MYJ5M:MI&HV\=[ 9[*:54"W
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M#HQ.TD!0<$C.>U73X<U74+_4M9N+'R&O]2TZ1;-W1G2"WD4LSX)7<1N. 3P
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MP9A\IW?>S@$<^M2^"H=4T30-/TV^TB1)IKJ[>8PNICM@97=223D@@C&,GUH
M[&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *AMK6WLXC%:V\4$99G*1(%!8G).!W)))-344 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>TL;
M:P25+6$1++*\[@9^9W.6/XDU8HH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "JEUIMM>7EC=S(3-92-+ 0Q
M&&9&0Y]?E8U;HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MASZ&K- !1573]1M=5LDO+*7S;=V95?:5R58J>" >H(JU0 4444 %%(64,%+
M%N@)ZTM !1110 4444 %%5Q?6S:BVGB4&[2(3-'@Y"$D ^G4'\JL4 %%%% !
M1110 4457FOK6WN[:UFF5)[HL(4/5RHW''T'- %BBJNHZC::39->7TPAMU9$
M+D$X+,%7IZLP'XU:H **** "BJ\E]:Q7\-B\RK<SHTD<?=E7&X_AN'YU8H *
M*** "BBB@ HJL=0M%U)=.-Q&+QHC,L.?F* X+8],U9H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#F?'MC)>>$KF>W4M=Z>RW]OC_GI$=_Z@$?C7%S*E[JEQ\0
M8WC:"VU:".*3<#MLU4PRD'TW2.W7'RUZRRJZ,CJ&5A@@C((JA!H>EVVB_P!C
M16,"Z;L,?V;9E"ISD8]\F@#S.YN+ZV\%?VE;EXY?$VM"2699Q"R0.V(U#_PY
M1% ;G&ZNJ\'V&MZ=K.IQWJ21Z;*D;P0SZB;MX7Y#8+#.UN#R>JFNEGTC3KG2
MAI<]C;R6 18Q;-&"@5<8&.F!@?E4.D>']*T%9ETNRCMO.(,A4DE\=,DDGC-
M''7-A)K?Q \36EQJ6I16UM86[0Q6UV\01V5_G&TCD8^GJ#Q6+I<^H1>'_!?B
M675M0GU'4]2M[>Y$EPWDM$^Y2OE [> !SC.>:]433;..^N;U+:,7-RBQS28Y
M=5SM!^F3^=5U\/Z2MA8V*V,0M;"1);6,9Q$Z_=(]QDT >;W^I2SZQ;:WI1U2
M.W_MV*U:YN=3/E3 S")T2WR1MZXR >,U;O;C5+<ZKX-COKE;R\U.(65RTS&2
M.TF!D8JV<_((IE]N/:NR_P"$,\.?VB^H?V/:_:WF6<R;>?,!#!AV!R <CKWJ
MI8:'?7?C&3Q'K$-M"\%N;2Q@AD\S8I.7=F*CYCP !P!GKF@#I8FC*E8W#A#L
M.&R01V/O7C^HV3:18_$34+&^U"*ZM[B..*3[9(=H9(B3@M@GD@$\@<#BO4=$
MT:+1+*6".1I7FN);F65A@N\CEB?PR!] *6?0M+N8+^&:RB>/4&#72D?ZT@
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M&-%DN[VZ;3X_.O0%N6!(\S&,9&<9^5>?:KG]F67VB[G^SH9+Q%CN&//F*H(
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M+%%*SNQ7[TA^505)XY^8<XZ]#IO@2TN9]:N-;M&,M[J$LF(KJ1%F@S^[#JC
M-QGA@>M;>K>%-(UF2UFG@DBN+1&CMY[65H7B4C!4%2.,<8/% ''PR^*]1O\
MPGIVI7MWI4TJ7S7OEF,23QQF,1DXW*K$,,XZ<XQQ3YM8URTTZ;1/[1*7 U^/
M28[^0J95MWC60-DC!DVMMR1R3ZUVEIX>TNQ>Q>WMBK6,<L=NS2NQ42$%\DD[
MB2H.3D_G4%YX1T._L[VTN;'?#>W(NYQYK@M* H#@@Y4X4=,?J: .$NH;G0?&
M/BEH=4N[F6#PN98)KA@TD1#.0-V.<$;LGGFMKSM5UOQM=:.=:O+.RCTJ"XVV
MH17,C%@3N*D@>P]![YW;?P5H%M)?2)9R-+?VYM;F26YED:6,]5)9B?QZBM"#
M1K"VU234HH-MW) ENTF]CF-22HQG'&3SC- '"1ZUK.KIX5T274WMIM0-V+R[
MMP%DD%NQ7"G'RENI(''.,5T'A"2_CU'7].O=6DU)+*[1()9 H9$:-6VDJ!DC
M.":9X@T&U2PL;>VT"YO(K>:2='M+ORI[9V.2R%F!.2S9&['M3O WAR;0+;4I
M)[=+5[Z[,RVZ2F4QH%"C<YR6<X))R>30!6<ZAXC\9:SIC:M=:?9:6D BCLV"
M22O(F_S&)!RH^Z!T)!SFL31O$6N>()O#%HVJM;&Y6_2\F@B3,Q@D159<@A21
MGM_$?;'9:KX/T36M0%_>6LOVOR_*,T%S+ S)G.TF-AD?6K%KX;TBRDTY[6R2
M$Z=%)%:A&8"-7QO&,X.=HY.3^= %'PA>7T\>KV5_<M=2:=J,EJD[A0\D>Q'4
MMM &0),<#M6/96,A^(OB:4:MJ#B&SMF>!_+\MMWVC"?<SM48(P0<DY)KKM/T
MJTTQ[U[5&5KRX:YG+.6W2$ $\]!A1P..*@N/#]C<:VFKMYZ70B\IO+G94D4!
ML!E!PV-[8R.] '&^&QJFDZ#X'N/[8GG@O8X+>6TDCC$:HUNS+MPH8%=@Y).>
M:S[7Q)XKUN.\U33+?5G9-0:.WMXTMOLIBC?:4?<WF!B 23V.,<5Z(FA6$=EI
M=HL3"'3"AM1O/R;$*+D]_E)'-4)/!6C/J,UZL=S$;B433PQ74B12R Y#,@."
M>GUQSF@!?&FK7>C>%[FYL"BWCO'!#(XRL;2.J!C[#=G\*H:M_:'AO0[>1]=O
M+NZGO+*V+3)'MRTZ"3:%08W*6')..,<\UTVH:?:ZKI\]A?0B:UG0I)&21D?4
M<CZBLI?!^E>4(Y3>SJLT4R>?>2R;#$VY -S' !_/OF@#)EN]4_X2#Q+>OJET
M+#1U1X;""./]Z?(61@Q*EB">@!!Y/-,TY=<_X1%_$5YK]Q)=36$EU]ECCB%O
M&6C+*%^7=\O')8YQ[UU-II-I975_<0HWF7T@EGWN6!8*%XST& .*S=-\&:/I
M#$6:726P#A+0W4C0('^]B,G'.3^?&* ,VYUK4$UGP-;I<D1:DLINQM'[W;;E
MQVX^;GC%<W_:_B9/!/\ PDL>O2/=_P!H-:Q6LL,?V<H;DPC< H8D9SD,.@XK
ML=.\"Z)IEWI]U"MW)+IVX6?G7<CK K+M*JI. ,'T_D*M_P#"*Z5_87]C>2_V
M(7'V@)YAR'\WS>O7[] '.RWOB+2]?U'0+"_?5+R31_M]H]^J+LE$FPK\BJ-I
MR" >A'7FN9\3WQU/X7^(HWUK66O;58C=6=_#%')&=V"IVH,HV<@@G[HYZBO3
M+[PYI^H:A)?RK,EV]H;/SH9F1ECWA\#!X.X YJH/!6C-8:C:7$<UW_:*!+J:
MYF:25U PHW'D =1CH>: ,37KV;3IK?1K?7M>N-0CMGG*6=K#),P+85Y6*!%0
M$$ 87W-0Z?J>O^))O#*1ZL;"*]T8WEZ8(D+,V8P-FX,%.6[YXSQZ;=UX$TJ\
M*O+<:E]H^SM;/<+>N))8F8ML=L_,,DXSTK0T_P -:;IDNGR6T<@:PLS90$R$
MXB)4X/J?E'- '%Q^*M9GTJWT>*\VZE+KD^CG46B4G9$6)DV_=WE0!TQGFM/7
M[O5]#32M%M-2U"\N=3NG'VQH(FEBB1-S*O"H6.."1T+<'%:\_@G1+G3[JRE@
ME,=Q?-J!=965TG8Y+HP.5YI9O!VF75@EK<RW\YCN1=17$EY(9HY NT%7SD<=
MNGM0!S5[?>,K719U2+4VA@OU!NO)@:\>S*99@@RA</QPHR,'&<UUOA?4+;4]
M!@NK75)=2B8L!<31A)."1M90JX(Z=!41\*VOV(6ZWVJJWG>>TXOI/-9MNWEL
M],8&.G'K46G>%(-*U2SEM)'%I;13_(\C,\DTKJS2.Q/S' /7UH FU?4KJT\2
M^'K.&0+!>S3I.I4'<%A9ASVY Z5SVIZSXB:U\6?V0TEQ<6.H0Q0I%&CO'#Y4
M32! >&;YG(!SR:ZG6= L==^R-=><DMG-YUO-!*8WC;!'!'L>E4[3P?I]A97E
MM;76HQF\N?M4TZW;B5I, $[NN,#I0!R-WXT==(TR#2-4U2^DO[Y[>69K-&N[
M4)&&=/+"J-_3JIX8GG KI_!NHZI>QZA%J$&HB&WG"VEQJ%NL,LT94$[@, D-
MD9  QCOFGGP-HATT69CN"1>?;OM'VA_.\_IYF_.<XX],5KZ;ID6F1RK'/=3M
M+)YCO<S-(Q. .,]!@#@<4 <3:Q7#_$#QLS:A<&.&RM<1;8]K*T<Q"GY<X4DX
MP0?4FJWAR;6-%\.^![N?6&EM;Y;>S>S\A!&L;PDQ[2!NW#"Y))!YX KM9?#E
MC+K$VJ!KB.XN(EBG$<I5)E4,%W+T. YQ_P#6I3X;TXZ;I-@8W^SZ4\+VHWG*
MF)=J9/?B@#B$\2Z]<:9:B"_2.XG\4SZ;YCPJP6#][@8XR1M!!]0,Y&0=.!]<
MU#Q->^'X?$-Q"FDV<+O<_9XC)<32%R"^5(V *.%"D^M;L7A'284A1(I,0ZBV
MII^\/^O;=D_3YCQ2ZAX4TW4-6;5&-U!=R0?9Y9+>X>/S8\YVL ?KSUYZT <W
MX1UN71?AMI=R^G7^JO)-.K#3(1(<^=(=V"P^7CK[BKUSJ.KZSK^DVEE/<Z1:
MW>GSW%Q'-"@N(]KQ@8!# -\W?(P3QG&.CT;1[/0=)@TS3XS':P;O+0L6QEBQ
MY/N36!K7AZ?6?'6GW3&[MK:ST^;R[RVF",LSN@VX[_*">010!EIXHN[*SU_3
M]2U>59=.U"*UM[Z&T$LTPD575 BC#2<E<A<=\51'BC7XO#NM_9;BZ-U:ZC:0
M6DFJVJQR[96C!$BJ "/F/( .#76OX)TA]'.G#[4A-R+S[4LY\\SCI*7/5OKQ
M[4ZW\&:5!;7<+-=S_:[J*[FDFG+NTD;*RG)[94<4 8&I:)K,/B?PZLGBF\F=
MYK@JS6L(V?NF)P-OIQSG&:=)XGU*&UOM#>Y!UY=42QMY61?GCD/F)(0..(MV
M3C&4-=7J^AV^L-:22SW5O-:R&2*6VEV,,@JPSZ$$C^6*YO2])DUKX@OXJNM)
MGT]+2T^R0)<[1)*Y)W284D  $J.><DT ;?BRXU2UT"2;24F:=9(_,^SQK)*(
MMPWE%;AFVYP#7)WGBZ9=#TH:+JM_J)O=0:"6X^QH]U"J(6=/*"J-_'=> 2<'
MBNZU731JMB;8WEY:$L&$UG,8Y!CW]/8UD+X$T5=(CT\"Z^2[^W"Y%PPG-P1@
MR%P<EB"1Z>U '*WWBCQ1'IL<5N;FTDFURVLK6ZU*R"/+#*O.Y, ?*V1E<9 '
M2M&77=3\(:KJ-KK.IMJ-K_9C7MG)+$B.TB-AX_D4 DETQ70_\(G8R6]O%=7%
M[=M!>QWZRW%P6;S4^Z?0#_9  ]JGUKPWIGB"2Q?483*;*<7$(#8&X>OJ.!Q[
M4 <C<>*-;\/-?+J<BW4UCX<BOI8]BJ&N2\@;E0/EX ^@]:T+Z_UOP[X*NO$%
MUJAU"Z2Q\P6S0(D(E8C!7: VT9Q@DYKH+GP_IMYJ%U>7,'FR75F+&96)VO#E
MCMQ]6/-4[?P=IT.GS:=+/?76G2P&V%I<7!>-(SCA>_&."22/6@#$\,ZWX@G\
M0V]I=PZK<6$MH6FGOM/%L(IUQ]TJ "K G@Y(QU-:6N3ZQ/XMTS2=-U-;"":S
MGN)W\E9'.QHP-NX$9^?\L^U:&D>&X='E1X[_ %*X$<7DQ1W-R72-.. . 3P.
M3D^]9^M^'I=7\9Z9=F2[MX;:QN +FVEV,DC/%@>^5#G!!'% '+:GXK\1VQET
M6UOX6U&WUVVT_P"W20*1+%,A<;E P". <8Z?6MTR:Z?%%IX:BUV0+!8F]NKU
MK>,S3;I&5$4;=B@8/..F*U8O!FC16EM;B*4_9[Y=1\QI27DG!)WNW5NM6-6\
M-V>JWT%^9KJTOX$:..YM)=C[#R5/!##/8@T <I8^*=7ANH([^ZBEBL=9?2KZ
M58U195= 89#_ '2&*J0.,M]*LZ-XDU.]N-,O;B0?8M1N;R2",1KD6R+^Z[9R
M<;O^!5MGP9HC>&;GP^;9C8W+%Y]SDO(Y()=F/);('/M5]-&LHWTUDC9?[.0Q
MVP#'"J5"X/KP* /,]<N-=U[X:0^(+K5?+M[J[MY3IZ0)L6(W"!%W8W;@=K$Y
M]1BK^M>+-;N/$VN6&G#58XM,5(X%L=/$XFF*;OWK,#A<D# QD9.:Z&7X=:#)
M;I:@WL=DES]J2T2Z<1+)G.0OIGG'09XJY?>$+&\UB;58KJ_L;NX14N'L[@Q^
M<JC W#U [C!]Z .?T_4_%&N>)(+"2]&E1II5I>W4*VRM()G+;D&X<+\N#GG@
M8QS5CPCKFHW>K26&OZA<6^L+YK-IDEJB1,@?"M$^W+J!CG<>O2NFM=#LK/49
M+Z(2_:'M8[5F:0G,:9*]>_S'GK5'3O"5I8:M%J<M]J-_=0QO% ][/YGE*Q!8
M# &<X')R>* %O=1O(?'&D:>DB"SN+.YDD3 R70Q[3Z@?,:Y&QU[Q1'X8T/Q)
M>:M%,ES>PPSV:VR!3%)(8\AL;M_(/4#V]?09M-MY]5M=1?=Y]K')''@\8?;N
MS_WP/UJA_P (IIO]@6FBXF^QVLL<L7S_ #91PZY/<9'Y4 .\576J6?AN[N-'
MA>:]3;M6- [A=PWE5) 9@NX@'J0*XV^\:S1>'K)-)U>[U"]O-2^R/*U@//M@
MJ[G7R0HRX"\ C^+VKO\ 4K#^TK,V_P!KNK4[@PEMGV."#GJ01CV(K#/@+1Y-
M,GLYFNY9)[L7KW;3D3>>!@.&& " ,<#'M0!S;>)O%"VES#&MW$QU.S@L[O4[
M$0F2.5MK*R@ ':0>0!P16M)K.I>%M>N(-;U0WVGRZ;)=VTKPI&PDB.9$^0#.
M592/H:UO^$2M7BB6YO\ 4;IX[R*]\V>?+,\9RHP %"\= !GZU8\0>&--\3)9
M+J4;.+.Y6YBVG&6'8\<J<\CO0!@>'M7U\ZYIVG:S-&T\NAM?3JL07;*9@ OM
MM4[<>V3FJ.EZUXCM]*\)ZUJ>JQW,6KRP03VJ6RHJB5"48-UW [2>W)P!Q7;-
MH]J^NC6#O^UBU-I][Y?++!NGKD55'AC3_P"R='TT^<8-)>&2V)?YLQ#"[CCG
MWH XNZU_Q-J'A37/%&GZK%:0VDMPMM9M;(ZF.(E2S,>=Y(8CG&<<$5Z;7DVN
M>&VU&+5]%TK1]>MFU"Z=F2>0"P#E@3/D-NZ ,%'&< K7K- !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!#-=VUO-##-<11RSDK$CN TA'4*#U_"FR7]G#)+'+=P(\4?F
MR*T@!1/[Q'8<'FL'QS83W.@K?V8S?:5,M_;C^\8_O+]&4L/QKB[ZRGU?P]-X
MI$,US;ZEK%O<7$4:$E]-A?:J[,9(*C>1WW4 >F6&M:5JHE.GZE:78B_UGD3*
M^SKUP>.A_*K N[8QP2"XB*7&!"P<8DR,C:>^0">.PKSSS[+Q#X[TV^\+!)+6
MVL;F'49X82B'<J^5&3@ L#DXYQ[55TKQ)I]]IO@32[<SO>65S##=QB!_]'=+
M>2,JYQA3NZ>P)Z"@#T5=9TM]06P34;1KQ]VV!9E+G;][Y<YXP<_2C4=9TS1T
MC;4M0M;-96VH;B54W'VR>>HKF? %C9%-:U$6\+7<FL7FZX\K#D"0@<GD#':J
M'CK5H[;Q);V5ZNFVMJU@\L=Y=V!NI)GW?-#&,@9P 2,Y.1B@#N;C4["TLTN[
MF^MH;9\;)I)55&R,C#$X.14-QKNDVE@E_<:G9Q6<GW)WG4(WT;.#^%>2>'IK
M?3M-\%7OBF%_['CT^>%'N(RT4%R9,*7!Z?NPR@G_ .O71ZE=Z+%XOTO5]1AA
M/AEM,>.RN'B/V>&<R9;*D84LH&"0.A'.> #N+G7=(LK&.]NM4LX;27_5S/.H
M1_\ =.<'\*G74;)DMW6\MRMR<0,)5Q*<9PO/S< ]*\]NKW0M/\;0ZCJT<$7A
M^?247399H,6Z-O+.H!&%8C:>G(%9,</]E6FCZO);O9:#!XCEN+?S$*B"UDC(
M5BO5%+ECSC[PZ9H ]8;4+)&G5[RW5H"HF!E4&,M]T-SQG(QGKFH(]=T>:*>6
M+5;%X[?F9UN$(B[?,<\?C7EMQ<V?B!O'\T#-+97=WI:*^TKO7]VI(SV.#@]Q
MS717NE6EM\1[6RL;"WBM[G1)TEBCA55?:Z;,\8XSQ0!UF@:_8>)-*AU"PF1T
MD4%D#JS1D\[6P3@^U7KJ[MK* SW=Q%;PKUDE<(H_$UQ/PZU?1K;PAHFGQO&E
M^P%I-%'$=XN$0LRO@<$!3R:N?$#5%TVTTM98-.-O->!9+O4H6E@ML(Q#%01R
M>@Y')H Z9-3L)+1+M+ZV:VD.U)A*I1CZ YP:6RU"RU&(RV-Y;W48."\$JN ?
M3(->+6YAU'0Q:.\5U87'C:&)@D'E1RQF-&.$[*3S[Y]ZZ3Q;I\UD_C"#0+;R
M9Y]#MI#':KMW'S)E8@#OL&..>* .OE\46KZ[I>GV$]K=I=R31RO%,',11-V.
M.Y]ZMZ]X@L?#MG%=7[L$EGC@0+C)9V"CJ1P,Y/M7!6=YX3N_'O@\>&OLI,=O
M<AS:H %3ROE5R/XO8\CG/6M;XK6MG+X8M;J\MH9([;4+9GDDC#>7&9%#Y)'"
MD<&@#;@\46[>(-3LKB6TAL[2&W=+EYP/,,F_CGC^'UK;GNK>UMVN+B>*&!1E
MI)'"J!ZDGBN!TG2O#VK^.]=98+&YMETVT2V545X1$PDR5 ^7L!QVKE;>>>'1
M/ K7=_9II@MYX_M&IQ--;><&Q&7 =0#M#;23@<_@ >RR7]G#9_;);N!+7&[S
MFD 3'KNZ437]G;VGVN:[@CML9\YY $Q_O'BO(Y-.TVU\/Z?<MXOT9E34;F^L
M8YX"MC(.CQ!"QRJG.T@\$\9--N=4.H7?A349[73-%T>2PE$*:C:[[..?>.0
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M1F5X8U!!8$_>&.2!GI4EC#9W^I?#[4-4DCDNKK3)3).TI!E<)$5YSR>3^.:
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MJBW5HA=?WR+Y3<<\$["!G'-='917M[XX@U>73+BTMFT<Q9G*;DD,V=A"L><
M'TYKI99XH IFE2,.P1=[ 98] ,]S4E ',>!M+O-)TB^AOH##))J5U,BD@Y1I
M"5/'J*QM5L=8DB\=Z7'I$\D>IPM/9W2.FR1C;)%Y9!((;<G'&.>W?T"B@#E]
M;TJ[N/&OA*]M[<M:6+77GNI $8>':O'N>.*Y'2/"<ULEKH6JZ%K=\(;H'[9_
M:S_9'0/N64Q^9PPX.W9U[UZM10!YQI6D:B/%9;3M&U#1;"Y-P=5CFG1[:5V4
MA7B4,3N+8).%XK/\.^%+BSCTK1]3\.ZO<26%PC&Z.K-]B 1LK*D9DZ]/DV"O
M5\C.,\T4 <SXULXK[3[6*;1M0U%4G$J/ITRQSVSJ#M=2S+SSCK7)7&@^(I[/
MPUJ>K6VJ7<MBUU%<06EX(KORI"/*)='4,0$7< W.?K7J=% 'G^E:#)!J6A36
MN@7=G;'4;F]NC>78GE5C 45W)9CEN.A.,<]:/%/AG5K_ ,5QI8+G2-86)-5/
MF;=BPONS_P #7Y./QXKT"B@#@-:\-:IJ\?C:V@@$)OA;?9&E8;)O+0$@XZ D
M;3GUIVO3:KXS\(:CI\7A_4].O(O)F"W1C197219"D;JQR3M(#$ 9KO:* .(\
M(6*3ZY-K$FF>(;:Y2U^RB;6)E8E2X8JJAB<94'/%0:KJ,^E?%1[N/2KF_B&B
M1I(+10\L>9WP0I(R,CG'/0],UWU5!IMLNL/JH0_:WMUMRVXXV*Q8#'U8T ><
MV7A_6Y;_ $?4KO3&@>X\0S:C-!N#FVC:'8N\CC/R@\>HK:N!?>&O&^JZK_9%
MYJ=IJT,*QO9(KO \:D%&!(PIR"#ZYS7;T4 >7R^'];TWPQ9Z];Z=(=<M-3GO
MTTY'#;8YW(>$8XX5@WU!K5T_PY<:-JG@^!;=Y1;V]Y]KN$7Y5FD5&+'TW-NQ
M7=T4 >-3V'B&#X9R>"E\.7LU];S@27:X\F5!.)/,5B<L3QD=1R3TK6U71;NR
M\8:_<7-GKUQ9:L(WA.D2?*=L8C9)1D8/'!/&#[&O3Z* .'\(Z%-I/BW4W6SN
M(;$:;8V]NTQW'Y%8%-W<KP#6/H<]UX>U)I=/L]9L/"UO:SW%[::I$JK;L!N4
M0-DGD[LC) ]>:]0J.>WANH'@N(8YH7&&CD4,K#W!ZT 1V%RU[IUK=M"\#3Q)
M(8G^\A8 [3[C.*\IM[;5[[X;:;X-/AF_MKV0Q1R3RPJ(85#[S+NS][ SCKDU
MZ\  ,#@44 >7:M;ZKIZ>.]-CT/4;QM9WO9S6T8:-@\ 0[CGY2"#P>3V[5KK%
M>Z=K'@RX?3;V:.+3)+2<PQ;O(=Q!C?Z#Y&R?:NZHH P/%5@^H1:3&MN9UCU.
MWED &=JJ2=Q]AQ7/^(+*]L/'_P#;0M]6FLKC3EM@^EH'>-UD+88'^$ANH[BN
M_HH \_\ #N@-IWBC19;:RU".Q32[K)O0I>*22='VL5X!^]P.U9VH:#J7_"LO
M%UI;Z?,+Z[U2YGBC2/#R@S@JP]?E P?05ZC10!Y/XTB\2ZD_B;3Y(=:F62(+
MIEK8QJ+>2/8=S228R2#GY,@G@ '/%[Q;HFIWNB^+(;:QFEDNM.L8H%5?]8RL
M^X#W&1FO2J* .;OK6Z/CK09XK9C:0V=TDLJIPA/E;5)]\'CVJEXRMKV+7_#6
MMP:?/J%KIT\WVBWMU#2#S$VK(%/7:0??FNQHH X/6);R^UKP[XGAT;47M-/D
MN(I[22#%POF*JK*L>>0""#WP36)X@TC5-?M/$>HQ:1=1PWUS8116LT>))5AE
M&^5D[ @XYYPO->KT4 <H=/NC\65U'[,YM!H9A\_;\HD\\';GUQS7/^'=$OHM
M5\)R7&F31I8C5-[21\1%Y04/MN4G'MFO2Z* /,IM"U$^#_B' NGS?:;_ %"Y
M>V41_-,A1-I7U&=V/QJ]=:-J-SHWBZUCM)#-=Z5## I&/,<0,I )XZG%=_10
M!P6HWDD]SX-U]=.U'[+:R2K<Q?8Y#-"7A9!F,+NP&XR!COR*PKK1IH+[Q+I>
MKR>)I(=1NFGB73+5'BN8I !M+^6=K+@@[F48 Q7K5% 'FFV[\-:IXNAFT+4-
M0_M,+)9RV\!E6=1$$$3$?=V\_>XQG'8'LO"-M-9^"]"M;F)HIX=/@CDC<8*L
M(U!!'J#6S10!Y*VD:C<>&-?TB/3KE[RWUU]1\B2%ECNH?.$@5)"-K9'8'.17
M2QW$WB7QIHNH6FFW]I::;%.9[B\MV@+F10HB"M@G!^8G&/E&":[6B@#GM8LC
M<^,/#DYMVDCMQ<L9-A(C8HH!)[$\@5S[Z1+'X;^(R1V$@FO)KIH0(CNGS:IC
M;QEAO+8QWSBO0:* /+O$,NO&2YL"NM);'2XULX--LU;[1(4(<2R,I"A<?=.W
M@\9/6&;2]4?P_?(]C=M._@JWM\&)BS3 2Y3IR_(R.O->KT4 <KJ=C-#XR\)?
M9()?LEO'=1R,BDJB^6H4,>W(&,]Q7/G4=:T_PE<V&FV>H6][!JTHNI18N[1V
M\MS(QEB!&)3M(X7)&>E>E44 >*7>EZM=Z7XV9+36;D74VF-;27MOMEN%20;F
M"JHZ 9Q@$#&0#7?:3I\@\:>,9YK1A%<BU5)'C^64"$@@$_> )P:ZVB@#S"PT
MR_33=,5K&Y5D\&/;L#$P*RXC_=GC[W!^7KQ5VTTF>/PK\/(Q8S+-:7%LTZ^4
M=T/^CR;RP_A^8C.>YKT*B@#QW6[EM*^&_B?0=2TJ].H-/<RF<6C-#.'D+K+Y
MH&P84CJ005QCI7K"VS1:6+53N98/+!Z9(7%8EQX-BOKIS?ZQJEW8//YYT^>5
M#"6W;@I^7<4!QA2<<=QQ72T >>:+$^H:;X$AETZ\C?3)!%=)/:R1^4Z6CJ#E
M@ 1NQAAQDCFL_P 1Z'J]_/XZ2VM[HPRS6$\**IQ<!$4RA 1M8D*!W!( ->IT
M4 <;X=2UU#Q$NJK+K\ETED8"=0L1;(BEE;9_JDW-D=L@8-&M22Z3\0;+6;FQ
MNKG3FT][59;6W:=K>7?N)*H"V&&!D#J*[*B@#A)+R/3_ !V=?NM-U">RO=,C
MAM;B*PE=[<J[%XVC52Z[MRG)'\.*Q-#T2^;5?#MU<Z9/':RZYJ-\D$L)_P!%
MB>-S'N&,(=P!'N1WKU:B@#S3Q1I=[)IGQ!CMK&X;[5]F:!8X2?.;RTW%0!\Q
MR.<>E6O%&C:GJ?B/Q#%812*UUX:6WAF(*HTGFR_)NZ9P1^=>@T4 ><6-VFH7
MW@>WL_#^H6HL'8SO/9/$+4?9I$V;F49!;'(..%SR17/+H5X_]I>&M9U+6K<7
M.J-.L5II@E2X5I0ZRB8(<8^7.YOEQCVKVBB@#BX=&!L_'+O8,9KZ>506C.9T
M%N@4#U&2P&.^:H6GG:9K_@Z[OK>[6-M%-DSB!W*3MY)"OM!*]&Y; X/I7H=%
M 'FMS)KNGZ=:V]K%>6EM<:UJ!N[N"S,\T$9GE,;*F"<-G[V#@'/>LK0]/U-K
M6R,EGJ9"^,FN1]KA(E$)A8^8X P 2W)&!DUZ_10!Y?JNFWP\%7Y^Q7!,7B62
M[9!$Q8PB[+;PN,L-O/&>.:7Q8LZZY'-I7GB/Q;:IISGRBIC=6'[UE;!'[EI>
MW&T>N1Z?60F@1_\ "1MK5S=W%S*J%+:&3;Y=L& #; !G)VC)))ZCI0 FKI/I
M'@^\CT6S$LUK9,EI;XW E4PJX/7H.._2O.+6'5]0UE;N<ZS>NVA7<,DUSIQM
MHTD*H1$B; <YSR<YXP3@UZ_10!PLNE26J^ 4M+&2-;.8+*(XB/)4V[AMWH"V
M,YZFN7D2>U^'>J>%[C0;R[UI;N61E6U9U??*76<28P?E/'.[(QBO8J* ,[7H
M+:Z\/:C;WL4\MK+;2)+';J6D92I!"@<DXZ8KS"]@U_5?"&NZ#I\EWJ6F06EN
M]E=36;02OMD!:## >8=BXSCV/6O8** /([O0[OQ#9ZQ=6.I:IJ&HR:0;2,76
MG"TCVF16,8.U<O\ *P]MU;VNZQ%KW@>X32]-U(36;VDTEK)92QL@CFC=D&Y0
M&8*IX4GI[BN^HH \WU2_D\0ZEKLMAIU^;7_A')X89Y+9T%Q(QSM0, 3V'O6C
M;Z;-!X,\&6T=I*KV\UDTT8C.8\)\Q8=1@YSFNWHH XFTL(K[5_&6A:A;SJFH
MRB5&,3;'B:"./<'QC(96XSGBJ_@%KW6[R76=25EGTZ#^QT!.0SQG]](.?XF"
MC_@%=IJ-K+>Z?-;07LUE)( !<0!2Z<]MP(]NG>FZ5I=KHVF0:?9H5@A7 R<L
MQZEF/<DY)/<F@#D]:8:%\0X?$6HV]Q-IK::;2.:"W>;[+('W'<J@D!@0-V.V
M.]8$VE7DND:KJ$-A<P6VH^(K2YMK5HB'""2,-(4QE=Q!;![>E>KT4 4=9TJ#
M6]%O=+N<B&[A:)B.HR,9'N.M>86-KK?C'PWK]ZZL-4M=/;18/GV[Y4YG8$==
M[!0#[8]:]3U&UGO;"6WM[Z:RE?&VXA569.>P8$<].G>H](TFUT32X=/M WE1
M#[SG+.QY+,>[$Y)/J: ."^U1>(X_"5CHFG75I-IM[#<7*2VKPBSBC5E="2,9
M;[H4$Y^E8TDD]IX N?"S:??R:K'JP9TCMG91']L602;L8*D$8QSD], D>R44
M <KX>L5B\;>,+UH"LDUS;(LA7[R+;1]#W&2:ZJBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** .:\7WMO92>'A/8QW7GZQ!#'O8KY+E7Q(,=2,'@^M8]_XUUV&
MTUC4;71+=].T>YEBN&EG*O*J,,F, 'H,DYP.PZ5TNO:-+J\ND20W*P&PU!+Q
MLINWJJNI7VR'ZU2N?#$\WA?7=(CO%235)+EA*8\B,3$Y!&>< D4 8&JPW^K_
M !.T>26VTR72[:Q:ZC2Z8L0"Z9D"[<"0<8Y_$5,/'.M#13XG?1(!X=#;N+@F
MZ,&<>=MQMQWVYSBNA7P^X\0V.I&:)HK?3VLGC:/);)4Y!SP/EZ>]<^G@35CH
M9\,2ZY WAW)78ML1<^5NW"/S-VW';.W.* +4_BW5Y->U2TT_2[233M+,3W-[
M+<D;HVB$AV(%.6 )[XZ>M9L'C_7_ +!HFH7'AZW,&M 16<,-V3)YK+N4OE0%
M0X)R,D#\JZE/#WEKKZ),JKJF-BA.(@($BQ[_ '<_C6<G@Z1=+\)V?VU,Z%)&
M[-Y?^NV1E..>,YSWH 6Q\1ZR\6MVE[IMDNJ:9Y;!4NRL$J."5;>RY7&&SD=O
M>L&^\;ZM<Z!XGM83I8U/3K#[4MS8W9DB\ME;)4[>'4KT.,Y!S6QKG@B?6O\
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M8(9&,,,$,N_ 8J"6.6/0"@#47Q'IFDZMXMN)OMH-E+;"8%S(LCO$NQ8D[$Y
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M;"+S=8N;J6U^?@B2%47=Z<@U/;^'K^/QA::FPC^S1:";!OFY\WS%;IZ8!YH
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M[I%>DT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG4;$.<X'/W1GK6CJ6M^*!'XEO[*XL8[/1)F*0R0%GN%6%)&4MN&WJ><'K[4
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M:7Q3=Q^%_$VJ"&#SM*FN8X5P=KB(9&[GOWQB@#K*B2Y@DN9;9)XVGB56DB#
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M+J)%?,6 -CHPVL. ?8C(KIJ* .6B\#VPAA:>]N+B]&HQ:E<7;JH>>2/A00
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MGTH Z2RO;;4;*&\LYTGMIE#QR(<A@>XK+O?&'A_3K]K*[U6"*="JR Y(C+=
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M?Q6]V)GR(8V9QN)X )"9&>U%O>1^(?&6A7FCV%U#:V$,PNYY[-K<!&3"Q#>
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MMC$KH\>(X<D D[OFP,XV]LTW1M*C@\!^!62R$=S%<VKDK'AUW [R>_.3GZT
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M_4[738WCOY[7"Q!L-V+)D=R,BL.^\3Z,OA"\_P"$?TL2S6MM&KVTNG/B&,L
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MLSB3'<#) P,_AVH [NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7@D4D)YK'*J3N95!P>F,>U=C#XRT]SKIE#11Z1&L\CD@B2%H_,5U]B,C'J*
M.BILD:2QM'(BO&X*LK#(8'J"*J66H->:)!J)M9HVEMUG^SG!D&5SM],]JP['
MQBTVJ2:;?Z3/878LFOHXWE1]T8(!!VGY6Y'!_.@#IXXXX8DBB14C10JHHP%
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M4K>^MH$DB-P(9(I(U*_>((92#^!KLZ* .9MM&O\ [=XHFF2-/[32(0X?(R(
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MLXIQ'Y415SY$A0'*9PAQC!&<?-NKJ)/A]H<MU+*_VWRI+L7IMA=N(1-G<7V
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M5 ![Y(/]*TWT"VDFT:5I[C.DDF$!E <F(QY<8Y^5CTQS^5 '"^#-8N-(T31
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M5S!</ [1HZQRXP0Z!P&VD$=>^:AN?!\!31VTZ\ET^ZTJ$V]O/$B.3$5"E&#
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MR.1T_.M/2_#L]OJPU?5M3;4=16 V\<@A$*1QDY.$!/)(&22>G&.E &_1110
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M<*QV]QY#NS,,#S,C:/4YZ9KS]M0U;0-#\9PV9_L][467EPI?M>"T$C%9&#N
M0=HW8[=: /8Z*X#Q5!#X9\&O+H][=1>>]O;SWQNWF:&!G :4;F(!P3R/7VX9
MXDL[;P[I%C#IM_>0VNH7]M;7UT][)*8X26^8,S'9NX4L,=?I0!Z%17E^O[O#
M^LW]AHM[=M;S:!=SW4+73R_9W1?W4H9R2I.2, CIGM4M[8#3](\-6K:E?1QZ
MU=0IJ5ZUTX>3]TS!0Q.(PS #"XXXH [J#5XY_$%YI B826MO%.TA/#"0N !]
M/+/YUHUY4EQH_A37?'4RW=W-:06%HLB"Z=Y(I&,BB-9&)93EE.<_*6[8K-EO
M=5TNX\6V6R;3E'APW:0#5'O&BD!8!@[<HQ!Y ST!S0![/17 :=;2:1J_A&6W
MOKZ0ZI'(M\+BY>83'R#(&PQ(4AA_#CJ12>#[7^TM#_X26\N[VZUEYIG,)O'5
M(75F40>6&"X&,<@YZ^E 'H%%>1>%&\2:HF@ZY%)"&N+D->W4FL.XG0YWQ?9R
MH5&7L >-G>NU\;W$VFV&GZS%,\<6G7T4MR%<J'@8F-PW." '#<_W: .HK*?Q
M!:6UI?7=_'/86UG/Y#2W*;5DY #)C.5)8 'N:\O77-8N!/9RW\ZGQ7+#-IN9
M"&@B:8JZKCH!"$/'<^]3^+(!>^ /%+7$D\GV37E6',[_ "KYL*XZ\C!/!Z'G
MKS0!Z6NN6S>*)- $<OVI+-;PO@;-A<IC.<YR#VK3KS>7P_:W?Q8-@T]XEG!H
M$1\N.ZD5G_?OC=)NWD#KU]/2ND\!3W$_A"V^TW$MQ)%/<0"65MSLL<\B+D]S
MM4<T =)17EQD.K^%/$GB2]U.]M-3LI[E85CNWC6S,1(CCV9"DG"D[EYW?2M/
MPCK%_=^)=0FU6=XEDT6PNQ%(Q5$+(YD95/ &[()]N: .^HKQ^PDU'Q#:_#JR
MNM:U.*._M+N2\:"Z='N-@0@,P.3WYZ\FNW\:W]SX9^'U[<:;(ZS6T,<4<TA,
MC("RH7.>6(!)YSG% '4U0T75H-=T>WU.V21(9U+*L@ 88)'."?2N2N(3X9\4
M>'$TS4+VXAU-Y8KJ.YNWN!(@3?YHW$[2" ,C PU<WIRRZ=\)+/Q#IVLWOV^%
M]T$8N&,,K><5$'E9VD'..F<\YH ]#7Q5:/<ZI!':WLLFG7,5M,L4/F$F0*0R
MA<G: W).,8-;M>66]Q?6]UXMNP6MI9-?TV+,;D<%X RY]U;!'N15V9I]>;QE
M>76L:C8_V9(]M;1VUTT"PJD8?S"%.&+$GEL\#M0!Z-4,UW;V\UO#-,B2W#E(
M48X+L%+$#UX4G\*\S?5)=6T'PSIH75[[5)-%COIA;:A]E4J0@\R20D$G<#@<
M]3FJ>F"7Q/IWP]U'4;Z_%S<2S02/%=NF=D4X#?*1ACMY8<D<=* /4[._6\EN
MHUM[F(VTQB)FB*"3@'<A/WEYQD=P:MUYQJ.KWZV>N0?VG/;++XEAL!<!OFMX
M72#<$)X7[S<]MQ-/U2>Z\.>)&TNQU2^N+>ZTBZN)(KFY:5[=XP-DBNV6&<D8
MSCC.* /1**\]LUOM&N?!MT^L:C>2:F?(O%N)RT<FZ!G#!.BD,HQMQQG.<YH\
M*37^F>(HM-\2OJ3ZM=+,\%S]M:6TNE!W'9'G$9"D<$=._- 'H5%8&H7KP>.-
M"M3<,D-Q:7F8M^%D=3"5X[D OCVS7*3WNHWNEZBEIJ]S!*_BD6B7$<FXQ1[D
M4JH.1@<\8QGM0!Z55.\U*&RO-/M9%<R7TS0Q%0,!A&\AS[80_CBN$U2^U'P;
M<Z]%8WEY?)'H@OH5O9FG:.579"02<X(()'3Y:2+3!8>(O \[:_?W\MU)*[QW
M-P9%E/V64^:@/W0-V,+QAAZ4 >D45Y!I%]XQ\00#6;."^6<ZBWSG4D6W$2R[
M3$8#Q]T$9ZD\YKI_"%O?:EKVO:C?:IJ+QV>K3VUI:F8K"$ !S@?>Y8@9R!MX
MH [BBN(\:7?VK6]/T2VCU:YO&@DN3;6%X+50@90'DDR#P00 .,GD=*YC1]5U
M;Q!<>";6]UN[M_MEK>K<FVGV&X,3A5^8=\+]X<]<8S0!Z]3)I5@@DF?.V-2Q
MQZ 9KRG5M3U32KG6]%M=9O!;6=_IQBO)I#))!YT@WQLY^\H&#@YX.#D5L:MY
M_A_Q1IVGVVI7MW#J=C=K=07=RTI7RTW+*N?NG)((& <\#C@ ZC2?$=MK-MIE
MQ;6MX(=0MVN(Y&A^5 ,<.P)"L<\#O@ULUY9X5U.[L-&\)^099(U\.W4YMD;B
M5T,6WCH3R0/J:W/#4:#PI%XJU'7M0N99K-KN=UN&,,0*EF"1<J-G('!.10!V
MDLBPPO*V=J*6./053T758-=T6SU6V25(+N)946488 ],@$UYSHU[?IXCMXW;
M58+&^T>XECBU'4EN6F*["LFP$[#ACWY]!@U5TP7&D?"_P[X@@UC4#?AK2..W
M:Y8PRJTBQ^5Y0^4C83T&?ESG.: /3=(UNUUIM06V60&PO'LY=X RZA22.>GS
M"M*O'9=3U&PTKQ#;Z8)A+J'C"2S:6&41/&K(GW7(PI. H)Z;O6NR\'6WB"TU
M+4TU.&ZBTZ18WMH[N_%U)&_(<!NNT_*<'OF@#H;35[:\U;4-,BW_ &BP\OSL
MKA?WBEEP>_ J_7G5WJ5MI6N^/KJ[N+BWB\NRC$EMCS0SQE5V9XW9(QFL99_$
M37?B72HCJUC+%I4=_:P7&HFXF617;HX)P&"X*Y(H ]>HKR*X^(%]%?S>)4N&
M_L&ZM'M;.'(Q]I6$2@CL6+EX_JO>K=W#KFAPZ?>>(+G6+C1H-.B^TW-G?-&\
M$^29'D4$,XY X)P!TH ]2HK$\6:E;:5X8N[JZFNHHRJQJUH0)BS$*H0G@$D@
M9-<!'J6NVNG>-+&2:]L7MK:VGM5GO?M,UN9-P/[S)_N [<\9/K0!ZU5/4M2A
MTJWBFG5V66XAMU" $[I)%1?PRPS[5R$[77A?Q990QZC?WT=UIEW+,EW<&0&6
M+RV# =%SN887 YZ<"N?BLYK_ ,*>%?$5YK^H3WEWJEE-+"UR?(D+SK^[$><#
M;VQS\M 'K=%<G\3+ZZTWX?ZC=V5U):7$;0;9HVVE,S(#S]"?PJC*LOAWQGH<
M,6LWUU!?PW'VM+NY,BX1-XE /"<\?+A><8H [JBO)K:\U:Q^'&B:LVN7TE_K
M,MI;3W<\FY;:.1@"RH?E! _B/))))K=NK>32/&6DZ#!JFI36>KVMQ]H6:]D>
M2(Q!2KHY.Y"=Q!QP<4 =/HFO0Z\EQ-:VURMK%(4BN)% 2XP2"T>"25R.I K5
MKQR*?4=+\*>#M+TE[Z4ZPY:?%\4?:B;O+C=N(]WM@\<=:U#8>.CH-U;^7=JL
M>II-'"-34W,EKM):$3=B&VG)()!(S0!Z?53^T8_[8&F^3<>;Y'G^;Y1\K&[;
MC?TW>W7%>?S7-[J6AZ;<Z$=<N].M;F=-3M?MICO4<<;=Y.6V'/RAN>.>,5:M
M_$:I!_:&DWUS>V47AV:ZA^U.Q,CH_!?/5N"">M 'H-%>9!K_ $[PKX?\31:[
MJ%U?W<UJ9X99]\-P)V4,@C^ZN QQM (V_6J3OJLWA[QMKO\ ;VIK<Z9J5V+.
M-9R(HUB.0I7HP/3!S@=,4 >M5GQZS:2>()]%4O\ ;(;=+E@5^4HS%1@^N5KA
M/&FI7=Q<:K_94FM-=Z98)-(UK>+;V]LQ#."P/,A( )!## QP:O>&=0EOOB!<
M3SQQA[KP_93[AU&6<D?FQ_(4 =[1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A52P8@$C
MH<=*8UO"Z.CPQLK_ 'P5!#?7UK/UCQ#I^AF!;LSO-<%O)@M[=YI'V_>(5 3@
M9&36#J/Q M[37=%L8=/OYX-0B>625;*;<@"@KA=OS')PP_A[T =;%;000""&
M&..(#'EH@"_D*R-=\-P:IX;N])LA!8^>58.D(V@JX;)48STJ.7QIHT.K_P!F
MRO=))YXMO.:UD$(E/1/,V[<D\=>M077Q \/6D]Y%)<7#-93F"Z,=I*ZP'CEV
M"X5>>IX.#Z4 =%%:V]NSM#!%&SG+E$ +'WQUI+BTMKQ%2YMXIU4[@)4# 'UY
MK+U?Q5I.B-;I<S22RW"F2.*UA:=R@'+[4!.WWZ5A>&/&J2^#%UK5[EYQ+?30
M0M!;EVD D8(JH@R?E'IVH [&:TMKB-8Y[>*6-2"JN@8 CI@&E%M;B)XA!$(W
M)+KL&&)ZDCO6%)XX\/PZ"^LS7K16<4_V>4O"X>*7.-CIC<IYZ$5&_CW0D@MY
M ]X[W+.(8$LI6F<*<,PC"[MOOC% &_#96MO&D<%M#$D9+(J1A0I.02 .AY/Y
MT]8(DEDE2)%DDQO<* 6QTR>^*XCPUXZMY]&U+4]3O6F@.LW%I8>5 6>2,',:
M*B+N8[?;/K78:9J5OJU@EY;"81.2-LT31."#@@JP!'(H DNK*TO45+NUAN%4
MY EC#@'\:;<:?970C%Q9V\PC^X)(E;;],CBFMJ=FFK)I;3@7LD)G2(@_,@(!
M(/3@D<=:S[OQ;HEE;O-+>YVW+6@2.)W=YE^\B* 2Q'L"* -CR8O-67RT\Q5*
MJ^T9 .,@'TX'Y4S[':^5+%]FA\N8EI4V##D]21W)]ZR8/&&A7&GK>I? 0FY6
MS(:)U=)F. C*1N4Y(Z@5H+JED^KR:4LX-]'"L[Q;3Q&20#G&.H/>@"PMO"K2
M,L,8,F Y"CYL# SZ\4@MH D*"&/;#@Q+L&$P,#;Z<''%9NK^*-%T&XBM]2OE
M@FE0O''L9F< @':%!).2.!SWZ U6O/&_AS3[E;>[U1(I"$9MT;[8P^"N]L83
M.1]XB@#3?2-,DG,\FG6CS%MQD:!2Q/KG&<U9-O"RRJ88RLW^M!4?/QCYO7@
M<]JR-8\6Z'H-PEOJ-\(IGC,H1(GD(0<;B$!VCW.*9J?C7P[H]U]FOM4CCF"A
MW549_+4]"Y4$(#G^+% &O%8VD$HEBM8(Y%B$(=(P"(QT3/\ ='ITJM!H6D6L
MDTEOI5C"\X*RM';HID!ZAB!R/K4.I^)M&TB"WFO+Y%6Y&8!&K2M(,9RJH"2,
M=P,5"WC+PZNFP:BVK6XLIYC!%.2=K2 $[0<>Q_E0!=LM$TG365K#2[*U905!
M@MT0@'!(X'? _*E@T72K:3S+?3+*)_-,^Z.!5/F$$%\@?>P2,]>361<^+M.N
M_#.HZEI&JVB&S&));J)]L#9_C3A^G3UJQ?>,O#NES/!?ZS:03Q@;T=\$9&>E
M %V70M'GU!=0FTJQDO5P1<O;H9!CI\Q&:MI;0)<27"0QK/*%620* SA<[03U
M(&3CTR:R]2\5Z%I$T4-_J4,$LJ"14;.0A_B8 ?*ON<"M;S8_*\WS%\O;NWYX
MQUSGTH S[CPWH5W#!#<Z+ITT5NNR%)+5&6-?101P/I5_R(?L_P!G\I/)V[/+
MVC;MQC&.F,=JS-*\4:)K=RUOIVHQ7$JIOVKD;EX^921\PR0,C(S3+3Q=X=O[
MN&UL];L9YY_]4D<RL7XS@>_!XH MV.AZ1I8D&GZ58V@E&)!;VZ1[Q[X S3-/
M\/:+I-Q)<:=I-C:3RY#R06ZHQ''&0.G XK-\2^,='T.RU")]6LX=1AMW>.%Y
M!N#[25!'N<<>];>GSO<:9:W$A&^2%'8C@9*@F@"M:^'M$L;PWEIH^GV]T<YF
MAMD1SGK\P&>:2W\.:'9WB7EMHVG0729*SQ6J*ZYSG# 9&<G\S3+#Q/H6J7AM
M+#5[.YN "?+BF#,0.I [_A2_\)+HG]K?V5_:EJ;_ '[/LXD!?=C.,>N* +R6
M5K';R0);0K#(69XUC 5BQ)8D="222?7-5--\/Z-HTDDFF:79V;R<.T$*H2,Y
MQD#I[=*2+Q'HL^K'2X=4M9+\$KY"2 MD#)&!W !HM?$6BWNI2:=:ZI:37L9(
M:!)06!'7CV[^E %R2SM9;@7$EM"\PC,7F-&"VPX)7/7!P,CVIITZQ:*VB-G;
MF.T96MT,2XA*C"E!CY2!P,=*S(O&7AJ>XAMXM=T]Y9B%C5;A26)Z#KUXZ=:@
MM?&VCW?BV[\.)<(+NW" $N,2.=VY%'JNWGZT ;EY96NHVDEI>V\5Q;R##Q2H
M&5A[@U6LM"TC389H;'2[*VBG&V988%42CD?-@?-U/7U-9_B/QCI/ABYT^WOY
MT62\F$8!<#RU(8^8W^SE<?4U73QIIMOK&I6VI:E8VMO$T/V9I) I=7C#$G)Z
M<]>* -2S\-Z'I\,\-GI%C!%<#;,B0*!(O/!XY')XZ<T6OAK0K&VN+:UT>PB@
MN1MGC2W4+*.<!ACD#)P#P,T[4O$.CZ.L+:CJ5K:B8$Q>;(!O QDCU'(Y]Q6?
MJ?C;1-*U73;"XO8-U^&97$J[44+D,?9CP* -"T\/:/8V4]G::9:06]PI2:..
M(*)%(QAL=>#CFK%UIMC?6!L+JS@FM"H4P21@I@=./;MZ4ZYO[2SEMXKFXBB>
MY?RX5=@/,?&=H]3@&HVU;3D^V;KZW'V( W.9!^Y!&1O]..>: *]OX;T.TMIK
M:WTBQC@GC$<T:P*!*HSPW'S=3U]34=MX5\/VD4T5OHUC&D\1@EVPJ/,C/56/
M<?6I+SQ)HFGW$-O>:M9V\TP#1I),JE@>AP3T/K3?$^ISZ-X5U74[81M/:VLD
MT8D&5+*I(S@CB@"\UA:-):R&VBWVF?LYV_ZK*[3M].#CZ52'AG0UU4:HNDV:
MWV[?YXA4-N_O9]>>O6F:-XBTS5DB@AU2PN+X0J\L5M<*^#CG&"<C.:EMO$>B
M7MZ]E:ZO8S729W11W"LPQUX![=_3O0 RW\+Z#::F=2M](LHKPL7\Y(5#!CU(
M]"?7W/K6A=6MO?6DMK=0I-;S(4DC<95E/4$5%_:FG_8X;S[=;?99BJQ3><NQ
MRQP K9P<GIBHGU[2(]2737U2S6^8X%N9U#D^FW.<\]* 'G1]-:>QG-C!YE@I
M6T;8/W ("D+Z< "B31]-EM+NTDL8'M[MR]Q$R K*QQDL.YX'Y5->7UIIULUS
M?74%K;J0&EGD"*,\#)/%0:=K6EZN)3INHVMV(3MD,$JOM/;.#0 6>C:;I\R2
MVEC!!(D(MU=$ (C!W!<^F23^-3VEG;V,'D6L*0Q;F?8@P-S,68_B23^-5;77
M]&OKK[+::M87%QS^ZBN4=^.O .>*O2RQPQ/+*ZQQH"S.YP% ZDGM0!EW7A;0
M;W4?[0N=(LY;O()E>$$DCH3ZD>I]!4FI>'=&UF>*?4M,M;N2(%4::,-@9R1S
MU'M2P^(=$N+.:\@UC3Y;6#'FS)<HR1YZ;F!P/QIT&NZ1=64U[;ZK8S6D'^MG
MCN$9(^_S,#@?C0 L&B:7;-9-!801FQ5TM=J >2K?>"^@.!5V2..:)XI45XW!
M5D89# ]01W%4;?7='NY9XK;5;&:2!2TR1W",8P.I8 \ >]9F@^.-"U^RDN8+
M^VB"3M"8Y9T#9#%5. >C8X]: +^G>&]&TF0R6&FV]NYC\K<B<A,YVCT&>U5;
M/P5X9T^XBGM-#L8I8FWQLL0^1O4>A]ZMMXCT-;%;YM9TX6CL46<W2>66'4!L
MXS[5FZYXD>SN/#ITZ2VN+;4]06V>0'>"A1FRI!QG*CGF@#470=*7[1_H,)^T
M72WDH89W3#&'YZ$;5Z>E<CXH\,:CK.HWGD^'=%=YU\J/49KALJF ,R1!<.PY
M*Y)' KO)98X(FEED6.-1EG<X 'N:HP:_HUU:S75OJ]A-;P<S2QW*,D?^\0<#
M\: ,^3P3X?NK#3K6^TV"Z^P0);PO(N&V* ,''4<=#Q5M_#&B2:5;Z8=-@6SM
MGWP1("HB;).5(Y'4]/4UHO=6\<D,;SQ+).2(E9P#(0,G:._ )X[57M-9TN_N
M);>SU*SN9X?];'#.KLG./F .1SZT ,ET/2I[2[M)M/MI+>[?S+B)HP5D; &2
M/7"K^0IMIX?TBQ2=;;3[>,3IY<I"<NF,;2>N.3Q4MEK&F:BY2QU&TNG""0K!
M.KG:> W!Z>]9_P#PEVCOK5YHT=];F_MHU?RS,GSL=^449R6782PQP"/6@#3?
M3;*3[)OMHS]C8-;Y7_5$*5ROIP2*HZ5X4T'1+IKG3=+MK:=E*^8B\@'&0,]!
MP.!4?A[Q+8ZSIVG;[VR&IW-G%<RV<<RETW(K'Y<[L<]ZT)-6TV'4$L)=0M([
MU^4MVF42-]%SDT ,U31=.UJ**/4+5)Q$^^,G(9&]588(_"F6GA_2+"T6TM-/
MMX;=)Q<+&B8 D'(?Z\#FKT\\-M"TT\J11+RSR,%4?4FD>X@CF6%YHUE=6=49
M@&*C&2!Z#(S]10!%)IME-=27,MK$\TL'V=W9<EHLD[#[9)XK,L?!OAW3+VWO
M+/2H8KFWW>3("28P000N3P,,>!QS5VVUW1[RZ2UM=5L9[AUWI%%<(SLOJ #D
MCWJ0:OIAU'^SAJ-H;[&?LWGKYF/]W.: *#>$/#[ZG_:)TN#[29!,6&0ID!R'
M*YVEO?&:U+:SM[,2BWB6,2R-*X'\3L<D_C2&^M%AN)3=0"*W)$[F08B(&2&/
M; (/-4)?$VDP:]#H\EY"MU- TZYE0# *@+USN.\$#'(!H =JOAK1M;N(;C4=
M/BN)H051VR#M/521U4^AXK U#P#8W6OZ&T5E:IHVGP7"&W!*E7D*LI3'3D$Y
M!!&:UM$\36FH6L(O+JS@O9IIXX[?S0&<1RN@(4G)X4&M&]UG2]-DCCO]2L[6
M23[BSSJA;Z GF@#$UCP?:3:!;Z3IEI;16ZW]O<S1R9(D5959]Q.2Q(!'/6M*
MP\,Z+ICSO9Z?%$\Z>7(_)8I_=R3D+[#BK=WJFGV S>7]K;#89,S3*GR@@%N3
MTR0,^X]:I#78+07<VKWVEVELESY,$OVL88;0P#%L!7Y/R\\<T 6++1--T\68
MM;2./['"T%N1DF.,D$J">QVK^55[3PIH5A++):Z;#%YJLKQKGRR&^]\F=O.>
M>*L0:]HUU9S7EOJUA-:P?ZV:.Y1DC_WF!P/QJ6+5=.GL#?PW]K)9J"3<),IC
M&.OS XH H6/A+0--F2:TTJWCFC1HTDP694(P5#')VX[=!VJ.R\%>&]/N+>>U
MTBWC>VQY/4K&0,;@I. W^UC/O3=/\30:IXHETZQGM+JR6Q2Y%Q!('RYD9"N0
M<<;16F]W,NM16H-KY#6[R-NFQ-D,HX3'*\\G/!QZT 0'PYH[6E[:OI\+V]].
M;FYC<;A)(<98@]_E'3TJ32M#TW1(Y$TZT2#S"#(V2S/CIEB23CMD\4ZWUG2[
MNY6VMM2LYIWC$JQ1SJS%#T8 './>JFC^*-,UN]U"TLY@9K&<P.&9?G( )9<$
MDK\V,\<@T 3W'A_2;O\ M#[38Q3#4%1;L2#<)0@PN0?3VIFF>&M&T>5Y;#3X
MH99$\N23EG=<YPS')/XU8M]8TR[6=K;4K.809\XQSJWEXZ[L'C\:(]8TN7S_
M "]2LW^S@&;;.I\H'INYXS[T 5%\*Z$FDVVE#3+?[#:RB>& C*HX)(8>^2?S
MHOO"NA:G?F]O=-AGG8*'+YVOMZ;ESM;';(-6HM9TJ?3WU"'4K.2R3AKA)U,:
M_5@<"I(=2L;BT2[@O;:6V<X29)59&^C X- !J&FV6K6,EC?VT=Q:RC#Q2+D'
M'(_6LU/!WA^.WNH%TR(1W:QK<<L3+Y9W(6.<D@GKUJP_B/1UTV[OX]2M)[>T
M!,S0SHP4@9VDYP#[&H[37(]2DTR6QEM'M+N)Y'WSCS00JD!5&02-WS<\<>M
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M>VUJL=Q]G2VWACQ$GW5 S@ 5H44 %%%% !1110 4444 %%%% !1110 4444
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M7MOK(GF620VDA29RS'SQ(%V[3UR3GMZ5WU% ' ^#KQ+;PK:^&?L5Y::S!#)
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MW4Z3QQ@.J[F5 QRY&0.W)I#X[2ZU2SL-&TJXU*2\TY=1B=)$C01EBN&+'@Y
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MXC\Z1-8&ZW"J,JNPNS,">  .>O453L?'%I?36<@T^^BTV^E\FTU"15$<KY(
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MS7M7=V6.SOM#%@L@/*R>8[=/3#"LC3/"5PEJL4OA+3[6\BLY8OMR7F[,AC*
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M'LHX-TT,8.,N <#)Z#.3VK#TWPJT7V.:VT%].QJZ74R7%^;F1XUB90[%F;#
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MYE9YXY#-+L*JJ;"3M^8G+8SZ4 -L]5=M4\&I#JEU<V][#=EGN,*]P0JE=RJ
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M P6/( 7(]R*V+CQAK.EV.M6M[;VDVIZ6]N7N(4?R3#,3B4H,L-H5BP&>@YH
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MFR%C]I%X'R"^SS-GI_J_FSFJ6G^(;K4KUKD:9;6^J3^'DO5F+,"J-(^V,]>
M/F^IH [YI8T9%=U5G.%!."QZ\>M.KRO3[[Q!-H_@.[DCM[Z_F),+/(PRK6QR
M\K')R.2<=:[KP[JUYJ(U&VU&"&*\L+HV\GD,2C_(CJPSR,JXXH V20JEF(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#'USP[;:Y):3/=7EI=6C,8;BSE\MU####H00<#@CM5&/P-I,5I%;+)>
M%(]3350SS;V:=<=20202,GOR>:Z:J.LZI%HFBW>IS1O)';1&0I&/F;'8>YH
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MVHI!'D[^2V<EMV?PXKL:* .-TCP$-+FLYSJ*O)#J4FH.D5L(HB6B:/8B!CL
M#9ZG)!]:;)X&ODM-2TNQU\V^BZA([R6S6OF21"0YD6.0N H;+=5.,FNITW4K
M;5;,75J9#$7=/WD;(<JQ4\, >HJW0!A:/X9AT;6;R]MYCY$]K;6L<&W_ %2P
MA@/FSSD-Z=N]9;^#;]/#5MH=OJUF;6.)XY5N]-$X<EBP8#>-I&>^:Z#6]:M-
M T[[=>B0P^;'%^[7)R[A1^&2*T: ,JQT./3_  M#H<4\CI%:_9A-)\S'Y<;C
M_A5?2_#?]F7&D2_:_,_L_2_[.QY>/,YC^?KQ_J^G/7KQ6[6/;^*-+N?*\N24
MF6\DL5_<L?WL9(8$@$ ?*>3Q0 GA[0?[!&J#[3Y_V_49K[[FW9YA'R]3G&.O
M'TJE'X:U'3M8OKO1M7@M;6_G^TW%K/9^=^]( 9E8.I&0HX.0.U=-10!R#>#M
M0MCJ=OI.N+9Z;J,CRRV[VGFO&S_ZPQOO&W/7D-@UJZ7X;MM'U"&:S<I;0Z?'
M8QP$9VJC$@[L\]?2MJJ-]JUGI^GW-[+*&AMCME\OYBIR!@@=^1Q0!B:3X-&E
MW&E2B^,GV"6\DP8L>9]H?=CKQMSCOGVJM>^ 4O(-97^TY(IK[48]1@FCB&;:
M5 H7@DAON^W6NRHH YF[\,W^M:)J&F:_J\=W'=1HL9MK7R/)93N#_?8EMVT]
M<?*..N8[GPQJ^K>'M0T?6M>ANTN;80I)%8^448<[V^<[CG' VCBNJJ-YX8I(
MHY)4224E8U9@"Y )( [\ G\* ,0>'9;N[CN=7NX;QOL$]C.D=N8DE61U.<;V
M(P$QC)SG/'2LV#P7?-9V&E:CK@O-'LI$>.#[+LFD$9S&KR!SD A>B@G:/?/8
MT4 <T_A,R>'?$&E-?#.KRW$GFB'_ %7FC&,;OFQ]1GVKH+FWCN[6:VF4-%*A
MC=3W!&#4M% 'G47PFM5\)PZ,^JSO<I=>?)?[,/(FTQF/&[@>4=G7_"NJ'AN$
M>(Y-4$H$+Z:NG?9@F %#LV=V?1L8QVZUMT4 <KHOA&ZTN'1(+C54N8]'9A;[
M;7RRT9C,85CO.2,YSCGT[ULZ?I?V#4-6NO.W_P!H7*S[=N/+Q%''C.>?]7G/
M'7VK1K,77;1]??1HEGDNHHUDF9(B8X@P)4,W0$X.!0!G7?ABYE\0WVI6NIK#
M!J%HMM=6[V^_.T.%96W#:?G[@].V:C7P<%\,:!HWV[_D$3VLWG>5_K?)8'&-
MWRYQZG'O7455L=0M]12=K<L1#.]N^X8^=#@_K0!SD7A+5-.O]3DT;Q +.TU&
MY-U+#)9B9HY&^^8WW #=[AL4_P"(\#7/@+4H%+@R&)<I]X9E3D5TT\\-M"TT
M\J11+]YY&"J/J34E ',)X6N[S5;*]UW5(]06PWFUCCM?(P[#:7<[SN.,C@*.
M2<=,1Z#X6U;P_!;Z=:^(%;2+>3,<#V0,PCSGR_,W8QVSLS@UU=% &"/#>/"^
MJZ+]K_Y"!O#YWE_ZOSW=NF>=N_'49QVJC+X.N()-$O=,U-+?4=+LOL7F2V^^
M.YCPORNH8$#*Y&#P3WKK*1F"(S'H!DT <G_PADLD8EN=3$E_+JD&HW4X@PLG
ME$;8T3=\@ 51G)/4G.:U$T'9XSE\0_:<^98+9>1LZ;9&?=NS_M8QC\:T-.OH
M-4TRTU"V+&WNH4GB+#!*L PR.W!K+3Q;ICWDMNJW96.Y%H9Q;.8C-NVE P'4
M'@GH,'F@"K;>$!;>#E\/_;MVVY-QY_E8_P"7CS\;<_\  <Y]_:L?6?AO-JB:
M]#%K$,$.L3B:1GL!)-'A0-H<N/E^4<8SUYYKKM*UJTUB2_2T\P_8;IK28LN!
MYB@$@>HY'-:- &-#H/E2:R_VG/\ :2J,;/\ 5[8A'Z\],]JR+'P3<Z0FC2Z9
MJZ17FGV/V"626U,D=S$#D90."I#<@ANY'-=A10!R&H>$=0N=8M-;@U&P_M..
MU-K<^=8;H;A=VX';ORA'/\1]*Z33;66RTZ&WGF2:5!\\B1")6).3A1P![<_4
MU///#;0//<2I%"@W/)(P55'J2>E/!! (.0>A% "T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P
M_BH07OCC1-,ULJNA26\LB)(VV*XN@5"QOV.%+$*>"?7%<O?V%A-I/CJRM$CG
MT*U,#VBABT<,^W]X(SV ^7@="2..E>MW%K;W<1BN8(IHR<E)4##/T--2RM8K
M7[+';0I;\_NEC 3UZ=* *JV:Z/H,EMI, !@A<V\3.Q!;D@$G)Y)KRMTTL?#J
MPUS3KDR^+9982LQG/VF2Y,BB2(@G.WE@4Z <X[U[+5--)TU-0;4$L+5;UA@W
M B42'K_%C/<_G0!P>J:O:6&@_$2*YOA!=!Y@B22X;Y[9!'M!/=NF.]):Z1IG
MB/QQ#'=B:6VM]!M)1;&5@I<N^&;!&XA<?G7=W&C:9=WJWMSIUK-=*AC$TD*L
MP4]5R1T]JLI;012&2."-'*A"RH =HZ#/H/2@#E?B.\">'[/[5>26=JVI6RS3
MQR&,JA<!OF!! QW[5QWB2VL=)U76H/#4ABMCX;NY;Z.WF+1J^ (W/. YPW(Y
M/)]37I6OZ/\ VW;V<!\HQPWD5Q(LJY#JAR5Q[U/;:'I5G:W%M:Z;:0P7&?.C
MCA55DSUW #GJ?SH \WNM%L-(T#PPIGN+>QU:>#^V+Q[E]\H$3,BNY/RJSG!P
M1UQ3-<TZP&I^+M.T_P#>:4-!:ZN(4F8QP72[BF #A25&2/8<<UZI)9VTUH;2
M6WB>V*A#$R I@=!CIBH+31]-L-/:PM-/MH+-P0T$<2JC \'( P<T >4-I[16
M?@;3;..S6TN-/-VT%]=2Q0SW&R/JRAMS8+$*>.OTJ:3PYJ\>@6*W&HZ9J5O9
M7=U*--&INJ20G ""8X):([OO<#/)KU&\T?3=1L%L+VPMKBS7&V"6(,@QTP#P
M,57N?#.A7EI;VMSH]A-;VW^HB>W4K'_NC'% 'F&M26ESIVE>)U@%YX;MM+5)
M-*>_>.XM\L?WB_-\YP O)YV\5>U?5;NSMO'4]E<W$,:R:>JRAB6@B>*(.P]"
M%).?QSQ7H5UX;T.]N(+BZT>QFF@4)$\ENK&-1T R.![5=%E:K+<2BVB#W( G
M;8,RX&!N]>..: //Y-.T[P_XW\-KX9FE,EX9$O;9+AID>W"$^:VXG&&VX;C.
M<5B:-I<>E>"_!_B&&>[?59[VTCEGDN9&W1ROL9"I;&W:< 8[9KU#3/#^CZ*\
MKZ7I=G9-+@2&WA5"V.F<#GJ:F&DZ<+*WLQ8VXM;9D>&'RQMC*G*E1V(/2@#R
MKQ%?P7%Q?:WIB2PSVFL16OVR?4G$A<2*CI'  0$P>C8R"3BNT\,_\CKXT_Z^
M[;_TFCK5N/"?AV[U!K^XT/3Y;QF#F=[=2Y8=#G&<\"M*&SMK>XGGA@CCFN&#
M3.J@&0@!06/?  'X4 ><^($;2O&L^LZV9K[29)K>*U>UOFC?3WX!#1!AN#,1
MDC)QU%9%W'KFOZAXDN;9_+U&SOVAMKA]6: 6:(1L!B"[2&'))/S9]J]+D\*Z
M!-K7]L2Z/9OJ.0?M#1 MD8P?KP.>M+?>%M!U+4DU&]TFTN+Q0 )9(P2<=,^N
M.V>E '&V.@_\)1XB\50ZIJ-_OM+B);>."[DB6W=K=,NNT@'GL<@8/')S4TS6
M=0\1-9VWVF:-] TZ<ZIL8J6N@&B16[G[KO\ ]\^U>FPV5K;7%Q<06\4<URP:
M9T4!I"!@%CWP.*9%IMC UTT-G!&;MBUP5C \TXQEO4X]: /.].NKC5H? VD:
MA=W*6-WI NI76=XWN)E1,*9 0Q^\6(!Y[T[7DNO^$OTWPS817$^FQ6#W:1'5
M9(#-(9"I!EPSMM!SMSQN'8"NYO?#NCZCI<.F7>FV\ME!M\J$IA8]O"[<?=P.
M.*@G\)>'KG3(--ET>T:S@):&(1@",DY)4CD$]SWH X>71?%9T#1UO)6OX+%[
M@7=I;ZHT4LT>?W9\X;<E.A!(SCFN[\-:CIU_H&G/IT\CP/;(\0G<F79T!;)R
M3D8SW/>HKGP=X=O+6TMI](M7@M 5@39@("<D#'8GDCO5VWT73+2]2\MK&"*X
MCMA:)(B %80<A!Z+GM0!?KB/A=/##X#@@G=([VVDF%^KD!TE\QBQ?WP0<GMB
MNWK#U+P=X=UB_-]J&CVMQ<D!6D=>6 Z!O7\: //["[EB32;FRFDBT^\\83&%
MHV*I+ ROC&."I8'CH35CQ%J=^9OB-';ZA,GV:*P%N5E.(&8'=MYXR>N*]&OM
M%TW4M-&G7EC!-9KMVPLGRKMZ8],=L52@\'^'K:QNK*#2+:.VNU5+B-5XE"DD
M;O7J: )M#T./1+:6-;V^NWF;?)+=SF1BV,'&?NCV'%>?G34T+0O$L]A=7Z21
MZY;PJ6O97PIEML\%CD\D;NN.,XKU4    8 JC+H^G307$$EI&T5Q,MQ*IZ/(
MI4AC[@HOY4 <+%:SZGXM\8SSZKJ2QZ9-#):V\5TR1*WV<-D@=>>W3VK"M+2]
MA\*^"=0AU[6%O-8N8;2\E-XS;HI$<D*IR%(V@!@,CKDFO68]*L8IKV:.V19+
MX@W+#K+A=HS^'%1#0=+6TL+4640@T]UDM$YQ$R@@$?0$_G0!@^%EDT_Q;XCT
M5+JZFL;5+6:!;F=IFC,@DW ,Q)QE <$^M.M=0N%^)^K6DUU(+./2X)DB=\(I
MWN&8 \#H,FNDBL+6"^N+Z*!5N;E46:0=7"9V@_3<?SJCJ_A;0]?E275-,@NI
M478KN,,%ZXR.<>U 'G.G2:YJ?@#PSK%Q)J.I6$,-Q)J,5O?-#<28<[)-V07V
MA3\NX9R*DNM0O/$.MV&GZ:FK7FEQZ3#=P"+4?LLSER1YDCDY=E &!G&3SUKM
M[CP)X8NK6TM9M(A,%HI6! S*%4DDC@\C))P?6K.J^%-"UN*WCU#3(95MEVPX
MRAC7C@%2"!P..G% '"W\7B6UT;2KWQ!]NN;"SLW^WIIU]Y<\;ASMF8JP\S"
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M9+:.V6VPQY9 NWG'M0!YW%K][X<TK67U"356\36VG-<-;WDPDMIBN,RP@<!
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MX$N+./5M16.,Q%$**'*KL;)"_P"R<X'':@#V%+F"1(G2>-EE.(R'!#\$\>O
M)_"G[T\SR]R[\;MN><>N*\H?2Y8QXSM]$MTBETC5+?4;"&-<*)!$C.JCMN&X
M8']ZNI\#W(U]]2\5F,JFH2^3:9&#]FBRJGUY8NWXB@#5TO7GU#Q/KVD- J+I
M;0!9 V3)YD>_D=L=*U+:^M+PN+6Z@G*8W>5(&VY]<=.AKRO7_M9U'XCBU#D%
MM.^T>7G>(/*'F[<=]F[]:LSOX7E\3:"_A&:PB$4=P;^33=H$=KY1YDV]PQ7:
M#SGZ4 >F1WEM-/)!%<0O-']^-7!9?J.U$%U;W08V\\4P0[6,;AL'T..]>0:$
MFD1V^HZ"M[H;VO\ 9<BCQ+8,JR1JS!2+@YX<D@_>YVG\.E^&MY:/<:KIUO;:
M*S6*6Z'4-( \NZ4A]N['1Q@Y&3]Z@#N[BZM[2/S+F>*&/.-TCA1GTR:=)-%$
MNZ21$&"<LP' &2:\\U!]$_X67JL?BW[&;?\ L^%M-%^%,80;_.V[OEW9 SWP
M/2N>T[3X-1OO!5E=P--I$E_J?V*.?/SV@1C%D'G&,<'MCC% 'LL<D<T:R1.K
MQL,JRG((]0:=45K:P65K%:VL*0P1*$CCC7"JHZ #L*EH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HK#UGQ(NF:K8Z5;6%Q?ZA>*\BPP%1Y<:XR[EB HR0!ZF
ML/PKJ]T^G>(M5;2M0:Y.J.@L&<&1,)&N!EMH'))(.,<\T =Q17'CQ_##INN3
MW^EW-K=:,(VNK4.DA*R#*E64X.>?RI7\<RQZG;Z8_AO5%OKR,RV<1,7[U!DL
M2V_"$#&0W/(H Z^LX:+:CQ(==S)]L-H+,C=\GEAR_3UR:SH?%;7>C+>V>C7]
MQ<?:GM)+1=@:&1"0VYBVT*-IYSW'K523Q_81:,UXUG=&\%]_9OV!-K2FX_N
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MIDV[5;L03D'K0!T<5G:P)(D5M#&LARX1  Q]_6GP6\-K$(K>&.*,=$C4*!^
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MDW-E:VCW*R/-)* <LR_*JY4 =3R>E=Y10!QMUX?U&:+P2JQ+G2Y4>[RX^0"
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MREN N6ZC/H:](HH \]OK74H/&,=SH6EZM9W,]Y']O=VC-E<0CAY"-Q(?;TP
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M/[N/:#M '+'J3CM@=3K?AV75-5T_4[34Y;"\LDEC5UB60,DFW<"&[_*,'^=
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M*+]9=1\EI)@FZ1(%*DN!T!;&2<=JZ[4=(DO=?T;45E54L&F9T(Y??&5&/SK
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MK137 N51W*'$ACC(^8+CN1G'%;OA[3Y]-TH175OIT$[.SO'IT)CB&>F,\DX
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M64 *<%"1QWYJ_<7'B+4O'.H:=8ZNEAIUC!:SOBU25G+&3*9)X!"]><8&,<Y
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M-5O&FDW/B@6OA_\ LLOI\DT<]S?2.H2-5;)5 #N+G&.F &ZUUU% "*H50J@
M 8 ':L2V\):3:#2Q##(/[,FFGM<R$[6EW;P?4?.>OM6Y10!CW/AG3KMM9,JR
M$ZQ L%WA\955*C'IPQINM^%]/UV:TN)VN8+JTSY-S:3-%*H(P5W#L?3VK:HH
M P[;PGI5I865I%'($M+H7BNTA+R3<Y=V/+$[CG-:2Z=;KJTFI -]ID@6W8YX
MV*S,./JQJU10!AOX3TJ30%T1XY6LA.)]IE))82>9U]-W;TK.U#X<:!J4UTTP
MO5CNI_M4MO'=.(C-D$R;,XW''ZUUM% &%J'A/3]2U:749);R*2>U:UN(X9RL
M<Z$,!O7N5#M@]L_2HKKP9IEQ:Z9%%+=V<VFPB"UNK6;9*L84#:3@AAP#@@C(
MKHJ* ,.Q\(Z1IUE;VMM#(JPW0O-[2%GDFP07=CRQ.:KZ]X1AU4ZA/;SR6]Y?
MPPVTTH<C]RDFX@8Z$@L,^]=)10!%<VL%Y:2VMS$LL$R&.2-AD,I&"#^%8FF^
M#M-TVYM9_,O+MK-"EJ+RX,H@!ZE >AQQGKCBN@HH JZ=IUOI=DMI;!A$KNXW
M')RS%C^K&LS5/"6FZKJT>J.UU;7JQ&!IK2=H6DC)SM8KU'\JW:* ,+3O"&DZ
M5;:;;6:31PZ<\SVZ^:3CS=VX$]3]XX_"H=.\&:=8W:W,USJ&H21Q/!#]ON3,
M(HWQN50>N<#).3QC-='10!R?_"O].&GW6FC4=6_LZ>%X%LS=9BA1AC" C/';
M)..U7-2\(6.H7%M<Q75]I]W!#]G%S93".1HO[C$@@CN..#TKH** .<_X0VQA
MTNTL-.O=1TV.V9GWVEQM>4M]XR$@[B3SD\YZ8IK^!M)%AIUK9R7E@VGEC!<6
MLY67YCEPS'.X,>3GO72T4 <_!X.TRVM[*")[H1V=\U_&&F+$RG=]XGEA\Q//
M/O4FK^%[75K^+4$O+ZPO4C\HW%E*(V>/.=K9!!&>1QD9XK<HH AM+9+.SAMD
M>5UB0(&E<N[8[ECR3[USB^ ]+6UN;3[3?M:SWJWP@:8%8I!)YF$XX!;J.?PK
MJ:* ,>_\-V6I7]W>327 DN=/;3G57&T1L220".&YZ_2EU#PW8ZEHUMILS3(M
MKY;6\\;[987085U;'#?ACD\5KT4 <[8>"]+M%U$W+W.HSZC'Y-S<7L@=WCQC
M8,  +[ 4S2_!-CIFI6>H?;M2N[BSC:&W-U.'"1L -@  &..O7U)XKI:* /*(
M?"S75SIEEIMAXAL[:WU*.\,&I.@MK54DWMY80G)/W5&2,,3VS7>P^&;&&/6T
M5Y\:P[/<Y8?*60(=O'' [YK:HH @L[6.QL;>TB+&."-8E+')PHP,_E7/VG@7
M3K-+:&.[OVM[2_%];0/*I2%QO^5?ESL_>'C/8<UT]% &)J/A>QU*75))9;A'
MU*VCMIBC ;50L5*Y!P<N>N>U7+;2;>UU>]U-&D,]Y'%'*&(VXCW;<#'^V<_A
M5^B@#BKOX8Z/>65W8/?ZJFG7,K3?8H[@"&)RVXE%V\<Y.#D<YQG!K9\96EQ?
M^"M;M+6)I;B>RECCC7JS%2 !6Y10!S6E>#;2PO;.]DO=1N6M(RMK;W4^^.VR
M,'8,9SCY<L2<57T_X>:5IMU8RPWFI-#I\[36=J]P#%!N# JJXZ?/W)(P,'KG
MK:* ,FR\.V-CI%YIB>;);7<D\DHD;D^:Q+@$ 8'S'%<OKGAF;_A'+?P?9/JM
MV)Y(RFH7#!A91HRY^<;>0%PHZDGKC-=]10!';V\5I;16T"!(8D$:*.BJ!@#\
MJPK;PC;V&K3WMAJ6HVD5Q<"XELH9$$#/QD[2I(W8YP1G)KH:* ,%_"6GR>%_
M^$?,EQ]C\T2[@XWY$WG=<8QN]NGYU?M])M[75;_44:0S7RQK*"1M&P$#''N:
MOT4 8\/ANR@TK1].5YO)TIHFMR6&X^6I4;N.>#SC%0Z=X2T_2TL5@DN"+*ZF
MNX][@Y>4.&!XZ?O&Q^%;U% '.WO@O2M0FUB6=K@OJK0/*5<#RWA&$9..", \
MYY_*J/\ PKG2WCU87.H:I=2ZK;K;W,T\ZLY53D$?+@'MTQ@=*["B@""2T@FL
M6LIHQ+;O&8G1QD,I&"#]16%8^#;2SM9[*74=2OM.E@:W^Q7DRR1(AQP/E#<
M8!)/%=)10!R^F^";>QU"TNKG5M4U(66?LD-[,KI"=NW< %&6 R 3G&3WYJT_
MA+3Y/"__  CYDN/L?FB7<'&_(F\[KC&-WMT_.MZB@#F=2\$V.HWE_<+?:C9K
MJ,82]AM9@L=Q@8R05)!(P"5(R!23^"+-K328;34-1L9=,MQ:Q7-M*JR/#A04
M?*X.=H/3@]*Z>B@#E5\ Z3'H$&E037L(MKEKJVNDF_?PR,Q8E6(YZD<YR#SG
MK4MUX.2_TRWM;[6M5FN+>[%Y'>>8BRI(%*_+A=H7!/&.]=+10!FZQH\6L^';
MS1[B1BES;M TC $C(QN[#.>>U8I\+W&LZ+I;ZE//IVNV,9B%[92#=_=;&<@J
MX ;!'''0BNLHH P[?PW';?9O,U35;I85E$D=Q<;UN/,Z^8N,''8# %<3IOAE
MKCQ!H26<?B)--TZZ:X\O4R%CM55&"11@\OEBO/.%&,CFO4J* .<'AR]35]-E
M&KWDME;3W%S*DTY+2.X CCX _=KECC/4#@]M'5=$M=8FTZ6Y:56T^Z6[A\M@
M 7 ( ;(.1ACZ5I44 8>J^%--UE=46\\YEU&"&&8*^-HB9F1EXX(9R>_054T[
MP/8V<][/=WU_J<M_:BTNC>RAA(@)QP ,<$CC _'FNGHH Y6W\#Q1V%U87&N:
MS>6<]O\ 9UAN)U81IQT^7D_+U.>":N2^$=+EU*]N]LJQZA$8[ZT4CR;G((W.
MN/O8/4$'US6]10!SNF^$H]-!3^V=8NH!"T"07-R&1%(QP H)(' W$U->>&_.
MT6QTVRU;4=.%DB1QS6TBAF55VX?((;CVZUN44 <4O@LV]UH>EVPD.D:?=/J<
M]Q/(&EGN,L47@>K%B< < #O74:;I[:=!+$UY=7?F3/+ON7WLNXYV@_W1T J[
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-^%]=@M/#K76F30-!KMQ>31R3B1HHG1MI+9RW) SU/6MSQ!X<U+4(/',=M;
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MQG(((QCGM5N^U"TTS3Y;^]N$@M8EWO+(<!17G>H:1<GXAMX=C0/HVJ3IK-T
M?N&/AD(Z$/(L1_[ZKI?'^E7NL>%7@L(1<317$-P;8D 3JD@8ISZ@>HH R#X[
MCU#QJNG:=?20V<>E3W-P+BRDC,;@KL?#JK$8).!P:W%\6Z5I^D:7+?:D;F6[
MMEF1[:TD=IEV@F01H&95YSSTSBN9U.+4M>\6MJ$.AW]O;#0[NV$EQ&%9Y&P0
MN 3CVSUY_&K<:;?VGAGPZ;6RUVV\0:?I$:0SV<2O$7*@&&52>1N49R.,@YH
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MTAEN]K2*1)*3&2O&0"F<<=*T/'=C=:CX8-O9P/--]LM7V(,G:LZ,Q_  G\*
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MS3QAQD;E0L,^V17E6KVU_:?#_P 1>%FT34+C5Y[N6X#PVQ>.9&E#B3S.A.W
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M%!(K[VQT^1IAGU(JCHGA_4H+O7+>[M9%M-&LKBQTL!<B9)B9-R\=0HC3CWH
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M) 8$J<$ ]*X'2_B'<Z];Z5;Z7IT#:I?&<N))R8(4B;:S[PN6#' 7C^+VYM>
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ME*!@O#(S \G\,4 =%167K&J7>FB$6>CW>I22$Y6W:-0@&.2SLH[\#Z^E8O\
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M:891RA7(SCHP!'3N* .1A\"7UA;>&_[.UM8+G0[:6!6>VWI<;]F0Z[@=OR]
M<]#GBICX(N9K.Y-WJPFU&\O[:\N;C[.%4K"RLL:J#P!MP"23S7944 9":-(O
MBZ77#<@QO8K:+!L^Z0Y8MNSSG/3':LO2_!K:=>Z+<-?"3^S/MWRB/'F?:) _
MKQMQCW]JZ"+4K:?5+G3D+FXMD220%"% ?.,-T/W3TJW0!QJ>";I?#FLZ"=7
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M:2R6]S$89(9[F25!&?X5#,=H^F.E '*VD7C>Q-Q!8V^JNLMA*%EU>ZMY=ER
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MO.T,L_REN7X&>,'C!JK92Z]K=IXKOI/$]Q9_V7J-U#9+&L:QQB/)'FY4[EY
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MU-GNHI[JW^SW*Q3%4F3:RC<O0D!C@T <9H$^MZ'X<\$WK:P9[*^^RV<EB;=
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M2Z?*\MK=Q.HFC+D[L$J00=Q&"/3TH Y?7/%?B'0X]4TN.YM[B_M+BR\F\EB
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M,;<<#B@#$U#QCK'AZ?6]+NFM[Z[M8;9[&X*>7YAF?RP) .!AN>,9'I6OJ/\
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MTXPMYC6X;;DR;N'QDXVXJW=ZYXGN;KQ)-ITVG6^GZ4JO"9H&DDE;[/'+L;#
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MN 4@#C Y/7%>D [E!'?FN?G\(6=QX;U71'N)Q!J4\\TKC&Y3*Y<@<8X)P*Z
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MEI?C_3XKB33=*T;^S&%LUY8B6U$^\[P%W*JN4V\GL,4 >J375O;VYN)YXHH
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M\'+<_=W#!P/2J>IP:#=_%*]M=<GC"MI-N\5O-*4CDVR3;F/(!*@\9Y 9L=Z
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M=@$<'(&3CK7.^%O#>M>(? &E:?>ZO V@3QH\D?V8K<N@;=Y9?=C!(Y.,XXH
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M0=?=LUJT %%%% !16-J.O#3_ !+HFC_9O,.J>?\ O=^/+\I W3'.<XZC%;-
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M06[S,VT9;A03P.: -BBL[1=>TWQ#9-=Z7<B>%)#$_P I4HXZJRL 0>1UK1H
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M.FTU].ELH'LG8NT#("A8OO)(_P![GZT <'=06VOZIXQFUF\NK<Z;B"VB6[>
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M^UN3=12WLDPVI'N68;V.T[L#(P#NKN3IEBT-W"UI$T5XQ:X1E!64E0IW ]>
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MGP&VOI6GNHMO$KMC+-[G _*C4?#^DZM8PV=]91RP08,*\J8R!@%2,%3CC@T
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MDA0Q(7/MBG:]X6T7Q.D"ZS8K="W),679=I.,_=(]!0!B^+?^1T\$_P#7[/\
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MQ297(E&W*<-GYL9X ZUSOAS0]<\/6GA#4;G1YKH6-E<6MS;(5,UN9'W*Z@D
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M]62SAEF>XLR8XUC8.V1D#:1D'VQFL/QWI$MI_P (S/9"]M]+TR9Q+_9\"2O
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MN#"<L.YZ9&>E 'HNE:SINN6INM+OH+N ,4+PN& 8=CZ&B76=-@AOI9;V%([
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MG.W.<8YS7$>&M'>?Q5<1Z[:1W-U'H-A%.\R!_P!YB02#/N>N*KZ-I-M:>"O
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MR>_:O*-^DV_@S7-&U:T>3Q7<7%P2@MV,TTY<^2\;8/&-A!S@ &NETO2+>_\
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M($D&F36FKW&I:D@O+*6V87-LV /,63&"BA<X/3L>: /5**** "BBB@ HHI*
M%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HKEI/%-[-XGO]%L-)60:<T+7=U-<B-%CD7=D#!)
M8#=QTXZ\UDVWQ/M[AM.NOLMLNF:A>"TB?[:IN%W,561XL?*A(_O9 .<4 =_1
M7$W?CR[M-/U75&T!SI>EW;VTTQN0'D"2[&>--OS =>2.XYQFKUYXJO&UVYTG
M1=&.HR6ENDUS(]P($0ODH@)4Y8@9]/>@#J**\T\,^+8]&\ ^&T%NDE[J+3>5
M#-<"%% =V8LY' ' Z9)(XK2;XC+]BM6@TIKF\FU,Z8T$%RK*)=F\%7QAEQMY
MXQD^G(!W-%<A?^-)[&]CTS[!9_VF+?[1<12ZDL4<0+$*H<K\S'!.,# ID'CP
MZJ-*BT/2VO+J_M7NVCEN!$L"(VQMS -SO^7 '8T =E17%_#>]N-0T[7+F[B>
M&=M:N0\+.&,1&T;<@#.,8Z=JV)/$:QZ?XAN_LI(T9Y%*[_\ 6[(4E].,[\=^
ME &Y17)_\)C=75QI]MIFB/=3WNFQZBN^X6-(T8XPS$'GD8P#GVQ3/^$[CETK
M2I;7399M2U*>2WBL?, *21DB3<_("KM//ICB@#H]/TRVTS[5]F##[3</<R;C
MGYVQG'MQ5RO.-*\4KIFL^-]7UNWGLHK/[()("V_!V$?(>A#'&#QG/.*O1?$:
M-3>QWFGQQSV^FRZC&MO>).LB1C+(6 &U^G&"/>@#N:*Q?#NM7NN6S7<^CRZ?
M:2)');--*K/*K DY0?<QQUZY[5R>I:_K5W;^/;*XLGCM;.TE$,@E3]S_ *-N
M'3YCN)W9[9QQ0!V&G>';/3M5N]3$MS<7ES\IEN93(8TR3L3/W5R>@_I6M7$>
M&/%$T=AX8T^^TF[@34+18[>Z=U8.Z1!OF .5W ,1GTI;'Q39Z;HFF1V5I?74
M^H7ES!;0S7(9BR2/O+2.< ?*<#W H [:BJUA<S75C'/<VCV<ISOAD96*8)'4
M$@],_0URT/Q%L9KFR?[%.NEWUU]DMM0WH5=\D E,[@I((!(]#T- %[5?!EIK
M%Q<O<ZIK"P76!-:QWK+"PP 5V]@0.0/4UT,,,=O!'!"BI%&H1$48"J!@ 5Q\
M_P 04MXKZ[?1;[^S=/O'M+N\RFU"LFPL%SEEZ$X'&?:M"\\5/'K-QIVG:3<Z
MDUI$DMT\,B*(MV2JC<1N8@$X'MZT ='17,V?BY]4\.:;J^F:-=W8O]Q6,.B^
M6HSR[,0 /E_,U7C\?V4VC6=W#8W;WMW=-91Z> OFB=<[E))P ,9+9Z4 ==17
M+6OCBU:/76U&QN=.;1(T>[68HV=REAL*DAN ,=,YJ&T\>PRSI!>:7=63SV<E
MY:B22-O-1!N9?E8[7P0<&@#KZ*XE?B,GEV$LGA[5DCU)3]A^1"T[C'&W=E00
M<@G P">*O1^-K:+3+ZYU&PNK*YLKE;5[,[7DDD8 HL>#ABP88H ZBBN5F\=6
MUC!JQU+3+ZSN--MQ=/;N$9I8B<!HR&PWH>>#Q267C;[3>1VMQH6IV<]S:O=6
M<4PCWW"J 64 -A7Y'#$=: .KHKDOA_XEU#Q-HLUSJ%E-!(EQ*BR,J*C@2, J
M@,3E0 #G'/3-=;0 45PA\3WFBZUXSMM1G,D=C;)J-BK 9,3(05& ,@.N/QK%
MT_Q-XA7X<ZC8WEV1XKMKR.P$C@9\R9E\L],<!_3^$\>H!ZK17GMMXIGT;Q%X
MJMWT[5]52UN(I&>W566)/LT9_B91DD,<+^7-=!>^,;*!=-%E:7FISZC!]I@@
MLT4OY. =[;F4*O(')ZF@#HJADM;>:XAGDA1Y8"3$[+DH2,'![9'%<M'\1-,N
M8M+-G8ZC=3:DLIA@AB4NK1LJNKY;"D%NI..#STSN:%K<.O64MQ%;W%L\,[V\
MT%PH#QNIY!P2/0Y!/!% &G17-_\ "81R^*+C0;+2[^ZGM9(UNIXU00PAP"&+
M%L]"> ,\&J]MX^L;B[MU.G:E#875Q]FM]2EC46\K\A<'=NPQ& 2N#QZT =91
M7.6WB^*_U22TT[2M1O+>*X-M+?1+&($<'#<LX8A>Y /MFJ3_ !$L%A>]72]4
M?1TE,9U18D,'#;2WW]VW=QNVXH ["BN;?QE;_P#"2W>AP:;J%Q/9O&+J:-$$
M4*NH8.S,PX /..?E/%8FH^.?[072_L%CJMO;7>J6T,-^\06&X3S1NP0V[:R@
MXR "* ._HKG[3Q;!J&N3Z=8Z??7,5O<&VGOHU3R(Y0,E3EMW' )"XS6EJNHG
M2[/SUL;N]<N$6&TC#.2?J0 /<D"@"]17*-X^TV+0KK5+BTOH?LEVMI<VK1JT
MT4C,H'RJQ!^\#P3Q^52S>,EACLH_[#U9[^[5Y$L$CC\Y$4X+O\^U0>,9;OCK
MQ0!TU%9^BZQ:Z]I<6H6@D6-RRE)%VNC*2K*P[$$$5B6'CZPO_MDRV&H0V%DT
MJ7-]-&BPQM&2",[LMG'& >H'!XH ZNBN2'C@2172?V)JMM>)9O>6\%U$BF=%
MP"5P_8E<@D$9J'P[XY^WZ/X=DU*RN(KS5R(T9441LWEERP^8D+QCU]J .SHK
MF]0\;Z5ID6MRW"W(31I(8[HK&#DR[=I7GG[PS_6J<GQ!MHKFTM7T+7!=7C2"
MV@-JH>4(%);!;Y5.[JV.ASB@#L**YR/QMI;^'SJYCND N/LAM#%^_P#/W;?*
M"@\MGT/3FD3QKIJV&H7%Y#=V4NGA/M%K/%^]!?[@4*2&W'@8)R>* .DHK@K'
MQ1>:I\3;.P^RZGI]L-+EE>VO(P@=O,0*XP2#QGOQTK5\4^*I] U+1[6'3+VZ
M6[N"LK00>8-OER':IR/GRH./[H:@#J**YO4O&=G87,\$6GZE?O:HKW7V. 2"
MW!&<-R/FQSM&3@YQ6M!JUI=Z(NKVC-<6KP>?&8QEG7&< 'O[>M %ZBL0>*=-
M?3M'O8S+)'J[QI:JB98EEW9(SP% )/I@UGCX@:666;[-?C2FE\D:J80+;=G'
MWLYVYXW8VY[T :,/AY1XF;7;J]GNITB:&VB=5$=NC$$[0!DDX R3G%;59AUV
MS6#5YCYFS2F9;CY>XB64[?7Y7'XU?@F6XMXYDSLD0.N>N",T 245SVHZTEAK
M\\*&^N;B/3#<K8PQJRN!)MW#^+?GC'3%)X*\17'B;PY;W]U8SVL[("X>(HC$
M]TR3D>] '145S \26&E6VL7=U>WMRD.H_91$T2EA*RIMBB"@%A\PQGGK6WIU
M^=1MFF-G=6A5RACN8PC<=^"01[@T 7**PV\6::N@76L,)Q!:S-;RQE/W@D5_
M+V[<]2V,>N15*]\>:99SWD:6>IW:6)Q=S6MJ9(X#C)5FSU .2!G% '4T5G6>
MMV.H7JVUI+YV^U2\21.4:-R0I!_X":R[GQOI5MI=E?\ E7DJ7MQ);01PP;Y'
MD0N"-H/<H<?ATH Z6BL^75X;?0)M8N(;B&"&W:YDBD3$BJJEB"N>N!TK)_X3
MC2_[,.H""^,#RI#:XMSNO&;./)'\0X)SQP,T =-17,KXYTHZ7->-%>I)%=+9
MM9O;D7'G, 50)W)!!],?2DF\<Z;:I9"ZL]3@N;TRK;VLEHWG2-'C("CUW#';
MKZ&@#2\/Z%#X>T^6S@F>59+B6X+.!D&1BQ''89K5KGK/QII%S::C/.TU@VG8
M^U0WL?E21AAE3M[ANV.O2F6GC73[B[^RW-IJ.GS-"\\27UL8C,J#+;.3D@8)
M'6@#I**Y+2_B'I&K2V BM=2B@OV\NVNI[4I#(^"=H;/7@CZ@U=LO%EGJFJ2:
M?96NH2*LLEN;U+8FW61 =PW^Q&,XQGB@#H**\X'BN>QU+PH3J%]?VEYIT\K(
M+8&:[D!3;\B# (R3U  !R:VY_%EIJ%BCVUY>:=<0ZA;VUQ!);+YRF1PJHZ-T
M5MP^8=N10!UE)@9S@9'>N M-?N(YO$K7FJW$$<.NPVL#I&LA16\H; && #N(
M)[9)J_+XZ%MXFUC3I]-O?LNG6J3^9';,S.?G+'TVX48/<YH [&D(!Z@'OS6;
M_;^GDZ2$D9SJO-KM4G<NPN6/H,8Y]2/6LS6?%;:5XKTO1_L-U(EVDCM(D#."
M%'1<'J"1GC@$4 =-2$ ]0#WYKFM1\=:7IUU=P_9M1NH[(XN[BUM6DB@.,D,P
M[@<D#..]=#!<PW5I'=6\BR02H)(W4Y#*1D$?A0!+2*JH"%4#)R<"N4M?B'HM
MWI,VJ+'?QV,<<;I-):LJS,_ 2,_QOG@@=Z@U3X@0VWAS5KZTTZ^%_8)EK.YM
MRKIE2RNXS_J^/O ]J .SHKGG\6)#IUK</H^LO-/N_P!'2R/F+MQDLN?E'(QD
M]Z@M_%&G:MJ'AR6SO[I8]2BN'A@6)=DNP#<)"1E2IZ8(YSUH ZBBN5MO'VDW
M5Q"D=MJ(@EN?LOVMK8B%9=Q0(6]2P ],D5TEU<QV=I-<RAS'$A=@B%FP!G@#
MDT 34FU=V[ W'C..:YN'QOIKVNIS3VU_9R:=;&ZFM[JW\N4Q $[E&>1P1UZB
MI=)\8Z;K&HI9P17D1FC:6VEG@,<=RBD9:-C]X<@_0YH Z"BO-_&WQ$BA\+:H
M^C?;XY8Y!#!J*6Q-NT@=0P5^0?XAG&,@C->D4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!@V/ATVWB7Q!J<TJ2PZLENGD[?N"-"ISZYS7/Z#X#NM!>TLXH="F
ML;68/'>366Z[*!MP4GIN[;\_A7?44 <A?^$+N\\"ZSH/VN'[3J$UQ,)2I"*9
M)3( 1UXSBEN/#^NV6O7VI:'>6"KJ%O%%.EU&Q,;Q@J)%QUX/W3CZUUU% 'G7
M_"NKN/1/#J^9IMWJ>D-*'^V0EX;E)&)8'@D'D$'!P:TV\(W<QT60QZ79M8ZG
M]MDALHBD97RRF!Q\S<CD@>G:NRHH XS6_!\]SXK;7;*UTF\\^V6"XMM3C+*"
MI)5T8*V#@D$8YH;PUKMAJNG:GI$^EQO%:-:W5F86A@<%BX9-N2I#$_7\:[.B
M@#G?!^@7GA^RU&._N8;B>\U&:\+PJ57]X0<8/3G/K65K?AOQ)*GB&UT>YTU;
M36?F9KK>'A8Q+&^ H(((48],UV]% '.:%X>N-*NK"66:)Q;:1#8,$SRZ')8<
M=*Q(O!&JV*:7>6-W9_VCIU]>3JLH;RI8KAR2A(&00".<'D5WU% 'GEQX!U37
M;+Q3%KMY:1R:R8#$;3<PA\K[N=P&>@_6IXO"%_<:?J\$^D>&["XNM.ELX[BP
MB8.S.N,L=HVKDGCD]*[RB@"KIMLUEI=I:NP9X($C8KT)50./RKF-0\-ZM->>
M*XX&M'L]<L]B.[LKPRB'R@" I#*>#G(QSP:[&B@#FTT"[2P\)V^^(MI$L;7!
MR<,%MI(CMXY^9QUQQFLQO"ETOA.WT>YTG2]6 NKB62.YN&B"AY7=61PC$, P
MSP._-=O4%Q>6UK)!'//'&]Q)Y4*LV"[X)P/4X!/X4 9GA[1[O3O"\&EZI>M?
M3K&R2RL2<@D_*">2 #C)Y.*Y#PU\/GT,V=C=>'?#M[';3$C56R+AD!)4E/+/
MSC@9W]J])JM?W]II=E)>7]S%;6T0R\LK!57G')/O0!RFJ^%-0O? 6NZ)$]N+
MJ_N;F6)F8[ LDYD7)QD'!YXZU3NXM1\)ZMKE]83:,]M?QI-*M[?&!K>54VEO
MN-N4@ XXKN[:Y@O+6&ZMI5E@F021R(<AE(R"#Z$52O/#^BZC=K=WVCZ?=7*@
M 33VR.X Z?,1GB@#SK1O"NJZAX \&*;*VNH+6*26YTZ\N&A2;>"8V)56Y&<X
M([U+;>#]2\/66FW0FT6#4;35Y[N"V,QBMWCE0JT:G;D$+G'!QBO4N@P*J:AI
M>GZM"L.I6%K>1*VY4N85D4'ID!@>>30!YS8Z=<^-I_'EA>S6T+726UN)+1S-
M%$RJQ"AR%WD94G@=<5IZ7X0N84E5_#/AK3IC920_:K(DR/(R[<C]VNQ3DYY:
MNVLK"STVV%M8VD%K #D101A%!^@XJQ0!SPT.Z \+?-%_Q*FS/\QY_P!&>+Y>
M.?F8=<<5A>)O!&HZ\FO1I):*MS=VMY:"0L0[1QJK)( . =O49ZUWU5H]0LI7
M@2.[MW:X0R0JL@)E08RR\\CD<CU% '"6G@R:31]8CC\-:7HMY<PB")XKQIS(
M V26;:-J\*0.3ZXKI-3T2ZO/&N@ZQ&T0MK"&Y24,QW$R! N!CG[ISS6S=7EM
M8PB6ZGCAC+K&&D; W,0JC\20*GH XCPO8^)?#FGR:7_9-K-$FHLRW)O,>9!)
M([L^W;D%<J-IZY/I7;T55L]3L-1,HL;ZVNC"VR7R)5?8WHV#P?8T <IXQ\)W
MNN>(=%O+)HT@5O(U/)PTEN'24*/^!1X_X&>V:9?^#+NX^)EIKD<D0THA+BZB
M/WFN(D=(R/;;)_XY]*[BB@#G+#1[N*^\4O)F--1G5[=T89Q]GC3/L=RG\JY*
M[\!79B\-WTVDVVJ26.D1:?=V$L_EG*@89'^[D-NSGJ/PKU"B@#A]&\*W.GZW
MH-Y'I=GIUO;07BSV]K,76-I&0K@D L2%Y..M;V@6-W8W6M&YB1([G4&G@8/D
MLA1!DCMRIK:HH P-*TNZA\1>)+JZB5;:^DA\DJ^2ZK$%.>XY!KC_  UX .DS
MV=E=^%].G^QS!EU5KQLNH;<K"/;G>.!@X''4UZ?10!R'A^PU[PU*VC1V%O>:
M8;J2:*]-SY;1QR.7960@EF!9L'.#QDBL=/#?B:'PG)X)CMK0V+AX?[6,H&('
M8D_N<9\S!(ZX[YKT>D5U?.U@V#@X.<'TH Y73?#<T%_XHB>-8K/4%ABMY0^Y
MRBVZQG(]B#U//-8UIHWBH:/X?T&73;2*WTFZM6FO!=!A/'"P^XF,@D $YQTQ
MSFO1*ANKNVL;=KB[N(K>!,;I97"*N3@9)XZD"@#AW\/ZI/XUCU*QTB/12MWN
MN[Z*\#K?0 GY6B 'S-\O)^[SR>^OXWTO5M4TZR32\RQQ7:R7=HMP8&N8<$%
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M6^68*O4#D\G) Q7I5% '$:=;:_J?Q!M=<O\ 1#IME!ILEL!)<QR.SLZMT4G
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M#&H/^]A7_P"V?3O5F"T\1^&Y]<L]/T9-1CU&\DO+:Z$Z1K&T@&5F#'<=I'!
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MH7Z/J)CM9+A#,("J!5:3A6<+R3GG'7O7KM59]-L[G4+2_F@5[JT#B"0YS&'
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MG3M0LH8&N$=-L+(TA(=202"&'0'K765%=6T5Y:RVTZEHI5*N Q4D'W&"/PH
MX#P#I<W]N:C),ZR66B23:7II!SA"^]_Q \M,_P"P16WXEM-07Q/X>UBRT^6^
MCLQ<1310NBL!(J@-\[ 8&WZUOZ?IMGI5FMI8VZ00*2=B#J3R23U))ZD\FK5
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M=^DZ1EEXQ>"7).<?=&:Z'Q=%K$_A74(M <IJC(! 0P4_>&[!/ .W.#ZUM44
M>1GPMK=W?^(KJ/0[RTBN_#TUE MYJ N)99V.>27;;GZX[\9(KLM<T>]O/%WA
M.\@@W6MBUU]IDW >6'@*KQG)R>.*ZJFO(D>W>ZKN.U=QQD^@]Z /)+K0?%B?
M#27P1#X?$LD!$:7PN8UBFC$H<,JD[@V.Q '!.>U>NT44 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY8$'(9LY'>@#C]3\<:W-J&M#2WNQ_9<YMX+>'2);E;J2,?.))%&$W$X&"",
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ME5#%CN4 L"< YQ^':6_ANRBL]8M)C)<P:M/)-<)*1_&H4J-H&!A0/7WK+L_
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M*U:TO%N=0N;F]OKR"[NKMPH9S$X9$  PJ@+@#MFK-QX5G36+[4=(UF?37O\
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M:TU!=I:2X?! FW9X?+'/!# XJ;2?!=_97]A=7NLPW LK.6SBA@L5@C"N$&[
M8_-\G/8\8 P<@%"W\8^*7T_1-0ET.P,.LA(K>..X;?%(ZEE9R5QL(!)QD@>M
M,U7Q7(--U&SUK3+.YOM+U&SCDCB=O*;S61HY!D9!&3QSROO72P^&C%I/ARQ^
MUY_L9HFW^7_KMD+1],_+G=GOTQ65J_@-]3O=:N5U%4.IW-E/M,.?+%OC(SGG
M=CVQ[T ,U'Q3XB74?$2:;ING/9Z($:1[B=U>?,0D95 4@$ ]3[>O$NK>,+F#
M2=,U2SET6VL[RT%UNU2\,3-E0P1% Y.#U[>AK3;PV2GB4"Z&=:Y'[O\ U/[A
M8O7YONY[=<5B'P-J=J=*ETW5+..YM-(CTJ62YL_.&$Y$B+N&&SG@Y&,>E %:
M7Q-KVM2^$=1T2"S2UU%7=H;BYD7+B)RR-M0@J,9![D=!UJ]/XEAT.TU)[/2D
M-U-K8L(8EDVK-/($P[L?NCGG /2I+7P9>Z9H'AZST_5(OMFC2%EFFMR8Y58,
MK H&R.'XPW45/?\ @Q;^SO8C?-%/)JBZG:SHG^HE4*%R"<,/E.>F0>U %6;Q
M9K.CW-Y9ZYIUDLZZ=/?VDEI.S1R^4,M&=R@@C*\]QS@=*CTSQ7XA-YX?;5],
ML8;/6P1%]GE=I(&\LR*'RH!R!T'3!ZU._A#4M5>[NM>U6":[DL)K*V6VMBD5
ML)1AVP6)=CA>I'3 ]:U+CP\\Y\/ 785-(E$I'E9,Q$31CG/R_>)[T 97Q%>:
M.QT%[>$33KK=J8XR^T.V3@$]OK56_P#&/B#1I=2L;W2[&;48+!M1MOLTS>5)
M$C .K%AD.,\<8/M6[XL\/W/B+3[6&SU$6%S:WD=W%.8/- 9,X&TD>M9UMH[:
M1JEUXJ\6:U:R3+;?9%*IY%O#"6!Z,3EF;')/H* -*#Q+'?ZYIMAI\:S17-D;
MZ:8MCRHC@1X ZEB3WX"FF>*-9O=(6U-K<:+;+*6#S:K=F%01C 4 ?,3SW&,5
MB?"W0O[-T6YU!TD!O92+82@ADM$)$*X/(X);_@5:OB+PU>ZGK5CJVG7MM;W-
MO#+;'[3;><H1RI+*,C#C;QG(/>@"A;^-[_5++PW)I6FP/-K*3%A/.52$Q8W'
M(!+#KCCGCISA8_'%W';0R7VF)"8M9_LF^*2EEC) V2*<#*DL@YQC=5G2/!\V
MEMX?W7XN/[+%T'<Q[3+YQR#@<#'>J/B'3M/TGPQXEAU:Z1AJ]U)/;1(/WC2&
M- B(.K,&C!X_I0!T>F:P^I:UJUI'"HM;!XX!/NY>4KN=<>BADY]2?2L;4/%&
MM27NM1Z)I=I/;Z0@$TMU.T?FR[0Y1,*1PI&22.2![UJ>$M(DT7PY;07)W7TN
MZXO'_OSR'<Y_,D?0"N,\2;-$UK7SIWB.RMWU2)6N--D@\RY,FS:#  >2PP.0
M0#S0!L6_C74]5M]!@TG3+:74M3L?M\JW$[)%;Q\#E@I)R3@<4D'CF\CNOLNI
M:?;P2VNI)87[1SEDC\Q,Q2(2!D$E000",U'I7A+5K30?#5W97<5CK6GZ>MK-
M'/%YD4J$*3&^"#P1D$'KFKP\#K/H.MVE_>^??:R_FW%TD>P(Z@"/8N3@+M7&
M23[T 1:IX]33_P"TR(;<)#>II]I)-<"-)9]F]][-@*B]">>A'7 K,_X6:\=C
MJ&;:PO+VRN+6-O[/O/-@E29@H*R8'S#Y@01U ]:T+GP )/"&GZ7#?*NIV-RM
M^E[)"'#W.XL[,I[,6;C/IZ5+>^%-7UG1I;34[_3XY6NK>=!9VA1$6-PQ'+$D
MG'<\4 -D\2>)8=:T_1)-'TXZA>0RSEDNW,4*(5'S'9DGYB.!UQVR:@F\>WJ:
M3$T6E12:HNLC1Y[;SR(Q(03N5\9VXVGD9&3QQ713:(TOB^TUP3@+!92VIBV\
MDNZ,#G_@)K$7P/*+J64WR8?Q NL@>6?NA OE]>O'7]* *_\ PE?BMM1U/2UT
M'36O--@6XF=;US$ZL,HJ?N]VX[7ZC'R^]-OOB/'YUE!I_P#9L+W&G)J!?5+T
M6Z!7&41>/F8]^@ KH[;0FM_$FL:MYX9=0MX(1'MP4,>_G/?.\?E6##X*U'3$
MTN?2KZS%Y!IL.GW2WD!DAF6-<*Z@$$,"6[XP: (;'Q]J>O-HT6AZ/:M+J5A)
M>,;NZ*)!LD","50EAG@8 Z@U2UWQ;KMYX-DN;&*VM-0M-733[U5N'PK"9% 1
MMO*L&7.<8#'J>*ZJS\.W,'B*QU:YO8II+?37LY D/EAW:1'+@ X4?+TYZ]:S
M)_ TTN@Z]8IJ")/J.JG4X)?+R(F#(RJPS\PS&,_6@#I6OI-/T1[[5_(A>"%I
M;CR7+(N!D[2P!/X@5S$'B[78+;3=4U71;6'2=0EBC0PW+//!YIQ&TB% N,E0
M<-QG\*ZE[)[[1GL=4,4KSPF*X,*%4;<,':"21U[DURUOX/UJ6+3=,U76X;K2
M-.ECEC$=N4GG\LYC61MQ& 0,D $XH TM'UO6-7UB[1=/M8=,L[N:VDG>9C)*
M5Z%$"XQG&23ZX%)K>OZI:^(K31-)T^WN;FYM7N!)<3F-(PCJIW84G'S=AUK2
MT;2WTM+U7D63[1>2W(P,8#MG'X5%-HKR^,+37/.4)!92VOE;>27=&SGVV?K0
M!Q^J?%!K">_98M(:#3)!#=1R:D$N)G7'F>3'CY@IR!N(SBM:Z\5ZQ?7FHQ^&
M-,L[Z#3E FEN;DQ>9(5W;(P%.<*1R<#)IK>$-6L-4U.71+_3H;74K@W4HN[(
MRR0R, &*$, 0<9P1UK$U^Y@\-:QKPL/%&F62WJ"6ZL9UWW0E*8S  RY++MP#
MD9_*@#I-(\7RZGJFA6C6B1C4]'&I,P<GRV.SY!QR/GZ^U8&OZT^M_P!A.\*Q
M?9/&0LP V=PC\U0WXU?L/"^JQZ-X5U#3Y;>SUC3]*CLIDNXVD1D,:;E(5@05
M91@@^M%IX#OX=.TZ"ZU6*YN;?7O[8FG\G9YN=Q("@\$EOI0!)K7C:]T/6Q!<
MPZ1]C:ZB@6$:A_IC*Y5=XBVXQELXST%16>NZ[;^.O$POS9_V-I\,4C@3ONBC
MVRLK(NW!9L#=DC&!@G%12^ =5,]]#%J=BMC<Z@+\NUH3<N?-638TF?NC! XS
M@ 5LW/A:XG\2ZI=&>V?2M7M$M[VWDB)D.Q74%&S@??&<@]* ,^V\8:[%;Z9J
MFK:';6NDZC/'#'Y=TSW$/FG$;.NP+@Y&<-D9]L5#!XU\0WVEZSJMIH5I]ATQ
M[B,^9=MYLYB)SL4)CH.YZU8MO"&MS1:;INKZU!<Z1ITR2Q"* I//Y9S$)&W8
MP, G !.*T]&TRV\(:#?C4KZW^RO=SW+S2X1%61R<-DX[XH DC\1B]UK2+/38
MX[BWO+1KV6?<1Y<7 0@8Y+,WMPIK?KAOAGH0T[2[K4-TQ2[E*6:S)M:.T1V\
ME<=1D,6Y]17<T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 &0"!GK17C_ ,0;V"ZN/$5S;6D$
M5SI$:*=0N=2>.1)B@9%@C&1G!]MQ)K7'V37/'FHVWB*[/V:UTF"6VA>8PIAP
M3++P1D@@#/;VH ])HKQ"WOK@^$/#=E:W8;2;O5[N.6:YN7C21%=S$CS %@&(
M'UQCUK9_LB_M;673I=5ACMYM;M EOI]\\KVF[[Z;R RAN"!VR: /5JKW]S)9
MV,UQ%:S74D:Y6"'&]SZ#) _6O.-1FNO#&K>*[#0O-6*/0EOH82[2>7-N=2RY
M)QP <>JBDU73=#TGX;W6I6%_<7-U)I^\W?VYVEG4LA=\;L9SCG'&<<9H ]0H
MKS#68-2U_P"(.L:8P@:*UM(3:17%]+;85P=\L8C4[B&XW'I@>M5]:MK^TTS3
MM<UF>#Q#9VFG*MY%:W[0E>6/VE""!)N4 <X/''>@#U>LNRU^TO=3U/3MLL%S
MIQ7S5F 7<C#*R+@G*GGGU!S5NRO+:[@4V\H;"(Q0GYU##*[@>0<>M<%\3-*D
MDOM&N;*[DL[C4[E-%NI(^KV\F6(]B"IP?]HT =KH>M6WB#2TU*SCF6VE9A$T
MJ[3(H) <#/W3C(SSCM6C7":K;6LOC?1O#4\LEKHR:;))#:Q2M$D\BLJA"5(R
M%7G;FN>6_FLY)[:VOYCHNG^)[2&&9YRP2,J/,C,A/*JYQ@DXZ4 >N45R6CWO
MVGXE^)($N3)'!9V:^6'RJ,?-)X['D5E^-[RWN];;2H[*>[N[;3VNY-VIM9P6
M\9)'F$CEF!'H<8[4 >@UFMK,*^)H]"\N3SWLWO/,XVA5=4QZYRWZ5YSI>I7'
MB*#P3INM:G<1VM]I\TTK1S-"U[,A550NI#?=)8@$9[TSQ5<2^'/%%NN@M*(4
MT26)[PNUT;.,W*;Y2&)9]G/&>/H* /6Z*\Y31HKSQ+H&EP:YJ<VF?V3-=221
M7\F;P^9$ S.&S@EL\$8Z#CBLB+4M1.B)HS:S=V]L_BF?2VO&F)F6W4L53S#S
MDD!<YSSB@#UVBO+M:MKVRUW6/#^B:EJ.P:-_:42-=O*T-Q'(-JAG);#@<J3@
M\\5ES>/;X:A=>*XYI_[#N[1K&S@.2HN1") >#C)DW1Y]1U] #U.+6[>7Q)<:
M&L4_VB"V2Y>0@>7M9BH&<YS\I[?C6E7E<4U_X9N]=G$C7.HV'A>U=GF+.7E7
MS22<G)YR:7P_!XFM9=-UJ#S6T]K%Y;U[C5C<BZ8Q[E=4(PF&_NXX.* /1-5U
M:#1X+>6X21EGN8;5?+ )#R.$4G)'&2,U?KQW[*LOA7P9KEQKU[<ZCJ&IV,DP
MDN6>.=FF5B@CSM781_"!]W!ZU?O3-J\'CK5;S6M0M)=*GD@LHX;MH4MQ'$K!
MMJMAMY/\0/M@] #U.BO*EO=3U5O!^D^9=W$,F@I?3Q17QMGN)-J+\T@^8XR6
MP",GD]*[;P?!K5KH7V;7&#W$4SK$YF\UVASE-[8&6 .">^,T ;]%>1:OKUS+
M?+K.D?VK%"FM1VAO+C4 (I5\P(\26^<%>3@[0>"<\5:DM]1O=.\<:O\ V[J<
M<VF7MP;&..=A'"8HU?[O1@<XVMD 9P,F@#U.J>FZG#JL$TT"R*L5Q-;-O !W
M1N48C!/&5./:N,\RY\2>/9]+N]1N[6SL],AN(X+6=H6FDD)S(2I!(7 &.F3T
M-:/PW01^$V07;W@6_O +ESEIL3O\Y/J>OXT ==17D7B?7+H7=YJ^CMK;QV>J
M1VSW4E\%M482(CQK"""R]LD=2>:U[J.;7M1\7W5SKVH:>FD_Z/;):W#1I !$
MKF5@#\Q)8]>P_$ 'HU%>7:<VH^(KGPC87&M:C#;W/A_[5=^1,4>=P8ARW4'+
M9R.>W>J4EYXLUBZ\0-I":E)<V-Z;6T9=1CCB@\HC&^-C\^\<DL#D'CI0!Z]1
M7EFIWOB?6_%FL6-O;ZD%TZ"&.-+"_CMU221 YD;<<OSP!]W"GUKO-.M[^^\*
MVEOK#RP:@]LBW3V\VUA( -Q5DZ9([>M $DVOV$2:7(DOGQ:E<"WMY8<,I8H[
M@YSTPAY&>U:=>/:9IC/X#\!I:ZE=Q276I1$R^;YAB_<3@B,-D+QD=.#]*VUU
M9]#NO&NGW>J:B]C86UO)!*TGFSQ-*C#",W4[@,9XR?2@#T5F"J68@*!DD]J9
M!/%=6\=Q!(LD,J!T=3D,I&00?3%>9Z5)J5SK&L:)>C6[*UETI;J-+R_$DZE9
M&&X,I.T,  5SV]ZZOP#9)9^"=(*7-S<>=9PR$SS&3;F-?E7/"J/04 =+17G;
M:Q>0^!_%MY)J<GG0:I=10NTF#"!*%1 >W; _VA4L4-WKOQ%\3:?/KFHVUG9P
MVK0VUK<>5@NC$MD<\>G0Y&<X% '?T5Y3I.N:OKA\,:+<:Q,L%Q)?++?VY$<E
MZMNY5-K=5R.3CDX-)K.L:KH]IXFT6TUBZE-I=V"VMY(X>6 SR?,A8_> "]#S
MA\'B@#U>HI+F&&:&*25$DF)6)"<%R 2<#OP":YC2DN=(\;-I']HWEY:3:;]J
M/VR7S&619 N5/8$'D=..,5#XITE+[Q?X;=KR^A+R3)B"Y:,#$3G( /!/0GN.
M* .GLM1@U!KM8-V;6<V\FX8^< $X]L,*MUYA>V=]#I?C?6;?6;ZVDLKN:>VA
M@8(BO'$C'<,?.&P 0V1@<4FJ:QKNO^(+:PLH]0-NNDPWCQ:?>QVTADES\Q9N
MH7' '&>OI0!ZA16-X9?61X8M#K\035$C*S@,K;B"0&RO'(P>/6O.?"^I>,];
MMM+UZ""]E%W>![EVOHOLWV;<59$AR"I '!^]D<]: /7Z*\ST#5=6N/&#>%9M
M6D>UTRYEF^V$DR7JKM(@W$=4+X?!R0 .YJO+<:I#\/KSQ=_PDE\U]:R3211-
M(OV?"3,HC9,#=D  Y).>F* /2X+Z"YN[JUC\WS;8JLFZ)E7+#(VL1AN/[I..
M]6:\KU/Q!KAM?&DEK>2P7%O<Z<EHI.1 9!%N ![$L<_6M;6%_LI[71#JWB;4
M]0N/,NO*M)(UE=?E4DOA0B*>0 1R<<]* .YEN8('B2:>.-YFV1*[@%VQG"YZ
MG )P/2H[:^M[N>YAA9R]M((Y0T;* Q ;@D ,,$<C(KQ^.74/$]IX"O;[5+^&
MZDO[BV=HS&K IYH#_=(WD* >H_G6]<^(]6B@\2P1WSI(-<@TZVG90PM4D$8+
M=.VXXSGDB@#TNBO-O$-WJGA"\:TM]:O;R*]TJ]E'VIE=X)H8MXD4@# )/(Z9
MQC XJSI$NM6MOX.U&YURYO&U4K%=Q2H@C(>W>12H R""@YSSDYZT >@4=!FN
M:\:ZC>V.FV$%A="TFU#48+(W.T$Q*Y.2H((W8&!D=367);7]CXI_L :[J,]G
MJ=A+/N9U:>T>-D&Y7(X5MY&"#@CC Z '3:+KMIKT,D]E'<_9U;"32PE$F'9H
MR?O+QUHU+7]-TK3+_4+BY5H+ ?Z1Y1WM&< X('0\CCWK#^&-HUK\/M'9KNXN
M/.MHY )F!$0*CY5P!A?KD^]>?7^F20>&?B3.=3OI5CNY(S%(R%')6,[VPH.[
MMP0,=J /;U8.BNIRK#(-+7#V_P#:7AS6].$VLWFI6MY93O+%<A!LDC57!CVJ
M,#&1@YZCTKG?#6L^,=6?1M:CBU>>*\N0UTCFV%FMNQ(.P!O,!7@Y/)VGCF@#
MTK5]<TW0H8IM2NA DT@BC)5FW,1G  !]#46D^)-(UR>XATZ\$\MN%,R;&4IN
MSC.X#K@U=O[V#3=.N;ZY;;!;1-+(?15&3_*N8\)Q7-IX9N/$,UI/=ZIJS?;Y
M8$*A\,!Y<2[B  J;1@GUH Z^BN*U_P 0ZM;Z+!K@TV^TV.PO8S=VUP8V,UNW
MRN?D9ON[@W4?=K%U[Q1K:6VIZCIL\C07FJ1:-IZQJK%,$K+*@; 9BX91DX^4
M=J /3Z*\SBU?6M(MM;?6Y]8T_2I(XA9W%VL$MQ',3M:-!&6W%N",CCGTYHR:
M_K^GZ/XNB,VKQBUTV.\M)-3$/GQLQ=?^6?!4[,C(!&#QZ@'K5! (P1D5C^'+
M.\MM.2:^U6YU"XN421VF5%5"1R$55&%YZ$GZUQ@.NWGAWQ!KI\37EK)I]S?"
MUBB6/R]L4C[1(&4ENF.". .^<@'I=%>477BK7_$&NK86<6JPPPZ;;W3+I/D!
MVDE0-EFF/W!TP!R<Y/2M*U/BO6+[0M.U#4[G29VTV6745A2/S'=)%4%3AE4G
M.>,\$C'H =Y9ZA;7_G_9W9O(F:"3=&RX=>HY R/<<&K.!7G-SK>L26MQIMMJ
M#PW%WXA?3H[QHPWV>(*&X[;L @9[FH]4\0:KX)U'5[)KZ;5X8]&?4X&O=OF1
MR*ZQ[24 !4[@>@/'7F@#T*XOK:UN;2WFDVRW<AB@7:3O8(SD<=/E1CSZ5/@9
MS@9KSR/2]1LO$7@VYOO$-WJ+7%Q*TL,ZQA0_V28[H]J@J!DC'/4>E>B4 <\_
MCKPO%JDFFRZU:Q7<<AB>.0E=KYQMR1C.?>NAKQG6[G5)-"\06$EA91^';O6)
MHKG5#)O:W#3 %S&!S@X .>.#VKKW_M#6_%=UH5IK=QINGZ59P,?LBIYMP\@;
M#;F4X4!1P!R30!V]%>8)KOB34=&MP]Q?&"RU*ZL=2O-+@0SR)%D)($(;&3C=
MM!]O2IY]>N]7U'2M&TG4]2GL3IOVV34+)8?/N/GV*/G 50""6P,YP.* /2*I
M:IJUAHMD;S4KJ.VMPP7>YZD] !U)]A5'PE+K,OAZ Z_$Z:@KNK%P@9U#'8S!
M"5!*XR!QFJOBG0+[5+O2M4TNZBBU#2I7EACG7,4V]=K*V.1QG!'3- &OI6L:
M?K=L]SIUR)XDD,3$*5VL,9!! (/(J]7GUQXGU+7[?3;.TDET34?[9.GWZ#;*
M4 @ED(4D8.0JD''I4-]?:]HUCJRKJEQ>+H5]!=-)(J^9-:,H:2-\  [06.0!
MT% 'H]4I=6LH-6MM+DFVWMS&\L4>PG<J8W'.,#&1U-<!KWBO6/M&JWNDWD<=
MB;BVTBRE8!HUFD8&2?ISMW!<=,@^XH_LR[T+XGZ,]SK%_JQ.F73 7 0LI79G
M;M Z^A_.@#TRBO)_"^L^,M8N-(UI8M5DM[VYW7,;BW%FENV1\@W>9E>#D\G'
M(]=[X?-K.JV\FLZCKMS<1BXN8([/RT6,*LI ).-Q/'7/3 ^H!U6JZYIFAQQ2
M:E>1VXE;;&#DLYQDX49)X]*LV5[:ZC9Q7EE<1W%M*-T<L;;E8>QKB?%4VJ:E
MXTL=/\.F"#5M.LY+IKB[YA\N7Y FT<EBR@Y[;>^<5G^#+NXEUG2M"@%W:MHL
M-R^KP3'.9I6!0$KA2"2[@@=,=* /1[N[M[&TENKN9(;>)2\DCG"J!U)-/0QR
MHLJ;65@&5ASD=C7-?$=U3X<^("[!1]B<9)QR1@?K7/\ B+5KFWMDL['5=8AO
MK'2TG:TT^S1PCX.UIF=3P<8V9'0F@#TBBO.X-<UOQ9J&C:;::B=(2;1(=4NI
MH(E:1VDP B;P0%!Y) /IQ5F236=5\6R>&8_$%S:0Z?8QS7%S%%$)[J1V.#RN
MU5&WG:!G- '77>K65A>V-G<S;)[YVCMTV$[V52Q&0,#@'KBKM>.7&IZMKNMZ
M#82WOEZAIVNW=A_:"PK^\"PD[PN-H;:V,8QG!QCBMG4+KQ7I5_K?AW1[^?4[
MHZ:E]97%SY9EA;S C(?E"G*@LN1U'>@#TJJL&H6=W>7=E#.DEQ:%1<1#K&67
M<N?J.:P/!%_#>6=Y$NK:G>W$$JK<0ZG&L<]LQ4?*0%7@]1U'7!JMX:_Y*/XX
M_P!^Q_\ 1% '4V^H6EU=W5K!.DD]HRK/&IYC++N /U!S6;=^,/#EA?265WK=
MA!<QL%>.6=5*D] <].HK(\*_\CYXW_Z^K7_TG6N:CFU6;Q)XXTK3_#RZDMW=
M(K333(L,1,*#YP>3CKP.U 'JRL&4,I!4C(([TM9^@Z:VC^'].TQYS.UI;1P&
M4C&\JH&?TK0H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#/NM!T>]N_M=WI5C<7.W9YTMNCOM],D9Q
M6-XCT'4=4O(3;6?A^X@C51$=1M#(]NPS\RXX/; XZ=:T;CQ3HMKK"Z3+>C[:
MS*OE+&[;2W0,0"%)]R.HK&L/'FE0W-[::OJ<,=S'J$UNB[#A$#[4WD#"Y]6(
MH U-%\*V&E^%(- N(XKZW13YHGB4K*S,68E>F,DX';BKUMHFE65NEO:Z99P0
M)()4CB@555QT8 #K[U5UGQ7HGA^9(=4OU@D9/,V^6SX3.-QV@X'7DXZ'TK U
MGQ-?V_B35;:SN8S9P^&FU& JJL/-WN ^>XP!QTH [(6EN+MKL01"Y=!&TNP;
MR@)(4GKC)/'O6=#X6\/6PG$&A:;$+A=LVRU0>8,YPV!R,\\U-HEY)=^'-.O;
MEP99;2.:5L8R2@).!5"P\;^&M3O;:SLM6AFGN5S"JAL/QNQG&-V/X<Y]J -#
M4M"TC63&=4TNRO3'G8;F!9-N>N-P.*BN_#.@W\L4EYHNG7#PH(XFEM48HHZ*
M,C@#TJ'4/&'A[2M0^P7VK6\-R "ZL3B//3>PX3/^T152\\<Z/8^+8/#\TN)I
M8/,\P*Q 8LH5>!W#$YS@8YZT ;\-E:V]S/<0VT,<]P5,TB( TFT87<1R<#@9
MHN+.UO#";FWBF,$@FB\Q VQQG#+GH1D\^]97B76QH2Z7-)/#!;37RPW$DQ 5
M4*.>IZ<J*LZ5XATG6HY7T^^BF\G_ %J\JT?H65L$ X[CF@"?4-)TW5DC34;"
MUO%C;<@N(5D"GU&1P:;_ &+I?]E_V7_9MI_9^,?9?)7RL9S]W&.O-5M-\4Z%
MK%VUKI^J6UQ. 2$1N7 ZE?[P]QD54UO6;NP\6^&=-A*?9]1EN%GW+DX2(NN#
MVY% &GIVAZ3I#RMINF6=FTV/,-O L9?'3.!SC)_.F:EX>T;6)XYM2TNTNY(U
M*JTT0?@]1SU'L:I+XDM-*\/QZCX@U734#.R^=;DB-R&. H)))P.0,\@U4UCQ
MA;65WX=GM[ZR;2=0FF$UT7!0(D3L"&S@?,H_E0!KW'AW1;O3H=.GTJSDLX/]
M3 85VQ'U48^4\]14MKHNEV3Q/::?:P&*%H(_*B"[8RVXJ .@)&<>M9&K>++)
M_"&M:KH.HV=Y+8VLDH,4@D"N%)&X ^U79_$>E:38V;ZQK%A!)-$K!WF"+)P,
MLN3TH LV>B:7I\T<MEI]M;/'&T:&&,(%5B&8 #CDJ#^%(^A:3+97-E)IUL]M
M=2M-/$T8*R2,<EB.YSSFK,MY;0V3WLD\:VJ1F5IBPV!,9W9Z8QSFL30/&NBZ
M_I<]]%?6T2V[2><K3KF)%=E#MZ!@NX?6@#2TS0M+T5)5TZP@MO-(,AC7E\=,
MGJ:C3PWHL>FV^G+IEL+.WE$\,.P;4D#%MP'8Y)/XU)IFN:3K2NVEZE:W@3&_
MR)5?;GIG!XJM=:I=0>+M-TM8XOLEU:7$S2'.\/&T8 '/3#G/'I0!>_LNR_M&
M;4/LR&ZFA$$DAYW1@DA2.F,D_G5+3O"N@Z1=_:]/TJUMIP"H>-,;0>H'H#[5
M9EUO2H+![^74K1;-&*-.9EV!AP1G.,^U/&KZ:=-&HC4+7[">?M/G+Y?7'WLX
MZ\4 9T7@SPW!=+<Q:+9I,LHF5Q']QPP;*^GS 'BN=\4>$KO6]1OQ#X=T0F[5
M8QJ<T[>8HV@;FB"89EYQ\W85U\6NZ1/91WD6IV;VLCB-)EG4HSG^'.<9]J=I
MVM:5JYE&FZE:7AB.)!!,K[?K@\4 4G\):+<:7IUA>V$-TFGPK#;O(OS( H7@
M]1D 9K3L;"TTRRCL[*WCM[>/.R.,8 R<G\R2?QIFH:KI^DVXGU&^M[2(G >>
M4("?09ZFF/K.EQVL-U)J5FEO.I:*5IU"R #)*G.#QS0!0/@SPVUR;@Z-:&4S
M?:-VSI)D'>/1L@<BM!=)T];>]MQ:1B&^9WN4QQ*6&UB?J !21:UI4\"SQ:G9
M20O*(5D2=2ID/1 <XW>W6K/VFW%V+3SXOM)3S!#O&_9G&['7&>,T 9VH^&=%
MU66&6]T^&62%=B/RK!.A4D8)7_9/'M5VQT^STRU%M8VT5M &9Q'$NU06))P.
MW)-,NM6TVR<I=ZA:6[@J"LLRH1NSMZGOM./7!]*0ZQI@U#^SSJ-H+TG'V;SU
M\SIG[N<].: ,V;P5X;N+R6ZFTF%Y99A.^2VTR#^/;G&[WQDU@^*/#-WJNIWS
MVWAG2YIKF,0IJ$UV5&-H&98@I#[3T!S]T=*Z^ZUK2K&Y6WO-3L[>=\;8IIU1
MFSTP"<TMQK.EVEVEI<ZE9PW+XV0R3JKMG@84G)S0!7TGP_8Z3:Z=''&))K"S
M6SBG8?/Y8"Y'XE0?PJ"\\'>']0OI;RZTN)YY\><<L%FQP-Z@X?\ X$#6A<ZO
MIMG(8[K4+2"0%05EF53EL[1@GO@X]<&L'QGXRM?#F@:E<6EW83:I:(&6SDF!
M8Y(ZJ#NZ'- &EJGA;1=9NA<WUD))PGEF1)'C9DSG:Q4C<OL<BM6**.&)(HD5
M(T4*JJ,!0. !5:\U?3=.ECBO=0M+:23[B3S*A?Z GFK$\\-M"TUQ+'%$N-SR
M,%4=N2: ,NT\*Z+81P16MBL4=O<_:H8Q(VV.3:RY49P!AFX''/2I;GP]I%XV
MH-<V,4IU&-(KK=G]ZJ9V@^F,G!'-2MK6E+:273:G9"VCD\IYC.NQ7_NDYP#[
M5E:KXC>VUKPU:V)MY[75IY$>4'=\JQ,X*$''4#GGB@"YIGAC1M(N'N+*Q6.>
M2/RGE9V=W3.<,S$D_C4^D:+I^A6IM=-@,,!;=L,C.!QC W$X'L.*D75M-?4#
M8)J%JUZO6W$RF0=_NYS6?I/BW2-:U:_TVSNXFN+*7RV7S%S)\H)*@') S@GU
M!H 2]\&>'M1N[BYN],CEDN"&ER[;688 ;:#C=P/FQGWK('@B"_\ &?B#4]6M
M5EM;Q+9;9DF9&PJ,L@.T@X)V\'@X]JZFTU33]0DD2RO[6Y>(XD6&97*'WP>*
MPM5\8VMKK.CZ?I]S97<EY??9;A4F#-"-C'. >#E<<T :-UX7T2\TVVT^738!
M:VI#6Z1@Q^21W0K@J?H::GA30X]-;3UTZ,6SS+.XRQ9Y%8,'9L[F.0.23TI_
MB3Q'8>%=$GU747(ABP BD;Y&/15!(R>_T!JP^M:5'8)?OJ=FMFYPEP9U$;'.
M,!LX/(/Y4 2FPM3J8U'RA]K$)@$F3]PD-C'3J :@U71-/UI(5O[<R^1)YD3+
M(R,C8(R&4@C@GO5V&:*XA2:&1)(G&5=&!##U!'6L%_&&ER7.KV5I<PRWFG0^
M85\Q2';:[;1@Y)&P[ACB@#2DT73Y;*_LWM@;?4"YNDW']X74*W?C( '%5+[P
MEH>HO:/<67[RTB\F"2*9XF1./EW(P)''0T_0=?M-9T^S875K]NEM8IYK:.4%
MHRRAN5SD#GO4EMJ\::6UYJD]C:*)9$+BY#1@!RHRQP,X'(['([4 7;6UALK2
M*UMTV0Q($1<DX Z#FL>'P9X?M[T7<.G^7()3,JI-((U<_P 00-M!]P*VXI8Y
MXUDBD62-N59#D'Z&HA?V9OC8B[@^UA=Q@\P>9CUVYSB@"A#X7T:WBL8XK)4%
MA,T]L0[;D=L[CNSDYR<Y)SGFL70/ >F6VG0G4K!6NQ</<2)YSF)GWL58H#L)
MQMY(KJ3?68E$1NX!(S% GF#)8<8QZTMQ>VMJ5%Q<PPENGF2!<_G0!0N/#.CW
M0U 368;^T7CDNOG8>8T>-AX/&-HZ8Z4FJ^&M,UF]MKR[BE%S;JR)-!.\3[&'
M*ED()4^E7IM0LK>T%W->6\=L>DSR@)_WT3BI'N8([<7#SQK"0")"X"X/3GI0
M!BMX+T+^QK72H;62WMK24S6Q@G=)(7))+*^=P)W-W[U9?PSHTMMJ%O)8H\6H
M2"6Z5V8^8X  ;D\'Y1TQTK0@O+6Z#&WN890OWC&X;'UQ21WMI-"\L5U"\2??
M=9 0OU/:@#(M?!VB6JW0%M),US UM))<3R2OY)S^[#,Q*K@XP,=!Z5HKI%@L
M&GP"W CT\JUJNX_NRJ%!WY^5B.<]:E%_9E96%W 5BXD/F#"?7TJ1;B%X//6:
M-H<;O,# KCUSTH @U+3++6+"2QU"W2XMI,;D?U'(((Y!!Y!'(JCIOA?2]+:Y
MDBCFEGN8_*EGN9WEE9.<)N8DA1GH*U8KB"XB\V&:.2/.-R,"/S%0-JEBMI/=
M?:X6@@4M(Z.&"@>N* %TS3K;2-,M=.LT*6UM&L4:DDD*!@<FLF]\&:/?S:B\
MT=P$U*/9=0I<.L4AX&\H#C?A0-W7BM#1-:LO$&DV^I6,FZ&= X!(W+D9PP!.
M#[5H4 4I-*M)=1L[]HV-Q:1O'"=YPH; /'0]!6=8>#])TN_%S9_:X8U8O':)
M=R"WC8]2L6=HZGMCDUO44 5-4TVVUC2[G3KQ6:VN$,<BJQ4E3U&15F*-(8DB
MC4+&BA54= !T%.HH P_%@OY_#]U9:=IGVZ>\B>##2(B1[E(W/N() ST4$_SH
M@\)Z6OA&W\-SVZS644*QX(P2P_C!ZALY;(YS6Y10!SW_  A6COIEU87/VR\2
MYV&26ZNY)9 4)*;7)RNTDD8QUIB>!M$2TU*W9+F7^TH5@NY9KEY))57.,LQ)
MR-Q&?3'I7244 -CC6*)(T&$0!5'H!7#Z1X!M9H;YM8ANE^T:C=3R6JW;"&X1
MIF9&D16VM\NWKSP >E=U10!A:IX2TO5;Z.^87-K>1Q^3Y]E</ [1]=A*$97V
MJ[;:+8V=U;7$$3(]M:FTB&\D"/*G'/4_*.36A10!BW'A72;JQO+.:!FCNKHW
MC$2$,DQQ\Z,.5(P,8I+#PGI-A'=J8I;M[Q/*N)KV9IY)$QC868D[>3QTK;HH
M YS3? ^C:5>6=U +N22R9C:^?=R2B %&0J@8D!<,>/8>E:'A_2Y-&T:&SFN3
M<SAGDFF.?G=V+,>2>Y-:=% &;;Z#IMMIUY8+;AK6\DEEGBD.X.9"2_7L23Q6
M;-X(TB6&S5'OK>:T@%M'<V]W)%,T0Z(SJ06'UKI** .>G\&:2]E:6=LU[806
MJLD:V-W)!D-@G=M/S$D9R<G.:)_!6BR6=A;P1SV(L$,=O)93M#(J'JNY2"03
MR<]^:Z&B@#"M?#45GK%E=QS2-;V5K)##%([.WF2.&>1F8DDG Y]SZU/K/AZS
MUM[>6>6\@GM]WES6ER\+@-U&5(R#@?E6M10!B6/A/2=.AM([>&0?9KHW@=I6
M9Y)BC(7=B<L2KGK[>E1:Y:3V=GJ=QI.E27]_J2B-T\U%0$(5#-N(^4=\9/M7
M044 <UHW@O3[#P);^%KM%N;98=DW\.]R=Q88Y'S<CN,"I-.\&:5INJ0ZFDE]
M<7L,;1)-=W;S,$;'R_,3QQD#W-=#10!SVG^"]'TO4/M5G]KB02F9;074GV='
M/5A%G:#U[=ZT](TBST.P^Q6,92'S'DPS%CN=BS')]R:O44 8VI^&-/U34XM2
M=KJWOHXS$+BUG:)V3.=K8/(SS@U1@\!Z/9WUM>V3WUK<Q-NFEANG#7?.<3G.
M9.?7UQTXKIZ* ,C6_#=AXA\E-1-R]O&<M;+.RQ2\@XD0'#C('!JCK7@C2]<O
MY;R>?4('GA$%PEI=O$DZ#.T.!][&3CZFNEHH YRY\$Z5/;Z<D$E[93:=;K:V
M]S:7#1RB( #83_$.!U%+=>"],NWMIC<:E%=P0_9_M<-[(DTD><[7<'+C//-=
M%10!S,_@+P_/IUA8FUDCBL7:2!HIF1Q(PP9"P.2^><GG/-3V_@_3;:QO+>.6
M_P#-O"AFNVO)#<-L.5_>YW #L >Y]:WZ* ,O1= L="2X^R^?)+<.'GGN)FEE
ME(&!N9B2<#@5GWG@G3;O6;O55N]4M;J\V>>;.^DA#[%"KD*1T KI** .6?P'
MIC7]Q?1WVL6]Q<B,3O;ZC+'YFQ0JEL'DX'4^]:^EZ'9Z1<7L]L)3+>.LD[R2
M%RS*H4'GV K2HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH \WO$OM-\:F7PU::Q'+>:A'_:4
M,]F39RQ\!I5D(PK >C9/I5RXTF9O 7C2W%A*;B[EU!XXQ$=\Q.[80,9;.%QC
MKQBN\HH \K\37.O2G4M*:TUR.S;2HXK-=.LA(MS*4.X2R%24 ) QD<9J.WTC
M4U)SIUV/^*%CM>86_P!<-V8^GW_]GK7K%% &/HL,L7@W3X)(G29-/C1HV4A@
MPC ((]<]JXK3-'NX/AOX+M)--N$NK?4;262+R&W18D)9F&/EP"<DXZUZ;10!
MYC'-<Z'8^*](NO#NJ7-UJ%[=36\EM:--%<)-]S<X&U<9 (8\ 5<TVTO?#6M^
M$X[VSO+A8]%;3I9[6!YDCEWPGYRH.U?E/)XXKT*B@#DO'VZ.ST:Z&F7>HQVN
MJPSR06D+2N%57^;:/0D&N:OH=0\8:UKNI:387MI;G0)=/BENH6@:XF9MP"A@
M#@8(R>YKU*B@#RWPK$-5UG0GO'\2+>:7&2+>ZTR."&V)CVE6=8UR".@SSQQ7
M1>)(9Y?B#X+:*VFDBBDO'EE2,E(QY!4;CT&20!GK7844 >71:GJ^F:)X;@$%
M[I]E.UT]S=QV/GS0-O8HFTA@N[=U(/ZUBZ5;W-EIOAF\U31]3EA@UN\NI8YK
M(^:B,K%9&C &,$AN!VXKVNB@#R+Q MWK$GC/7-*T^Y6RET5;%2]NZ-=R;B2Z
MJ0"0JG;G':GRQ:E9>*I;K5KS5[."_P!+MDBEMM/2X4E4Q)"RM&Y4EB3C SGG
MH*]:HH R/"UA#I?A;3;*W^U>3% H07:[90.H#CL1G&.U>=3QSW'@6"R&GWDS
MZ3KINM1M/(<-)!]ID<[01A\@@X&>E>N44 </:21:S\2[;4]*M9DM;739(;N[
M:%HEE+LACC&X#<5VDGTS5;X@V&KZGK>FP:4K@QV-T\HP0MPFZ'=!O'W"X4C(
MYKT&B@#R36Y_-C\'ZIIUO<:)I>G_ &B*=9=/,IL)-BA=\?7LPW>^>]5;K2)X
MM'M=1L]2GNK-]>^VW$XTDA8R8MOF"#JR[MO/8Y->RT4 >):Y86SZ6VI-J$^N
MV]]X@LFN8HM/\I)-@(?RU_C++P2."179V,MIK7Q*M]3T>!E@M-.D@O+KR2BR
MEF3RXAD#)7:Q..G2NIU?1X=8%B)998_L=W'=H8R!N9,X!R.ASS6C0!Q?C?6+
MO3]4T6UA:*S@N&D+ZG+9FX\AE VHH'1FSC/M7'^&;;[=I/ABPU"RGFBD\175
MR!/;F-0JQRLI*'[N68$#IP:]DHH \ZN_#CZKJWC>QAA:#S!9W5FX7:OVE49@
MX[$[E7-7O =P?$TUUXSFA:-KR-+2V1A]R*/[V/K(7_!5KJ-8L;K4;!K:TU&6
MP=C\TT2*S;>A W=#SUZBI=-T^VTG3;;3[.,1V]O&L<:^@ Q^= '-6VF6MU\4
M-8N[BU25X=.M%B:1 0NYIMV,]^!7 6.EFZ272]4UW[!JSZJ9GMUTK=.TOG;E
MD23.2I !W#@+GL*]NHH \ZT.YTG2=;\0VWB*)$U*ZU1I83/ SFXA(41%.#D#
MD8'0@]*R4.FV?AKQ-I&N633^(KF>Z/EM SR7A8GR6B."<8V@8/R[3TQ7K=%
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MS,=OIEOXJ'VE7A,D,4!B1SN12/W8D920"!^%>P[1D' R.GM1M7!&T8;KQUH
M\1UG3K>YTG47CUK3-4M;R_L%N(-,MC' K>:%+ AV7<R\'!SP,^_<2:+I=EXU
MN8K;2[<07&BN9K:.,!)BLHVY7H3R1G'>NU$:*NT(H7.< <4N!G.!GIF@#@_A
MOJV@6W@O0;2"YLTO+B-8)(XL;VG5,LK@<AL GYJ[VFB.,'(10<YSCO3J "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>arwr-20250930_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 arwr-20250930_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ' !, # 2(  A$! Q$!_\0
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M )^?@_\ (^G**^8_^&Z-!_Z%N^_[_K_A1_PW1H/_ $+=]_W_ %_PH_L+,?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO.W[/]GS<_[5<)XP^!^N^*O@4W@>^\93Z[KLM[:WMQK^JVZKYK1WT=TZB*/
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M5-=S:,\SF25;62*9 \9D=W5) =N< D= #R_X0_$_Q3X'T3Q#=SZ1::7K.O\
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M,EL-1;:0OVJ6>21@@SGRXPH) ).!@^ST %%%% !1110 4444 %%%% !1110
M5Y+\!8SK\WC#QI-\TNN:M+' Q[6L!\J(#\FKU'4W:/3KMER&6)R,>N#7G?[-
M2A?@;X28<E[9G8^K&1B37H4O=PE62W;BOEJ_S2..I[V(II]$W\]%^K/3:0G
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MX3W%L)) VP87#DD#//6NC\-?&^&?XG?$_3==U31]-\*>&XM(ELM3FF6%&%W
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M&L:G:/;6GPUT_P G4[21,(OBB96BN(\'@_9XE?!'_/T"* /6O@-\4KGQ_P#
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MHD#;4:ZOKI+:!I".BM(P'/.!G-6].\0Z7J\BQV&I6=Z[0)=*MO.DA,+DA)
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MOC;X&7W@E?!)GU6WNO\ A*3&(?+B9?(W^7C=GK_K!T]#7L7QS\"ZY\6OA?\
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M(VGPAM_@S8^(/B#X134==O;8:W>O/%;PW-DUI.SW<*O(?+A:9(\/DCY@,\T
M>Y^$_!7A[P%I":5X9T+3?#NEHQ9;+2K2.VA!/4A$ &?PK*'P?\!CQ?\ \)8/
M!7AT>*=V_P#MO^RH/MN[U\[9OS[YJEX&O]?N_'?C6/4O%>@ZYHZ26LFEZ5ID
M&R[TV)XRQ^TMO;?YG#*=HX!ZYXN:3\8_ 6O^*I_#&F>-O#VH^)("1+I%KJD$
MEVA'4&)6+#'?CB@#HTT73XM8EU9+&V75)H5MI+U8E$SQ*2RQE\9*@LQ S@%C
MZTVQT'3-,2]2ST^UM4OIGN;I88503RN 'D? ^9F &2>3@5C^)?BAX.\&)J#:
M_P"*]%T-=/6)[PZCJ$4 MUEW>49-[#:'V/MSUVG'0UJ^'?$ND>+]&MM7T+5+
M+6M*N5WPWVGW"3PRCU5T)!_ T <OIWP(^&ND'4C8_#[PM9'4_P#C^-OHUO&;
MKYMW[S"?/\P!YSR,UM>,_A[X6^(VG)I_BSPUI'B>QC?S$MM8L8KN-6_O!9%(
M!]ZQ;;X[_#:]U/4].M_B#X7GU#3(WFOK6+6+=I;5$&7:10^5"@$DGICFLK2_
MB'J>H?M%ZEX12>WE\.Q>$[/68#&@+M-+=3QEM^>5*1I@?CGF@#MK?P7X?M/#
M!\-P:%IL/AXPFW.DQVD:VAB/5/* V;3Z8Q3O"O@_0? NBPZ/X;T73_#^DPDF
M.PTNU2V@0DY)"( HR>3Q6;KGQ3\&>&=433-7\6Z)I>I27$5HEG>:A%%,T\HS
M%&$9@2[CE5QD]JA\3_&'P'X)UVTT7Q#XU\/:%K%WC[/I^I:I!;SRYZ;8W8,<
M^PH U1X)\/*D2C0M-"Q7YU2,"TCPEX22;@<<2DLWS_>^8\\U=U#1-.U:XL9[
MZPMKR>PF^TVDD\*NUO+M9/,C)'RMM=ER,'#$=ZEO=1M-.L9;V[NH;6RA0RR7
M,T@2-$ R6+'@#'<UR/ASXW_#KQC%YF@^//#6M1_:8[/=I^K03CSY#B.+Y'/S
ML> O4GI0!V4\$=S#)#-&LL,BE'C=0RLI&""#U!KC-%^!OPX\.)>+I/@#PQI:
MWDB2W(LM'MX1.Z.'1GVH-Q5U# GH0".:ZG2]=TW7#>#3K^VOS97#V=R+:99/
M(G7!:)\'Y7&1E3R,BO,_B;\69M(USX<0>&=2L+VUU?QA_P (_JC1E9]@6VN7
MEBR#\DBR0J#GD8((H [CQI\.?"GQ(L(K+Q;X9T?Q/9Q-OCM]9L(KN-&]0LBD
M ^XJQH?@OP]X8F\[1]"TW29?L\=IOL;2.$^0A8I%E0/D4NY"]!N..M9?B[XO
M>!?A_J5GI_B?QGX?\.7]X0+:UU74X;:6;G'RJ[ GD]JY#X_?';1?AM\$/''B
MO3?%.AV^HZ5:W%O9RW5U$T7]HB R16Y&X;I#\I$>=Q!'K0!U^E?"'P)H7BR?
MQ1IO@OP]I_B6X+&;6;72X([R0M]XM,JASGOD\UNCPYI(N]2NO[,L_M.I1I%?
M3>0N^Z10559#C+@!F !S@$^M<UX2^+'A?7_AA8>-3XIT6;06M5DN-9BOHOL2
M.!B3,N[:-KY!!/!&*T_"'Q(\)_$'2)M5\+^)]'\1Z9"2);S2;^*YBC(ZAG1B
M!T/6@!FO_##P=XK\.6?A_6_"FB:QH-EL^RZ7?Z=#/;0;!A-D;*57:.!@<"NB
MM[>*T@C@@C2&&)0B1QJ%5% P  .  .U<AI_QI^'VKZU;:/8^./#M[JURL30V
M-OJL#S2"12T95 V3N )7CD#BNDO=>TW3=1T_3[O4+6VO]19TL[6:95EN2B[G
M$:DY;:HR<9P.30!)!I5E:ZA=7\-G;Q7UVJ)<7*1*LLRIG8'8#+!=S8STW''6
MDM-&T^P@N8+6QMK:&YDDFGCAA5%ED<Y=V 'S,Q)))Y.>:R/%GQ(\)^ T9O$O
MB?1_#RI ;EFU2^BM@(@RJ7^=A\NYE7/3+ =ZJ^+/BYX&\!Z=87_B7QEH/A^Q
MU !K.XU34H;:.X!&08V=@&!!!XS0!JKX/T%-,TO3ET73UT_2Y(Y;"U%JGE6C
MQ_ZMHEQA"N>"N,=JM6NAZ=8ZG?:C;6%M;ZA?B,7=W%"JRW&P$1^8P&6V@D#.
M< \57?Q=H<>GZ=?MK-@+'4I8X+*Z^TIY5S))Q&D;9P[,>@!.>U6-5US3M"2V
M?4K^VL%NKB.T@-S*L?FS2'"1KD_,['@*.30 MEHFG:=?W][:6%M;7FH.LEY<
M0PJDERRH$5I& RY"J%!.<  =!0NBZ>NL/JXL;8:J\ M6OA$OG-"&+",OC.T,
MQ.W.,DFN0^%6HZX/#>L2^+/%F@^);NTU.[C:]T6'[/!:Q(W$$H+MB2/!#DD8
M[CC)T/!GQ;\#_$:ZN[7PIXRT#Q-<V9Q<0Z1J<-T\/./G$;$KSZT )X@^$/@7
MQ9XBMM?UOP7X>UC7;7'D:G?Z7!/<Q8Z;9&4L,=L'BM.+P5X>@2V2/0M-C2VO
M7U&!5M(P(KI]V^=>.)#O?+CD[FYY-2VGBK1;_P /MKMMJ]C/HBQO*VI1W*-;
MJB9#L9 =H"[6R<\;3GI3]1\2:3H^G0:A?:G9V=C.\445S/.J1R/(P6-58G!+
MLRA0.I(QUH EFT33[C5K;59;&VDU.VB>&"]>)3-%&Y4NBOC(5BBY .#M&>E5
M[KPKHM]<ZA<7&D6,]QJ-L+*]EEMD9KFW&[$4A(RZ#>_RG(^9N.37#?&/Q[K'
MA[7/ 'ACPT\$>N^)];2!I)XO,6&P@0SWDFW(Y\M!&">C3*?:NC\:?%GP1\.+
MBT@\6>,-!\,SWAQ;1:QJ4-JTQSCY!(P+?A0!J?\ "(:$)5E_L;3_ #4LCIBO
M]E3(M#C-N#C_ %? ^3[O XINH>"_#^K>&1X<OM"TV]\/"%;<:3<6D<EKY2C"
MIY1!7:   ,8&*A_X6!X7^S7-Q_PD>E?9[:XAM9Y?ML>R*:;9Y,;'=@,_F1[0
M>6WKC.16;H_QD\ ^(?%,_AK2_&WAW4O$4!(ETFTU6"6ZC(Z@Q*Y8$=^.* +'
MAKX5>"O!D5C'X?\ "&A:''8R22VJ:;IL-N+=W4J[($4;2RD@D=0<&MS1]%T_
MP_8K9:78VVFV:N\@M[2)8HPSL7=MJ@#+,S,3W))[UC^(_B;X0\'+J#:]XIT7
M1!I\<4MX=1U"*#[.DA81M)O8;0VQ]I/7:V.AJ30OB'X6\4>&9?$>C>)-)U;P
M_$CRR:K8WT4UJB*,LQE5BH ')R>* *#?!SP"WC#_ (2QO!'AT^*=WF?VV=*@
M^V[O[WG;-^??-=&FB:='K,NKK86RZK+ MK)?"%1.\*LS+&7QDJ&9B%S@%B>]
M8^A?$OPCXHNM5MM&\4:-JUQI2))J$5E?Q3-:*ZED:4*QV J"06QD FH/!OQ;
M\#_$6[O+7PIXRT#Q+=69Q<PZ1J<-T\/./G$;$KSQS0!MG1;.UU"^U6ST^S36
M;J!(9+LQA9)ECW&-)) -Q52[8'.-S8'-<=\"_AI=?"WP#'I^K7D.I^)+^[N-
M6UK48%*I=7UQ(9)67/.T9"+GG:BUVFDZYIVOPS3:9?VVH103R6LKVLJR".:-
MBLD;$'AE8$%3R#UK-N_B#X7L-#U#6KKQ'I5MH^GS26]YJ$U[&EO;RQL5D220
MMM5E8$$$Y!&#0!,W@GPZ_AAO#C:#IC>'F0QMI+6<9M2I)8J8L;<$DG&.IJ'P
M9\/?"WPXTY]/\)^&](\,6$C^8]MH]C%:1LW]XK&H!/O5/PQ\6?!'C6.QD\/>
M,-!UU+^22&U;3=2AN!.Z*7=4V,=Q506('( S7 _"'X\V-W\'K#Q7\1/$FB:!
M)=:OJ&G)=7UQ'8PR&*^GAB1=[ %MD:\ Y)!- 'JMOX4T2U\.OH$.CV$.A/$\
M#:9';(MLT;YWH8P-NUMS9&,')SUI]]X;TG5-(CTJ\TNSN]+C\O993P*\*^6P
M:/"$8&TJI''!48Z5H1R++&KHP=& 964Y!!Z$&N+B^.'PZF\0WN@Q^/?#,FN6
M2/)<Z:NKVYN(54;F+Q[]R@#DY' H ZFVT73[+4KW4;>QMH-0O1&+JZCB599P
M@(0.P&6V@D#/3)Q7.6WP;\ V?B]O%=OX(\.0>*&8NVM1Z5 MX6/4^<$WY]\U
M:U/XG^#]%M/M6H>*M%L;;["NJ>=<ZA%&GV1B%6XW,P'EDD /T)(YJ*Q^*_@G
M4_!MQXNL_%^A7?A6V5FGUN#487LH@/O%I@VQ<9&<GO0!O6VBZ?9:E>ZC;V-M
M!J%Z(Q=74<2K+.$!"!V RVT$@9Z9.*Y_Q1\(_ WC?6;35_$7@SP_KVK6>/L]
M]J>EP7$\.#D;'=2RX//!KP[X3?'C6OC9\$?!/B+0OB-X,L-=&MQ6_B%IT2='
MC:>1%M$191Y4\B^5LSDG/ YKWKQM\2O"/PTL8KWQ=XHT;PO:2MLCGUB_BM$=
MO13(P!/TH U;O0=-O[O3KJYT^UN+G3G:2RFEA5GMG*%"T9(RA*,RDC'!(Z&E
MN]#TZ_U*PU&YL+:XU"P\S[)=2PJTMOO7:_EL1E=R\'&,C@UP_P 2_$U_J_PN
M_MSP%XW\-:&))8)8O$6J!;S3C 9%##*R*I+9V@[NI [UN>(_BIX,\&17[^(/
M%VAZ(-.\H7K:AJ$-N+<R F/?O8;=P5BH/4 XSB@"/Q#\(/ ?BWQ#;:]KG@KP
M]K.N6V/)U/4-*@GN8\=-LCH6&.V#Q70W6B:=?7]A?7-A;7%[8%S:7,L*M);E
MUVN8V(RNY>#C&1Q5;POXMT/QOHT.K^'=9L->TJ;_ %5]IEREQ"_T="0?SK$G
M^,G@&U\7CPI-XW\.Q>*"<?V*^JP"\SZ>27WY]L4 =)_8FG_VS_:_V&V_M7[/
M]D^W>4OG^3NW>7OQG9NYVYQGFJ=[X,\/ZDNKK=Z'IUT-75$U$36L;_;0B[4$
MV1^\"C@;LX%>/?'[]ISPW\,=,^'E[9^-O#5E;^(?$%C$\UY?0E)M,:0K<31D
MN!M48S(,A<\UZGXF^*'@[P7X>M=>\0>*]$T/1+H(UOJ6HZA%;V\P8 J4D=@K
M9!!&#R#0!)XR^''A/XC:=#8>*_#&C^)K&%M\5MK%A%=1QMZJLBD ^XJUH?@S
MP_X8D631]#TW276W2T#6-I'"1 A9DB&T#Y%+L0O0%CCK5G0/$.E>*M)M]4T7
M4K/5],N5W0WMA.LT,H]5=201]#7GWCCX\^$+'1_&&FZ!XT\.WGC72-*N[M-'
MBU&&:ZCDBA9QO@#[\ @9&* .OE^'7A2X\8Q>+9?#.CR>*HHO)CUQ["(WJ1XQ
MM$VW>!@D8SWKG+;X:W]Y\=[SQYJ]U;7%C9:.FD:#91@E[;S'\R\F<D8#R%(4
M&W^&+_:(K*MO%GBCQ1^S!H_BBR\0:-X9\4ZAX;L]4DUK5K?=86LCP1RRR.FX
M83!?^+ X/.*ZNY^)'AOPEHR-XH\7Z#8W-II\-[?7,]Y%;1"-\J)\._R1NZN%
M)..",DB@#H8=$TZWU>YU6*PMH]4NHHX)[U(5$TL:%BB,^,LJEW(!.!N..IHM
M=$TZRU2^U*WL+:#4;X1K=7<<*K+<",$1AW RVT,P&>F3CK5;PKXOT+QSHL.L
M>'-:T_7])FR([[3+I+B!\=<.A(/YUYO\2?B)XZN/B%#X#^&^E:0=7BTU=7U'
M7/$JSG3[2%I&CBB1(BK2S.4D. ZA%7)SN (!U,/P/^'-MJ^HZK#X!\,1:IJ4
M;Q7MZFCVZS7*.-KK(X3+A@2""3D=:Z33_#6D:3>-=V.EV=G=O;Q6C3P6Z(YA
MCSY<98#.Q=S;5Z#)QUKY_/[3WBBR\*WNC7?A.PF^+4'B:/PA%I-O>L--N;N2
M 7*7:RE=ZVXMR96!4NNTIR<$[_AKXP^,_!/C)_"GQ:LM#6ZN=)NM:TS6O"RS
MBVNDMMIN;<P2EG69%='&&8.I.,%2* /2/%WPF\#_ ! O[.^\4>#M \1WMGC[
M-<ZMID%U)#SGY&D4E>>>*W+W0-,U%;!;O3K2Y&GS+<68F@5A;2JI57CR/D8!
MF (P0"?6OFZZ^/WQ;\/>#=.^*FO>%/#=K\,[LV]Q/HL<\_\ ;UA8SNJQW$CG
M]R[J'1W@"@@$@.2O/J?QV^+EQ\,-"TRST'3XM=\=>(KM=,\/:+(Y5;FX/+R2
M$<K!"FZ21^RKCJPH ] GT73[K5;75)K&VEU*TCDBM[QXE,T*/MWJCD94-L7(
M!YVC/2B/1-.AUB?5H["V35)X4MY;U85$TD2%BB,^,E068@$X!8^M6;?S?L\7
MGE#/M'F&/.W=CG&><9J2@#D(/@]X#MO%[>*X?!/AV+Q0S;FUI-*@%X6]?.";
M\^^:Z^BB@#S/P1\)'\.>(_BBNI"PU/PKXNU--3BTZ6,R%6>UBANDF5AM97:(
M,!SPQ!KTB"".VACAAC6**-0B1H,*J@8  [ 5)10!RGC;X3^"/B5Y'_"7>#M!
M\4&#_5'6=,ANS'_N^8IQ^%;FD:#IGA_2H=,TO3K33=-A79'9V<"Q0HOHJ*
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MB#X2^%;?Q_:_%.Z\.:7\3GUO4)/$S>+FACN+N%IY#:M$9_\ 66OV;RA&$RH
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M_$GB#]G/QWKLOA+39+]?BB$M='@CC+16GB?"Q+))CA8I8<2N3WLW[O6)XJ\
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MCQ%XR^!/A;5_%,T]WJMQ%+B^NK;[-->VZS.MO<O%@;&EA$<A7 Y?H*]5HHH
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MW_/Y?<_\@_LO&_\ /O\ %?YGRY17U'_PPIJW_0SV7_?EZ/\ AA35O^AGLO\
MOR]']N9=_P _E]S_ ,@_LO&_\^_Q7^9\N45]1_\ #"FK?]#/9?\ ?EZ/^&%-
M6_Z&>R_[\O1_;F7?\_E]S_R#^R\;_P ^_P 5_F?+E%?4?_#"FK?]#/9?]^7H
M_P"&%-6_Z&>R_P"_+T?VYEW_ #^7W/\ R#^R\;_S[_%?YGRY17U'_P ,*:M_
MT,]E_P!^7H_X84U;_H9[+_OR]']N9=_S^7W/_(/[+QO_ #[_ !7^9\N45]1_
M\,*:M_T,]E_WY>C_ (84U;_H9[+_ +\O1_;F7?\ /Y?<_P#(/[+QO_/O\5_F
M?+E%?4?_  PIJW_0SV7_ 'Y>C_AA35O^AGLO^_+T?VYEW_/Y?<_\@_LO&_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %^R/^>7_@+/MFBOB;_AN?Q=_P! 31/^_<W_ ,<H_P"&Y_%W_0$T3_OW-_\
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M1/\ OW-_\<H_U;S#^5?>@_U^R/\ GE_X"S[9HKXF_P"&Y_%W_0$T3_OW-_\
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MXTZP5[RT-XD^;IQ&=KQ9/"^AQCGZ]*G:#5OM&I%;FW$+H!9@H<QMMZOZC/\
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MHB$7P$9!D; P4]!G/^>*8UOKGV/4%%U:_:7ES:ML.U(\]&XZXXSSSS[5LT4
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M5?BUX(T+Q/'X<U+QCH.G^()$\Q=*NM2ACN67&<B-F#8P">G2@#K**XZ+XR>
MI]&T;5X_&OA]]*UFY-GIE\NIPF&]GW%3%"^[$CY!&U23D&DL/C-X U73=9U"
MR\<>';NPT5MNIW4&JP/%9'.,3,'Q'SQ\V* .RHKG=+^(WA36_"DGBC3O$VD7
MWAJ-6=]8M[Z)[1%7[Q,H;: .^3Q4G@[Q[X:^(FD_VIX5\0:7XDTW>8_M>DWD
M=S%N'5=R$C/M0!O45YY^T#\2KWX1_"'Q%XHTNSAU'6;:..'3K.X)\N>[FE2&
M!&VD'!DD3."#C/(K"_:-^(/C?X3_  @?Q9X?3P_<WVE-#)JD6IPSM%-$S*CB
M (X*MN8$%R0 .0>M 'L%%>;?'#XIZA\-]&T2U\/Z5#KOB_Q)J4>D:+I]S/Y,
M!F9&D>69P"1%%'&[MM!)"@#DBL+X?_$SQQI/Q*M_ 'Q.LM!75M3T^74]'UGP
MUYR6=XL+HL]NT4Q9XY4$D;?>8,K$C!4B@#V:BJ-UKFG66JV.F7%_;0:C?+(U
MK:22JLMP(P#(44G+;0P)QTSS3TU:QDU273$O;=]1AB6>2S653,D;%@KE,Y"D
MJP!Q@E3Z4 6Z*\?^(GQA?1/BC\-M#T;5M-ETW4=:O]-U_P"99&M_)TV:Z",P
M/[I@5C8YYVGWS7=>"_B=X/\ B.MX?"?BK1?$PLW\JY.CZA%=>2W]U_+8[3]:
M .FHKCO$/QD\ ^$O$EMX>USQMX>T?7KG'DZ9?ZI!!<R9Z;8V8,<]N.:Q/B!X
M]U?P]\8_A5X<LI(5TOQ%-J:7ZO'N=A!:&6/8V?E^8<]<B@#TRBO)?V:_BS-\
M3_A;X:O==U*PE\6WUG+>W%G;E8W\D7,L*RB+)(3Y N[ID&O2[;7M,O-8O=)@
MU"UFU2RCCENK*.96F@23/ELZ Y4-M;!/7:<=* +]%4-=U_3/"^DW.J:SJ-II
M.F6R[Y[R^G6&&)?5G8@ ?4UA^'/BQX)\8>'+WQ!H/B_0]:T*Q5GNM2T_489[
M>W502Q>1&*J  2<GH* .KHK/N?$&EV>G6^H7&I6D%A<-$L-U).JQ2F0A8PK$
MX)<LH7'4L,=:9JWB;2- GM8=3U2ST^:[\S[/'=3K&TWEH9)-@)&[:BLQQT )
M/% &G17$CXW?#LZ[INB?\)WX;_MG4XHY['3_ .UH/M%U&Z[HVCCW[F# @@@<
M@\5N>+?&OA[P#HTFK^)M=TWP[I49"O>ZK=QVT*D] 7<@9]LT ;5%9'A7QAH/
MCK1H=7\-ZUI^OZ5,2([[3+I+B%R.H#H2#^=8=[\8_ UOXIE\*#QIX?'BT(Q7
M0SJ<'VW< >/)W;\\=,4 =G17C_[.GQC/CSX,?#;6?%NKZ9;^*_%-B9H[8.EN
MUW*NYI!#$6RVU1DA<X')KJ?C7\2U^#OPK\1^,GT^35?[)M_-6S1Q'YC%E1=S
MD'8@+ L^#M4,<<4 =O17@?AKXL?$?PS\4/!_A?XAV_A#4+;QBER=,G\(O<>;
M9O##YS><LQ/FQ%05$R[ &V K\XQ[;J^NZ;X?A@FU._MM.BGGCM8I+J98UDFD
M8+'&I8C+,Q  ZDG H OT5QOA[XS> /%WB.X\/Z'XW\.ZSKMN2)M,L-5@GN8\
M=<QJQ88[\5I>-/B%X7^'&EKJ7BSQ'I/AG3V8(MUJ][':Q%O0-(P!/M0!T%%<
MM9?%7P7J5@]]9^+=#N[)+$ZFUS!J,3QK: E3.6#8\L$$;^F0>:\G_:,_:J\)
M_#OX2>*=6\-^/O"I\2:;+!:Q0R:C!-MN'D4F)HP^2_E>8VWKA2>@H ^@:*XX
M?&7P"='CU;_A-O#W]E261U)+XZI!Y+6H?RS.'W8,>_Y=V<9XSFM;PAXX\._$
M'1TU;POKVF^(]+=BBWNE7<=S"6'4;T)&1Z9H VZ*XZW^,O@&\\8OX2@\;^'9
MO%*,4;18]5@:\##J/)#;\^V*L>)OBIX+\%W36WB#Q;HFAW*M$IAU'4(H'S*6
M$0VNP.7*L%'?:<=* .IHKD?&'Q?\"?#W4K/3_%'C3P_X<O[S'V:UU;4X;:6;
MG'RJ[ GGCBNFDO[6*Q:]>YA2S6/SC<-(!&$QG<6Z;<<YZ8H L45X%\6_VE]$
M3P%'JGPU\8^'/$=_!XBTC2[W^S[R&^$,5Q?0P2AEC<[24=@">AKM_"OQ)O\
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MK]K6'P&T[>,9?A[I8L_LAQ<,3#;^8(\<^84+;<<[B,<XK]#7\$>')-!CT-M
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M'OQ,U7]E2;]C+3M-\+:+J,'QLMK>V^V,8+D7,-T'4737$C#RC"27 4<C=&,
M@X^AOV@CX&T?]IKX2ZM^T#97M[\'7\ VT.C/Y<TMA%J&T&3S4B^8G') !/,1
M((''Z63_  \\*W4FHR3>&='FDU+'VUY+")C=8(8>:2OS\@'YL\BO#_VFOV9O
M'/Q7U#3M3^'_ ,49_!4EK;K:RZ#J.GQ:EHTZJ3MD^RRAD20 XW;3P%QC&2 ?
M#/[.\6C:G\7_ -J?_AG&TU#3[&Y\$EO#4;K)'*TC;"6MQ)\ZJS[S'NY&5Z=!
M\WZ!9>#+[X86?A[4M;^'>B>+9I1%/-=^'_$$GB2TNC)R6DC#1%U;LH/^Z3Q7
MZ[?LH?LCW7P"UKQ5XP\5^+YO'?Q"\4"*/4-6:V6WABAC&$AAC'11\OH,*H"@
M#GW8^"O#QUX:X=!TPZT/^8D;./[3Z?ZS;N_6@#&^#.DZ_H/PG\(Z;XIU2/6_
M$-IID$%[J,2NHN9%0 R8<*^6P"=P!R3D5^1'P)U?]E/1=-^*Q^.NCWMQXIN/
M$.I"QGDM[J1);=6.$M&B^5)0[-DMCJG..G[55\\_LR?LH6WP6\&>(-$\5-H_
MC![_ ,3WGB&TDDL RVOG!,*!)NPPV?>&.HH _.7P/\-KGQM;?L;^$OB3IMY<
MZ#J6MZY]ATS5799VTK=;O!&_1@A(.!QE",<$5ZW\9].^%7P__;:UZ+]I#2+@
M?#:+P_9V?@$26]Q+I5K!'&JR1!(<G<&##&#@\GJIK]-+[P[I.IZA8W]YIEG=
MWUB2;2YGMT>6W)ZF-B,IG Z8Z4FN^&](\467V/6=+LM7M-P?[/?VZ3Q[AT.U
M@1F@#\I_AKI>KZU\+_VM[K]GZQUVR^$5]I\ \.6[B56EN1M-[]D5OGP8O.&/
MO8:('D #Q+X[ZM^RQ>_LF>&[3X;Z/?0_%>V2T_M&5K>Y66%N!<_:Y&_=,K-D
M+M)Y*XP,BOVP\9>!T\3> -3\+Z9J=[X16YM3;6VH:"XMI[$_PO"0,+@@<8P1
MD=Z^+'_X)R_$;QSJ]KI7Q+^-B>)_ $%]'?7&G6.@P6=YJAC;*"ZG0;I#@G+.
MTAR21R<T 9?PB^%_ACX@_P#!2_XLZGKFE6^JZCX<T/1;_23<$E+:Z^RVVV;:
M#@LN!@G.,U\X^";G]GW0?"OQ9TG]HC1-7N?CU)J]^7,]O=RWEP[9,#6CI\B_
M,<Y<@'@Y*XK]BK+PUI&FZG<:C::796VHW$:Q37D5NBS2HH 56<#<P   !/&*
MCO?".A:CJ\6K7>BZ==:I"ACCOIK6-YT4@@J'(W 8)& >YH _'F+PUI_C;]AG
M]D?P]J9;^SM5^(<UC<B%]CF.2\G1PK#H<,1GL:]EU?\ 9#^%%E_P4?T;X>6O
MAI+3P/?>#/[9O/#L-U*MK<W$<LB(9%WY91M5L$XW+GUK]&H_ ?AF*QT^R3P[
MI*6>GS?:+.W6QB$=M+G.^-=N$;))R,')JZWA_2WUM-9;3;-M72+R%U P(;A8
M\YV"3&X+D],XH _*'3/AQ\/-$^%/[7'P^UOQ-=^ _ NG>/+.#3KF""6]CLI?
M,81!XER6CRBALG[J YRHKW[_ ()D>+['4M7^*GA^T\->%1/I5U:"?QGX(@:#
M2];_ ';!-L9 1'51E@@4$NQ*@\G[:C\)Z'$NIJFC:>BZHQ>_"VJ 79/4R\?.
M>3][/6IM$\/Z7X9L%L='TVTTFR5BRVUC L,8)ZD*H R: /(/VME5_!'@]9?^
M/1O&_A\3^FW^T(L9_P"!;*=^VFP3]F#QV6(4"W@Y)_Z>8J[#XY_#:?XM?##5
M_#5E?1:9J4S07-E>S1F1(+F">.>)RH() >-<X-=G>:=;:M8/::A:P7EO*H$L
M$T8DC?ORK#!&1WH \-_:>OXO!?B7X0_$'4B8O#7ACQ%)_:]V$++9P75E/:K<
M/C[L:R2Q[F/"ALG@&LZZ\8Z'\9OVJ?AX_@W5;3Q'IW@S2]4OM7U33)EN+6%[
MI(H;>#S4)4R-MD?8#D*F3C(S]$SP174$D,T:30R*4>.10RLI&""#U!':J/A_
MPSH_A/3Q8:'I5CHUB&+BUT^V2"(,>IVH ,GUH \S_:9\/7LO@BQ\8Z+ 9O$?
M@>_C\0V:(/GFBC!6[@'?$ML\RX'4E?2OG-_',_@B,?M;2P:C>:/XAN9K"?3H
MHW,AT!U$>E,(OX6-Q''(>,XO7]*^Z'19$964,K#!4C((JL=)L6T]+ V=N;%%
M5$M3$OE*JXV@+C  P,#M@4 ?%_B#X&6T9_9L\+>.((]1U/6_%&I:[XEB?[E[
M?RZ?=7,T<@S\\8?$>TY!2,*01Q7J/Q#\.Z;X0_:F^#=SX<TZPT;4=6TW7=-N
M)+6!81<0QV\4T4<@4#<J2*& .<9..IKZ!N=-M+RYM;B>UAGN+5B]O+)&&>%B
MI4E"1E25)!([$BB?3;2YO+:[FM89;NUW>1.\89XMPPVQB,KD<''6@#X\^!WB
M/X'^'O@CJ.E?%"Y\,6/C,-<_\)Q9^+/)_M&YORS&=Y$E_>3*W!C*A@4*!.PJ
M/X1V^K6.J?LOP:NE] OVKQ(=+AU4M]K333;2FR64-\V\6_E##<@8!Y!KZVU/
MP3X=UO6+35M1T#3+_5;3'V>^NK..2>'!R-CLI9>?0UI3Z=:75W;74UK#+<VI
M8P3/&&>(L,-M8\KD<''44 ?$_P .+F+X;_LZ_!SXR)N%GX5%]::^T*EF?1[F
MZD69B!RWDRK!-@=D?U->G_"?P;\1-6^&5SXUT35M*\*^.O'6J'Q#J+Z]I3Z@
ML%FR;+2S")/$5,<"P#.X@-YG&6S7I7Q<^$Q^(G@2S\&Z;/:Z%X>GU"V?5K>&
M#;]HL$E$LUM&%P%\TJ$8]-K/QDUZ,JJBA5 50,  8 % 'RA\6+6X\/\ C_X0
MW?QUU/2-=\'VK:@+C4H=.>TT:+6&:+[!)<PR22J@$7GJCR.5$AS\I*XGN9O
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M,-7\>_M'W/PS-A]BF^%MS_:EWI "V,]WYLRL\++\C,%VAV3@MC)+9KV;X[>
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MT'[(/Q(GU!;4V%E&AB$OVE[L>4,DC;D G=QT KSCQQX USX=>(GT37+,VU\
M'0(=ZRJ> R$=03D?48KZ%_;6\6:OIGB3PE8V5_<6=O%9F\58)"G[W?M#''7
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M]$G'A^\\//"NH27!A81+&\?[URQ.'#$Y4OOXS78Z6=63XL:8^@+&WB(?!?\
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MV65]09;;<9)-['EB^2!@9"\#%?4O_!0P _L7?%;(S_Q*U_\ 1\= 'M=IX_\
M#%_K$.DVWB/2+C59X5N(K&*^B:>2,C<'5 VXJ1R"!C'-++X]\,P:G+ILGB+2
M8]1BN([62T>^B$J32#,<93=D.PY5<9/:OQE\7VW[,EG^S'X3O?AE?:Z?VC =
M/^Q_9)+PZG_:.Y!*'4_NP@P^S9S_ *O&:^D/@'\)['XB_M__ !JUWQ7I<6H^
M,_"^G:+J%BDDK+!;ZJUE%NE*J0K%74@9R!D\=#0!^A.J^/?#&A:Q;Z3J7B/2
M=.U2XQY-C=WT44\F>FU&8,?P%7+KQ+I%EK=IHUQJME!J]XC26VGRW"+<3JN=
MS)&3N8#!R0.,5^"VFVUGJ]OXWN?BM)\/'^(4FHW(U23Q[?Z]#K<,V3_JH[53
M#@=5Z]AC Q7V7XD^&7CCPS^Q-\*/BT^NV7B[QQ\*[P:YIVLZ:\T@OM#9QYD+
M--&DA41$9W*/DC/7.: /T?3Q)I,FO2:(FJ63:U'"+A].6X0W"Q$X$ACSN"Y(
M&<8K)F^*/@RW_M+S?%VA1?V80M]OU*$?9"6V@2_-\F3Q\V.>*_/WP'IGCCXD
M?LS?M%?M%Z79WEMX\^(4$\>@00;C=6>C6Y$:QQ%>=Y19/N]3&A')KY5^,-E^
MRA'^QUHMQX&O+]OC')!:?;%:6Z-P\Q93="Z5OW(C!#%2N.1'C/- 'ZE:?^T!
MXBOOVXKWX2JFFOX1C\'IK\4Z1,;EIVF"?ZS?M*;3TV_C7M;>/?#*^(AH!\1:
M2-=/_,+-]%]J_P"_6[=^E?G]XFF\16_[8_C23P:'/BU/@6&TA8AE_M0V^7L'
M=LXQ[XKX4\/Z3X7U7X8AM5U7X8Z7XRN)B9]9UO4_$*^([6[,G,DB)&T.Y6Y.
M%8<$\F@#]\]3\7Z%HFI0Z?J.M:=87\T3SQ6MU=QQRR1H"7=48@E5 )) P,'-
M3:#XCTGQ5IJ:AHNJ6>L6#DJMU87"3Q,0<$!T)!Q]:_-#XI?!R7XK_M._LH^!
M_BW>1^)+B;PC<#6+BPN)4343$DKJ3(0DF'V*6X4G+=,US.F^&?$?P;\,_MO>
M"/@\VH6<6BW6FR:=864\DDMK;2%S=&$Y+;Q#N&[.["#DD"@#]2+3Q]X8O_$$
MF@VWB/2;G7(L^9ID5]$URF.N8@VX8^E6O$/BG1?"-B+W7=7L-%LRP3[1J-RD
M$>X]!N<@9K\JO!NF_L(+X2^'<]CK'B"#QR]W9EKO1YK_ /M<W1/SF8*"JKOS
MDQ 'IL-4_P!N_P#M"_\ VU[JV^()\,-X-AT6!_#4/CZZU2WTET*+YS(UD-QF
M\POG<1_#GHHH _6O3=4L]:L8;W3[N"^LYEW17%M(LD<@]59201]*74=1M-(L
M9[V_NH;*S@4O+<7$@CCC4=2S'  ]S7Y_?\$LM"U'3]?^)%[H?B3PI?\ PZGD
MC1-"\+W>HSV^G7X/+1?;(U;8Z%B2'8G"9[5N_P#!4CRG@^#T/C"35(?@U)XB
M*^+I-++@A=J^1YFSG9_K??/3YMM 'JWC_P#:<U+3OVI?@EX%\+7FB:QX-\:V
M^I27M_ ?M#EK>)F40RH^P?, #D-^%=1^SQ\5?&GB'P%XGUSXM?\ ")>'WT[6
M;FVAN-%U:*>U2T4KL,T@D=4?)(P6!Q@E5)Q7P5\/(/@'9_\ !1/X)0_ *Y>7
M1/)U%M1BAEN9+*.<V<VWRC.2V\J/GP<<)WS6'H?A3POXR_9"US3?$'CS2O =
MP/B_?W&F/KT;OI>HW*(I%O>!0<1%>2[?*N!G@T ?KEI>N:=KFEQ:GINH6NH:
M;*N^.\M9EEA=?4.I((XZ@U1\/^.O#?BV>Y@T/Q#I6LS6QQ/'I][%.T7./F",
M2OXU^1OB+QUJFN?\$_\ QE9?#_PK:^#[#3?'0M?%]QX7N[BXTN]MF4F2>W<%
MF2V+B$,B$J%*XX8BN8^$7ABRO?C7\,5^%?B+X2^%O%T-_%+$_A;5/$$L]_$N
MTRV\XN8GC^= V1\H/S9(% '[.ZWXQT#PS=6=MK&N:;I5S>OLM8;Z[CA>=LXP
M@8@L<D<#/6DM/&GA^_L]2N[;7=,N+33)'BOIXKR-H[1U&765@<(0.H;&*_+W
MQ5:_!#4OVP?CFO[5=Q>PW\=Q&/"R:C+=QV@TW:=C0>1SNQLP/NYW\$[JXWX(
M>'/ GB_]B'XV:3>>.Y? WA>Z^(RKI6L:U')()B$B-O%=JGS%74 N?X2"Q^[B
M@#]?-!\1Z3XJTU-0T75++6+!R56ZL+A)XF(Z@.A(./K5+1_'OACQ#JMQIFE>
M(])U+4K?/G6=G?12S18Z[D5B1^(K\G]#\::RW[(?[1>A?#;PMH^A^)]'U"P_
MMS7OAW=2SZ5JEH_R2R6?)$>(XR7$>!M=CA>@\=\)^%]'U*^\ 6_PZ\2_"7PE
MX\:]MCIFL:+JGB(ZF;CC:DZR1/$-Y^4@*!DXZ9H _<C5/&6@:'JUEI>HZYIN
MGZG?<6EE=7<<4UQSC]VC$%N>. :V*_([]MZT\$>$_CWXS\;ZEK/@_P"(VHI%
MI=MXD\ :Y<SVFJ6+A8]ITFX7!(/#,$R5#-N4@U^KGA34H]9\+:/J$5I-817=
MG#.EI<#$D 9 P1AV9<X/N* -6BBB@ HHHH *\E_9^<Z';^*_!TQQ/H&KS"-3
MU-M,?,B;\06KUJO'OB>DOPT\>:;\1K:-WTJ6-=,\011@G$);]U<8']QN#[8%
M>CA/WL9X;K*UO\2V7S3:7FT>%F;^KSI8_I3;4O\ !+1OY-1D_),]AIKHLB,C
MJ&5A@J1D$>E,M;F&]MHKBWD6:"5!)'(ARKJ1D$'N"*EKS]CW$TU='SWH?C&'
M]GGQCK/@J]LM2U+0;@?VMHJ:7;-<R6\3N1+$R+R%5P<'W]ZZ*^_:<T*TLKB=
M?#?BPM%&S@2:+*BG SRQX ]STJS=9_X:IL<?]"A)G_P+%=WX_P#^1$\1_P#8
M-N?_ $4U>]5G0G4IRJTVY32;=[:[;6^_S/C,-3QE.C7AAJRC"G*2BG&]DM4K
MW6BO9::*R.)_9[T&0^%)?&&HRK=:]XL<:E=3+T2,C]U"O^RB8&/4FO5*X/X#
M?\D7\%?]@FW_ /0!7>5YN-DY8FHWW:^2T2^2/?RJG&G@:*CUBF_-M7;?FVVV
M%?FY^T5XLC\9?&/Q'>PN)+:&86<++T*Q (2/JP8U]F_M&?%V#X5>!+@P3+_;
MVHJUO80Y^8$C#2X]$!S]<"OSK)+$EB68\DGJ37VW"^#DN?%R6CT7Z_Y?>?D/
MB-FL)>RRRF[M/FEY:6BOQ;^XO^'M>O/"^NV&KZ>ZQWUC,L\+NH8!U.02#UKU
M*_\ VMOB9?VDMO\ VU!;B0;3);V<:.OT..#[UX[17VM;"8?$24JL%)KNKGY%
MA<SQN"A*GAJTH1>Z3:O]QUOAOXJ>(_"FB^(-*L+M/LNO*5OS/$)'ERK*3N/(
M)#MS[UE>$O%^L>!=<@U?0[Z2POX<A9$P0RGJK \,I]#6/16GL:7O>ZO>WTWZ
M:_(P^N8B]-^T?N?#J_=UOIVUU]3UWQ=^U1\0?&.B2:5<:A;V%M,ACF;3X/*D
ME4C!!;)(![[<5PW@'XB:]\,];&J>'[XV=P5\N1"H:.5/[KJ>"/U':N;HK*&#
MP].FZ4*:47NK;^ITULUQ^(KQQ-6M)SCL[NZ].Q[3=_M>_$FZU%+M-1L[94C*
M"VAM%\HY(^8ALDGCUXR?6N(\ _%SQ/\ #36[O4]"OA#)=L6N8)4#PS')/S+[
M$G!&",UQM%3' X6$'3C323W5EKZFE3.<RK58UJF(DY1=T^9Z-[V[7/8[_P#:
MT^(^H7=Q*VI6L44\)@-K':+Y2@YR0#DYYZDFO' , "BBM:.&HX9-48*-^RL<
MV+S#%X]IXJK*=KVNV[7WL=6?B=KY^'H\$^?%_P (^)O/\GR5W[]V[._KUK T
M75[G0-8LM3LV5+NSF2>%F4, ZG()!Z\BJ=%:1I4XJ2C%)/5^;>YA/$UJDH2G
M-MP22UV2V2[6Z'TE^SC\49?$WQXU'Q)XMU2RM;B?2'A:XF*6\9*O$%49P,X'
MZ5S4W[6GQ$TZWO=+@U2UGC662.*^EMU><)N.,-T/&.2#7B1 /49HKS7E>&E5
M=2<$U9))I65K[?>?0+B3,(8:-"E4E&2E*3DI.\N:U[_=OYFE9>)=5T[7TURV
MU"XAUA9C<"]5SYOF$\L3WSDYSUS7K%U^U_\ $BZTM[07UC!*Z[3>0V:K-CV.
M=H/OBO%:*ZZV$P^(:=6FI6VNCRL+FF.P2E'#5I04M[-J_GZ^9U_A+XK^)/!0
MUW^S;U=^MQF.^DN8Q*\H.[)RW()WMS[U'>_$[7]0\ V'@V:XA.A6,PG@B$*A
MPV6/+]3R[5RE%:/#T7+GY%>Z>W5:+[D9+'XM4_9*K+ELU:[M9N[7HWJ_,ZKX
MA_$W7_BEJ%I>^(+B*XN+6'[/$885C 3).,#KR:7QY\3M?^)%SIL^N7,4TNGP
M^1;M#$(MJY![=3D#FN4HHCAZ,.7EBERWMIM?>PJF.Q57VCJ5&^>W-J_>MM?O
M;H>S:+^UO\1M%TJ.Q^WVE_Y:;$N;VV#S*/\ >!&X^Y!KR[Q/XIU7QGK=QJ^M
M7TNH:A.?GFE/8=  . !V X%95%12PF'H2<Z5-1;[(VQ.:8[&TXT<36E.,=DV
MV@HHHKK/+"BBB@ HHHH **** "NZ^!?_ "6#P?\ ]A2W_P#1BUPM=U\"_P#D
ML'@__L*6_P#Z,6N7%?[O4_PO\CT<M_WZA_CC_P"E(_3&BBBOP8_M(*0@$8/(
MJO;:E:7L]Q!;W4$\ULP2>.*0,T1/0, ?E/UJS0!G6'AS2=*T)-%LM+L[/1HX
MC FG06Z);K&004$8&T*<GC&.:2Y\-:1>^'FT&XTJRGT-K?[(VF26Z-;&#;M\
MHQ$;=FWC;C&.*\;N/CSXR\?ZUJME\(_ UGXETK2KJ2RN?$_B+56TW39KB-BL
ML5MLBEDGV,"ID"!-RL QQ71?"[XP:[XF\0ZCX6\;>![_ ,$^*+"V%X767[;I
M=Y 3M\RWO%4*2&X,<BHXX.".0 =OJ?@3PWK0N!J'A_2[X7,$5M.+FSCD\V*-
M]\<;9!W*K?,%/ /(J[JGA_2]<>Q?4=.M+]["X6[M&N8%D-O,H(66,D':X#,
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MH"^*6\3#0].'B-K?[(=8%I']K,.<^5YV-^S/.W.*T-.U.SU>U6YL+N"]MF)
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M/2RQ-XZ@E_/'_P!*1^E=1W$;3021K(8F=2HD7JI(ZCZ5)17X,?VB?G_^PO\
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M?"BQTOPYXNU749(-9T+PVB06]UHH@E::>ZMXL(!'((2DI4'>0H)W$5Z3XB^
M=EJOQ-\!W<&DZ-_P@F@^']4T2?1)H08RMPUH8D2':4* 6[9!(Q\N >W8_#SX
M->!/A+%<Q^"_"&B^%UN3F<Z58QP-+_O%0"1[&@#X@\(^!/$_Q.OOB#KGB/P_
M\&_$^OPZW?P:M)\0;F[?4M)CCF<0Q!3&R6T2P!&1HB%92'R22:[GP6VIGP!^
MS]]O\0Z7XFM!\195TN\T>>YGMDLA:WPBA2:X422K'AD61L[E52&;K7TWXX^
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M3UPJ@"JFK_#KPOK_ (MT;Q1J6@:??>(]&5UT[5)[=7N+0."'$;D97()!QZT
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MI4)G\S^_NV_>YZ]: /DSXF-:2?MT_# V%]<:I8-\)]0,%]>.SS7$>R?;)(S
M$LPP22 22:^5- \$VGQ#_9R_8J\,7=S<V-IJWC#5+2>XL9/*G1'O%#E''W6(
MSSV-?L!J?PW\+:UXKM_$]_X?TZ\\16]F^GPZI-;JUQ';OG?$'(R$.YLCIR:Q
MK#X"_#G2[+PU9VG@C0[:U\-7+WFBPQ6,:KIT[-N:2$8^1BP!)'>@#\]+7X3Z
M+^SS\;OVI?AUX.>\L_!<OPIN=572;BZ>=%G,*KNRY))&Y\$DG#D9Q7$ZOJ&E
MZE\/OV2O"7Q3UW5/#?P&U'PP\VHSV,DD-O=:BK2;8KB1!PH'E_0.QXY8?JEJ
M/PG\&:MKNLZU>^&-+NM7UG3SI.HWLMJC2W=F1@P2,1EHR /E/%)<?"3P3>>!
M(/!5QX3T>X\(V\8BAT2:RC>TC49P%C(VC&3C [T ?'/[,WAW]GSP-\3_ !S:
M_L[>-]4U7Q&/#;SIX:M[^>ZTB24 [90[J0\@;RQRYV[CCJ0/CGPSHW[/7B+]
MF#QCXR^(WCO6X?VB)%U 7:W5_.FH"]W,L<"P=)(W&U7+ X#."5V\?L;\/OA+
MX*^$]C/9^#/"ND>%[:=M\T>E6<=N)&]6V@9_&LG5_P!GGX8:_P")K[Q%J7P_
M\-WVO7T+P7.HW&F0O/,CJ5<,Y7)R"03UP: /SQ^&@ \6?\$]<?\ 0+U7_P!%
M"OHK_@K,%/[&'B#>2%_M/3LD#) ^T+TKZ1L_@KX"T^?PM/;>$-&@F\*H\>A/
M'9H#IBN,.(./W8(ZXKSC]M_X$>(?VC_@!J7@GPO<Z?::O<7UI<I+J<KQPA8I
M5=LE%8YP..* /SN\?Z9\!_ EK\+/%'[.'C;6-<^-MYK5DBK%?SW-U?J_^N%Y
M$_$>3@%< '+ @CD>L?L\_":#6?C/^UC\1]+L)=2^(OA'Q!JW_"+0>:Q@M[R:
M*Y!=8A\K2,=JY(/05][^$O@7X!\(>(CXGTWP5X?T[Q7/$%N=8L].BCN)&V@,
M?,"@\XY/?O6YX7^'GACP3J&MWV@:#I^CWFMW)O=3GLK=8WO)SDF24@?,WS'D
M^IH _'OP[H7[,VM?LPZEXZ\9_$+64_:#%O=74]S/JEPFJQ:J&;RXT@Z%-VP;
ML'@L=RD?+Z)\7=?U'QYIO[*&E_M(:QK&A_#K6-$FN==G+R0)=WRY^S_:V7E2
M8_(9B>1YCGCDC](=0_9[^&&J^,AXLO?A]X:N_$H;?_:LVE0M<%N?F+%<EN3R
M>:\Y_:^^!WQ$^,NAZ7'X$\1^'X8K5F-[X8\7Z1#?:5J?]QG+1.\;KSRO4'MW
M /SY\):-\*="_:G^*6F_!W79]?\ !=M\)M:1&EN7NH;>4P$O#!(_+1@$'J0&
M=QFM>S^&X^%7_!+JS\=^#VU:VUSQD]E%XMUJVGDDN8]+CN9H]D0SB.-1L0@8
M!!.>*^I?V6_V&_$'@CX@:YX\^*]YX7U+4K[0V\-VGAKPMIPM])L[%S^\39L0
M-N (QM_C?).>/K70/ WAWPMX3A\+Z1HEAI_AR&%K>/28+=5MEC8DLGEXV[3N
M;(Q@Y- 'X^_%KP=^S-X1\4_ 9/@;XMN=6UB[\6Z7+J%@E_-<Q21"1!Y\Z/Q%
M,&( 4!>'<;1BO:]-_9A\'?M-_M\_M+:;XU?4IM*TZ#3)([&QO'MXY)GM4"RO
MM(W&/:=H.1ECD&ON/3OV7?A!I$4,=C\,_"UFL-_'J<?D:5"A2Z3[DH(7(9<G
M![5UVD?#OPQH'BG6_$NFZ#I]CX@UL1C4]3@MU2>\"#:GF.!EMHX&>E 'X^^$
M?V;?#_CK_@GOXS^*?B#5M=U7QAX0GN++P_<S:C)Y6FV]O.FV**/.T!B[DYZ$
MC&,5W/[6&CZ;XDM/AWX]UOQ/X:\;:GI_PVLI]8\ >*=8DLKHPO%N:^L9%8#[
M2Q.<<L2 =K@@#]-['X+> ],\#7_@RT\(:/;>$[]G>ZT6*S1;6=G(+EX\8))
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M<I$\NT[ [ $A2V,D G':@#\RO@!X[UW]O/XG_"+PQXFL+F/1/A'8C4_%:7B
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M<GFNBH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ($CXCHK[<_X89\'?]!S7/\ ON'_ .-T?\,,^#O^@YKG_?</_P ;H_UCR_\
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M ($CXCHK[<_X89\'?]!S7/\ ON'_ .-T?\,,^#O^@YKG_?</_P ;H_UCR_\
MF?W,/]0L\_DC_P"!(^(Z*^W/^&&?!W_0<US_ +[A_P#C='_##/@[_H.:Y_WW
M#_\ &Z/]8\O_ )G]S#_4+//Y(_\ @2/B.BOMS_AAGP=_T'-<_P"^X?\ XW1_
MPPSX._Z#FN?]]P__ !NC_6/+_P"9_<P_U"SS^2/_ ($CXC ). ,FOK[]CSX*
MWFESMXVUFW:W9XS'IT,HPQ###2X[ C('KDGI@GT[P3^ROX"\%W<=V+"76;N,
MY234W$BJ?78 %/X@UZ\ %  & .@%?.YMQ#'$TGA\*G9[M]NR/NN&>!ZF7XF.
M-S&2<HZQBM=>[?ET2ZZW%HHHKX4_9 HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^T(?RL^JZ*^5/^%A^(_^@Q>_^!#_ .-'_"P_$?\ T&+W_P "'_QH_P!;,/\
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M_P +#\1_]!B]_P# A_\ &C_6S#_\^I?@']H0_E9]5T5\J?\ "P_$?_08O?\
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M^_U)Z\8T:* ,E=#F6'3T_M&YS:ON9MW,PSG#>W;G/'OS0VB2M_:?_$QN1]L
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MO]HW)^R'+G=_KO\ >_ESG@GOS6K10!E'192FHK_:%Q_I9RIW?ZG_ '?Y<8X
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M\_..APMI^V!\.+S2+NX2XUI=7MKD6<GA>30KM=;\TIO4"P,?G$%/FW!=N.]
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M,5ZG^QWX8\2_$?\ :N\>_'/_ (5W>_"GP3J>BQZ/::3J, MKG4IQ)&S7,D(
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M-)$5*F6>&56V K@Y.>!A6/%?I?\ MC_\FH_%WM_Q2^H?^B'H YG3_P#@H/\
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MTN"Q>_NHPDTYCC"[G4,P#''."?J: /@?X*?&WX@^-?@S\(=6UCXU/X9U2_\
MB/<Z7.VHZ<]W)K4*R*$LU,<9"<;A\^U?GSN!45]O^%?VA_A]XT\'>*O%&E>(
MHI-$\+3W-MK4\\,L#6,ENNZ99$=0PVCGISVS7YC?#;PUK,/P0_9RC?1]126#
MXRS3RHUI(&BC,@P[#;E5]SQ7I7[6GP-\>Z9^TOJ'@7P+%-;^!/CU+9MKUQ!&
MY6RFM90UV^X<)OC^8Y^]O84 ?;&O?M9?"?PM\+-%^(NL^,;72O"6MH7TV[O(
M98Y;P<_ZN IYK=,\)T(/0BF^"/VN/A'\2/ _B#Q=X;\:V6JZ+X?M7O=4:*.0
M3VD*J6+O RB0#"MCY><<9KXM_P""@?P1\1^#_BY\+_&^BV&M'X;>&="71T/A
M[0[;6I=&DC9MKFSN#Y;*R%!O.,;.H.,^>?"SX;WWCO1?C5\4+.X\=-]G\#:I
MI?F:QX)LM$MM862V8"-$M9#OD1PK<(V=HRPX% 'Z5?![]H[X=?'U]27P#XEA
M\1C38K>6[:W@E181.K-&I9U W85LJ.5QA@#7I5?.O_!/SP?8^$?V1_ARD&BQ
M:/?W6F+-? 6PAFEF+N2TO 9FY/+?RKZ*H **** "BBB@ HHHH **** "BBB@
M HHHH **** "N,\ G^R=1U[07.#;737$ />&3YACV!X_&NSKCO&UC<:7>VGB
M?3XC+<6(,=U"@YFMSRP^J]1^/I7G8Q.GR8F*^#?_  O?[M'\C&II::Z?D=C7
MGUY/_P *Y\77%]*"/#NLN#-(!Q:W/3<?17[GUKM]-U*WU>PAO+2436\R[D8?
MYZ^U27EG!J%K+;7,23V\JE7C<95AZ&M*]+ZQ",Z4K26L7T_X*:T8YQYTG%Z]
M"1'61%=&#(PR&4Y!'K7 ^/!J/BC7D\)6EW%86ES8M<7$K1>8SC=M"CD8^M2Q
M>"];\*/_ ,4QJJ/89S_9>IY>-!Z(X^9?I4WB32-<M?%5GK^D6=OJ,@M&M)K:
M:?RL9;<&#8_"O/Q,ZM>@X5*<EJN9+6\>MFM6ON=NAE-RE&S37?T^1A2^$=9\
M0,=*/C&"=](EAD:%=.4&)PN8\G//%=9\/M?N_$.@M+?^6UW;W$MM))&NU9"C
M8W8[9]*Q;6Y\665[=W<'@ZPCN;LJT\@U,9D*C"Y^7L*V_A_H%WX>T%X;_P L
M7<]Q+<R)$=RH7;.T'OCUK#!0Y<0G34DFI<U^>UKKE^/K;MY]"*2M.ZOUOO\
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ME4%%3S2[A=D\=]<Q6TEO'<S);R<O"LA"/]1T-0444FV]Q!71_#O_ )'71_\
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M^"W@K2=<,?@[Q#HNHWE]8QQQ/'=/'&[1/O*EAC (VL ?>@#Z?HKQ[Q#^U_\
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M[%U!=.BDT&:71=<MGGR]FT!3<IN3'#,D899E$G\7(/V1\.=2N]8^'WAJ_O\
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MM6UC4_#]MI%EJ<D0<_:+9(D1IL!_+:9D 8*H5F"@CKO%GF?\-?\ PZP'\O\
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M=_Z EC_WX7_"C_A!/#O_ $!+'_OPO^%'^J>(_P"?D?Q#^SY_S(^4,48KZO\
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M1_S\C^(?V?/^9'RABC%?5_\ P@GAW_H"6/\ WX7_  H_X03P[_T!+'_OPO\
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M#9QC/K3_ +7!]H:#SH_/5=YCW#<%]<>E $U%55U.S:&&87<!BF;9&XD&UV]
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M -J?IS]K@_Y[1_\ ?8H^UP?\]H_^^Q7YC;SZT;SZT?ZP/_GU^/\ P _UL?\
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M,;>?6C>?6C_6!_\ /K\?^ '^MC_Y\?\ DW_VI^G/VN#_ )[1_P#?8H^UP?\
M/:/_ +[%?F-O/K1O/K1_K _^?7X_\ /];'_SX_\ )O\ [4_3G[7!_P ]H_\
MOL4?:X/^>T?_ 'V*_,;>?6C>?6C_ %@?_/K\?^ '^MC_ .?'_DW_ -J?IS]K
M@_Y[1_\ ?8H^UP?\]H_^^Q7YC;SZT;SZT?ZP/_GU^/\ P _UL?\ SX_\F_\
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MM $)T.P+7A-K'F\ %P<?ZP#.,_F?SH70[!'LG6TB5K-=EN0/]6N,8'X"KU%
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M[\#\JTJPM9\=>'/#FNZ/HFJZ]IVFZQK#,FG6%U=)'/>,H!81(3ER,C.T'&:
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MPXJ-O#NF-:W%L;*+R+B7SI4QPSY!W?7(!K*TWXG^#]9L(KW3_%.C7UG+J/\
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MM)XYRI')VD XWO%/[$]_X[_9*^&GPZO/$4>@>/? L5E=:7K^GAI8;>_MTP&
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MOV:OVH_B7^SW\&_B1J?A+X4CQ9X0T;QE?7NOZ_=7ZP1PK(T2B**,?,S  %F
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MO43\*_"^E6.IG0/#.B:-J5U:2VRW5G810/AUQ@LB@XSC(]J /F[X ?$GQ/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRX$N)EC,K?W5!(W'D<#UH \\3]F'X3Q^//\ A,U\ :&/$OG_ &K[=]E'^O\
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M$P,YQS0 !T&*6B@!  .@Q2;%W9VC/KBG44 )M&,8&*,#&,<4M% "4@C4'(4
M^N*=10 F 3G%#*&&" 1[TM% ";0,<#B@ #H*6B@!.M&!C&.*6B@!,<8[4@15
M.0H!]A3J* $90W4 _44 8&!P*6B@!NQ=V=HSZXIU%% #0B@Y"@'UQ2X!.<4M
M%( IH15.0H!]A3J*8"$9ZTBHJ]% ^@IU% #616ZJ#]13J** "NT^#'_)5/"W
M_81@_P#1BUQ==I\&/^2J>%O^PC!_Z,6MZ'\:'JOS.K"_[Q3_ ,2_,_0RH[B-
MIH)(UD:)G4J)%ZJ2.HJ2BOU8_>3X _88_8(^)/[-O[0GB_QKXK\7VFIZ/>6T
MUK$MG/+)+JC22JXFG5@ I7:3R6.YC@XR3]^RRI#&\DCK'&@+,[' 4#J2:=4%
M_8V^IV-Q9W<*7-I<1M#-#(N5D1AAE([@@D4 ?CKJWBWQE^T1\0_CWXXTKX):
M_P#%+PYXSMI/"N@ZU8RB*+3;6!@$>,&-]S%XX9#@CD,/XCCO?%GQS\6^._\
M@F!86OVG5-.U7PSK=MX3\;/9[A>VME"Y5BPZ@E/(#9ZG<#QFOTZ\'^"] ^'W
MAZUT'PSHUCH&BVN[R-/TZ!8(8]S%FVHH &6))]S5+1_AAX1\/3>(9=,\,Z58
MOXAE:?6#!:(HU"0YW-.,8D)W-DMG.30!^2'Q-\+_ +-'A/XC_L^0? CQ1<ZE
MJ-UXQTN74K&._GN8'B$T8$\RR<1SY. H"\,_RC%>A>,]*^#OCW]LOXTP_M1>
M(+[2I]*F@3PE:WM]/9VB6&W(DA:/&7^XV,X)9SAB#C]"=-_9F^$FC1VR6'PU
M\*V2VU^FJP>1I$"&.[3[DRD+PZ]CVK;\;_!WP)\2[_3[WQ;X.T/Q+>:>P:TG
MU73XKAX"#GY2ZD@9YQTH _'?29-(N/V _P!H%]#O[S5]#;XD69L;[4\FXN(/
M,A\N27/.YEP3GN37T+X?^!/@I?\ @IUJ<@TE]]OX.3Q=%_I,F%U-F0&;&[D?
M,?D^[STK[UF^ 7PVGT'6-$D\">'VT?6+T:CJ%@=.B\B[N001-(FW#."!R>>*
MTY_ /@S2?$TWC&;0](L]>:S739=;D@C2<VV0!"92,[,[?ESC.* /R&\.:G+:
M_L2_ C2M>U/5-#^#^J>--3@\9W^D;E981<#R4=E!(0_O#T/*C@D"O5_!%C\)
MOAS^V-\'M._94\0WFI1ZK-,GB_3-/OY[S3O[/ &996D)PX&\CDX*IT)&[]'-
M$^&O@3PWX9D\#Z7X;T*QT"5'F?P_#:1+;NK/EF,&,$%NIQUI? 'P>\"_"F.X
M3P9X/T3PLMP<S?V3816YDZ?>**">@X- 'Y,>$?V8_!OQ2^"W[6'C_7%OIO$'
MACQ'K,FC^7>21P6DD69?,\M3M9FR%.X'A1C!YKK?B5K6F>/-*_9%T_XX>(-7
MMO@YJ?A);C4;T7$B0W>IK'A!<R+ST$7S=0&8Y&21^G6F_!_P/H^A^(-&L?"6
MCVFD^(999]7LH;*-8K^208D:90,.6'!)SFGZE\(_!.L^![;P9?\ A+1KWPG:
MQI%!HMQ8QO:1*G"A8R-JX[8'% 'YC? 72OA/HG[<?C.P^#.M7&M>#+?X<:@B
M-)<R7$-O-\A>*"23YFC&0>I&YG -?7/_  2[_P"3)? /UO?_ $KEKVWP]\%_
MAEX;UD2:'X.\-:9JMIIO]EYL+"&*:*R<D^2=H!$;$,<'@X-=-X.\%Z!\/?#U
MMH7AG1[+0-%MMWD6&G0+##'N8LVU%  R22?<T ?GW\7/@-X6_:'_ ."HFH^&
M?&,=W<Z#'X%BO)K.TNGM_M++(%5'="&V@N&P".56O#M+U3Q;\/OV)?C!X6\.
M:QK,/A;0/BG)H>H7%E(TEQ8:)@"781R 6V;L8!WMGAC7ZW)\/?#$?C>3QDN@
M:<OBN2U^POK0ME^UM;Y!\HR8W;,@'&<<5'X<^&OA/PA;:S;Z)X;TO2K?6KF2
M\U**UM$1+V:08DDE &'9AU)SF@#\JO&^D_ ;X9>)OA/J7[*'BK4+_P"*M[KU
MI ;+3M0N+H7UHP_?"\1^$SQE<*,%\K@97L]._9B\&?M(?MG_ +5D/C)+ZYMM
M'2UEM+:UO'MXQ</;G;,X0C>4V?*&R/F;(-?H?X+^!OP[^'&KW6J^%? WA[P[
MJ=R29KS3-,A@E?.<_,J@\Y/%:FE?#?PKH7B#7==T[P[IMEK.O!1JM_!;(DU\
M%!"^<X&7P"0,^M 'PQ^R!KWQTUC]@3X>O\)[C0-3\2V^JWMI._BV21HDL4FF
M"HA4YRIV  \!>.PK._;HN_%-UX=_9WT;X[:A_8G@?4M3E3QY=>%WE6T^T +Y
M"$@%A'@L><G[Y'*C'W_X+\"^'?AQH$.A^%M$L/#VC0L[QV&FVZP0HS,68A%
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M6P&96?J!Q]::)XDTKQ(MZVE:A;Z@ME=26-R;:0.(;B,XDB;'1E/!':N9\)?
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M?A?4/AUXT:RL]2U7^Q[J%);<37LC@C&&4DGG# _@17)BL96PE/VE2FFO)_\
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MBS12AADC8X8\K@&@"31/C[XF_M+5_"WB7X>2>'OB!%I$^KZ/I<>J+=6&MI$
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M.\TT(?W/B&ZA:!$)Z%1$C7.!TDE#=Q0!]1AYGTT-.BQ7!BS(D;[E5L<@-@9
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M9QVH ]8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M $]_#_@A_JFO^?\ _P"2_P#VQ^8_]G7/_/!_RH_LZY_YX/\ E7Z<44?ZO_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>arwr-20250930_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 arwr-20250930_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'E M4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=HQDX)Z<CKZU63QM:"^:RNK"^MK@$@*T8()'7D''<?G6D8NDW-:&%J*5N_\
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M0 4444 %%%% !129 (!(R>@]:6@ HHHH **** "BBB@ HHHH **** "BBB@
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MWX9R*W],UBTU5&\ARLJ??A<8=?J/ZBNRUCG::+]%%% @HHHH **** "BBB@
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MT=%5+:^CN.#\K^GK5NL&FMSI335T%%%%(84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8GB74H;+3FB+L
M+B4?NE1L'(/4^U8VE:/>ZT\VH:B=B72J'&!\X7H0.@^O6NKN=/L[Q@US:PS,
M!@%T!(%60 !@# %82H\]3F;T[$M-O79'&ZS\.K#4V:6VU'4;&X.#OBF+*2.F
M5/!_2N7O=(\:Z#%+%.BZYI\LT<L\EN2L[A"" W?'R@<9KUJBK=*/30ATDFI0
M=FNQYI9>,K#49BCDV]Y-=JK07*[1!%_%SQS_ %-:USK5O8P?:3Y"P)J0M7+/
MG,7 +CWR1^%=%JF@Z=JPS=6L+R#H[1@FN=F\*-9MOM])LK@+]TJ<$?\  6./
MUJ7&:5E9A!5%*\K-?<4[B_DUB=8++?(+:Z,L5R01E#P5SQA<$C\JU5>*VB,:
MN&=FW.PZ$^WH*R[B34XTV26%U"@_A2 D?^.\53\^7./*GSZ>2V?Y5C"$HZRU
M86?,Y-:FK=7C,C*2&0@@J>00>HI]CK'F'<\:">%?*W;>=G4#Z=./:LZ&QU*]
M($-C.0?XI5\M1^+5H#PGJD"F6.XM9)'P70[E ]@><_D*Z*7-?78N"UU+3ZD=
MFU2%4# 51@"LZYNQM+,V .22:F7P_K;G!CM4']XS$_R%:EAX4BBD6;4)OM3J
M<K&%VQ@_3O\ C^5;\R6QOS)$?A6PD!EU.92IF79"I'(3J3^)_D*Z:BBH,V[A
M115>ZNTMD]6/04TK[$MI*['7%S';IESSV%8D]U+=/CMG@"FDRW<W=F)K7M+%
M( &8 R?RK6R@M=S&\JCLMBK::9G#S<#^[6JJ*B[5  ]J6BLY2;-8Q4=@HHHJ
M2@HHHH **** "D"J#D*!^%+10 4444 %%%% !1110 4444 5I;..699,8(//
MO3KBTCN!\PPWJ*GHI\S)Y4<_<6LMJ^>W8BK=GJ/2.8^P:M-T5U*L,@UC7E@T
M)+Q\I_*M5)2T9DXN#O$VP01D=**QK&_,1$<ARI_2M@$, 0<@]#6<HN+-8S4D
M+1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2YGH<[KTY2Y8.[\CJJ*9#*L\$<R?=D4,/H:?6)84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% %74RZZ5>&/.\0.5QZ[3
M7!:7''L5W=4AC0,SL<!0!UKT8@$$$9!ZBN!O[%]!N'ADC#V,AQ$S#*X_N-[C
M]:SFMFR9IVT&'Q%]H94M4D2T,R0!PIR2[;0SD<JN3T'XU9N_#4FI1QPW%Q-"
MZ79#R02^5NAVG!7&><XZ^AJ&'4?LZ%+>*.!&.2(UP"?6IDU!B<EJVEBTI?NE
M9+^M3FIT_<M5?-+\/DCG(-/\7Z-)&^GZI+=K/=2PP65\,NZ)G#9/&"!GMU%2
MP^,K.](36+";3YU8KYJJ6C8@X//UX[UU46K%2"V#CH>X^E0QC2@EI ;=#:VL
M31QVSKN3GN<]3_C1]8C/^(K^>S-/9QNY1ER]ENOZN7M.>WNK826MS#-'C.Y'
M!Q]?2J]YX@TVP<0QRK=7;'"Q1'< ?]HC_P#76'9Z%HT+Z:DL$.Y5D-WY;,HE
M)'  '8$_I6AIUO9:5;6BH5:XMG=O.1<&0,3@-GG@$?E6UZ*DVKR7W#7UBK#=
M1?S?W?EO]Y;M9C=QIJ4DF4^;RAGEFZ$D=@.0!^=9EQNGO[1$^^US'C\&!_D*
MENKZ,(V D4>2Q &!D\D_C6CX;TJ6:Z75+E"B*"+=&')SU<_AP/K43DWN;TX>
MSA9[G5T445D(**** "N3@L-;T7Q5JES9V-O?6&JS1S/(UQY4ENP148$%3N7"
M@C'N/>NLHH \VD\$:K#'972HMQ+:7]_*;>*\>W,D5Q)N!61>C#"\'@Y(S2WG
MA+6#;06MEIXCTZ6UF$EB=4D4174CDF61P,R@@].QSQSFO2** /.[CP'J$]MX
M=@$D"QQV$&GZRNX_O8HRK@+QS\RLO/9S3;[PMXAO_$,<]RJ3I!K,5Y#<O>N%
M2V5@1&L(&T,!U)Z]<\\>C5G:MKNEZ''')J5Y';B5BL8;)9R.3A1DG'?CB@#S
M'4/M-A;0^%+:YTN\4:]'+&8KC=<D&Y\UE>(#Y2O.7)Q@>M;NF>#;BQUCR;S3
MFO;-=1>^AN_[3D54)<R*3!TW*3CC@]:MZOXNLXO$&B66C/I[3ZLAE^VO$TBF
M($  %.I8G')P,'-:]YXOTZR\76OAR;>+JX@,ROM)4'<JA>!U.2<]!CF@!]QI
M%S+XYL=87R_LL%A-;MD_-O=T88'IA37,V'A;7M#30+NVMK6[N-/:^CFMS/Y8
M*3R[U96VGD8&1CN:W8/&VD0:19W>K:E8P2W,+3*(79T=0V"4. 6 XSQ5^R\4
MZ%J6H+866JVUQ<M'YBI&^=RX!R#T.,C..E '->'/"6K:;J&AW-Z;4FS_ +1,
M_E.2,SRJZ;<CI@'-06?A?7=$NK#4[6VM;RXMKG4-]J9]@:*XF\Q65B" PVKD
M8Z$UUEMXIT*\N;BW@U2V>2W1GD^; "KPS G@@=R,X[U8TK6M.UNW:XTVY6XB
M5MI8*1SC/<#L: ./TCPCK%OJ6EWEZ+,-!JU[?3+$Y("S(P4+D<D%JCLO!ES:
M:W+%=Z<U]8R:DU]'<C4Y$6/<_F#=#T+*W3'!XZ5Z'10!YQ:^%_$<6GZ+H36U
MC]BTG5([H7OGG=/$LA883;\KX;G)P<''6M?P[HNJ:?XFN[A+4:;I$B.7LQ=^
M<DDS/GS$7 \L8W9 ZENG&:["B@ K!\5ZEJ^FZ7NT;37O+E\C(&1$/4CJ?85O
M44I*ZL72FH34FKVZ,\R\/>!M3U,IJ/B"ZDA+ %+=?O*/QX7/H!^5=#JWP]TC
M4[%8(Y;RSF0'R[B"=MP/N"<$>U=916<*$(*R1T5<=6J3YKV\EHCQR9?%WP_E
M62\1=7T^WA>&SNP.+?=CEE'3H/;'&:Z"QU+3-3L)+M+IIDMX$>XN)%VR22'@
M_(/Z>N*]"90RE6 *D8((ZUR&L>#[",_:[*W,(5M[)"OW2#G<H'3GL/RI<CB^
MZ_$J=6C6IM3CRS[K9^J_R^XE\J.U$HEGC01;?,W-C9N^[GTS6=K6VU@N9&A6
M?[.5\U78J%![Y%9FH0ZY>65[#9WVESB]>-Y)Y]P<;-NT8''\/ZFLZ]\/Z[K4
MYEU[7[<1DAFBLT(#8Z<<#CWK.4G]E&5/#4I0O.HH[^?IH7+?5+O7$DT33]TU
ML[;E*L> ",$,^2J \\\^GI76ZS(]KX?AM))H)+A0JNTAD$9.. Q4Y /8G@UR
MMA;V^CJD5D"H:>-I7)Y94.0"?<\_A4BRR'8Q<ETWQG/(>,MN"GUP2:4/=CJ]
M2<36I2E:C&R7?=^H:-JL=O=6EE?6?V:""1I9?+)F1F/W3W.,DFK45GI.J-H]
MQ):0O)?W\N\(!D(%<A3C! P <5!]J6'RS)$DJ*P&&'/)QP>M79[71[LAIK9P
MXZ.DA5AVZCFMZ3G9M:^>S#EP]6*4DTETW7EYE&RO=)T5(96: W5O?7,,D)(W
MNFY@I/H!\O)K7EU&:[C%]-++%:H#)U*B4XX55_N#U/WC6=:V.A:5E[+2X$?.
M3+)\[9]<FM#3K2X\07B3S!OL$;!F9O\ EJ1T4>WJ?PJN6;DY39K.5&*M2C;[
ME]R1U.E(T>DVB.,,(5R/3BKE%%4<@4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !3)(HYHVCE171AAE89!I]% '.77@^
MT<EK.>2U)_@^^GY'I^!K+E\*ZM'_ *N2UF'^\R'\L&NWHJ7"+Z":3.".@ZT#
MC[$#[B=:DC\-:Q*V'2WA7U>0L1^ ']:[FD9E099@!ZDU/LHBY8G-Q^#;819E
MN[AKG_GJA"@>P7D8^M,_X0]NG]J2X_ZY+FNDCFCE)"-G'6I*TM;0I2TT,:R\
M,:?:2++('N9EY#SG.#[#I^E;-%% !1110 4444 %%%% !1110 5RNLV6I6GB
M^S\066GG4HDLI+.2!)%22(EU8.NX@$'&#R#TZUU5% '!>'O"VJZ=J^BW=Q%"
MB1C4);B..0%8&N)%=8U]0,')'&<UKZE8:@GCS2M6M[0W%G]CFLYRDBJ82[QL
M'()Y7Y"..>E=-10!P'A7PKJFF7OAV6]MX@MCI5Q;2D.&VR/*K #UR >:BTSP
M?JEMHW@^T:&."339+G[4T;K^Z62*505QUY=>E>B44 >8Z%X/N(+&WLM8T?4K
MMM/LI;=0^H1M;3!D\LA%R" Z_P!X#'KWKI_!EIK%E:WD&H_:5LEE46$=Y*DE
MQ''M&0[)P1NSC))QU-=/10 4444 %%)2T %%%% !1110 4444 9=]X>T^_<R
M-$8ICUEA;:Q^O8_C6+/X/N0?]'U%7'I-'S^8/]*ZZBI<4]PM<X5_"VL*?E6S
M?W$K#_V6G1^%=7<X<VD0]?,9OZ"NU,@\Y8QRQ&3["H;RZ-LBD '/J*%2BWL0
M^5*YB6G@ZT52;Z5[IR. ,HJ^X .<_C2MX/M<_N[Z\1?3<I_F*V;.[-T&)4 #
M%6JKEY="XRTT,2W\*:9"X>59;IAT\]\C\A@?I6T %4*H  & !VI:* N%%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[0@'.Q<"L.!/.NE7KD]_2IANV74V43>MUV6\:]]O-2445B;K0**** "BBB@
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M-!@-OH5FK??:,2/_ +S?,?U-.O;V2WDV*H^M.G25MM2ZV(DKQ3T\B\ %
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MH+J_><[4RJ^@[TZST]IB'DX3^=:J*CK(PE-RTB16EF]R^3PO<FMV.-8D"(,
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MBBB@!&564JP!!Z@BJ$VA:5<-NDT^V+>HC /Z5H44 9/_  C&C9S]A3_OIO\
M&K=KIEC9<VMI#$?5$ /YU;HH **** "BBB@ HHHH ***1F"J68@ =2: %K/O
M;\1 QQ'+=SZ5#>:CG,</3N:K6MF]R^3PO<FM8PMK(QE-O2(VWMY+J7V[FMZ*
M)88PB#@?K1%$D*!$&!3ZF4[EPARA1114%A1110 4444 %%%% !1110 4444
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M[N$O:1[KC<A<QR8&-ORD#: >>IQ7H]SI]G>6RVUQ;120(R.L;+\H*D%2![$
MCZ5%-H^G7 OA-90O]O01W6Y<^<H! #>HP2* /*?$S3SW'C=_[-M);&5;/[7=
M2'=+:HT*YD1,?,5!W#YAR*OS1SZ3XVUWQ%8&2?\ LTVD=X@.3/:-"-Y]V7 <
M?1AWKT@Z1IQ2\4V4)6]0)<@H,2J%V@-ZC;Q]*=;:996;S/;VL4;3*BR%5^^%
M7:H/K@<4 >3P7,=[X"\,:%':S:A;ZC>7%Q<0VH5C);1S.YX) P6,8Z]Z[?X<
MW\UUX2BL[I9$O-,E>QF24 ./+/R[L9Y*%#^-;ECH6E:8T+6.GV]N88C!%Y:
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MIII?#S<+V%:RJJ*%48 [4M%3*39T1BH[!1114E!1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>arwr-20250930_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 arwr-20250930_g3.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )7!<<# 2(  A$! Q$!_\0
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M&(2B1/+/\>X8_.G>8NX+N&2,@9ZUV'==#J***!A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!3U/5[/1H5FO;F.UB9PBM(< L>@JY7/>-+S3K+38'U.P;483<(JQI
M'OVMV;%= * %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPWK1:2Z@#".5SELJ>5)[^U>K5Z>"QE/'455IZ=&GNFMT;TJBJQYD%-#JQ(#
MD>AKR3XH>,M4OO$,7A?0W:.5RJRO&<,S$9VY[  @FL;5/AKXI\*:<VK6VL-+
M- OF2)%(P8#N>>&KRJV<2C4G&A1<XP^)KIWMWL<\L2U)J$;I;GNU)D'O7!^"
MO&\GC#P5J$T^$OK:)TE*<9.TD,/K7E7@2W\3>+9KO3;#4IH;9@KW$TDC$*!G
M SUYR>!Z>U.MG,(>Q]C!S]HG:V^G]:]ARQ*7+RJ_,?2*L&Z$'Z&N;^(NKW6A
M>#]0O;*7R;F(+L? .,L >#]:\DUW1O$OPGOK348]1-W;.^TD,Q1CUVLI]?6N
MG^*L,OBSP-8Z]:W!@M(XO,DMR3\^XJ ..."#UKGJYI4JX;$4_9N%6$=K]'U3
M\MR)5W*$URVDE_3-WP+X@UC7_A[=7IE%UJW[Y82RA06 ^4$# ZU7^$UWXFN1
MJ']O>>801Y37*;6W<Y X''2N4^%'A^]M_#VHZT+TBU-O/$MN&/# ?>]*N?!2
M_N;O1O$)GN)9BBC:9'+$?*W3-<.#Q52=3".JY)N,NNCLMWZF5.HVZ?-?9_,]
MBR#WH5@WW2#]#7S?X$M/$?B^ZN].L]5FM[=@'GE>1C@#H/7D]A3KJY\1_"_Q
M2UE%>F=Y%&T$EDD#<#@]\_RKHCQ#^[C7E0DJ;=KW6_DNI2QGNJ;@['T=N4-C
M(SZ9KF_B'-JT'A6Z?1=_VT$<QC+A>Y ]:\G\6>!?$NB:,->NM8>>Y!5I421M
MR$^^<<'TK?NO$U]K/P8>\FG?[6DHA:96VLV&QG([XK6IFLJL:U"M3E3DH.2U
M5[?HRI5W)2A*+3M<[3X;7.L7/A>)];#B[WL%:48=D[$_K74Y'J*\N\)Z/>^+
M_A;#:Q:A);7#7#-Y[,Q. W3.<UY]XOT+4_#.LVVEPZW/?WLH!,<4CC:2?E!R
M>IJ'FE3!82E4]DYQ<8^\Y*]WT[MA[=TJ<7RW5EK<^D@<TC.JG!8 GL37G>MZ
MK-\+?A_;1*YN-3E^4/*Q;$AY8\]0.PKB-)\(7?B:R&I:GXLBMKB<;TC>?+#Z
M\C'T%=M?-94IQHPI<U2UVKI)?-]32>(<6HJ-W^1[[17C?PY\7ZCHGBEO#>J7
MBZA YVPSJ^\!NV#Z&O9*]# XV&.IN<59IV:?1HVI555C=!1117HFP4444 %%
M%% !1110 4444 %%%% !1161KWB6VT![&*17GNKV8006\(R[GN<>@')/:JC%
MR=D)M15V0:CXM@M?$-GHEM"]]J$WSS)$>+:+_GHY[>@'4U-K4.FZ5:ZCJL]K
M 96@VS2N@S(H'"D^GM4\T]AIEWNV1Q7-V<&14QO*C^)O;WKXV_:4_:)U#P](
M=,>14=BV=CY4#./I7+C,1]7IIQB]?Q/*QN-IX.FY5-7T/./B?XHLVU+7M)\/
M^$DO[>>1GF"Q^9&O4DH3]P4WP)X)6[BN-3MM-_L.UN-,""UTZ;R_,[[G+>E<
MO\+_ (D7'C[6K[PMJ-Q<V#F%IXHK:,![GZGZ5U>HP:M!HFHV5K;:K#-&JPQO
M*A9IE XVKZ#UKY:-1T5*7,U-:Q:_K0_.E*7,JK6G]?YGDJWYU/Q[%X4UBXU#
M2]!MEE>YO!*K>:0,HBMT![TLVC:3:>,-#5=<5M-N6+8N+C<RKC(+#NV*^=_B
M]J.KZ=JZF9KRRN8IOF'((4'YLY[UT7B/7_A;JOA6\33([Z37I$#6\\EX[/$0
MO15' .[/6O:H4JM?$0J.2C*SUMU2W?F][]6;K!NI"$WU[)O[SVSQ=\$?#OQ,
MU;[7X-EN--N(#MNH[?"P38_C(Z9/M5[2/AGXETWP_8>3:Z@SB9H7C5!MEC(^
M\ >F,=:V=+^,-OX0^%OA&VTNQ>R@>QCD\V:/8TIQ\[LQ^\<YKQ?Q1^T%XBUN
M\OCI-Q=KIJRDQ7*AO)C]?GZ 5YM&K7FXTKM16C\]>M[ZKH85*:K/DUDX^25C
MZD^$-O<>#K"ZW:6;;1[;,;7?F;)IW')C.3G@GMQ73ZEJ&FZKI$.IW&I3Z9?3
M2[EB@<-N7MN!R.?2OD+P?XI^(WC:PM=+TI/MLMRQFC267:5'\3$^@ZUZ==B2
MWU'0_#=OJ4%ZNGS+%]MBC8$RNW(;/0 ^M.M1K^].FW*,'==;*^]NFR\A^T=.
M')9-;?,]T\*_&.'X8W$^FZ9>O>:E.%@E#(J'>3D%0/3-?6/A?QC(UIHUCKJ&
M'4;ZW#B0@&-V)^YD<;L8R*^5+B'0_#EZ)4_LZYU2WAWM<FW!<X')SUXKFHOB
M/XNN]?M+;3 EU+8SK>[FFVQ+%CY6&>N3VKIPV8T55C&<>6-K.W?O\WT/4PV,
MK9>FG+FUT71*^J]?,^Z=*\-Z=X6EU"ZL4DMX;@^=+;HQ,2L!RR)_"3W Z^E7
M='UBSU[3XKZPG6YMI1\KI^H/H1Z5Q7P:UC7];T*>ZUV>&21V5HHT<,R CD-B
MNGMM&TOPK/JNJ1M]BAN2)KE2V(@P&"X7L2.I[XKWZ558B'M)7N]KGWE&HJD(
MS@K19MT4V.1)HUD1@Z. RLIR"#T-.H.H**** "BBB@ HHHH **** &R.(T9V
MX502:^=_C=\?=7\/KX?E\'XNY]0N3:I9M&"\CAL'KV %>]:]KEEX<TJ>_P!0
MD\JTB&7;&?TKX]^)]K:Z_>Z5X@M8V06%^SP)#^[(!)Y('8@^E8U,1AZ-HUT]
M>SM;U\CR,PK^RARIV]-]]SL=4^./BNPGO=3CE673I(&C2W&W<LHZE!['(YKG
MS^UEK5_H]M8302Z?JEW,@M9I(2CE<@?..G)].U?-FM:9XGU?QC;:597UW9?Z
M2TYLY9!B>#=G;'^N2:]XM]?U"2_N==M;:V72[:4K(UPN'0(A&4XYY_E7FJ=6
M$I0HRY^?5:^\ET\DW=::[61\ZL57;]VH[/YM+KZ=#H/"WQ;\7Z?X@OX$>.2=
M2I^SA]XD7EI)&!/R^@KZ#TKXQ^&M3U/3]+2]_P")E=X AV$8;&<9KX L/B&E
M[%XKUQ89[6"Z2.&/5W5D2 $MN!;OSC.*R/AEXJNKGP_+XG:Y6SO?#\SSP++(
M2;XX):3)YV$8  [U[6&PE:K"G.<US2Z*UHI+LNKZZK[U9]>&Q.(II/=/OT7^
M;ZGZGT5Y/^S[\7;KXJ^'YIM1C@AOHMKF.$8PC#@$>M>L5E":FKH^HHU8UX*I
M#9A1115FP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 <[XW@T:?3;==;F>"V$ZE&1B,OS
MCIVQFNA'2L3Q9J":;80R/I3:N&F5?)1 Q4_WL$?YS6V.E "T444 %%%% !11
M10 4444 %>&^"O\ DLVH?]=9OZU[E6#8^"=)T[6I-5@@9;QRS%BY(R>O%>/C
M\'4Q52A.#7N23?IY'-5IN<H-='<P?C7_ ,B)/_UWC_G7F=QX4:]^%VEZU:)B
MXLW?S2O4INX/X'^=>\:YH5GXBL&L[Z,RVY8-M#$<CIR*9IOAVPTK1SID$/\
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MG6L,-EE:C/"RDU^[33^?;0F%"473;^RF>3>#P#\<-0]IKG^M:O[0G_(/T?\
MZZO_ .@BN_LO!&D:?KLFKPV[+?2,[,Y<D9;KQTJ;Q%X3TWQ3'"FHPM*(22FU
MRN">O2H_LJO]0KX6ZYIR;7:S:?;R)^KR]C*GU;/,OBG_ ,DT\,?2'_T57H'@
MH > M, X'V0?RJUJO@[2]:TRTT^Z@+VMKCRE#D%<# Y^E:-CIMOINGQ64";+
M:)/+5<YPM=V'P-2EBYUY-6<5'YHVA2E&HYOM8\;^! '_  DFL'OY7_L]+\:_
M^1QT;Z)_Z'7J&@>"M)\,W4UQI]N8I9EVN2Y;C.<<T:YX+TGQ%>PW=] TLT(
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M$F-R@X/!SUK,C\#:/%H+Z.MNPL&?S"F\YW9SG/6NO&Y=5Q&(E5@U9TW'YO\
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MK5?^ 6G6<XU2\D1)+Z-U52_)12#R/Q[UT7PI\#W_ (3M=3BU)(P+DKA4?=D
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MM/#5OK.-ERNTHI+S?+T.GDESU7;=?H<C\(99+?X;ZC- N9T>9DP.<A>*\_\
MALOB(WM]>:%!!<70"B22959E!SR,D=>:]C^&'A>\\*>''LK]4$K3,^$;<,'%
M<?K'POUSP]KTVI^%;GRXY2280P5DSU7G@CTKS:V!Q"P^$J\LOW:U4?B5^J,)
M4I\E.5GIO;<SO%/AOQSXPAACU'3[=S$V5=$16'MG=T]JB^*5K>V/@?PO;WXQ
M>0AD<$YZ#C],5M:;X3\=ZSJUO<:GJLEC#$0=RN,@=P%7C\ZW/BMX*U'Q=8Z=
M%IX21H&8N97V]1C-1/!3K87$580J<TDE[UKO5/9:Z Z3E3G))W?<W=+MTM?
M$$4:A%6PZ#_<R:\U^ .FV\U_J5X\8>>%55&89VY)SCWXKUF#3IH_#*6)QYXM
M?)//&[;BN0^$W@G4O!RZB-06-?/V;/+?=TSG^=>U6PLY8W"2Y/=BG?LM-#IE
M3;JTW;1'(?$*VCM?BWI[Q((VD,#MM&,G=U_2NF^)O@#4=3U2#7M$?-_ %S%D
M G:<@KGC/M2^,O >J:WX[L=5MEB-I%Y6XL^"-K9/%.^('AGQ7=Z]!J>B7[&.
M)=JP*^PIZ\'ALUYL\+)+%>THR:E--<NC_P 2]#!TW:IS1;3?3\RO\.OB$]_K
MDFE:Q8I;:Q)\K7"Q[&D*_P +CU]*]1KROP1\/=;_ .$J/B#Q!*IG4[E3<"S-
MC )QP !7JE>[D[Q/U=_64]W:^CMY^9UX;GY/?_X(4445[AU!1110 4444 %%
M%% !1110 4444 %%%% !2$X&3TI:;(GF1LIZ,"* *.A:=I^EZ9';Z8L:V6YW
M41-N4EF+,<_4FK[,%!)( '4FN>^'^@7/A?PE8Z9=E&GMS("8SD$&1F'Z$5F_
M%U=:/@J[?0HFN+M!EH4^\ZX.<?SI8B?L^>2]ZU_F<\I^SI<_+LME^1XM^U!X
MDNO$=O>Z!:Z;%=PVR;WFD VH"/O!NQ_PK\Z/B5\#;WPXLFJW1CFDD!;#D.R!
MNF>U?2/C;7-<TWPC<))?&ZOKZ9F:UA!+0H!C;GUSVK#\+>$;#QAX4T1=3GNW
MU350RS32$E+>-<X 7ID8ZU\Y*OB<-S3JQLJB3ULW;HD^A^;8G%5,16E."M)V
MWM]WY'F-O\*?"/PX\#^'] O[B[L?$VMSPW-W?K+F--S JJKTP%[>M<W^U[K>
MGZ,UK)I&HW%TENZP3>:^=R]#CZ@5K?$K1M0\2>)YO"NM3F">S4/;7Q!4W$*=
M"OH<#/%>5P?![5?C3\1+7PGI>M[D$3SSW=^^4MXE_B/N>@%11DZE2-2M._+=
MZZJWEY&F&?UC$QE5?6[NNB.:T#X5>(?C8U_X@TKR]*TRTP8Y[C<@E<#[D7=B
M,<XZ5JZ%XAN?ANT%QKLDUQ.H9 UROS(W0D9ZBO:/#_AS5?AYXN\(^ 9O%,,W
MA^RE=A?A-C6_!+*!T);L37F_QB\*:1K'Q>TFTBFN-2\/W-VJ71+_ #D%@#@]
MLYKJ>)>+K/VKT>J.B5>.(J*A.WL];6WT_'4];_9.FD\?WWBI8+%6TV:)2-9U
M.#="A!.43/4GVK$_:"^"6HZ+9:EKOA;7('@@0R7EKLV,RC[P0C@=SBOHV^TW
M3/AOX$A\+Z#;S6D,%N(]+B49=RW/3^,^]>"^.[S7- \-WFC:WI[6IU"TD!EG
M./-F88"]>W7%<\\;7JN-"DTX1>B_%]+G'*M"E4BJ<=%WU^_IYG@O@(O/'(VI
M,[+(?E1&QP>]3Z%XWO=!76-,L=0D$+73*B$<.&XY['TKSC5SXBT8-I95PD;"
M,S*."3TVM72> + W-I%8WUXMO]FN?-96 W+[DGJ.M>M"G""E4JQYHV^5^AZ]
M;#4TIXB<DXNUDM?F?6OA^#0=&\#P7.DNBRZ5:&:5+@XA1L?,[8]"2:\#\?>.
M+%K Z%IF^[MKNX1[_7T4JS-G=LB4]LXR>]=\LC>(O FO:!:W\*V448D>YLQ\
MUT,C;&3_ $KRG3?#>O7$VI^%[U!*8Y5:(A,3<C(7/MQ7ETJ/LIN=7XKWMMIO
M?;_@'BX6,(R=6M\2>M]/GYAX3N?$>@7UM<7&H!+.5BL<LC8D"CL3Z5].>!/C
M=JGA+XL65LNLP&$)&T5S&Y*G<F#D^W/%?.D'P\\3VWB!+'55FU!X@JP(W)0'
MU]A7:ZKI,'A_4TB;2(-4FC@5)6CD9A [?Q97N..*]6.)PD,4Y\KY6K:/H]]?
M^#Y#Q52DZJE%W?=::_YG[4>&=576_#VG7ZS1S_:+=)#)"<J6(&<'ZYJ"V\/-
M;^+;S61/E;BUCMS#CH58G=G\:^5?V*_BAXIUNU/A^2S)T^VA)A$V0L8'/!Z_
M_KKZ@C@\2+KDUVSVK630+&EIN/RN"27S[CBNO"UHUX.5-V6VNY]]@L7'&4(5
M;._7U.DHK)\[6?\ GVM?^_AI?.UG_GVM?^_AK;D\ST^;R-6BLGSM9_Y]K7_O
MX:/.UG_GVM/^_AHY/-!S>1K5Y]\7_B->?#W2(KBPM([RX8D^7)G! Z]*Z>QN
M-=?6Y([NTLX]*$ 9)XI29#+GE2OICO4GB7PW9>*-+FLKV%)5="JEARI(ZBL:
M].;BXPE9OJ8U5.I3DJ;LSX\\<?%__A*_#=_J@N;PVNI)BW2+=(C..&B"CN#W
MKYVU76-:\&^&=$DUM;R.RM[HS[+-\-Y;M_J3CJ#FOH_XH>$[OPEJ7]FV=V+.
MQ@D\V."RA##S/7'7!/45RVKZ7/<#0;+Q%! VG2RK)?%8@(ER<KMQR/FQ7SU>
MK2P\YQH3DV]'?1-:W^5['PU9S55\S=U9/[SQFZ^'=IXG\4Z5H&D:;J'AGQ#/
M='4I+FZD+P+"/G!9,XSCC%>K>/?B!IG@*6Q\3:]I\DNG>5Y%Q<VT6)4?< TZ
M=Q\N<8J;Q3X$.D_$T>+I;N_AT:R4Q3(DGS71VY Q_=QU_"J/QSU80?#)[Q],
M@U/3;JT\N*W.5:)&;"8]6Y''M73#$S<:55N*Y6HO3WGK>[ZO;?S-$VE%/H_G
MO_6OF<'^T%?>!=3\$ZCJ:RV]\)H%73FB ,^7Y!R.>.I-?.OAWQ=<ZUX$O-#U
MSQ#+%I5HAGME$>/,E494,>K<]C5F7X>W'A/4]'N=6$T7AK4UVA6<MY9]&';J
M*P=2T32(-6UFUB^V-* SV,2='Q]TX/49%=<:<,5.<XN_,^;;;6S2WU.ZE&FT
MTFW=\UTMM;:;V\_(B\$,VMS0B\^TVT*JTDKQ_,)FYYQV'2NDUWXP-=^&;?3]
M8M1J\7D-#:QQQ;%A<G;EO4UU_@;2=$T'PS:>(+O2[R#4[5L3V[\1SLW C].2
M<_A7G-]_:-GXUU*/Q!IRP7$4HU..R5PD:1D[OE]<@X ]:];$4\)B*TJ5)J;2
M;OYI)^ZU;?9[V=^]S5NEB:DK*_+Y_E^%]2FUWJ/C;4+?0[1#.$M%C4/&5\HC
MMS7KWP2^"?BJ/6[/5=>MKF\TRU=D:W.,@] 5S75^#=1T75?$:^*H;"/2[:TM
M MIIL_,FHN!D@<=<D#VKOM-TK7OB/!;7ESJ]_I.HWLC"72+,'RK-1D <=. !
MGOFOG9U)2;II<J2]Y;OSM;3;K]YP5,1*4?9122[;OSU_X!WWA;0_#OBU HLK
MO3].TVX;]S?.$C=QQN S@#.:][^ E_J4GB/68X=C^'753"5CP$9>.#W%><^
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M7D9RA&34GN@HHHKI- HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@# \-ZW<ZEJ>O6=T%#V-WLCV
MC&8F4%2??K6MJ5A'JEA/:2EE29"A93@C/<55O=9L-+U:QLICY5UJ+,L)V\.R
M+N()]<9Q6G6D][I6O_7YF:2:<6[GSKK?[.MCX6T'7]8E:37M4=2;5/+P(<GD
M@#OC\J^?]7UJ2/Q5H&AII,MKIT"-O,2[1A5RP)'OU-?;_P 3KQK+P?=LER+2
M1R%20],YZ5\3:UXSTSX>C46\07$=Y</<&19$(WHC#H/QZXKYC'0C*=/#Q3O;
M373?2]]DM7_P#XK-,/2P\XQI^ZNOWW]=?T//O''Q6T74_'&@V"SZ=ID1F^RR
MS7B@21HX(.-PR3V!KQC7IM#^#_Q"NO$/A&ZO'659+2YAFPX="<9'X\\5S/Q3
M^)GA_P"(GC)[O5%^VVT3M%)<0* D2$?*<]20<5V>B?#/PM\5=)TRQT;7+TW$
M($<I;=C:!DRJ#R>G%2J<:,/82C[S=F_O5NQXK4J;4IW7-OZ=D+)\-=7\7V>L
MZ[/JEI:MII5U@F)WS2,NX#';CUK6\(Z)J'QLO=$UJ^T5=+\-V[YNKF#:K 1=
M6 '."P S78ZMX0\(:%X U&:.YU"X::);6.1IB#+L&&E8=V-:WP@DT"V\&ZK8
MB]G?3H(!&D _=^87^8L>Y':N*<TE+I;;0Y5R)J';7\]_4DDUOQ+K'BRRUG2=
M'_MRS#F"QN7+*( #MW<=\=ZV;WX;P>./!TTOC97EO;RX9K:V\[:UL!P'&/XC
MU^E,T;XCCPKH^F:59I-8B"W>.WM4C,DCJQP&'IGU-</9?%=D\1WVG-IMS=7%
MHS"WGNIQLW]S^!/Z5M2H1K8>+HO][S6MMH^M]MS2$HI<R=W^KMJ?'OBCQ!/?
M3W_A_3+:9H1,T;R,A,CLC'&!VZ"M+X9_#ZR\33S'4+N2SU*$,<RC'W1G!!ZU
MZ!KOA#4;#QE<O;1-<3F0R+<Q)N#ACECQ[UVUQ\/-7M-0L/$$)B:[N=H>"953
M;@8#8[^]>_4IXBO2G.G9).SU6^WH>E+%.-&4<.N7SOK?M\S#^TOX'^&>HWWA
M5H5U*S1)[VXNX \?+8$: _Q<YS[5P'@7XKWME>76I:II]O?71?[0;B4GENIR
MO0^E>W_$;P)9+\-XM(OKJ*#5II0[QI*55OP[G%>0:%\+Y=?L+C2W\B.&V+>9
M<-)M(4=&)]/I7#&I"K3E.O+;17WLNFG0Y*56C*DUB-97^=OU.JNO$]UX\&O>
M-;#5;33KV6X2)M&LR=TB,O\ RS3^ZH'/UKZ&_9N_9GNOBS'HVIO>:I;^&7E;
M[080(U+J,D,>I!/&*\>^#'[-OB;6(]-N='TVXFTY9<?:DC/S8.3^)KZ8_9P^
M*'B3PI\47\-#3+F#3S=R0_99$*A0S#)(['(S6[QV&E-NI3]&N^VO?]"*:I2Q
M4'-/D;^_\#[*^'7PHT'X86LD.CQR;I %:69]S;1VKLZ**]&$(TX\L%9'ZC3I
MPHQ4*:LD%%%%6:!1110 4A.*"<4TG- '.7W@'2=0UU-5FB+3*=QC)^1CZD5Q
MWBWX#V/B":8VMXUG#.Q9X&7<J9[KZ5ZI17/+#TI;QZW^9S5,-2JIJ43Y#^(/
M@/6%TW7O#VIPO')<6K"WU"-^)"!A3[,1CD>E>,^$Y]:UWX8ZQ:>(DLGU72Y8
MK>S$F3O=0<$CL3Q^-?;?QMM8;G0K0B;R[N.=2BKU*DX-?.7C!+#X?^''%Y%%
M<07%ZUS<7;*,D*<@$]^F*YW.G"2H5J2J.4KIMV>K6CMY]7T['S6*H*E)PM=>
M?GT/FCXA>-K_ $'?IOB'08UEN=L27"D".$* 6V@]6)KB?AW??\)%\05UC65T
M^R\FY7,1B!^79A"3Z$X_&IM8^,L/Q1^(,ZZSIPC\.0>9-!$R;I0^< KZY]*R
M-=^#GC<^)7OM-M6TNRG:(0VK'<[(2&#L!T'?VKFJ06$E*FDH*5[-7U3TLF]=
MEKIW.-452O3E:+:W]7M]Q] ?$+6XK'PU/INF:9'KIEB*(;5%"17;9\O<3Z=>
M.]>"^)+!_$VI>&[UH9+[QOYY2^ANT*+Y<8VA".F >F*^D9+G6/ OAVPL[JPM
M?$<AG619[,B.,,.I9>IQR:\\^)OBJ6\^)>A#PU<68AEMF,UTRJQ\QFR6Q_#C
MH,UYM!*BVX+973;MY:]UVMZG-2;IWY;)I/\ +\BW\/X;N+QUHEMKNG!K]?-*
M0+A;6T!;J3^6?PKZK\ >&-8\7ZA&^E"QM+:*3=>2]#.<XRB]UXZUX=X=T*ZD
MUN*"Y*ZI]F5KK49X\&1]XSLXX]./I7US\"='TFYL8M2L8;D&V5XO-GPOS,1E
M0H/ 4#'XU[65SY7SJ*7Q7??LK7\[VMU3.S+X>UJI-6/6K*UCLK6*"-%1$4+A
M1@5-117H[GVR5M!0<4H.:;0#B@8^BD!S2T %%%% !1110 4444 %%1I<1222
M1I(CO'PZJP)7ZCM7.V_B^]O=:6R@\.:DMJ)"DE]<!(XP/[RC<2P_ 5<82E>W
M0ER2W.FHKY=_:_\ C-XV^'][HNF^#P\$MQ/'YDZQY 4G!))&,=L>M<>O[7_C
MOPW,8-8TBWU.ZE9(UMK.#$D+$'@'.';V[5-AW/M*BO%?A%^T9IWBZ:VT'Q$W
M]D^*I<E+650!*.VTC(W>HKVJD":>P4444#"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#G_&=YIUEIT#ZG8-J$)G55C2/?M;GYL?G6^.E9/B6[U2TLHFT
MJRCOIS*JO'(V $[FM:@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ+7R6GJH_G8\U9;!RE"+DK=7:W](^:? ?@+_ (1+XAC2TL+E+:8Q$6P&$$;
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MJ0TR42JQE*@[E_N_C6M7.^.(='GTRW76IVM[83J496*Y?G X_&NA% "T444
M%%%% !5/5]5M]#TVXOKIMD$*EF/?Z"KE<'\:B1X$N "5S*F<?B?Z5QXVN\-A
MJE:.\4V9U9<D'+L>;ZW\<M<N[QS8F.RM@?E0(&;'N3GFLW_A<OBC_G_/_?M/
M_B:X>BOQB>:XZ<G)UI?)M?D?-.O5;NY,[C_A<OBC_G_/_?M/_B:/^%R^*/\
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M'HH_M+&_\_I?^!/_ ##VU7^9_>=Q_P +E\4?\_Y_[]I_\31_PN7Q1_S_ /\
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ME?J%';K7.M\=OBW\!?%.@VWQKTSP_J7@O6[I-/C\6^&1*@L+ISB-;F)^B,>
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M2=1D_>28V-$N>CYY/'I7VL[K&,LP4>I.*1948$AU('4@UQ5L/&O9RW6QPXS
MTL=%1JWT['PW8_\ !/;4-+TN?2[768%%Y%NNKH J"1TBQUQ[U['^SC^RIIWP
MCTUI-;AM-4U8-B*7;N$:@Y&,U]!/(D8R[*H]SB@NJKN+ +ZD\4Z-"-"7/2;3
M?F]3GH91A,/452*U7=W'=**9YJ;-V]=O][/%)]HBQGS4P>^X5T'LDE%,$J,,
MAU(]0:7>..1STH =29J/S%+[-Z[O[N>:=0 NZD)S110 4444 %%%% !1110
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M^VOJWBCQHPTWP;X^T6UT^R\1W'%M:7L#'-O-(>(PZG()."12_MX_M&^ [/\
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M?%>C7>EV=_ILVG7-K#/831&"2UDC#1O&1@H5Z$$<8H \_P#V:?\ DWOX<?\
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MB0 #E@>*U+O_ (*'_".&ZF>V?Q'J>A0.R3>(K#0;F;3D(."?-"?,/]I01[T
M?35%9'A/Q;HWCKP[8:]X?U*VU?1[Z(36U[:2!XY4/0@BH?'7C/3/AUX-UGQ/
MK+O%I.D6LEY=/$A=EC098A1U.!TH W:*RO"GB6Q\9^&=*U[3'=].U.UCO+=G
M7:QC=0RDCL<$<5P]A^T3X-U+PCX^\20W-R=+\#W5U::PYMV#1R6\8DE"+_&
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MQG8^./#/BG4_A_X[M8/LAUG2521;NWSD0W$+@I*H)X)&1V- ' ?M^:5I=GX
M\)>*X/+M?'6D>)],'AZYB^6XDEDN%26%2.2K1-(2.GRU: :V_P""A]F]P5B:
M[^',HB!/WV6^B+ >N*W?!_[*TS?$'2O&_P 2?'&I_$O7M&RVD0WL$=K8Z>Y!
M!E2",!6DP2 S9([=L='\=?V>;'XRW.@ZU9:[J'@_QIX>D>32?$6E%?.@#C#Q
MNC?+)&V!E6_QH XO]MTA_"WPU@!!FE\>Z,(X\\N1,6.!WP 3^%1?%GX:_$'X
M<?%K5OC#\,H;3Q/)J.FPV6O>$+]_*>\C@)*26TW19 "PVMP<U>\)?LJZI/\
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M9X-\/:=H6BV46G:3IT"6UK:P+M2*-1A0/P%:= !1110 4444 %%%% !1110
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M+-V7-;PK \:7&EV^G0-JUDU] 9U"1HF[#\X/\ZWQTI +1113 **** "BBB@
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M%T>A5AWXK[#'PF\-R^#--\-7EA'=6-C;+;1L1M?:!V(Z5X-X&_;.\&^'M/\
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MPYH **** %!Q3LYIE*#B@!U%'6B@ HHHH ** :"*  T4 T$4 %%%% !1110
MX'-+3 <4^@ HHHH **** "BBB@ HHHH Y_QI#I,^G0#6+A[:W$ZE&1BI+<\<
M=L9K?%87C#4+?3M/@DN-,?54:=5$4:;BI_O8]JW1R* %HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FL:=3#S0 45R?CWXG
MZ#\.[:*35;I4>5@BQ(07Y[D>E?(?[4/[0^OV'A?39[.^E@2XN#G[-&5:)=V
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M6T33HL<S*"RJ<@'TJ6CI161N%%%% !1THII.:  G-)110 44M)0 4$TA-)0
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M*GRI@#[WIUHMO$D%UX@NM)6&836\8D:1D^0YQP#^/\_2M8J"02 2.AHV@$G
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MGB2"SURQTMH9FENU++(J91<9ZG\*U=BX P,#MBE*@D$@9'0T +1110 4444
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M3: <4 .HHI: $HI324 .!I::.M.H ****  444IH 2BBB@ HHHH *#12]A0
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M.F/J\*7%BLUXN9HG&4D&,X4CHQP#6S\<\#X+^.LC(_L2\R#_ -<6KP;]B?\
M9L\$6O[+/A*;6M!L_$.J>)=%AGU*^U6!9Y98WC&R(,P)5$CVJJC@8SWH ]X^
M('QU^'OPKT"RUOQ9XQT?0]*O@&M+FYNEVW((!#1@9+C!!RH(Y%=!X/\ &FA?
M$'P_:Z[X;U:TUO1[H9AO;*421OZ\CN/2OC7_ ()Z_!+PY=^%?&&IZ[81>(YM
M'\2ZGX<T?^UE%RNGV%O.RK#"'R%!+$G'7CTK-E\47'[/EM^U_:>!X4TFTT*.
MPU+2[2!0(+&>Y@<2R(G11N"O@<<4 ?4OCS]J#X3?##Q"NA>*?B!H6B:P2 ;*
MYNQYB$]-X&=G_ L5UNF?$CPMK6I#3]/\0:=?WIL5U,0VUPLC-:L2%F&"<H2#
M@CBO*_V=_P!FWP#X,^$.BQ-HFG^(M0UBQAOM5UG4X$NI]2GEC#R2/(X)()8X
M'0#%>-_!'X3Z'\(/^"AWCG2/#H^SZ-<>#+:\@T[?N2QWW!#11C^&/(+!>VXT
M ?8OA?Q=HOC;1(=8T'5+75]+E+!+NTE$D9*DAAD=P001VQ7D7QB\06'Q+\*^
M'[OPC\8;;P7;6_B2&VFU*Q=)4OI$?#V.20-S'C SSVKY(_:9UJ]_9N^-.H?#
MSP%XRM_#/A+XG/%/KJF-W'A1Y91'+=QE>(A< D -CYAD5ZW^UK\//#_PN^"O
MP6\+^&K6.VT33O&NC1VX3!W_ +PDR,?XF8Y8MW)H ^K-=^(WA?PM=7EKK/B'
M3M,N+*R.HW*7=PL1BM@VTS-DC"[N,^M8?PU^/_PY^,,6H2>"_&>D>(A8#-T+
M.X!:%?[S*<$+Q][&/>OG/XI?"30_B[_P4+\.6GB.V_M#1M,\%F_ETYR?)NI%
MNR(A*O1U4DMM.1D"L7]L?X,^'U^/7P%70K1/#4GBC5+CP]K#Z.HMOMFGB(2M
M!)LQE3MQ]#0!]->#_P!I?X5^/_&$_A7PYX]T/6/$,)8-86MVK2,5ZA>SX_V2
M:S-)D/ASXT_$#7=5^)ZWFAP:9:R2>%)RBQZ*H!)N&;.0' )Y Z'K7D?[:WPO
M\'_#OX*Z+XE\->&]-T'6O#&MZ8^EWNFVR02VX-RD;H&4 E61B"#UK=^&-G;:
MG^VK\<H;FWCN+>XT#1%EBE0,KJ4ER"#U'- '>C]L+X(MT^*?A8_]Q*/_ !KO
MM7^(WA?0/!P\6:GK]AI_ALQ+.-4NIUC@*,,J0QZY[>M?)/Q0^&7A#]H7X_Z?
M\*/#O@_1K7P=X3EBU7QGJEK811^;+]ZWTY751RV-SCTP#[YOQVEU/X@?MFZ7
MX(E\"'QSX.\&>'8M6M?#"74=K;27,K[5N)%<;9%C"[0N, \T ?3_ ,-/VE_A
M9\8M3ETWP9X[T;Q!J,0+-:6MP/-('4A&P6 ]0#7IE?#?QU^&WBSXF^'(I_#'
MP!_X0SQYI4D=SH?B33]6M(9;.9&! ;8H+1L 5*G@@U]G^%9M3N/#&DRZU"EO
MK#VL1O(HSE4FVC> ?3=F@#3=UC4LQ"JHR23@ 5Y19_M9_!O4/&"^%K;XE>')
MM>:3R5M$OD)9\XVAONDYXP#7GG[<6I:CJFG?#7X?6^I3Z-I/CGQ/!I&KWMN^
MR0VFTN\*N.5,F N1[CO7ITO[,WPMF\"+X//@;14T)(1"D*6:*Z8Z,' W!\\[
MLYSS0!W&@>+=&\5'4!H^IVVI'3[I[*[^S2!_(G3AHVQT8=Q7#_$7]IOX4_"3
M5UTKQ?X^T/0=38 _8[FZ'G*#TW(,E<Y[XKY._9KOM0^!'[,_[2<^BWDFJZCX
M:\2ZRMI>S-YDDC1@*DCG^)AP3[@U[]^S%^SIX'\(_"?0-3FTFR\2^(=>L8=3
MU77]3A2ZN+Z>:,2.Y=@3MRQ"@< 8H ]9TWXH^$-9\%R^+[#Q+I=[X7AC::75
MH+I'MXT7EBS@X&.^>E?,?P<_::TKXQ67QH\./\6=-T_53J]_!X=O[>:,RVEB
MMNA2XC7^-48NV3Z&OH'P/\ O WPWUGQ)?^'-$BTN+Q"$_M#383_H4C*"-X@^
MXK'/) Y[U\Q?#3PSH]K\-_VKKB#2;&&>WU_6(898[9%:)/L47R*0,A>3P.*
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MU"TF62%D'4[AQQ@Y]*X?Q?\ M1_"7P%I6D:EK_Q!T+3;/5XQ-82278/VB,G
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M_!WP4\-.FE66OZCJ^E6]SJ6LZA"MQ/?R/$K,SNX)V\X"] ,"N$^%6D6_P/\
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MI(]DGR,2,E?8\4 :%Y\=5NOVJ/#,%CXKM7^&UWX$NM;DG6=/L;NET$$YD/
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M /C?X+?!G]I/X'>%;C1])NOA?JMQ>7DNH:AJVIQ:@UW?7$C9:25ED )Z 8
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MG[/_ .S[?_#;4_$7C'QGKX\7_$GQ*5_M'5Q#Y4,$*_<M;9/X(EZ^I/->VT4
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MJ>LW22![Q)6;[.A PX()Z_2OH[X7?M[_ /"2>+-&TK6)=.2VO"?M$H^5H!G
MZ$YKGJY-6BG*G)22.F&94V^6<6F?:5':J=GJ]E?P1S6]RDT4F"CJ>&^E6RZC
MJP&?4UX%FCUDT]A:*;YB?WU_,4>8G]]?S%(8Z@]#3?,3^^OYT>8G]]?SH 2B
MD+IG[Z_]]"CS$_OK_P!]"@#(UO7FTC4]%MC"'AO[AK=I,\HVPLO'?.#6Q5'4
MTTZ0VLE\T&8IE:!I& VR'(&/?DBKN]?[Z_\ ?0JW:RLB5>[NP:DI?,3^^O\
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M_/X7\//J<(0I;S1&?>,@0EP'/X DUT"D, 0<@\BM9<SA%O;5?K^I"MS-+?\
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M- "J,"GC@4T#M3Z ,:75[]]0NK>ST^.=+<JK223[,DC/3!IPOM:'_,)@_P#
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M_P ^8_<'U>E_*CSS_A1?AG_I\_[_ '_UJ/\ A1?AG_I\_P"_W_UJ]#HH_LG
M?\^8_<'U>E_*CSS_ (47X9_Z?/\ O]_]:C_A1?AG_I\_[_?_ %J]#HH_LG ?
M\^8_<'U>E_*CSS_A1?AG_I\_[_?_ %J/^%%^&?\ I\_[_?\ UJ]#HH_LG ?\
M^8_<'U>E_*CSS_A1?AG_ *?/^_W_ -:C_A1?AG_I\_[_ '_UJ]#HH_LG ?\
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MXM+M$@#GU;:!N/N<FNEHH P/&?@'PU\1M(.E>*= TWQ%IQ;?]EU.U2>,-_>
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M9D!],EE0RLN[&54'Y@#7I4L;1K?#)--V_I$.G*#LTSZE^ /[6,?B+PP+?Q;
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M?EF''W6@8\.!WSUJK9ZEX@L-!\6ZA<^(GN3IDD]O"'MD55VXPYQU(YKJ=/\
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M*2C;RT_X"_3YA3A43C?^OQ?]=C?HH-*!FO/.P4"EHHH **** "BBB@ HHHH
M**** ,?Q/>R6-E$\6E-JY,J@PJH)7_:Z?YS6O67XBCU:2TC&CRP17'F N9QD
M;._]*U* %HHHH **** "HY((Y61GC5V0Y4LH)4^H]*DHH C$$8F,OEIYI&TO
MM&['IFD6VA02!8D42'+@*!N/OZU+10!";2!H5A,,9A7&(R@VC\*<T$;R([1H
MSI]UBHROT/:I** (U@C65I!&@D889PHR?J:1;2!(FB6&,1MDL@48.>N14M%
M$3VL,B(C0QLB$%5*@A2.F/2E,$9F$IC0R@8#E1N ],U)10!&D$2,[+&BL_+D
M* 6^OK3?L=N(#!Y$?DG_ )9[!M_*IJ* (VMXG,9:-&,9RF5!VGV]*/(C$QE\
MM?-(V[]HW8],U)10!$EM#&'"Q(HD.7 4#<??UI#:0-"L)AC,*XQ&4&T>G%34
M4 1M!$\B.T:,Z?=8J"5^A[4JPQK*T@C42,,,X R1[FGT4 0K:0+$\:PQB-R2
MR!!AL]<CO2M:PM&D9AC,:$%5*C"XZ8':I:* (V@C:593&AE48#E1N ] :$MX
MHW=UC17D^^P4 M]?6I** (19P" P"",0GK'L&T_A2O;0R>7NB1O+.4RH.T^W
MI4M% $?D1^=YOEKYN-N_:-V/3-"V\2>9MB1?,.7PH&X^_K4E% $/V.W\@0>1
M'Y(Z1[!M'X4YX(Y'1VC1G3[C%02OT]*DHH C$$2S-*(T$K#!<*-Q'H32+:PK
M&\8AC$;DEE"C#9ZY'>I:* (6M('B2-H8VC3!5"HPN.F!3S!&TJRF-3(H(5R!
MD#O@T^B@"-8(DD=UC17?[S!0"WU/>FBS@6!H1!&(6ZQA!M/X5-10!$]M#((P
M\2,(SE,J#M/MZ4OD1>=YWEIYN-OF;1NQZ9J2B@"-+>*/S-L2+YAR^% W'W]:
M:;*W-N(/(B\@=(]@V_ETJ:B@"-[>*1XV:-&:/[C%02OT]*!!&LS2B-!*PP7"
MC<1Z9J2B@")+6"-'188U1R2RA0 V>N?6D:T@>)(FAC,28*H5&U<=,"IJ* (V
MMXGE25HT:5!A7*C</H:$@C21Y%C19'^\P4 M]3WJ2B@"$6=NL#0B",0MG,80
M;3GKQ2M;0NL:M$C",@H"H^4CICTJ6B@",P1F83&-/- VB3:-V/3-"6\4;2,D
M2*9#ER% W'W]:DHH A^R0>1Y'DQ^3_SSV#;^5.>WBD:-FC1FC.4)4$K]/2I*
M* &"",2F41J)2-I? W$>F::MM"BNJQ(JR$EP%&&)ZY]:EHH A-I T*PF&,Q+
MC;&4&T8Z8%.:"-Y$D:-6D3.URH)7Z&I** (U@B25Y%C19'^\X49;ZFFBT@6%
MH1#&(FSNC"#:<]<BIJ* (GM89%16AC98R"@*@A2.F/2E,$9F$IC4R@;0^T;@
M/3-244 1I;Q1M(RQHK2'+D* 6^OK3?L5O]G\CR(O(_YY;!M_+I4U% $;V\4C
M(7C1C&<H2H.T^WI0((A,9A&@E(VF3:-Q'IFI** (DMH8UD58D59"2X"@!B>N
M?6D:S@:%83!&85QB,H-HQTP*FHH C:"-Y$D:-&D3.UBHROT/:A8(TE>18U$C
M@!G"C)QTR:DHH A6T@2)HEAC6)L[D"C:<]<BE:UA=$1H8V2,@HI4$+CICTJ6
MB@",P1-,LIC0RJ,!RHW >F:$@BC:1EC16D^^0H!;Z^M244 0_8K?[.8/(B\@
M_P#++8-OY=*<]M$YC+1(QC.4RH.T^WI4E% #/(C\[S?+7S<;=^T;L>F::EM#
M'YFR)%\PY?"@;C[^M2T4 0FS@, A,$9A&,1[!M'X4Y[>*21)&C1G3[K%02OT
M/:I** (U@C65I1&HD8 ,X49(]S35M(%B>,0QB-R2R!!AL]<CO4U% $36D#1I
M&88S&A!52HPN.F!VI3!&TRRF-#*HP'*C<!Z U)10!&EO%&[NL2*\GWV"@%OK
MZTT6< @, @C$)ZQ[!M/X5-10!$]M#)Y>Z)&\LY3*@[3[>E+Y$?G>;Y:^;C;O
MVC=CTS4E% $:V\2>9MB1?,.7PH&X^_K339VY@$'D1^2.D>P;1^'2IJ* (W@C
MD=':-6=/NL5!*_3TH6")9FE$:"5AAG"C<1Z$U)10!$MK"D;QK#&L;DED"C#9
MZY'>AK2!XTC:&-HTP50J"%QTP*EHH 88(VE64QJ95!"N5&0/8TBP1([NL:*[
M_?8* 6^OK4E% $(L[=8# ((Q"W6,(-I_"E>VAD$8:)&$9R@*@[3[>E2T4 1_
M9XO.\[RT\W&WS-HW8],T);Q1F0K$BF0Y?"@;C[^M244 0_8[<VX@\B/R!_RR
MV#;^72G/;Q2,C-&C-'RA*@E?IZ5)10!&((Q*91&HE88+A1N(],TB6L,:.BPQ
MJKDEU"@!B>N?6I:* (3:0-"L1AC,28VH5&T8Z8%.:")Y4E:-&D085RHR/H:D
MHH **** "BBB@ HHHH *P/%&G:U,UM>Z'?+#<VV=UG<#,%RI_A;'*GT8=*WZ
M*J,N5W1,ES*Q%:/++:Q//$(9F0%XPVX*V.1GO4M%<UXL\6RZ#=Z?8VEFMY?W
MQ?RUEF$,8"C)RQ[^@IQBZDK1"4E!79T9&*2N)U7QMKMI9:?<P^&_ENI$@:*Z
MN5B>.5F*X(QR,C.1U!JU)XZ:S\2Z3HMWI[1SW46ZXFCD#1VSG[B$]RW./I6O
ML)]//JNAG[6/](ZRBN&U+XC7.GZK>QG2XY=.L[E+:6872^<2V!E8^I^\/UK4
M/C1/MS6_V5N-2&G;MPZE=V[_ .M2="HE>P_:P>ESI:X+XBZ-K>KV,T.EGRFG
M_="7C*9&,\UT.JZ_<VVJMIEE9"ZO#:&ZC#R!%;#[=I/;US61HGCR\NWUW^TM
M,CL[?24S)<0W D1Y,9,8..HXS[G%.-*=N9(F<HOW6<MX9^ _]B:#<V$VK32F
M?!(1V !ZG\S7H>F>%K&QTJ&SFMX;G9'Y9:5 V5[CGM7.GXBWUYX-CU[3]%$N
MP/\ :[2XN!');LIP5/')K0M?&L]O+;1:S8)I[2VLMV6CF$BI&FWT[G=5.E5Z
M]^ZZ$1E23T.FMK6"SC$<$,<$8& L:A1C\*EKC%\<:G#%%J%[X?EM-$E8#[09
ME,L:DX5WC[#IGN,TY_B5:QW7B:U:V=;C1HC,J,P ND";BR'V/!]./6I]A4?2
MYI[6"ZV.QHJ*SG%W:03@;?-17VGMD9J6N?8V"BBB@!"*0C%.HH 913B*3!H
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M076I2HT;7-I<[?L\JLP!$:@90\\<G]:ZQ?#=BMYJMP\9E;4E5+E)#E&54V
M=N*Q[3X=65O<VQGOM0O[.U</;6-U-NAB8?=.,9;';).*]'V\)6;\KZ;Z;??<
MX_926B\^NVO^1F_%'59[*7PY#'=ZI9V]W=NDW]DIOG<")F  P>,@9K-OM<U7
M0-3\/R6=Y?7>FQV4UU>V^I)_I$L>]!D\ ADW9QZ BNU\2^%8?$WV%WO+NPGL
MI3+#/9R!'!*E2.0<@@FC3O"D%C<V]S-=76H74,,EN)KMPQ9'8,0V  ?NBIA5
MIQA%-7M>_P"(Y4YN;:\OT.+?QQ=VQL+HSW5Y:2ZY/;[+2+S6DA$3,B@#D@$
MU8D^(4B6WBN^47,"6P@BM(+^$PE9'! X/."2.?:NBTCX?:1H45K%9)+%%;7D
ME]$GF$A9'!##_=PQP.U6;WP=IVH:BUY<(\CO-',T;-E&9%(7*]Q\Q/UQ3=2A
M?;3_ (-_R$H5;;_U8X6+Q'K4O@N.RM-:CNM>L]3AL9+_  &6?+ @L!V8'''I
M3KCXBW\MW?36S+#(+*"+[-/_ *NVN6F,;EO8?J,5V<W@72I=3^W)$UO(6B=H
MX"$C9HV+(Q4#KR1]*1_ &BRZMJ^H26OF2ZM D%W&S?NY%7.#M['GK["J5:AK
M>/GMZ77]?J+V57H_ZU,^?0=2\-Z7J5__ ,)'J-](MI(SI<["@?:2&0 #;CTY
MJM\+I6O;$73W^OW<KP1EQK";$W$ DQ_**T[/P'%;++'/JNJ7T#0M!'#<W&5C
M1A@XP.3CN<U;\-^%3X<&Q=6U&_B$8C2*]E#J@'3& *RE4BX2C>[]+%J$N=.V
MGJ;@&:=THI:XCJ"BBB@ HHHH **** "BBB@ HHHH P?&.GV^HZ?#'<ZI)I*+
M.K"6.0(6/]W/^>E;HZ5@>-+C2;?3H&UBU:[MS,H1$0MAL'GCVS]>G>M\4@%H
MHHI@%%%% !117,?$CQ!+X:\(WEW =LYQ%&P_A+'&?PK&O6CAZ4JL]HIO[B92
M4(N3Z&CJ7BS1M'F$5[J5O;RG^!W&[\JJ?\+!\._]!:W_ #/^%?*T]Q)<RO)*
M[.[')+'))J.OS>?%F(<GR4U;SO\ \ \5YA.^D4?5O_"P?#O_ $%K?\S_ (4?
M\+!\._\ 06M_S/\ A7RE14?ZV8K_ )]Q_'_,7U^IV1]6_P#"P?#O_06M_P S
M_A1_PL'P[_T%K?\ ,_X5\I44?ZV8K_GW'\?\P^OU.R/JW_A8/AW_ *"UO^9_
MPH_X6#X=_P"@M;_F?\*^4J*/];,5_P ^X_C_ )A]?J=D?5O_  L'P[_T%K?\
MS_A1_P +!\._]!:W_,_X5\I44?ZV8K_GW'\?\P^OU.R/JW_A8/AW_H+6_P"9
M_P */^%@^'?^@M;_ )G_  KY2HH_ULQ7_/N/X_YA]?J=D?5O_"P?#O\ T%K?
M\S_A1_PL'P[_ -!:W_,_X5\I44?ZV8K_ )]Q_'_,/K]3LCZM_P"%@^'?^@M;
M_F?\*/\ A8/AW_H+6_YG_"OE*BC_ %LQ7_/N/X_YA]?J=D?5O_"P?#O_ $%K
M?\S_ (4?\+!\._\ 06M_S/\ A7RE11_K9BO^?<?Q_P P^OU.R/JW_A8/AW_H
M+6_YG_"C_A8/AW_H+6_YG_"OE*BC_6S%?\^X_C_F'U^IV1]6_P#"P?#O_06M
M_P S_A1_PL#P[_T%K?\ ,_X5\I44?ZV8K_GW'\?\P^OU.R/KG2_%6D:U*8['
M4;>YD'5$<;ORK5KXWM;N:SGCF@D:*1"&5D."#[5]3^ O$#^)_"MC?R?ZYE*2
M'&,LIP3^E?3Y-G?]IRE2J1Y9)7TV:.[#8KV[<6K,Z&BBBOJCO"BO%?BC\6M=
M\(_M$_"#P78&V_L;Q1'JC:AYD6Z3-O'&T>QL_+RYSZUZI>^+=$TW^T/M>KV-
MK_9Z+)>>=<(OV=6&5,F3\H.#C/6@#6HKG_"/Q \,^/K:6X\->(--UZ&%MLCZ
M==),$/H=I.*Z"@ HKG)?B1X4@\4+X;D\2:5'X@89&F->1BX/_ ,Y_2O&OVG?
MVB)?A#XU^$VCZ;KND67]N>*8-/UN&]9&>*Q:*1B^"P,8RJ_.: /HBBN=G^(O
MA6VTVXU&7Q)I4=A;PK<37+7D8CCC8X5RV< $@@'O5W2/%6C:^T2Z;JMG?O+;
MK=(MO.KEH6.%D !^Z>QZ4 :M%5;W5+/36MUN[J&V:XD$,(FD"^8YZ*N>I/H*
M35-5LM$L9;W4;N"QLX1NDN+F01QH/4L>!0!;HKEO"GQ4\&^.KB2W\.^*M'UN
MXCSOBL+V.9QCKPI)KR']I7]HB3X3?$#X2Z'IVO:/9)KGB:*PUR&\=&DBLFB=
MMW+ Q\@?.: /H>BLW3O$FDZO+''8ZE:7DDD N46"97+1$X#C!Y4GOTJ?4-6L
M=)$!O;R"T$\@AB\^0)YCGHJYZD^E %NBL/6O''AWPY;W\^JZ[IVG0V 0W;W5
MTD8@W_<WY/RY[9ZU->^+=$TW0%UR[U:RM=&9!*+^:=4A*D9!WDXP>U &M17-
M>#_B7X2^("RMX9\2Z5KPB_UG]G7:3%?J%)Q72T %%%<EJWQ<\$:#KJ:+J7B[
M1+#5W;8+&XOXDESZ;2V<T =;15.WUBPN[RXM(+VWFNK95::&.0,\8894L <@
M$<C/6L36OBAX/\.:-%JVJ>*-(T_3)7:..\N+V-(G920P5B<$@@@XZ8H Z>BJ
M.C:YIWB/38=0TJ^M]2L)QNBN;259(W'LRD@UD^+?B1X4\!"'_A)/$FEZ$9O]
M6-0NTA+]N Q&: .DHKY_\??&G5;3]H_X+^&_#VJV=WX3\4VFJSWC0!9A.84B
M,920'C!9LXZU] 4 %%8WBCQGH'@C3_MWB'6K#1+,G GO[A(4)] 6(S7A_P"T
M%\?;C0M(^&6I^ =?TW4+'7?%]CI%Y<VS)=1O;R%MZ @X5C@<]: /HFBJFJ:M
M9:'837VHW<%A9PKNDN+F01QH/4L>!6!X1^*G@WQ]/-!X;\4Z1KL\/^LBT^]C
MF9?J%)- '545B>*_&_A[P+91WGB+6]/T.UD?RTFU"Y2%6;T!8C)KC_C(_B#Q
M+\/+2?P#XWTGPK>37MM(FM7:K/;RP;QOC7G!+C@$4 >ET55N+V'2M/:YO[J&
MWAA3=-<2L(XUQU8D\ 5SOASXM>"?%[W::)XMT75GM%9YUL[Z.0Q*O+,P!X [
MF@#K**SD\1Z5);Z?.NI6C0Z@P6SD$RE;@D9 C.?F) )XK&MOBMX,O/$[>'+?
MQ7HTVO@X.FQWT;3Y]-@;.?:@#JJ**;)(D,;22,J(H+,S'  '4DT .HKE-&^*
M_@OQ%K+Z3I?BS1=1U-#M:SMK^*27/IM#9KD?VI_BY)\$O@1XO\565Y96NM6=
MA(^G+?, LL^/E 4GYB.N!Z4 >LT5\?:S\8/$/P2_9$\6>-+KXJZ;\0/%#6B3
MZ?=7"0(D%PZ)F%4C/S[2Q8*><#FO9_V:XM87P )]:^)$7Q+NKAUF.HQ1Q(+<
MLBEH?W9Q@$DC/.#0!ZU17%Q?&GP!-X@_L*/QIH+ZSNV_85U&(RY]-N[.?:NI
MU'5['2%A:^O(+-9I5AB,\@0.YZ*,]2?2@"W17.6OQ&\*WHU<V_B/2YET<XU%
MH[R,BT/I*<_)^-6?"OC70/'-@;[P[K5AKEFK;3/I]PDR ^A*DX- &U137=8D
M9W8*BC)8G  ]:Y76OBQX*\.65C>:IXLT;3[6_.+6:YOHT2?G'R$GYN1CB@#K
M**P]=\<>'?#&A+K6KZ[IVFZ.P!6^NKI(X6!Z8<G!S[5-I/BW1->T(:UINKV5
M_I!0O]NM[A7AVCDG>#CB@#6HJ"QOK;4[.&[M)X[JUF4/'-"X9'4]""."*\V^
M/OQ'G\(?!'XAZ_X9U&U;6]!TV>5&!646\ZIN =<]>AP: /4**^3?C5^U!K'P
MW^ 'PL\0VVN:3;>*M?O]$2_CO%0E[6X8"XD6,D;1R?FZ"O83=:[XC^,7AW6-
M!\>Z-+X#.E3K<:!"$FGO9]^!/'(#]U> <=_K0!ZC16%J7CSPWH^GWM]?:_IM
MG964I@N;B>[1$AD'5'). WL>:7PIXX\.^.K)KSP[KFGZY:J<-+I]RDRJ?<J3
MB@#<HKPZ'XH>(7_;)F^'YN8O^$87PA_:PM_*&_[3]I5-V_KC:3Q7I/B_XH^#
M_ $D,?B7Q1I.@R3?ZM-0O(X6;Z!B#0!U%%4](UFPU_3X;_3+VWU"RF&Z.XM9
M5DC<>S D&KE !163JOB[0]":Y74=8L;!K6#[5.+FX2,Q19($C9/"Y!&3QFG6
M/BC1]2T"/7+75+.?1I(_.74$G4P%/[V_.,>^: -2BN9\,?$[PAXUNYK70/$^
MD:S<PDB2&QO8Y77'7(4DUM7NKV.G7%I;W5Y!;3W;^7;QRR!6F;&=J@_>..PH
M N457OK^VTNSFN[RXBM;6%2\DTSA$1?4D\ 5X?\ M>_'F3X+?!FZU[0-;TJT
MU]Y;0V27K)()HGG1794+#<-C'D=.M 'O%%96D>*='UW2#JFGZK97VG*#NO+>
MX5XA@<Y8' Q6)X?^,7@3Q7K+Z3HWC#0]4U-#@V=I?Q22Y]-H;)H ["BLWQ#X
METGPEI4VIZWJ5II.G0_ZRZO9EBC7ZLQ I= \1Z5XKTN+4M%U*UU;3Y?N75E,
MLL;?1E)% &C117-^*?B5X3\#RPQ>(?$NE:)+-CRX[^\CA9\],!B#0!TE%5;'
M5+/4[".]L[N"[LY%WI<02!XV7U##@BOE+PO\5]=^+/[5GBS3-/\ BMIVA^%O
M"EU96MGH%HL$O]L^9"))BSD[B03M&SIB@#ZWHHHH **** "BBB@ HHHH *YC
MQSI=[J=K MMI=EK5N"?.LKMO+9L]&1_X2/Y5T]8'B7Q#<Z;<V6G:;:K>:K>E
MO*21ML<:+RSN?0>@Y)-:TN;G3B9U+<KN8VG>#]3@\*:/I]Q.LMQ;7T=RP9RP
MBC#EO+#'EMH. 3Z52U+X>ZKJHUB^;4WMK^XN5N(+="#$/+_U0)QGZ_6MFY\3
MZIH%K;-KD%C 9;V.V^T0S$1%&_B^;E2/0U3UOXC+9_VV-/-G=K86T4RR^<"A
M9WVX8CH!UKLBZ_->-M?\U^MCFDJ5K2Z?Y'/:QX%UG4M0U,?V)I_F7T\<Z:JU
MS\]LVU<D+C)*D''K6O?^%=9M!+<V<4-]<KJR7R1R2^7YB!-IR<<'/-3:CXUU
M?1?#%WJ4D6F:S<K-'%!!I4S,'R?F!)S\V,D#VJQXF^(UOHMGH=Q:0_;5U.>-
M3\V/*B)PTA^A(&/6KYJ\K))/I^7F3:DKML@U2P\3W3R:Q:65K;ZO_9KVL=M)
M<9593)D'<!TQS]:RX?">OZIX9MO#LUC%HEB)4>ZNHKH2RR@'<QZ=68#.>U:F
MK?$"YLS=1106L$B:@;%+F\D*P( H;>Y'3/0"H]=\6>)M.\.6VJ0V.F;O,6&:
M.25F5BT@17C9>"IR#SS2C[5)))+73].HY>S=VV_,4^!=0M8O$EO#>F\AU:)9
M UP0"LX^4\ =" #]:O:SX/FUC4+(O(J6J:;-92LI^8,^W! [XVFJ^H>(?$MM
MJ,>GQ0Z/]KCLS=3O-)(L9^8@!/3IU-1/\2)9-%FOH;.-"-,COU69^ S.5VDC
ML,9S4_OG:2M_6A7[I73_ *ZBW%AXJUC3_P"P;VTLH+-E$4^IQS;O,C&,[8\9
M#$#N<"J7BGX<7NL:1K@LY8;?4Y)6DL)F/ 5HPC(_LP'/T![5<N/&NIZ9X>DO
M[E]'NW::.")[*9C#$6ZM*W. /:NC\,:G>ZI8-)?1VPD5RJ364OF0S+V=3U'T
M-)SJTESI)),%&%3W7=FA80M;6-M"^-\<2HV.F0 *GHHK@>NIV;!1112 ****
M "BBB@ Q2%<TM% #2"*2G]::1B@!",UPGBWX'^!O'.KSZGKOARTU&_FB\EYY
M0<E>WXCUKNZ,9K2%2=)\T&T_(F45+22N?+'B_P#8(\-ZVTYTG7+K1U<*%'EA
MV&.Q;KBOEWXX?LT^,O@U=7T2ZM<WWABYD$D=TN=I..C>C>U?J'-/';C,CA!Z
MFO-?BI\2[+0!+I_V2PU3RHS<7,5VZD(%Y^Z>_-?0X+-,6ZBC+WUV?^9Y]?#T
MHQ;6A^4UIXSUJ">[MDO-0N;TD1PP,A,A(&!CN,5[O\-_!>LV?A"UO/$&K7EG
M>7'/ES-ODB+#LG7@<FNRT+XB^$M9?Q!XDT'PLL&LPP/*+VXM@$60$[XPW3)&
M,8KDOA[XQ\0^/=*UGQ9'9V5F)S_85K%-)DI.2"TOL.0/7BOJYU93T:Y?6VYY
M#C=:';:IX;O4TN*/P7/:6MC?-':1ZQ>-N=WSR5';K57QO\7M=\!:>D<-RFHZ
MA&BI?W:J$\X0LK, .JY'<5YOX.\':AH'@K4M!UG7;R#Q/-J[7T2I(?L]O&.4
M:,'ID@DBL#3X-;\1WE]<>,KN:SL")K:,0Q[6F!7YWQZG _"L(T565JBNM=U^
MI5^1^ZS['\0?$S6+'_A&O$FF:5<ZC::@PBN(8V&;=)%SO/L#C\,UN7OAJ?QB
M-,D627S[6Y,S2P?>"D8V'U4^GM7S-HWQRUKPA\/W\/V=XVMZD(U%I?2QB$6,
M*]-X;EV(!''2O9_V=/VN=*\4/?V?B2WMM#-NBJEXH.)V  (/UZ\5\M/+,1&F
MZL8WM?UMZ'J1KPE+E;W/>M%\(72O ]UL2).J#^(=LUV44,<";8T6-?11BH].
MU"VU>PAO;.9;FUF4-'+&<JPJR!7@R;O9GHI+=" 9IP'I0!3NE24%*!F@#-.H
M ***<!0 #@4M%% &1I)_XG&L_P#75/\ T&M>LG2>=8UG_KJG_H%:V:N>_P!W
MY$QV#I0>A[44<5!1XYX:6\O+FQNM,.LG4FOG^USW3M]D,(9MW7@\8QCO5A_%
M^K-X"M4^P:DDAN8$.I%EVD&X4$YSG!''XUZCI^FV^EV8M;:/RX 6(7.>IR?U
M-5F\-:<VC)I1@_T%&5A%D\%7#CGZ@&O1>)A*5Y1ZK^O^ <:HR2LGT//+_P >
M-%\1UN$U!_[*MKE=(EM-IV,S#)FSC&5?:G7UK*M]1,WBN\AM[C6#XBDUB5+9
MM["T,*.-R\_+@)G(ZUZO'X8TV+1I-*6V46+[BT>>26;<3GKG)SFHAX0TH0K$
M+; 2Z^VJVX[EFSRP/;/]::Q%**LH]+?\/^J_$ET:C>K\SA[#QO<^']9UZ\U*
M:2XTR\N9H[!3T2:+">2O^_@D>X-5H]?U71?"&L6>K:FZZO<:@+9;@9/V<S*K
M$)@=$!;'^[7I%OX<TVWM$MA:1O"D[72K(-V)2Q8N,]\DFFGPSIS:L-3:W!NP
M_F!B3C=MV[L=,XXJ?;TK_#_2V_X)7LJG?^GO_P  X/1]?FUS1]&T1=3G0&[E
ML+F_4[9I5C4E.2.&==N3]:U=5T=_#,5EIEAJU[;6^IW20/+--YC0#!)$;-R"
MV,=^:Z+4/!^DZI]M-Q:AC=F-I65BIW)G:RD=&&>HJ"#P!HZ6%Y:S0R7J7FWS
MGNIFD=MOW<$GC';&*3K4[W6B[67]:?H-4I[/[S"N].;P5J=E!I]]=RP7Z3)+
M;7,QEVE8RPD4GD$$<]N:YWPUKVHZYX!U75[K4)8+^WLC!'8A\/ !_P M']7;
M&0>F/QKT/2O!&EZ1/-.BS7%Q+$83-=3-(XC_ +H)Z#Z4^3P5H\J(IM  ML;/
MAB-T1_A/J!V]*:KTTK/5Z:_U]Q+I3W6F^AP5_P")=2T'7]<NY[N6316M8+=P
M3Q:2M"2LOL">">W!J.<3:SK6EQ74.L:@G]E6\F;&X**C,>6?D9)KT>;POIEQ
M!J,,MJLD6H1K%<HW(D4+M /X5GWGP]TB[DMG N;9K>W6U0VUPT?[M?N@X/.*
MJ.(I]K.WZ"=&?>Z_X)S>N>%;>3XD:1']LU%(;J"::6%+MU0LFW;Q4::C>ZIJ
MJ:))?W%M:WFIWBO<1OB39&%*PJW;.?R%=^=$M&U"TO6C+75K&T44A8DA3C/U
MZ"JEYX/TJ_L9[66VS'+.;HLK$,LI_C5AR#]*A5UHI=%;\]?R+=%W;CU?^1SG
MB+PM=:1H:6>E75[=PR7*O)9R7NV5X\'<D<C<CUQ]:V/ 5S%+H\D$<UX[6\S1
MO%?\S0'KY9/<#L>XH'P_TG[!+;.+B5I)EG-S)<,9A(HPK!L\$#TK5T30K3P_
M9FVLT8*SF1W=BSNQZLQ/)-1.K&5/EO=W[%1@U/FM9&A1117&=(4444 %%%%
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MG.:^R'^#NLW'[6EWX_GBM)?"L_A Z&R-)F5IC<*Y!3'W=H/.:\[T/X=_&_\
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MVN^+=$^)'PWU.STKXAZ';2V:PZFA:RU2T<AFMIMO*_, 5<?=- '"_M%?LD^
M]'^&NH^+O >C6W@'QMX3LWU+2-9T,?965H5+^5*%P)(V *D-GK7*?%3QG/\
M$;7OV,O%D\1MYM9UF.]FCQM"R26!9ACTR3CVKH_$?A;]HK]H739/!OC+2?#7
MPR\&7@$6LWNCZBU_?7L'&^"$;0(PXX+'G!->A?'O]GF7QW\.?"MAX*O(/#OB
M;P1=VVH>&+F=2\$,D">6L4@')1H\H?3.: )OVTL_\,I?%+&0?["N.GTKPO\
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MUS3)A<:;J5K%>6TP_CBD0.A_$$55\<>--'^'7A'5O$VOWB6&CZ7;O<W-P_\
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M:$^&]C+XH\??"+1)_!D"^=>)X8U9I]2L8?XI'C<;9-HY(7L#7:?%O]IF31=
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 W;2=*?10
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M3OM,TIGFCBWQPS.3DL\2L$8Y]10!XU^RGXYT#XD?'[]IKQ!X9&[1[FYLDCN
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M#O#%GI%Y=@+<7J[I+B4#H&D<EB/;- 'CG[.W_)X_[2?_ %VTG_TF->/^$?\
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M7$GG7!ARTD[]-SNQ+,?J:X_QU^Q_\(/B/XDN->UWP38W&JW1!NKB%GA-R?\
MIJ$8!_QH \*^'FAW7QE\._M:WW@^Z%S:>*=2EL-'U"$_N[F6&S\IS&W0KO\
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M7VH!<IMY?;D;L8QWH ^Q**X+XF_'?P#\';2SG\8>)K/1?MO_ ![0R;I)Y_\
M<B0,[?@*PO#_ .U?\)?$^CMJ>G^-K"2V2[AL7659(9DFF;;$C1.H==Q! )7'
MO0!ZU17R?^W!^T5I?PN?P#HUKXPG\/ZV?%>F3ZA!:&5&?3B9/-#E1AD/RY7/
M/I7NU[\<? >F_#J/QW>>)[&S\)2KNCU2Y8QQOS@!0P#$D@X &3Z4 =U17CG@
M']K[X0?$WQ%#H/A_QK:SZO<?ZBTN[>>T>?\ ZY^<B;_^ YKJ/BI\<? WP4L[
M*X\9^((-&6]<QVL1CDFEF8==D<:LY SR0,"@#NZ*Y_P+X_\ #OQ,\.6^O>%M
M7MM;TB<D)=6K97(X*D'E2.X(!%;=S<Q6=M+<3.(X8D,CN>BJ!DG\J ):*\NT
M7]I[X7^)->T#1=(\76FJ:GKJ>98064<LID7D@L54B/(5OOE>E.^)?[3'PR^$
M&JQZ7XJ\66NGZHZ>8+"&*6YN O\ >,<*NRCW(% 'I]%>;>%_VC_AGXTFT&'1
M/&.FZC/KDLL&GPPNWF321KND0J1E64<D, :N^*/CKX \%7&N0:[XJT_2IM$2
M"34([F0J8!-N\KC'S%MK8"Y/'2@#O**\H^'G[5/PJ^*FNIHOAOQC:7>KR*6B
ML;B&6UFE4=2BS(A<?[N:K_%#P]I>I_&SX77UWX_U/PYJ-I)=FS\.6DI6#6CL
M4N)5QSL SS_>- 'K]%<7\3/C+X*^#FG07WC+Q%9Z%#</L@6<EI9F]$C4%G/T
M!KYE_:I_:K\+>-_V=]:O/ACX[9-<LM4TQ95M&EL[V*-[N-6_=R*C[6&03C%
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MXK_;3^"W@KQ!=:+JGCNS74+1_+N5M+>>Z2W;N))(HV1"/<C%>F:1\0O#6O\
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M?B+X9^%_A^77/%FMV>@Z5$<-<WD@0$]E4=6/L 37SY\7?VN_AYXX^"/Q)MO
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M^[\B8[!1114%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ[5V'Q,_9"^(G[0OA&YTGXG_ !5AF6,I+86&@:4;:RBG5P5FF4R;IR #A25
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M3$22V[."3CIVKM?V8?A1\0/#?Q>^)DOB?PAH'A/P%XHLXYY_#FEZDMY'%?\
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MOM6&"-3]P$'<<=<BN5_;Y^%OA>#QE\$/&EO9VUAXDC\<:;8-+ @1KN%G+;7
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M9P^-^H:AI4GAK5_BE>76IZ;I-YF.6WA\M8[<2C^%G6-21_M5PWPET[]E>[\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !6=JGB/2M$_Y"&I6MD?2>94/Y$UX%^TU^T=/X#E/
MAGPU*%UIDW7-WC/V93T"]MQZ^W%?&.JZQ?:Y>27>H7<UY<R$LTLSEF)/N:^N
MR[AZKC*:K59<L7MI=L^=QN<0PTW3IQYFM^Q^F?\ PM/P?_T,VE_^!2?XT?\
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MC_52C_S]?W(/]8*G_/M?>?I]_P +3\'_ /0S:7_X%)_C1_PM/P?_ -#-I?\
MX%)_C7Y@[V_O'\Z-[?WC^='^JE'_ )^O[D'^L%3_ )]K[S]/O^%I^#_^AFTO
M_P "D_QH_P"%I^#_ /H9M+_\"D_QK\P=[?WC^=&]O[Q_.C_52C_S]?W(/]8*
MG_/M?>?I]_PM/P?_ -#-I?\ X%)_C1_PM/P?_P!#-I?_ (%)_C7Y@[V_O'\Z
M-[?WC^='^JE'_GZ_N0?ZP5/^?:^\_3[_ (6GX/\ ^AFTO_P*3_&C_A:?@_\
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M?XU^8.]O[Q_.C>W]X_G1_JI1_P"?K^Y!_K!4_P"?:^\_3[_A:?@__H9M+_\
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M)XTTF30#K*W).GAMOF!#G.<8QUZUKI;0QO(Z1(K2??8* 6^OK3?L%M]F-O\
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M65RA!!'MWZBG77B[2[.PL+V6XVV]\RK VTG>6&1QVK26QMD@>%;>)87R6C"
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M+C$10;1CI@=*<]K#++'(\,;R1_<=E!*_0]J *EOKMG<ZK<:='(3=6Z[I%VG
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M%#<=UP:^+#T-?4G[1LAM_@;\)Y2FX)# VTC@X@0XKVLRIN6+PK4FO>>WI?\
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M6;_7;QKO4KR>^N6ZRW#EV_,U3HJ5""ESI*_<?/)KEOH%%%%:$A1110 4444
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M_$CPI:M+)"LORF2%MKK\W4'M7&>/_"-Q-\18M'LIKB]GN(T(DN7WL,YR2?0
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M&0?Q%2Z7X#TVU^'5QXCUDS><^3;0QOMSV7ZY/-=3\/D@^(WPZG\/7<NVXLW
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MYE^SCXC\9>,OA1IGB'QS%%:ZQJTDM[#9QP^4UK:.Y,$3C^^(]NX^IKTZD
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MRW_GW^,O\P^IT/Y?Q9XK_P ,[2_]!V/_ ,!3_P#%T?\ #.TO_0=C_P# 4_\
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M(20/88S78?\ "N?#W_"PQXY_LY/^$H&G'2O[0W-N^RF02&/&<8W '.,UTM%
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M< 9KWZB@#G_ G@#P[\,?#%IX>\*Z/::%HMH,16=G&$0$]2?4GJ2>3WKH***
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M*/\ 6;'?W?N_X(?V'A//[_\ @!_PQG\0O^>>F_\ @7_]:C_AC/XA?\\]-_\
M O\ ^M111_K-CO[OW?\ !#^P\)Y_?_P _P"&,_B%_P \]-_\"_\ ZU'_  QG
M\0O^>>F_^!?_ -:BBC_6;'?W?N_X(?V'A//[_P#@!_PQG\0O^>>F_P#@7_\
M6H_X8S^(7_//3?\ P+_^M111_K-CO[OW?\$/[#PGG]__   _X8S^(7_//3?_
M  +_ /K4?\,9_$+_ )YZ;_X%_P#UJ**/]9L=_=^[_@A_8>$\_O\ ^ '_  QG
M\0O^>>F_^!?_ -:C_AC/XA?\\]-_\"__ *U%%'^LV._N_=_P0_L/">?W_P#
M#_AC/XA?\\]-_P# O_ZU'_#&?Q"_YYZ;_P"!?_UJ**/]9L=_=^[_ ((?V'A/
M/[_^ '_#&?Q"_P">>F_^!?\ ]:C_ (8S^(7_ #STW_P+_P#K444?ZS8[^[]W
M_!#^P\)Y_?\ \ /^&,_B%_SSTW_P+_\ K4?\,9_$+_GGIO\ X%__ %J**/\
M6;'?W?N_X(?V'A//[_\ @!_PQG\0O^>>F_\ @7_]:C_AC/XA?\\]-_\  O\
M^M111_K-CO[OW?\ !#^P\)Y_?_P _P"&,_B%_P \]-_\"_\ ZU'_  QG\0O^
M>>F_^!?_ -:BBC_6;'?W?N_X(?V'A//[_P#@!_PQG\0O^>>F_P#@7_\ 6H_X
M8S^(7_//3?\ P+_^M111_K-CO[OW?\$/[#PGG]__   _X8S^(7_//3?_  +_
M /K4?\,9_$+_ )YZ;_X%_P#UJ**/]9L=_=^[_@A_8>$\_O\ ^ '_  QG\0O^
M>>F_^!?_ -:C_AC/XA?\\]-_\"__ *U%%'^LV._N_=_P0_L/">?W_P# #_AC
M/XA?\\]-_P# O_ZU'_#&?Q"_YYZ;_P"!?_UJ**/]9L=_=^[_ ((?V'A//[_^
M '_#&?Q"_P">>F_^!?\ ]:C_ (8S^(7_ #STW_P+_P#K444?ZS8[^[]W_!#^
MP\)Y_?\ \ /^&,_B%_SSTW_P+_\ K4?\,9_$+_GGIO\ X%__ %J**/\ 6;'?
MW?N_X(?V'A//[_\ @!_PQG\0O^>>F_\ @7_]:C_AC/XA?\\]-_\  O\ ^M11
M1_K-CO[OW?\ !#^P\)Y_?_P _P"&,_B%_P \]-_\"_\ ZU'_  QG\0O^>>F_
M^!?_ -:BBC_6;'?W?N_X(?V'A//[_P#@!_PQG\0O^>>F_P#@7_\ 6H_X8S^(
M7_//3?\ P+_^M111_K-CO[OW?\$/[#PGG]__   _X8S^(7_//3?_  +_ /K4
M?\,9_$+_ )YZ;_X%_P#UJ**/]9L=_=^[_@A_8>$\_O\ ^ '_  QG\0O^>>F_
M^!?_ -:C_AC/XA?\\]-_\"__ *U%%'^LV._N_=_P0_L/">?W_P# #_AC/XA?
M\\]-_P# O_ZU'_#&?Q"_YYZ;_P"!?_UJ**/]9L=_=^[_ ((?V'A//[_^ '_#
M&?Q"_P">>F_^!?\ ]:C_ (8S^(7_ #STW_P+_P#K444?ZS8[^[]W_!#^P\)Y
M_?\ \ /^&,_B%_SSTW_P+_\ K4?\,9_$/_GGIO\ X%__ %J**/\ 6;'?W?N_
MX(?V'A//[_\ @'5^"/V(M6GOXI?%.J06EDIR]O8G?*_MN(P/KS7UCX7\+:9X
M-T2VTG1[1+.Q@&$C3N>Y)[D]S117CXW,L3CVO;RT71:(]'#8&AA/X2U[]36H
MHHKRSO"BBB@ HHHH S-?\.V?B6TCMKU7:))!* CE3N'3I6G110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
D !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>arwr-20250930_g4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 arwr-20250930_g4.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &$ ^D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBDZ4 +37=8T9W8*JC)9C@ 5XS\0_VE-,T'4?[#\*6C>+/$;MY:PVN6A1_0E>
M6/LOXD5S$/P:^(OQ;D%W\0/$;Z-IS_,NCZ>1P/0@':/QWFO-GC4Y.G0CSR7;
M9>KV/&J9E%S=+"P=22WMLO66WYGI?B?]H'P%X3:2.Z\007%Q'P8+$&=L^GRY
M _$UP5S^V!I%S(4T/PMK6L-GC"*F?RW']*[OPK^SYX#\))']GT&"]G3_ )>-
M0_?N3Z_-\H_ "O0+:T@LHA';PQP1C@)$@4#\!4\F-J:RFH>BO^+_ ,B/99E5
MUE4C#R2YOQ;_ $/ ?^&E?%EP=UM\+-7>/U;S,_I%0?VK+^PP=5^'.M6<7\4@
MR0/^^D'\Z^A*3K3^K8KI7?\ X"A_4\:ML4__  &)XQH/[6G@/5Y1%=S7NC2'
MK]MMR5'XH6_6O4] \4Z/XJM!<Z/J=KJ4'=K:4/CZ@=/QJIX@^'WAKQ5&4U;0
MK"^S_%+ N_\ !L9'YUY+XC_9/TN*Z;4O!FLWWA;4E^9%25GBSV&<AU'XGZ4K
MXVCNE->7NO\ 5"<LRP^K4:J\O=E^-U^1[U17S=;?&#X@?!JZALOB-I#:OHY8
M1IK5D 6^I(PK'V8*WUKW;PCXST7QUI*:EH=_%?VK<$H<-&W]UE/*GV-=%#%T
MZ[<%I)='HSKPV/HXIN"O&:WB]&OE^J-NBBBNP]$**** "BBB@ HHILDB0QO)
M(P1$!9F8X  ZDF@!U1SSQVT+RS2)%$@RSR,%51ZDFO#_ !M^TM$VJ_V!\/\
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M18U"HH51T"C H]EC9ZRJ*/HK_B_\A^PS*KK.M&'E&-_QD_T/GW_AI3Q?]_\
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MKJW<966%PZL/8C@UR7B;X,^"O%RO_:/AVR:5A_KX(_)D'ON3!KRK4?V:]?\
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M>""#U%<&(PL:UIQ?+-;-?UJO(\W%X&&):J0?+46TEO\ /NO)F+X*\;:1\0-
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MYO\ 1'S].E/-6JU=6H_9C_-_>EY=E]Y3T?1;#P]IT-AIEG#8V4(VI! @55_
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M..CZ7?;T7XO0\LU_]CWP4^B!?#<=SX>UZW&^TU2*YD9UD'(+Y/(SZ8([5K?
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MRQN.C*PR#^1J>O53OJCW4TU='G7[0/B@^$OA)X@NXY/*N)X?LD+#KND.WCZ
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MJJ.K(/F8?CA1^->G> _#47@[P;HVBQ*%%G:I$V.[XRQ_%B3^->+_ ![']O\
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MNJ!U;C('8<4_K$:=/VDDXPEM%/WZGG*6]OPZ)=1>R<Y\B:E);NWNP\HK:_\
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MJ5IU,)6ESRBN:$NNBYK7W=XZV>S-*;A3C#$4URQD[27373\'^!8_9#OIM/\
M"OB3P?=L?M?AO5YK;:W41L25_P#'@]>]U\^:+_Q0/[7FL6./+L?%VEK=QC.
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M/7'FS?X5]"5\]? H_P!F_'?XIZ:XVN\_VA1ZKYC'/_CX_.OH6C+?]WMV<O\
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M";I1P]%N,;>]WE+JV]WY!1P<54=:K9N_N]DNB1QOQ;^)-G\*/ U_X@NU$SQ
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MP ^/ZZLRF'PEXJRL[*/DAE)RQ]MK'=_NNWI7M7BK_CZ3ZG^2UC>,?!]E\7/
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M.0&_W1ES_P  ]:]+^,OQ7L?A3X5EO)&2;59P8[&T)YDD_O$?W5ZD_AU-<C\
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M\PCUSPH[GV!J7X.?#F/X/>"'>]*S^(-0(GO9<[B9".(P>X7)R>Y+'O7SM?\
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MSP\7"<>7%45>=/I_-%[KUZH]NHKS_P"#/Q8LOBMX6CNU*0ZM;@1WUF#S&_\
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MB CO;,'F&3';_9/4'^H-=S6M.I&K!3@[IGMT:T*]-5:;O%['S?\ $KP[JGP
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M#U'XXKT.N+'SJRJVKT^6:WTM?SMM\UON=6$C",/W4^:/3K;R_P"'V"BBN/\
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M)^](;[*&[#MO(XXX4<#O79:IJ3ZG=&1OE0<(GH*=JFJRZI-N?Y8Q]V,'@?\
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M9_G_ )G(L'*G_ Q$X^3M)?CK^)Y-_P -?V<61/X*UV)\<+M4Y_/%(?VK=0U
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M?_9JYZNZE\".:I\3"BBBMC,**** "BBB@ HHHH **** "BBB@ HHHH GLO\
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MCZ#_ -"%=K7%>'?^0B/H/_0A7:UYV(^(ZZ.S.&UO_D(2_P"\W_H1JA5_6_\
MD(2_[S?^A&J%=T?A1S/=A1115DA1110 4444 %%%% !1110 4444 %%%% &S
MX7_X_A]?_96KKZY#PO\ \?P^O_LK5U]>;B/C.RC\)P.I_P#'Z_T7_P!!%5:M
M:G_Q^O\ 1?\ T$55KT([(Y HHHJA!1110 4444 %%%% !1110 4444 %%%%
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MR>.]"\3_ -HS&;2=/33TMO+7;(JHR[B<Y!^;.*N6-I^RY)U7.5IJ]GU2MO\
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M$8N-6E&C3ARI.^[?W7V7EJ;4</*G4=2<KMJVUOO[L****\X[0HHHH T_#O\
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M/K$NP>Q7<XC^P;O^Z?\ OAO\*/[!N_[I_P"^&_PKMZ*/K$NP>Q7<XC^P;O\
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M&';#R>O85J45$JTI*Q<:<8ZA1116!J(RAU*L 5/!!K!U'PRLS&2!MK$Y(/\
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M=/#NK_#CXDZU:^#/$ND:MJ-V;G66\F/6H)[J6>*\@E8;9BRR!64$LK(00.*
M.RM?VU?AW>>"?'7BJ)-:&E^"VM(]86:P,4T$DY5?+\MV#!XV.V16 *E3C=QG
MGM3^,FI^//C/\$)M/TWQ'X6T#4-6U6(1:H%MEUBW73'DBF\E7+>7NPRB558'
M!VBO _B%XAL_B7X$_:QUK3-&O=/TO5K_ ,,?9DO+)X)+R+=;I]I\M@&"R ;A
MD E<$@9KZ?\ C9$?^&C?V=]D;;$U+6<E5X4?V9+C/I0!Z7\./B;I'Q.TS5;O
M3$NK632=4NM'O[2^C$<UM<P/M=6 )&"-KJ0>5=3WH^%OQ-TGXO>$T\2Z%%=K
MH\UU<6]M/=1A/M2Q2M$9HP"<QL4)5C@D8.!FOF;]I6T\5_#?XIW^F>!XF ^-
MMK'H#31$#^S-4B 1[['7'V%I22O.ZU0FOJ_P;X3TWP'X2T;PWH\ MM*TFSBL
M;6$?PQ1H%4>YP.3W- &Q1110 4444 %%%% !1110 4444 %>#_MK>(]1\,?
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MQFT*9+'4+1H9FB:33?WKQD97S!^\(/(W\X.:^FOB'&Y_;'^#CA&*+X>\1 L
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M?XC:CH\H@U63PW;0FVL)< F%YYI8T:4 @F-"S#(S@UQ'QT^.,/C/]FK7=?\
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MR1(D+S31_:&5@5/E!AD8R37D/PITR]UGQ]\(K2"66SNKKX&?9TNRI'DRL]D
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M^->JZU<_#'_A&?#O@O2M0FTR+6_$EK/>S:M/ YCG:&&*2,1PK(K('9B6*D@
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MM2\/^*_$>K:[=6]Q&(PEVMWY4J+NR0[3(0HRRAOF P:^OJ** "BBB@ HHHH
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M394D<HZG'49P<&NF\&?$VU\9^-?'?AN&QN+6?PG>V]E//*1LN&FMH[@,F.0
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MT_9&T+P)X U;Q/X6\4^)]*^(VD64NHQ^,+S7+F>:[GC0N?M<;N8I(G*X9-@
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M]I/QAX]UJUBM],@T2R\/>'MDP=I(=[W%W*RC[A:5HT /)$.>]>N444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFF_^!<?^-'M(=T'M:?\ ,OO-BBL?_A,= _Z#FF_^!<?^-'_"8Z!_T'--_P#
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MFF_^!<?^-'M(=T'M:?\ ,OO-BBL?_A,= _Z#FF_^!<?^-'_"8Z!_T'--_P#
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M:/M$O_/1_P#OHTRBBP60_P"T2_\ /1_^^C1]HE_YZ/\ ]]&F446"R'_:)?\
MGH__ 'T:5;F9'5UE<,I# YZ'UJ.B@#[%_96^*>H>,=*OM"U>=[N[TY%D@N)#
MEWB)P58]RIQR>?F]J][KY&_8R_Y''6_^O _^C(Z^N:_1\JJ2JX2+F[O5'['D
M-:=? 0E4=VKK[F?(7[9G_(\:/_V#E_\ 1LE?/E?0?[9G_(\:/_V#E_\ 1LE?
M/E?%YE_OE3U_0_-\Z_Y&%;U_1!1117FGB!1110 4444 %%%% !1110 4444
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MSXNL?!W[6UYK&I.!81W0BEE/(B5[=4#_ $&1GVS707?[/>M7?Q>/BU-7T_\
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M)/<DUS5%==7%5*T>25K;Z)*[\['=7QU;$0]G.R6^B2N^[LM10[*" S 'J <
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MAUSDD_4+Z5Y[16M.K*E+G@]3>C7J4)^TINSU_'00# Q2T45D<X4444 %%%%
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F=S,QR\C'JS'N>!^0 P*W:**_5J<5&"4596/WFC&,*<8Q5DDC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>arwr-20250930_g5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 arwr-20250930_g5.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (- \L# 2(  A$! Q$!_\0
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M:QR 1&2)<99URQ)ZXPN"17S-XQT^#2/&&O6%JACM;74+B"%"2=J)*RJ,GD\
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MFT*WFLO#-Y/I\]T;AH9Y))BZM(3\Q!&,CCC@5H\3@?:1I1HJ[Y>D>KBNC?\
M-NM'M?<R6%QZIRJRKNRYNLNBD^J6_+L]5O8\9_X:5^*O_0_ZY_X$_P#UJ/\
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MELJ@JZ&,%BS G#3?*"I4\@U3QV6QCS.C_P"2Q?5K=.VZ[]NYFLOS-RY57_\
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MT:U25:5Z;MN[/5)ZW\_ZUMP'_#2OQ5_Z'_7/_ G_ .M1_P -*_%7_H?]<_\
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M$1^CXQ^M=YXC@T[PY^S_ /$K1V\%R^'[J+Q381BUNM3:XEM':%V7+ !6VA7
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MDD_]\U^OGGR?\]'_ .^C1Y\G_/1_^^C1_KA5_P"?*^]_Y"_U+H_\_P!_<O\
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M^-/_  JSQG_T*>M_^"^7_P")H_X59XS_ .A3UO\ \%\O_P 37[+44?ZXU?\
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M?_B:_5C_ (7SX!_Z&:U_[X?_ .)H_P"%\^ ?^AFM?^^'_P#B:/\ 7J'\D?\
MP(G_ %9R_P#Z#5_Y+_F?E/\ \*L\9_\ 0IZW_P""^7_XFC_A5GC/_H4];_\
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M,UK_ -\/_P#$T?\ "^? /_0S6O\ WP__ ,36O^O,/Y(_^!&7^K67_P#0:O\
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M ,%\O_Q-?JQ_POGP#_T,UK_WP_\ \31_POGP#_T,UK_WP_\ \31_KU#^2/\
MX$'^K.7_ /0:O_)?\S\I_P#A5GC/_H4];_\ !?+_ /$T?\*L\9_]"GK?_@OE
M_P#B:_5C_A?/@'_H9K7_ +X?_P")H_X7SX!_Z&:U_P"^'_\ B:/]>H?R1_\
M @_U9R__ *#5_P"2_P"9^4__  JSQG_T*>M_^"^7_P")H_X59XS_ .A3UO\
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M /Q-'_"^? /_ $,UK_WP_P#\33_UYAOR1_\  A?ZM9?:WUU?^2__ "1^4_\
MPJSQG_T*>M_^"^7_ .)H_P"%6>,_^A3UO_P7R_\ Q-?JQ_POGP#_ -#-:_\
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M_P!\/_\ $T?\+Y\ _P#0S6O_ 'P__P 31_KU#^2/_@0?ZLY?_P!!J_\ )?\
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M_P"A3UO_ ,%\O_Q-?LM16W^N-7_GROO_ . =/^I5+_G^_N7^9^-/_"K/&?\
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M?VH/^2*:[_OV_P#Z/CKX-K]/-7T>RU_3I[#4;:.\LYQMDAE&589R/U -<?\
M\**\!?\ 0LVGYO\ _%5\]F.6U,9552$DM+:_,^*SK(J^9XB-:E)))6UOW;[>
M9^>=%?H9_P **\!?]"S:?F__ ,51_P **\!?]"S:?F__ ,57E_V'7_F7X_Y'
MS_\ JEB_^?D?Q_R/SSHK]#/^%%> O^A9M/S?_P"*H_X45X"_Z%FT_-__ (JC
M^PZ_\R_'_(/]4L7_ ,_(_C_D?GG17Z&?\**\!?\ 0LVGYO\ _%4?\**\!?\
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M!?\ 0LVGYO\ _%4?\**\!?\ 0LVGYO\ _%4?V'7_ )E^/^0?ZI8O_GY'\?\
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M^AG_  HKP%_T+-I^;_\ Q5'_  HKP%_T+-I^;_\ Q5']AU_YE^/^0?ZI8O\
MY^1_'_(_/.BOT,_X45X"_P"A9M/S?_XJC_A17@+_ *%FT_-__BJ/[#K_ ,R_
M'_(/]4L7_P _(_C_ )'YYT5^AG_"BO 7_0LVGYO_ /%4?\**\!?]"S:?F_\
M\51_8=?^9?C_ )!_JEB_^?D?Q_R/SSHK]#/^%%> O^A9M/S?_P"*H_X45X"_
MZ%FT_-__ (JC^PZ_\R_'_(/]4L7_ ,_(_C_D?GG17Z&?\**\!?\ 0LVGYO\
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M ,.>#^9J[10!E)X6TB*0.FFVRN#D,(QD5->Z#IVI3>;=64%Q)C&^1 3BK]%
M%*+1;""TDM8[2%+:0[GB5 %8\=1^ _*H;?PUI5I,LL.GV\4JG*ND8!!K3HH
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MEW""/_'J+G7/ 5Y,TT^J:!+*QR7>[A)/_CU?G5YTG]]OSH\Z3^^WYT?V[/\
MY]K[P_UOJ_\ /E?>_P#(_1J3Q-X(ELTM'UG0FMD.Y8C>0[0>><;O<_G3;+Q%
MX&TZ;S;75]!MY,8W1W<(/_H5?G/YTG]]OSH\Z3^^WYT?V[/_ )]K[P_UOJ_\
M^5][_P C]$Y-7^'\TC2/J7A]G8Y+&ZAR3_WU4]QXE\$75O%!-K.A20Q#$<;7
MD)"CV&[V%?G+YTG]]OSH\Z3^^WYT?V[/_GVOO#_6^K_SY7WO_(_1JR\2^"--
M9FM=8T*W+#:QCO(1D>GWJK#5/A\#G^T?#V1W^U0__%5^=WG2?WV_.CSI/[[?
MG1_;L_\ GVOO#_6^K_SY7WO_ "/T:O?$O@C4=GVK6="GV#:OF7D)P/3[U%KX
ME\$644T4&L:%#',-LBI>0@..>#\WN?SK\Y?.D_OM^='G2?WV_.C^W9_\^U]X
M?ZWU?^?*^]_Y'Z)IJ_P_CD#KJ7A]7!R&%U#G_P!"J6]\1>!M2F\VZU?0KB3&
M-TEY"3C_ +ZK\Y_.D_OM^='G2?WV_.C^W9_\^U]X?ZWU?^?*^]_Y'Z-0^)?!
M%O:26L>LZ$EO(<O$MY"%8\=1N]A4-OK7@&UF26'5- BD0Y5UNX00?^^J_.OS
MI/[[?G1YTG]]OSH_MV?_ #[7WA_K?5_Y\K[W_D?HM=:[X#OIVGN-5T":9_O.
M]W"2>,?WJW[?3=+N],CB@@MYM/?YT6,!HVSW&.#7YE>=)_?;\Z^]?V9G9_@K
MX?+,6.;CDG/_ "WDKTL!F4L94=-QM97W/>R?/9YG7E1E34;*^_FE^IZ!:>'M
M,L)UFMK&""5>CH@!':F3^&-)N97EETZWDD<EF9HP22>IK4HKWC[ I3:+87-K
M';2VD,EO&<I&R JOT%-L="T[39C+:V4-O(1MW1H <>E7Z* ,IO"NCN^\Z;;%
M\YW&,9J>[T33[](DN+.&98AMC#H"%'H/R%7J* *-GHEAIZR"VLX8!(-KB- -
MP]#5?_A$]&W;O[,ML^OEBM:B@"C?:'I^I2*]W9PW#J-H:1 2!Z?K2P:+86UM
M);Q6D,<$@P\:H K?45=HH RXO"VD02K)'IMLDBD,K", @CO4EYH&FZA,9KFQ
M@GE/5Y$!-:%% %%=$L%LFLQ9PBU8[C"$&TGCG'X"H[;PWI=E.LT%A;PRJ<JZ
M1@$5I44 9MSX;TN\F::?3[>65N2[Q@DUR'Q-^(O@GX5Z+;Q^(FB2.0EK;3H8
MO,EE(ZE4';D\G YZUZ#7Q+\1[*V\:?M:2Z;XG_>V4:^3;6DTOE)/MB9X8=W\
M*R.<$]]WO7KY;A*>*J3=5OEA%R=MW;HCS<?B9X:G'V:]Z325]M3UWPE^U!\+
MK^6\DL[.\TNYM;>2YVS6(5I$126"E&89QG@D5Z!\/?$'@_XLZ')KNC:>);4S
MO"SW5MY;EUP3P?KUKY-\>Z9!HGPYN=<USPG9^!_%4TLNEV=A91F 7=NZC?(T
M18D>7@@/_%FOH3]D:U33?A!:V6"+I)WFN%/\+2XD4?78R?G756P^#JX!8[#1
MDN9V2E^/Z'GX+&XBK75*K:UK[-/RWVZGKUQHEA=6\4$UG#+#$,1QL@(4>WY"
MDL=$L--9FM;.&W9AM)C0#(]*O45\\?1&3_PB>C9S_9EKGU\L58O=$L-1V?:K
M.&?8-J^8@.T>@J]10!1M=$L+**:*"SAACF&V140 ,.>#^9J!/"VCQR!UTVV5
MP<AA&,UJT4 4+W0=.U*;S;JR@N)<;=\B G%6+.QM].A\JVA2"+.=D8P,U/10
M 4444 %%%% &'>?Z]OJ?YFH*GO/]>WU/\S4% !1110 4444 %%%% !1110 4
M444 %%%% %O3?]>WT'_H0K(^+OAZ^\5_#3Q%I&F)YFH7EJT4 RH^8D8.6^7C
MKSQ6E;0"Y\R(NZ!EQNC8JP^8=".E5M>;1_!6B7_B#6=:NM/TG2X'O+NZNKQ_
M*ABC!9V;GH #F@#S'4_AUXGL?%VK7MX^J>*-"NKFV>[CMYX+6ZO(TMY$51Y9
MB&V.1E8J2I;.<MMP5T_X6>*;K3?$$^I7=\+ZX\/BQM[;[9'(MPVZ]\N&=R"7
M9$FA4OD!CDY/)K(\-_M4^%?&WB:QLK_P_P"/O!L6LQ/)H6H:]I[V-GK.R(R;
M;=@YP[1J75)1&S $@&NJ\$_M!?#7QCX-\+W9\96FAS>);6VO;'3-:U>&WU(B
M==\*%#(6W, <!2<X.,T 7_AMX"U[PQXN6]U6_N-3MSX=LK$37*VZF*6.24O$
M!$JY #*<D'V->HUP5YX[\"^%O%L.@ZCX[TZS\1'RRFCW^N1K</YC!(_W+/N.
MYF 7CDD8K'\1_%GP79ZG91VWB"36'NM:&AW7]CZM"Z:;<&.24_:!YJ^6 L3Y
M !88^[@$@ ]5HKSJ[^+GPUAT#3IY_B1H-OIMW/)!:7[>((46YE09>-)?,PY4
M'E03CC-26OQ+^'NFZWI]@?B#I#:GJ B^QV-SKL327(F3?$8XR^7WK\RX!W#D
M9H ]!HK)D\.Q22,_VW4%+'.%NW 'T&:L7.DI=00Q&XNHQ$,!HYV5F_WB.M %
MZBJ-CI*6#.RW%U-N&,3SLX'TSTJK_P (U%G_ (_M1_\  Q_\: -BBJ-]I*7Q
M0M<W46P8_<3LF?KCK1:Z2EK!-$MQ=2"48+2SLS+_ +I/3K0!>HK)3P[$DBM]
MMU D'.&NW(_+-37VC)?S>8US=Q'&-L%PR+^0- &A15&+24BLY+87%TRN<F1Y
MV+CIT;J.E0VV@1VTZ2B\OG*G.V2Z=E/U!/- &I169=:%'=SO*;N]C+?PQ7+J
MH^@!XJ4Z2AL1:_:+K:#GS//;S/\ OKK0!3\8^$=/\=>'+S1-45VLKH+O\MMK
M JP92#SR" :\E_X8[\#_ //WK/\ X$1?_&J]CL]$CLKA95NKR4C/RS7+.OY$
MU'/X?CGF>0WE^A8D[4NG51]!GBN6KA:-=\U2";//Q&7X7%R4Z]-2:TU/(/\
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M:ZO(B?X8;AD7\@:/[/PO_/M!_8N7?\^8_<>.?\,=^!_^?O6?_ B+_P"-4?\
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M%_Y]H/[%R[_GS'[CQG_ACOP/_P _>L_^!$7_ ,:H_P"&._ __/WK/_@1%_\
M&J]FM=)2TAFC6XNI!*,%I9V9E_W2>G6J\?AV*-U;[;J#8.<-=N1^6:/[/PO_
M #[0?V+EW_/F/W'D/_#'?@?_ )^]9_\  B+_ .-4?\,=^!_^?O6?_ B+_P"-
M5[)?:,E_-YC7-W$<8VP7#(OY TZ+24ALY+<7%TRN<EWG8N.G1NHZ4?V?A?\
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M-_C1_P )OX@_Z#5__P"!#?XU]+_\,4:=_P!#//\ ^ 8_^.4?\,4:=_T,\_\
MX!C_ ..4?V9COY?Q7^8?V#FW\G_DR_S/FC_A-_$'_0:O_P#P(;_&C_A-_$'_
M $&K_P#\"&_QKZ7_ .&*-._Z&>?_ , Q_P#'*/\ ABC3O^AGG_\  ,?_ !RC
M^S,=_+^*_P P_L'-OY/_ "9?YGS1_P )OX@_Z#5__P"!#?XT?\)OX@_Z#5__
M .!#?XU]+_\ #%&G?]#//_X!C_XY1_PQ1IW_ $,\_P#X!C_XY1_9F._E_%?Y
MA_8.;?R?^3+_ #/FC_A-_$'_ $&K_P#\"&_QH_X3?Q!_T&K_ /\  AO\:^E_
M^&*-._Z&>?\ \ Q_\<H_X8HT[_H9Y_\ P#'_ ,<H_LS'?R_BO\P_L'-OY/\
MR9?YGS1_PF_B#_H-7_\ X$-_C1_PF_B#_H-7_P#X$-_C7TO_ ,,4:=_T,\__
M (!C_P".4?\ #%&G?]#//_X!C_XY1_9F._E_%?YA_8.;?R?^3+_,^:/^$W\0
M?]!J_P#_  (;_&C_ (3?Q!_T&K__ ,"&_P :^E_^&*-._P"AGG_\ Q_\<H_X
M8HT[_H9Y_P#P#'_QRC^S,=_+^*_S#^P<V_D_\F7^9\T?\)OX@_Z#5_\ ^!#?
MXT?\)OX@_P"@U?\ _@0W^-?2_P#PQ1IW_0SS_P#@&/\ XY1_PQ1IW_0SS_\
M@&/_ (Y1_9F._E_%?YA_8.;?R?\ DR_S/FC_ (3?Q!_T&K__ ,"&_P :/^$W
M\0?]!J__ / AO\:^E_\ ABC3O^AGG_\  ,?_ !RC_ABC3O\ H9Y__ ,?_'*/
M[,QW\OXK_,/[!S;^3_R9?YGS1_PF_B#_ *#5_P#^!#?XT?\ ";^(/^@U?_\
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M-7__ ($-_C1_PF_B#_H-7_\ X$-_C7TO_P ,4:=_T,\__@&/_CE'_#%&G?\
M0SS_ /@&/_CE']F8[^7\5_F']@YM_)_Y,O\ ,^:/^$W\0?\ 0:O_ /P(;_&C
M_A-_$'_0:O\ _P "&_QKZ7_X8HT[_H9Y_P#P#'_QRC_ABC3O^AGG_P# ,?\
MQRC^S,=_+^*_S#^P<V_D_P#)E_F?-'_";^(/^@U?_P#@0W^-'_";^(/^@U?_
M /@0W^-?2_\ PQ1IW_0SS_\ @&/_ (Y1_P ,4:=_T,\__@&/_CE']F8[^7\5
M_F']@YM_)_Y,O\SYH_X3?Q!_T&K_ /\  AO\:/\ A-_$'_0:O_\ P(;_ !KZ
M7_X8HT[_ *&>?_P#'_QRC_ABC3O^AGG_ / ,?_'*/[,QW\OXK_,/[!S;^3_R
M9?YGS1_PF_B#_H-7_P#X$-_C1_PF_B#_ *#5_P#^!#?XU]+_ /#%&G?]#//_
M . 8_P#CE'_#%&G?]#//_P" 8_\ CE']F8[^7\5_F']@YM_)_P"3+_,^:/\
MA-_$'_0:O_\ P(;_ !H_X3?Q!_T&K_\ \"&_QKZ7_P"&*-._Z&>?_P  Q_\
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MVIOA7I?@*Q\>WWQ4TJ?PC>W36$%ZX55>X RT>U5WAE W$$<#DX'-?/D?P?\
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MNPO_ #ZE^'^9]^7]C>7,@:WU)[-0,%5B1LGU^8&EM[*[BM98Y-0>:5ONS&)
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MYE5K?4I+- N"BQ(V3ZY8?YQ7P'_PO?Q[_P!#/J'_ '^-'_"]_'O_ $,^H?\
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M#''J+P2H,/*(D)<^N",#\/6DL+*\MG8W&HO=J1@*T2+@^ORBK]%?II^<&/\
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MSZ?K1_8^%[/[P_U7R[L_O/CW_AC;QK_S_:+_ .!$O_QJC_AC;QK_ ,_VB_\
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MQ/X:\;?"_0_%GPZ\7>%AX=T_1]1-_P"'_L-S)>6"6%T6D^R17+JI=H9!*""
M0LB=>IW/$'Q]UK1I]$UE]-M6\/7]IJ-W#8VMP);R<0>6B*Z[?D.]P6*E@G(;
MD5JQ_&3Q5<W6GZ5'X4MX-7N;J:$RZA<2VUOLCMO/WJIC,F>B;2HZA@2.* /9
M:*\&U3]H74]*M=#OM1T9+**^M(=62UMKM9"UO+:W#I%*[( C+)$I9E.T#G.
M0?1?!/C+5M9\3>(=!UFQT^VO=(CM93+IUX9TE6<2$ JRJR$>7T/7.1P: .TH
MHHH **** "BBB@ KY0\1_MB:YINO7]I:Z)IXMX)GC3SO,9R < DA@,_A7U?7
MPAXJ^ 'CV?Q+JDD/AZ>:)[F1DDC92K#<<$<]#UKPLUJ8FG&'U>_6]E<^1XAK
MXZC"G]2OJW>ROVMT?F=?_P -H^)/^@+I7_?,G_Q='_#:/B3_ * NE?\ ?,G_
M ,77G?\ PSW\0?\ H6KK_P =_P :/^&>_B#_ -"U=?\ CO\ C7SWUG,O[WW?
M\ ^)^O9YWG_X#_P#T3_AM'Q)_P! 72O^^9/_ (NC_AM'Q)_T!=*_[YD_^+KS
MO_AGOX@_]"U=?^._XT?\,]_$'_H6KK_QW_&CZSF7][[O^ 'U[/.\_P#P'_@'
MHG_#:/B3_H"Z5_WS)_\ %T?\-H^)/^@+I7_?,G_Q=>=_\,]_$'_H6KK_ ,=_
MQH_X9[^(/_0M77_CO^-'UG,O[WW?\ /KV>=Y_P#@/_ /1/\ AM'Q)_T!=*_[
MYD_^+H_X;1\2?] 72O\ OF3_ .+KSO\ X9[^(/\ T+5U_P"._P"-'_#/?Q!_
MZ%JZ_P#'?\:/K.9?WON_X ?7L\[S_P# ?^ >B?\ #:/B3_H"Z5_WS)_\71_P
MVCXD_P"@+I7_ 'S)_P#%UYW_ ,,]_$'_ *%JZ_\ '?\ &C_AGOX@_P#0M77_
M ([_ (T?6<R_O?=_P ^O9YWG_P" _P# /1/^&T?$G_0%TK_OF3_XNC_AM'Q)
M_P! 72O^^9/_ (NO._\ AGOX@_\ 0M77_CO^-'_#/?Q!_P"A:NO_ !W_ !H^
MLYE_>^[_ ( ?7L\[S_\  ?\ @'HG_#:/B3_H"Z5_WS)_\71_PVCXD_Z NE?]
M\R?_ !=>=_\ #/?Q!_Z%JZ_\=_QH_P"&>_B#_P!"U=?^._XT?6<R_O?=_P
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M3;Z_+IOANP_X3C37CBUF\FN=1E#2"W!MV/DVRVQ5BCQ'>=V#@4 ?>DOAJR6
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MWX,/]9<L_P"?C_\  7_D?4=K>7TL,S3:?Y$BKE$\]6WGGC(Z=OSJO'J6JM(
MVC;$)Y;[4IP/IBOF3_AM;4O^A<M/^_S4?\-K:E_T+EI_W^:C^U\'_-^##_67
M+/\ GX__  %_Y'U#?WM_;S;;;3?M<>,[_/5.?3!IT-Y?/9R22:?Y4ZG"P^<I
MW#CG=T'?\J^7/^&UM2_Z%RT_[_-1_P -K:E_T+EI_P!_FH_M?!_S?@P_UERS
M_GX__ 7_ )'T[;:AJ<LZ+-I/D1D\R?:5; ]< 4MW?ZE#<.D&E?:(ATD^TJN?
MP(KYA_X;6U+_ *%RT_[_ #4?\-K:E_T+EI_W^:C^U\'_ #?@P_UERS_GX_\
MP%_Y'U&;N]^P"7^S_P#2<X-OYR\#UW=*CLK[49[A4N-+^S1'K)]H5\<>@%?,
M'_#:VI?]"Y:?]_FH_P"&UM2_Z%RT_P"_S4?VO@_YOP8?ZRY9_P _'_X"_P#(
M^G+C4=4CF=8M(\Z,$A7^TJNX>N,5/<7=[':Q21:?YTS'YX?.5=OX]Z^7/^&U
MM2_Z%RT_[_-1_P -K:E_T+EI_P!_FH_M?!_S?@P_UERS_GX__ 7_ )'U%87M
M_<3%;K3OLD>W(?SU?)],"JYU+5@^!HV5S][[4G^%?,O_  VMJ7_0N6O_ '^:
MO>_@_P#$9OBCX-CUI[(6$OG/ \2ON7*X.0?HP_6NFAC\/B9\E.5WZ,[L'G&#
MQU3V5"=Y6OLU^:.GO+R^ACA,&G_:69<NOGJFP\<9/7O^5+97E].LIN-/^S%1
ME!YZOO/IQTJ_17H'M&/_ &GJV_']B_+GK]K3_"K%_>7UO*JVNG?:T*Y+^>J8
M/I@UH44 4+:[O9;:5YK#R9E^Y%YRMO\ Q'2J\.I:J\J+)H_EH2 S_:E.!ZXQ
M6O10!FWU]J$$Y6WTS[5'VD^T*F?P(IXN[XV+2G3\7(.!;^<O(XYW=/7\JOT4
M 9=IJ&I37")/I7V>(GYI/M*MC\ *+K4-3BG98=)\^,'B3[2JY_ BM2B@"A)=
MWJV*2KI^^X)PT'G*-HYYW=#V_.FV-[J$\VVYTW[+'C[_ )ZO^@K1HH R)=2U
M5965-&WH#@-]J49'KC%6+F\OH[:%XM/\Z9AEXO/5=A],]ZOT4 4+"\OKAG%S
MI_V0 9!\]7R?3BJHU/5]P']B\>OVM/\ "MFB@"A?7E];[/LVG_:LC+?OE3:?
M3GK1:7E]-#,T^G_9Y$7,:>>K;SSQD=.WYU?HH R$U+56D ;1MJ9Y;[4IQ^&*
MFO[V_MYMMMIOVN/&=_GJG/I@UHT4 4(;N^>SDDDT_P N=3A8/.4[AQSNZ#O^
M50VVH:I+.BRZ1Y,9(#2?:5;:/7&*U:* ,R\O]2AN'2#2OM$0^[)]H5<\>A%2
M?:[W[#YOV#_2<X^S^<O3UW=*OT4 9EE?:C/<*EQI?V:(]9/M"OCCT ID^HZI
M',ZQ:1YL8)"O]J5=P]<8K6HH H3W=]':121:?YL['YX?.5=O_ NAIMA>W]Q,
M5N=-^R1X)W^>K\^F!6C10!D-J6K"0@:-N7/WOM2_RQ5B\O+Z&.$V^G_:69<N
MOGJFP\<<]>_Y5?HH H65Y?3K(;C3_LI494>>K[CZ<=*K?VGJ^[']B\>OVM/\
M*V** ,_4+R^MY%%KI_VM",EO/5,'TP:6WN[V2UEDEL/)F4?)#YRMO_'M5^B@
M#(AU+57E17T?RT) 9_M2G ]<8J6^OM0@G*VVF?:H_P#GI]H5/T(K2HH H+>7
MQL6E.GXN0V!;^>O(XYW=/7\JBM-0U*:=$GTK[/$3S)]I5L?@!6I10!EW6H:E
M%.RPZ5Y\8Z2?:57/X$5)+=7OV!9!IP>=B0UN9EX'/.[H>WYUH5Y5\:?VA]!^
M#/V>UN8)=5UFX3S8["W8)MCSC>[GA02"!P2<'BMZ%"KB:BI48WDS&K6IT(.=
M1V2.^TEKE)3&VC1Z?"W):.5",_0"B74=525E31@Z X#_ &I1D>N,5\]>%_VW
M++6C?QWOA2YM9[>TFNT\F[617"+NVDE5*Y X.#7L7P<^*<7Q?\('7H--ETN+
M[3);B&:0.25QDY ]_P!*[,3EV+PL7.O"R7FNOS.:AC</B&HTI7?S.KN;R^BM
MH7AT_P Z9AEXO.5=A],]Z+"\OKAV%SI_V10,AO/5\GTXJ_17F'>8W]IZOG_D
M"\>OVM/\*M7UY?0"/[-I_P!JW#+?OU3:?3GK5^B@"A:7E]-#,T^G_9Y%7*)Y
MZMO//&1T[?G5=-2U5I &T;:N>6^U*<?ABM>B@#.O[V_MY]MMIOVN/ /F>>J<
M^F#5FQFGG@W7-M]EDSCR_,#\>N15BB@ HHHH **** ,.\_U[?4_S-05/>?Z]
MOJ?YFH* "BBB@ HHHH **** "BBB@ HHHH **** +>F_Z]OH/_0A53XC^(AX
M0\ ^(=;^QIJ+Z?8374=G(VU;AT0LD9.#C<P S@XS4L%R+7?)Y<DV!]R%=S'D
M=!4.L)8^,M-FT;4=,U V5V DH>)HP0"#RP.0,B@#EQ\6(=4\5>!])CT=9EUN
M"9[V69QG37$4A6$C'S,S0SH1D8\IJQO"WQ\L/&&K>-].\/Z3;7U[I4#S:7';
MW2,^K11$Q2$JHS'MF#(%.=RM&PX? Z&\\!>&K6^UAH]'U5+G4+\ZC/=6C2Y\
M\P&$M&P;Y!M9^%P-SLV,DFKVK^#-!U30-%C.F:A9Q:2IAL$L&DM[BW3RS%M4
MHP8+MQQGJJGJ!0!Q$O[0=EX8TZ5;^/35,>B7&IPMI_GF*66.5T,14QAHCE1N
M5AE6)!SC->OZ/<+J.G6>H-"D4US;QR-CDC*YVY[@9-<7H?@'P]&;VW73M6\S
M4;.:RN[J]=]TZ2,S2%FS]XECR,8X P *Z:WU2'2H([*'3=0,-LHA0K 6&U1@
M8.>>!UH U_LL.PIY,>PMO*[1@MG.?KGG-*+:(1N@B38Y)==HPQ/7([YJK/JH
M@M89OLEW)YG_ "SCB)=?]X=J2QU87TI06EW!@9W3PE ?;/K0!8M["VM#F"WB
MA.,9C0+QUQQ2_8K<X_<1</YH^0</_>^OO6<?$0!Q_9NH_7[,:L7FJBS$1^R7
M<WF#.(8BVWV/H: +]%4;/51>),WV2[A\L9Q-$5+>R^IXJLOB(,P']G:B,]S;
M'% &O15"^U<6,PC-G=SY&=T$)=?IFE@U43VDL_V2[C\O_EF\1#M]!WH O45E
M0:\)YDC_ +/OX]Q W/;D*/<FGWFM"SG:+[#>S;?XX8"RGZ&@#2HJC_:H^PFY
M^R7> <>5Y1\SZ[:BM=;%U<)%]AOHMW\<L!51]30!IT5EW&NBWG>/[!?R;3C?
M' 2I^AJ6751%9QW'V2[?><>4D)+KUZCMTH OU\">+?@IXXD\3ZHT?AK4)HVN
M9"LD4#.K#<<$$#!%?==CK OI_+%G>0<9WSPE5_.H7\0A'9?[.U!L'&5MR0:\
MW&8&&-45)M6['AYIE-/-5!5)-<M]O,^!/^%)>.O^A6U3_P !7_PH_P"%)>.O
M^A6U3_P%?_"OT#NM5%K##)]DNY?-&=L419EZ<,.W6DLM5%Z9!]DNX-@S^_B*
MY]AZFO,_L*E_._P/G_\ 5'#?\_9?A_D?G[_PI+QU_P!"MJG_ ("O_A1_PI+Q
MU_T*VJ?^ K_X5]\_\)&/^@;J7_@,:LWVJBQ9!]DNY]PSF"(N!['WH_L*E_._
MP#_5'#?\_9?A_D?G[_PI+QU_T*VJ?^ K_P"%'_"DO'7_ $*VJ?\ @*_^%?H'
M;:J+FWFE^R7<7E#.R2(JS?[H[U7C\0"214_L[4%W$#<UN0!]:/["I?SO\ _U
M1PW_ #]E^'^1\"?\*2\=?]"MJG_@*_\ A1_PI+QU_P!"MJG_ ("O_A7Z WNL
M"RG,?V*\GXSO@A++^=.CU4264ES]DNEV''E-$1(>G0=^M']A4OYW^ ?ZHX;_
M )^R_#_(_/S_ (4EXZ_Z%;5/_ 5_\*/^%)>.O^A6U3_P%?\ PK[^MM=%S.D7
MV"^BW'&^2 JH^IHNM<%K.\7V&^EVG&^* LI^AH_L*E_._P  _P!4<-_S]E^'
M^1\ _P#"DO'7_0K:I_X"O_A1_P *2\=?]"MJG_@*_P#A7Z!-JH6Q6Y^R79#'
M'DB(^8.O)7TXIMGK(O)UB^Q7L.<_/-"54?C1_85+^=_@'^J.&_Y^R_#_ "/S
M_P#^%)>.O^A6U3_P%?\ PH_X4EXZ_P"A6U3_ ,!7_P *^_)M?$,KI_9^H/M)
M&Y+<D'W!]*GN-5%O;13?9+N3S/\ EG'$2Z_4=J/["I?SO\ _U1PW_/V7X?Y'
MY^?\*2\=?]"MJG_@*_\ A1_PI+QU_P!"MJG_ ("O_A7Z!6&K"_E*"TN[? SN
MGA* ^V?6JY\1 '']FZC]?LQH_L*E_._P#_5'#?\ /V7X?Y'P+_PI+QU_T*VJ
M?^ K_P"%'_"DO'7_ $*VJ?\ @*_^%?H%>:J+-8C]DNYO,&<0PEBOL?0T6>K"
M\29OLEW#Y:[L30E2WLOJ>*/["I?SO\ _U1PW_/V7X?Y'Y^_\*2\=?]"MJG_@
M*_\ A1_PI+QU_P!"MJG_ ("O_A7WT/$0+ ?V;J(YQDVQQ5B^U<6,PC-G=W&5
MW;H(2Z_3/K1_85+^=_@'^J.&_P"?LOP_R/S]_P"%)>.O^A6U3_P%?_"C_A27
MCK_H5M4_\!7_ ,*_0.#51/:RS_9+J/R_^6<D1#M]!WJ"'7Q-,D?]GWZ;B!N>
MW(4>Y-']A4OYW^ ?ZHX;_G[+\/\ (^ _^%)>.O\ H5M4_P# 5_\ "C_A27CK
M_H5M4_\  5_\*_0"\UH6<[1?8KV;'\<,!93^-.&J@V)N?LEW@''E>4?,^NWT
MH_L*E_._P#_5'#?\_9?A_D?G[_PI+QU_T*VJ?^ K_P"%'_"DO'7_ $*VJ?\
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M:^2?+;T-'EMZ&OG?[6QG\WX+_(^(_P!9,S_Y^?@O\CZV_P"&U-'_ .A=NO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW1;V=88+B"25C@*%Y/Z476NZ-8SO#//!'*APRE>1^E?-O_#S?]G_ /Z&B_\
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M_$4?ZPT_^?;^\/[-E_,?S[XHQ7]!'_"E_@O_ -"+X$_\%%E_\11_PI?X+_\
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M]?\ &@"_15#^W]+_ .@E:?\ ?]?\:/[?TO\ Z"5I_P!_U_QH OT50_M_2_\
MH)6G_?\ 7_&C^W]+_P"@E:?]_P!?\: +]%4/[?TO_H)6G_?]?\:/[?TO_H)6
MG_?]?\: +]%4/[?TO_H)6G_?]?\ &C^W]+_Z"5I_W_7_ !H OT50_M_2_P#H
M)6G_ '_7_&C^W]+_ .@E:?\ ?]?\: +]%4/[?TO_ *"5I_W_ %_QH_M_2_\
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MS?#31M)N_#>EW/B3P[;36T>-:T;;/]ENONY7>]LX8#[NY?6N:^&'[5]MX_\
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M_P" ,7_Q->>Z5^SC!X=^,E[X\T3QGXBT6TOC;&\\*V9MQI=P(+5;:(,IB,@
M1%^ZXY4=N*]9BU&UFOY[))T>[@1))80?F17+!"1Z$HV/]TT 9'_"OO"W_0MZ
M1_X Q?\ Q-'_  K[PM_T+>D?^ ,7_P 36^2 .>*,C..] &!_PK[PM_T+>D?^
M ,7_ ,31_P *^\+?]"WI'_@#%_\ $TRY^(OAJS\1MH,^L6\.K*Z1M;R$C:[@
M,B%B-H9@00N<G(P.:V=-U.UUBSCN[.9;BVDSMD3H<$@_J"/PH R?^%?>%O\
MH6](_P# &+_XFC_A7WA;_H6](_\  &+_ .)K?W# .1@]Z,XH P/^%?>%O^A;
MTC_P!B_^)H_X5]X6_P"A;TC_ , 8O_B:WP<TM '/_P#"OO"W_0MZ1_X Q?\
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M?Y!_Q$?,/^?,/_)O\S]$O^$Z^"G_ #\>%_\ P$C_ /B*/^$Z^"G_ #\>%_\
MP$C_ /B*_.VBC_4S!_\ /V7X?Y!_Q$?,/^?,/_)O\S]$O^$Z^"G_ #\>%_\
MP$C_ /B*/^$Z^"G_ #\>%_\ P$C_ /B*_.VBC_4S!_\ /V7X?Y!_Q$?,/^?,
M/_)O\S]$O^$Z^"G_ #\>%_\ P$C_ /B*/^$Z^"G_ #\>%_\ P$C_ /B*_.VB
MC_4S!_\ /V7X?Y!_Q$?,/^?,/_)O\S]$O^$Z^"G_ #\>%_\ P$C_ /B*/^$Z
M^"G_ #\>%_\ P$C_ /B*_.VBC_4S!_\ /V7X?Y!_Q$?,/^?,/_)O\S]$O^$Z
M^"G_ #\>%_\ P$C_ /B*/^$Z^"G_ #\>%_\ P$C_ /B*_.VBC_4S!_\ /V7X
M?Y!_Q$?,/^?,/_)O\S]$O^$Z^"G_ #\>%_\ P$C_ /B*/^$Z^"G_ #\>%_\
MP$C_ /B*_.VBC_4S!_\ /V7X?Y!_Q$?,/^?,/_)O\S]$O^$Z^"G_ #\>%_\
MP$C_ /B*/^$Z^"G_ #\>%_\ P$C_ /B*_.VBC_4S!_\ /V7X?Y!_Q$?,/^?,
M/_)O\S]$O^$Z^"G_ #\>%_\ P$C_ /B*/^$Z^"G_ #\>%_\ P$C_ /B*_.VB
MC_4S!_\ /V7X?Y!_Q$?,/^?,/_)O\S]$O^$Z^"G_ #\>%_\ P$C_ /B*/^$Z
M^"G_ #\>%_\ P$C_ /B*_.VBC_4S!_\ /V7X?Y!_Q$?,/^?,/_)O\S]$O^$Z
M^"G_ #\>%_\ P$C_ /B*/^$Z^"G_ #\>%_\ P$C_ /B*_.VBC_4S!_\ /V7X
M?Y!_Q$?,/^?,/_)O\S]$O^$Z^"G_ #\>%_\ P$C_ /B*/^$Z^"G_ #\>%_\
MP$C_ /B*_.VBC_4S!_\ /V7X?Y!_Q$?,/^?,/_)O\S]$O^$Z^"G_ #\>%_\
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M:/\ A7WA;_H6](_\ 8O_ (FN@HK\^/UDY_\ X5]X6_Z%O2/_  !B_P#B:/\
MA7WA;_H6](_\ 8O_ (FN@HH Y_\ X5]X6_Z%O2/_  !B_P#B:/\ A7WA;_H6
M](_\ 8O_ (FN@HH Y_\ X5]X6_Z%O2/_  !B_P#B:/\ A7WA;_H6](_\ 8O_
M (FN@HH Y_\ X5]X6_Z%O2/_  !B_P#B:/\ A7WA;_H6](_\ 8O_ (FN@HH
MY_\ X5]X6_Z%O2/_  !B_P#B:/\ A7WA;_H6](_\ 8O_ (FN@HH Y_\ X5]X
M6_Z%O2/_  !B_P#B:/\ A7WA;_H6](_\ 8O_ (FN@HH Y_\ X5]X6_Z%O2/_
M  !B_P#B:/\ A7WA;_H6](_\ 8O_ (FN@HH Y_\ X5]X6_Z%O2/_  !B_P#B
M:/\ A7WA;_H6](_\ 8O_ (FN@HH Y_\ X5]X6_Z%O2/_  !B_P#B:/\ A7WA
M;_H6](_\ 8O_ (FN@HH Y_\ X5]X6_Z%O2/_  !B_P#B:/\ A7WA;_H6](_\
M 8O_ (FN@HH Y_\ X5]X6_Z%O2/_  !B_P#B:/\ A7WA;_H6](_\ 8O_ (FN
M@HH Y_\ X5]X6_Z%O2/_  !B_P#B:/\ A7WA;_H6](_\ 8O_ (FN@HH Y_\
MX5]X6_Z%O2/_  !B_P#B:/\ A7WA;_H6](_\ 8O_ (FN@HH Y_\ X5]X6_Z%
MO2/_  !B_P#B:/\ A7WA;_H6](_\ 8O_ (FN@HH Y_\ X5]X6_Z%O2/_  !B
M_P#B:RO%&D> /!>C3ZMK>E:%INGPXWS3640&3T &W))[ <FNUKY!_;3O9=2\
M>^#M!O+MK/1'1)7D/W$9Y3&\A[$J@'TR?6O3R["+'8F-&3LM6_1*^APXW$O"
MT'52N^GS.ZT+XZ_!#7M:ATV/2[.UDFD$44UUHJI$[$X W;3C)QU KL? 6O?"
M_P")E]J5GH&D:9=SZ=C[2KZ2L>S+,HY9!GE3TKP34? ?A_2+GQ,U[X*_X132
M_"A2\TWQ!YDK-?M'(NR-V8[93,.1M^[D5T'["\(CB\57<_%UJ#QO&/5(RX<_
M3?)C_@)KT'A\!B<%5QF%YURM+WK;WUZ=M3R,/CL3*O"C5MK?9-;>OG]Y]'?\
M*^\+?]"WI'_@#%_\31_PK[PM_P!"WI'_ ( Q?_$UT%%?.'TIS_\ PK[PM_T+
M>D?^ ,7_ ,31_P *^\+?]"WI'_@#%_\ $UT%% '/_P#"OO"W_0MZ1_X Q?\
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M[T?VMF7_ #_G_P"!/_,/[ R;_H%I_P#@,?\ (\M_X9$^&/\ T!;C_P #9O\
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MYLTS%\8_=W;H/R5@*G@T>UAM)+=/-\F0[CF=V/;HQ;(Z=C2_M;,5_P OY_\
M@3_S&N'\G>V%I_\ @$?\CR?_ (9$^&/_ $!;C_P-F_\ BJ/^&1/AC_T!;C_P
M-F_^*KU.W\.V5K,LL8N-ZG(W74K#\BV*6Z\/V5[.\THGWMR=ES*@_(, */[7
MS'_H(G_X$_\ ,?\ J]E'_0)3_P# (_Y'E?\ PR)\,?\ H"W'_@;-_P#%4?\
M#(GPQ_Z MQ_X&S?_ !5>LG1[8V0M,2^2#G_7ON_[ZW9_6H[30+.QG6:(3[UZ
M;[F1QTQT9B*/[7S'_H(G_P"!/_,/]7LH_P"@2G_X!'_(\J_X9$^&/_0%N/\
MP-F_^*H_X9$^&/\ T!;C_P #9O\ XJO4I_#=C<2O(XN-[$D[;J51D^P; J>?
M1[:YMH[=Q+Y<?*[9W4_BP;)_$T?VOF/_ $$3_P# G_F'^KV4?] E/_P"/^1Y
M-_PR)\,?^@+<?^!LW_Q5'_#(GPQ_Z MQ_P"!LW_Q5>KV.B6FG3&6 3!R-O[R
MXDD&/HS$=J@/ABP+[B+G/7_C[F_^*H_M?,?^@B?_ ($_\P_U>RC_ *!*?_@$
M?\CR_P#X9$^&/_0%N/\ P-F_^*H_X9$^&/\ T!;C_P #9O\ XJO6+O1;6]2)
M)1,5B7:NR>1#CCJ0PST[T6>C6M@LBPB7$@VMOGD?CVW,<?A1_:^8_P#01/\
M\"?^8?ZO91_T"4__  "/^1Y/_P ,B?#'_H"W'_@;-_\ %4?\,B?#'_H"W'_@
M;-_\57J'_"+Z?NW8N<_]?<W_ ,75B^T6UU&023B8L!M'ESR1C'T5@.]']KYC
M_P!!$_\ P)_YA_J]E'_0)3_\ C_D>3_\,B?#'_H"W'_@;-_\51_PR)\,?^@+
M<?\ @;-_\57K-OH]M:V\D$8E\N3AMT[L?P);(_"J\7AJPAE61!<;E(89NY2,
MCV+8-']KYC_T$3_\"?\ F'^KV4?] E/_ , C_D>7?\,B?#'_ * MQ_X&S?\
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M?ZV99_,_N#_4+._Y(_\ @2/AW>?6OT@_9GN9KOX'>%I)Y7FD\J9=SMDX$\@
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M\#)/\:/^%B>*?^ACU7_P,D_QH_MV'_/M_>'^M]+_ )\O[U_D??'_  @VI?\
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M+_GR_O7^1]\?\(-J7_0Z:[^5M_\ &:/^$&U+_H=-=_*V_P#C-? __"Q/%/\
MT,>J_P#@9)_C1_PL3Q3_ -#'JO\ X&2?XT?V[#_GV_O#_6^E_P ^7]Z_R/OC
M_A!M2_Z'37?RMO\ XS1_P@VI?]#IKOY6W_QFO@?_ (6)XI_Z&/5?_ R3_&C_
M (6)XI_Z&/5?_ R3_&C^W8?\^W]X?ZWTO^?+^]?Y'WQ_P@VI?]#IKOY6W_QF
MC_A!M2_Z'37?RMO_ (S7P/\ \+$\4_\ 0QZK_P"!DG^-'_"Q/%/_ $,>J_\
M@9)_C1_;L/\ GV_O#_6^E_SY?WK_ "/OC_A!M2_Z'37?RMO_ (S1_P (-J7_
M $.FN_E;?_&:^!_^%B>*?^ACU7_P,D_QH_X6)XI_Z&/5?_ R3_&C^W8?\^W]
MX?ZWTO\ GR_O7^1]\?\ "#:E_P!#IKOY6W_QFC_A!M2_Z'37?RMO_C-? _\
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MMV'_ #[?WA_K?2_Y\O[U_D??'_"#:E_T.FN_E;?_ !FC_A!M2_Z'37?RMO\
MXS7P/_PL3Q3_ -#'JO\ X&2?XU]+?L>>*]8\01^)X-3U.ZU"*#[.\0N93(4+
M>8&P3R,[5_*NK"YM#$U524+7/1R_B.GC\3'#JFTY7UOV5_T/8O\ A!M2_P"A
MTUW\K;_XS1_P@VI?]#IKOY6W_P 9KKZ*]X^P.0_X0;4O^ATUW\K;_P",T?\
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M_?AJ^G/LVM[L_;[+;Z?9&_\ CE6+Z'49) ;.ZMX(\<K- TA)^H<>U']D8/\
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M=[DGY)%@(0#CJN\Y[]Q4-O;ZNLR&:]M)(@1N5+5E)'L?,./RH_LC!_R_B_\
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MB!K8::^M#266_:WQMV&X^YC;QOZX[UZ)^S5X-\0> OB'9Z;=^']4MM/%I/\
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M[:/X4_&+P=X[NKS3O&7Q*US3-!^(&E6NE6NI:A]H@O=&N%@;4)9_E!G1&DF
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M\,>>./\ GOI/_@0W_P 11R9G_?\ O8>RS[_IY][_ ,S$_P"&H_B/_P!!U?\
MP#@_^-T?\-1_$?\ Z#J_^ <'_P ;K;_X8\\<?\]])_\  AO_ (BC_ACSQQ_S
MWTG_ ,"&_P#B*.3,_P"_][#V6??]//O?^9B?\-1_$?\ Z#J_^ <'_P ;H_X:
MC^(__0=7_P  X/\ XW6W_P ,>>./^>^D_P#@0W_Q%'_#'GCC_GOI/_@0W_Q%
M')F?]_[V'LL^_P"GGWO_ #,3_AJ/XC_]!U?_  #@_P#C='_#4?Q'_P"@ZO\
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M_P!"YI/_ (-G_P#C%?+'_#>?B#_H6]-_[[D_^*H_X;S\0?\ 0MZ;_P!]R?\
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M/[6\;?\ 0N:3_P"#9_\ XQ7RQ_PWGX@_Z%O3?^^Y/_BJ/^&\_$'_ $+>F_\
M?<G_ ,51_K/EG\[_ / 7_D'^JN:?R+_P)?YGU/\ VMXV_P"A<TG_ ,&S_P#Q
MBC^UO&W_ $+FD_\ @V?_ .,5\L?\-Y^(/^A;TW_ON3_XJC_AO/Q!_P!"WIO_
M 'W)_P#%4?ZSY9_._P#P%_Y!_JKFG\B_\"7^9]3_ -K>-O\ H7-)_P#!L_\
M\8H_M;QM_P!"YI/_ (-G_P#C%?-7AO\ ;DUG5/$&G6=SX;L?L]Q.D4AAD=7"
MLP!())&>?2OL.O7P.98;,5)X>5^7?1K?U/&Q^5XK+'%8F-N;;5/;T.1_M;QM
M_P!"YI/_ (-G_P#C%']K>-O^A<TG_P &S_\ QBNNHKU#RCD?[6\;?]"YI/\
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M>-O^A<TG_P &S_\ QBNNHH Y'^UO&W_0N:3_ .#9_P#XQ1_:WC;_ *%S2?\
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MC_#WPWH>C.EIX>N_*^QOIHM;BX>>06SA T2[Y6"IA%^4$?=XH Y/5?VC+/\
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M='^I^%_Y^R_#_(/]<\7_ ,^H_C_F?G'_ ,,Z_$?_ *%+4O\ OT:/^&=?B/\
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M;VX'%?4?[)]U /AS<:7:RI/;Z3>-:>=&<K+)M5I7![@R,^#Z 5J^&O@;\/\
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MM^1KX'B'.,7EV(A3P[235]K]6?H?#>2X/,L/.KB$VU*V]NB/MW_AN_PA_P!
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M17Z ?G04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,J7,$<T3"2*1 Z.O1E(R"/8@BG8- !12X/I28)[4 %%&#Z48/I0 448-&#0
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MWR+%NPL90D;LU]IT 4;'6K346=8'D8J-QW0NG'_ @*K?\)7IO_/2;_P&E_\
MB:UZ* *-[K5IIY03O(I<;EVPN_'X XHMM:M+R&:6)I"D(RY:%U./8$9/3M5Z
MB@#)3Q1ITCJBR3;F.!FVD'_LM37NNV>GS>5.\BOC.%A=QCZ@$5H44 48M9M)
MK.2Z1I##&<,3"X.>/X2,GKZ5%;^(["ZF2*-Y2[G !MY%'YE<5IT4 9MUXBL;
M.=X97E$B<$+!(P_,*14AUFT%B+O=)Y!.T'R7SG_=QG]*O44 9MMKEAJ4OV:,
MR2%P1MDMW52,<Y++BLF9/"UO,\;Z9;!T)5L:<2,CW"5T&H7\.F64UU.2L42[
MFP,FN,/QBT0'_4WA_P" I_\ %UQU\1AZ+2K22?F=M##XBLFZ,6UY&U/8>&[>
MUBN'TNT$4OW2+#)_(+D?C26-EX:U&8Q0:7:,X&[#V&P8^K(*QO\ A<>B?\\+
MS_OE/_BZ/^%QZ)_SPO/^^4_^+KF^NX'^>)T_4<?_ "2-%CX55BITRVR./^0:
M?_B*L7=CX;L4A:;2[0"4;DVV&[(]\*<=>]8W_"X]$_YX7G_?*?\ Q='_  N/
M1/\ GA>?]\I_\71]=P/\\0^HX_\ DD;-G8^&[]93#I=H1$-S;K#;Q^*C/X57
M!\*$X&F6^?\ L&M_\16=_P +CT3_ )X7G_?*?_%T?\+CT3_GA>?]\I_\71]=
MP/\ /$/J./\ Y)&S?6/AO3I%CGTNT5F&X;+#?Q]54TL%AX;N;:6XCTNT,47W
MB;#!_ %<G\*Q?^%QZ)_SPO/^^4_^+H_X7'HG_/"\_P"^4_\ BZ/KN!_GB'U'
M'_R2-.%/"T\J1IIEL78A1G3B!D^Y2M6?6M/TEQ:MOB\L !(K=RJC' &U<5R_
M_"X]$_YX7G_?*?\ Q='_  N/1/\ GA>?]\I_\75+'X..TT2\OQLMZ;.M76K1
MK%KL/)Y"G:3Y+YS_ +N,]_2H[7Q%8WDZ0Q/*9'X :"11^94"N6_X7'HG_/"\
M_P"^4_\ BZ/^%QZ)_P \+S_OE/\ XNJ_M'"?\_$3_9N,_P"?;.HN?$=A:3O%
M*\H=#@A;>1A^87%2R:U:164=VS2""0X4B%R<\_PXR.A[5R7_  N/1/\ GA>?
M]\I_\71_PN/1/^>%Y_WRG_Q=']HX3_GX@_LW&?\ /MG5V6NV>H3>5 \C/C.&
MA=!^9 %12>)]/BD9&DF#*2#BVD//UVUS/_"X]$_YX7G_ 'RG_P 71_PN/1/^
M>%Y_WRG_ ,71_:.$_P"?B#^S<9_S[9UMSK5I:00S2O((YAE"L+L2/< 9'7O1
M8ZU::BSK TC%1N.^%TX_X$!7)?\ "X]$_P">%Y_WRG_Q='_"X]$_YX7G_?*?
M_%T?VCA/^?B#^S<9_P ^V=)_PE>F_P#/2;_P&E_^)JS>ZU::>4\]Y%WC<NV%
MWX_ '%<E_P +CT3_ )X7G_?*?_%T?\+CT3_GA>?]\I_\71_:.$_Y^(/[-QG_
M #[9UMKK-I>0S2Q/(4B&YRT+J0/8$9/3M5=/%&G2.J+)-N8X&;:4?^RUS7_"
MX]$_YX7G_?*?_%T?\+CT3_GA>?\ ?*?_ !=']HX3_GX@_LW&?\^V=7>ZY9Z=
M-Y4[R*^,X6%W'Y@$4Z+6K2>TDN4>0PQG#$PN#^1&3U]*Y2+XP:))(J^5=KDX
MR43C\FKMT=9$5U.589!]1731Q%&O?V4D['-6PU;#V]K%JYG6_B.PNIDBCDE+
MN< &WD4?F5Q2W7B&QLIWAE>42+U"P2,/S"D5I45T',43K5H+$7>^3R"=N?)?
M.?\ =QG]*9::_97TZPPO*9&Z!H)%'KU*@5HT4 9<_B6PMYGBDDE#H2I MY",
MCW"XJ:?6K2WM8KB1Y!%+]TB%R?R R/QJ]10!0L=<L]1F,4#R,X7=AX708^K
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MA=N/? ..O>KU% %&SUJTOQ(87D(C&YMT+KQ^(&?PJM_PE6FDX\R;/_7M+_\
M$UKT4 4;[6K33I%2=Y%9AN&R%WX_X"#1!K-I<VTMQ&TABBY8F%P?P!&3^%7J
M* ,J+Q-I\TJ1I),68A1FVD')]RM2WFO65A.89GD60#.%@=A^84BM"B@#-74M
M/:W?4 IVJ=IE\A@_8=,;NXI+;Q%87DZ0Q/*7<X :WD4?F5Q6G7&_&'XGZ?\
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MZG'/0$#/3M5=/%&G.X423;B<#-M*/_9:UJ* ,^]URSTZ;RIWD5\9PL+N,?4
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M*A2.Y9"3C 8@$=2U?<_F.'W;VW>N>:3>V",G!.3SUH ^ O!>G?'.7PGX-O\
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M)_.@"]152XU:QLY#'/>V\$@_ADE53^1-.&IV9MC<"[@-N#@R^8-@/IG..XH
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MX&^%=6L(/"\2>";SQ%H6I:'Y&B72H=9LY[=1*7#AO,,8"2*PQAN3D'%;MO\
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M='=6\;>JQ$'^5-;Q1X99B3/;$GDDPG_"OGRBC^W:_P#*OQ_S#_5_#_SO\/\
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M8US4TE:VWS/"S3+Z>!4'!MWOOY6!+"VC8,EO$K#H50 BB2QMI7+/;Q.QZLR
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M ^/_ +Z;_&C_ (0?0_\ H'Q_]]-_C67<^+? EW;PP3>(=$>*$;8U.I1_*/\
MOOVHL?%O@336=K;Q#HD3.-K$:E&<C\7HY<'VC^ <V-[S_$U/^$'T/_H'Q_\
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M  )A_P#C5'^JN8]H_>'^MN6]Y?=_P3X0\U_[[?G1YK_WV_.ON_\ X8<\ ?\
M/_KO_@3#_P#&J/\ AASP!_S_ .N_^!,/_P :H_U5S'M'[P_UMRWO+[O^"?"'
MFO\ WV_.CS7_ +[?G7W?_P ,.> /^?\ UW_P)A_^-4?\,.> /^?_ %W_ ,"8
M?_C5'^JN8]H_>'^MN6]Y?=_P3X0\U_[[?G1YK_WV_.ON_P#X8<\ ?\_^N_\
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M$/\ T&]0_P# E_\ &C_A./$/_0;U#_P)?_&C^W8_\^_Q_P" '^M]/_GR_O\
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M_P *U_ZFKQ-_X,?_ +&O@7_A./$/_0;U#_P)?_&C_A./$/\ T&]0_P# E_\
M&C^W8_\ /O\ '_@!_K?3_P"?+^__ (!]]?\ "M?^IJ\3?^#'_P"QH_X5K_U-
M7B;_ ,&/_P!C7P+_ ,)QXA_Z#>H?^!+_ .-?</[.&L7NN?"#1;K4+J6\N2TR
M&:9BS%5E<*"3UP !^%=^"S..,J.FHVTON>SE>?0S.LZ*IN+2OO?JE^IL_P#"
MM?\ J:O$W_@Q_P#L:/\ A6O_ %-7B;_P8_\ V-=G17M'U)QG_"M?^IJ\3?\
M@Q_^QH_X5K_U-7B;_P &/_V-=G10!QG_  K7_J:O$W_@Q_\ L:/^%:_]35XF
M_P#!C_\ 8UV=% '&?\*U_P"IJ\3?^#'_ .QH_P"%:_\ 4U>)O_!C_P#8UV=%
M '&?\*U_ZFKQ-_X,?_L:/^%:_P#4U>)O_!C_ /8UV=% '&?\*U_ZFKQ-_P"#
M'_[&C_A6O_4U>)O_  8__8UV=% '&?\ "M?^IJ\3?^#'_P"QH_X5K_U-7B;_
M ,&/_P!C79T4 <9_PK7_ *FKQ-_X,?\ [&C_ (5K_P!35XF_\&/_ -C79T4
M<9_PK7_J:O$W_@Q_^QH_X5K_ -35XF_\&/\ ]C79T4 <9_PK7_J:O$W_ (,?
M_L:/^%:_]35XF_\ !C_]C79T4 <9_P *U_ZFKQ-_X,?_ +&C_A6O_4U>)O\
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M"D>GV1?\:/[)P?\ )^+_ ,P_U;RS_GW_ .32_P SYJ_X8FN_^AJ@_P# ,_\
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M%C:7T#.;F_%TI&% @"8/KP:/[)P?\GXO_,/]6\L_Y]_^32_S/F'_ (8FN_\
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MDOQ)<,?DF\@#:..-N>>_YT?V3@_Y/Q?^8?ZMY9_S[_\ )I?YGS#_ ,,37?\
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M5AT88-=A)\8?$UO/X?LKZ^\/Z5)K/V.X:_N8)?)LXY[6YF,0!D&]E>W"AV*
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MRW_#2WQ(_P"ADD_\!8/_ (W1_P -+?$C_H9)/_ 6#_XW74_\,;^-O^?W1?\
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M-T>RS+^]][_S#ZOGW_3S_P "?^9RW_#2WQ(_Z&23_P !8/\ XW1_PTM\2/\
MH9)/_ 6#_P"-UU/_  QOXV_Y_=%_\"9/_C='_#&_C;_G]T7_ ,"9/_C='LLR
M_O?>_P#,/J^??]//_ G_ )G+?\-+?$C_ *&23_P%@_\ C='_  TM\2/^ADD_
M\!8/_C==3_PQOXV_Y_=%_P# F3_XW1_PQOXV_P"?W1?_  )D_P#C='LLR_O?
M>_\ ,/J^??\ 3S_P)_YG+?\ #2WQ(_Z&23_P%@_^-T?\-+?$C_H9)/\ P%@_
M^-UU/_#&_C;_ )_=%_\  F3_ .-T?\,;^-O^?W1?_ F3_P"-T>RS+^]][_S#
MZOGW_3S_ ,"?^9RW_#2WQ(_Z&23_ ,!8/_C='_#2WQ(_Z&23_P !8/\ XW74
M_P##&_C;_G]T7_P)D_\ C='_  QOXV_Y_=%_\"9/_C='LLR_O?>_\P^KY]_T
M\_\  G_F<M_PTM\2/^ADD_\  6#_ .-T?\-+?$C_ *&23_P%@_\ C==3_P ,
M;^-O^?W1?_ F3_XW1_PQOXV_Y_=%_P# F3_XW1[+,O[WWO\ S#ZOGW_3S_P)
M_P"9RW_#2WQ(_P"ADD_\!8/_ (W1_P -+?$C_H9)/_ 6#_XW74_\,;^-O^?W
M1?\ P)D_^-T?\,;^-O\ G]T7_P "9/\ XW1[+,O[WWO_ ##ZOGW_ $\_\"?^
M9RW_  TM\2/^ADD_\!8/_C='_#2WQ(_Z&23_ ,!8/_C==3_PQOXV_P"?W1?_
M  )D_P#C='_#&_C;_G]T7_P)D_\ C='LLR_O?>_\P^KY]_T\_P# G_F<M_PT
MM\2/^AD?_P !8/\ XW7UY\"_%^H^.?AEI6KZM(DU_*94DD1 N[;(R@X'&< =
M*^;/^&-_&W_/[HO_ ($R?_&J^G/@[X'NOAU\/=,T*^GBN+NW,CR/!DIEW9L
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MS&"RT%X-[>6TMW.KE=QQN C(!QC.#4'V/QK_ ,^'A[_P-N/_ (U7<44 </\
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M:)CM*LCJ<,CJP#(P/!5@".XH P/.^('_ #Z>&O\ P*N/_C='G?$#_GT\-?\
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M'_/IX:_\"KC_ .-T>=\0/^?3PU_X%7'_ ,;KK]Z[PFX;B,[<\X]:5F"*68X
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2W$HZ/*W+$>V3Q["M2BB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>arwr-20250930_g6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 arwr-20250930_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?(G_  64_;3\7?L@?LSVUM\+]3-EXL\::@VFZ7J"8WV%NB;[
MBXCS_P M #&BG^$RAARHKZ[K\S/^#DOPCK5]\/\ X4^.[>W<Z=IFL:K8W<@'
MRK-<Q6TD0/N5M9<?0T 9/[)7_!"GP1\>O@9I?QR_:G^,'C(^*?&=@FK1PZ3>
M0 VT<ZB2(W#W$4KSRLA5FY3!8KR1NKV#Q[/\0O\ @C?_ ,$V_%&E1_%E_&&K
M?\).]G\.K_4;=A]A2Z2,11-&[.O[D17,P4$HS8& &('TY^QG\4?"/QD_97\
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MC]HCQE9^-[:%9(M=*6_V$7( (9;=$65%W#C$Y8=<G@5Y)_P7]\/>)/!_A/\
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MEY_P3O\ A'^W!\4/B!X(^)GB_P 1Z9;>$H87L)="GMTDE+SRQGS#+#(#P@Z
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M\*M$NV75_B+J\>FI'$?WGV*$K-<LN.H)$,1'<3FO1/\ @CQ_RC<^&'_7A?\
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M^ORZ+>:RVGVMY:_8Q/;V1*J UN7V$Q+D;\\G!'&/D'_@E#_P2\^"7[>?PO\
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MMU>,]!T6UFB^&GQ6\(ZG:VD$2DQ1VEY%(JH .-UI=%?5O)Q_STKZF_X-T_\
MDR?Q3_V5.]_]-NFT ??-%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1N9(6W;CCR\8^;(^E:* /C']LC_@DQK?[8?PT^$W@CQ-^TFUCJ'PUT%]-O\
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M<.DCX?"R#^'_ .P_/^W_ &:\DNEQ/YR^5N,FT_(V ,\]*] _;4_9%\"?ML_
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MF6/V$/B%XY\=GXSGQ0/& B2*U_X1_P"Q_9$2623EO/D\PGS,=%^[GO@?55%
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M:""&56'QNG_!"#]H>]T*+X3Z]_P44UV?P%"RA= &GW9@V*V0JVK7IA0\#!Y
M/.#BOTOHH \T_9._92^$_P"QM\'K3X-?"*QG6RBF:YO[^]</<ZA=.%#SRL
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^TU;? +QOX3\2ZEJGP-TUK34/A3X:FTS3[ZX2348W%NOVJY%S.(]T0GBDP6
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M0!P: /J?_A.O!/\ 8]CXB_X3'2O[/U1T73+[^T(O)NV92RB)]VV0E58@*3D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH HZUX;T'Q%]G_MW28+K[+.)K?SDSL<="/\XJ]115
M.<G%1;T6Q*C%2;2U84445)04444 %,GMX+E/*N8$D7.=KJ",_C3Z* "BBB@
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MD^2E &A_PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\
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M8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\
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M'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\
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M^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\
M"8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"
MG_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0
MH I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\
MOT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\
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M8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\
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M'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\
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M?^P%:?\ HE*X7]N?_DT?Q[_V 7_]#6NZ^%W_ "3/P[_V K3_ -$I0!NT444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 >4?MS_\ )H_CW_L O_Z&
MM=U\+O\ DF?AW_L!6G_HE*X7]N?_ )-'\>_]@%__ $-:[KX7?\DS\._]@*T_
M]$I0!NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >4?MS_P#)
MH_CW_L O_P"AK7=?"[_DF?AW_L!6G_HE*X7]N?\ Y-'\>_\ 8!?_ -#6NZ^%
MW_),_#O_ & K3_T2E &[1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!Y1^W/\ \FC^/?\ L O_ .AK7=?"[_DF?AW_ + 5I_Z)2N%_;G_Y-'\>
M_P#8!?\ ]#6NZ^%W_),_#O\ V K3_P!$I0!NT444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >4?MS_\FC^/?^P"_P#Z&M=U\+O^29^'?^P%:?\
MHE*X7]N?_DT?Q[_V 7_]#6NZ^%W_ "3/P[_V K3_ -$I0!NT444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 >4?MS_\ )H_CW_L O_Z&M=U\+O\
MDF?AW_L!6G_HE*X7]N?_ )-'\>_]@%__ $-:[KX7?\DS\._]@*T_]$I0!NT4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6#\28OB))X1N&^$Z:"?$",ATYO$B3&T4[@'+^3\X/EE
MP-O<C/&:WJY#XP? OX;_ !UTJRTKXAZ;?/\ V9=_:M-O=*UN[TZZM)MI4O'/
M:2QRKE200&P1U!H ^"_B)?:]HWP/_:+^'OQDT^T3QM%\5O"&I?$_4-'N-^D7
M6F7][8B 6JLJO%$MM"5DCEW/RS,[!QCVS_@H.VKV7[07PPO? .Y-?A\!?$$J
M;3B46PT0&/..=HNOLVW_ &CQS7N/@W]DO]GOP+\.M?\ A7HWPY@GT?Q69&\4
MIJ]Y/?SZN\B;&>YN+EWFF;;P"SG;_#BF_!S]DOX%_ C7KCQ5\/\ PU?G59].
M73AJ>N>(;[5+B"R5@RVL4EY-*T,(8 ^6A520"0<# !\U^/;7PXG_  31_9Q3
MP8D O%\0?#IO#/V<#=]N,]KO*X_C*FX+=_OY[U]N5Y)X"_89_9B^&GC6R\=>
M#_A[/!<Z5=S76AV$^O7UQIVDSS;O,EM+*69K>U=M[<Q1J1N(7 ->MT %<9\9
MOB;XO^&6F65_X0^#NM>,9+J=HYK;19(U:W4+D.V\C@GCBNSHH ^2?VK?VC_B
MQXK_ &=?%WAS6_V2?&&AVEWI+1SZM?7$!AM5W+\[A3G'T]:]_P#A7XGUAOAA
MX<8^#KT$Z#9D@LO'[A*Y_P#;G_Y-'\>_]@%__0UKNOA=_P DS\._]@*T_P#1
M*4 2_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q
M10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q
M10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q
M10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q
M10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q
M10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q
M10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q
M10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q
M10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q
M10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q
M10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\
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M.R,!L%C5#]FO_@@'_P $_/@)]GU;QAX-OOB-K$6&:\\9W(DM0_?;9Q!(2O\
MLRB4^]?;E%;++L*W&52//**M>6KT[]+^=CH658*3A*K'GE%)*4M79=^E_.UR
MAX9\+>&/!6A6WA?P;X<L-)TRSCV6FG:99I!! O\ =2- %4>P%7Z**[4DE9'H
M))*R"BBBF,**** "BBB@ HHHH **** "BBB@ HHHH \H_;G_ .31_'O_ & 7
M_P#0UKNOA=_R3/P[_P!@*T_]$I7"_MS_ /)H_CW_ + +_P#H:UW7PN_Y)GX=
M_P"P%:?^B4H W:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RC]N?\ Y-'\>_\
M8!?_ -#6NZ^%W_),_#O_ & K3_T2E<+^W/\ \FC^/?\ L O_ .AK7=?"[_DF
M?AW_ + 5I_Z)2@#=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^.=.^#=]XW/C&6>'1[FTU..VL8G2.-U\V7:[DNLA9%5#N$;_ #+@5\E_!_\
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M/_1*4 ;M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_G6W71@\#B)<E;$U).2UY;V2]4MV=&"RW%3E#$8NK-R6JC>T5ZI;L^6_"O\
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MFE16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\
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M_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5
M&E16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\
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M9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]511I45F_P#"8^&/^@U!_P!]4?\
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M_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^&/\
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M_/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% $/]G:?_SXP_\
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M_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\
MY\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ*
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M]"L[Q9K_ ("\!>'[GQ9XYUK2-%TJS3?>:GJUS%;6\"_WGDD(51[DU^6'BO\
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M_/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% $/]G:?_SXP_\
M?H4?V=I__/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% $/]G:
M?_SXP_\ ?H4?V=I__/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4
MU% $/]G:?_SXP_\ ?H4?V=I__/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\
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MO.PM_#>DZF/"OCP0YN_!>M7*^9*0,LUI+@+=)U. !( "611@GZHDCCEC:*5
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M&H#,>[')/<FNAHHKT%%15DM#U8QC"-HJR"BBBF,**** "BBB@ HHHH ****
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M.29OGN*6'R^A*K/M%-V\WT2\W9$3J0IJ\G8^LJ\I_:7_ &WOV5_V0='.J?M
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M0(C@YQ7EG_!,W_@E1^V+\ /VCE_;(_:T_:MDUSQ/>:/<:?J7A^*ZGU-KNWF
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M_3G_  5&_P""A?[1?_!/,^ Y/A+^SU>>/O#TMA<OXTUW4K"[,4 C\I(%^UP
MQPS/B9V\Q6X"D+R:UPN;XS OZS4C*C*FTU*+UO?>+CJK?@$,SJT\/.>.HNFH
MVO\ :3OII;MU['RA\>O^"57[;?\ P3'^(5S^T]_P3*^(VMZ[H$7[S4_#2 3:
MA%;@DF&:V \O4H!S]U?-7.0F5,E?27_!/3_@NI\"?VJ9;/X6?'^*T^'?Q"=A
M L-W.4TO5)NF()I#F&0GCR93G)"J\A.!F?LT_P#!QI^QA\:=2L/"GQ1\*^)_
M &M7\\<$2W%F=3LGE=@JHDULIE)+$#+0*.1SUQW7_!0O_@C?^S!^V_/=^*M
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MBB>64JM?VLYR>MTN;1>B"ID]&OB?;5*DWK=1YGRKT2/DW]KG_@C9^R;^VO\
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MRQQJK HSR*5W,@^4G!^0_P#ABC_@XJ_:N^?XU?M-2>!;*YYGM9?&,=@IC/\
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M_P %(-2UBZD<^>FE>$Y+B>09ZF[N[LG/UB-?1/PF_P"#13_@E1X!\N?Q[?\
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M&$_KO<D'VZ5W'_#K[_@Z[_:M&[XZ_MY/X#MK@?Z79R?%"2Q4J>JF'0(7B?\
MW2=OO7[T45^K1XWC@X\N7Y?AZ*6S5/FDOFW^AZ4,'"$>5-V[+1?<C\+/!_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ J.\L[34;22PU"UCG@F0I-#,@9'4C!4@\$$=C4E%&P'D7@[]@7]BGX<
M_'"#]I/X<?LM>!_#GCJVMI[=/$OA[P]#8W#I,NV7?Y"HLC,O!9P6QQFO7:**
MVK8BOB))U9N32LKMNR[:]/(226Q^,W[=?PJ_X.D?@;^U_P#$+]HC]COXC)XM
M^'>M>(YKO0/!VDZW9:G#8:8H"00FPU2-&BD,:(9%M,_O&<AFR6/F_A;_ (.K
M/V_OV4M=@\"?\%+O^":\]A=;O+>\L[._\-73 =9!!?),DY(Y^1XU.<@@5^\-
M9_BGPEX4\<Z%/X7\;>&=/UC3+I=MUIVJV4=Q!,OHT<@*L/J*^QH<6976H0H9
MEEM*HHI+FA>G.R5E>4;W9@Z$T[PFU^)^>W[-_P#P=-?\$D_CU]GT_P 7_$[Q
M!\,]3GPHL_'GAV1(B_<?:;,SPJO^U(Z<>AXK[I^#O[0GP%_:&T#_ (2GX"_&
MKPIXUTW:"U[X5\0VVH1KGH&:!V"GV.#7RO\ M(?\&\'_  2+_:6^T7NM_LEZ
M5X3U.?)75?AY<2:*T9/5A!;D6S'OEX6_G7PK\8?^#.R\\$:__P )]^P7^WUK
M_AK5+5BVFVWBZQ*SQGL1J.GM$R8]K<_I6WU/P_S/^#B:N%D^E2*J1^3AK;S8
MN;%0W2?IH?N%69XS\%>#_B-X6OO!'C[PO8:UHVI0&'4-+U2T2>WN(SU5T<%6
M'U%1?#OPG)X"^'^A>!9=>OM5;1=&M;!M4U.Y>:YO##$L?G32.2TDC[=S,Q)+
M$DDDU\A?\%:_^"VGP4_X)&^(_AUH7Q5^%FN>+/\ A//[0EGC\.7L"7.FVUJ;
M<>;Y<VU9=[3[5!=/]6W/%?)Y=@,?F&81P^ BY5+MQMH_=3=UJK62OO\ B;3E
M&,;RV/GW]L#_ ((7_%#X%>./^&H_^"5WCS4]#UG39&N1X-756BN(>[+8W+G]
MXA'!MYR0PR-[9$=?(GPYM/V!OVE?'^I?##]O_P '>)/@=\5)]2E&I^.]&FE3
M3[S4'<EVU*PNQ)]BD9VRS1>7$223Y('/Z2?LX?\ !R7_ ,$AOVCOL]BG[3">
M!=3GQ_Q+/B1IDFE>7G^]='?:#_O_ /IS7J/[5?["G[$'_!4GX<Q^*I=3T;4K
M_P"S[-"^)'@G4;>>>+ RJF:(M'<Q#/\ JWW  G:4)W5^GXC/*&<86&4^(&!G
M.,=(8CE<:]/_ +>:_>1[WN]W[SL>7B<NPF,CHE)=GM\NJ?H>=?\ !*3_ ()?
M>.?V!/&WBGQA)^U$_CWP9KFA01^$K#3I)H;4[Y/.DN7MO-D@WE4B$<J,Q*R2
M<J#\WSCKW_!<O_@HO^R3X^O]-_;0_89D3P_-JLQTR:6RN-*G2!I&*1K=XFMK
MG8N%RBC<5.6YR.)AU'_@IU_P02\5+::C$?B-\$YKW"'=(^FX9OX6^:32K@Y^
MZ<Q.Q/\ KL9'Z2?L:_\ !0O]E#_@H?X&EA^'6N6[:I]D_P")_P"!?$,<8O;9
M3@-NB8E9X<D#S$W)R VUCM'Q/%'AAF619=#'9/B%7P-WRUJ?O1UZ58N[@UM9
MZ*]KWT.6.":HPH82HZ+C?3XD[^NZ[:E7_@GU_P %-/@=_P %&-#US4/A'X7\
M2Z3=^&5MO[=L]?L8T6%I_,\L1RQ2.D@/E2?W6P,E1FO=?!7Q \!_$G0D\4_#
MKQMI&OZ9*<1:CHNI174#_22)F4_G7*>'OV6O@7X \(^+/!_P?^'NF>!8O&EO
M*FM7/@W3X;&0RO"T0N$"H8UE4,2I*$;N2#DY^$O@;_P06U_]C?\ :>T'X]?!
MS]I_4]1\)Z7/-+K7AR]ADL[R>+R)5C0RVS^7<J)6C9D=(U*JPYZ'X&K7S#"4
M8N4%4WYFG;TLO3<Z*N(S7!4(.5-57KS-/EMV:3WTW/T;_P"$U\*_;/L/]M0^
M9G'?;G_>QM_6M,LH7>6  &22>,5XI7Q=^U3_ ,$9_P!LS]M;X_\ B#QIKO[9
MDN@?#75)+=]!\.WVIZCJ<EG']GB6519L\<$2&42LJK)C:PS@Y \_#9UBZ[<8
MT>9^3M][9YV&S_'8AN,*'.^B3M][9^B?C?XW?"7X=?#;5_C!XO\ 'VG6WAG0
M8W?5]8BF\^*U"L%;=Y08Y!(! !(STKXQ^+/_  <=?\$\/ /FP>!9_&'C>=<B
M)]#\/&V@8_[3WK0L![A&^E>O?LA_\$R/AW^S+^QGXD_8H\6^/]1\;^'/%<]\
MVJSWEJMFRQW=O'#+%"(V8Q@>674[BP=R<]*TOA-_P2<_X)S_  6\J3P9^R5X
M3GGBP4NO$-JVK2AA_$&O6E*G/.5QCMBO1J_VK5C'V?+"ZUO=M/RMHSTJW]MU
MHP]CR4[KWKWDT^RMHT<=X3_X*,_$;]IK_@FMXF_;,_9%^#?VGQCILMS!I?@O
M4XI=2:2:"Z170I:F.25VMF\U40@[F5?F Y^./[:_X.8?VLO^/+2KCX<Z1<_>
M'V?3]#\G/_74M?#\,_G7Z[:+H6B>&M-BT7P[HUKI]G ,0VEE;K%%&/154 #\
M!5JBK@*N(4?:5I*RL^7W;ON%?*Z^+4/:XB:LK/E?*I/OUW['R#HW_!/OXW_'
M+_@E^/V(?VU/C1'J?B^[F,E[XWLKN?59EV:G]MA8R70B>614 @.> HX) Y\W
M^$W_  ;:?L">!_*N?B+JWC3QM.,>=%J6MK9VSG_92T2.11]93]:_0:BM99;@
MIN+J0YG%))O71&TLGRZHX2JTU)Q2BG+71;7Z,XOX9_LZ_!+X/_"#3_@%\/\
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MKP5X(^+?Q'UWPQ#X,UV?4(+SP];P/<3I-"(Y(-TRLJ E8VW;6Y0<5X/\)O\
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MUI3<(N7[INW+>WP7\E&RNR#KT9*,O>7?JO4_:+_A=_[+_P!L^W?V_#YF<_\
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M;/3Y87X]_P!*_:'Q9X/\)>/?#]QX3\<^%].UK2KO9]JTS5K*.YMYMKAUWQR
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M_P#DT?Q[_P!@%_\ T-:[KX7?\DS\._\ 8"M/_1*5PO[<_P#R:/X]_P"P"_\
MZ&M=U\+O^29^'?\ L!6G_HE* -VBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S_ !3X6T'QKH,_
MAGQ-8_:;&YV^?!YK)NVL''*$$?,H/![5H44FDU9@>!:G^Q;;WOBRXL[/7);/
M0YH':*[@<-=0,00$4.&4E3R&8$8'(/2OD?\ :"_X-R;?XS>/;_XI6/[:^NIK
MM\T3376M>$+68N8XTBCYM)+94PB(,JG;."2:_36BOI\BXNSOAG$O$95*%&;C
MRMQI4[N-T[-N#T;2;6S:3Z(Y%@J234FY7=]9-V]+O1'Y%_\ #EW_ (*[?!<^
M9^SW_P %!P]M#]RU3QKK&FF0=AY*I)$?HS8I?[(_X.;_ (%'_1-3?QA80_>_
M?Z%J7F8_ZZA;D_A7ZYT5];_Q%C.,1_R,,%A<3W=2A&_WQ<;,/J<%\,FO1GY&
M?\/=_P#@M+\%#Y7QU_8!^VVD/^LOG\ ZM:[\=?W\4CP'\%K7\)?\'/NC6=W_
M &5\7_V--4TR:([;A](\4K*X/_7&>WC*_0N:_5RL?Q;\/? /C^U^P^._ ^CZ
MW %QY.KZ9%<ICTQ(I%'^N7 F,_W[(()]Z5:I3MZ1U7WA[#$1^&I]ZN?#O@3_
M (.//^">_BK9'XFL?'GAESQ(VJ^'8YHU/L;6:5B/^ @^U>S^!/\ @K__ ,$U
MOB)L&A?M<>&K4OVUY;C3,'W-Y'$!^>*V?'?_  2[_P"">7Q'WMXE_8^\"QM)
MG?)I&BIISL?7=:>6<^^<UXQX[_X-Z/\ @FQXOWG0?!GBGPN6S@Z#XKF?;]/M
M@GHY_!S';QQF'EY.E4BOO]X/]MC_ "O[T?6O@7X\_ WXH[#\,_C/X3\1>9_J
M_P"PO$5M=[OIY3MFNLK\M_'7_!KY\&+XNWPQ_:J\4:2>L8UW0;;4,>F3$]M7
M*'_@A?\ \%//@V=_[-W_  4+6*.'_51+XEU?1BP';;!YR_@3BC_5+P\QO^YY
M\HO^6K0G'[YIN/X![;$Q^*G]S/USHK\BS\-/^#FCX%8/ASQ])XPM(?\ 6'^U
MM%U'>H_Z_E6<_P# ?FI?^'H__!=;X(_N_C%^PD=9M(O]??/\/-2'3_IO9RF%
M?^^31_Q"K'8G7+\RPF([*%=*7SC)*WWA];BOBC)?(_7.BOR;\._\'-^K^';X
M:'\;OV)+S3[E,>>^G>*&CD7_ +=[BU!'XR5Z[X%_X.3?V#/$I2#Q;X2^(/AR
M0X\R2[T2WN(5^C07#N1_P 5PXSPF\0L&N:6 E)=X.$[_ /@$F_P*CC,-+[1^
M@]%?+_@3_@LY_P $S?B#L32?VJ]'LI&P#'KNGWFG[#Z%KF%$_$,1[U[/X%_:
M=_9L^*&P?#7]H+P3X@,GW%T7Q5:73$^F(Y"<^U?)8WA[/\MO];PE6G;^:G*/
MYI&T:M.6TDSN:***\<L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?\:/L7C?_H-V7_@,?\:^MP7B;Q_@+>RS&J[?S/G_ /2U(QEA,-+>*/RD/_!
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M?@M'UGP=QW\3#XO#O^Y*G4BO7G]ZWH%L;'K%_>?2_@3]L']D[XG[!\._VF?
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M16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%
M8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C
M_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
M8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T
M&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\
M]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45Q
MGC[QY9?"GP[+XO\ B?\ %;PUX<TJ#_7:EKES':0)[%Y65<^V:^*_VB_^#@K]
MDCX--/I'PS\2WOQ(U2+*A?#VE&"Q5QV:YN-N1_M1)**][)>%^(>(JG)EN%G5
M\XQ?*O63]U?-HSJ5:5)>\['Z#U@?$CXK?##X.^')/%_Q9^(FB>&=*BSOU#7M
M4BM(<^@>5@"?8<FOR5M_^"BO_!;C_@H,#I_[('P&E\'^';LE8]=T_2D52AZY
MU*_"PD@<YA5'].<5O>!/^#>']HGXX^($^(W[>O[8-WJ>I38-Q::7>3ZE=E3S
ML-Y>#$9'3:L;KZ' K[C_ (ASEF2>]Q+FE+#M;TJ?[ZMZ.,=(^K;1S_6IU/X4
M&_-Z(]R_:._X.)?V'OA!Y^D_"*WUOXE:I%E4.D6YLM/WCLUS<*&(_P!J.*13
MZU\Z']OG_@N)_P %$3]C_9+^!,O@/PO><1:WIVG"%&B/4G4M0PCD#G-NJ/TP
M.>?N']G3_@DK^Q_^S 8-0^'OP8\.WVK08*Z]XGM&U.\#C^-&N"RPM[Q*GZFO
MHH6/C8# UJR '0"U/^-/_6K@#A_3),K]O46U7%/F_P#*4;0\T[IA['$U/XD[
M>2_S/RX^%_\ P;I_%?XN^(E^)'[?W[7NJ:SJ=Q@WEGH-U+?74@ZX:_O@<$=,
M"%AZ-7V_^SE_P2W_ &$_V6_(OOAA^SYHTNK6^"NO^((SJ-\''\:R7&[R6_ZY
M!![5[3]B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-?.YYXB<8<00]EB<5*-+;
MV<+4X)=N6%KK_%<UIX:A3=TM?O-BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E
M_P" Q_QKXHW-BBL?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -BBL?[%XW
M_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -BBL?[%XW_P"@W9?^ Q_QJUI4&OPR
M.=8OX)E*_((HMI!H O4444 %%%% !1110 4444 %,AMX+<%;>!(PS%F"*!DG
MJ>.]/HH 8MO DS7"0()' WN%&6QTR>]/HHH **** /*/VY_^31_'O_8!?_T-
M:[KX7?\ ),_#O_8"M/\ T2E<+^W/_P FC^/?^P"__H:UW7PN_P"29^'?^P%:
M?^B4H W:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** ([RSM-0MGLK^UCGAE7;)
M#,@97'H0>"*\W^)/[-?@G6]!?_A7_AK3=$OXF:6--/LTMXKECU$BH -Q_O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH " 1@C(/4&O./B-^QY^R?\7?,?XG?LU^!==ED^]<ZEX5M))@
M?42F/>I]P0:]'HKHPV+Q6#J<^'J2A+O%M/[T)Q4MT?'OQ&_X(0?\$S?B#YDU
MK\#;KP[<R=;GPYXCO(<?2.21XA^"5X)\1O\ @V"_9[U7S'^$_P"TMXPT-FR4
M77M,M=353Z?NOLQ(_'/O7Z>T5]CE_B7Q[EEO8YC5=OYI>T7W3YC"6%P\]XH_
M(O\ X<D_\%5O@*?,_9@_X* *UM ?W=FGBG5=(,@'0>2@EB/T9L4G]O?\',O[
M.G_'_HTOCC38/NC[-H^J^9C_ *XE;L_C^'>OUUHKVO\ B+&;8K3,\%A<5W=2
MC'F^3CRV?R(^IP7P2:]&?D6/^"]?_!1/X$GR_P!JS_@GVEND/$TK:3JF@E@.
M^ZY6=?Q QZ5Z/\.?^#G']EG6O+A^*/P$\<>'Y'X9]*EM-1A0^I9I('Q]$)]J
M_2T@$8(R#U!KSCXC?L>?LG_%WS'^)W[-?@7799/O7.I>%;228'U$ICWJ?<$&
MC_6GPXS#_?<C=-_S4:\E]T)+E_$/8XJ/PU+^J/$_AS_P7!_X)F?$?RX(OVC(
MM%N7QFU\1Z)>6>S/K*T7D_D]>]_#G]IO]G#XO^6/A3\?/!GB1I/N1Z'XGM;I
M\^FV.0D'V(S7SK\1O^"$'_!,WX@^9-:_ VZ\.W,G6Y\.>([R''TCDD>(?@E>
M"?$;_@V"_9[U7S'^$_[2WC#0V;)1=>TRUU-5/I^Z^S$C\<^]']G>$.8_P<;B
M<*W_ ,_:<:B7_@MIV_$.;&QWBGZ.WYGZ>T5^1?\ PY)_X*K? 4^9^S!_P4 5
MK: _N[-/%.JZ09 .@\E!+$?HS8I/[>_X.9?V=/\ C_T:7QQIL'W1]FT?5?,Q
M_P!<2MV?Q_#O1_Q#G*<;_P BS/,+4[*I*5&3]%)/7RN'UF<?CIM>FI^NM%?D
M6/\ @O7_ ,%$_@2?+_:L_P""?:6Z0\32MI.J:"6 [[KE9U_$#'I7H_PY_P"#
MG']EG6O+A^*/P$\<>'Y'X9]*EM-1A0^I9I('Q]$)]JY\3X1<>T:?M*.&5:'\
MU.<)I^B4N;\!K&8=NS=O4_2VBODSX<_\%P?^"9GQ'\N"+]HR+1;E\9M?$>B7
MEGLSZRM%Y/Y/7O?PY_:;_9P^+_ECX4_'SP9XD:3[D>A^)[6Z?/IMCD)!]B,U
M\=F'#?$.57^NX2K3M_-"45][5C:-6G/X9)G<4451UKQ)H/AW[/\ V[JT%K]J
MG$-OYSXWN>@'^<5X\82G+EBKLJ4HPC>3LB]1537O$&@^%M(G\0>)];M-.L+6
M/?=7U_<K##"O]YG<A5'N37R%^T=_P79_X)[_   \_3-'^)-QX^U>'(&G^!K8
M746[MFZ=DMRN>I21R!_">,^KE'#^=Y_6]EEV'G5?]V+:7J]EZMH4ZE.FKR=C
M[(JAXE\4>&?!>B3^)?&/B*PTG3;5-]UJ&IW:000KZM(Y"J/<FOR2U;_@LS_P
M5"_;>U*?PI_P3[_9-ET:Q>0Q?VW#IS:K/ >@+W4ZI909ZXD0X_O'&3/X:_X(
M8?M_?M>:W!XZ_P""AO[7]Q;*7\Q=(34)-9NX,]8U!9+6U[_ZHR*/[M??KPRI
M90N?B7,:6$_Z=I^UK?\ @$-O6[.;ZTY_PHN7X(^H_P!HW_@O5_P3[^ WGZ7X
M9\=WGQ"U>+*BR\%VHFMPW;==R%("OO&TA'H:^4]0_P""OG_!6#]NR^F\.?L"
M?LJR>']+ED,2ZY:Z=_:,L)Z8>^NU2RA/LR CLW&:^R_V<?\ @B;_ ,$]?V<_
M(U&W^#B^,=7@P?[7\=S#4&+#N("JVRD'D$1;AZ\5]6Z?I]AI-C%IFE6,-M;0
M1A(+>WB")&HX"JHX 'H*?^L/AOP]IE672Q=1?\O,5+W;^5*&C7^*S#V>*J?'
M+E79?YGY)^$O^"#/[;G[56O0?$#_ (*&_MAW0D)W_P!EV]_+K-Y$#UB5Y66W
MMO\ MD)5'IZ?9/[./_!&'_@GO^S;Y&H:1\$H/%6KP8(UKQS(-2E+#HPB=1;H
MP/(9(E(/?@5]4T5XF<^)7&.<TO82Q+I4=E3I)4X)=K1LVO*39I#"T*;O:[[O
M4CM+2UL+6.QL;:.&&% D4,2!510,!0!P !V%2445\&VV[LZ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH \H_;G_Y-'\>_P#8!?\ ]#6NZ^%W_),_#O\ V K3_P!$I7"_
MMS_\FC^/?^P"_P#Z&M=U\+O^29^'?^P%:?\ HE* -VBBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ (!&",@]0:\X^(W['G[)_Q=\Q_B=^S7X%UV63[USJ7
MA6TDF!]1*8]ZGW!!KT>BNC#8O%8.ISX>I*$N\6T_O0G%2W1\>_$;_@A!_P $
MS?B#YDUK\#;KP[<R=;GPYXCO(<?2.21XA^"5X)\1O^#8+]GO5?,?X3_M+>,-
M#9LE%U[3+74U4^G[K[,2/QS[U^GM%?8Y?XE\>Y9;V.8U7;^:7M%]T^8PEA</
M/>*/R+_X<D_\%5O@*?,_9@_X* *UM ?W=FGBG5=(,@'0>2@EB/T9L5].P^&?
MC;X/\)Z#X<^/>M:WJ.NVNEHES?:[?17,LS_QMYD/[M@6S]W'&,C.:^UZHZUX
M;T'Q%]G_ +=TF"Z^RSB:W\Y,[''0C_.*[\3XEYOFLX/,J=.;C?WHTXPF[KJX
MI)KRL>7F>2K&X?V=.;C\[KYK\C\Y/VB_^",_Q>_;P^)FE_$/Q]^TSK_A[PH+
M-/,T/5+NXU-U=0 &M+>218[1&3J=Q^;)\O!^;VS]G'_@AU_P3U_9Y\C4I_A.
MWCC5X<'^U/'<XOE+>UL%6V STS$6']XU]>T5Y^-\1>+\9@8X*&*E2H15E"G[
MBMYN-I2^;?H=^&P%'#4XQ^)KJ]65])TC2M!TV'1M"TRWLK.VC$=O:6D*QQ1(
M.BJJ@!1[ 58HHKXAMR=WN=H4444@"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /*/VY_\ DT?Q[_V 7_\ 0UKNOA=_R3/P[_V K3_T2E<+^W/_ ,FC^/?^
MP"__ *&M=U\+O^29^'?^P%:?^B4H W:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /*/VY_P#DT?Q[_P!@%_\ T-:[KX7?\DS\._\ 8"M/_1*5
MPO[<_P#R:/X]_P"P"_\ Z&M=U\+O^29^'?\ L!6G_HE* -VBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#RC]N?_DT?Q[_ -@%_P#T-:[KX7?\
MDS\._P#8"M/_ $2E<+^W/_R:/X]_[ +_ /H:UW7PN_Y)GX=_[ 5I_P"B4H W
M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*/VY_^31_'O_8!
M?_T-:[KX7?\ ),_#O_8"M/\ T2E<+^W/_P FC^/?^P"__H:UW7PN_P"29^'?
M^P%:?^B4H W:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*/V
MY_\ DT?Q[_V 7_\ 0UKNOA=_R3/P[_V K3_T2E<+^W/_ ,FC^/?^P"__ *&M
M=U\+O^29^'?^P%:?^B4H W:*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N9^-/C*_
M^'7P<\6_$'2HEDNM"\,W^HVR.N0TD-O)(H([C*BNFJIKVAZ7XFT.]\-ZY9K<
M66H6DEM>6[])8I%*NIQV*DC\: /A.\^#_AGX*_LM?!7]LKPC<7W_  LJ_P!>
M\(WWBOQ5)J4TEUXA35IH$OK:Y)8B6)Q=-M0C";$VXQ7WO7S7X'_83^(^EZ=X
M&^%WQ%_:+3Q#\.?AOK%IJ'ACP^GA5;:_N#9DFPAO;P7#)/';G80$AC\PQ(6Z
M8/TI0 5QGQF^)OB_X9:997_A#X.ZUXQDNIVCFMM%DC5K=0N0[;R.">.*[.B@
M#Y*_:J_:/^*OBS]G?Q;X<U_]DOQCH5G>:4T=QJ][/;M%:KN7YV"MDCZ>M=/X
M(_:K^,^F>#-(TVR_8K\;7D-OI=O%%>0W$(2=5C4"1<]F R/K7;_MS_\ )H_C
MW_L O_Z&M=U\+O\ DF?AW_L!6G_HE* /(O\ AKGXX?\ 1C/CO_P)@H_X:Y^.
M'_1C/CO_ ,"8*]ZHH \%_P"&N?CA_P!&,^.__ F"C_AKGXX?]&,^._\ P)@K
MWJB@#P7_ (:Y^.'_ $8SX[_\"8*/^&N?CA_T8SX[_P# F"O>J* /!?\ AKGX
MX?\ 1C/CO_P)@H_X:Y^.'_1C/CO_ ,"8*]ZHH \%_P"&N?CA_P!&,^.__ F"
MC_AKGXX?]&,^._\ P)@KWJB@#P7_ (:Y^.'_ $8SX[_\"8*/^&N?CA_T8SX[
M_P# F"O>J* /!?\ AKGXX?\ 1C/CO_P)@H_X:Y^.'_1C/CO_ ,"8*]ZHH \%
M_P"&N?CA_P!&,^.__ F"C_AKGXX?]&,^._\ P)@KWJB@#P7_ (:Y^.'_ $8S
MX[_\"8*/^&N?CA_T8SX[_P# F"O>J* /!?\ AKGXX?\ 1C/CO_P)@H_X:Y^.
M'_1C/CO_ ,"8*]ZHH \%_P"&N?CA_P!&,^.__ F"C_AKGXX?]&,^._\ P)@K
MWJB@#P7_ (:Y^.'_ $8SX[_\"8*/^&N?CA_T8SX[_P# F"O>J* /!?\ AKGX
MX?\ 1C/CO_P)@H_X:Y^.'_1C/CO_ ,"8*]ZHH ^;/$O[>?Q,\)ZOI&B:Y^QE
MXOM;G7+PVNFPW.H0J]Q*%W%(P%.YL<X)'UK9_P"&N?CA_P!&,^.__ F"IOVL
M/^2V? __ +'N7_TF:O=* /!?^&N?CA_T8SX[_P# F"C_ (:Y^.'_ $8SX[_\
M"8*]ZHH \%_X:Y^.'_1C/CO_ ,"8*/\ AKGXX?\ 1C/CO_P)@KWJB@#P7_AK
MGXX?]&,^._\ P)@H_P"&N?CA_P!&,^.__ F"O>J* /!?^&N?CA_T8SX[_P#
MF"C_ (:Y^.'_ $8SX[_\"8*]ZHH \%_X:Y^.'_1C/CO_ ,"8*/\ AKGXX?\
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MGXX?]&,^._\ P)@H_P"&N?CA_P!&,^.__ F"O>J* /!?^&N?CA_T8SX[_P#
MF"C_ (:Y^.'_ $8SX[_\"8*]ZHH ^;++]O/XF7_C:]^']K^QEXO?5-/LX[JZ
ML4U"$S112$A79=N IQP<GZ5L_P##7/QP_P"C&?'?_@3!4W@'_E()X_\ ^Q$T
MK_T8U>Z4 >"_\-<_'#_HQGQW_P"!,%'_  US\</^C&?'?_@3!7O5% '@O_#7
M/QP_Z,9\=_\ @3!1_P -<_'#_HQGQW_X$P5[U10!X+_PUS\</^C&?'?_ ($P
M4?\ #7/QP_Z,9\=_^!,%>]44 >"_\-<_'#_HQGQW_P"!,%'_  US\</^C&?'
M?_@3!7O5% '@O_#7/QP_Z,9\=_\ @3!1_P -<_'#_HQGQW_X$P5[U10!X+_P
MUS\</^C&?'?_ ($P4?\ #7/QP_Z,9\=_^!,%>]44 >"_\-<_'#_HQGQW_P"!
M,%'_  US\</^C&?'?_@3!7O5% '@O_#7/QP_Z,9\=_\ @3!1_P -<_'#_HQG
MQW_X$P5[U10!X+_PUS\</^C&?'?_ ($P4?\ #7/QP_Z,9\=_^!,%>]44 >"_
M\-<_'#_HQGQW_P"!,%'_  US\</^C&?'?_@3!7O5% '@O_#7/QP_Z,9\=_\
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M_AKGXX?]&,^._P#P)@KWJB@#P7_AKGXX?]&,^.__  )@H_X:Y^.'_1C/CO\
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MX:Y^.'_1C/CO_P "8*]ZHH \%_X:Y^.'_1C/CO\ \"8*/^&N?CA_T8SX[_\
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ML^>&?&'@+QQX=^'NMI>ZEIWCJ9_#SZHT5_97+VK1VD<DR(D;R12.3(7949%
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MW%T"=L(2*:%(8=H!:4F1LGA!MRP!Z317R=X-_;?^,7QP^ WP1F^'VB:'X?\
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M]FGAD>ZLF-N?(E>W98P6CZ>;AL'@ 'T!%%%!$L$$:HB*%1$& H'0 =A3J**
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M>'](\1W=I)J%[<W5W%/<W+):33)%$BV\<:@ON8LS8 Q7T!110 4444 %%%%
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M? 50B+GZ]HH ^&5^'7[17AK]D/Q/_P $X=*_9_\ $-SJ>H:CJFD:%XX46_\
M81T6^OY9Q?33F4/&\4$[J8 A<O&H .[(Z[]IRU^+GB[XNZ/\$-;_ &8?'OB;
MX/\ A&RLKR6'PO\ V:Z>+-0B5'A@NC=7D&VS@959H@&,LJ_,-B#=]<44 >#>
M*OV?/B7\;OB9X?\ VG/#GQ@\4_#'5H?"!TE?#-WH&E7\NGK+.9ICF43QQRR%
M8%<QDY6!!GJ*7_@G!\$_B[\ OV6-$^'OQFUV\EU2WEN2FD745H!I41N)2L2/
M;#$H8$2Y=F8&0KD !1[Q10 4444 %%%% !1110 4444 %%%% !1110 4444
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M?6WU.[T;0[2QNM1ESNNI(H4C:4YYRQ4MSZUN44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Nov. 19, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARROWHEAD PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-0408024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">304-3400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">177 E. Colorado Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARWR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,809,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:30.6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">Portions of the Definitive Proxy Statement to be filed for Arrowhead Pharmaceuticals, Inc.&#8217;s 2026 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 226,548<span></span>
</td>
<td class="nump">$ 102,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">6,824<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available-for-sale securities, at fair value</a></td>
<td class="nump">692,818<span></span>
</td>
<td class="nump">578,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">10,933<span></span>
</td>
<td class="nump">9,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">13,516<span></span>
</td>
<td class="nump">4,973<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">950,639<span></span>
</td>
<td class="nump">695,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">382,515<span></span>
</td>
<td class="nump">386,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">6,861<span></span>
</td>
<td class="nump">8,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">43,891<span></span>
</td>
<td class="nump">45,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,389<span></span>
</td>
<td class="nump">4,482<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">1,385,295<span></span>
</td>
<td class="nump">1,139,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">17,674<span></span>
</td>
<td class="nump">11,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">90,419<span></span>
</td>
<td class="nump">63,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and benefits</a></td>
<td class="nump">26,895<span></span>
</td>
<td class="nump">21,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">7,289<span></span>
</td>
<td class="nump">6,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">2,399<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Credit facility</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">10,811<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">195,487<span></span>
</td>
<td class="nump">103,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">104,112<span></span>
</td>
<td class="nump">111,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RoyaltiesLiabilityNoncurrent', window );">Liability related to the sale of future royalties</a></td>
<td class="nump">367,397<span></span>
</td>
<td class="nump">341,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Credit facility, net of current portion</a></td>
<td class="nump">214,883<span></span>
</td>
<td class="nump">393,183<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">686,392<span></span>
</td>
<td class="nump">845,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Noncontrolling interest and stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 135,702 and 124,376 shares at September 30, 2025 and 2024, respectively</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,139,725<span></span>
</td>
<td class="nump">1,806,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">6,443<span></span>
</td>
<td class="nump">4,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,627,154)<span></span>
</td>
<td class="num">(1,625,523)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock; at cost; 2,661 and 0 shares of common stock at September 30, 2025 and 2024, respectively</a></td>
<td class="num">(53,193)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Arrowhead Pharmaceuticals, Inc. stockholders' equity</a></td>
<td class="nump">466,052<span></span>
</td>
<td class="nump">185,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">37,364<span></span>
</td>
<td class="nump">5,619<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total noncontrolling interest and stockholders' equity</a></td>
<td class="nump">503,416<span></span>
</td>
<td class="nump">191,063<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities, Noncontrolling Interest and Stockholders' Equity</a></td>
<td class="nump">1,385,295<span></span>
</td>
<td class="nump">1,139,802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember', window );">Consolidated Entity Excluding Variable Interest Entities (VIE)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">88,706<span></span>
</td>
<td class="nump">76,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 137,842<span></span>
</td>
<td class="nump">$ 26,477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RoyaltiesLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RoyaltiesLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481573/470-10-45-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481573/470-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">290,000<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">135,702<span></span>
</td>
<td class="nump">124,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">135,702<span></span>
</td>
<td class="nump">124,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">2,661<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 829,448<span></span>
</td>
<td class="nump">$ 3,551<span></span>
</td>
<td class="nump">$ 240,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">607,159<span></span>
</td>
<td class="nump">505,870<span></span>
</td>
<td class="nump">353,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">123,943<span></span>
</td>
<td class="nump">98,761<span></span>
</td>
<td class="nump">92,549<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">731,102<span></span>
</td>
<td class="nump">604,631<span></span>
</td>
<td class="nump">445,737<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">98,346<span></span>
</td>
<td class="num">(601,080)<span></span>
</td>
<td class="num">(205,002)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest income</a></td>
<td class="nump">37,289<span></span>
</td>
<td class="nump">22,720<span></span>
</td>
<td class="nump">15,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(89,361)<span></span>
</td>
<td class="num">(32,352)<span></span>
</td>
<td class="num">(18,326)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">5,259<span></span>
</td>
<td class="num">(1,748)<span></span>
</td>
<td class="nump">1,538<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(46,813)<span></span>
</td>
<td class="num">(11,380)<span></span>
</td>
<td class="num">(1,489)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income tax expense and noncontrolling interest</a></td>
<td class="nump">51,533<span></span>
</td>
<td class="num">(612,460)<span></span>
</td>
<td class="num">(206,491)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">21,419<span></span>
</td>
<td class="num">(2,767)<span></span>
</td>
<td class="nump">2,784<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss) including noncontrolling interest</a></td>
<td class="nump">30,114<span></span>
</td>
<td class="num">(609,693)<span></span>
</td>
<td class="num">(209,275)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interest, net of tax</a></td>
<td class="nump">31,745<span></span>
</td>
<td class="num">(10,200)<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</a></td>
<td class="num">$ (1,631)<span></span>
</td>
<td class="num">$ (599,493)<span></span>
</td>
<td class="num">$ (205,275)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Net loss per share attributable to Arrowhead Pharmaceuticals, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (5.00)<span></span>
</td>
<td class="num">$ (1.92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (5.00)<span></span>
</td>
<td class="num">$ (1.92)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average shares used in calculating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">133,758<span></span>
</td>
<td class="nump">119,784<span></span>
</td>
<td class="nump">106,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">133,758<span></span>
</td>
<td class="nump">119,784<span></span>
</td>
<td class="nump">106,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive loss, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on available-for-sale securities</a></td>
<td class="nump">$ 2,125<span></span>
</td>
<td class="nump">$ 3,775<span></span>
</td>
<td class="num">$ (2,964)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(432)<span></span>
</td>
<td class="nump">4,197<span></span>
</td>
<td class="num">(122)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributed to noncontrolling interest</a></td>
<td class="nump">31,745<span></span>
</td>
<td class="num">(10,200)<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Other comprehensive income (loss)</a></td>
<td class="nump">$ 31,807<span></span>
</td>
<td class="num">$ (601,721)<span></span>
</td>
<td class="num">$ (212,361)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Common Stock in Treasury</div></th>
<th class="th"><div>Non- controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Sep. 30, 2022</a></td>
<td class="nump">$ 418,339<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">$ 1,219,213<span></span>
</td>
<td class="num">$ (136)<span></span>
</td>
<td class="num">$ (820,755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">78,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">3,054<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">913,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on available-for-sale securities</a></td>
<td class="num">(2,964)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,964)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(209,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(205,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">287,162<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">1,300,395<span></span>
</td>
<td class="num">(3,222)<span></span>
</td>
<td class="num">(1,026,030)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">73,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,048,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued</a></td>
<td class="nump">429,265<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">429,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on available-for-sale securities</a></td>
<td class="nump">3,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">4,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">$ (609,693)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(599,493)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,200)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="nump">124,376,000<span></span>
</td>
<td class="nump">124,376,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">$ 191,063<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">1,806,000<span></span>
</td>
<td class="nump">4,750<span></span>
</td>
<td class="num">(1,625,523)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,619<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 63,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">535,140<span></span>
</td>
<td class="nump">535,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 3,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,526,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,926,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued</a></td>
<td class="nump">241,388<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">241,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Common stock - repurchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,661,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Common stock - repurchase</a></td>
<td class="num">(53,193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (53,193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on available-for-sale securities</a></td>
<td class="nump">2,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="nump">$ 30,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,745<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Sep. 30, 2025</a></td>
<td class="nump">135,702,000<span></span>
</td>
<td class="nump">138,363,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2025</a></td>
<td class="nump">$ 503,416<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
<td class="nump">$ 2,139,725<span></span>
</td>
<td class="nump">$ 6,443<span></span>
</td>
<td class="num">$ (1,627,154)<span></span>
</td>
<td class="num">$ (53,193)<span></span>
</td>
<td class="nump">$ 37,364<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, ending balance (in shares) at Sep. 30, 2025</a></td>
<td class="num">(2,661,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,661,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 30,114<span></span>
</td>
<td class="num">$ (609,693)<span></span>
</td>
<td class="num">$ (209,275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">63,366<span></span>
</td>
<td class="nump">73,968<span></span>
</td>
<td class="nump">78,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">23,928<span></span>
</td>
<td class="nump">18,595<span></span>
</td>
<td class="nump">12,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Accretion of note premiums/discounts</a></td>
<td class="num">(5,789)<span></span>
</td>
<td class="num">(3,244)<span></span>
</td>
<td class="num">(2,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expense on liability related to the sale of future royalties</a></td>
<td class="nump">26,036<span></span>
</td>
<td class="nump">23,035<span></span>
</td>
<td class="nump">18,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense on credit facility</a></td>
<td class="nump">63,325<span></span>
</td>
<td class="nump">9,317<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_GainLossOnTreasuryStockSettlement', window );">Non-cash gain on treasury stock received</a></td>
<td class="num">(3,193)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized loss on investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(56,967)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(9,939)<span></span>
</td>
<td class="num">(1,664)<span></span>
</td>
<td class="nump">11,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">6,286<span></span>
</td>
<td class="num">(5,536)<span></span>
</td>
<td class="nump">32,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">41,497<span></span>
</td>
<td class="nump">32,117<span></span>
</td>
<td class="num">(14,965)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">2,399<span></span>
</td>
<td class="num">(866)<span></span>
</td>
<td class="num">(129,183)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease, net</a></td>
<td class="num">(4,605)<span></span>
</td>
<td class="nump">2,240<span></span>
</td>
<td class="nump">46,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other</a></td>
<td class="nump">3,094<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">179,552<span></span>
</td>
<td class="num">(462,851)<span></span>
</td>
<td class="num">(153,890)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(22,666)<span></span>
</td>
<td class="num">(141,469)<span></span>
</td>
<td class="num">(176,737)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(796,258)<span></span>
</td>
<td class="num">(720,947)<span></span>
</td>
<td class="num">(246,141)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sales and maturities of investments</a></td>
<td class="nump">689,630<span></span>
</td>
<td class="nump">442,344<span></span>
</td>
<td class="nump">326,723<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(129,294)<span></span>
</td>
<td class="num">(420,072)<span></span>
</td>
<td class="num">(96,155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercises of stock options</a></td>
<td class="nump">3,983<span></span>
</td>
<td class="nump">2,389<span></span>
</td>
<td class="nump">3,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net of offering costs</a></td>
<td class="nump">241,388<span></span>
</td>
<td class="nump">429,265<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ProceedsFromSaleOfFutureRoyalties', window );">Proceeds from the sale of future royalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from the issuance of warrants</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(3,134)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from credit facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">392,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayments of credit facility</a></td>
<td class="num">(201,625)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Visirna credit agreement</a></td>
<td class="nump">10,260<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">74,006<span></span>
</td>
<td class="nump">870,520<span></span>
</td>
<td class="nump">253,053<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">124,264<span></span>
</td>
<td class="num">(12,403)<span></span>
</td>
<td class="nump">3,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash, cash equivalents and restricted cash</a></td>
<td class="num">(401)<span></span>
</td>
<td class="nump">4,197<span></span>
</td>
<td class="num">(122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract', window );"><strong>CASH, CASH EQUIVALENTS AND RESTRICTED CASH:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BEGINNING OF PERIOD</a></td>
<td class="nump">102,685<span></span>
</td>
<td class="nump">110,891<span></span>
</td>
<td class="nump">108,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">END OF PERIOD</a></td>
<td class="nump">226,548<span></span>
</td>
<td class="nump">102,685<span></span>
</td>
<td class="nump">110,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosure of cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes (refund) paid</a></td>
<td class="nump">814<span></span>
</td>
<td class="num">(3,744)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable', window );">Treasury stock received to settle accounts receivable</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract', window );"><strong>Supplementary disclosure of non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures included in accrued expenses</a></td>
<td class="nump">$ 277<span></span>
</td>
<td class="nump">$ 4,206<span></span>
</td>
<td class="nump">$ 14,044<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Noncash Investing Activities Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_GainLossOnTreasuryStockSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Treasury Stock Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_GainLossOnTreasuryStockSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Interest Expense, Liability Related to Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ProceedsFromSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ProceedsFromSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock Received In Exchange For Settlement Of Accounts Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Significant Accounting Policies</a></td>
<td class="text">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#8220;Company&#8221;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#8217;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.962%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:27pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">plozasiran</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">zodasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">olpasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-PNPLA3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">GSK4532990</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">GSK</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-INHBE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-ALK7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-DIMERPA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-RAGE</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">SRP-1002 (ARO-MMP7)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">fazirsiran</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Takeda and Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">daplusiran/tomligisiran</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Neuromuscular</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">SRP-1001 (ARO-DUX4)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">SRP-1003 (ARO-DM1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">SRP-1004 (ARO-ATXN2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-SNCA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Pre-clinical</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Novartis</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-MAPT </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-C3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-CFB</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-style:italic;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Greater China rights for plozasiran are out-licensed to Sanofi.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in California and Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company also operates an active pharmaceutical ingredient manufacturing and supporting laboratory facility in Verona, Wisconsin. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity for which the Company is the primary beneficiary). Subsidiaries refer to Arrowhead Madison, Inc., Arrowhead Australia Pty Ltd., Arrowhead Pharmaceuticals Ireland Limited, Arrowhead Pharmaceuticals NZ Limited, and Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;). For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). All intercompany transactions and balances have been eliminated.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as a single segment as the chief operating decision maker, or CODM, reviews operating results on an aggregate basis and manages the operations as a single operating segment. Refer to Note 16, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, for further details on the segment information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s primary sources of financing have been through the sale of its equity securities, credit facility, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#8217;s pipeline of drug candidates and its headcount have both expanded. Additionally, significant investment will be required as the Company&#8217;s pipeline matures into later stage clinical trials and commercialization efforts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the Company had $226.5 million in cash, cash equivalents and restricted cash ($1.9 million in restricted cash) and $692.8 million in available-for-sale securities to fund operations. During the year ended September&#160;30, 2025, the Company&#8217;s cash, cash equivalents and restricted cash and investments balance increased by $238.4 million, which was primarily due to the $500.0 million as an upfront payment under the Sarepta agreement and $325.0 million in the form of an equity investment under the Sarepta agreement, $100.0 million relating to the achievement of partnership milestone achievement of which $50.0 million was settled in cash and the remaining $50.0 million was settled through the repurchase of Company's common stock , $37.3 million interest income earned on investments, and $25.0 million in the form of pre-funded warrants, partially offset by ongoing expenses related to the Company&#8217;s research and development programs, $201.6 million payments on its credit facility and $22.7 million relating to capital expenditure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company is eligible to receive up to $13.4 billion in additional developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, judgments and assumptions. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results could materially differ from those estimates. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid interest-bearing investments are classified as cash equivalents. These investments mainly include  term deposits, money market instruments, corporate debt securities, and certificate of deposits with maturities of three months or less when purchased. The carrying value of these cash equivalents approximate fair value. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There was $1.9 million and $3.5 million restricted cash at September&#160;30, 2025 and 2024, respectively, that is primarily held as collateral associated with letters of credit for the Company&#8217;s facility leases. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company classified all of its investments in debt securities as available-for-sale and as current assets as they represent the investment of funds available for current operations as of September&#160;30, 2025 and 2024. The available-for-sale investments may consist of investment-grade interest bearing instruments, primarily corporate debt securities, U.S. government and agency securities, commercial notes, certificate of deposits, and municipal securities, which are accounted for at fair value.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dividends from these funds were automatically re-invested. Changes in fair values are reported as unrealized gains or losses and are recorded in the Company&#8217;s consolidated statement of operations and comprehensive income (loss).</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its investments for impairment based on a security-specific analysis as of each balance sheet date. If the fair value of a security is below its amortized cost, the Company first assesses whether it intends to sell the security or is more likely than not required to sell it before recovery of its amortized cost. If neither condition is met, the Company evaluates whether a portion of the decline is attributable to credit loss. Any credit-related impairment is recorded as an allowance for credit losses through earnings, with non-credit-related unrealized losses recorded in other </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">comprehensive income (loss). The Company did not recognize any credit loss relating to its investment for the years ended September&#160;30, 2025, 2024, and 2023. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentration of credit risk primarily consist of cash, cash equivalents and restricted cash and investments. As of September&#160;30, 2025 and 2024, the Company&#8217;s investments were primarily invested in money market funds, U.S. Government, commercial paper, and corporate debt securities and term deposit through highly rated financial institutions. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity. The Company also maintains several bank accounts at two financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Visirna maintains several deposit and term accounts in mainland China, Hong Kong, and Singapore. Cash balances are held with various local and international financial institutions, which are subject to their respective jurisdictional deposit insurance programs. The Deposit Insurance Fund Management Corporation in China provides coverage of up to RMB 500,000 per depositor per institution, and the Hong Kong Deposit Protection Scheme provides protection of up to HKD 800,000 per depositor per bank, and the Singapore Deposit Insurance Corporation provides coverage of up to SGD 100,000 per depositor per member bank.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property, Plant and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at cost, net of accumulated depreciation. Depreciation expense is recorded on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the asset life or lease term. Construction in progress reflects amounts incurred for construction or improvements of property, plant and equipment that have not been placed in service. Upon disposition, the cost and accumulated depreciation of assets retired or sold are removed from the respective asset category, and any gain or loss is recognized in the Company&#8217;s consolidated statement of operations and comprehensive income (loss).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The estimated useful lives of property, plant and equipment are as follows (in years):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Buildings</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">39</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7 to 10</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Shorter of asset life or lease term</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically assesses long-lived assets or asset groups, including property, plant and equipment, for recoverability when events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the Company identifies an indicator of impairment, the Company assesses recoverability by comparing the carrying amount of the asset to the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset. An impairment loss is recognized when the carrying amount is not recoverable and is measured as the excess of carrying value over fair value. There were no impairment charges during the years ended September&#160;30, 2025, 2024, and 2023. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intangible Assets Subject to Amortization</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include certain patents and license agreements. The Company evaluates intangible assets for impairment annually or whenever events or changes in circumstances indicate that it is more likely than not that the carrying amount of intangible assets may exceed their implied fair values. No impairment charges were recorded during the years ended September&#160;30, 2025, 2024, and 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether a contract is, or contains, a lease at inception. All of the Company&#8217;s leases are classified as operating leases. Leases with terms greater than one-year are recognized on the Company&#8217;s consolidated balance sheets as right-of-use assets that represent the Company&#8217;s right to use an underlying asset for the lease term, and lease liabilities that represent its obligation to make lease payments arising from the lease. Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the expected lease term. As of September&#160;30, 2025 and 2024, the Company is not reasonably certain that it will exercise renewal options for any lease facilities. Therefore, these options are not included in the right-of-use assets and liabilities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Accruals</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues liabilities for products received or services incurred, particularly for ongoing clinical trials, where service providers have not yet billed or where billing terms do not align with the timing of the work performed as of the period-end. These costs mainly include third-party clinical management or clinical research organization (CRO), laboratory analysis, and investigator fees. Accrual estimates may be based on vendor communications to obtain pending invoices and/or estimates for services performed during the period. In some cases, these estimates require significant judgment, drawing on an understanding of research and development programs, services provided during the period, prior experience, and, where applicable, the expected duration of third-party contracts. Actual costs upon settlement may differ significantly from the accrued amounts in the Company&#8217;s consolidated financial statements, though historical estimates have not differed materially from actual costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that it determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing. If the license is not considered to be distinct from other performance obligations, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time. If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Typically, the Company&#8217;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a New Drug Application (&#8220;NDA&#8221;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#8217;s consolidated statements of operations and comprehensive income (loss). Typically, milestone payments and royalties are achieved after the Company&#8217;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or preclinical program. Milestones or royalties achieved after the Company&#8217;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its licensing or collaboration agreements. Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment. Additionally, future royalty payments are not substantially within the control of the Company or the customer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, the revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using the input method; Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations. If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#8217;s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of Financial Accounting Standards Board (&#8220;FASB&#8221;) Topic 808 - </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606 - </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue for Contracts from Customers</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to research and development expense or general and administrative expense, as appropriate. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred. Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#8217;s research and development operations, and costs to acquire technology licenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense for all stock grants are based on their estimated grant-date fair value. The fair value of stock option awards is estimated using the Black-Scholes option valuation model which requires the input of subjective assumptions to calculate the value of stock options. The Company uses historical data and other information to estimate the expected price volatility and the expected forfeiture rate for stock option awards. For restricted stock units, the value of the award is based on the Company&#8217;s stock price at the grant date. For performance-based restricted stock unit awards, the value of the award is based on the Company&#8217;s stock price at the grant date, with consideration given to the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">probability of the performance condition being achieved. Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#8217;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting basis and the respective tax basis of the Company&#8217;s assets and liabilities, and expected benefits of utilizing net operating loss, capital loss, and tax-credit carryforwards. The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent management does not believe these assets are more likely than not to be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or laws is recognized in earnings in the period that includes the enactment date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Variable Interest Entity (&#8220;VIE&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is an entity that, by design, either (i) lacks sufficient equity to permit the entity to finance its activities without additional subordinated financial support from other parties; or (ii) has equity investors that do not have the ability to make significant decisions relating to the entity&#8217;s operations through voting rights, or do not have the obligation to absorb the expected losses, or do not have the right to receive the residual returns of the entity. The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. The primary beneficiary is the party that has both (i) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance, and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE through its interest in the VIE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, the Company entered into a license agreement with Visirna (Note 2) and consolidated Visirna&#8217;s financial statements in which the Company has a direct controlling financial interest based on the VIE model. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all the facts and circumstances, including its role in establishing Visirna and its ongoing rights and responsibilities to assess whether the Company has the power to direct the activities of Visirna. In general, the parties that make the most significant decisions affecting a VIE and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company also considers all of its economic interests to assess whether the Company has the obligation to absorb losses of Visirna or the right to receive benefits from it that could potentially be significant to Visirna. This assessment requires the Company to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to Visirna. Factors considered in assessing the significance include: the design of  Visirna, including its capitalization structure, subordination of interests, payment priority, and the reasons why the interests are held by the Company. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At Visirna&#8217;s inception, the Company determined it was the primary beneficiary and that Visirna should be consolidated based on the facts and circumstances. The Company performs ongoing reassessments of the VIE based on reconsideration events and reevaluates whether a change to the consolidation conclusion is required. As of September&#160;30, 2025, there were no events to be reconsidered in the consolidation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Loss per Share</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units outstanding. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended September&#160;30, 2025, 2024 and 2023, the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units outstanding during the period due to their anti-dilutive effect. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Currency Translation Adjustments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Three of the Company&#8217;s wholly-owned subsidiaries&#8217; functional currencies is not the United States dollar, which is the Company&#8217;s reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Translation adjustments arising from the use of different exchange rates from period to period are included in the accumulated other comprehensive income (loss). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Segment Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as a single segment because its CODM reviews operating results on an aggregate basis and manages its operations as a single operating segment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in November 2024, and ASU 2025-01,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Clarifying the Effective Date</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. These updates require entities to provide disaggregated disclosures of income statement expenses. The ASUs do not affect the expense captions presented on the face of the income statement but instead require the disaggregation of certain expense captions into specified categories within the footnotes to the financial statements. The ASUs will become effective for the Company beginning October 1, 2027, and the Company is currently evaluating the impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standard Update (&#8220;ASU&#8221;) 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to improve its income tax disclosure requirements. Under the guidance, entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. This guidance became effective for the Company beginning on October 1, 2025. The Company does not expect any material impact on its consolidated financial statements and related disclosures resulting from applying this ASU. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses. The guidance requires public companies with a single reportable segment to provide all disclosures required under ASC 280. In addition, the guidance requires public companies to include in interim reports all disclosures related to a reportable segment&#8217;s profit or loss and assets that are currently required in annual reports. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. This ASU is applicable to the Company&#8217;s Annual Report on Form 10-K for the year ending September 30, 2025, and subsequent interim periods. Refer to Note 16, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, for further details on segment information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. ASC 740, "Income Taxes", requires the effects of changes in tax rates and laws to be recognized in the period in which the legislation is enacted. The Company has implemented OBBBA in the fourth quarter of fiscal 2025. Refer to Note 11, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, for further details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">COLLABORATION AND LICENSE AGREEMENTS<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of revenue recognized:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">GSK</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">29,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Horizon</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">23,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">162,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Sarepta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">696,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">130,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">829,448&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">240,735&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of receivables and contract liabilities related to the Company&#8217;s collaboration and license agreements:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Receivables included in accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">6,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities included in deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GlaxoSmithKline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;)</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">           </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">GSK-HSD License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#8220;GSK-HSD License Agreement&#8221;). Under the GSK-HSD License Agreement, GSK has received an exclusive license for GSK-4532990 (formerly ARO-HSD). The exclusive license is worldwide with the exception of greater China. GSK is wholly responsible for all clinical development and commercialization of GSK-4532990 in its territory. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has completed its performance obligation related to this agreement, and the upfront payment of $120.0&#160;million was fully recognized in the year ended September 30, 2022. Further, GSK dosed the first patient in a Phase 2b trial in March 2023 and paid a $30.0&#160;million milestone payment to the Company in the third quarter of fiscal 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is eligible for an additional payment of $100.0&#160;million upon achieving the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $190.0&#160;million at first commercial sale, and up to $590.0&#160;million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">           </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">GSK-HBV Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">           On December 11, 2023, the Company entered into an Amended and Restated License Agreement with GSK (the &#8220;GSK-HBV Agreement&#8221;) pursuant to which GSK received a worldwide, exclusive license to develop and commercialize daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989), the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">           Under the terms of the GSK-HBV Agreement, the Company received $2.7&#160;million in December 2023, upon signing the amended GSK-HBV Agreement. Further, GSK dosed the fifth patient in a Phase 2 trial in December 2024, triggering a $2.5&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2025. The Company is eligible to receive up to $830.0&#160;million in development and sales milestone payments under the GSK-HBV Agreement. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">           There were no contract assets and liabilities recorded as of September&#160;30, 2025.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, Horizon and the Company entered into a collaboration and license agreement (the &#8220;Horizon License Agreement&#8221;). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for HZN-457, a clinical-stage medicine being developed by Horizon as a potential treatment for people with uncontrolled gout.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 6, 2023, Amgen completed its acquisition of Horizon and subsequently notified the Company of Amgen&#8217;s intent to terminate the HZN-457 license. Horizon exercised its right to terminate the Horizon License Agreement for convenience, which took effect on December 21, 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;). Under the Takeda License Agreement, Takeda and the Company will co-develop the Company&#8217;s fazirsiran program (formerly TAK-999 and ARO-AAT), the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, fazirsiran, if approved, will be co-commercialized under a 50/50 profit sharing structure. Outside the United States, Takeda received an exclusive license to commercialize fazirsiran and will lead the global commercialization strategy, while the Company will be eligible to receive tiered royalties of 20% to 25% on net sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the key deliverables included the license and certain research and development services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study, and to ensure certain manufacturing of fazirsiran drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Takeda is responsible for managing clinical development and commercialization outside the United States. Within the United States, the Company and Takeda are responsible in the co-development and co-commercialization efforts. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Takeda License Agreement, the Company received $300.0&#160;million as an upfront payment in January 2021 and an additional $40.0&#160;million upon Takeda&#8217;s initiation of a Phase 3 REDWOOD clinical study of fazirsiran in March 2023, and is eligible to receive up to $527.5&#160;million in additional potential development, regulatory and commercial milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the total $300.0&#160;million initial transaction price to its one distinct performance obligation for the fazirsiran license and the associated Takeda R&amp;D Services. The Company has substantially completed its performance obligation under the Takeda License Agreement by December 31, 2023. As such, all revenue has been fully recognized as of December 31, 2023. There were no further deferred revenue and contract liabilities as of September&#160;30, 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded $31.3&#160;million as accrued expenses as of September&#160;30, 2025 that was primarily driven by co-development and co-commercialization activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 7, 2023, Janssen voluntarily terminated its collaboration agreement with the Company and the Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795. There are no currently active trials for ARO-PNPLA3.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, on December 11, 2023, the Company entered into the GSK-HBV Agreement, as discussed above, pursuant to which GSK received an exclusive license for JNJ-3989 (formerly ARO-HBV). JNJ-3989 had previously been licensed to Janssen in October 2018.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amgen Inc. (&#8220;Amgen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen received a worldwide, exclusive license to the Company&#8217;s novel RNAi olpasiran (previously referred to as AMG-890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the Olpasiran Agreement, Amgen is wholly responsible for clinical development and commercialization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has substantially completed its performance obligations under the Olpasiran Agreement. There were no contract assets and liabilities recorded as of September&#160;30, 2025. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;) and the Company entered into a Royalty Purchase Agreement with Royalty Pharma (the &#8220;Royalty Pharma Agreement&#8221;). In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional  $485.0 million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma. See Note 13.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sarepta Therapeutics, Inc.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 25, 2024, the Company entered into an Exclusive License and Collaboration Agreement (the &#8220;Sarepta Collaboration Agreement&#8221;) with Sarepta for the development and commercialization of multiple clinical and preclinical programs in rare, genetic diseases of the muscle, central nervous system, and lungs. The Company concurrently entered into a Stock Purchase Agreement (the &#8220;Stock Purchase Agreement&#8221;) with Sarepta (see Note 6). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Under the Sarepta Collaboration Agreement, Sarepta received an exclusive sublicensable worldwide license to SRP-1001 (formerly ARO-DUX4), SRP-1003 (formerly ARO-DM1), SRP-1002 (formerly ARO-MMP7), and SRP-1004 (formerly ARO-ATXN2) clinical stage programs (the &#8220;C1&#8221; programs). Sarepta also received an exclusive sublicensable </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">worldwide license to the Company&#8217;s ARO-HTT, ARO-ATXN1, and ARO-ATXN3 preclinical stage programs (the &#8220;C2&#8221; programs). The Company will perform certain research and development activities for the C1 and C2 programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Further, Sarepta may select up to six gene targets for which the Company will perform discovery, optimization and preclinical development activities to identify RNAi compounds against each selected target (the &#8220;C3&#8221; programs). Upon target acceptance, Sarepta will receive an exclusive license to the Company&#8217;s intellectual property rights to exploit  compounds directed to those targets and is wholly responsible for clinical development and commercialization of each compound after the Company delivers a Clinical Trial Application ready data package (the "CTA package").</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company identified 17 performance obligations under the Sarepta Collaboration Agreement. The four C1 licenses are distinct performance obligations from the four C1 research and development performance obligations since the customer can use and benefit from the licenses separately. The performance obligations for the licenses were satisfied in the second quarter of fiscal 2025 upon delivery and the research and development performance obligations will be satisfied as the work is performed. The remaining nine performance obligations include three C2 preclinical stage program licenses and research and development activities, and six C3 unidentified discovery target licenses and research and development activity. Each of the three C2 programs and the six C3 programs were determined to represent one performance obligation, as the customer cannot benefit from the use of the product license at the point of transfer until the specified research and development activities are performed. As such, each of the C2 and C3 product licenses and respective research and development work will be combined to form one performance obligation. For these nine performance obligations, revenue is recognized over time as the work is performed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For performance obligations recognized over time, the estimated performance period over which revenue will be recognized is determined to be the period over which the Company estimates it will perform the research and development activities. The Company determined that the most appropriate method of measuring progress for these performance obligations is an input method based on research and development costs in the program budget. Accordingly, the Company has estimated the total cost required to complete its obligation and recognized an amount of revenue equal to the proportion of services performed, which is reassessed on an ongoing basis as the program progresses. In the period an agreement expires or is terminated, remaining deferred revenue, if any, is recognized as revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of the Sarepta Collaboration Agreement, the Company received an upfront payment of $500.0&#160;million on February 14, 2025. In addition, on February 7, 2025, the Company received $325.0&#160;million in the form of an equity investment under the Stock Purchase Agreement. Based upon the Company's share price on February 7, 2025, (the &#8220;Closing Date&#8221;), the difference between the $325.0&#160;million and the fair value of the shares on the Closing date resulted in a premium of $83.6&#160;million. The premium is included as part of the total consideration of the Sarepta Collaboration Agreement for revenue recognition purposes. The Company is entitled to receive $250.0&#160;million to be paid in annual installments of $50.0&#160;million over the first five years of the agreement. The Company is also eligible receive reimbursement of certain costs related to carrying out the research and development activities for the C1 programs. The fixed consideration of $833.6&#160;million and an estimated variable consideration of $71.2&#160;million for a total of $904.9&#160;million were allocated to all performance obligations based on their relative standalone selling price. Standalone selling prices for the product licenses were determined using an adjusted market-based approach through the net present value of the expected future cash flows for each program. The standalone selling prices for the research and development work were determined based on an expected cost plus margin approach. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company estimates the stand-alone selling price for each distinct performance obligation, which involves assumptions that may require significant judgment. The Company&#8217;s estimates of the stand-alone selling price for license-related performance obligations includes forecasted revenues and expenses, phase dates, probability of success, development timelines, and the discount rate. The estimates of the stand-alone selling price for research and development performance obligations generally include forecasting the expected costs of satisfying a performance obligation at market rates. The Company identified a discount based on the difference between the aggregate stand-alone selling price and the transaction price for accounting revenue recognition purposes. The Company allocated the discount proportionally to each of the performance obligations based upon their standalone selling price. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company receives reimbursement of certain costs related to carrying out the research and development activities for the C1 programs and may receive development milestone payments of up to $300.0&#160;million. Further, for each of the 13 programs, the Company is eligible to receive regulatory milestone payments between $110.0&#160;million and $180.0&#160;million per program. Variable consideration associated with the milestones that may be achieved will be allocated to the performance obligation to which it is determined to be related, which will be the respective development work that is being reimbursed and the respective programs to which the milestones relate. ARO-DM1 development milestones were allocated between the license and development work based on the allocation of the standalone selling price. The Company will recognize the ARO-DM1 development milestones and other development milestones as revenue in the periods the underlying milestone events are achieved as achievement of the milestone events are highly susceptible to factors outside of the entity's influence and therefore there is a possibility that the milestone event will not be achieved.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company is also eligible to receive sales milestone payments between $500.0&#160;million and $700.0&#160;million per program as well as tiered royalties on net sales of licensed products of up to the low double digits, subject to the terms and conditions of the Sarepta Collaboration Agreement. The Company has applied the sales-based scope exception to the sales milestones and the royalty-based payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Sarepta Collaboration Agreement commenced in February 2025 and may be terminated by either party in the event of a material breach as defined therein. In addition, Sarepta may voluntarily terminate the Sarepta Collaboration Agreement with 30 days' written notice to the Company if terminated prior to any regulatory approval of a licensed product. Unless earlier terminated, the Sarepta Collaboration Agreement expires on a product-by-product and country-by-country basis, upon the date of expiration of the relevant royalty term for such product in such country.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2025, the Company repurchased 2,660,989 shares of its common stock from Sarepta in connection with the $100.0&#160;million DM1 first development milestone under the Sarepta Collaboration Agreement. The repurchase satisfied $50.0&#160;million of the milestone payment through delivery of the Company&#8217;s common stock, with the remaining $50.0&#160;million settled in cash. The shares were recorded as treasury stock at their fair value of $53.2&#160;million, resulting in a $3.2&#160;million gain on settlement. The repurchased shares are presented as a reduction to total stockholders&#8217; equity in accordance with ASC 505-30.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">As of September&#160;30, 2025, the Company recorded $696.8&#160;million in revenue from Sarepta and $6.8&#160;million in accounts receivable. The recognition of the remaining revenue for the performance obligations is dependent upon the time it takes to complete the respective research and development activities and in consideration of the timing of the selection of the C3 programs. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Visirna Therapeutics Inc. (&#8220;Visirna&#8221;) and Genzyme Corporation (&#8220;Sanofi&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2025, Visirna Therapeutics HK Limited (&#8220;Visirna HK&#8221;), a wholly owned subsidiary of Visirna Therapeutics, Inc, a majority owned subsidiary of the Company, entered into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with Genzyme Corporation (&#8220;Sanofi&#8221;), a wholly owned subsidiary of Sanofi S.A., pursuant to which Visirna HK sold all of its assets and rights in investigational plozasiran to Sanofi, which included an assignment of Visirna HK&#8217;s rights (as successor by assignment from Visirna) to develop and commercialize investigational plozasiran in Greater China pursuant to that certain License Agreement by and between the Company and Visirna dated, April 25, 2022 (the &#8220;Visirna License Agreement&#8221;). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Asset Purchase Agreement, the Company consented to the partial assignment of the Visirna License Agreement by Visirna HK to Sanofi (as so assigned, the &#8220;Sanofi License Agreement&#8221;), amongst other agreements between the Company and Visirna, effective as of the closing of the Asset Purchase Agreement. This agreement was not deemed a legal sale of intellectual property from the consolidated perspective of the Company. After giving effect to the Asset Purchase Agreement, Visirna HK retains rights to develop and commercialize in Greater China three other cardiometabolic drugs licensed to it pursuant to the Visirna License Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing of the Asset Purchase Agreement, Visirna received an upfront payment of $130.0&#160;million from Sanofi and is eligible to receive further development milestone payments of up to $265.0&#160;million upon approval of plozasiran across various indications in mainland China. The Company is also eligible to receive royalties from Sanofi on net commercial product sales in Greater China under the Sanofi License Agreement. During the year ended September&#160;30, 2025, the Company recorded $130.0&#160;million in revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Visirna identified the licenses as defined in the agreement as the performance obligations under the Asset Purchase Agreement. The performance obligations for the licenses was satisfied in the fourth quarter of fiscal 2025 upon delivery. The fixed consideration of $130.0&#160;million was allocated to the performance obligations. The Company will recognize the development milestones as revenue in the periods the underlying milestone events are achieved as achievement of the milestone events are highly susceptible to factors outside of the entity's influence and therefore there is a possibility that the milestone events will not be achieved. The Company has also applied the sales-based scope exception to the royalty-based payments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Sanofi License Agreement may be terminated by either party in the event of a material breach as defined therein. Unless earlier terminated, the Sanofi License Agreement expires on a product-by-product basis, upon the date of expiration of the relevant royalty term for such product in Greater China.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Accounts</a></td>
<td class="text">BALANCE SHEET ACCOUNTS<span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property, plant and equipment: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Buildings</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">251,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">75,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">62,758&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">65,353&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing equipment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">18,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,594&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,594&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">104,425&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">104,410&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">15,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">188,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">462,684&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">444,053&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(80,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(58,021)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">382,515&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">386,032&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for property, plant and equipment for the years ended September&#160;30, 2025, 2024, and 2023 was $22.2 million, $16.9 million and $10.7 million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of fiscal 2025, the Company substantially completed the build out of its manufacturing facility in Verona, Wisconsin, leading to the reclassification of $162.7 million from construction in progress to buildings and $2.6 million from construction in progress to manufacturing equipment. The Company subsequently incurred and capitalized $10.6 million to buildings and $16.0 million to manufacturing equipment during the remainder of fiscal 2025. Furthermore, the Company began depreciating the newly completed manufacturing facility over a 39-year period and the manufacturing equipment over 7- or 10-year periods.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of fiscal 2024, the Company completed the build out of its laboratory and office facilities in Verona, Wisconsin, which resulted in the reclassification of $71.8 million from construction in progress to buildings. The Company subsequently incurred and capitalized $4.2 million from construction in progress to buildings in fiscal 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></div></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">30,330&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">28,069&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accrued research and development expenses; co-development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">31,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">23,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accrued capital expenditures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,206&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accrued income taxes (benefits)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">20,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7,717&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7,391&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">90,419&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">63,017&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the Company&#8217;s accrued research and development expenses was primarily attributable to ongoing clinical trial operations, preclinical animal studies, and associated toxicology assessments. In addition, accrued research and development expenses; co-development relates to the co-development and co-commercialization activities under the Takeda License Agreement (see Note 2).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">INVESTMENTS<div style="margin-top:6pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:7pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:35.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.449%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">689,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">692,818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total current investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">689,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,956&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">692,818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:35.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.449%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale securities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">577,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">578,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total current investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">577,465&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">578,276&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the contract maturity of the available-for-sale securities as of:</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">   </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.807%"><tr><td style="width:1.0%"></td><td style="width:51.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">224,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">578,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">After one to two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">468,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">After two to three years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">692,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">578,276&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of September&#160;30, 2025, the gross unrealized losses were immaterial. The Company has determined that the available-for-sale securities that were in an unrealized loss position did not have any credit loss impairment as of September&#160;30, 2025 and 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">INTANGIBLE ASSETS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The following table presents the components of intangible assets: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:24.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,426&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">24,857&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">17,996&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">6,861&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">14,873&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">6,855&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total intangible assets, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">24,857&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,295&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8,562&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during fiscal 2025 and 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense in each of fiscal 2025, 2024, and 2023 was $1.7 million. None of the intangible assets with definite useful lives are anticipated to have a residual value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the estimated future amortization expense related to intangible assets as of September&#160;30, 2025:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.272%"><tr><td style="width:1.0%"></td><td style="width:60.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Expense</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">6,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s shares of common stock and preferred stock:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"><tr><td style="width:1.0%"></td><td style="width:31.294%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Common stock </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">135,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">135,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">124,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">124,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(1) Does not include shares of common stock into which the Avoro Pre-Funded Warrants may be exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025 and 2024, respectively, 9,851,400 and 11,492,293 shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#8217;s 2013 and 2021 Incentive Plans, as well as for other inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  <br/>         <br/>        On November 25, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;Securities Purchase Agreement&#8221;) with an institutional and accredited investor for a private placement of pre-funded warrants to purchase shares of common stock with an exercise price of $0.001 per share (&#8220;Avoro Pre-Funded Warrants&#8221;). Pursuant to the Securities Purchase Agreement, the Company sold pre-funded warrants to purchase up to 917,441 shares of common stock at a purchase price of $27.25 per pre-funded warrant, for an aggregate value of approximately $25.0 million. The outstanding Avoro Pre-Funded Warrants are exercisable at any time and do not have an expiration date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined that the Avoro Pre-Funded Warrants are freestanding financial instruments because they (i) are immediately exercisable, (ii) do not embody an obligation for the Company to repurchase its shares, (iii) permit the holders to receive a fixed number of shares of common stock upon exercise, and (iv) are indexed to the Company&#8217;s common stock. As such, the Company evaluated the Avoro Pre-Funded Warrants to determine whether they represent instruments that require liability classification pursuant to the guidance in ASC 480. However, the Company concluded that the Avoro Pre-Funded Warrants are not a liability within the scope of ASC 480 due to their characteristics. Further, the Company determined that the Avoro Pre-Funded Warrants do not meet the definition of a derivative under ASC 815 because they do not meet the criteria regarding no or little initial net investment. Accordingly, the Company assessed the Avoro Pre-Funded Warrants relative to the guidance in ASC 815-40, Contracts in Entity's Own Equity, to determine the appropriate treatment. The Company concluded that the Avoro Pre-funded Warrants are both indexed to its own stock and meet all other conditions for equity classification. Accordingly, the Company has classified the Avoro Pre-funded Warrants as permanent equity. As of September&#160;30, 2025, no shares underlying the Avoro Pre-Funded Warrants had been exercised. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Sarepta Collaboration Agreement, on November 25, 2024, the Company entered into the Stock Purchase Agreement with an affiliate of Sarepta for a private placement of shares of common stock of the Company (the &#8220;Private Placement&#8221;). Pursuant to the Stock Purchase Agreement, the Company sold 11,926,301 shares of common stock, at a price per share of $27.25, for an aggregate value of approximately $325.0&#160;million. The Private Placement closed on February 7, 2025. On August 13, 2025, the Company subsequently entered into an agreement with Sarepta to repurchase 2,660,989 common stock of the Company from Sarepta at a price per share of $18.79 for an aggregate value of approximately $50.0&#160;million and approximately $50.0&#160;million in cash to satisfy the milestone payment of $100.0&#160;million due from Sarepta. The shares were recorded as treasury stock at their fair value of $53.2&#160;million, resulting in a $3.2&#160;million gain on settlement. As of the end of fiscal 2025, Sarepta no longer holds an equity position in the Company. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">On December 2, 2022, the Company entered into an open market sale agreement (the &#8220;Open Market Sale Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#8217;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#8220;ATM Offering&#8221;). The Company is not required to sell shares under the Open Market Sale Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the Open Market Sale Agreement. Unless otherwise terminated, the ATM Offering shall terminate upon the earlier of (i) the sale of all shares of common stock subject to the Open Market Sale Agreement and (ii) the termination of the Open Market Sale Agreement as permitted therein. The Company and Jefferies may each terminate the Open Market Sale Agreement at any time upon prior notice. As of September&#160;30, 2025, no shares have been issued under the Open Market Sale Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of September&#160;30, 2025 and 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2025, the Company filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ionis Pharmaceuticals, Inc. (&#8220;Ionis&#8221;) to declare that the United States Patent No. 9,593,333 (&#8220;the &#8217;333 patent&#8221;) is invalid and not infringed by the Company&#8217;s planned commercialization of investigational plozasiran. On September 11, 2025, Ionis filed a Complaint for Patent Infringement against the Company in the United States District Court for the Central District of California alleging patent infringement of the &#8217;333 patent by the Company&#8217;s planned commercialization of investigational plozasiran and seeking damages. There were no contingent liabilities recorded related to this litigation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns land in the Verona Technology Park in Verona, Wisconsin, where it has constructed an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility to support the Company&#8217;s manufacturing, process development, and analytical activities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the build-out of these facilities was substantially completed, with total costs incurred of $296.4 million. These costs included $173.4 million capitalized to building related to the drug manufacturing facility, $78.0 million capitalized to building related to the laboratory and office facility, $18.6 million capitalized to manufacturing equipment, $15.9 million in construction in progress and $7.9 million capitalized to research equipment and $2.6 million capitalized to furniture.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pasadena, California</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases 49,000 square feet of office space located at 177 East Colorado Blvd. for its corporate headquarters from 177 Colorado Owner, LLC, which lease expires on April&#160;30, 2027. The lease contains an option to renew for one additional five-year term. The Company is not reasonably certain that it will exercise this option to renew and therefore it is not included in right-of-use assets and liabilities as of September&#160;30, 2025.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">San Diego, California</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases 144,000 square feet of office and research and development laboratory space located at 10102 Hoyt Park from 11404 &amp; 11408 Sorrento Valley Owner, LLC, which lease expires on April&#160;30, 2038. Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent. The Company is not reasonably certain that it will exercise this option to renew and therefore it is not included in right-of-use assets and liabilities as of September&#160;30, 2025. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The lease agreement, as amended, granted the Company the right to receive an Additional Tenant Improvement Allowance (&#8220;ATIA&#8221;) funded by the lessor. The Company received $30.8&#160;million in ATIA, including a final payment of $3.1 million during the first quarter of fiscal 2024. As a result, the Company remeasured its lease liability and right-of-use assets to reflect these additional allowances and the related increased lease payments. The Company has further concluded that these ATIAs have no effects on the classification of the lease.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Madison, Wisconsin</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases 110,956 square feet space, which it increased from 107,000 square feet on June&#160;30, 2025, located at 502 South Rosa Road for its office and laboratory facilities, which lease expires on September&#160;30, 2031. The lease contains options to renew for two terms of five years. The Company is not reasonably certain that it will exercise this option and therefore it is not included in right-of-use assets and liabilities as of September&#160;30, 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:33.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.080%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">43,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">45,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7,289&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">6,342&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">104,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">111,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.388%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">11,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,952&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,006&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease cost</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,511&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">13,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) Variable lease cost is primarily related to operating expenses associated with the Company&#8217;s operating leases.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There was $0, $0 and $1.4&#160;million in short-term lease cost during the years ended September&#160;30, 2025, 2024, and 2023, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents maturities of operating lease liabilities on an undiscounted basis as of September&#160;30, 2025:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"></td><td style="width:82.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">15,873&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">15,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">13,696&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">13,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">14,282&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2031 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">100,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">173,558&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(62,157)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">111,401&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"></td><td style="width:64.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash received for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">48,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets adjusted in exchange for new/amended operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">17,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">15,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">11,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">11.70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">12.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">13.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three plans that provide for equity-based compensation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2013 Incentive Plan (the &#8220;2013 Plan&#8221;), 2,276,279 awards are granted and outstanding, relating to stock options and restricted stock awards to employees and directors as of September&#160;30, 2025. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2021 Incentive Plan (the &#8220;2021 Plan&#8221;), 8,000,000 shares (subject to certain adjustments) of the Company&#8217;s common stock are authorized for grants of stock options, stock appreciation rights, restricted and unrestricted stock, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#8217;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of September&#160;30, 2025, 6,231,559 shares have been granted under the 2021 Plan. The total number of shares available for issuance was 2,378,770 shares, which includes 170,898 and 439,431 shares that were forfeited under the 2013 and 2021 Plans, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s Inducement Plan (the &#8220;Inducement Plan&#8221;), 832,950 shares of the Company&#8217;s common stock are authorized for issuance pursuant to grants of stock options, stock appreciation rights, restricted and unrestricted stock, stock units (including restricted stock units), performance awards, cash awards, and other awards convertible into or otherwise based on shares of the Company&#8217;s common stock. Awards under the Inducement Plan may only be granted to new employees of the Company in accordance with the provisions of Rule 5635(c)(4) of the Nasdaq Listing Rules. As of September&#160;30, 2025, 660,020 shares have been granted under the Inducement Plan. The total number of shares remaining available for issuance was 255,244 shares.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, prior to adoption of the Inducement Plan, the Company previously granted stand-alone inducement awards in the form of stock options and restricted stock units outside of the Company&#8217;s equity plans to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules. As of September&#160;30, 2025, there were 598,605 and 53,713 shares underlying outstanding stand-alone inducement options and restricted stock units, respectively.   </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding attributable to Arrowhead Pharmaceuticals, Inc.:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.529%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Inducement Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">776,279&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">32,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">598,605&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,407,035&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,750,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">560,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,810,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,276,279&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,782,222&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,158,885&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7,217,386&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expenses included in operating expenses attributable to Arrowhead Pharmaceuticals, Inc.:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.940%"><tr><td style="width:1.0%"></td><td style="width:28.210%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.313%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">27,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">29,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">34,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">27,528&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">37,570&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">43,798&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">54,848&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">67,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">78,130&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Awards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the stock option activity for the year ended September&#160;30, 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 30, 2024</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,978,516&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">23.39&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cancelled or expired</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(36,341)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">45.44&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(535,140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 30, 2025</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,407,035&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">28.90&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">19,099,141&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at September 30, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,407,035&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">28.90&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">19,099,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values represent the amount by which the market price of the underlying stock exceeds the exercise price of the option. The total intrinsic value of the options exercised during the years ended September&#160;30, 2025, 2024, and 2023 was $6.4 million, $4.2 million and $12.2 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to stock options outstanding for the years ended September&#160;30, 2025, 2024, and 2023 was $0.1 million, $2.8 million and $8.4 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the pre-tax compensation expense for all outstanding unvested stock options is considered nominal.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. No options were granted during the years ended September 30, 2025 and 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Black-Scholes option pricing model: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3.69% &#8211; 4.57%</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">86.4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">25.61</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) The dividend yield is zero as the Company currently does not pay a dividend. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(3) Volatility is estimated based on volatility average of the Company&#8217;s common stock price. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(4) The computation of expected term was determined based on safe harbor rules, considering the contractual terms of the awards and vesting schedules.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(5) No options were granted during the year ended September&#160;30, 2025 and September&#160;30, 2024.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Visirna ESOP</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: As of September&#160;30, 2025, Visirna, a subsidiary of the Company, granted 14,612,000 stock options to its employees from the Employee Stock Option Plan (the &#8220;Visirna ESOP&#8221;), which authorizes 20,000,000 shares for issuance. The Visirna ESOP is independently managed by Visirna, including the valuation process. For the years ended September&#160;30, 2025 and 2024, stock-based compensation expense related to the Visirna ESOP was $8.5 million and $6.9 million, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted Stock Units (&#8220;RSUs&#8221;), including market-based, time-based and performance-based awards, have been granted under the Company&#8217;s 2013 and 2021 Plans, the Inducement Plan and as inducements awards granted outside of the Company&#8217;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s common stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2024</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,913,312&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">49.61&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,779,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">19.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1,525,693)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">47.15&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(356,957)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">30.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2025</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,810,351&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">36.97&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs was determined based on the closing price of the Company&#8217;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.</span></div>For the years ended September&#160;30, 2025, 2024 and 2023, the Company recorded stock-based compensation expense of $54.9 million, $64.3 million and $69.7 million, respectively, related to shares of RSUs. As of September&#160;30, 2025, there was $73.3 million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of 1.7 years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date using the exit price. Accordingly, when market observable data are not readily available, the Company&#8217;s own assumptions are used to reflect those that market participants would be presumed to use in pricing the asset or liability at the measurement date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on the consolidated balance sheets are categorized based on the level of judgment associated with inputs used to measure their fair values and the level of market price observability, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#160;&#160;&#160;&#160;Unadjusted quoted prices are available in active markets for identical assets or liabilities as of the reporting date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#160;&#160;&#160;&#160;Pricing inputs are other than quoted prices in active markets, which are based on the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Quoted prices for similar assets or liabilities in active markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Quoted prices for identical or similar assets or liabilities in non-active markets; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Either directly or indirectly observable inputs as of the reporting date.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#160;&#160;&#160;&#160;Pricing inputs are unobservable and significant to the overall fair value measurement, and the determination of fair value requires significant management judgment or estimation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. Thus, a Level 3 fair value measurement may include inputs that are observable (Level 1 or Level 2) and unobservable (Level 3). The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and consideration of factors specific to the asset or liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. At September&#160;30, 2025 and 2024, the Company did not have any financial assets or financial liabilities based on Level 3 measurements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicate the fair value hierarchy of the valuation techniques utilized by the Company: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:33.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">150,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">150,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">12,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">12,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Commercial notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">13,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">13,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">509,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">509,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">692,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">692,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">64,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">64,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Term deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">134,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">134,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">64,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">153,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">218,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">64,460&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">846,358&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">910,818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">     </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:33.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">160,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">160,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Commercial notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">179,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">179,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">237,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">237,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">578,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">578,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">66,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">66,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">66,966&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">66,966&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">66,966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">578,276&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">645,242&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Provision (Benefit)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income (loss) before income tax expense and noncontrolling interest are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(42,573)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(582,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(194,639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">94,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(30,127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(7,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">51,533&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(612,460)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(202,491)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision (benefit) consisted of the following components:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:69.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.170%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.170%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.174%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,710&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(3,290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total current tax</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21,419&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(2,767)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Income tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21,419&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(2,767)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the tax expense based on the statutory rate to the Company&#8217;s actual tax expense in the consolidated statements of operations and comprehensive income (loss). A notional 21% tax rate was applied as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. federal statutory income tax</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(44.4)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Permanent and other items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(37.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(27.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant components of the Company&#8217;s net deferred tax assets and liabilities: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.404%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">70,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">102,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">232,360&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">156,015&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">48,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">85,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">171,262&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">81,556&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">23,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">27,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">9,184&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10,989&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,034&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,384&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">562,686&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">473,008&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Valuation allowance</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(497,543)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(448,867)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(30,503)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(13,155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(9,424)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(10,792)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Original Issue Discount</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(24,586)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax liability</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(65,143)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(24,141)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded to reduce deferred tax assets to the amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended September&#160;30, 2025. Such objective evidence limits the ability to consider other subjective evidence such as its projections for future growth. On the basis of this evaluation at September&#160;30, 2025 and 2024, a valuation allowance of $497.5 million and $448.9 million, respectively, has been recorded. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> As of September&#160;30, 2025, the Company had accumulated federal, state, and foreign net operating loss (&#8220;NOL&#8221;) carryforwards of $20.6 million, $815.5 million and $46.3 million, respectively. Of the $20.6 million in federal NOL carryforwards, $20.6 million was generated before January 1, 2018, and is subject to a 20-year carryforward period (&#8220;pre-Tax Act losses&#8221;), with expiration beginning in 2031. Of the $815.5 million in state NOL carryforwards, $2.7 million can be carried forward indefinitely, while the remaining balance begins to expire in 2031. The Company also has foreign NOL carryforwards totaling $46.3 million, which begin to expire in 2027. Additionally, the Company has federal and state income tax credits of $49.4 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and $26.3 million, respectively. The federal credits begin to expire in 2041. Of the state income tax credits, $13.6 million begins to expire in 2035, while the remaining credits can be carried forward indefinitely.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), the annual use of an entity&#8217;s NOL and research and development credit carryforwards may be limited if there is a cumulative ownership change of greater than 50% within a three-year period. The annual limitation is determined based on the entity&#8217;s value immediately prior to the ownership change. Future ownership changes could further affect the limitation. If a limitation is applied, the related tax asset would be removed from the deferred tax asset schedule, with a corresponding reduction in the valuation allowance. To date, the Company has completed an analysis pursuant to Sections 382 and 383 through September&#160;30, 2024. Ownership Changes may have occurred since then, and future changes could potentially limit the Company&#8217;s ability to utilize these attributes. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertainty in Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold of more-likely-than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more-likely-than not that a tax position </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s gross unrecognized tax benefits:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance of unrecognized tax benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">14,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Gross increase for prior period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">9,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Gross decrease for prior period tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1,489)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Gross increase for current period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Lapse of statue of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance of unrecognized tax benefits</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">22,152&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,613&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">14,536&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded income tax (benefit) expense of $0 and $3.3 million for the years ended September&#160;30, 2025 and 2024, respectively, related to uncertain tax positions inclusive of interest and penalties. The Company&#8217;s policy is to recognize potential interest and penalties related to unrecognized tax benefits associated with uncertain tax positions, if any, in the income tax provision. As of September&#160;30, 2025, the Company has not accrued any interest or penalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If the unrecognized tax benefit as of September&#160;30, 2025 is ultimately recognized, there would be no reduction in the Company&#8217;s income tax expense or effective tax rate, excluding the impact of U.S. Tax benefits netted against deferred taxes that are subject to a valuation allowance. The Company does not anticipate any changes in its unrecognized tax benefits over the next 12 months.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to taxation in the U.S. and various states along with other foreign countries. Due to the presence of NOL carryforwards, all of the income tax years remain open for examination. The Company is currently under audit by the IRS for September&#160;30, 2023. California income tax examination has been closed. There are no other audits in any other jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes undistributed earnings of each foreign subsidiary and has determined that no withholding taxes are applicable to earnings which are currently available for distribution. No additional deferred tax liability has been recorded as the parent entity would not be required to include the distribution into income under the current law.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act subjects a U.S. shareholder to tax on Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740 No. 5. Accounting for GILTI, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year that the tax is incurred as a period expense only. The Company has elected to account for GILTI in the year the tax is incurred. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. ASC 740, "Income Taxes", requires the effects of changes in tax rates and laws to be recognized in the period in which the legislation is enacted. The Company has implemented OBBBA in the fourth quarter of the current year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">EMPLOYEE BENEFIT PLANS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a defined contribution retirement plan which is under Section 401(k) of the Internal Revenue Code and is designed to adhere to ERISA Fiduciary standards. All of the Company&#8217;s full-time employees are eligible to participate this plan. Under the terms of the plan, an eligible employee may elect to contribute a portion of their salary on a pre-tax basis, subject to federal statutory limitations. The plan allows for a discretionary match in an amount up to 100% of each participant&#8217;s first 3% of compensation contributed plus 50% of each participant&#8217;s next 2% of compensation contributed. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended September&#160;30, 2025, 2024, and 2023, the Company recorded expenses for the matching contributions under this plan of $3.9 million, $3.4 million and $2.2 million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company also provides certain employee benefit plans, including those which provide health and life insurance benefits to employees.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract', window );"><strong>Liability Related To The Sale Of Future Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock', window );">Liability Related to the Sale of Future Royalties</a></td>
<td class="text">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $410.0 million in cash to the Company in consideration for the Company&#8217;s future royalty interest in olpasiran, a siRNA originally developed by the Company and licensed to Amgen in September 2016 under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $250.0 million upfront and agreed to pay up to an additional $160.0 million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $50.0 million on completion of enrollment in the OCEAN Phase 3 clinical trial for olpasiran, (ii) $50.0 million upon receipt of FDA approval of olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $60.0 million upon Royalty Pharma&#8217;s receipt of at least $70.0 million of royalty payments under the Royalty Pharma Agreement in any single calendar year. During the third quarter of fiscal 2024, Amgen completed enrollment of the Phase 3 OCEAN(a) outcomes trial of olpasiran, which triggered a $50.0&#160;million milestone payment that the Company received in the same quarter. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the terms of the Royalty Pharma Agreement and concluded in accordance with the relevant accounting guidance that the Company accounted for the transaction as debt and the funding of $250.0 million and $50.0&#160;million from Royalty Pharma were recorded as liabilities related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay these funds received under the Royalty Pharma Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Company records the obligations at their carrying value using the effective interest method. In order to amortize the sale of future royalties, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize non-cash interest expense for the remaining periods. The Company periodically assesses the amount and the timing of expected royalty payments using a combination of internal projections and forecasts from external sources. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration, probability of success and sales price, among others. To the extent such payments are greater or less than the Company&#8217;s initial estimates or the timing of such payments is different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate. As of September&#160;30, 2025, the estimated effective interest rate was 8.3%. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the activity with respect to the liability related to the sale of future royalties.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Beginning carrying value </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">341,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">268,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Upfront payment received</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Milestone payment received</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">26,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">23,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Ending carrying value</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">367,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">341,361&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To The Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To The Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Financing Agreement</a></td>
<td class="text">FINANCING AGREEMENT <div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2024 (the &#8220;Closing Date&#8221;), the Company entered into a Financing Agreement with the guarantors party thereto, the lenders party thereto (the &#8220;Lenders&#8221;), and Sixth Street Lending Partners (&#8220;Sixth Street&#8221;), as the administrative agent and collateral agent for the Lenders (the &#8220;Financing Agreement&#8221;). The Financing Agreement establishes a senior secured term loan facility of $500.0&#160;million (the &#8220;Credit Facility&#8221;), consisting of $400.0&#160;million funded on the Closing Date and an additional $100.0&#160;million available at the Company&#8217;s option, subject to mutual agreement with Sixth Street. The loans under the Credit Facility bear interest at an annual rate of 15.0%, which is paid in kind and added to the outstanding principal balance of the Credit Facility each period. The outstanding principal balance of this Credit </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facility, including amounts representing accrued but unpaid interest previously paid in kind, is due and payable on August 7, 2031.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is permitted to use the net proceeds for working capital, capital expenditures and general corporate purposes of the Company and its subsidiaries.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company will have the right to prepay loans under the Credit Facility at any time. The Company is required to partially repay loans under the Credit Facility with proceeds from certain asset sales, condemnation events and extraordinary receipts, subject, in some cases, to reinvestment rights. If the Company repays in full the aggregate principal outstanding under the Credit Facility and such payment in full occurs on or prior to August 7, 2028, the Company will be required to make an additional payment to the lenders under the Credit Facility on such date in an amount necessary for the lenders to achieve a two times multiple of invested capital (&#8220;MOIC&#8221;) of the aggregate principal amount funded on the Closing Date (the &#8220;MOIC Payment&#8221;). If such payment in full occurs after August 7, 2028, the Company will be required to make a payment to the lenders under the Credit Facility on such date in an amount necessary for the lenders to achieve the greater of the MOIC Payment and the present value of all interest payments that would have been payable from such date through the maturity date of the Credit Facility discounted at the Treasury Rate (as defined in the Financing Agreement) plus 0.5%; provided that such payment amount in this instance will not exceed the amount necessary for the lenders to achieve a 2.5 times MOIC.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 26, 2024, the Company entered into an amendment to the Financing Agreement (the "Amendment") to modify, amongst other things, some of the prepayment terms of the loans under the Credit Facility, including, the prepayment terms related to the Sarepta Collaboration Agreement. The Amendment was effective on February 14, 2025, following the closing of the Sarepta Collaboration Agreement and receipt of the $500.0&#160;million upfront payment from Sarepta. The Amendment added an additional prepayment clause that requires certain contractual prepayments of principle and MOIC payments throughout the life of the loans under the Credit Facility. Additionally, any prepayment will be split with 50% of any such prepayment paying down the principle balance of the loans under the Credit Facility and the other 50% being applied to prepay the MOIC Payment. In the event the prepayment amounts result in fees being prepaid in excess of the actual amounts required to be paid, the excess fees shall be reallocated and applied to reduce the amount of the principal balance upon repayment in full of the loans under the Credit Facility. As of September&#160;30, 2025, the Company has paid $100.0&#160;million in MOIC payments of which $25.3&#160;million is expected to be applied to principal upon repayment in full. To date, the Company has paid $201.6&#160;million of the loans under the Credit Facility during fiscal 2025. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Amendment was accounted for as a debt modification under ASC 470-50, &#8220;Debt&#8212;Modification and extinguishments&#8221; since the Amendment did not result in substantially different terms. In connection with the Amendment, the Company did not incur significant third-party fees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">All obligations under the Financing Agreement are secured on a first-priority basis by security interests in substantially all assets of the Company and material subsidiaries of the Company, including its intellectual property, subject to certain exceptions, and is guaranteed by material subsidiaries of the Company, including foreign subsidiaries, subject to certain exceptions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Financing Agreement contains customary covenants, including, without limitation, a financial covenant to maintain liquidity (cash, cash equivalents and investments) of at least $100.0&#160;million if the Company&#8217;s market capitalization is above $1.5 billion, and negative covenants that, subject to certain exceptions, restrict indebtedness, liens, investments (including acquisitions), fundamental changes, asset sales and licensing transactions, dividends, modifications to material agreements, payment of subordinated indebtedness, distributions from certain parties, and other matters customarily restricted in such agreements. The Company is subject to restrictions on sales and licensing transactions with respect to certain core intellectual property, subject to certain exceptions, including certain transactions related to areas outside the United States, United Kingdom, European Union, Japan and China.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Financing Agreement contains certain embedded features that were identified and evaluated as not material to the consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 13, 2025, the Company entered into second amendment to the Financing Agreement (the "Second Amendment") that permitted the share repurchase of the Company's common stock from Sarepta and required the Company to pay a nominal administrative fee.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding balance of the Credit Facility consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Initial Term Loan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated interest on the Initial Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">66,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">9,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated accretion of the MOIC Payment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Less: Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(13,912)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(15,817)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of credit facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(40,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Less: Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(201,625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Credit facility, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">214,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">393,183&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth total interest expense recognized related to the Credit Facility:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:54.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,906&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of the MOIC Payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">57,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">9,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Total interest expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">63,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">9,317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The amounts shown in the table below, related to the Credit Facility, represent the expected repayments of principle and accrued interest balance as of September&#160;30, 2025 as well as any mandatory prepayments that the Company is obligated to make to the Lenders during the indicated periods. The principal balance will increase from accrued paid in kind interest and the table does not include MOIC payments beyond those contractually determined. Actual payments on current principal may vary from the amounts presented in the table. </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">214,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">339,990&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2025, Visirna entered into the Revolving Credit Agreement with Bank of Zhejiang. The maximum aggregate credit facility is 72.9&#160;million Chinese Yuan ($10.3&#160;million) bearing an annual interest rate of 4.1%. The term of each loan is twelve months. The amount outstanding as of September&#160;30, 2025 was 72.9&#160;million Chinese Yuan ($10.3&#160;million) on the credit facility which was classified as other current liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">NET LOSS PER SHARE<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted net loss per share for the years ended September&#160;30, 2025, 2024 and 2023. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1,631)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(599,493)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(205,275)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average basic shares outstanding</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">133,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">119,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">106,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average diluted shares outstanding</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">133,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">119,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">106,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Basic net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(5.00)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1.92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Diluted net loss per share</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(5.00)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1.92)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:52.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.798%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,020&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,737&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,053&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">SEGMENT INFORMATION<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a single segment dedicated to the discovery, development, manufacturing and commercialization of RNAi therapeutics. The Company's RNAi therapeutics are comprised of siRNAs that function upstream of conventional medicines by potently silencing messenger RNA (&#8220;mRNA&#8221;) that encode for proteins implicated in the cause or pathway of disease, thus preventing them from being made. Consistent with our operational structure, our Chief Executive Officer (&#8220;CEO&#8221;), as the CODM, manages and allocates resources on a consolidated basis at the global corporate level. Our global research and development and technical operations and quality organizations are responsible for the discovery, development, and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region and therapeutic area. All of these activities are supported by corporate staff functions. Managing and allocating resources at the corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources in line with our overarching long-term, corporate-wide strategic goals. The determination of a single segment is consistent with the consolidated financial information regularly reviewed by the CODM for the purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with our management reporting, results of our operations are reported on a consolidated basis for purposes of segment reporting. The CEO evaluates performance and decides how to allocate resources based on consolidated net loss that is reported on the consolidated statements of operations and comprehensive income (loss). The measure of segment assets is reported on the consolidated balance sheets as total assets. The CEO uses consolidated net loss to evaluate income generated from the Company&#8217;s business activities in deciding how to allocate company resources (such as pursuing clinical development or entering a strategic collaboration), monitoring budget versus actual results, and establishing management&#8217;s compensation. Please refer to the consolidated financial statements for further information related to these measures of segment performance. In addition, research and development and selling, general and administrative expenses are significant segment expenses regularly provided to the CEO with the following categories:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Candidate costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">347,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">259,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">162,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D discovery costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">66,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">74,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">55,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Salaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">109,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">96,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">73,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Facilities related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">29,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">25,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expense, excluding non-cash expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">552,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">455,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">307,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">32,582&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">33,586&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">34,332&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">607,159&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">505,870&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">353,188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General &amp; Administrative</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Salaries</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">31,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">27,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">22,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Professional, outside services, and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">53,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">24,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">20,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Facilities related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total general and administrative expense, excluding non-cash expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">91,130&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">56,438&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">47,134&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">30,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">40,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">43,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation/amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total general and administrative expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">123,943&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">98,761&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">92,549&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Novartis</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2025, the Company entered into an Exclusive License and Collaboration Agreement (the &#8220;Novartis Collaboration Agreement&#8221;) with Novartis Pharma AG (&#8220;Novartis&#8221;) for the co-development and commercialization of multiple preclinical programs in rare, genetic diseases. Under the Novartis Collaboration Agreement, Novartis has received an exclusive worldwide license to the Company's ARO-SNCA preclinical stage program. The Novartis Collaboration Agreement closed on October 17, 2025 subsequent to clearance under the Hart-Scott-Rodino Antitrust Improvement Act. Under the terms of the Novartis Collaboration Agreement, the Company received $200.0&#160;million as an upfront payment. The Company is also eligible to receive $30.0&#160;million associated with certain target nominations. Further, for each of the 4 programs, the Company is eligible to receive development milestone payments between $175.0&#160;million and $245.0&#160;million per program and sales milestone payments between $285.0&#160;million and $370.0&#160;million per program. The Company is also eligible to receive tiered royalties on net sales of licensed products of up to the low double digits.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Sarepta DM1 Milestone</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2025, the Company earned a $200.0&#160;million milestone payment from</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sarepta. The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ARO-DM1, also called SRP-1003, an investigational RNAi therapeutic for the treatment of type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy. The second milestone event included the achievement of a patient enrollment target, drug safety committee review and subsequent authorization to dose escalate and proceed, and completion of day 105 study visit by at least one patient in the clinical trial. </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">REDEMPLO Commercial Launch</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA approved the Company's New Drug Application (NDA) for REDEMPLO (plozasiran) injection for Familial Chylomicronemia Syndrome (FCS), on November 18, 2025. This approval, which was based on the results of the Phase 3 PALISADE clinical trial, was completed within the Prescription Drug User Fee Act (PDUFA) VI timeframe. This approval is a significant milestone for the Company, and the commercial launch of REDEMPLO is in progress. We expect to begin generating revenue from sales of REDEMPLO in the upcoming fiscal year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal quarter ended September&#160;30, 2025, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.242%"><tr><td style="width:1.0%"></td><td style="width:15.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.479%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.479%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.479%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.479%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.479%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.429%"></td><td style="width:0.1%"></td></tr><tr style="height:28pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Title</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Adoption or Termination Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Plan End Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Shares Vesting and Subject to Sell-To-Cover </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:114%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Other Shares Being Sold (Subject to Certain Conditions)</span></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">Adeoye Olukotun</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">Board Member</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">09/04/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">12/24/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">10,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">Christopher Anzalone</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">President and Chief Executive Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">09/19/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">12/24/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">50,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">Daniel Apel</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">Chief Financial Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">09/16/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">04/30/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">James Hamilton</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">Chief Medical Officer, Head of R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">09/03/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">01/16/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">72,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">Mauro Ferrari</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">Board Member</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">09/25/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">12/31/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">7,530</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">Patrick O'Brien</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">Chief Operating Officer &amp; General Counsel<br/></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">09/03/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">01/07/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">77,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">20,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">Victoria Vakiener</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">Board Member</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">09/03/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">12/31/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">10,040</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%">William Waddill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">Board Member</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">09/03/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">12/31/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">8,367</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) This column indicates the total number of shares vesting, but the 10b5-1 Plan provides for the sale of only those shares necessary to satisfy payment of applicable withholding taxes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arwr_AdeoyeOlukotunMember', window );">Adeoye Olukotun [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Adeoye Olukotun<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Board Member<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">09/04/2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">12/24/2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">111 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arwr_ChristopherAnzaloneMember', window );">Christopher Anzalone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Christopher Anzalone<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">President and Chief Executive Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">09/19/2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">12/24/2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">461 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arwr_DanielApelMember', window );">Daniel Apel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Daniel Apel<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Financial Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">09/16/2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">04/30/2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">226 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arwr_JamesHamiltonMember', window );">James Hamilton [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">James Hamilton<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Medical Officer, Head of R&D<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">09/03/2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">01/16/2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">135 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">72,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arwr_MauroFerrariMember', window );">Mauro Ferrari [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Mauro Ferrari<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Board Member<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">09/25/2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">12/31/2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">97 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">7,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arwr_PatrickOBrienMember', window );">Patrick O'Brien [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Patrick O'Brien<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Operating Officer & General Counsel<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">09/03/2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">01/07/2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">126 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arwr_VictoriaVakienerMember', window );">Victoria Vakiener [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Victoria Vakiener<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Board Member<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">09/03/2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">12/31/2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">119 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">10,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arwr_WilliamWaddillMember', window );">William Waddill [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">William Waddill<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Board Member<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">09/03/2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">12/31/2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">119 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">8,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=arwr_PatrickOBrienSharesVestingAndSubjectToSellToCoverMember', window );">Patrick O'Brien, Shares Vesting And Subject to Sell-To-Cover [Member] | Patrick O'Brien [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">77,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=arwr_PatrickOBrienOtherSharesBeingSoldMember', window );">Patrick O'Brien, Other Shares Being Sold [Member] | Patrick O'Brien [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arwr_AdeoyeOlukotunMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arwr_AdeoyeOlukotunMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arwr_ChristopherAnzaloneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arwr_ChristopherAnzaloneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arwr_DanielApelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arwr_DanielApelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arwr_JamesHamiltonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arwr_JamesHamiltonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arwr_MauroFerrariMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arwr_MauroFerrariMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arwr_PatrickOBrienMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arwr_PatrickOBrienMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arwr_VictoriaVakienerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arwr_VictoriaVakienerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arwr_WilliamWaddillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arwr_WilliamWaddillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=arwr_PatrickOBrienSharesVestingAndSubjectToSellToCoverMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=arwr_PatrickOBrienSharesVestingAndSubjectToSellToCoverMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=arwr_PatrickOBrienOtherSharesBeingSoldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=arwr_PatrickOBrienOtherSharesBeingSoldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a cybersecurity program, with direct oversight from senior management and the Audit Committee (the &#8220;Audit Committee&#8221;) of the Board of Directors (the &#8220;Board&#8221;), to manage information, data, and technology security. The cybersecurity program is informed in part by the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF) and is designed to help identify, assess, and manage cybersecurity risks relevant to the Company&#8217;s business. The Company&#8217;s cybersecurity program has been developed in light of the nature of the Company&#8217;s business, resource availability, requirements from stakeholders, and industry trends. The Company has formed an internal cross-functional Technology Risk Management Committee comprised of representative leaders from various aspects of the Company&#8217;s business to broadly implement its cybersecurity program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cybersecurity program prioritizes vulnerability management, risk reduction, detection, and prevention to help protect against material risks from cybersecurity threats to its information systems. The Company periodically conducts internal and third-party cybersecurity risk assessments and penetration tests and incorporates relevant findings and recommendations into its overall cybersecurity strategy, as appropriate. Through these assessments, the Company develops targeted strategies intended to address the most significant cybersecurity risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cybersecurity program emphasizes defense, rapid detection, and remediation of cybersecurity threats and incidents, including the use of various security tools and systems based on defense-in-depth and zero-trust principles that are intended to meet control requirements. The cybersecurity program also encompasses crisis incident response guidelines that detail the processes for the detection, response, mitigation, and remediation of cybersecurity incidents, in order to support the effective management of, response to, communication during, and recovery from any such incidents.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A key element of the Company&#8217;s strategy is fostering training and awareness through annual cybersecurity training and role-based phishing tests for employees and certain third parties having access to the Company&#8217;s information systems. The Company also utilizes a third-party cybersecurity operations monitoring center to help identify threats and incidents to the Company&#8217;s servers and computers. The Company&#8217;s cybersecurity program includes specific requirements and guidelines for the information security team relating to the Company's computer emergency response preparedness, intrusion response preparedness, and incident response preparedness.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">When a potential cybersecurity threat or incident is identified, our processes require that the Senior Director of Information Security be promptly notified of the incident, who then is to conduct an initial investigation to determine the probability and potential of the threat or incident to have a material impact on key business systems and processes. If there is a reasonable possibility for a material impact to the Company&#8217;s business or information systems, the cybersecurity program requires that the Technology Risk Management Committee be promptly notified, which then assigns a risk level to the threat or incident. All threats and incidents identified as high-risk are promptly escalated to Company leadership and the legal department, who, in collaboration with the Company's Information Security department, are tasked with activating and implementing a high-risk information security incident mitigation and response plan, which details the roles, responsibilities, and strategies to respond. Our cybersecurity program also requires that high-risk cybersecurity incidents or threats be reported to the Company&#8217;s Materiality Committee and the Audit Committee within 24 hours of their designation as high-risk by the Technology Risk Management Committee.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity risks are incorporated into our overall risk management program. If a cybersecurity risk is identified as high-risk, a response and mitigation plan is developed, and progress updates on the plan are routinely reported to the Technology Risk Management Committee and tracked by the Audit Committee as part of our overall risk management process.</span></div>The Company is not aware of any cybersecurity threats or incidents in the last fiscal year, including as a result of any prior cybersecurity incidents, that have had a material impact on the Company, including its business strategy, operations, or financial condition. However, we face certain ongoing cybersecurity risks and threats that, if realized, are reasonably likely to materially affect us.  Additional information on cybersecurity risks we face is discussed in Part I, Item 1A &#8220;Risk Factors,&#8221; under the heading &#8220;Our business and operations could suffer in the event of a cybersecurity incident or other information technology system failures.&#8221;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity risks are incorporated into our overall risk management program. If a cybersecurity risk is identified as high-risk, a response and mitigation plan is developed, and progress updates on the plan are routinely reported to the Technology Risk Management Committee and tracked by the Audit Committee as part of our overall risk management process.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity risks are incorporated into our overall risk management program. If a cybersecurity risk is identified as high-risk, a response and mitigation plan is developed, and progress updates on the plan are routinely reported to the Technology Risk Management Committee and tracked by the Audit Committee as part of our overall risk management process.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity risks are incorporated into our overall risk management program. If a cybersecurity risk is identified as high-risk, a response and mitigation plan is developed, and progress updates on the plan are routinely reported to the Technology Risk Management Committee and tracked by the Audit Committee as part of our overall risk management process.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Senior Director of Information Security reports to the Vice President, Treasury &amp; Head of Information Systems, and they meet periodically with senior leadership and the Audit Committee to review metrics on cybersecurity preparedness, incidents, mitigations and remediation efforts.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Execution of the Company&#8217;s cybersecurity program is delegated by the Board to the Senior Director of Information Security, who has over 25 years of relevant experience in information security, including 14 years at the Company, and is further supported by a team of security professionals within the Information Systems &amp; Informatics department. The Senior Director of Information Security reports to the Vice President, Treasury &amp; Head of Information Systems, and they meet periodically with senior leadership and the Audit Committee to review metrics on cybersecurity preparedness, incidents, mitigations and remediation efforts. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also established a management-level Technology Risk Management Committee, which includes leaders from finance, legal, operations, quality &amp; compliance, and information systems &amp; informatics, who are responsible for overseeing the execution of high-risk incident response and mitigation plans. This committee actively reviews technology strategies, physical and cybersecurity threat assessment, and emerging issues and related initiatives. It is also responsible for evaluating the materiality of information for SEC filings and, as required or as otherwise appropriate, coordinates with the Company&#8217;s Materiality Committee to support timely disclosure of relevant information.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Execution of the Company&#8217;s cybersecurity program is delegated by the Board to the Senior Director of Information Security, who has over 25 years of relevant experience in information security, including 14 years at the Company, and is further supported by a team of security professionals within the Information Systems &amp; Informatics department. The Senior Director of Information Security reports to the Vice President, Treasury &amp; Head of Information Systems, and they meet periodically with senior leadership and the Audit Committee to review metrics on cybersecurity preparedness, incidents, mitigations and remediation efforts.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Execution of the Company&#8217;s cybersecurity program is delegated by the Board to the Senior Director of Information Security, who has over 25 years of relevant experience in information security, including 14 years at the Company, and is further supported by a team of security professionals within the Information Systems &amp; Informatics department.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also established a management-level Technology Risk Management Committee, which includes leaders from finance, legal, operations, quality &amp; compliance, and information systems &amp; informatics, who are responsible for overseeing the execution of high-risk incident response and mitigation plans. This committee actively reviews technology strategies, physical and cybersecurity threat assessment, and emerging issues and related initiatives. It is also responsible for evaluating the materiality of information for SEC filings and, as required or as otherwise appropriate, coordinates with the Company&#8217;s Materiality Committee to support timely disclosure of relevant information.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div>The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, judgments and assumptions. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results could materially differ from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash, Cash Equivalents and Restricted Cash</span></div>All highly liquid interest-bearing investments are classified as cash equivalents. These investments mainly include  term deposits, money market instruments, corporate debt securities, and certificate of deposits with maturities of three months or less when purchased. The carrying value of these cash equivalents approximate fair value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company classified all of its investments in debt securities as available-for-sale and as current assets as they represent the investment of funds available for current operations as of September&#160;30, 2025 and 2024. The available-for-sale investments may consist of investment-grade interest bearing instruments, primarily corporate debt securities, U.S. government and agency securities, commercial notes, certificate of deposits, and municipal securities, which are accounted for at fair value.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dividends from these funds were automatically re-invested. Changes in fair values are reported as unrealized gains or losses and are recorded in the Company&#8217;s consolidated statement of operations and comprehensive income (loss).</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its investments for impairment based on a security-specific analysis as of each balance sheet date. If the fair value of a security is below its amortized cost, the Company first assesses whether it intends to sell the security or is more likely than not required to sell it before recovery of its amortized cost. If neither condition is met, the Company evaluates whether a portion of the decline is attributable to credit loss. Any credit-related impairment is recorded as an allowance for credit losses through earnings, with non-credit-related unrealized losses recorded in other </span></div>comprehensive income (loss). The Company did not recognize any credit loss relating to its investment for the years ended September&#160;30, 2025, 2024, and 2023.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentration of credit risk primarily consist of cash, cash equivalents and restricted cash and investments. As of September&#160;30, 2025 and 2024, the Company&#8217;s investments were primarily invested in money market funds, U.S. Government, commercial paper, and corporate debt securities and term deposit through highly rated financial institutions. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity. The Company also maintains several bank accounts at two financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Visirna maintains several deposit and term accounts in mainland China, Hong Kong, and Singapore. Cash balances are held with various local and international financial institutions, which are subject to their respective jurisdictional deposit insurance programs. The Deposit Insurance Fund Management Corporation in China provides coverage of up to RMB 500,000 per depositor per institution, and the Hong Kong Deposit Protection Scheme provides protection of up to HKD 800,000 per depositor per bank, and the Singapore Deposit Insurance Corporation provides coverage of up to SGD 100,000 per depositor per member bank.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property, Plant and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at cost, net of accumulated depreciation. Depreciation expense is recorded on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the asset life or lease term. Construction in progress reflects amounts incurred for construction or improvements of property, plant and equipment that have not been placed in service. Upon disposition, the cost and accumulated depreciation of assets retired or sold are removed from the respective asset category, and any gain or loss is recognized in the Company&#8217;s consolidated statement of operations and comprehensive income (loss).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The estimated useful lives of property, plant and equipment are as follows (in years):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Buildings</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">39</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7 to 10</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Shorter of asset life or lease term</span></div></td></tr></table></div>The Company periodically assesses long-lived assets or asset groups, including property, plant and equipment, for recoverability when events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the Company identifies an indicator of impairment, the Company assesses recoverability by comparing the carrying amount of the asset to the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset. An impairment loss is recognized when the carrying amount is not recoverable and is measured as the excess of carrying value over fair value. There were no impairment charges during the years ended September&#160;30, 2025, 2024, and 2023.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets Subject to Amortization</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intangible Assets Subject to Amortization</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include certain patents and license agreements. The Company evaluates intangible assets for impairment annually or whenever events or changes in circumstances indicate that it is more likely than not that the carrying amount of intangible assets may exceed their implied fair values. No impairment charges were recorded during the years ended September&#160;30, 2025, 2024, and 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether a contract is, or contains, a lease at inception. All of the Company&#8217;s leases are classified as operating leases. Leases with terms greater than one-year are recognized on the Company&#8217;s consolidated balance sheets as right-of-use assets that represent the Company&#8217;s right to use an underlying asset for the lease term, and lease liabilities that represent its obligation to make lease payments arising from the lease. Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the expected lease term. As of September&#160;30, 2025 and 2024, the Company is not reasonably certain that it will exercise renewal options for any lease facilities. Therefore, these options are not included in the right-of-use assets and liabilities. </span></div>The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ClinicalAccrualPolicyPolicyTextBlock', window );">Clinical Accruals</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Accruals</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues liabilities for products received or services incurred, particularly for ongoing clinical trials, where service providers have not yet billed or where billing terms do not align with the timing of the work performed as of the period-end. These costs mainly include third-party clinical management or clinical research organization (CRO), laboratory analysis, and investigator fees. Accrual estimates may be based on vendor communications to obtain pending invoices and/or estimates for services performed during the period. In some cases, these estimates require significant judgment, drawing on an understanding of research and development programs, services provided during the period, prior experience, and, where applicable, the expected duration of third-party contracts. Actual costs upon settlement may differ significantly from the accrued amounts in the Company&#8217;s consolidated financial statements, though historical estimates have not differed materially from actual costs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that it determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing. If the license is not considered to be distinct from other performance obligations, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time. If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Typically, the Company&#8217;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a New Drug Application (&#8220;NDA&#8221;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#8217;s consolidated statements of operations and comprehensive income (loss). Typically, milestone payments and royalties are achieved after the Company&#8217;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or preclinical program. Milestones or royalties achieved after the Company&#8217;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its licensing or collaboration agreements. Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment. Additionally, future royalty payments are not substantially within the control of the Company or the customer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, the revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using the input method; Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations. If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#8217;s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Arrangements</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of Financial Accounting Standards Board (&#8220;FASB&#8221;) Topic 808 - </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606 - </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue for Contracts from Customers</span>. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to research and development expense or general and administrative expense, as appropriate.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred. Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#8217;s research and development operations, and costs to acquire technology licenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense for all stock grants are based on their estimated grant-date fair value. The fair value of stock option awards is estimated using the Black-Scholes option valuation model which requires the input of subjective assumptions to calculate the value of stock options. The Company uses historical data and other information to estimate the expected price volatility and the expected forfeiture rate for stock option awards. For restricted stock units, the value of the award is based on the Company&#8217;s stock price at the grant date. For performance-based restricted stock unit awards, the value of the award is based on the Company&#8217;s stock price at the grant date, with consideration given to the </span></div>probability of the performance condition being achieved. Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#8217;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting basis and the respective tax basis of the Company&#8217;s assets and liabilities, and expected benefits of utilizing net operating loss, capital loss, and tax-credit carryforwards. The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent management does not believe these assets are more likely than not to be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or laws is recognized in earnings in the period that includes the enactment date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entity ("VIE")</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Variable Interest Entity (&#8220;VIE&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is an entity that, by design, either (i) lacks sufficient equity to permit the entity to finance its activities without additional subordinated financial support from other parties; or (ii) has equity investors that do not have the ability to make significant decisions relating to the entity&#8217;s operations through voting rights, or do not have the obligation to absorb the expected losses, or do not have the right to receive the residual returns of the entity. The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. The primary beneficiary is the party that has both (i) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance, and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE through its interest in the VIE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, the Company entered into a license agreement with Visirna (Note 2) and consolidated Visirna&#8217;s financial statements in which the Company has a direct controlling financial interest based on the VIE model. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all the facts and circumstances, including its role in establishing Visirna and its ongoing rights and responsibilities to assess whether the Company has the power to direct the activities of Visirna. In general, the parties that make the most significant decisions affecting a VIE and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company also considers all of its economic interests to assess whether the Company has the obligation to absorb losses of Visirna or the right to receive benefits from it that could potentially be significant to Visirna. This assessment requires the Company to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to Visirna. Factors considered in assessing the significance include: the design of  Visirna, including its capitalization structure, subordination of interests, payment priority, and the reasons why the interests are held by the Company. </span></div>At Visirna&#8217;s inception, the Company determined it was the primary beneficiary and that Visirna should be consolidated based on the facts and circumstances. The Company performs ongoing reassessments of the VIE based on reconsideration events and reevaluates whether a change to the consolidation conclusion is required. As of September&#160;30, 2025, there were no events to be reconsidered in the consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Loss per Share</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units outstanding. </span></div>During the years ended September&#160;30, 2025, 2024 and 2023, the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units outstanding during the period due to their anti-dilutive effect.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Currency Translation Adjustments</span></div>Three of the Company&#8217;s wholly-owned subsidiaries&#8217; functional currencies is not the United States dollar, which is the Company&#8217;s reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Translation adjustments arising from the use of different exchange rates from period to period are included in the accumulated other comprehensive income (loss).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Segment Information</span></div>The Company operates as a single segment because its CODM reviews operating results on an aggregate basis and manages its operations as a single operating segment.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">in November 2024, and ASU 2025-01,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Clarifying the Effective Date</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. These updates require entities to provide disaggregated disclosures of income statement expenses. The ASUs do not affect the expense captions presented on the face of the income statement but instead require the disaggregation of certain expense captions into specified categories within the footnotes to the financial statements. The ASUs will become effective for the Company beginning October 1, 2027, and the Company is currently evaluating the impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standard Update (&#8220;ASU&#8221;) 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, to improve its income tax disclosure requirements. Under the guidance, entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. This guidance became effective for the Company beginning on October 1, 2025. The Company does not expect any material impact on its consolidated financial statements and related disclosures resulting from applying this ASU. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses. The guidance requires public companies with a single reportable segment to provide all disclosures required under ASC 280. In addition, the guidance requires public companies to include in interim reports all disclosures related to a reportable segment&#8217;s profit or loss and assets that are currently required in annual reports. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. This ASU is applicable to the Company&#8217;s Annual Report on Form 10-K for the year ending September 30, 2025, and subsequent interim periods. Refer to Note 16, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, for further details on segment information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. ASC 740, "Income Taxes", requires the effects of changes in tax rates and laws to be recognized in the period in which the legislation is enacted. The Company has implemented OBBBA in the fourth quarter of fiscal 2025. Refer to Note 11, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, for further details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ClinicalAccrualPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Accrual Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ClinicalAccrualPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Paragraph 2AA<br> -Subparagraph (a)<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-2AA<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfCurrentProductsTableTextBlock', window );">Schedule of Company's Current Pipeline</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.962%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:27pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">plozasiran</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">zodasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">olpasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-PNPLA3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">GSK4532990</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">GSK</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-INHBE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-ALK7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-DIMERPA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-RAGE</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">SRP-1002 (ARO-MMP7)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">fazirsiran</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Takeda and Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">daplusiran/tomligisiran</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Neuromuscular</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">SRP-1001 (ARO-DUX4)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">SRP-1003 (ARO-DM1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">SRP-1004 (ARO-ATXN2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Sarepta</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-SNCA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Pre-clinical</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Novartis</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-MAPT </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-C3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">ARO-CFB</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-style:italic;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Greater China rights for plozasiran are out-licensed to Sanofi.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Useful Lives of Property Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The estimated useful lives of property, plant and equipment are as follows (in years):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Buildings</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">39</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7 to 10</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Shorter of asset life or lease term</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property, plant and equipment: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Buildings</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">251,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">75,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">62,758&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">65,353&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing equipment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">18,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,594&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,594&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">104,425&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">104,410&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">15,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">188,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">462,684&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">444,053&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(80,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(58,021)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">382,515&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">386,032&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ScheduleOfCurrentProductsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Current Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ScheduleOfCurrentProductsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of revenue recognized:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">GSK</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">29,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Horizon</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">23,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">162,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Sarepta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">696,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">130,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">829,448&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">240,735&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Receivables and Contract Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of receivables and contract liabilities related to the Company&#8217;s collaboration and license agreements:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Receivables included in accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">6,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities included in deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Accounts (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The estimated useful lives of property, plant and equipment are as follows (in years):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Buildings</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">39</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7 to 10</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3 to 5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Shorter of asset life or lease term</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property, plant and equipment: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Buildings</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">251,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">75,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">62,758&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">65,353&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing equipment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">18,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,594&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,594&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">104,425&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">104,410&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">15,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">188,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">462,684&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">444,053&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(80,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(58,021)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">382,515&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">386,032&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></div></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">30,330&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">28,069&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accrued research and development expenses; co-development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">31,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">23,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accrued capital expenditures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,206&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accrued income taxes (benefits)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">20,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7,717&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7,391&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">90,419&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">63,017&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock', window );">Schedule of Short-term, Long-term Investments and Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:7pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:35.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.449%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">689,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">692,818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total current investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">689,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,956&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">692,818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"></td><td style="width:35.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.449%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale securities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">577,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">578,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total current investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">577,465&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">578,276&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Contract Maturity of Available for Sale Securities</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the contract maturity of the available-for-sale securities as of:</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">   </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.807%"><tr><td style="width:1.0%"></td><td style="width:51.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">224,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">578,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">After one to two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">468,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">After two to three years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">692,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">578,276&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Held to maturity securities and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text">The following table presents the components of intangible assets: <div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:24.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,426&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">24,857&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">17,996&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">6,861&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">14,873&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">6,855&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total intangible assets, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">24,857&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,295&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8,562&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Intangible Assets Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the estimated future amortization expense related to intangible assets as of September&#160;30, 2025:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.272%"><tr><td style="width:1.0%"></td><td style="width:60.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Expense</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">6,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Shares of Common Stock and Preferred Stock</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s shares of common stock and preferred stock:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"><tr><td style="width:1.0%"></td><td style="width:31.294%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Common stock </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">135,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">135,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">124,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">124,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(1) Does not include shares of common stock into which the Avoro Pre-Funded Warrants may be exercised.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Assets and Liabilities and Lease Cost</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:33.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.080%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">43,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">45,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7,289&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">6,342&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">104,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">111,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.388%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">11,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,952&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,006&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease cost</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,511&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">13,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) Variable lease cost is primarily related to operating expenses associated with the Company&#8217;s operating leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities on an Undiscounted Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents maturities of operating lease liabilities on an undiscounted basis as of September&#160;30, 2025:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"></td><td style="width:82.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">15,873&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">15,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">13,696&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">13,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">14,282&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2031 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">100,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">173,558&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(62,157)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">111,401&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"></td><td style="width:64.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash received for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">48,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets adjusted in exchange for new/amended operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">17,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">15,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">11,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">11.70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">12.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">13.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Awards Outstanding</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding attributable to Arrowhead Pharmaceuticals, Inc.:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.529%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Inducement Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">776,279&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">32,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">598,605&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,407,035&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,750,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">560,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,810,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,276,279&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,782,222&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,158,885&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7,217,386&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Payment Arrangement, Expensed</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expenses included in operating expenses attributable to Arrowhead Pharmaceuticals, Inc.:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.940%"><tr><td style="width:1.0%"></td><td style="width:28.210%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.313%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">27,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">29,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">34,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">27,528&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">37,570&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">43,798&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">54,848&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">67,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">78,130&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Summarized Information about Stock Options</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the stock option activity for the year ended September&#160;30, 2025:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 30, 2024</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,978,516&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">23.39&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cancelled or expired</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(36,341)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">45.44&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(535,140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 30, 2025</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,407,035&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">28.90&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">19,099,141&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at September 30, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,407,035&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">28.90&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">19,099,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Value Stock Options</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Black-Scholes option pricing model: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3.69% &#8211; 4.57%</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">86.4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">25.61</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) The dividend yield is zero as the Company currently does not pay a dividend. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(3) Volatility is estimated based on volatility average of the Company&#8217;s common stock price. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(4) The computation of expected term was determined based on safe harbor rules, considering the contractual terms of the awards and vesting schedules.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(5) No options were granted during the year ended September&#160;30, 2025 and September&#160;30, 2024.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Share Activity Related to RSUs</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2024</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,913,312&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">49.61&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,779,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">19.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1,525,693)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">47.15&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(356,957)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">30.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2025</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,810,351&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">36.97&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicate the fair value hierarchy of the valuation techniques utilized by the Company: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:33.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">150,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">150,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">12,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">12,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Commercial notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">13,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">13,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">509,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">509,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">692,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">692,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">64,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">64,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Term deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">134,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">134,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">64,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">153,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">218,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">64,460&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">846,358&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">910,818&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">     </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:33.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">160,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">160,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Commercial notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">179,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">179,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">237,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">237,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">578,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">578,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">66,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">66,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">66,966&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">66,966&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">66,966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">578,276&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">645,242&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Components of Income (Loss) Before Income Tax Expense and Noncontrolling Interest</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income (loss) before income tax expense and noncontrolling interest are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(42,573)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(582,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(194,639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">94,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(30,127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(7,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">51,533&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(612,460)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(202,491)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Taxes for Provisions (Benefit)</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision (benefit) consisted of the following components:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:69.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.170%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.170%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.174%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,710&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(3,290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total current tax</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21,419&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(2,767)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Income tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21,419&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(2,767)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the tax expense based on the statutory rate to the Company&#8217;s actual tax expense in the consolidated statements of operations and comprehensive income (loss). A notional 21% tax rate was applied as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">U.S. federal statutory income tax</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(44.4)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Permanent and other items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(37.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(27.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of the Net Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant components of the Company&#8217;s net deferred tax assets and liabilities: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.404%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">70,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">102,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">232,360&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">156,015&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">48,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">85,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">171,262&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">81,556&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">23,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">27,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">9,184&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10,989&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,034&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,384&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">562,686&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">473,008&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Valuation allowance</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(497,543)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(448,867)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(30,503)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(13,155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(9,424)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(10,792)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Original Issue Discount</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(24,586)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax liability</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(65,143)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(24,141)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Gross Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s gross unrecognized tax benefits:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance of unrecognized tax benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">14,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Gross increase for prior period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">9,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Gross decrease for prior period tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1,489)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Gross increase for current period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Lapse of statue of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance of unrecognized tax benefits</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">22,152&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,613&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">14,536&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract', window );"><strong>Liability Related To The Sale Of Future Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock', window );">Schedule of Liability Related to the Sale of Future Royalties</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the activity with respect to the liability related to the sale of future royalties.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Beginning carrying value </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">341,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">268,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Upfront payment received</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Milestone payment received</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">26,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">23,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Ending carrying value</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">367,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">341,361&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To The Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Liability Related To The Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Line of Credit Facilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding balance of the Credit Facility consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Initial Term Loan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated interest on the Initial Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">66,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">9,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated accretion of the MOIC Payment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Less: Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(13,912)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(15,817)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of credit facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(40,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Less: Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(201,625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Credit facility, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">214,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">393,183&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock', window );">Schedule of Interest Expense Recognized Related to Credit Facility</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth total interest expense recognized related to the Credit Facility:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:54.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,906&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of the MOIC Payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">57,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">9,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Total interest expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">63,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">9,317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-Term Debt</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The amounts shown in the table below, related to the Credit Facility, represent the expected repayments of principle and accrued interest balance as of September&#160;30, 2025 as well as any mandatory prepayments that the Company is obligated to make to the Lenders during the indicated periods. The principal balance will increase from accrued paid in kind interest and the table does not include MOIC payments beyond those contractually determined. Actual payments on current principal may vary from the amounts presented in the table. </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">214,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">339,990&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Interest Expense Recognized Related To Credit Facility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted net loss per share for the years ended September&#160;30, 2025, 2024 and 2023. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1,631)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(599,493)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(205,275)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average basic shares outstanding</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">133,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">119,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">106,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average diluted shares outstanding</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">133,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">119,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">106,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Basic net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(5.00)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1.92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Diluted net loss per share</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(5.00)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(1.92)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Income (Loss) Per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:52.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.798%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,020&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,737&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,053&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text">In addition, research and development and selling, general and administrative expenses are significant segment expenses regularly provided to the CEO with the following categories:<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Candidate costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">347,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">259,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">162,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D discovery costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">66,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">74,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">55,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Salaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">109,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">96,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">73,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Facilities related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">29,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">25,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expense, excluding non-cash expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">552,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">455,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">307,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">32,582&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">33,586&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">34,332&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">21,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">607,159&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">505,870&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">353,188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General &amp; Administrative</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Salaries</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">31,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">27,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">22,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Professional, outside services, and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">53,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">24,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">20,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Facilities related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total general and administrative expense, excluding non-cash expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">91,130&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">56,438&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">47,134&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">30,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">40,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">43,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation/amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Total general and administrative expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">123,943&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">98,761&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">92,549&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 13, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 24, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 14, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 07, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 25, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>segment </div>
<div>subsidiary</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226,548,000<span></span>
</td>
<td class="nump">$ 102,685,000<span></span>
</td>
<td class="nump">$ 110,891,000<span></span>
</td>
<td class="nump">$ 108,005,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available-for-sale securities, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">692,818,000<span></span>
</td>
<td class="nump">578,276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_IncreaseDecreaseInCashAndInvestments', window );">Net increase (decrease) in cash and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Value of stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,193,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,289,000<span></span>
</td>
<td class="nump">22,720,000<span></span>
</td>
<td class="nump">15,299,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from the issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayments of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,625,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,666,000<span></span>
</td>
<td class="nump">141,469,000<span></span>
</td>
<td class="nump">176,737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible assets subject to amortization, impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency', window );">Number of subsidiaries with foreign currency as functional currency | subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember', window );">Sarepta | Sarepta Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ProceedsFromCollaborationArrangements', window );">Proceeds from collaboration arrangements</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentMilestonePayments', window );">Development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Value of stock repurchased</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_IncreaseDecreaseInCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in cash and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_IncreaseDecreaseInCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Subsidiaries With Foreign Currency As Functional Currency</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_OrganizationAndSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ProceedsFromCollaborationArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collaboration Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ProceedsFromCollaborationArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Useful Lives of Property, Plant and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">39 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchEquipmentMember', window );">Research equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember', window );">Manufacturing equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember', window );">Manufacturing equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ComputersAndSoftwareMember', window );">Computers and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ComputersAndSoftwareMember', window );">Computers and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_OrganizationAndSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ComputersAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ComputersAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 829,448<span></span>
</td>
<td class="nump">$ 3,551<span></span>
</td>
<td class="nump">$ 240,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">2,645<span></span>
</td>
<td class="nump">2,685<span></span>
</td>
<td class="nump">29,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">866<span></span>
</td>
<td class="nump">162,516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_AmgenIncorporatedMember', window );">Amgen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_SareptaTherapeuticsIncMember', window );">Sarepta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">696,803<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_HorizonTherapeuticsIrelandDACMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_HorizonTherapeuticsIrelandDACMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_JanssenPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_JanssenPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_AmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_AmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_SareptaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_SareptaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements - Receivables and Contract Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Receivables included in accounts receivable</a></td>
<td class="nump">$ 6,824<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities included in deferred revenue</a></td>
<td class="nump">$ 2,399<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - GlaxoSmithKline Intellectual Property (No. 3) Limited (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 22, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 11, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,399,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | GSK-HSD License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree', window );">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | GSK-HSD License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommercialMilestonePaymentsAtFirstCommercialSale', window );">Commercial milestone payments at first commercial sale</a></td>
<td class="nump">190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SalesRelatedMilestonePayments', window );">Sales-related milestone payments</a></td>
<td class="nump">$ 590,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage eligible to receive tiered royalties on net sales</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | GSK-HBV Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentMilestonePayments', window );">Development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | GSK-HBV Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentAndSalesMilestonesPayments', window );">Development and sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 830,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommercialMilestonePaymentsAtFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone payments at first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommercialMilestonePaymentsAtFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development And Sales Milestones Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of eligible to receive tiered royalties on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SalesRelatedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales-related milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SalesRelatedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_GSKHSDLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_GSKHSDLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_GSKHBVAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_GSKHBVAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>obligation </div>
<div>bundle</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,399,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,419,000<span></span>
</td>
<td class="nump">$ 63,017,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda | License and Co-Funding Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctBundle', window );">Number of distinct bundle | bundle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda | License and Co-Funding Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage eligible to receive tiered royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda | License and Co-Funding Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage eligible to receive tiered royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 527,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctBundle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct bundle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctBundle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of eligible to receive tiered royalties on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements - Amgen, Inc. (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>agreement</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 2,399,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember', window );">Amgen | Olpasiran Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfAgreements', window );">Number of agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember', window );">Amgen | Olpasiran Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments', window );">Additional remaining development regulatory and sales milestones payments</a></td>
<td class="nump">$ 485,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional remaining development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Sarepta Therapeutics, Inc. (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 13, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 24, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 14, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 07, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 25, 2024 </div>
<div>USD ($) </div>
<div>program </div>
<div>obligation</div>
</th>
<th class="th">
<div>Aug. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Value of stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,193<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_GainLossOnTreasuryStockSettlement', window );">Gain on settlement of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,193<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">829,448<span></span>
</td>
<td class="nump">3,551<span></span>
</td>
<td class="nump">$ 240,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,824<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember', window );">Sarepta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember', window );">Sarepta | Sarepta Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfPerformanceObligations', window );">Number of performance obligations | obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ProceedsFromCollaborationArrangements', window );">Upfront payment</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SaleOfStockPremiumOnIssuanceOfShares', window );">Equity premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AdditionalCashReceivableUnderCollaborationAgreement', window );">Total annual installments amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments', window );">Annual installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod', window );">Annual installments period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationArrangementFixedConsideration', window );">Fixed consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationArrangementVariableConsideration', window );">Variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationArrangementConsideration', window );">Total transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 904,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_EnrollmentRelatedMilestonePayments', window );">Enrollment related milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfCollaborationPrograms', window );">Number of collaboration programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval', window );">Collaboration agreement termination notice period prior to any regulatory approval of a licensed product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Common stock repurchased (in shares) | shares</a></td>
<td class="nump">2,660,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,660,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentMilestonePayments', window );">Development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Value of stock repurchased</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock value</a></td>
<td class="nump">53,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_GainLossOnTreasuryStockSettlement', window );">Gain on settlement of treasury stock</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember', window );">Sarepta | Sarepta Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfNewTargetPrograms', window );">Number of new target programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RegulatoryMilestonePayments', window );">Regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SalesRelatedMilestonePayments', window );">Sales-related milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember', window );">Sarepta | Sarepta Collaboration Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RegulatoryMilestonePayments', window );">Regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SalesRelatedMilestonePayments', window );">Sales-related milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalCashReceivableUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Receivable Under Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalCashReceivableUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Receivable Under Collaboration Agreement, Annual Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Receivable Under Collaboration Agreement, Annual Installments Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationArrangementConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationArrangementConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationArrangementFixedConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Fixed Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationArrangementFixedConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Termination Notice Period Prior To Regulatory Approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationArrangementVariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Variable Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationArrangementVariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EnrollmentRelatedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Enrollment Related Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EnrollmentRelatedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_GainLossOnTreasuryStockSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Treasury Stock Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_GainLossOnTreasuryStockSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfCollaborationPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Collaboration Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfCollaborationPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfNewTargetPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of New Target Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfNewTargetPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ProceedsFromCollaborationArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collaboration Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ProceedsFromCollaborationArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulatory Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SaleOfStockPremiumOnIssuanceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Premium On Issuance Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SaleOfStockPremiumOnIssuanceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SalesRelatedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales-related milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SalesRelatedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Visirna Therapeutics Inc. (&#8220;Visirna&#8221;) and Genzyme Corporation (&#8220;Sanofi&#8221;) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 829,448<span></span>
</td>
<td class="nump">$ 3,551<span></span>
</td>
<td class="nump">$ 240,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_SanofiMember', window );">Sanofi | Sanofi License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FuturePotentialMilestonePayments', window );">Future potential milestone payments</a></td>
<td class="nump">265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationArrangementFixedConsideration', window );">Fixed consideration</a></td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationArrangementFixedConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Fixed Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationArrangementFixedConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FuturePotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future Potential Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_FuturePotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_SanofiLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_SanofiLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Accounts - Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 462,684<span></span>
</td>
<td class="nump">$ 444,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(80,169)<span></span>
</td>
<td class="num">(58,021)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">382,515<span></span>
</td>
<td class="nump">386,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">2,996<span></span>
</td>
<td class="nump">2,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">251,317<span></span>
</td>
<td class="nump">75,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchEquipmentMember', window );">Research equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">62,758<span></span>
</td>
<td class="nump">65,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">18,588<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">5,594<span></span>
</td>
<td class="nump">5,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ComputersAndSoftwareMember', window );">Computers and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">1,064<span></span>
</td>
<td class="nump">981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">104,425<span></span>
</td>
<td class="nump">104,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 15,942<span></span>
</td>
<td class="nump">$ 188,731<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ComputersAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ComputersAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Accounts - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense for property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.2<span></span>
</td>
<td class="nump">$ 16.9<span></span>
</td>
<td class="nump">$ 10.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ConstructionInProgressReclassifiedToBuildingMember', window );">Construction In Progress Reclassified To Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges', window );">Property, plant and equipment, reclassification</a></td>
<td class="num">$ (162.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges', window );">Property, plant and equipment, reclassification</a></td>
<td class="nump">162.7<span></span>
</td>
<td class="nump">$ 71.8<span></span>
</td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 years<span></span>
</td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember', window );">Construction In Progress Reclassified To Manufacturing Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges', window );">Property, plant and equipment, reclassification</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (16.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges', window );">Property, plant and equipment, reclassification</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember', window );">Manufacturing equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember', window );">Manufacturing equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 years<span></span>
</td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges', window );">Property, plant and equipment, reclassification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (71.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of physical assets used in the normal conduct of business and not intended for resale, from reclassification, impairment, donation, or changes classified as other. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTransfersAndChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ConstructionInProgressReclassifiedToBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ConstructionInProgressReclassifiedToBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Accounts - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 30,330<span></span>
</td>
<td class="nump">$ 28,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent', window );">Accrued research and development expenses; co-development</a></td>
<td class="nump">31,296<span></span>
</td>
<td class="nump">23,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AccruedCapitalExpenditureCurrent', window );">Accrued capital expenditures</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">4,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued income taxes (benefits)</a></td>
<td class="nump">20,799<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">7,717<span></span>
</td>
<td class="nump">7,391<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 90,419<span></span>
</td>
<td class="nump">$ 63,017<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AccruedCapitalExpenditureCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Capital Expenditure, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AccruedCapitalExpenditureCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Co-Development Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Current Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Current investments, Adjusted Basis</a></td>
<td class="nump">$ 689,882<span></span>
</td>
<td class="nump">$ 577,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent', window );">Current investments, Gross Unrealized Gains</a></td>
<td class="nump">2,956<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent', window );">Current investments, Gross Unrealized Losses</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Current investments, Fair Value</a></td>
<td class="nump">692,818<span></span>
</td>
<td class="nump">578,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Current investments, Adjusted Basis</a></td>
<td class="nump">689,882<span></span>
</td>
<td class="nump">577,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent', window );">Current investments, Gross Unrealized Gains</a></td>
<td class="nump">2,956<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent', window );">Current investments, Gross Unrealized Losses</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Current investments, Fair Value</a></td>
<td class="nump">$ 692,818<span></span>
</td>
<td class="nump">$ 578,276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of held to maturity securities and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Contract Maturity of Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Within one year</a></td>
<td class="nump">$ 224,328<span></span>
</td>
<td class="nump">$ 578,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo', window );">After one to two years</a></td>
<td class="nump">468,490<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree', window );">After two to three years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 692,818<span></span>
</td>
<td class="nump">$ 578,276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One Through Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year Two Through Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 6,861<span></span>
</td>
<td class="nump">$ 8,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">24,857<span></span>
</td>
<td class="nump">24,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">17,996<span></span>
</td>
<td class="nump">16,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">6,861<span></span>
</td>
<td class="nump">8,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">21,728<span></span>
</td>
<td class="nump">21,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">16,426<span></span>
</td>
<td class="nump">14,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 5,302<span></span>
</td>
<td class="nump">$ 6,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Lives</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 3,129<span></span>
</td>
<td class="nump">$ 3,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,570<span></span>
</td>
<td class="nump">1,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 1,559<span></span>
</td>
<td class="nump">$ 1,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Lives</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FiniteLivedIntangibleAssetsImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_FiniteLivedIntangibleAssetsImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 24: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=arwr_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Expected Future Amortization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="nump">795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2030</a></td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 6,861<span></span>
</td>
<td class="nump">$ 8,562<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Shares of Common Stock and Preferred Stock (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">290,000<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">135,702<span></span>
</td>
<td class="nump">124,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">135,702<span></span>
</td>
<td class="nump">124,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 13, 2025</div></th>
<th class="th"><div>Feb. 24, 2025</div></th>
<th class="th"><div>Feb. 14, 2025</div></th>
<th class="th"><div>Feb. 07, 2025</div></th>
<th class="th"><div>Nov. 25, 2024</div></th>
<th class="th"><div>Dec. 02, 2022</div></th>
<th class="th"><div>Aug. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,378,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">917,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights', window );">Warrants purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from the issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Number of warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Value of stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,193,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,193,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_GainLossOnTreasuryStockSettlement', window );">Gain on settlement of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,193,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember', window );">Sarepta | Sarepta Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Common stock repurchased (in shares)</a></td>
<td class="nump">2,660,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,660,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Common stock repurchase price per share (in dollars per share)</a></td>
<td class="nump">$ 18.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Value of stock repurchased</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ProceedsFromCollaborationArrangements', window );">Proceeds from collaboration arrangements</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentDueFromCollaborativeAgreement', window );">Milestone payment due from collaborative agreement</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock value</a></td>
<td class="nump">53,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_GainLossOnTreasuryStockSettlement', window );">Gain on settlement of treasury stock</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares of common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,926,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember', window );">ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued to institutional investors (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember', window );">ATM Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance', window );">Common stock shares value reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock', window );">Percentage of commission to sales agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember', window );">2013 and 2021 Incentive Plans and other inducement grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,851,400<span></span>
</td>
<td class="nump">11,492,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Purchase Price of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, capital shares value reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommonStockCapitalSharesValueReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_GainLossOnTreasuryStockSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Treasury Stock Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_GainLossOnTreasuryStockSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentDueFromCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Due From Collaborative Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentDueFromCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on aggregate gross proceeds from sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ProceedsFromCollaborationArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collaboration Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ProceedsFromCollaborationArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> ft&#178; in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember', window );">Drug Manufacturing Facility | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Planned area of site (in sq ft) | ft&#178;</a></td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember', window );">Laboratory and Office Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommitmentsCapitalExpendituresIncurredToDate', window );">Capital expenditures incurred</a></td>
<td class="nump">$ 78,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember', window );">Laboratory and Office Facility | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Planned area of site (in sq ft) | ft&#178;</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember', window );">Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommitmentsCapitalExpendituresIncurredToDate', window );">Capital expenditures incurred</a></td>
<td class="nump">$ 296,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommitmentsCapitalExpendituresIncurredToDate', window );">Capital expenditures incurred</a></td>
<td class="nump">173,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommitmentsCapitalExpendituresIncurredToDate', window );">Capital expenditures incurred</a></td>
<td class="nump">18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommitmentsCapitalExpendituresIncurredToDate', window );">Capital expenditures incurred</a></td>
<td class="nump">15,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchEquipmentMember', window );">Research equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommitmentsCapitalExpendituresIncurredToDate', window );">Capital expenditures incurred</a></td>
<td class="nump">7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommitmentsCapitalExpendituresIncurredToDate', window );">Capital expenditures incurred</a></td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommitmentsCapitalExpendituresIncurredToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments, Capital Expenditures Incurred To Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommitmentsCapitalExpendituresIncurredToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>option</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 29, 2025 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember', window );">Corporate Headquarters In Pasadena | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember', window );">Corporate Headquarters In Pasadena | California | Colorado Owner, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ProceedsFromTenantImprovementAllowance', window );">Proceeds from additional tenant improvement allowance | $</a></td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember', window );">Research Facility in Madison | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfOptionsToRenew">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options to renew.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfOptionsToRenew</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ProceedsFromTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Tenant Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ProceedsFromTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Lease Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 43,891<span></span>
</td>
<td class="nump">$ 45,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">7,289<span></span>
</td>
<td class="nump">6,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">104,112<span></span>
</td>
<td class="nump">111,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">16,511<span></span>
</td>
<td class="nump">16,689<span></span>
</td>
<td class="nump">$ 13,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">10,483<span></span>
</td>
<td class="nump">11,035<span></span>
</td>
<td class="nump">10,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">4,076<span></span>
</td>
<td class="nump">3,648<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">2,006<span></span>
</td>
<td class="nump">1,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 15,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">15,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">13,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">13,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="nump">14,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2031 and thereafter</a></td>
<td class="nump">100,672<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">173,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(62,157)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 111,401<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow and Other Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash received for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,099<span></span>
</td>
<td class="nump">$ 48,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability', window );">Right-of-use assets adjusted in exchange for new/amended operating lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="nump">17,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 15,474<span></span>
</td>
<td class="nump">$ 11,038<span></span>
</td>
<td class="nump">$ 5,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">11 years 8 months 12 days<span></span>
</td>
<td class="text">12 years 6 months<span></span>
</td>
<td class="text">13 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset Adjustment In Exchange For Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Awards granted and outstanding (in shares)</a></td>
<td class="nump">7,217,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,217,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">2,378,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,378,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">1,407,035<span></span>
</td>
<td class="nump">1,978,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,407,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation</a></td>
<td class="nump">$ 54,848<span></span>
</td>
<td class="nump">$ 67,097<span></span>
</td>
<td class="nump">$ 78,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">5,810,351<span></span>
</td>
<td class="nump">4,913,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,810,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation</a></td>
<td class="nump">$ 54,900<span></span>
</td>
<td class="nump">$ 64,300<span></span>
</td>
<td class="nump">69,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized pre-tax compensation expense</a></td>
<td class="nump">$ 73,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize pre-tax compensation expense</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">12,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Awards granted and outstanding (in shares)</a></td>
<td class="nump">2,276,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,276,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares forfeited (in shares)</a></td>
<td class="nump">170,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">776,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">776,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Plan | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Awards granted and outstanding (in shares)</a></td>
<td class="nump">3,782,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,782,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">6,231,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares forfeited (in shares)</a></td>
<td class="nump">439,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">32,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Plan | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">3,750,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_InducementPlanMember', window );">Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="nump">832,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">832,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">660,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">255,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">598,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">598,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_InducementPlanMember', window );">Inducement Plan | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">53,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_VisirnaESOPMember', window );">Visirna ESOP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,612,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation</a></td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_VisirnaESOPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_VisirnaESOPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Granted and Outstanding Awards (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options (in shares)</a></td>
<td class="nump">1,407,035<span></span>
</td>
<td class="nump">1,978,516<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">7,217,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options (in shares)</a></td>
<td class="nump">776,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">2,276,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options (in shares)</a></td>
<td class="nump">32,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">3,782,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember', window );">Inducement Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options (in shares)</a></td>
<td class="nump">598,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">1,158,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units (in shares)</a></td>
<td class="nump">5,810,351<span></span>
</td>
<td class="nump">4,913,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | 2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units (in shares)</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | 2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units (in shares)</a></td>
<td class="nump">3,750,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Inducement Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units (in shares)</a></td>
<td class="nump">560,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_InducementAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Expenses Included in Operating Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation</a></td>
<td class="nump">$ 54,848<span></span>
</td>
<td class="nump">$ 67,097<span></span>
</td>
<td class="nump">$ 78,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation</a></td>
<td class="nump">27,320<span></span>
</td>
<td class="nump">29,527<span></span>
</td>
<td class="nump">34,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation</a></td>
<td class="nump">$ 27,528<span></span>
</td>
<td class="nump">$ 37,570<span></span>
</td>
<td class="nump">$ 43,798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summarized Information about Stock Options (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">1,978,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled or expired (in shares)</a></td>
<td class="num">(36,341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(535,140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">1,407,035<span></span>
</td>
<td class="nump">1,978,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Outstanding, Exercisable (in shares)</a></td>
<td class="nump">1,407,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 23.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled or expired (in dollars per share)</a></td>
<td class="nump">45.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">7.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">28.90<span></span>
</td>
<td class="nump">$ 23.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)</a></td>
<td class="nump">$ 28.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term (Years)</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 19,099,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 19,099,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions Used to Value Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.69%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.57%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of RSUs Activity (Details) - Restricted stock units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning of period (in shares) | shares</a></td>
<td class="nump">4,913,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">2,779,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(1,525,693)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(356,957)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">End of period (in shares) | shares</a></td>
<td class="nump">5,810,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 49.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">19.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">47.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">30.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 36.97<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">$ 692,818<span></span>
</td>
<td class="nump">$ 578,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">692,818<span></span>
</td>
<td class="nump">578,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">218,000<span></span>
</td>
<td class="nump">66,966<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">910,818<span></span>
</td>
<td class="nump">645,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">64,460<span></span>
</td>
<td class="nump">66,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Term deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">134,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">3,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">16,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">150,695<span></span>
</td>
<td class="nump">160,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">12,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">7,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">13,801<span></span>
</td>
<td class="nump">179,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">509,257<span></span>
</td>
<td class="nump">237,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">64,460<span></span>
</td>
<td class="nump">66,966<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">64,460<span></span>
</td>
<td class="nump">66,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">64,460<span></span>
</td>
<td class="nump">66,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Term deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">692,818<span></span>
</td>
<td class="nump">578,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">153,540<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">846,358<span></span>
</td>
<td class="nump">578,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Term deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">134,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">3,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">16,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">150,695<span></span>
</td>
<td class="nump">160,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">12,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">7,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">13,801<span></span>
</td>
<td class="nump">179,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">509,257<span></span>
</td>
<td class="nump">237,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Term deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income (Loss) Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (42,573)<span></span>
</td>
<td class="num">$ (582,333)<span></span>
</td>
<td class="num">$ (194,639)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">94,106<span></span>
</td>
<td class="num">(30,127)<span></span>
</td>
<td class="num">(7,852)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Total</a></td>
<td class="nump">$ 51,533<span></span>
</td>
<td class="num">$ (612,460)<span></span>
</td>
<td class="num">$ (202,491)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Provision (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 21,440<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 1,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="num">(56)<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">1,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">35<span></span>
</td>
<td class="num">(3,290)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax</a></td>
<td class="nump">21,419<span></span>
</td>
<td class="num">(2,767)<span></span>
</td>
<td class="nump">2,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 21,419<span></span>
</td>
<td class="num">$ (2,767)<span></span>
</td>
<td class="nump">$ 2,784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory income tax</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal tax benefit</a></td>
<td class="num">(3.10%)<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(44.40%)<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Permanent and other items</a></td>
<td class="num">(37.90%)<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="num">(4.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent', window );">Non-deductible compensation</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
<td class="num">(4.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent', window );">Foreign-derived intangible income deduction</a></td>
<td class="num">(16.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent', window );">Other income</a></td>
<td class="nump">11.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">10.70%<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">95.40%<span></span>
</td>
<td class="num">(27.00%)<span></span>
</td>
<td class="num">(20.50%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">41.70%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Other Income, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 70,858<span></span>
</td>
<td class="nump">$ 102,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost', window );">Capitalized research and development</a></td>
<td class="nump">232,360<span></span>
</td>
<td class="nump">156,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">48,867<span></span>
</td>
<td class="nump">85,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">171,262<span></span>
</td>
<td class="nump">81,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">23,919<span></span>
</td>
<td class="nump">27,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">9,184<span></span>
</td>
<td class="nump">10,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Accrued compensation</a></td>
<td class="nump">4,254<span></span>
</td>
<td class="nump">4,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">1,034<span></span>
</td>
<td class="nump">1,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">948<span></span>
</td>
<td class="nump">2,843<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">562,686<span></span>
</td>
<td class="nump">473,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(497,543)<span></span>
</td>
<td class="num">(448,867)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(30,503)<span></span>
</td>
<td class="num">(13,155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="num">(9,424)<span></span>
</td>
<td class="num">(10,792)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome', window );">Unrealized gains</a></td>
<td class="num">(630)<span></span>
</td>
<td class="num">(194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DeferredTaxLiabilitiesOriginalIssueDiscount', window );">Original Issue Discount</a></td>
<td class="num">(24,586)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total gross deferred tax liability</a></td>
<td class="num">(65,143)<span></span>
</td>
<td class="num">(24,141)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets right of use assets/ lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DeferredTaxLiabilitiesOriginalIssueDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Original Issue Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DeferredTaxLiabilitiesOriginalIssueDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 497,543<span></span>
</td>
<td class="nump">$ 448,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Income tax expense (benefit) related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">20,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards subject to expiration</a></td>
<td class="nump">20,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Income tax credits</a></td>
<td class="nump">49,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">815,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards not subject to expiration</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Income tax credits</a></td>
<td class="nump">26,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_TaxCreditCarryforwardAmountSubjectToExpiration', window );">Tax credit carryforward, amount, subject to expiration</a></td>
<td class="nump">13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 46,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Not Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_TaxCreditCarryforwardAmountSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Amount, Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_TaxCreditCarryforwardAmountSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Gross Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance of unrecognized tax benefits</a></td>
<td class="nump">$ 16,613<span></span>
</td>
<td class="nump">$ 14,536<span></span>
</td>
<td class="nump">$ 3,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Gross increase for prior period tax positions</a></td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">654<span></span>
</td>
<td class="nump">9,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Gross decrease for prior period tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,489)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increase for current period tax positions</a></td>
<td class="nump">4,379<span></span>
</td>
<td class="nump">3,415<span></span>
</td>
<td class="nump">3,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statue of limitations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,992)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance of unrecognized tax benefits</a></td>
<td class="nump">$ 22,152<span></span>
</td>
<td class="nump">$ 16,613<span></span>
</td>
<td class="nump">$ 14,536<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employee benefits costs</a></td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionsUpToThreePercentMember', window );">Employee Contributions up to 3%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Discretionary match percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of compensation</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionNextTwoPercentMember', window );">Employee Contributions Next 2%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Discretionary match percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of compensation</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (m)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionsUpToThreePercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionsUpToThreePercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionNextTwoPercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionNextTwoPercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember', window );">Royalty Pharma Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial', window );">Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponFDAApproval', window );">Milestone payment receivable upon FDA approval</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments', window );">Milestone payment receivable upon receipt of royalty payments</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RoyaltyPaymentThreshold', window );">Royalty payment threshold</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate', window );">Liability related to the sale of future royalties, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember', window );">Royalty Pharma Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability, Sale Of Future Royalties, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilitySaleOfFutureRoyaltiesInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable Upon FDA Approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable, Upon Receipt Of Royalty Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Received, Liability Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RoyaltyPaymentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RoyaltyPaymentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment Received, Liability Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties - Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilitySaleOfFutureRoyaltiesRollForward', window );"><strong>Liability, Sale Of Future Royalties [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RoyaltiesLiabilityNoncurrent', window );">Beginning carrying value</a></td>
<td class="nump">$ 341,361<span></span>
</td>
<td class="nump">$ 268,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties', window );">Upfront payment received</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties', window );">Milestone payment received</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expense recognized</a></td>
<td class="nump">26,036<span></span>
</td>
<td class="nump">23,035<span></span>
</td>
<td class="nump">$ 18,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RoyaltiesLiabilityNoncurrent', window );">Ending carrying value</a></td>
<td class="nump">$ 367,397<span></span>
</td>
<td class="nump">$ 341,361<span></span>
</td>
<td class="nump">$ 268,326<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilitySaleOfFutureRoyaltiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability, Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilitySaleOfFutureRoyaltiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Received, Liability Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Interest Expense, Liability Related to Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RoyaltiesLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RoyaltiesLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment Received, Liability Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Agreement - Narrative (Details)<br> $ in Thousands, &#165; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 13, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 24, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 14, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Nov. 26, 2024</div></th>
<th class="th">
<div>Aug. 07, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>May 31, 2025 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayments of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,625<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember', window );">Sarepta | Sarepta Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ProceedsFromCollaborationArrangements', window );">Upfront payment</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMember', window );">Financing Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Financing Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit facility, remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtInstrumentCovenantMultipleOfInvestedCapital', window );">Multiple of invested capital rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayments of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,625<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold', window );">Debt instrument, covenant, minimum liquidity cash, cash equivalents and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold', window );">Market capitalization threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Financing Agreement, Initial Term Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtInstrumentPrepaymentPercentage', window );">Debt instrument, prepayment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Financing Agreement, MOIC Payment | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtInstrumentCovenantMultipleOfInvestedCapital', window );">Multiple of invested capital rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtInstrumentPrepaymentPercentage', window );">Debt instrument, prepayment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayments of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment', window );">MOIC payments expected to be applied to principal upon repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,300<span></span>
</td>
<td class="nump">25,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 72.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 72.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtInstrumentCovenantMarketCapitalizationThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Market Capitalization, Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtInstrumentCovenantMarketCapitalizationThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Minimum Liquidity If Capitalization Is Above Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtInstrumentCovenantMultipleOfInvestedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Multiple Of Invested Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtInstrumentCovenantMultipleOfInvestedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Multiple Of Investment Capital Expected To Be Applied To Principal Upon Repayment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtInstrumentPrepaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtInstrumentPrepaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ProceedsFromCollaborationArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collaboration Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ProceedsFromCollaborationArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementInitialTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementInitialTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMOICPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMOICPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Agreement - Outstanding Balance of Credit Facility (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Less: Current portion of credit facility</a></td>
<td class="num">$ (40,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Less: Payments</a></td>
<td class="num">(201,625)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Financing Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Initial Term Loan</a></td>
<td class="nump">339,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accumulated accretion of the MOIC Payment</a></td>
<td class="nump">3,478<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Less: Unamortized debt issuance costs</a></td>
<td class="num">(13,912)<span></span>
</td>
<td class="num">(15,817)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Less: Current portion of credit facility</a></td>
<td class="num">(40,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Less: Payments</a></td>
<td class="num">(201,625)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Credit facility, net of current portion</a></td>
<td class="nump">214,883<span></span>
</td>
<td class="nump">393,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Financing Agreement, Initial Term Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Initial Term Loan</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Financing Agreement, Initial Term Loan Interest | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Initial Term Loan</a></td>
<td class="nump">$ 66,942<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementInitialTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementInitialTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementInitialTermLoanInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementInitialTermLoanInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Agreement - Interest Expense Recognized Related to Credit Facility (Details) - Secured Debt - Financing Agreement - Line of Credit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">$ 1,906<span></span>
</td>
<td class="nump">$ 317<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of the MOIC Payment</a></td>
<td class="nump">3,478<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">57,941<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">$ 63,325<span></span>
</td>
<td class="nump">$ 9,317<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financing Agreement - Principal Repayment Related to Credit Facility (Details) - Financing Agreement - Secured Debt - Line of Credit<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2027</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2028</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2029</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2030</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">214,990<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 339,990<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Basic and Diluted Net Income (Loss) Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</a></td>
<td class="num">$ (1,631)<span></span>
</td>
<td class="num">$ (599,493)<span></span>
</td>
<td class="num">$ (205,275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average basic shares outstanding (in shares)</a></td>
<td class="nump">133,758<span></span>
</td>
<td class="nump">119,784<span></span>
</td>
<td class="nump">106,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average diluted shares outstanding (in shares)</a></td>
<td class="nump">133,758<span></span>
</td>
<td class="nump">119,784<span></span>
</td>
<td class="nump">106,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (5.00)<span></span>
</td>
<td class="num">$ (1.92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (5.00)<span></span>
</td>
<td class="num">$ (1.92)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">5,020<span></span>
</td>
<td class="nump">4,737<span></span>
</td>
<td class="nump">4,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">707<span></span>
</td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">4,276<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">3,420<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Research and Development and Selling, General and Administrative Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation</a></td>
<td class="nump">$ 54,848<span></span>
</td>
<td class="nump">$ 67,097<span></span>
</td>
<td class="nump">$ 78,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">22,200<span></span>
</td>
<td class="nump">16,900<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expense</a></td>
<td class="nump">607,159<span></span>
</td>
<td class="nump">505,870<span></span>
</td>
<td class="nump">353,188<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expense</a></td>
<td class="nump">123,943<span></span>
</td>
<td class="nump">98,761<span></span>
</td>
<td class="nump">92,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation</a></td>
<td class="nump">27,320<span></span>
</td>
<td class="nump">29,527<span></span>
</td>
<td class="nump">34,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation</a></td>
<td class="nump">27,528<span></span>
</td>
<td class="nump">37,570<span></span>
</td>
<td class="nump">43,798<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arwr_OperatingSegmentMember', window );">Operating Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ResearchAndDevelopmentExpenseCandidateCosts', window );">Candidate costs</a></td>
<td class="nump">347,571<span></span>
</td>
<td class="nump">259,280<span></span>
</td>
<td class="nump">162,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ResearchAndDevelopmentExpenseDiscoveryCosts', window );">R&amp;D discovery costs</a></td>
<td class="nump">66,788<span></span>
</td>
<td class="nump">74,150<span></span>
</td>
<td class="nump">55,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ResearchAndDevelopmentExpenseSalariesExpense', window );">Salaries</a></td>
<td class="nump">109,085<span></span>
</td>
<td class="nump">96,418<span></span>
</td>
<td class="nump">73,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense', window );">Facilities related</a></td>
<td class="nump">29,233<span></span>
</td>
<td class="nump">25,782<span></span>
</td>
<td class="nump">16,267<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense', window );">Total research and development expense, excluding non-cash expense</a></td>
<td class="nump">552,677<span></span>
</td>
<td class="nump">455,630<span></span>
</td>
<td class="nump">307,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Salaries</a></td>
<td class="nump">31,916<span></span>
</td>
<td class="nump">27,589<span></span>
</td>
<td class="nump">22,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional, outside services, and other</a></td>
<td class="nump">53,589<span></span>
</td>
<td class="nump">24,733<span></span>
</td>
<td class="nump">20,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense', window );">Facilities related</a></td>
<td class="nump">5,625<span></span>
</td>
<td class="nump">4,116<span></span>
</td>
<td class="nump">3,415<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense', window );">Total general and administrative expense, excluding non-cash expense</a></td>
<td class="nump">91,130<span></span>
</td>
<td class="nump">56,438<span></span>
</td>
<td class="nump">47,134<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expense</a></td>
<td class="nump">607,159<span></span>
</td>
<td class="nump">505,870<span></span>
</td>
<td class="nump">353,188<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expense</a></td>
<td class="nump">123,943<span></span>
</td>
<td class="nump">98,761<span></span>
</td>
<td class="nump">92,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arwr_OperatingSegmentMember', window );">Operating Segment | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation</a></td>
<td class="nump">32,582<span></span>
</td>
<td class="nump">33,586<span></span>
</td>
<td class="nump">34,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">21,900<span></span>
</td>
<td class="nump">16,654<span></span>
</td>
<td class="nump">10,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arwr_OperatingSegmentMember', window );">Operating Segment | General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation</a></td>
<td class="nump">30,785<span></span>
</td>
<td class="nump">40,382<span></span>
</td>
<td class="nump">43,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 2,028<span></span>
</td>
<td class="nump">$ 1,941<span></span>
</td>
<td class="nump">$ 1,617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General And Administrative Expense, Excluding Noncash Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General And Administrative Expense, Facilities Related Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ResearchAndDevelopmentExpenseCandidateCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Candidate Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ResearchAndDevelopmentExpenseCandidateCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ResearchAndDevelopmentExpenseDiscoveryCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Discovery Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ResearchAndDevelopmentExpenseDiscoveryCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Excluding Noncash Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Facilities Related Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ResearchAndDevelopmentExpenseSalariesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Salaries Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ResearchAndDevelopmentExpenseSalariesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=arwr_OperatingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=arwr_OperatingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 20, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 17, 2025 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Aug. 13, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 24, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 14, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 25, 2024 </div>
<div>USD ($) </div>
<div>program</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember', window );">Sarepta | Sarepta Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ProceedsFromCollaborationArrangements', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfCollaborationPrograms', window );">Number of collaboration programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentMilestonePayments', window );">Development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember', window );">Sarepta | Sarepta Collaboration Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SalesRelatedMilestonePayments', window );">Sales-related milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember', window );">Sarepta | Sarepta Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SalesRelatedMilestonePayments', window );">Sales-related milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Novartis | Novartis Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ProceedsFromCollaborationArrangements', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination', window );">Payment receivable upon target nomination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfCollaborationPrograms', window );">Number of collaboration programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Novartis | Novartis Collaboration Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentMilestonePayments', window );">Development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SalesRelatedMilestonePayments', window );">Sales-related milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Novartis | Novartis Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentMilestonePayments', window );">Development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SalesRelatedMilestonePayments', window );">Sales-related milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Sarepta | Sarepta Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentMilestonePayments', window );">Development milestone payments</a></td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfCollaborationPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Collaboration Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfCollaborationPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Receivable In Collaboration Arrangements Upon Target Nomination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ProceedsFromCollaborationArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collaboration Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ProceedsFromCollaborationArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SalesRelatedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales-related milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SalesRelatedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_NovartisCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_NovartisCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>329</ContextCount>
  <ElementCount>475</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>107</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Balance Sheet Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/BalanceSheetAccounts</Role>
      <ShortName>Balance Sheet Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Liability Related to the Sale of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties</Role>
      <ShortName>Liability Related to the Sale of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Financing Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FinancingAgreement</Role>
      <ShortName>Financing Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Organization and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Organization and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables</Role>
      <ShortName>Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Balance Sheet Accounts (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables</Role>
      <ShortName>Balance Sheet Accounts (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/BalanceSheetAccounts</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/Investments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/IntangibleAssets</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/StockholdersEquity</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/Leases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/StockBasedCompensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/FairValueMeasurements</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Liability Related to the Sale of Future Royalties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables</Role>
      <ShortName>Liability Related to the Sale of Future Royalties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Financing Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FinancingAgreementTables</Role>
      <ShortName>Financing Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/FinancingAgreement</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/NetLossPerShare</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/SegmentInformation</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Organization and Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Organization and Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Organization and Significant Accounting Policies - Useful Lives of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Organization and Significant Accounting Policies - Useful Lives of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Collaboration and License Agreements - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails</Role>
      <ShortName>Collaboration and License Agreements - Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Collaboration and License Agreements - Receivables and Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails</Role>
      <ShortName>Collaboration and License Agreements - Receivables and Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Collaboration and License Agreements - GlaxoSmithKline Intellectual Property (No. 3) Limited (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails</Role>
      <ShortName>Collaboration and License Agreements - GlaxoSmithKline Intellectual Property (No. 3) Limited (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails</Role>
      <ShortName>Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Collaboration and License Agreements - Amgen, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails</Role>
      <ShortName>Collaboration and License Agreements - Amgen, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Collaboration and License Agreements - Sarepta Therapeutics, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails</Role>
      <ShortName>Collaboration and License Agreements - Sarepta Therapeutics, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Collaboration and License Agreements - Visirna Therapeutics Inc. (???Visirna???) and Genzyme Corporation (???Sanofi???) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails</Role>
      <ShortName>Collaboration and License Agreements - Visirna Therapeutics Inc. (???Visirna???) and Genzyme Corporation (???Sanofi???) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Balance Sheet Accounts - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails</Role>
      <ShortName>Balance Sheet Accounts - Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Balance Sheet Accounts - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails</Role>
      <ShortName>Balance Sheet Accounts - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Balance Sheet Accounts - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails</Role>
      <ShortName>Balance Sheet Accounts - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Investments - Current Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails</Role>
      <ShortName>Investments - Current Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Investments - Contract Maturity of Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/InvestmentsContractMaturityofAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Investments - Contract Maturity of Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Intangible Assets - Expected Future Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails</Role>
      <ShortName>Intangible Assets - Expected Future Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Stockholders' Equity - Shares of Common Stock and Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquitySharesofCommonStockandPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Shares of Common Stock and Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/CommitmentsandContingencies</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Leases - Components of Lease Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails</Role>
      <ShortName>Leases - Components of Lease Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails</Role>
      <ShortName>Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Stock-Based Compensation - Summary of Granted and Outstanding Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Granted and Outstanding Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Stock-Based Compensation - Expenses Included in Operating Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails</Role>
      <ShortName>Stock-Based Compensation - Expenses Included in Operating Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Stock-Based Compensation - Summarized Information about Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Summarized Information about Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Stock-Based Compensation - Schedule of RSUs Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of RSUs Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Income Taxes - Components of Income (Loss) Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofIncomeLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Components of Income (Loss) Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Income Taxes - Income Tax Provision (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails</Role>
      <ShortName>Income Taxes - Income Tax Provision (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails</Role>
      <ShortName>Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Income Taxes - Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - Liability Related to the Sale of Future Royalties - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails</Role>
      <ShortName>Liability Related to the Sale of Future Royalties - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955564 - Disclosure - Liability Related to the Sale of Future Royalties - Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails</Role>
      <ShortName>Liability Related to the Sale of Future Royalties - Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9955565 - Disclosure - Financing Agreement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails</Role>
      <ShortName>Financing Agreement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9955566 - Disclosure - Financing Agreement - Outstanding Balance of Credit Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails</Role>
      <ShortName>Financing Agreement - Outstanding Balance of Credit Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9955567 - Disclosure - Financing Agreement - Interest Expense Recognized Related to Credit Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails</Role>
      <ShortName>Financing Agreement - Interest Expense Recognized Related to Credit Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9955568 - Disclosure - Financing Agreement - Principal Repayment Related to Credit Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails</Role>
      <ShortName>Financing Agreement - Principal Repayment Related to Credit Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9955569 - Disclosure - Net Loss Per Share - Basic and Diluted Net Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Basic and Diluted Net Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9955570 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9955571 - Disclosure - Segment Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9955572 - Disclosure - Segment Information - Research and Development and Selling, General and Administrative Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails</Role>
      <ShortName>Segment Information - Research and Development and Selling, General and Administrative Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="arwr-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9955573 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/SubsequentEvents</ParentRole>
      <Position>90</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="arwr-20250930.htm">arwr-20250930.htm</File>
    <File>arwr-20250930.xsd</File>
    <File>arwr-20250930_cal.xml</File>
    <File>arwr-20250930_def.xml</File>
    <File>arwr-20250930_lab.xml</File>
    <File>arwr-20250930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>arwr-20250930_g1.jpg</File>
    <File>arwr-20250930_g2.jpg</File>
    <File>arwr-20250930_g3.jpg</File>
    <File>arwr-20250930_g4.jpg</File>
    <File>arwr-20250930_g5.jpg</File>
    <File>arwr-20250930_g6.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1023">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="62">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>122
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "arwr-20250930.htm": {
   "nsprefix": "arwr",
   "nsuri": "http://www.arrowheadresearch.com/20250930",
   "dts": {
    "inline": {
     "local": [
      "arwr-20250930.htm"
     ]
    },
    "schema": {
     "local": [
      "arwr-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "arwr-20250930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "arwr-20250930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "arwr-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arwr-20250930_pre.xml"
     ]
    }
   },
   "keyStandard": 386,
   "keyCustom": 89,
   "axisStandard": 29,
   "axisCustom": 0,
   "memberStandard": 43,
   "memberCustom": 53,
   "hidden": {
    "total": 13,
    "http://xbrl.sec.gov/ecd/2025": 8,
    "http://xbrl.sec.gov/dei/2025": 4,
    "http://fasb.org/us-gaap/2025": 1
   },
   "contextCount": 329,
   "entityCount": 1,
   "segmentCount": 107,
   "elementCount": 818,
   "unitCount": 13,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 1023,
    "http://xbrl.sec.gov/ecd/2025": 62,
    "http://xbrl.sec.gov/dei/2025": 39,
    "http://xbrl.sec.gov/cyd/2025": 15
   },
   "report": {
    "R1": {
     "role": "http://www.arrowheadresearch.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.arrowheadresearch.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
     "longName": "9952153 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "shortName": "Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity",
     "longName": "9952154 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-30",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-30",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952155 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies",
     "longName": "9952156 - Disclosure - Organization and Significant Accounting Policies",
     "shortName": "Organization and Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements",
     "longName": "9952157 - Disclosure - Collaboration and License Agreements",
     "shortName": "Collaboration and License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.arrowheadresearch.com/role/BalanceSheetAccounts",
     "longName": "9952158 - Disclosure - Balance Sheet Accounts",
     "shortName": "Balance Sheet Accounts",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.arrowheadresearch.com/role/Investments",
     "longName": "9952159 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssets",
     "longName": "9952160 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquity",
     "longName": "9952161 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.arrowheadresearch.com/role/CommitmentsandContingencies",
     "longName": "9952162 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.arrowheadresearch.com/role/Leases",
     "longName": "9952163 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensation",
     "longName": "9952164 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurements",
     "longName": "9952165 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxes",
     "longName": "9952166 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.arrowheadresearch.com/role/EmployeeBenefitPlans",
     "longName": "9952167 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties",
     "longName": "9952168 - Disclosure - Liability Related to the Sale of Future Royalties",
     "shortName": "Liability Related to the Sale of Future Royalties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.arrowheadresearch.com/role/FinancingAgreement",
     "longName": "9952169 - Disclosure - Financing Agreement",
     "shortName": "Financing Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.arrowheadresearch.com/role/NetLossPerShare",
     "longName": "9952170 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.arrowheadresearch.com/role/SegmentInformation",
     "longName": "9952171 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.arrowheadresearch.com/role/SubsequentEvents",
     "longName": "9952172 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Organization and Significant Accounting Policies (Policies)",
     "shortName": "Organization and Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Organization and Significant Accounting Policies (Tables)",
     "shortName": "Organization and Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:ScheduleOfCurrentProductsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arwr:ScheduleOfCurrentProductsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables",
     "longName": "9955513 - Disclosure - Collaboration and License Agreements (Tables)",
     "shortName": "Collaboration and License Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables",
     "longName": "9955514 - Disclosure - Balance Sheet Accounts (Tables)",
     "shortName": "Balance Sheet Accounts (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.arrowheadresearch.com/role/InvestmentsTables",
     "longName": "9955515 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsTables",
     "longName": "9955516 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquityTables",
     "longName": "9955517 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.arrowheadresearch.com/role/LeasesTables",
     "longName": "9955518 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationTables",
     "longName": "9955519 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurementsTables",
     "longName": "9955520 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesTables",
     "longName": "9955521 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables",
     "longName": "9955522 - Disclosure - Liability Related to the Sale of Future Royalties (Tables)",
     "shortName": "Liability Related to the Sale of Future Royalties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.arrowheadresearch.com/role/FinancingAgreementTables",
     "longName": "9955523 - Disclosure - Financing Agreement (Tables)",
     "shortName": "Financing Agreement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.arrowheadresearch.com/role/NetLossPerShareTables",
     "longName": "9955524 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.arrowheadresearch.com/role/SegmentInformationTables",
     "longName": "9955525 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9955526 - Disclosure - Organization and Significant Accounting Policies - Narrative (Details)",
     "shortName": "Organization and Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails",
     "longName": "9955527 - Disclosure - Organization and Significant Accounting Policies - Useful Lives of Property, Plant and Equipment (Details)",
     "shortName": "Organization and Significant Accounting Policies - Useful Lives of Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-73",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
     "longName": "9955528 - Disclosure - Collaboration and License Agreements - Revenue (Details)",
     "shortName": "Collaboration and License Agreements - Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-80",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails",
     "longName": "9955529 - Disclosure - Collaboration and License Agreements - Receivables and Contract Liabilities (Details)",
     "shortName": "Collaboration and License Agreements - Receivables and Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:AccountsReceivableNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:AccountsReceivableNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails",
     "longName": "9955530 - Disclosure - Collaboration and License Agreements - GlaxoSmithKline Intellectual Property (No. 3) Limited (Details)",
     "shortName": "Collaboration and License Agreements - GlaxoSmithKline Intellectual Property (No. 3) Limited (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-101",
      "name": "arwr:InitialTransactionPrice",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
     "longName": "9955531 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)",
     "shortName": "Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "arwr:DevelopmentRegulatoryAndSalesMilestonesPayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-112",
      "name": "arwr:NumberOfDistinctBundle",
      "unitRef": "bundle",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
     "longName": "9955532 - Disclosure - Collaboration and License Agreements - Amgen, Inc. (Details)",
     "shortName": "Collaboration and License Agreements - Amgen, Inc. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-117",
      "name": "arwr:NumberOfAgreements",
      "unitRef": "agreement",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
     "longName": "9955533 - Disclosure - Collaboration and License Agreements - Sarepta Therapeutics, Inc. (Details)",
     "shortName": "Collaboration and License Agreements - Sarepta Therapeutics, Inc. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TreasuryStockValueAcquiredCostMethod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-127",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails",
     "longName": "9955534 - Disclosure - Collaboration and License Agreements - Visirna Therapeutics Inc. (\u201cVisirna\u201d) and Genzyme Corporation (\u201cSanofi\u201d) (Details)",
     "shortName": "Collaboration and License Agreements - Visirna Therapeutics Inc. (\u201cVisirna\u201d) and Genzyme Corporation (\u201cSanofi\u201d) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-129",
      "name": "arwr:InitialTransactionPrice",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails",
     "longName": "9955535 - Disclosure - Balance Sheet Accounts - Property, Plant and Equipment (Details)",
     "shortName": "Balance Sheet Accounts - Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
     "longName": "9955536 - Disclosure - Balance Sheet Accounts - Narrative (Details)",
     "shortName": "Balance Sheet Accounts - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-144",
      "name": "us-gaap:PropertyPlantAndEquipmentTransfersAndChanges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails",
     "longName": "9955537 - Disclosure - Balance Sheet Accounts - Accrued Expenses (Details)",
     "shortName": "Balance Sheet Accounts - Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "arwr:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "arwr:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails",
     "longName": "9955538 - Disclosure - Investments - Current Investments (Details)",
     "shortName": "Investments - Current Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.arrowheadresearch.com/role/InvestmentsContractMaturityofAvailableforSaleSecuritiesDetails",
     "longName": "9955539 - Disclosure - Investments - Contract Maturity of Available-for-Sale Securities (Details)",
     "shortName": "Investments - Contract Maturity of Available-for-Sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
     "longName": "9955540 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)",
     "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:AmortizationOfIntangibleAssets",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails",
     "longName": "9955541 - Disclosure - Intangible Assets - Expected Future Amortization (Details)",
     "shortName": "Intangible Assets - Expected Future Amortization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquitySharesofCommonStockandPreferredStockDetails",
     "longName": "9955542 - Disclosure - Stockholders' Equity - Shares of Common Stock and Preferred Stock (Details)",
     "shortName": "Stockholders' Equity - Shares of Common Stock and Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails",
     "longName": "9955543 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-167",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails",
     "longName": "9955544 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
     "longName": "9955545 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShortTermLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShortTermLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails",
     "longName": "9955546 - Disclosure - Leases - Components of Lease Assets and Liabilities (Details)",
     "shortName": "Leases - Components of Lease Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails",
     "longName": "9955547 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)",
     "shortName": "Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails",
     "longName": "9955548 - Disclosure - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)",
     "shortName": "Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
     "longName": "9955549 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-215",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails",
     "longName": "9955550 - Disclosure - Stock-Based Compensation - Summary of Granted and Outstanding Awards (Details)",
     "shortName": "Stock-Based Compensation - Summary of Granted and Outstanding Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-202",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails",
     "longName": "9955551 - Disclosure - Stock-Based Compensation - Expenses Included in Operating Expenses (Details)",
     "shortName": "Stock-Based Compensation - Expenses Included in Operating Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R69": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails",
     "longName": "9955552 - Disclosure - Stock-Based Compensation - Summarized Information about Stock Options (Details)",
     "shortName": "Stock-Based Compensation - Summarized Information about Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails",
     "longName": "9955553 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)",
     "shortName": "Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails",
     "longName": "9955554 - Disclosure - Stock-Based Compensation - Schedule of RSUs Activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of RSUs Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-214",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-215",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "longName": "9955555 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-241",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofIncomeLossBeforeIncomeTaxesDetails",
     "longName": "9955556 - Disclosure - Income Taxes - Components of Income (Loss) Before Income Taxes (Details)",
     "shortName": "Income Taxes - Components of Income (Loss) Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails",
     "longName": "9955557 - Disclosure - Income Taxes - Income Tax Provision (Benefit) (Details)",
     "shortName": "Income Taxes - Income Tax Provision (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "9955558 - Disclosure - Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails",
     "longName": "9955559 - Disclosure - Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Details)",
     "shortName": "Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9955560 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails",
     "longName": "9955561 - Disclosure - Income Taxes - Gross Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Gross Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-35",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansDetails",
     "longName": "9955562 - Disclosure - Employee Benefit Plans (Details)",
     "shortName": "Employee Benefit Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
     "longName": "9955563 - Disclosure - Liability Related to the Sale of Future Royalties - Narrative (Details)",
     "shortName": "Liability Related to the Sale of Future Royalties - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-284",
      "name": "arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails",
     "longName": "9955564 - Disclosure - Liability Related to the Sale of Future Royalties - Activity (Details)",
     "shortName": "Liability Related to the Sale of Future Royalties - Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "arwr:RoyaltiesLiabilityNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R82": {
     "role": "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
     "longName": "9955565 - Disclosure - Financing Agreement - Narrative (Details)",
     "shortName": "Financing Agreement - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RepaymentsOfLongTermLinesOfCredit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-289",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails",
     "longName": "9955566 - Disclosure - Financing Agreement - Outstanding Balance of Credit Facility (Details)",
     "shortName": "Financing Agreement - Outstanding Balance of Credit Facility (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:LinesOfCreditCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-297",
      "name": "us-gaap:DeferredFinanceCostsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
     "longName": "9955567 - Disclosure - Financing Agreement - Interest Expense Recognized Related to Credit Facility (Details)",
     "shortName": "Financing Agreement - Interest Expense Recognized Related to Credit Facility (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-296",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-296",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails",
     "longName": "9955568 - Disclosure - Financing Agreement - Principal Repayment Related to Credit Facility (Details)",
     "shortName": "Financing Agreement - Principal Repayment Related to Credit Facility (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-297",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-297",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails",
     "longName": "9955569 - Disclosure - Net Loss Per Share - Basic and Diluted Net Income (Loss) Per Share (Details)",
     "shortName": "Net Loss Per Share - Basic and Diluted Net Income (Loss) Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveSecuritiesDetails",
     "longName": "9955570 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details)",
     "shortName": "Net Loss Per Share - Antidilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.arrowheadresearch.com/role/SegmentInformationNarrativeDetails",
     "longName": "9955571 - Disclosure - Segment Information - Narrative (Details)",
     "shortName": "Segment Information - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R89": {
     "role": "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails",
     "longName": "9955572 - Disclosure - Segment Information - Research and Development and Selling, General and Administrative Expenses (Details)",
     "shortName": "Segment Information - Research and Development and Selling, General and Administrative Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-314",
      "name": "arwr:ResearchAndDevelopmentExpenseCandidateCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.arrowheadresearch.com/role/SubsequentEventsDetails",
     "longName": "9955573 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-171",
      "name": "arwr:ProceedsFromCollaborationArrangements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-323",
      "name": "arwr:ProceedsFromCollaborationArrangements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20250930.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r1084"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables included in accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r952",
      "r1105",
      "r1399",
      "r1400"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1275"
     ]
    },
    "arwr_AccruedCapitalExpenditureCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "AccruedCapitalExpenditureCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued capital expenditures",
        "label": "Accrued Capital Expenditure, Current",
        "documentation": "Accrued Capital Expenditure, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued income taxes (benefits)",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r119"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development expenses; co-development",
        "label": "Accrued Research And Development Co-Development Expense, Current",
        "documentation": "Accrued Research And Development Co-Development Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_AccruedResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development expenses",
        "label": "Accrued Research And Development Expense, Current",
        "documentation": "Accrued Research And Development Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r154",
      "r824"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r86",
      "r162",
      "r819",
      "r857",
      "r858",
      "r1366"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r11",
      "r19",
      "r649",
      "r652",
      "r724",
      "r853",
      "r854",
      "r1248",
      "r1249",
      "r1250",
      "r1264",
      "r1265",
      "r1266",
      "r1267"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1163"
     ]
    },
    "arwr_AdditionalCashReceivableUnderCollaborationAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "AdditionalCashReceivableUnderCollaborationAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total annual installments amount",
        "label": "Additional Cash Receivable Under Collaboration Agreement",
        "documentation": "Additional Cash Receivable Under Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1367",
      "r1437"
     ]
    },
    "arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional remaining development regulatory and sales milestones payments",
        "label": "Additional Remaining Development Regulatory And Sales Milestones Payments",
        "documentation": "Additional remaining development regulatory and sales milestones payments."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_AdeoyeOlukotunMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "AdeoyeOlukotunMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adeoye Olukotun [Member]",
        "documentation": "Adeoye Olukotun"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1176"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1176"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1176"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1176"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of pre-funded warrants",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r41",
      "r108"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash flow from operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1221"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1134",
      "r1145",
      "r1155",
      "r1188"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1137",
      "r1148",
      "r1158",
      "r1191"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1222"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1176"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1183"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r1138",
      "r1149",
      "r1159",
      "r1183",
      "r1192",
      "r1196",
      "r1204"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1202"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r567",
      "r576"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_AmgenIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "AmgenIncorporatedMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amgen",
        "label": "Amgen Incorporated [Member]",
        "documentation": "Amgen Incorporated."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated accretion of the MOIC Payment",
        "verboseLabel": "Accretion of the MOIC Payment",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r93",
      "r393",
      "r1380"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount and issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r1006",
      "r1007",
      "r1253",
      "r1380"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r180",
      "r340",
      "r347",
      "r971",
      "r976",
      "r977",
      "r979",
      "r981"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AreaOfLand",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Planned area of site (in sq ft)",
        "label": "Area of Land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition",
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r861",
      "r1361"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition",
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r861",
      "r1361"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r132",
      "r157",
      "r189",
      "r191",
      "r192",
      "r229",
      "r241",
      "r266",
      "r270",
      "r313",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r636",
      "r641",
      "r692",
      "r806",
      "r807",
      "r816",
      "r903",
      "r994",
      "r995",
      "r1008",
      "r1084",
      "r1099",
      "r1100",
      "r1112",
      "r1306",
      "r1307",
      "r1386"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Assets and Liabilities",
        "label": "Assets and Liabilities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r165",
      "r189",
      "r191",
      "r192",
      "r313",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r636",
      "r641",
      "r692",
      "r1084",
      "r1306",
      "r1307",
      "r1386"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r665",
      "r1071"
     ]
    },
    "arwr_AtTheMarketAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "AtTheMarketAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Agreement",
        "label": "At The Market Agreement [Member]",
        "documentation": "At-the-market agreement."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.arrowheadresearch.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1117",
      "r1118",
      "r1141"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.arrowheadresearch.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1117",
      "r1118",
      "r1141"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://www.arrowheadresearch.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1117",
      "r1118",
      "r1141"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsContractMaturityofAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsContractMaturityofAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within one year",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r811"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arrowheadresearch.com/role/InvestmentsContractMaturityofAvailableforSaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsContractMaturityofAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Available-for-sale securities",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r321",
      "r664",
      "r685",
      "r686",
      "r687",
      "r688",
      "r802",
      "r969",
      "r1071",
      "r1074",
      "r1081",
      "r1276",
      "r1371",
      "r1372",
      "r1373"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale securities, at fair value",
        "verboseLabel": "Current investments, Fair Value",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r321"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1199"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1200"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1195"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1195"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1195"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1195"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1195"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1195"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r533",
      "r534",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1198"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1196"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1196"
     ]
    },
    "us-gaap_BankTimeDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BankTimeDepositsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term deposit",
        "label": "Bank Time Deposits [Member]",
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "CA",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital expenditures included in accrued expenses",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r686",
      "r687",
      "r688",
      "r1369",
      "r1370"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r116"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "periodStartLabel": "BEGINNING OF PERIOD",
        "periodEndLabel": "END OF PERIOD",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r98",
      "r188"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH:",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r98"
     ]
    },
    "arwr_CashFlowNoncashInvestingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "CashFlowNoncashInvestingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplementary disclosure of non-cash investing activities:",
        "label": "Cash Flow, Noncash Investing Activities Disclosure [Abstract]",
        "documentation": "Cash Flow, Noncash Investing Activities Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:",
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received for amounts included in the measurement of lease liabilities:",
        "label": "Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities [Abstract]",
        "documentation": "Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CashReceivableUnderCollaborationAgreementAnnualInstallments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "CashReceivableUnderCollaborationAgreementAnnualInstallments",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual installment",
        "label": "Cash Receivable Under Collaboration Agreement, Annual Installments",
        "documentation": "Cash Receivable Under Collaboration Agreement, Annual Installments"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual installments period",
        "label": "Cash Receivable Under Collaboration Agreement, Annual Installments Period",
        "documentation": "Cash Receivable Under Collaboration Agreement, Annual Installments Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificate of deposits",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r1106",
      "r1107",
      "r1108",
      "r1109"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1174"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1171"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1169"
     ]
    },
    "arwr_ChristopherAnzaloneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ChristopherAnzaloneMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Christopher Anzalone [Member]",
        "documentation": "Christopher Anzalone"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r231",
      "r402",
      "r408",
      "r409",
      "r410",
      "r412",
      "r415",
      "r420",
      "r422",
      "r647",
      "r867",
      "r868",
      "r869",
      "r870",
      "r1009",
      "r1226",
      "r1255",
      "r1257"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r195",
      "r423"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities called by warrants (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "arwr_ClassOfWarrantOrRightNumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsExercised",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants exercised (in shares)",
        "label": "Class Of Warrant Or Right, Number Of Warrants Exercised",
        "documentation": "Class Of Warrant Or Right, Number Of Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants purchase price (in dollars per share)",
        "label": "Class of Warrant or Right, Purchase Price of Warrants or Rights",
        "documentation": "Class of Warrant or Right, Purchase Price of Warrants or Rights"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ClinicalAccrualPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ClinicalAccrualPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Accruals",
        "label": "Clinical Accrual Policy [Policy Text Block]",
        "documentation": "Clinical Accrual Policy"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1175"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1175"
     ]
    },
    "arwr_CollaborationAndLicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration And License Agreements [Abstract]",
        "label": "Collaboration And License Agreements [Abstract]",
        "documentation": "Collaboration and license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CollaborationArrangementConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "CollaborationArrangementConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total transaction price",
        "label": "Collaboration Arrangement, Consideration",
        "documentation": "Collaboration Arrangement, Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CollaborationArrangementFixedConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "CollaborationArrangementFixedConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed consideration",
        "label": "Collaboration Arrangement, Fixed Consideration",
        "documentation": "Collaboration Arrangement, Fixed Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement termination notice period prior to any regulatory approval of a licensed product",
        "label": "Collaboration Arrangement, Termination Notice Period Prior To Regulatory Approval",
        "documentation": "Collaboration Arrangement, Termination Notice Period Prior To Regulatory Approval"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CollaborationArrangementVariableConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "CollaborationArrangementVariableConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable consideration",
        "label": "Collaboration Arrangement, Variable Consideration",
        "documentation": "Collaboration Arrangement, Variable Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and License Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r632",
      "r633"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "arwr_ColoradoOwnerLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ColoradoOwnerLLCMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Colorado Owner, LLC",
        "label": "Colorado Owner L L C [Member]",
        "documentation": "Colorado Owner, LLC."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CommercialMilestonePaymentsAtFirstCommercialSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "CommercialMilestonePaymentsAtFirstCommercialSale",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial milestone payments at first commercial sale",
        "label": "Commercial Milestone Payments At First Commercial Sale",
        "documentation": "Commercial milestone payments at first commercial sale."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CommercialNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "CommercialNotesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial notes",
        "label": "Commercial Notes [Member]",
        "documentation": "Commercial Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 7)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r122",
      "r817",
      "r889"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r361",
      "r362",
      "r953",
      "r1298",
      "r1303"
     ]
    },
    "arwr_CommitmentsCapitalExpendituresIncurredToDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "CommitmentsCapitalExpendituresIncurredToDate",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital expenditures incurred",
        "label": "Commitments, Capital Expenditures Incurred To Date",
        "documentation": "Commitments, Capital Expenditures Incurred To Date"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CommonStockCapitalSharesValueReservedForFutureIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "CommonStockCapitalSharesValueReservedForFutureIssuance",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares value reserved for future issuance",
        "label": "Common Stock Capital Shares Value Reserved For Future Issuance",
        "documentation": "Common stock, capital shares value reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1102",
      "r1103",
      "r1104",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1264",
      "r1265",
      "r1267",
      "r1367",
      "r1432",
      "r1437"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquitySharesofCommonStockandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquitySharesofCommonStockandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r890"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquitySharesofCommonStockandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.arrowheadresearch.com/role/StockholdersEquitySharesofCommonStockandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Common stock, beginning balance (in shares)",
        "periodEndLabel": "Common stock, ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r80",
      "r890",
      "r909",
      "r1437",
      "r1438"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 135,702 and 124,376 shares at September 30, 2025 and 2024, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r400",
      "r405",
      "r818",
      "r1084"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1180"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1179"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1181"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1178"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plans",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r1315",
      "r1316",
      "r1317",
      "r1320"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss, net of tax:",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income (loss) attributed to noncontrolling interest",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r59",
      "r65",
      "r170",
      "r172",
      "r178",
      "r804",
      "r832",
      "r833"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income (loss)",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r114",
      "r170",
      "r172",
      "r177",
      "r803",
      "r832"
     ]
    },
    "arwr_ComputersAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ComputersAndSoftwareMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computers and software",
        "label": "Computers And Software [Member]",
        "documentation": "Computers And Software"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r690"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r190",
      "r199",
      "r636",
      "r637",
      "r640",
      "r641",
      "r642",
      "r726",
      "r810",
      "r958",
      "r1305",
      "r1308",
      "r1309"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r190",
      "r199",
      "r636",
      "r637",
      "r640",
      "r641",
      "r642",
      "r726",
      "r810",
      "r958",
      "r1305",
      "r1308",
      "r1309"
     ]
    },
    "srt_ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entity Excluding Variable Interest Entities (VIE)",
        "label": "Consolidated Entity, Excluding Consolidated VIE [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity (\"VIE\")",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r61",
      "r62"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ConstructionInProgressReclassifiedToBuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ConstructionInProgressReclassifiedToBuildingMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction In Progress Reclassified To Building",
        "label": "Construction In Progress Reclassified To Building [Member]",
        "documentation": "Construction In Progress Reclassified To Building"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ConstructionInProgressReclassifiedToManufacturingEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ConstructionInProgressReclassifiedToManufacturingEquipmentMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction In Progress Reclassified To Manufacturing Equipment",
        "label": "Construction In Progress Reclassified To Manufacturing Equipment [Member]",
        "documentation": "Construction In Progress Reclassified To Manufacturing Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Receivables and Contract Liabilities",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r1312"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerAssetNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract assets",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r427",
      "r428",
      "r440"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities included in deferred revenue",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426",
      "r428",
      "r440"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426",
      "r428",
      "r440"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r1018",
      "r1020",
      "r1022",
      "r1071",
      "r1085",
      "r1101",
      "r1429"
     ]
    },
    "arwr_CorporateHeadquartersInPasadenaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "CorporateHeadquartersInPasadenaMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Headquarters In Pasadena",
        "label": "Corporate Headquarters In Pasadena [Member]",
        "documentation": "Corporate Headquarters in Pasadena"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r197",
      "r198",
      "r381",
      "r410",
      "r725",
      "r746",
      "r815",
      "r973",
      "r974",
      "r975",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1362",
      "r1363",
      "r1364",
      "r1365"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r1304"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r1304"
     ]
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1229",
      "r1255",
      "r1261",
      "r1358"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1229",
      "r1255",
      "r1261"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current tax",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r1255",
      "r1261"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1229",
      "r1255",
      "r1261",
      "r1358"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1126",
      "r1215"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1126",
      "r1215"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1128",
      "r1217"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1128",
      "r1217"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1130",
      "r1219"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1128",
      "r1217"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1121",
      "r1210"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1122",
      "r1211"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1122",
      "r1211"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r1120",
      "r1209"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1120",
      "r1209"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r1120",
      "r1209"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1123",
      "r1212"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1125",
      "r1214"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1125",
      "r1214"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1126",
      "r1215"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1129",
      "r1218"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1127",
      "r1216"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1124",
      "r1213"
     ]
    },
    "arwr_DanielApelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "DanielApelMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Daniel Apel [Member]",
        "documentation": "Daniel Apel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r68",
      "r69",
      "r118",
      "r121",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1082",
      "r1255",
      "r1256",
      "r1258",
      "r1263",
      "r1299",
      "r1300",
      "r1301",
      "r1379",
      "r1381",
      "r1396"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis spread on variable rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Term Loan",
        "totalLabel": "Total",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r121",
      "r395"
     ]
    },
    "arwr_DebtInstrumentCovenantMarketCapitalizationThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "DebtInstrumentCovenantMarketCapitalizationThreshold",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market capitalization threshold",
        "label": "Debt Instrument, Covenant, Market Capitalization, Threshold",
        "documentation": "Debt Instrument, Covenant, Market Capitalization, Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, covenant, minimum liquidity cash, cash equivalents and investments",
        "label": "Debt Instrument, Covenant, Minimum Liquidity If Capitalization Is Above Threshold",
        "documentation": "Debt Instrument, Covenant, Minimum Liquidity If Capitalization Is Above Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DebtInstrumentCovenantMultipleOfInvestedCapital": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "DebtInstrumentCovenantMultipleOfInvestedCapital",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multiple of invested capital rate",
        "label": "Debt Instrument, Covenant, Multiple Of Invested Capital",
        "documentation": "Debt Instrument, Covenant, Multiple Of Invested Capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r379"
     ]
    },
    "arwr_DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MOIC payments expected to be applied to principal upon repayment",
        "label": "Debt Instrument, Multiple Of Investment Capital Expected To Be Applied To Principal Upon Repayment",
        "documentation": "Debt Instrument, Multiple Of Investment Capital Expected To Be Applied To Principal Upon Repayment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1082",
      "r1255",
      "r1256",
      "r1258",
      "r1263",
      "r1299",
      "r1300",
      "r1301",
      "r1379",
      "r1381",
      "r1396"
     ]
    },
    "arwr_DebtInstrumentPrepaymentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "DebtInstrumentPrepaymentPercentage",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, prepayment percentage",
        "label": "Debt Instrument, Prepayment, Percentage",
        "documentation": "Debt Instrument, Prepayment, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, term",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current investments, Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current",
        "documentation": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Current investments, Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current",
        "documentation": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current investments, Adjusted Basis",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r1277"
     ]
    },
    "arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsContractMaturityofAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsContractMaturityofAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After one to two years",
        "label": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One Through Two",
        "documentation": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One Through Two"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsContractMaturityofAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsContractMaturityofAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After two to three years",
        "label": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year Two Through Three",
        "documentation": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year Two Through Three"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale securities",
        "label": "Debt Securities [Member]",
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r1104",
      "r1439"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1255",
      "r1261",
      "r1357",
      "r1358"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Unamortized debt issuance costs",
        "label": "Debt Issuance Costs, Gross",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1379",
      "r1381"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1255",
      "r1261",
      "r1357"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r139",
      "r1255",
      "r1261"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total gross deferred tax liability",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r120",
      "r605"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1255",
      "r1261",
      "r1357",
      "r1358"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopmentCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development",
        "label": "Deferred Tax Assets In Process Research And Development Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets (liabilities)",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1353"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Deferred Tax Assets Right Of Use Assets Or Lease Liabilities",
        "documentation": "Deferred tax assets right of use assets/ lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails",
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right-of-use assets",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DeferredTaxLiabilitiesOriginalIssueDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "DeferredTaxLiabilitiesOriginalIssueDiscount",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Original Issue Discount",
        "label": "Deferred Tax Liabilities, Original Issue Discount",
        "documentation": "Deferred Tax Liabilities, Original Issue Discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesOtherComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized gains",
        "label": "Deferred Tax Liabilities, Other Comprehensive Income",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains in other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fixed assets",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r491",
      "r492",
      "r493",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r520"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefits costs",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of compensation",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discretionary match percentage",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r35"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization expense for property and equipment",
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r181",
      "r229",
      "r246",
      "r270",
      "r976",
      "r994",
      "r995"
     ]
    },
    "arwr_DevelopmentAndSalesMilestonesPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "DevelopmentAndSalesMilestonesPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and sales milestone payments",
        "label": "Development And Sales Milestones Payments",
        "documentation": "Development And Sales Milestones Payments"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DevelopmentMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "DevelopmentMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development milestone payments",
        "label": "Development Milestone Payments",
        "documentation": "Development Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DevelopmentRegulatoryAndSalesMilestonesPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "DevelopmentRegulatoryAndSalesMilestonesPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development regulatory and sales milestones payments",
        "label": "Development Regulatory And Sales Milestones Payments",
        "documentation": "Development regulatory and sales milestones payments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1313"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r531",
      "r562",
      "r563",
      "r565",
      "r1031"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1117",
      "r1118",
      "r1141"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1117",
      "r1118",
      "r1141",
      "r1184"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1162"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "arwr_DrugManufacturingFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "DrugManufacturingFacilityMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Drug Manufacturing Facility",
        "label": "Drug Manufacturing Facility [Member]",
        "documentation": "Drug manufacturing facility."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1173"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Basic net loss per share (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r179",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r217",
      "r219",
      "r221",
      "r222",
      "r223",
      "r228",
      "r398",
      "r566",
      "r626",
      "r631",
      "r661",
      "r662",
      "r805",
      "r834",
      "r985"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Diluted net loss per share (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r179",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r219",
      "r221",
      "r222",
      "r223",
      "r228",
      "r398",
      "r566",
      "r626",
      "r631",
      "r661",
      "r662",
      "r805",
      "r834",
      "r985"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r225"
     ]
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareReconciliationAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to Arrowhead Pharmaceuticals, Inc.:",
        "label": "Earnings Per Share Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r224",
      "r226",
      "r227"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate on cash, cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r1034"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. federal statutory income tax",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r194",
      "r587",
      "r617",
      "r1034"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r1034",
      "r1255",
      "r1262",
      "r1350"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationFdiiPercent",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign-derived intangible income deduction",
        "label": "Effective Income Tax Rate Reconciliation, FDII, Percent",
        "documentation": "Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)."
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1350",
      "r1352"
     ]
    },
    "arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1255",
      "r1262",
      "r1350",
      "r1352"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent and other items",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1255",
      "r1262",
      "r1350",
      "r1351"
     ]
    },
    "arwr_EffectiveIncomeTaxRateReconciliationOtherIncomePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherIncomePercent",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Effective Income Tax Rate Reconciliation, Other Income, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Other Income, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes, net of federal tax benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r1034",
      "r1255",
      "r1262",
      "r1350"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r593",
      "r1255",
      "r1262",
      "r1350"
     ]
    },
    "arwr_EmployeeContributionNextTwoPercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "EmployeeContributionNextTwoPercentMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Contributions Next 2%",
        "label": "Employee Contribution Next Two Percent [Member]",
        "documentation": "Employee contribution next two percent."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_EmployeeContributionsUpToThreePercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "EmployeeContributionsUpToThreePercentMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Contributions up to 3%",
        "label": "Employee Contributions Up To Three Percent [Member]",
        "documentation": "Employee contributions up to three percent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1347"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period to recognize pre-tax compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized pre-tax compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1348"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveSecuritiesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346"
     ]
    },
    "arwr_EnrollmentRelatedMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "EnrollmentRelatedMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Enrollment related milestone payments",
        "label": "Enrollment Related Milestone Payments",
        "documentation": "Enrollment Related Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation State Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1224"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1225"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1167"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1220"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1220"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1220"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r144",
      "r146",
      "r147",
      "r174",
      "r175",
      "r176",
      "r200",
      "r201",
      "r202",
      "r204",
      "r211",
      "r213",
      "r215",
      "r230",
      "r314",
      "r315",
      "r354",
      "r397",
      "r424",
      "r566",
      "r615",
      "r616",
      "r623",
      "r624",
      "r625",
      "r627",
      "r630",
      "r631",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r660",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r705",
      "r708",
      "r724",
      "r830",
      "r853",
      "r854",
      "r855",
      "r875",
      "r928"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1177"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1134",
      "r1145",
      "r1155",
      "r1188"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1142",
      "r1152",
      "r1185"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1183"
     ]
    },
    "arwr_FacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "FacilitiesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facilities",
        "label": "Facilities [Member]",
        "documentation": "Facilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r665",
      "r675",
      "r1071"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r665",
      "r675",
      "r1071"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r494",
      "r495",
      "r663",
      "r665",
      "r666",
      "r667",
      "r668",
      "r674",
      "r675",
      "r677",
      "r686",
      "r733",
      "r734",
      "r735",
      "r969",
      "r1004",
      "r1005",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1071",
      "r1074",
      "r1081"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r665",
      "r666",
      "r668",
      "r1071",
      "r1372",
      "r1375"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r670",
      "r672",
      "r673",
      "r674",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r801",
      "r1071",
      "r1075"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r465",
      "r470",
      "r494",
      "r665",
      "r675",
      "r686",
      "r733",
      "r969",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1071",
      "r1081"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r465",
      "r470",
      "r494",
      "r496",
      "r665",
      "r666",
      "r675",
      "r686",
      "r734",
      "r969",
      "r1004",
      "r1005",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1071",
      "r1081"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r494",
      "r495",
      "r665",
      "r666",
      "r667",
      "r668",
      "r675",
      "r686",
      "r735",
      "r969",
      "r1004",
      "r1005",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1071",
      "r1074",
      "r1081"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r665",
      "r666",
      "r668",
      "r1071",
      "r1372",
      "r1375"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r494",
      "r495",
      "r663",
      "r665",
      "r666",
      "r667",
      "r668",
      "r674",
      "r675",
      "r677",
      "r686",
      "r733",
      "r734",
      "r735",
      "r969",
      "r1004",
      "r1005",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1071",
      "r1074",
      "r1081"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1375"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r394",
      "r420",
      "r647",
      "r658",
      "r682",
      "r691",
      "r694",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r814",
      "r831",
      "r1001",
      "r1071",
      "r1072",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1085",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1368",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377"
     ]
    },
    "arwr_FinancingAgreementInitialTermLoanInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "FinancingAgreementInitialTermLoanInterestMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Agreement, Initial Term Loan Interest",
        "label": "Financing Agreement, Initial Term Loan Interest [Member]",
        "documentation": "Financing Agreement, Initial Term Loan Interest"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_FinancingAgreementInitialTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "FinancingAgreementInitialTermLoanMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Agreement, Initial Term Loan",
        "label": "Financing Agreement, Initial Term Loan [Member]",
        "documentation": "Financing Agreement, Initial Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_FinancingAgreementMOICPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "FinancingAgreementMOICPaymentMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Agreement, MOIC Payment",
        "label": "Financing Agreement, MOIC Payment [Member]",
        "documentation": "Financing Agreement, MOIC Payment"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_FinancingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "FinancingAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Agreement",
        "label": "Financing Agreement [Member]",
        "documentation": "Financing Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful Lives",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r327",
      "r346",
      "r971"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1293",
      "r1440"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r967",
      "r971"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r967",
      "r971"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r967",
      "r971"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r967",
      "r971"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r967",
      "r971"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r349",
      "r350",
      "r765",
      "r766",
      "r861",
      "r967",
      "r971",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r346",
      "r766",
      "r971"
     ]
    },
    "arwr_FiniteLivedIntangibleAssetsImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "FiniteLivedIntangibleAssetsImpairment",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment",
        "label": "Finite-Lived Intangible Assets, Impairment",
        "documentation": "Finite-Lived Intangible Assets, Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r346",
      "r349",
      "r350",
      "r352",
      "r765",
      "r967",
      "r971",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r349",
      "r350",
      "r861",
      "r967",
      "r971",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails",
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r1292"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r588"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation Adjustments",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1138",
      "r1149",
      "r1159",
      "r1192"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1138",
      "r1149",
      "r1159",
      "r1192"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1138",
      "r1149",
      "r1159",
      "r1192"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1138",
      "r1149",
      "r1159",
      "r1192"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1138",
      "r1149",
      "r1159",
      "r1192"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1172"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_FuturePotentialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "FuturePotentialMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future potential milestone payments",
        "label": "Future Potential Milestone Payments",
        "documentation": "Future Potential Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_GSKHBVAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "GSKHBVAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GSK-HBV Agreement",
        "label": "GSK-HBV Agreement [Member]",
        "documentation": "GSK-HBV Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_GSKHSDLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "GSKHSDLicenseAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GSK-HSD License Agreement",
        "label": "GSK-HSD License Agreement [Member]",
        "documentation": "GSK-HSD License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_GainLossOnTreasuryStockSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "GainLossOnTreasuryStockSettlement",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-cash gain on treasury stock received",
        "terseLabel": "Gain on settlement of treasury stock",
        "label": "Gain (Loss) On Treasury Stock Settlement",
        "documentation": "Gain (Loss) On Treasury Stock Settlement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "totalLabel": "Total general and administrative expense",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r912"
     ]
    },
    "arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "GeneralAndAdministrativeExpenseExcludingNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total general and administrative expense, excluding non-cash expense",
        "label": "General And Administrative Expense, Excluding Noncash Expense",
        "documentation": "General And Administrative Expense, Excluding Noncash Expense"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_GeneralAndAdministrativeExpenseFacilitiesRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "GeneralAndAdministrativeExpenseFacilitiesRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails": {
       "parentTag": "arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facilities related",
        "label": "General And Administrative Expense, Facilities Related Expense",
        "documentation": "General And Administrative Expense, Facilities Related Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails",
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "arwr_GlaxosmithklineIntellectualPropertyLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "GlaxosmithklineIntellectualPropertyLimitedMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GSK",
        "label": "Glaxosmithkline Intellectual Property Limited [Member]",
        "documentation": "Glaxosmithkline Intellectual Property Limited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets Subject to Amortization",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1283",
      "r1284"
     ]
    },
    "arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Short-term, Long-term Investments and Marketable Securities",
        "label": "Held To Maturity Securities And Marketable Securities Table [Table Text Block]",
        "documentation": "Held to maturity securities and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_HorizonTherapeuticsIrelandDACMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "HorizonTherapeuticsIrelandDACMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Horizon",
        "label": "Horizon Therapeutics Ireland D A C [Member]",
        "documentation": "Horizon Therapeutics Ireland DAC."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1117",
      "r1118",
      "r1141"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets subject to amortization, impairment",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r1253",
      "r1297"
     ]
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofIncomeLossBeforeIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r176"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofIncomeLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r193",
      "r586"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) before income tax expense and noncontrolling interest",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r125",
      "r131",
      "r806",
      "r808",
      "r826",
      "r978",
      "r980",
      "r982",
      "r988",
      "r994",
      "r1269",
      "r1271",
      "r1272",
      "r1273",
      "r1274"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofIncomeLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r193",
      "r586"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails",
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r357",
      "r358",
      "r643",
      "r644",
      "r645",
      "r646",
      "r669",
      "r671",
      "r676",
      "r693",
      "r694",
      "r695",
      "r850",
      "r852",
      "r913",
      "r967",
      "r969",
      "r1035",
      "r1036",
      "r1069",
      "r1070",
      "r1073",
      "r1081",
      "r1359",
      "r1360",
      "r1402"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails",
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r358",
      "r643",
      "r644",
      "r645",
      "r646",
      "r669",
      "r671",
      "r676",
      "r693",
      "r694",
      "r695",
      "r850",
      "r852",
      "r913",
      "r967",
      "r969",
      "r1035",
      "r1036",
      "r1069",
      "r1070",
      "r1073",
      "r1081",
      "r1359",
      "r1360",
      "r1402"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r587",
      "r588",
      "r598",
      "r611",
      "r1034",
      "r1354"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r587",
      "r588",
      "r598",
      "r611",
      "r1034",
      "r1354"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r194",
      "r581",
      "r587",
      "r594",
      "r595",
      "r596",
      "r603",
      "r609",
      "r618",
      "r620",
      "r621",
      "r622",
      "r813",
      "r860",
      "r872",
      "r1034"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/IncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax expense (benefit)",
        "totalLabel": "Income tax provision",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r140",
      "r189",
      "r214",
      "r215",
      "r229",
      "r249",
      "r270",
      "r585",
      "r587",
      "r619",
      "r837",
      "r978",
      "r980",
      "r982",
      "r1034"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r583",
      "r584",
      "r603",
      "r604",
      "r608",
      "r613",
      "r866"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes (refund) paid",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r187",
      "r610",
      "r611"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "arwr_IncreaseDecreaseInCashAndInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "IncreaseDecreaseInCashAndInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net increase (decrease) in cash and investments",
        "label": "Increase (Decrease) In Cash And Investments",
        "documentation": "Increase decrease in cash and investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r763",
      "r1252"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, net",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1228",
      "r1252"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1138",
      "r1149",
      "r1159",
      "r1183",
      "r1192",
      "r1196",
      "r1204"
     ]
    },
    "arwr_InducementAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "InducementAwardsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement Awards",
        "label": "Inducement Awards [Member]",
        "documentation": "Inducement Awards"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_InducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "InducementPlanMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement Plan",
        "label": "Inducement Plan [Member]",
        "documentation": "Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_InitialTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "InitialTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial transaction price",
        "label": "Initial Transaction Price",
        "documentation": "Initial transaction price."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1202"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1119",
      "r1208"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1119",
      "r1208"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1119",
      "r1208"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r351",
      "r353",
      "r966",
      "r967"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r391",
      "r396",
      "r1006",
      "r1007",
      "r1434"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual interest expense",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r392",
      "r1006",
      "r1007"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r978",
      "r982",
      "r1251"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r185",
      "r186"
     ]
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterestAndDividend",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest and Dividend",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of note premiums/discounts",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r862",
      "r863",
      "r864",
      "r865",
      "r935",
      "r936"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contract Maturity of Available for Sale Securities",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r143",
      "r280",
      "r282",
      "r683",
      "r684",
      "r1395"
     ]
    },
    "arwr_JamesHamiltonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "JamesHamiltonMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "James Hamilton [Member]",
        "documentation": "James Hamilton"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_JanssenPharmaceuticalsIncorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "JanssenPharmaceuticalsIncorporationMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Janssen",
        "label": "Janssen Pharmaceuticals Incorporation [Member]",
        "documentation": "Janssen Pharmaceuticals, Incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_LaboratoryAndOfficeFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "LaboratoryAndOfficeFacilityMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory and Office Facility",
        "label": "Laboratory And Office Facility [Member]",
        "documentation": "Laboratory and office facility."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LandMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r1313",
      "r1314"
     ]
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LandSubjectToGroundLeases",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office space leases (in sq ft)",
        "label": "Land Subject to Ground Leases",
        "documentation": "Area of land subject to a ground lease."
       }
      }
     },
     "auth_ref": [
      "r1382"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r714",
      "r1083"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Cost",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Assets and Liabilities and Lease Cost",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1384"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r722"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r723"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r723"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities on an Undiscounted Basis",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1385"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r1256",
      "r1263",
      "r1396"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2031 and thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r1256",
      "r1263",
      "r1396"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r1256",
      "r1263",
      "r1396"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r1256",
      "r1263",
      "r1396"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r1256",
      "r1263",
      "r1396"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r1256",
      "r1263",
      "r1396"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r1256",
      "r1263",
      "r1396"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1383"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1383"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities, Noncontrolling Interest and Stockholders' Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r124",
      "r822",
      "r1084",
      "r1099",
      "r1100",
      "r1255",
      "r1260",
      "r1282",
      "r1378"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r151",
      "r189",
      "r191",
      "r192",
      "r313",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r637",
      "r641",
      "r642",
      "r692",
      "r1084",
      "r1306",
      "r1386",
      "r1387"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total long-term liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r73",
      "r74",
      "r75",
      "r78",
      "r189",
      "r191",
      "r192",
      "r313",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r637",
      "r641",
      "r642",
      "r692",
      "r1306",
      "r1386",
      "r1387"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Related To The Sale Of Future Royalties [Abstract]",
        "documentation": "Liability Related To The Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Related to the Sale of Future Royalties",
        "label": "Liability Related To The Sale Of Future Royalties [Text Block]",
        "documentation": "Liability Related To The Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_LiabilitySaleOfFutureRoyaltiesInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "LiabilitySaleOfFutureRoyaltiesInterestRate",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability related to the sale of future royalties, interest rate",
        "label": "Liability, Sale Of Future Royalties, Interest Rate",
        "documentation": "Liability, Sale Of Future Royalties, Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_LiabilitySaleOfFutureRoyaltiesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "LiabilitySaleOfFutureRoyaltiesRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability, Sale Of Future Royalties [Roll Forward]",
        "label": "Liability, Sale Of Future Royalties [Roll Forward]",
        "documentation": "Liability, Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_LicenseAndCoFundingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "LicenseAndCoFundingAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and Co-Funding Agreement",
        "label": "License And Co Funding Agreement [Member]",
        "documentation": "License and co-funding agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LicensingAgreementsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "Licensing Agreements [Member]",
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r1051",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289",
      "r1290",
      "r1292",
      "r1294",
      "r1295",
      "r1296",
      "r1349"
     ]
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term line of credit",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r121",
      "r1398"
     ]
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Line Items]",
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r1255",
      "r1258",
      "r1304"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r72"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility, remaining borrowing capacity",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r72",
      "r368"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Table]",
        "label": "Line of Credit Facility [Table]",
        "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r72",
      "r368",
      "r1255",
      "r1258",
      "r1304"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LinesOfCreditCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LinesOfCreditCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facility",
        "negatedTerseLabel": "Less: Current portion of credit facility",
        "label": "Line of Credit, Current",
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r118"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r1256",
      "r1263",
      "r1311",
      "r1396"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r190",
      "r199",
      "r389",
      "r810"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Long-Term Debt, Maturity, Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r190",
      "r199",
      "r389",
      "r810"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r190",
      "r199",
      "r389",
      "r810"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r190",
      "r199",
      "r389",
      "r810"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r190",
      "r199",
      "r389",
      "r810"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facility, net of current portion",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Agreement",
        "label": "Long-Term Debt [Text Block]",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_LongTermLineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermLineOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facility, net of current portion",
        "label": "Long-Term Line of Credit, Noncurrent",
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r38",
      "r39"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r1299",
      "r1300",
      "r1301"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r40",
      "r1299",
      "r1300",
      "r1301"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent liabilities",
        "label": "Loss Contingency Accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r1227"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r278",
      "r1010",
      "r1013",
      "r1094",
      "r1098",
      "r1401",
      "r1403",
      "r1404",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412",
      "r1413",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1428",
      "r1430",
      "r1431"
     ]
    },
    "arwr_ManufacturingEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ManufacturingEquipmentMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing equipment",
        "verboseLabel": "Manufacturing equipment",
        "label": "Manufacturing Equipment [Member]",
        "documentation": "Manufacturing Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ManufacturingFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ManufacturingFacilityMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing Facility",
        "label": "Manufacturing Facility [Member]",
        "documentation": "Structure used in the manufacturing of goods."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "arwr_MauroFerrariMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "MauroFerrariMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mauro Ferrari [Member]",
        "documentation": "Mauro Ferrari"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r236",
      "r364",
      "r365",
      "r366",
      "r367",
      "r525",
      "r557",
      "r558",
      "r559",
      "r577",
      "r668",
      "r762",
      "r849",
      "r851",
      "r859",
      "r881",
      "r882",
      "r933",
      "r937",
      "r939",
      "r940",
      "r942",
      "r947",
      "r948",
      "r950",
      "r951",
      "r964",
      "r965",
      "r1000",
      "r1009",
      "r1030",
      "r1035",
      "r1037",
      "r1038",
      "r1074",
      "r1075",
      "r1079",
      "r1080",
      "r1095",
      "r1310",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1175"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1175"
     ]
    },
    "arwr_MilestonePaymentDueFromCollaborativeAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "MilestonePaymentDueFromCollaborativeAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment due from collaborative agreement",
        "label": "Milestone Payment Due From Collaborative Agreement",
        "documentation": "Milestone Payment Due From Collaborative Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "MilestonePaymentEarned",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment",
        "label": "Milestone Payment Earned",
        "documentation": "Milestone payment earned."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "MilestonePaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable",
        "label": "Milestone Payment Receivable",
        "documentation": "Milestone Payment Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial",
        "label": "Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial",
        "documentation": "Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable upon achievement of phase two and first patient dosed in phase three",
        "label": "Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three",
        "documentation": "Milestone payment receivable upon achievement of phase two and first patient dosed in phase three."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceivableUponFDAApproval": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "MilestonePaymentReceivableUponFDAApproval",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable upon FDA approval",
        "label": "Milestone Payment Receivable Upon FDA Approval",
        "documentation": "Milestone Payment Receivable Upon FDA Approval"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "MilestonePaymentReceivableUponReceiptOfRoyaltyPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable upon receipt of royalty payments",
        "label": "Milestone Payment Receivable, Upon Receipt Of Royalty Payments",
        "documentation": "Milestone Payment Receivable, Upon Receipt Of Royalty Payments"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment received",
        "label": "Milestone Payment Received, Liability Related To Sale Of Future Royalties",
        "documentation": "Milestone Payment Received, Liability Related To Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r236",
      "r364",
      "r365",
      "r366",
      "r367",
      "r525",
      "r557",
      "r558",
      "r559",
      "r577",
      "r668",
      "r762",
      "r849",
      "r851",
      "r859",
      "r881",
      "r882",
      "r933",
      "r937",
      "r939",
      "r940",
      "r942",
      "r947",
      "r948",
      "r950",
      "r951",
      "r964",
      "r965",
      "r1000",
      "r1009",
      "r1030",
      "r1035",
      "r1037",
      "r1038",
      "r1074",
      "r1075",
      "r1079",
      "r1095",
      "r1310",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r123",
      "r189",
      "r191",
      "r192",
      "r313",
      "r369",
      "r371",
      "r372",
      "r373",
      "r376",
      "r377",
      "r821",
      "r892",
      "r1378"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1195"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market instruments",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1318",
      "r1319"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1203"
     ]
    },
    "us-gaap_MunicipalBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MunicipalBondsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Municipal securities",
        "label": "Municipal Bonds [Member]",
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments."
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r278",
      "r1010",
      "r1013",
      "r1094",
      "r1098",
      "r1401",
      "r1403",
      "r1404",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412",
      "r1413",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1428",
      "r1430",
      "r1431"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1176"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to Arrowhead Pharmaceuticals, Inc.",
        "terseLabel": "Net loss attributable to Arrowhead Pharmaceuticals, Inc.",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r100",
      "r126",
      "r147",
      "r149",
      "r169",
      "r171",
      "r176",
      "r189",
      "r191",
      "r192",
      "r196",
      "r203",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r214",
      "r215",
      "r220",
      "r313",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r398",
      "r401",
      "r403",
      "r406",
      "r566",
      "r626",
      "r631",
      "r662",
      "r692",
      "r829",
      "r910",
      "r926",
      "r927",
      "r978",
      "r980",
      "r982",
      "r1110",
      "r1306"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) attributable to noncontrolling interest, net of tax",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r115",
      "r169",
      "r171",
      "r211",
      "r214",
      "r215",
      "r828",
      "r1250"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1175"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r1138",
      "r1149",
      "r1159",
      "r1183",
      "r1192"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1166"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1165"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1183"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1203"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1203"
     ]
    },
    "arwr_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense on liability related to the sale of future royalties",
        "verboseLabel": "Non-cash interest expense recognized",
        "label": "Noncash Interest Expense, Liability Related to Sale of Future Royalties",
        "documentation": "Noncash Interest Expense, Liability Related to Sale of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non- controlling Interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r424",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1437"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other expense",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (expense) income:",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NovartisCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "NovartisCollaborationAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novartis Collaboration Agreement",
        "label": "Novartis Collaboration Agreement [Member]",
        "documentation": "Novartis Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NovartisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "NovartisMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novartis",
        "label": "Novartis [Member]",
        "documentation": "Novartis."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NumberOfAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "NumberOfAgreements",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of agreements",
        "label": "Number Of Agreements",
        "documentation": "Number of agreements."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NumberOfCollaborationPrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "NumberOfCollaborationPrograms",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of collaboration programs",
        "label": "Number Of Collaboration Programs",
        "documentation": "Number Of Collaboration Programs"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NumberOfDistinctBundle": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "NumberOfDistinctBundle",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of distinct bundle",
        "label": "Number Of Distinct Bundle",
        "documentation": "Number of distinct bundle."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NumberOfDistinctPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "NumberOfDistinctPerformanceObligations",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of distinct performance obligations",
        "label": "Number Of Distinct Performance Obligations",
        "documentation": "Number of distinct performance obligations."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NumberOfNewTargetPrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "NumberOfNewTargetPrograms",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of new target programs",
        "label": "Number Of New Target Programs",
        "documentation": "Number Of New Target Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SegmentInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r995",
      "r1270"
     ]
    },
    "arwr_NumberOfOptionsToRenew": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "NumberOfOptionsToRenew",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options to renew",
        "label": "Number Of Options To Renew",
        "documentation": "Number of options to renew."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NumberOfPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "NumberOfPerformanceObligations",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of performance obligations",
        "label": "Number Of Performance Obligations",
        "documentation": "Number Of Performance Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of subsidiaries with foreign currency as functional currency",
        "label": "Number Of Subsidiaries With Foreign Currency As Functional Currency",
        "documentation": "Number Of Subsidiaries With Foreign Currency As Functional Currency"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_OlpasiranAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "OlpasiranAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Olpasiran Agreement",
        "label": "Olpasiran Agreement [Member]",
        "documentation": "Olpasiran agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating income (loss)",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r978",
      "r982",
      "r988",
      "r1269",
      "r1271",
      "r1272",
      "r1273",
      "r1274"
     ]
    },
    "arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities",
        "documentation": "Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r1083"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r711",
      "r718"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r1083"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r1083"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "arwr_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards not subject to expiration",
        "label": "Operating Loss Carryforwards, Not Subject To Expiration",
        "documentation": "Operating Loss Carryforwards, Not Subject To Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_OperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards subject to expiration",
        "label": "Operating Loss Carryforwards, Subject To Expiration",
        "documentation": "Operating Loss Carryforwards, Subject To Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "arwr_OperatingSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "OperatingSegmentMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segment",
        "label": "Operating Segment [Member]",
        "documentation": "Operating Segment"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_OrganizationAndSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "OrganizationAndSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization And Significant Accounting Policies [Line Items]",
        "label": "Organization And Significant Accounting Policies [Line Items]",
        "documentation": "Organization and significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_OrganizationAndSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "OrganizationAndSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization And Significant Accounting Policies [Table]",
        "label": "Organization And Significant Accounting Policies [Table]",
        "documentation": "Organization and significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Significant Accounting Policies",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r1237",
      "r1254"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r1084"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains (losses) on available-for-sale securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r830"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustments",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r830"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r1084"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r1068"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1175"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1136",
      "r1147",
      "r1157",
      "r1190"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1139",
      "r1150",
      "r1160",
      "r1193"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1139",
      "r1150",
      "r1160",
      "r1193"
     ]
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense on credit facility",
        "label": "Paid-in-Kind Interest",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1290",
      "r1292",
      "r1295",
      "r1296"
     ]
    },
    "arwr_PatrickOBrienMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "PatrickOBrienMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patrick O'Brien [Member]",
        "documentation": "Patrick O'Brien"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_PatrickOBrienOtherSharesBeingSoldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "PatrickOBrienOtherSharesBeingSoldMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patrick O'Brien, Other Shares Being Sold [Member]",
        "documentation": "Patrick O'Brien, Other Shares Being Sold"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_PatrickOBrienSharesVestingAndSubjectToSellToCoverMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "PatrickOBrienSharesVestingAndSubjectToSellToCoverMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patrick O'Brien, Shares Vesting And Subject to Sell-To-Cover [Member]",
        "documentation": "Patrick O'Brien, Shares Vesting And Subject to Sell-To-Cover"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "PaymentReceivableInCollaborationArrangementsUponTargetNomination",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment receivable upon target nomination",
        "label": "Payment Receivable In Collaboration Arrangements Upon Target Nomination",
        "documentation": "Payment Receivable In Collaboration Arrangements Upon Target Nomination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property, plant and equipment",
        "terseLabel": "Capital expenditure",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1174"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1174"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1166"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1183"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1176"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1165"
     ]
    },
    "arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of commission to sales agent",
        "label": "Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock",
        "documentation": "Percentage of commission on aggregate gross proceeds from sale of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage eligible to receive tiered royalties on net sales",
        "label": "Percentage Of Eligible To Receive Tiered Royalties On Net Sales",
        "documentation": "Percentage of eligible to receive tiered royalties on net sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1167"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1223"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1166"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquitySharesofCommonStockandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r408"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquitySharesofCommonStockandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r890"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquitySharesofCommonStockandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r408"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquitySharesofCommonStockandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r890",
      "r909",
      "r1437",
      "r1438"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r325",
      "r326",
      "r972"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ProceedsFromCollaborationArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ProceedsFromCollaborationArrangements",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from collaboration arrangements",
        "terseLabel": "Upfront payment",
        "label": "Proceeds From Collaboration Arrangements",
        "documentation": "Proceeds From Collaboration Arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of common stock, net of offering costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of warrants",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of equity",
        "label": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r867"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Visirna credit agreement",
        "label": "Proceeds from Lines of Credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r1255",
      "r1258"
     ]
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from credit facility",
        "label": "Proceeds from Long-Term Lines of Credit",
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales and maturities of investments",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "arwr_ProceedsFromSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ProceedsFromSaleOfFutureRoyalties",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the sale of future royalties",
        "label": "Proceeds from Sale of Future Royalties",
        "documentation": "Proceeds from Sale of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercises of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r15"
     ]
    },
    "arwr_ProceedsFromTenantImprovementAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ProceedsFromTenantImprovementAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from additional tenant improvement allowance",
        "label": "Proceeds from Tenant Improvement Allowance",
        "documentation": "Proceeds from Tenant Improvement Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails": {
       "parentTag": "arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional, outside services, and other",
        "label": "Professional Fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r980",
      "r994",
      "r1110",
      "r1435",
      "r1436"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) including noncontrolling interest",
        "verboseLabel": "Net (loss) income",
        "netLabel": "Net income (loss)",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r149",
      "r169",
      "r171",
      "r183",
      "r189",
      "r191",
      "r192",
      "r196",
      "r203",
      "r211",
      "r214",
      "r215",
      "r313",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r398",
      "r566",
      "r626",
      "r631",
      "r635",
      "r638",
      "r639",
      "r662",
      "r692",
      "r806",
      "r808",
      "r827",
      "r874",
      "r910",
      "r926",
      "r927",
      "r1066",
      "r1067",
      "r1111",
      "r1250",
      "r1306"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r722"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r153",
      "r825"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r722",
      "r812",
      "r825",
      "r1084"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r137",
      "r138",
      "r823"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Useful Lives of Property Plant and Equipment",
        "terseLabel": "Schedule of Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTransfersAndChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTransfersAndChanges",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, reclassification",
        "label": "Property, Plant and Equipment, Transfers and Changes",
        "documentation": "Amount of increase (decrease) of physical assets used in the normal conduct of business and not intended for resale, from reclassification, impairment, donation, or changes classified as other. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r722"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Lives",
        "verboseLabel": "Useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r236",
      "r364",
      "r365",
      "r366",
      "r367",
      "r463",
      "r525",
      "r557",
      "r558",
      "r559",
      "r565",
      "r577",
      "r668",
      "r736",
      "r745",
      "r762",
      "r849",
      "r851",
      "r859",
      "r881",
      "r882",
      "r933",
      "r937",
      "r939",
      "r940",
      "r942",
      "r947",
      "r948",
      "r950",
      "r951",
      "r964",
      "r965",
      "r1000",
      "r1009",
      "r1030",
      "r1035",
      "r1037",
      "r1038",
      "r1074",
      "r1075",
      "r1079",
      "r1080",
      "r1095",
      "r1104",
      "r1302",
      "r1310",
      "r1372",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r236",
      "r364",
      "r365",
      "r366",
      "r367",
      "r463",
      "r525",
      "r557",
      "r558",
      "r559",
      "r565",
      "r577",
      "r668",
      "r736",
      "r745",
      "r762",
      "r849",
      "r851",
      "r859",
      "r881",
      "r882",
      "r933",
      "r937",
      "r939",
      "r940",
      "r942",
      "r947",
      "r948",
      "r950",
      "r951",
      "r964",
      "r965",
      "r1000",
      "r1009",
      "r1030",
      "r1035",
      "r1037",
      "r1038",
      "r1074",
      "r1075",
      "r1079",
      "r1080",
      "r1095",
      "r1104",
      "r1302",
      "r1310",
      "r1372",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1393"
     ]
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RealizedInvestmentGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Realized loss on investments",
        "label": "Realized Investment Gains (Losses)",
        "documentation": "Amount of realized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized Tax Benefits [Roll Forward]",
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1142",
      "r1152",
      "r1185"
     ]
    },
    "arwr_RegulatoryMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "RegulatoryMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory milestone payments",
        "label": "Regulatory Milestone Payments",
        "documentation": "Regulatory Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayments of credit facility",
        "terseLabel": "Repayments of credit facility",
        "negatedLabel": "Less: Payments",
        "label": "Repayments of Long-Term Lines of Credit",
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r197",
      "r198",
      "r381",
      "r410",
      "r725",
      "r746",
      "r815",
      "r973",
      "r974",
      "r975",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1362",
      "r1363",
      "r1364",
      "r1365"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "totalLabel": "Total research and development expense",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r967",
      "r978",
      "r979",
      "r994",
      "r1394"
     ]
    },
    "arwr_ResearchAndDevelopmentExpenseCandidateCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ResearchAndDevelopmentExpenseCandidateCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails": {
       "parentTag": "arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Candidate costs",
        "label": "Research And Development Expense, Candidate Costs",
        "documentation": "Research And Development Expense, Candidate Costs"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ResearchAndDevelopmentExpenseDiscoveryCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ResearchAndDevelopmentExpenseDiscoveryCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails": {
       "parentTag": "arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D discovery costs",
        "label": "Research And Development Expense, Discovery Costs",
        "documentation": "Research And Development Expense, Discovery Costs"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ResearchAndDevelopmentExpenseExcludingNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total research and development expense, excluding non-cash expense",
        "label": "Research And Development Expense, Excluding Noncash Expense",
        "documentation": "Research And Development Expense, Excluding Noncash Expense"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ResearchAndDevelopmentExpenseFacilitiesRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ResearchAndDevelopmentExpenseFacilitiesRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails": {
       "parentTag": "arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facilities related",
        "label": "Research And Development Expense, Facilities Related Expense",
        "documentation": "Research And Development Expense, Facilities Related Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails",
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "arwr_ResearchAndDevelopmentExpenseSalariesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ResearchAndDevelopmentExpenseSalariesExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails": {
       "parentTag": "arwr_ResearchAndDevelopmentExpenseExcludingNoncashExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salaries",
        "label": "Research And Development Expense, Salaries Expense",
        "documentation": "Research And Development Expense, Salaries Expense"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ResearchEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ResearchEquipmentMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research equipment",
        "label": "Research Equipment [Member]",
        "documentation": "Research Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ResearchFacilityInMadisonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ResearchFacilityInMadisonMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Facility in Madison",
        "label": "Research Facility In Madison [Member]",
        "documentation": "Research facility in Madison."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ResearchFacilityInSanDiegoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ResearchFacilityInSanDiegoMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Facility in San Diego",
        "label": "Research Facility In San Diego [Member]",
        "documentation": "Research Facility in San Diego."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1132",
      "r1143",
      "r1153",
      "r1186"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1133",
      "r1144",
      "r1154",
      "r1187"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1140",
      "r1151",
      "r1161",
      "r1194"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash and Cash Equivalent, Current",
        "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r152",
      "r188"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveSecuritiesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r108",
      "r820",
      "r856",
      "r858",
      "r871",
      "r891",
      "r1084"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r146",
      "r147",
      "r200",
      "r201",
      "r202",
      "r204",
      "r211",
      "r213",
      "r215",
      "r314",
      "r315",
      "r354",
      "r397",
      "r566",
      "r615",
      "r616",
      "r623",
      "r624",
      "r625",
      "r627",
      "r630",
      "r631",
      "r648",
      "r650",
      "r651",
      "r653",
      "r660",
      "r705",
      "r708",
      "r853",
      "r855",
      "r875",
      "r1437"
     ]
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetirementPlanTypeAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Axis]",
        "label": "Retirement Plan Type [Axis]",
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r526",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029"
     ]
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetirementPlanTypeDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Domain]",
        "label": "Retirement Plan Type [Domain]",
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r526",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r229",
      "r242",
      "r243",
      "r264",
      "r270",
      "r274",
      "r276",
      "r278",
      "r437",
      "r438",
      "r439",
      "r764",
      "r978",
      "r982"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r968"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets adjusted in exchange for new/amended operating lease liabilities",
        "label": "Right-Of-Use Asset Adjustment In Exchange For Operating Lease Liability",
        "documentation": "Right-Of-Use Asset Adjustment In Exchange For Operating Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_RoyaltiesLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "RoyaltiesLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability related to the sale of future royalties",
        "periodStartLabel": "Beginning carrying value",
        "periodEndLabel": "Ending carrying value",
        "label": "Royalties, Liability, Noncurrent",
        "documentation": "Royalties, Liability, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_RoyaltyPaymentThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "RoyaltyPaymentThreshold",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payment threshold",
        "label": "Royalty Payment Threshold",
        "documentation": "Royalty Payment Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_RoyaltyPharmaAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "RoyaltyPharmaAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Pharma Agreement",
        "label": "Royalty Pharma Agreement [Member]",
        "documentation": "Royalty Pharma Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1203"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1203"
     ]
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalariesWagesAndOfficersCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails": {
       "parentTag": "arwr_GeneralAndAdministrativeExpenseExcludingNoncashExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salaries",
        "label": "Salary and Wage, Excluding Cost of Good and Service Sold",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of stock",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock issued (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_SaleOfStockPremiumOnIssuanceOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "SaleOfStockPremiumOnIssuanceOfShares",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity premium",
        "label": "Sale Of Stock, Premium On Issuance Of Shares",
        "documentation": "Sale Of Stock, Premium On Issuance Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock offering price (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_SalesRelatedMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "SalesRelatedMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-related milestone payments",
        "label": "Sales Related Milestone Payments",
        "documentation": "Sales-related milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_SanofiLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "SanofiLicenseAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi License Agreement",
        "label": "Sanofi License Agreement [Member]",
        "documentation": "Sanofi License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_SanofiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "SanofiMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi",
        "label": "Sanofi [Member]",
        "documentation": "Sanofi"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_SareptaCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "SareptaCollaborationAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sarepta Collaboration Agreement",
        "label": "Sarepta Collaboration Agreement [Member]",
        "documentation": "Sarepta Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_SareptaTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "SareptaTherapeuticsIncMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sarepta",
        "label": "Sarepta Therapeutics, Inc [Member]",
        "documentation": "Sarepta Therapeutics, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Income (Loss) Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Taxes for Provisions (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1356"
     ]
    },
    "arwr_ScheduleOfCurrentProductsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ScheduleOfCurrentProductsTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company's Current Pipeline",
        "label": "Schedule of Current Products [Table Text Block]",
        "documentation": "Schedule of Current Products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of the Net Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1353"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Defined Benefit Plans Disclosures [Table]",
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r50",
      "r51",
      "r52",
      "r53",
      "r490",
      "r491",
      "r492",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r520"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1268"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r1034",
      "r1350"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Payment Arrangement, Expensed",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1369",
      "r1370"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r346",
      "r349",
      "r350",
      "r352",
      "r765",
      "r967",
      "r971",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r971",
      "r1291"
     ]
    },
    "arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]",
        "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]",
        "documentation": "Schedule of held to maturity securities and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]",
        "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]",
        "documentation": "Schedule of held to maturity securities and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income (Loss) Before Income Tax Expense and Noncontrolling Interest",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1255",
      "r1261"
     ]
    },
    "arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Liability Related to the Sale of Future Royalties",
        "label": "Schedule Of Liability Related To The Sale Of Future Royalties [Table Text Block]",
        "documentation": "Schedule Of Liability Related To The Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Line of Credit Facilities",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r72"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Long-Term Debt",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsNarrativeDetails",
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r722"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Awards Outstanding",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r110"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r530",
      "r532",
      "r533",
      "r534",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r565"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Activity Related to RSUs",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Summarized Information about Stock Options",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r109"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions Used to Value Stock Options",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r106",
      "r107",
      "r108",
      "r159",
      "r160",
      "r161",
      "r231",
      "r408",
      "r409",
      "r410",
      "r412",
      "r415",
      "r420",
      "r422",
      "r647",
      "r867",
      "r868",
      "r869",
      "r870",
      "r1009",
      "r1226",
      "r1255",
      "r1257"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Shares of Common Stock and Preferred Stock",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r79",
      "r80",
      "r106",
      "r107",
      "r108"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Gross Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r1033"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets Future Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r971",
      "r1293"
     ]
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementInterestExpenseRecognizedRelatedtoCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementOutstandingBalanceofCreditFacilityDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementPrincipalRepaymentRelatedtoCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security12b Title",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132",
      "r229",
      "r238",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r278",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r352",
      "r359",
      "r360",
      "r628",
      "r629",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r991",
      "r994",
      "r995",
      "r1002",
      "r1097",
      "r1401",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412",
      "r1413",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1428",
      "r1430",
      "r1431"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r233",
      "r276",
      "r277",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r806",
      "r807",
      "r808",
      "r809",
      "r878",
      "r879",
      "r880",
      "r934",
      "r938",
      "r941",
      "r943",
      "r947",
      "r949",
      "r950",
      "r951",
      "r954",
      "r955",
      "r956",
      "r957",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r970",
      "r986",
      "r1010",
      "r1012",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1096",
      "r1104",
      "r1401",
      "r1403",
      "r1404",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412",
      "r1413",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1428",
      "r1430",
      "r1431"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r229",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r253",
      "r255",
      "r256",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r278",
      "r989",
      "r992",
      "r993",
      "r994",
      "r996",
      "r998",
      "r999"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r273",
      "r276",
      "r990",
      "r991",
      "r997"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails": {
       "parentTag": "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment award (in shares)",
        "verboseLabel": "Restricted stock units (in shares)",
        "periodStartLabel": "Beginning of period (in shares)",
        "periodEndLabel": "End of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of RSUs",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r530",
      "r532",
      "r533",
      "r534",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r565"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock reserved for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Awards granted and outstanding (in shares)",
        "totalLabel": "Total (in shares)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options Outstanding, Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled or expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value per share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails": {
       "parentTag": "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options outstanding (in shares)",
        "verboseLabel": "Options (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r537"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r537"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationScheduleofRSUsActivityDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r533",
      "r534",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled or expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r535",
      "r554",
      "r555",
      "r556",
      "r557",
      "r560",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Contractual Term (Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued to institutional investors (in shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Debt, Type [Axis]",
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r1299",
      "r1300",
      "r1301"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Debt, Type [Domain]",
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r1299",
      "r1300",
      "r1301"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r716",
      "r1083"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SegmentInformationResearchandDevelopmentandSellingGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132",
      "r148",
      "r229",
      "r238",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r278",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r352",
      "r356",
      "r359",
      "r360",
      "r628",
      "r629",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r991",
      "r994",
      "r995",
      "r1002",
      "r1097",
      "r1401",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412",
      "r1413",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1428",
      "r1430",
      "r1431"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r80",
      "r83",
      "r84",
      "r144",
      "r146",
      "r147",
      "r174",
      "r175",
      "r176",
      "r200",
      "r201",
      "r202",
      "r204",
      "r211",
      "r213",
      "r215",
      "r230",
      "r314",
      "r315",
      "r354",
      "r397",
      "r424",
      "r566",
      "r615",
      "r616",
      "r623",
      "r624",
      "r625",
      "r627",
      "r630",
      "r631",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r660",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r705",
      "r708",
      "r724",
      "r830",
      "r853",
      "r854",
      "r855",
      "r875",
      "r928"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r233",
      "r276",
      "r277",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r806",
      "r807",
      "r808",
      "r809",
      "r878",
      "r879",
      "r880",
      "r934",
      "r938",
      "r941",
      "r943",
      "r947",
      "r949",
      "r950",
      "r951",
      "r954",
      "r955",
      "r956",
      "r957",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r970",
      "r986",
      "r1010",
      "r1012",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1096",
      "r1104",
      "r1401",
      "r1403",
      "r1404",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412",
      "r1413",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1428",
      "r1430",
      "r1431"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r230",
      "r399",
      "r400",
      "r402",
      "r404",
      "r708",
      "r764",
      "r862",
      "r876",
      "r877",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r890",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r899",
      "r900",
      "r901",
      "r902",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r911",
      "r912",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r928",
      "r980",
      "r982",
      "r1105",
      "r1433"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r230",
      "r279",
      "r399",
      "r400",
      "r402",
      "r404",
      "r708",
      "r764",
      "r862",
      "r876",
      "r877",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r890",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r899",
      "r900",
      "r901",
      "r902",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r911",
      "r912",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r928",
      "r980",
      "r982",
      "r1105",
      "r1433"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1135",
      "r1146",
      "r1156",
      "r1189"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued, net of offering costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r79",
      "r80",
      "r108",
      "r867",
      "r928",
      "r944"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock - restricted stock units vesting (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r108"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizedInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r79",
      "r80",
      "r108",
      "r541"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r79",
      "r80",
      "r108",
      "r875",
      "r928",
      "r944",
      "r1111"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock - restricted stock units vesting",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r79",
      "r80",
      "r108"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r80",
      "r83",
      "r84",
      "r108"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Arrowhead Pharmaceuticals, Inc. stockholders' equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r83",
      "r84",
      "r101",
      "r892",
      "r909",
      "r929",
      "r930",
      "r1084",
      "r1112",
      "r1255",
      "r1259",
      "r1260",
      "r1282",
      "r1378",
      "r1437"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total noncontrolling interest and stockholders' equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r63",
      "r144",
      "r145",
      "r146",
      "r147",
      "r175",
      "r200",
      "r201",
      "r202",
      "r204",
      "r211",
      "r213",
      "r314",
      "r315",
      "r354",
      "r397",
      "r424",
      "r566",
      "r615",
      "r616",
      "r623",
      "r624",
      "r625",
      "r627",
      "r630",
      "r631",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r660",
      "r698",
      "r699",
      "r703",
      "r706",
      "r724",
      "r854",
      "r855",
      "r873",
      "r892",
      "r909",
      "r929",
      "r930",
      "r945",
      "r1099",
      "r1100",
      "r1111",
      "r1255",
      "r1259",
      "r1260",
      "r1282",
      "r1378",
      "r1437"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest and stockholders' equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r407",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r424",
      "r647",
      "r659",
      "r931",
      "r932",
      "r946"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r728"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r728"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r728"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r728"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r728"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r729"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FinancingAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Interest Expense Recognized Related to Credit Facility",
        "label": "Summary Of Interest Expense Recognized Related To Credit Facility [Table Text Block]",
        "documentation": "Summary Of Interest Expense Recognized Related To Credit Facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccounts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Accounts",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r1238"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplementary disclosure of cash flows:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1182"
     ]
    },
    "arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Takeda",
        "label": "Takeda Pharmaceuticals United States Of America Incorporated [Member]",
        "documentation": "Takeda Pharmaceuticals United States of America Incorporated."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax credits",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "arwr_TaxCreditCarryforwardAmountSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "TaxCreditCarryforwardAmountSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward, amount, subject to expiration",
        "label": "Tax Credit Carryforward, Amount, Subject To Expiration",
        "documentation": "Tax Credit Carryforward, Amount, Subject To Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1174"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1181"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1202"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1204"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsCurrentInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r394",
      "r420",
      "r647",
      "r658",
      "r682",
      "r691",
      "r694",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r814",
      "r831",
      "r1071",
      "r1072",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1085",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1368",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1205"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1206"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1206"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1204"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1204"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1207"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1205"
     ]
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock repurchase price per share (in dollars per share)",
        "label": "Shares Acquired, Average Cost Per Share",
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock in Treasury",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock (in shares)",
        "negatedPeriodStartLabel": "Treasury stock, beginning balance (in shares)",
        "negatedPeriodEndLabel": "Treasury stock, ending balance (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Treasury stock; at cost; 2,661 and 0 shares of common stock at September 30, 2025 and 2024, respectively",
        "terseLabel": "Treasury stock value",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r83"
     ]
    },
    "arwr_TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock received to settle accounts receivable",
        "label": "Treasury Stock Received In Exchange For Settlement Of Accounts Receivable",
        "documentation": "Treasury Stock Received In Exchange For Settlement Of Accounts Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Common stock - repurchase (in shares)",
        "terseLabel": "Common stock repurchased (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r80",
      "r108"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Common stock - repurchase",
        "terseLabel": "Value of stock repurchased",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r48",
      "r108"
     ]
    },
    "arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2013 and 2021 Incentive Plans and other inducement grants",
        "label": "Two Thousand Thirteen Equity Incentive Plan, Two Thousand Twenty One Equity Incentive Plan And Inducement Grants [Member]",
        "documentation": "Two Thousand Thirteen Equity Incentive Plan, Two Thousand Twenty One Equity Incentive Plan And Inducement Grants"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_TwoThousandTwentyOneIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "TwoThousandTwentyOneIncentivePlanMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Plan",
        "label": "Two Thousand Twenty One Incentive Plan [Member]",
        "documentation": "Two thousand twenty one incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_TwoThousandsThirteenIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "TwoThousandsThirteenIncentivePlanMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2013 Plan",
        "label": "Two Thousands Thirteen Incentive Plan [Member]",
        "documentation": "Two thousands thirteen incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxoSmithKlineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsSareptaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncVisirnaandGenzymeCorporationSanofiDetails",
      "http://www.arrowheadresearch.com/role/FinancingAgreementNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityNarrativeDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government and agency securities",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r983",
      "r984",
      "r1018",
      "r1020",
      "r1397"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1201"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance of unrecognized tax benefits",
        "periodEndLabel": "Ending balance of unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r599",
      "r1033"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross decrease for prior period tax positions",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r1033"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense (benefit) related to uncertain tax positions",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r1033"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross increase for current period tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r1033"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross increase for prior period tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r1033"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Lapse of statue of limitations",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "arwr_UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment received",
        "label": "Upfront Payment Received, Liability Related To Sale Of Future Royalties",
        "documentation": "Upfront Payment Received, Liability Related To Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r232",
      "r234",
      "r235",
      "r236",
      "r806",
      "r808",
      "r987"
     ]
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity, Primary Beneficiary",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r636",
      "r637",
      "r641",
      "r642"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r1083"
     ]
    },
    "arwr_VictoriaVakienerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "VictoriaVakienerMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Victoria Vakiener [Member]",
        "documentation": "Victoria Vakiener"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_VisirnaESOPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "VisirnaESOPMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Visirna ESOP",
        "label": "Visirna ESOP [Member]",
        "documentation": "Visirna ESOP"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1170"
     ]
    },
    "stpr_WI": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "WI",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wisconsin",
        "label": "WISCONSIN"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of dilutive securities (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r1268"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average diluted shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r223"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average basic shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r223"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used in calculating",
        "verboseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_WilliamWaddillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20250930",
     "localname": "WilliamWaddillMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "William Waddill [Member]",
        "documentation": "William Waddill"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1168"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-13"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-14"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Paragraph": "2AA",
   "Subparagraph": "(a)",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AA"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479024/942-230-45-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-7"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2AG",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AG"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1392": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1393": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1394": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1395": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1396": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1397": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1398": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1399": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1400": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1401": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1402": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1403": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1404": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>123
<FILENAME>0000879407-25-000029-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000879407-25-000029-xbrl.zip
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M">W0X1^1FLJ*5GYY+W[\Y;T8^M:SQA]_L>Q[(PC'#O]UQ[*#D</&)Z[G<EB
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MPT(@:H*-0Q5K/"KDH=;R$!&5V(1=$()MT<\$Y6+WV_7U.?W=O/G=.&WVFH4
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M%SE3WW.0;L/T@N7O(<AQ/C7$3+ A^9DL2'X'!HBG!(BX$4\]08)U^1TI6$G
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MA"VH#Y)JP/M>Y(M8L>NY9<MV(BK<40GW% <J99,J>W@ U]09E\&2XU9ZKR*
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MV83P,U7Z]]9VXS3I#%!CC>O0L^(HM)1W8YL[PN,;@AK/&K:I+%J\JGQ[0\U
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M NYB.[_F?@3_"YNT1V#M($QOHH"V>,95 6?)Z )B!H88&8LR "D >[!H\2_
M#QMY6 LA7OL*_X;?>P,\98CKZC'[ 5?_S0=ERL"0_0ZFUU\1.%N"-+^#U'?9
M4/NXP9)6$K%Z3YY(WHCXWOEXLO9YY[A':<&)2<1)$8GG8N-;>&9)B.>%ILK)
MPA+ON<JC]E$F9IKK3XJCC&TA9:.ODJ5/Q'K4[1<B(2<,F]0AXDQ#%'&T'8@=
MC):0<]55( .!N!N&"PLQ.>4K,#,G&JJ!3<7_C+!=2:JCFC+>Y#PE0S4L>%*
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M^M1CBT=T1\$,!T-A[39MX9Z58P2?8TFD<CA6S\K'8+,+VA:MK O@CT8X':B
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M-2EBVYE*;W6MX]\CJ8KD*3!BNLH_LJ:>E>WG,8_L6WCJ?6([/Y<I3RB;O_]
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MFY#<V9M<N@#,UJL";@SY&4J!QFSD!-Z-!LT/'&#P1'FQPBB^<=2JS>%%>V0
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MD7TYUH#(<(V[L;F)D:!D2M^(S9>RWS"8 QI,CQ?:L:Z6%NO07![+N38]QZ3
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M/%3=[K74?6V"3U(UKV<$>\H0"'6=L\'V6PE:#X'X'1C7X''5%T6GO.HF@U_
M8:A7*"BHFWJC-N&+%ZX7%9=.BQ^OMNYR&:+<Z8W)1MMC>:#'4&LV>9=C:1D]
M]>&D!QGFFMN ?CEE/40U&&PEPHH-1_T3PBQSMN$:J;,FV!:L3Q=T2^Q-DZ#S
M?S 1N><1"@J/#LVK7R_-=?KL"K%S )N@D=(0IE^I?V :_RST"1+:&283%9*K
MGBO+M=M\6,2$1 /?+ 5+WW!V?";8$%;(6D*#6>]"%1V<F8='1/=HA#V<^7'H
MW'@((E;AJK 7-[Q&)4&_UQNP=QLV2 *F;PPV'@Q=%_PBYYNL%0Z,8$>)UC>
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M)D9Z%^9[.'$F?CQ:K/O>+!<(=HUE<')$AAJ4!:HH?;\!W&:YQ-U6'')!F7_
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MLXR-S'$.B];B3AJ5ZJPTFK.S;B"=2@\>)'[^3X(SF\GD0>@L;%IJUI.#3/A
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M\*A@])<H@_<[5KYC89-CP:55WFIGR1D82#68Z^!MRJQSSUV@59'3C[>3 $1
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MDP3;$!X.PA9NBB+GX0]QBCCYZ;2I\SE,9%4VC2D7R53C%TB;O"RF#5$!,!/
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M:Q.THP _CB43CJTME4S:#S8"SW4$'L/^^DA:U<?E@L/]SF=798MV@; (26Z
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MNE+T$=PJ'_>.W+KUS+6]/B;'9#&.B:*0M+Y$"H7*TYDZ>OS#]R_##SQV'V3
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MCQ#D^H7US5L\P+F=:KWGQ\M[FJ>26XLS8QO)'7+3,1!3<M QH).&# +[F$8
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MQN1;' =P(X2VZHC3J%-F](K!6O6N#KL YQL_SB)R![>LT[$D)\AY@OUJ);D
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MDG(ATT9@8(8<C96/"-)..T30$H<QTA,CE#+>!6M DAKKX9EHZDP(W%/RQ!'
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M66/AI10$ R6[A2E&XNAT ,-+^7VN%%J*B^8CHVL$_,P3EI3\?3'ABEHSM8
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MDV[7D]/19J6$LR%G'Z7<":5A F9X.NX*,G[YHYC,?E=X@*^.#0_PD-TO:;(
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M&S<7+-F9)_W8?8=EP/O@K-4)$4:(L#\?&R+L(7B4/SE_H7]4#)R&BCODZ^9
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M*9S/_BH7Y^]K$2F"9%655HYB0RK%,,N@I://%,N6# J(*HYQ[_*]4TYT+2$
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M6$)EO^7(./B@S66R[+#?7J;E1KLP\J#!2\XA[*@(X:P?B+L<0629D?F&L]U
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M0]O8:SC:,FRLT=I>.4Y$2:=J9C!CNN.^V(6E&K8^\XDO 1QQ?'H>64P'+C(
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MY#3C=DY)#-GRAN=.S]P1(]TRQ:']@K>DJ47P5M82SZ#?A]<3I:&N@J<<DU4
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M$S[M,T+P/I.5V6ITR60%W??6<7FH:=1(?S1R$+21%<%BW(-"TWFI^BC)<#'
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MYV&[<[T1#:TH?:^;"EIJEBTLLL7;\)Y71+]A.'0%@;=&7[*S[#:J165R,+]
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M8\''59]+MIFC6YDC[;:4KBZL2H(518P*YK^Z4X5)7?Z7KX632F[M:Y!<(_[
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M@B_@NJ>61R; &S$2];=_X4MA+QIFB=5>)4=S#"1@CF!0\$9_@$T;U=E55OQ
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MNFR<1FO)%5=*D+;ZR8I]FR*UG*Y,[ROND:1>NV9^S.>DM\2I$.>3$LC,14(
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M/D8)CH;PY@/$,B,-ZBP?*FDY<IM28DT "TB#-F<.>M/MI() F@G7'JK:"S'
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M82<3TB7+[AJ=;?H:7K+(AN^#;"UL^/%X67.&LB(Z7KQ54K_;5952N00@])_
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MK8!,B6J' ZN)O^ ../77M9O>E\N[WOD%QT&,-\,*A["*OQ!EAU[4=UBU#^^
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MBO6\Q*%AN]-(^C!J?(:-!KOV ?4Y[@"*1:2<H7DF"@.H83EW(V6,HDG<_E'
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M%IFBO;KHMC48^V3RC!G^#A:(]E%[M/T(Q=M(=B3>$5S.;H.4M%'C;3R%VK*
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M@]V&#,.)=A)?3S7J3.[#2WS(1XQS"E+DMIY/1EZD 92U34Q&^/[LN(N 9_X
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M&F&-X[7%7&TY?!M Z[ '?(D5#>VP0H/?(R<$RL9![R&-U+9A 3@EMA\%L)(
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M_)78KR)?&%!T#1TQ0_KPQ,+'<3D8B[)"=)>%0--S#I<@'5Z?C^2+@'T-I06
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MWX'+BW$RO+$X12J>/!\5(A0#E&.*JPX]!P0"T/@2IERT$S;,G#$F2@QJX-L
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MV#_$/J:1#W*)AQA C0%]BE9$G/777N]FQZN)R)\MM,,D/R8<XV#-*48(;+;
MCY"7K33!;"&031Z0YP+9W6W X<@^1@&"Y)2DI2$RNU)IXLHTWSV-Q%8P=<C@
M0:=">BXJ8UA0A*JQ9?NDAHT<BL'1-%'+#3"H1LF>+JF9TJ&6.\\;"(&%P8>7
M)0\4&>8(]&5TSZ5F"F0^B\T:Y&!2(Z6("!S@Q [GB3YKZ& >-2MVC,AJ"N(:
M@#A]$=?09\AF*#^*5.V,]Z6FU>:>K<+S.3K =T//A]/&?^[?B3]WY FKAV,$
M)9*?HF*RA6P@3S9R)8P1&0:@7'-"JF!M(#ZD$-=RVA+5*!1KHCB3$F/BFE=>
MC"ESI.5.BX2/;&!%?%8W#YJ.F<\GAP)QR3#NZG(>P_L8OA/'2<="AZA-[$ =
M ]IS J\BA\M*DJ%4R)1CB0<E5_UZDH@OW1E(O4I6!,\%X*<OU&]<<1]XS 0_
M%"M6?0$69O/2'UFE%X>#1:G=D&'ZEZB;G(*F$C.$6)["G8HXQ<\A1&!Y*#MV
M&WD2!9^2KY"ZT.V4;QF^7(%\)CGO$E-"OG.=T98KX<:N:E='<G5QW@06Z8XP
M842VZ^"9B"$_U#O4R3V*6U_[#Y8[S]_O@:L-G^!(Z2E>27ET=GUW38UWYVV;
M*O[PX'-=U+<F#&O,M"-3-^K'*?-T;@>*U%C!QEP=INC442S-I1!^.SS=3!5G
M-@+_?O/U5^W+EYN*8#1#AI*?>^T>[(#G$4XC,,0&)/$CEP WLOV)<.9%P!<$
M3FVI1N99$R=K7=L$>BK&3<A.B>;YKIL*<1<L4F>\:B.B;*'XQC=C-ULZT1P:
M+-HYQH462M8":@^VN[)/:L,-4K+=5&=)6N&"-^IZ3[U1/B.:ZC/F8LPA2=KZ
M.;)1"F 63!\,!OB\T'ID!Y@Z!JJ6'Y(SV^(*A-3"T:(F>L9 !U;F!HGY, /5
M]#L:!Y0]-W=_MC-WY?6G\R-!!$2.A3:]T$E9(&J$<_S4Y*7[CG=-T.I)C$]5
M.AQV@DX]/T&GZ+DV1>GGI$17%H1>[#5.(GR9:,H=JQ,VM&-+"S$>/<381X$G
MZ!)SY^:19B.[XG'AF,837^++\TJZ.YY7\K$@>26$UM?WGR]NM<NK3]>W7WOW
ME]=7/R&&-RJFLB&,D=+_M7^<NIY[%4W@'0/":5C7+1O!"JJ-=YH+5M0_W['!
M\/3*<S&J8>C]IM'S_7M_XH;#3X[U\$[CV0F CS_"TY']@PUAJ4[ WA&2CJI-
M$_:V\G=>^I'Z.A^9VTQOZ(%&N.*'&B#@?8N<:C>.A8UG4I_]Y?E_JTBS\I*_
MAKYSCR6?UZ-[?XC @1L_.M[@>[RRYCM@4 -KBK+(C]B[G5.<E&YL<RK,,SU.
M><09,U)(2Y)N7QXBY^'C=*D9* VI_!Z>0-"RJL;1Z/A8LSA": ,9Q! 'CHUW
MN+Y#ZU&ZX? 7 #[!&P;'*P=T,@4>KP")%1&:6$"-4Z8!.Y5_^8#N6,>:G=HN
M 9(>^B!>+[07%-MSC7#I@_RRD.B=;LUL8"F,[) O/BSD?0T.YB3C]V:MK7<R
M+^DU8\W?&^WN6D_D+:K>JNF==3_^UHOJUKKU9N'6U#!;Y9I66M/R-V6/_3 [
M67,_?.^)_WW-X7-S_<FY<?'FO;P[SRD11@/3GD% Y4ZE?(59'_L(LWL[=$J@
MK0DTTM%$^!+U(-OEIM6Y%9:P7!.6J+=J%Z ;[0CPGAL&N0D/S&J0O1M;Z /X
M0Q9\ XSODO#H'7.<ZKU7/2,'V6M;MLW:?+.QK#5F^,!0&:V:M<ZBMMBW L:[
M;AX9QW.NG.*B2Z%H[9H"W (O/E*BRYWG#+4C!2_.A)D1-ZL-TF/XLI6,NEX.
M%\M]_M5F@.5.C$.$69-GP4M>$_^P,ND9IS!BX%(?0U/U,7#'PJ4[1*TN=BNT
M4/@R;\:T:R?Z[H61F^O26(<G+!GA<S#G0UZ/%YP/:9#Q ;7?_?+1L_RA]I6<
M(_MP.MDLO.CGLX9/D1QT\@ [ZR.!5(=1@XO?TWWWB]X]T1LG/)R]HA^R1(N-
MD.W%CZG-\VC5,VOI."KZQ,P[L_*,?N:,W!/K9T"X$@@.&;Z"!C[Y/*-<P[XX
M1 $!Z;OOYJBB]8ZJ1">6$_SSW>75IT4BN8L[_?0>'GK8,J@W"=/\TXTFU:%'
MTP'P30!H@ *\1(])RL AAA78M20GN;Y?LK3J%VN@154JGE?ZVL\J?2T3\W9\
M.X#5H_W2<_^R',]EK\*@7MD2*.HY/"\ELL\AI=RUZN]^N0%2H@0!I3QRH71R
M1TZF@-QKA;-YH6)'<UC61( LQ:[5),7.Z+Z=8E>>_+)#R='=6HKNUBJ/X:W5
MA\YFU <PIYLKJ _ED:ZB<;_4[59TX?Z\DM5]7LD"N__<<FWF:+TI<XID_!4=
M_,]S\6SPIW6K+BJYF<TF=N0LBD3YJY_&"[4I:@VZYI%G:5-M@VM3K<*[R?;N
MY)=I4VTP.?7&25U_/6WJ((]A56W*T#>B3F&W3[/Y>NK489WI3ZM3.^(K>5Z=
M,HQG]:DVF-N_6;B8S[BTT'N=0&7IKEI^!"F=JMV4.M57-J0&YG%+L\_,HO9B
MMW^W)M,/YSMR-D7B!FN?3J;ZTUKK12]5UMH\%EDO759;.OL<+0ML3MT0RF_I
MLWI[+<O<C);5Q>[LE6;IM"J=5C^E9=6?U;(Z.C:FB7Q/^\1\W_+M'3'5"G$"
M*[#R[!-(*5D=H[@97SM"\FN?098JU7FNLC7]HA>J4ITZJ5)FL_17;>GLLU6I
M3H/"?W6C<*E;.W(./YF==2!06E?A;&Q$X>R G=^N-.MECE4>'WD^L[X#EOB-
M%<*SW[7K?WST;58ZK%Z7EZ^0/=]I2X?5->^EC[T(1<=Y<E1IOS(7+F#/JL@-
M,L*TJ38WQ3JG O*QU4\J4^-Z+E7>>(V$_$ZW=%YM]^RS-:ZN3LXKO5TZKS:C
M2VPF8;L+YFR[73JO-G.F[<V<*9C&YELDX>^(HV<%!;'SK(+8!<O_#QM;&=F6
M]H?UW49-9$<,S4*<P@K")_L44BIBMU&ZVS9W!B_4V;K-%YQTEHK9;;VY\E>>
M_=)3R5'^VJ6[K72W%4Z=ZFY&G>KPFL9&Z6_+822F_KPZ!6;]OVS'L:V)]B_<
ML/,Z.?>EOVWY&:24*4/7WT";.DB3;Y5#>*$V9>C&"\XZ2YTR=+-TIFV7!+/U
M*4.OO[I"=5@'\5*%ZK"@M*9"91H;4:@,'8SZ3J7>:J^@4)U0<^7EW9SK;SV^
MH"NA3>\ZM4/XT& %^!\9QQH-)H6/1Q,7IS#1K/B C]#TX#T:@ LD,29G\T/1
M'GD#PXK6C_@4+-[:FCJ>RY&#?+8K3<H&V.+#-+R1CSL5[TE-E)2]LJ?6C(9M
MX52$Z11V0?VN<:K;V'/X8%KKQ\*$\GG^M/H4!(Q5[_04A+."3$$P&@B#\\N[
MLR_7=]]N+[3;BU][M^>75[]JGZYO+RY_O=)^^W9[>7=^>8;C$>ZT^\^]>^WF
M]N*/BZM[[?+J[N:"7UBK/?I66])?>:&"I"\>Q$%QRV=1<*,39+(1[J9W"R=U
M>?G2C6(L9Y=IS="+0&MUO59O<5J[!9*YOKVK:!?_W\79M_O+/RZTZT^?+L\N
M;N^TWM6Y=G9]>W-]V[N_T'Z]_N/B]JIW=7:QZ].S0$9Q88[Z @ANAPU)UM (
M29!DER&;@+QP'!J=XPX\?^KQL8]]&A"-(U8'3!OYWB1S8-4Y3H&PJ7O.C>_]
MF"7#_"J@G@P9EVIC1D,? KQGZ@58RN0RC5YB?M NG&1T[KD<. &G]-\()ZGC
M%YD;\!V0T+Q,ME2!RV+%VJ_8"IC&8L.S[J/M>RZN SY&O8,]*DKG,S/Y^I+&
M/^HW:-1R1;-5B5J!?0)X_QNAK+T3JS5:1]:QF+,6Q)L!X=S'F1L2T%E PY"[
M'"+XE3%*E,&!EJ$W^(YRFT9LX(/XA*E_R <RW6!\.'XQ-\6 S$XS&:-03";A
M+&?77V\NKNY6'FYT2$QD+::10Z8OQ_CVCF.\62B,OP.$O[V\_[=V_:\K$*2?
M+V] J&H@4^][EU?:QXNK"Y"PE[TOXCH)VJ^]J]ZO%U]1D\5_WEY\ :%[KMW=
M7Y_]_OGZR_G%+=QR?P^WEY3S,Y3SAT>B)3'R4<K<^/ =>TIS=Q5Y@S(R&9*=
M/Q;UH&9 -O)G0*[.<,A-OR.3(XO.^^J%XGV2RQ$#0V,<N!^8%Y*?W=_V0 $0
M]CLR.FF"@/U^?@':P?E%:6'\'(L+0/]^M&$;R+YZ4W2G 6/#S@C(D=BP>F/Y
M8$/<^Q:H#:2V<TXGQT30;?CKV)[R*^+!U"-D$L2F"=@?<OCZX.5N#(H9[#0M
M-@I%BS>WEU=GES>@:/3.SJZ_7=WW0+OX=''!*>_NXO8/,/3O\F<;E]2V@D+1
MHW'VG]B"1WD=O&_ME/_NCY=O-'-B<#5@@RIL#D,DIT$T@8W//NP0U3<+1?47
M_]_GRX^7]YS(/UVBRPYMC;M[$,!D7]R=?;XX__9E7<K?.IDK(UB]0<3'LUN^
M="Q9@38%P8:"CJA>^)*X+TH#SO )>(1FZ-7?3U?>]S,XA^KGYG%.F96U372K
MU^H4KTF:6\9L,HL3K@!@Q*P4@-\:OMFH=L<8J3,_T&^9M3ON.QV,V1"G\@)F
MH=VB?:H:M1U'++/HB!5#_:<Q+%^-V3VDZX%FX]$<N$""A_BB-['#D'-&5%A\
M]M\(U/5A2ET"1NEZH3;U64 Q<W_^%S (K(D7X0J"" M7;?P5%BE>![_V)W80
MB%@%Q>O%*BKXNCX;6%' Z(+ZX60U./%ZX$1#/C>;QP9<FE=".EHF,.#%L$B>
M9."ST-MURJL7BO(N?HSMO@UL_&50+2Z5I;4()K:I*!%'2 "Y%@+BFNT>KZ-J
MK ) @ZNNFYW+;NAZ3><^LW4&LW=K3?W5QFBO^::\-36-FM$V"[8H$QXPBK8H
MPZQUN\L7]4R*_TOG8[[=;=V%VPH\LY4([G*.P=S&#.8S,9BU2BXXGQ"4GY[T
M]>*9QYL%AY VY)6_BGC._K-IKZMFM^X^>,Y9,/!M2GS?$%QR1\?MPE1D@AG*
MWU5RIY_=Z&&#<6%^>_:DZ.:R0=$_"^+U3N(0O[/^H11/B&_LMA75FZT4R76?
MLV&(*,V:01ENC0^O)PY>M&VR:'+V/AJ]P=[YLH9LX/%RHU,*QN!=L!HK,Y@@
M3+P/6UR:-O:Q]&0<AM/@].3DZ>FI!BNL/7B/)SU_,+8?67#"A@^6?S*T0NND
MT^XV]/8)+-0PNG7#;!I&O=&NUQLG0[/5U+O&D/TPC=HX!'% R2H\S!L$+-1N
M(GBA%3"M]^ S[C#KL_"),5?K^;[WA"$KT#8#9L%]<98H>F,HRNL-P#R&AR@M
MIJ)Q]\OU(/2P>,,T*IH):_K?$VL^=V([Z+=9JLLW\=$;(%18#6ASRT2Y6:B<
MLP$5V0)F2.SX*6VA&#*B%$PO%$QF*9@.0C U6XUF%_ZCZ_6N;IY8_I-?1:GT
MIXD_UD%J=3M<0LW))10S%S\&3A1@<L47&ZR=ETJK*^_1@K,/M$LW (D5A:)@
M\*/MR=$P\MD*W#.H28'VE5Y7)W[5/%!I]G\1P [08)8AT/ZO<L@2[:LUTPQ#
M(D<IS Y5F-6WCO>E%-N,>=5JULUZ"\PKH]VL&VTPK^IU(;PFF- Z%"FP04CB
M [-D[1&5N&/\+_'EDW_V(*7)6>3[*+WG9$DG;1O5:_6#DB2]J6\[6HM$2:L4
M)8<L2LQ7#-R\:GNO4L:\L8QIF1VSHYMUW6ATFBVPE(1=,QU;_L0:L(C.).#R
M9DZTD/B9B&PK3(M:6Q[16V)3ZB;]36X5':C(6MT >E7JW0'(H %DHM RZZ70
M.F2AM6UMK91-FY)-NMDPZB=B+W53Q);@8QA8RI(Y'V>.]10<J.A8U=HY++'Q
MF^5&V(>MKI>RX]!E1Z/TG>V[[,CUG35$:@+Q1# _L+<4L$B>J3!OX)2FR5KR
M)667;)_(2G?:#MZV#])EVYI5*5W>0KK@$A<E3+>N-\RV<3+LZ.V&T1T&=2OP
MTR+FDBK*(I\=J,"X90]V$ J/7U(J*P7'7;4^)SBV33^;!4^2HT:RHUO*CD.6
M':57:Q]EQZ+<:.M=L]UMGPSK1K?1JBN6R2U^/U"2SGA:F$6- 'ERF,AU;E?B
MA#2E8RWOE05_CT+F4Q]Z[=Z/@E!>KVA7M5Z-6*[//V4]4.N@I[$-[Q:U[H'*
MDC_2^Z4\$PM4C*4#%6RE)903H2$<Y1F,[5*<';(X:Y3B;+_%F4BU[NJ-1KW=
MDJG6C<:?71&G4<J#>8]';@SP-NC463UI=7N@<B2_=F=.CFR;FC8+EBOO41A&
MS3S+*'<RT<8Z'F>V!BQ"&^3F'"$I?Q:^H7'9;V:E)\I^,S^[J++?3!':.)3]
M9LI^,V6_F;+?3.'!^ K]9HHG+TI_QAK^C&;IS]AK?X;>;>J&63>Z&.PU.]*?
M8>B-/XVF*+M+Q3,7O/5][H!?K!3/S"&B>W_SQFX [_J[-9E^B/]UZ;K>(WVD
M^MMOYV?I(G'9]80[63L'ZCA9O4K"T _,>?*)]7U*>&VO'%6NEV)KB=@J9?RA
MR/A6*>/W6L;+PI*&WNB:[792]%BU'CW?^^$+^9[.XEI+ZJNA^!Z^5/MBCYAV
MA\WI!P"53[ -[<N7,^TH;BV?"K?;;DIR=8\+(^"7(>?K4Z316"<\TBX$A+85
M)*'48[-1"OI#EEWM4G8=M.S"^27>:#J7@7SCLRJ*'! S_X(G+!!8V(ILF60J
M!<X* J=3" B5 F=';]M]@0/*J?$__U/*G/V6.2)EV=3U;J=;/QF:[2;\.ARR
MD=$05M(S#3'AT89V\=_(#F?HQL0>SCB\U+%<XJ@6+^(OC,S9+!'%0].,QAF!
M ^0/^Z%]/"A_I:S/-W@5C%F&V0Y:JIBE5#D0J5)O=$"R=$^&K4:[56^N)U6,
M^IPX*46(*D)Z!R5"YIO]ESU>#EN&U$L9<B RI*$W.CH64[9DFQ=#G^OSPAN\
M7/,ZE"1N@VXPG/[[9(=C*G(L9<J:U8WH C@H,1-G5@A3914'6"EF]E?,-$HQ
M<\!BQIS/$@A"WQY@BAZ7.-]<X)&EO'E5>7-8_6%*>5/*&U7>-$MYLY?R!I>X
M('-,,&2ZK89^,FRW3*.;XQW+3BTW==,HJFC9;%1_WD?62TF47B$@LIUPB]FA
M('XY%_.P94JKE"F'(%-XLQ:0*0VCV:TGQ4W&GW*D6&S'W'V;LUJN1R-[P/R
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MK]M!8$O@$+H1,<VK",W<5VRNL/O@.6?!P+>I*G-#<!$7232M#+%"41@JWRL
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MSU"M"J*&%SC(O>UL_RT%N0U]0_4;6Q("1BD$2B&P82$06#Z;AI8B 1Q[P-R
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M@G6>6LZ3-0L0OLH>)[9;50&:!PMQ1E7D>:=FF_"6KZ'OG\P3X_R) > >X#O
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M!V?@P',F7R?P] _.1\7S(W@@W@7Z$BM;?W#@TRB@+%D#5-PH<%[A=\098&[
MGP7?A1%E-&\.[K#BJ#,@9F?0&+2U]J#9U(EA6F:W;5);&S2[1K/3_J>FZ;45
M-:JP8L0,BSOZ>Q9W]-VR>*Y(!6/QU>/E=T5KUU=DK^SF];,D,1IU#O-OM_??
MN:%[^/']>__^'PNE)D/B]R*3J2BV1XFY\3VZ6'_MK<Z<""7ES,4EY8J(5FLB
M6L(7HNOF%:/9MT@ORP1\N/KMIO_XX_YR'8'2]-GI_"L.00&/!1"RNTP:,^KO
M@/X[3MH>,..2IC9K!FI\K?7!_CA)<:96'( 04?1[>:>:-,]9,PWPF?%+O(Y
M@&]X >MAQ^Y889;(YN8MR'')82A/5 F!4/ MN.)$:+]>B#M(K0SC _\">TU
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M#R+0^53AA?<Q9UV7B6P[X5RD*%7N,['+(BJ<ISRST_WSH8JY:.C:#TY#G)E
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M?4DR'Q]XYJ/(X_[ J_^P(H/H&?S"I20Z(DKXPIQ^[A-\7'?I"#-@[>&F*B
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MJ1/Q\UG9;D@)*^-3W->=L]L+%&YYHF)B.SJUJY70NUAF%%08>6O;^M*@IS=
M2V/!>)G,<N+06S>9I3SHX1$\M9FSGR<0\@1*:-F^9J(<V9*1'4MZS*+=DDPV
ML_)$051IFN(<D5^IJ\@.*R]HN'8R&RRE[J^D"7]I:2?'BX$0TQ+>7Q@K^/<>
MR2\:7OZ* @*P=3P2C*\B.@Q+Z5:EZWJMU\(%F3SP+#X$=^,UBH1&H]9K:[K:
M;)?@>$HDBH+$=9U(D9#8Q,SJMMHT!=BX/I&-HZMYQ^/#$_7HP(DV.VIU[*';
MM=P,$)-D*?:%T[*P*+1 %&!)5EH'9!GY%T4Q%W,1MD=2&Y"D=MKSQUGE[I%
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M@0=V\983.*6\G2,,G09VA9B/4LKB_)5!3UY@8#/H,'6Z-G+P7(S$S7'A9D5
M:0/<%+/-'1W[BS5:\_G8$EBB 6LSYUTR1C)&,D8R1C)&,D8RIK*,*3- M'NO
MTN!>Y7SOT,, ZS227Y+R-SS6<Z9@'E7@6%CUDW^$D F55_@8*Z*<2D;,/H-
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M0TC&2,9(QDC&2,9(QIP88XIXH7-=>@1W0MN".:$E'8(1/!1R^8L&EA-2Q1_
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M, 8@:\CCG8=:M(_(^,16['M9L-]QLA86B"XV2=>[LBA2%9"TFWJ?Y8/*Q,/
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M)[=9) :C#Q\.Z\J/D 4%E:? A]F._" :@(#XZ!O<W_05"[[DX.DNRHMJTL$
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MIQ,?X[1_IX'O$74ZW_S"4"-XI.6,6&5V:L5L(#Y6Y4JJ?+J^Q2H,PA/O2$B
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M['S,W5K/6+:%,Q>&CQ9%^-GTX)>FFDD6<UF;6;2IV7#W"W6YJ.)")\),*;2
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M]$02R4TTE\8VE^N1BBJGS'5:YMD\? Z_XF 4,Z).;CM:H/V#R"2)K>?E,PV
M$'4=9S/L'!LL$@0EZQO)D77-;%F<!LMT". 4XW%A2N5<O2KNG^(E '!B:B58
MC=U^RND'"=-&7$*8@8S;JGZ3J#6-NZ.*^VW3FCU747XXUK]$AO*EJ!=V0="N
ME W;R@G#M4HUL3UPJ2UWP9+;8/%]4)&KORXO9.#JJ*7ZR(*56+R*FD#Q(>G5
M\/X'RH/)*F\[UH1 BQ,SU2:@+A"J!W6(2*;TSER96!2)#[F\YB@8(_ HN[8;
M681@B_J!@[I)LHY-/$<YGW%K8YZ;'_!B%-3<GL^#5T3R@V0N%>5ND&HEU$99
MD]/4?+"H<$A:53JIF"]'W1I&:D[T$%!IG4>?GJ?BDKS0:OK-R?1>-'^"NZ1I
MB[<&R_^QJE4JD#SRHG.=F&Y"N%,]=<GQV7+A!2;B#*4?O\-@0P.1HR4.70&?
M"+&DL#Y\KPHE''X+ Q2_0I3RXQ611/O>D >FD8CH._^)Y[-S7V Z,JW?PG]/
M273)0DE86UG\4# CG8XJX6?HPOPR)EHI/ N^_1(QG=EQI06HM#LUMS'A_>8^
M7KD<6G67I"Q!1OP'G& X$DZ(%B'Y<4N/6I9<>]8(R&%JB4K5K53(B]8K<GCM
M;.5X[K?X"Y@P\&SKS15LJ-5Z*PPO X<FGE GGE?TJA@I;$N*$Y#Y*2]](X=0
MAY)PP.#1D3OMR!'TIM8I'40A6;FD7%-\FO;;++!O=CE!NH5-(^5&J7SXA3PV
M0K!3[4M>O(^+1%G>0N?UN2P/#I,^K/4DA7@WE9L3H;>:$D *&T,"GT"E*5EB
M2'X. N2Q83QSG'96"L>>*ZJ04@@#.X0+?5..=(HO"\(4>D*-M'I)]O%+@X2%
M,PW]%,&)_!TEKB7CK4L62X6XHHDUY;D;K2_*%;7=IM*3"A-0R'#1V.0D'ME8
M8ZBK]!+3<;JX!_EX3WY=7J5)%2@QIUDTQT] 5J@-&3]S/3%I&4;0OQVKS/9W
M] U7 '$[Y8AI62!,7AE2#T'MQZ ?JQGZG, K&$N3P&0JO>ABSR1MO2,@ T]^
M(4(5DBIP\0]L2I@W8X-7%>L^,J8I\GR2<74VBC*77T$1,@-%@]75=>).1E?C
M.V^KD8W\A13ZV[@/"VZ*@CP^=1<PS2T)%4^-C::Q&;80W5_X[9&M+*%,;5G]
MQS1D\5] JJ&JK\55W145[$6A-=6I2<Q >PE,/LJ\<\M^T@OA&_C* @I)%KI+
M6SGF>.M80\I7++(^8[LN(""+UGW4]R N9RJ7$SY0^9"0PLIQ,IS+1V'.J8U5
M*X"JO1CIDZK/^;,9BE?\-5!O'*E"N#E%=S^Z4QI9>9:V]F*"8>#HA"V6U\\&
MLUOV>RZDL-Z\P/QE L]2F\P)[IIO_UFN!F3TLX\;-!)2?83XW2%C_D;:BW1^
M3O2QKWT2JE"-!DJ4.[\L]4BL(P=78![TJ9H7G^J6!? G/X C\,XIWP4DKY&+
M.O(<^J= (!:*YG:.:&X?JV@6^V')#;&,+;!&NI#.S\%X[=-EW=4P5]]U4,?*
MM##K%;0PH\X(5R1\KR<W\O=@$F)A[!0MCL)/L3?FSE/Y6;:G,$CR)\PY8UY.
M7[-6!ZTT4*RRC<L* F9/#SY8&Z?^$RJ6H3%!\80U47,226)CEU=?Y?WW4J7*
M+ <1OT&J T@6!2@C?6+(15WV9<P+*D6")&6U#Z:+,HO>(E*LB:\3>8T"S//-
M+.0D4%]%P\M;,Q 9=^IU\X!A>GE*E*7+:]433)2L1I5J$855*$@6RS2ZQ,J$
M+2L#2+ZJ=)A3L,P>B\)63 *TEE686BE4*\R0Q@QUCQLSU%_1>3V+A67DU_@F
MR7IY*Y=6MC01?':L]Z%8NW6IT8T_Q]7737?0YD$Q%O(R!RBVIEC30F")1 4=
M5/#.KS]^P5Q?ESV9K0-Y'D@HFGTHIY<![N!@!IYC:5;',]ZGAQ-OWK(Z"!MJ
M)/X&ON?'HN%>N(+J>VO2=[.UHV,N3%WK%Z0?H 0U4SB3RSUJB_S2LWZW@1Z"
MA7;Y/"-OU0U#[-.2\S/KSSF%4^7/1C=_JE^A 7;: -/K8-(5!5+M1@;12 %K
MO5>"G7A=JPC\<?&0A%9^=$/)NR@NX)]C4"%BM.O?@$(;43(<;,5II_'V7?II
M4&W2<U#)/+O<IZ6[ @K3E?](-K31?1=.DFCGM-&L'<P!6N>@3!N5HRYX- O.
MZB-LYXOE*]]29",F5M ]GPBF(** HAL,EB)2DM^APD22>"A^D,J1E&HY]SK#
MB>BV7KJ6A\S8 -G+[PN11IGP92OX?>8==W&D<@_ES"DRDJ%<61TY\T(*=XO:
MRIA/(JI9"Q2,K%WA^Q',G&]'$NBH@]K&0@7ZCV;+U#%+O*6\E.\8R&**,EV/
M(Q\IN$F>G[X.N!CE:T15CZE*3E7E?CC2(J\F3&[LG;MWINE#/.YP)EP:'^%2
ME') ^,SP(MC\ FB?-H:'=P$05-EZPQ.7^R2H+V?(HKJ*A7[2%/$O)&$(]>KR
M&0I@#<T.P9>:_"3["D[ZDRH]$88_!EHFD) 223.@.J!B4!$PMOJF^5:.PW21
M=(./9;D\F=3N8=ZD[KWRIO5623@#\&9F1,E^5_1+"JVRF5F"W+;^QGQZ-^))
MQ$8I;PI"RR60HKVF1("W)H5"-QF],XI@SLE90O5\>&NX;4D$H^,);S4G,_.I
M\B<PRY'#;2Z3ND.>S.!Z! B"_@$) FG6:M5/2(/6($\:\,<(+BM_>0A203D5
M$41 T1!#3@1ZSM)*+9 5-2,B)>%[!AN;Y&S?(:C5Q&+(L9.ZBN)7!1F9QW=3
MLC^1^:1NH W;G-D::A,&6))<E2AG-[HYQX,C>)2<>"TA^I;, [=,U*%T/0['
M<&=B/F'.FU4^MYTS:5UD/?"Q=Q&"XC$R2G42N$=7%8?0VHA9R8\+9?E^OINJ
M/"FF(20DW\1%G[<(B&G1QZNSJMN\R<-A;=E3E2^1.T^5DE9JJ$Y-]K# 7K:V
M(W)3.4):E60%2>TYG(F,FI&BWDG HL"7F2Q36<A6-"N5<].ZK)M.CTEJC5R:
M$LQ;-30M2KH?\2WF3(TB_A,V:FHV3O]0MPGN@B7:Q*H(HZ6#B]2 1#>42&TI
M>M<G'/]&&,]F[Y!%WXN)+R)@7O$8X3RV.^4=<YB$D2GUX;@5ZVO/^CT&"N\8
M !SKVF/6!_?>^L#L&.893^%?4W3-1$J7OO[PX8/NA(,0)YD_)+OBU&\XH]&3
M.IG&E,\D0D->2$+6CQ'Q9E@3E]P1.CPR1IXKNUF)WTL3$G7B\UCH/+_[=R%.
MNH;H857.1QEYQ!@<(8?5,^"7N@6JD<\6R8KF\(J)_0C_(O:%QZ. V3PG"*E%
MSNX.H1V(G]2SXQLQ!;DE TV(H]35P938)"-=II"+\8Q%Z@?A<SPNG>(?XMW*
MJXSA#2!N2K0VZW0%@251LTY,&^.DEL1,\L%I)\W2CBJ'BJ)]F$2ET5@ZC\I
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MV%=^2MJ<+[V3PY.S]NJ-G,D7*KI(1H#EI@)5!4Y^Q^#V*V(X;*<,T].2">@
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M%-.U&G.]&*2QM%;!TO(Q4G5)'VZ8 :#!L_8]4G@9%%J1>K1,73-)"X>52G#
M$G,2/]9JL#&/T^Q4P'X#:9"*68]Q,-#T0C&4<FF ;H0[]4CRI9:21VN^DB0,
M*%XVR+6YC0H:40GRHDCP)+Z"==SZ<]"5!QCEPL% -0[C\4--,!*,/1&VACWC
M>:%\+[3WK5"BLA]SY%=0[ *+Z_!3_@JAM8NURL=JI):C?CP/4/4^;J=%@3^I
MV-S:0M"JN0S%M*6@5;^-L+4U8"HHUC.81J"WW^'&LH,%.?PX.20@7"57O RZ
MD@XG7=@!7!.E%PQJ4V=-Y)5V60@7$FZYU (TXNK;Q<=_75]_U,*,KOC4[9U
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M_]L!XT!\VTY_^Z6IOVREOOSRY6O_+:<*\40G]<3H]O]>M=Z:(4],>U $:=+
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M-0U-U^V3LU:MUVO4AH-L@$(A!B:BRI)1682 I)+LR-7C>;Q;HK;URH$'EB&
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M4!=Y4KS5K1%5![B'.QSF*+K%BA,I/DACTP,642$X7?9@&<.FN)+G ?-]YK5
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MM[DM1_4VCO% \^LJMJW8=@?6W29LVT>V[=4:[6?[0E^8;4F+^(5*FZQ5LNK
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MZ?>'7G%@B5U0L6S%LCLWJ+; LH.3LUZ[UMA:U]0#JS9@I,H<'8 X1*!P854
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M+VDXJ$YFA-3CDI7C4H">.FWGE!)5BR3ZG;L3KM*TGQ@W#>B<[#4A9\0:(57
M52D3BAK]RG$LH_!2&JHU5IRT7WWP4<+_^[\IZ:"*>18\S70+%"PCOX_E[+6M
MTH@-KHQH(-*[6A,/_.J<)'1C4<N:6;!P(5@)BLB._Q6'':$Q[NN0VN7UM0H^
M*K 3XL)5UH-7LN:@;';4.([9!1.BSD1HD B+Y&AQ#C/-$11<X@+>,^ZE[L]
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M^/;N^O[;C?0X^7]O'D(EYB,9IR6>S[(2WC7O86JG2.*#M./]9^#YUOSM('-
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M,J3:6\,'G;$ZS.F#JU "(I1;*/=! JJ]E1N)-GHY30Z7I-PET6:;'35%VI*
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M#W\ZP_?R&7X-?0&O*TU2_.(K"R['FSM/_R13.H[,@. /*D)XFU>3491/@V7
MV+\9CR",):"2<T 'Z2_\%Y>0JS=BNM(*9LZ92<1&:4<DN\R"M)XL(5UL5WH(
MIB^)440/7UA+BQ.C\WP-OBCHI <_<"4'3TTD+\A>Z.$-8;QX]<IUZ/=P%3J
M4#Y@I*_^2U>ZM^G]8<8LSK,._TL2BN,7C9M.(1*URI*9JVEPM__8(RKI[U2
MSWW9(.'+!K3MI)LMB)+ WA9TS/ FU88Z/,Q0A[0=H)O%,0R'*B,-UXK-]^)-
MEEY@EI\(L2.;[JZ1W;?,9TD3JH4%*B=37<6#0M-^@W>?2>:4VR/8UYR 59@+
M&88+_Y;IK(+&P^W!264)0-_A J?V/M[=?Z5_*1_?ITE!JROP<+19+38QY^5H
MPPB)D+O90YI8&2H.SZAU>!3]OE^O78UZ=0Y1ZX$]#;K9Y&*^.8$WG%,-.^6L
M:\J668<5)U1U"70WK;.55:)@[/38J'C@#VS1>71N?J\LESJVW'=1M[T+KJK/
MQ,;G8-Q T%ZE_S(AY()574&K5T;,DF%9XDL=+H(F?,.6V.3KA^MM:-HKEUPA
M%]8$+D*;)UYHZ;+T:ODO$HF&#\\&YVBC=P#YJCU-V54;:C4R3=MJ9);-'%X-
MRE P]"W*<.?X9?4!.0F[V5:WZ%T@,,- $M_"(M1[TVG%)6ENP=#IFO?Z8BT(
MG1F7+$V+SMF3N: Q!YU%&KK2J27Q9#XF5@YX/X<NG>'RD!$=W %Y+^'.)_5?
M_:W^"X0!L1Y][?6W5H<0\L(^!Z^ J.QM??7T(C>"]L5TB$?6?DP@5_\JF,M]
M-5FRT^<<(=#XK9NM^ F%$ 8\)4.5B6N9"PA03-N[RD0I:KDHI>(CZXJ.=HA3
MMWBCJG,! :I:94%%JPNU+%2H7&758W];I(FUNK,-+U[6F2&/E+9I<2MP1OU\
M%Q:*IX0/[+8ZQO\>N%Z .W 0S$.X-=5&*G5#VDACVU BW<)LNEA,]H.QIX'K
MFM%=I6*,!C+N;V$ZZ<[Z'?Z<K_GXHWB5IWMG&\*)A81M%W QO"J\.NRE:7YK
M^-&CSA\?741PS&=F;8%8FF\X372/#D.PZ)A=FE\QDTD"YQ6B&^_%6DG3%ZPE
MQS$\NP14W&7YDW[O#QJ,@'*8V=P!,R'^"O1A+%RQL*0#[K$$\282+OB^:Z^'
M6W,8UG()+V&B]D@KN+$;IG?6Q]>5OK ,P?H7H)E.L "%#%R:>##G<QJ,O9#$
MN+K2+8AX;:#F:K4 59:YPK/=6I1HDE[I;6G^:.G\0I5WG27];38K!7;X0F;!
M@O  #D3MN.AR')MFC5R6]F%A$=XB)S$!(G6D&=TBKB^("%&_(#@\S%R![KUA
M6F2U36%AUIS@^:5@VZJ#9XMD><UEB>KS8J)^3'G^R+,P@($1V7SKRJ8A+?R5
MX^/TXG+.A)Q\A6C*$]FBP+=H6@Q^AFU'ON]:3X%/O')Y EP/#^(@Z,T^4&[Q
MZ>8S4I45[$^)ZX.CA)>"B65'Y!+X\ 2I5QM=X>.:_IDS9X7:]QQ8,YZM]9 Z
MX>F-SO.7R<,GEHB=+DQXH$5X=G!*:_?0 ##%%Z2E%:^DA.5^GVV:I;5L[@R)
M"Q[!(Y'ZP#(##P<E8TLQ[7ZA*@G[*6\*"D30Q_$[4=M"M^6].*"@X-TP0WS%
M,L174888+S>E)3$]4&KJ55>,EIHE);-/3-T?KTY>BWZ<.@663\81F#^)+<&M
M8*D%$V7)[2?"/V>^%7[O$C J]%(V6.!/%!A->,9):IFZ%#8C2]"3V,O"HDVH
MX[.B/'CF+>G<K(TLK: ;3Q6X;NA84AA>_X$Z3%A)/KY:,_\E/#=*7,7/5'KQ
M)>:3YRS R@LO21C#E"K 455?Z2-BP)6FK8DF\=\7-SZJ>2973[!@_KPRYS#2
M#^;BU7SS\- F:>Q@Z4GI%;TX/_BYP@/1I,V/__/)Q6.@['C6YBLB?U25*[U3
MS>$<W[\@*CA:@0<#,&FD$,!*"38"S['I^\@\=@"%P=" AQ ^F;[8>)X&5N?R
M32!^'BDU-4@T#["< )T+*CZ],JGZX>/9\[@?,W^CV9F!_^*X]&QR?2EBX?1=
M@(^>K@7UROH&YH'' _=S;.H*?1NL#"$OQ0]GL?C"@K9'/#QZA)M]6CC3GXE(
M'C8*X-C,%5J&&Y"*T]J0=63N8(!#71H])(-Y@:'#3;S<&(&5!0<)H=&Y>^)B
M^[#[NHHX0&P$H7^BA[L@AH6Y\LB'\(^/,\M;+<RW#Y9-WXA>])'?GCLUM.6U
MLUWZ0/9U;.;='C-U7B7&G\R_[L)7?\M^K@^[JJ;E?M7K*KF?%]U*Z7>'RJC2
MK8H_UWN#,Q^4L?%66\K]-K: */W,[W+*8=B:=_ 2D%&I^K]_X&;O)GU"+,'6
M(55AL8],$L5*9<LL&BLL/ 4L R.U-S1IJEQE[1YG(49=B+$.,6JUF6G"=;5?
M,N]H^L4)/ @4UZJ7SZ6:.[^@[U-TC!@>24'H7!AE5:VB.^M"SXLKV"S8L51N
M]M![G;$RD ?*WJPC^:;6Q%)I80FG?JLJEJ!O:3BHS1(4L 1=[FO[\V@(2Q"6
M< !+T/I'L@2U,]9D?93M_SN-(5P(LA3E*<$3%Y>8'J%G&^RTE5>F)=.CEP,[
M5<5 E)WLXY9+W/M!O&"!)V%?7&?Y'47_G4H>?OL]E'MU8T*">1G,IM&L;@*N
MJG* /CJ&LN7HDXZP!X);_<RTR6BBZ^I32%,C6T!\&F6K*?O3CC@ YN5@<4#9
MZ+^MUK1;'/"9[&Q,FSMB80=;<T=L [:60M%V#P(.IVE#H6GMT;1J$$"[10A[
MJ%J9" 'KV&5]E&TZK8PZ(Y($NR8): TP%D6*-,'QTP373/AUV)+1&>NR-LS:
MDMC:M5G;:DT4U*=N_1Y-\BI-V=P)=6M@)J%&=5-0W7IZ4[S;A>02OF*Q+):1
M8&]$0/^*^ZM$\J"^Z.!'V#R6-B J__OY!+O8IEBC_(#SX,-'7^-IJ++#ZZMB
MA]<>O:NVP]LM4*A/\\JX<7J:9>Q'2R3TKDG^;L> X6@.KW80T(9D&AH:,=RP
M9NA:*U#38- "HK1VH9R%'SI2G5^_WQFKJ@R15$U;D6;!DQZ"6D!8K+#8$]:H
M]P=UU:@+BQ46>\D6>ZQ:^OZPKEKZ$UML ;9WC#'0RG;_)&Q,!.B= $U[QR/\
M]Q01Q?:JXS$KFZ'CBI/0C+[F.['-!>([3.P9A?(BGG_#AI('I]8?=<;9^MI=
M(&2/.VRC,]8V .+1TUW$7T!,+V\S$G@"43N-\AQA9CDQMD_ZC)@!IWL4<&P.
M_V#C9J ]X0NE,# C'(@5&-KT#1%M*(@Z%TT,-%5PL_28"C:7B [B3"V&GXYP
M706CEQ$^#08EAZA="3U>N<XORZ/08I6PH3T&.S2=N@&%\WJ+7X26X85":35^
MU"V#92F: ,3(*Y88SCDF?98,%2Z^A<RA[")@-MO) JNMZU%BRB*'XTJ$@L2A
M6E+T)0JZ1GZ'&/]TJN$V4XKH]%?WH8N87K'ZV,2G6&R4I#O-DD1131!LR25I
M7.!\P+>$:LP<PG4#]'MJK1!L$C\/@=80,<O?@(P2 _W;,/^2HDI+F*>7[9K$
M%SY4IC;H5E)F:?!EI&%(J@*=./0.OTS7<@*/'E0A1MC"@4FFAL^X"D*X78I6
MYE*7]#D@(1(AHHL1GJ_*P3*&Z0QAB!*ZQMPJ0]%$A'?F<!, 1^G)AQ?AI3:@
M\1"B((YA@.".'&'M]L<#O4&^R6A=Z1JF"7Y@6V9:XZ/GQ9#\TX7C$0;@"$J*
MB@IVQ 1!G^DQ!+8W_MD_ ]?R9A;+QYZS,E%<180E OE;'@<DG$DPD=@W3ST6
M,:<OD;: YGG6S$)$<%0RE&\"^I)Z 1 LJADBT#$ )/0/*'$SRF%3&-;P$0PU
M&7\0:X/YR[06])>H -'(J K=@6>)D)0+N%2S7 P2IPQ9F;2VB^%R<J^*#HA"
M7OXKL%RVC#+N$P8+FWP\+EQ.J&U,9QD1"2L96YBOYZ@MN!!<!QQX\+^<)X^B
MN',OA/B#U.MX+R!;G';B<L^$$&9_+IPG)"&W?7#IE /FJ_.*2/ @:(X=&4+$
M_WG[]?$VXG] !6$P96&<DE'"*)"B8(P/OCF?2__W_S&7JX\367IT5M94&NH]
MT)BNU(>0)8W,2)\FA_Z1+6 A'BT%_EV:/PG%'HVOXP$:63#D4:K'%O48<;2V
MMC+2F),L5XZ+1L.X7686+,4N^E<OA9'H$EC.$!K48Z.C] (,>I3Y5@852\.P
M&8G"V>0ZGP@%HUN$(6\:&<Y*\.4@W&5$D!-&#'8(&IT,Y.BKL_MSN<3"7'M6
MYC';<4Y;9AOWMO1? ;@K/1GVWMM$^F0]2Y^("2YC'BS@7[!<HL6$BG[_Z=.G
M2:3HR+L (3 5:W(51]'37X;>R$MS)H7!.*S'(<D0]7#@C4V;.KG?L&_ 7Z ;
M#XV(PE]378ZN#Y?R7#.7(:2:T6>RS0T/$"P&",V],$[TW(6]W:OC_J27,WAA
MSW<XI0,21YF_X%_4_<//?<1=I@"BM.:6C^X)]DTV(I'&HV."6)!GRUO$J_H2
MH^45W"N.:A%&V.-8Q.']$B\9_Y A\K,M'EWO/8Q\%Q3.E*YB#$&8H_8_7*,3
MD:5.$NFV(X?+!1,ZNSF59")V#>-L)E%8'+R(G2N)_,IG#8T/_L760W_MG:U(
M1[(VF1Q\J##T!G,'\:&E?P6FBQ#7?)K#Q0K-=&VURD=$Q?VU-3>-X;PW'RB#
MN:ZKIF9,C=' (#-EKH\T?3CX'V4XZFQ!,!X=UDCS\8KO[A]O8&< SJ<2F"4*
M&*R'$479LQN0L?-&",]1?%^8MI<#7SGHL1P(")#,)G[X(=X^C6IY\^W[U_M_
MW-Q(GV[N;K[</DK?OT[N'C+)L'4PSCSX4W;_UNV7DUJ,F.&>X^(J1)'UR8Q*
M,8JZ7.);(50Q2)[;B.7Q$(P#@4MZ3WGW\_UFS'K.7P/>%,3!%[(9W17 7S<_
M;A\FTA<+]M<TQH7@P)[AE@?\0+SE6=]N@X]?7,'>'=P UQ(6\!*0N,7#78@[
MHQTNA3G&]^A*?T4A) ;1,;8K?"G3<"2\17AG"E9.%V'./\=C=ER_'3=TM7 /
MRY4\<X$O@=MOW-!=T9TS!B!R<@<94D+0BD;PUV_)BD;F;*C,Z1:>Q3,FQL13
MG!3P_G#!TO1Q.AC'(*,H#%9X[\)DH1W@ABZ;+TSE.6_OON20N:%V7">4 TV1
M6Z?[#0<"BUOJ>^(B'-O]G'X9Y0VOU(35(E1-+YOQ_"/:_T339_L):&[7\_=\
M1;6^%\Q_,X0>R7^O:<+!)11I!K,=>-5?2SW-S&F=<;_JQ-%<T7XO>/!Y0W:F
M:O/6<K;!+^5S\W)(=<E2]%HZW1SM^/E&QHOV24L^":FUQ8NV\=PIUWTV4Z 9
MUXX'-PC#P+SCC$$?CS,V\4_6>ABS^S@'.,YB3J@=SHVV,"7M/E3D3.IF#:N(
M,NG,]JL9WC6>2?#BW6$89H2G%F@17I(+V']Q/,(#L# 1\4+,A<^X>A;6'#=8
M7N!R#CB>J,=,21@<E=IT<*E<& V#OB::Q'\K[,1&2K03:PYY0T/VA%32;$^H
ME=T34I:RD,'][0=+L3TZ8$X/)M(=,):F'\X;.\?,VQ>.\O:%H^R^\.OMY-/M
MU]O'?T@_;KY.'F\^2X_WTN/_OI$>)E]OI/LOTI>_'O_Z<2/]N/_'Y.OC[<VN
M6\91&[>,M[9TY_QBJ.RP\*OIA1_=#YN#-^G[B^DN34:H0Y,L/&VU]OWDV26$
M4<TDB:68=UO[K8F_G;&]W!O?WU1<@+4-)'BW2*]C+A[!;WKL9M]A.G/K' ;8
MV:STNCDE&@DBTJGIO839NNC(S8XHRYD^A*%1=DM+L\XN%T%T7(\'>XL5["%=
MND&5/.O'W41R7-BE4E[+D*LMYDE*SLX"7LCVF! GRV=&!A0#[:L]99 X5+D/
M'Q1/4\MCW"3;WF9M7/MF95J52V_T#<KVUVKNPL^_FV_X.(B9"*RFLZR'RW5O
M>2HY[$%@U=^HD@%[)F.?RK$ES!W$YWH57[:_X66_60M,1-LD];J8B,Y]$\P%
M#+89E_D,;_",R1P'V5(P][,,'X/OQ'BZ9DCV-Z=O_/I"PIQL2 T37X#Y*4P>
M(_W<!^F=];[JZP]V>OV_5HX]@1T1/'Y)]]DWM@NCP[]O;= \CVC7H,18R/>(
M1*VYXE)Q [Y)6G272JG\>'**1$\)\]3WUS>3.XD^4=*D*7^FY.-#J8M*^)QW
M5G7Q[*8=*)XOGR>3%8:Y!6^O;7M[RO'DXCU7M+ &;H@'X?2.^._HS5ABS>9?
MTC5KQ@]=I'>9BA_7\GY2?K<W9VJZ,U8;-C==^B-9"MQG2I;IN"Q!YY)?IC<-
MD*CNWYQJ"@]=PJ\A?G=]S.E1#)09,7V6S9L%"U!+QL[M8=&FY;U@:A:?Z(1W
MC*Y#-2<+>!(FD;ZNWIGOW[,].DS9,>?L!Y/V_9P[4?ZC?+^%Z(_;)S#MCJ-5
M,C&OIB\M0 I^G:^9'O]CR.N7^Q[]SGBXV0SGT6H>^:=XK2U:B<*R& \<U@*)
M<!<$$^+L[$CZ'+AAZ9C_8KFSY$G3W,)1\DP-6^QC1L^$"^ 9[]#XJ2L U9&<
MP,?C-H][@:2IA$S;\,WS,XWOS*IB'U;6K@K+8YGB[N3<#0J<",MZA1.865_B
MX_Q$ZHN.-/02'KQ4."<M#YUNBR+74!A<C[!&Y-FAK';T(**,DF?"+7K8ZEO^
M(BS+H&*E56]N.,WLY/@5?!\.@1YK0\3+%'TMZMX2TCZF9A"+Y[S4T5'T>*3!
MS 8921K:S$CVC*9;G-^BQ2JL )7,LB=LA0X/%RS0-%IPP7A9IYA/IMDLNA)R
MXF2XM^TG:X,BGMB,6?(?,0)Q-I1XER?1$KHG/ZJ:F >L8[AJ&OK8$?]P:\2_
M0[] H_SRJ)1?I@S9:^KTBN?)R=+#L#)QK5J?.>D%+;--;;FI@V'%S^CVL &'
M7A.VD4,<1GPO4T^+E8P.A&G/9E11AALL1CB-BN7%:\1VO]C>)8,F^=)^%>>"
MU>IP =&S'V:IELL*G-'L&$4[EB$])RI[6-D03X(LB?^";/"W2'+,JQUAM7%]
M3NY=.*7I?!6G ^=56ZX3'CSP^].4N<=: KAC6%,05DM$<P-KR1:N6LSMN'@&
M^A:7RM,4/7>#\-98K<1F.RY&R(X&DSTV3$F..+#"B9541(7 C,>6$]C"YL/"
M?T8O@Z$H7>?H61RFJ>986L"T&1\2WI%7W[(R0Y?) 6:,_"O@-9MAH;K/IXV_
M5=DGQ@X]FGY>OL!OA(Z9[6$L/V+0#;PH+. EG^ <KNA=(YF$192APX^?S@J]
MUDR7?8B;7BQ^I@38(9TX&T^X.,#[\+4AJAO-1O54=REU]E-8"!\V(F%J!2;W
MGZQ@AM6E8<@$HX<KJ2O#JD'Z.\\)W&E881N*TDOHM4UH%2)N3:G*>]([O)\;
MXI=DAO:>EL5$RO&3O#'.XE6B;VK&ZFQ7P8)O5$&0Q'?#?[C.4UCCC2A<P93R
MEN-CV0A6F#2546PH)EK<!R_ S('60_JL6#*2%H[H&6L1<=OBPB;.H\7 18TU
M-$F;E(:[-B_INR>*?7UV6]JUPO.E\7W2GH%J6L(&42EFZ%A#E4!7$TTLU2\N
M:4[>CD-)>CFN/07&6ZJ;*QSJK- %8!UKY:J*5.9*RS]PR5W.PW[ '_#HW!**
MH=$9CW*Z ?_8B>.:CB@FN*YP&%1 =#WJM9CH.EI?UXFNN3OFO@NUA+99H)OE
M)^OAVA3W:I2,A_;H#FP+"S9$F\UCB5;5KC;2FSBHS;>JAZ9YX\^,,@37&X$>
MCE2 4(XH-I_RFAWAUT=\+?BQ!;'S7OS81S7L]LNO0?3/U)4<%\TEYH!>V^'G
M^#=!$"H(0M/;DP) KL3I' 2FT5[@SK%Y;U5E@!^LV--T1=8&32$)%<8@C"%E
M#$585P<P!A56_<%(UM2F4$<?&Z+V! LE/R"*SE/#<X(]UDE!+;$3,GX=YW7E
M\:!'6FUXT(*YI%'J581_?V3]J@]OO%E4)0T-5+YERH0RGKRFO8Y ^]_BPVLM
M6-AB9?VFH?H+!3N"%S]*24Q2S6BIHMS+Z96_C,#\N'IR5UA7$ /([.351>BT
MNU?'C2W,R1H>[<$L#LOL!G*O-N1G$9TW0\4V^O4CZ]@(=$P#'6L*=^4%G$MP
M6J#TH<1ISB0$Q<&AA'(6?NIX:5^$;Q\,9<T8UA1=-IV71!BM,-J6'UP:O;H/
M+AM,3;(7/"8F0AL+A:)7A<?\ZMC/C\1=?B9/?DYUJZ'DX)T82A;OY,OMW>3N
M^O;N3VGRYX^;FV\W=X_2;I F[.YY#U5;55L;(@M/@F>L^!XRM#/I'=;&<OS@
MZX5#:_P_PRX@A!%.5Y"G@$],Z4M4%AXWND6]#\^!Z9KP.]>36*<(5LT3WY$Y
M""UVA:Q]E1K-5_:+>"!8;OX _N-%>O#A:;Z$O\"'?X=[V'BS$ @Y^:O$];Q\
M>+:T;,1>IUA/DOD<M^<M</^#H)7LP[#+@H\D-;J<5P^?Q+'#<V03=[LC)*E'
M; N>X!%PDEBG#&HO+1QLV3>G42M"Q4:W+6!L7T$C[N?7\#C+_\*?\LW\;2V#
MY2?'=6G)];6Y@F_\M\J-;0;%;-C>V992.3H4*1Q+/%FT*]?S=^M8K""%ZF^I
M=<9ZB;?$MKBX62EI6@RJ9!]8DAUF^4?8*53#/.L4UG2K!&*VA73C:M3VXJQ8
M]TT"-789^ &UOY0[2=HSQ^T&.TGV8*_ID?2$6/$QK1'%X#=M&^_M\LZMRCTE
M1FY/20P>^.3?VN!6 @9T$K>1(+4RF7%83O LN6TE1A^$VL^1Z1]R#$M,>_(L
M6_II40V:H0K%'0Y.X%-@88;";MD(3[I(,@3G"8JAF=(^,2;9$G>!D?#;",2]
M(L2]_IIH$O]M#G;>AIA'S8]YM(HQSPD 7[EF)\$E0\P&E_!&(OHAYPU["GRP
M?6Y:W&&LL-73"3R*?1#;G$P;[P+FP4-0!"<=4VE*N_G&UEJ_D?;!\D,6.(]P
M5BS:H0D;JQF#P45^!I9W7%F^N9##/]C!$GB*P.5L!1!8T0AKZKC(70*N>!7
M7QZ)(!22R&[8U9BF96EM[WA&N+0;\\7\13CR$OR*L;#0WOIM"QQ=TMZP091D
MVO63C$,4J)KV_Y:[+UUOX[G%SMT0Q!4;B'E'+HW/9F3)VX YT!A%:OH-@35L
MIBT.$$61C&)D>$K_YR'?Q=3T:'\J-CQ;]B^P.E95@G* >;Y-*P,=O,>(:T!L
M-(Z/L-+B92JY>&V0';;U)OIIH]M2I#2*D(#\@:[%>'%2.Z913DOM&LE31/ 3
MQW<1M(Z3VOP4#]&QV0AGM&4]B8!O$VQ-1N&&VY/P;I0[A\*NP>:B:G1C] J
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MH R!5BS0BIL+$UL2K5A@$K<4D[@]AET 6%S:LL\!'H"S04MXEB)]=4S[I-
M%]I'?!&=PD8!#DE^N=PUQZN8T*/PJMW":F]$>[)J!) ZAR9^85YG;%[&,<W+
M:(]YG3=RVV0Z#9;!@A\#\-IK7L->O+8+"+?Z+$_K]8YH>4JO,QX,9$-7&P*A
M)=2H+C4JP (\C!HIG;%1A_L60&R[>&KL-"5)6L5DT>IA=F "XS:GQ#!C9),$
MY>7]'$WN,^\P^NZ2I14LJUN:VAEKLCX<-03(5JA27?Y:K565-L)NJTI]Y D"
M$+F$)GPEGO=!^LL.V;9GK,K5\KR GKU.'<_W1#A=4IKO]JDLRPF$YL1UR8S5
M19!KG(H_7<>KC$>K*HA;H\F&D@VFWXLXNJ7ZH_6TH^D/A>B11TH61_3H^G/>
M9"/,'U\S[$AIA4Z9!<]35OT2 J0)ZI&3N.14%\[U;@B?JC+ I&+NIK2\-8DH
MN6%1\A9GO%USM@3&0Q$8']\1\TR%B( /Y&ZW9"EJ:H1,FM&(-D+* S7;;2%"
MX08I4JTIBHIZM,43&X)_[YB:<)V.?&6*P8<1<3I(KCLB+GF0*_@"!%_ 3CN)
M!-S[[FP!JMJ#]4S1Y=&H"/^@+6P!PF2%R39\"U>3R2J=L69HLM)ZDRT@^$CW
M5I5JAZ/-U _!$COI$3XFQ=+V(Z)FC&C:T@COCSB"G$XY52W1$A=+[6->D]S)
M.^(26&ZLAPFQ)$#E$-K#P7;L#526ZU!S:RUT:WUR)VB4,HSN2!_MT"<UU-6&
MM20I6K>GB$&5'=3F6QVA^T/IGU?WUC^0]^&&0ON*1JY3-')M?U'1XB7$6(<8
MM2J=<KN=Y>Q[?<*[[E\*WTZ'7'_7W9X'**>H!4W4AF'.CA87A5CF')0LM]*H
M>DGHAB3YMFLN;>=?[;7/86]?L1XV0J*A-3,3>Q96-%8OG5&USEB1C5Y=;/.G
M3\ )0Q.&5E>U\"9#R[$EO3/6<FK0A"4)2SI#2](/L61M/MM6^W6?;3>HW[55
MI]Z34IU3HOJSU3U3ZD#T3)VC*AVW9TIM7&FHT*.3Q #[ZM&H:7IT 1FR:R>F
MBEH_R3U,-DR4C)99[-=J$-"T;GYSP.VDU55?\Y&K;"@;NM*0ZE&A4D=:] ^F
M4EJO62 70J..M/SOIE&;HP!-N?3R]A-$ 4RPC[GU7"<%JA2ULJ)6MJ;PJ?JR
MIG;& TW6<EJUVE4G*\Q5F&OK0M/JYJIA%%K#^9RP5F&MEVVMU</^2A&^7G>>
MKV$-*$FRGQW9F+XAXQ=E8(H[AE'.1:TF6K]\J\F@H-6$O5VS^)A"]F_O!5G7
M+8:WRWI$GLC">96WM)C@]RO0U9"5/*)@CBB6*>%H3.5.R<*G4Q!A N<W9((R
M-Q%ZX[>OA/*M4OIX>/69Z3ON6X(*G5.X^6EB/\X-RUYB:?XDX<M\)<@4ZX5\
MQ_@1S(C%:,U7(%5GQFD"L]SEK]8"]W)3Y-XCC&PL?*^0;_VG92=>,F2E9]*=
M.<0+R7EA0T_6V+R?R)M#?^]XE%PNS"$C*3!!,F"8S5E7FG!.P4C4=MPV'8UX
M:;Y)OY#"E [23\PZGSE&CQB-;1].U\ZQ.XQVI&(:&EVMKS>M<6;8'>GY7U5L
MG#EI2J1\/TOIU$?%EI56UY4S).2\4NEMB;*:.BL.>8-6STSC>':.&^/"(CRH
MNS)I[Z/_!LFG\H[H['8VE5 QXA \"=_S/0Q;;NT[N/$C1'R_R#=XRDOUVGRM
M&(CO,NH=CNX?A@)(K?%FA8'7XZM3W9J&=5E32\\-CVY-(U$'W YK>G$)J6Y/
M(PJZ+%:GH]F3(5:G5MC3%R=PJYN349<YB>6IE#EI/;$\M<.<K%_55R>]=^&K
MTPFJQ!Y?B$O,N4_*)T;%<G5*^YK@7.UN8@K#]C2,2UVR3F%C6(,I2BX;DP,5
M52'EZ:)JY,W4D<U/,^KP/<VO$:EX@,W>^\G%FV\^!V]9P<>M+7TSWV@QA2S]
MW?(LUS8E>I3&BC%84<0/\LM9_,)Z"%[K,7EV"4&=DUXM_T7Z9-H_L4SC_WLA
M_[1,^YD52"S-W]8R6$KF,_P:BRW6&8VP$*/0'J;V6[9*JI^RAWX>XTJ([Q^6
MHWQCH_CDN"[%5+TV5_"-_U;./@8)^] ZXZ':-0J, ^9E@2]P_8(L T3Z1P 3
M^>X_JE6!G?3]D#&NURU"*.;O]UYZ@N &50%>S[3M5!.CBY,,>E#XTC",)^)N
M>>\M;BXLA?L!#WOPL2[G.W'Q^-=\)M%[7:F)%^MWQGHWVWOW!U-3+)W!01-S
M^B(M''BM6"WSB\BTWF#S$#%63,G_RB/3#[/ ?06?YQ$[,;9!9^S3 RUI24^T
MUCT5&R.KSI&<P/=\TYY1\6\LC'HUJYK6<+OJ[4:#E52QX>%-Z"CO,2IG*IRL
M?MWMO;Y8H&HX1=.%Z7G6W$+>9)A/^+$;56LM+/,)?P\[C>Y:=)I!W*ZRG!6M
M.EO6-[YLZ%B"M7(\"Q_\@58"PD8GKKSZ(UVAP9?#7GR)^00K?> 77W+(HH[M
MJZ+2A^%\N=*&:R)/_!?'BII@S4UC.._-!\I@KNNJJ1E38S0PR$R9ZR--'P[^
M1QF!PO.K7MRX).F97#W!MO[G%=W9?S 7K^:;AY%+<AYA$I,R+Q(7#Y:N,.+?
M-IV;BO>4T6'CCTS]#)7TW?WCC:3TNYL=;J9J]\9T;7AI#SS_PXOIYI7GZ@;S
M#6 D9#;QPP_Q7NFJW;N;1^GK_<.#]/WFA_3POR<_;C+18DJ(:\:7>"#<>^?J
MX_4W^F1ZUI1B.J&QS(J*D/N]$D7(C8Y \P#O>1&JQ[RGLUP%?H0G^H2"H96S
M,R8:2@ZT<#P/RW,E#X6'_IQ>^P:QBB>1-$1V>JFD_]7I#1%GMW2E:UO*6OMJ
MMS>J6KYZ!#QXH[>YK%4,*A[4YH<W!CF_4:#96\'Q!2Q^99D*6'P!B]\H,5:"
MQ:_9$1ZTLKTX<N-3<,# ;8?*=UDBOZ?@91,A&&\H.N>:^'S!T- ?N] ^'*P8
M0EQ?_?IJ;5+TS&'8 !W+/T6Z"[<\IN^[UE/ =B*^(TTP"_Q"S)GT':QP:4Y)
M0(<+%GIK3[LE-'+#,>8YG#JVXI"P$J6VLGY&Z,'(X:_U7 /H#*B LR1?07$J
MGP[V%20U&&C9-'H1A_9A0!F$>IY^\-48WT?'T4^U,^X;AJP;V:R\T%"AH1O+
M+(ZCH1IN6?JR.LR"6QU*0WG0LW:&H^@L?=GRB.[2KS]0X_]Q=TN?B>TL+;OL
M?JG>C%PS?G:"$LO<P\-!K5F$<H[ZO^D_R.S*A-&:SX0?[] 4@I>L=PAUHZ[A
M];NC?HD1YAQU8T[F2NLJ.8<V,'B"=^B,I7=*7N9#=$3L4!G)E&'KMB>]5H>*
M-6%Z=4<+C^[G]&S5NX_UBIZS5E_+L59*T^1A7_!XG)UF97<L1U6M/JB68LC#
MD2Y4Z^Q4*[/5.*IJ#;!L;0!>JR4=7.U*RM[,YV3J4\Y;K$R!6$'RR)0W"^T;
MVZJY0CDW^]AE4><54AD;F<RPR&F9J>_<C)39WY59Z7C)I O3B9V6XYJ58E>:
M)*$435I(:U8*XT1*(?(%B7Q!6 0J,@8B^#Y(QJ#(:52.O@<]D3,X6]W:,6=0
MGW(I(FMPOLJU6]:@/N52&YHWJ'*NV8RSGHLX8#KN"2+-A>4T 0E<XAHQ.=I?
M]1$VUFV,"M7"VH_<_KS(6?82SE+KC'O=7ODZN2:OP$+GSU+GT]%J'4JO=\;]
M;@XPG%!ZH?1-47JC;J7'D]JNH9Y>Z<^C$JRPG5MT+9RO5>X8?G%ER37+0<4
M3)2!"XVL(3C:I)+#BN&14$FADC6$+IM4<E0Q>#D *&-^O[.V"82QUHFB]_I@
M^?"@Z>:IHT@U[Y3WV$2)U(Q>=-XX1WR:I8,#<Z8_&60BP_="_)G)+\=UI.\N
MN?H24"B*_S9=UT1D&V1@?$)R3.).+0^)&Q\(D>X<GTB#'+BO&OA-)[9OA85)
M#U%=TLUO^D*S+ZZSO(Z1=K* 1#G@0P/C',&'/ +3,W=<GTWA"J8$),=X-K-U
M78Q=],7\A>RHQ,8^>"K/F%D3C&$:+"+\H@VH14]D:@8>[>,-*4#A!DOIU0D6
M,]06T!SK*AS$FI8TFI+3,+H#8[ #=)%F]&L#Y!G6!<@S-#0QJ)*#&@GHHLK0
M&@*ZZ"!@,0*Z2$ 7-4>, KJH&=!%YPQ0E+\%O5]A+%JF(T%4Z^Q0K:/UMM2"
M[;D1"^D=LG4ZPUYG/-1% =@9JM26"K##J90"*M4;"I4Z.Y52>J=2*;4S'FA%
MV/D-.SIM.</I#^+YKC6E#1(T/XE:L=O*+TCD2MC4EA:#FFRJ8OGN4.N,=5D=
M#AI"*2<TKD:-4QNI<3IJ'*6#%1IW;AJG-5+C^IVQ)NMJ4S3NO#,(:<;,$^0/
M#L:;V6++;&;L,>B,^W)O?[L\,:6DT.^3Z_>V%LL3*?@00YVA5E>*1"CXY2KX
M<9)\515\1&/Y?ET)FP:3 N_'JUB)1E$;7 :-XJ@.&D4=4X9-I%$\$5WBH"I=
MX@-Y1G2;'V3E@'78SY\M;[IPO""WJF^81YPXS"%.?+CY\]O-W:-T>_?E_L>W
MR>/M_=UNS(E#QIS8LMK!_R:2LR*4\MBR)5/R0+"T?)#*&CSY#/P09EXYB?8,
MA.Z >WJ3X;M?9.&L\'>R!&,(YN!2 \ZJ/*,5I5@6"F_\[ZAN\,?=Q,+[N# #
MR.GA,69@=/FF_?:_O.P/)*PI1/9$%PM,\1Z>!3_B)8OSP.:KTLKSP8J6K);5
M_H75CHYM+J0EO@'2Y4I/;[P,<O$&]U@0>XI#!3%ZQ'XF+CY:>H=82&KOXQ+^
M0?]4/KYG3X*?.S/&R;ARX3:6[4G6<K7@XK$X22XM?<3?F/X+&#*KE?2(Z1$9
M?A!XR I)!X>5FE@622LLGP@=BCDC79"%[5F>']&2.X'+IXB]$-(SHYSAAOC5
M]8M%YM+-;UA*:5'G_7QN3>%MPC>YOKD/7T1&>EX<Y?7]YV]TRL#Y>'2RS 68
M#[R()\&2#K>=8E4PZ@/(DBY?]"41UAC96NA-GA?.$PQGZKA@CZ@_"]2'KG0/
M@^+?(0&FZ4Y?&-%EK"[TWSZ9OMBXR,5OQ\;RK\"D!,..^VS:7'>8&L#]5B@=
M7&A#<LPBA<0[><%JM:!S %/V_[=WM<V-XDCXKZAR5WN9*CEKP 9[IBI5WKSL
MI6HFR24SNQ^O",@VN]AX$23G_?77+03&;\$V."&VOF0\-@BI^WFZ6T+=<D%J
M',6;PI* (P=+(I'D!."TL82WV*X*P@G_9*@E2C@$$UR>U<F3@VHDFN%"SK*V
M11=EIU%84S)@P0" / 3;%K(!WB0&/D,WWF*?D9[OSYK#N.0YV96+#>(8H)=)
M@S-A\\CN]S/XP[B^H393[DEUXG]G^I1Z6U 8 !NC"9Z Z>H.B6X#)7@"%10M
MM":OA4[FVGNV/5]LP,5'#H,7O/4)3U!WV<0/IG(\LQN (VB <K#&Q@$?V$\_
M +^%IYC360\;X.=PJ/AY -(:!!!4)A;#97@MZDOJ8LET 5*=!2HEP\\!N@\-
MC 46O'$246)KH*O8MT- #G#58R^)[%/B9,B;Q-!-GFR?9\^V'R<"!S"+IL8.
M,!0^,<?FXH=^C*S%W[T@_V@04.Q'G*[1&N*81>);;XQ!$+(\ M?"HL4CM9=]
MCPRYT/U\!&^TRO8E9DJH-$Q=/TV%AK*?,Y"IH9"<66?#A!G/Z2\%3?8$Z9>
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M'#\FP?@[6"T6W0;@);=8!<Z+J(L[7#:0$ ]P 1JT+DR  W&;C06JQ//)..L
M,/$Z#C$AGPKN,]L9IC!;*R9)EP)1W=Q>S\D*_!5PY:X_)Z![:2JRL39G8S4@
MJ%O>$Y=9EWF4@\)7Z3IOQ$ XC$?!F*60X>2)12^,C;>%1/L52.1*PGY+'RAA
MLCTC#'R%9+6+]3W>FM[FFXU!Q[SQXC%,P-1)W8KQ<&B(5Z@TZY4!/^*S9 Y4
M!2,V8,2=O6BM\W:#P+K$5K&IR:EM<Q,<>2(2"H.I[8OT9&@((@2I<[ _THN[
MV+0;.Y'X,IZD7MT/7M*)K0NM1_QLPT#QE5E&78++U0'Q(\11D\@FE]\TDBFW
MG@-8&QW?8G"#\9+>7!D?V^$8X[IM.=%],TO6WBP^6;)9!"*54:JL#>7>"R'2
M!FG;8]Y8$KFVD<C)EH^L2M42JXDYF GC!>(VJ>.7(=AO"(X"^&"#RIVAQS!$
M13AP!@IVUWANAO-IG%?8.)N!,%_[62>Y:#YVIV@I,-8'IM#$ L%//M8:?KAO
M:,VF@56(H(EG:-(;B"@$;GVX[7GX^!"FWC%.5=*94!0R.Q*]P+!H.H%'DM$T
M@-[@?&;*HS"8#*?D%![W*<'S*(!8'F=+:.)=F" U(,X"XS:*N1/[=CB[*Y&0
M'/#R(#&_0 I%2BCMAPW( KN)QPZ-0XBGQ/=)<$>)&\8#L*1]%DU%-[PH8@Q,
M[[,'FA6>=39+L>-H&(3IA ZLJPMS&[$"@6Y$7#U)8GV:3@+E?@;LAFM/B=9L
M2[D_>]R+R-.4V!&!F0\((:% TE%1'I7-=!4AOL](:1/V\4SYP]7EU;?[KW=H
M^.2,FGRUX[$SK.<H5I,<D7M]V2/V1$Q:W879-C[@$H'8FTS F2?X.KV]["5K
M#)D,3B=^\+?-/9@G?0*,_,$2BX_77&./43@7PZD/,Q8'IGMLY-GD<3IVP: R
M<GI]\0BD"W*N1>LDK@6IA1&(Z!W6(GL9>C"U01OT9,OI._8X9!P8FDVM$Z-B
MD/O>UYO'WN75 EZI:$"20$ZN)+#OH24G]":B^V+D/T"RY!JH!W-Y<GI_^>,:
M!O_;#00_(]:'<(DM]%%$3(2#5KT^/'+.[J762 HX(6.R4)-AR!<8PI%DTO7$
M&HP(SQB'N=[OR7X51RQ//#' E-S:$F%J>(B&)V;"6\U"L5ECR4#CB8/3QP'I
M>V@FR!1L^D+XM7*A_ZV)G7SEC5VP/D4KS$>[]-]JKE_Z__DI<*?PSS :^>?_
M!U!+ P04    " "Y@7E;\A!8"X<;  !@1 $ $0   &%R=W(M,C R-3 Y,S N
M>'-D[5WK<]LVMO_>OX+7=^;>=*:*7W';9)ONR*_4NXZEL91T[Z<.1$(2-A2A
M J!M]:^_!P!)4>(#?$@QLO1^Z,84<%Z_@]?! ?#+WY\6OO. &2<T>']P_/KH
MP,&!2ST2S-X??!I?]WX^^/NOWWWWRW_U>O\ZO[]U+JD;+G @G N&D<">\TC$
MW!%S[/Q.V1?R@)RAC\24LD6O]ZNJ=D&7*T9F<^&<')V<Q<7B7]F['W_"/Z*?
MWN+>R9N3M[TWZ*=)[^W)&]0[/CH[?7MV<G;V]O3TA]F[B7OZ\QG&I[V3GX^]
MWILW1R>]R9%[TCL^1F^F/T[>3,\\3Q%]XN^X.\<+Y(!J 7_WQ-\?S(58OCL\
M?'Q\?/UX^IJRV>')T='QX;\^WHY4T8.HK$^"+QNEGR;,C\N?'LJ?)XCCN#AB
MCVRC.&*,/LXQ\ACF&#%W_MJEBT.I]]';TZ.XFB1*2MB0@ L4N D;3[">6"TQ
MSZ\#/Q_*GR6?-[VCX][I<9J3)Y)J:39GA_K' P<)P<@D%/@:4+O$4Q3Z4"4,
M_@R13Z8$>^ 2/I:@;Q1(_2P0FV%QAQ:8+Y&+ZYCDU^\<1T)&%DO*A!-D:$P1
MGRB9.1.JVH&CX;VE+A+*:V5)'JN7*7^(?<'E7SWYU^LG[AT<5N<:\MX,H64M
MSNDZFGOTI8X$96Z1)T9N%?E7+Z[7DY]ZQR?@'XUE6+> >C+$]5K*D.OJ1:"8
M:JJ_>44Q\IM.12/$%:3V5?%7]3EV7\_HPZ&[\GIHVN/AI(HCIFII'UQ7K^.!
M&[0\3.JPCHO+?S3FB5VO#L^XN/Q'8YY<+%D=IDEY]:\<MB@(J% 4Y)?HVW))
M@BG5'^"3;!WOXB9RCZ=Q[YT9CJ+!Z_CMV[>'ZE?HZ%5EZ%@9]7%YX<,EHTO,
M!,$\/90I G.&I^\/Y(#6B_OF/Y8,OP9)XB(9!IOM7/X,'*"7#[2^MVN%8A*R
MQ;T_X "%C[6);-;?P].Z^D,5$I#_".U]-*FK/53!_C>ON(O\NHI#%3?TFWB]
MK#Z&WQWBO3^XH# 3'Z(9B">_?[J_J3"54@*L:\;D8P9KC_SU2/WOV.FM9_$]
M1]5T9-5?#K<K;)$*.?8&P:_JW]L-/:H<%2FIN&6JRO4V6U9NM>AC;-(20_=#
MCXB;0"Y3E"2U[9TA8#3[R:;9%0$G1:%#UK^@ :<^\>3Z\1SY<FXZFF,L> .W
M+Z)4@L=;6%4>G\EF, (+XJ0=K$DY$2U'$WN!1O A8J#5' L"<NX.ITVR1M!.
MJH/FO-J@_7U'04RLQ>ET *.@$HVCP+N@"]!RC@-.'O!- %#A6\K;-<':S(R
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M^D$0(O]&.JCOE_=SK6A:NCIJH=-0R;X/:\64]S1!BRO53O1>IR5<DR=Y]WC
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M0WD<BR,R>AYY9&"DPMK7OF9EN B%!V<(5)*BM:'=A2-[CW=EM^X1@LJL=K2
M[$-M.N$]+=2DH* VR=+B;>]9/ )I2*JS(5LV+(XF@FF].E:>\EU0F.G)4EB@
M/P%4++7VAV.D'(RR0EOCFE=8?@32D'3H$=C20C"MV7(C0K\+S:5D/"\29 R9
M+$@M;)90@#2QF&"Q^.;5.K8"-J30I7_F-!32T7=_+Y.U?RT%TW+\Y6H#^QV-
MZAVFV32-)^.PL?[\SCO">SVRKUWBP\??:.?X_N??=\XP\BXQ[UV 1$$O4984
M4K".@PV&_A=5D>@;K_KMT1VJ^+:10Y>E^#3_]_FJ9>K(61N%CQ&DDC4MD;1S
MK%V]HW>"1ZL4;UXY<Q^<0W*_>N+;;179NSB;6=QMD#[[5#-J7T[7(3J]Z2+7
MIV;@7$AR,IE]#=.$HT!15TXV TFG#H+1K"F7JL^IK9!*(1,GX.0.0QB2_S<@
MNO9%@J,RF5Y\1MC'M-J\-8EG\DJ21;_J!1[(#=*A6"^D3>0BG8"H5P@'U:%I
M0$3<4X9'Y=F+/!Z_Q7FJZ1?":X]96A!>4=@MR0>.-A70PFKF(BE]W3I:V1'B
MCM4&_FV8MJ\4CTJUU[/JAI_3V^($5S'8_3=C+FJM>J%\\AQT5 X41?'@93;@
M GT-JA2:RQ.P<;=1#*EFP8#XVB,5VC1"W'<0UZ%?+DAR)GRM$%UO8-%DB@3.
M&PGUX-5&U-K%6SE%&ZX@-P0UI+(&/?/RI/(\'AN[(.WB]U= 0TG))EHVG)P.
MGRPXIQ(8ZZ5.G'$C?3/BW7W^-ARS_V8<.U!*1[77]V>?U1;Q2)"D+2"-5J"B
MTA S"Z"U(FWL0Z*_3V"9-^'=AH?N]\'#HXOWJ(1\NCX#JM#/Z?.^WWCSR*)C
M4= 4>5[;I@D?2"<+FK%8"E/T5=K6]4<;P-Z&GO[?CYXMA7W2.W2D\5_C\MIF
MU&4UI3#-W<94^ZMTVS_S&#?J]IR!OE+^K]V!'\G$)?/)0(S=Z2(Z<);Y>OW#
M$+&4L;GUWMI#>%HE"][\U+?S&:W;Y?>WDS!=KNI>?.X:BHM VCV+""S%""ID
M6D161HC,V<RLL#'U==UA2XA#.I)IQJ1-&85]B*UYNO9-D)U#6Q?['#]1H'2I
MTT=").MK^])D:ZN<D#G$4"1XEDASY^@%:^TD[H9P2*<G1V96$Z&U"6TW )R/
M/XZGY)8N%A<7Y[O>#\DZY1@F<C3(.U5>Y5I *H%7M1!YDL&Y\)C!W/6A0\J4
M:<Z27B70L^*IA2EKN<*K(DJ+4>#DBVIG:_X.P;.I,C=[D#$+$U(2R;4^P-@:
MW) *)1]9W1PJJCZ8='$B_-?Y;+$8&1H9^A (AJ* UVD)0:@ F<LL@Y<R--_/
MN!])*TUZ\9$OI^1!U-8Y[U:..OD0S_$+3F:=%]'MK!>12[+20G%1@U+<T-"#
M N>5S*X4Z?3.*G7KIP_1MSN &INT:C_2Z&]17!Y;/Z-0[WN9S;N*L"-;0A"\
M*^S+:E*VJ<UR<YT*EZ4VQ5OL4;D^!&V(GEP#'O4IH.;.VP6R=W6&WY3?UKU\
MW\QO]W0:%:F=,#Y3[.*(XYZ\AYADUV6^:*DDS_+178]]'SY$9ZXWA=-8%OWI
MFZM:XS0!-RG-!"H6'86W/--L*.,@<.O!9@S>)B5-Z'%_XC%X0W3I^M0[C035
M'Y-N^K4CF[),BC.(K':IS*00??0!3 J:68E:V;ZNQFZ -*1TD&,PY@"!].K?
MK%^[YY2?W++5Q1 *4G+BWK%(L8]BH$RD*(C17(BD<F0$V>36E4CW1SNDE(XC
M>4$]B'$ M'L@$:I$;VP*'-!U^R^:8@.'G,:4,)I<G&O>=;*/<0PI,V105&TD
M^AXW3&:S_'4\F1#FE]-EF'ZLN5(7OQIEQXN/I-BSCYGB#\(:&$_D37J&)?+D
M4NL+%;O@&U(:R#%(UTI4/3K^]1ABY*374I!B3J@-J!!J?S03P0N&0M'T4N#:
MNX]?D0PI$>,H[OS.T]\?%:Y%I:]Q.4(1L-1"H*786'/8%?C,'3#G3-9)E^1Z
MC_MN0FH^XOLN(_G"A*BWC[CC]9((N<?."PB&A*NQV&Q:UX!O=,N,'^O.14OB
M/+I #A11W\<6SGJ9G"Y0*\F 0BMJ H $H8ORD6M=;N>5'^788F#[KWT29'<Y
M-.?$O4=XF%'*>HVQL"XWCP;I,'FP+'!2ZXJ;YL7"M\]J.O']P&,0Y&"A'*DU
MSWA*2JV>S'Z<8W<N2XXBTON6JRBE9F1^G([_A?D=TG,Q+V<7!P\O0NKR]PYI
MO-/LX6W;ZO0S)\V:!-S 4KN3C() 885-D +I((5.07295Y_0N!!3<*'UGL ]
M, YNE',VFR_'_[JX)%$NI5!#W]JJ:YV!LAC%E)G-/ //LG;H<)WQM5",HH7E
MA>#8NL?)MMB&=)Y]*%/NM,CI0S[-K.%-='6P:T!OYW@V/C\;":,]*Q@A=&6$
MN';@5**(MU DI1-ZG5H70'P4U)#\IG[Y<JA$&M:+O3/,7[^ER7G7^?8:Y)'S
MB<NB$G0;Q^34)0C.D[76)KN2E)*N?0'9[; -Z12[-6UZD<^IO*FW\S&]\#E,
MWN'GBZ:.QW"C=GYJS_[38;/0[!)(7%ZUT>S.KB\85;-:0S*9!4<^ON=$6)44
M!)TXB)RLRQBY[.$2R&8\A^JX5[/IQP\X/ZO/^%M8KGK77<[^XDVY%,G-)NZ!
M,QJWJ]WM2KWXA[2ZA.<4IC@>HN$YR-8Z;U^L0W*UFG'KMC(\BB";F=8=T+Z<
M7D)E)15#H""'6MK!20]D(R0D1LZ!,HA:MSYBWPOHD'RU(1!N3Q&>D&VS\_F(
M4 H9O0(? BT,+6E-F!C!8F%<6U9$\XR@O8 .R<4;$-MV%>'IV/:!V(.C[(Q.
M5C#(NK;FJ242 ZT',"8(Z6C=4 QT:KIU2(>5R3@4ONTNQ-,0[C4YR1^^XN0+
M_FTV77Y:C +2S#!:(]:RVHK%VWI#*P&GEW75R#*W/ADZ"/"PTB*'0+^#1'I"
MM?=U-BK!Y20%A?_UB$/)F*%>"R0WU-OB#.H43N[1$<YAI4L.@7/["/ X6RNO
M<5E3SM_B?)T@-TZA;CI/SI>8Z;<O+YM_KM]SP);* 4]KNI72:M2-ME#^T:T$
MS$^_X#Q\Q-?G9Q'G;\H*3O?XQ9OSY6))&(F]H^!BR"B)-TG[^L5 K$>J0A6I
M9;&"Q];I@#M"/%0];GC<G>=TDALQ4MP\!@92HJ5EY1,X:1DDP3B2UVK;'USM
M!'!(6RI]<NVVCNQ/BLWL\+T0-TW&5:'V472)*98L!)D31>:10<A9@BCD2TC!
M,&'KA+(]H0YI>^7DY&LLV>/8Z/?X\2);HLSF%].\ON@<;EQTII_>XX2>]/&O
M.*WUO6H-J'PVGH[)_PFU*-CJ[&=Q@ GO#TQ3"W^D.3O0 >BNEZX>_'3#@R\/
MZ5[/IBDL/JU>'C&C%2E)!LH*6B"^. BUSYTOT0L1"N<Q/B;, YY_J.)]3U,]
M)X_Y'[0V:YK#FU+&">>+Z[<SR"0(80J:>O>1UC^GI>_(1P9M5$*#3OC8NGS$
M-KB&8,^/19W;:K6YW)J9\K?S6<%%[78?)B^PI@5*:8*1!;*K>?TUU3 H,B8\
M(F/*R)ALZ\/'VQB&8'Q/Q92#Y-&FBL(CHUX=CW=Q>W=NOAXVQLB]5P)*4(14
MV0#>E (V^HC<"%="$]VZ"< 0#BF.39NC":R9PKF_W,P:DC2%999Y;6PKR'?E
M#!RJ>B4L)B518K*M(X0' 1VTD![\Y$TL4,P4<MD]Z.!K;P&B@C,9ZX1PD90E
M6:6M5M$^3Q^"C6Y/E!N+I7>AM$LBG73O605>=V[A7JJ-D*/7-:\B*$.A%Y?@
M1#WSSCXAD]Y$T?H,>3MD0S#C_9&I1RDUO)3S>8YIW8N2XM35]>X;F8M<.V/(
MRP")AFR/4T1K"N#!DW4H27K-3&C,GVUP#<&:]\^>YA)JXP+NI22-T9%9Y2#&
M6@&=()+_XC-@I-B%M*5R*(YDN5H.]UG=[,I=V?G%DOQQ[:PMY(5+7:]-Q8(0
M<HI 'E/P.F0AV'9>[@X/'8)9/@XOMC?5!XCE"&NDNUSP!>??+]!QYZ/6RH-)
MK-30WD!@.4*FY9LMTQBT.9PT-Q\Z!/,[--(<()8CD&:]2[2> XTB:F,+%,<I
M/I-9D(EQ"K@HRIGBA;K=_W ?UMQZZA#L[M!H<XA@CL";C0&^\SR[(@-DX6MY
MCEHYW:0"+AA>,M>"HO_#"73(?DS?27Q#8U(3436+#Q[9.!K%(+17T8,TW-0K
MXAZ"=@Z\**+N22N;6H>6CT#J<V-S$Q-X2$&%1%(QN6[.(3'!8ZX[=.3A"\6R
MM5NMHA9G1J?=DVE)F%VV,%N(YMC[,IISJ1234(JCL%#; $'1LK92F! 44RFV
M3K;^\?9E^B!4CW(Z[LZ,D *M$>1FA)K;XY*$:)P!5$+F&+S%'LJF_%@[,WWR
MI[F,MDQ\6;U>OT0B[5_^\/\!4$L#!!0    ( +F!>5OGG&NQ28L  "5#!@ 5
M    87)W<BTR,#(U,#DS,%]D968N>&UL[+U9=ULYDB[ZWK\B;]W7BTK,0ZWN
M/LMIIZM]CC/M9;NJSAM7  C8[*)(%0>GU;_^!BC)FDAID\0F)<J5E4X-],:'
MB&\#$4 ,__Z_OIV,?OJ*T]EP,OZ//XD_\S_]A.,TR</QY__XT]\^O6;^3__K
M/__MW_[]_V'L__[RX>U/KR9I<8+C^4\OIPASS#_],9Q_^6G^!7_ZQV3ZS^%7
M^.G]".9E,CUA[#^7?^WEY/1L.OS\9?Z3Y-)<?NSRM]._6(<67$ FM0Q,@XLL
M2 U,<*."D<8$I?Z_SW^)27F#J)CT(C.MN621)\F$ %ULU,7DO'SH:#C^YU_J
M'Q%F^!--;SQ;?OL??_HRGY_^Y>>?__CCCS]_B]/1GR?3SS]+SM7/EY_^T\7'
MO]WY_!]J^6D10OAY^=OO'YT-5WV0'BM^_K^_O?V8ON )L.%X-H=QNAJ AL_S
M[W_Q.AKS\_DOZ:.SX5]FR[__=I)@OE30@U/X:>TGZG?L\F.L_H@)R93X\[=9
M_M-__MM//YU+#J9I.AGA!RP_77SYMP]O[B(=CN<_Y^')SQ>?^1E&(T*\?,+\
M[!3_XT^SX<GI""]_]F6*92WZRRE74*;"^7_KTW[>&=,7 C)-BXB,?HKC2O&&
M&%<]?7?,WY_%,A98C.8-$=]]=E.\DQ,8MA3PG4<W0+M\$#O!DXC3EE!O//<:
MSDN0MQ'61\)T.OGC"T*>X@P)X9<_I\G)STN<+R?CV60TS'6%_05&=>GX^ 5Q
M/GL8,TS_F+*ZTO*@^!+<^H== TJ,&(Z'=9%Y2]]>/+%B:0P9O\UQG/%\Q;D<
M?#1)-SXTJNO=Y+N"1A!QM/SI8#%CGP%.!Q_G-$[=AP@MOJ$O9P-N=2@&(]/!
MUC]X8 $R,HTEFL YU\[?5>_LDBX%9G&IX(LA?JXR_!E'\]GE3Y9274IT/8IS
MD3:8UR>((QS$!"(;1S.)H3"=DF+>0&0Y^6A+<5A,Z&M.2P0WYW-%DA?3RYE=
MO%H;[1!E.CEIJL_YI)D8SS5%H/_TTV2:<4I&$?UJ^;[_)8TF,\S_\:?Y=(%7
M/YR,Y\3J7T?+ >FEQ,_UBVV9,)O.!]??I5_'<Y(XSEY\&\X&Q3B><G ,,GBF
MA4T,DG;,) _."X=>K5C"[O*!!KG&!?KNB@?WC=^0#??LS?>P8PMU3AJ+=14_
M&JOZU7(WZ81J<,M*:*ST5]<VWB9J7VO>7"F]G:8>4/T.8MX?"514TCLN6#:<
MUCXA#?/9*98CFE2X=PCJ"2K_AJUX.-UO(MV^=7[VZ[<T6E3'^^\P'=:%[@UM
M+&1HS2]!__W-K[\M+<R!D=('GRPSRDO:&S&QZ'U@5N6<!+<@0^F#%1M@;,F;
M55;[PZ391L?WT:8O!=TE%M_5C%P)\.S]='@"T[-?<$S:2$/Z\@)M02'0.<,<
MCT ;JHO,BQ(9%ZY(87**RC8V,S=#^*3)M >E-%R;+M&^F,W(>7L19_,II/G
M8M3>.F0\9$,3A\! Q$#? CBRRY7(N3%%;B+8'P5Z\DEV$&@/*\0YFI>+Z90F
M^!T40>+@P#*T)C.=A6'!",N*L\YDZYW0L1<MWP*R?V7OHIV5BMY%M#V\SB]A
M]J7^^^N_%L.O,")DLP^T!DV'B1:Y^HL7XWSS!]<^.7!*) Z%A%"=+6V39]%F
MP80*0@E%MAAV\CLWX,5.@ _%GYV4/CF4QOK8/5*:+):($Q(FVO5^Q_F%= :Q
MBD4;SU!5_YW'0IMHB"Q)D4 *GY5.K5>9>_ < UF:R?LN%^3.7/@*PU&%]'HR
M_4CT_(AI,3TWJC#.K[Z[A"M1<.F49+;D1'*0ED' S))34:""(-N;&IM!/ K&
M]*B5NR12NY+H_11/89A__7:*XQE^9S;MSKX$8)FC8SIZ0ZN<2\R2/:92C)"X
M:$R5E4".@1"[2_BNVO6N:G\W_X+3&W,=Y.*B!/*YD@9.<]2<Q4+.6+*2!%^X
M<;:U+7(7Q3$H?$?9WM6V:>J4#%217F:O6-!>UQ6'P%B"10!]B#RI)'6?SL@Q
MZ'A[B=Y5K]U]#9^<XG1^]GX$-+UQKO;J:76PR5891.&U<9S6&"BTOY1L6?!"
M,*U\!!L!L^#-E_+U>)ZT!]I,T#U8@Z^K(/'M\"OF-^,YC#\/R08YGWM%IV4.
MRF5@4J9 Z PP*+3S< %@0K'TM6Q,@_L1/6DB-!1V#S;=.R(IS(?CSV\19OBA
MQ@B^*W^;G0,<:)<3>' ,*T5U1K(\0B )< XF891:M#Z+NA?0DR9".U'W:^3]
M/AFGB\U*".^DQL0X6&3:B,1B=IY9$"X3-27RUF[@2B!/6^\[B[8W,V]@N<F0
MA62I&B+$-4)AB779N!S0:M2I]5)_/O*3UN@6PNO!E'L[A#@<G=_-C_/'^23]
M\\MD1,^>55MC?O9]JAZ%+M%ZYKDFD]/JPH($P;BB1:5$8IIH_19WQ?;D;Y1Z
M44(/A\'7<-[V;7R0*7JEF B%?)ODD46$3&:(2R9(GRQOO<FO1[-_0O2CP?4T
MV47\/=X2O(>S>A)YZ::BP"*,TDQX\G5U/:J..@0F<K+&V!)%MRC'+>X';B(Y
M*"%VTM6:ZX$=!-V/^J<+S'?G/! ^Y,2K&8J2YLJ=8($<$N8$6A(#=[XT/_I9
M!^:82-! W#T<"?QZ<CJ:G"%^P%$-N5D!$#EFP&28LD(10"T8Y.*8BEI)8XV4
MX!KSX4%01\.+MN+O_9S@$M_9]U--GK5UWK/@D5?#*3!OM:(-DEOCA$M2MB;'
M_8B.AAD-!=_#L<'+R7@YQ7\,YU]>+F;SR0E.[V!TRAA09%J;N#2<R-(.A=8W
M#$;FG!7JW"E2=I/(E0ZXCH8BS970PWE#];9F[\K+*>;A]Z (J<";9,CGPN28
M+DJ2[2,5\PHC6(*;'#3W/.[B.!HB["SD'DXIEJ=?*_:S%#D7L0AFN"=L3ED&
M* 3+NO!B2 )<MTZK6P/E:-3?0M1W&>#:'ST,,*%(T7)&KC,A@I18=,4R7H2/
M]*W0HO6QXQ'K?4<!WU6Y;ZCRJR/O[W-U@8Q5KB4+*M4+CD2N3I2:>7)QP 2A
MR,[M3_MW 1W_F=..2NC!WUQCUEZ[(,F8O2&CA):I0 Y/X9Y%1?-'GK@*7O(@
M6L>5/0CJH$S958G='(LM-=#P:*I63QA\F)S!J,YZ%3#4UOIHZ%VPM$[J1"]$
M%"B8<]'DXC6]%;>\S;L5&1X<Y1ATW5:4/2P#;R?CSY]P>E(MUTO#=0  (EF+
M+#M1S58R6D 9VAI3-M86GJ-LOC^LP'$,!&@FYQZ.E%;.=F"Y]<HD9!+K%9PP
MGD 50[.4Z M]F:'ULK\2R%%I?V=)]W)T='(RG->;V&H#U3,,VHMPG CD0!:R
M>D 85CQ4:*5F2]38Y^R4<1Z5:QZ!=@^<([4/6RF@AZ7A[HS?C"_ROM]/IDO9
MS^?385S,ZU7:ITEE=3T$FXSHB9\ODWN_2ZE$@[G(2(9,DK3)9<, DF8R0 HN
M)5M$Z\O,MC,X4@8>4,T]+6B3\7).?X?1 @<AN^2" ::2Y[6J8F8Q)\4L8"S!
MZ B^=6#%;0R'B*\YG$Y7+'!;*Z2/N_:<E\*'T7L8YC?CEW ZG,/H&LR!0AX<
M5T!ODZCKKD-ZFY)ETJ,MWH"TIO4]VL.HGC6)&BNMC]S.E!8GB^6]\?($F*"=
M3O%++?/S%4ENDQ-\.YG58/-WY1-\&R24R?O@6)11,*T3)Y//">9#21A$0IY;
M5QK9$.+S)ER/ZNS!5/N <Q(PYE]A.B91S*[!?[6LID*NBP.M<TD,2\UVB8*,
M!><+ RE=+L6'B*8QX1Y&]:PYUEAI/1A3GZ8(L\7T;"FT\\7V? \768%UFKS?
M'&C:0C@6"D0FE%' 57T56I\/K,/RK"G41$$]!!K<%=$@D+^*GJ;IE0"FD:89
M8ZQ^"@9>G(\$JG?W[UF394>E]!"6\-MP/)DN17(^S4%2VD;E$Z,O'.%QP&I&
M+K,V1A<"\-@\T_DVAF=-D9T4TD/40AO1#+PVB2<T##U-@'P#LLY"O6XQQ=D"
MX(1I;6RW0?ZLR7@ Y?<;A;'R#&^0M4 N=&#<(-EXP2@&MM[W\B!C 51)M-X8
M'\)TI">=356QUFKZ]Y]O2>TM?=NT$<+W[+G9I*Q0W@V FW=&>.#I?;5*V&12
M_?5.$#'G+%UARAFB%^K((A+;>/$>1$X(I77QC=Y[)Y3 >8C&LY@PTP+(+3F1
M%AGYELH;3UR'H^V=L(D^'^B=L(D8#]T[X<X4SM^B>HHU&2_O&FL=<=!&&&\<
MR\+3SNBP5C*+D1F3)=E\7D!_C4)6 7HD714V4O0ZSNPL\!ZN/FYANJCDW 74
M)MT5-F##2D#[;;+0@^)N9Y4UD_K>*)%C5 (4,EHYR>O3U60NTK*4"_=HC!/-
MK^KW2(4U+1<.Q81-A-U'/>2K.[2+>NM9I%SO+)C@!6F*2;$88F(!.0<75>&N
M4Z>-[6[,]UWGOJ%RUM]\;R'9/DJ=K[Y%O0!'!A+Y4"62@^Y2[2IB&!';$DQ?
MBG+9N^:Y0/<".@8*M)-X/U4''KKCO  J)2BAHJF5T3SYQ33[8 SAQF1E<MY8
MW_KNL#.XHZ!)+YKH(<KA]I7E!2H,16:G!., 9#%+7B-B769<9J$"+]JDUDO'
M:B3'0(8&,NXAPF#%3>-EAY\,(O!$<(JCM2OFQ#QZ1RXV1[!%@E>MS86U8(Y!
M_VTDW4,TP.KS]0ML'%-Q+@2:+-DWVN;((H!B:"$HK8F>OC4+[L-S#$1H)N\>
M+OAI4ZHTQ5=X_M\WX[MGMA\(^.O)] ^8YH&)*>OB TLQ:Z:AFCHA669K:JW4
M5F%H761@0XB/H@C>+L>5?:JD!V?DFG?T\0L0L]\MYK4W?+W>&] "YXPE"R<E
M59,>"5;03I*C%+D5J9BH6AL4]^'9/S=Z5>9Z/W4W3?3@HS2Z S8<O V:WJM2
MBTM&"2P4$A3WUJ 0 ?7M7-5G&P"P3^8=0+L].$4K#+;S]VC DZVEPP-#0%'+
MA0$#'SPC*\X'C@Y4;'V.NA;,<3.IC0YZ\)M>Y/]>S,[S^SY-UAP'+9%&DE"N
MYB-Y_5 _] %)0K/A'#_B].LPX7N<#B?Y Z;)YW/-G4=Z%E6<E#6!U %9@QC)
M*?#D(P1Z*XRQ]+UK7B&RYSD=-U4?%2-Z<!.7DGLSFRTPOUI,ZU*^A'G^.BY_
M^>ZT@IW]^@VG:4AS'*C$5<HN,1>@AKF'6N."1T;_FNA<(1NC-8<W1WG<K.Q9
M:WW%F-]%O'P'5@,N-M470S&I:_:^B"0?&S(C&9$QZ[ 67]@/S=:#?)8L:Z2S
M'B+4[WTMKIJ.+C_VHHKGK]/);#90F5<WOC 22*ZWQ+735#VQM1"M+MH9V?JX
M8SNDSY)N+;775]#[FI=D/6BT1GB.G&%2>!X8ZW7)+&4>K/3*([3N+[$5T&?)
MN(:ZZR%$_=[7Y'?\8_FKV<"F;&,QG'D!R\-)9-'EQ(I1WAA>@A"M*T)U0_8L
M*;6+=NYR*/2Y:%V!3,)QR4MD.IM:*#M8YHU/3!@LV6D0VK0N0MT)V+-DT ZZ
M67'2N_.%P(TCG'-VOT@DAVEU-0QB*(6S5)//-*9,FS$WS('B(I>8T;<.R[\'
MSG&SI94>5G!DY^N &]B6_+V$]G)2KT;G7R9Y(" +*  L8R3S347- JV,3$@O
MB-:IB.;1*%UP/2/6M-#,"OKL7J2EP]';/V ZA?'\?+D<..UKM2+)# ^UV;M6
M#(1RQ'_R.S%Y'F)KFV=CD,=-K'YUMH)ENW=IN:=@S(NO,!S5RRP2S4<8X4=,
MM",O,Q*_S_-[41DC8H@*/9/&"*9]->YJWPB7@A*U2:W(K<G7"OMQ<_(@&EY!
MU38-9]=,A/#C\//XO)A].OM$;]@,TE*)X[S\;K2\E5@Q+2$4%$UN2-#.,RVR
M9\ Y3<M:[F/PH&3K>.%^9O)\:;PG[:\@]<X7 ^^GDS*<UTD,K!49',G$9E.8
M#BDPD*HPSY6R16B5FS=0O!K]N,FSI917*'SG0_I[ YAL,"G4?CN\KJZ:F\0@
MB$AN+>=*8$H0>LQF>B"4[& !45)%S! CD\DJLL1#85#(]_=<8XQ6N_PD J):
M!NN0^\H56,$XULR^%&M$K<X,I2.B)&YE\W8X#P3K]%-)XMWT,XR'_[-<O8F3
M'VF5'Y9A(OOYHCGJ4B&C82U!_7LUK.>T,;RJ20FCV<VWN%MMB9W&:UEMHMW$
M=ZP_L6P(<1W-BP?0O/T>($QOIB[DQS"7#;VWB?@9#9AE/'DQ7H$OY2&%;#_\
M3LU$-AGQ(A$?C;"%#&,RARTMW6"93R*1L5R\M%Z5J-I/=B\5*_;$@!L=2/J5
M_Z$K7LRF<]IW%W67.(7I_.QW.,%EPK9S5G$OR?W7M8B^48%%;X %).O4!B4M
M[W0:2 -<6]+INZOE?-W8^ZYGL0\U3QJ*NV&\>,7S 4\7M."3W?OB\Q27M+H-
M\2(KIPO(34I>/,"-SL#V6_JBC0XG^U+ X=A"EF' )%FPA=X/5+4I>.(L8;9.
M:._HNZ?/DC55,0Y)D@WDWKKSV4>RPD_G\.D+3N$4%_-AFI&W<IF'J9)0*02&
M*F>FO?8,DG*ULR<MED*!R=#)+KEOE/V='O2HE4D?(NTA&>T3?>Y=>5%O$3XO
M)[^DN)6>1ZT*PR#K\0A-%6JR?2V,RW.QRNG68<DK@1RQ'=%. 7WT=+B"4PM&
M_DYNX]5/KIV(7J;H=X';4R6M#:$>IL96 R7?OAS<@X;ZJ+RR(>P0?0G1)E9/
M4NN-IJ?55VNF3##":'K)FO?J?12$>J!2U^'YM(EB>C)17DY&])O)]'RAOMR\
M+_%IXU(A"62?@)%0+ O@!!-"2A]\BN6VZ7J_I7+?8/N_[NA56RM,EV:B;FC!
M+(VW.N<E]W72(D0PK- ;4.M()19$LDPD*4UM+IMBIS/LAUR5RP&/V#+97K -
MLTB_@[@@61<8+0\NKH;>_]'$EL*_K;X=)-?ZQ.$:G%R EAS)F;&15@LK,@,'
MDFGIC,B0HNM6X.+0"KSGU*"M_C816&.]_0;?AB>+D\NB?4KG[ 0R*!AIG7><
M!0^1F5)R$%GZW.0\^<:@>SX+V%;LDQ8RZZ/4#,R^U'_KK?-7&%5SX2H7I_Z"
M=I&;/[CVR4%0-G!%5D.NU9LT"L6\XXF,2F^S@Y23;-WK:B? ^R/+GF^Q]J_.
M'KAX!^DM?"_F+\F(/2.AG2?SHQ"0/4>6.!1Z=;BN:3V*V5!TR$9K)=J75MP(
MXM'SK4^5]7&XL#8 ]17&^=5W+R\ZT">!F*T4+"E!< TX%G6(#!.]#";P6&3K
M&+D-(1X]P_I46<-ST:5T[L887KP5;\9?\2)0?T!60XE)2V9-KB'X3I+9P M;
MAMSIVBK5WEJUUIP[=!GM:.G1C[P;NJ=+@.^GDT1TG+TF,=T\(;EV/#/@1D$P
M9/-%$8BRCAL6C,*:YVRRDK%@$IT8T6FXXZ9$>XGW4 ;H.LB:F /CA.^6J]N[
M<M%NBQ-MN8B)83VNU2$H\@L%K6I%>FMH$PVQM6WS,*JCI4Y/BFE8V6<ID%?X
M%4>3T^7)ZG!$*]QDC._A[)S3B9ODHD>&?-E.,!I:YR34 OH9LQ'"&]]I%;EO
ME*-E0%OY]E!MIU,2:4K9F]IWQ<1,#ERMDP% #EP$6P!!F6AZC=,^>'KO@=:-
MYLKIH73.E4UTGLGTO1_I.+\:?AUF'.=!= 4TL9IDP&O9,D/&LQ/ <@KT/Q&\
M:EXPL0.LHZ=/:]7T4 =GY<Y8+I*+9X.,M(5DJ5BLF3):5X-*1F N6@ZBQ!*:
MUQ6X']'1<Z:A0GHH>?,!3R_VS7?E[63\^1-.3^J\Z=N7M"H.YP/!R6 23K,<
M>:@F^#(Q3C",Q3J=,@1L?73\(*BC)TU;M?11Z>;2W/HTN=A!B>>G.)V?O1]5
MN8QS-<.7%MH M"C)&<E\7B:E%<ZB5YH!SP:5JNMEZZINW=$=/95Z4E3+RCBW
M;?H/^+DVDII,SZJ(R*F;?;?R9]_-?!$TQ%*;2Z0H&'UM623[GCDI9/8ZVJ*[
M)59M./#1$J9W+?11#>?-R2D,IQ7+NT+6&(P_#^,(7\QF.)^]KIK!T? K9L)I
M)6;-&2A56ZXKR[P.G)EZ2N"S0JY:.UP=H1TMG_I44<N2-TNQ_+ZH,GM7/B[B
M;)B',*7I_V,X_W*KA,2+V>O%.)U7[[G\V4!(K;.QFG&A:]2<,?4V%I@$;WA2
MQ437[:)@!Q!'RZ*]:J>/\C27V-_1I@M5+A_/DT1G@^# **,U$SR56K'0LE +
MD%LKG),>;+&M+RW7@CE:_K15P_I2+X>O<_"W&9;%Z"VMI;-)N6'DP34C;T]%
M$#8#<Z@*"3N(['#E$Q**:'6RS&1/)I<CYD85 DM&!(@:2[:ZTW;S%,HGT.Q0
MHY7,EJAKYYO$0I'(,E<V.,>+"[+Y9!][^81-&+!C^81-Y'_H\@G73MQ6.[B_
MG-5LFV4XKRS*>U%EQCTM^M9GY@W2O P4HX/,(K?V!SK >B*I"!N1XNYQ:%/E
M]!!\MA9B!7B10=P%8D]IDAW@'28ULKEJNU)G1[T<B$(\@]$UMD4$&6I7RESK
M9B:6/"@TJ(MH7D?^8-1Y( GR,3!G$W7TP)A?%L-1+2-WF8D'@0L>"8C0CFDC
M) /A.),F*<F3TU*T+A9_$\'^,R&;*VG23,(-8^B76^Z'"Z_E^Q0O,($ 1"T*
MS<>D"DPQB+8P2*%8"SQHVRW5=<T QZ/49F)LG='\&XP7!=)\V:/B-C"IC';1
M6)94!J:1:P929-I:DU)":^>]Z:3?^T8Y,B4W$V@/Q35>+Z8DV\44:=*OA]_J
M5Y=YVEF%R*TJ+  :6EZ"IJ^29K58JU?$2][\<&\]FN.A1&/)MXXCKX6H%W.<
MUE3^CY,R_P.FEUF(H'G-T09F=<U"C-ZS*')@!FR0,@20UG9Z]]>/<3QJ;BG,
MAG'A-U."4\:0>;9D@BJ:F.3(0G"E$JW(I.JI=*>JS$=6J&";TX'M!=MP5;^=
M-]P%QO$5*MA(^&L2W;>17(^%"E1Q(ELEF!1H"8Z4Y#K6KI@UHC<9Z2$W>U$/
M7JB@A?XV$5CK0@4DJ:ND>XFT8%0G38HH:Y*@8 #&,(=")(/9F=S)BGJH4,'U
M00]7J& CL4]:R*QQ$9^;%1,RB !&6A93J4R4-0/'D:]=E"C.DU]F.\7]/8TJ
M$ULK;VN9[?/<\O*FM. @<RE$T.1.H\RUFS59VMD:%I6S'G6.'/9V=7(%ZTD$
M,&QS<=>7:M:^^OU$,MS(\81Q?CM,M*U=56J=?<"O.%[LTJ1ATR%:1AWL-+T=
M8PDN&?)J.(//-.#G)8AWY6+(*_J!EHD6$&"I:/*,:W:3ER*P+*7WKN0<0^N&
M*0]AVG7!6O/\<T\$."?+9^GZ"WH=2BC,.[*, +.)(2OR0%N7G+P/3]\1!;WP
MX/8RU$S@AXX6.-][_WLR?;F8S2<G]9BAFL]<! 5"6": UX!F XR08\TBSL5S
MK93ME.[RH-%R>^1]>_?M%3II)MC&/D6M_/VNW,!T>3;5 51#%W\MD/T[_+MJ
M:-*7>/>F>U>X%LIXIL B&6,ILRA=9 9YIH71RV0Z-7A\7#J_YXQ@+RK?1*JM
M[][^.H)OD]G)</[EGZ.ZV=%^,1IAFB]@=&D]OQW2KS%?>%NQ6)-\"K2HU3++
M-8\EH#),H(+BT2.XV.E,?M.1]^NF-M+69%^B;GW=_E^3Z?!_)N,;71NF2'Y4
M?O7BY04^KF(Q(3NF:@J*SDBN&2^UC:3.IB"7,3SH@'0=[,EKO[5 6R\$G^"?
MF.']%YB>0%KB@]'L;S75*'^<P[RFT;X@,="/:Q[_]+3Z;=^9ZH.0P63)L(C:
M5K+$FI&46.W''9Q0Z+!;8N$N*)X\1?:F@M:UX?XWC&<S'-]"?@62E'!YXA?(
M<S+6L"1C9#H@9Q&-9%H3\[7E%I/K1)3.0SYY5O0CW-:W^"]./N-X!2VAAA4%
MF1AM5I;\9F<864S( G=:%E^"[:CP-0,\>?6V$%S#Z_J'6S9Q\$)K;YE<=E/0
MWC/(-;P4LU5@@H'PU+I@]:#69B)L76?M(XPG97A9H+LXXWV1+'.;:,4PF7FH
M!H?-'@,Y,AJZI>%>?^H1Z&Y+$?50&NWB:.F\Y.-X/H4TKUF\EU/]]=M%*^V:
M&T[_SY_@VX"'% FL8+X: !H1F;?1,QFSE:"UP-"^_,S&,/<?>=7K(6_?BGIL
M=T]+;_9C]6;_SSIO]O>)NG!H^[RAV@K(7N^Q=A=5H]NN:TB_XMTN2FG-KZ^W
M5+IZ61*]*U&F6NT/Z ]>Z&71Y'^D6OE<H349;.-5IB7^71?FC^D+YD4MGMH
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MWKH8RK%G8&QC7+13TB/(P.@"]T<&QDY*WC5B?@L-/8(,#*60)^X+,]S4&JO
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MFV:B[B]HSSLMO 8FH(8_H/ ,9"W6G+U0)4)0V"2GZ B#]K8]*=E.^'T&[76
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M3!9%;Z2,D47!+:VW3GH1N4:)C6??%=N^HB<:<V1]3$1#51PZTN%!V?UR5@_
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M 1Y+=K0N,F5\(I.#C(]8.U%B .&2M,:7;I5.5S]_SXTU^]'$I*T86UIN-]K
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MJ]+J7D)MBPI:<B'0<.Y%:RO\):24]-)YKY22/@H;(!SZ5G$1%3V+M5YRT::
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MT]%%(3*46@=725Z+@65#'E845OI<"_>WC\79!VM\-[JA(N^'UC35P@!7G__
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M_$&^1^MNO WP]6RQ?']]GWG&>)0QU:*XQOB:QN;!%UH:UH<B;2HQR=8ITYV
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ML-08[<7GV7D^JY&WH20+Q=.>J9(*X(U,M&<**YATTG4\!'<,\%(ITD+>.U.
MFVXRW9T Z]%9+S@8;QVH&"4$E0I(&8HL)0=W-YJEUV[SPX5[U+8SC/[N<\\>
MQ+UKC%NA;1+EWQ/\LV"9+SJD6ES?U294A7S-C,"\T\)@0,6Z.77=QWRIC!I(
M*_?)XX8,1%UW*9Y^NGYO;!%PVN%36P:6]IU$HP#22J*WY:IVRJ\AK<CPG5@E
M2!T$!G *B5C.,8@8.,3$+7>TFPAL'3_Q(*!#XT>V??C5TV80.89@!93D;*U%
M)^A<S@8DT;H4P[.Z>SDYR$Q'#;ALI_N[X2!MY'PJ@9"WY[%ZBE.:"<8"([FD
MNN,:,N.$H_-4FQAYTJ7$UE&0]U$<*[*@D7;O-ELZ3,I#M*.\A6B=*MD%TT"Q
MBMOP'*GS]H&Z>E#U!PAZ+!(88V6QS &WM3>B(G/::T\&EV0Q%L.RR?')*G]?
MY^L1=-]'O@/H?-5#$'-M)[AIZ\Z=RXYGD(+^HY0G0+DP8-HIJS4W[FZ!S\,3
M.>Z".(*3<K!N[F96'"38 9)QW^/7V?G7FK)Y:ZJ;N@68>"@B0=:F-BKU9 PE
M'<$%:Z-1,D?>NH3G@X"> 0/:"7R0)-FX?#-=D$UY'11=C,RL]G0D[Q=!U6[I
MD84(F"V2'U?08>NV$O=1/"]#[T I#]),X":B/\*735V,+K@&,O9V83J.P7>H
MSAZDP($"'WPCN(%/JJ 4\YGL&U5;@'('M?\)G5ZZQ)Q<$KSUA<BX1-AC_(W%
M@SYR;AUO=/\F;A/[;-#:VJ35D;D+RML$OA@%12OA8Y2!;)9.%].[1CA&F8,6
M"IBUEE[KP,7[H#;AE3C_\MLL;'H9:;)%,X\.;'&N]KA*9'IX#39X9#*FD$RW
ML(R. XZG\(:Z>5C;APMVA/7\]LWK]1O:IIM1=D87S2 0K\F>D:[6!!+U085Y
M5OL<E4<O[;N#/4.E'R;0 2RZWV;33TNB8-W?KNL<IF Y44]#$D;6EE46 L\"
M)!FR+#J&7.O6=_Q;<#PO:_Y@20_0EN,NIO69U@750-;\=D3'L>4/U]@>"AP@
M[@%L^1WH1,DZU-#EB+'FHD8%,3)-^Y45%FGS\J)U0_8Q2;#'CA^+ WVD/(3N
M;VQYZX/)*FV%B 84UE,/1:#S3Y/CPHLKJ)4F*W? A]YC&?HM]// (^\CA-LX
MP7O5G1+G%V&^_%;]F!6CC0Y2\F# *LR@3)$T46)T-"R0(6I]OMNW[5%)AMO&
M?AZG?!/)-@R67N55XL7E/-70_VO[\R[$S45U!Y MT[R[ AL_"?QP'<[&4D#K
M;/'N8(W2BC':LFSME\X8@N.V(@Y84TJ"$$T*0QR7)0]DFA^+)#WDWOINX$.8
MX\4R?/R,\W"!E\M)JIV<-DG;V9;L:-O5G@=0RF4ZS5* [)"\6*EU2=U:LSTT
MRL@YZ<-H93:$2 =X[MU>^"@4] J3 ZVSIX.Q:'!26TB:U_ZTNICFC_LG5=)N
MF(N!PV7=, ?FL760NL#]49GN("4?6$GL,1HZ@<IT2/Y0-EY!,<AJ'I" $)(
MAT4A6J:E:[WGG 2A'E69;DP^]5',0-;(C=P0$O>=6WL;70Q<T1[LBB-9,$L>
MN\G@HT ?G$\F]S)*'AKL].O4]=+6%BNEF:@',%8^?)[-EQ_O7M*98JU0)H*L
M*3@J,P/!J0BB<)%#*O3CUKTEMP)Y7L;*X;)NF*RY$]3&-.\ :R"C9 >DXQ@?
M#92VCP8'2'R(N.1=\&H')<]R;7(N0)4<(9"?!:@*8]X20-NZ;<>H1-AC-(S(
M@QZ"'N<Y(\K";;8:K X&5 P>8L:KNIQ">N-B<SOR%)XSFBAH_WM&'^D.8 %L
M.^O6%0%_FM54TAI''2[H-\MO9S)HY%$Y"+Q>K<C(:F$X18"C<587GYHWG>Z#
M[PA/7J.F-S;1R\ <.HN^.!$9ARRBKB5N.'AG%*T19([7.H)RR,?/Y\J!7G(=
M^%S8S/(]5@$1$>\S,CC,DK$:C*<4;9)1@<>D@!D18R$3VN?676GZ(7RN/&FL
MF\$S(6X6@/BPK*5%UMWLPB<\8US16>@3:!YK,7 RK8(/ 8S7VF"LQE?[7G%=
MT3TG!@VDD];%[V[#?#W[BM,P7?Y.'M'DHA87>3/]2K Q$]4GRW!^5DP0'"U"
MM"079:0&VC(YA* -2R08+>^D4NRXR.HY\'.@QN ";QBRL9W&/X7%9/'A8HXA
MOYW^%>:3>H53.<W/T)IH(]G;/@4B,7$:7!$,6.3%9>U]ML/FV.S&]ARX,Z@^
M6I>M>S>?)<2\^)4$<_NN]L9%\5GF4JNH) 3F"*%FM.T9(8";8CSWS.FXM]Q/
M]^&> PD&$F[KBG6W.?INCA=7208WCCPAK3:YYB&+1+L:#P6"R@%B08%.*RYC
MM\R-_6,]&\4W%FO#6G'?T\37D!9O2PU=7:43T<07URZ7EX[1_ T8C?6V7]-I
MIHL%9UTUF)7/V+H"SUY0SX$@PVA@9T6X)AO#79MG90]=63V__'V!:543\2=\
M=7%Q/JE?OIM/IFER$<ZORK6N)WI6A#.A9%DS61D92!C!26X@.X?:E*C)NG[$
M5M(&W7/@UFFH[CX7_1".#^GGRR4MF?^YG)  O[TIZVE-_KTZ8]\L7D7ZT^^5
M89D)BB=6(-+F2@*5])4S"!BS\5$Z8UBW2KQM\#Q3OHVBGBU7?(?E+^^80YC_
M$Y>W<7\'G&7VP1)@$;RA8UPHB,8*6A+>2.EE*+9;H,@C!G_NY&DF^"U,:5R\
MHI[;9SIXC:4&VV)]@V""MD=M%: /.0@7DO&M"QG=1_$<2-%(QEO4?GC*\TWC
M[/7E?%[/1:U,9)%)B"+6\EH*:Z97 <2(UELAA&UM)6_#\9Q4?["<MRA?CEL>
M^>WE<K$,TUQ?(,(Y_1)G=T35M&YR]^&&+:C\R&F/4FE9U7="J3WPQ%6]G T0
M))D7(7DZ0*QPC(WQ)G<-:+A*RTRE1">D@91"+05B&9GJ]!\5-**21D7QPBHM
M]]%]]TK+?>1\PI66C?<8@R)KF]D"JB8C>64T%)$+,BFB=:T+\#V%2LN]M+N_
MTG(?*8]69+<#II=8:;F7KCI5VWV$H,<B05 L<$.(K"SD3*FL(: E([N^7&1E
M<K"=&CR?I/+[5UINKOL^\AVETK(OA6&("8)Q=!CZ3.>@535A- B;C?1.OI1*
MR[UTL[?2<A_!#A"'N*5RI#"!%58R,!YK6I=4$()+D+@.+.L<??-HQ*=06_>0
MH_U *8]96[<+KI=:6[>7SKK65'V,P,>LK<N$M2+H #*L+F6\HYTN29#"%6M]
M8HF]M-JZ@_"@CYQ'JZWK)<;HC01K2WU,=A:BLQ:XL*&:-87+.^78GFYMW5X*
MZ%1;MX_TCE5;E_M<FYQZX,K6^W'M( C,D%V.QBN4I6/B\A.KK=M+-X^IK=M'
ML,.OYSL8-^'*:ZPEV\QJVT!W51;6*!(&*[5_1"BY!*VR:T."VP,_?S(<(.BQ
MZN]J[:7/3(&(I?8_)G\F9L^ 61F#)&"$J_7-[Y.HOWN(Q7^PI,>KO]L%U4NM
MO]M+8]UJKSY&W./5W[68G(@A0M1H0)DD("!+$+GFC/L0C&^>N'SB]7<'X$ ?
M*8^3L.Z]\"+;VC>J(F(B >URBB99"\$9SGUZC@GK+?2S/U^]CW 'O^-['>;S
M;]5B^5(K#)ZQR ,748)>F:FFIN:S:,$86W/I%5FJK?/3'\)S:B$IASP"-Y/[
M )P@%//E.D;N;:E(?YXL4D7V;HY?)I=?SLA/*8%K"UFZRMQ@:X4E!EY)\I2Y
MKJ%4C8FQ%]1S8D=;#0QR(UAP3A._\G'P]6RQ7/QC/ELLSIQ042ORE!!K.0_D
MO#Y^U'*AQ49N6*9ML_F>L0/,<Z)$&XD/X3=N"ZXC G)#XX(1F4ZU[!5XSAD$
MQ7*PWAF:S0L,8CPT;.@@.0_@->[/.!)D+7D3:Q9:[2(5>"$_V0N(0A3'8TQ9
MM@Z2>W(Y7X>PHJT&!L@AWX"JA]@?LVG:$)<I)+,W@I6,@8J> R'3M0!"LCRF
ME-OW]-B*Y#F1H8&L=V:#CQ7HO+D4K:EDTP5]9II]FD[^C?D]GM?2&<O9@&'/
MCQU\V"#H)B(9)22:"VNE#1F8))(IK#T#R3:M?>2BSEQABJT+S#P(:+B0:!&9
M*$4;6IRUT*QP&ISUA5:MCC8Q9BUKG9ZS$\QIA$3WT7WWD.@^<C[AD.@8-&VV
MD8%A*M?LE5#[=!F24"K117+?4GF!(=&]M+L_)+J/E,>*ANV"Z26&1/?259>P
MV,<(>BP2D(F=4"0#/-0B7]Z2/9>M!,Z%*2%)85GKB]13#HENKOL^\ATE))HE
M#!*UA!@L'8::#D-O @,9).=DX#,E_0L)B>ZEF[TAT7T$.TY(M-=%A1(SI&CK
M PZ7M=-%AD+8B- 6@VI]P_$40J(/.=H/E/*8(=%=<+W4D.A>.NL:"OL8@8\9
M$FTQVF*3!MK8")^L&2 A9\A2))NCEC&U3GX\]9#H07C01\ZCA40C&J6<#)"L
M2@1J57LF1C!%&A.RB$7?L?.>;DAT+P5T"HGN([TARJYO"_#QJ6AK@KYJHZD8
M3= 7&\'+C$X:LE6[M2-^=@&0AYSO!TMZO #(+JA>:@!D+XUU"WY[C+C'"X#T
M1FJ?:5O*G%E0JX=6DQ2D9$V)*7%G6]_BG7H Y! <Z"'ED3KV&.5RD;Q.LO:*
M< 8<CQ9*]-G$B)C*D'U:3BP LI=^.C3LZ2'<P8/=KFV357S-JVG>Q%TMSHI"
MEGCV4)S/H&PF*S8Z"=&*8#5WW.;6ED!7;*?VAGW(4] @^CA*D&1RDC&T"J),
ML3:V(H#H.,CBN1*,EA%OWB_VJ05)MF/*H1H8X"2Y\VY?$?[R=SJ_S%>1OM?@
MSYPUV?)5\%YM@ZF#(JLZ(*"W5B#7R30OC-T5VW,BS"#Z&."R<0O.,Q]SDLJ1
M?^5EM;-DIGEG S$;440TF8O6M\Q;8#QS-O22\DX?=*Q(J>NZVM<Q@&.$2/4>
M==C8J,.$,$I0E#3)*2D%%%4+C1)!:R@FK_W!+*^-J:/B WH/(P9%I6A8=!@@
M\MJ!PA0.KIA8YZRC9T;9EU8GLH_NNP=%]9'SJ01%;7D7L)F3WU<\*.]UW;T%
M>,0")63R^9B@G;RUV?,47DY[:7?_RVD?*8_Z4-8!UTM].>VEL\XO9H\0^)B$
M4,(6YER$$!.KH1W$>R(\>(T662@YN&$KWI_>R^D@/.@CY]%>3IG4Q:'5H),F
MRUL:LKRY]L!*TC9RKJ*7^XS5I_)RVDL!G5Y.^TAO@+NP+2%^W'O#N7 @4HWZ
M2K: #TE#\DJP)"0CC"\PX/F0L_U *0]P4;$UWJ\+II<8\-Q+5UV"7A\CZ-&B
MW@6SB:4,@;QK4+PD\,EX"-[SZ+/RLOE+Z2D'/#?7?1_YCA+P7(3U-&Z"5&K:
MHG(6@E(2F)/!(W,<FU>$.-6 YUZZV1OPW$>P8P5%61.+%J:6I&9$9Z,8>,L"
M<(>92QY%L:VCVY]&4-0AQ_O!DAXO**H+JI<:%-5+8QTK@CU"W.,%14EMF=9)
M0D)-$#,7$%-.X#+#0+"EX2\M*&H #O21\CA!4=DJH[$@^%PK$%E4$)'F3*@,
M_40GYII7<#C=H*A>^MD?%-5'N .=^IM"$K^'Y>6<A(J+F[5&KM_=WDS_P+^7
M'_^%YU_Q]]ET^7EQQKA-DGL#4D4'JJ0:Q\W(@HDHDY<8K&J= G$0X%-[U3[H
MT6@TS1V;=O^%8?[Q7[,S9HHI-B;@@JUL+B1+6ZAZ 98$HA R#W'^],7Y8DGV
M&#T-9+WTPTQDP3,9LW;2NIJ]NHHP">#1<,B>?JH#IVWZJ'O9-=*7S:_>NAJH
M@'HOU+_.+N=GDHA??#:@);+JW].*( F!ML5P[5A /X0OW1OHB^97;TT-Y(OW
M SWYBF?%1VMLX,!-C*""B;0F7 +#!7I409OV(3F/ ?JRZ=574P/7Z=L#^E4A
M!^@:MT]85,@6$DN&;,8:?FE- LF8YUIKDEWK'E"/Q?I"2?9X?>VL!CA0P7',
MJH3L#&3K)6VQ!##*Z"&35!(JS4MSS_$I%1P_A"_-Y'Z?$V;(N.<_</G;;+%X
MA_,/G\,<7TV7DSPYOUP2E5>/)2O:'Q#AW.OS6\8R/WYBC:*6MX]XE1&!^5?B
MYNO9EXO+Y3K!YI<PGQ)CK@%_IR43JUX%%H)A'I2T9!@E9\D,KP=8X:FXUKD)
MK; ?_!":/F.^/*<U>R"BJ_<CIXVW1@=@J.O38?(0+<DT1V>4)7?9ZM8YAFUG
M,%;4]5&X>^^Q]GC*/Y6H[@,G_M.W[1^P>D7!Y%WVV@/)Q)*A$A)XS6I#Y6 ]
M%LRI><K3@-,YUF/U,4EZ-V'S1,@RP.WB=F0W8CZ[X!OHR7P?MN,\GI\,&3J1
M]$!-'H-Q+BAOLM! @-C5BV30R*!H([)5T8?8^N;G.$S;\T+_9(G61X$#$.P7
M\IYFWQ _+&?IGV\OJG36C],BI&!4"!!*38^VQM7X=0>8BA':J"*<:<RLG6#&
M=]';ZFTVA- '>)I]CXOE?)*6F%?0_B0I+]Y_^',-+M"LZ/1'2++6@G,L0%06
M(28MF%<L>]9ZKWD0T#-C13OACW80==Y?US=0+@84CA?@]3_*" F>9P92%>^P
M6(7-D[^: #\5IHWL^HZO])U[VC#7CA^N_.,WTS*;?UG-XOWZ;\(T_XQ?\7QV
M4?^ OON YS32IW_@%.?AG'[P*G\A*+1D0Q7/NK[$(7>4PX%I>:$YDL@:W7ZN
MT;['BUKX9?KI!NSO2X3FZ62* BS6(I>U&DR@[1IT8='P8,@;;FWI=,'5[M;R
M@=%^^K;^Y97CKR2=8-QJ2,K0*>-S!.\E@I!<AJ)8X+)U:Y]'P!SK_K$Y>W;?
M+0ZCHE.Y0/Q 1\3J$W^Z7-2V=8OUC*[\*T7'@]**T0%1Z("PED$0J($5KLGX
MY<'FUG;E@X".?XDW$!ONLJ^95@9)/EMAV213=P ST,7:+2#'N45KJ*A[F6B'
M2GEPU?-BLN0Z@;:FU*Q*#\[2MT7;E&)A.LJ!3N<C7F>-I?$^PFU=)>(M;8VA
M[FYK2&M'UQ6%V9'W'#+6G#J>("@9(;,B4@Z,Q="MNO[VSQ_?E3M XK.VXAK@
MQNC-E#P#O*;K;_4?5&E6FCJA'09R/1G&0-#JM99@B?Q/J2S'%)QK'?3Z )R7
M<JJWTL@@)2^W0MO<G74 -] 9_R"PXYSYS=38C1X'Z&"0FKH/@43G%8\F /*B
M0,52K[24!>L2\R$'FVSK4HM'(,@>"^$X_.@C^@%XL;EJ>G7KJFE]D;0^$#5'
M3-X(,*Q>>#)?HQQ=!B5*X2(E44+K2.4.L,8W.QHJ\OY#15,M#&"6K.\<7^VX
M<]S83C:%F&GJ'"798J)6@/91 AJ'2F")SK9V+3H!>TYD::^)UG[(@W1^':9Y
MDDDLJ]8$9VB5Y(G\K9AE J4X V\R>5XRZ!*3B4'[3LY)CT&/YK&TO_<<5-X-
MMY'].%=-"+[B_-L5SE1H4;C (:1 .%,1$#@YZ(*.W*R3TS[%PWEQ>] 7Q8L#
MY#WJ?O$AG(?YZI%T]>U9U"SS&.U5$UL5:H6HPC70MF8#6E>T"H<3X\ZH+XH9
MATB\H8^['^@ZTV>5O[4J7K]!'%@0'$4 PVO*J<\2?% !O,C)*V:,+OIPCNP:
M_D61I8D.&J;][D=\W;ODC]DTA<7G#>"4::,SR4'0TA#71:$=4#.0/-!O$I/Z
M;G6VQY!FQ^@OBC,M-#! *N]FW_O/\ EKSZRWI4P2SA<U)(?P7?6X82X:K159
MT]P3K6TAB3"'J[K!+F*22;?N3M4%US/BSV#J&" K]]U\5G!1KY?"^:^(9$8A
MC6Y2 !>M!E50@EN%*^:@+?TRYMR:'G<Q/$,J'"3FG8FWCSQ<]OC?.P_$J*0I
M-6,\^U*IF@/$&#QXCH5+J41TW0S71P)X1KP830_WN6.'Y,ZN@Q&1></H3+1H
M2$;9*8B<:3 E&$G'9#"<M:#."S%.1M#"?>*X@P/&SU=_@_DJOR8L,-\\"C<H
M2XY9)<4!-9>$,FF($A4PY85,Z%U"W?@$ZH;L&;%H0)7<)XX_O'3(Q1S3Y.K^
M&2_.<25U(O_-WHU2&9\21X@^(2@5:G.-C, B4U*Z(8I/=L'U#$G37!U;KN-:
MY"WM]M_.F,$2C:.9:Y^J^67I"'492JG-K%WP6%H_\SP(Z!FRI)T"MM#CX&?C
M/2?HF5AE<I+_[JR+M3".A'J+"+G$6*RU.LK6 05[(#U#BK14PA:2B$'SA"[C
M O_GLE+Z:XW"/"3+9\='-<W1Z0*W58;-[;&^<\5;BRC)ZA0VY=J6.X+7N@ :
M)51FK.CV<;L[L!Q\U7;[<Z]B] B_S1$].",%J) 81"<4R"QB$8IV-M4ZNG$;
MCM%R85KH^=ZEV:&"/9D$ESL3V?0(X)BX2,6#5#*0]YYH>W.)O'?%<RI!Z"):
M-TC; >5HX:\'JW@/9QXCZB&2%N[#VD1\=P V5.[*+E!'RF-IH;K]=#A [J,2
MPY"EHY,3H+6E55!$;4%OR:020>9B7;&I=3;\R(38E^4R*A_ZB'MX'JP#WV3!
M(K7*8 ,9O,I:"<$K"<:BYD+33MB\?L]6($=P.-HHZF'U/T+*#</(%O/EV>M:
M P'G%V&^_%8+A:P(+ICD3!1)YQ]CY$=%!CX3'F%X]#)JY;K5P: !;FB<OONN
M[5UC/WD[H(E0&P;^5#SD-5_6"@@+O.[9>Q?BFMM=0/8Q!O8PH#.P<0V"-CJ<
MC:6 AJ=!/[ .HT>6-"@>."AO/<2@' C/;$DL^_*],_C39<D.*^&().DC]];A
MI7_,OA*:R6)]=!F'A?& $%&E6HJ3OBK<0V:^)@,:9/K.-<J.Q]3;GSO>>3^@
MY&=MQ-8Z</Q#F./%,GS\C/-P@9?+25J\F:8UL*1TL<@0I/5DVRH5:8+9@XXA
M1-*9,FGO'>+>49Z==IN)= ##OEJN;\NK^3Q,/ZTF?Y6CGPE-40RD)OM&<<=K
MU2L)Z%PLQ21+OV]LV&\%\N3MO79B'J!=SPTX->COC]DT?/_)1_IJ$5*5]F9;
MZ@)WJ +!_: >YX:H@9+O!CV,H*$AZBWVA)WH5,LR6##>%UI94M9FM ZTXRF6
MG'31K?LCG@2A]MPP'9]/?10SE"GY>G9.OYK-KS+$-V?T&F"4"8VL[<N505 "
M!42I,W G4Q%6.\&Z&21=1CM"(<TA];7- &TF[(',T@?QE=IR.!@#67JL![0%
M)S."#;96_C<8G.ICG;Y0+K06=>L+B#KGJTH1&16J&$ S-'6&II8V3Y"R126-
MY2B:7#!L!GSRUNCCQ=<P!>@:Q"9[O@.,EI>*WX<>_]KPD<*_J[X#)#?$8MR4
M?S?>(2=*QU +NVDOP!7A(!7&F9/D'<M.X0+'5N #-WIM]=='8(WU]CM)ZLOE
MEPT0SG512H )2$!DHJ.")@%2*-K>I;-,M]A(;PTZ\BW/8\4^:R&SQJ]ROX>_
M;P#A)7-1FRV*(&K>.,\0K1$$!)-3PBHI.H5R[5/>S4&?H/(>+;/6?LV[^2PA
MYL55!?J;-M8- ^\LJ9*MB +0UR96B;R\&$2MJ5>\]BR5Y+K5Y.@TW-$?T'\[
M*")O(+FV]F'>7?6]?8\))U^K$?=FNA/HGQ>SZ<<P_X3+/V9?)M-U!J[-3M,D
M(=M00TN,JLFWBLA?._DDEGSLEIMV*))GP9<QM='\<N2RBNMMN8685L"G>:B1
M[IESE8J$(+FOQHF^>F/,D@>G>90^=:M"^^ PSX$$[>38NAK+C4R4WR?GN%C.
MIKBF[.*L/@HY- 6T570*9E]3&0RA\S%E-+J(8CLI^*%1GH-^FTFQ==F4#^'\
M.EOZ/K* /&&A#25I3?9)Y#1?C!J4\2RJK$N(W?3[X##/0<'MY+CSBN.163DK
M62TP_>]/LZ__!U.^RFYY,\V3KY-\&<X7;Z?GWVX/OBT)YY:Q?O/CKFQUDM:U
MF7[WLWMEY3P"[H%).#1(S>J],<3OM^C3>_X[/_"0A?HJX^P;OCV__.=L>;GI
M=*<U%Y@5)S8QVCD\IYVCT%<R\VA1"B=\-^M\VZ>/MRSW:>#62CM8$*U/R->?
MYQ-:[A>?<?YJ^N]P3@M_TVY.LER"1- B("WVZ E?(IM?1Y$L+X8GUTD].X<X
M41VU$4GKL^[G,)W@^:L+/-\\4WNAM4P<A)02%,L&(KE?8&3)0G)#3K[L9K[<
M^>035<M! FAX];X"\__"%US\1_@R.5]>=^YT7**/F,%J%*"<9Q 3(T/7Y53+
M*?C<\;9ARX>?J$X.%4/#"E<K/+^'R_GL5R2G<S[9W%))JQ4Q!% ILEE4<4"+
ME= Y9Z)3QIC0K;3B_<\^4:4<*(36Y:?>A=K3])]O?YI/\/K$\^3H>]H^"V..
M3$H=@'C"P#%R#[U.1?!NI:6V?/B):N50,;2N[/37)-%O)^&O\,])S<O?O$D7
MAMQ+ 9JG:HN("#$F#>BDM0ZK']&MJ.3VSS]1Y3001L,"2BM(_SDY/Y^$+_\9
M<J:O-@:(Y5)Z8T FPXDP-2..'&VPP7D;;?%,=(O4V?;I)ZJ;@P6QLT)14Y_T
MXSS4$EPW+SR;^Z:WQO@^1 ,7M1/Z-J[JEJ':N*R[/[C9\;4JF[7X"Q>U/LJK
M:?YP&?\;T_+CK#:Z_3A[7>N3;][8HBH<ZQN)1&*HB@9<\ :$2&BU\,[(CF]/
MCP,P^FK>J]?=Q^% 8FW^Z'@3\]OEYW63Z\5/6'NRS<[S!J--0L80@/MZ82:8
M!J\-^?/DT"?CHB4'I;_J=P_XE%3=2&P[KT%V[.GK']?_Q+# __N__C]02P,$
M%     @ N8%Y6_MZ0&360@( O6$" !0   !A<G=R+3(P,C4P.3,P7V<Q+FIP
M9^R[=U04;[,N.N0H.:=!LI($21)F!"2+""@YJ(@D <E#&@0DAR%($ 140%22
M9(E#1@F2<Y@ DL,,(K0P#)??M\_=]WY[[;7N/6>M\\]=MZ;KGWFKNZNZJMYZ
MGK6Z+^8NT" F0UT#71 )"0DH[?('NE@$:8/(2$G_.2Z%_/*@H*:@(">GH*6B
MHJ2FIZ6GIZ.EH[O"P,)TA8&9@8Z.B8.)F96-G9V=GI&3BX.-BX6-G>V?BY"0
M79Y#3D%#04'#=H7N"MO_M%QT@IBI23K).\E(A$"DS"1DS"07O2 P"$1"0?(O
M ?T/(2&]])&2BIJ&EN[2H($)1$I"1D9*3O:/UY>KX9?K(')F"I:K<IJ4K*:/
MJ81\V.0CT]]3"VO5=+&;C>-$;C[QC:*AY>#DXN81%1.7N'9=05%)6>66JO8=
M'5T]?0-#\P</+2RMK&V<GCH_<W%U<_?S#P@,@@6'1+^*B8V+3TC,R'R=E9V3
M^R;O0W%)Z<>R3Y^_U-;5-S0V?6MNZ>[I[>L?^/YC<&)R:GIF=FY^ 8-=7?NU
MOK&YM8T__'WTY_@$^'OZ3UPD(#*2_U/^V[B8+^,B)2<G(Z?Z)RX2TJ!_#)C)
M*:[*4;)HFE(]]F$5DH^D9M-*?U_312-\TPS'_L1WG)9#1 $CBO\GM']%]O\N
ML*C_I<C^,[#_*ZX%$#T9R67RR)A!4-"Y^8=$"=!_:EO$0%$#-++M2H!T;FN.
M34<R!COY0/7S3VH9?8?EA"IFI%<*F<\B9NA0S:N A*C;GFBM"ZD/QA@L[A-V
M@Z=O\HF*#UU/O !%K(4KZX0-7("NC+^[ (TUA5_^-4N0N #%;HY%;-IV7("0
M.T3VIF,.IPL0!,E.?.:X\$WV[U\ >@AY^Z'#Z=_MV")Z_%VA1]*H"-2?"Q M
M]&L=^.\?H/HWXYX=)X%  /\%WS-UE+L _;L5ID4!?,IQ@#PXO0#%@.>L$813
M@N7?N.,J.B(<SDA E$E4YUZ _MT*M\S#>$X7A#HYC^A&[$H-$,/ADH2>,TN*
M"Q 42D74FWQM.1SQ;T: 5PH5,:;UX(R(Q.C]9SB/S\NC+D!%1=$7(.&M0<EU
MZ+^9$91U+Q>TED_.+T".N.(SNDO?BQPOG]H-XG17Q.AHUP4H_>@7^V_P?S$D
M\A9K7H#>>YT1+T#5@.EYS*7_H]5]$;D1[FCDQ@;Z O3]U#?Q+^*_V/W7)!"[
MAR,V9K'(86C#"\??OW&7N;KU_Y@KMHC'SZ"_=_".Z^#_/U/_FS)EAE@LOCT*
MX>T8J-\V.2P]C_OGK+*3__OC,QYWD$5'+ QU=LBWI$ZX;8Q5E:@]#&!_F%QT
M,I4&15M5NU@PO'\=:R9/?8O<\DU\]VSW4'8;G^,;E&[[]9V\UYE:XSKL@UYL
MICJ@_^^J@R=6-K5%INB+0?&F4DZ'W"QK7.VXTV\.X0N0L>C9Y[\9&I(A#ZY;
MAM6O1DQ.'_U]\Z"<UO!WH(98QY/SKQ %>\"+.HR_V$ZQ?7K)(> (G\']1"0F
M66#QJ\%QYZ9QR'5W)!=!,[MIO$T9X\J[GZ*%-6I^><*,B: ]9(P'UWHCX(*P
MV!/'J3:C#R:?EO:6TGND# X_W:>RHY>H?C^X^?@KD&7.;:9D*XERR+>'BR,0
MY0X-5/0*_"A;6Y/"LA^]&;[WC-FW!>3.\R!7 9EKXM_&%DWK[V;ZE"(+0?R#
MB%S&[K:V**[/Y#=4!).9PJ_ RW3;I>X$?_IA$*Q61&:68BB;76(#?ZS#9JF9
M9JK#!OI?55+-[^C9F0M0S6R_1^OB1QRD^L7DIY222>>T7SFN0SI%=YWC/E+O
M@_X*M5Z 7EK*NN$SN^5U]9T^Z0AH[H[4$Y,]?HS<&.M[?%W+X^G"H>O1#?9?
M<;U:IMN[Y]RGYI?.8?6V2738[I/HO+#Q'D#%VHS&4T8_QC-VS[;,O^Y4F%/,
M#_HF3Q95:!6^&+G*-6*'+^LW(0E31D8-]14JXDYBO<41/Q-1EM-7&S+N_.#-
M>OI(_[NP\,1+-1[)F*)59(^'(YTM+-L[7H KJ:?I9D,%3]WV,7;&^J5(?^W!
M@M6C7YJC[#7H@_@.-B#.0W0TILVX&,A8N1F78]"1N&6Y;9HJ0?;A0]M)+[@>
MVCU*XZ%LH]N$%^X.@92[+LI(>?\I=WT6\Y6!G[O+/(J!^L#VY +$HBY>VO=N
M*!3K*3"A$3ZA<76C(X'RW3")*8GTV83V-1*_MP@;T.9FA0D;;+6G@]J($\_1
M_M'5(/Q%8W;E9_L!+_$W';MN;2G#H1+K=01OO&,7](K >)@]]IRQ>R^0:S'%
MR31V:IB3MS$X6=E)6&4K_3:_/?O/(3QG=QJ@2; 43_!_A6L13&\H#N><ZUZ3
MN;O8Z"1"O_&Y<DAR,=SP)UVKP6ISP[<4YUB8E;Q^LGQ%R0M-<B8=D+&.ST)U
MOS?(%2YJPK#MH(+[%=NQ=GTKR*:">2DCA%'ZK5)XC4WA#7Q'$EKC6L 5]S^>
M@AF:](8D+GG:&<QL3VLZQ5-?LKP@42!IU?$MI /RW\/VW?;J_Y;&$JE[)ZSM
M>Y_DZAJ0=*K+KS$W&X!P+V!5B/M3TO[Y=/D[.[D5NY7%;F7?"KKUV-SEAX=A
M()"!^$L*D-6'\JW3F*KJLD5'JR6=8.< EE&*7@:!6TZ/:%N^HJ.H!5/?32>"
M)"H0-+ F/3PJ[GG#'BE1VD2_W>SXY,7&TY=R9KJW-33!,1YC_U%<[,,K!$-<
M?\'JN5H7I^I(/41R2EH$V3"16Z1DQ819XW,"1:-JCMXQY"5*O"--O)[:4.6V
MPCLI/M7@<>9YTR2:TK;UAX5$,7D,[YMX,I'(T4J0PX?,2NG_9L>Q0_8B$CHX
M 6V,41$K;, Z6G.L<EDX^W1-[H[+HR^0^R8BD1,O51.O2W@]^=:8BKU%IBE$
MPW[&+BQ(?#@2I@I\QH"3\A1_5J)13%8 XEYC2\:@1Q*W<H6?F/+5$VZJ)29=
M3<J7JE\D/E5Y/:YKRL9B'T11OV[+^-[UD(T^PP -4ALCK[=41J,2("Q  OMP
M(3M>-P5KM><X5%"?!%2],MY<L>4#5^I0]3E2+,.Z36AZL'NTWFP#!:?7W>_G
M]PV(WXA=N:'QB>SSA^9JKC C'*)G\IFZ.;: M^<9GM#ZN-R=V>;OR&:ATY6!
M+<N&"Q#GI@,;CM!RW%#I=JH;QU+>41KNG[9XO8;$(#W^/HT@6:&O!)E#XEH;
M*]ZO$\6RT1+=#9$;"S-5_%*^I%>\?7]9X;H!Z&M*ZIB^RFBI&A;<9T)#D/@Z
MZ1UF6[FX&=B2=13B6=*D5J,X_/)U\B,!?0O")[+R_T"G_>-M+N]@2>;3]<N2
MMI-_I+7UT[0_+=C8B]3.?]>\ZOQ0Y+V*NI(J#VC^0W/[3:S)JX9J^F48P@2O
MBPC%[%@$?)NN/,"&6AF&XPYC%TI#U_ 6;:*KCHRP,WU[RQ[5_7PLO]S;?EG_
M\F_[CZ54JXY$GH8\>ZGTJ<JC'\5"$,;-+"RL]G5(C!/DO/W7541G9+$-UE;T
M6>;"('T^M,6=" $BCS$F.,P(W NF0\8];N8P<Q^JL,U_\+8*PYP#'UOCV_OI
M<YO_%_LP<!,;%$T4UI,J9,,[)&&?)IT[N?&\LK2%KAS.K>(KP:Q ]1W<O21(
M#9;?84!KPO/X[^Q"UJ!MEX ^F5\SZ&D:I8GY;9[ZAZ%T9YX6_2O'@UC)5K7<
M&5<OP1?XP<ONKE 1C*(6KG+O^^_*5 K)1Z @5S+[@0WE6FV?S>\^'NZ+R_\B
M*=_P:?4@5E?@;< [ANU_-<,_^AWOF.0?0;:9L</SAV#S[ U;^IV3FR[N;1E2
M/JDD9S^WBY=FVD%L%GJO"+;%P$[/<<MZ= 1'6<FR-].R=D%US3PO-P@WV(.K
M# %)?/BRW5):E?#1P5UY4KHAJT361WWTQ"F%K4[N&,1ZF^-3E:0^,(Y.">UM
M <?57X"8YY<];%;26HX+GL8T+<TI*?UL"Y\L))SYV%=>WA":H&Y?#&A)0XR?
M$27)IV0?3WK>;3[?&ZYLE.BGLE"GG?O'=UQ14GT$ORM'R\J_G%K*^6^<2OP/
MK?"^ @SHX$.WAXJWF1T;,R/$<L*$1O=EBFD=Q+YODWU>G6ET!?T;2?HO^FFC
M4,U*),^-0\+)[$#X[?5/W"*%G;09;4G8D;Z!7D;VK:(K_G_S>(WBB:AJ$^8>
MT5P5*\W=IUZ0Z+'9>P*(IL^#R]E[QT9!1/N56/8O9Q)^HD&U]O.%LR&C>W1!
M"C;AR_W1N'5N>N]@JA\!%4PONAAQVE,NG\^IRF&.W3;0J*/<^F56D^A[M<D^
M?)+)118:5F=O\Y!E6\<+QC'M66]I/-V\N1(EG+@>W+\!8G]27YT0P%GWL?E1
MHV/Y/H&X(W3M_EK8[QGOH%.9H=.0W!4Y?. ;M.,5QYV6-J).S-O0Y9=#<IOL
M>H'B($9SAW#<Y*I89160X"_+M0G%)6W;O!:[ .EJG66O+U;U:WPTC1K:#*&W
MY,8[];84)<%EY[:4!-BGU.W?P8PS]D]_=NM//VT/6*;.# :]<O#9=@<G$@7Q
M<;V.C#WLR.YJIJV\E2+5E:V\W.9&L84 =0&PJ/YWP0#*]A NZE"5[@^6>>U+
M&;^0/<41RA]'C4U4JV3L#E_SUOLWY*\?5'88C88SENQ\)\H11U;X@,\>BE-R
M>L6P)#>Y;:6MR*N[HJ8G TC3G856DU@'I20L.-(_!:[ K+$$[8@C!AN65"0
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M-9:]UXA20-T E+)#9@BW8L(]P -+,LGK\W+*&E>B>>(TJ$2S24*>P>4"(MM
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MVAK5">\F,+'33'$O%P;DY9[]9#A08$[-52")Q)M@+9-YL6(YN%7,<F&VND'
MQXZ:B$J/#WIU$[N]A6;*6=P6>9:9+QXL15/W-AG^JH]( '.V7<6/=L$I\,,0
MSJEZ?O=1TQ8!T?%'>7.#8[K)5SV"12)$<P*#O .<H=V:53W8ZF[I"#M\=N;J
M* F0N-@#5YY\OC9IYQX8NV,R5;'<6ZC3ZSZXZI$R)'3#633N:GD.[J +G!!2
MW8^@";N#/T@Y2KF[V9AS'-VS()8OVI LY*^#XL[0"_(U7W=1Z2>-_"'(3A!=
M/4A&\2A\(GBBD<"=,&7T8D[0^-$HDXW=DL-V]G:?A5MIZAU;4['EP?>B5ZU8
M,_N"1[L8XWDV8N#@K3H[U\9LU>QV?.;]244Z.M11M/.&W9)"E#(YZ?9]BC G
MJC+%+1[E+I,D,)VG* [9X\T/"YSMK)1".#'&'P57'=1;+0]Q>2Z+Z>0I2@72
MZ#YX['N[6K89)Q5!;H[1Z_&T[4^#M?;GY?0Q @:O(5/(YH:T90/1WG2R\> E
M-#E59"H%*)P?YX$5^[QZKH=5YWD;.%X6UV;I]\'ZO( V.TI%>LWLK[CL&UN1
M1TY\ELE \7$!$%FV^?7'N\T0W;J*)8)Y&TZQX74?.F7/U.5P>6TIL#9WNJ 3
M>KV14\32KY(@!&2B+T!\L'P[P!I;Q&CM1KS6;+MG9("_EZ\X:&L?GR'VK1'F
MK/MW0F&9=\W9E_H'NT#!F;R=ZP*X9TBE33= 6EL+_ZI0=B9 ;4ZIH\Q/*DCK
MR:>XY]:A:0]\V<WY"EU!XX1P/!1STN=(!;A@10=B%<\E^Z4#O)TC,#O7=DLF
M]S&15>3R(K5#&\)Z?+DO[D>]K58TT<(?]!VDS,Q"1( (/XPL+4S.JZQI M7+
MP<EY$E*K+7QG\D:J:_:*DK\G<H>KBBLR37(<+D10:,%7IQ)Y=L8<M3T88Q0]
M4G1A3[5&7M1:FWBQZZLS/;N2.<?L$.Z$<\(BNM_(*A3%P&5Q:PY76EKR]J^(
M]^79S<J[22NDB"1X2LD/M&CL[WX65/-+Z?4'K4$]N(EB0-*Q8^+ZL09C5TNO
M366R3?NK=*4RMC5WBRWR[,.*]"RMKJ<]GSW+'M,&5W^X5[3*"%BBG'AF,M0]
MCHV+%LJ,,W>AKL0+T'S;WAET_K<?<?I%X0T 7 64H\UA F?]YCLMNTV-34T\
MQ'*O\O7ZH/%EU?CBSCO=;#K<"TIK;UG"4U]"9,X+($*P(8SL;C'&V@M9VV9?
M"41;A?-V+SPLK9L36C(*\/FV-#AAD#O[-"/[(;G0'DD"9?M-<_P%J \5S=DB
M4XEGB* !BKI:4M][ESG:P4(&L?T;>AE8G41N.:G:I/BP@0=.AS?HN:Z!(H,,
MSG/73%Y"^'#\J'B'H5X!,-+3U@C/D4\]4HINSG8M8>[0_L3R^JD7MW4<]W<$
MD>V@]R"!YR/"&V_2M\+?@JO*#&=X?YZ.\93Q>#;]+":ZVZLDS^U&DE!%K$HG
M_6UR]*.7(8@^D_AL,$T'/RRZ[_3M3;OY+8Y*WYGC'OGA918%\,JSZ\5+L[$$
MK:+C:,<8R/69/TG>%/8V=JY-NJM="_Y!=,&>O+?GK0X6M#(&BVMBV%-O/^ZJ
M#@7BT!KBV(C(/TB:G1KU!=UJ]^,<.M;7:9*,;<F0G6M=5#6@V3A8-'IVH)H5
M)FN*DS[H"R?QITOBEC*)?S?VU-X7JY1<)2+F1%I#=45(+/0E#9H4'(5D$L.=
M-W4B&=HXA U;@&>*DOE;5Z&NR8M]3]DD-U[U5NEW_2";:&L<.CXJZK<8Z,US
M[ ._*F29+'D6"J8!$JW7D'E,^MI^_AE?%O57"Y+8\N5)I/P<;P/*Z"NHN 9D
M;%!02TK!K^J8,&[QF*J]&0[2K65/S71?F,E1X-][)L,:DH43<!J" Q!>TG?9
MJ63 28\%D39:SNTD;SU&=*6ZU'9C+5;).OO:*Z=?NNDWDRF7D],8(< JGJJW
MB+^#E<",1T8JA@MK3C1XL[O=67!?\%MI"T*ZS[W2S]3E45GF8Z(ZH*1VKBYO
M,(*R&*&;I>O/3>XUX4WK'QCKAHIGC-EY<J=UBM";WU)3'T:O!H5@PSQQ7F>]
M*XPXC@1PO%AK44_(_IMR.W>;K[_%.VRME2'82+U<XCL0S9;#Y]M@3OA/)+.Z
M,R[SV!37-JMG@ ]LJMYA+(;9&M8WAI)SRB\O>9W=K11YDV)H<,WYOI;,&!=Z
M]J-[(11HQ3WYK3M-O#J*@;("RO>GI(]VSA",UG962YNC/D)];-^RK75ZA?0>
M.)TUDD13"#+);$'K>,LZP8PPAM^]LL[5FYQ[Y6Z%0I./>2L.*(;K=(3Z_]*_
M,S1-_^8LI?+SC@OZ7_5:>%FO1GU$_E;<Q\S0?]5K^/7+>OWX/^I5Z</W\JNI
M-\B82%2X!/F#]F3QDI8 %'>SKT-NS%,0.7V4[Y^W,//+(/69_(?G*H*'7)&C
M5.R_BM@B7".X""2XPDA&1 ""PA:&[&LZU"L;>2%6.Z%@ZQ]O(+L@ZL:_STVS
MT'H'[J2:+/BC^BFPA\/N8%'=!:'=@98U;K.JB=V?_50Y[\S+Z_N2D*]=!:<\
M!+IPA3M8^D+P3#V_*\RO'\+W+6/5<*JDD?,&LU"PGZ:Z2 I>_QL5A16[!97D
M=ZI+P'9>(S0-D0 BND*:>F5!!#T3IK8TZVT!>FM/+VD9#J4TD>-1J>:$+"Z:
MA\!S4N0-Q3E8$):J[P*48KH,*^HT@QGU0&A3#[&+=TV8YI<<['?HZ%-8[_9?
M<^(8K^O'J*0G8N*Y25N*XHB40*EXLG3# 1@8TE$*-#7@$^#'I>8=-_JUT@?/
MLMP]-+AJ6O"I](' O7MR(]9AG$ QKF/5=**#$S;4,]-!CVPK/.:_V<?S8-;/
M=?3F&U%;:Z$W9/U/@P(,2!;?DNK=9I0%M/'0/@C5N+IV$"3=K71']0+4C]JU
M-^MW4:8A]ZML&7P2L-@:0Y^LIR7?C.U(  ;PK ]P#)6XF47CU 5]@@[VDX)M
MSXN8Q,[C6?F,7.$K+6QK:T[JEGDPQV.#&84+4 S\&FZF9O7''T96=P$9;RXW
MXG4C159;!\H8;-"K@F2R7DW-F+E%7;D\U%@',T$?'Y&J?K,ZS!QO$E?]/$S:
M]V3A62;&7LG#=5]FV(3I6W-P:: :B]Y"0F3.#W'0?0HC,#C,$A@/K7 ',WBI
M2V,<J;864OKS/3X!L?WA6AL6&2NZB6X<$K]B'L<-6SY\\G/D:R-(Z!WP_LP
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M#CA^&C\="?-DMA+MBPP&_>RBW.PE"5*[RK^F@;Y?M78-(>G!=8>DB!PF\7?
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M$C<;WV_#^4$D39G<,%&DSM;H@\G,$^Z.X)5=&[F4XZ"V[2-W?VF1\CB8Y0V
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M88GLH[J;PQU7:F*\)5IUR+)SW)8,.JZ&$9G_,OQ30;N<<G9P4L63C:X+,P$
MYS).+K[HF7<[NY1:<"_0=>@4CTQS3/9,Y$VA''[5^<8[<>+#A.?&G6M6ZR 1
M-$5 2(T_53G2X+(ST=)B[HUQI6^PY\,T$ZM3F /W;FY%,]Q%X7=NW: 4W/&J
MI? ^_1A("/ZCD?1W8MP8&PW4\8WZR^_*()GC6Y(YE%+6M.C <&: B_=.]2#^
M%8:!K)8KXVP,J;PI+?.W1Q)MTX:KT<M^#%*X9H90R827R49_H0"7-.>\FZOD
MB_O<T$J4YIE45HAV&MP@#Y*;S0>B\Z/.DBG,=*_M5YRQXA;:$U?(A@JBRWE5
MBO^TG&C?D#ZX_F3:=ZXW31=L:3A7V$;?\=COU=*HY^N[,>QADE;4 US),K*A
M)-5*IACZH6S^#WP+=14N8[<3Y$B08*XKC^*U/B0 I]8!ME,, 0$UO9%2!K94
M/1^HDNVH(C!*E&4Z;O%NOWK\"A,H.RV]'>Q)!)1=+M;99GP-N94%3PV:.F>V
M3K#FP#M=0COUSNB(-V#!$L]^HZ2,0O9X8=<__;_"'!WEB3@C6)%(' *]#Z%9
M_R..NQB4 &7JGECM556M?(UYK?U;C//J!V![V^,1867++Y]+$?T+H]:&EO 7
MW;3Q517(UYD>81%4_V/44\]R3.7!:$B?3(@8A&$%QS.8 BW\W DRVGLA@K"?
M^]O_G]9 +W'YFU>,LRB+Z%O'8H/4UU;N6NW3:N<[O&5PEY4DV$E3HYY.DZ^H
M#A'"";Q$@T?CJ_&VA=8XDV7S\H7-.;O 1V&7PV64#9ZI.7EG!-W@HCVL1<91
M,<0>3%P8P,-D:C14)8P@(.4(&P<3?<C[(E<;.LQ%BJ?<"GXW:XIA"E=2K7-=
M@%XJ8\M+^SV5Y.39..8:-T_[ZZAPAI@M"]PR6J=?A7NZAP<J,6C-NFIR_=#E
MEX!.8GDJXR]:1\Y7)V(93?("2E2@]2XP1FA E5+X;3?&+TX*0@[77^')-^N-
M^\71??]['_U9 :5E-XEA;^=L;:W/I65\KCS<X'%II#DJIU#C5YI$1+%$FG@_
M3V%IY_39P97^H%%[?4O;G+#25*.U 1FLY7(1]-=-V]0+[9F01.EQ Z##&X96
MX46O5]%,B7CIPEB^CV9=6M_N=LTF$&M12#0*IBW#J8Y*J,[;D:IQ>11H!]-;
ML3,Y!SR8[2H,@$<54K:U2MRQW^B.6NLWJU!6DYM\=$>5!O\ S14?I FN ^61
MH;%-M9;V8W/GE(+WCNQ'#1L5&)E1X<,^LK<%,SC4+MC;#NP9^,8*;C5.!LO<
M601]7DJHW=G<8F%_#2''M6IB>A*IZA!K[P9M9LIN *^#RZQ*A\3.;C/)9(,
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M)61'9WXL)QLZ,R$1F<ST1T96)CM(MG51<ET+3)-X4A2DB$_MK(KDW?HHH5M
M%<5!_[QU_LC7K%JD>%ZT*.G>L3$#O0$KXZ,$W+A@EA>!W&U&R!;Q,508?]4S
M5W,H4C 'B0#Y^K$+-JZ2]M-&>TBL:#YAV4M/:K8<Z!&;[O(N&JR&>EO,GE_Q
MN\4<P\9+VCY@%JDBPO\N?L7KX6*WJI)C7N"H$3T9)1PV(M*^P3I6&,%)GTM=
M"^VD1ZG<@C,_=WCEJ H9O+S;[A#,#:)5$1,M=17[]3B205K7[$\0!M2^,_9
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MRAX_]+K= @0G-FH'4-Y3!4RFX(VQ9COEGN>/[,^<OO%^RA^Y!)2OFO"JCDR
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MV1.OX[0UC2.N.1F"]U)F]22L8IQFKG0&/UN5>J,=F"\R>0D83S]"* %LOB*
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M"IRR4#*W!8$QW1$(OY?/AZ$J>?9GZ5\()A>)T3NNFK8+<XF,X8JMBX$C-1N
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M_>3%#]/3%IMI;<_ZYTLMLNR2C!!K_J,PB V'ZV!"0I,\J>22O1^LW4@EXO#
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M(TWYB'30*N@N]+ > (U8!N]V!_C6(157HKS++"RLQ;/N5UEK][RC$[(1;'4
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M?NL8=!M]I6FL=<)#8?96:\(Q>"[TJ]G@6C=C:"-CPJ7NMYZJI_(UGHNA?HW
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MAMK] !^$#J!G&L8(5K+"<!='^2@]<,A,@#LFUNXT!GB++:DE9'';"32=2?I
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M;D#66SK;DE, ?8NP;4W1*(2^_4]-T:TQEK6)I7G.F<BT/U#R$X[^S("R^1A
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MU8&@F\F!3K)B"=9O'@M,7 <.M/(^9QM;:52X2!V$L4+=<%^:3)!D>O3; 90
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M+-LVDH(W^#JPN=@+N]^J:M:8 6N$SV#FTB#M 0?L@  '$:MPVT^#9YH&'YW
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M4P!0F /U+]!/_*?7\$B7P+D@V=UHWF+5F4\2&>4V'6K&,F^O'91P5Q'!,:>
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M]BES.ZPH;74M*(!GRY[6;X=^#!X,YB6.M7"W$/<8J0*Q%^ULIDU5T^^?N?5
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MKO3%WGDIQM'M R:D*DDJLD42$C.)<V@K=M>[']@LT97)E=[_ZIDN8QZ#N6W
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M5)]Y-;A?>\;@W2?\93\^>:/-4._KJ8"C[)A#&:QE!]X=Y8&:9KHSJ67ZYA3
M'!R6XY+B-V%9:U7Y@^V\2H6T8S7=TJ?]?G<RC'I>_U@;DM)]#NL& K;65OPC
M%K.-^W^$' IF^*B]1K]>=)6.X0S[K6V95NJUX#D8 Y65<NM#6_ U8NX-Z\,7
M)E%/:Y-]*^5"6P*SD^ 13 Q+[&9G 8%XGD7JN9-2'5[R =:^E@@$$[4LYEF&
MRY8JFL:KF3/G51+.7.!6/%NY(F:7M2U%?Z4>\1Y8.]FZ$R^J"&^?YR,FZC1>
MYZZI0E4G#\UQGNLPT*>+ISOT^?3;G&EHS+(?P8E:^'8*H*>93^O(%"5*Q124
M3^RQY%8VE@OZ[D@8M2+F\/=%=(436G_N\ZR]/<#?)*#1#LPE+5*N.HH_PMK4
M?B)="I?AT^<&).( \X-)3\S9T"X_^=4!^^=ET%0&ZC2,&>2,MPZ2:!.5B=]]
M'"[X(-_>IL?M-;%,>:U">IXQ@(;HSK=\G0XQ5![RU86T4P ON=?B@\'0%D$R
M4]_II9_ZPSOFC^?@=+I70C0V9!8Q\;!JJ3 =Q>!>426B5 A5UA7$80 /=/&$
ME:)S;87FM*??G%$+8Q&[X#O;#,_7!YX+II5VSYF<KA;A,<I36!'D 9C F/9=
MTC(QP&+>A?,PQ=YR+NX+KV-\6AP@*%P?VNE"TZST2082ZDX+>0>,T[US..6G
MS6KUUU>/=V-90M.4$+@!#-3R*1%.^D4&$U@Z+6BEL#N:/>Z[G4M<L6YPKVQY
M+T VQRW[H^WG)]S>D/TL#G=:?<8ZX?4)O8M2Z#B3;GM!XJ.2%L&1WCB#C=T;
M73^_ST*7/YX)\Q3+9%Y/W1UDAK49HIPP0N05A?/K+=K1JN>6_\BM-E6ESD\$
MG -<ZUOC2X3T".!U@?_<<Y#^3;$I)WO1VBF_<8H)T>'A>),VMOG""'6SK< X
MI6?XF73<2K?8SX\_)+&,X"_^WMFU31RT!;*1V8@7NP6![ZO 0KE' Y7"+X<O
M5Z5*3QL*6 D:F!<KJ$^#[36(ND"C>_9<M(4ND*\3A+J26[B)\-A+Y9,O?S^O
MKJU-7MPJ^CT]RC\6U<8@+$IK$^S\VSBFA5HQ569)I:[!#.,.5J-[::11#_E_
M."X(/-*#AH?,YBJ*1S*IT*VK_,?%JD\X&&<;-NZ22<_#7X?G6&4.\CZ>C ,=
MEE,GRJY)BLH0*2-&:E;.NI*N;U71K,FG@)!X[3BO9T4#7.8%Q)ZI8'=*HB=!
MN?!*4DZC'.1!^TCGS8G];/DWO>\R VQ>X 79?V_#>C8V,LL+K\#S[!U^YN74
MA*^\8$KDO@@?J6N4)$;&R2XT)E)GT*EOVF6C1?XOKKX[&JXO;'=$BVC1NY%H
M2;1$C1X1+8(@>ID(HDP0!"-&KU&#A" ,T:+W7D8O$48?1IV1$'TF87+"X/I]
MW[KWCWO6.O^>O?9;GO=Y]C[[W=G_6BAU1\84:'OW+6_/] H__&!;=#P3L-*\
MU_0G)&K%Y._-Z@G4L_E*65WX[NF"^,;YT30E:D9.+O>XN^#*.%0EX)Z"SKM^
M<B!^\PTRAIL!H8[Q% BV/OKMZ<<A(Q\2&PY<B_F#??E!%)I[$XI@M,N#CRN9
MQ!NU@S^<?S@KD0N:^.RQE /IGO_GML-1T96YZN]'OU*D,#]ML_PHO??F/NP'
MESE_U"5+JH*5]B108!J;WVZFS0A)O8EW:$WQI:2H65$-LB@P/_)F&O#5&"QI
M,0@XG3&RRY&4,6VO^^,U*!5+O][QL[V![D2KWX'F1]_:LNC,))H:8@]+T&PA
MB"0$E-I^=2U]V':^O=>_S,O]3_)\R$/Z!#>Q[I&WJOUNN/5^S1@L4CSY2GV9
M7E Z"6QV#L$STG)HF'S<:!";,HH7S3-+%G(3\HU^Q"4>#"H[>%.Q*RSA[>A[
M);E*2#P_1,AB[.MH17%!_TNS+_%W'OV_!4NS_L*UZHSVU(9/;GOGEFT+_NQ'
MXZ;E'YQY?,5L/>1:C;6LNF8\C]!:G4W9<Y\]C66=:1F-LUEM#(J_L,7/&FOI
M4K(:/Z!D-:NPDR:>R*=A)H+B9K'9M\9 P81G7W[LL[UN(MZ9,C&@:/X=Z*LE
M)!WJHW4G5-#4G=OL(/VF3K";ZN?DCH\NB04..S*89"NKCE?*TE6LS^8S?-<F
M:FTTA ?&<^L&BC^=7TDSZ+AQ?<IB[PV?OFEWVK?Y/EQ0ZY]N"LVV>VC!E@VS
MZBK1NK:TU4V.")Q,$^Z]PX<3IF?;XSI9I0Z+F!^7H?X@XO_VN&E7CPW]K?3K
M G1\S'$>TS3Q_RW)MM<B#EDO0 -(63OUI+>%.^U.D\4#TEHW8Y-F*VX?,%*8
M_JI92ZE2LS[+O@"MYZDSJK\$QV=O)7<JAU9 UNS[A9MRJTCQ+VICM.EV.AY(
MAIB1Y;RG+A/I+OX2#P(:B)YX!F0 (9;8WY0Q<0'2A%QW'V//*;-=TF/U\8K!
M4M3= ]TWZ?GINS3?#9D\!K.0[IUEJ%B<JNX@&QB:*F&KF.E_0F@)V2FYZ![Q
MB995F&W#E_62:;U[^10NY,<3\2#2=X >C[3(V?B[ERG?@N7Y.W.$B/FCY2=\
MGB6:[N)#.3_WOGY?CTJ;_/EO52VH_3+T E3_=]^9$&F-#KFZJ\[>B +;:7D7
M[EK3IZWI7=N@=[OU_!$TXYIORK'[ZW[.,[Z:S&[9T%Y5$CDA=/AM9J)$IP8.
M>07:7FM</H:UT]^;VN&TR_^66$DS;'(OC_1CDKH/<C6$'E:S<;CG2+@ /<2'
MQ/*G5I8.2.W?P.;H?;BA^]%JKS"T?4GF-U%$[IC-MU^='JYY^@!ZSHRG*BXF
M^3:TS'CBW"3E5,F?-#1.V:M0?A1>R'HF6$<1WN,8#OD*OM)- 5,G^@*A'NN'
ME)9ZSD6#8BA!U.T,Z+L<GJ)4E/E]\EH0"'2EZUJ8&D\M8%6Y"VE!#AL)&K3/
M>/AY@;0<'7!4]4[AGJOWW[?KM[B]9Q?:5UQ'#^5Q %X$6BPDXJ";:7>5'>CG
M+Y.M7T(5 RZ:,P='T+D P>\VF8EU=(JCHIR\R6M-1T^I-Y&#:XM; PBRQI3%
MCB%Y-;KY$#' %+O2-:N$B/'"Q0=K+WKR?$_Z;NRIXZI/^>T U ^^K\A^3@^U
M'AX,!6X%1)W?L"%QH=6X ,]06CN;A"HC@[NJ&V'K^O)333P Z[UE,[)?#\"%
MC4^IP\Y73^0+<.!%<IQ_;K&E[<[;Z*'/[^B+/TO(UH/59**U*-+#WC+,_:'>
M&\0G;Q ?GQ63^+S=UG?;5#@(RGW-&C4S!H'%DTUF[^AJ1T6F)X<%\S2O2^\B
MCEW^Y^M;HOV(Q9>'&Z712+=#^AVBPCG/7 D0Z5T)<[%H;TXCIY_VO+O\:.#*
MB-$W*]_?=</WJ]6)4 +C("3B M3 N"]6 XOL6Q7(Q-D75S?*XX=+GKQLZ\I6
MOUTM>!6I5,'NL_N;U!7(=I*I!0K1W4746NR+85&+_C.:*8,A7 A-_+\+4%0Y
MNC_#G\[O4;>9FZY>%$^V0ULF#_XUJW?\WW$I2P)X$(%!$6T)9VLQ?@D4.7W<
ML<0&6[??0QD*+V^S;7SX2$;S>F$E,>+>K,7JLZ?48V"\R5APJ-79AV,$ ^!E
M@)R34[_N+J_DDEYJHW)0ES6O\_(J#6VS-(V*C]C/0PPCT8KP)K0)$=M)AAV7
M)W1SPA_9,>\.I"]9*UL/O9D<$P@@=V?7[?=-^HY#FMS*9QROLEE72((;E9UC
MP-?@JB5VVVXXG@3Z (WV-/:("4*R</:*L,"-9?FAU[##,'KO$'4".*Y;,02%
M<=F[ .6'C"FMQ<*AK/+^TNX!&'>;[7:;@=%-V^*AJ;^U/GJ\NLLMA)#*J0?@
MW-6; ..&^O7S:0@KZ;:KU_A\ ?XE(\,2+ ,FI ]-F&.Z\7UAR+9L6>8]9][<
M'W#L.3\,M]1C#J$Z7KM*@G*4LK>T\V?E;X\7@W,DA"PD/Z?@&&S.J5>14-=\
MQ@FOA#4JDM&I @D":!!N=-)6D*!X]6B5&^"8DCHFX8F"DC$NCTRUIW252Y:2
MV-3?>3K?H//=Y+!J"(;E*9#UU2H$]8<DWC#7^'+F.<&PP8.O^"!_+S'F]LVK
M8/<TAI_B:O:&KZG1E_FQ,5>=2C =1#8@(T.=10!57+#ZP(GZ.V8;%)/M XO'
M^LZM::9W<WAT![HT>FG?Z]VO"0**\?J#%R!6=3<O3/JCR;T:<9X!_BLS>[+C
MACC1^/E-9TN:J"?:,QUNVKWK+'DQR(=?\QD'DVBQ6XE^:U1N8&HY) W<ZT_F
MMZ;N*8E&/KDW(Z\UW&ZVO>$B/Z1ZR6<(:?OKA;D 87\.]W<%]#,!D(= OIJ@
M:][UEJE&%*^KDCO$"KI$A:I=ZVNSY:>]MY'^\3D[\HEK/H/@>A(ZOB;D.DPI
ME&<;[V8O&2Q)7K9H<[/H-:K6\VFYKFWHF]>,Y,7PX=-;)/B4&AN<O7'ZOPO<
M8.F&,N[M1?,*)Y*1OF4:E>S(UG_]2X)[F8*.XAW>3;K*NL,8OU'X'<"CE"2(
METB);NS(R>D04_04UJNYED63'2CZZB/H]70M[YLK86KV]7CPNP(\,;S&'O;R
MKP:_,-#O@K.$J_[TRGG2X- 0W%>"Y6G3%(^\;YY)L24W!Z/%"8$;U"HVO.AA
M2_UJ@E9RZLSNW)L('#V/9OOL_O&G@V)I@9<M.O=0G#=%K*XD:A<Q7QV>_?"4
M>@1,OS'7J87_2RR>_8$7J5@?E5NJ&$N0X"?.C+6UTA<]JKBM-2)]F1%W,FZ\
M,_U#;@>):S0P-"(/^7Y/)!<VO;!K;;IZ<ZD-ZFPGB;4JYOP'>L&:,41#7E93
M?)D]V;'Q:*(?,$,0-2?X1U;;N_+?;6N<?:5B5+@MLP/EC%\4D)<I;E>I^^#D
MHME82&/S7@.5 W^(SZ@BR&@ 'S?,\/YEQ4#H8/9A=%7E4="NB/[8KWVIPC\U
M)2V@1O<=[(/7/&-1,J"[U$NS3ZGCX7J3PK-(=W"D4OB,<WO3S-%9X/A"6*?_
MM(K_MZCNNXD]K5P"B!R^'0G&OA\A&'X) EVV4WQI+[?S!Z6$!P_OG7HLC7*/
M)K(,.(7Y)K7MVV.U0+#AGA5I8C\.,:SH*7X@X5'=:> AUS#&<O,)<K$Y?B(J
M\>YR$;/,B.#7KU+7ED(P;XT_..[;D[7K^ZMB5!^2"X"CXD*O$7=^'%^ 8MGY
M!8!PK!&GZOAX<RGVU\%ZM, =P=9X+)N=, 7S@WN%=$P17;_(M\!1(3QS>__M
M&R'YY'*2[IS0\Q_V8YZ98Z*:)YK_M \R_-2[BAEX_N.*=^0VA N()3H2V'Y>
M@(; "2>0\(-C,"=, 9=X4M6<\W5[@K!K;9PNK9VJA#.CIKL6^1["=;]FP?T6
M.=:(?Q=3@CQUALL"B$( :JLD'DHGQ_.].TNID>55JU_+^U?_G"<X''Y\?NXC
MMID+70\="(U9JPOH1;U;99D\=@9R2MVM6Y&-L48?:[2ZB[>T!W'DH=_8[J4.
M9V6?A7\)4U<FT>!YS,]RU%W5%S7>[#/\WOP.6)]J$"A_YA9V/K5M;]R;48I@
MY=JZ+ZZS0JQI'^[WHF.\#HNT/1]L/I]'[PO6S4GB U9ZN>N+O% /^&(W["18
MR7I"^R*!P+-$V1K@4>-:+?U5P$GS)^(?%4NZV^>ML9$)&5OU 0DEM-%903?H
M5[L3+65W#E6#M,WP7X?FY%$!>U5R?>[XOV\W4OK%:-0D:@9H:B2W9K],);_S
M>/E3#>7%\D3XXZS'2M>W(1IQ;4%;LHD'2@;NW^R,=+H;8K!5(JT1NFEO3J<:
M;I/%MHJJ1\-[\0$;9C4]R.ALZGX("UR=X(%(5%%]V?YB.ULT]L#+H\D_18R8
M _U@2F,5)\TB5D#Y24$@_=B9E>S?(?8P.N3.G+J+470[=A)NAKU%DL&M^#Z=
M):EBC7G?-B/H_BIX%V6,"KVJ#U1[_L],SW4QWA_EC5_JM_8:,$K(8VR;(ND0
M2H<P_N$P3%%[:4+83.,25X:HEEWZ8K_X >YAL> &E-DFT0+#^I1Z-)3B>*E*
M<..S/2]>,G>#AY%R.??A[H ]#\$P14B^F[]5',6S:">][Z!2.3R:]/.)\OW%
M1/Z@'C4NM H8/T.$$ZK6HH\-/%%]^N4BQ05+2RRA[I)6J5*.S:]DD]BOWLEO
MU<OZP/O\K,+6:) QJEU]T$9"SJO:CU[4;+I:#5T"M58=;>FJ^U!F[KI&<?W;
MX_J[SL]?:^#"U/P )"%'!VC;\(I(P![201L6K&$[HVL#UD-)WB6#GIL\X3\&
M)(V%4A=\EBQ<S495Q6:0SEYTS>%>!//-8$D#M4-3(+)JI3&]YT70)Q*^3B^-
MS/E6(=3GWG0CB>=4J?\+T&]$,(J'>^"\XC"KF<A3"9*F."U5WD0QOVY^2_PM
M4E]QYG?GEV1Q%"^[0L+4KG4"!CB;M:ASECF!9H)S# (K%:<FV-E>AV\75VHT
M3[>WUV$;K_09ZGL0\6#I8=I4!^L6UW8(#P!] B00?'O1W.IQY[+ DN&D%,^S
MS&<$GR1E@[JL%V_,EE0_2T\<"-TR49.O$VX=#"[0 L%K\&.X)^ &N98X$L=&
M*"WLH]2:_:R?,I^OUF1UDW)PL&0U_YM0Z16PT[ING9)^"[_U^KX@3VA=A[M"
M ]QA[IB1VIV?BKLEJ;0[\O%LU8 ,9_8TFKF6RVY"XR5&E\Z2Y3WT%^86^1:-
M"F45;'@HM)&8]-)3]EVGIH.#<ZF[R= V4VIC _\/.+S7<OWCA%I34BG\;>WT
M^?5>_,X&%I+ F)0_-10/9V,(E['6Q4F)NJ^^.I5:3!']+AT\\7@K_N12V_R+
M7-?I.[/!7@(.DF$1^E0O*/@+7'Q&UDK.F^>3M5/'AU%F76T&^5*N"38]MKGS
M)>0U%4U" Q%"0$6IW-DZ]2>N*DJLK[+LB]PV,64P(H<]+%1Q2B38;U]2Q0<A
MDR'*\^=W0\:[^?#L":=2L,P^S'#TP9X@<G8BSD2,/>6'@T>3RJA*'P-LW>DS
M'MI]5A7""IQBA_>]JT@6R:CA@&YV])LQ:)"!48]U<'-!H,/-1ZE-G:E/2E^D
M%4?2N028CH"_REZR>(Z^M46=P5!6-7*2W_S1IT[O J!P6 GN_QH#PZQ.#^QH
MWS9Q2G>Z\9C=S'74C_QO:?IH#>]4"!^L8=B><[*;$1K"#JRK--!7':3)\LE+
MR,^X\13%8U-AU.\',P4^M]3L4UZF>3CAR\E_=!G_%$P] :?^"G<THH?+-L7C
M5CD=L\],;@LEU:1)7PW4X2)O3-2^9U]ZR@<X#B"9+D#NA_PDWPM0=$ 0OK17
M*2^!/\6M:.<N+33WL;?0*[3T0U OOQ7%!O7K7L=6] QS"(J;%=&8&,K-4/#U
M M2GQ1_YWQ5]=2O@1964NZ-('H7#T>'5(66+\J?4 Q>@E@M0F(H!]4!-)(*]
M\9#2B*#0;T_3T::$C*["_2D6NV770L/.\#M:9G*]W"4Q=?,"1*NB44%Z?@&*
MB(:K I%0O(T] ,4VX_>/Z[KF9-=NZ@\S/:9(?V7W54.9PWL4Y!L!.A.X1'\Q
M-1X2?:L7(%(Z-"(%I_;OENJ:/]B*N'T4R_'G5<9RWTAES@BYOSQA[&WV=F<
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M=4+)4M6L^3?(TW;QA[VIO_./7P3YLTVXAX )'%%-/%_A8MQCI>[?]?08V5G
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M(/I$=*@;Q^93><G]Y>0V/K&*>6H2))?CO'?\ M0D5AW#_/%.?&7M<K*<(%N
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MX([M;CGP>/XR*C !88ZGUVRWL7OY'W2_7KG207;U +2?'O^O3=T%Q06;(9H
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M=VL1;R![C<7**TC1Q_;-R*^HM8)-X6 SHK(K3<V*FYF@4 1A6?/>(B-7SV(
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M9-ADPK_J2@F<ZEMC[1A8_C<5\AK$*G[&Q?5.EHJO[S2T#D&I<AP:GRFVM#,
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M:[P:,=(RG1^CX#L?#;PNX/I\57_YX)1H-FMTT^,@?9B>X)U\R9=V'?-?*];
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M]A<_>=,)"CKSY NIK(MK;/?]@P+O[1^3O3/Z?0]XSYG:>25]6OU^_MI^J9W
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MAQ@O#< Q9^ISWME:MNC1JJ6K@>).-F?RX>2_0_&CC?>I?LK^F>5-VLAAD0N
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M1D15\*FKWSA,K==6PG-H<*6V=]/C($*%N())YB4.BZ8O?E2LI]:K:WD[.RK
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M/=!RC2ZR!H:\!C"4AAT5H/VB?=)T(F</*@LR<E!/O\>+/>W__II9BCPY Y!
M<=ZL-Z\Q0'B4:S19#6%$IW0SRTVRNWOT$^@;TW0-L3.MF?SV8 /WWQ5M.JR\
MB'NKHCUYM'XH>#1*CQ,Z\>E5N)_+*HWIRT9T<>I09*->5.+'=^^M.WO\)>X,
MECPN>?FBJI-9C=\8\-N-Y9+*$+W5!T38OTPT0M,T)Y*''!*6D!Y$BHMI)M('
MI'_3&6I2J3K?5 RP CU9OS"F8,?BH"RXYZA'P;31J%SJ'1N>2=N%#?/=YFA/
M#@=JXOR>GNY!-3;3WB/R;1O*5G1$%C+P05]ORYU.1N?968,A-\'W'=863XD_
M]X4F_=Q3 0I"K*]R.FG08UB5#HQ);+Y%SUHNW0XS8JDE-F;+U.UO9YO"7,<U
MP&SAZQWCYD51*_N8B\VY 3;K/RU749)4]M5"F:#ATLK0/V:L,8+AG\(%*XE.
MR;(KP98:&/+(]Q(T>B^;NB:$N2\EV@/[M=%:S**U^:O5 %2Y,YQDHI&.:6_Y
M06,SC]EL_VW_CX=F7Y&Z2>IMEV5M]HV>Z?;3X^294 3PG[N2V(4%;,?A[AAA
M9D@;CH'U!K(,SKD[H3N,9H3M9_'#+Z7\I'7(]M@#6DCM6%+\$4-N<NJEL@,!
MRUW( _$!"[7!],J_EKN9[H,K4I.'HKP?W=_T/0'+O*&;IH2VY;O 'TV^;_QA
MT[M@/"6<,I+SY]_=-%;3B:1@TD!GDK65>"@ )[H*BU\A8>QES@1&*M@KQPHE
M8I4C27TQBXBH4B%!+,:6=G!P^)Z3H H?KRD]<LW%$Q,YU R[FPDF4(ZMC:H*
MDCK0"+N;_<S0M;I"<D&Z>*7NO_T)R2Z #Z%K]J_08]V8[APN-%VDA,$M!$C]
MG?=/.X$/06&?[^K[\;_M.4C9L^9&2T>JIU:ZY/[]Y#_5E.&8:]CHYB!JH\7?
M7_4D*5(0,"P["H!$8];Z"-R8] ,#NDC'.EQ@V7:S#6=+5M\GNG[F5L)8J]V_
MJL5FM'K)8T>5^X8<S"^>W!P^U\2@2HC':J#T6B47Y;0"#6VQ+7(H69D2(G=I
MA<7*U9E3>SUX"3?^6$],+9J4PN'XQ8EO#W0'PH66CE5XZ(@,].J5DZI#+O :
M-TV)[!?F4!#'\:N]\5VE]D0T08"KN700Q7'D!$2TP(7 -7F?=\BQQ/)AYQ,]
MHR8 JPS'I3[Y"$FW<H-DS?[?9>&$0$KV1U-LZ[CIQ;(YFOFXM,]+6V/22F^]
M6-\=_4HEL*'P1.[(%7K<<ZP%^J@_>APBTXE^DSD[II\R,G4JY&*X\C-BCU<@
MZ7;&6C3!Q'V1(<]TMNI2$?\4QC*"*KD![S0,;U'#;J1VZ 'U4 7+PK=<FZ8V
M?_14KT5B2 $Z<"6BL:*&<H!X0:-@S(D=P>OZ]/L#'F> ]UK"--&_LZA.%G1*
M#Z@9U..F1]Q7M WG33K5Z!K'*]<+& "F-FY+-&/P2<,I399$&>87P4.SF7S1
M-WQ4:,_%(AR>UVQJ:+:8Y4(2]9Y')OG1D+I1#V=%!CJ]^R@23L1,TF=S>]R;
MT59\T:(YNW3@=H3&LX3=UZK4!AE:)[PF8\$0FD*\#'H&'IYOR>Y&8:,%]1/3
MXDV6U^)-V$KS]7TKZ,\[3AZ]O2PRI40#G8(KU6%2%RTD:Q)I(O*15V_/PWSG
M=&_5+XS:;]8AZ@NYD_0_F[]]^%&UL@9ACRKM5R;92Q,%4PT1&%IG)#,.]AOU
M2,?R%0_S_07$*JO?ZC3-,PB?LSWGFC:6Y47!8S'2X1(@-N=C%R7N24&?'\(>
MIVF?XMOU&*]>!]_]@U?& =''R)?'8ZLKI,Y<]W(\H]].-FY7+0WE.^I['JAP
MD6".^VW85=>ZHFVH,%9*]+@Z-&)Q8;?\$_4=5W21G7=C>W#=UG-^N_NI4$=?
M>?8(HS_X-^BN*+@@80)(W6F+7&!WNWDY%YD'X\X%67/,[!FC9+_.PV_]B4OP
M>3/>PJ_KE$M$-=\5=-&P;K@$1BH#I0CKN>!JJG'Y>LE5#"L=D!R TZH/.?*^
M^2>[^D_ OU.Q1#J*T5J*><M<Q]ZA95-TBX**7#1RK[$^-"&#.$@FEPCR"5V:
MH,2^!!YTZT'N63_ME%LJJ>V]?>+V%9=)]1FZ=O]H/.0>PSW&[;*]!P+EU)5B
M%-MJGM!'-TBQPCQ6-EKF;%(2^ KU9\LPC8F^.<_=2H'J@RF7:_GK<TONX(1O
MINXJ0'XS/&\H:BN.(+N@6J:3A\O2POB4Y.>Y8?O$7=(KBA'AG^E0ZJ1%23F<
MK%].23W9I/L3H[@>8#R&1LHZE95",2!5]*W4+]BG^6#$.=MI&NIW[FF=)D6R
MTKF\Y6>W VOIOG:;^,!R&[,=[*S?IV^]*"S8GO),C-28=CT0=??U#6FZ^\8E
MS:U<*D_(EN7@3G!UF/UOYQ[!.RV&><DJ.\G_0=^2)7)L'^EV^50Y5F)>PLS:
M>ZS9'#>[["AW["I/Q1NR#52LCEOY]_M;^OE_E,K'YL&,3V*XG'0?*(&+/[C2
MX\&$D'=BE&@E3&Q!.V;DXZ^N 8^/6MRT#"Z! O/W<>3HV97!H4%Z,'E?$JZL
M*^NJMMWJP1;L##_:MD28L]@_510>LYRJ]KYZ-LN^Q_X5\?B@FH=!XPE]2&5I
M",7^S>K&&"W!R2+SN4,@IIK!_ *W'/FN^JZ91W74(HV)M($%_+/\O_Y5<28E
MJ_/<LG$Q^RC CJW!@2ZE<$Y8PSD?=^:Y/C;2FN(N+&T=<M[><F\GQI;'O/"1
M3C'DX,-&CXG=DIC2VK^47_^P(NGQ':*#BJ([-IZ.EQ+X1U,>33HC>A'PN\WM
MTZAD]N&"26Z3;(X[N_TBZJ0A\IM!"E[_76WPH )O8>LPLQTH(>81R[8)O#QR
MNC:"<"N3W865STNLD+A M0X >:]/2S%<&<B([ J#R%="9_W:]<*]=87_(98.
MD*WU4_D1F@4I:C%:].;&=TT_6@>MU@UOPNNG\*)%+G+%F\6.)0C$+DO2<YK1
M:=%;R0Y1] P-M)KZOP&*8JY W'-O(022\+/^SXWGOO]\7>3"X[ ?]&-MZ^KO
M[3';&  N':41WJE,'@(A6EMZM= +EVJ\H2!9O+,*K#4V0C\VFJ)?I!P@O,,(
MNVO\P]^$KV*^;VLHNX #!BVXJH0B,IP^Q9;IE#PO+\F21^T(@3:T.&\ODJE:
MY:PF-*6CZ$)@='B3"ZH]&\IQ'Z?QNXS:;DMRCW632Z0$+;_LD[BNTLK<K2@"
MLVA,0"QKP)F(I:[F__Z4'RGG:!/M+;:+]SK3?^^+D%G<_Y0)0"<F,-MP8#0.
M1%=!M)"78%"WT7:+M-RKK/+F)7&#V33O6WSDZVDO@@X3I'_*%W$S""1E]?S7
MRHK]\@-$J %-[/+)I-7[P$;7Z/FX.<,DTZ48Q2:8Y_Q!:AL@B/4+QSK ;;>+
M!2>B@@O.URO 9:G58LB2E!1&.+7G^<*CMK5K>7AFZR /T:;=7,1R_NB5D!.A
M6XW8U /V5U.HH-Y)X7G*5'U51P#C(K4^^6]@?>E^"WIJ\!I0?UJ2CP)1F8$C
M3>98]%TDA;3O2PX47'WWB1=RL&U?T@>HQ-6,INUZF2TSS>Y#><%NV+?UN+8R
M]AKBW6769!.V;_WFKNWK=O0>=]>227+Y7VTG^':$]CRY%=B0!W;30I?$DB46
MNLPB;%(!MG>SBY[)?!9G?L>_ZE#'MY@YFHO,#:ONO L,W4+_25$.YPFS+(D5
M^N;A7)<0<^/02%HX;IRNDA2ZJS>1%#J72]S812*<FH^+L+QZ%G! TK?QH/D?
M69:,^49+XGI\C_QK;,2;L;.@M?UV)(0/S8<<"U;JALBN>M!MN]O*6ULTYY:J
M43T7X%'_4VQ\9X S72E.S<_X?]9#(-I:EL0Y*1[6*N@@+3?&.PUC[FX(?!71
MAXW(3OM@WQ>ND# UKL1_V&&Y70K>TLWJ_93C&[UQ:[]449RC+R&03L_B9#<$
M.[A@V!P0T &NKEJT+<@@J0A41;5NJ Z^\K;.6GJ?.]*5>;YXO!'QA7?7=N/7
M\AZX2][%:3/SN(TK^_N\*W9/,7Z=I;9%2VC#U @7:M)NF@/"$Z'5%DLL Q^?
ME$?_N1+;U('A?<Q$=D BA'$HR[02)WBBLO)4R/22:Y<I;5$W@"=$-,)0:XN:
M;E7MHUU=:NV7JV)MEQJ^:P#@&-.6P"-2?. ZJ6N#T,&C OU1-=&$NVACP8O!
M-A?7D6N X(O@#:4>%J$+T]\KS%VN-V;(9#E6##9Y[!TOI]JLLT,K[&B#5+D&
MF-#5\.V E'/,ZC82#3]E6IR_,_$$W6F[?U@C1#A&UG6JQ0RH394>JF%7CJX!
M K>8#&SH__T_EHKY?S/^;^5D:O2NLO#2RE%00><#-D::V*SA7(XGI3S'[H68
MZF\25A4]PGO'\A_TOV","SG/TS<#U]283'<C#WMNE)%OZO51Y0;)U81)"DD=
M]\(?SD&EHD_=@B#R);NAABXT5[]Z)*0U2;7)Z%]T]!*W\H4([&U#A< =R*U0
M. =.[$PU:ZB+55*10?9(XC+@2W.(.)-GU>C,Z/ MNSA-Y,?O QFUWP,\$7S[
M2-05W>I1N \G9Y4W*';Y#GSZ2&*>>J&JIFH+GO-VZM <>B(^.)R#:=7@*"=O
MP:R$0?SIXA4D,:!>.:'XL>@'$^R:LYWWRU<$;0([VG\SLQ=3QTH81K#RV$<H
M5!/EW9;02X0_(DS.X(50H,AD< "*U.+%!3RQ>.B[T$Q$<Q* 33Z@CNWS[BA;
M?>>;ZM,WK/Y5G/;8J*E"G-;J$:MS9H";-%2XM:Y^XB1%^LN_1:M:&G;X5,LO
M P'9GN[P"I&>'$;,4;]>#$(D$0\K, .+3?4UFYJT2T>ZBPQ<C>AZUCFUMF:_
M-F+GH4PJ@1XSRW9S\/4D1HJ!H%-*XLXUAD?=2H"N-KF[!8^)5UY/%VH=I2A2
MA%N%DQS&MG"6D<!GH8K@"FN,[X]\O!@.K.#&$ED-[ZMP8TNKSWR=;'V+&CLN
MFF"2^8*Z _Y:C8^]8< ?.' -2&@!LA*((+:3IW3DKERT7>CFTB(S:W/7^L)?
MDS]&*RO5?Y>KYJ;.?)5#1HC'G BXDZ!RNVN8P.4*G$A.>91T&$2M8JRJA\KM
M=HG-CA\CLC3^=]2PX,,>'\?[$2@*;A(KM6M ]U$L7!!M.KB"T]H_D<+PQ4DJ
MLAV]:IFL'INW#UG9OT0MKXKR/WAC'K2LR@U0R:.)UP!A3D ML'2WU1^/UO1
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ML;!QO0;$3YPG7F5[70,4@/\*+^6V"&#E#5 IDS&LXAIP<H:^"0N<".4UY]>
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M@UMH)+@W!&L<-K^YLW-W9N[NWIF]L\]NG>?]YU0]=>I]ZJOZON^M.D^_GM8
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M'RUU# >];*NKWT6')A;.*V]T@;<7IH9?B_-F#9>P69BDC3_KH>]^3+&8;YY
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M=S<6YE<^)M"U\/1X5VX$M'D@Q^B8]<9+$77:*"FS[R_.Z58@TZ;44B #_ ^
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M$_<S<S?W^^L\/.%5FL;&68_1V53+5[D?'0O0H_GILG+$[T,N*[^WHV$D&WU
M>D$#0.[%W5P4YVR*(T/KF6XIO1ZEF]?ASE*A#9.@^@EWX0(X"!9F\-NQ&R]:
M5$(U(=9](*#"N??V[#!^);PA=?QX?&UI>6FD.U(4$/UZ+9CRF1(4\+[QCW"Z
M,U+];-F$4GO;FK_FU785WT[]Z>QF$Y_"CY#3(A,[&+QQ!9G$4ML4"[>6G2J1
MN^M'^09P4??X:R@BD&OURL;, *,KP\Y99VY$SKQPULO2F,B<R$+NLVB8CBG+
MOUFHZIZ$T>&%^#JE>83NWYT">O7?1M.1A\L+&/AE.+:QWBT_ 7+G&[D8 @KN
M7(TF=--CI)@W# LBY64'E*E$J2ICXIAF&/2:9]HYO1Z9YKP/KF86EX->+VT3
M"7XI9. DXB+HS=&4>KW;,KL3\')<8MW5W6*C#,%=TC&:&(7^%8L)(P)?T>^B
M^LV4)QZ!$=P[>,HB=N#,P86.#.SQ$9)&)Y!T,Y^V"-4+H7R!]?,<Y9?TS:;W
MPNH7R< [86Z;C07U.5?D82ZQZ6 IY6<]0X4*1Y^VH ;%KASWX0KA'.;.&:$/
MI*8'H"< :0RO8O#T.Q[T<]_$B.R HM7P V6$6372P5EP=*M_!W/U@_GXD:78
MY2"#JE)38ZK\!#[/$5GB>Q+YK.HM7S*477H\6,<?6"38H^)!TE"I;+^<["'?
M^KPJ[P[11<E5G7M-X.>I>-ISQJ2<4#_@_<(<Q^0T87]?<V@E.GI3- _CO_)8
MJXCQF=R>#Z24EV>]MB%UQVN)S"%59M)_$KVV)(VZY$J1/8;B\&O\Q7O7RRHM
MF[GV-R^DW1?A.0E]+JZ/,YX3TR72I#"T5SN: G=+XX&2\](K 2GNFI9@YB-/
M07U:Z[D&'!3#U>-?GI' 9=?'44_,U@K.(>>CC=8@F!+CT(36 5%S1:CRA(4&
MH43*98LGI:#:L,=W$O^+B.],[KTB^_?];L!5QF;#B]SZEP?>^B)C#MXLLW@.
M4ITO>6NJQ$]S70_C'9K:FIY[U1DW)/8Q4_[&2_:\0O<0BI;D+'Z#*Z'FN:OD
MP4N-.";*F,983'56S^41_U@90G4/=G@>/MX$Y^AW8!J23?5)V-:5$>"XM$Q9
M\Q3%BN68N&=!E@#-6R6+?YGVVES=:-"_!49OGA#?=1$5VV]U8D]MU\,:47?8
MUL*,73YF)S=H9[62B >[WN@E_VGZGB!HP0Q?>+^2N\IPF8"._3FWS4QB$I,\
M+6+GQZEPA&,E]<R[V<_3CR"<QV1BQ7E&M_:MZ$N&%*_+$,MU EZ-6?-VV)VR
M@^4+V+<22]J7FNW$F@"&F4;G?UYK>K.--.I,ZLVSO,7/X$OYOK31:P%8.@C#
M!)^4G1I_R*1GRHLYX'.87D(WU3**(\IA(I\L3>.(PEKI^@P7&'C3OL2MU\A6
M?!;F-MU69RF%V\832%WA>@H0SL]3*M[W]O:Z3:[OY\-&CV^P@+W"(_K.GX7L
M$AT#BWR#YL^O3Q\[GD S-H!AJQL&7R)M ;5Z8A.RRD. S4A "7A]S%AE!CCS
MEU"4B CID!/7?=>J8V@7I6M,"]-JV9(/P46$QTV#NB&TD4;9C.I5*@JS-]NQ
ME?D>]N!X7]4T7Z(860[1J=\JB.+9P4Q+9\:T0[U$GJY'+%"QFVX6/#0H3Z#.
MVH=G@+BXRSTR-5^RQV1I2I;][LZZ0OD[:S-I$"T#L)"DG*GS9WL^I<IDT,.I
MT >2B-V>W]B\9EVC5.5 >-(C/@XI&"RQ%T=T##5E4($7*VN8^;(VK'^'8T4'
MQ2H&5*CR4N[7';C"N?0_4CE1SW/./#]F3G=/)LC:Y5!T#98#S#3F4ACNP3-
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MK4T9],=VTRR7=\; JUBJM:D1^DVSP9MU(DLU'<!T.HRZ&KP8O=&F.UD/$3:
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M&7>GAH9)E=W#ZNBX;PP4BAM^ZANO)^U.H":T2BS,=*%G;"?9K?;'\H^Q]<3
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M"A6ULH'K685\4_NADM>?2;\\]O^.3MHAM#N7$YD%5MH4ZYU>YQ>"VY6,#10
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M(.Q%7QBX_7__=/_3H'B9_R]02P,$%     @ N8%Y6P]'?DEOF0( ,\$" !0
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MK>&] S"<.$4U\D4M,X2JK*C%;DY8M86;NA!#*A]ZMYKEF6>R<UQDI(+])2W
MHX_RG12T?W*U^LQ#+/(W?UP;3A^#2@0B1+AR&IL>O00_MWS!_>FQX?FSLS)+
MC)32)%F"E?5GQ6.3TH>K[TOW]<@3_VD;G8@E7MKQ^0OM/HC(KXS44,]3^3@?
M-;)Y0*:\Q*BW_ Q#EKGF6K1#3V\"HN_B';))*[3+63BW&KT#E,,1H7H[<'8B
M^'"S#Z=CNI-G%@9<O:0)XCR&9%XP"02[0VC-O4!=]!X-16;;DC*I^#4)@\=L
MORHZ7^+^84+G8%51_G)=K93")@Q:E Z4)@L]XVR>^*YJ[=Z;?] S<"V%FQRW
M89.V>1/"&?44)NA6Z 9KAOQ)MY@"ACE\+7\&;IUKZHWPE#<R0JP'/L 5]MKR
MH31/(I<H"RW0(4K>GSY!++6JH[>"YY72U1R%9D2;#SS!X-:^&\ X_'71UN6O
M1+BZ;Z'AAXV),_'9OR>=A?BQ>:I(\L<[DM1];N/\(GQ2'P1$4O$3R2%+IZS;
MT&.6.30*;UEPTJ!7KR'"*'Y1B[3]!XW7'6#^9(>G'F/178;?:2 XQ#^QKW<'
M2'+^A-I1]+QQ9"PNLP:+^@08R"GD1&09!)41&D',1@8(9Y $ZS@_5+*"&O<L
MX](>^]#'U[,0>^4H8A%K8E[Y\2]@QV75Z^PA84L?E#>$NMWFW]+*,H^;.LQG
MG@76+:Y\CG\5NQZC=/U%A4FEQY_'4%PO*(UYTUJRHH1:'$0[-9O]NZ*E;JKL
M16-U"C_?NED_+[C!T)<^([0L1VSQ97;$/U3:BH#_5'4>D+^!&@/NR_S_HH,8
MTIXBL#VEO6B%V8CU^VV>/1PIZ%0IA')VV6).(<DX\\PT4K B&;#/LE3VW]^]
M'O#<P7@C->\-1S#NJ,NGSF_?^D/:=V4PYKI@C'K/N4_P;.?C> PA*=%\_&H,
MW!WVFZ?3C_H.P)[Z_MXTJR#&V&MDNA?R9:-['K6.FJB6XH;W;**(^%%_21.3
M31ER&**"=8#F#?BG&AP'"0Z2+3[H\I_<,S6#=<LQ1,M=J>_:RP2BA8Q%1\CE
M7J%.RZ]0%M??$^X B/L13_<V",?HH)4.OXY]F$3];&PD3 ^_6ME%+<.'1I](
MB_)I9[S0C@B:!GE[PX2(CK\49F],U"%]5D+]7.6BX2S^G@4=SZ<ME;0X)9AM
M! G.1+36^%;"^;.GE!HY7_,(Q".(:ZI&UDZVC2S(_(0@:ZT/0$"@W<RD:=<H
M/3.='E>[;&CR*M]>]WIHL2-GDDLE!TF,":,O(B^TRZ#(@O TC%U""6C"N1.=
M)2$QN=D\;RU'?VTX=2V#"N>UM!M)Q_T=IV;]O8UO= P!ZQ34(E*+HF-ZPT/V
MC?["U[ ZM;OQ#O"]AD"PGSS%#;*T#&")N^&9=!-@2'4*=C4CE)O8>S]7-/J\
MD>OZNUR(JW5*Z9+//CPU&)ZSE=KX]GV7K/=QLPCHKW8MMJEPR4\A5DOUQ6V_
M[VC5US^?RCV",\M\/,/):OE8;SMI0E&0$0&A.D<IJQ;0AL$$OYN_G.I,)#6M
MD)1BKQ8O3"Y<+L_?R%YRR;A3,*WT.Z,_P;!3'!*$LC+.>*$A0X_0RRTO-:=Q
M*<ZC:Y6#'S7C]K2(8LB*"@U-NG,)2V/FB$N^IL7U#H^J>4;<O@3),F),9B-]
M[7E_&T(]9CT!'OO/]D^EG;6PAGE^SL@.>4!_C_(56-O<7K7TVG"&-T_G8_T?
MN^,MM7+2#P417FJN!0:F1YG\L#J15G87 >U)#=6EI@#;-QC:WB.LQ;L*\&O6
M!CA<*@?X,'D0E_T/P5F90%@&:R,&&)K3"C=,\H@;^ZX7TB;]114F<+B<XE\T
M!P(:_[*1Y(M*>OR G/3XT]6J\P70]]!:#<O\6(D\4\#BO*0.-ZKK8\5XVL+[
MGV8Y6Q.M*Y"X,NZ$=)-FZ.R^/?%#5C:22^@ QJ"QA7Y,0(2BQ3)$L.AF0QKG
M A&)=>U8YL#^LITN%S&H_=:@[V'S]Y([)M -IDOW"RYBN+:MZYI64SDQV&1S
M"G)15>#>R[CZ(85(O'Z/<81E86$:-17-OEYLBOP15*%2L85GY>3=Q$@Y<O2,
ML4U!H89@!WX"MTJ;)&7<:("RSU;+*U<4$\-M ^>QP\5B %A:D[[4DE;S_4]=
MA)E%\LF(9'V8N"K;I ;S4AJ_!DXP21#!&8P1BRC?>>(P'Y"4+&!E^:)$N%B%
M-"%(4Z+MI,PI])9RNMK?J#P'D3WE!GP7RS<83FX9%&#J@VBL4I:VZIC,G8]4
M;2J3WEL8VCD[+]PNW/5Q%S$SR<+? O7X>2/+;+M;>.X WT *<:LAC#T'#&#^
MS@,*9<6G(IFE6(9N64 U?7=YZ60N&]U;S967I\\.%5VG1J _E^CYOP17Y\+K
M*M$?V<.GCWJV'4>]LAM: =@_7KV=%>:5!/M4OS;DQU[MR\0:;_-LO9P)\7$N
MT5@2<?-04G/6,1'J;Z'VZC5$7 .+YE>6:[J>*.U^'P#@R>++;YO_>2JF0#[1
M\NDP-+,$S<S=_&>"/SIAQ%3CE?C"T\\9RK+I/+KOZ0\Z8FGF"47P&T,U*EG2
M(P92.A^0![3F^8E:I.EUKNF5*.C$"FD"YP\.;!.5*5\J'&F4[/L_47E*&2@O
MFP*3P':B?&%DVP:U4-=?Y0>5?M,[WU^G^::ACLNMWF&!R+R*6%V-3^T!P&'#
M=S$F,O]PYD.(+NDO<K.^>_G)<&IWFQM4UMP!1#TTFW2_?',"CX+[1HWI@DZ?
M^8,Z6B@<H.F;75P3MTC;Y,'4H>C%U5>L=?++50(' M?V*'^%R?<SH;'K3;F$
M0H*_YV?UGTHSND*1M\M1A4JE]DT#FEQF?$UU%9DSB!?Q,?N]X\) SL/-MS/"
M,M19TP<AJ.2A?T1O(F_/_4[+*UOB0U0-\NCC(R/]F;=VOZ5EIQI0?J'[ZZRT
M%NCR"K09+;I@A%&.=@?3(W22Y@EMXO[:>#SCKA!'[R@_J G@,3'S,N[L-'83
MJTH@$>11J7S%[R(AC1CAQ312OY;M/E)67W(X  FTW &^]I["G$>3W_JF6V,S
MCDQ8R';$1 \J[7Y[*C.N?FTO;:4:98.0'>2ITK'3, 07M>/;;8ILW@'('#>;
ML*[(!.F)=WJO'BGSQ28L-V$,;]5*2)(J(SWW/H%T:O+ZP9.VZH=.7=#D<.$E
M-0VU[?(,N@[65X"O=;/ +*&'=&PX!^;RAUKO8U4/>[\[<=QS?[P6JP!"T]/<
MQH*N&\V=G2NS6-6J\-I2#?XQF0?E2E[[H/X.FYA08G*:M!T-&8&Y9A-;&<GK
MG[_K$F0#\5[U23!/U:QR:D_=TJ*3HA]5,5?DCP2X&7F2V/Y0TB27*2G&3B)]
M%S3(-<UD@:'S)[3V.>)L'RQ=%X*TULP&)?,+]8MT2-7284S,5T9[3D+Z$::5
M"<;E846AI&/!)WDPAD/\;^YV-;ZD;S0QC$"H/4ZYJ(35?@CACC]HCF>B#5D0
M63 JZ9<I?+ !%<O3GHJ>_Z/S" _%>F^,LMANE'HF\=:AB:%$Q-%AW 9,3SXJ
M;M_EH8LQL*.56MV*.;]QT&2E,=R (W'0MA!ODZZ<5\F6VRLLK'/"G5%_'<1C
M<6RC6SYU\9QAP76A4F@F*@HEC0CVXYT648>%ZR@7+@X=?TX=_M<0T;UJ(].P
MFH7,\,N0I$1_:4^*)542JR$I/<;@7OFO4-3M<NR?:'?5JXGU.@MTWR@:%*>>
M[&FU];LM[8'0MKJ%%!:F@"'OU%#H.7$8_6)C%4Z]P!#&]HHSSCP%Y<2BGHTE
M&M6MQ7%R)T ]/I\=:@J_?@11V\Y)4RP>?(*/KV%6=F+=2]&\[VX3<^"ROQ"7
M^0[Q<PG;"HQ%[AJK+;^:'!K()\UYRG-_6FYM)?26 R.:R5S%7WE6.2+=]RU>
MXJ,4,SE=Z2@9J:9<I*BVPZ[YK51@O,0M+Q=@L_4IC($V!<G#39O'[: ;G7YN
MEM[*"LWS'DQ8<MAC4=16_-)*<VWEO&9&R%H)3J[[K,UV0'_.NMS22?T]E"*J
M9&J>,T>BV-DEJ6]?K'SWD^VD< ,=VIPI^YH?HY13T%N<;ET&8W]@B/)FK"OL
M'WEH@/4OW#GVTS0\50^/;O,TTD[;Z],A9Y("!E5!X])?SG367RG%>YI!RF+T
MPQ.1><2FVW )Y+#Q.3)])D4$W?\A]J4A@2D UZK6E^C4&*-%".FW:[ZG70D0
MSEQ,[_=3&)U7']95*7VU3NEU @.81'G9AC6-A![9;J-%&EHD69>6KJK$XW%6
M>2)88!%/.@CTB-NS_#=*G#X*=)V <W:9XV.4@X2E(IO\+<O!:GOU*DNA8[ZK
M=X#79A;M>T:_#V5.]W8G5'ZH[ _M&@924<XTJ]&5%G\TH&^F)31J-JZ)@[\F
M'8W7KI+A_:,=_P]S?N ;DN"X/7-BISL (6?WC</>6A.(21(WL.E[-+[EU_-H
MOJX,=JQ,R7QS]USKI*UT.;+O-@?_!RCSRE,+O&N]Z^0(Z3A;[O('[;FTF&_"
MX_%U#6\%4M]'=OH$V^-Z9%=LL)O2[ A]14?=4\!1E$'3*RWR94/300IUAG=-
M3Z..<FV9'+K,J:9.6/#1/DNW!>S=>],QJ[@L2_'RTK?Z99^'ITJ I)JDA66?
MH ::8HW'NWHE=5SR?(W7T:UA\V'?6]<>3W/.1&5[!=? $\H9 QNVE-]=3K$\
MNC8IQN8SJ=9(P:I_&3VPIG;^X3I&M"'-5^# S(VU+%1*/E+FI05SQ2M_5..U
MY4G;;+;QHSE<WR@HO6EAF,2CT<E1)],ZD,>/U1J!2SX=4B@+CJ)*,S4_6D%<
M<_)R:T&A0(>E\SM J"2,!-MKV(*%^>9I^8P6Y"84=^A]>#@B9=/\X15;H/R+
M%L?Z8#TXMJAHP9XR%=2_GQ^E1B9:Q.D\.E&*+5##X'?<&/?L.L!<.-@3IQ?P
MHJP-*0_TOPWOK-GK)ZJYI.DMK?LGGAC'9+S00W&RS6NY;@7]@^YFE2SL_X!S
M*K*>^?0T?.-0,]K7B3=IS_6%BE\=]Y?W:<ZF,YFKL51>K1V8G<J=$>H7<K9U
MGA^,@*V,)%>(!@NQGSR#Y$J1J:KJRN/INETB8@0]-UK>68;W 7D,,<I,,@77
M1;V$K#'639DSN,E^2FABV@J.SCUEE2DZ*J\[;.JI]=@K%.G2J:0,96=3F'T6
MO%+FHOR=*HM^)ZHYU5XL/W825@3M7N)R:?*4_<:&D]"69?BJ[UFLMKD(IL2L
MU<Q):Y("L\O+IN@1IXH3+LZ&BL=G2?_L)W:8!,O9B7:!GAB'1@S^8'5!*BAG
MR?'+@%HD<C($#8W=4K4]'-%:4A['(O]!<)9["X!)7@L]QBT)&'*M2;" = F7
M=#KFLV[Z<' _'4P7!H7;KX$66)C9?R8O?SX7Y,EM2OU+UHN;J>6P,8JA_G/R
M;&O%B$^W;G!#B=_E&ZV Z[:QO3O^P\#[N5H(8]/J>SC:3N-![,+OKNKY8D33
M(^IH\>8?ZJ'M%6*X+LQ^L%BCI)KVOHXX=9[]S;AX<NH:TQGGPD+M[$WAA/C&
M<Z>)FX%$CTQ>*T]$W[D:ST  M=>*3H)!9J?/N#W_;Q+6Q!$3;F\=WRM@"; @
MJ$>W5UO??GN\H!'DYJ267<+\B6ILIRNP+6X+U"_[TFM0KP5#8DX[MI23.% *
MH^L4>I+>L MX!NV9EJ7'%G1 71UFYCO5A8DW5.)4V@/WO==*!LK2U$0XZ:E,
M4>3AY>E[R[W2%7RJA4K;CKXU'/('IBQ!<"?.*&GJ0@U9BLMY3E4UYX3J'YUH
M<_U5=0BE5RVH6;13!\I@0W1.J<KZ^+<MKHQW_ZJ/KVY96@=S[VS[Z#PGR*G@
M%&8Y2)$LP-WZ^B3BC^,WEJQR)R0_S#W+2^Y]<V5R?\-W_MXV\4& EYSQD8:G
M$D:@PQ>MH23S=FE!:H]-B,H* >(Z/2W/1)8*8JO:9B1/R]J#)L3A_7S]<K+(
MWV3BJ\$S#3L;B=QK%50WJ2&&RJ 3?]VCQ7"@RS<$7V[RR?#* VRP(>*6><D\
M17&F[&K]6V7(P\ +>5S<,B!6PQ,)BBN$.'EO/%;^B>"JJ7/](<[H5JZ[IAQV
M +Z6*40KG$3J.DFK.SX];/,_4&LXU+G=.%#"$&8@C2)>SG]RZ?(KFQ3I#.[6
M2W_'6OPW-:IQ:[<N(%]O1W3[V,+V6";RV?F]HRP]NR'U6UE5UWJ";=DYT*R:
MMJFK^\#L;:XDCOO[].\9%;HD\\FU $;=2-''UIL*C)>DBOM%7.;XNB1;^LU5
M/2*1D!L\?VYRP9_':]N8O[KKS]3PQNJ>)=QW(N-\-3-UHS\M9$&>L4=PS?>'
M#*C_VFC5@F(+^@I17A.6\9?:7IL-W*?5XMQ^4G8%H[0 R3UB/K)?V;-_&9)O
M,#\<VN,BA:PI@@Z4@MZ7:>K]_?VW!EBW-9#HR?Y2C4_*=$^6P11-*TL;?OH'
M>>#[T%Z)*:%"KLQ=@CD;WM3A(W,0>4O3":+)8J_I-!7RWAW2Q'4;<37W1]X0
MZQZ.5('S.LM&(;XO\7JI8D3C ]Z[^$##H'KMEEQZ9YK.SK'POS#/R2;+O25N
M9[\Z ^/%2Q7&":'B-!I 1A<B'>U3ND(<P++PMMQ11"+@_5'%9Q5OJ]'W4D1(
MX4P",RRTS\$X,_)%;7V:D\JRWY_+H]<GU L6(HE</5%<KGHU\XVJ?BNZJDA&
MXXCHE;^^>]0H")F?1>%6!I<3Z4YR9.$_FY^%2@YPFCY<TI^IG;P2G[4J:N@V
M*K#)5(HNTM>W<J/25O3A:%>D>H_SWREU',PK:>$?WZ>YP(R=,TL\FL.HIHQ-
MYD 7+8?"[OXYPAIJ#_E";"VQQ>.YK:2QYK,LL5'!MUZUD;<^$GM;^+JZH/?;
MC?KE.<6C()S$WPO"Y<&"+QFY9#.FI2=G[9-]:Y6IA^?:XW09!F*13DX^V(6S
MGS?9[N3D*FZ]<=JSM1ZR>B2H;=/Z(>7I[8*GS1#*@1Z4_>IV@][TB30*"8G@
M7=!!5&>28U4%]C;C,CY47,3!=-0HSQ^*M640FM27BTB!Q:[(9E#O"/C<MN&M
M0BV;?-NFK1UW@'!:9MD9&)RO<-%T5B*D((+'KLTWL^@2""QL+Y'/=A UJ)TO
M%5(J(7'BIK'_228*^WT*2XI65E0S'=8 T;26D8_\S!LJKBDXO;6-+[N8NO:E
M#1&)C'ZC/@9. C; *4J\<TFR>=SPFWGG11/L4:2D0%.#24?#6GY^,<%R06*R
MO8B+%>193LGV?&,*]&A@@ZO%LN^Y_$55QNFX5ZP%]CXN&V"$^PYR$;G_S!SW
M>^UB'C=3*P/V1XW/"G5*+)X0Q:@)5LTLZ2Q=-!],IY8R%!%HG.ZF7HU^QGBV
MLY!=OYMN0:S..0HO?"=;*-P[_*,1BV+-UZHQGY"EPR9K'-Z$)8 *A<*AM-'O
MP4F"LH?X^:]G:MU:HT1O'V--UNXSW^[=W[Y/_Q[;Q%JI.1\WO;[JE8#18I3W
M'B+Y'(^PVV*TH/S2W&Z7+/BOFX" 0&"J4IEW_423MK&<C,_R97DH-5?Q:(*1
M^ 6[U8[6-]%S9K(_C4MYJ6#FA=<U*RF5]HLN5A(2JQF+0*TB!WK'DMPW18L.
MNMO)D^H-'[]V.IHO?.W;G&A1.(1$!+!ZS7<@U"<2]BH7*Z#"269YRIC7LL%E
M/NZS\2O:8]=B3D7R/HU^@[0+'Z._"C:Y,,@ 9*O1VK #S527*":$"<^!8ZK
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M!_H&,U8YY#) ^6&K=:$?X<?7X8NVLKI#'I!8M-FW1OW2>2O[#6H3T=B!HX1
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M]8+1S2D;LN6^0X\?5)U)LJ3A7+#P*R_%HX'?)&J3<;S<2T 50[TKYCDF7*4
M4&#\VMZW?6#N,@"Z ]CP,B'$1*[K6JW(2T9G?67K;C0]D62P-:/-FG%WY-M*
MCO5T?-$+1@I?FWJ6!XN9I-?*89KC-91%VPGURN[X("X=UY@4YIR)9M>N6]SQ
M:^/'*PN9(H]H[%)!J$F9;K&.6\ X_,4>>T@3W2SX.!^\C_];IAA#Y\'=(BK2
M/)4]N0'<J-RZE$./N>;HN.M55Z(18UOHKA;6^VXSG&C=6[D#O!'9JPDIPO*H
M3I]ZU4@5TNVC%FHZ?\CJQO7.-+^;)-1E4!+>KG%G.SV2Y)ET_QB__T6.Q4VB
M_'.IR,O$#'$Q18[Q<_EVO-NW!F?!&%#GD9</8;EC=S7F;0E[$Q=?/=ERS>(H
MGN=[N*Y291<*Q!H5)-/M3"OW$"[DZF%[Q!G)*6OJ^C@ST1G8CGKYL2"B7;S%
MK3S/?V;8<$!O1RFG2&W^P#4<Z\K8PH--]2_OI52V*SW:WR5\JGT#6G3(2,B9
MV_( @:P<D\8$#G_O^*ON.ZQ[KM=S!F6O29CK@.LVKNC'\G9S;$Y]JCK\+%K;
M[@ TEC..+[QY_R:,DN"_'ZP)/&>\39S#UB%K@UKH&VB2/^YO;+ R?KD/GDJR
M3N^ MF5VHLS/JT0;0RI-%:<>[11,,?]&\%@=VG:*BGV$5 W+DKUU53.2>[(,
M#__P&FL_'4/:&Y_C9++,=^"X*95G0*:6:N!_R;C2P42#[&V77-_MTW9$.?$R
M[Q0J001!*5@QE(D \8Y8[7RP]RNS;UVS?4JFIV<2,/=IE(H;SY0B023X&5$.
M@#0?;K$Z&EI]0#F'3IH/:1P*[N=>HB,?[9,I&>VRY%[%B$O+TJM#N8V;,Y(]
M3Z]);#7U-M4>^Y0D![SV.M9 N%WYL[[[:=YG32$=%Z1G]9LY=V:F-6\XQX]<
M-!E0NHWG.W5OYOQD<L9;<+G#JLY;QF:3)E]/J+N$4KW_%7DA<\T8FEZQO+E
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M 1C56AS7Z"M"F6(R7$S]1"4N!*D'P["AVG,YT^B5U+^9["9]$I>4_SR5VVO
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MS.%-/.1IL;0_DH%I8_P#CHBJ/2N/%PY*Q.SL:OJSRVJ#Y>)ZV31A^K;ZT7<
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M#^(4D1?N"F[>8/XNCV<]KK<5*LTU"OG<RRU#6L/=Z0/5PJ9>%1)JY[&(&^W
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MO+6</(A.F)"(7V'%7^TID[GL)Q ^=6[E^30#-W*RH?GB+L00L.41EZ2:9ZX
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MU@'3U<0A4,VWK]@$/1>Y'ZYR>N;R/.EN:+:PI-CI$0,>+>G=4M4A(8G2YA@
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M\ML1<<<]9AZNBK=PS'M\"%F*'0+;^B$VZ]$JI=$&]WQW_12KIB[>[;4.0>R
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M93=$D[!MNV?8\0Z?IM2&J&4;<OTPXP\=L"1S5,R'X6?P>+/+K(\D1X@>*/2
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MI-K,CVEVB#'ZP>^>3WN&MW3X4N8SFCW<&==:$@WH]<A*C?[=;2S,PATVP0;
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M1 %(T\BC)YJO *&1!-Z(;:<&!-VV/P--O\*'<EGVSW6KW,O9LH*_0;.&X%9
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MNE$RP\WT&.,J=/P-X!YU!11<=2GGRZ>I,\%&KE[4&,<P$- #(_H>=2=8@5$
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MP:HWI->G7"ZYEPNK4^+7NIZ3$I7,B^4GOS#*@ <2A=C/\V\IP0/)VX\_G4X
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MAO8?'[*S+6Y?O:ILKADO>U0/_\)9DZ*4]]']?F*"LS-F PU"1G<OX</Z)%^
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MAF^(,'#H^ :PE/KG$H5_^W42%\WSM$4O?2.&?S4@'FV6?9O8(5LW@!:^:\I
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M/"!GOYL;(%%=^5$0VR85C@T%(;\OS+-\>PKZWF]@'NDM&+DMH8?Q)B60I2\
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M3S7U6Y?_3?IC<#,@K3LX9=6J,V)4)":B3'1)LB/EYEQ8P!_VU^.)-7 !CPL
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M4T5XZB5 ?Z2T+/_U\>\I5XK@J5A;]^/RE$; MFCQ>]9@\PD=@+2[[HNOUKD
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MU\U?A&P@'9BKG]J)^)CP>#\$UK*[+>CQ'M*4Q>/D17'P_ * X$>[/#TO#6.
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M4Z8D*I\MZ7VNLZ4:ZYM68=AHS%G\_.5%!K(8EDF[\BR:,O8<!Z64M6]X0+J
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M]-*DV+L$$Q:DIFKM<:,I("@AGC__E;^V_!H+O8(+";J-971%&]+.$^R[A_>
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MW5,TB*#SDK&=W!MVC'N G/4E]O1N$)?,Z;^?+OI/2&=2''<#'4&C7V\[_S]
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MNS<U='WDB"V%\].YH0J6@%S$SW$%$I.%;GLG\AH25C$$4YQ$KO8/Z*,'P1(
M0D%S;[<;411'$T(<Q2KL+P'O:9K]:BL>FZ]H.I!V+,^'9X^,ESO?%=%^Y-(*
M2V?IE1)94*G.G]];T.O@J1.OX!F3P"+&%6!:"_;U*D&\^/0BX44TG4.V/IDE
M!SV X?,U!R9_3P;E>(MUWD#^_H)F2FW!K\%C^R*3/'@U]Z/7.IU8H1AT[Y3!
MS#P.15!R/4L.*H!N41:1!(+Q  8O[[UCDOI3#S_NEBKX.=QZS%?38*Y..SU@
MD78/:$T]HY66#I";X78R8JFK^ZBHBL]!0J*J %@C<DR% DZ/:0)'V_'O6)PX
M2Y"9'8&,LYXO^O]>=:1+K*#'%*2VE"54]EAP#4%)YSJZ.4H%AA48[9& RF*\
M#682^KE,PA)P+(6(&;S.+LJ:.#"AR'"X88<%A7([ZID<\3A*[0*EQ)=KESA
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MRQ=0L2/].C;X"#.9-OAL6%T9H/+I1<Q!94[UR2;'P[:VFM7*Q2A\AA>!ZO>
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M>?!L[F\&[$6(RW"?Y/ZS]G_RRWHQ\K!R-]:A+EQS%#;L!KYCSRHN5 FKQET
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M;89/HG?+&64"2J8Q$%M">B/]BTT3=F:1_$B;>H%&79;_%2AK8E\VCC!@CH]
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M3Z4]"Q2D>G\;CZ>X (CS3\QR4A>"N0Y4@)U<UHG*8[F#GIYBZLPRXX."D1>
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MI9FGEMA"CK8T@&*2K76A3^.F6VJ6^*81?N>YX+=[GZRYSC-@1G(1+8^<<[9
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M!>!M]B>NQ<Z$Z<E.:UK"K08N3**;D,F=43TI\4'I>-GZ:U#;F1 0Y#P1[LC
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M"R75K[GZYZ$\PCV'(3)8 '9WI$T<WJEM6T<0HC8<KOM/D<$%[8)^]/:Q%.W
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MVM4<L"]R72NGJ+[FODQ_(:/*:O;>7 R</^PDV[5<BXGU:U(Q_U(=P:TVS,C
M&9E[[>';R$Y$;OD%RX\%,,ZPR<+T(W8I"T5H)OK-W]40\G[7P?I"9\5'=Y&W
MH^.VQ=^C)F":R^@$<ID7VSR^_;5246.DWLB3\<DWL\)>$]<C-+5W-S?A=U,
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MS0QC 9((J\_J>XQ]Q6HT6OEG%3;G94"DY].7OZ\Z;'N3T2V9V>@7:X[DA<2
M7#Z?"S$\75OCE^_D=?W92I//.,F [\A91(UX>'O86;)1SB<$S]>J_=/6NH.P
MC;^?/[)<H?6KTOW&5+FEE.O*'8-:KE5C!.TGT*XS")'S&=,UC41U1.PSQA"W
MU#7#>T"J!__<>M&A6M G\ \RK>BB6R6S$XA6B,NGR(2C(,1C$ N4$.ID4HTG
M[U"DE3T&NPXS#24_KXN'W^\:?-\(^!+*##I$9&(W_!#6U;T\+ I5JXO069O.
M>:9[.N$@MS]ZX*NTT?TK5%V 0M8@AN&B&CD_.,S\F4R:.M-5V.LK9/($_LTN
MHJ#^S#9<#[E*K'V!.CV/F.-;S1Y)<[_<[+*=>?^E!?-?J\LLV\+?0&>6U 80
MP1+OB/875LU&2O.&_58_7H$B_KT??*2#)0$SOCV_'TDU]"KS"&/Z$K$WTE[3
MTM/-WY"<)/:XX][1:5!0'Y4W>$5T<T*]=7%V>M*VK]CS3L>3-D8U1,Q9D_7G
MB.8-_ *? &:7BC]XIG; .S]W"HDF;$0=)1!Z+TP9#S9.7#@\_WG=?.N*V^/@
M-%.U^#D&%/,QB!/67-1Z$$2.P%'R_Z*_L2\&O9FB'8-Z=_,X68!BM =Y::\"
MT"=A>&]FYO(VD(^Z8AR'GS _N.3]V_&<H%-K4,(6HR9847X4[9X23^,"0LB(
M]LFL6']1T\<;57_+O-;:X[?@W1?Y3![I]V1=8@3I^ XV]/$BM0PHF)AR5?'
MFU4C58@76PM?&V)-194<(QU\YC<G! F<SZGZC+7Y2"EHS)U:K]$A<YQW)>;
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M3YE40R4\<3)#F^L*90^T:]3WMEDNU*6#?4Z=4O9Y-[+#V=X7J<L"=#AY>Y#
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M])8%ZNXQZ&$)]HAOA%R4 EF0@%3N'T7]4XL\OR/L!=Q:OWC"SGKF1N64G=&
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MONR&WE\!:YO :+4CLOZ'Z+HN ^9^NHGEM<O95T\)Z&3I[GZ3_:==)DCV_T,
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M(Y(VET["J[#.(Q2R;YE*6L[#<H\ 26XA\\+T-YOEG%A'_.O%AH.+M!%B,ZM
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M6AK>S_JL  ::&L/O,W#IYXMJL;J\[DA-Z4I2[N+K%6[R@&')__8U>4)VU2M
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M7:<]#.VG1-#CLR:0HXSXJG+W);7F-->TWT-1,K 'P("9$??CODS/;O$#T6?
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MLQLZ2I=1R0Y7@.,[0;CS\B=[K\*O<:B$2?)^!NBV?+P"-+0GVRPPM^8L7P$
MP:,0$UR;G2&6TP1T2?3R"M!6 EOE^7$%^,5.?'EBDJT#<X7Q2A?@UG!Z<(K1
M\]_$K0M#;'S_^%W]"G#3(OX*($\".O@R<9AX$?E;>YWKC/XP#[6+NP)@" Z\
MA$&K_U%=&=^+\B7177POI5J#6ON"Z\I).0N6@Y'=U1=X*L1?^_L5X$.IRA4@
M]P/P; J(2MX"_FT,(!X0WFJVOZP1I!C%W]- MC,W81Q5*Q#W_A%L60_695@
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M5.Z"9.7=46F>1#8\&)F*&%PGN1OK?*GH)%##(SQ8>7\0>6M5SHYMLU64'Y)
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M'+]K %:^ 2SCA1;TH#N;O;ZU==IVJBQ=^S1#O8S6G2L3YG[.=.)_;5[KLBB
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MR0V-F3])4VH0T9)OBW_YU?C[O';3>Z_5\;:7^<N+-?HA(3\*/[X;8;W//X.
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M^()YLPD+\MKFH(\$??0@M=)YN_(4ETA]SC^]AFKC[:7 %Y.(.PVMR!_-C4T
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MS I;JB>KCV2Q_%R<&%"PT]CE\%'GQ'PJ1NTPYW@+WGA?XEP,:DQWDASM!;@
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MMVE.L;C9\>L_!YU:"$U\:"9R;=)(^YU,T9#5M+6!?_K&?H\.M 1^$R[*%+E
MY\UC#O]V\8&YFDO$P-@7_#OIQC.8#!F1=("^BV&4T,%$?9L2=SAOHS0R237
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M_IV$CI[VF[,,%Q@8+G"Q,K-R_7\>IZT CO-T'^G7Z>FN \YPT-%ST)UV (
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M*\5(@5\>VN2C[ HR:38']>-_1*NR^A1P<;V9=WAEM!KZUT7R!9]OO@O=]DY
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MHD/F!-\1* 9)!O>U_EP/*[ @M$K/M;+16&2GW VSS7-BUO L:=Q=;8_38Z]
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M<#E)%+$K,L)*](*=C/B<HX7"<4?M<E\;-;$I+%)R\:Q-!5B=7^MQ<<A[8^M
MMD"@$X0%+OKZVSK'V2"&W_%Q^P/73H:5Z\#)]-_*X ^NK)587#<831ORE1)
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MKV*0A5KPU6]>$"J!&\=/YLQOK1ED=#-+B@T5P9H^TP$?++WP^TL)T+NDD,#
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M;.8<[?@[O#QX%\+6YC!#&X5??P7TRZW]0O5'X(M_@R,[NLG%U-'/>!6+GW1
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MJU5)"D6K9LK%MP+4SA)/9:^8;$K*]& A^;O6T $1I]!6M]3&\^5%2LH'N72
M"QTP!6IC;M9:,G0BYN)9:#RXYD/7K*ME*],EVV^9:D^ ![UWZ0 V.J ,'QHL
M_3GKOQJVR>7?C?!(J&)AMU?Y0 ZKN#;J8L9,>B B_LF@Z3A"*.^*19RS<L6[
MIW5V-YK04?E54Y(6K*-)&E;D&J<FFLMD8$"(OPYWUSZ[=,0#0> B,%1J1##
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M$5YP=,@%GM;*/RN#=([U,P\N3<W%'0:O8%XE,?4.WF^VV8WQK_(S],:?+E$
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MTIM=@\,"1$_5YWW,=?B !%B>5K;]I]W8QP\_A>N0EG(4(-6I?.TMHVH3^Q3
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MI)"L96;M%L1&C18I)]#E\0D#?;)$*[3==VN5&"#S&W+#8-_,J+H)FBYZCG3
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MLZ,F^Z>J\-R^HLZ!5YH^AD_,GA'PN^(CU48H.73&&<;>8R!_DFR]-BY1KU[
M6\@]AIPAGS5H-#YS/9B1E@KQSC>V;_6+55<\BW0[D0G-;"FPM2.UK((()3FB
M K?D +BO6RX XB5?>3DO4"FPC+KMTI(@MC!>6P6?:'38R9D)36UQ,=07BQ-4
MOLE&W<0DO:PU+VRE9)C0B XB,B/J!0P3=AO'*( 0H[Q5FV,*(/77#[<"XN6G
MF.4M0<(&(4N+ F" V%Q]2J9#O0UP:7JUNM=U@U3BR?#H_4@0KX.AN\P<4Q.0
M@.4Z9,8PS_\FLT .BN 8&OX_-0 *H/J8G 3202IN0)8+X98Q&U'4A,:,*</
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M2%0[EJ(F&+^:TI 29020L LQ/J!54 NDN:AS>_^SS4%)/*%5YV@K'C'W5GC
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M1CI'PK8/1U=.?+-257P1P:WW3!W\R@N^.9SP9/'AI6*KS )CEQ=X\!\S<H+
MS1X*^DQA$$[/A2B.B1VFL)$^5>W[8I[G7(QT7SXH# $DJ,ZN3A2_OHO73316
M18U[3D]O!"6S=.DF1FD;+I\X!TWL*8*C;I>S%O[]W"ZKCZQ$,XR(ARO#E?ZA
M9R&LC7*%![(@=@AR)%![U[BC;.A_3\N+S<^*PSK;J<[[&5W4TC:]E$%]EK"G
M9<WSD?/G3RYGU8CZ1&R!OS<+HS-B*(!.-&3_8GFI*%/I1.RM+7<8L^&D;I(F
M&%DW;(KJA' @/C2S%FX,3^=M3!4SGVMX=)IJ6$C#ZW"N"\*^@D.URP.Y;J6R
M=Z+NS_QZG_:VN-59I^D:9ETCBZM,G^,"7DD?*XLJN#B6U;OS>U]#N%?!']\-
M.6].,#C_^T4!J>Y=RJV'[V[JOVNC#>%\GT CZ2.&D2XK(APH""Y!+\M$2 E'
M]M=^T["Z+&["< !8C%N,FL%R0FVV?#VJ_$NFG/-VOL,FUO9.Y3=JA[QKF_C@
M*KX7J_!]!BUX,_*G1?BEOJ60_ K-/IC,VXLTY\66:'L4/KM0Q:1#+.8(>(5H
M46*;:"N:$QC,)!6ZFRCN\M/HF@O@IQ"5 WYP1HYZ\GAH[.A[-(]O"T;GW"D4
M*O&:FMF9/*"ZBGK&MNRHVV<G4JB!IFC?F70>%6C*^,\+SLSA<;5WKF0A*EF'
M!$(.]4O])O_9#60&^LBIO60!-L-[H^WP-:3\$C1)W6.(VV[8-_F/(-VH*M.9
MICCU,XWN(5U^L;X1T%9:H:CF%ZT"PS6G"Y<W8CFC'*)-X^]^C.N\XHJDH>$5
M'OGYZE7QGNSN\?3&<'G_4I?R(.PN5&9P06K%_7Z 1A,A#">!U+&?:$>!1QRM
M:EKT.0V=^FDL?Y[WBQ,>4KBFL, JIL"QZ.CWIUJ;T=CXTE*M0(D]-$&5NT#A
MX]H9I-0V&$@0RB?XMW&MAB\AZM,"[3C!6+?;#^3YT'YOW+O],]+>E>$DU"8"
M+N3XN/DW3*P^>RERX/-%!)\YI32IE(H]LP$>4'!B25&P6\LHSVP%>LWV^.W/
M(U-$I&\6B!24:.HOF$P1&[?<AUH5M-R],3!ZGUM]&HW-OW-J.&A41P6N2$W0
M SYDB7\'Z<U7[D,O^T1W9,D,2T$N!<A/$,6<$D6,0UGF/BUFL;1)*R^_L3I:
MH^WRVXENO?($X\BJ'JTSX12.R(/N._K-G7>G -J^\/!]P*DIX!/UF[EQP4?*
M> 'C[1H,KWFGS(_O<;?_?$9>H3GMJ]\^\1@JNVU9V,'X+:U12_*X9>5D.[EE
MOM"M?2S)YE:=74%^EMG^[G#&K912+?10-(3+4U.%Q=3HM<+PV0?T]V:!&Z9"
MH<VWYV_C1K%^T(X!_Z[IN.PAH<--X\CGM<]Z[\GS-541Z$XDGA L;7)\,)WS
M @YU37*[ONY&FBS'MLU6Y\96.5<GZGM -NJ;7-C1#K+T^+XHW7J?>G[7WMW5
M0KUZUYGX@P$[3:"RV1VC::[3.?YW+3.*Y.>?T'>;I,OAHI+8[:PZDX#A;@<P
MS\0VPL91 W1M$CR#!0/KY_);9M#]CM5G)X5<SJ3Z'NX7!AB^R[I*$%XT8WV6
MIB6]T&7(K%ED>NU2CY76[*'NLX?KNZ@Z>_/+96)DKI[%\3%GE9+."NZ9B+T5
M=(A5\HDE+R#? 71I'\8<(/\#E_Q=H$K9\K+K3Y]O(H5K34\^CC[$RO%,O.RW
MRV^H777JL7.PW=HHBQ4,SH3=(Q:9#YZ:CVIF2>%G%B$12GP!\H%J*LG8$8\T
M8=^<9+<^+T9?X5$7?A<DKX,]T_%#[0@*X%"T@P+(%BBC'YI*UG)^?M5O(4XJ
M5LOBC./YZ"]UO$R]_6[/,+7"M=IA!CV8%GJJ[YZ6N%:=J2BY7[N+>A]5V%>?
ML0Q,?UB2+ VK7,XTE#6V/PS4K:4 4+^^HNWE,O %O7#>>XV*+[!1M^$IBIC_
MH4]KJ#/@V5]O!O]'!=,XZ ;U_A]/@*1+)0^:+' Y:28_LJ/N]M#=+E=;&HJQ
MQG%T;)D;U=(Y+:G$+?C\8I&_<#Z., BA&\F4U<^P0WIM'<7+%KNZ)_]:D^)U
MUQJ>NDH!Z%17V)R6N,NI:O]F-4"GR4?JOK92SW9-2I"^7*H8N8@*\Z$Y]!MN
MUD)OF$&Z)< ;?A-%G(WQ6>C/JCS6:CR)P8I-9\P0'>:A.L0'XP?JDB3[0XSJ
M_Z+NNZ/A_KI^1R1(M.B]A40G6O011 ^B=R*(,M&B#09!]!8$0?0>O8Q>HK>H
MHW<S1&=&G3"X?L]:]WU^[[WO>^]=]UGKONO^<=;::]:LL\_99[?/_N[O^39K
M;=B[?=&F/.RYD X$N,Z*+!J'TJ9]M=)KXN=ERNOX'6NL!QHIXC#F']/;]4J^
M\+R(''%VI>@J61@A"/P)#,,MQ_?"-A5I7GHU^TAP/ ++15IU2P1UU.E,9PX1
M1MU/RYBL0A860<ZI$HCT.95^5<;VX& 4CU3/ @B^RD#CPI<H;"2TO^P-L'X0
M \*;430F.>)%W 54;%<+@Y6\HSYB9_H"D'K'^8K9]J(:S;*=\]F)>?5B8P5?
M]J7Z! \CNNW\WQ4DP1:L]OZ$X\Y27G!B(HA<PL5KE/3F5KIE^9\>UGOS -NX
M]&HIS[7(R]&A"?<K,5Z]S?BW,5;$DBF> "N>_@0_]8^(YU5=Q\6#]=/GL&G)
MW=CH%T_T_J3K-V1VB(RGW1V]\,%?R/$_[T&JE"1!,;A[VA*6W_TF9W&1?J<@
M(G*5>W]O/-K&</SVK2JNX#O8'Y?N[='?UL!69WZI6:A2 KK[1UR5!48;'8P;
M7!>MW/PB2^3ZYZ[4<GK]M6NU4LML3G WCYZYBEH2VZ)?@AA*I.VS>$++/-_6
M)(-=!>Z:131QC#_MCH%@^]ZBWA7%*&(4C<22T5L(D-C<0!]5@)IO<G"#(32B
M$<+E+^09>M>^YGR);1'KMPH<!'Z=>51;(F$/D5S.;[]8S6Z'JLL).<,7*S=\
M6GW.4SG;'A8OB-?<7W9,U8R/W@J0X9>?G2R$G=&IFP]Q#],5._,^I<O+Q"6*
ME0[?LQ"!"$_S0(<#8B0*^C*/C99^.K%5IT8[*=H\I0GCDD4 I\?MF<@/@)08
M"F1L0:'=HP]'AS81Y38MMG;(7T87!W\B^E]CF4$_#BIJ9$@VF?%E6(VLWF"-
M:#+0/!7?+ELUCUV.\\]M5;U"7(1+24L7YL&)L99W@)3-+O$K=4U)NL=EP]&V
M] >(19$YB JZR6:-FU!H/SFNPJ&Y7J9VWW'L<EJL.P%+;,,*FRT- ::7^VHU
M[.]8!C-V_N$)*YFL=C>UX3YH@YEG>:],F"NMK\8L%'1$[ OSTX&-+?!-=]D=
M,_J.)R09[WT_W<)F1BH/T.2C OK:;#50]07KJX1@+8PL7R)U,OK/H@7U_?!Q
M@N_6/M><U_(D8X,VT",/D&/;07O0Y2:C.>BL?O3B=.EL@7L,XX:R@=#DV95?
MQ[AYP'G?<M1-8!,+"V"S#(S)O4248$!TK]']%=LW+##W#GKT&[23M#JF5&W;
M]N3="?&K (UL#X2T@!8]A7=W!M^UWG)#3=MR:V0RUU>;H=6U_4KHJF;JGO ;
M12)B8^[PW7^QS$JNYR=W+BVDV=R:_HS;+M,6NU&/[1; E5^Q_WD9^LYB5]]'
ME]'C;+GM*]N:BBM77Q'J68:-GV.)2<3^H67+)]1O668/3&=E)I .(VT19^&(
M*HKA<W(Z^-T(_N"^;<-)K]SFXXXM!O#H9)L$]W=U($?-V2:DE-:CT@.SS9>B
MU*Y?>(N6C$G[HA(>;E#L!9NO3G&ZM4J47$U/+EA CSJ&^E/.FK^WSW=?^#<O
MMG6L92E-F#NCZ!"/D;$-MNO7Q$KI/>VL+;)<1EV>97:*LN^PQ%F_>](G<$*P
M4>P]:4?AB_(H_J C8;I*[E&UXI.G[:OGZ?6^;S-!P;L>;2E0D)J%AZ\7],BJ
M<D^XZ3KC;-$6=-[>GS=%-7N^8%.ZM&*J8/_AVZKP(0E5U:#4(X0_/48EI=^?
M%:6?\BR+(6$[Y=V\C8I::J M#7-@7,OE;!IX$:[;0=K^"'U=",NMNOG5&CGR
MZF.J5.=OXF\;!.X[QI,_IY,L;$6LO^LL:H!,3H0R^;[;G_2N*CDG;XT_UJ28
M(ADAB! 6Y+#^R]D3R^'M<JFBKK(BOV!>H"W7PIFK_"R,ISXPQXYIAJ^UD\A:
M?=(0?/F3AFW&O/1*%IW2!;.O-V=&LN[XA&SL1MHT/J&,_H+/"<#\S-3_(>[A
M$W?AL'NXD+_</%\MY4@-<3;CSYO<:M8R5_)%99DWHL/*T/+RR!\.7CY^0WU.
MA(.ZAN!5UFC7F&Z 005)D*+;D6F2G6[.\(%$:;E^OX+$>*F_1MH=_#3]W;?U
MSWKN(/K?RKSF-@'1^WG(3%_O.]4D/&4:T!41^>_%@=G\>O%[K>P_:SIMKC31
M,[S*GSN:PFZ>_M8H"[/LVFJ271R?;3%X@!):.XQ'\2R:J0M?FE<[".#DV5_\
M')6K.L3:&6"MKE3"U<\0%=/SU-'O<-2YJIN"]\"^3]D\\*+R]9($[;4X J>+
MVM*X06_EZE((* 0U &RH6>I*,O0B>:8PNG1M%=ML1<TVURRGJ9&D'B9D4]5T
MZ/*-,:16I_OJQ4BIV4N( 4+=H$?_\8O-&D\;_<N$?J8PX-D\1@&M5 "1@PFC
M:>WKTI=%[_5=SJ9\)H"T9BIAM\O2C+B/)]/A&POJB=?Y+*X[&DE[>)X^_U$*
MYZQ;=ZQKO]RMFT,Y1S,].M4,H[T(RA]?@:\L'.DH^#XL%.2P<;^&;^5LX2++
M.^ZCR=10#?UW8JLO)UOJ+%PM__7<F2O3-3'LK<0:O_R>R=:YT\UX.PS*8-LG
M45'YPV@T(>*07/"K-K4B%CLV:V+:(80;N4N,#Q[N97P2>6D2 =VA5.%=!ABZ
M]*PK;YP=F4V[(G7%6?6&(.7F(\YWELY7Q/8\P<,[0SC/_:#(]C)39LWYP<XJ
M@Y0K0MVV-\'4/)VNV][Q7<*W'LYD &H P =@.%;G[SHB5EC7O,.1CX7#^3;;
M@F#*R6*;&1>-IBR/^IO>>-Y0+*'SUB0<S+D:4;AAK2H!ZVI[8V@,I3PWI[3A
MVVBR6?KHDUXC)/O/86+ 7EI% :AT9:4]Y_U, N]DZ7/>H$G*717FK+[OJ*D"
M#7M=3U<5Q3'%\N.=DUV2KBF=F/4?CDT6?F-D$Q#U8C#H_%V,\/S"I+J22<*H
MR5<Q@3Y=RLZ#[U; U(I:./O/$=SUL>YZ%%](@*]-Q4XI^5ZQ7_;-=12'E#O-
MJ*(,_6P^.& M-B8?(]:$M-D_<6B&G C_MB=7>B+>]P@AQAQ+Z$;942LW\K2\
MHA9!:&(TSDLM+*$;YO#67=OK,:X3X+S7_NR2*.^K@UC%^Y6X58T%_V0?D)O,
M#[TW6E_%L[C4+$)N <;;[J(RY&?J0C\SR6>40D4(_8_TH$;L<9H69[QUI#UO
MUP2D#&S7>3V=R<">8SJ-,"=A[PILRIJ66X ))76T*':%$'HFG^1IF4#W(QXM
MQ1R2QV^Y C\!3N]E:H!^[^H6<2P\KVV_\/6L[V_"T^ [3IJNOY:+Y*APL\I%
M9JT&Y 7L0V$&0G^KMU?R=?2-+OSO&[7(M4QH0EPZZ'.]VTG!J:R*\0MS@/""
MB#^SV13+;XB(*<JY,H?R'8S/[:_[/%@.6#B\]('^:"^4_N3)^G5#T"V@V@/L
M@5<'"E?_5?7NWC!^)I';F&R_\3A:?FT"03S?=HH_D$;5#/J2Z4#!R0S)>WL+
MJ'O@FPSWG23+A&[K]C_+J@GC_JB]<EGZQ_L&E_YYC,C!TQ'KF9F)14Q<QBW
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MTER?RIOGE"!VZ,7;7[OA?L9P79IIJ.IN7V3LF=BBPKV_,+U::OY^HD<C?Z&
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M[N_1=3<[SS.?F%HNN=[IN!BF;>]]:_.D=F:8!\>"Q'?-<%:!74%KU\3+[[<
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M6VVB"3(N4FRRX)>,_XV]]XQJZMO>1@,(2)?>"0J(2I6J" F(=)&B4J4H4D-
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M"NV(#U-04M^T\'FK%%9?#B/9S3A[?'VD=B%,IEQNS]^MS>]:49G.3?*J)M8
M@G7/@PEOE, W!,ID;#!T&(YS9TRIL9&VY;I<E327%"$2FO,%JWWQG@S9='QD
M!C,,Q?1(*M+[4VBGS"\>Y6(_;BLUO*6K*+3IQCEB?>GQ(&3:*-9X!\.;:\)8
M+/>X]?%(<,!T3R:(: D.:R$/ZIMB^+AND7\X^:V"4^D5.E4B3GPG[R=\&*_S
M+F3MN$3#-X@3J"3$+W%&D2XZM;!4X?/#O'=I$'&;FJ2Y*8D=2=+,9R%A9W+M
M=[8E=+V/F-)O?VP3I%@@ZBTQT+6]_C98[G)HH6PZ[>%\6!Z@U"E:]QIWXW4%
MMZ\@5DN4O=)&<HX8B"9(=9R":!\APMN5V$C"54"2X^*<=?\*PV1I]=CW",S&
M2,UY>,D7S<'^W;8AL=+IEBN(4Q!.M%.*&=#"/N7A2'?$1@I532&-<#?RZB.L
ME6%2,_!2G+=D;US,SA!HGHW<2Y4?'4EB+X\.$@>@7;_#LI]^QC<WCYNMDTN]
MGA_*AE;+KB6\\8\HCE.>NEGVN\F%*0HB"Y@O[O+ 4)S>@Q?ET(SF)RW\J Y/
MZ7"CNPI/.,8J$JZ^H*T3[^_6Z/"A^%!)8-J^J! +CA$95>9(+@=CXH.#ZTBC
M%^S\D@ZW23887T*\F,..HMUJ%A.B@4"5:E_R;5V1YU453]Z>CDCIVX2B026M
MVJ]/;WNV^4EJK]<YECJ9GN6T#*0K"T17(/]8!EAZ6%D[?L!@US$OFJ8',VR[
MU#$K2.$A>L/H0T9]^9<KH.RH?Y0"MYW%SU5IJZL/0C!LSB+)FK0%64\K1+-
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M^25VZ0F\3^W2VZ\R_GCV[1D7GV,HZO -D$((O7^2 1$TW[!A+(& 6^7$Z@[
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MH:W'J4L?@9W3,DTD1'KD9!-U^*,0*O9E_G^ONOV?S0!C3N):%KTFS@#KK6>
MU=_KZ]F'W/LR9X#D;MLS /S2&:!( %X-WN/).1D(:ND_>1\#7 3Q6Q["[D#^
MPG94WIP!]EE )]Q"(8<@[=._.+M_"Q)TQI-=.#T-P#L%IFH=_E3H83M:^Z&^
MDRBH9142EE?RDP&Y?73[_$+]*@_^#X7N%S1^F!1\N;_V-9>_/04JPDEX%*.8
M/!B@Z#1PVX_![.%E54N5_Q8 5C.%R<[Q.$6V)?LK-*'TI88J2)FLU^G+:>1
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M)<5P",I%\.>/]6A\\";#;<LT0JTL@PR:3(,+D4&=9% >8D*3##*N?H%?"U0
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MC(VO39@J>!-H0O.$NI>[^ S!?OJ#%Q<!5G]XIG%;1B>:L!@3@> XT '@WI@
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MH1=+&C:2&B\F)*]=[UGKYBLK#+1\;A\F?XC)FZ%9;^G\H?#DX'OI.?Y#[6R
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M/U^!AH6S:U:0TOWVVFO8;#=%VQ)C*7?)W6P7+\%&F3:G=DS4CT X_A2(K45
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MG=_TZB,"J!!O03]$H:0*3$L0W47@;BND$ 'W94C;H !A%X&_:VUIADA @Y>
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MH3+"]O,/K]H[: <]47EEZD2COC5QW@A'!!3*+$!XUWDL]9ZO*626.XV-[;W
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M96S2%(:F5[X/!6Y/&59!R1^_L06;Q7;9J55:+7"S6DJL=4.L"6V-&*@'-/_
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M0J*AV^;\4.$&?W][)#/%DN[F%+3>PM"5 <.*<X&I]<+[C6X+5&X(JMEKS%/
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M!UZ ]C(J$P$-)&(RO]9-!/RV1>"O"Q0N@:>/$+.4(^7=.R1F#YUE#_[_P8Y
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MD4$N=34;F_8W4H=O&D_OL/L\^D:E=[L5]?BLM+^^"%GW*LOECZK6)JBN\+E
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M308ET0Y(?<\KT)R2QQHAP/XIB<:!<=Q$0,!U)/R0H5(-=PJ*@O=*%VGJ-]'
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MQE(D,FV@2:++.J15CK;M?>[SYF!\TXZ46&,FHR!?=_,V1=4=[.EGS.MB.XF
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M;<0ZD&IC[]3D8H:!L@N#P^=I*[N,$B/(]2:5.@=[T\GKY[0K%N\'W98YKPQ
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MC5+-CZMQG3RE=3 K%O.K,>HR"T,0S*TZ28+/.TC$ _RT\8!@9[T_Y\(1(&'
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M7? Y/.#9FF&$D&O< ].=I3OLUU@WS\U\X7O2=962=_DZT#]-&'8GI5E!5/7
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MA^\=1VRH][95#RK,")$7 <_Z@W;I-JA3<?Y6!'JB> !/)_2W8YXE[KJ+,25
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MBVUI/>#]4/DXM^. QE^9-4'GVIZ7#0$@36@LWGM=:^'BT!+X$L>7:OK)T&J
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M;E*J@+:*?_CT,-9RU&FK"X6S\GR_H_;]XV4N .7^#!'F<6^H#;VVRJ6PWV:
MD=%T:AH9D8-WQ;KGZ)=&IPJ2*JG?;6>GZ8N/6MCQ&J+#W-D''K.[]'R?/BL
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MM?PXR^K'A^H/E0WCV!&=)9_?Q\LN[EHML#%K19*65QBZ;X8O,&US9)T>MX>
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ML9O54%O?^[5 DD//8$!HK_.NU58!OU\+N[9 9ZF\>C" 6%V!MHQH1MP:2*_
M:#X\=<TKJ6YX7U[1<!@LWW%CKNR=O:FTKE>0S>(WGI_:ZES!J?PIQ5;S#I?=
M2V^CNEQ-N&L&"T1HXYURIU2RV1PVQD-K_!1N*;/H1B]>92_69A:Z7T%7Z.[4
M)@=L ;/5II-C$,@TOOY+1PQ*J6(0[CA95<OL;_QIM#(%$9V:U0-EEE_A6>7^
M'W5B@#<FPC*CE8EN._0 3.$ ]] P7UY,J7K1L-W6?OX'/DTQP;V![=;H@]"A
M@A>QS8XEU^>WSOUH;WI'19]%QET+N6 M-UP[0R4?V7UC6ZL^Y.1^BNSS5!I1
MZ9M'44SBU7ID)?"?[Z/,:T:&IN\/.W?2:!GW?ZH9-+Q;5O)RYW.-0/#$7>J@
M8AVR&*)OI$/KJ3[&2Z9DFUF.%HMZY>8\Z"E0(L##K07&I)EAW2!2&K/E4E>%
M&M3\/'8M_G @M'IZ,1BG0/JCGVWK1 =RP7U[CB:*\TI)29&5/58N2\M'../"
MM%!_3BRO_I/:[WX=O/ZWCOKTF&4*'Y6-< _E(/KW3ITTJH?+.BY*GGO>'&UK
M[/:I@]FG+^GQ5VE.51ZX24GHDQC;R<G_C[WWCFIZZ]I%?PB"2E/I-=*5*KT(
M!$%ZDR*]B(@(,2 ]2 FB%*E2! $I4@2D2>\@73K2I7>D)]0 (3G![VU[?WOO
M<]_SW3/&'>.^?V0P,@:9O[GF>N8SG[FRLM:D)K7LIL%F$%AW]?@^432*HLU"
M'$D3ZGK'V UB[ W&)$N//3>E2T&R43=+]+3?U%'QS#J.NMWD-&(T1I%K[SR)
M<M1/:AF3*N@/-[P_"BXKB#9-(/I!K5[GF:,UW!Q<5U(E.4[C#_E9S5<>PT/9
M6&JTUUR><9UHK*=0:751^15#*[4%W:L%@=>+2.F=)?[W1XCRUMUMGG*6/855
M9XD.+FYE:SEF*+AUA]YTO+QF.M^]V+[$U!P20&!PB+Q4J4#Y;$!%P7;)A56,
M]BKMCBX7DKP51R%V)[K='KE,/$;J=VX]>_9LWY.?;211B=D%^,GXD!'*0 +W
M?*E[T:L^5BKL&1: U%2^O[8;G';KU4Z\Y.?9)V/"6("%F!$^E@1'=@%(4H6%
MH'"VU\T";($3,@:'Q 6N[6R5YB_I9VA5*V/\F5H<Y2<7'I.I$IP&O2X\(,;I
MJ35QJ1(%YFS1?&>S@IJ:=G9N8B@9/EY*#Q[3!I<JLCUF4;6NB!A5)#_"H>Y:
M'7U'-7KMM59?+N=UK6N)XL ^!T,*J46,6:A:8^E@N8R+>I#1<.LKK7)O18ZF
M< _5$C'G0:@9167:T@#A 54O?RDW+$*&3/OJSU4CB,L+D29F?I.IVPHW(WNG
MOP@2U])VMD$L6G([Q:#\6Q]#0>ZF[BZI.4[HG MG5$HWR_'L6#M='([8T=&\
M!#<8W<R74L[6>2 ^YD_T9+8RHVQ7],MMV'T\4I?EZ%T-H,/TI7TK,X>#-U6/
M#=2?N(-T&6UW<S5,@L;]0Y/@Y:L)WJ]*0=O;_1MR-)#E:?BA>-V(:.W&-VGE
M"PK2_:R\;\7F+G\C(BKP8;,ES(G)K:DK3V3>H"IE8Y913UW62)PULC-K\WD2
M%>V>9U)Z]<[CXU?@=\Z/;L<ZJ7)_/I2><C /[*$T8!6OF"@_!MW& BV4]N!]
M(1,L,!N8@:'-.%_CCA[#H$5]U*5-7IFT%YM-9GT]W490Z^V;MX 2/HVWY"H+
MBGL8#+5%4#.XAZVNFV$![GG,MR8L(+" !7IVX2/YI3A1?K[3+6%W%2VH=+[&
MS5%TAK('SX>(@D[H^. [+89#@9,FLU'PQS0#$V+P?1NCVB =UV!3<]/6)CCL
M\<L/@HM10;0[&\J'2N3'<!J,%:; )G5OZ[\VB<?A1/(_#)U_$:ASOD;>B2-^
M7_J&S-(@'<7X+4.#/4%0K:"<GMU1]P?,.S-3B.G>X2E?0^IC'$1_=H%+;L.[
M48U[Y ?GET*E.O[:].S=\5M;D:A'X<J80'7+4\3( <>^5%@TOIV;XP7K*!%"
M!=S$;ZD32/E/JI6:3=:M;DO)/3!<%_^ >12Y&0;:Q0B@6\Y,NG%]W:\-A:E\
M\#\-L@QI0TG)Q[B3WD4"AP=E#U5V7JTPZL>_M8\4%*MT_]+VPZ;2%OP>![)_
M!AC\K_'=^;/X#J<SR1D+)26Y>*1P[))]!4_/IEH<4.73EVA]6C@<-(*_L:YX
M;(V*!W?]H<,"?P$+L(MC7EG/P_JR"%;?!]$C[U]N>T0NZZF2I3W[KKLR[?#R
M.//I97G)G[6[=SPR3MF(T(VA6  ',X.2_N/#7_LW;;LM$6WTD6<D<8U'\^=?
MC-X<AO]\7(X%&DDM=7XHY';P.VQO?8H\+38M ?548QZ0Q$UT1H58_OAL&P!1
M8B<O2OA#5+QO_ M05 7I0&#W: R0/40[3'.\^;"?XF$>VT^+@W3"D[8\#/8N
MR.I07KSML[ORQ]/W%]$0/X2Z@'>OEG2<>>+4%F.>^)?UZP2G?+UU$B#Q)#SO
MU&<2;: ?M.!EM.5QT$EY'*Z]_+575M;T-^-6_M=I/(D>9;K+\M[,;++[%JCV
MZ1PWY=XPC>36E/YE:/X;/*]3,8W=BQGXD?\'<<BH#]*-?C9A/JF JU$5FZO@
M^XO'NBUD:171O)5B.\[:G:Q?Y5]V/)AQF:WZLZF#_^G4:4].KF\()>Q V8-!
M";HCL5&;WBWH7(>TD11WL:.X* 4T#T?I'?)<,O"[/PR(Y5\$)+8MQR>8:P**
M&4NQV27K@=?6@@N4?W%?=5UYW#^XSV$8_O@A%HA'PE= ZZ/&YWWRKTWTQU[_
M.F6@?XX@;VUMZR PH4=\U.X:EWU]GB!^A?9[X6/]O;8<T3((:6^-&7G##IX-
M6'%*\#CQCSFC_"\X@RE,*M8YQL,-*FTT;U7YM,\WJ[_1WF\28KHKL.E_PJ#4
MCPG[DS#W_'F8=<U;<FKN\146+#QOK!.2,Q-<?(L?YG&0WL>D2*U=;F[:T^H=
M>/,*X+.["L[ZMY'GLCDQLWG6T.V8_8,!"T0\"/WI1L=.V+<^<PG9U8NOHGH2
MQ/QG,7;\LQBOF\+*+U:^LZVNC'8Y8KK!G7? $ $7?+!0,6J@+V1I7/<PO*LB
M[#(3PKLEY(]#W/87(:9:HD_JT2R8+A-T-X;^Z%]AA',_#[U_2G&KNE+<<\'R
MQB;^V?3QP<Z_7T?2RBM'HMW$:2JBFV5W.YYU=?Q4_^"K;S:YWB_,X#6ILH"A
MPE%?9 <,H_\G\8#_:3R,689)$[G-)@L&P"*!%^Y'O.#?C)A>B[N_[M2;5%MK
ME]XQ'3+]%F/3O_MG.=CXI^#0ZH3F)]!FG25^@AF4/9([.7XGTRH5:MKZ96JR
M0P)4Y^%74GS(T'[G2.3?GD1U6C?:'PUC;HY"43AQ=_,NVFP$7@KQQ )O ^)D
M9-MGT<Y_2)V"?T&=JEYD'SG[2\Q-6U[N>7ZAZ3QL"=.!D*5':?#S%RR_C9PN
M>TYYQ7/)?U6F_N:?5+_9/U47N=""RWB04Z&$)6(E(I"ET*<_8#Z=LZA7&,NV
M7QORC6W1I[]^ZR&\W/]/? W_:]TNRK4*O6^J2FV:Y%'-M13UD 58_+PCN3.E
M+W9X4M,3")E4925P.%=Y7J#;BW\V=SW_&M11S$7OZS%SZ!>UVKF%&;@J$RO(
MZ/7@@L/!NM;>L6'Z=-/GNDUH$=^C()0N3B0R>K"TP[GCNX9EVRJWQ'!"N_]D
M]L9FQVEMZ<GHOO.FZ.7/L8N?]VP-:-B_SJU_WK>RXRMW[*YV#^DK>Z6O.CPU
M8])-XQ;R(RIRX5RP/3X\:5%;8=@0"8LIM\#5\$FN'CITWJ#,HFY(UC]E'U@Z
M\IS]9G#L!_TGEYT79L8SG-24H_F9_ZEB-'39<=/?]F/9,XROC;8'6?K:U8J:
MRC?-&$0GWO..86"1Z>S7)91]3'<)4NUQW4'4+NU_=0=GW(T_RNMG<=5S<NT0
M-Z+%V%^;TX-THN6>;1?,:3AS^GW[13E?%'/XRD)%>VNGKNW^E])BQ#SRXQ^+
M\1VTO&2+JIRS+%UK(RQ_N.*E&%617SV_R%4Q)R&;YEYT+V32^'IN]$EOQC_4
ME7[EVW7'<W%5K/AW<96706X!LR\NT-R@H!^VLDC*DDE 5(U@^#7I!@R;=+.#
MZ<?MB@I(.>+."I"55E6G[R?;,54[%F].16'BK<P74$&VGZ91</V*H;9,+& W
MG%GFZF_ZZ8H<B?+4 \W/VKI&1U0'4K@"]B9V:C*I#EURB>$AKCW D9*.Z=T\
MWG4' ;[S@FE=86.]SZF SON1FY2KFTSO:DW%,S-MNNY)69*EE6DO%5X^>[(Q
M\JX.DF$ORXJ(*_AD1U^72);E\0S1E*M(ZU[YZ#8C_I1O<G51$MBV\77&H>GH
MDWID^4B>&<I/IO)P@'UR4DI-36GWRT7O99;=\8LQ#BYA9Y(NA/E[@I4X)<??
MS5$J" K&Z<SZH>VB_0R(\(^^71N;O8+0UHW^B\0^4C&6/+JO;25&3M4=9IV.
M8+PS%13$AGA8@/]S><^[V.2*HP(O+EMHV9X' DR!(D%%&B*I*V:D$4>'*06?
M)_ I+!Z!-B'>48^-C6[O,<8[5Y' ULPBT3<G0PMD^W@B@V5I*J5LIFK>E1<$
M#"E>'.D96H&#5WG9Q!8[[VE "0YV]DDKFQM)FB1.'8.\>=AM4=;?'X5'+JAB
M]'_(7ONIR4:+OC,O&O8A!THH)'>R7:@<J/=B E,TMB>S;G;OIZ+2]6BUT2.K
M[\XX2L(;&D Z(0J716>O0J[!3IN_;(C+NCR=2%0/'%1H6N;5Z:AET''.\;#R
MH!XW6BGEDR4Q,UY_M"Y B^*7>.S%7E-.HQOEX4@"?6\#%W8)3*@;8\<@/@=^
MI=JGZFBV)!6MDR<G@3V2_'JVV!!*P0.R.B=:8V\.Q+##+ 31$<AI]ISE^R-Y
M\L74%W#]1L6CDOCK59]BLTHL2<0,*J<AA7U;QA4P_H^(,6VD97/XG?D+]B8&
MM0MW0ML;JX;+G@\I9X?WLIFIM"8'O#^V__!8XOXE7<@PV 8+O,9PHNX@ED6T
MKV_D?NYYO&=5^IHZI$EEA=VEFV1O %#]6KBCC*C#,/LU97&&?S(MGGI4.B2=
MQ35V9>Y)^8[5,/N/0],DV'-9N-B%8]EQIY")%.K;B3E':K,"P[O%/S!L5$$I
M5\ M'ZJG!QV3\DR\*C=K'?/JU[G#\Z5"%&]6U53&R8/=OW_5O[6:P^\R695S
M?=+D^H6Q0T7A;]1AY*LKAG:[[054\H=,:JJE=AY0$J/3DLG2#V<*N);A!T?/
M\X5UHY5X\(N;720^E\%]?KQ_NTH-[\W?]V]=35$$+M/B#5R Y;J1H] Q"(Q\
MWL"%[3ON2UM]3BG"6GN97QDF\=\*#R8H K<XWK OI60._L%N0M,A^%CE /RG
M?#7YA++\L+3.J0Q:_?M^DJ0;J=Y]Q$P&!&('],2H'?;EA-R)5L'?,/?]Q[)>
M%-*EU7#F.@JRP&2M :T\="_@Y;*O[+GTM<6I7PN61A[B"L9'JX[RN6$!*F]>
ME%6>-]<(KRQ(("B3/KR\,-FC8%W6FWQ%X4HM/RH]8DY9Y'VW5D::Q')YLNF"
M;8 TSX*G=>JB0?C\EH(EXEW@&YH0-Z/V6O$$I^?Q7R95S-)LNTA4/+NVC]U?
M'FQG(XM:7\!##S0YI._ *BG,32;&?TQU,'Z:8K#CC%/>9:K<OC9OZ.X2\Y4P
M 8YTQP)F%;75#8B&$-XR'@89A_4A_3IC?O&RF(N[E+?N=UE-16CW].7M?GB+
MMV>0@)A<!(58(WH&C&$S/%Y0A=:6%IH&H1KET?U:SS*NP.DB+@,.8@N::W&/
MOE)UKAFZV6&D8!OS8V&B3S=]66'<7IH,+2?F*:D2G@Y%Y<1/$HI^6%<F]1@]
MX;LNVOJL4([4'X]JOVVUG>G%BJFPE6W&7;L\,WL# [!]K6/Y7;Y\O8KC1\1[
M%QXNZR_CDRRE2.(A@SJ(,TS-90X3-0Q6U!>*G3M.KUK@DW<''/?MI'JPG=;=
M)XK_*4N$JEZ AYGHV8^F""!\ W(V3&3ZBLZ2<L6OMLUO=I/$\_04GQ53BSOD
MM^[W0>(0<?'(%7!P'&G>7:3^1D@#BRQ;R@I&##$U6![>?^@YE!&^F]O8.7$[
M34PX?LGG+AQI:CDL"X(%JNBXSEX=MS0R5:;4"-0C.;JF%.T81:+<H^2<C\\=
MXX\GSY..R ZNTRQ""YB.Q(J_*=NH?E0;]$CB0]/S;G:Z^Y2EK%LS+Y46W])L
M^Y$G8$"5;99^%=<M-NC[P[S5)E;]1+(C!*BFSW(?(<U;L8 M=;$#%C#T1\:%
MV0;PJDJ*_EB'ERX?O<((>O/ B7]25Q;-[^!OB+&UBL>I(<,UDA2@O#O^'F6A
MPB?H0>O<@OYKO@,3Y;T!.^$BEUA&I%D3.P[%PB$L*O'ZT;2VPE.>^6$/2-99
MY04Q'Y/>CA>N.X;1#[_@JXSY.#$+V;67BDMT/?5J()[H$+Z0Y2=A?9U,#@L8
MR2@"WIX93\%E.-5 +FWK^!@+4.:+TKGZ2#$I65ZS5!#]/M98!L5\%WO[R+IB
MX.ZAOUPSU?@%Q(^M#)0>,K1IYDY-W5"=#9+';$@$%$S_H/ =)-<>]-3_2*G*
MB.%^'#R6[CN]JM\3G$9B.Y9;:>A&6 9G(!T#7'LM)%ECS>49RZZL)]7<OC(G
M-.=_^^M5)5+H -'*Q9172.&YCJ:U[.&,L;IK:0I9,-\Q/2_U;Z[3=PO:,W+K
M-\6$U;KR7(JW^L0)N9_719E87BJW# 91E]F,2HL7HH[N#Q1XWUVH59?QW58Y
MT-36KI"2J3'Q[L*817#.4.D@+-G<-Q//;HRZ:MYI??'LQ+W "O+9;B^\9,)"
MOE3QQD:@$@&H57>-7C0H:']<9(N_?5)S:&OLL5C<\WP=I8:0$ #_YTW\O5''
M*^@78]*2\^WFX'8IYOP91DW^1;VRFH3M)EG6BFGQ!&&1XMH?QR6>SL*4&J\^
M/*K L,%L%V5CD"\@/,+()\<%:.5,Y8S9GQ/IXD':08/J-K'FN7#1;:T?/6%W
MG_2YE-XX.\+-#!2G0006=@*DO1 ;!DBQRL5PW3'SP?+B!5/RJS,,H3*R3PMC
M-O&N-8X(*_6_BC8B>_&HH?-O9^?P+&A3888:P!5(SBS2PCRF@CH/LJCFN"]?
M%(D F[<QJ,13AP9I)-=FU"*3@N4P/[2PK+(RT0/V8]7F46:TD!@"TMQKP-$.
M,FPT'3]F9HF0O9]]P ^=/C:O-75,Z(2WZ*"5L4#:.J[38@2A'2)Q\CP8"^PS
M6:+Q<:0:/HI3[JL1X-6&&%Q/2OI?5YN1>"Y&'N_@)-2< AQ)M3>5D'J$.?0V
M+.EO7%N=P2E_7'H$9J BL<#=$5QO(0%&38-P OT:%O@IU8@B(L("# 6-*.M^
M1GB_#Q>N<63X=8,7[5X':&]6%?>!P/,[MY9Z<&W2T9=#XZ,SZ=/9X_>IO[.0
M@:&/7 "?$1EB 6 .)TC=*G_G%R6\A1FVB/%: Z.NSJ(5&7\YR=PMBP6R4[UP
MW0/%[PRX_CX2%;BF,U+:"0O([*>B+SF>'UKZ.Y]CA#%88*;EA^WL_MX.?.71
M_SB6E,Y/X+.GXUZ\IY@4GQUTC_;O#)Q?]ZJ,!&%>Y6$!O^=P9 U.* 5*(SO0
M1X-P!$OC^3F'O_$X0J/_% MXD=NDPH?ZZW%]V)O?&P#/YV#8<+VT&QQ!1HX1
M-X4C.E(DL$#*B3:&0/S7-0._\[@S 0O =ZPV2W=./(\:]P1_9T 9UXRVPD_(
MBC!XN#ZP?</Q]_/Z.X<EA<$[9YLR<3Y80%OV"/.$Z[>?__G?D 3%M:G_.J^@
MWSO,:7N&!>J#_@/&_X#Q/V#\?P6,;OL[FZM(?$-4^)SD 9.#?LHNPUCEGN[M
MI%C6V^P H7-'&E/>ZNSOW"Y*;P#08L,--#!.J,"#Q,N%*W5>,8?NO)^OI+^,
M)M3N3&VOUZB1&+$\0D]5>$V=D$30Y3MYM.WM&J,U)Y$R_"$WBSZ#%?[LCN'_
M[>O8=A$+M#E2V/ORCWCSI=E_1WFH#::,CNX>)[3T.CF#W?W2XXB''S]\[JPE
M5Y2;M[PS(="<_969=<S;"X@U@8C%'<;K\E*H,EY7FHMS(<X,IGL /'1ZQU)3
M /-LDWIWNU?/W1SZ*0Y>4+3D4WGIS'Q%NCP]B[. 8.1L^^G^B&5\XIBVJ9T7
ML^9\ZD7(552E:I#I"/WJUI'PY&>3NOP]$:5[T))GDU72<-?D\:8.UGKK.7BH
MV[1X>YP4Z<C1A/=7ZI412U@ ,DY)1KSHN;"_8 JI]T:ZMXTVV?1,RSQ4C$=&
MUJ[U,_]2G#&(;L*(AIN!U]=JSQJ(Z?.M.?M0AY^K: ,*K5-]&G?2-E+31O/-
MP)B"=B^+2;J=ENXK^^,/,98Q5B7O%Y#[OMFP/@K=V'?[(>4C^_5;62/ED%[,
MQS9&E :3VGM4H3&/XAVNWH(RP_*8,8-][4ZO=Y0ZEC6I_2R*E/?Q?O<B2H74
M9(=1&%136S -%O+A/[IE.S(A_E"B4P<?[YOTXQ'R+4=&7%H6I</GD%C@F+E6
MO?]@ZP#<,TR)UPF'P%8Q 3X46( (EQ??]G_W_F#TNQQC_&%E!/RGX7<P H8%
MT)'*OWUK#OW_FID^NYK*"-D!E_EP.B5)-E/G%Q&SM@4\M44T]M2#IM,P0\7J
MRK=6"TGZ3Y287]/>AKAHGI_C>1<+?+R2C02U.WE+(<B#O;5%RXYR,\=[87S0
M##N.Y*C+1M_UKQM'4%I7IY%YZ5:.BGX3H,8"3;ZTC8%*EF6AX7(J^7K;.[W5
MG6;(E(3\24OBF<X\)J@TS7QMKKS\VSOV+(L55[<O+V&!#/3[J1?,+8,-G*B[
MG]#:*/-YQU +)F3_RSK%="S0W(YX4E HVMO68^)7@[QP5WB:MJW:\88ZY?>+
M$1J"8B@Z:0.!9G!@ RMB]NODF; 9XK"DAI&99[ 0#9F;O6(\=9>QANOPZ>Y*
MA6;;BO&'%KZN=@4*QKRRA_YX)Q<=/]G'K#L6W)VS)%;-T4R>>.V1ULUU4>LQ
M];&TC;:,1&YX176,(Q:X9!E8TIG*LW5F:/MN:/-,S H\O9A-M>?Q]:FI$G(L
MPFWVQ]'7DX#&%NN/=QFE.*L/PVFTA]V*G7KB<IWH8.^@1Y>9K*_T7'WX5M,)
M7@8*QG _M63:]N5Y:L%0![5L;J ;JA/T2!L/2KG%[Z:R;=ZC]^R"?F7UZ35>
MX-LZT4/R(G"I*$6FI2F\F7A>>[.V0VBZY7!DU_:ADLG=0V_!K@CMM/V\PYJ@
M-])@*T<(=#Z5?*U"14R!Q"0W1)0YA #P?8"(1+/.B"(J-SN(-A>S41X6R,),
M;XA7YFQ!1JBD@(A*LL VNVEN10<H:37S[ON]^J^=M)\@OI>1_1W:@2!\7P98
M?(N3,:RRQ8)EN$XF-SN4E[VA-$*BK--DPE.#+%W>ZJG[MZ*R'JD/U^1 +CT3
M]:W/UYQ1RLV[F?R/(SH/;L@+$D3G+CWWM?[&U%_ .\%?[.3IY2'@5R?(-[*O
M1)P[@Z"I"O.[<L<GE3<3N.TL034')H';DA+-[VS%S!]_&IPU&]Z'!XY^K#/T
M<F@WS4.MGK(D+RUY]CI\5.F\X_-B;-P5K^W'-*Q6NSQP=*RYAJ^\C/NZA-4(
MW37*YQ=>$@+,_I\PH\C*,^)$;0QI*A8(,S17!)S!$S-B.'"[X$I84RD60(:
MR^MPI5-^!5?(7]GB*@S5F(X<8^1A97CC3S-<+7Z&RZ-'D5N.#/"!ZO.:]0,+
MH-K<AN\3L9T5+#J>T(BDHAG 6( VX]2T?7:?WPZ,$H-C!,W=*/&^80$(;!(3
MT(LK0X3]N)I]\__('<B">"A.<%U R)8NX$$/*[[X=7UQF& J 0@.Z=A$=SW/
MZ@ZPP GU_NSIMC:&N^Z9N^/K[D^Y"QQ/1@Z?'2+HQ(2%7N4&A@^Z3_/YV@[/
M_F\?M]N!%D\-!O\T'8+O5(//SU^J0]\]/Z0X"0OX=)X?-)2$*5U.[<,""!J,
M<C;F\TKJMT8$!\9V& O\SXWK_-/VW?^8_O^AZ3U#G*YTT+351Q(FV[K,UX)*
MI[2B5*RB1II+ 17VJ!0?GDVI X1D'(.@+LS3,MZ'?G8867QLP</K9/1^,@FJ
M-SFP!/^=34KX;].0IS"]7J%+$O2[G ;]WK>-G#0RY=]DM?)O6:%F_29^U&]S
M6N>WI%!8$P+\/_''[S_>_,>;_WCSQ][H>]#,"-;ZJW AVL-%A&XI1VCJ)!@Q
MI[TB8JWE/EX]?'664:Z-CXJ>;,*0%ZOC&EV-G,?O%H6.-5:7PME GOT6,""B
M>K&(^'5>>.YF+A^<H+8TI8&3ULA++6(V&1U>+SRWE1*>7YAG@ZAM'K#D<30F
M3%O6J7] <D?_]*7YSF^]:WA:B3I#AC;%6)K"&C4"+YQ >Z?+QMSEI:4A4?Y!
M$&<Y;L^5^OY#)U1  5H+Y2S:Z[6)$P%>G1\5H#1Q691^$IVKDH6)/Z01(LD/
MNKO=\BV.<#TX47*_\.>/%BZQT:<>4(XA@[Z8OPX03[?4_Y49I:I/-[,W%#,]
M,)7@=:B\MFS:]\2\/F(AK]]"T.2?[14AT^K)X4GJBOV5E+^?[/6GAW'\X^NS
MLNW"C\7EB2L+^OXSE$*JO.$!BOCL,>, #_.$-5$":^O>.[/@Q?:5I>="<F?V
M,CII2-'7)P99:;.:5N[2N8OQ#Y7D/4G?"$?J3#WQDXYI 94Y9"Q U <3]<7&
M'#\;,0D1!]N^GK*+-[QUH?0XI.K]XVWB:KV>4,D^'GE0I!2Z)J81S7ISXK&8
M^%'AP&S&<;%)]Q61[]_D+FH=7\BU?/_)F=+?:Y8>9JF(U!QY/X(6=<JK?\,'
ME;8Q[.8K2\Y4R73^[/N9_*%]823BJ.4%<]B:W?Q&(\^FXZ=0T]"@E+O/YO'O
MU2X_S'UM&7OM")9&IOW@+(,7"RRXG<5GSDQ-_.AP833QJXP:Z@^A?AMO_O&>
ML6YMV*N518!I^%0@\D7 DF"=+VE=G.3H<<&GT\?<I7P?DOCI K7CR/6).&J8
MZB%905]3&!OJWZK.FU;I+G#Z/XC3,-UZ6O?)FC:V<!'TS8Q_D_%)(8CT9\W3
MD%%R8BW$9$&/$ZT\E/CY9#:^$/Y>BB;@+(SY/O&PON&4/S1G9JTB9/W(2?YX
MCQHDXB\&O20AOXRR'@*)VFLB%1X,UHE^@L7H?_?M^&0_:,(N%J-R75-:C;9T
MNHM8*6,;+P+_MN[4=H$D!H1R[#JU0DRWE!6_9^[E8'$_5F+J!;UGXUM&)QT_
MNRILN+TO(]QFXE81E?/3T.Y34UFFL(1*L(Y?V'7M!*<F@ZZH87I@L<YJ$0M<
MKRAXD4C:EVJ3;;SQPC?P24T9)##1.$%Z5Y 5N*I)R^1K\]PGW''QQT"^GCZ<
M9,;LI["ZV\6*CU2M5EDP:OG3=*Z;^5;/L]D_.%/7F&J3K]4X)#&_=R55.KE4
M3CC\NO3]C\2E/ML]U9G+K I1';3XY8;#LG0H+?7E$1M$TLRT]FIUT)UHSH0K
M&O<TN>(*6&L)N66?1:M*#Q"89+>]L48V9,SS@>12C48W/YIFATUU$$#Q%#E>
M5?KT!=-42[+C)?8.-4C?S5/FS(6FS<";^4A&WVKF=8K8=XT)-O^\)\DKG[!H
M*$G .'>;*L\6T=\\-@JWB6GQB.N*&/))]\K>FTZ0ORU\62/L2H!N_CB+7#OP
M6<JC9>M*2RM-8BW,XL1XI29PY:9_^]OF1_X2Z<PFW<45EYITN]1BVF_?Q!>V
M0,WGFZ!>+)RT-&N1C@9Y%*Q1S%BTLZ9(&(BU?G3^7LK[>5[)&>]B+%*?7U8:
M8N(;F:N=^U1PO&3=,!&:/*'&&9X5J"OV_HCG6K'EZK=NEF,Y-IFP1I(ZKLQI
M=6EFRNCE;2A7J15%G$K:^U<B-PMN7,N@(O@,2%"Y.UZ$>9D.V03NM?"SA*R8
M'O@_%-KKK/JV$006Y)U6 8D"3H>-9>85'ZUS9G[ '/5K2T,F3/-4TP/--.FE
M<NTN1U[S9X U.>L8+;)!7^#0T9&W9N#Q7<21JN>64)E0?HX"H#1F0>O2Q$B_
M:(5P>,U1=WD^66MRZV74Q)TXQ3#A($>>9[,UW4!']V2T$"0K/!VQ7%"1E/WS
M"/2HXLVC #YJ0<:G&7ARO%)X<@R4#VC+Z3C*HEVLW!AN?0UH=G3X$"9VY^0P
MIZ#\C0.GT:1:PVN*\-U+AY&%C(G 4'JI0[DG-!LVIEY?13RH\MK+="V>:#]7
M*^-&"0WH80V_EG08UWLP<M.W#*_;VWY H$X'4=1:8Y& 5]U85<YZ\RY032!&
MZ/7!R?("O$7J?*7[H[H.%FA4:E3A/;!SR#::U*BK(,*8:+!-2!PZP]4>3PP/
M]/P423J6C\9/BX1XA545)?4*24EF&8WDBB4:#,[4Z^P?&\ M;V5QZ\]E)C54
M[O_L[P.A;"W/E[QOV5L>_?R.!4@VD"!, )\ZYHS^C"-5)YK!:(6:1K?T(.""
MHV6A$?EHDG5NIZ>@\M#VEI)PP_,DWU0>>F3C,%H ?18_CU&NQ%0O8('583AH
M#RP.GD_V/5^JSLJ%SV8HHX6+6N$GE.4"I_N0?:?RSE=;F([A2QC$-5S"*N31
MO(B-RZ7@3W5S-G<VN)J@;1W'>"8\&'D )O[[]56%L,;C U 'NK^W\2]<9B\=
MSJPQ5K<[,I@DE'O/U;]YNR.UD+OQ<&GR$ M8KS.]6."%_W2%YZ(LCT\%6M"O
MSES:L$!_#@:\XNN$!?X>9=WS*$?^ZV/&UC@.LS@^O-33KJTAL'7%NRU3;:5.
MF,$^.MCUC/_CXS7*E^*-0R3**T^Q@!ZB\=<-?T0GJ[@..U4'#>]!3^ *LMOY
MHKA\7!86\ T'(?H:SQ>T=8<;=[X7??_IEIOU[OX:#3+PAJ,3,U%URW!\8GY%
M#.V89ETU/L9$GL(./0[ZDVC,_M4$TH<%=A;*-KDR,GH2<+WWP1R"+4:H"HOX
M>C88[#PJYAN7,]-E,C:"N/8SSK2;<8'XX0M: FVD"&!\E)%80'@/CJ$;6P"?
M73&)/SL1@?\F/(W*VVYOH"M/Q]0:/MSJ2*"-M#NQ:<I]//PXHI>+FD:KY_G#
M^TEC15PK'8X6"W_H>;_ )=]^RZOS2(,H]@;JAD#VFC>)JGKV.5-"JC) T?>:
MCS:?53WX.X8*MY2/5B]7[EO?[RSH90S+4!EFQ _O8FLZ.CW8I[/04^<.&[DE
MW@O=&AHX[IF4R$OJ(LO7]W0L/SDYH2][P!"NIL(W_^X9_R<[0@VGUU/)$L^^
M@*)D;A8/9]8](;=R@Y39"K]>';<*]\KVLT@O 5?:]H&+RT&%K+A:NSZRG<&1
MIEE!8V@:J!U-L7PH:25'\_2SV$1L_-5>-B-S.6NZRS<U^\<"6IAA.Q'E%R N
MTB^UHGS]/CA8,1-AP'*XQQ-/ZZI+5G F>[@*)B,()D^^B/QT.^</Z]_PQY%,
MSH4MJ@3'?'7I;@8[PX% B=D;D4]/YCNS:D:6*Y(SS/D/YP309<'*96="<YA8
MO"Q%7:DP_V]F/OX;GA*[MU-LQW:L#W*V1/^ $X#OZ26KHY\";>]FSG911M43
M>&E7=8>D^"BI0#-BC<S5^D=O-O]*[&\#%R>X R*R.9;:0%JU98"M][S8F:P!
MERC>&"=YY2GH/AL8=JD8-_L#A.542CNZT:,2":ZG>:]8E_+O"B5+2%KU#\G<
M_)5\Q$;FIL_H+CQ,<+0*!!< N*C"*SFG(S=]%#:"SPV,A&ZIJ4M>X$QU<[_4
MA[KPT,N[Y^:% RJU69UH+T\."'&.L93B#<W^_99KQXE%U)4B)9^96#&W6TFW
MV;X>2;P 1M)+=T2-H9R"A4F>SD3(YO/<H(<-/Q;3=#HD3IM;_,8BW3*46A\Y
M5@Z8IY="W3P=;(TFU>O]Q-%EL<IE/L^7,+%F&]<G>[X7QOM(@'8'69B']KM?
MR='K/[@E2G?]']A->72PA![?VIA).H>AV#D,E631\V*8,$W ,KTD<W0E0DDG
MT[**B"%6^=6V[(N41=UH8E@6-8V>R"O.F\T.. ;#W^4\/P+W6?DM ;I7X^8F
M6W0]\[=] FE'G I[5$#C$Y%CU_YV!'+]<&;9CY+F]8WGG;ORW@T=O#?+AS.K
M0VQQP2"Q9N&X7'V"J++N9T*.XNP9JQ;T[%Z4DDU+^QO.]"S6HXU[BT4V:C^&
M[?AQSF;SDN(\S%7(Z>3+C&$@SOFA1<!/X>6Z9%4\6[UU?W)#6%N([1\@.Y)P
M?HJO%=);>PZTQ7\"#3G)3[Z&R_.GG8<"93B<^3HM64GW%\UT;.!2(']#T\0T
M=U1L2(#O)1:(B\'5N\[.LULQ&WH*/&F#CLM75&;\9;*G;-H >QW][.''@:.2
M 0'#^:N$E)?K?:L?@MDTBX>7ZMYGK(VY9]#-2F@V:M$F HV*-F+50IV_H"8Q
M10##%8YUKWHU=?TW\=HU5?S5/)<TLHN[R7P3UN1H<CZ+O8B-5V>!$.=!7]W0
MH%@YI+4^&8%O_:BT/F6X?_*+XW_MWAW.+(UZ('*:EZ;D(4>!/[GR-\Y6>\:?
M_ICNF@J%U]GM5M\GYV=EZT!<5+D_#@HLDLC-+$B3NP3E.OX39>BRUYRS(R_3
M2*]PAZSKBL;@,N^GA,3N)>W;^TO>XSL;$QGEHQQ5R=90_D-@=G=0A_G[04O,
MR7W"=]X/D"\6+%^#RF;1[(D%Y:T36ED4=1[44RJY[$I<@C$="722^&L;EE93
M?T.DUS\1:>S+.R 220_S-MEH8)*JSZOP[9!^VO?:=H7(HPNV3N99I"?0UG%9
MUV)0>B#1"5*0:MW?/F_!??GNA(Y=T8,IE'6KK.#W+30>%KC$];KH $QEMI[H
M/R4SO97[NOTV$,C.7K%ZP]&!B.H M)GJ!J!<G+(FNF(FU\3#[5:5G$LZRTT,
MB:J$A.=.\$P:Z%$,""R@X15<X'WEF>]WN@C5;5//B1<YCH()=]?:A0=&L<!K
MM.!';VG3/$<RF-*B1J [H8Y]SG7Y:F"/J[JP9CR?Y#8/_NO7L7HU]2GUIF,5
MP7M?8%=0+[KR)\H+;'QH;."RJU!%G:KA3/^96XH!PSV+_TR@4"8U]?:'AS0&
M:20KS]_+MI! OLJ^KE=\C 4<^C_ K>W!9HJ_CM&?5E._RSQ)G%?0PM5Y>?>4
M\4L:\? #!G,U]?>?W+_4^+4+7;^?E%I$'"B-G&6R)QA=\;R0#+I_7WN&5?H<
M*GF*]QM&V$N3'MF->2C0S0(X1!K1%]LZCSW?@7A"(YQ*H+6-\HJ ]O^D68UO
MPW />9/.:]JVOFAKGE@ST?Q0.:8G^%4E0WX3?L-.Y&\G4^?OA(B?.+Q#[+2*
M)[:_@Q3:Q1TZJSME6Q+<-KM)-W':9-Z0Z4]D=I^H*?4"W%Z;=GWF*JHS&Y9A
M,98^>E!TR=Y"9"![Y)D#K]8[J0Z!9"O[P<_';RXDJ5)E=*'[?#9 \P+MD<'%
MWI<-D.2M?(XM],S9BWS@>R/ET_;'HJ26+6*1#SD2[?CI;Q=S]+2SD(3E%[//
M;7/1GEH(!%M<1_K#6T];*DP*SC)+QR<*4QU$@Y??S&F7,7A22[]'5S]@/Y;K
M''=Y2Z9O28.A>$-"[Q!O+9N:SRY6\Z[UA6J()!NUDNE3<PWK?NNK^BI*1H3X
M3]?DF*T020MEC62^;*C%EAE&9.2;!AD8L1+BK*'PB'J7LS)W?)W<:?DLXD[P
MX1OTM\[X[D?&!+8?;E/I=5C2+)>>?<8PK]-87BTO "F.9 SQ*OO-5P?.[&G7
MU%ZG-#V3&4E\G.2,SRWVDYY?:917IN5KZE5<CZGS!#$3\+%I/AA:F/"D9-#U
M4^#HI$_K6_;H]XOZ8751MV_L7EI]F5CMB9.Q034-'S-AA9JD;E![L"R?V)F(
M4E6CD?4-=79>-J%+@?-QM 1?&&-" %3J?./69:12U]B\=A!:IV#=P]V7#^4?
M\S.%U=^ <Z&+3WZ!N)=[:V_$O7TCA0F$DXB&(?N.+RTDRI$K6?-8@ Y6>Q@X
M4D8>/-; XB.[-S\WS)=16NGT'!DN<"HYT+#U.:/O=/7.JX<A)\H:2,<63:4]
MK0&1+:%V+PCQN&WI4]?4?0;3SHS3>WR,2=)E[T8?-<6N\CO??<:0PE2.\"U?
M'!WF1/@FVR )B2]]:JC']$6H)^G<.+:"?/GP ?]E[5M2P/O=/'QB4;_^K#2K
M+MYDE!T%^0RA@'&.-FO*.F7)([EYQ==<#3OM..J,YR88W$>UJA9W/K=9$J#<
M1"ZY<@RX-J7+;[";/"V-W/Q>TKG"P^OE[L](1$!&:UL _6_?HO_*'N50;VV;
MN492>ZF5=,M-=T&ZS&O\1B\'\-:UB!8MP:F3C<V@?;Q1^,U&5,V!P 2S6,Q<
M4:C\K4>\1U<)8229J5\O0/; G3$8S\HER!PL2*)M>3Q8KZ4LQG#BS/@$1+I4
M)=U-+E7U>E*WXO!G9"5\OA;-@@7DF&QW<6H\- /#\"_F4:&_["PKQW"A]QR[
M&@S/GO8T)OM\.YD]T./%*!^5;LVB'' ,"A\@,D:GXR3A^?Z8'430&>"6VB6
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MVY B-#Y2EOP22J]E!N\+,J#@4U;Z7;["]"&9'VTM&GG2W)T$ULO<W2D)M#=
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M&RWOM4&;NZ4=[VZX$U/V4R=1WKS:39I',+5,&<>A>D>EP)'\)YP6PVGNS3V
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M5K5@5%URDP7JFUF\X^4S&.+]M%"J,(^G\C//7I-6) <3H3OY(VD183RZ9,*
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M64-0C4G>=7!=3:-3MEE1Y+&W<^7RL#?^@;/_ZG O:<6!W5;*%)XN1>CUUG@
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MU:A\)G  ^L\7AE$B;D41H^I@!U1IUI+XRQUO42C1%=8)$1P7#"WENG0#'1U
MD8"?]]G%HAK"N[D9@78V^0?;HOXPO#<>*LJ[WX-_BN2!EY11$H$1DNP1C CP
M"D9@-L.&KQH8S\]@J&L1G32EP<_!8#C&0>G_:_LR?S./<<<'='Z(0$D<[$63
MWX_P1[\(0>[!V1GN(('TA2\HP7'O^J&&TPKC!<$V(XP4)>(43G?!FXNK2
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M^RTC5$4QCHU 2[O^8.1+F^8+FG14>2& !#HG1ZO=$H>*,E;@A@E4#V_C?KV
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MV$O^X)]]E@!^RP$R=?2UBY&_:[%4X*TPYGK%WL)PIP%2\NFJ:L6RR-R.OWU
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M""@OIA1#AK!EGI !/Q[":7D^ CDV]0W*,#?$#G#J\=#/>K>CYE.*6C<&@.#
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M'FP\<4*[ '3&*<@Q%>;3K/.%U=3%V?1Z#.FGR!Y&%V-<T7*BL*9UB^;;D_Y
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M0\Z9_%G%)\T_NS$=:EH<[?L?WK6+7'->0C!EIO< 91Y:&:L%A?U5L?#08 \
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M![WLAF\KMSP^-6P>&":F\N42<.4=NS7@\XHC:??V6)^TW1 /RP/J4<QT_GI
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M]X#:0:;('M ]A"YST9/3I"(?_396[BQ7>YY-XN=K';@_.Y@G3:I<5W3$G8,
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M\//$EK;5\=-A*Q#NM0?VGO&N=S)).L*3$8="?3(2H]1.-+R3%[H+[0.[<=:
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M)SA/X)K6R(EK7@'2W^45R]ML2LM<3%>OMM$]-NE^-I"O=*E9I!D+W2Y?; K
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M2V\?^CA,NQPRY1\[1%B<.Q%R9<R(AJ7Q)&O5&[;N.I\T,Z_N#S>N]);$L'.
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M5)MTIIC18_^):AL"3"RB^#J?*2F<\JC]UO):5XB83M-^7>N[UHN?QRJHSC]
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M\FH77[JHH:29^[9FJ:7>],^H-PXZL)P3\B69+Q1;GV0V9BTNN<K>G2U;*<_
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M<(Q!:[G4F3OD5,.Q?%^KSB=7L1W%_(?5R672R'<H7#$6, ]UH[,,N.#^-&H
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M"0QM01W6\K18]3G\)ZTX-Y[*P,WP'H:);Z-PE:C*9(+LW!$H&@(\0$R^@AD
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MB.- '*0:L9&,$]%=MP0,7,^N-@L1=>KS]_<M22Z^@A\)!;ZU#RG<I[H?Z_$
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M<S1,R9'D)N0Q>U?437OFK]WV0NJ.HF;.WE<='GV)TG\G?OQ?2?U [%N8<?X
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M>:S=,>GI!^-@+I9"7"9\SKD@%N^!>X2&4).?&D"I&/)*)LF^T2?@N)^=D<
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M-)+@X$T]1@P\"<2A%=!$8M7*A^)?H8=TTL,$!FM&K@G6^C%(=TTO[;,/TXK
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MQ^I$&\63@Z%=Q,IO>/(J'[_FNJ;AM949Z^!@R-[*FA3CI#Y)_>RNG]UK5'3
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MPH("T@E"$#;TMB@@$5&*2!,E]"($C1"S+J*@(:A+D9905EQ1BM1(BT*4*H%
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M/(YA^M$9N_=20_#I&1Z0.9OE[H.Z+MA<W^Z&U-FL3\^QJ\^B;/!RAL]B2V;
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MX"0*2.3Q,/1T=)<]"Q,KM0%5,"2KMZ#/0'9<V<V#EYD6['B!+3-@RPWHV+D
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M"PUXB< B09!EA*ORHRE,(^K)'3L6F* T\2-D%_9\D-[$>F6P>"1YL$/?KN;
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MY4&$0<M=7VU0JY/")- ;A,[..P5V8;'M5#0E>%I/1;T%7'WL3]NIV/[%514
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M6:^_!IK&(L*JECM!$,4J<Y]G,0Q]Y$=^R' :ZS=J/DQCXM6])=I75C-8&$=
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MV@1%]AV@;L6'')-\*17Z)[[$#6?WY?TC[WJY=!V@/I6O>*E26=YT6\L0#ZG
M' HOCB&*60Q)*D(8()[XE-.$QUJMDQWQ,[%>&?9CV[ (>AY5609U.;'N5=0W
M9-MP:A+G>/[$:)SOYX7;3$UMD+X]A/1]">[72-_N(VW2[VX2\$U"4V>=!,N
MUG,FPU4<K#.<QJ-GSR<S8\RM,TQV(W7=#6MWQ7U):;7B;$U=#K_._ TR'C*:
M!% @U:1+B 22B"*8^0CYJ1]'A!AU 3Q*:6IW34=W703>\-KZ.#X$AQZ.F32+
M>*R*OQ(/8D8]&')"PR@-DB ,3-+/W>!CGF7>6:EX(I3&]T:GLANZLWJ!!S0G
M2 ,_*9BCN_OC=&:]LS\I[MN[^M,OV):3Z&H4WN.O77/5G\N2?<F7R\MBK^_J
M(F$T"/W$@YDJ!H^2-($ISD+(& X%28(L\+1NZVV(3WZ3M6E>C%MZI@4C#&#4
M6^I3@6.V^M=<M%T@UFV=UYRT6=U[;9]=UH8PA\!950@#TC/7@S '9;\2A,48
MWVW'U*[UXT)PPE(F$!3$#U4&90 Q"0+(O8B@ &>!'VA=IL_.^=0.@K;-)FG;
M;#[W;3:QXM.^-/)\D^I1QC)&"&291R'B/(38#P5DJ8BC%*4\QH9MEK[+:;5J
MW*2Z7E5Y&X3=Q9NNBKRI_PBS2CV?DX0P&/.4081(($]+/H8HX)2&2>+C-%@\
M\RHOV><&5\T?>&;?2J$]NS_QA[PHU"5R*4 WRA]A:OTXP,CS,^C%2)[VLE1:
MBQBIAE\11YD((\_S^JF]+M@??F+7,NC?44J3Z0\UH7K6ZG<Y18;NW6_7MOH/
MU9UZ=Q[^.(VI>[[_O]:3>G<ZOD$[ZC<,V!T3)'=/>1>L(<\@5V71R)V/%S3G
M];N\ILM2I2M=$LD-ILV"B2B)<,1A$HM,6H4B@2EE$:2"^A'F*<IBH]9T1M0G
M-M<'O+3GZQUNP)8=\/N:(<V+)#NH]=3_9 ":J7"7V!FK7BL,'*E/,]JSJD K
M6-ZJ,;M!+,(/+E<L;VX*459/G:;46P>C[T[HFU<4P8"DL5(8%]K@SMB%\'8W
MP7L@.+K=/271Z)WMT9?GNXD]Q?_._>K)A^VV]8^\N<+UXYWJE\PX^^GUUUH5
MUK]];C-JBH=+VN0O[77&(LV0")D?0:8:1:*4$$ABWX-^C$4BO-3G66)R3:A/
M>N)[0\D(H)*3KFNT9$4=(GY8J>-#7OP9E&N& -YP9+:A&X"LMYM/ YWA5JX0
MNQLB]NL:L0T?H&?DM:V2N%RU(?=J/VCW!W5IV3_J0B?8@^-HCS<@/.L&;P[(
MV]W=8@07O:_O>?6T"+@\.,1I#*-,<(APX$$L,@83J7%2@K,T)F=TN58D)CXO
MM&7<\T'/9CG&TSE]K%M8=.\HSQ'6]";R36_J^S$YSVQ!/11EDF;3+8%OV%9Z
M*.!X ^F=)UUT(;W#U6WUN5&Q6VV+C#M>M2Z(!8\)#EG,( J3 "(:1I!$D8"1
M\!'C/O7Q.1U)CY&=>'GN=2=]QA5X:1N[*.<O4WG'5:W\P9TC^*PFI4>AU5O.
M[@$S6^)[S4LE"T#UVFJ9Z-OA2#8Z%^Q4S4Q/R3U)8].C1+]AD]-30(PW/#WY
MMN.>$M)F$*OEAUSP14Q1E/J1!VG@2VV2B0BF@? A\V(1Q'[H$<:=-);8TIQ8
MBUS73?[4+H*.)/B0OY@>$W20HP3'D4<)C%(L(/(0@SB($:2)X$0DV.<>,;MN
M=XR=U45YC]E2TG(/F:YJ=0J#J5X=;<:Q^:1&X''7DF-?X*G[<@PH?A_-.?8A
MT.[0<>!5R[BL%:GY/U=RR.L7^9]U80I.J4!)!L, 4[G^HP!F3)Z&1$9$D(1A
M&L2)40S5(2I3QSMM:(*6J.'%^D%<]!;YV=*:+>NW@CHL,* ED:NKWX,TYKVF
M'1-S[TIU]&'+U;A);SE\&SLLSZ:LJ<Y'6]>KI^YW;W*]/!Q%81P$4&[8*411
MB"&A#,$D(7Z6Q%F,B)$!Y):]J=?_("%RP -H_8=-V1\C=JH2&JH(MY.EJ5N^
MV108*J4!^B.1,COP7X -QSLS9I R::[9)L'3E4ITR]R\NG028/>4\#14; K$
MJ#B9 R3>Y4*>AKG$S*INC,FH4Q\^NZBV0VL4;/FQJRUC!-ZXIIP6-S,M: K9
M)&5I;*"PK%9C1&K&(C8V$.S6MK$:P5R-W/&RS2]MBW8_-;IZXLUK4_NRKV]!
MEP6[&Q_[5*YTCUF'9#V]K,\0T]!38B6AT;H\(HO5PGL[UFPKZX@0PZ5S[!&[
M ]*'LGA0%YOJ;NI>#J$ZJ2\H"D*6$ %QE%&(<!C +$@B2#(<QR*+Y#G'Z,+H
M$)&)EY0B"=45&U!$+X B"WY7A VC.@\"I'>T.%=LLR5F([&Q=3\FDB,;_2")
M62WM,2'?VLNCS]HMR5_*@K_^@JO_Y,W[5;%I>(;\.,T0CF&(H@"BA"60A"2%
MG.+ )XS'&!L%5!PF,_&R;(F"IY;J(+C"T%%P!"&]57F^W&;KLA.Y(PA:BA/X
M$\>%<K0RCQ"9=6V."_IV=9YXVCKV4C6L?>(?RKJ^?,'YLCWSEBJ6NBS: W)7
MQ:U^ER]7#6>;L-_(RTB:!0QF'$=]>B;G\I\"AT)$'O59:+*$K3F9>)5_E(NZ
M4E_L7XT#+BV1U5OZL^!EIAU4$&O'$_A!<?5GL.%+^50[SL"0M0O0,S=)LL79
M$+D+RK3D8^X8S?/@.A"R>>: -LD9C.7J/(:7G_@3SE5R]#O^PI=E>S7ZB3^L
MENJS>;TLF"H(5O^2R_\T4K?6O6NP7OC,\[,,Q3")B"H2P2A,$Q1"@3%%&8["
M2.AW7#B?GXD5W)9!4*TY!&S+HOSMFL<V**!67(*G#9OK>A$F=2(=3-*XEOP&
MT)OIR@'J&^; @#NP90](_MHJA378<KB^*YD9=9-DGUG1MTP+<O7MN^I4Z@ZT
M\<RC\\G,F*/D#)/=;"9WPUIL4_=?ROO'<E7+K^K^BQSL];;@<K.4/^4O?- %
MAH@D383OPY1XTLSV,@I)BCP8\(#C),B(GVF9V29$)]YPY.?HF[8"TH5+8U>8
M  0SU2\9 &L.0,<"D#R #1/6?81T43+0XA.@9:>J%6K-&K6F0TTN1I!O4'N6
MS[O2PX9BCRI;W;'FTZB&TNVH3=-W+6.=5$RX^DBZRS5U/R G6V5V*Y>UG\4\
M(2H#U,<<(J;<AQ$/H,^#+/(3CD.J5;Q=B]K$VG!X*C8,,1K%2,^+X$QR,Q78
M7WUOR3EW[FL)YBH29Y36O($U.F+OQ<EHO>0X%>-#+O6&)%LO0A'BC&($B>>G
M$.',@UGF"YB$,9%KV0^#T#"EZQ3)J:_ QT+IP>^*#=#R87A]IX&EWJIWBY#9
MTG< CKL\@SUYITXSV!+\/K(,]@#03C+8?]/B%/0^+W!!5?;V0\5;%713R$,9
M7JJ[WP_EUF -<-26?!!<%0Q, @%QD"'(!8]$1% <!X'V*4B3Z,1*8L,%V+"A
M*A2TC+1IRT"Q8F#\ZV*I<42: "$S):$'CLT12?N+TS\B38"6W1'IS$_*[(1D
M*/7H"4EWK/E.2(;2[9R03-^U/2') \--7:\X>[>J)+6[MEIHF[BP+?K;/M4&
M._]<E76]"%(?18AX,!#4@\@+"4RY3V$4QCXB/J*<&-W:6G$QSXFJ*W<,076X
M K*J2RCY-3URV8"N>Q2;&$HS%=PE7W3\@(XAT''496+P"S"H+=T]W>=MM)RY
M/,J= 8RS(YX-#S,?_<Z :?](>,Y@9AJM;IZKQ=]N%C'C"8X9AE'"I6Y*@QBF
M?NQ#$4>>" (1>9&6D=>/-[&6^5M;0JK.-4VTM9#CNL""=;-5_;>;SU>W'S_?
M?#Q_>;[A=20V63W9+3+UTW9QK4>899F\87?]P;_]M7E4_L>R^+1:<M\CD7]9
M59>L?)9+X_T2/^@&Z!\?8>K8IK* BC)0I*&_4\2ZYT(_8G\$A_&/WAT$9FM!
M0WKPNV+!4;+-:1FMXOM'AITMU/^T:,.H?XVG;9K"XJ(4^8><JI9K&].[/\[Y
M" 4Q2@445%5PBT0$21"$D*0)06F$4T^O*]5)2A.OV(XTZ&EOSWDF;4+'<-)P
M#KB2WM </2*XC0]@% &3%JB.D+!L;FKZ*1CV+=40;KPCZ=@ ,_8:U9!CMXNH
MS@O6!>RWY?4+=OWTO"Q?.?^)%USDC7*QUH->O#SP"$<)]*,L@TAE2Z1^$L$,
MQQGU1)A&7!C6K]<F/K$66],&/?'V*L P;\((2[T3^%0(F6FZG:3"]G;D(%J.
MLX'/P<!=?7I]TG.7IS<&Y4!U>O,Q9FZGU]="N/[ZG'<5D>N;HCOX+W@JM5 F
M IAFJ32@>$@A05D*HR#P4,R(2#.R*/B#JC^GZ3ITSZ76HLRZ13GD57]M8OF]
M+)?R8%!6JKMOKNI0SM^?:62>-'V-WPC[;]5S:5-#9L XD-/6L?X==%8ZC>NW
M[J$TPN$?HUO2:8B=]472(&6FV1G/%]=%DS>OEXS)I5*W(3NW55L-7<*V\$7*
MDS!%T*-"0)21!&89Y3#"F,4^]F@6,!UC\12AJ0W#EC3H:5]T17V5KEW3UU.P
M)^$:UY(N03!3=?;R:ZLJ7>%&?%%RB$[5R!^V&N;DP+.H"5WQUFM=^_ES:_9=
M2B),I;GE+_PSIZNJ[55P_56UI.#LO11 *9E5YP2X%=>X4AD)];HB<EN+:I%&
MGD<3A.5QD,LS(8DQ)#C \H@8($8\A*-4:YE/P][$RF'((NAY?%5;>L<CN+[[
M#*[PDJJ\C;;-4<N488R=XPG3-,>^V328J2?7,W!&03Z70#DOR.>$N6]4D,\E
ML,<+\CFE8EDM*,<D7[9TKU95)6VW!<L\GL0TA2EFD;2B,(.8XQ2RE,:I$#Z-
M(FK27FJ?A)&*-&\CU96EHATML-R2-ZP3M ^-GB([3V S932@=0%Z:@Z+ QV5
MQ%5IH'T"\Q8&.BK@7EF@XT\Z#5UK5W9]/(Q*9&G$U>H4,?<APIQ!DD041FF
MDR!*/>1IQ8><Q\;W%+QVANO);@HTS9G)@35T((V$LG5,?>M8-DUHI@UF.\7$
M]Q#-I@F49CB;[FCF04$W!<M?<K;"RS893S,0:/>MB37-EIAF9:,#<HWK@_-$
M,EOC6SK.4@F/LV\5I_-FJ-EB<PZ+,(S'.?*$;?M$D1>\;;]<Y62E['=UN755
MULTG3LN'(O\79PN*,(UP&D-?&M40Q1Z'ZH(),I*1($8,4ZY58L>(ZERWVJ2[
MTZL!E>0-36\]^/3V8>>@F"W)GCP8TF_OKJ6Y+EEPV9;10$YGG1IU:,[<O-$
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M2^OWW5G(8SG%L0Q@1(9P$$5RVN,(<9+2(! NB2)0'T1MR3.[S)$>/57<?A?
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MKN6[7YOB]JG1G107AIEYENS.)YR.GGFD@%PEFTU5@!I1Z0!S>6Y9Q 0VV2S
M 9IQFH8:3<%+8R\V)S6-'$]2W5=F94R%5(7#1YTQ[0@G\#2IT38 <A;VSN5J
MI]\^>2>HDME@V+=(W3E987S%,/"(X'-9W//R,R]AO>D.7IMYQ9?2D$I%?G[_
M17])/[3L\A)^A5$P;S>RQW+7MC,F&"W&AV,MMOB>,6*\V)Y[9.&RVN.-[$>Y
M7\V+.J<=HUW(,R]SHP1EG'@(LY2@)'5C%)"(^AY+*8NT.J[-KNG<9RJ/CU5;
M9NMLQ5X@T5OX0P%2EZ\-_QM)4.I^R.4J7W5!?NTZUXMZ_F=4M>K";:V&55N@
MV2HP:@L^NI&E3L?5+:^=>O4J\]R,8QZB-"0885\Z]#2-Y?+)PRC#6'"1),/5
MB =]YZZM@):WV+_=\ #WV5]52A:5 FUJ1?:J>B7#O+4^H'K>URX^1MYT4,&1
M.HSOC-XXO1ICMVKQ\A78=$L^3E_NHCX+#,>A#X(/8)"VN66\?.%?UIL_RV8#
M(#\_]=Z<%1]*FC.(,Z$*.VDH('%RK<%FJ9$#PRTE/J9LF4QMG'QQN>3%E-Y[
MZ8G)!PWW7YNLSEE.JI<NS=%V(;C]F=<K1EP<<YPB+XABA#WFHS3 (6(>"WV?
MI1G!,6C_=$[2S/N?H8]3UP;C#R51<X)=QDASZV+#<N#6 V(T?)MPR2!;8?Y9
M.<N&Z9?,/0JS+[Y@6$ N0^_>Q8=QB%,O<!'%D9"STW=1%GD>HAXF$8D%2_68
MAHZ'GGDZ*D' LN^=U7KSS<P6X*F)ZC!DOZOBL>JVBJMW R];-WUDT%%)]/$3
MA@1?'?6'ZF[T>\%4!\6U_.NRZO:XP\V.VZ+8D+6ZC4G6ZVX+Y*5^ZI$@18''
M&,*Q\%'B9A1%#'M"3B\2^UJ9PFL5F3L1V IT\IU$(,62*;X:<?="J,'F^(C3
MJ&V9U:KE[.GE;!6[<7I\Q[HM!#"0F&H!H*]@FYH'<#B!U)4H762%,AU_6:JG
M*U$XXF^Z=KR93IGJ<XG/]A\/4NIMP>[ECW5T[S2.2)*ZC* P=MLV%PRE8>BC
MS*6IH#@3E-D]8#)0<NXEI6W1I"1;/DPR^1Z6SI%F1AF8(=H";/&^\!)0+'70
M8Z+BVSKCN0)D\/'.-;(,@O*_\X)79"W'O&5/>9&KDIDF_\'?_U3*\0^$]MG?
MOMRF__-51%SAQ3Q$3%""<)!%B"1>+/\MP3A,,^PR+4Z$:Y28V7/NQ#I5)Q<0
M*YKBJA&(+X 6S /V"LE@CSG[*CF][!MG!.90:M?_W0*@ H+O!< U"[QG AD6
M=%^)SF3 ;3KV<L'VE=;O!=K7CC4OO<5G_K-Y^(NO?_!/9=%\KU<X9*F748H\
M-PIE(!UDB'@^0:E/0D[#%#,OG(/GXE"1F5V^_%5&\Q!>'"&JF2== "=@5M6$
M N-+8;$"ZEI,%N;".%+C39)BG /+E!WC['AFCNM37I152]$G9S6OFY7+&(]C
M+T)Q&KL(1S1"J9<2Y!.1>@%+ S_%$(=T*&!F1_-9?CUU>;-<K]44RGNI,-]S
M!(J>3[G&5)BOZ&@5;YS;IJGR;-.T&4/I' ZL_WC)>K"+.&>BI:E_-/RB4_J<
M<8=3]>QS\'L0[__5O-S^5;'ZEOU/#;L+<>+5F>=6ST_;[I=K9T?9HIGJ/V?O
M].2R8*K)W#IAI>4[$Q-&&=V;.#7>8G<G)HP9WY^8>LPT\);KI+KP^/'IN2I_
M=)F>_H>5L(#$+.7(]V5$C4//18F/$T12UXW\(*59!*KBF9 U=^' (-G)1Z*A
M ?5YI'1C9BOV0\/BP?2QU#G*#RY;9RW /2]IX1CVHLG'8>KE5PP( HJZ^+40
MC?(+!H1M9UZ?>5+>\Z)6I[*_\H*+O-E;*TSHVLZ!<'E]M& _;%+JF3X#6=L%
M2\UN_Y\9<[E;_]-&[=WVO_"HX164O";]33GY5;^(K_P'+S9R^UGPCPU_JE=Q
MFJ0Q%Q3YH2M74AIRE&'FH20A210G"75#+6H;78$SS]Q]\:I6M%? ^4.IX+0Z
M  ME+V*HM\;:1 8VIZ\$!7ZW1--26U=*+HE;]B:)IO%'%TATWS.^BR9'8KU;
M5X>A4B!=EZISV.Z7+.-G+\MD-!UEB8]P'/F(9")$ZL\H\QFGJ0?R!CI2YW8)
MG0[#BN8H+9R=&M<X!BU,-;V#;:2 +L(&2":7T/2-MG<!34/FTI?/]&$X<?$,
M\#(\@!]=COW*J=P75"^J# - [G5^A)EG_O[M=""!UX3=E\-V.R;#IO!(IC,(
M=2 0@,+URQ8:1>P3PRX6M%\V;1RW:SQ]W>WQCP4MG_@#^=F?9_<S71%9YL5&
MBNU/ELIBQ#'%HP1[OH<R+\P0=K%<P@6A*,"9FS)/9/!UW%27^5?W5C/-/MHV
MP-5>T)> #+S,=[?-.ZW:2^>]7LXOO69_NW%VRCD[[70(THROH5^!DN6+Z2::
MO,I5]2L@.W=Y_9HAC5@(J9)R6["[\L.F=:';8OD^?8TY\T,6Q(A0RA'&C*(T
MX1P1HHB.TCC"1*M9C*:\N9/]G0*.NF5W5Z)>A]WE#Q#QX$7LIOW4#(@ T_\]
M&+<M&,X1&":\ 1JH@.@7;:)C2K>X^\G0$HD>)3+H\=_6Z!5U;;U IWAQF"7I
M$W5M.J!+U'[--+++FEWCS-%=CR1U4R^(I:/C@8]P%'*4!HE F+(T##$.71S!
MPK;3@F:/R;)FU.OVQJ19WD6L=*.PZQ& AEA&QAM$3M.660N+SHA9..:9-O8X
MH+GP_,*TCA](7K6,8K=UO7GJ6,=4C$4;SMXI$GM>L*^DX2L1X81E<8:2.'41
M%G&*4D(%BHF7A4'H17Y"%Z%WU-5X[L*D7J3#>IG.2\[70*J%^3^;GC-Z4Q\#
MYM4LD#XJ(SIF1V=DQHVS_<2#)8XRY0VP/T)1?VT62&U]W]9-05OP6V.%! LV
M6TSN>-7D(I<_7UY_$>_X<UGGPR8EB'P/AQ%%$<$>PJE< 3+7E7M?WXN#)/9#
MXC'(,C A:^X<_$ZR.GAFG6A@@=L45'JNUQ( ,*<Y%JJ,[\7.4.&F89XE[S0E
M:5&_HF'RH4?0>05^0#9D_;^(]U6E7 W\$%AWF/E^JML#(_DSE?++@I>;>MW7
M2A^N^;.="T-Q,#IBTA*PV&$3Q-SQL1/H/;,%ZBMO\JI=*=6ILKI&WV^]?4YB
M3V08"<PRA ,W021)U&%3X@<B"4.N=Y']DJ"9EZ:=V*[<08^/ @:5WNID P#H
M?#>Q';PN73+,TJ)T5LRB*](E8P^7HXO/P]>B3\5SKAS!0_[$V8>R=0PRE/VP
M)H^ZU1H30\P\'S]]OO\X7EM:#1Q15ONK#Z#+PR5(+J_*EM" 34X($,X?2A=+
M:Z^&M49+[M2XBZVT&L:-%UB=QPW./+]4CZ3(_]WM10OV+7\LVI!4[CTI5>4Y
M>?%X7ZYSJMC#M^%CF*8\YB1 3$2^(N6B*&-AB!(A.%;;0^+[VL>@1BK,//?'
M.K4G@B.MG)U:SJ"70=7F%?!KG*3.#BK,A;QM/ %GL+/C:G8LNX>O.INM1_B2
M';[/O6JVCFFO@F/RY-9LY.4.<Z^R?.]\][J13-HV- _?^2=2_<F;PVH$&KLI
MCJF'0AI$"&>9BU*:4102ZE),72'_2]NQGY<SL_>^??AD5,0R 8R&R[5C+LRO
MWC9MK\M.ZG6U*A/&0SI=6 '!L-]%@YKO'#UU8%@O2;ELVG3[B_.O+]@$XZ(-
M^ZTP+C]NELOY)U>]ESB[_<$K\L@_;]287T1[ #+N?_4N7V_:8XYA\]$ZOVWI
MJQ^F(A,)18+Q5,:A;H*RQ,^0R#SIJ%(W]@BH0,6.6C-[MT%)1#HMG;I5S]FH
M0\Z\<"A9T\VZY?:!98UL?13.<412'PDN_X&Y"%'J,8&XFWC<IZ&7160E163E
MV_TL8_4 I39%^907RH< R[\M(:^7W5L>3=B:-NCG] HZG89MHY7NEWYXM:10
M3'M=[#M'4;A=P"SE&"TIM6A&TBZ0A_E+RZ/#%C;&\]6[/FJI5=UZ]:SXUCG[
M]>6KJF;G$J =T0*E<49#+GUB$G&$(R^4ZU8D_T'<-.;,"]U0B_H,)'7N*LM!
M#V>LB"K"V:JBYQ1A4$[[O-D @KDT#6PL4U@8&3Z13)7C=5Y)_LO.&<&D+.)K
MC P?7(G9RV8AL-S<;YXV+3/L%[EM:1.Z%?^N^$Y^\.[FRV]E77_FS1?Q0'ZN
M_"R)4^&ZB&%!$$X#@5+AI2BB89C$&4NS&'2'#BA_[BW[3ANG5.HX=*R/C&N5
M0K"H"HJP7O@T(V[ O?\(LE839T^5X4[=+TJ;O]TX4B$50DF5[$5&AEA8"H&@
MTA>-=0RA.0QJ3(<Q2 M^+5_(>LL ^R _4JWHMU9)&D8D$51NX"(J-]G<1R3*
M(A1'*4M\+_,RD6KG!,\(F;NTHI/J//<EP,T@%Y ?.P>/1F;0@M$PUS#8.Y0\
M/UBT%Y ,M&"W6280;C\L%7C!L,D\X+EWETL"7M!^+P-XZ5E#+LVR>'S@U9.Z
M%_.)-)NJY\GOYV?]1=Q7<L7/GU5_JB/>]2A@D2M<C#R:>JHK9X@2@CD*HX![
M22#CHPS$$7:5-C-[+@,Z^ZNPU8N!%D,,YO:46DCIY2C%;IQ>M9=9*.QM0&"+
MYO,J798E K4!VQ%5J)5!S5S90T6*6FX-:W5TRZL?.56\!.)#7A IL>NOUUW[
MJU5)77WZK_KR3"^6#BP.?91X7H8P;>MJ HHH9TF2QC$5$>@\PZ9R,SNZK>#1
M9=7:L/S5ZC?1\XBOA33,01J"#':.<Z!AR5=:56U1USD'J(>>=!899HYU:KM[
M^X/D:]6*XD-9J>;OWSCMG?Z.'GB;UG&%EQ 2ARCR68(P8QDB@G(4\2 5;AAQ
M CLDMJ78S [U]Z+B9)W_FS/G47Z-VOEE+17D]=\<52(VZ(E$6:%::NK46U5A
MSM;:=])SM*^!/LS)?KG[>-,&H,Y._HUSNX>XTN[&^;O\+MO\'!'R(X_HK=LR
M/JO9.MO06?+(UM1:U!O;!O/0$UL?WQ+KW] I2@I;,1;&<1QE* UCBC#W&,JP
M<K01XZ[Z?]A/5H6B$.;LH6S(6L_!3LG4FK9I-VV/)&M/X?85Y[&26#MLX*AK
MR$]G/?3)NI+>;XRBGM^[&I3K"/H4,]](HO1="IP9B?=.F#<7L]Y8U.M2YYTP
M^B(WWJEW%LC*J8S*!^F55B0C'D]8A/R X*YD.%,'!7X<>RQV>1AG[FS9N$&+
MV;-P@3MC%FZ+Y0S9-Q.$K&;=E/!72KL=VOX:Z;:M#F\WS78(TU7IM:/!X+=&
M;Q\?&]5^1+7N^O:#WM5#';KFE=%S[\]=PM"W2^#.T+1FW-*MVTUSYZ[4[1$Y
M"<6TI["% LP1Z -@N<'=)5.-+HF>'72Q&Z*7S!I?#[WXK%E(\"$O\H;_)N>S
M##@:^;%SN>NXK6O>U+^^?"+_4U9W:R(W)#_S>N71,(@CCE&6J=U YG.417)+
MP .>>")D'L<!)!  R)X_-RTU0:TJSDX7IU-&E?&UZCBM/K X 0*P7G0P$VS@
M1+,^8LX?2AF+Z6<#""R%!A#)BP8$!I <A@$F0\"\3ETUJN5M_K1Y&FZ>I82S
M0'J2. X#A!GAB"0X0"P-.$]"X8=ZU"Y'(\_L,7I9>K[@V.SIF7Z5,;!YW(NQ
MN%Z?57YJ!LJ71K-/_M=NYAV/M\B\.FO&,&O./P /B._*;WS=\OU]XD3=6% ,
MLKK1\,F79_[YJ[PE*5Z<0;+3BV[)A_6CW]-V7PY]KS89-DG,K 5%N),6&86W
MIT=<++:=-&@<V$X_>$69ZW=2/9'#F\YAG 9Q'#,4Q;$GUYO(0ZF'8X0#D61Q
MZ(G(U>_O,"5IY@FX+8!L91M=AI_$:7H.6K4>-A?/&6YR(WX2 8,RV&N1N+(6
M5O>G8%8*.V6<5CWLR0&6+XJ=LN-D9>SD"P;^Z1NII*[DX3NOR#/?-#E5-Y'Z
M7UTJ0N%R-T4B]60\[(8,I3R507$8)DPD<13%6K4,%R7-[)]ZT8#). F+ACNR
M92S,'?52G;'8&W4SQ\0?34( \$>VH##S1V<AL>20=*R;=$B3 RSGD'3LV'-(
M6B_ -Q\/%;NMJE&)P>-C6W\ Z+@Y,<1B.?EMS83^]F/*\LN;$$M&P_S-0T6Z
MKE4[6OF;41F2<P(/JVTX-8PVVJU,C;O8GD7#N/'.1>=QXZO#ZI/5]^1%?<&[
M357)#[W*2.@*[$8H8R)".)$[F,3#3!W,"T()YS)P -X0/B%F[AG;"U5W]?2G
MZP5D]#+GU]L+FZQ;4WN!-TXOTNH%W0F3[-W#/25DZ>NV$X:>N%4[]?1UI7+[
M-3F?>;/EYXE(+*+,=5$6^AAA+PQ5);*+@B#Q(X_% :6Q21O<LQ)GGJOO3I7&
M20T,F]^>!TYO_EJ% S:5S]?)J6OW<W:JO6BLY:JY\_)>I73NHOGGZN<NOVAX
M;:%K25L\_L9)S?M[L_4J\;F;^7& .,XXPB%59#^QBQCAS$W=5&[=!>@2PDDQ
M,\_WK5"'DOJ[(];E7[6COHU3;O]FK?2!7B$XC9G>K+\>"=A4WX'0"KP9+IE;
M+(:=-LE6V?UI(<L6T4\:>E02/_VT0:[MOBHIYZS^(#6[*]?RS\OJL"U7O2)^
M3(,H2E#F1S*N9JJ_2,R8_$]*HD0$-!&>'J&AOE#([]>(K'#0HIN_=*R'0T:*
M /)3>FC&898RGW&4^B)$F(H4D20BB&<\C4C L'2+VBE,ZUB:7+1ZEA 6S4 N
M8ATPC>2F=1A@+G'[6U+RG3T%QID(^[\E0-+3.D1FV<^KH8(E0T%63V9%]49:
M+CT*LFPO3PI[TRP*_-:4],_;Y^>*TXZ8]*OBIJR_W7[]IE_+K#W8W(<U2KXS
M5L#I-'!^D3K4?P-VO[T(C5[<9Q45F+^[!,@,'16UK;75]?6BO&6[MNJ:?]1U
M5?M%DZ/:S=,343WO/A9R6O&Z46U9BYHK3N+'0EV]_LK7W17$.[GES)L/A+:W
M!Q]4UFG'8<I%Z/$X]1!+*$,XYAG**(EE2)32($U\-_2UZ&!M*C6W3Z'?.=NL
MVR:L@Z).KZFS4]7I=76:TNFT=09U(0>GEKZ31B3V"N@#?5>GH/-%#_>'(]R=
M/UI5'1VZVOD^!>2X>_E/8G@R?NVGL76";A>PZ<-V2[(6/)>WB\[^$;[EL0W6
MM'XWVV=7I&"N"OZ'5.G+5K[B'?@B/FR:3<6[4BAUE]V/4KE]SP+D)BY5C<(Q
M(O)/4)BYH>"NY[)$OS[I*E66W?0[5:\=P!5>A[3&6K08?K 5:(!N(.<<%+O9
M'IR\C'V<TDZYQ$X_9ZO@8D@#EIK%$#=;8.9&'K;,6 %K<G&Y3L)R2XH5)/86
M$CLCFN4^^M/T#V7%\\?B@?SL%[%?><%%WJP2X?$P2X7<XPAU"IZX*&,Q1JZ7
MA&$2L2PFH#*5"_)F7@AZL; <R"6(]#(@%@V'>?!>L--+;@^]AT#UEU[Z^:P0
M./>A::>ES,<E:8OF/31-/\QZZ+YF.,'+IZ>\N]5_6["[LNU0R0O5GW+75&?4
M[";@+B><HX10-=]CCHB+!8K<*/(]YI+4!S6N@(F?>?J/E&D)V_;4 3H%&*R:
M/F(VL( N8PJG<7-QNVUPKH/!ED>!"5_6P1@!<^1OS$:QVCNR;^MUU.YKE; X
MBEQ"$8]5D\@LD/$&(1BI?:I+1!QZ 8B@"BA_[AJ\3JSS2U[TC2"!YS%0. 4G
M?H0Y1A%. X2C(%7A6X88XY1Z81S$;K!J]-G^YH03SOQWU%R3]?CV33;+4>O!
MQ2#7<_4S @GS]: &CC=.K^#L_1HO 3%O8\:STM]"!\9+T&BV6KPXC.%A.G_L
M=K'/9;5MAO[2_7,7#XDPBDA$&6(B% BS+$"$$X)$Q&DLTM#%!%1<K25U[E.R
M3@?G8R'*ZJE-]@ /V[6@TSQPMPT(\."JQV(K_\;I9#M_]/\[2^0(LMK6X;N6
MS&4/X"$P'!W"@UZ&7U'\7!9_EW)Z@HAWO*95_JPFR^XGKGE3\?)(,\]XJ0#Z
M^^WM_99#9*2#_LU%#4"FY[Q]+&"3?0H&RUM$F*E&MQ<UAE_L$J.^J>.[C("W
MX'V3W\OM8O/R[8FLU[]NZKS@=;T*O23V!.;(3],88>I'<C47')$@<4GFAV$L
MM X2SXP_\RSN)#JM2&>0J=_]^!0@T_/5@IFP"0JS$-2V>,(.HP;%I\9;K!7Q
MA#'CIL-3CQD<XK\7@M-FVS/@@?S\2IJVBJ!0]0)M(-DV&.C^_I[+CUPTJU@&
MT,PG(8IQJ"X0IQ01XB4H8EGFRBE'N*M?FF^FP\P3L^N3"VDF? V>TW-V(92
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MX;8A !B.^XA 7C9@,7]\;-Y7E6*"@K0_WWMK[N/SQ\>*/Y*&.U*DW$N4F_J
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MRV=]D7,[^ZT@P.&&'E8:)T#6$8"YTTX\:N4[.P6<X6QW1G  IS[603([\;$
M%NRT!V3WY$F/WDC+G?* +-L[X8&]"=^?WG->_;TJ-\\?ZWHCO<F' MQ=:V*(
MF7V9DNRTHIU>]HWSH2R;HM3M:7\)@LM[5TO6P_S8E.&6[T9IVFBTKYT:=[%-
MKH9QXQVOSN.&F6-2L.WU?B6B8.T99+WR0X*9GW$4QF&",!>*Z%-=1*8\9'Y$
M R\"=84Y*VGF^?I%"$5.5S\3VI>'URT_7?TO1S1 3KKS:&EFAVU@ ,P(J\/3
M;SMZETYJ5T-^/D\.3PM?LLQ6*OBLG&73OY?,/4KY7GS!</[N#CWZ@K;M\7Y
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M:JQ%)MF$$<,LFGK$\.CH!\G7*C_]H:Q4)FDW#]7TW/W7<$@29"1.>8!5-B=
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M4.Q&E+@ICK-0BZI05^#<I3J=!LY!X_-!!T *0P<\C02194B 1P+3:)@PA.G
M LC<6(;'+#-C^J.!95H IDYF4G3&62Y3 K!J+Q,">0_F^CAEJX>*W5;5^Y_/
M>3?R.QF,Z7BQ<^_.G;+8"G.4-+WI>-;.::]DPT28%WJH2$O^-*Z\T[58>XI=
M,FLB#R%?[>,0RG;AQ]D!%YE;E\P9YM+%YY:Z[/!!/KNBOHLI"1,4418AG+(
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MFF,'ES?CYD7+ADDAVG0T6VX9 9R$EFA:'/[^,8+M\!8>K=8Z#G8:OMV-"0_
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M+/E(G_ZY4OKT9W$:9Y$,J 1->#Q/<FP7!&M<?,V(B&\-3: I;X&;I=_3*QI
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M<!;&UN'77_\#??AX]X^OZ,.7NT_H]O,?[[\^F&XIUS</MW_</MR^_PH,$3O
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MI: >Q!H1O3>23 84-+[)CN[8;I$M%]4K$MN\A*5J1C8JS1:T*Y(MI';VQ0A
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M2G.VZ48/;'8!@M1.=8P&%$R'?&U1J1DQ\T!ZK*".%U/YW>/&8R\,%Q!\=<4
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MT!)'?>JH)8_>H6MTXY),98,,('O*,T)NZ5+#2%W?^.K$#1!V,!_*9IWI$J
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MFYL"*1::'*F;Z; ![,:V,3+;H[=8]9_1J:_(UB8.$7MT:]<::+X-'R+7GAD
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M$,8PE=8JCN.(^23./!%[W9?QH="\M_X1!(-_%[UXVE_%A\;F_=_W26@:V#\
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M$1M2!&S" /@T#)1I0(&M[3T>AG&)JG_9]R9N<7*H ';+-)"9V2^6H(.9,7
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M*H?X"96;6!QF$2:!*W<R)W$P=ST_\%WAA#&H@]$AB:FM5'5NJ>RQAB0TK/8
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M":_G:;$D$[81_ >2/SY?G,[7R[/GBXP3[6QBEKS@[ ,!6_ ,+A<%CL<848B
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M)-?!8XVW4[W#(\V"8\[6FYO@9-9&\>,N1N]?>S]T=)R];"36+HS'A\\4:E]
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MC13/M#Y'#R!SW,"R!7)N7]X/JZL.#MJ+=VN[R0R7+2H%V7A=AVJS^BY B6+
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M5GEYC'<=F(6))%A",+77O,HJ@,<ZAUX*R9C)P9G6#U7NIN3H:[_=!)'ZZ5<
M;6O-L2O <QW=ZS-23.,M$,PY=W58L.6-V;N3D)%SWL?K_M9EW]'B[MY^_(;K
M-XM5[3^_2<H?8CQN?D1;R_$@@:T**<-R3K;I8I$+\* JF6NC0=M4&XX7\GV%
MYU!L8M89%:-KG9Z]CY:C&_#?^-Q+/#LIK*3=0%"N-RXET Z1Q@,/5DCND G3
M>B[VO<2,7#S9 @>W&N$W$7SWAN0#?JK'^I7^:0<5"MS^E,9% M\ALY%%V2WS
M'K\LEIO>2A=(\MG)HFLSW1JQ(WT5+%=06%(F)^5\3(TWVWVT'%VN?>-S[RR7
MLZYP+SU('^I9&1"\-P$XL\71-LHYMI[/M =9(W=(;8&-6\7:C971O[TYC2O\
M/Z?TF2^_'GJK?NLS&MN:!TEL96EN+'+93B@%BJJ+ ^U]H3,K>'"":1 J:&$]
M(2NW3K?>1\OQ70FN?^Z5#*5#^H]3X!G+]763AE@2@YRL]HHB>=^\V_*]Q(S=
M=[D!#FZW$&@A^.YMR6/ZV3U5R[X.6O>-U<+/^$0'$F9P6NP.0X]2 7I>06=<
MUJW3-<.U\/O;"M^6EZOUE+S-S>S#.E"D:$A&U'WC. 2=,F2GLN'1:)Y:C]NX
M3D&W[>\>H_6;=NH((7?1SW8SAN-[8SINC@RL CR;L,B,$4&2G R9=VUJ[WN4
M((0V1JFD K8.*(ZA=]SF\@/![\D4V %8+SMJ;.F_$EXDKKB2%J*4M.N<D.#J
MM;1,*1>1!!?-T]#W$C-N8_F!8-9&]!U@Z/EBGHB+;5O ]]/5/[=SJNM7DRRB
MC,YR* 7K.'1'HDH8P*)6-A694#2W9_>3,^ZLVJ',52/Q=X"D=\O%%URNSVKA
MRGD3H2]W[1 RJ38;C!"\.K]AMCJ#\(9;Q00OJ74=UKZTC3L =B",#:*8#@#W
M0'.76YP9*RD0#F $.:"*XG"(S OP/J>H8TC.MK9D^U,W[OS4@4 WD'(Z@-WV
MV>GVM>DM5H)*.M&^L<760N8ZGL8G!,Y\\EPQGF^65#5Z['LG.>-.KQL(6*W$
M/_J,'OKI-(49B6EY&F9;5FXR%*0.@BD/CC,%*N@"WM6.48$9%HW23NY7MK;/
M:N/.X&D,EV%DW('Y>8]?<7Z*KTB M4-&%= _INO/ST]7Z\4)+F]M"1FYSH7B
MCV T*"X=1"L]&$U"12E*SJTK"AY'X5ZH\S\(ZIY 21U \+XF[S>$>38)Q>88
M@@5>D/A*28/7L8!.ON12%.>Y?0"Y'VW[Y5[9#X:[0333 >+>[RY/ZH!FVEJS
MQ29^V4RQ6N&.)8J**5KVFSOZ.GG4(%GT*,'JP'.AC25TZW3^'F3MA[,?+<G?
M6A\=0.RR$<+5=SEOO^Q>Y[S>Y&EH5VW>Y>Q8U);B%!,RL%@?Y3A!(E1"D_&V
MVFNIBLS-K[P?3^9^$/S1$OU#ZZL#2%X\;;WI+\3D$]/! \I,+BNO$P)2(/=!
M$G<64V&F?7K_;EKV ]>/E]YO(/D.$'1MVL7?PW):6ZV?C^Q^27);[\*A20G>
M1ZGL[MF/K44DF!28C":X*)A)K2&U-W'[8>P'3/T/H)L.0'>SROKF'F*T4= 2
M_5&61 &WB! ""4U(A5RG$HUN/=CP.R3M![ ?+>_?4@\=P.K58HG33_/G=5CM
MG/B@X&9%(B(EU6ZAFV]G&YW=2@N6*&3V3H)3]=U1B<2HLK4=H,Q%%H:F>>7S
MP<3N!\4?[3;@:737 4AOUG[?G7)$'4T,Y#MX7KT(%(5,NZ:OI';!6R\UMNYY
MNA=A^X'O1[LQ:*^3#H#V&_Y^15S+Q9R^3-L^<7?SY[(QV5A#-EYY\EQS 1>0
MV+4N,,D4N1:M>[D]EL;]X/>CW$ \B:;^4/7<'ZL'/'@U]VZ5\6JY[V)S^$IN
MQ41(RCM@2=?A-IK70882=-:IML(B,]?ZS&E?R;VYU?N0/F,^K7TEMO[$FC95
M/DWKK6"OSE%,ECLRX76P#J@D>7UC5: 6'7,,6A5AOP>LQRS8;3GW8U1_[?YT
M"$EW<';>6Q!UI?5MDDQPBHB\,)DX\A1\9Z8@E$(1=W A-;\V_3Y5W19L'P*P
M@91Q,+R^XC(N^AAQ?_@YN.]'/_&X^P%.O,?.-'<$$Y<\<*\#*)<D>",S),>\
MT>2_(=^SD.:IAMZ_F*[")_K43[O1Q+N2@AN6-]+64LIYT%PBJ"PD!*2M87U!
MS.B=DJUS:7L1]F,,NG\$*.[HK=Y8/1T<C'?5JFQJ-C=BW+7WNL&B98PI68<F
MVGJGAD% J!U7DS+:YJ)33*U?"!Y YCA'YQ/B<6C5=1]H7AVKOG-5CCA('_BT
MMF?GOF0W"A"OQJG7+J ()N^N</.V[-K$A=D'^LD-H(J$.6N>(;(Z6D<P QY3
MAE(TBUDC5[;UT)0FA#]%X(#%.1X9),]M;>Q!OJKQM)N%8[Q88U5HG69K%#@,
M%ID^/>8.B3$>H;<.3NK+R'Q3VXP7-OX\OW3%RG,NO?<*$H]U6$/@$+P,]']T
MHI#P*#IK/J!U;^K&#6G'1^9 >OP!HN#+%[1''-.W/Z3UH(P'B6PV+N-BE=K>
M<F>@UF<?,)TNI]>Z\XHB2O990MGTJ?.Y0(Q9@#1>N8(Q%];Z>-F?NJ.RNO\=
M9_GCXM>PKA]Z]</G^=>P_">NJ_PO?[S='-=W2$$6E><17+:UC#XFB(6^<HY^
M7#PR>[,L[IX@_WA:QIZU,0B@KN6&GUA?'9RY5Z3Z?!96JVF98O[E[#SR.@VS
M<VF\H#/B!J].:Y&5-B!](?^B3C>*T0I H7S"A!C%<!T9'D_ON.?RP/A]<H5V
M'SS??*)[S(E\YR>U/I:_3VZCL_F!=\QW#3(RP9EB,HAD/*B2"!0Y<[">96,3
M+\*W3H8]BL!V80<YQ-,UOIE^Q5O+WM@HP2IE6$!@NF"=7)+ E6BAV-IM(!IC
M<FO+=P"9XQ[8PZ'L_H!C& UV<$Z?L[AXB,7M2(IG)[4D;!L [EXOW>!=V^RU
M0 7%N,W59GV:F0U@R0)3T%G+YJT[&](_[CG^]+!^<IUW?[1O1G%_7LQ(TZNM
M%W7XX7[O9PTP/?R[)+<:.+!9X *$$7D(49"94W7>,DL%O-<)F&*%"1MD$*UK
MQ:]3T.Z(W@YA/]NXME>,N<Y>>,$A!U=[T$9%\1;YSUHHR[Q76OCF7<\?)FGD
M00.'Z__^L_5XT7=O5[8=6 ZW)=?^?N,Y;/>2ULAF;!>XP$QB:3.H%(RM;Q0"
M'14^&EO'(3N1G>16M^_Z<Y6"XUL:T:?5<? W#L)4=.8NT!%<L%;"HX9HH@<*
MJCFJ'%+&UL;P'E+&M1%'Z/MV^Z+C1=V!C[WMPO3V"]:RAOFG#5<790;G69.;
M%Q@BL" D6;Z0#*@H/82-@Z48?:-<M$PV1].CR1S78VZ*M&%5U/T)M3V$;W8(
M.-+[O>_S!O" ]R*]U;2^BW#L;;FZY&Z68S58J\TCTEB)>A?.KE^!HK;"Q20A
M;0J #29P:!VD+"UC0J&(KO'6/H[BAE[VG7THGJ7U].OM_668-\%XK /J(NTJ
MDAC9? &F%*US8L8WOP4XC-*1YP<^'1H?\.&'4FP'Q_<EE^=3IS_@\NNTUJ'=
MR?1L\Y&[0M>T^#2?_HODCLOI8JN,2T%PRUWAC#@74I,?8R(X38+P7!8?E)7F
M9L?"A@AOS,RXKD 7FV!,>'2U3^[F?'-.;WL.K>ZQ#-Q$4Z?[0$R9DQX\N7"L
M4-#O66:B>&92ZY=$QU,];L_^+I#_) KO%.([D3[[/2SS58[_'F:G6Q2L5J<G
MVY_=O"N*BD)6"AZBJ$WK8PK@K*1S4:BL3* H(@Q7;=B"@W''#'0&_2<"0J?;
MX+H"SB?(;.3PM_F4Q%[%<H\5L *MS;8 5]$1^\61(!*#:#DOQDMOFN<$&[,P
M[BR$SC;"4T&A^Z3*JS!=UMV/OV*HVCFR@/>ACVN;4MF;\$89E8OU+I%\"<]
M_%NI$+1 7\/%!%Z&6@@9K9.*YUQ:6X>'Z&E8%G2^RO;&_<KCLRFN=I+/;VD+
MI=/E<CK_1)MK>O/DT#F8++D#GA0Y4#&27&)M5:Q8SB(G5'JHDHLF#(R;.VF&
MNP<JAYY8R=T;Q8MVH<=<B-[^D-9%DP\2V>PMPVZ5.PI\I \B*"_!&19 !:?(
M)60.9#0QJ228:]Z"Y@%RVAF][2*_8%DL\7)!^M=J/4VT.W;=[V[L &^**JQD
ML+[N@! +.!\<,*,X"U9E5*V?[A])\MB/&MH@ZWZ[-KP>NPITJD^[F%<WZ)QU
M8G=7$?<+SK%,;UY22U5TM-H <YR1T0ZU^[%2@#(Q99,.W P7U#R:W+'?, P-
MUV'UUQ547Y:"-;BZW);O*0JLN>9Y(K_C\G;T2M3EF7=,,3 ^(I!0!02O:5M&
M)FJ]5>;8O#?_$?2.FW$='JP#:[ KM+[8$4!,WN4AW_2$=?1!,=J/1FM0WC,(
MD;9GEC'P4+0F"0\&U$>1.FYJ='B,#J>WKN#YM_GRXI*.6-T=%:OWB]F,/)R:
MR+I9F^:+9R$P E+8M,9%"(8"-NT3$YG7VOSA3.ECJ1TW;3D\2 ?57O>1]D4!
MVRX/O%ZL/^.'L'GXL7G=\7YQ%F;KHYK)/GJ-QM7+1['8HJW>30H^+CYN*7A[
MDX++UE4IJ( !ZQO83,;0!0@E:P@AVY1DX.+FI+=[GMX_?NU&O63W7_C&_A*,
MK+Z4"71TMC8_C<1ZR""DL3[*DF/Q>[%^/"TC=MT;&#/WM*5]$J5U;Q1WS6GF
MGRYZRAUQ(7/?9S6^C=F+Y%;%K1C7=YS'PG+OG19@(QW%RDHZCVNOQIQJ KH4
MDU3SHM4[*6GGVI$V:F*  #I=OPKIW'&]['*E2L08#$1=<U44[H-/R5)(E;.*
M-F656C_HV)NXD4M.C\?(_3Y;2[6,/;?ZP^G)25B>U933;E35-N-T6?AW88NO
M,7SS5AP=CY'Q:G=3+9/B"J)0"HS5!K,L=M]F/8T(&KG8LQW\1M-25T'N[H$+
M;3/:?HOYIX^X/*E"OEFWC4I('PVP1)Z'TEF C\E YI9%XT*.?KC0=C\:1Z[%
M'-(N#J"D[IVUWW#]9K&Z&,IVN*=V]P>U==/V(+;5,_P;P^HND%828UG7)VDH
M*4JP/D/TOD"0R2LL-F;>>JSS?;0TO,^XL4*MD*@WC"^FL]-JE&]<VWAG'3.F
M3AF-) >6P0LI02;I@Q8FZQR&N\IX#*DC/^5O@:$'KC &4UI7)^>S^7J:*TO3
MKU?Z][W\EF:GM,U?D=3KQ>/I>6?4FU*Y^M8C9$U!/F"2@N)[;<BKI6A;<NVS
M94KS 2\V6G$QKELX,*)'477W)_1N7N#K>5DL3XY],WS?9S5^+[P7R8V.ZIOS
M%"^GY$7-B?6T"Q9\-N"XB6 SERY:&6(<>JSE .][;ZQP1<:_G.W^\$I+4^=\
MD"Z#3DB;L]X'>EN?NWECT ?:FVRX>.)1I(Y[5#?!T .%^X,IK7OK]9A)A+_1
MYX1J_%_@.DQG@X]>O+7>>$,8'V9]^'&,@>5L:ZT@Q<N23G%"7PRE'N 4S69#
MYW?S-EP#C6.\*O5G^XR^G!34W!3-P29O0+% >SSQ!$(7)XR3)<KR/=@=MG2W
M(QH? X=KB;YAI3]B8+):KB?/*P.X).FNSWX+)_CLVW0UL=9(YH2%I *"TM)#
M=#J 1V6=\5(8MM<=!BUP9=?0=Y<[YKZU1[Q?'5C/BX9"'QDT=.B?TK$0KHS8
MNLG2B\5)F,XG-I?H,0GPII@:27'P.C%(F(WEREF_WQO-[R!I;X+&@5<;G2^&
M5L#H]UXDQ"_K\/$S+L,7I) YK5[/TZ]X$G$YT3)QBKP]4#1.X;A3M;!:6M"L
M[C,NPZT,W7V760^L,AX\!M+H8@CQ=I!+^TB_][8\(P=S_FDCK,UV,L*QJ&0!
M]$*!"B2:H'6$8EUDN1AI5>MGC7<2,N(HQ*<YQ-JIH0,L72&_EB/_1I'-Y4\^
MTE<K<A]K^X7=5O'1%1]- IDW$T=IJWBC%$CM*;!6)#ML'E<\CL1Q?? &H%@\
MG88Z.?2NCS ]/P+.^5':ID(2RRX%("$:\,%RX%P(YUV*Y:87]?#9]]!B(\=O
M0VKZCL.PF=C']LBKC#;[3"7%?0P:"NTV(#<R@>?) $]":&\<IOTRQ-_SN,\7
M'*=VXHD#ML/$VP,F=E#.)=!^$ RTB:$6&64(-@A0PFJ>0XI6MHCHKRPYHBM]
MF+)NJOL R8VL\%_#M^G)Z<F.<"M5SI8CA(*1K)=EX%V(H$O)GF?A<I,DSK5%
M1U;Z(2I;M)#?V$[$8RSAF^D<7Z_QA%PR956QZ,!F3=LCJ0Q1TVY)N;"BG0RN
MM$\27RP_SE/')SPXGD@S'410S\/J<_VG#OKX&F;5>;OLX%7_@#B__H,KOSGQ
MTG@FR8?+BO:80B[KH[U$X8$SV8:44_..S4<1_(.DJ ]$TV(LU7: XUN<W>#G
MV?HYA2-G).1-;Z8)<AZR8PB)A4)'!%-UBI4$XXOR62LE>>NW'H\D\0?)1+7!
MZI#JZP"=S[Z&Z:R>1J\6R_H [[*<K!9T7W[W_'19E3-)'#$;P2%)3NSI8"$J
M'P$3;3SM62RB]:3,1Y+X@\2.;= YI/K&]C]?S].R#C]Y@=M_OY[O=N"5^;\3
M\LI+3$J T3F!RE:06\X*$#$<E4C.F?U>\>ZSV@_B71X'K6%D/S:8WBT7B:"_
MVA;'7LW/74D.3IB6P6N*QR+WM#TLT^!U;7ZLBLY2Q()IO\=M>RTW3LN+,>#4
M7OH'X^DK+N.BT>%YE:W7J]5IF"=\N]R^8]_.)YPPVB2,QP18KRF4]Q(\YV1_
MBW!&DZO@8VMO[OM4[04\\X,#;R EC6W(7N!7G"V^;&X4IC.RQ8LYGK?1GB2F
MDXT. 5D2=5*E)HLL H1@,V;-N=-N+_OUT"I[H<?^X.AI*^L.'/V/RTV#W[--
M[_-M%^!$Z%]N>[+_BNO/BSQ)*3MMT8".F4)K53*Q0Z%U#*8$#%)'W?HEP#YT
M[84X]X,C;C!%=0"^2Z]QVVCK_'7[YA7>UVG&>9Y$6X*B'40R(T94U+9VV@^0
MDZ?_<.^D;5UGLP=9>T'/_T&@UUI-'2#OSM.__&-3 $!&/",=>UE(B*74^6_5
MY10Q@(V&!5YB\<T;JSQ,T7YY8/8' 5Q#[72 M??X9><<7+9%J'):G?>0F7!&
M'B6W"G)DOD8X'H*0'# 68U7*P6/K6XGO$K4?XOXH5P]M==0!Z,[]T8^+G9M
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M](7.EMM]>*F[JV&Q1NF$TG$ G6,$8Y2"Y*J&+!)%[;7U.&RTU0Z+/H6DS5V
M]=WSV[&4,_:;[;U\/5_>PV2-1@<.Y8I*!HP(D@U-X3^\L!B58?=WV(R9?2D8
MUP6<,AQ[J6TBV'R.G^<;/-LR4K9-,JY'9E,T(2;V>-CYX!",V<(8"82/0I!$
M:S'O@L$[5QK7]YL&UOJH80(AR"4_+Q?L,]%[_)O65XQ(7X3D/T"V*CA3BP5$
MR5_66%W1+O#AW=GMN).8<5-9QH-<7RU- &ZO-Q]I=<G-JSFFEF0Q_\8-56&=
M)@1LT\E,J1$2Y@RJ2BGYE"(;>P>[]U,T;LK+^,#KJ*\)H.]N1MJ@$.5EXZ%D
M,+HQXH0';8(@9XP,J7=/@<,P=[2,F/$QUT=+DR^>?;GX0NO-5FR7_-WXS@&7
M+8,^M^\UR^ZL=+I@^6Z9='57M_GZCO+Y:@N=:T062<59<N"M840JU:93Z@HI
MVHK%**RF=Z7=<.H.FWYZ_>#XO^ALFT+=<AB_6V91_L#5?[,BTAE]^_;%,V2)
M2,R]9#>58W-C0P ,+"?>PIFW%2H9AM7F'$;'N!<J1P+2]\-3'T]/$["UU];A
MY38#LHGV(G-*1$O2)W"^,!M")XA.QN8R^*"4%*;[<)$[2!D'<8\.A=O--3OH
M90+PNOGZ]XY67^9YOOAPPR?YQMVZI?*N?_ZCRPQ?'U-TUCE UV8[R<A^1? 5
M3')5&0[G9>SM_?6D?]RCLPN@EA/1[@20W>S/MPU_58LGHE"I1 A."0[S6W6+
M\QHL&E?0A41N4-;U3HDO/](Q+M+&0\4/*3$'JFCLR^2][<^W!W8V-$%E#L,4
M!@[SM):0;'(0*\=HJ+7. Q_=#J=EG,>/L0SY& J<W+'X[ O'E(VS%\O5.SRC
MRV2T-E!QO;F^&\U!HTW(KGE-O+&# !2\([5,CK>_*Z9[C[[=J3Q%+W1/$-U[
MBG;7:+<+H#W/V ?8^]:G<-M(\U^+%>%9X_=WMD[7%UXR2>6+@%Q+;9.B6MTA
MFYA8C=184O:E##ID.Q!SBJ?L84 =18UCNP;[\ON*O[KBMQ0I2Q4!1&LP8D16
M$(+VH ,%G8P52@]+A^A S#BOU2<+VWW5>&@+U/?]'GEN\?I-"M_+Y(I+39K=
M=K2MJF=;S\<>O(@%A%=4G9="4.\:^QU)'.?U>PHNPC%U>0)9N3??59:+[?7S
ME0*6]5HV]4?9='D\VF/%XSTK'<K^XS\X114P$B.0++;)>50AL?L*)8:4K./_
M$[VO;([_X#1L8UYJB;_ZK_GFXWSQ>D'_FW7[ N>K?^/9.<T$:A4(^1"@4-N\
M \VRR:VP,BCK2=E0NC^W'T3QR;Q.[8*ZW4[;KDJ=MI=[S=/5<?/L;/MY5-K-
MXWSQX>SZ)[_R=Y]5IJK)@D7R_N-J>?[AX_N_EC.M*YF2"-C0(1@3!42G$B1O
M@A0&I0P]@K<NQ(Z;/WQD?$]2XT]S![ 4KN3!D"8.(4AHKS104-MY;!FP6@7>
M:",K6B>=&'$/W")WW,SFT]T%AVA] E?+0Z.,&<?"R2M%D+=%A5C;DZ8FD*'J
MBCDYKWHWD1]*V[@9TI-P4/94U DD"FYP\6'.;#];KVFSOHK)E_7V3PX*_'9=
MI'>L=Q"3G<*[WY?+\M?\[(P!_,.R\W4^6Z[;5-KK)%=V>*U%S^=:LFSN)4+0
MN8!PP1KOC ^^]W&P$X']AFN\F"_F&WHU_T(_+'OQD&E,,+GR#J.$!,:1A4!9
M0NN09P1FLJGW_)'AU(T;O!T/4W</TNBJKRE8Z$;ZL\PV93W?ZJTE&$G#)[DI
MDN/-EFA>M&X=7RTDLL5G%$:IWK,,?D;'5(9E]-7Y;<M[J (F"*++1""3 GG%
M^\RS ]*:<FF(@65#$34*[T.]':)TA]$4TO@.U_ #D-E#W&/'R'\NO^!J,[_*
M\*I\$&LJ%:)L31^1#^B0:H:H,I8D12+M'_*S?O*YT]+[/FI:]I'9!,Z(>P[1
M7[[^@?]GN7K>FM5O-X>C)*S"##EYWAS>!4"G,SAI8Q1.J>AZIQ?M0-Y4^N8>
MU2P=2UW31N(WQO[$3U==JFW(TH9J@(QJCB,)B-5GD$(9X[VS1?=NC;<CB:.G
MJ1\'*L,A>;#>)@#+-[AIMSQ7.<^RU6,*":T_/IB8D0_V=MAG4]@]R#9C]U'<
M-PF8+*0.5_7MGF1[RWT"H'DUS[18SQ<?GGU8T46E\"4C,5.NGI@'&UN*$?N6
MH<8*+@L6%+L+.O8^M>XD9ER+^9A@ZJ./"0#K'J&]NDY (N,+QS *BLSJ@J>8
M2P&,DJSWR@0WJ$-]'\OX:FI=BL=RT/93T+1!MTVFG$E,V65L;3!TX)TD Z10
MVHN'<]H7FYWKW;#O(9HF:RCW1,%PF.VNDFE#[$;J[G<=F),R&9$44"F\2[,U
M++Z<(:E (DG?<LT?#W1W4#E9$WMT&/90V]C78?>P]_+39YROFB<Q2QA\TH[
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M']@T?\ -_;[B+773([RX;;LAFIE#]$H[R^&IT7SH\LG;7C"A!I&R\\X)/ZR
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MA</I"F2]0(]68^A=RW8/.6.CIY/*E\>1_W2A=/FB*T54SL0"SF$$0\Y"H!1
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MZ>:P0>5LV>+*UH'VV^*7EY<M>W_][B.C.S7RKNSH-82#HD)H!,CB6P1@B2.
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MD\V_O'6JG"L:8W60@F2[%CC62Y[=J^I%%<615M2['\QW!(QK$Z81K^ROD0G
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MEY[OLWDFCY#]/;:6I35:%M1EIO/U?-+YXGHDT=6/NB=![;#F8^1 [2N"::1
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M4842(421>3L8!ZE:"2K9*#EN<-@]Q6DJX]CVK^"X:)B?JO19)0.Q:/8<M8^
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MC"R(6D-<W*8.<=Y2SQ*RT@?$A5+9^3%($,8D8<[06#J2WB-2W:BF-OM*X-1
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M"-IGPO?7W^SD"G[AX?0+?NF^^$$N?'#/@?%X^J>=^'@)\2#7(C*4G]Y$W)"
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ME- >.U-ZJ_8 \7K?C/#?8#8?PR3]!BP/P^\9!(_=K1)M3>">.$X1#I8@SIA
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MR]?X$*44AA1\BUSB'N'@#'9.>.$Z>7;0ZI-)"+[[,0$]Z["53>VJ2]_Q$+3
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M//NN;@QYHG70)"!&X1_.#2@0$D98:*Z$(%++TD7@7@C1$DV.P76].$8O(S?
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MB]_;V")*W3/HDW#G&*,79,^)]K0O)HM1R)J.OL?E'9;EP5&Y7>S=[0^Z;WV
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M>@]/0'IUM_KPWHGG# )4 K.#YQ*"2!-<3MB.B#+";.+8$E;Z8;(CQ&QU:CV
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M33!3"XP8L?")QTRL/\9V#.&V]%ZWLG-%OI5 HX%2% _S\__:JS@'13^F-/)
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M&CZ\Q/%,0QAM5S.;\YH#(=PGABPC)OO]XOZH-3!BM2".&=^MDO'.;IK:^R]
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M=:$]]$X=U*LT4@SK[69K#N$7F\Q#(;VCHTZ(-[5W=(09*R._8?K)FJ\VO\J
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M^<HO%>I/_Z.)$_=CC?\!4$L#!!0    ( +F!>5N9B!7ZO0<  )4A   7
M87)W<BTR,#(U,#DS,'AE>#,Q,BYH=&W=6FU3VT@2_GZ_8@[JLE!E&]N80 RA
MRD?,Q;5;L$5([7V[&DLM-,=(HYV1;'R_?I^>D;'!)C&5ETM(58REZ>GIEV>>
M[I%\DI:9/CU)2<:G?SOY>[,IWIFHRB@O161)EA2+RJG\1OP1D[L5S68M=6:*
MF54W:2FZ[>Z!^,/86S618;Q4I:;3N9Z3O7!]LN<7.1F;>'9Z$JN)4/';+=63
MO?B(.NW]))*]]G[WZ# YZ(ZINW\HCXY>4^<_G2U,A7B8X\J9IK=;F<J;*?'Z
M_=Y!41Y/55RF_4Z[_8\M+W=ZDIB\Q&(6D\/7H&-%4TEW95-J=9/WO3];8>I\
M.#+:V/YVV_\[YI%F(C.E9_U?KE5&3ES05%R93.:_-!Q9E009I_Y', >6^<MI
M,/40*K3*:6YZI\OV#N]2-5:EV.^TN@^-7798VAOX7)H"LZ!VR>P(02;[_>T^
M&UY=C\Y'9X/KT>6%N#P79^]'PW-Q/KH87)R-!K_A%D:'5^))IWX )W[_>/7A
MX^#B6EQ?BJN/OPU%9U\V.[T=N2LNK^H[!W%]YT=V!/&_?C\4'X9G'Z]&UZ/A
M!S'\]]G[P<6_AF)P=LWIZ;S9[SWMPA+ 7C_$UW\K5ZID]BU=ZJUU:=00[V2N
M2(M!0;HASE)%B3A7N<PC);6X3!(5D14F$0-KS93Y1?R>2IO)B*I215*[AACE
M4:LA(,=.B#*5Y:OM@Z/C+XA$N*7R&*GN=P^+;\H9ZT/3:8F12.6$A*6)HBEH
MNDR5$X,\KQ"9*RJ,+87)Q;FQF>BTF[]N$"7$Y<U/'I=N2_Q3.D0#KF<S<9N;
MJ:;XAAHA/#;$)398+#<H<5 H52YD/A-57MJ*8"N*GJ]_")@4&:XL@RV1$6X!
M;!FHNC1!;D4@IXB<DW;&(IF\):R[I-/A7@QCL*3VQ1-KL$"D+(HEQ'),AR4Q
M4#U-590*5_''8OZ4+-5*V(%,.8U\<H&>JC*%@ZZ@R!O(>@N89F*X.<&T6(QG
MRV%X >G>_T2Z223W3+$(8 .YACB&[=*XRA/L$UDJZ%%YI*L8.I&DI6@UD&!E
M]4P4B#'#@V&C]2+_=>C=HZ4!L5BQX@9+5!H"2+I!9OQRSML329>*1)NIFR/"
MTHURI9582/+-8#>L;"PEULV-6;'V!>2VUQ+7#P+Q:ONHVSD\=G7V:D9GZ)M0
M"';<KH_22$A+/A^(KQIKXK@) @C&6KF49[!8AIW/NY^O8^4B;5R%><P)UNB0
MF,*:B&+<=F('>8@)B0W!'MY%J<QO2 RPW:XJ#0G?.ASL4+#"MPU\%2X5MP5Y
M  3K%[PGEW 2\L:V;+Q0\F"A! NQGX_1 PDN%,\K>H6,F52:FI*0_\]A9/_U
M_P,CW)2](P>C$"M/E9]/9(-9/)*5VWP*T^F8D)1ZI4#0IK)0@)TX4<[O;TA1
M[O5PE[%@AF5VL:2ESW+-T(M,-6KFX4$%EH MSF@5^S.8J\9.Q4I:Q0ZH4$<\
MW^6LJ7+,[7Y?.%\(/!L81S (IR\_J9" 5U1IR20&M[P1BQJ!&:'B+!=*?!L3
M"X)G,)_BY_'*SX*B\6,4;;Q95\"T^3;?&%/ X43%#!7I3"Z9SZ0#S+A98/Q(
M&\]S"70I.59:E3,N).N6963[M/N,!E ^$%UJ-CQMWM4.%94M@"CG"U\4&1M[
M WS;<4,YZID&L#!"!2.61=!2!?  V:H <[U,^$2[8CB1NO([E6-+28).0$T0
M%;>FHM\7L@V8)URN+_(>+9@(UG"AE1B;JGS:@DVX4=Y+$_=)R>?;2#&>=V!^
M U"(!.P)R>8%7EK"8_!%B.5J3O@H41=L/[(V\<]@":XD)HHJRY%?HNTU6C/C
M2MSG)Q#0Y7"P$W]68'VHWGEB2@((8?\^DJX-1U=*_A3$!R1_K@QV[0:K4NGN
M:QSO? \YBCTE^GC4=#7#6>>6='TD>B3?^.(0/1]F/V2[>_ %[:Y_$!#/$=E8
M[$@FB&54+#8GY_4956ZE6[FW3J)C*8UU]X7%WX#*# ?EDN@3]#<V*%T\'BO8
MYY7L #M@&\=LAK_<-\T!3W]6"N9[<%=YY ]/NR^VJQW@:,F=@4*JN8WG T&D
M"(FIB\)]=SDE><LL'RJSYWG?4_B'%?-CYK/273>"X1"U9A/+&!,=W>_A)Z%1
M=R*8@ORB86B$4N-09UR5(3D(BG>FYLZU!_*76T;0=@Y0+1*++=- T,EO=*3-
M/]FI\]L(9*ORB=$38L;-Y4W]@,K6W$!9H<V,,#I-36 #^0 ]R/97*4>M3=]/
M()JE[U3KX3&R3[:)J&I9..K/OQR#M0HM9WV5^P#Y2<>ULK$I2Y/U^?W.A-D/
M):I.HD]>&%Z\^FFUP^N?TN)_/%^Y'F[YH;TR7AWK';7>M)\>;K<Z3XY]);5[
MWN1@-B+C"IF_W=K?FD^H\=SO%G>B\Q#-#/&5X)AB^278=T3T.V V,/(%$)2-
MR;[:[KQN'W</&OXUX:-7<758/N%QF_U]%*6YS'SE@X"VS?4\?\FOJ'Y-#L,;
MH\=9#.C^KJSDT?IJNP=*\)_+;U_N4_=UPU+S@J>- F[R P_!_AW_@ %;>?'6
M#J#_UD'Z:4+QQ NZ=6'Y[KMXSY>6-95K^6<$A7'^67T_/*:;T,H/"Q; ];6I
MO9@BQT!O5:Y.^<QO$>K/\+.(/?]SC+\ 4$L#!!0    ( +F!>5NAD$!\C00
M )L0   7    87)W<BTR,#(U,#DS,'AE>#,R,2YH=&W56&UOXS8,_KY?P:58
M+P7R8N>E+TFN0)"Z:[ A/:3I;M\&V9)K[6S)D^2DN5\_2G;:7M/T.J K>OD0
MQ*1(/@]%B71&B<G2TU'""#W]:?1SLPEG,BHR)@Q$BA'#*!2:BQOX3)G^ LUF
MM6HB\[7B-XF!CM?IPV>IOO E*?6&FY2=;OR,VN7SJ.V"C$))UZ<CRI? Z<<:
MC_HL#FD8T4/:Z=$^.V9=+^Q&)XS$AR?,#__R:VB*RTL;;=8I^UC+N&@FS,8?
M]/JY&:XX-<G ][Q?:F[=Z2B6PF PA<;ES]+'EB?#;DV3I/Q&#!R?6FFZ44<R
ME6JPY[G/T&J:,<EXNAY\6/",:9BQ%<QE1L2'AF:*Q^4:S;\RA(/(W..JA'J$
M+E(NV :ZW[%X@]N$A]Q M]/ROP7[D#!1-\C9R!RMT.T#V!$FF:FWQST)YHOI
M^70R7DPO9W!Y#I.+:7 .P9_!Y'HQ_2- $6J#^4Y.[X##I^OYU?5XMH#%)<RO
M?P_ [Y*FWZN'!W YKR1]6DG>,Q%,_^(B@"O,_7RZF 97N ^3B_'LUP#&DX7=
M'?^DVWO7%,:S,_"/X;IUU9JT+!-75WZW[^V&_<RQ^+O0AL?K4L0%15:#SE'^
MOQ[PWI/$I@V8)(IK1)DP!6/QE:12,"OE+(;@ED6%X4L&EW',(UPA8Q@K)5?V
MPH1/"5$9B1@NB4BJ&S 540OJ)F&POW?<Z7C#B<QR(M;NR1\>- !]6.H-R NE
M"X)DC81YD3+,9IT<5.4L527KU^F=+ ;K^ H1*6XXT@]NHX2(&P;CR%BU*R,B
MZ,.M8I'A4KBM:J ],5#G!\[16(B"I#!GN51H+N!<J@Q\K_G;)E0%'F*$8Y_7
MC"A@N%T4_>:&92$FI(M^;9]I0%RDZ1HB-$HMNA4WB3-3[)^"*V8;CK:N[S$A
M84O5L7PAOX8C6.<5"2X07$:<OPAWF^ .4Y2"+J+D.8HQX0K1YHIIAPM-2)H"
MNL)"0AN4YXA3NR@Q%T1$5HPQ*'?1+ Q<5*0E*9DSY6#H1]EKO?B$8/4;$N*N
M5^I0*LI4$T]!2G+-!IL?0\IUGI+U@ M7T,YH6#D+I3$R&]C&N[2EAG59'3IW
MV$KU?4]N>65?-MB,#=U$KM0MIVH;NJWK';=.O-UJK^7OU+V2V[:#7,+&S&C,
M]<=:M[8QR FE.!L-.ODM^-_>/BF+MY,C\X?3R1O>0&=8<?M[_>,AS.32':G]
M/?_0&]H39<_5HQFI2LLSC#W+]U&6-FLVD?MEM;W<SW\/^8KNG]C#LA$^WL6R
MNM^^B^SO]8Z&VGT_U4WNMO!UTU/=#^[ZR)&N3#D%RW/X#A.W8TY]NVS]0#EY
M<O+83DO;7?P_ZN0U!HV L%E+?+?#_II6?5,S6&'_-PQ[N,&[L1P;JAF"0KC>
M,=U 0C2$#,UR)9?<#BDX67UO5K-=?,6Q\8=V3JG&!XSQ$KNX4(+KI ST:'2Q
M^KOQ!2>!C&MMD>*TPY$.,HMC*'*46&9,FV?&A(<OT[G4;OP8*)826QY;K]?W
MMX,;!+Q[$Q+B%5&8;9/OO)%7W^6? VWWI\2_4$L#!!0    ( +F!>5M*)]6K
MC 0  (,0   7    87)W<BTR,#(U,#DS,'AE>#,R,BYH=&W56&UOVS80_KY?
M<7.PU '\(OEE26PG@.#(B['"*1P'W;>!%JF(*R5J)&7'^_4[4G+BQDV:#6F1
M^H-A\7AWSW-WY)T\2DPJSD<)(_3\I]'/S29<R*A(668@4HP81J'0/+N%CY3I
M3]!L5KO&,M\H?IL8Z'B=/GR4ZA-?D5)NN!'L?&MGU"Z?1VWG9+24=',^HGP%
MG)[5./4[?NS[Q]T3UNMUHMZIU^U%E,1=/V*Q%\=_^C54Q>VECC8;P<YJ*<^:
M";/^![U^;H9K3DTR\#WOEYK;=SZ*96;0F4+E\F=I8\^287>F202_S0:.3ZU4
MW8HC*:0:''CN,[229DQ2+C:#=PN>,@TSMH:Y3$GVKJ&9XG&Y1_-_&,)!9.YQ
M74(]1A."9VP+W>]8O.%=PI?<0+?3ZL#G:'<9$W6+I(W,40WM[N".,,I,?7_@
MXW"^F$ZFXV QO9K!U03&E]-P I/I+)B-I\%[7$)I.'^:U!L@\>%F?GT3S!:P
MN(+YS?L0_"YI^KWZ\@BNYM5*GU8K;YD(QG]Q&<)U.+Z93Q?3\!K"/\:7P>RW
M$(+QPJ;'/^WVWC2%8'8!_@G<M*Y;XY9EX@K+[_:]_W4N_BJTX?&F7.(915:#
MSG'^38]X[XO$I@VX(!EG H*<B0:,$\YBF/",9!$G J[BF$=,@8PA4$JN[4T)
M'Q*B4A*QPO"("-V :1:UH&X2!H<')YV.-QS+-"?9QCWYPZ,&H W+N %YH71!
MD*.1,"\$PR#6R5%5Q5)5:_TZO5^+P1J^9E&AN.'(.KR+$I+=,@@B8\6N>DA&
M=S/$(L-EYC+40'UBH,Z/G*$@RPHD-F>Y5*B>P42J%'RO^?O6504>8H1CGS>,
M*&"8)8IV<\/2)0:DBW9M@VE 7 BQ@0B5A$6WYB9Q:HK]77#%;*?1UO0#)B1L
MJ3J6+^37< 3KO"+!,P27$F<OPB033"S%5=!%E#Q',29<(=I<,>UPH0H1 M 4
MU@_JX'J..+7S$M^7 ?J@W'FS,'!3(4I2,F?*P="/HM=Z\<' HC=DB5FOQ$NI
M*%--+'Y!<LT&VQ]#RG4NR&; ,U?'3FE8&5M*8V0ZL!UW94L-Z[(Z:^Z,E>*'
M9MSRRH9LL L;NO5<B5M.U#9T7]8[:9UZ3XN]EO^D[)7,MAWD$C9&1F.LSVK=
MVE8A)Y3B4#3HY'?@?W[I"!;O!T?FNV/)=[QX+K#B#@_Z)T.8R94[4H<'_J_>
MT)XH>ZX>#4=56)YA[%F^CZ*TW;/UW"^K[>5V_KO+5S3_A1R6_>]Q%LOJ_J[-
MPU7KX4'O>*C=]VX7N4_=ZX:ENA?<M9$C32DX!<MO^ 8#MC=&>&71?^L@_3"A
M>&+0V ]+V]WS/^I\%8!&0-B;);[#(5E1M4G-8(WMWC!LV0:OPG)*J$8&"LO-
M$\,,)$3#DJ%:KN2*VYD$!ZFOC6:V::\Y]OFE'4NJ:0%]O$0O+E3&=5(Z>C2I
M6/G]M(*-/^5:6Z0XW'"D@\SB&(H<5RPSILTS4\'N2W,NM9LV!HH)G"Y6;.\U
M^N%2<'W?>U A2[P9"K.O\I4W[^J[_!.@[?Y\^!=02P,$%     @ N8%Y6R$X
MCI18D0$ ^=H/ !X   !P<F]J96-T875C:VQA;F0M;&EC96YS96-O;"YH=&WL
MO6MW&SF2-OA]?P6V:J=><@[%L23+EW)/GT/+<MO=OKV2JGMGO^P!,T$2Y60B
M"\BDS/[U;T0 R N9E"5154IE87JJ2B3S @00@;@^\9=%ODS^^I>%X/%?_Z^_
M_-\'!^R-BHJE2',6:<%S$;/"R'3._A4+\Y4='+BK3E6VUG*^R-G1DZ,3]B^E
MO\H5M[_G,D_$7_US_O)?]O-?_HM>\I>IBM=__4LL5TS&__V#?/;D\.7QD^.3
MZ<LG3YY.9R]?B-GS9Y&8'4V/3YX_%<?__^$/<"M<;N\Q^3H1__W#4J8'"X'O
M__G%R?C9BRQ_=27C?/'SX9,G__%#\U*NYW#U5.6Y6OY\> 27YN);?L 3.4]_
MCF"$0L,=,P53=K=$*E'ZYQ^?T/^]PE\.9GPID_7/_^M2+H5AG\05.U=+GOZO
MD1%:SNPU1OY;_'QX""^@CU=V?,_A$8E,A1_OX1&.\*<?7QZ^^L___$_X[_$K
M]M./SPY?L=.S\\O)^T_LR^?SR_>?/UVPSV_9Y;OW%^S-Y]-?/IY]NARQCY/S
M?YR]8?]Z?_F.32XNS\[?7_SC8L3>3?YYQEZ?G7UBYV=O)J>7<,GKL]/)+Q=G
M\( S]OX-W/S^[7OXNGSVY/R,#=X/V:?/E_!4?-+D YM\>@-?PK>7YV<3?,KD
M@GTY?_]/^)M]/F>GGS^]M<^":U__#SW[_.QO[R\NSR>?+O_R7SAMOUC;2W;[
M=9CRZ.M<JR*-#]R2S.C_7OT!"W3V+4I@YZ\$^R!A<$8PGL:P[9.$3Y7FN50I
MF\RU$':/UZ?^>"?]>DVS?"WR*R'2OLQJHK6Z0N'#OBRX7O)(%+F,>&)&['T:
MC?LR35BY^YS*'S#B3VK%=2Z-6Q<V^5M?UF)2S L#9^/+$9V/.Z?E;GJ.\\F4
MD2A6?M8B ?FR$CN/-$>%)]4M?&I44N2[;[F>?K_"8.5L#;?D?)J(ZCTZ%AJI
ME_#,B)_]'Z]B:;*$KW^6*4V=;GK5?,4)O&$E-#&:>PN]T/[LQOGT>'SXY 4.
M-=?P3^Q?[&8QIEG\5QYO__;RQ?CED]T_/QD?EK_]%SU;;Y#\$ ;X ]T(LS(9
M3__[A^,?OKMU,A['H W]_(0=TNVTGG9MI_"6S67>^5LUL/\BXC5/S6J;W$Q%
M>EJJ2(MRFAF?BX,IJ'!?#_@,F.-GGESQM?DAJ%%_.C7JC]"6_M_3#[]<O ?R
M?7A_>O8)"(8T./W\X</D]>?S"=(*I/OYV1G2_XY"W@DI^Y5,8YCJS\?/B U_
MM]D^;9TM[:9;39D-\@6<<S_]^.+HZ,DK3X _>)&VU-4_F&PT^\-7PQ&C70JF
MI4QSQ;AA:L8V3DPDF'A@>IU]$U%!BOX;,(0?G&BP?QITFUIE?6J5=;:M3(T8
MA\-M"6?;FBD]YRF\%LQYX!S-D+H)OR+27US)_-]")_BT1$5D]/,<[9Y%;G+-
M#1@_QR<C=OKNX.F3DV<C]IH;D8P:]PT>=JG\Y!]\D9 6W[$W<%G>@(IWQ;6
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MV^1;JSVF/& GLYE,),_1 6=/3CC!TM9#^=;OV_4F)I?H:(8_X0R$TP[]@\Y
M2!35 *"#$)^P]?#=;.VSRYZ.7SX+.8Y=RG'\(U,9^Y.6^"2D)=XT+?'Q'-]/
MP_&]Q_$=6X\X3]CY3S\>OW@%^PJ/2;DK^:(+9_J-%-KC\5/09J^;7E_UV9/
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M-(B/(J873&9@W6DS9IT-!-7HU#EW\<COPD= /-@&G24?LNXC(&'WW#Z>@-X
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M9RW[HDR H.:92&1XOW\8#K5^7&V+IMW"KB'6VH7@781=N1]LR0,E*APD/NY
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M$<;5A&U5?7EFCU@Y+6P;LC,.IXH_0QA\B=D8E#-<Y<;N]/B '(>GI2Z)B;9
M>5=U2#F[MKRO_ 5V,R&,PD'7[G9RI8P)]M^T#*/9''W!_AA%!L(Y^?:=-$E+
M"4PSH;X=N*WMC&@8Y5QIR[L&-N1@=CDF*3V1&"?3BFGLST>NLCI3D7)";Z@M
M 3W?OMV]E-J'V)?_.6SV;A>L=/YD>P2]"D:VNQO(@XSJ1$>E8#E'*5.*_[*3
M7L4?<)$IO5GV;CB$Z%O/B,!Q![8Q-#%@S&$BCOLD:)@"@Z!<7Z,9!HBYPR<!
M8RY@S 6,N8 Q=Y\'>[>+-KI_L)]WN,RZ=JY3^1N=S-A%!)3P"(U2I_ VH;5
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M1VNTQ*2CG[!0E-V9"UO4-SWWZ+(5(>.62B$^F[Z8OHI&'PHB"BK1-\Q!KH1
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MS5$\_CF6L42*0POLS$CKJ$?1!7Q-VA&,.;I&COKU^*I>QPK3.]*<E<J:SV1
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MUJYQSH)S;@^U174_."'?+93CW9J28K=2='TZVZDB;_ZJH$$3'7'3 .*+.7&
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M(%9$Q<X$5ET/I]>IV8@?HZ9O?(5\3G$)7@TV>2Z2IN0F-OA%@\W4"=AZ0W/
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MGGEMI*; DR$$G:BX41I_VNHXM:?5'*,B&GDO.*9LV("9[\7,/W\V8.8'S/R
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M*\913O" (^JU0*@G_A GS,ASCP-?K+\B?XO#%*O0BY:-@ZM&EW&&:,8R^J>
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M)[A5'QI\!G3E@*X,=.V& S@<P.$ #@=P.(## 1P.X'  AP,X', @#^#0X!-
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M?L9IA,1T[%?:3QK?D;#"\J;5JD&G15UY$)A["\S0 M+? O)J: $96D"&%I#
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MK(9VBZ>VY'S>*EM)ZM&1%OQ"D6I:=YW"#VK\I,),IC:DJJ=1W8U(^F)NF[]
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M#W%?>%RTFI?][!/=#<!LH*H_0X'/$$-SU2F]HJ4YXJ."+\Z=(JUCM13U=9'
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MPGJ$Q,;(5\,0'7]XARWJ:NU4!DH!7T! \#EE*(RI RJ0J_**/_V"PK*,B:[
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M\QS]VD!53Y-F#&4HRFVF[H27E,$P#E9IBAJ6> <1'L+0D6=,.<0;_KPP/M6
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M\,Z<K JN5\A<X_QTC0[]8MTB<4@".Y?]85OJP/O$M:7^4'!A-M#F)HT7<'9
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M<R>AQ[G/*="]TOMV96 G^&\VCM1ZON5"HP9PV(U)EBO.*YH]*0K0,<;&"IL
M8/%5)!0=\PX3_>;>S@'/QE.8?5O,;QWB(9<9SJ$^VDY$,UXOLV:87_IDOAT:
M& ;[T".9$<3G(!LB:(,1T>'-2GQCPEO!IYK)",&('IW>N*4=?HQQ#ZJCO@"G
MLJNQYRNX5 +?4M/0M]26J:-979*3X@NK:ND>5NMAHATMR5>BMUC@Z)-6/.[2
M+:1$1?&TZNJ#V7)3NXQ8S._3/*1=1Q@+"DT\7_,X$6Q?L04+$3XH^=S.9H,E
MGA5I-"NPC1*?NZWAUN)\-+?&\5BNC \(Q^)AZF6$G99_\>+H!?<E?GAS^OX#
MA- G1-_,;07OSMX[=,[OSH28FC\\^W#Y":+BD]/]IV-^'CK7[BMN'4W5(D>^
M6/9G70WCL(QQ0[F-#&TF3W\?1S?%'.7<RL5<54*[R]Z( ZAN]Q^F[6"]DW#)
M(61RZ)5&:'A>_/"$1<GNM6?.'9G=E0J/E8"&[OFO8W:1>%!14'WEM;C.BZK"
M07<@T.!E)@N8@ HCC@H#V)F9%RQ.4,CO\"$Y9PN<;T69JWMS8. OZ8=X:2'#
MT]<81R/,6?.JF,,*"W2RW]$0!3N],!$UD7/*/-\S.V;%7)E5['!?BL(JNMCL
M)K$[,X%7P$ #3)/?I+,?\W-"KQOL_.A=1S%-E^&PF1^*471."#,)W$X-MK.>
MDXN)4PSG^.O#E4#'0_TIC_7-48J!FN)6LVDWBM?5$N8*J;9U<_R=EHPA,5+W
M[&\ST<4Z#K$%<4:F2V,](_99U(&^:GN%9NNN2X[?02^8IV3RWF'!X":'!ZJJ
M*%?7,)2*:?;(TYK5\VB155JT0#CY9UL$J;'SR<Z^%BTC<K6DHZ+!>-L1&_JM
M4T+M:>AQ)3CM;WHNRH->BD])5+OC4FR*8GC=0EH4 ^>XV4+4;&U=*[[;FUL9
M45&)/$@Z&AM+W[V:6Q3LH7;UD)9)%7D"%94G6.$^'6;N::V.W3(-49S(XTBJ
M@P21I2O7-!LCP:F1=Q#M$-N\V_6U1\^6?'\<RX=BA6DE(F[5@V4ZR5O,$S?)
M+7)>-\BP35CIM^#V.T4FK<[..#E)JN4BL0O<9M%F:R0<VA'L4\K\MN)R_1QK
M\K\#C.FGEP.,:8 Q#3"FP&!,>Y2U#5QWIR]KJT^'L/R[CE["K7*VYIC^^R1M
MK6>R]UE;\8+:J3_.A?DYI\[W'I).#9MTR$DG8Q\>-^?4?]E#3SF]..24TU80
MW):*V[?*0#71#T/^:>VZ'/)/K8S15FOX\!,SOI.X35YF&\?A$1,S(F[V_.AY
M9W;&/,V:],P>14&!*YIU1D'G6$E.ZS(\S>@#MNDO0X<Y6>H=!%P&MS2BZ I!
MS 1H(.'(.7>J9(W%[;H,&B'<MD0"L<L6SL'U3FM*",0.2230?4%AN#Q4U(1Y
M+TV5%MK$F4A8=T;H8XFGDO&\58:IY!G5>*8WK3D=X?<#GP KD1KL##B*MRCM
MMES-[UE]3UH.F/T4O FDT:..^GP@.=EEI,=1O23_%8>8ECIN2_:@P%/#OQI!
M8!.68ZJ'\%R2\P'_JUQQ:Y"C5JQ30;@36GM^30^6Z;M:9R?WE<\\N!91G(=O
MU_ZYXR@%.#I@XY-L3MQ,!:]4HZ<]5;9WKE3S3$G+8]N^ZBA05O3*[<6T2 !L
M=D6)UHXXA^ZI'\1IVUB6ZJ\ZS;BSI.O.A^V?!E[0L2).S6DQH*8+W6CWAJHC
MH:U_\&'_Y$Z>L 8Z\%,UH@JWV[0D]H*;!CL/1('[T)D:]]D1FT$Q7.NX>'1S
MII#'505U6U<K%SDO7'/4K5;#O^>N?%Q%TL),H=Q]:Y9T8KP4G?^3>RWU;$2#
M';RW*$:AV6/98DK?I 4\6RS">B)+K[N3980*(<VG'TERJ'O I,6,OCVLSAU6
MYS/IQ!M\I\%W^L:^4X<)6R3W7:I0Q/1.(O9,(K]:S:5.6.>((4#V>,[3"F:S
M^^O$[<:R"ZBH@+VLT:+(6;C%<;J8/*'K^3BZ%'D8%D:O<T. D,R)QL$P+U"9
M*[L5D3XN#:!YE*KE<HX-\MELILU[VXQAB^Q<H<P'U]*Q-4JG=3#,U1KLVC#*
M 4%T(<A^OZHH_K7JHG=ED5^GG'JWHCBI)K_089DK/$K5+WB:WJ?43!9X4^X=
MQBFD@PB%XX5%A^7=FV-K+M)24O&:N0SMP#K%+)<9AID)]$C)DY\GY#236U7%
MT;\@=GWV1W'G*/ED;N/]4AKO-6K7Q>7JJAVJ"?#*ZYY X=&@ V[MVGPTX@V]
M)=;O!&%:J&A+$(;#K $8K+FZAO>W:Z5Y\CM3STL-B4=8E;+WJY[44.9\VC6A
M+)! *PHO1GLV<RMRJ 3)@$T*KF8;$@HC(^? M;D179@:S/@V<<\/T2#1B"-D
M";>3GA\]G]Z86@<KS:IIJ?")OX*V81^BK, +1LTHJVUOP@^RSF9]QU%:*-Y/
MY!"SV%55+ZA-@"1"Q/!1",!HA,1ZZ WGNM>7QG3J=%J4*8$?*$IP0.LO7=CZ
MYB"6=UK/(= 5PE#@PBF/I7Z)OBB$GFU R?>CY%\-*/D!)3^@Y -#R3_8#PB(
MZW/]8=*5[5Z)&R5Y'_@O\@2)4ZMQ:#F9I9FX^G@BU7DK*'%N--HUGV6.H?&0
M_'B$Y,>Z(_ZS4LO>&'NYQ'I?JAFS=$4#%@1)J!)])1_U.OPUP14ND2-"5G2[
M\COD%@QO(L6_75R)ZSP1W3M:<0F:'G&K2"Y^% [%?8@<7NU'Y'!28!: $D.A
M[3(!$?7LL:D\N+CL:S):N#,PPY--LR7IY^9Q-*EYW4HDP1E^8Y*]C>)5_N7[
M\W7E@@:7(P3^3:SERS;6TJ#\QE889Z(2;KTN[G)F!?+I@#J-A'U3 YP:+/V0
MYOZ>:6Z[>.6<:*W<;&8\%^WQ=%S'.4Q2Q0S"FD92+LR7T$<?9S3G3G=.!$?(
M6MO0>8@?!-0Y\/.'H,X]B,[0ECDV>YY"X'5Z$9T?7US]&Z*P=Q &G1+-X[O3
MZ"U$2)?GIR<0',71V8<3BI3POR%LNCS]_S]QW!1C('7^Z</9U1G$;&^.WQ__
M?HK1V-GEV8??HX^?KDS4=_S[Q>DIAWWP$XRU3O_G].+D#((Z^,K9U65T<?;[
M'_!_\NGYZ04\PGLDF-1?^/C;N[/?CSG@@^<^_?3AS>D%74[?\.W%Q_?X[XO3
M=_ ]^,/51X@"_QW]!@'@R1\]S_+NX^45Q(4?W\(]8HP CR_>O#N]I( 5?PPQ
MY1D_!#W7Q\O+,^;!Q#]=?H+KRGO'\$HGI^=7-'9Z+*[^.+ZBYSO%\/,8KG_Y
MZ1T-R^AXS/&L3[WIC(/[PO@P,E/TWM'EZ0E]7=H<&A>!>/;XXN+CGW^<'K\9
MX[6<K[_H_/J'C_\-5S^[E$AJ])L42>2NDAR\C'Z_@!& M?,[/-LIS$Y,*^?M
MIW?1^[-+6!QO/IU<X0W?7AQ_>A,_E10!/$!H.VYT8D;4KD<<\A/8;K]$(S<?
M@:L+TQ?GGV )\!QU$BY_%T-Q""?'CWMP<ABX?V@K%\Z*4]*H,)Z0@2:A%R\>
M$/-#(J"1 Q1ADD\;(J/X(?I'B>:/AE,RK+G9 N[S/3!GH:T"@DA0$AO;)F6I
M1LL"_'SB>K6E_R5W5WJX!_W].ZPD65)]6$BI^D^-(2QR]A>WJFRII%A +7NW
M";(,J!8;?XZ]ON"CUQ6ZU!4\!;*23IFH:UG6:($H=93D2+-5@9\V3]"SKK(5
M/D!Z%%URZX=Y5J>@CW=;E35W_(A =0)O",X>U^C\$II]]69 Z^"&3:#<1[_^
M2-U#1\WM:\!ZN"L91F$Q>"9GIO KN8/ALR-#308E"GI7JQVOSGT?'3#!*5YY
MSHP!,?P]?U:J7-TE<U&FD)3B]";)KY61F[#/Y'0@M!6A+ F^J5)6YKW<9_07
MF_<Z/E!\/U&T?T?#Q>!="W?=99T=1<UFZ(9B3Z$Y_E8E0M(Z>#%,NS2&]+ 2
M9\]HS;)XZ-T-0D]8W 6S7+'?;.UT.-N%COLN*UD3ZC!%$\+N W!$$ZY.W[V#
MP.K3\3N,("%FO?KW_GO+3TMALZVW_)MYFH!EX(A2JVT_1'W,6!&J2GGHR(9=
M 3LELL.62B'O9:1@MHKJ)J&4);KJ^+T5O)/OI64DB11'3/;#9A*<^:PT!$"N
M?EKK(6,CUX>7%\1E;-"@,19\T1'#6R"X;EZ@V=-J=#P&W/+0])&,R>R<Y -(
M93XM[<_V 2FVXZ)7&MR^.M@RZXLG9A#;":")RZ,HJYML&=P"B2+W\9BKF9GI
M/ RY_J.',]?%'ENA2;L0E9^0QR:-+E=D=)=\A7?)W5<X9?NP.@.W7'IU?KS+
MU0/F/KB%?*@*@LD3*@ANX>,W%02#6Q<1LH[])0Z3F]0HHY:<LB<7TM96;KIU
M207&;W6G!/.-B1'*\#48V3'WB_N(E48)^%5*GPZ1X\32>R5]21E_6S!<0D!*
M=*#4VX'EL.8VC>':UTF94G<,,4A8DQZ;[A3LWJ ".9*&I'HXWJAY=JM*9(*[
MQIN%M=JV3]7,9G^C5$W(-#MZ<387EEZLH8VEU8W"5K_?[.X:NBWZNRU^'+HM
MAFZ+H=MBS[HM^EW=@-HM3.RA_99ID9,H=,KI,:Q]TG\S9IX[A*W6.E%PBZO3
MP5-;Y%1&6!0E.&P0^*#&]-R7*!KU"W^-JGHR]I2.P+GDY"-1+H\976R%EE@?
M?OV!2 ?/?Q7@ +;CKQ'3PFYQ ? -X?#"9I-KA8/!%9)@?00]V,TW#M4[,$P
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MBL:YC,G1./U26R=IVH1V0:5I++2DAT/X&R9I'FD-A99]&> F/_\PP$T&N,D
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MLW;0CAZ<Z8Z RWGM9#]'H^Z,]9@.X7N\:_A!ZZ+&ZG.%E/\(_@POW7X(";7
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M)'B2WFO\YT3E:I;1S\ :I7C\5+X1BSNX3H/&X>B%QX\:VN+3B!RFEMR?OO8
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MQR@QJ98KIRQH%J/&?%&1"GF@YO<6O4V18:X0-Y6(%+3^CN9K6<'@2\13Z:9
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M@B,^RYI[1''G?#>M;_,5)WU[,J;CDK6(;1C_VMV"&0Q'8WQ+1Z8%G5UKJUG
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MG[" +BK*C#T<7<Q4MY:FHU/>:6DPXCYA,)<Z8S)\L6RZ&(?*R#=V]<PT9JM
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M=M%RQHRYGRN:$4&$TJPW!_+/J'F6?18,]4K=!R.(U!W,@T(X3%.)/JQG7G0
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M !$              ( !GP$  &%R=W(M,C R-3 Y,S N:'1M4$L! A0#%
M  @ N8%Y6_(06 N'&P  8$0! !$              ( !X*0# &%R=W(M,C R
M-3 Y,S N>'-D4$L! A0#%     @ N8%Y6Z"GLR.#+@  E]T! !4
M     ( !EL # &%R=W(M,C R-3 Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( +F!
M>5OGG&NQ28L  "5#!@ 5              "  4SO P!A<G=R+3(P,C4P.3,P
M7V1E9BYX;6Q02P$"% ,4    " "Y@7E;^WI 9-9" @"]80( %
M    @ '(>@0 87)W<BTR,#(U,#DS,%]G,2YJ<&=02P$"% ,4    " "Y@7E;
M(&0MXE!R  #2@   %               @ '0O08 87)W<BTR,#(U,#DS,%]G
M,BYJ<&=02P$"% ,4    " "Y@7E;#T=^26^9 @ SP0( %
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M2P$"% ,4    " "Y@7E;:A>^5;]I 0"-'0X %0              @ %#K T
M87)W<BTR,#(U,#DS,%]L86(N>&UL4$L! A0#%     @ N8%Y6S*=P2&+Z
MR.(* !4              ( !-18/ &%R=W(M,C R-3 Y,S!?<')E+GAM;%!+
M 0(4 Q0    ( +F!>5M6V"_),@,  ,\)   7              "  ?/^#P!A
M<G=R+3(P,C4P.3,P>&5X,C,Q+FAT;5!+ 0(4 Q0    ( +F!>5L\1E2@P <
M +,A   7              "  5H"$ !A<G=R+3(P,C4P.3,P>&5X,S$Q+FAT
M;5!+ 0(4 Q0    ( +F!>5N9B!7ZO0<  )4A   7              "  4\*
M$ !A<G=R+3(P,C4P.3,P>&5X,S$R+FAT;5!+ 0(4 Q0    ( +F!>5NAD$!\
MC00  )L0   7              "  4$2$ !A<G=R+3(P,C4P.3,P>&5X,S(Q
M+FAT;5!+ 0(4 Q0    ( +F!>5M*)]6KC 0  (,0   7              "
M 0,7$ !A<G=R+3(P,C4P.3,P>&5X,S(R+FAT;5!+ 0(4 Q0    ( +F!>5LA
M.(Z46)$! /G:#P >              "  <0;$ !P<F]J96-T875C:VQA;F0M
M;&EC96YS96-O;"YH=&U02P$"% ,4    " "Y@7E;J[>*Z[$"  #-$@  &P
M            @ %8K1$ <W5B<VED:6%R>6QI<W1I;F<M97@R,3$N:'1M4$L%
3!@     4 !0 3@4  $*P$0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>arwr-20250930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:arwr="http://www.arrowheadresearch.com/20250930"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="arwr-20250930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2025-11-19</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:AdeoyeOlukotunMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:AdeoyeOlukotunMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:ChristopherAnzaloneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:ChristopherAnzaloneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:DanielApelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:DanielApelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:JamesHamiltonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:JamesHamiltonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:MauroFerrariMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:MauroFerrariMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:PatrickOBrienMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:PatrickOBrienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:PatrickOBrienSharesVestingAndSubjectToSellToCoverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:PatrickOBrienMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:PatrickOBrienOtherSharesBeingSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:VictoriaVakienerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:VictoriaVakienerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:WilliamWaddillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:WilliamWaddillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-24</startDate>
            <endDate>2025-02-24</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-07</startDate>
            <endDate>2025-02-07</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ComputersAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ComputersAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHSDLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-22</startDate>
            <endDate>2021-11-22</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHSDLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHSDLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-22</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHSDLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-22</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHSDLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-22</startDate>
            <endDate>2021-11-22</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-11</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-14</startDate>
            <endDate>2025-02-14</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-25</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SanofiLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-01</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SanofiLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ComputersAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ComputersAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ConstructionInProgressReclassifiedToBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ConstructionInProgressReclassifiedToManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ConstructionInProgressReclassifiedToBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ConstructionInProgressReclassifiedToManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2024-11-25</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-25</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-13</startDate>
            <endDate>2025-08-13</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-13</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-02</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-02</startDate>
            <endDate>2022-12-02</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:DrugManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-25</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-29</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">arwr:EmployeeContributionsUpToThreePercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">arwr:EmployeeContributionNextTwoPercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-07</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-07</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-07</startDate>
            <endDate>2024-08-07</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMOICPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-07</startDate>
            <endDate>2024-08-07</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementInitialTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-26</startDate>
            <endDate>2024-11-26</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMOICPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-26</startDate>
            <endDate>2024-11-26</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMOICPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-07</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMOICPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementInitialTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementInitialTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementInitialTermLoanInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementInitialTermLoanInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arwr:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arwr:OperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arwr:OperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arwr:OperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arwr:OperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arwr:OperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arwr:OperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arwr:OperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arwr:OperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arwr:OperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-17</startDate>
            <endDate>2025-10-17</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-17</instant>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-17</startDate>
            <endDate>2025-10-17</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-17</startDate>
            <endDate>2025-10-17</endDate>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-17</instant>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:NovartisCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-17</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SareptaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SareptaCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-20</startDate>
            <endDate>2025-11-20</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="subsidiary">
        <measure>arwr:subsidiary</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="bundle">
        <measure>arwr:bundle</measure>
    </unit>
    <unit id="obligation">
        <measure>arwr:obligation</measure>
    </unit>
    <unit id="agreement">
        <measure>arwr:agreement</measure>
    </unit>
    <unit id="program">
        <measure>arwr:program</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="option">
        <measure>arwr:option</measure>
    </unit>
    <unit id="cny">
        <measure>iso4217:CNY</measure>
    </unit>
    <unit id="segment">
        <measure>arwr:segment</measure>
    </unit>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-33">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-35">0000879407</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-36">false</dei:AmendmentFlag>
    <ecd:TrdArrDuration contextRef="c-5" id="f-105">P111D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-7" id="f-106">P461D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-9" id="f-107">P226D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-11" id="f-108">P135D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-13" id="f-109">P97D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-15" id="f-110">P126D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-18" id="f-111">P119D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-20" id="f-112">P119D</ecd:TrdArrDuration>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1326"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2025-09-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-38042</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">ARROWHEAD PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">46-0408024</dei:EntityTaxIdentificationNumber>
    <dei:CityAreaCode contextRef="c-1" id="f-10">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-11">304-3400</dei:LocalPhoneNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-12">177 E. Colorado Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-13">Suite 700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-14">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-15">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-16">91105</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">ARWR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-29">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-8" id="f-30" unitRef="usd">1400000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-31" unitRef="shares">135809558</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-32">&lt;div style="margin-top:6pt;text-indent:30.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Portions of the Definitive Proxy Statement to be filed for Arrowhead Pharmaceuticals, Inc.&#x2019;s 2026 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-37">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a cybersecurity program, with direct oversight from senior management and the Audit Committee (the &#x201c;Audit Committee&#x201d;) of the Board of Directors (the &#x201c;Board&#x201d;), to manage information, data, and technology security. The cybersecurity program is informed in part by the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF) and is designed to help identify, assess, and manage cybersecurity risks relevant to the Company&#x2019;s business. The Company&#x2019;s cybersecurity program has been developed in light of the nature of the Company&#x2019;s business, resource availability, requirements from stakeholders, and industry trends. The Company has formed an internal cross-functional Technology Risk Management Committee comprised of representative leaders from various aspects of the Company&#x2019;s business to broadly implement its cybersecurity program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cybersecurity program prioritizes vulnerability management, risk reduction, detection, and prevention to help protect against material risks from cybersecurity threats to its information systems. The Company periodically conducts internal and third-party cybersecurity risk assessments and penetration tests and incorporates relevant findings and recommendations into its overall cybersecurity strategy, as appropriate. Through these assessments, the Company develops targeted strategies intended to address the most significant cybersecurity risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cybersecurity program emphasizes defense, rapid detection, and remediation of cybersecurity threats and incidents, including the use of various security tools and systems based on defense-in-depth and zero-trust principles that are intended to meet control requirements. The cybersecurity program also encompasses crisis incident response guidelines that detail the processes for the detection, response, mitigation, and remediation of cybersecurity incidents, in order to support the effective management of, response to, communication during, and recovery from any such incidents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A key element of the Company&#x2019;s strategy is fostering training and awareness through annual cybersecurity training and role-based phishing tests for employees and certain third parties having access to the Company&#x2019;s information systems. The Company also utilizes a third-party cybersecurity operations monitoring center to help identify threats and incidents to the Company&#x2019;s servers and computers. The Company&#x2019;s cybersecurity program includes specific requirements and guidelines for the information security team relating to the Company's computer emergency response preparedness, intrusion response preparedness, and incident response preparedness.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When a potential cybersecurity threat or incident is identified, our processes require that the Senior Director of Information Security be promptly notified of the incident, who then is to conduct an initial investigation to determine the probability and potential of the threat or incident to have a material impact on key business systems and processes. If there is a reasonable possibility for a material impact to the Company&#x2019;s business or information systems, the cybersecurity program requires that the Technology Risk Management Committee be promptly notified, which then assigns a risk level to the threat or incident. All threats and incidents identified as high-risk are promptly escalated to Company leadership and the legal department, who, in collaboration with the Company's Information Security department, are tasked with activating and implementing a high-risk information security incident mitigation and response plan, which details the roles, responsibilities, and strategies to respond. Our cybersecurity program also requires that high-risk cybersecurity incidents or threats be reported to the Company&#x2019;s Materiality Committee and the Audit Committee within 24 hours of their designation as high-risk by the Technology Risk Management Committee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cybersecurity risks are incorporated into our overall risk management program. If a cybersecurity risk is identified as high-risk, a response and mitigation plan is developed, and progress updates on the plan are routinely reported to the Technology Risk Management Committee and tracked by the Audit Committee as part of our overall risk management process.&lt;/span&gt;&lt;/div&gt;The Company is not aware of any cybersecurity threats or incidents in the last fiscal year, including as a result of any prior cybersecurity incidents, that have had a material impact on the Company, including its business strategy, operations, or financial condition. However, we face certain ongoing cybersecurity risks and threats that, if realized, are reasonably likely to materially affect us.  Additional information on cybersecurity risks we face is discussed in Part I, Item 1A &#x201c;Risk Factors,&#x201d; under the heading &#x201c;Our business and operations could suffer in the event of a cybersecurity incident or other information technology system failures.&#x201d;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-38">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-39">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-40">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-43">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cybersecurity risks are incorporated into our overall risk management program. If a cybersecurity risk is identified as high-risk, a response and mitigation plan is developed, and progress updates on the plan are routinely reported to the Technology Risk Management Committee and tracked by the Audit Committee as part of our overall risk management process.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-42">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cybersecurity risks are incorporated into our overall risk management program. If a cybersecurity risk is identified as high-risk, a response and mitigation plan is developed, and progress updates on the plan are routinely reported to the Technology Risk Management Committee and tracked by the Audit Committee as part of our overall risk management process.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-41">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cybersecurity risks are incorporated into our overall risk management program. If a cybersecurity risk is identified as high-risk, a response and mitigation plan is developed, and progress updates on the plan are routinely reported to the Technology Risk Management Committee and tracked by the Audit Committee as part of our overall risk management process.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-44">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-45">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-46">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Execution of the Company&#x2019;s cybersecurity program is delegated by the Board to the Senior Director of Information Security, who has over 25 years of relevant experience in information security, including 14 years at the Company, and is further supported by a team of security professionals within the Information Systems &amp;amp; Informatics department. The Senior Director of Information Security reports to the Vice President, Treasury &amp;amp; Head of Information Systems, and they meet periodically with senior leadership and the Audit Committee to review metrics on cybersecurity preparedness, incidents, mitigations and remediation efforts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has also established a management-level Technology Risk Management Committee, which includes leaders from finance, legal, operations, quality &amp;amp; compliance, and information systems &amp;amp; informatics, who are responsible for overseeing the execution of high-risk incident response and mitigation plans. This committee actively reviews technology strategies, physical and cybersecurity threat assessment, and emerging issues and related initiatives. It is also responsible for evaluating the materiality of information for SEC filings and, as required or as otherwise appropriate, coordinates with the Company&#x2019;s Materiality Committee to support timely disclosure of relevant information.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-47">Execution of the Company&#x2019;s cybersecurity program is delegated by the Board to the Senior Director of Information Security, who has over 25 years of relevant experience in information security, including 14 years at the Company, and is further supported by a team of security professionals within the Information Systems &amp;amp; Informatics department. The Senior Director of Information Security reports to the Vice President, Treasury &amp;amp; Head of Information Systems, and they meet periodically with senior leadership and the Audit Committee to review metrics on cybersecurity preparedness, incidents, mitigations and remediation efforts.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-48">Execution of the Company&#x2019;s cybersecurity program is delegated by the Board to the Senior Director of Information Security, who has over 25 years of relevant experience in information security, including 14 years at the Company, and is further supported by a team of security professionals within the Information Systems &amp;amp; Informatics department.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-49">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-50">The Senior Director of Information Security reports to the Vice President, Treasury &amp;amp; Head of Information Systems, and they meet periodically with senior leadership and the Audit Committee to review metrics on cybersecurity preparedness, incidents, mitigations and remediation efforts.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-51">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has also established a management-level Technology Risk Management Committee, which includes leaders from finance, legal, operations, quality &amp;amp; compliance, and information systems &amp;amp; informatics, who are responsible for overseeing the execution of high-risk incident response and mitigation plans. This committee actively reviews technology strategies, physical and cybersecurity threat assessment, and emerging issues and related initiatives. It is also responsible for evaluating the materiality of information for SEC filings and, as required or as otherwise appropriate, coordinates with the Company&#x2019;s Materiality Committee to support timely disclosure of relevant information.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-4" id="f-52">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-4" id="f-53">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-4" id="f-54">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-4" id="f-55">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fiscal quarter ended September&#160;30, 2025, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.242%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.708%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.479%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.479%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.479%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.479%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.479%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:28pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Title&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Adoption or Termination Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Plan End Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Shares Vesting and Subject to Sell-To-Cover &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:114%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Other Shares Being Sold (Subject to Certain Conditions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:30pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%"&gt;Adeoye Olukotun&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Board Member&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;09/04/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;12/24/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%"&gt;Christopher Anzalone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;President and Chief Executive Officer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;09/19/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;12/24/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%"&gt;Daniel Apel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Chief Financial Officer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;09/16/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;04/30/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%"&gt;James Hamilton&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Chief Medical Officer, Head of R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;09/03/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;01/16/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;72,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%"&gt;Mauro Ferrari&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Board Member&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;09/25/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;7,530&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%"&gt;Patrick O'Brien&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Chief Operating Officer &amp;amp; General Counsel&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;09/03/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;01/07/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;77,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%"&gt;Victoria Vakiener&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Board Member&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;09/03/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;10,040&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:114%"&gt;William Waddill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Board Member&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;09/03/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;8,367&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) This column indicates the total number of shares vesting, but the 10b5-1 Plan provides for the sale of only those shares necessary to satisfy payment of applicable withholding taxes.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName contextRef="c-5" id="f-56">Adeoye Olukotun</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-5" id="f-57">Board Member</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-5" id="f-58">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-5" id="f-59">09/04/2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-5" id="f-60">12/24/2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-6" decimals="INF" id="f-61" unitRef="shares">10000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-7" id="f-62">Christopher Anzalone</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-7" id="f-63">President and Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-7" id="f-64">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-7" id="f-65">09/19/2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-7" id="f-66">12/24/2026</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-8" decimals="INF" id="f-67" unitRef="shares">50000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-9" id="f-68">Daniel Apel</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-9" id="f-69">Chief Financial Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-9" id="f-70">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-9" id="f-71">09/16/2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-9" id="f-72">04/30/2026</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-10" decimals="INF" id="f-73" unitRef="shares">25000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-11" id="f-74">James Hamilton</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-11" id="f-75">Chief Medical Officer, Head of R&amp;D</ecd:TrdArrIndTitle>
    <ecd:TrdArrAdoptionDate contextRef="c-11" id="f-76">09/03/2025</ecd:TrdArrAdoptionDate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-11" id="f-77">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrExpirationDate contextRef="c-11" id="f-78">01/16/2026</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-12" decimals="INF" id="f-79" unitRef="shares">72500</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-13" id="f-80">Mauro Ferrari</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-13" id="f-81">Board Member</ecd:TrdArrIndTitle>
    <ecd:TrdArrAdoptionDate contextRef="c-13" id="f-82">09/25/2025</ecd:TrdArrAdoptionDate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-13" id="f-83">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrExpirationDate contextRef="c-13" id="f-84">12/31/2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-14" decimals="INF" id="f-85" unitRef="shares">7530</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-15" id="f-86">Patrick O'Brien</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-15" id="f-87">Chief Operating Officer &amp; General Counsel</ecd:TrdArrIndTitle>
    <ecd:TrdArrAdoptionDate contextRef="c-15" id="f-88">09/03/2025</ecd:TrdArrAdoptionDate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-15" id="f-89">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrExpirationDate contextRef="c-15" id="f-90">01/07/2026</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-16" decimals="INF" id="f-91" unitRef="shares">77500</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-17" decimals="INF" id="f-92" unitRef="shares">20000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-18" id="f-93">Victoria Vakiener</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-18" id="f-94">Board Member</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-18" id="f-95">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-18" id="f-96">09/03/2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-18" id="f-97">12/31/2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-19" decimals="INF" id="f-98" unitRef="shares">10040</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-20" id="f-99">William Waddill</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-20" id="f-100">Board Member</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-20" id="f-101">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-20" id="f-102">09/03/2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-20" id="f-103">12/31/2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-21"
      decimals="INF"
      id="f-104"
      unitRef="shares">8367</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-113">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-114">185</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-115">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-116">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-22" decimals="-3" id="f-117" unitRef="usd">88706000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-23" decimals="-3" id="f-118" unitRef="usd">76208000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-24" decimals="-3" id="f-119" unitRef="usd">137842000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-25" decimals="-3" id="f-120" unitRef="usd">26477000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-26" decimals="-3" id="f-121" unitRef="usd">6824000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-27" decimals="-3" id="f-122" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-26" decimals="-3" id="f-123" unitRef="usd">692818000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-27" decimals="-3" id="f-124" unitRef="usd">578276000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-26" decimals="-3" id="f-125" unitRef="usd">10933000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-27" decimals="-3" id="f-126" unitRef="usd">9537000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-26" decimals="-3" id="f-127" unitRef="usd">13516000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-27" decimals="-3" id="f-128" unitRef="usd">4973000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-26" decimals="-3" id="f-129" unitRef="usd">950639000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-27" decimals="-3" id="f-130" unitRef="usd">695471000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-26" decimals="-3" id="f-131" unitRef="usd">382515000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-27" decimals="-3" id="f-132" unitRef="usd">386032000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-26" decimals="-3" id="f-133" unitRef="usd">6861000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-27" decimals="-3" id="f-134" unitRef="usd">8562000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-26" decimals="-3" id="f-135" unitRef="usd">43891000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-27" decimals="-3" id="f-136" unitRef="usd">45255000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-26" decimals="-3" id="f-137" unitRef="usd">1389000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-27" decimals="-3" id="f-138" unitRef="usd">4482000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-26" decimals="-3" id="f-139" unitRef="usd">1385295000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-27" decimals="-3" id="f-140" unitRef="usd">1139802000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-26" decimals="-3" id="f-141" unitRef="usd">17674000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-27" decimals="-3" id="f-142" unitRef="usd">11388000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-26" decimals="-3" id="f-143" unitRef="usd">90419000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-27" decimals="-3" id="f-144" unitRef="usd">63017000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-26" decimals="-3" id="f-145" unitRef="usd">26895000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-27" decimals="-3" id="f-146" unitRef="usd">21989000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-26" decimals="-3" id="f-147" unitRef="usd">7289000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-27" decimals="-3" id="f-148" unitRef="usd">6342000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-26" decimals="-3" id="f-149" unitRef="usd">2399000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-27" decimals="-3" id="f-150" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LinesOfCreditCurrent contextRef="c-26" decimals="-3" id="f-151" unitRef="usd">40000000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent contextRef="c-27" decimals="-3" id="f-152" unitRef="usd">0</us-gaap:LinesOfCreditCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-26" decimals="-3" id="f-153" unitRef="usd">10811000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-27" decimals="-3" id="f-154" unitRef="usd">432000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-26" decimals="-3" id="f-155" unitRef="usd">195487000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-27" decimals="-3" id="f-156" unitRef="usd">103168000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-26" decimals="-3" id="f-157" unitRef="usd">104112000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-27" decimals="-3" id="f-158" unitRef="usd">111027000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <arwr:RoyaltiesLiabilityNoncurrent contextRef="c-26" decimals="-3" id="f-159" unitRef="usd">367397000</arwr:RoyaltiesLiabilityNoncurrent>
    <arwr:RoyaltiesLiabilityNoncurrent contextRef="c-27" decimals="-3" id="f-160" unitRef="usd">341361000</arwr:RoyaltiesLiabilityNoncurrent>
    <us-gaap:LongTermLineOfCredit contextRef="c-26" decimals="-3" id="f-161" unitRef="usd">214883000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit contextRef="c-27" decimals="-3" id="f-162" unitRef="usd">393183000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-26" decimals="-3" id="f-163" unitRef="usd">686392000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-27" decimals="-3" id="f-164" unitRef="usd">845571000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies contextRef="c-26" id="f-165" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-27" id="f-166" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-27"
      decimals="INF"
      id="f-167"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-26"
      decimals="INF"
      id="f-168"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-26" decimals="-3" id="f-169" unitRef="shares">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-27" decimals="-3" id="f-170" unitRef="shares">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-26" decimals="-3" id="f-171" unitRef="shares">135702000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-26" decimals="-3" id="f-172" unitRef="shares">135702000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-27" decimals="-3" id="f-173" unitRef="shares">124376000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-27" decimals="-3" id="f-174" unitRef="shares">124376000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-26" decimals="-3" id="f-175" unitRef="usd">231000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-27" decimals="-3" id="f-176" unitRef="usd">217000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-26" decimals="-3" id="f-177" unitRef="usd">2139725000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-27" decimals="-3" id="f-178" unitRef="usd">1806000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-26" decimals="-3" id="f-179" unitRef="usd">6443000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-27" decimals="-3" id="f-180" unitRef="usd">4750000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-26" decimals="-3" id="f-181" unitRef="usd">-1627154000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-27" decimals="-3" id="f-182" unitRef="usd">-1625523000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares contextRef="c-26" decimals="-3" id="f-183" unitRef="shares">2661000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-27" decimals="-3" id="f-184" unitRef="shares">0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-26" decimals="-3" id="f-185" unitRef="usd">53193000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-27" decimals="-3" id="f-186" unitRef="usd">0</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-187" unitRef="usd">466052000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-188" unitRef="usd">185444000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-26" decimals="-3" id="f-189" unitRef="usd">37364000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-27" decimals="-3" id="f-190" unitRef="usd">5619000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="-3" id="f-191" unitRef="usd">503416000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-3" id="f-192" unitRef="usd">191063000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-26" decimals="-3" id="f-193" unitRef="usd">1385295000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-27" decimals="-3" id="f-194" unitRef="usd">1139802000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">829448000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-28" decimals="-3" id="f-196" unitRef="usd">3551000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-29" decimals="-3" id="f-197" unitRef="usd">240735000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-198" unitRef="usd">607159000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-28" decimals="-3" id="f-199" unitRef="usd">505870000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-29" decimals="-3" id="f-200" unitRef="usd">353188000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">123943000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-28" decimals="-3" id="f-202" unitRef="usd">98761000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-29" decimals="-3" id="f-203" unitRef="usd">92549000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-204" unitRef="usd">731102000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-28" decimals="-3" id="f-205" unitRef="usd">604631000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-29" decimals="-3" id="f-206" unitRef="usd">445737000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">98346000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-28" decimals="-3" id="f-208" unitRef="usd">-601080000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-29" decimals="-3" id="f-209" unitRef="usd">-205002000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-1" decimals="-3" id="f-210" unitRef="usd">37289000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-28" decimals="-3" id="f-211" unitRef="usd">22720000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-29" decimals="-3" id="f-212" unitRef="usd">15299000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">89361000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-28" decimals="-3" id="f-214" unitRef="usd">32352000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-29" decimals="-3" id="f-215" unitRef="usd">18326000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-216" unitRef="usd">5259000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-28" decimals="-3" id="f-217" unitRef="usd">-1748000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-29" decimals="-3" id="f-218" unitRef="usd">1538000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">-46813000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-28" decimals="-3" id="f-220" unitRef="usd">-11380000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-29" decimals="-3" id="f-221" unitRef="usd">-1489000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-222" unitRef="usd">51533000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-28" decimals="-3" id="f-223" unitRef="usd">-612460000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-224" unitRef="usd">-206491000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">21419000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-28" decimals="-3" id="f-226" unitRef="usd">-2767000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-29" decimals="-3" id="f-227" unitRef="usd">2784000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-228" unitRef="usd">30114000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-28" decimals="-3" id="f-229" unitRef="usd">-609693000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-29" decimals="-3" id="f-230" unitRef="usd">-209275000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">31745000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-28" decimals="-3" id="f-232" unitRef="usd">-10200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-233" unitRef="usd">-4000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-234" unitRef="usd">-1631000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-28" decimals="-3" id="f-235" unitRef="usd">-599493000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-29" decimals="-3" id="f-236" unitRef="usd">-205275000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-237"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-28"
      decimals="2"
      id="f-238"
      unitRef="usdPerShare">-5.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-29"
      decimals="2"
      id="f-239"
      unitRef="usdPerShare">-1.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-240"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-28"
      decimals="2"
      id="f-241"
      unitRef="usdPerShare">-5.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-29"
      decimals="2"
      id="f-242"
      unitRef="usdPerShare">-1.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-243" unitRef="shares">133758000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-28" decimals="-3" id="f-244" unitRef="shares">119784000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-29" decimals="-3" id="f-245" unitRef="shares">106750000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-246" unitRef="shares">133758000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-28" decimals="-3" id="f-247" unitRef="shares">119784000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-29" decimals="-3" id="f-248" unitRef="shares">106750000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-249" unitRef="usd">2125000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-28" decimals="-3" id="f-250" unitRef="usd">3775000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-29" decimals="-3" id="f-251" unitRef="usd">-2964000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-252" unitRef="usd">-432000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-28" decimals="-3" id="f-253" unitRef="usd">4197000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-29" decimals="-3" id="f-254" unitRef="usd">-122000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-255" unitRef="usd">31745000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-28" decimals="-3" id="f-256" unitRef="usd">-10200000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-257" unitRef="usd">-4000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-258" unitRef="usd">31807000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-3" id="f-259" unitRef="usd">-601721000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-260" unitRef="usd">-212361000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-30" decimals="-3" id="f-261" unitRef="shares">105960000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-3" id="f-262" unitRef="usd">198000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-263" unitRef="usd">1219213000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-264" unitRef="usd">-136000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-3" id="f-265" unitRef="usd">-820755000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-34" decimals="-3" id="f-266" unitRef="usd">19819000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-35" decimals="-3" id="f-267" unitRef="usd">418339000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-36" decimals="-3" id="f-268" unitRef="usd">78130000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-29" decimals="-3" id="f-269" unitRef="usd">78130000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-37" decimals="-3" id="f-270" unitRef="shares">439000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-37" decimals="-3" id="f-271" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-36" decimals="-3" id="f-272" unitRef="usd">3053000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-29" decimals="-3" id="f-273" unitRef="usd">3054000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-37" decimals="-3" id="f-274" unitRef="shares">913000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-37" decimals="-3" id="f-275" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-36" decimals="-3" id="f-276" unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-29" decimals="-3" id="f-277" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-38" decimals="-3" id="f-278" unitRef="usd">-2964000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-29" decimals="-3" id="f-279" unitRef="usd">-2964000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-38" decimals="-3" id="f-280" unitRef="usd">-122000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-29" decimals="-3" id="f-281" unitRef="usd">-122000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-39" decimals="-3" id="f-282" unitRef="usd">-205275000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-40" decimals="-3" id="f-283" unitRef="usd">-4000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-29" decimals="-3" id="f-284" unitRef="usd">-209275000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-41" decimals="-3" id="f-285" unitRef="shares">107312000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-41" decimals="-3" id="f-286" unitRef="usd">200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-3" id="f-287" unitRef="usd">1300395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-3" id="f-288" unitRef="usd">-3222000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-3" id="f-289" unitRef="usd">-1026030000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-290" unitRef="usd">15819000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-291" unitRef="usd">287162000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-41" decimals="-3" id="f-292" unitRef="shares">107312000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-41" decimals="-3" id="f-293" unitRef="usd">200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-3" id="f-294" unitRef="usd">1300395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-3" id="f-295" unitRef="usd">-3222000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-3" id="f-296" unitRef="usd">-1026030000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-297" unitRef="usd">15819000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-298" unitRef="usd">287162000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-47" decimals="-3" id="f-299" unitRef="usd">73968000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-28" decimals="-3" id="f-300" unitRef="usd">73968000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-48" decimals="-3" id="f-301" unitRef="shares">226000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-47" decimals="-3" id="f-302" unitRef="usd">2389000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-28" decimals="-3" id="f-303" unitRef="usd">2389000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-48" decimals="-3" id="f-304" unitRef="shares">1048000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-48" decimals="-3" id="f-305" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-47" decimals="-3" id="f-306" unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-28" decimals="-3" id="f-307" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-48" decimals="-3" id="f-308" unitRef="shares">15790000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-48" decimals="-3" id="f-309" unitRef="usd">16000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-47" decimals="-3" id="f-310" unitRef="usd">429249000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-28" decimals="-3" id="f-311" unitRef="usd">429265000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-49" decimals="-3" id="f-312" unitRef="usd">3775000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-28" decimals="-3" id="f-313" unitRef="usd">3775000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-49" decimals="-3" id="f-314" unitRef="usd">4197000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-28" decimals="-3" id="f-315" unitRef="usd">4197000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-50" decimals="-3" id="f-316" unitRef="usd">-599493000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-51" decimals="-3" id="f-317" unitRef="usd">-10200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-28" decimals="-3" id="f-318" unitRef="usd">-609693000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-52" decimals="-3" id="f-319" unitRef="shares">124376000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-52" decimals="-3" id="f-320" unitRef="usd">217000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-53" decimals="-3" id="f-321" unitRef="usd">1806000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-54" decimals="-3" id="f-322" unitRef="usd">4750000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-55" decimals="-3" id="f-323" unitRef="usd">-1625523000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-3" id="f-324" unitRef="usd">5619000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-3" id="f-325" unitRef="usd">191063000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-52" decimals="-3" id="f-326" unitRef="shares">124376000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-52" decimals="-3" id="f-327" unitRef="usd">217000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-53" decimals="-3" id="f-328" unitRef="usd">1806000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-54" decimals="-3" id="f-329" unitRef="usd">4750000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-55" decimals="-3" id="f-330" unitRef="usd">-1625523000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-57" decimals="-3" id="f-331" unitRef="shares">0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-3" id="f-332" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-3" id="f-333" unitRef="usd">5619000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-3" id="f-334" unitRef="usd">191063000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-58" decimals="-3" id="f-335" unitRef="usd">63366000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-336" unitRef="usd">63366000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-59" decimals="-3" id="f-337" unitRef="shares">535000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-58" decimals="-3" id="f-338" unitRef="usd">3983000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-339" unitRef="usd">3983000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-59" decimals="-3" id="f-340" unitRef="shares">1526000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-59" decimals="-3" id="f-341" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-59" decimals="-3" id="f-343" unitRef="shares">11926000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-59" decimals="-3" id="f-344" unitRef="usd">12000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-58" decimals="-3" id="f-345" unitRef="usd">241376000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-346" unitRef="usd">241388000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-60" decimals="-3" id="f-347" unitRef="shares">2661000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-60" decimals="-3" id="f-348" unitRef="usd">53193000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-1" decimals="-3" id="f-349" unitRef="usd">53193000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-58" decimals="-3" id="f-350" unitRef="usd">25000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-1" decimals="-3" id="f-351" unitRef="usd">25000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-61" decimals="-3" id="f-352" unitRef="usd">2125000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-353" unitRef="usd">2125000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-61" decimals="-3" id="f-354" unitRef="usd">-432000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-355" unitRef="usd">-432000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-62" decimals="-3" id="f-356" unitRef="usd">-1631000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-63" decimals="-3" id="f-357" unitRef="usd">31745000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-358" unitRef="usd">30114000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-64" decimals="-3" id="f-359" unitRef="shares">138363000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-64" decimals="-3" id="f-360" unitRef="usd">231000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-65" decimals="-3" id="f-361" unitRef="usd">2139725000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-66" decimals="-3" id="f-362" unitRef="usd">6443000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-67" decimals="-3" id="f-363" unitRef="usd">-1627154000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-68" decimals="-3" id="f-364" unitRef="shares">2661000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-68" decimals="-3" id="f-365" unitRef="usd">-53193000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-69" decimals="-3" id="f-366" unitRef="usd">37364000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="-3" id="f-367" unitRef="usd">503416000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-368" unitRef="usd">30114000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-28" decimals="-3" id="f-369" unitRef="usd">-609693000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-29" decimals="-3" id="f-370" unitRef="usd">-209275000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-371" unitRef="usd">63366000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-28" decimals="-3" id="f-372" unitRef="usd">73968000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-29" decimals="-3" id="f-373" unitRef="usd">78130000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-374" unitRef="usd">23928000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-28" decimals="-3" id="f-375" unitRef="usd">18595000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-29" decimals="-3" id="f-376" unitRef="usd">12493000</us-gaap:DepreciationAndAmortization>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-1" decimals="-3" id="f-377" unitRef="usd">5789000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-28" decimals="-3" id="f-378" unitRef="usd">3244000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-29" decimals="-3" id="f-379" unitRef="usd">2017000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <arwr:NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-1" decimals="-3" id="f-380" unitRef="usd">26036000</arwr:NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-28" decimals="-3" id="f-381" unitRef="usd">23035000</arwr:NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-29" decimals="-3" id="f-382" unitRef="usd">18326000</arwr:NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <us-gaap:PaidInKindInterest contextRef="c-1" decimals="-3" id="f-383" unitRef="usd">63325000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-28" decimals="-3" id="f-384" unitRef="usd">9317000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-29" decimals="-3" id="f-385" unitRef="usd">0</us-gaap:PaidInKindInterest>
    <arwr:GainLossOnTreasuryStockSettlement contextRef="c-1" decimals="-3" id="f-386" unitRef="usd">3193000</arwr:GainLossOnTreasuryStockSettlement>
    <arwr:GainLossOnTreasuryStockSettlement contextRef="c-28" decimals="-3" id="f-387" unitRef="usd">0</arwr:GainLossOnTreasuryStockSettlement>
    <arwr:GainLossOnTreasuryStockSettlement contextRef="c-29" decimals="-3" id="f-388" unitRef="usd">0</arwr:GainLossOnTreasuryStockSettlement>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-1" decimals="-3" id="f-389" unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-28" decimals="-3" id="f-390" unitRef="usd">-80000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-29" decimals="-3" id="f-391" unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-392" unitRef="usd">56967000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-28" decimals="-3" id="f-393" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-29" decimals="-3" id="f-394" unitRef="usd">-1410000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-395" unitRef="usd">9939000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-28" decimals="-3" id="f-396" unitRef="usd">1664000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-29" decimals="-3" id="f-397" unitRef="usd">-11603000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-398" unitRef="usd">6286000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-28" decimals="-3" id="f-399" unitRef="usd">-5536000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-29" decimals="-3" id="f-400" unitRef="usd">32998000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-401" unitRef="usd">41497000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-28" decimals="-3" id="f-402" unitRef="usd">32117000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-29" decimals="-3" id="f-403" unitRef="usd">-14965000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-404" unitRef="usd">2399000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-28" decimals="-3" id="f-405" unitRef="usd">-866000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-29" decimals="-3" id="f-406" unitRef="usd">-129183000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-407" unitRef="usd">-4605000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-28" decimals="-3" id="f-408" unitRef="usd">2240000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-29" decimals="-3" id="f-409" unitRef="usd">46590000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-1" decimals="-3" id="f-410" unitRef="usd">-3094000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-28" decimals="-3" id="f-411" unitRef="usd">1200000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-29" decimals="-3" id="f-412" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-413" unitRef="usd">179552000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-28" decimals="-3" id="f-414" unitRef="usd">-462851000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-29" decimals="-3" id="f-415" unitRef="usd">-153890000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-416" unitRef="usd">22666000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-28" decimals="-3" id="f-417" unitRef="usd">141469000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-29" decimals="-3" id="f-418" unitRef="usd">176737000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-1" decimals="-3" id="f-419" unitRef="usd">796258000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-28" decimals="-3" id="f-420" unitRef="usd">720947000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-29" decimals="-3" id="f-421" unitRef="usd">246141000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-1" decimals="-3" id="f-422" unitRef="usd">689630000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-28" decimals="-3" id="f-423" unitRef="usd">442344000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-29" decimals="-3" id="f-424" unitRef="usd">326723000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-425" unitRef="usd">-129294000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-28" decimals="-3" id="f-426" unitRef="usd">-420072000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-29" decimals="-3" id="f-427" unitRef="usd">-96155000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-428" unitRef="usd">3983000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-28" decimals="-3" id="f-429" unitRef="usd">2389000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-29" decimals="-3" id="f-430" unitRef="usd">3053000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-28" decimals="-3" id="f-431" unitRef="usd">429265000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-29" decimals="-3" id="f-432" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:ProceedsFromSaleOfFutureRoyalties contextRef="c-1" decimals="-3" id="f-433" unitRef="usd">0</arwr:ProceedsFromSaleOfFutureRoyalties>
    <arwr:ProceedsFromSaleOfFutureRoyalties contextRef="c-28" decimals="-3" id="f-434" unitRef="usd">50000000</arwr:ProceedsFromSaleOfFutureRoyalties>
    <arwr:ProceedsFromSaleOfFutureRoyalties contextRef="c-29" decimals="-3" id="f-435" unitRef="usd">250000000</arwr:ProceedsFromSaleOfFutureRoyalties>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-1" decimals="-3" id="f-436" unitRef="usd">25000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-28" decimals="-3" id="f-437" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-29" decimals="-3" id="f-438" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-3" id="f-439" unitRef="usd">5000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-28" decimals="-3" id="f-440" unitRef="usd">3134000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-29" decimals="-3" id="f-441" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-442" unitRef="usd">241388000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-1" decimals="-3" id="f-443" unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-28" decimals="-3" id="f-444" unitRef="usd">392000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-29" decimals="-3" id="f-445" unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit contextRef="c-1" decimals="-3" id="f-446" unitRef="usd">201625000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit contextRef="c-28" decimals="-3" id="f-447" unitRef="usd">0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit contextRef="c-29" decimals="-3" id="f-448" unitRef="usd">0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-1" decimals="-3" id="f-449" unitRef="usd">10260000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-28" decimals="-3" id="f-450" unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-29" decimals="-3" id="f-451" unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-452" unitRef="usd">74006000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-28" decimals="-3" id="f-453" unitRef="usd">870520000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-29" decimals="-3" id="f-454" unitRef="usd">253053000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-455" unitRef="usd">124264000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-28" decimals="-3" id="f-456" unitRef="usd">-12403000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-29" decimals="-3" id="f-457" unitRef="usd">3008000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-458" unitRef="usd">-401000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-28" decimals="-3" id="f-459" unitRef="usd">4197000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-29" decimals="-3" id="f-460" unitRef="usd">-122000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-27" decimals="-3" id="f-461" unitRef="usd">102685000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-46" decimals="-3" id="f-462" unitRef="usd">110891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-35" decimals="-3" id="f-463" unitRef="usd">108005000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-26" decimals="-3" id="f-464" unitRef="usd">226548000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-27" decimals="-3" id="f-465" unitRef="usd">102685000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-46" decimals="-3" id="f-466" unitRef="usd">110891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-467" unitRef="usd">19000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-28" decimals="-3" id="f-468" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-29" decimals="-3" id="f-469" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-470" unitRef="usd">814000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-28" decimals="-3" id="f-471" unitRef="usd">-3744000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-29" decimals="-3" id="f-472" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <arwr:TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable contextRef="c-1" decimals="-3" id="f-473" unitRef="usd">50000000</arwr:TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable>
    <arwr:TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable contextRef="c-28" decimals="-3" id="f-474" unitRef="usd">0</arwr:TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable>
    <arwr:TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable contextRef="c-29" decimals="-3" id="f-475" unitRef="usd">0</arwr:TreasuryStockReceivedInExchangeForSettlementOfAccountsReceivable>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-476" unitRef="usd">277000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-28" decimals="-3" id="f-477" unitRef="usd">4206000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-29" decimals="-3" id="f-478" unitRef="usd">14044000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-479">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#x201c;Company&#x201d;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#x2019;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#x201c;RNAi&#x201d;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#x2019;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s current pipeline:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.962%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Therapeutic Area&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:27pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Stage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Product Rights&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cardiometabolic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;plozasiran&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;zodasiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;olpasiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-PNPLA3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GSK4532990&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 2b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GSK&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-INHBE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-ALK7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-DIMERPA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pulmonary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-RAGE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SRP-1002 (ARO-MMP7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sarepta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liver&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;fazirsiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Takeda and Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;daplusiran/tomligisiran&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Neuromuscular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SRP-1001 (ARO-DUX4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sarepta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SRP-1003 (ARO-DM1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sarepta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SRP-1004 (ARO-ATXN2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sarepta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-SNCA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Novartis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-MAPT &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-C3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-CFB&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Greater China rights for plozasiran are out-licensed to Sanofi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates lab facilities in California and Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company also operates an active pharmaceutical ingredient manufacturing and supporting laboratory facility in Verona, Wisconsin. The Company&#x2019;s principal executive offices are located in Pasadena, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation and Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity for which the Company is the primary beneficiary). Subsidiaries refer to Arrowhead Madison, Inc., Arrowhead Australia Pty Ltd., Arrowhead Pharmaceuticals Ireland Limited, Arrowhead Pharmaceuticals NZ Limited, and Visirna Therapeutics, Inc. (&#x201c;Visirna&#x201d;). For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as a single segment as the chief operating decision maker, or CODM, reviews operating results on an aggregate basis and manages the operations as a single operating segment. Refer to Note 16, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further details on the segment information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company&#x2019;s primary sources of financing have been through the sale of its equity securities, credit facility, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant investment since the Company&#x2019;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#x2019;s pipeline of drug candidates and its headcount have both expanded. Additionally, significant investment will be required as the Company&#x2019;s pipeline matures into later stage clinical trials and commercialization efforts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2025, the Company had $226.5 million in cash, cash equivalents and restricted cash ($1.9 million in restricted cash) and $692.8 million in available-for-sale securities to fund operations. During the year ended September&#160;30, 2025, the Company&#x2019;s cash, cash equivalents and restricted cash and investments balance increased by $238.4 million, which was primarily due to the $500.0 million as an upfront payment under the Sarepta agreement and $325.0 million in the form of an equity investment under the Sarepta agreement, $100.0 million relating to the achievement of partnership milestone achievement of which $50.0 million was settled in cash and the remaining $50.0 million was settled through the repurchase of Company's common stock , $37.3 million interest income earned on investments, and $25.0 million in the form of pre-funded warrants, partially offset by ongoing expenses related to the Company&#x2019;s research and development programs, $201.6 million payments on its credit facility and $22.7 million relating to capital expenditure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In total, the Company is eligible to receive up to $13.4 billion in additional developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, judgments and assumptions. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results could materially differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All highly liquid interest-bearing investments are classified as cash equivalents. These investments mainly include  term deposits, money market instruments, corporate debt securities, and certificate of deposits with maturities of three months or less when purchased. The carrying value of these cash equivalents approximate fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $1.9 million and $3.5 million restricted cash at September&#160;30, 2025 and 2024, respectively, that is primarily held as collateral associated with letters of credit for the Company&#x2019;s facility leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classified all of its investments in debt securities as available-for-sale and as current assets as they represent the investment of funds available for current operations as of September&#160;30, 2025 and 2024. The available-for-sale investments may consist of investment-grade interest bearing instruments, primarily corporate debt securities, U.S. government and agency securities, commercial notes, certificate of deposits, and municipal securities, which are accounted for at fair value.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividends from these funds were automatically re-invested. Changes in fair values are reported as unrealized gains or losses and are recorded in the Company&#x2019;s consolidated statement of operations and comprehensive income (loss).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its investments for impairment based on a security-specific analysis as of each balance sheet date. If the fair value of a security is below its amortized cost, the Company first assesses whether it intends to sell the security or is more likely than not required to sell it before recovery of its amortized cost. If neither condition is met, the Company evaluates whether a portion of the decline is attributable to credit loss. Any credit-related impairment is recorded as an allowance for credit losses through earnings, with non-credit-related unrealized losses recorded in other &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;comprehensive income (loss). The Company did not recognize any credit loss relating to its investment for the years ended September&#160;30, 2025, 2024, and 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially expose the Company to concentration of credit risk primarily consist of cash, cash equivalents and restricted cash and investments. As of September&#160;30, 2025 and 2024, the Company&#x2019;s investments were primarily invested in money market funds, U.S. Government, commercial paper, and corporate debt securities and term deposit through highly rated financial institutions. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity. The Company also maintains several bank accounts at two financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, Visirna maintains several deposit and term accounts in mainland China, Hong Kong, and Singapore. Cash balances are held with various local and international financial institutions, which are subject to their respective jurisdictional deposit insurance programs. The Deposit Insurance Fund Management Corporation in China provides coverage of up to RMB 500,000 per depositor per institution, and the Hong Kong Deposit Protection Scheme provides protection of up to HKD 800,000 per depositor per bank, and the Singapore Deposit Insurance Corporation provides coverage of up to SGD 100,000 per depositor per member bank.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are recorded at cost, net of accumulated depreciation. Depreciation expense is recorded on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the asset life or lease term. Construction in progress reflects amounts incurred for construction or improvements of property, plant and equipment that have not been placed in service. Upon disposition, the cost and accumulated depreciation of assets retired or sold are removed from the respective asset category, and any gain or loss is recognized in the Company&#x2019;s consolidated statement of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated useful lives of property, plant and equipment are as follows (in years):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.143%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7 to 10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Shorter of asset life or lease term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically assesses long-lived assets or asset groups, including property, plant and equipment, for recoverability when events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the Company identifies an indicator of impairment, the Company assesses recoverability by comparing the carrying amount of the asset to the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset. An impairment loss is recognized when the carrying amount is not recoverable and is measured as the excess of carrying value over fair value. There were no impairment charges during the years ended September&#160;30, 2025, 2024, and 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Intangible Assets Subject to Amortization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets subject to amortization include certain patents and license agreements. The Company evaluates intangible assets for impairment annually or whenever events or changes in circumstances indicate that it is more likely than not that the carrying amount of intangible assets may exceed their implied fair values. No impairment charges were recorded during the years ended September&#160;30, 2025, 2024, and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether a contract is, or contains, a lease at inception. All of the Company&#x2019;s leases are classified as operating leases. Leases with terms greater than one-year are recognized on the Company&#x2019;s consolidated balance sheets as right-of-use assets that represent the Company&#x2019;s right to use an underlying asset for the lease term, and lease liabilities that represent its obligation to make lease payments arising from the lease. Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the expected lease term. As of September&#160;30, 2025 and 2024, the Company is not reasonably certain that it will exercise renewal options for any lease facilities. Therefore, these options are not included in the right-of-use assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Clinical Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accrues liabilities for products received or services incurred, particularly for ongoing clinical trials, where service providers have not yet billed or where billing terms do not align with the timing of the work performed as of the period-end. These costs mainly include third-party clinical management or clinical research organization (CRO), laboratory analysis, and investigator fees. Accrual estimates may be based on vendor communications to obtain pending invoices and/or estimates for services performed during the period. In some cases, these estimates require significant judgment, drawing on an understanding of research and development programs, services provided during the period, prior experience, and, where applicable, the expected duration of third-party contracts. Actual costs upon settlement may differ significantly from the accrued amounts in the Company&#x2019;s consolidated financial statements, though historical estimates have not differed materially from actual costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that it determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing. If the license is not considered to be distinct from other performance obligations, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time. If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Typically, the Company&#x2019;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a New Drug Application (&#x201c;NDA&#x201d;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#x2019;s consolidated statements of operations and comprehensive income (loss). Typically, milestone payments and royalties are achieved after the Company&#x2019;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or preclinical program. Milestones or royalties achieved after the Company&#x2019;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its licensing or collaboration agreements. Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment. Additionally, future royalty payments are not substantially within the control of the Company or the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further, the revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using the input method; Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations. If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain judgments affect the application of the Company&#x2019;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#x2019;s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Topic 808 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue for Contracts from Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to research and development expense or general and administrative expense, as appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred. Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#x2019;s research and development operations, and costs to acquire technology licenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense for all stock grants are based on their estimated grant-date fair value. The fair value of stock option awards is estimated using the Black-Scholes option valuation model which requires the input of subjective assumptions to calculate the value of stock options. The Company uses historical data and other information to estimate the expected price volatility and the expected forfeiture rate for stock option awards. For restricted stock units, the value of the award is based on the Company&#x2019;s stock price at the grant date. For performance-based restricted stock unit awards, the value of the award is based on the Company&#x2019;s stock price at the grant date, with consideration given to the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;probability of the performance condition being achieved. Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#x2019;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting basis and the respective tax basis of the Company&#x2019;s assets and liabilities, and expected benefits of utilizing net operating loss, capital loss, and tax-credit carryforwards. The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent management does not believe these assets are more likely than not to be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or laws is recognized in earnings in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Variable Interest Entity (&#x201c;VIE&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A VIE is an entity that, by design, either (i) lacks sufficient equity to permit the entity to finance its activities without additional subordinated financial support from other parties; or (ii) has equity investors that do not have the ability to make significant decisions relating to the entity&#x2019;s operations through voting rights, or do not have the obligation to absorb the expected losses, or do not have the right to receive the residual returns of the entity. The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. The primary beneficiary is the party that has both (i) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance, and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE through its interest in the VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 25, 2022, the Company entered into a license agreement with Visirna (Note 2) and consolidated Visirna&#x2019;s financial statements in which the Company has a direct controlling financial interest based on the VIE model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all the facts and circumstances, including its role in establishing Visirna and its ongoing rights and responsibilities to assess whether the Company has the power to direct the activities of Visirna. In general, the parties that make the most significant decisions affecting a VIE and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also considers all of its economic interests to assess whether the Company has the obligation to absorb losses of Visirna or the right to receive benefits from it that could potentially be significant to Visirna. This assessment requires the Company to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to Visirna. Factors considered in assessing the significance include: the design of  Visirna, including its capitalization structure, subordination of interests, payment priority, and the reasons why the interests are held by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At Visirna&#x2019;s inception, the Company determined it was the primary beneficiary and that Visirna should be consolidated based on the facts and circumstances. The Company performs ongoing reassessments of the VIE based on reconsideration events and reevaluates whether a change to the consolidation conclusion is required. As of September&#160;30, 2025, there were no events to be reconsidered in the consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended September&#160;30, 2025, 2024 and 2023, the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units outstanding during the period due to their anti-dilutive effect. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Three of the Company&#x2019;s wholly-owned subsidiaries&#x2019; functional currencies is not the United States dollar, which is the Company&#x2019;s reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Translation adjustments arising from the use of different exchange rates from period to period are included in the accumulated other comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as a single segment because its CODM reviews operating results on an aggregate basis and manages its operations as a single operating segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2025, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standard Update (&#x201c;ASU&#x201d;) 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in November 2024, and ASU 2025-01,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Clarifying the Effective Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. These updates require entities to provide disaggregated disclosures of income statement expenses. The ASUs do not affect the expense captions presented on the face of the income statement but instead require the disaggregation of certain expense captions into specified categories within the footnotes to the financial statements. The ASUs will become effective for the Company beginning October 1, 2027, and the Company is currently evaluating the impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued Accounting Standard Update (&#x201c;ASU&#x201d;) 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to improve its income tax disclosure requirements. Under the guidance, entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. This guidance became effective for the Company beginning on October 1, 2025. The Company does not expect any material impact on its consolidated financial statements and related disclosures resulting from applying this ASU. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses. The guidance requires public companies with a single reportable segment to provide all disclosures required under ASC 280. In addition, the guidance requires public companies to include in interim reports all disclosures related to a reportable segment&#x2019;s profit or loss and assets that are currently required in annual reports. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. This ASU is applicable to the Company&#x2019;s Annual Report on Form 10-K for the year ending September 30, 2025, and subsequent interim periods. Refer to Note 16, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further details on segment information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 4, 2025, the One Big Beautiful Bill Act (&#x201c;OBBBA&#x201d;) was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. ASC 740, "Income Taxes", requires the effects of changes in tax rates and laws to be recognized in the period in which the legislation is enacted. The Company has implemented OBBBA in the fourth quarter of fiscal 2025. Refer to Note 11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <arwr:ScheduleOfCurrentProductsTableTextBlock contextRef="c-1" id="f-480">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s current pipeline:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.962%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Therapeutic Area&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:27pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Stage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Product Rights&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cardiometabolic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;plozasiran&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;zodasiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;olpasiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-PNPLA3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GSK4532990&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 2b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GSK&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-INHBE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-ALK7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-DIMERPA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pulmonary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-RAGE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SRP-1002 (ARO-MMP7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sarepta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liver&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;fazirsiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Takeda and Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;daplusiran/tomligisiran&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Neuromuscular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SRP-1001 (ARO-DUX4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sarepta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SRP-1003 (ARO-DM1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sarepta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SRP-1004 (ARO-ATXN2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sarepta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-SNCA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Novartis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-MAPT &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-C3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-CFB&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Greater China rights for plozasiran are out-licensed to Sanofi.&lt;/span&gt;&lt;/div&gt;</arwr:ScheduleOfCurrentProductsTableTextBlock>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-26" decimals="-5" id="f-481" unitRef="usd">226500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-26" decimals="-5" id="f-482" unitRef="usd">1900000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-26" decimals="-5" id="f-483" unitRef="usd">692800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <arwr:IncreaseDecreaseInCashAndInvestments contextRef="c-1" decimals="-5" id="f-484" unitRef="usd">238400000</arwr:IncreaseDecreaseInCashAndInvestments>
    <arwr:ProceedsFromCollaborationArrangements contextRef="c-70" decimals="-5" id="f-485" unitRef="usd">500000000.0</arwr:ProceedsFromCollaborationArrangements>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c-71" decimals="-5" id="f-486" unitRef="usd">325000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <arwr:DevelopmentMilestonePayments contextRef="c-72" decimals="-5" id="f-487" unitRef="usd">100000000.0</arwr:DevelopmentMilestonePayments>
    <arwr:ProceedsFromCollaborationArrangements contextRef="c-72" decimals="-5" id="f-488" unitRef="usd">50000000.0</arwr:ProceedsFromCollaborationArrangements>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-72" decimals="-5" id="f-489" unitRef="usd">50000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-1" decimals="-5" id="f-490" unitRef="usd">37300000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-1" decimals="-5" id="f-491" unitRef="usd">25000000.0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit contextRef="c-1" decimals="-5" id="f-492" unitRef="usd">201600000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-493" unitRef="usd">22700000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments contextRef="c-26" decimals="-8" id="f-494" unitRef="usd">13400000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-495">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, judgments and assumptions. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results could materially differ from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-496">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;All highly liquid interest-bearing investments are classified as cash equivalents. These investments mainly include  term deposits, money market instruments, corporate debt securities, and certificate of deposits with maturities of three months or less when purchased. The carrying value of these cash equivalents approximate fair value.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-26" decimals="-5" id="f-497" unitRef="usd">1900000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-27" decimals="-5" id="f-498" unitRef="usd">3500000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-499">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classified all of its investments in debt securities as available-for-sale and as current assets as they represent the investment of funds available for current operations as of September&#160;30, 2025 and 2024. The available-for-sale investments may consist of investment-grade interest bearing instruments, primarily corporate debt securities, U.S. government and agency securities, commercial notes, certificate of deposits, and municipal securities, which are accounted for at fair value.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividends from these funds were automatically re-invested. Changes in fair values are reported as unrealized gains or losses and are recorded in the Company&#x2019;s consolidated statement of operations and comprehensive income (loss).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its investments for impairment based on a security-specific analysis as of each balance sheet date. If the fair value of a security is below its amortized cost, the Company first assesses whether it intends to sell the security or is more likely than not required to sell it before recovery of its amortized cost. If neither condition is met, the Company evaluates whether a portion of the decline is attributable to credit loss. Any credit-related impairment is recorded as an allowance for credit losses through earnings, with non-credit-related unrealized losses recorded in other &lt;/span&gt;&lt;/div&gt;comprehensive income (loss). The Company did not recognize any credit loss relating to its investment for the years ended September&#160;30, 2025, 2024, and 2023.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-500">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially expose the Company to concentration of credit risk primarily consist of cash, cash equivalents and restricted cash and investments. As of September&#160;30, 2025 and 2024, the Company&#x2019;s investments were primarily invested in money market funds, U.S. Government, commercial paper, and corporate debt securities and term deposit through highly rated financial institutions. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity. The Company also maintains several bank accounts at two financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, Visirna maintains several deposit and term accounts in mainland China, Hong Kong, and Singapore. Cash balances are held with various local and international financial institutions, which are subject to their respective jurisdictional deposit insurance programs. The Deposit Insurance Fund Management Corporation in China provides coverage of up to RMB 500,000 per depositor per institution, and the Hong Kong Deposit Protection Scheme provides protection of up to HKD 800,000 per depositor per bank, and the Singapore Deposit Insurance Corporation provides coverage of up to SGD 100,000 per depositor per member bank.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-501">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are recorded at cost, net of accumulated depreciation. Depreciation expense is recorded on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the asset life or lease term. Construction in progress reflects amounts incurred for construction or improvements of property, plant and equipment that have not been placed in service. Upon disposition, the cost and accumulated depreciation of assets retired or sold are removed from the respective asset category, and any gain or loss is recognized in the Company&#x2019;s consolidated statement of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated useful lives of property, plant and equipment are as follows (in years):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.143%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7 to 10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Shorter of asset life or lease term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company periodically assesses long-lived assets or asset groups, including property, plant and equipment, for recoverability when events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the Company identifies an indicator of impairment, the Company assesses recoverability by comparing the carrying amount of the asset to the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset. An impairment loss is recognized when the carrying amount is not recoverable and is measured as the excess of carrying value over fair value. There were no impairment charges during the years ended September&#160;30, 2025, 2024, and 2023.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-502">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated useful lives of property, plant and equipment are as follows (in years):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.143%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7 to 10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3 to 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Shorter of asset life or lease term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s major classes of property, plant and equipment: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;444,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(80,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(58,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;382,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-73" id="f-503">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-74" id="f-504">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-75" id="f-505">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-76" id="f-506">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-77" id="f-507">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-78" id="f-508">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-79" id="f-509">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c-1" id="f-510">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Intangible Assets Subject to Amortization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets subject to amortization include certain patents and license agreements. The Company evaluates intangible assets for impairment annually or whenever events or changes in circumstances indicate that it is more likely than not that the carrying amount of intangible assets may exceed their implied fair values. No impairment charges were recorded during the years ended September&#160;30, 2025, 2024, and 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-28" decimals="INF" id="f-511" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-1" decimals="INF" id="f-512" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-29" decimals="INF" id="f-513" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-514">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether a contract is, or contains, a lease at inception. All of the Company&#x2019;s leases are classified as operating leases. Leases with terms greater than one-year are recognized on the Company&#x2019;s consolidated balance sheets as right-of-use assets that represent the Company&#x2019;s right to use an underlying asset for the lease term, and lease liabilities that represent its obligation to make lease payments arising from the lease. Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the expected lease term. As of September&#160;30, 2025 and 2024, the Company is not reasonably certain that it will exercise renewal options for any lease facilities. Therefore, these options are not included in the right-of-use assets and liabilities. &lt;/span&gt;&lt;/div&gt;The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred.</us-gaap:LesseeLeasesPolicyTextBlock>
    <arwr:ClinicalAccrualPolicyPolicyTextBlock contextRef="c-1" id="f-515">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Clinical Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accrues liabilities for products received or services incurred, particularly for ongoing clinical trials, where service providers have not yet billed or where billing terms do not align with the timing of the work performed as of the period-end. These costs mainly include third-party clinical management or clinical research organization (CRO), laboratory analysis, and investigator fees. Accrual estimates may be based on vendor communications to obtain pending invoices and/or estimates for services performed during the period. In some cases, these estimates require significant judgment, drawing on an understanding of research and development programs, services provided during the period, prior experience, and, where applicable, the expected duration of third-party contracts. Actual costs upon settlement may differ significantly from the accrued amounts in the Company&#x2019;s consolidated financial statements, though historical estimates have not differed materially from actual costs.&lt;/span&gt;&lt;/div&gt;</arwr:ClinicalAccrualPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-516">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that it determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing. If the license is not considered to be distinct from other performance obligations, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time. If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Typically, the Company&#x2019;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a New Drug Application (&#x201c;NDA&#x201d;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#x2019;s consolidated statements of operations and comprehensive income (loss). Typically, milestone payments and royalties are achieved after the Company&#x2019;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or preclinical program. Milestones or royalties achieved after the Company&#x2019;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its licensing or collaboration agreements. Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment. Additionally, future royalty payments are not substantially within the control of the Company or the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further, the revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using the input method; Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations. If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain judgments affect the application of the Company&#x2019;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#x2019;s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c-1" id="f-517">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Topic 808 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue for Contracts from Customers&lt;/span&gt;. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to research and development expense or general and administrative expense, as appropriate.</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-518">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred. Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#x2019;s research and development operations, and costs to acquire technology licenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-519">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense for all stock grants are based on their estimated grant-date fair value. The fair value of stock option awards is estimated using the Black-Scholes option valuation model which requires the input of subjective assumptions to calculate the value of stock options. The Company uses historical data and other information to estimate the expected price volatility and the expected forfeiture rate for stock option awards. For restricted stock units, the value of the award is based on the Company&#x2019;s stock price at the grant date. For performance-based restricted stock unit awards, the value of the award is based on the Company&#x2019;s stock price at the grant date, with consideration given to the &lt;/span&gt;&lt;/div&gt;probability of the performance condition being achieved. Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#x2019;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-520">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting basis and the respective tax basis of the Company&#x2019;s assets and liabilities, and expected benefits of utilizing net operating loss, capital loss, and tax-credit carryforwards. The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent management does not believe these assets are more likely than not to be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or laws is recognized in earnings in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="c-1" id="f-521">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Variable Interest Entity (&#x201c;VIE&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A VIE is an entity that, by design, either (i) lacks sufficient equity to permit the entity to finance its activities without additional subordinated financial support from other parties; or (ii) has equity investors that do not have the ability to make significant decisions relating to the entity&#x2019;s operations through voting rights, or do not have the obligation to absorb the expected losses, or do not have the right to receive the residual returns of the entity. The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. The primary beneficiary is the party that has both (i) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance, and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE through its interest in the VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 25, 2022, the Company entered into a license agreement with Visirna (Note 2) and consolidated Visirna&#x2019;s financial statements in which the Company has a direct controlling financial interest based on the VIE model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all the facts and circumstances, including its role in establishing Visirna and its ongoing rights and responsibilities to assess whether the Company has the power to direct the activities of Visirna. In general, the parties that make the most significant decisions affecting a VIE and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also considers all of its economic interests to assess whether the Company has the obligation to absorb losses of Visirna or the right to receive benefits from it that could potentially be significant to Visirna. This assessment requires the Company to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to Visirna. Factors considered in assessing the significance include: the design of  Visirna, including its capitalization structure, subordination of interests, payment priority, and the reasons why the interests are held by the Company. &lt;/span&gt;&lt;/div&gt;At Visirna&#x2019;s inception, the Company determined it was the primary beneficiary and that Visirna should be consolidated based on the facts and circumstances. The Company performs ongoing reassessments of the VIE based on reconsideration events and reevaluates whether a change to the consolidation conclusion is required. As of September&#160;30, 2025, there were no events to be reconsidered in the consolidation.</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-522">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units outstanding. &lt;/span&gt;&lt;/div&gt;During the years ended September&#160;30, 2025, 2024 and 2023, the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units outstanding during the period due to their anti-dilutive effect.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-523">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;Three of the Company&#x2019;s wholly-owned subsidiaries&#x2019; functional currencies is not the United States dollar, which is the Company&#x2019;s reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Translation adjustments arising from the use of different exchange rates from period to period are included in the accumulated other comprehensive income (loss).</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <arwr:NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency
      contextRef="c-26"
      decimals="INF"
      id="f-524"
      unitRef="subsidiary">3</arwr:NumberOfSubsidiariesWithForeignCurrencyAsFunctionalCurrency>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-525">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;The Company operates as a single segment because its CODM reviews operating results on an aggregate basis and manages its operations as a single operating segment.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-526">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2025, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standard Update (&#x201c;ASU&#x201d;) 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in November 2024, and ASU 2025-01,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Clarifying the Effective Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. These updates require entities to provide disaggregated disclosures of income statement expenses. The ASUs do not affect the expense captions presented on the face of the income statement but instead require the disaggregation of certain expense captions into specified categories within the footnotes to the financial statements. The ASUs will become effective for the Company beginning October 1, 2027, and the Company is currently evaluating the impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued Accounting Standard Update (&#x201c;ASU&#x201d;) 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to improve its income tax disclosure requirements. Under the guidance, entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. This guidance became effective for the Company beginning on October 1, 2025. The Company does not expect any material impact on its consolidated financial statements and related disclosures resulting from applying this ASU. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses. The guidance requires public companies with a single reportable segment to provide all disclosures required under ASC 280. In addition, the guidance requires public companies to include in interim reports all disclosures related to a reportable segment&#x2019;s profit or loss and assets that are currently required in annual reports. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. This ASU is applicable to the Company&#x2019;s Annual Report on Form 10-K for the year ending September 30, 2025, and subsequent interim periods. Refer to Note 16, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further details on segment information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 4, 2025, the One Big Beautiful Bill Act (&#x201c;OBBBA&#x201d;) was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. ASC 740, "Income Taxes", requires the effects of changes in tax rates and laws to be recognized in the period in which the legislation is enacted. The Company has implemented OBBBA in the fourth quarter of fiscal 2025. Refer to Note 11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-527">COLLABORATION AND LICENSE AGREEMENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of revenue recognized:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Horizon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Takeda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sarepta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;696,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;829,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balance of receivables and contract liabilities related to the Company&#x2019;s collaboration and license agreements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Receivables included in accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract liabilities included in deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;GlaxoSmithKline Intellectual Property (No. 3) Limited (&#x201c;GSK&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;           &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;GSK-HSD License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#x201c;GSK-HSD License Agreement&#x201d;). Under the GSK-HSD License Agreement, GSK has received an exclusive license for GSK-4532990 (formerly ARO-HSD). The exclusive license is worldwide with the exception of greater China. GSK is wholly responsible for all clinical development and commercialization of GSK-4532990 in its territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has completed its performance obligation related to this agreement, and the upfront payment of $120.0&#160;million was fully recognized in the year ended September 30, 2022. Further, GSK dosed the first patient in a Phase 2b trial in March 2023 and paid a $30.0&#160;million milestone payment to the Company in the third quarter of fiscal 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is eligible for an additional payment of $100.0&#160;million upon achieving the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $190.0&#160;million at first commercial sale, and up to $590.0&#160;million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;           &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;GSK-HBV Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;           On December 11, 2023, the Company entered into an Amended and Restated License Agreement with GSK (the &#x201c;GSK-HBV Agreement&#x201d;) pursuant to which GSK received a worldwide, exclusive license to develop and commercialize daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989), the Company&#x2019;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;           Under the terms of the GSK-HBV Agreement, the Company received $2.7&#160;million in December 2023, upon signing the amended GSK-HBV Agreement. Further, GSK dosed the fifth patient in a Phase 2 trial in December 2024, triggering a $2.5&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2025. The Company is eligible to receive up to $830.0&#160;million in development and sales milestone payments under the GSK-HBV Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;           There were no contract assets and liabilities recorded as of September&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Horizon Therapeutics Ireland DAC (&#x201c;Horizon&#x201d;) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, Horizon and the Company entered into a collaboration and license agreement (the &#x201c;Horizon License Agreement&#x201d;). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for HZN-457, a clinical-stage medicine being developed by Horizon as a potential treatment for people with uncontrolled gout.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 6, 2023, Amgen completed its acquisition of Horizon and subsequently notified the Company of Amgen&#x2019;s intent to terminate the HZN-457 license. Horizon exercised its right to terminate the Horizon License Agreement for convenience, which took effect on December 21, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#x201c;Takeda License Agreement&#x201d;). Under the Takeda License Agreement, Takeda and the Company will co-develop the Company&#x2019;s fazirsiran program (formerly TAK-999 and ARO-AAT), the Company&#x2019;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, fazirsiran, if approved, will be co-commercialized under a 50/50 profit sharing structure. Outside the United States, Takeda received an exclusive license to commercialize fazirsiran and will lead the global commercialization strategy, while the Company will be eligible to receive tiered royalties of 20% to 25% on net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the key deliverables included the license and certain research and development services including the Company&#x2019;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study, and to ensure certain manufacturing of fazirsiran drug product is completed and delivered to Takeda (the &#x201c;Takeda R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of these Takeda R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Takeda is responsible for managing clinical development and commercialization outside the United States. Within the United States, the Company and Takeda are responsible in the co-development and co-commercialization efforts. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Takeda License Agreement, the Company received $300.0&#160;million as an upfront payment in January 2021 and an additional $40.0&#160;million upon Takeda&#x2019;s initiation of a Phase 3 REDWOOD clinical study of fazirsiran in March 2023, and is eligible to receive up to $527.5&#160;million in additional potential development, regulatory and commercial milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated the total $300.0&#160;million initial transaction price to its one distinct performance obligation for the fazirsiran license and the associated Takeda R&amp;amp;D Services. The Company has substantially completed its performance obligation under the Takeda License Agreement by December 31, 2023. As such, all revenue has been fully recognized as of December 31, 2023. There were no further deferred revenue and contract liabilities as of September&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded $31.3&#160;million as accrued expenses as of September&#160;30, 2025 that was primarily driven by co-development and co-commercialization activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen Pharmaceuticals, Inc. (&#x201c;Janssen&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 7, 2023, Janssen voluntarily terminated its collaboration agreement with the Company and the Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795. There are no currently active trials for ARO-PNPLA3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further, on December 11, 2023, the Company entered into the GSK-HBV Agreement, as discussed above, pursuant to which GSK received an exclusive license for JNJ-3989 (formerly ARO-HBV). JNJ-3989 had previously been licensed to Janssen in October 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amgen Inc. (&#x201c;Amgen&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#x201c;Olpasiran Agreement&#x201d;), Amgen received a worldwide, exclusive license to the Company&#x2019;s novel RNAi olpasiran (previously referred to as AMG-890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the Olpasiran Agreement, Amgen is wholly responsible for clinical development and commercialization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has substantially completed its performance obligations under the Olpasiran Agreement. There were no contract assets and liabilities recorded as of September&#160;30, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, Royalty Pharma Investments 2019 ICAV (&#x201c;Royalty Pharma&#x201d;) and the Company entered into a Royalty Purchase Agreement with Royalty Pharma (the &#x201c;Royalty Pharma Agreement&#x201d;). In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional  $485.0 million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma. See Note 13.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sarepta Therapeutics, Inc.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 25, 2024, the Company entered into an Exclusive License and Collaboration Agreement (the &#x201c;Sarepta Collaboration Agreement&#x201d;) with Sarepta for the development and commercialization of multiple clinical and preclinical programs in rare, genetic diseases of the muscle, central nervous system, and lungs. The Company concurrently entered into a Stock Purchase Agreement (the &#x201c;Stock Purchase Agreement&#x201d;) with Sarepta (see Note 6). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under the Sarepta Collaboration Agreement, Sarepta received an exclusive sublicensable worldwide license to SRP-1001 (formerly ARO-DUX4), SRP-1003 (formerly ARO-DM1), SRP-1002 (formerly ARO-MMP7), and SRP-1004 (formerly ARO-ATXN2) clinical stage programs (the &#x201c;C1&#x201d; programs). Sarepta also received an exclusive sublicensable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;worldwide license to the Company&#x2019;s ARO-HTT, ARO-ATXN1, and ARO-ATXN3 preclinical stage programs (the &#x201c;C2&#x201d; programs). The Company will perform certain research and development activities for the C1 and C2 programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Further, Sarepta may select up to six gene targets for which the Company will perform discovery, optimization and preclinical development activities to identify RNAi compounds against each selected target (the &#x201c;C3&#x201d; programs). Upon target acceptance, Sarepta will receive an exclusive license to the Company&#x2019;s intellectual property rights to exploit  compounds directed to those targets and is wholly responsible for clinical development and commercialization of each compound after the Company delivers a Clinical Trial Application ready data package (the "CTA package").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company identified 17 performance obligations under the Sarepta Collaboration Agreement. The four C1 licenses are distinct performance obligations from the four C1 research and development performance obligations since the customer can use and benefit from the licenses separately. The performance obligations for the licenses were satisfied in the second quarter of fiscal 2025 upon delivery and the research and development performance obligations will be satisfied as the work is performed. The remaining nine performance obligations include three C2 preclinical stage program licenses and research and development activities, and six C3 unidentified discovery target licenses and research and development activity. Each of the three C2 programs and the six C3 programs were determined to represent one performance obligation, as the customer cannot benefit from the use of the product license at the point of transfer until the specified research and development activities are performed. As such, each of the C2 and C3 product licenses and respective research and development work will be combined to form one performance obligation. For these nine performance obligations, revenue is recognized over time as the work is performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For performance obligations recognized over time, the estimated performance period over which revenue will be recognized is determined to be the period over which the Company estimates it will perform the research and development activities. The Company determined that the most appropriate method of measuring progress for these performance obligations is an input method based on research and development costs in the program budget. Accordingly, the Company has estimated the total cost required to complete its obligation and recognized an amount of revenue equal to the proportion of services performed, which is reassessed on an ongoing basis as the program progresses. In the period an agreement expires or is terminated, remaining deferred revenue, if any, is recognized as revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under the terms of the Sarepta Collaboration Agreement, the Company received an upfront payment of $500.0&#160;million on February 14, 2025. In addition, on February 7, 2025, the Company received $325.0&#160;million in the form of an equity investment under the Stock Purchase Agreement. Based upon the Company's share price on February 7, 2025, (the &#x201c;Closing Date&#x201d;), the difference between the $325.0&#160;million and the fair value of the shares on the Closing date resulted in a premium of $83.6&#160;million. The premium is included as part of the total consideration of the Sarepta Collaboration Agreement for revenue recognition purposes. The Company is entitled to receive $250.0&#160;million to be paid in annual installments of $50.0&#160;million over the first five years of the agreement. The Company is also eligible receive reimbursement of certain costs related to carrying out the research and development activities for the C1 programs. The fixed consideration of $833.6&#160;million and an estimated variable consideration of $71.2&#160;million for a total of $904.9&#160;million were allocated to all performance obligations based on their relative standalone selling price. Standalone selling prices for the product licenses were determined using an adjusted market-based approach through the net present value of the expected future cash flows for each program. The standalone selling prices for the research and development work were determined based on an expected cost plus margin approach. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company estimates the stand-alone selling price for each distinct performance obligation, which involves assumptions that may require significant judgment. The Company&#x2019;s estimates of the stand-alone selling price for license-related performance obligations includes forecasted revenues and expenses, phase dates, probability of success, development timelines, and the discount rate. The estimates of the stand-alone selling price for research and development performance obligations generally include forecasting the expected costs of satisfying a performance obligation at market rates. The Company identified a discount based on the difference between the aggregate stand-alone selling price and the transaction price for accounting revenue recognition purposes. The Company allocated the discount proportionally to each of the performance obligations based upon their standalone selling price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company receives reimbursement of certain costs related to carrying out the research and development activities for the C1 programs and may receive development milestone payments of up to $300.0&#160;million. Further, for each of the 13 programs, the Company is eligible to receive regulatory milestone payments between $110.0&#160;million and $180.0&#160;million per program. Variable consideration associated with the milestones that may be achieved will be allocated to the performance obligation to which it is determined to be related, which will be the respective development work that is being reimbursed and the respective programs to which the milestones relate. ARO-DM1 development milestones were allocated between the license and development work based on the allocation of the standalone selling price. The Company will recognize the ARO-DM1 development milestones and other development milestones as revenue in the periods the underlying milestone events are achieved as achievement of the milestone events are highly susceptible to factors outside of the entity's influence and therefore there is a possibility that the milestone event will not be achieved.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is also eligible to receive sales milestone payments between $500.0&#160;million and $700.0&#160;million per program as well as tiered royalties on net sales of licensed products of up to the low double digits, subject to the terms and conditions of the Sarepta Collaboration Agreement. The Company has applied the sales-based scope exception to the sales milestones and the royalty-based payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Sarepta Collaboration Agreement commenced in February 2025 and may be terminated by either party in the event of a material breach as defined therein. In addition, Sarepta may voluntarily terminate the Sarepta Collaboration Agreement with 30 days' written notice to the Company if terminated prior to any regulatory approval of a licensed product. Unless earlier terminated, the Sarepta Collaboration Agreement expires on a product-by-product and country-by-country basis, upon the date of expiration of the relevant royalty term for such product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2025, the Company repurchased 2,660,989 shares of its common stock from Sarepta in connection with the $100.0&#160;million DM1 first development milestone under the Sarepta Collaboration Agreement. The repurchase satisfied $50.0&#160;million of the milestone payment through delivery of the Company&#x2019;s common stock, with the remaining $50.0&#160;million settled in cash. The shares were recorded as treasury stock at their fair value of $53.2&#160;million, resulting in a $3.2&#160;million gain on settlement. The repurchased shares are presented as a reduction to total stockholders&#x2019; equity in accordance with ASC 505-30.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of September&#160;30, 2025, the Company recorded $696.8&#160;million in revenue from Sarepta and $6.8&#160;million in accounts receivable. The recognition of the remaining revenue for the performance obligations is dependent upon the time it takes to complete the respective research and development activities and in consideration of the timing of the selection of the C3 programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Visirna Therapeutics Inc. (&#x201c;Visirna&#x201d;) and Genzyme Corporation (&#x201c;Sanofi&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2025, Visirna Therapeutics HK Limited (&#x201c;Visirna HK&#x201d;), a wholly owned subsidiary of Visirna Therapeutics, Inc, a majority owned subsidiary of the Company, entered into an Asset Purchase Agreement (the &#x201c;Asset Purchase Agreement&#x201d;) with Genzyme Corporation (&#x201c;Sanofi&#x201d;), a wholly owned subsidiary of Sanofi S.A., pursuant to which Visirna HK sold all of its assets and rights in investigational plozasiran to Sanofi, which included an assignment of Visirna HK&#x2019;s rights (as successor by assignment from Visirna) to develop and commercialize investigational plozasiran in Greater China pursuant to that certain License Agreement by and between the Company and Visirna dated, April 25, 2022 (the &#x201c;Visirna License Agreement&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Asset Purchase Agreement, the Company consented to the partial assignment of the Visirna License Agreement by Visirna HK to Sanofi (as so assigned, the &#x201c;Sanofi License Agreement&#x201d;), amongst other agreements between the Company and Visirna, effective as of the closing of the Asset Purchase Agreement. This agreement was not deemed a legal sale of intellectual property from the consolidated perspective of the Company. After giving effect to the Asset Purchase Agreement, Visirna HK retains rights to develop and commercialize in Greater China three other cardiometabolic drugs licensed to it pursuant to the Visirna License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon closing of the Asset Purchase Agreement, Visirna received an upfront payment of $130.0&#160;million from Sanofi and is eligible to receive further development milestone payments of up to $265.0&#160;million upon approval of plozasiran across various indications in mainland China. The Company is also eligible to receive royalties from Sanofi on net commercial product sales in Greater China under the Sanofi License Agreement. During the year ended September&#160;30, 2025, the Company recorded $130.0&#160;million in revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Visirna identified the licenses as defined in the agreement as the performance obligations under the Asset Purchase Agreement. The performance obligations for the licenses was satisfied in the fourth quarter of fiscal 2025 upon delivery. The fixed consideration of $130.0&#160;million was allocated to the performance obligations. The Company will recognize the development milestones as revenue in the periods the underlying milestone events are achieved as achievement of the milestone events are highly susceptible to factors outside of the entity's influence and therefore there is a possibility that the milestone events will not be achieved. The Company has also applied the sales-based scope exception to the royalty-based payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Sanofi License Agreement may be terminated by either party in the event of a material breach as defined therein. Unless earlier terminated, the Sanofi License Agreement expires on a product-by-product basis, upon the date of expiration of the relevant royalty term for such product in Greater China.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-528">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of revenue recognized:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Horizon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Takeda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sarepta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;696,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;829,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-80" decimals="-3" id="f-529" unitRef="usd">2645000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-81" decimals="-3" id="f-530" unitRef="usd">2685000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-82" decimals="-3" id="f-531" unitRef="usd">29657000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-83" decimals="-3" id="f-532" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-84" decimals="-3" id="f-533" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-85" decimals="-3" id="f-534" unitRef="usd">23206000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-86" decimals="-3" id="f-535" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-87" decimals="-3" id="f-536" unitRef="usd">866000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-88" decimals="-3" id="f-537" unitRef="usd">162516000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-89" decimals="-3" id="f-538" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-90" decimals="-3" id="f-539" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-91" decimals="-3" id="f-540" unitRef="usd">356000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-92" decimals="-3" id="f-541" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-93" decimals="-3" id="f-542" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-94" decimals="-3" id="f-543" unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-95" decimals="-3" id="f-544" unitRef="usd">696803000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-96" decimals="-3" id="f-545" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-97" decimals="-3" id="f-546" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-98" decimals="-3" id="f-547" unitRef="usd">130000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-99" decimals="-3" id="f-548" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-100" decimals="-3" id="f-549" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-550" unitRef="usd">829448000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-28" decimals="-3" id="f-551" unitRef="usd">3551000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-29" decimals="-3" id="f-552" unitRef="usd">240735000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-553">&lt;div style="margin-top:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balance of receivables and contract liabilities related to the Company&#x2019;s collaboration and license agreements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Receivables included in accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract liabilities included in deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNet contextRef="c-26" decimals="-3" id="f-554" unitRef="usd">6824000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c-27" decimals="-3" id="f-555" unitRef="usd">0</us-gaap:AccountsReceivableNet>
    <us-gaap:ContractWithCustomerLiability contextRef="c-26" decimals="-3" id="f-556" unitRef="usd">2399000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-27" decimals="-3" id="f-557" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <arwr:InitialTransactionPrice contextRef="c-101" decimals="-5" id="f-558" unitRef="usd">120000000</arwr:InitialTransactionPrice>
    <arwr:MilestonePaymentReceivable contextRef="c-102" decimals="-5" id="f-559" unitRef="usd">30000000</arwr:MilestonePaymentReceivable>
    <arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree contextRef="c-103" decimals="-5" id="f-560" unitRef="usd">100000000</arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree>
    <arwr:CommercialMilestonePaymentsAtFirstCommercialSale contextRef="c-104" decimals="-5" id="f-561" unitRef="usd">190000000</arwr:CommercialMilestonePaymentsAtFirstCommercialSale>
    <arwr:SalesRelatedMilestonePayments contextRef="c-104" decimals="-5" id="f-562" unitRef="usd">590000000</arwr:SalesRelatedMilestonePayments>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales contextRef="c-105" decimals="2" id="f-563" unitRef="number">0.20</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:InitialTransactionPrice contextRef="c-106" decimals="-5" id="f-564" unitRef="usd">2700000</arwr:InitialTransactionPrice>
    <arwr:DevelopmentMilestonePayments contextRef="c-107" decimals="-5" id="f-565" unitRef="usd">2500000</arwr:DevelopmentMilestonePayments>
    <arwr:DevelopmentAndSalesMilestonesPayments contextRef="c-108" decimals="-5" id="f-566" unitRef="usd">830000000</arwr:DevelopmentAndSalesMilestonesPayments>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-109" decimals="INF" id="f-567" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-109" decimals="INF" id="f-568" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales contextRef="c-110" decimals="2" id="f-569" unitRef="number">0.20</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales contextRef="c-111" decimals="2" id="f-570" unitRef="number">0.25</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:NumberOfDistinctBundle
      contextRef="c-112"
      decimals="INF"
      id="f-571"
      unitRef="bundle">1</arwr:NumberOfDistinctBundle>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="c-112"
      decimals="INF"
      id="f-572"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:InitialTransactionPrice contextRef="c-113" decimals="-5" id="f-573" unitRef="usd">300000000</arwr:InitialTransactionPrice>
    <arwr:MilestonePaymentEarned contextRef="c-114" decimals="-5" id="f-574" unitRef="usd">40000000</arwr:MilestonePaymentEarned>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments contextRef="c-115" decimals="-5" id="f-575" unitRef="usd">527500000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:InitialTransactionPrice contextRef="c-113" decimals="-5" id="f-576" unitRef="usd">300000000</arwr:InitialTransactionPrice>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="c-112"
      decimals="INF"
      id="f-577"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-116" decimals="INF" id="f-578" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-116" decimals="-5" id="f-579" unitRef="usd">31300000</us-gaap:AccruedLiabilitiesCurrent>
    <arwr:NumberOfAgreements
      contextRef="c-117"
      decimals="INF"
      id="f-580"
      unitRef="agreement">2</arwr:NumberOfAgreements>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-118" decimals="INF" id="f-581" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-118" decimals="INF" id="f-582" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments contextRef="c-119" decimals="-5" id="f-583" unitRef="usd">485000000.0</arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:NumberOfNewTargetPrograms
      contextRef="c-120"
      decimals="INF"
      id="f-584"
      unitRef="program">6</arwr:NumberOfNewTargetPrograms>
    <arwr:NumberOfPerformanceObligations
      contextRef="c-121"
      decimals="INF"
      id="f-585"
      unitRef="obligation">17</arwr:NumberOfPerformanceObligations>
    <arwr:ProceedsFromCollaborationArrangements contextRef="c-122" decimals="-5" id="f-586" unitRef="usd">500000000</arwr:ProceedsFromCollaborationArrangements>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-71" decimals="-5" id="f-587" unitRef="usd">325000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-71" decimals="-5" id="f-588" unitRef="usd">325000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <arwr:SaleOfStockPremiumOnIssuanceOfShares contextRef="c-71" decimals="-5" id="f-589" unitRef="usd">83600000</arwr:SaleOfStockPremiumOnIssuanceOfShares>
    <arwr:AdditionalCashReceivableUnderCollaborationAgreement contextRef="c-123" decimals="-5" id="f-590" unitRef="usd">250000000</arwr:AdditionalCashReceivableUnderCollaborationAgreement>
    <arwr:CashReceivableUnderCollaborationAgreementAnnualInstallments contextRef="c-121" decimals="-5" id="f-591" unitRef="usd">50000000</arwr:CashReceivableUnderCollaborationAgreementAnnualInstallments>
    <arwr:CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod contextRef="c-123" id="f-592">P5Y</arwr:CashReceivableUnderCollaborationAgreementAnnualInstallmentsPeriod>
    <arwr:CollaborationArrangementFixedConsideration contextRef="c-124" decimals="-5" id="f-593" unitRef="usd">833600000</arwr:CollaborationArrangementFixedConsideration>
    <arwr:CollaborationArrangementVariableConsideration contextRef="c-124" decimals="-5" id="f-594" unitRef="usd">71200000</arwr:CollaborationArrangementVariableConsideration>
    <arwr:CollaborationArrangementConsideration contextRef="c-124" decimals="-5" id="f-595" unitRef="usd">904900000</arwr:CollaborationArrangementConsideration>
    <arwr:EnrollmentRelatedMilestonePayments contextRef="c-121" decimals="-5" id="f-596" unitRef="usd">300000000</arwr:EnrollmentRelatedMilestonePayments>
    <arwr:NumberOfCollaborationPrograms
      contextRef="c-121"
      decimals="INF"
      id="f-597"
      unitRef="program">13</arwr:NumberOfCollaborationPrograms>
    <arwr:RegulatoryMilestonePayments contextRef="c-125" decimals="-5" id="f-598" unitRef="usd">110000000</arwr:RegulatoryMilestonePayments>
    <arwr:RegulatoryMilestonePayments contextRef="c-120" decimals="-5" id="f-599" unitRef="usd">180000000</arwr:RegulatoryMilestonePayments>
    <arwr:SalesRelatedMilestonePayments contextRef="c-125" decimals="-5" id="f-600" unitRef="usd">500000000</arwr:SalesRelatedMilestonePayments>
    <arwr:SalesRelatedMilestonePayments contextRef="c-120" decimals="-5" id="f-601" unitRef="usd">700000000</arwr:SalesRelatedMilestonePayments>
    <arwr:CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval contextRef="c-121" id="f-602">P30D</arwr:CollaborationArrangementTerminationNoticePeriodPriorToRegulatoryApproval>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-72"
      decimals="INF"
      id="f-603"
      unitRef="shares">2660989</us-gaap:TreasuryStockSharesAcquired>
    <arwr:DevelopmentMilestonePayments contextRef="c-72" decimals="-5" id="f-604" unitRef="usd">100000000</arwr:DevelopmentMilestonePayments>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-72" decimals="-5" id="f-605" unitRef="usd">50000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <arwr:ProceedsFromCollaborationArrangements contextRef="c-72" decimals="-5" id="f-606" unitRef="usd">50000000</arwr:ProceedsFromCollaborationArrangements>
    <us-gaap:TreasuryStockCommonValue contextRef="c-126" decimals="-5" id="f-607" unitRef="usd">53200000</us-gaap:TreasuryStockCommonValue>
    <arwr:GainLossOnTreasuryStockSettlement contextRef="c-72" decimals="-5" id="f-608" unitRef="usd">3200000</arwr:GainLossOnTreasuryStockSettlement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-127" decimals="-5" id="f-609" unitRef="usd">696800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-128" decimals="-5" id="f-610" unitRef="usd">6800000</us-gaap:AccountsReceivableNetCurrent>
    <arwr:InitialTransactionPrice contextRef="c-129" decimals="-5" id="f-611" unitRef="usd">130000000</arwr:InitialTransactionPrice>
    <arwr:FuturePotentialMilestonePayments contextRef="c-129" decimals="-5" id="f-612" unitRef="usd">265000000</arwr:FuturePotentialMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-130" decimals="-5" id="f-613" unitRef="usd">130000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <arwr:CollaborationArrangementFixedConsideration contextRef="c-129" decimals="-5" id="f-614" unitRef="usd">130000000</arwr:CollaborationArrangementFixedConsideration>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-615">BALANCE SHEET ACCOUNTS&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s major classes of property, plant and equipment: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;444,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(80,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(58,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;382,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for property, plant and equipment for the years ended September&#160;30, 2025, 2024, and 2023 was $22.2 million, $16.9 million and $10.7 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of fiscal 2025, the Company substantially completed the build out of its manufacturing facility in Verona, Wisconsin, leading to the reclassification of $162.7 million from construction in progress to buildings and $2.6 million from construction in progress to manufacturing equipment. The Company subsequently incurred and capitalized $10.6 million to buildings and $16.0 million to manufacturing equipment during the remainder of fiscal 2025. Furthermore, the Company began depreciating the newly completed manufacturing facility over a 39-year period and the manufacturing equipment over 7- or 10-year periods.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of fiscal 2024, the Company completed the build out of its laboratory and office facilities in Verona, Wisconsin, which resulted in the reclassification of $71.8 million from construction in progress to buildings. The Company subsequently incurred and capitalized $4.2 million from construction in progress to buildings in fiscal 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued research and development expenses; co-development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued income taxes (benefits)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2025, the Company&#x2019;s accrued research and development expenses was primarily attributable to ongoing clinical trial operations, preclinical animal studies, and associated toxicology assessments. In addition, accrued research and development expenses; co-development relates to the co-development and co-commercialization activities under the Takeda License Agreement (see Note 2).&lt;/span&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-131" decimals="-3" id="f-616" unitRef="usd">2996000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-132" decimals="-3" id="f-617" unitRef="usd">2996000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-73" decimals="-3" id="f-618" unitRef="usd">251317000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-133" decimals="-3" id="f-619" unitRef="usd">75988000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-74" decimals="-3" id="f-620" unitRef="usd">62758000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-134" decimals="-3" id="f-621" unitRef="usd">65353000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-135" decimals="-3" id="f-622" unitRef="usd">18588000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-136" decimals="-3" id="f-623" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-77" decimals="-3" id="f-624" unitRef="usd">5594000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-137" decimals="-3" id="f-625" unitRef="usd">5594000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-138" decimals="-3" id="f-626" unitRef="usd">1064000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-139" decimals="-3" id="f-627" unitRef="usd">981000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-140" decimals="-3" id="f-628" unitRef="usd">104425000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-141" decimals="-3" id="f-629" unitRef="usd">104410000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-142" decimals="-3" id="f-630" unitRef="usd">15942000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-143" decimals="-3" id="f-631" unitRef="usd">188731000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-26" decimals="-3" id="f-632" unitRef="usd">462684000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-27" decimals="-3" id="f-633" unitRef="usd">444053000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-26" decimals="-3" id="f-634" unitRef="usd">80169000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-27" decimals="-3" id="f-635" unitRef="usd">58021000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-26" decimals="-3" id="f-636" unitRef="usd">382515000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-27" decimals="-3" id="f-637" unitRef="usd">386032000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-5" id="f-638" unitRef="usd">22200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-28" decimals="-5" id="f-639" unitRef="usd">16900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-29" decimals="-5" id="f-640" unitRef="usd">10700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-144" decimals="-5" id="f-641" unitRef="usd">-162700000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-145" decimals="-5" id="f-642" unitRef="usd">162700000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-146" decimals="-5" id="f-643" unitRef="usd">-2600000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-147" decimals="-5" id="f-644" unitRef="usd">2600000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-148" decimals="-5" id="f-645" unitRef="usd">10600000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-149" decimals="-5" id="f-646" unitRef="usd">-10600000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-150" decimals="-5" id="f-647" unitRef="usd">16000000.0</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-151" decimals="-5" id="f-648" unitRef="usd">-16000000.0</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-152" id="f-649">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-75" id="f-650">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-76" id="f-651">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-153" decimals="-5" id="f-652" unitRef="usd">71800000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-154" decimals="-5" id="f-653" unitRef="usd">-71800000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-155" decimals="-5" id="f-654" unitRef="usd">4200000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-156" decimals="-5" id="f-655" unitRef="usd">-4200000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-656">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued research and development expenses; co-development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued income taxes (benefits)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <arwr:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-26" decimals="-3" id="f-657" unitRef="usd">30330000</arwr:AccruedResearchAndDevelopmentExpenseCurrent>
    <arwr:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-27" decimals="-3" id="f-658" unitRef="usd">28069000</arwr:AccruedResearchAndDevelopmentExpenseCurrent>
    <arwr:AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent contextRef="c-26" decimals="-3" id="f-659" unitRef="usd">31296000</arwr:AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent>
    <arwr:AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent contextRef="c-27" decimals="-3" id="f-660" unitRef="usd">23351000</arwr:AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent>
    <arwr:AccruedCapitalExpenditureCurrent contextRef="c-26" decimals="-3" id="f-661" unitRef="usd">277000</arwr:AccruedCapitalExpenditureCurrent>
    <arwr:AccruedCapitalExpenditureCurrent contextRef="c-27" decimals="-3" id="f-662" unitRef="usd">4206000</arwr:AccruedCapitalExpenditureCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-26" decimals="-3" id="f-663" unitRef="usd">20799000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-27" decimals="-3" id="f-664" unitRef="usd">0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-26" decimals="-3" id="f-665" unitRef="usd">7717000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-27" decimals="-3" id="f-666" unitRef="usd">7391000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-26" decimals="-3" id="f-667" unitRef="usd">90419000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-27" decimals="-3" id="f-668" unitRef="usd">63017000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-669">INVESTMENTS&lt;div style="margin-top:6pt;padding-left:63pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;689,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;692,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total current investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;689,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;692,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;577,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total current investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;577,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes the contract maturity of the available-for-sale securities as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;   &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.207%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.440%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;After one to two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;468,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;After two to three years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;692,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of September&#160;30, 2025, the gross unrealized losses were immaterial. The Company has determined that the available-for-sale securities that were in an unrealized loss position did not have any credit loss impairment as of September&#160;30, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock contextRef="c-1" id="f-670">&lt;div style="margin-top:6pt;padding-left:63pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;689,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;692,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total current investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;689,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;692,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;577,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total current investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;577,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-157" decimals="-3" id="f-671" unitRef="usd">689882000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent contextRef="c-157" decimals="-3" id="f-672" unitRef="usd">2956000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent contextRef="c-157" decimals="-3" id="f-673" unitRef="usd">20000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-157" decimals="-3" id="f-674" unitRef="usd">692818000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-26" decimals="-3" id="f-675" unitRef="usd">689882000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent contextRef="c-26" decimals="-3" id="f-676" unitRef="usd">2956000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent contextRef="c-26" decimals="-3" id="f-677" unitRef="usd">20000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-26" decimals="-3" id="f-678" unitRef="usd">692818000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-158" decimals="-3" id="f-679" unitRef="usd">577465000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent contextRef="c-158" decimals="-3" id="f-680" unitRef="usd">837000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent contextRef="c-158" decimals="-3" id="f-681" unitRef="usd">26000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-158" decimals="-3" id="f-682" unitRef="usd">578276000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-27" decimals="-3" id="f-683" unitRef="usd">577465000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent contextRef="c-27" decimals="-3" id="f-684" unitRef="usd">837000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent contextRef="c-27" decimals="-3" id="f-685" unitRef="usd">26000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-27" decimals="-3" id="f-686" unitRef="usd">578276000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c-1" id="f-687">&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes the contract maturity of the available-for-sale securities as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"&gt;   &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.207%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.440%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;After one to two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;468,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;After two to three years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;692,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-26" decimals="-3" id="f-688" unitRef="usd">224328000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-27" decimals="-3" id="f-689" unitRef="usd">578276000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo contextRef="c-26" decimals="-3" id="f-690" unitRef="usd">468490000</arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo>
    <arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo contextRef="c-27" decimals="-3" id="f-691" unitRef="usd">0</arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo>
    <arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree contextRef="c-26" decimals="-3" id="f-692" unitRef="usd">0</arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree>
    <arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree contextRef="c-27" decimals="-3" id="f-693" unitRef="usd">0</arwr:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearTwoThroughThree>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-26" decimals="-3" id="f-694" unitRef="usd">692818000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-27" decimals="-3" id="f-695" unitRef="usd">578276000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-696">INTANGIBLE ASSETS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The following table presents the components of intangible assets: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.967%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during fiscal 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense in each of fiscal 2025, 2024, and 2023 was $1.7 million. None of the intangible assets with definite useful lives are anticipated to have a residual value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the estimated future amortization expense related to intangible assets as of September&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.272%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.106%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.107%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending September 30, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-697">The following table presents the components of intangible assets: &lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.967%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-159" decimals="-3" id="f-698" unitRef="usd">21728000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-159" decimals="-3" id="f-699" unitRef="usd">16426000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-159" decimals="-3" id="f-700" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-159" decimals="-3" id="f-701" unitRef="usd">5302000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-159" id="f-702">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-160" decimals="-3" id="f-703" unitRef="usd">3129000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-160" decimals="-3" id="f-704" unitRef="usd">1570000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-160" decimals="-3" id="f-705" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-160" decimals="-3" id="f-706" unitRef="usd">1559000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-160" id="f-707">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-161" decimals="-3" id="f-708" unitRef="usd">24857000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-161" decimals="-3" id="f-709" unitRef="usd">17996000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-161" decimals="-3" id="f-710" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-161" decimals="-3" id="f-711" unitRef="usd">6861000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-162" decimals="-3" id="f-712" unitRef="usd">21728000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-162" decimals="-3" id="f-713" unitRef="usd">14873000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-162" decimals="-3" id="f-714" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-162" decimals="-3" id="f-715" unitRef="usd">6855000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-162" id="f-716">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-163" decimals="-3" id="f-717" unitRef="usd">3129000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-163" decimals="-3" id="f-718" unitRef="usd">1422000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-163" decimals="-3" id="f-719" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-163" decimals="-3" id="f-720" unitRef="usd">1707000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-163" id="f-721">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-164" decimals="-3" id="f-722" unitRef="usd">24857000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-164" decimals="-3" id="f-723" unitRef="usd">16295000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-164" decimals="-3" id="f-724" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-164" decimals="-3" id="f-725" unitRef="usd">8562000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-29" decimals="-5" id="f-726" unitRef="usd">1700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-727" unitRef="usd">1700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-28" decimals="-5" id="f-728" unitRef="usd">1700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-729">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the estimated future amortization expense related to intangible assets as of September&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.272%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.106%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.107%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending September 30, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-26" decimals="-3" id="f-730" unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-26" decimals="-3" id="f-731" unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-26" decimals="-3" id="f-732" unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-26" decimals="-3" id="f-733" unitRef="usd">795000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-26" decimals="-3" id="f-734" unitRef="usd">149000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-26" decimals="-3" id="f-735" unitRef="usd">817000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-26" decimals="-3" id="f-736" unitRef="usd">6861000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-737">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s shares of common stock and preferred stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.294%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Par Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Does not include shares of common stock into which the Avoro Pre-Funded Warrants may be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2025 and 2024, respectively, 9,851,400 and 11,492,293 shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#x2019;s 2013 and 2021 Incentive Plans, as well as for other inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  &lt;br/&gt;         &lt;br/&gt;        On November 25, 2024, the Company entered into a Securities Purchase Agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with an institutional and accredited investor for a private placement of pre-funded warrants to purchase shares of common stock with an exercise price of $0.001 per share (&#x201c;Avoro Pre-Funded Warrants&#x201d;). Pursuant to the Securities Purchase Agreement, the Company sold pre-funded warrants to purchase up to 917,441 shares of common stock at a purchase price of $27.25 per pre-funded warrant, for an aggregate value of approximately $25.0 million. The outstanding Avoro Pre-Funded Warrants are exercisable at any time and do not have an expiration date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company determined that the Avoro Pre-Funded Warrants are freestanding financial instruments because they (i) are immediately exercisable, (ii) do not embody an obligation for the Company to repurchase its shares, (iii) permit the holders to receive a fixed number of shares of common stock upon exercise, and (iv) are indexed to the Company&#x2019;s common stock. As such, the Company evaluated the Avoro Pre-Funded Warrants to determine whether they represent instruments that require liability classification pursuant to the guidance in ASC 480. However, the Company concluded that the Avoro Pre-Funded Warrants are not a liability within the scope of ASC 480 due to their characteristics. Further, the Company determined that the Avoro Pre-Funded Warrants do not meet the definition of a derivative under ASC 815 because they do not meet the criteria regarding no or little initial net investment. Accordingly, the Company assessed the Avoro Pre-Funded Warrants relative to the guidance in ASC 815-40, Contracts in Entity's Own Equity, to determine the appropriate treatment. The Company concluded that the Avoro Pre-funded Warrants are both indexed to its own stock and meet all other conditions for equity classification. Accordingly, the Company has classified the Avoro Pre-funded Warrants as permanent equity. As of September&#160;30, 2025, no shares underlying the Avoro Pre-Funded Warrants had been exercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the Sarepta Collaboration Agreement, on November 25, 2024, the Company entered into the Stock Purchase Agreement with an affiliate of Sarepta for a private placement of shares of common stock of the Company (the &#x201c;Private Placement&#x201d;). Pursuant to the Stock Purchase Agreement, the Company sold 11,926,301 shares of common stock, at a price per share of $27.25, for an aggregate value of approximately $325.0&#160;million. The Private Placement closed on February 7, 2025. On August 13, 2025, the Company subsequently entered into an agreement with Sarepta to repurchase 2,660,989 common stock of the Company from Sarepta at a price per share of $18.79 for an aggregate value of approximately $50.0&#160;million and approximately $50.0&#160;million in cash to satisfy the milestone payment of $100.0&#160;million due from Sarepta. The shares were recorded as treasury stock at their fair value of $53.2&#160;million, resulting in a $3.2&#160;million gain on settlement. As of the end of fiscal 2025, Sarepta no longer holds an equity position in the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On December 2, 2022, the Company entered into an open market sale agreement (the &#x201c;Open Market Sale Agreement&#x201d;), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#x2019;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#x201c;ATM Offering&#x201d;). The Company is not required to sell shares under the Open Market Sale Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the Open Market Sale Agreement. Unless otherwise terminated, the ATM Offering shall terminate upon the earlier of (i) the sale of all shares of common stock subject to the Open Market Sale Agreement and (ii) the termination of the Open Market Sale Agreement as permitted therein. The Company and Jefferies may each terminate the Open Market Sale Agreement at any time upon prior notice. As of September&#160;30, 2025, no shares have been issued under the Open Market Sale Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="c-1" id="f-738">&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s shares of common stock and preferred stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.294%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Par Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Does not include shares of common stock into which the Avoro Pre-Funded Warrants may be exercised.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-26"
      decimals="INF"
      id="f-739"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-26" decimals="-3" id="f-740" unitRef="shares">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-26" decimals="-3" id="f-741" unitRef="shares">135702000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-26" decimals="-3" id="f-742" unitRef="shares">135702000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-26"
      decimals="INF"
      id="f-743"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-26" decimals="-3" id="f-744" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-26" decimals="-3" id="f-745" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-26" decimals="-3" id="f-746" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-27"
      decimals="INF"
      id="f-747"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-27" decimals="-3" id="f-748" unitRef="shares">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-27" decimals="-3" id="f-749" unitRef="shares">124376000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-27" decimals="-3" id="f-750" unitRef="shares">124376000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-27"
      decimals="INF"
      id="f-751"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-27" decimals="-3" id="f-752" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-27" decimals="-3" id="f-753" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-27" decimals="-3" id="f-754" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-165"
      decimals="INF"
      id="f-755"
      unitRef="shares">9851400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-166"
      decimals="INF"
      id="f-756"
      unitRef="shares">11492293</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-167"
      decimals="INF"
      id="f-757"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-167"
      decimals="INF"
      id="f-758"
      unitRef="shares">917441</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <arwr:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights
      contextRef="c-168"
      decimals="2"
      id="f-759"
      unitRef="usdPerShare">27.25</arwr:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-168" decimals="-5" id="f-760" unitRef="usd">25000000.0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <arwr:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="c-26"
      decimals="INF"
      id="f-761"
      unitRef="shares">0</arwr:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-169"
      decimals="INF"
      id="f-762"
      unitRef="shares">11926301</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-170"
      decimals="2"
      id="f-763"
      unitRef="usdPerShare">27.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-169" decimals="-5" id="f-764" unitRef="usd">325000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-171"
      decimals="INF"
      id="f-765"
      unitRef="shares">2660989</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-171"
      decimals="2"
      id="f-766"
      unitRef="usdPerShare">18.79</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-171" decimals="-5" id="f-767" unitRef="usd">50000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <arwr:ProceedsFromCollaborationArrangements contextRef="c-171" decimals="-5" id="f-768" unitRef="usd">50000000</arwr:ProceedsFromCollaborationArrangements>
    <arwr:MilestonePaymentDueFromCollaborativeAgreement contextRef="c-171" decimals="-5" id="f-769" unitRef="usd">100000000</arwr:MilestonePaymentDueFromCollaborativeAgreement>
    <us-gaap:TreasuryStockCommonValue contextRef="c-172" decimals="-5" id="f-770" unitRef="usd">53200000</us-gaap:TreasuryStockCommonValue>
    <arwr:GainLossOnTreasuryStockSettlement contextRef="c-171" decimals="-5" id="f-771" unitRef="usd">3200000</arwr:GainLossOnTreasuryStockSettlement>
    <arwr:CommonStockCapitalSharesValueReservedForFutureIssuance contextRef="c-173" decimals="INF" id="f-772" unitRef="usd">250000000</arwr:CommonStockCapitalSharesValueReservedForFutureIssuance>
    <arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock contextRef="c-174" decimals="3" id="f-773" unitRef="number">0.030</arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock>
    <us-gaap:SharesIssued
      contextRef="c-175"
      decimals="INF"
      id="f-774"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-775">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of September&#160;30, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 10, 2025, the Company filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ionis Pharmaceuticals, Inc. (&#x201c;Ionis&#x201d;) to declare that the United States Patent No. 9,593,333 (&#x201c;the &#x2019;333 patent&#x201d;) is invalid and not infringed by the Company&#x2019;s planned commercialization of investigational plozasiran. On September 11, 2025, Ionis filed a Complaint for Patent Infringement against the Company in the United States District Court for the Central District of California alleging patent infringement of the &#x2019;333 patent by the Company&#x2019;s planned commercialization of investigational plozasiran and seeking damages. There were no contingent liabilities recorded related to this litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company owns land in the Verona Technology Park in Verona, Wisconsin, where it has constructed an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility to support the Company&#x2019;s manufacturing, process development, and analytical activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2025, the build-out of these facilities was substantially completed, with total costs incurred of $296.4 million. These costs included $173.4 million capitalized to building related to the drug manufacturing facility, $78.0 million capitalized to building related to the laboratory and office facility, $18.6 million capitalized to manufacturing equipment, $15.9 million in construction in progress and $7.9 million capitalized to research equipment and $2.6 million capitalized to furniture.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-26" decimals="INF" id="f-776" unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-27" decimals="INF" id="f-777" unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:AreaOfLand contextRef="c-176" decimals="-3" id="f-778" unitRef="sqft">160000</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand contextRef="c-177" decimals="-3" id="f-779" unitRef="sqft">140000</us-gaap:AreaOfLand>
    <arwr:CommitmentsCapitalExpendituresIncurredToDate contextRef="c-178" decimals="-5" id="f-780" unitRef="usd">296400000</arwr:CommitmentsCapitalExpendituresIncurredToDate>
    <arwr:CommitmentsCapitalExpendituresIncurredToDate contextRef="c-73" decimals="-5" id="f-781" unitRef="usd">173400000</arwr:CommitmentsCapitalExpendituresIncurredToDate>
    <arwr:CommitmentsCapitalExpendituresIncurredToDate contextRef="c-179" decimals="-5" id="f-782" unitRef="usd">78000000.0</arwr:CommitmentsCapitalExpendituresIncurredToDate>
    <arwr:CommitmentsCapitalExpendituresIncurredToDate contextRef="c-135" decimals="-5" id="f-783" unitRef="usd">18600000</arwr:CommitmentsCapitalExpendituresIncurredToDate>
    <arwr:CommitmentsCapitalExpendituresIncurredToDate contextRef="c-142" decimals="-5" id="f-784" unitRef="usd">15900000</arwr:CommitmentsCapitalExpendituresIncurredToDate>
    <arwr:CommitmentsCapitalExpendituresIncurredToDate contextRef="c-74" decimals="-5" id="f-785" unitRef="usd">7900000</arwr:CommitmentsCapitalExpendituresIncurredToDate>
    <arwr:CommitmentsCapitalExpendituresIncurredToDate contextRef="c-77" decimals="-5" id="f-786" unitRef="usd">2600000</arwr:CommitmentsCapitalExpendituresIncurredToDate>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-787">LEASES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Pasadena, California&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company leases 49,000 square feet of office space located at 177 East Colorado Blvd. for its corporate headquarters from 177 Colorado Owner, LLC, which lease expires on April&#160;30, 2027. The lease contains an option to renew for one additional five-year term. The Company is not reasonably certain that it will exercise this option to renew and therefore it is not included in right-of-use assets and liabilities as of September&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;San Diego, California&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company leases 144,000 square feet of office and research and development laboratory space located at 10102 Hoyt Park from 11404 &amp;amp; 11408 Sorrento Valley Owner, LLC, which lease expires on April&#160;30, 2038. Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent. The Company is not reasonably certain that it will exercise this option to renew and therefore it is not included in right-of-use assets and liabilities as of September&#160;30, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease agreement, as amended, granted the Company the right to receive an Additional Tenant Improvement Allowance (&#x201c;ATIA&#x201d;) funded by the lessor. The Company received $30.8&#160;million in ATIA, including a final payment of $3.1 million during the first quarter of fiscal 2024. As a result, the Company remeasured its lease liability and right-of-use assets to reflect these additional allowances and the related increased lease payments. The Company has further concluded that these ATIAs have no effects on the classification of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Madison, Wisconsin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company leases 110,956 square feet space, which it increased from 107,000 square feet on June&#160;30, 2025, located at 502 South Rosa Road for its office and laboratory facilities, which lease expires on September&#160;30, 2031. The lease contains options to renew for two terms of five years. The Company is not reasonably certain that it will exercise this option and therefore it is not included in right-of-use assets and liabilities as of September&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease assets and liabilities along with their classification on the Company&#x2019;s consolidated balance sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.409%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.080%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Assets and Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Variable lease cost is primarily related to operating expenses associated with the Company&#x2019;s operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $0, $0 and $1.4&#160;million in short-term lease cost during the years ended September&#160;30, 2025, 2024, and 2023, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents maturities of operating lease liabilities on an undiscounted basis as of September&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.696%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2031 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.856%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.856%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.860%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash received for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets adjusted in exchange for new/amended operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LandSubjectToGroundLeases contextRef="c-180" decimals="-3" id="f-788" unitRef="sqft">49000</us-gaap:LandSubjectToGroundLeases>
    <arwr:NumberOfOptionsToRenew
      contextRef="c-181"
      decimals="INF"
      id="f-789"
      unitRef="option">1</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-181" id="f-790">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LandSubjectToGroundLeases contextRef="c-182" decimals="-3" id="f-791" unitRef="sqft">144000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-182" id="f-792">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arwr:NumberOfOptionsToRenew
      contextRef="c-183"
      decimals="INF"
      id="f-793"
      unitRef="option">1</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-182" id="f-794">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <arwr:ProceedsFromTenantImprovementAllowance contextRef="c-184" decimals="-5" id="f-795" unitRef="usd">30800000</arwr:ProceedsFromTenantImprovementAllowance>
    <arwr:ProceedsFromTenantImprovementAllowance contextRef="c-185" decimals="-5" id="f-796" unitRef="usd">3100000</arwr:ProceedsFromTenantImprovementAllowance>
    <us-gaap:LandSubjectToGroundLeases contextRef="c-186" decimals="0" id="f-797" unitRef="sqft">110956</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LandSubjectToGroundLeases contextRef="c-187" decimals="0" id="f-798" unitRef="sqft">107000</us-gaap:LandSubjectToGroundLeases>
    <arwr:NumberOfOptionsToRenew
      contextRef="c-186"
      decimals="INF"
      id="f-799"
      unitRef="option">2</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-186" id="f-800">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-801">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease assets and liabilities along with their classification on the Company&#x2019;s consolidated balance sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.409%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.080%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Assets and Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Variable lease cost is primarily related to operating expenses associated with the Company&#x2019;s operating leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-26" decimals="-3" id="f-802" unitRef="usd">43891000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-27" decimals="-3" id="f-803" unitRef="usd">45255000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-26" decimals="-3" id="f-804" unitRef="usd">7289000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-27" decimals="-3" id="f-805" unitRef="usd">6342000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-26" decimals="-3" id="f-806" unitRef="usd">104112000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-27" decimals="-3" id="f-807" unitRef="usd">111027000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost contextRef="c-188" decimals="-3" id="f-808" unitRef="usd">10483000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-189" decimals="-3" id="f-809" unitRef="usd">11035000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-190" decimals="-3" id="f-810" unitRef="usd">10350000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-191" decimals="-3" id="f-811" unitRef="usd">1952000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-192" decimals="-3" id="f-812" unitRef="usd">2006000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-193" decimals="-3" id="f-813" unitRef="usd">1730000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-188" decimals="-3" id="f-814" unitRef="usd">4076000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-189" decimals="-3" id="f-815" unitRef="usd">3648000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-190" decimals="-3" id="f-816" unitRef="usd">1179000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-191" decimals="-3" id="f-817" unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-192" decimals="-3" id="f-818" unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-193" decimals="-3" id="f-819" unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-820" unitRef="usd">16511000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-28" decimals="-3" id="f-821" unitRef="usd">16689000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-29" decimals="-3" id="f-822" unitRef="usd">13259000</us-gaap:LeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-5" id="f-823" unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-28" decimals="-5" id="f-824" unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-29" decimals="-5" id="f-825" unitRef="usd">1400000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-826">&lt;div style="margin-top:6pt;text-align:justify;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents maturities of operating lease liabilities on an undiscounted basis as of September&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.696%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2031 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;173,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.856%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.856%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.860%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash received for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets adjusted in exchange for new/amended operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-26" decimals="-3" id="f-827" unitRef="usd">15873000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-26" decimals="-3" id="f-828" unitRef="usd">15050000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-26" decimals="-3" id="f-829" unitRef="usd">13696000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-26" decimals="-3" id="f-830" unitRef="usd">13985000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-26" decimals="-3" id="f-831" unitRef="usd">14282000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-26" decimals="-3" id="f-832" unitRef="usd">100672000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-26" decimals="-3" id="f-833" unitRef="usd">173558000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-26" decimals="-3" id="f-834" unitRef="usd">62157000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-26" decimals="-3" id="f-835" unitRef="usd">111401000</us-gaap:OperatingLeaseLiability>
    <arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-1" decimals="-3" id="f-836" unitRef="usd">0</arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-28" decimals="-3" id="f-837" unitRef="usd">3099000</arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-29" decimals="-3" id="f-838" unitRef="usd">48391000</arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-839" unitRef="usd">0</arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability>
    <arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability contextRef="c-28" decimals="-3" id="f-840" unitRef="usd">-29000</arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability>
    <arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability contextRef="c-29" decimals="-3" id="f-841" unitRef="usd">17071000</arwr:RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-842" unitRef="usd">15474000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-28" decimals="-3" id="f-843" unitRef="usd">11038000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-29" decimals="-3" id="f-844" unitRef="usd">5204000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-26" id="f-845">P11Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-27" id="f-846">P12Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-46" id="f-847">P13Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-26" decimals="3" id="f-848" unitRef="number">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-27" decimals="3" id="f-849" unitRef="number">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-46" decimals="3" id="f-850" unitRef="number">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-851">STOCK-BASED COMPENSATION&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three plans that provide for equity-based compensation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2013 Incentive Plan (the &#x201c;2013 Plan&#x201d;), 2,276,279 awards are granted and outstanding, relating to stock options and restricted stock awards to employees and directors as of September&#160;30, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2021 Incentive Plan (the &#x201c;2021 Plan&#x201d;), 8,000,000 shares (subject to certain adjustments) of the Company&#x2019;s common stock are authorized for grants of stock options, stock appreciation rights, restricted and unrestricted stock, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#x2019;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of September&#160;30, 2025, 6,231,559 shares have been granted under the 2021 Plan. The total number of shares available for issuance was 2,378,770 shares, which includes 170,898 and 439,431 shares that were forfeited under the 2013 and 2021 Plans, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company&#x2019;s Inducement Plan (the &#x201c;Inducement Plan&#x201d;), 832,950 shares of the Company&#x2019;s common stock are authorized for issuance pursuant to grants of stock options, stock appreciation rights, restricted and unrestricted stock, stock units (including restricted stock units), performance awards, cash awards, and other awards convertible into or otherwise based on shares of the Company&#x2019;s common stock. Awards under the Inducement Plan may only be granted to new employees of the Company in accordance with the provisions of Rule 5635(c)(4) of the Nasdaq Listing Rules. As of September&#160;30, 2025, 660,020 shares have been granted under the Inducement Plan. The total number of shares remaining available for issuance was 255,244 shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, prior to adoption of the Inducement Plan, the Company previously granted stand-alone inducement awards in the form of stock options and restricted stock units outside of the Company&#x2019;s equity plans to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules. As of September&#160;30, 2025, there were 598,605 and 53,713 shares underlying outstanding stand-alone inducement options and restricted stock units, respectively.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of awards outstanding attributable to Arrowhead Pharmaceuticals, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2013 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inducement Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Granted and outstanding awards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;776,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;598,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,407,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,750,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;560,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,810,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,276,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,782,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,158,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,217,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock-based compensation expenses included in operating expenses attributable to Arrowhead Pharmaceuticals, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.940%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.210%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.313%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.821%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the stock option activity for the year ended September&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.849%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,978,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cancelled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(535,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,407,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,099,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,407,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,099,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic values represent the amount by which the market price of the underlying stock exceeds the exercise price of the option. The total intrinsic value of the options exercised during the years ended September&#160;30, 2025, 2024, and 2023 was $6.4 million, $4.2 million and $12.2 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to stock options outstanding for the years ended September&#160;30, 2025, 2024, and 2023 was $0.1 million, $2.8 million and $8.4 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2025, the pre-tax compensation expense for all outstanding unvested stock options is considered nominal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#x2019;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. No options were granted during the years ended September 30, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Black-Scholes option pricing model: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.69% &#x2013; 4.57%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.61&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) The dividend yield is zero as the Company currently does not pay a dividend. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(3) Volatility is estimated based on volatility average of the Company&#x2019;s common stock price. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(4) The computation of expected term was determined based on safe harbor rules, considering the contractual terms of the awards and vesting schedules.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(5) No options were granted during the year ended September&#160;30, 2025 and September&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Visirna ESOP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: As of September&#160;30, 2025, Visirna, a subsidiary of the Company, granted 14,612,000 stock options to its employees from the Employee Stock Option Plan (the &#x201c;Visirna ESOP&#x201d;), which authorizes 20,000,000 shares for issuance. The Visirna ESOP is independently managed by Visirna, including the valuation process. For the years ended September&#160;30, 2025 and 2024, stock-based compensation expense related to the Visirna ESOP was $8.5 million and $6.9 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted Stock Units (&#x201c;RSUs&#x201d;), including market-based, time-based and performance-based awards, have been granted under the Company&#x2019;s 2013 and 2021 Plans, the Inducement Plan and as inducements awards granted outside of the Company&#x2019;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x2019;s common stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of the Company&#x2019;s RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,913,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,779,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,525,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(356,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,810,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of RSUs was determined based on the closing price of the Company&#x2019;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.&lt;/span&gt;&lt;/div&gt;For the years ended September&#160;30, 2025, 2024 and 2023, the Company recorded stock-based compensation expense of $54.9 million, $64.3 million and $69.7 million, respectively, related to shares of RSUs. As of September&#160;30, 2025, there was $73.3 million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of 1.7 years.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="c-194"
      decimals="INF"
      id="f-852"
      unitRef="shares">2276279</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-195"
      decimals="INF"
      id="f-853"
      unitRef="shares">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-196"
      decimals="INF"
      id="f-854"
      unitRef="shares">6231559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-26"
      decimals="INF"
      id="f-855"
      unitRef="shares">2378770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-197"
      decimals="INF"
      id="f-856"
      unitRef="shares">170898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-196"
      decimals="INF"
      id="f-857"
      unitRef="shares">439431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-198"
      decimals="INF"
      id="f-858"
      unitRef="shares">832950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-199"
      decimals="INF"
      id="f-859"
      unitRef="shares">660020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-198"
      decimals="INF"
      id="f-860"
      unitRef="shares">255244</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-198"
      decimals="INF"
      id="f-861"
      unitRef="shares">598605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-200"
      decimals="INF"
      id="f-862"
      unitRef="shares">53713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="c-1" id="f-863">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of awards outstanding attributable to Arrowhead Pharmaceuticals, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2013 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inducement Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Granted and outstanding awards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;776,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;598,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,407,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,750,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;560,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,810,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,276,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,782,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,158,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,217,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-194"
      decimals="INF"
      id="f-864"
      unitRef="shares">776279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-201"
      decimals="INF"
      id="f-865"
      unitRef="shares">32151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-202"
      decimals="INF"
      id="f-866"
      unitRef="shares">598605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-26"
      decimals="INF"
      id="f-867"
      unitRef="shares">1407035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-203"
      decimals="INF"
      id="f-868"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-204"
      decimals="INF"
      id="f-869"
      unitRef="shares">3750071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-205"
      decimals="INF"
      id="f-870"
      unitRef="shares">560280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-206"
      decimals="INF"
      id="f-871"
      unitRef="shares">5810351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="c-194"
      decimals="INF"
      id="f-872"
      unitRef="shares">2276279</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="c-201"
      decimals="INF"
      id="f-873"
      unitRef="shares">3782222</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="c-202"
      decimals="INF"
      id="f-874"
      unitRef="shares">1158885</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="c-26"
      decimals="INF"
      id="f-875"
      unitRef="shares">7217386</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-876">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock-based compensation expenses included in operating expenses attributable to Arrowhead Pharmaceuticals, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.940%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.210%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.313%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.821%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-188" decimals="-3" id="f-877" unitRef="usd">27320000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-189" decimals="-3" id="f-878" unitRef="usd">29527000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-190" decimals="-3" id="f-879" unitRef="usd">34332000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-191" decimals="-3" id="f-880" unitRef="usd">27528000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-192" decimals="-3" id="f-881" unitRef="usd">37570000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-193" decimals="-3" id="f-882" unitRef="usd">43798000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-883" unitRef="usd">54848000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-28" decimals="-3" id="f-884" unitRef="usd">67097000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-29" decimals="-3" id="f-885" unitRef="usd">78130000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-886">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the stock option activity for the year ended September&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.849%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,978,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cancelled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(535,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,407,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,099,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,407,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,099,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-27"
      decimals="INF"
      id="f-887"
      unitRef="shares">1978516</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-27"
      decimals="2"
      id="f-888"
      unitRef="usdPerShare">23.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-889" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-890"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-891" unitRef="shares">36341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-892"
      unitRef="usdPerShare">45.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-893" unitRef="shares">535140</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-894"
      unitRef="usdPerShare">7.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-26"
      decimals="INF"
      id="f-895"
      unitRef="shares">1407035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-26"
      decimals="2"
      id="f-896"
      unitRef="usdPerShare">28.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-897">P3Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-26" decimals="0" id="f-898" unitRef="usd">19099141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-26"
      decimals="INF"
      id="f-899"
      unitRef="shares">1407035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-26"
      decimals="2"
      id="f-900"
      unitRef="usdPerShare">28.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-901">P3Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-26" decimals="0" id="f-902" unitRef="usd">19099141</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-207" decimals="-5" id="f-903" unitRef="usd">6400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-208" decimals="-5" id="f-904" unitRef="usd">4200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-209" decimals="-5" id="f-905" unitRef="usd">12200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-207" decimals="-5" id="f-906" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-208" decimals="-5" id="f-907" unitRef="usd">2800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-209" decimals="-5" id="f-908" unitRef="usd">8400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-28"
      decimals="INF"
      id="f-909"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-910" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-911">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Black-Scholes option pricing model: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.69% &#x2013; 4.57%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.61&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) The dividend yield is zero as the Company currently does not pay a dividend. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(3) Volatility is estimated based on volatility average of the Company&#x2019;s common stock price. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(4) The computation of expected term was determined based on safe harbor rules, considering the contractual terms of the awards and vesting schedules.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(5) No options were granted during the year ended September&#160;30, 2025 and September&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="3" id="f-912" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-28" decimals="3" id="f-913" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-29" decimals="3" id="f-914" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-29" decimals="4" id="f-915" unitRef="number">0.0369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-29" decimals="4" id="f-916" unitRef="number">0.0457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-29" decimals="3" id="f-917" unitRef="number">0.864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-29" id="f-918">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-29"
      decimals="2"
      id="f-919"
      unitRef="usdPerShare">25.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="2" id="f-920" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-921" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-29"
      decimals="INF"
      id="f-922"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-210"
      decimals="INF"
      id="f-923"
      unitRef="shares">14612000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-211"
      decimals="INF"
      id="f-924"
      unitRef="shares">20000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-212" decimals="-5" id="f-925" unitRef="usd">8500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-213" decimals="-5" id="f-926" unitRef="usd">6900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-927">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of the Company&#x2019;s RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,913,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,779,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,525,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(356,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,810,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-214"
      decimals="INF"
      id="f-928"
      unitRef="shares">4913312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-214"
      decimals="2"
      id="f-929"
      unitRef="usdPerShare">49.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-215"
      decimals="INF"
      id="f-930"
      unitRef="shares">2779689</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-215"
      decimals="2"
      id="f-931"
      unitRef="usdPerShare">19.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-215"
      decimals="INF"
      id="f-932"
      unitRef="shares">1525693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-215"
      decimals="2"
      id="f-933"
      unitRef="usdPerShare">47.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-215"
      decimals="INF"
      id="f-934"
      unitRef="shares">356957</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-215"
      decimals="2"
      id="f-935"
      unitRef="usdPerShare">30.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-206"
      decimals="INF"
      id="f-936"
      unitRef="shares">5810351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-206"
      decimals="2"
      id="f-937"
      unitRef="usdPerShare">36.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-215" decimals="-5" id="f-938" unitRef="usd">54900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-216" decimals="-5" id="f-939" unitRef="usd">64300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-217" decimals="-5" id="f-940" unitRef="usd">69700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-206" decimals="-5" id="f-941" unitRef="usd">73300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-215" id="f-942">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-943">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date using the exit price. Accordingly, when market observable data are not readily available, the Company&#x2019;s own assumptions are used to reflect those that market participants would be presumed to use in pricing the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value on the consolidated balance sheets are categorized based on the level of judgment associated with inputs used to measure their fair values and the level of market price observability, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#160;&#160;&#160;&#160;Unadjusted quoted prices are available in active markets for identical assets or liabilities as of the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#160;&#160;&#160;&#160;Pricing inputs are other than quoted prices in active markets, which are based on the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;     Quoted prices for similar assets or liabilities in active markets;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;     Quoted prices for identical or similar assets or liabilities in non-active markets; or&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;     Either directly or indirectly observable inputs as of the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#160;&#160;&#160;&#160;Pricing inputs are unobservable and significant to the overall fair value measurement, and the determination of fair value requires significant management judgment or estimation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. Thus, a Level 3 fair value measurement may include inputs that are observable (Level 1 or Level 2) and unobservable (Level 3). The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and consideration of factors specific to the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. At September&#160;30, 2025 and 2024, the Company did not have any financial assets or financial liabilities based on Level 3 measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis, and indicate the fair value hierarchy of the valuation techniques utilized by the Company: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.194%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;509,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;509,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;692,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;692,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market instruments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;153,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;846,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;910,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;     &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.194%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market instruments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;645,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-944">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis, and indicate the fair value hierarchy of the valuation techniques utilized by the Company: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.194%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;509,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;509,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;692,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;692,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market instruments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;153,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;846,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;910,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;     &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.194%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market instruments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;578,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;645,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-218" decimals="-3" id="f-945" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-219" decimals="-3" id="f-946" unitRef="usd">150695000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-220" decimals="-3" id="f-947" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-221" decimals="-3" id="f-948" unitRef="usd">150695000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-222" decimals="-3" id="f-949" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-223" decimals="-3" id="f-950" unitRef="usd">12019000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-224" decimals="-3" id="f-951" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-225" decimals="-3" id="f-952" unitRef="usd">12019000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-226" decimals="-3" id="f-953" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-227" decimals="-3" id="f-954" unitRef="usd">7046000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-228" decimals="-3" id="f-955" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-229" decimals="-3" id="f-956" unitRef="usd">7046000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-230" decimals="-3" id="f-957" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-231" decimals="-3" id="f-958" unitRef="usd">13801000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-232" decimals="-3" id="f-959" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-233" decimals="-3" id="f-960" unitRef="usd">13801000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-234" decimals="-3" id="f-961" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-235" decimals="-3" id="f-962" unitRef="usd">509257000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-236" decimals="-3" id="f-963" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-237" decimals="-3" id="f-964" unitRef="usd">509257000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-238" decimals="-3" id="f-965" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-239" decimals="-3" id="f-966" unitRef="usd">692818000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-240" decimals="-3" id="f-967" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-241" decimals="-3" id="f-968" unitRef="usd">692818000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-242" decimals="-3" id="f-969" unitRef="usd">64460000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-243" decimals="-3" id="f-970" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-244" decimals="-3" id="f-971" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-245" decimals="-3" id="f-972" unitRef="usd">64460000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-246" decimals="-3" id="f-973" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-247" decimals="-3" id="f-974" unitRef="usd">134357000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-248" decimals="-3" id="f-975" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-249" decimals="-3" id="f-976" unitRef="usd">134357000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-250" decimals="-3" id="f-977" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-251" decimals="-3" id="f-978" unitRef="usd">3001000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-252" decimals="-3" id="f-979" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-253" decimals="-3" id="f-980" unitRef="usd">3001000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-254" decimals="-3" id="f-981" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-255" decimals="-3" id="f-982" unitRef="usd">16182000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-256" decimals="-3" id="f-983" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-257" decimals="-3" id="f-984" unitRef="usd">16182000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-238" decimals="-3" id="f-985" unitRef="usd">64460000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-239" decimals="-3" id="f-986" unitRef="usd">153540000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-240" decimals="-3" id="f-987" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-241" decimals="-3" id="f-988" unitRef="usd">218000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-238" decimals="-3" id="f-989" unitRef="usd">64460000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-239" decimals="-3" id="f-990" unitRef="usd">846358000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-240" decimals="-3" id="f-991" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-241" decimals="-3" id="f-992" unitRef="usd">910818000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-258" decimals="-3" id="f-993" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-259" decimals="-3" id="f-994" unitRef="usd">160723000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-260" decimals="-3" id="f-995" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-261" decimals="-3" id="f-996" unitRef="usd">160723000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-262" decimals="-3" id="f-997" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-263" decimals="-3" id="f-998" unitRef="usd">179714000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-264" decimals="-3" id="f-999" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-265" decimals="-3" id="f-1000" unitRef="usd">179714000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-266" decimals="-3" id="f-1001" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-267" decimals="-3" id="f-1002" unitRef="usd">237839000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-268" decimals="-3" id="f-1003" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-269" decimals="-3" id="f-1004" unitRef="usd">237839000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-270" decimals="-3" id="f-1005" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-271" decimals="-3" id="f-1006" unitRef="usd">578276000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-272" decimals="-3" id="f-1007" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-273" decimals="-3" id="f-1008" unitRef="usd">578276000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-274" decimals="-3" id="f-1009" unitRef="usd">66966000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-275" decimals="-3" id="f-1010" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-276" decimals="-3" id="f-1011" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-277" decimals="-3" id="f-1012" unitRef="usd">66966000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-270" decimals="-3" id="f-1013" unitRef="usd">66966000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-271" decimals="-3" id="f-1014" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-272" decimals="-3" id="f-1015" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-273" decimals="-3" id="f-1016" unitRef="usd">66966000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-270" decimals="-3" id="f-1017" unitRef="usd">66966000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-271" decimals="-3" id="f-1018" unitRef="usd">578276000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-272" decimals="-3" id="f-1019" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-273" decimals="-3" id="f-1020" unitRef="usd">645242000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1021">INCOME TAXES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Tax Provision (Benefit)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the income (loss) before income tax expense and noncontrolling interest are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(582,333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(194,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(612,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(202,491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax provision (benefit) consisted of the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.170%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.170%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.174%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of the tax expense based on the statutory rate to the Company&#x2019;s actual tax expense in the consolidated statements of operations and comprehensive income (loss). A notional 21% tax rate was applied as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. federal statutory income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(44.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Permanent and other items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(37.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-deductible compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income deduction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the significant components of the Company&#x2019;s net deferred tax assets and liabilities: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.404%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;232,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;562,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;473,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(497,543)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(448,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;Original Issue Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(65,143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is recorded to reduce deferred tax assets to the amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended September&#160;30, 2025. Such objective evidence limits the ability to consider other subjective evidence such as its projections for future growth. On the basis of this evaluation at September&#160;30, 2025 and 2024, a valuation allowance of $497.5 million and $448.9 million, respectively, has been recorded. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of September&#160;30, 2025, the Company had accumulated federal, state, and foreign net operating loss (&#x201c;NOL&#x201d;) carryforwards of $20.6 million, $815.5 million and $46.3 million, respectively. Of the $20.6 million in federal NOL carryforwards, $20.6 million was generated before January 1, 2018, and is subject to a 20-year carryforward period (&#x201c;pre-Tax Act losses&#x201d;), with expiration beginning in 2031. Of the $815.5 million in state NOL carryforwards, $2.7 million can be carried forward indefinitely, while the remaining balance begins to expire in 2031. The Company also has foreign NOL carryforwards totaling $46.3 million, which begin to expire in 2027. Additionally, the Company has federal and state income tax credits of $49.4 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $26.3 million, respectively. The federal credits begin to expire in 2041. Of the state income tax credits, $13.6 million begins to expire in 2035, while the remaining credits can be carried forward indefinitely.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), the annual use of an entity&#x2019;s NOL and research and development credit carryforwards may be limited if there is a cumulative ownership change of greater than 50% within a three-year period. The annual limitation is determined based on the entity&#x2019;s value immediately prior to the ownership change. Future ownership changes could further affect the limitation. If a limitation is applied, the related tax asset would be removed from the deferred tax asset schedule, with a corresponding reduction in the valuation allowance. To date, the Company has completed an analysis pursuant to Sections 382 and 383 through September&#160;30, 2024. Ownership Changes may have occurred since then, and future changes could potentially limit the Company&#x2019;s ability to utilize these attributes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has adopted guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold of more-likely-than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more-likely-than not that a tax position &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s gross unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.719%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Beginning balance of unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross increase for prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross decrease for prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross increase for current period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lapse of statue of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ending balance of unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has recorded income tax (benefit) expense of $0 and $3.3 million for the years ended September&#160;30, 2025 and 2024, respectively, related to uncertain tax positions inclusive of interest and penalties. The Company&#x2019;s policy is to recognize potential interest and penalties related to unrecognized tax benefits associated with uncertain tax positions, if any, in the income tax provision. As of September&#160;30, 2025, the Company has not accrued any interest or penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the unrecognized tax benefit as of September&#160;30, 2025 is ultimately recognized, there would be no reduction in the Company&#x2019;s income tax expense or effective tax rate, excluding the impact of U.S. Tax benefits netted against deferred taxes that are subject to a valuation allowance. The Company does not anticipate any changes in its unrecognized tax benefits over the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to taxation in the U.S. and various states along with other foreign countries. Due to the presence of NOL carryforwards, all of the income tax years remain open for examination. The Company is currently under audit by the IRS for September&#160;30, 2023. California income tax examination has been closed. There are no other audits in any other jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes undistributed earnings of each foreign subsidiary and has determined that no withholding taxes are applicable to earnings which are currently available for distribution. No additional deferred tax liability has been recorded as the parent entity would not be required to include the distribution into income under the current law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Tax Cuts and Jobs Act subjects a U.S. shareholder to tax on Global Intangible Low-Taxed Income (&#x201c;GILTI&#x201d;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;amp;A, Topic 740 No. 5. Accounting for GILTI, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year that the tax is incurred as a period expense only. The Company has elected to account for GILTI in the year the tax is incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 4, 2025, the One Big Beautiful Bill Act (&#x201c;OBBBA&#x201d;) was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. ASC 740, "Income Taxes", requires the effects of changes in tax rates and laws to be recognized in the period in which the legislation is enacted. The Company has implemented OBBBA in the fourth quarter of the current year.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-1022">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the income (loss) before income tax expense and noncontrolling interest are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(582,333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(194,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(612,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(202,491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-1023" unitRef="usd">-42573000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-28" decimals="-3" id="f-1024" unitRef="usd">-582333000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-29" decimals="-3" id="f-1025" unitRef="usd">-194639000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-1026" unitRef="usd">94106000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-28" decimals="-3" id="f-1027" unitRef="usd">-30127000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-29" decimals="-3" id="f-1028" unitRef="usd">-7852000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-1" decimals="-3" id="f-1029" unitRef="usd">51533000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-28" decimals="-3" id="f-1030" unitRef="usd">-612460000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-29" decimals="-3" id="f-1031" unitRef="usd">-202491000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-1032">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax provision (benefit) consisted of the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.170%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.170%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.174%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1033" unitRef="usd">21440000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-28" decimals="-3" id="f-1034" unitRef="usd">148000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-29" decimals="-3" id="f-1035" unitRef="usd">1074000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1036" unitRef="usd">-56000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-28" decimals="-3" id="f-1037" unitRef="usd">375000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-29" decimals="-3" id="f-1038" unitRef="usd">1710000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1039" unitRef="usd">35000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-28" decimals="-3" id="f-1040" unitRef="usd">-3290000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-29" decimals="-3" id="f-1041" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1042" unitRef="usd">21419000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-28" decimals="-3" id="f-1043" unitRef="usd">-2767000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-29" decimals="-3" id="f-1044" unitRef="usd">2784000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1045" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-28" decimals="-3" id="f-1046" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-29" decimals="-3" id="f-1047" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1048" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-28" decimals="-3" id="f-1049" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-29" decimals="-3" id="f-1050" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1051" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-28" decimals="-3" id="f-1052" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-29" decimals="-3" id="f-1053" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1054" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-28" decimals="-3" id="f-1055" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-29" decimals="-3" id="f-1056" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1057" unitRef="usd">21419000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-28" decimals="-3" id="f-1058" unitRef="usd">-2767000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-29" decimals="-3" id="f-1059" unitRef="usd">2784000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1060">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of the tax expense based on the statutory rate to the Company&#x2019;s actual tax expense in the consolidated statements of operations and comprehensive income (loss). A notional 21% tax rate was applied as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. federal statutory income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(44.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Permanent and other items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(37.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-deductible compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income deduction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-1"
      decimals="INF"
      id="f-1061"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-28"
      decimals="INF"
      id="f-1062"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-29"
      decimals="INF"
      id="f-1063"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-1064" unitRef="number">-0.031</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-28" decimals="3" id="f-1065" unitRef="number">0.026</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-29" decimals="3" id="f-1066" unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-1" decimals="3" id="f-1067" unitRef="number">0.444</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-28" decimals="3" id="f-1068" unitRef="number">-0.030</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-29" decimals="3" id="f-1069" unitRef="number">-0.068</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-1070" unitRef="number">-0.379</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-28" decimals="3" id="f-1071" unitRef="number">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-29" decimals="3" id="f-1072" unitRef="number">-0.046</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <arwr:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent contextRef="c-1" decimals="3" id="f-1073" unitRef="number">0.051</arwr:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent>
    <arwr:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent contextRef="c-28" decimals="3" id="f-1074" unitRef="number">-0.009</arwr:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent>
    <arwr:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent contextRef="c-29" decimals="3" id="f-1075" unitRef="number">-0.046</arwr:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent contextRef="c-1" decimals="3" id="f-1076" unitRef="number">0.162</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent contextRef="c-28" decimals="3" id="f-1077" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent contextRef="c-29" decimals="3" id="f-1078" unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent>
    <arwr:EffectiveIncomeTaxRateReconciliationOtherIncomePercent contextRef="c-1" decimals="3" id="f-1079" unitRef="number">0.111</arwr:EffectiveIncomeTaxRateReconciliationOtherIncomePercent>
    <arwr:EffectiveIncomeTaxRateReconciliationOtherIncomePercent contextRef="c-28" decimals="3" id="f-1080" unitRef="number">0</arwr:EffectiveIncomeTaxRateReconciliationOtherIncomePercent>
    <arwr:EffectiveIncomeTaxRateReconciliationOtherIncomePercent contextRef="c-29" decimals="3" id="f-1081" unitRef="number">0</arwr:EffectiveIncomeTaxRateReconciliationOtherIncomePercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-1082" unitRef="number">0.107</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-28" decimals="3" id="f-1083" unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-29" decimals="3" id="f-1084" unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-1085" unitRef="number">0.954</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-28" decimals="3" id="f-1086" unitRef="number">-0.270</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-29" decimals="3" id="f-1087" unitRef="number">-0.205</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1088" unitRef="number">0.417</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-28" decimals="3" id="f-1089" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-29" decimals="3" id="f-1090" unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1091">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the significant components of the Company&#x2019;s net deferred tax assets and liabilities: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.404%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;232,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;562,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;473,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(497,543)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(448,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;Original Issue Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(65,143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-26" decimals="-3" id="f-1092" unitRef="usd">70858000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-27" decimals="-3" id="f-1093" unitRef="usd">102716000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost contextRef="c-26" decimals="-3" id="f-1094" unitRef="usd">232360000</arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost>
    <arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost contextRef="c-27" decimals="-3" id="f-1095" unitRef="usd">156015000</arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-26" decimals="-3" id="f-1096" unitRef="usd">48867000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-27" decimals="-3" id="f-1097" unitRef="usd">85428000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-26" decimals="-3" id="f-1098" unitRef="usd">171262000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-27" decimals="-3" id="f-1099" unitRef="usd">81556000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities contextRef="c-26" decimals="-3" id="f-1100" unitRef="usd">23919000</arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities>
    <arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities contextRef="c-27" decimals="-3" id="f-1101" unitRef="usd">27999000</arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-26" decimals="-3" id="f-1102" unitRef="usd">9184000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-27" decimals="-3" id="f-1103" unitRef="usd">10989000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c-26" decimals="-3" id="f-1104" unitRef="usd">4254000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c-27" decimals="-3" id="f-1105" unitRef="usd">4078000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-26" decimals="-3" id="f-1106" unitRef="usd">1034000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-27" decimals="-3" id="f-1107" unitRef="usd">1384000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-26" decimals="-3" id="f-1108" unitRef="usd">948000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-27" decimals="-3" id="f-1109" unitRef="usd">2843000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-26" decimals="-3" id="f-1110" unitRef="usd">562686000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-27" decimals="-3" id="f-1111" unitRef="usd">473008000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-26" decimals="-3" id="f-1112" unitRef="usd">497543000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-27" decimals="-3" id="f-1113" unitRef="usd">448867000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-26" decimals="-3" id="f-1114" unitRef="usd">30503000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-27" decimals="-3" id="f-1115" unitRef="usd">13155000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-26" decimals="-3" id="f-1116" unitRef="usd">9424000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-27" decimals="-3" id="f-1117" unitRef="usd">10792000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome contextRef="c-26" decimals="-3" id="f-1118" unitRef="usd">630000</us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome>
    <us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome contextRef="c-27" decimals="-3" id="f-1119" unitRef="usd">194000</us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome>
    <arwr:DeferredTaxLiabilitiesOriginalIssueDiscount contextRef="c-26" decimals="-3" id="f-1120" unitRef="usd">24586000</arwr:DeferredTaxLiabilitiesOriginalIssueDiscount>
    <arwr:DeferredTaxLiabilitiesOriginalIssueDiscount contextRef="c-27" decimals="-3" id="f-1121" unitRef="usd">0</arwr:DeferredTaxLiabilitiesOriginalIssueDiscount>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-26" decimals="-3" id="f-1122" unitRef="usd">65143000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-27" decimals="-3" id="f-1123" unitRef="usd">24141000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-26" decimals="-3" id="f-1124" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-27" decimals="-3" id="f-1125" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-26" decimals="-5" id="f-1126" unitRef="usd">497500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-27" decimals="-5" id="f-1127" unitRef="usd">448900000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c-278" decimals="-5" id="f-1128" unitRef="usd">20600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-279" decimals="-5" id="f-1129" unitRef="usd">815500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-280" decimals="-5" id="f-1130" unitRef="usd">46300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-278" decimals="-5" id="f-1131" unitRef="usd">20600000</us-gaap:OperatingLossCarryforwards>
    <arwr:OperatingLossCarryforwardsSubjectToExpiration contextRef="c-278" decimals="-5" id="f-1132" unitRef="usd">20600000</arwr:OperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards contextRef="c-279" decimals="-5" id="f-1133" unitRef="usd">815500000</us-gaap:OperatingLossCarryforwards>
    <arwr:OperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-279" decimals="-5" id="f-1134" unitRef="usd">2700000</arwr:OperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards contextRef="c-280" decimals="-5" id="f-1135" unitRef="usd">46300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-278" decimals="-5" id="f-1136" unitRef="usd">49400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-279" decimals="-5" id="f-1137" unitRef="usd">26300000</us-gaap:TaxCreditCarryforwardAmount>
    <arwr:TaxCreditCarryforwardAmountSubjectToExpiration contextRef="c-279" decimals="-5" id="f-1138" unitRef="usd">13600000</arwr:TaxCreditCarryforwardAmountSubjectToExpiration>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-1139">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s gross unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.719%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Beginning balance of unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross increase for prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross decrease for prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross increase for current period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lapse of statue of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ending balance of unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-27" decimals="-3" id="f-1140" unitRef="usd">16613000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-46" decimals="-3" id="f-1141" unitRef="usd">14536000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-35" decimals="-3" id="f-1142" unitRef="usd">3481000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1143" unitRef="usd">1160000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-28" decimals="-3" id="f-1144" unitRef="usd">654000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-29" decimals="-3" id="f-1145" unitRef="usd">9495000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1146" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-28" decimals="-3" id="f-1147" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-29" decimals="-3" id="f-1148" unitRef="usd">1489000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1149" unitRef="usd">4379000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-28" decimals="-3" id="f-1150" unitRef="usd">3415000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-29" decimals="-3" id="f-1151" unitRef="usd">3049000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-1" decimals="-3" id="f-1152" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-28" decimals="-3" id="f-1153" unitRef="usd">1992000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-29" decimals="-3" id="f-1154" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-26" decimals="-3" id="f-1155" unitRef="usd">22152000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-27" decimals="-3" id="f-1156" unitRef="usd">16613000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-46" decimals="-3" id="f-1157" unitRef="usd">14536000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-1" decimals="-5" id="f-1158" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-28" decimals="-5" id="f-1159" unitRef="usd">3300000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c-1" id="f-1160">EMPLOYEE BENEFIT PLANS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors a defined contribution retirement plan which is under Section 401(k) of the Internal Revenue Code and is designed to adhere to ERISA Fiduciary standards. All of the Company&#x2019;s full-time employees are eligible to participate this plan. Under the terms of the plan, an eligible employee may elect to contribute a portion of their salary on a pre-tax basis, subject to federal statutory limitations. The plan allows for a discretionary match in an amount up to 100% of each participant&#x2019;s first 3% of compensation contributed plus 50% of each participant&#x2019;s next 2% of compensation contributed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended September&#160;30, 2025, 2024, and 2023, the Company recorded expenses for the matching contributions under this plan of $3.9 million, $3.4 million and $2.2 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also provides certain employee benefit plans, including those which provide health and life insurance benefits to employees.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c-281"
      decimals="INF"
      id="f-1161"
      unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c-281"
      decimals="2"
      id="f-1162"
      unitRef="number">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c-282"
      decimals="INF"
      id="f-1163"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c-282"
      decimals="2"
      id="f-1164"
      unitRef="number">0.02</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-1" decimals="-5" id="f-1165" unitRef="usd">3900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-28" decimals="-5" id="f-1166" unitRef="usd">3400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-29" decimals="-5" id="f-1167" unitRef="usd">2200000</us-gaap:DefinedContributionPlanCostRecognized>
    <arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock contextRef="c-1" id="f-1168">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $410.0 million in cash to the Company in consideration for the Company&#x2019;s future royalty interest in olpasiran, a siRNA originally developed by the Company and licensed to Amgen in September 2016 under the Olpasiran Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $250.0 million upfront and agreed to pay up to an additional $160.0 million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $50.0 million on completion of enrollment in the OCEAN Phase 3 clinical trial for olpasiran, (ii) $50.0 million upon receipt of FDA approval of olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $60.0 million upon Royalty Pharma&#x2019;s receipt of at least $70.0 million of royalty payments under the Royalty Pharma Agreement in any single calendar year. During the third quarter of fiscal 2024, Amgen completed enrollment of the Phase 3 OCEAN(a) outcomes trial of olpasiran, which triggered a $50.0&#160;million milestone payment that the Company received in the same quarter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated the terms of the Royalty Pharma Agreement and concluded in accordance with the relevant accounting guidance that the Company accounted for the transaction as debt and the funding of $250.0 million and $50.0&#160;million from Royalty Pharma were recorded as liabilities related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay these funds received under the Royalty Pharma Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company records the obligations at their carrying value using the effective interest method. In order to amortize the sale of future royalties, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize non-cash interest expense for the remaining periods. The Company periodically assesses the amount and the timing of expected royalty payments using a combination of internal projections and forecasts from external sources. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration, probability of success and sales price, among others. To the extent such payments are greater or less than the Company&#x2019;s initial estimates or the timing of such payments is different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate. As of September&#160;30, 2025, the estimated effective interest rate was 8.3%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the activity with respect to the liability related to the sale of future royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Beginning carrying value &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Upfront payment received&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Milestone payment received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ending carrying value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;367,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock>
    <arwr:InitialTransactionPrice contextRef="c-283" decimals="-5" id="f-1169" unitRef="usd">410000000.0</arwr:InitialTransactionPrice>
    <arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-284" decimals="-5" id="f-1170" unitRef="usd">250000000.0</arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:MilestonePaymentReceivable contextRef="c-285" decimals="-5" id="f-1171" unitRef="usd">160000000.0</arwr:MilestonePaymentReceivable>
    <arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial contextRef="c-286" decimals="-5" id="f-1172" unitRef="usd">50000000.0</arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial>
    <arwr:MilestonePaymentReceivableUponFDAApproval contextRef="c-285" decimals="-5" id="f-1173" unitRef="usd">50000000.0</arwr:MilestonePaymentReceivableUponFDAApproval>
    <arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments contextRef="c-285" decimals="-5" id="f-1174" unitRef="usd">60000000.0</arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments>
    <arwr:RoyaltyPaymentThreshold contextRef="c-285" decimals="-5" id="f-1175" unitRef="usd">70000000.0</arwr:RoyaltyPaymentThreshold>
    <arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-287" decimals="-5" id="f-1176" unitRef="usd">50000000</arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-284" decimals="-5" id="f-1177" unitRef="usd">250000000.0</arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-287" decimals="-5" id="f-1178" unitRef="usd">50000000</arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:LiabilitySaleOfFutureRoyaltiesInterestRate
      contextRef="c-286"
      decimals="3"
      id="f-1179"
      unitRef="number">0.083</arwr:LiabilitySaleOfFutureRoyaltiesInterestRate>
    <arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock contextRef="c-1" id="f-1180">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the activity with respect to the liability related to the sale of future royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Beginning carrying value &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Upfront payment received&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Milestone payment received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ending carrying value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;367,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock>
    <arwr:RoyaltiesLiabilityNoncurrent contextRef="c-27" decimals="-3" id="f-1181" unitRef="usd">341361000</arwr:RoyaltiesLiabilityNoncurrent>
    <arwr:RoyaltiesLiabilityNoncurrent contextRef="c-46" decimals="-3" id="f-1182" unitRef="usd">268326000</arwr:RoyaltiesLiabilityNoncurrent>
    <arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-1" decimals="-3" id="f-1183" unitRef="usd">0</arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-28" decimals="-3" id="f-1184" unitRef="usd">0</arwr:UpfrontPaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-1" decimals="-3" id="f-1185" unitRef="usd">0</arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-28" decimals="-3" id="f-1186" unitRef="usd">50000000</arwr:MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-1" decimals="-3" id="f-1187" unitRef="usd">26036000</arwr:NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-28" decimals="-3" id="f-1188" unitRef="usd">23035000</arwr:NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:RoyaltiesLiabilityNoncurrent contextRef="c-26" decimals="-3" id="f-1189" unitRef="usd">367397000</arwr:RoyaltiesLiabilityNoncurrent>
    <arwr:RoyaltiesLiabilityNoncurrent contextRef="c-27" decimals="-3" id="f-1190" unitRef="usd">341361000</arwr:RoyaltiesLiabilityNoncurrent>
    <us-gaap:LongTermDebtTextBlock contextRef="c-1" id="f-1191">FINANCING AGREEMENT &lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 7, 2024 (the &#x201c;Closing Date&#x201d;), the Company entered into a Financing Agreement with the guarantors party thereto, the lenders party thereto (the &#x201c;Lenders&#x201d;), and Sixth Street Lending Partners (&#x201c;Sixth Street&#x201d;), as the administrative agent and collateral agent for the Lenders (the &#x201c;Financing Agreement&#x201d;). The Financing Agreement establishes a senior secured term loan facility of $500.0&#160;million (the &#x201c;Credit Facility&#x201d;), consisting of $400.0&#160;million funded on the Closing Date and an additional $100.0&#160;million available at the Company&#x2019;s option, subject to mutual agreement with Sixth Street. The loans under the Credit Facility bear interest at an annual rate of 15.0%, which is paid in kind and added to the outstanding principal balance of the Credit Facility each period. The outstanding principal balance of this Credit &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Facility, including amounts representing accrued but unpaid interest previously paid in kind, is due and payable on August 7, 2031.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is permitted to use the net proceeds for working capital, capital expenditures and general corporate purposes of the Company and its subsidiaries.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will have the right to prepay loans under the Credit Facility at any time. The Company is required to partially repay loans under the Credit Facility with proceeds from certain asset sales, condemnation events and extraordinary receipts, subject, in some cases, to reinvestment rights. If the Company repays in full the aggregate principal outstanding under the Credit Facility and such payment in full occurs on or prior to August 7, 2028, the Company will be required to make an additional payment to the lenders under the Credit Facility on such date in an amount necessary for the lenders to achieve a two times multiple of invested capital (&#x201c;MOIC&#x201d;) of the aggregate principal amount funded on the Closing Date (the &#x201c;MOIC Payment&#x201d;). If such payment in full occurs after August 7, 2028, the Company will be required to make a payment to the lenders under the Credit Facility on such date in an amount necessary for the lenders to achieve the greater of the MOIC Payment and the present value of all interest payments that would have been payable from such date through the maturity date of the Credit Facility discounted at the Treasury Rate (as defined in the Financing Agreement) plus 0.5%; provided that such payment amount in this instance will not exceed the amount necessary for the lenders to achieve a 2.5 times MOIC.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 26, 2024, the Company entered into an amendment to the Financing Agreement (the "Amendment") to modify, amongst other things, some of the prepayment terms of the loans under the Credit Facility, including, the prepayment terms related to the Sarepta Collaboration Agreement. The Amendment was effective on February 14, 2025, following the closing of the Sarepta Collaboration Agreement and receipt of the $500.0&#160;million upfront payment from Sarepta. The Amendment added an additional prepayment clause that requires certain contractual prepayments of principle and MOIC payments throughout the life of the loans under the Credit Facility. Additionally, any prepayment will be split with 50% of any such prepayment paying down the principle balance of the loans under the Credit Facility and the other 50% being applied to prepay the MOIC Payment. In the event the prepayment amounts result in fees being prepaid in excess of the actual amounts required to be paid, the excess fees shall be reallocated and applied to reduce the amount of the principal balance upon repayment in full of the loans under the Credit Facility. As of September&#160;30, 2025, the Company has paid $100.0&#160;million in MOIC payments of which $25.3&#160;million is expected to be applied to principal upon repayment in full. To date, the Company has paid $201.6&#160;million of the loans under the Credit Facility during fiscal 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Amendment was accounted for as a debt modification under ASC 470-50, &#x201c;Debt&#x2014;Modification and extinguishments&#x201d; since the Amendment did not result in substantially different terms. In connection with the Amendment, the Company did not incur significant third-party fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"&gt;All obligations under the Financing Agreement are secured on a first-priority basis by security interests in substantially all assets of the Company and material subsidiaries of the Company, including its intellectual property, subject to certain exceptions, and is guaranteed by material subsidiaries of the Company, including foreign subsidiaries, subject to certain exceptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Financing Agreement contains customary covenants, including, without limitation, a financial covenant to maintain liquidity (cash, cash equivalents and investments) of at least $100.0&#160;million if the Company&#x2019;s market capitalization is above $1.5 billion, and negative covenants that, subject to certain exceptions, restrict indebtedness, liens, investments (including acquisitions), fundamental changes, asset sales and licensing transactions, dividends, modifications to material agreements, payment of subordinated indebtedness, distributions from certain parties, and other matters customarily restricted in such agreements. The Company is subject to restrictions on sales and licensing transactions with respect to certain core intellectual property, subject to certain exceptions, including certain transactions related to areas outside the United States, United Kingdom, European Union, Japan and China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Financing Agreement contains certain embedded features that were identified and evaluated as not material to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 13, 2025, the Company entered into second amendment to the Financing Agreement (the "Second Amendment") that permitted the share repurchase of the Company's common stock from Sarepta and required the Company to pay a nominal administrative fee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outstanding balance of the Credit Facility consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.719%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Initial Term Loan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated interest on the Initial Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated accretion of the MOIC Payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of credit facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(201,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Credit facility, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;393,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth total interest expense recognized related to the Credit Facility:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.012%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.012%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount and issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accretion of the MOIC Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;Total interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts shown in the table below, related to the Credit Facility, represent the expected repayments of principle and accrued interest balance as of September&#160;30, 2025 as well as any mandatory prepayments that the Company is obligated to make to the Lenders during the indicated periods. The principal balance will increase from accrued paid in kind interest and the table does not include MOIC payments beyond those contractually determined. Actual payments on current principal may vary from the amounts presented in the table. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.840%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;339,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2025, Visirna entered into the Revolving Credit Agreement with Bank of Zhejiang. The maximum aggregate credit facility is 72.9&#160;million Chinese Yuan ($10.3&#160;million) bearing an annual interest rate of 4.1%. The term of each loan is twelve months. The amount outstanding as of September&#160;30, 2025 was 72.9&#160;million Chinese Yuan ($10.3&#160;million) on the credit facility which was classified as other current liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-288" decimals="-5" id="f-1192" unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit contextRef="c-288" decimals="-5" id="f-1193" unitRef="usd">400000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="c-288" decimals="-5" id="f-1194" unitRef="usd">100000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-289"
      decimals="3"
      id="f-1195"
      unitRef="number">0.150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <arwr:DebtInstrumentCovenantMultipleOfInvestedCapital
      contextRef="c-290"
      decimals="INF"
      id="f-1196"
      unitRef="number">2</arwr:DebtInstrumentCovenantMultipleOfInvestedCapital>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-290"
      decimals="3"
      id="f-1197"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <arwr:DebtInstrumentCovenantMultipleOfInvestedCapital
      contextRef="c-291"
      decimals="INF"
      id="f-1198"
      unitRef="number">2.5</arwr:DebtInstrumentCovenantMultipleOfInvestedCapital>
    <arwr:ProceedsFromCollaborationArrangements contextRef="c-70" decimals="-5" id="f-1199" unitRef="usd">500000000</arwr:ProceedsFromCollaborationArrangements>
    <arwr:DebtInstrumentPrepaymentPercentage
      contextRef="c-292"
      decimals="2"
      id="f-1200"
      unitRef="number">0.50</arwr:DebtInstrumentPrepaymentPercentage>
    <arwr:DebtInstrumentPrepaymentPercentage
      contextRef="c-293"
      decimals="2"
      id="f-1201"
      unitRef="number">0.50</arwr:DebtInstrumentPrepaymentPercentage>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit contextRef="c-294" decimals="-5" id="f-1202" unitRef="usd">100000000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <arwr:DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment contextRef="c-295" decimals="-5" id="f-1203" unitRef="usd">25300000</arwr:DebtInstrumentMultipleOfInvestmentCapitalExpectedToBeAppliedToPrincipalUponRepayment>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit contextRef="c-296" decimals="-5" id="f-1204" unitRef="usd">201600000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <arwr:DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold contextRef="c-297" decimals="-5" id="f-1205" unitRef="usd">100000000</arwr:DebtInstrumentCovenantMinimumLiquidityIfCapitalizationIsAboveThreshold>
    <arwr:DebtInstrumentCovenantMarketCapitalizationThreshold contextRef="c-297" decimals="-8" id="f-1206" unitRef="usd">1500000000</arwr:DebtInstrumentCovenantMarketCapitalizationThreshold>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock contextRef="c-1" id="f-1207">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outstanding balance of the Credit Facility consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.719%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Initial Term Loan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated interest on the Initial Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated accretion of the MOIC Payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of credit facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(201,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Credit facility, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;393,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-298" decimals="-3" id="f-1208" unitRef="usd">400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-299" decimals="-3" id="f-1209" unitRef="usd">400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-300" decimals="-3" id="f-1210" unitRef="usd">66942000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-301" decimals="-3" id="f-1211" unitRef="usd">9000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-296" decimals="-3" id="f-1212" unitRef="usd">3478000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-302" decimals="-3" id="f-1213" unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-297" decimals="-3" id="f-1214" unitRef="usd">13912000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-303" decimals="-3" id="f-1215" unitRef="usd">15817000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LinesOfCreditCurrent contextRef="c-297" decimals="-3" id="f-1216" unitRef="usd">40000000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent contextRef="c-303" decimals="-3" id="f-1217" unitRef="usd">0</us-gaap:LinesOfCreditCurrent>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit contextRef="c-296" decimals="-3" id="f-1218" unitRef="usd">201625000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit contextRef="c-302" decimals="-3" id="f-1219" unitRef="usd">0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-297" decimals="-3" id="f-1220" unitRef="usd">214883000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-303" decimals="-3" id="f-1221" unitRef="usd">393183000</us-gaap:LongTermDebtNoncurrent>
    <arwr:SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock contextRef="c-1" id="f-1222">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth total interest expense recognized related to the Credit Facility:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.012%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.012%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount and issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accretion of the MOIC Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;Total interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:SummaryOfInterestExpenseRecognizedRelatedToCreditFacilityTableTextBlock>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-296" decimals="-3" id="f-1223" unitRef="usd">1906000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-302" decimals="-3" id="f-1224" unitRef="usd">317000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-304" decimals="-3" id="f-1225" unitRef="usd">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-296" decimals="-3" id="f-1226" unitRef="usd">3478000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-302" decimals="-3" id="f-1227" unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-304" decimals="-3" id="f-1228" unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-296" decimals="-3" id="f-1229" unitRef="usd">57941000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-302" decimals="-3" id="f-1230" unitRef="usd">9000000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-304" decimals="-3" id="f-1231" unitRef="usd">0</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebt contextRef="c-296" decimals="-3" id="f-1232" unitRef="usd">63325000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-302" decimals="-3" id="f-1233" unitRef="usd">9317000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-304" decimals="-3" id="f-1234" unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-1235">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts shown in the table below, related to the Credit Facility, represent the expected repayments of principle and accrued interest balance as of September&#160;30, 2025 as well as any mandatory prepayments that the Company is obligated to make to the Lenders during the indicated periods. The principal balance will increase from accrued paid in kind interest and the table does not include MOIC payments beyond those contractually determined. Actual payments on current principal may vary from the amounts presented in the table. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.840%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;339,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-297" decimals="-3" id="f-1236" unitRef="usd">40000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-297" decimals="-3" id="f-1237" unitRef="usd">40000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-297" decimals="-3" id="f-1238" unitRef="usd">15000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-297" decimals="-3" id="f-1239" unitRef="usd">15000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="c-297" decimals="-3" id="f-1240" unitRef="usd">15000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="c-297" decimals="-3" id="f-1241" unitRef="usd">214990000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-297" decimals="-3" id="f-1242" unitRef="usd">339990000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-305" decimals="-5" id="f-1243" unitRef="cny">72900000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-305" decimals="-5" id="f-1244" unitRef="usd">10300000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-305"
      decimals="3"
      id="f-1245"
      unitRef="number">0.041</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm contextRef="c-306" id="f-1246">P12M</us-gaap:DebtInstrumentTerm>
    <us-gaap:LinesOfCreditCurrent contextRef="c-307" decimals="-5" id="f-1247" unitRef="cny">72900000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent contextRef="c-307" decimals="-5" id="f-1248" unitRef="usd">10300000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-1249">NET LOSS PER SHARE&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the computation of basic and diluted net loss per share for the years ended September&#160;30, 2025, 2024 and 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Arrowhead Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(599,493)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(205,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average basic shares outstanding&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average diluted shares outstanding&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-1250">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the computation of basic and diluted net loss per share for the years ended September&#160;30, 2025, 2024 and 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Arrowhead Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(599,493)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(205,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average basic shares outstanding&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average diluted shares outstanding&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-1251" unitRef="usd">-1631000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-28" decimals="-3" id="f-1252" unitRef="usd">-599493000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-29" decimals="-3" id="f-1253" unitRef="usd">-205275000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-1254" unitRef="shares">133758000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-28"
      decimals="-3"
      id="f-1255"
      unitRef="shares">119784000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-29"
      decimals="-3"
      id="f-1256"
      unitRef="shares">106750000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-1" decimals="-3" id="f-1257" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c-28"
      decimals="-3"
      id="f-1258"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c-29"
      decimals="-3"
      id="f-1259"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-1260" unitRef="shares">133758000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-28"
      decimals="-3"
      id="f-1261"
      unitRef="shares">119784000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-29"
      decimals="-3"
      id="f-1262"
      unitRef="shares">106750000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-1263"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-28"
      decimals="2"
      id="f-1264"
      unitRef="usdPerShare">-5.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-29"
      decimals="2"
      id="f-1265"
      unitRef="usdPerShare">-1.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-1266"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-28"
      decimals="2"
      id="f-1267"
      unitRef="usdPerShare">-5.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-29"
      decimals="2"
      id="f-1268"
      unitRef="usdPerShare">-1.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-1269">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-308"
      decimals="-3"
      id="f-1270"
      unitRef="shares">744000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-309"
      decimals="-3"
      id="f-1271"
      unitRef="shares">707000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-310"
      decimals="-3"
      id="f-1272"
      unitRef="shares">633000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-311"
      decimals="-3"
      id="f-1273"
      unitRef="shares">4276000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-312"
      decimals="-3"
      id="f-1274"
      unitRef="shares">4030000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-313"
      decimals="-3"
      id="f-1275"
      unitRef="shares">3420000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-3" id="f-1276" unitRef="shares">5020000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-28"
      decimals="-3"
      id="f-1277"
      unitRef="shares">4737000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-29"
      decimals="-3"
      id="f-1278"
      unitRef="shares">4053000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1279">SEGMENT INFORMATION&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in a single segment dedicated to the discovery, development, manufacturing and commercialization of RNAi therapeutics. The Company's RNAi therapeutics are comprised of siRNAs that function upstream of conventional medicines by potently silencing messenger RNA (&#x201c;mRNA&#x201d;) that encode for proteins implicated in the cause or pathway of disease, thus preventing them from being made. Consistent with our operational structure, our Chief Executive Officer (&#x201c;CEO&#x201d;), as the CODM, manages and allocates resources on a consolidated basis at the global corporate level. Our global research and development and technical operations and quality organizations are responsible for the discovery, development, and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region and therapeutic area. All of these activities are supported by corporate staff functions. Managing and allocating resources at the corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources in line with our overarching long-term, corporate-wide strategic goals. The determination of a single segment is consistent with the consolidated financial information regularly reviewed by the CODM for the purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with our management reporting, results of our operations are reported on a consolidated basis for purposes of segment reporting. The CEO evaluates performance and decides how to allocate resources based on consolidated net loss that is reported on the consolidated statements of operations and comprehensive income (loss). The measure of segment assets is reported on the consolidated balance sheets as total assets. The CEO uses consolidated net loss to evaluate income generated from the Company&#x2019;s business activities in deciding how to allocate company resources (such as pursuing clinical development or entering a strategic collaboration), monitoring budget versus actual results, and establishing management&#x2019;s compensation. Please refer to the consolidated financial statements for further information related to these measures of segment performance. In addition, research and development and selling, general and administrative expenses are significant segment expenses regularly provided to the CEO with the following categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.719%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Candidate costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;347,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;259,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D discovery costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Salaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Facilities related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total research and development expense, excluding non-cash expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;552,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;455,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;307,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;607,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;505,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General &amp;amp; Administrative&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.719%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Salaries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Professional, outside services, and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Facilities related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total general and administrative expense, excluding non-cash expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation/amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-1280">In addition, research and development and selling, general and administrative expenses are significant segment expenses regularly provided to the CEO with the following categories:&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.719%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Candidate costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;347,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;259,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D discovery costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Salaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Facilities related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total research and development expense, excluding non-cash expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;552,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;455,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;307,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;607,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;505,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General &amp;amp; Administrative&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.719%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Salaries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Professional, outside services, and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Facilities related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total general and administrative expense, excluding non-cash expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation/amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <arwr:ResearchAndDevelopmentExpenseCandidateCosts contextRef="c-314" decimals="-3" id="f-1281" unitRef="usd">347571000</arwr:ResearchAndDevelopmentExpenseCandidateCosts>
    <arwr:ResearchAndDevelopmentExpenseCandidateCosts contextRef="c-315" decimals="-3" id="f-1282" unitRef="usd">259280000</arwr:ResearchAndDevelopmentExpenseCandidateCosts>
    <arwr:ResearchAndDevelopmentExpenseCandidateCosts contextRef="c-316" decimals="-3" id="f-1283" unitRef="usd">162459000</arwr:ResearchAndDevelopmentExpenseCandidateCosts>
    <arwr:ResearchAndDevelopmentExpenseDiscoveryCosts contextRef="c-314" decimals="-3" id="f-1284" unitRef="usd">66788000</arwr:ResearchAndDevelopmentExpenseDiscoveryCosts>
    <arwr:ResearchAndDevelopmentExpenseDiscoveryCosts contextRef="c-315" decimals="-3" id="f-1285" unitRef="usd">74150000</arwr:ResearchAndDevelopmentExpenseDiscoveryCosts>
    <arwr:ResearchAndDevelopmentExpenseDiscoveryCosts contextRef="c-316" decimals="-3" id="f-1286" unitRef="usd">55586000</arwr:ResearchAndDevelopmentExpenseDiscoveryCosts>
    <arwr:ResearchAndDevelopmentExpenseSalariesExpense contextRef="c-314" decimals="-3" id="f-1287" unitRef="usd">109085000</arwr:ResearchAndDevelopmentExpenseSalariesExpense>
    <arwr:ResearchAndDevelopmentExpenseSalariesExpense contextRef="c-315" decimals="-3" id="f-1288" unitRef="usd">96418000</arwr:ResearchAndDevelopmentExpenseSalariesExpense>
    <arwr:ResearchAndDevelopmentExpenseSalariesExpense contextRef="c-316" decimals="-3" id="f-1289" unitRef="usd">73668000</arwr:ResearchAndDevelopmentExpenseSalariesExpense>
    <arwr:ResearchAndDevelopmentExpenseFacilitiesRelatedExpense contextRef="c-314" decimals="-3" id="f-1290" unitRef="usd">29233000</arwr:ResearchAndDevelopmentExpenseFacilitiesRelatedExpense>
    <arwr:ResearchAndDevelopmentExpenseFacilitiesRelatedExpense contextRef="c-315" decimals="-3" id="f-1291" unitRef="usd">25782000</arwr:ResearchAndDevelopmentExpenseFacilitiesRelatedExpense>
    <arwr:ResearchAndDevelopmentExpenseFacilitiesRelatedExpense contextRef="c-316" decimals="-3" id="f-1292" unitRef="usd">16267000</arwr:ResearchAndDevelopmentExpenseFacilitiesRelatedExpense>
    <arwr:ResearchAndDevelopmentExpenseExcludingNoncashExpense contextRef="c-314" decimals="-3" id="f-1293" unitRef="usd">552677000</arwr:ResearchAndDevelopmentExpenseExcludingNoncashExpense>
    <arwr:ResearchAndDevelopmentExpenseExcludingNoncashExpense contextRef="c-315" decimals="-3" id="f-1294" unitRef="usd">455630000</arwr:ResearchAndDevelopmentExpenseExcludingNoncashExpense>
    <arwr:ResearchAndDevelopmentExpenseExcludingNoncashExpense contextRef="c-316" decimals="-3" id="f-1295" unitRef="usd">307980000</arwr:ResearchAndDevelopmentExpenseExcludingNoncashExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-317" decimals="-3" id="f-1296" unitRef="usd">32582000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-318" decimals="-3" id="f-1297" unitRef="usd">33586000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-319" decimals="-3" id="f-1298" unitRef="usd">34332000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-317" decimals="-3" id="f-1299" unitRef="usd">21900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-318" decimals="-3" id="f-1300" unitRef="usd">16654000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-319" decimals="-3" id="f-1301" unitRef="usd">10876000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-314" decimals="-3" id="f-1302" unitRef="usd">607159000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-315" decimals="-3" id="f-1303" unitRef="usd">505870000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-316" decimals="-3" id="f-1304" unitRef="usd">353188000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="c-314" decimals="-3" id="f-1305" unitRef="usd">31916000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="c-315" decimals="-3" id="f-1306" unitRef="usd">27589000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="c-316" decimals="-3" id="f-1307" unitRef="usd">22999000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:ProfessionalFees contextRef="c-314" decimals="-3" id="f-1308" unitRef="usd">53589000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c-315" decimals="-3" id="f-1309" unitRef="usd">24733000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c-316" decimals="-3" id="f-1310" unitRef="usd">20720000</us-gaap:ProfessionalFees>
    <arwr:GeneralAndAdministrativeExpenseFacilitiesRelatedExpense contextRef="c-314" decimals="-3" id="f-1311" unitRef="usd">5625000</arwr:GeneralAndAdministrativeExpenseFacilitiesRelatedExpense>
    <arwr:GeneralAndAdministrativeExpenseFacilitiesRelatedExpense contextRef="c-315" decimals="-3" id="f-1312" unitRef="usd">4116000</arwr:GeneralAndAdministrativeExpenseFacilitiesRelatedExpense>
    <arwr:GeneralAndAdministrativeExpenseFacilitiesRelatedExpense contextRef="c-316" decimals="-3" id="f-1313" unitRef="usd">3415000</arwr:GeneralAndAdministrativeExpenseFacilitiesRelatedExpense>
    <arwr:GeneralAndAdministrativeExpenseExcludingNoncashExpense contextRef="c-314" decimals="-3" id="f-1314" unitRef="usd">91130000</arwr:GeneralAndAdministrativeExpenseExcludingNoncashExpense>
    <arwr:GeneralAndAdministrativeExpenseExcludingNoncashExpense contextRef="c-315" decimals="-3" id="f-1315" unitRef="usd">56438000</arwr:GeneralAndAdministrativeExpenseExcludingNoncashExpense>
    <arwr:GeneralAndAdministrativeExpenseExcludingNoncashExpense contextRef="c-316" decimals="-3" id="f-1316" unitRef="usd">47134000</arwr:GeneralAndAdministrativeExpenseExcludingNoncashExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-320" decimals="-3" id="f-1317" unitRef="usd">30785000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-321" decimals="-3" id="f-1318" unitRef="usd">40382000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-322" decimals="-3" id="f-1319" unitRef="usd">43798000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-320" decimals="-3" id="f-1320" unitRef="usd">2028000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-321" decimals="-3" id="f-1321" unitRef="usd">1941000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-322" decimals="-3" id="f-1322" unitRef="usd">1617000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-314" decimals="-3" id="f-1323" unitRef="usd">123943000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-315" decimals="-3" id="f-1324" unitRef="usd">98761000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-316" decimals="-3" id="f-1325" unitRef="usd">92549000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-1327">SUBSEQUENT EVENTS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Novartis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 29, 2025, the Company entered into an Exclusive License and Collaboration Agreement (the &#x201c;Novartis Collaboration Agreement&#x201d;) with Novartis Pharma AG (&#x201c;Novartis&#x201d;) for the co-development and commercialization of multiple preclinical programs in rare, genetic diseases. Under the Novartis Collaboration Agreement, Novartis has received an exclusive worldwide license to the Company's ARO-SNCA preclinical stage program. The Novartis Collaboration Agreement closed on October 17, 2025 subsequent to clearance under the Hart-Scott-Rodino Antitrust Improvement Act. Under the terms of the Novartis Collaboration Agreement, the Company received $200.0&#160;million as an upfront payment. The Company is also eligible to receive $30.0&#160;million associated with certain target nominations. Further, for each of the 4 programs, the Company is eligible to receive development milestone payments between $175.0&#160;million and $245.0&#160;million per program and sales milestone payments between $285.0&#160;million and $370.0&#160;million per program. The Company is also eligible to receive tiered royalties on net sales of licensed products of up to the low double digits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Sarepta DM1 Milestone&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 20, 2025, the Company earned a $200.0&#160;million milestone payment from&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sarepta. The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ARO-DM1, also called SRP-1003, an investigational RNAi therapeutic for the treatment of type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy. The second milestone event included the achievement of a patient enrollment target, drug safety committee review and subsequent authorization to dose escalate and proceed, and completion of day 105 study visit by at least one patient in the clinical trial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;REDEMPLO Commercial Launch&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The FDA approved the Company's New Drug Application (NDA) for REDEMPLO (plozasiran) injection for Familial Chylomicronemia Syndrome (FCS), on November 18, 2025. This approval, which was based on the results of the Phase 3 PALISADE clinical trial, was completed within the Prescription Drug User Fee Act (PDUFA) VI timeframe. This approval is a significant milestone for the Company, and the commercial launch of REDEMPLO is in progress. We expect to begin generating revenue from sales of REDEMPLO in the upcoming fiscal year.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <arwr:ProceedsFromCollaborationArrangements contextRef="c-323" decimals="-5" id="f-1328" unitRef="usd">200000000</arwr:ProceedsFromCollaborationArrangements>
    <arwr:PaymentReceivableInCollaborationArrangementsUponTargetNomination contextRef="c-324" decimals="-5" id="f-1329" unitRef="usd">30000000</arwr:PaymentReceivableInCollaborationArrangementsUponTargetNomination>
    <arwr:NumberOfCollaborationPrograms
      contextRef="c-324"
      decimals="INF"
      id="f-1330"
      unitRef="program">4</arwr:NumberOfCollaborationPrograms>
    <arwr:DevelopmentMilestonePayments contextRef="c-325" decimals="-5" id="f-1331" unitRef="usd">175000000</arwr:DevelopmentMilestonePayments>
    <arwr:DevelopmentMilestonePayments contextRef="c-326" decimals="-5" id="f-1332" unitRef="usd">245000000</arwr:DevelopmentMilestonePayments>
    <arwr:SalesRelatedMilestonePayments contextRef="c-327" decimals="-5" id="f-1333" unitRef="usd">285000000</arwr:SalesRelatedMilestonePayments>
    <arwr:SalesRelatedMilestonePayments contextRef="c-328" decimals="-5" id="f-1334" unitRef="usd">370000000</arwr:SalesRelatedMilestonePayments>
    <arwr:DevelopmentMilestonePayments contextRef="c-329" decimals="-5" id="f-1335" unitRef="usd">200000000</arwr:DevelopmentMilestonePayments>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
